<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>MOFA drug effect</title>

<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/x-font-truetype;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<style type="text/css">.hljs-literal {
color: #990073;
}
.hljs-number {
color: #099;
}
.hljs-comment {
color: #998;
font-style: italic;
}
.hljs-keyword {
color: #900;
font-weight: bold;
}
.hljs-string {
color: #d14;
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">



<h1 class="title toc-ignore">MOFA drug effect</h1>

</div>


<pre class="r"><code>library(tidyverse)
library(MOFA2)
library(here)
#library(MOFAdata)
library(ReactomePA)
library(biomaRt)
library(gridExtra)
library(cowplot)</code></pre>
<div id="introduction" class="section level2">
<h2>Introduction</h2>
<p>I start out by loading the trained MOFA model and additional gene expression data.</p>
<pre class="r"><code># input data
morphology_profile &lt;- readRDS(here::here(&quot;data/processed/morphology/pca_absolute_all_drugs_aggregate.Rds&quot;))

# input model
model &lt;- load_model(here(&quot;models/mofa/model.hdf5&quot;))

# model outputs
weights &lt;- model@expectations$Z$single_group %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()
loadings_size &lt;- model@expectations$W$size_view %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()
loadings_expression &lt;- model@expectations$W$expression %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()
loadings_morphology &lt;- model@expectations$W$morphology %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()
loadings_drug_activity &lt;- model@expectations$W$drug_activity %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()
loadings_mutation &lt;- model@expectations$W$mutation %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% janitor::clean_names()

# additional data
## UMAP morphology
umap_df &lt;- readRDS(here::here(&quot;data/processed/morphology/umap_absolute_all_drugs_sampled.Rds&quot;))
## gene expression baseline
promise_long_filtered_top &lt;- readRDS(here::here(&#39;data/processed/expression/promise_expr_filtered_tidy_top.rds&#39;))
## gene expression drug response
# expr_long_gsk &lt;- readRDS(here::here(&quot;data/processed/expression/gsk_expr_tidy.rds&quot;))
# expr_long_mek &lt;- readRDS(here::here(&quot;data/processed/expression/mek_expr_tidy.rds&quot;))</code></pre>
<p>Next, I use the organoid phenotype profiles to estimate factor scores given the models trained loadings. I do not supply additional data.</p>
</div>
<div id="morphology---factor" class="section level1">
<h1>morphology -&gt; factor</h1>
<pre class="r"><code>new_morphology &lt;- morphology_profile %&gt;% 
  filter(concentration == &quot;nan&quot;) %&gt;%
  mutate(rep = paste0(&quot;r&quot;, replicate)) %&gt;% 
  mutate(line = substr(line, 1, 4)) %&gt;% 
  mutate(line = paste0(line, &quot;_&quot;, rep, &quot;_&quot;, drug)) %&gt;%
  dplyr::select(line, contains(&quot;pc&quot;)) %&gt;%
  # I treat every drug induced phenotype as a dedicated line
  # accounting for D020T duplicate
  group_by(line) %&gt;% 
  summarise_at(vars(contains(&quot;pc&quot;)), funs(mean)) %&gt;% 
  ungroup() %&gt;% column_to_rownames(&quot;line&quot;) %&gt;% as.matrix() %&gt;% 
  scale(scale = FALSE, center = FALSE)

new_morphology_conc &lt;- morphology_profile %&gt;%
  #filter(concentration != &quot;nan&quot;) %&gt;%
  mutate(rep = paste0(&quot;r&quot;, replicate)) %&gt;% 
  mutate(line = substr(line, 1, 4)) %&gt;% 
  mutate(line = paste0(line, &quot;_&quot;, rep, &quot;_&quot;, drug, &quot;_&quot;, concentration)) %&gt;%
  dplyr::select(line, contains(&quot;pc&quot;)) %&gt;%
  # I treat every drug induced phenotype as a dedicated line
  # accounting for D020T duplicate
  group_by(line) %&gt;% 
  summarise_at(vars(contains(&quot;pc&quot;)), funs(mean)) %&gt;% 
  ungroup() %&gt;% column_to_rownames(&quot;line&quot;) %&gt;% as.matrix() %&gt;% 
  scale(scale = FALSE, center = FALSE)

# extracting model loadings for morphology view
W &lt;- get_weights(model, &quot;morphology_view&quot;)[[1]]
Winv &lt;- pracma::pinv(W)

z_projected &lt;-  new_morphology %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)
z_projected_concentration &lt;-  new_morphology_conc %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)</code></pre>
<pre class="r"><code>z_projected_anno &lt;- z_projected %&gt;% 
  mutate(target = substr(id, 9, nchar(id))) %&gt;% 
  mutate(line = substr(id, 1, 7)) %&gt;% 
  dplyr::rename(drug_id = id, 
                id = line)

z_projected_anno_plot_df &lt;- z_projected_anno %&gt;% 
  filter(target == &quot;DMSO&quot;) %&gt;%
  left_join(weights) %&gt;% 
  dplyr::select(-target, -drug_id) %&gt;% 
  gather(variable, value, -id) %&gt;% 
  mutate(factor = if_else(variable %in% c(&quot;V1&quot;, &quot;factor1&quot;), &quot;factor1&quot;, &quot;none&quot;)) %&gt;%
  mutate(factor = if_else(variable %in% c(&quot;V2&quot;, &quot;factor2&quot;), &quot;factor2&quot;, factor)) %&gt;%
  mutate(factor = if_else(variable %in% c(&quot;V3&quot;, &quot;factor3&quot;), &quot;factor3&quot;, factor)) %&gt;% 
  mutate(source = if_else(grepl(variable, pattern = &quot;factor&quot;), &quot;MOFA&quot;, &quot;pseudoinverse&quot;)) %&gt;% 
  dplyr::select(-variable)

df &lt;- z_projected_anno_plot_df %&gt;% 
  spread(source, value)

r &lt;- cor(df$MOFA, df$pseudoinverse) %&gt;% round(3)

z_projected_anno_plot_df %&gt;% 
  spread(source, value) %&gt;%
  ggplot(aes(MOFA, pseudoinverse)) + 
  geom_point() + 
  facet_wrap(~ factor) + 
  theme_cowplot() + 
  geom_smooth(method = &quot;lm&quot;) + 
  labs(title = &quot;morphology&quot;,
       caption = paste0(&quot;cross-factor correlation &quot;, r))</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>z_projected_anno_plot_df %&gt;% 
  spread(factor, value) %&gt;% 
  ggplot(aes(factor1, factor2, color = source)) + 
  geom_point() + 
  geom_path(aes(group = id), color = &quot;black&quot;) + 
  theme_cowplot() + 
 # ggrepel::geom_text_repel(aes(label = id), data = z_projected_expression_plot %&gt;% 
 # spread(factor, value) %&gt;% filter(source == &quot;MOFA&quot;), color = &quot;black&quot;)
  NULL</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
</div>
<div id="morhphology-moa" class="section level1">
<h1>morhphology: MOA</h1>
<pre class="r"><code>## load drug annotation
drug_anno &lt;- readxl::read_excel(here::here(&#39;references/layouts/Compound_Annotation_Libraries_New.xlsx&#39;)) %&gt;% distinct(drug = `Compound name`, target = `Primary Target`)

z_projected_anno_tidy &lt;- z_projected_anno %&gt;% 
  dplyr::rename(drug = target) %&gt;%
  left_join(drug_anno) %&gt;%
  mutate(line = substr(id, 1, 4))

z_projected_anno_test &lt;- z_projected_anno_tidy %&gt;% semi_join(z_projected_anno_tidy %&gt;% 
                                                               dplyr::select(target, drug) %&gt;%
                                                               distinct() %&gt;%
                                            dplyr::count(target) %&gt;% 
                                            filter(n &gt;=5)) %&gt;% 
  filter(drug != &quot;DMSO&quot;)</code></pre>
<pre class="r"><code>drug_projection_test_result &lt;- rbind(
  lm(V1 ~ target, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor1&quot;),
  lm(V2 ~ target, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor2&quot;),
  lm(V3 ~ target, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor3&quot;)) 

drug_projection_test_result &lt;- drug_projection_test_result %&gt;% 
  filter(term != &quot;(Intercept)&quot;) %&gt;% 
  dplyr::select(term, statistic, factor, p.value)</code></pre>
<pre class="r"><code>hist(drug_projection_test_result$p.value)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>moa_factor_shift &lt;- drug_projection_test_result %&gt;% arrange(p.value) %&gt;% 
  mutate(fdr = p.adjust(p.value, method = &quot;BH&quot;))
  

moa_factor_shift_tbl &lt;- moa_factor_shift%&gt;% 
  filter(fdr &lt;= 0.2) %&gt;%
  head(15) %&gt;%
  tableGrob(., theme = ttheme_default(), rows = NULL)

grid.arrange(moa_factor_shift_tbl)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>moa_factor_shift %&gt;%
  ggplot(aes(statistic, fdr, color = factor, label = term)) + 
  geom_point() + 
  scale_y_reverse() + 
  geom_hline(yintercept = 0.2) + 
  theme_cowplot() + 
  #facet_wrap( ~ factor)+ 
  ggrepel::geom_text_repel(data = moa_factor_shift %&gt;% filter(term == &quot;targetMEK&quot;)) + 
  ggrepel::geom_text_repel(data = moa_factor_shift %&gt;% filter(term == &quot;targetAurora Kinase&quot;))</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>  NULL</code></pre>
<pre><code>## NULL</code></pre>
<pre class="r"><code>set.seed(12234533)
df &lt;- moa_factor_shift %&gt;%
  filter(factor == &quot;factor1&quot;) %&gt;%
  mutate(fdr_bool = if_else(fdr &lt; 0.05, TRUE, FALSE)) %&gt;%
  filter((term == &quot;targetmTOR&quot;) | (term %in% c(&quot;targetAurora Kinase&quot;, &quot;targetCDK&quot;, &quot;targetPLK&quot;)) &amp; factor ==  &quot;factor1&quot;)

# gg_shift &lt;- moa_factor_shift %&gt;% 
#   filter(factor == &quot;factor1&quot;) %&gt;%
#   ggplot(aes(statistic)) + 
#   geom_vline(xintercept = 0) +
#   geom_histogram(aes(fill = factor), alpha = 0.2) + 
#   geom_rug(aes(color = factor)) + 
#   
#   geom_vline(data = df, aes(xintercept = statistic, color = factor), linetype=&quot;dashed&quot;) + 
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$statistic - .5, 
#                 label= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$term, y=.350), color = &quot;black&quot;) +
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$statistic %&gt;% .[1] + .5, 
#                 label= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$term %&gt;% .[1], y=.350), color = &quot;black&quot;) + 
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$statistic %&gt;% .[2] + .5, 
#               label= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$term %&gt;% .[2], y=.370), color = &quot;black&quot;) + 
#   theme_cowplot() + 
#   theme(legend.position = &quot;bottom&quot;)
# 
# gg_shift + ggsave(here::here(&quot;reports/figures/mofa/drug_shift.pdf&quot;), width = 3, height = 3)  


gg_shift &lt;- moa_factor_shift %&gt;% 
  mutate(fdr_bool = if_else(fdr &lt; 0.05, TRUE, FALSE)) %&gt;%
  filter(factor == &quot;factor1&quot;) %&gt;% 
  ggplot(aes(statistic, factor, label = term, color = fdr_bool)) + 
  geom_jitter(width = 0.1) +
  geom_vline(xintercept = 0) +
   ggrepel::geom_text_repel(data = df) + 
  theme_cowplot() + 
  scale_color_manual(values = c(&quot;grey&quot;, &quot;black&quot;)) +
  geom_rug() + 
  theme(legend.position =  &quot;nothing&quot;) + 
  labs(caption = &quot;FDR = 0.05&quot;)

gg_shift + ggsave(here::here(&quot;reports/figures/mofa/f1_moa_shift.pdf&quot;), width = 6, height = 2)  </code></pre>
<p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABUAAAAPACAMAAADDuCPrAAADAFBMVEUAAAABAQECAgIDAwMEBAQFBQUGBgYHBwcICAgJCQkKCgoLCwsMDAwNDQ0ODg4PDw8QEBARERESEhITExMUFBQVFRUWFhYXFxcYGBgZGRkaGhobGxscHBwdHR0eHh4fHx8gICAhISEiIiIjIyMkJCQlJSUmJiYnJycoKCgpKSkqKiorKyssLCwtLS0uLi4vLy8wMDAxMTEyMjIzMzM0NDQ1NTU2NjY3Nzc4ODg5OTk6Ojo7Ozs8PDw9PT0+Pj4/Pz9AQEBBQUFCQkJDQ0NERERFRUVGRkZHR0dISEhJSUlKSkpLS0tMTExNTU1OTk5PT09QUFBRUVFSUlJTU1NUVFRVVVVWVlZXV1dYWFhZWVlaWlpbW1tcXFxdXV1eXl5fX19gYGBhYWFiYmJjY2NkZGRlZWVmZmZnZ2doaGhpaWlqampra2tsbGxtbW1ubm5vb29wcHBxcXFycnJzc3N0dHR1dXV2dnZ3d3d4eHh5eXl6enp7e3t8fHx9fX1+fn5/f3+AgICBgYGCgoKDg4OEhISFhYWGhoaHh4eIiIiJiYmKioqLi4uMjIyNjY2Ojo6Pj4+QkJCRkZGSkpKTk5OUlJSVlZWWlpaXl5eYmJiZmZmampqbm5ucnJydnZ2enp6fn5+goKChoaGioqKjo6OkpKSlpaWmpqanp6eoqKipqamqqqqrq6usrKytra2urq6vr6+wsLCxsbGysrKzs7O0tLS1tbW2tra3t7e4uLi5ubm6urq7u7u8vLy9vb2+vr6/v7/AwMDBwcHCwsLDw8PExMTFxcXGxsbHx8fIyMjJycnKysrLy8vMzMzNzc3Ozs7Pz8/Q0NDR0dHS0tLT09PU1NTV1dXW1tbX19fY2NjZ2dna2trb29vc3Nzd3d3e3t7f39/g4ODh4eHi4uLj4+Pk5OTl5eXm5ubn5+fo6Ojp6enq6urr6+vs7Ozt7e3u7u7v7+/w8PDx8fHy8vLz8/P09PT19fX29vb39/f4+Pj5+fn6+vr7+/v8/Pz9/f3+/v7////isF19AAAACXBIWXMAAB2HAAAdhwGP5fFlAAAgAElEQVR4nO3dB3wb9d348a/tTOIsEggjQFhlhT0KNEDhYfWBQqGFQin82QRoCaWUDWUWKJTSNrRm9WEVKKQtT0sLfaCynUVCEhLIADII2QlZzna87n9TOsmSLMk63VfS5/16PY/l0/n0k+t8kHR3vxMDAJATCXsAAFCsCCgA5IiAAkCOCCgA5IiAAkCOCCgA5IiAAkCOCCgA5IiAAkCOCCgA5IiAAkCOCCgA5IiAAkCOCCgA5IiAAkCOCCgA5KgYA/rh4Yc/HPYYAKAoA/ofkevCHgNQODOefnpG2GNAUgQU0O63IiPDHgOSIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKKLVq5sQJUxc2E1DFCCigUvPHEdvYtQRULwIKaNQ2NeKq30BA1SKggEbLI1FTlQe0ddmMKdPmbgh7GKEgoIBGH8cCGnlCdUDXf+CM8rPWsEcSAgKK0tMw//N5K4v8n/M4X0Af0RzQTaO9Yc4MeyghIKAoNZsm2/+cx60MeyCdMtoX0F9oDui02DhXhz2WwiOgKDGbxnj/npeHPZTOmOgL6KOKA9roG2cZvgQloCgxU6L/nkdvDXssnTA71qXRv1Ec0FW+gE4IezCFR0BRWjb4/kEvDHswnbC5Lvo05mveC+87WiAyNuzBFB4BRWlZ7PsH/UnYg+mMZd6zmNaqOaBrfL/vD8MeTOERUJSW+b5/0FPCHkynrLY/Bq3/olX1mUgtsVfKkdlhD6bwCChKyyJfQD8OezCd07Z+2eLVLYbyc+E/j/66azeFPZbCI6AoLet8AZ0f9mDyRHVAmz/0ft2Lwx5KCAgoSktb9N9zpG5L2IPJE9UBNZpn1Vq/7XErwh5IGAgoSsy6+lLYCR9Hd0ANY8vSL75cXeRnfuWIgKLUNIy381lfOu8otQe0jBFQlJzW5Z9+PHNRU9jDyB8CqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqlZZBbTtvZvPv+RXi/I8HCBgBFStcgro3KPE0u3ulnyPCAgSAVWrjAK6cCdx/SjvQwICREDVKqOAni9RY/I+JiA4BFSt8gnoqi6xgF6c/0EBgSGgapVPQP8d66d8Lf+DAgJDQNUqn4C+5gvogPwPCggMAVWrfAL6ni+g++Z/UEBgCKha5RPQhm6xgF6R/0EBgSGgapVPQI3/F+1n5Yd5HxMQHAKqVhkFdMWeXkDvzPuQgAARULXKKKDG4lPtfFY/0ZbvEQFBIqBqlVNADWPSg1ff8Pzq/I4GCBoBVau8AgoUIwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAUVxWhf2AAqIgKpFQFF8Wl8c1kV6nvbPsMdRKARULQKKorPpNHFc1Rr2UAqDgKpFQFF0LhDPPWEPpTAIqFoEFMVmcrSf0mNF2IMpCAKqFgFFsbk9FlD5Y9iDKQgCqhYBRbH5ni+gt4U9mIIgoGoRUBSb7/gC+tOwB1MQBFQtAopiM8IX0PLoCgFVi4Ci2PxfrJ+V88IeTEEQULUIKIpN23HRgF4e9lgKg4CqRUBRdJZ+ze3ncZvCHkphEFC1CCiKz/qf9TfzufOjTWEPpEAIqFoEFMWoZea42WGPoXAIqFoEFNCOgKpFQAHtChLQDQvnzl/dFvjDlBgCCmhXgIBu/ihiGb864McpNQQU0C74gG4eG3HUfhXsA5UaAgpoF3xAp0Y8o8vl0Ib8IKCAdoEHdGMkZmGgj1RqCCigXeABXewL6PRAH6nUEFBAu8ADOt8X0CmBPlKpIaCAdoEHdJEvoB8H+kilhoAC2gUe0AZfQOcH+kilhoAC2gUe0LaJ0X7WbQ70kUoNAQW0C/4wpoY6L6BfBvtApYaAAtoV4EykNc6R9HULAn6cUkNAAe0KcS58y9JZU6d/2Rj0w5QaAgpox2xMahFQQDsCqhYBBcLUunzW1I/nbUy7DgFVi4ACIVr/gbPz+/N0M3ESULUIKBCMpgVTP5g4c1XadTaN9g4fmpVmLQKqFgEFArF6jHtqZHOalabFzgBak3otAqoWAQWCsD56aPq01Cs1+k6hnJl6NQKqFgEFgjAllsbUk7yv8gV0QuptEVC1CCgQgC2+NH6Scq3lvrXGpt4YAVWLgAIB8L+2HJ9yrdW+tT5MvTECqhYBBQKwIqPXls11sbVmp94YAVWLgAIBWJvZa8vPoivVbkq9FgFVi4ACAWitjwV0burVmqMTcS5KszECqhYBBYIwL9rPui1pVmuaWWu/y1+RblsEVC0CCgSh1bvUem3aNhrG5iXz5q9qTbsKAVWLgAKBaJ1nv4v/cG3nN0VA1SKgQEBaVi9ZtiEfGyKgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAu/wGtHHeh2PGfbw83YXokSkCCmiX14CudC9FP6Upb5ssYwQU0C6fAW2IXkVkMq9BO4+AAtrlM6CTYzPlL8vXNssYAQW0y2NA/ZdbnpanbZYzAgpol8eA+i+3PC5P2yxnBBTQLo8B/coX0DF52mY5I6CAdnkM6LrMLreMDBFQQLs8BrRtTEaXW0aGCCigXT73wi+I9rO+MV/bLGMEFNAunwFtm+5drn5lvjZZzggooF1ez0RqW2i/i/9ofd62WM4IKKBdnicTaVv31cotedxeOSOggHbMxqQWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAQW0I6BqEVBAOwKqFgEFtCOgahFQQLtUAV07c/zo8TMbCj0cxBBQQLvkAW2bHXHMLvyI4CKgyL+mtrBHUFqSB3RexPNF4YcEBwFFns27drBUHnA/byzzJ2lAG+uiAa1rDGFQsBBQ5NeoXmLbbUbYIykdSQO6KBKzKIRBwUJAkVeTuolrMK9B8yVpQD/zBfTzEAYFCwFFXp0sUT8PeywlI2lAZ/kC+mkIg4KFgCKfVlXFArp/2IMpGUkDOs8XUPYihYWAIp8mxvopXVvDHk2pSBrQtb6A8mlJWAgo8mmsL6CVzWGPplQkP4zpo2g/pxZ+SHAQUOTTQl9Adw17MCUjeUAbx7v9/ICjmEKTOqCP9OhxaAEHkgUCqthBsYBeG/ZYSkaKUzmbPrMOBa37nFf64Ukd0PtEBhZwIFkgoIr9JdrPbeaHPZaSkXIykZa1K9a2FHgw8Esd0L+Z/wbmF24gWSCgmt3l9rPH/4Y9ktLBbExqpQ5oy1CRBwo4kswRUNX+fpiZz6ozPgl7HCWEgKqVZifS7J2l97TCjSRzBFS5xWM+4LiafCKgaqXbCz//WOl5g8KzbAkoygsBVStNQJ988ld7ilRsd/BpZ0YVbmBpEFCUFwKqVpqAShKFG1gaBBTlhYCqRUAB7QioWmmS+FwShRtYGoEGtKG7yL6BbPk7ItFdK1tPEzlpcyAPg9JDQNXS8ZoyO4EG9I/WC+2Pg9iyL6DN5u3jNgbxIChFBFSt4g/ovdKvk9uL28IpVkBv7+QWk4oFtPVCkaPXG/bUG4cE8VAoLQRULQIav4UVVXJKX9m9k1tMKhrQtstFjrBvElBkgoCqlVFAlc3rGGRAfyfy2sUiEzu5yWSiAf2xyMFr7FsEFJkgoGp1ENC2d350xMAuFf2HXvOWnopmEdDRNRlc7MC/hWOl16b/FflJuvVTbzTtw3kBvVXkgJXOopaGhg0djw/ljoCqlT6g/9ordgTTHv8s0JA65A/ocGdwj1i3x11wUP9e+57xF2d6mmp5e8MpIk9atyPf27H77tcuNIaIcxzBxl8eM6DX0CtnJm7B+LJCfmg09padnQubLxd53Xmc90VmJGx08Y/27dXra8OnG+0eLn4gHjeg94nss9xbVi33Ol/eMsaeu3PP/S6Z496RsIn1D50weJv9z6nzfs7/BFDyCKhaaQP68/iDQO8r1KA6kCKgV3rjPLHJuqda/m7tEDKL1jbCWb5dxA3oR4OdBRX3GAkBfUTkX4bxA5HR9rdJAupt1Pjrts4PVj1oxD9c4kA8TkAfF9lrSXRZLKC/q+rx9b1Fur5vL0/YxAcD3G/d5x33BFDyCKha6QL6jPVvdJ+bR77975pbDrBu/7Fgw0rLH9DWlnukb0uL+YLx9yJDHvzzm78wXzTfb91TLafK9j97foFhPCay4y2vP3KMVHWzA7qin8jZv/vTiN72hSNjWzAdLNs12zP5OQ+QJKDeRt8yY3fFs38c3kPkpfiHSxyIxw6odefC2LJoQIdX3r3VMOr6yw7W7LgJm/hqR+lxzUt/eXAnkTeNdk8AJY+AqpUmoGv6i+z2uvvRZ+tru4gM0DHHTvLPQI+RPew9M+v2kBOtr9UiJ9sfNTb0l4MXm19brjH/G2AF9HqpfM26Y84+0m2u4f8MdJbI9eaXLdWynf3eOUlA3Y027yPb2q9SJ+8gQ7b672k3EI8V0BcqRL7mO4A+GlD3yKnfOcegJmziBTHf4pu+6CkXGEmeAEocAVUrTUB/LVI9I/bt9F4ivw1+QBlIGtCmQf0edhZcI4OtL9VSOdv+/m6RD+wbTTvZAZ3X1a6kaXyF3GT4A2quOt76eoHI/1lfkwTU3egfRZ5w7nlW5Cn/Pe0G4jED+nSVmC8eR8SWRQPax9kt/4nIX9pv4gbp4nwWest3rJ9t9wRQ4gioWmkCeorIH/zfPyVyetDDyUgHe+Ev9AJ6kvP90XKse8/9dkBHiniX0T5ajorbwt7uEaCjRK6wviYJqLvRq6X3JufW1oHyQ/897QbiMQNaKcet2F0qaqPLogE9zfl+scio9pswx/2qb2G7J4ASR0DVShPQwSJx7w/nabnOYpqANs19+/pKL6CXO8sGRq9u9g87oDfKIG/1q6W7fwuTRe60b2zuJf2s9+VJAupu9CQ5wtvI8XKM/552A/GYAZVjNhi1FTIkeuxSNKDuE/IHNLaJj7uZ/+16erZ3R7sngBJHQNVKE9Du0id+QX/pEexgMpQioCse/taQSnvntBvQO+zFa7097GaI7ICeGXdowXrfFn7qv+MfRtKAOhs1dpXveQO4WLb339NuIJ7vuOcf/Vjkam9ZNKA/d773ApqwiVftPf7bX/jGFuu7dk8AJY6AqpUmoH2kyxb/91u7dfqcn/xIHtBXeps12faoi5++2Auo3SZjicij7qqz7IAeGdeflbEttA3233GR4Q/ou15AnY0au8QCepn9H5roPe0G4jEDak/vv2lPkXfdZdGAuj/sBrTdJlY9cUKVNag9rB1X7Z4AShwBVStNQPcSmeD/fpLIPkEPJyNJAzqpSnYZaX80eGN8QI1e0bXfsQP6fTkofnteQOtFvvO24++9pHqzP6DPJgT0xNhb+G/K4f572g3EEz2Vc3SFDF7rLEse0KSbWP/uHUNFBqxI8gRQ4syAPtkW9iCQTJqAXiJyif/7y0UuC3o4GUka0Kulq7tn5dKEgB4qw9xVH7cDeo90jTvAPRrQ4SLve8vOsw+5NAP6mvP9LQkBvUr6uEcjNQ+yjy2K3tNuIJ7YbEwjor/Z5AFN3ERDg/tYD4u8kuQJoLRtuF3khtGzmD9WoTQBfUvi3jg8bX6r41LfSQN6ivfyuHW3hIBeLzLJvtGyhx1Q83m97Nyz9cghd8a20DxQto+efPmGWO/RV3ifn27eMSGgz4n8JnrrCf897QbiiQV0097ugZ0pApq4iZ29Pfxf2qc6tXsCKGnL6n5sBjQSqV8d9kjQTpqAth1hJvOMD51vppxtfnOkjrcRiQGttr5cLT3tPLVdZb7PtcYZi1JPOdw6+bztFudA+rajZIBzfOsIZ9oldwv/kujuerNx20iP9UZbbxlq7Y1vu1ESAtq8twy0jy6dsoMM3mzEvQJNGIjHN6Hy2EoZtMowUr8Cjd/Et6XrVPvuX9qHtLZ7Aihl62ojTkAj9Vs6XhuFle5Uzpn9rZ0UO33joh8Os3ev9Fcyd0V8QB8UeX3GIuNNka//dfrY3+8n1SI/Geffq3OnyOA7Rz15khy0nbxofv9BhXS95vl/PHWsyFW+LVwsUhfb7Hftd8vfFjn6r9Ne+5Z8KyGgxl9Eug1/4eUf9XRfDkbvaTcQj/+SHjeJnO/7qYSAJm7C/H7A7aP++fw5FXJYU5IngFI2LeIFNJLB1GIorLSTiUza3b+7d7cPCzWoDsQH9B1rbOYb7YvcYV4x3Wzayf7Wtd5dYd9z+PJBzkFC73lzcVzWEtvClt6yg2/KvtdFzjSMRds7a564KjGgxpv9nbv6OG+nY/ckDsTjD+jmfZzdUyn2widu4kfe/wb7OPOQJDwBlLCW2lhAx4Q9GCRKP53d+ru39/7pDrxjXYGG1KGEayI9OqTbTs+bX984aXD3IZdNMIwJ55/827jWGe+cum3PA3+5tbHC3Uu09raD+lQfeslU/xZGifzYt9WNPaXrGsNYffMh1f2Oeqql+cYblxnxG110/T69ttn7mvnOd757Egbi8QfUGF8pA5YlCWj3gf9MtokJFxy8ba/9znjd62XCE0Dp2hiJBTTSHPZokKCjGembxj1+ww8v+tEvx2wtyHAykvNF5eaILOx4LUARAqpa8V8TqUMvXnCp+9b8PtlOx24wIFO8hVctTUAfeSQSv+DpR14KdjAZyjKgo7zzyxf0i51DCRQJ306kz8IeCxKlCajIzfELjpFdgh1MhrIM6Ia9pedDM1dNHdlPeswLbFBAMNZzGJNi2QT02FRT/7Q+e1j19oXbR5/tZ6Czd3Z3hHUb1fHKgDLL3QPpR3MgvT7JA/q+ReS8933+/URV4vRMnnutOtUlvy/euyIvZDq0pgGyPOkdWe9E2jLyxCFd+x54A68/UYw22qdyflrurz+fkwSPO8vrbjx0ULedjrxlfHTN96OrVO524s++CnJQyQOaOFLPEUnXbu4uPW98OXnsEmQT0LckXwEFihqTiViSB3TKcdHvT/EuoPF+3Gq9g7yWW3YBTb4T6TPJeOdMFgHdMJSAApaimM6u3aUh8r2FmSNtV4h837llHQb95+4iPc6681e3ndZVpNfbzppmQM9yVvnFVTuLdPu4kwNLI3lAh1pEBgyNc3qKnfDTYlMWdyTjgDa/9XUhoICFgPqMEqmJfvO/FVI5wpkb8qurRKqcA4fe9xVp84XmS9NODiyNbHYipZLHgDa89qR1suI9h/e0X/ESUCAxoG1rFsxfqu8D0TACumhbqYpdLqymQnay5+jxB9RY3UsGdHJgaXQ+oE+6b+/tnUgbfn3i3j0HHnLee9G7t9acvEOPfc961foI50Z31S+tO1pePGtwt20PvcW7PtowucB4Z6AzJec33RUJKJAQ0JXjrUNCa2dqmxM2bf5G12QwEUr2AR0u3gVqbT9wL2oWF1Dj0FQhyYc0AX3wwfdT3xnjD2htP+/T0pPdUz9n7O0uOHJRfEDnDXW/6faYs6YZ0DHdxQlo/SjTIQQUsPgDujTimqCqoMOdf812t8ZdcFD/Xvue8Rdn5oZqeXvDKfZEtoYR+d6O3Xe/dqExxJpX0rTxl8cM6DX0ypnxWxgobxnPH9Ov12FmKDfdu/822x33F98j+QL6VQ/p67+kzfzu0t+6WG58QE8I8ro3nT+Vc+W0P4vcMG3aRnP8A0R2H37vT0+rMpfYdy4xl+x0/l0/7CPyjWZjybSnRO6fNs38X75hR5Hq0269dF/x/jaGybd2k91+9OQSb8OnE1AEqWmTvvfByfkCuqXOC2hkVqhjSuAL6JXeq6gT7cRXy9/NfloBbRvhLN8u4gb0I29WsXuM+ICO+q7sflRPsyJL9pW9juge10NfQF8ReTBuFCOcy43FB3TnIK/l1kFAmyc68643XPT8/JQrRT8DvdN8QW2fdj6lj3vS0uUi51v/SfjqWBFrVqHoZ6A/EznM3uLDVbKt/SHwMPOXd+Mm32YJKAK0YpJ1cvmcopiewxfQedF+RmoDfgm6btaEMRM/29DxipbWlnukb0tLm2H8XmTIg39+8xd7mS+WrHuq5VTZ/mfPLzCMx0R2vOX1R46Rqm52QFeYb1jP/t2fRvQW66q0sS0MlP23rzVffZnvQXfeZYJhzN1Teq6NPpIvoGZepseNIiJym5EQ0DdEfpL7L6EjaQPacne1G+9V5n8lbko1IVM0oCfKNo3Ooh+IrDG/TK+0L7hmWtRFzjBiAbVea7vT490mcov11QzoaXGbbRfQ1bc6LjB/7f/pSMJ5/ECcT90KjS+GKw35AjolFtBIsBdkneNm+ouOV7V5n2AeI3tY//aNdXvIidbXapGT7ZE29JeDF5tfW64R+9IQxvVSaV9ybM4+0m2ubwsDReydKO+JVE62brwqMjb6OL6AHi894g+PXS9yruEP6IaZ91XLIQHOxJkuoCuON59oNKAih69Kvl40oLXveicDXOvE7zpvHg/DOHuHr7XFAvqL2Gvvlb3s66pbAa2N22y7gM6LHZB6dqRDmTx7lKsF0b+TCUVwhLovoB/4/sSXpP2hToq91F2Q2Q+4+Wsa1O9hZ8E13sXJKmfb399tX5DGWmUnO6Dzunp7gMZXyE2GP6BH2l/Xiv2qy3wJKhLb1+4L6H7xVx0z9ZDjjIQD6SuuXJPpc85BuoBa86Jv8337ZuPt+5vfXJN8vfaHMU3eyYnfwVLRGHeHF9CzRKIHt54sMt+wA9oQt27nAvqfNE8M5a51dOwvZWnYg+mYL6CTfH/jKwJ8SN9nrfWZfVTQbh/6hV5A3UsiHi3Huvfcbwd0pIj36vZoOcrwB9S9Uo3I3fbXVfb1dVy+gO4puycMor8cZiQEtNsdm4zgpAnopAqRK2KP/WRXqfwo6Yr+gH72xkNXnryTdwhSP9kxflUvoEeKrPeWXem8Ph8m28Sv2y6gG99w3CNy1vsdec8AUlnty9AnYQ+mY76AfuobeZCfPiz0PU5m/4mJC2jT3Levr/QCermzbGD0oo3/sAN6owzyVr/anqcoFtDbnMXuvvuUAf164uwcLZVyquE/E+nXNwwRObPVCEyagF5pX9k35mdmT5OuGA1o2wt7OtHfaU8nfhXeR6AeL6D7OhfCtP1cxDoDa5jsHL8uO5EQlCW+PGi51FcavoA2xAY+JciH9Id6TrwiE0MAACAASURBVEY/EQ3oioe/NaTS7oAb0DvsxWtjr7M+tgN6pv91ovWCKuuAnisS/zHGpyKXGvE7kTae4P8ANe/SBPQ45zpqUUvFu1x5gmhArQMRDrj81/+YY10G2IpfLxkSv6rvFWh0795w5xjSYYmfZxDQLLT869IDB1Qfev6T3kcm0ZkX+u1/XfTvx39Zpq2niZxUDHtQglC8AY2VrT7D/eO5men7DWU2j7OXv1d6m3912x518dMXewF1Lvi1RORRd9VZdkCPjAvoyhwC+pvEExvNX5Q1c0jcXvix4ruQWd6lCegO0j3+pW+fFNPZeQGtE9nd/Wsc4cRvD6nyDhNpa7EOq/V9Bhp953SKiPW/EAHthA8P8f4Od/uzsyRu6prvux+j+wLabN4+bmMog1VgjS8P0ztePWz+gLZ97gx7XEO6n+i0Ob7f0PyMfsLN36Qq2WWk/dnmjfEBNV9Oef9s37ED+n05KOkWMg/oZyJ7+Y8N2jhYqqz9/HEB3ZRy500+pAloD+kTv4Oyn/RIuqIX0J8678Ut33Li9wMRb2fO1fYF3byAPiTi7qozVveW/tbjlFtA83nq8N+6iuw8/JF7L93NrKVz1oYZ0MvsD4FuP6FK5DCnoLGAtl4ocvT6JBstD61jYnkI7jS/vIk/F37j3KmTpy8J8HM9i/9T4syOAnL/HK+Wru6uoUsTAnqoDHNXfdwO6D3StSnZFjIPqHFG/P7r20Qusr7GH0hfLedn9ARykiagQ0Q+938/VxLfkLu8gF4lMs1ZsnAbJ35mL49zlmzeQfY2YgGd100GuO9AbnMvJ0xAc97CmK7S83f2P6imkVXSxz5o5DnnwvOW6Yebr0HtW9GAtl0uckSwL2F0Wxytw6TiOoypUNpiu/szvHi2++d4ivdBX+tuCQG9XmSSfaNlDzugb4m87Nyz9cghdxq5BHRKV+kV+4Dz391kGztZ8QHtJf+d2TPIRZqAnhud8tnxpMi3k67oBdT8n/kee8Es6wR4+yNuM4KXW+fLNZqvRW837ID+wV7lJvMF0CLrxqNV0t++VAEBzXULW/aRLu94C38t8gPrqy+gRsMBzhQDsYD+WOTgII+O02+uW4cJjR2vG7owprPbPNb9DY3P8Dd0r7Nj+Grpaf+NtZmvpwZY/3GKBnRxTznc+hfddotzIH3bUTLA2csyQmRibAtZBNT6FLTHo84ZuRvu7uIVOTGgx2f+tLOVJqCvinQbHft2cg9xZwBI5AV0Xi+p+O5Tr/zizArZT2SfW8zf40zzh3a96P7rdhE5xPrfoV7koJeeM98SrB0k0vfbd11pHV76lL0VAuqT1eQ1f3B2Pbr2kj7Wb9ofUGOMc4JGNKC3ihwQ7Gks+q2eWheJfDC/JexxZCKU+UC3zqg181n7aaYnjD5o/sXNWGS8KfL1v04f+/v9pFrkJ+N8AbVO9R5856gnT5KDtpMXze8/qJCu1zz/j6eOFefAT3cL2QTUeKRCpN8F9//23nN7i3R5xlkYH9BdEo/vyac0AW0Zag7tAfd1yuZfb2e+g0/+36LoXvhXuzr7LKpHrjD7KNbHuaMHufsxhtkfjDTY0zVZszHN3s+9o/sTzlbKK6D5nLzmEKn0fdZyj8jfjYSAGodKV+sDTzeg95n/eSuCT/6C1trY6RPhm5Z/8cXy4GdFCmlC5aZVy1Zl/it6x/1zvMj9h33F9J4iJ/sD2np3hX3P4csHOWcovudNJnJZi38L2QTU+PeB0X2lXx/nLosP6DD3zNBApDsTabJ1PEL1Gdc98uRN52xv3uyaYhixA+nnXXFwdb/D711m3hp+6lX2PooNj31jYI+h33vNXXfssN7dd7cPzG3+45k7det3yC3z3XvKNqCdnbxmscg5vi23bNxobSc+oPc6h4o5AX1cZK9AzwIsF21f2Kfr1H8R9MeoRTEjvfHokG47PW9+feOkwd2HXDbBMCacf/Jv/QE1E3nqtj0P/OXWxgrnIyVj7W0H9ak+9JKp8VtoH9DuA/8a3UZCQI3Wf1574HZdBx0yInbyYXxAHxDpn8enGS/tZCKjd/AfC9PrjcBGkZ2gAjrKe6Zd9j7T/VzFuEAkbgaAfB1JmcfJa0a5PxgvPqBviTzhjd56wIW5jRp+bTO83SwzAi5ocQQ0c3PsQ3JKQvrp7FZes40XlcqzZhdoSB0KPKCWPertZWkC2skjKfM2ec0vojsz/eIDOtXZh2eN/gXzbdTXyvUA+rxaFjvQZ1mwj1QaAX3xgkvdY6/uk+2K4NiHjHQ0ofKaP113yuEHnnDRU4quqR4f0PztzR7lXe7voUvMF3mD7GMDUge0s0dS5m3ympuTnqoWH9C5IsOd0T9dJeYL2RG5jxse37wek4J9pNII6ChvbrYF/TK+jK96nZ+RvvACDKj34cryY93TF1IGtNNHUuZt8pofRw+/9YsP6DyxJ3IwR18px63YXSpqOzFy2Fp8h5pHgt2ZXxoB3bC39Hxo5qqpI/tJD0WvxzqHgCYNqDG/i33gf+qAdvpIyrxNXnOPyN/abz7VW3g5ZoNRWyFDAj2Ruixs8Qc02M9ESiOgxuyd3c/Huo3qeOUikU1AB1c/Ftg4spFFQLM6njJu997+UmXtR0oV0M4fSZm3yWt+LxL3v8unM6ypBeID+r/RnUj2q2az/iXzHio0zf6ABnsoU4kE1Ngy8sQhXfseeEPJvP7MKqDm28ALgxtIFvwBzefxlHEBHeYcx5oioHk4kjJvk9dMjp9mcHmFHGEkBvQ+Z7p/c/T26V+b9nQuvoXO8E0OP77jtTujVAJagtJfE2n041dd6bl4oMgPCzWstFIEtNMXA/QHtLW/M/VU8oDm40jKvE1e09xfqn1zk7/snNYRH9DD4g6kN1+ZV8jgtQY6ZX628xXljICqlS6gG+LfNJpeKti40vEHNJ8XA/QH9GFxTqBNGtC8HEmZv8lrbvYuIm07M8mZSGMTTuW0zz6+pLPPoNy1fOj188OATwgloGqlC+ipif38QcBTaGUo+Wegnb8YYDSg6yddUeme/pUsoPk5kjJ/k9csrJZu0QOZ3hTZyZoi0R/QdUPdaQVjAd20t8hbnX0KJa+1YVVDmjZuneb0c1qq69XmCwFVK01Ap5q9OfCWu/YTGf7gAz/YTuShwg0rraQBzcPFAOMOpHd3gScJaJ6OpMzf5DXGsyK9apz/uL3YX+R/rBu+gH56pMgF3ui9I6/GVsqgFFdZhaNlTr1Zx7p0s2msmT1t2uzgp7UioGqlCaj5gu3ERsNY2UN+bX635UzpO6tgw0qrg73wOV8M0B/Q/u6lApIENE9HUuZv8hp7H5EMvubRR6+yJqZ39iiZAb2ixjTynlO6JJlQ2Z5QMMB5ZktAk/cOfdyWsIdCQNVKE9Dj3Qu1nyFnWl+aDpFvFmRIHUoT0E5dDDB6JtLIVz7xJqFJEtA8HUmZv8lrTK97R9hJtwecl6Jxl/Q4r/0lPYzN+8TtZkKi6XrmXCagaqUJ6B5SaWfkNnci+j+7s/KGLkVAO30xwMRpXixJApqvIynzNnmNZePL3/1an247nHi/d3BANKB99h0+xjf62MlT4ytlQMDncBezTb6jPMP+rIOAqpX2mkjb21+flUr7Q/KW7kFenCkLyQPa+YsBZhjQwh9JWUKT1xQP/4XRw55Hh4CqlSag20lf++t7IvYR58Z+sl8hhtShpAHNw8UAMwxooY6kLMnJa4qH/7KUn3S8eqAIqFppAnqoiH05vnnedNDfTHFZ40JLGtA8HE+ZVUCDP5KyJCevKR7zfAGdEfJYCKhaaQJ6loh9iZHW7s5lM439A5zYORtJA5qH4ymzC2jgR1KW5OQ1xcM322dkfshjIaBqpQnosyI72JfWPEK23WR+WVRlH/QTvsSA5ut4yuwCGvyRlKU4eU3xaKqP9rM292mz84OAqpUmoI07iHQ9aaFh3CFy/maj4XQtZ//FBzR/x1OmCOjjNZ53C3wkZQlOXlNEFkQD+nnHKweLgKqV7lTO16yLbE42X3r2MEu6Z5VIxUcFG1c68QHN3/GUKQIa8x2OpCwn3qXjZ4a+B4+AqpX+onKD7IAaD3ltKtCgOpBwTaS8HU+ZbUA5krLENcwcVzv2k9VhD4OAKpZ+PtCWj0baRz0+3MvMR5eHdMwlkvtF5TieEkWJgKqV4YTKq/7+TP26YEeSuSwDyvGUKHIEVK3ivyZShzieEkWOgKqVLKC3XWpPDHfppUr3kGQZUI6nRJErWEAbF8+Zs6SxIA9VIpIFtJ+cYN8lNxd2LJnK9jNQjqdEcStQQFtn11pHHdTNVbKzoxgkC2hf2ck6vKdkAsrxlChuhQlo2zTvwNfp7CrIVLKAHilyznMvvCBy+guJCj6+ZHLeCw8UpcIEdFHs3FUOzstUsoA+ISkVfHzJEFCUl8IEdEIsoJODf7QSkSyJTacQUECPggS0yTd7SoRPQTOUNIltr1xz+umniww5PVGhh5cUAUV5KUhA/VPwR9gTn6E0rylLZycSUNQKEtCt/oAGfKH70kFAAe0K8xno+Fg/rVkejXVfzPpsUdCXvC92aQL6+utTU98ZJgKK8lKYgM6PBXSRYTROtW/VfcEhTeno2C2UHQKK8lKYgLZM8vo5pc1o+kDNbKiqEVBAuwKdidT0sXsJqGbD+Cz2cnRNAR66aBFQQLuCnQvfMPeTT+atN2+01MUCGvYl9VQjoIB2hZ+NqcG3R35cYR+6uBBQQLvCB3SlL6B1hX3o4kJAAe14BaoWAUU5WfPZR1NmfVVsR+YUPqB8BpohAory0eRO2DZpS9gjyU4IM9KzFz4zBBRlo3Wy14TxTWGPJSshBJTjQDNDQFE2fBNezg57LFkJ45pInImUEQKKsvFhLKBjiioL4VxUruGLWZ9yLnwHCCjKRVutb9fy5rBHkw2uyqkWAUW5aPb1M7I+7NFkg4CqRUBRNnyH5hTXjMEEVC0CirIxLdbPD8IeS1YIqFoEFGVjdSygi8MeS1YIqFoEFOVjttfPT4pqJzwB1YuAoowsGm3ls35ecfWTgOpFQFFOWlZ+OX9FcZ2GZBBQxQgooB0BVYuAAtoRULUIKKAdAVWLgALaEVC1CCigHQFVi4AC2hFQtQgooB0BVYuAAtoRULUIKKAdAVWLgALaEVC1CCigHQFVi4AC2hFQtQgooMCWtQ3NKe8koGoRUCB0KyZGIpHaTzamuJuAqkVAgbB5Ez3XrU5+PwFVi4ACIVsWvdJIffJr3RFQtQgoELLxsWs1zUm6AgFVi4AC4drku9ryhKRrEFC1CCgQLt/FQiP1SdcgoGoRUCBca3wBHZ10DQKqFgEFwtXoC+jkpGsQULUIKBCyKbGALky6AgFVi4ACIWuoje5Dak26AgFVi4ACYVte5/Zzc/L7CahaBBQI3ebPxkdqP1zQkuJuAqoWAQU0aEtzHwFVi4AC2hHQ/Es991VWCCigHQHNr9aXju8u/c6py8OmCCigHQHNq42niq3ip+k+N8kMAQW0I6B59V3xPN7pbRFQlKDW1QvmL90S9ijyhoDm07hoP6X3us5ujICi9Hw1zjqqsnZWnnYUhI6A5tNPYgGVP3d2YwQUJWexd2LPxBIpKAHNpzN8Ab2/sxsjoCg1m+uip5Z/FvZY8oOA5tMpvoDe3dmNEVCUmjmxuTnqSuMlKAHNpyt9AX2usxsjoMhRw6cLkk99EbZJvunhUlylrcgQ0Hz6a6yfVYs7uzECipz8/dhKkQE3fBX2OJIY5wvosrAHkxcENJ9aDo0GdHinN0ZAkQtvT+ZOM8IeSXsTfQHVGPjsEdC8+mJX96/3mylmv8oCAUUOno7+N3xI5/8G822WL6ClcSwoAc2v1df1Mv90d3w0D5+QE1Bkr2WH2MdIvwl7MO34rjE0Neyx5AcBzbetH/3n086fx2kQUORivG8/5n+FPZj2oi9BR28Meyj5QUDVIqDI3p98Ad097MG01/q508/xnT5RTwkCqhYBRfZe9QV0j7AHk8yGuVOnzFiq8yirHBBQtQgosjfRF9BTwx5MGSCgahFQZK91cCygfwh7MGWAgKpFQJGDl6P93Lcx7LGUAQKqFgFFLn5e4X4COjfskZQDAqoWAUVOak/rLrLrXaWyn1s3AqoWAUWOGhetCnsI5YKAqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQU0I6AqkVAAe0IqFoEFNCOgKpFQAHtCKhaBBTQjoCqRUAB7QioWgQUiNO4eM6cJY1hjyIOAVWLgAI+rbNrI6a6ua1hj8SHgKpFQIGYtmkR1/S2sMcSQ0DVIqBAzOJI1LKwxxJDQNUioIFZ+89nXpsd9iCQnYmxgE4KeywxBFQtAhqQDdd3F9OwaWEPBFloivjo+RSUgKpFQIPRcIg4evwn7KEgc5v8AdWzJ56AqkVAg3G5eLZvCHssyNhWf0Bbwh5NFAFVi4AGYkVVNKDyZNiDQebGx/o5MeyxxBBQtQhoIF6P9VPOCHswyNz8WEAXhj2WGAKqFgENxBO+gB4a9mCQudZJXj+n6NmHRED1IqCBeNoX0GFhDwZZaPrY6eeM5rBH4kNA1SKggRjnC6j2sSJew9xPPpm3PuxRxCGgahHQQLTuFQvouLAHg2JHQNUioMF4J7ob/tKwh4KiR0DVIqABebXa6eclW8MeCYoeAVWLgAZlyV3H7j700vqwh4ESQEDVIqCAdgRULQLa3tgrD/vaNx9YEeRDAFkgoGoR0ERbL3U+vOz7l+AeA8gGAVWLgCa6xNt93uX94B4EiLNl7bo0R+4TULUIaIKxsQM491V0UQeUshXWPM61n2xKdT8BVYuAJhjuO4dI0Xw8KGGz3dPv61enWIGAqkVAE3zDF9BnAnsUIGppdAKo0SkOGiagahHQBAf7AvpEYI8CRPnmIJ2bfA0CqhYBTXC6L6CvB/YogGejbxL8FB8aEVC1CGiCx2L9rOJQUARvlS+gKU5cI6BqEdAEq7eNBvTywB4EiFrjC+iY5KsQULUIaKJ3urn9PJirwaEAtvgCOiX5KgRULQLazsQjrXx2G65rTl2UrMkdXoeJgKpFQJOY/sLIv60K9BGAqLW1Xj8npLgOEwFVi4ACIVte5/Zzc4oVCKhaBBQI26bPxkVqP1zQkvTOjavW/JqAakVAAQVSzbuw1DrM/scEVCsCCuj1qf3e3gzoI2GPBEkRUECtJREvoDduCXssSIaAAmqNjwb0htlhjwXJEFBAK+80eSugE8IeDJIhoIBWq30BrQt7MEiGgAJarfEFdHTYg0EyBBRQom313Fmzl/mOBm30BTTFafIIFwEFdNgw0ZmRaXls0UexgC4Kb2BIjYACKmwY7Z0SvyS6bF2dF9CfpThNHuEioIAKsUmZ6hujC1fWuwF9MuXPbZkzcfTYacu5hGwoCCigwQbftKBfxhY3zplQN/pnaU7lXF7v/MxHTYUYJRIQUECDxb6AfpJwX5rZmNZE58L7iNegISCggAbz00xMnyagE2M/xSW8QkBAAQ38r0A/TrgvdUD9l/RMfN2KAiCggAbrk38Gaksd0K98P/VB4GNEOwQUUCHpXnhH6oAu9wV0XOBDRDsEFFAh2XGgrtQBXZvmk1MUAAEFdFg/we7g6GXt7kkd0NbRsYDOD3R0SIqAAkq0rZoz4/Olze3vSLMXPrbzfjQHgoaAgALapQlo28duP+vWFHRIcBBQQLt0lzVuWzDG6ue0jYUcEDwEFNAu/XXh29Z9tWpr4QYDPwIKaJc+oAgRAQW0I6BqEVBAOwKqFgEFtCOgahFQQDsCqhYBBbQjoGoRUEA7AqoWAUV5aV2zZGlDkU3eTkDVIqAoJ20L7fN2xi/veFVFCKhaBBRlpG1mUU5dREDVIqAoI0tjk7+tDXssWSCgahFQlBHfJdiK6QpCBFQtAory0eibv70+7MFkgYCqRUBRPvwXboskmbhYKwKqFgFF+djk62dtER3KREDVIqAoH631sYBODHswWSCgahFQlJFPYwFdEPZYskBA1SKgKCONY6MvQFvDHksWCKhaBBTlZOMHTj8nN4Y9kmwQULUIKMpK65KPJ0ycvqKI9iAZBFQxAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRULQIKaEdA1SKggHYEVC0CCmhHQNUioIB2BFQtAgpoR0DVIqCAdgRUrbIJ6Au3N2S6av2I2VlvPrX/uWNdHremwosd/C6n3PBRYQbScPtLKe5pW/hlm9G2YEFb/OKNs9eZ97S637V8sST5T2+ds9L+v8y0zFuaZOmm2Zn8wS2d12J/XT1ni/Wlcc4q68uWaTNbYus0zvmfaECb5y23vy6f2+TdvX72hoSNZW6FuxnvN+UOI2GdVbM3pt7EsnnNWT5oqD4fMTqv2yuXgM4UuTPDVVv7yUnZbj616SJ3529rKpi/yzvSrrCP7FeYkdwuMiv5PSsjkWXG8khkRfziDyPjV0UiXu8WRCLJIzcrUtv8aaS2Kemd7XwRiWxov3RKZGzHP7ohEplvfW2ti3xifZ1pPrD9s5EvYyvNiPynhxfQuZHIZvPLlkhkjnf3hMjE+I1lztyM81phhfObMocxPck69ZHJKTexMRL5IrsHDdc3pX9bx2tlrlwCWidyTYarbhU5KNvNpxYRuTZ/W1OhXuTqtCsMkO0KM5KrRFK8nlgSiSw0FkUii+MXj4vUL41EFrjfmTVK/irz40hkyydOqjLweSSypv3SCZHajn90tVuwpkhkivV1mvnA9s9GfG+CpkYiA7yAfuo0f10kEv0vxxiv1GvifioT6yORmfYN9zdlDqPdewdznUjkg5SbMB/08+weNFxDRfL6ipmAtkNAO0BA4xHQIkJACWjYCGg8AlpECCgBDRsBjUdAiwgBJaBhI6DxCGgRIaAENGwENB4BLSIElICGjYDGI6BFhIAS0LAR0HgEtIgQUAIaNgIaj4AWEQJKQMNGQOMR0CJCQAlo2AhoPAJaRAgoAQ0bAY1HQIsIASWgYSOg8QhoESGgBDRsBDQeAS0iBJSAho2AxiOgRYSAEtCwEdB4BLSIEFACGjYCGo+AFhECSkDDRkDjEdAiQkAJaNgIaDwCWkQIKAENGwGNR0CLCAEloGEjoPEIaBEhoIbxD5HzJmfpGZFzM1z1A5G9s918ajUi38vf1lTo8HfZV/oXZiTniDyb/J53amr+OflfNTX/il/8x5pn3q2pedv97q2amveT/vRrNTXjX6+pGZfZKP5aUxNpv/SFmqc7/tFITc1fra8Tampesb6+aj6w/bPOYoe5sK/c4tweVVNTZ36pr6l507v7uZrn4zeWudE1NW/YN9zflDmMPyVZp6bmfzp8BsViT5GJuf/0zHYxKsaAPi4AUHAHtosRAQWAjJRGQP82ePAR56V3lMjQDlZBHvSULmEPoRwcKnJo2GMoB12kZ/oVftouRsUY0Ay8KPJQ2GMoBztL77CHUA5+K95OJASpWgZn+yMEFJ1AQAuCgBYGAfUQ0MIgoAVBQAuDgHoIaGEQ0IIgoIVBQD0EtDAIaEEQ0MIgoB4CWhgEtCAIaGEQUA8BLQwCWhAEtDAIqGfKrbdGwh5DOXjo1nvCHkI5GHfrrePDHkM5uPvWNpJKkgAADR5JREFUX2T7IyUaUAAIHgEFgBwRUADIEQEFgBwRUADIEQEFgBwRUADIEQEFgBwRUADIUQkHNHLJkX12OfW2r8IeRzmY0FXeD3sMJWviFXv2HHDEL5Jc+RP5lvUfcskGdPnZ7mVM+jwZ9lBK3+pdhYAG5Y5K5w95Z87mDFz2f8ilGtDm40W6nfXTqw4x//JeDnswpa7tDCGgQXlEpOKkm4cPFhkwN+yxlLoc/pBLNaAPiBz0pXXjlUrptSzs0ZS4R4SABmV+N+nxjvl164UiZ4U9mFKXwx9yqQZ0T5Hpzq1rRd4IdyylbnQX6U9AAzJc5BH7xpa9on/SCEYuf8glGtDWShng3vyzyM2hjqXUrdhJvnkjAQ1G2yDptd65+VuR+8IdTInL6Q+5RANq9JWuW5xbI0XuCncspa31ZBm07GYCGoxpIt9yb84T+UaoYylxuf0hl2pAvy/ymH1j04Eio0MeTEn7uVS+bxDQgLwqEp2yelvpH+ZQSl1uf8ilGtCFu0rVdVM3LPvfw0SuDXswpey9SrnXIKBBuU/kj95t8095VZhjKW05/iGXakCNhSe5x4H2eKwt7LGUsCXby3+1EtDA/ETk797tU0Q4kCkouf4hl2xA19/kBnTIu2EPpYQ1Hyc7LDcIaGCuFnnPu322yLQwx1LKcv5DLtWAzhsiss8Nv33ooh4iI8IeTOm6Varsi/cR0IBc5fvFmgGdHOZYSlnOf8ilFNDb3Necqwxj024ij7dYCxcOE3kg7JGVFN+v+e0K93dLQANivoV/27t9qsjnYY6lhOX+h1yiAX1c5Cp36bIBUr061HGVmNivef22ckqrvYyABuRekZe820eIcE5dIDrxh1xKAZ35lmOrYZwpUu8tPl/k/8IcVqmJ/ZoXS7xLwx5a6XnF9/5pe+kd5lBKWCf+kEspoD6Hiyzybt8h8kKYYyldBDRwU0XOdW8uEfl6qGMpXQQ00bdE/u3dPlvknTDHUrrW3eY5SuSC2257M+wBlZ7W7WXbrc7NF0TuDncwJasTf8glGtDHRb7j3pxdLd3XhzqYMsBnoEG5xjuSvs38t/1xyIMpfWX9GajP2iEiIzZYtybvz3+4g0dAg/JFVxnwqXXj5yJnhz2Y0kdAXR92E9n+vNuGH18hckJL2KMpeQQ0MA+L9LnppZEniWz3RdhjKX0E1FN7kPuBcNVwDmIKHAENzu3uJT12nRT2SMoAAY1q/eMPj+g9+OQfMwltARDQAE24dPce2x756Lqwx1EOCCgAFAoBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVAAyBEBBYAcEVCUl2EisjgP6wAGAUWpGJr+ajbRu9PEMZN1AD8CitJAQBECAorSkGlAzxk8ePCy3NcB/AgoSkOmAe3kOoAfAUVpIKAIAQFFcaq//Pidtjng27/caH3zoLgese/b+vzZh23fY88Thk9z1vXf/ZzImR1twrdOy+vn7dFzxxOumlLQJ4diQUBRjD47yevdoNeMxIC+vqP3rZyeOo5pNhEL6JSD3KUVF68I5YlCNwKKIrR6Tytq1QOt/99tkmG8f/PNA0TOu/nmiHnnmG7W4j7bVVhfvt1qxN/txTHdJqIBHdPH3lR36/+f0BLiE4ZSBBRF6Gwzeg8uM4yNNb1FDrQXRT/AbBkkssPT6wyjOXKi2b3RRvzdXhzTbcJbZ9UOIl0f+7Stdfp3zS3dU8AniCJBQFF8VlWKPOvc/JNZttXWjWj9PjKj535i2XigyOPOzcQ4pt2EF9DhIv3qnZUuN1+tNgf7rFCECCiKz0QzeWucm5v2GDJkvHUjWr+RIid5K94icpVzKzGOaTfhrrNmG5EH3C1tNG9PDPI5oSgRUBSfObG35lHR+i2aPHmht/AukSsT7nbjmHYT7jrmS9Pq1d6d3+/X7zd5fRIoBQQUxae1WmSH1+J36iQ7iHPV/ikDmnYT7jrXifx3/gePUkJAUYR+b+0W73/+yCmxjyXjA9o6//3nbj+zp6QMaNpNuOucInJtwE8ERY6Aohg91ts5PLP6e69sdJb4Arr4ziN7RI8ETRXQdJtw1zncOzAfSIGAoigtu2tft5C7/M1eEAvowz3t5ZW7/fevhqcJaJpNuOscKPJkwZ4QihIBRbFa/Or1h1gHy1fY1YvW72Hrrfn1L89sNOzTi1IHNPUm3HVOELmpUE8GxYmAopit+FUf9zB4r36rq0XO2+Te/UAHAU2+CW+dH4icE12tcdWqhuCeB4oUAUXxqX3llQne7VdEqrYYsfr9XaTrZu/OH6QMaLpNeOuMFBkU3dTtIhcF94xQpAgois8IkcO921PMd+CrjFj9nhHZ07uvcfuUAU23CW+deZW+D0H3F3k+uGeEIkVAUXxeFKnwXj/eKjLQ+mrW79/W13rz5aT7Xrv522YZL3Zue3d7cUy3iejbfPPnt3PPCn3SXH9+kM8JRYmAovjM724m72Xrg87pw81G3mwtM+v3a+vruiqR060LGrW+eai1h33gPMN/txfHdJuIBvTzbUR6/OYLw1h+S1d2KCEJAooi9JR9nNLAXeyJ64ZusBadbr7y/MaxzzgTe3Y54Jv79xDp+5B1/+C4u704pttEdEfTn7tY9/bra/3/w7eG9GShGAFFMbprG+9A+W6XOXOCvOTNhtx6WYV71/GzjAutI+Xj7o7GMc0mYnvq/72ru07l1StDeJrQjoCiKK2851tD+/YeeuadS7wlLx7ep9vgl6xbUy4+sn/vfa76P/Nm6wsXXfDLuLtjcUy9Cd+hTlueOXPX7tVfu/yjAj0vFBcCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCgA5IqAAkCMCCkChF8Svh7nkOe+b/gfc8KG32rvRVaqG/Nedawo9SgIKQKE0AbX8v43Oau/Grdb/jQKPkoACUMgM6GU1Uc8adkCvtm7/7s4TqkSOcwpqBvS7ziqPXLOjSPW8DDe/7sFD+/ba/9ZlHSzfK9rm6qSbIaAAFDID+kr8EjOgo9yb0w4SGW7fMgP6uLfCxrNELshs6zN3c7I4oD7t8uYuBBRA8UkbUGPVXlIxxbrhD6ixtEr2yWjjDUNETnvi9+dWSP8v0y2fLXLujY5bkm6IgAJQKH1AjX+KXGl9jQuosYdUNWay8btEfmJ9fVzk0nTLzUf5LO2GCCgAhToIqLGn9G4xEgN6sFS1ZLDtloFyQJt96xTp2pBm+ZPSpSntlggoAIU6CuiNIp8YCQFtq5a9Mtl2vcjPnVvPiLyWZvn1snf6LRFQAAp1FFDz/heNhIA+K/JgJtv+lcgU59ZykZ+lWX6qnGE0fTZ2VcotEVAACpmBvOI5zwfWkviA1jrljAV0/Yw7esqwLZls+yqRTe7N7vLtNMt3l4t/2kNEdrx9c/ItEVAACsUdSH+jtSQ+oJNF7jISDqSv/NH6jLZ9jvTxbu4sR6devrUquuk9ZybdEgEFoFBHAR0ncreRENCe98ftg2+JO0vJd7zSKTLIu3mQDE29/FOzycPfX73k3WEihyTdm0RAASjU0Wegr4v8yvCfifTbEbuIXOj/gTQB3cG7eZjsm3r5+KOP/pP9XdslIr9MNkoCCkChjgL6mMhLRvxOpPVHiszIZNvnSF/v5n5yZMfLDWN1tZyWbEsEFIBCHQX0RyLTjYS98P8S+U0m275SKrz3+gP8YUy13HSsbJ9sSwQUgEIdBXQv6dPuQPqlIndksu3Ho69U17mfr6ZfbrpAqtqSbImAAlCog4C+I3KV9TUuoC0i1/p+oKWLn+8z0FqRR51b7zofBKRY/ofH/+bddaTsmmyUBBSAQukDunrvZJOJNItc4vuBlDuRmreVrzu3LpUua1Ivv0Sq3RM95/eQy5KNkoACUChtQGccInKdfSsxoOdmtPHbREZaXyd0cYrbtHFjY5LlEZFvN1vfrz5Oes1NtiECCkChpAEdbp2W9If7Tunin1DZN5lIHzk4o42v3U0qb3rv/Tt7y4CF1vePu9OLJi7/ocieD4964ZYBbljbIaAAFEoa0BjfJT18AT1IKj7KaOszdnE2s904+1svoInLt57pPlzfmmS7kAgoAJXSBLTv/j/2X1TOF9CfSkfTJ3nW3Xdwn17737bC+S4a0ITlhlH33aHV1fvfuDTFZggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjggoAOSIgAJAjv4/6l81AFlyLpoAAAAASUVORK5CYII=" width="672" /></p>
<pre class="r"><code>set.seed(123)

df &lt;- moa_factor_shift %&gt;%
  filter(factor == &quot;factor2&quot;) %&gt;%
  mutate(fdr_bool = if_else(fdr &lt; 0.05, TRUE, FALSE)) %&gt;%
  filter((term %in% c(&quot;targetMEK&quot;, &quot;targetFAK&quot;)))

# gg_shift &lt;- moa_factor_shift %&gt;% 
#   filter(factor != &quot;factor3&quot;) %&gt;%
#   ggplot(aes(statistic)) + 
#   geom_vline(xintercept = 0) +
#   geom_density(aes(fill = factor), alpha = 0.2) + 
#   geom_rug(aes(color = factor)) + 
#   
#   geom_vline(data = df, aes(xintercept = statistic, color = factor), linetype=&quot;dashed&quot;) + 
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor2&quot;) %&gt;% .$statistic - .5, 
#                 label= df %&gt;% filter(factor == &quot;factor2&quot;) %&gt;% .$term, y=.350), color = &quot;black&quot;) +
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$statistic %&gt;% .[1] + .5, 
#                 label= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$term %&gt;% .[1], y=.350), color = &quot;black&quot;) + 
#   geom_text(aes(x= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$statistic %&gt;% .[2] + .5, 
#               label= df %&gt;% filter(factor == &quot;factor1&quot;) %&gt;% .$term %&gt;% .[2], y=.370), color = &quot;black&quot;) + 
#   theme_cowplot() + 
#   theme(legend.position = &quot;bottom&quot;)

gg_shift &lt;- moa_factor_shift %&gt;% 
  mutate(fdr_bool = if_else(fdr &lt; 0.05, TRUE, FALSE)) %&gt;%
  filter(factor == &quot;factor2&quot;) %&gt;% 
  ggplot(aes(statistic, factor, label = term, color = fdr_bool)) + 
  geom_jitter(width = 0.1) +
  geom_vline(xintercept = 0) +
   ggrepel::geom_text_repel(data = df) + 
  theme_cowplot() + 
  scale_color_manual(values = c(&quot;grey&quot;, &quot;black&quot;)) +
  geom_rug() + 
  theme(legend.position =  &quot;nothing&quot;) + 
  labs(caption = &quot;FDR = 0.05&quot;)

gg_shift + ggsave(here::here(&quot;reports/figures/mofa/f2_moa_shift.pdf&quot;), width = 6, height = 2)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>aurora kinase, PLK, CDK, leads to reduced factor 1 - smaller organoids mTORi leads to increased factor 1 - larger organoids? MEK, FAK leads to increased factor 2 - more cystic organoids</p>
<p>Wnt inhibitors lead to reduced factor 3 -</p>
<pre class="r"><code>doi &lt;- c(&quot;MEK&quot;, &quot;ctrl&quot;)

z_projected_anno_tidy %&gt;% 
  mutate(target = if_else(drug == &quot;DMSO&quot;, &quot;ctrl&quot;, target)) %&gt;%
  left_join(drug_projection_test_result %&gt;% dplyr::rename(target = term)) %&gt;%
  #filter(line %in% c(&quot;D004_r1&quot;, &quot;D004_r2&quot;, &quot;D007_r1&quot;, &quot;D007_r2&quot;, &quot;D019_r1&quot;, &quot;D019_r2&quot;)) %&gt;%
  filter(target %in% doi) %&gt;%
  ggplot(aes(target, V2, label = id)) + 
  geom_jitter(width = 0.1) + 
  ggsignif::geom_signif(comparisons = list(doi)) + 
  theme_cowplot() + 
  labs(y = &quot;factor 2&quot;)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<div id="concentration-dependend-effects" class="section level2">
<h2>concentration dependend effects</h2>
<p>I check wether these shifts in factor scores are a function of drug concentration</p>
<pre class="r"><code>z_projected_conc_anno &lt;- z_projected_concentration %&gt;% 
  mutate(target = substr(id, 9, nchar(id))) %&gt;% 
  separate(target, c(&quot;target&quot;, &quot;concentration&quot;), sep = &quot;_&quot;) %&gt;% 
  mutate(concentration = as.numeric(concentration)) %&gt;%
  mutate(line = substr(id, 1, 7)) %&gt;%
  mutate(target = ifelse(target == &quot;&quot;, &quot;DMSO&quot;, target))

z_projected_conc_anno_tidy &lt;- z_projected_conc_anno %&gt;% 
  dplyr::rename(drug = target) %&gt;%
  left_join(drug_anno)</code></pre>
<div id="mek-inhibitors" class="section level3">
<h3>MEK inhibitors</h3>
<pre class="r"><code>gg_f2_mek_conc &lt;- z_projected_conc_anno_tidy %&gt;% 
  filter(drug %in% c(&quot;DMSO&quot;, &quot;Binimetinib&quot;)) %&gt;%
  mutate(concentration = if_else(drug == &quot;DMSO&quot;, 0.00032, concentration)) %&gt;% #adding a pseudo conc for plotting
  ggplot(aes(concentration, V2)) + 
  geom_jitter(width = 0.1, aes(color = drug)) + 
  scale_x_log10() + 
  geom_smooth(color = &quot;black&quot;) + 
  geom_hline(yintercept = 0) +
  theme_cowplot() + 
  labs(y = &quot;factor 2&quot;) + 
  scale_color_manual(values = c(&quot;black&quot;, &quot;grey&quot;)) + 
  theme(legend.position = &quot;bottom&quot;)

gg_f2_mek_conc + ggsave(here::here(&quot;reports/figures/mofa/f2_mek_shift.pdf&quot;), width = 4, height = 4)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>gg_f1_mek_conc &lt;- z_projected_conc_anno_tidy %&gt;% 
  filter(drug %in% c(&quot;DMSO&quot;, &quot;Binimetinib&quot;)) %&gt;%
  mutate(concentration = if_else(drug == &quot;DMSO&quot;, 0.00032, concentration)) %&gt;% #adding a pseudo conc for plotting
  ggplot(aes(concentration, V1)) + 
  geom_jitter(width = 0.1, aes(color = drug)) + 
  scale_x_log10() + 
  geom_smooth(color = &quot;black&quot;) + 
  geom_hline(yintercept = 0) +
  theme_cowplot() + 
  labs(y = &quot;factor 1&quot;) + 
  scale_color_manual(values = c(&quot;black&quot;, &quot;grey&quot;)) + 
  theme(legend.position = &quot;bottom&quot;)

gg_f1_mek_conc + ggsave(here::here(&quot;reports/figures/mofa/f1_mek_shift.pdf&quot;), width = 4, height = 4)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>gg_f3_mek_conc &lt;- z_projected_conc_anno_tidy %&gt;% 
  filter(drug %in% c(&quot;DMSO&quot;, &quot;Binimetinib&quot;)) %&gt;%
  mutate(concentration = if_else(drug == &quot;DMSO&quot;, 0.00032, concentration)) %&gt;% #adding a pseudo conc for plotting
  ggplot(aes(concentration, V3)) + 
  geom_jitter(width = 0.1, aes(color = drug)) + 
  scale_x_log10() + 
  geom_smooth(color = &quot;black&quot;) + 
  geom_hline(yintercept = 0) +
  theme_cowplot() + 
  labs(y = &quot;factor 3&quot;) + 
  scale_color_manual(values = c(&quot;black&quot;, &quot;grey&quot;))

gg_f3_mek_conc + ggsave(here::here(&quot;reports/figures/mofa/f3_mek_shift.pdf&quot;), width = 4, height = 4)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>doi &lt;- c(&quot;DMSO&quot;, &quot;Binimetinib&quot;)

gg_f2_shift_signif&lt;- z_projected_conc_anno_tidy %&gt;% 
  filter(drug %in% doi) %&gt;%
  filter(concentration == 0.04 | drug == &quot;DMSO&quot;) %&gt;%
  ggplot(aes(drug, V2, label = id)) + 
  geom_jitter(width = 0.1) + 
  ggsignif::geom_signif(comparisons = list(doi)) + 
  theme_cowplot() + 
  labs(caption = &quot;3rd concentration from 5&quot;)

gg_f2_shift_signif + ggsave(here::here(&quot;reports/figures/mofa/f2_mek_shift_test.pdf&quot;), width = 4, height = 4)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>Organoid size does not change as a function of MEKi treatment</p>
<pre class="r"><code>umap_df %&gt;%
  filter(drug %in% c(&quot;DMSO&quot;, &quot;Binimetinib&quot;)) %&gt;%
  mutate(concentration = ifelse(drug == &quot;DMSO&quot;, 0.00032, concentration)) %&gt;% #adding a pseudo conc for plotting
  mutate(concentration = as.numeric(concentration)) %&gt;%
  ggplot(aes(concentration, v2)) + 
  geom_jitter(width = 0.1, aes(color = drug)) + 
  scale_x_log10() + 
  geom_smooth(color = &quot;black&quot;) + 
  geom_hline(yintercept = 0) +
  theme_cowplot() + 
  labs(y = &quot;factor 2&quot;) + 
  scale_color_manual(values = c(&quot;black&quot;, &quot;grey&quot;))</code></pre>
<p>I demonstrate that organoid size does not change with rising MEKi treatments, even when only analyzing alive organoids</p>
<pre class="r"><code>umap_df %&gt;%
  filter(drug == &quot;Binimetinib&quot;) %&gt;%
  filter(prob_live == 1) %&gt;%
  mutate(concentration = as.numeric(concentration)) %&gt;%
  ggplot(aes(concentration, size_log)) + 
  geom_jitter(width = 0.1) + 
  stat_summary(fun.y=mean, colour=&quot;blue&quot;, geom=&quot;line&quot;, size = 1) + # draw a mean line in the data
  scale_x_log10() + 
  labs(title = &quot;Binimetinib, filtering for alive organoids&quot;) +
  #facet_grid(prediction ~ line) + 
  theme_cowplot()</code></pre>
</div>
<div id="mtor-inhibitors" class="section level3">
<h3>mTOR inhibitors</h3>
<pre class="r"><code>doi &lt;- c(&quot;DMSO&quot;, &quot;WYE-125132 (WYE-132)&quot;)

gg_f1_shift_signif&lt;- z_projected_conc_anno_tidy %&gt;% 
  filter(drug %in% doi) %&gt;%
  ggplot(aes(drug, V2, label = id)) + 
  geom_jitter(width = 0.1) + 
  ggsignif::geom_signif(comparisons = list(doi)) + 
  theme_cowplot() 

gg_f1_shift_signif + ggsave(here::here(&quot;reports/figures/mofa/f1_mtor_shift_test.pdf&quot;), width = 4, height = 4)  </code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
</div>
</div>
</div>
<div id="morhphology-drug" class="section level1">
<h1>morhphology: drug</h1>
<pre class="r"><code>drug_projection_test_result_drug &lt;- rbind(
  lm(V1 ~ drug + line, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor1&quot;),
  lm(V2 ~ drug + line, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor2&quot;),
  lm(V3 ~ drug + line, data = z_projected_anno_test) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor3&quot;)) 

drug_projection_test_result_drug &lt;- drug_projection_test_result_drug %&gt;% 
  filter(term != &quot;(Intercept)&quot;) %&gt;% 
  dplyr::select(term, statistic, factor, p.value)</code></pre>
<pre class="r"><code>hist(drug_projection_test_result_drug$p.value)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>moa_factor_shift &lt;- drug_projection_test_result_drug %&gt;% arrange(statistic) %&gt;% 
  mutate(fdr = p.adjust(p.value, method = &quot;BH&quot;)) 

moa_factor_shift_tbl &lt;- moa_factor_shift%&gt;% 
  filter(fdr &lt;= 0.2) %&gt;%
  head(15) %&gt;%
  tableGrob(., theme = ttheme_default(), rows = NULL)

grid.arrange(moa_factor_shift_tbl)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>moa_factor_shift %&gt;%
  filter(!grepl(term, pattern = &quot;D0&quot;)) %&gt;% 
  filter(factor == &quot;factor1&quot;) %&gt;%
  filter(statistic &gt; 0) %&gt;% 
  mutate(drug = substr(term, 5, nchar(.))) %&gt;%
  left_join(drug_anno) %&gt;%
  arrange(desc(statistic))</code></pre>
<pre><code>## # A tibble: 299 x 7
##    term             statistic factor      p.value       fdr drug          target
##    &lt;chr&gt;                &lt;dbl&gt; &lt;chr&gt;         &lt;dbl&gt;     &lt;dbl&gt; &lt;chr&gt;         &lt;chr&gt; 
##  1 drugPP242             5.76 factor1     8.53e-9   3.29e-7 PP242         mTOR  
##  2 drugWH-4-023          4.96 factor1     7.15e-7   2.09e-5 WH-4-023      Src   
##  3 drugWYE-125132       4.90 factor1     9.69e-7   2.70e-5 WYE-125132 ( mTOR  
##  4 drugCC-223            4.64 factor1     3.60e-6   8.79e-5 CC-223        mTOR  
##  5 drugINK 128 (ML      4.15 factor1     3.31e-5   6.09e-4 INK 128 (MLN mTOR  
##  6 drugOSI-027           4.12 factor1     3.86e-5   6.89e-4 OSI-027       mTOR  
##  7 drugSunitinib M      4.07 factor1     4.69e-5   7.50e-4 Sunitinib Ma VEGFR 
##  8 drugGDC-0349          3.95 factor1     7.95e-5   1.11e-3 GDC-0349      mTOR  
##  9 drugPF-04691502       3.92 factor1     8.91e-5   1.20e-3 PF-04691502   mTOR  
## 10 drugWYE-354           3.90 factor1     9.59e-5   1.28e-3 WYE-354       mTOR  
## #  with 289 more rows</code></pre>
<p>when accounting for line differences, mTOR inhibitors (PP242 and WYE-132) are among the strongest inductors of factor 1</p>
<pre class="r"><code>drug_shift_test &lt;- moa_factor_shift %&gt;%
  filter(!grepl(term, pattern = &quot;D0&quot;)) %&gt;% 
  filter(factor == &quot;factor1&quot;) %&gt;%
  mutate(drug = substr(term, 5, nchar(.))) %&gt;%
  left_join(drug_anno)

aggregate_drugs &lt;- drug_shift_test %&gt;% group_by(target) %&gt;% summarise_at(vars(contains(&quot;statistic&quot;)), funs(&quot;median&quot;))

include_drugs &lt;- aggregate_drugs %&gt;% arrange(desc(statistic)) %&gt;% .$target

gg_f1_drug_shift &lt;- drug_shift_test %&gt;%
  drop_na() %&gt;%
  mutate(target = factor(target, levels = include_drugs)) %&gt;%
  ggplot(aes(y = target, x = statistic)) + 
  #geom_point() + 
  geom_vline(xintercept = 0, color = &quot;grey&quot;) + 
  ggridges::geom_density_ridges() +
  
  #coord_flip() + 
  cowplot::theme_cowplot()

gg_f1_drug_shift + ggsave(here::here(&quot;reports/figures/mofa/f1_ridge_drug_shift.pdf&quot;), width = 4, height = 3)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>drug_shift_test &lt;- moa_factor_shift %&gt;%
  filter(!grepl(term, pattern = &quot;D0&quot;)) %&gt;% 
  filter(factor == &quot;factor2&quot;) %&gt;%
  mutate(drug = substr(term, 5, nchar(.))) %&gt;%
  left_join(drug_anno)

aggregate_drugs &lt;- drug_shift_test %&gt;% group_by(target) %&gt;% summarise_at(vars(contains(&quot;statistic&quot;)), funs(&quot;mean&quot;))

include_drugs &lt;- aggregate_drugs %&gt;% arrange(desc(statistic)) %&gt;% .$target

gg_f2_drug_shift &lt;- drug_shift_test %&gt;%
  drop_na() %&gt;%
  mutate(target = factor(target, levels = include_drugs)) %&gt;%
  ggplot(aes(y = target, x = statistic)) + 
  #geom_point() + 
  geom_vline(xintercept = 0, color = &quot;grey&quot;) + 
  ggridges::geom_density_ridges() +
  
  #coord_flip() + 
  cowplot::theme_cowplot()

gg_f2_drug_shift + ggsave(here::here(&quot;reports/figures/mofa/f2_ridge_drug_shift.pdf&quot;), width = 4, height = 3)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>z_projected_anno_test</code></pre>
<pre><code>##                                           drug_id            V1            V2
## 1                        D004_r1_1-Azakenpaullone  -0.924366758  1.0829862986
## 2                         D004_r1_3-Methyladenine   1.474247806  0.4530041510
## 3                                D004_r1_A-674563 -13.055336156  1.7029130236
## 4                                D004_r1_A-769662   4.562524181 -0.2530433753
## 5                                     D004_r1_A66   7.667278263  0.4484828177
## 6                               D004_r1_Acadesine  -4.133007315 -0.1220337938
## 7                     D004_r1_AEE788 (NVP-AEE788)   3.982571664  1.2178252353
## 8           D004_r1_Afatinib (BIBW2992)_uncertain   5.604767887  1.3121311600
## 9                                 D004_r1_AG-1024  13.911581790  2.4213725037
## 10           D004_r1_AG-1478 (Tyrphostin AG-1478)   5.486088006  1.2920590438
## 11                                  D004_r1_AG-18   1.603464079 -0.1852516289
## 12                D004_r1_AG-490 (Tyrphostin B42)   3.295806343  0.4322410528
## 13                               D004_r1_Akti-1/2   7.848219343 -0.3388614455
## 14                    D004_r1_Alisertib (MLN8237)  -8.168905235 -0.0180797039
## 15                                D004_r1_AMG 337  -0.650893201  0.1794538070
## 16                                D004_r1_AMG-458   2.703668918  0.5058738781
## 17                                D004_r1_AMG-900  -5.534254067  2.7477990942
## 18                                 D004_r1_AMG319   2.655162556 -0.2468648519
## 19                    D004_r1_Amuvatinib (MP-470)   7.301728932  2.4663419255
## 20                               D004_r1_Apatinib  -3.677550249  0.4032624889
## 21                             D004_r1_AR-A014418   2.562874610  0.4118428156
## 22                              D004_r1_AS-252424   1.342911439  0.7201974367
## 23                              D004_r1_AS-604850   3.634329282  0.3142104941
## 24                           D004_r1_Asiatic Acid  -1.952390412 -0.5873947797
## 25                               D004_r1_AST-1306  -3.769925545  0.1300554411
## 26                                D004_r1_AT13148   7.038333038  0.3449536404
## 27                                 D004_r1_AT7519  -2.232743680  2.3582496098
## 28                                 D004_r1_AT7867   7.959141945 -1.1123749653
## 29                                 D004_r1_AT9283  -8.934110690  3.0039158311
## 30                   D004_r1_Aurora A Inhibitor I  15.283226480  3.6183135480
## 31               D004_r1_Avagacestat (BMS-708163)  11.733243528  2.3273088954
## 32                                D004_r1_AVL-292   0.427106915  0.9269224716
## 33                               D004_r1_Axitinib  14.427717254  3.2054374398
## 34                               D004_r1_Axitinib  14.427717254  3.2054374398
## 35                                 D004_r1_AZ 628  -0.346430693  1.8328277799
## 36                                 D004_r1_AZ 960   1.238665301  3.2140509263
## 37                                   D004_r1_AZ20  -1.848426206  2.1801167997
## 38                                D004_r1_AZD1080  -7.450384533  1.4417022994
## 39                                D004_r1_AZD1480  -5.066796738  1.6694263116
## 40                                D004_r1_AZD2014  13.717198415 -0.6838454397
## 41                                D004_r1_AZD2858  -5.136035401  2.5014587848
## 42                                D004_r1_AZD2932   2.181758235  0.0361666047
## 43                                D004_r1_AZD3759   1.712909872 -0.3684468865
## 44                                D004_r1_AZD5363   7.640047500 -2.4566037265
## 45                                D004_r1_AZD5438 -10.178382658  1.1585499721
## 46                                D004_r1_AZD6482   3.729324007  0.0360668103
## 47                                D004_r1_AZD6738   3.597241504  2.2359038961
## 48                                D004_r1_AZD8055  14.885813901  0.6043922882
## 49                                D004_r1_AZD8330  -1.529086822  2.9468804095
## 50                    D004_r1_AZD8931 (Sapitinib)   4.728331671  1.8150417204
## 51                                D004_r1_AZD9291   4.780285180  4.1534201388
## 52              D004_r1_Barasertib (AZD1152-HQPA)  -4.594907436  0.0476030079
## 53    D004_r1_Baricitinib (LY3009104, INCB028050)   2.791981219 -0.2858460542
## 54                    D004_r1_BGT226 (NVP-BGT226) -21.944357290  2.0814595964
## 55                                D004_r1_BI 2536 -11.355292715  1.5873781071
## 56                                D004_r1_BI-78D3  -2.743966238 -0.2978247220
## 57                               D004_r1_BI-D1870  -0.871932789  0.5193459384
## 58                                D004_r1_Bikinin   5.296502003  0.3470612037
## 59                                    D004_r1_BIO   8.653781768  3.4017979756
## 60                 D004_r1_BIRB 796 (Doramapimod)  15.994353730  3.6129491791
## 61                              D004_r1_BIX 02188   0.038087567 -0.2924794443
## 62                              D004_r1_BIX 02189   6.079246260 -1.0306086935
## 63        D004_r1_BKM120 (NVP-BKM120, Buparlisib)   0.307958854 -0.1907583109
## 64                             D004_r1_BMS-265246  -5.700113973  1.4867745434
## 65                             D004_r1_BMS-536924  15.412734882  3.7297809414
## 66                             D004_r1_BMS-582949   6.957871475  0.7555503373
## 67                             D004_r1_BMS-754807  -8.785238362  1.1531645603
## 68                             D004_r1_BMS-777607  -1.752016917 -0.2753537662
## 69                             D004_r1_BMS-794833   0.080030178 -1.0118651399
## 70                             D004_r1_BMS-833923   1.721412400 -0.3648039152
## 71                    D004_r1_Bosutinib (SKI-606)  12.035450624  3.5737149262
## 72                  D004_r1_Brivanib (BMS-540215)   5.605643247 -0.0312592800
## 73        D004_r1_Brivanib Alaninate (BMS-582664)   1.510363561 -0.4033805984
## 74                             D004_r1_BS-181 HCl  -1.223847323 -0.6550680910
## 75                                 D004_r1_Butein   3.359911386 -0.0493448226
## 76                                 D004_r1_BYL719   9.611676729  0.0074422150
## 77       D004_r1_Cabozantinib (XL184, BMS-907351)  -3.321524112  0.3307380355
## 78            D004_r1_Cabozantinib malate (XL184)   1.238238262  1.1324022946
## 79          D004_r1_CAL-101 (Idelalisib, GS-1101)  -3.312951549 -0.3325621080
## 80                               D004_r1_CAY10505   4.052871819 -1.3431409549
## 81                                 D004_r1_CC-223   8.937805278 -1.4518858876
## 82                              D004_r1_CCT128930   6.643359401 -0.6452758741
## 83                    D004_r1_Cediranib (AZD2171)  22.734587161  4.9670345322
## 84                              D004_r1_CEP-32496   0.763934095  0.5116336052
## 85                              D004_r1_CEP-33779   1.683064315 -0.0341006756
## 86                                D004_r1_CGI1746   3.870202940  1.0670075029
## 87                                D004_r1_CGK 733   3.002462972  1.1159976189
## 88                              D004_r1_CH5132799  14.016148324  1.1124482497
## 89                             D004_r1_CHIR-98014  -6.414218522  2.5012835929
## 90                   D004_r1_CHIR-99021 (CT99021)   0.621195991  2.2601842176
## 91               D004_r1_CHIR-99021 (CT99021) HCl  -2.523018091  1.8975659630
## 92                      D004_r1_Chrysophanic Acid   1.103746830 -0.6998694908
## 93                               D004_r1_CNX-2006   6.232202015  1.5125817316
## 94                                D004_r1_CNX-774   3.150254026  1.4219092062
## 95                      D004_r1_CO-1686 (AVL-301)   1.846841302 -0.3844989082
## 96         D004_r1_Cobimetinib (GDC-0973, RG7420) -14.136062065  2.2677069817
## 97                              D004_r1_CP-673451   1.380925887  2.7412801058
## 98                              D004_r1_CP-724714   0.997664545  0.9447844224
## 99                 D004_r1_Crenolanib (CP-868596)   0.671001641  3.0720467035
## 100              D004_r1_Crizotinib (PF-02341066)  -2.608349613  0.6945191420
## 101                                D004_r1_CYC116 -10.484949412  1.3504307337
## 102                                D004_r1_CYT387   2.470378428 -0.0826119886
## 103                              D004_r1_CZC24832   2.104038784  0.8672145251
## 104               D004_r1_Dabrafenib (GSK2118436)   4.584921402 -0.1898253375
## 105         D004_r1_Dacomitinib (PF299804, PF299)   2.561587888  0.9288224859
## 106               D004_r1_Danusertib (PHA-739358)  -8.228511614  1.3755684915
## 107                         D004_r1_DAPT (GSI-IX)   6.974206159  1.1141355881
## 108                             D004_r1_Dasatinib   7.171502642  2.3037126258
## 109                 D004_r1_DCC-2036 (Rebastinib)   5.164268958 -1.9445065223
## 110                 D004_r1_Decernotinib (VX-509)   4.118087478  0.6034355131
## 111                D004_r1_Dinaciclib (SCH727965)  -5.448813584  4.0624691938
## 112     D004_r1_Dovitinib (TKI-258) Dilactic Acid   3.423788805  1.6092834543
## 113                             D004_r1_ENMD-2076  -6.869003874  1.3590990066
## 114                D004_r1_Enzastaurin (LY317615)   4.855579067  1.7676962646
## 115                             D004_r1_ERK5-IN-1   4.368694578  0.4976756596
## 116                              D004_r1_ETC-1002   5.338214569  1.4537065519
## 117                             D004_r1_ETP-46464   3.394345900  0.7102673158
## 118                   D004_r1_Everolimus (RAD001)   2.297902621 -1.8735685577
## 119                 D004_r1_Fasudil (HA-1077) HCl   3.818086435  0.9351088469
## 120                                 D004_r1_FH535   3.675543361  0.5136917544
## 121                 D004_r1_Filgotinib (GLPG0634)   7.393327688  1.8056995710
## 122              D004_r1_Flavopiridol (Alvocidib)  -8.286706412  1.6682727547
## 123                      D004_r1_Flavopiridol HCl -11.236379436  1.7135812019
## 124                D004_r1_Foretinib (GSK1363089)   9.793014116  4.7531330211
## 125                   D004_r1_Fostamatinib (R788)   3.610990760 -0.1107817864
## 126                                 D004_r1_G-749   4.291274033  0.8996751614
## 127                              D004_r1_GDC-0068   5.457025208  0.1848028018
## 128                              D004_r1_GDC-0349   8.798227643 -1.6315738940
## 129                              D004_r1_GDC-0879   0.009218761 -1.3025236296
## 130                              D004_r1_GDC-0941   6.917474525  1.2445756032
## 131                     D004_r1_GDC-0980 (RG7422)  10.704682243  0.9403890250
## 132                    D004_r1_Gefitinib (ZD1839)   5.737039345  1.9279835488
## 133                             D004_r1_Genistein  11.542763782  0.9465300106
## 134                             D004_r1_GF109203X  -0.338648249  2.5304818185
## 135                                 D004_r1_GNF-2   1.559425443  1.3051534655
## 136                                 D004_r1_GNF-5   3.820960013  1.6422758028
## 137                               D004_r1_Go 6983  -0.408637963  1.7105007639
## 138                    D004_r1_Golvatinib (E7050)  -6.246745750  2.4348188303
## 139                           D004_r1_GSK1838705A   6.873506989 -0.1480058053
## 140                           D004_r1_GSK1904529A   0.550663766  0.0807391145
## 141                   D004_r1_GSK2126458 (GSK458) -18.959128623  1.9656305995
## 142                            D004_r1_GSK2292767  -0.389625529  0.6975345397
## 143                            D004_r1_GSK2636771   2.537831575  1.0374794149
## 144                            D004_r1_GSK429286A   7.418918270  0.7755011870
## 145                             D004_r1_GSK461364  -6.215552292  2.9400370314
## 146                                D004_r1_GSK621  -0.680266036  0.3014014713
## 147                             D004_r1_GSK690693   4.257160124 -0.0612320025
## 148                                D004_r1_GW5074   1.553501855  0.8159305823
## 149                              D004_r1_GW788388   7.163507581  0.8113347919
## 150                                D004_r1_GZD824   1.378088831  2.5909402041
## 151                             D004_r1_H 89 2HCl   1.481162499 -0.9407309808
## 152                            D004_r1_Hesperadin   3.190955448  0.2862936007
## 153                               D004_r1_HMN-214  -8.659815782  1.6074002402
## 154                              D004_r1_Honokiol  -1.690032082 -0.4539980528
## 155                                D004_r1_HS-173  -8.256868883  2.1908364247
## 156                            D004_r1_HTH-01-015  -3.342209307  1.3654528009
## 157                 D004_r1_Ibrutinib (PCI-32765)   3.130197029  0.8672051094
## 158                               D004_r1_ICG-001   2.725569783  0.6995336503
## 159                              D004_r1_Icotinib   2.501965022  0.1237647075
## 160                                 D004_r1_IM-12   0.972734813  0.6854244169
## 161            D004_r1_Imatinib Mesylate (STI571)   6.308184992  2.6071276282
## 162                             D004_r1_Indirubin   2.801235212  1.0736838382
## 163                     D004_r1_INK 128 (MLN0128)  13.624326068  1.8340047406
## 164                     D004_r1_IPI-145 (INK1197)   1.737828641 -0.4136130834
## 165                                D004_r1_IWP-L6   1.905895352 -0.0149124444
## 166                            D004_r1_IWR-1-endo  11.709904100  2.5858462987
## 167                          D004_r1_JNJ-38877605  -0.801653792 -0.1385534209
## 168                           D004_r1_JNJ-7706621  -6.795484809  3.7700713031
## 169                      D004_r1_JNK Inhibitor IX  -6.213106550  2.7694102156
## 170                              D004_r1_JNK-IN-8   0.269289182  0.4409526546
## 171                                D004_r1_K02288  11.320476330  2.3656977594
## 172                                D004_r1_Ki8751   2.240626066  1.0820682460
## 173                               D004_r1_KRN 633   3.167556485 -0.8361890040
## 174                            D004_r1_KU-0063794   7.886340385 -1.4128520492
## 175       D004_r1_KU-55933 (ATM Kinase Inhibitor)   2.760174083  0.5424135793
## 176                              D004_r1_KU-60019  -8.114312408  0.3494630448
## 177                               D004_r1_KW-2449  -0.829285713  1.9141808101
## 178                               D004_r1_KX2-391  -7.145973574  3.7479847529
## 179                               D004_r1_KY02111  -0.034585642  0.9849355567
## 180                             D004_r1_Lapatinib   4.989482472  0.9908429341
## 181      D004_r1_Lapatinib (GW-572016) Ditosylate   5.502201559  1.8129127752
## 182                             D004_r1_LDC000067  -0.127292782  2.4461614067
## 183       D004_r1_LDE225 (NVP-LDE225,Erismodegib)   6.050342819  0.3437163435
## 184                            D004_r1_LDN-214117   5.063757855 -0.6313465020
## 185                    D004_r1_Lenvatinib (E7080)  18.877293958  1.7638714284
## 186                               D004_r1_LFM-A13   1.717808677 -0.0690600923
## 187                               D004_r1_LGK-974   1.390826777 -0.5383320218
## 188                   D004_r1_Linifanib (ABT-869)  30.223757419  7.4864352508
## 189                                D004_r1_LJH685   5.287426774 -0.9016031828
## 190                                D004_r1_LJI308  14.800145635  1.6822321066
## 191                D004_r1_Losmapimod (GW856553X)   2.060224401  0.5641129605
## 192                             D004_r1_LY2090314 -10.250683439  2.0027556418
## 193                             D004_r1_LY2157299   2.045388212  0.1124437315
## 194                             D004_r1_LY2784544  -3.861153411  1.3288793304
## 195                             D004_r1_LY2835219  -0.913998500  2.5526113354
## 196                              D004_r1_LY294002   0.400856519 -1.2223696965
## 197                             D004_r1_LY3023414  -1.239490011  0.6550673326
## 198                              D004_r1_LY411575   0.969460838  0.9098144393
## 199        D004_r1_MEK162 (ARRY-162, ARRY-438162)  -8.554332220  3.0467632907
## 200                              D004_r1_MGCD-265   5.990494958  1.5717013429
## 201                D004_r1_Milciclib (PHA-848125) -15.872646302  3.3394277452
## 202                               D004_r1_MK-0752   6.631631276  0.6360837382
## 203                          D004_r1_MK-2206 2HCl   9.492373932  0.0043663532
## 204                               D004_r1_MK-2461   2.403241095  0.4069375934
## 205                      D004_r1_MK-5108 (VX-689)  -1.332242285  1.3274616452
## 206                               D004_r1_MK-8745  -2.734891371  2.8467372608
## 207                               D004_r1_MLN2480   3.305129998  0.3494201918
## 208                               D004_r1_MLN8054   3.055604967  1.0375623512
## 209       D004_r1_Motesanib Diphosphate (AMG-706)  26.620207634  4.8147618363
## 210                   D004_r1_Nilotinib (AMN-107)  13.420459289  3.4616042997
## 211      D004_r1_Nintedanib (BIBF 1120)_uncertain   5.259967781  0.4735141565
## 212                                D004_r1_NU6027   1.141669248 -0.4701787972
## 213                            D004_r1_NVP-AEW541   9.055770548  0.9635905223
## 214                            D004_r1_NVP-BHG712  -2.782220346  0.2545979100
## 215                       D004_r1_NVP-BSK805 2HCl   3.236819622  0.7012906576
## 216                            D004_r1_NVP-BVU972   0.143884454  1.5832437531
## 217                           D004_r1_Oclacitinib  -0.108461851 -0.0407514284
## 218       D004_r1_Olmutinib (HM61713, BI 1482694)  -1.073778074  0.2839980176
## 219                              D004_r1_ONO-4059   1.685398256  0.1889277950
## 220                               D004_r1_OSI-027  14.526114776 -0.9622033513
## 221                               D004_r1_OSI-420  -0.080090884  0.7057736491
## 222                  D004_r1_OSI-906 (Linsitinib)   1.334624607 -0.4309397418
## 223                               D004_r1_P276-00 -12.104659613  1.5236157380
## 224                   D004_r1_Pacritinib (SB1518) -16.111472359  1.2189966815
## 225                    D004_r1_Palomid 529 (P529)   1.230477989 -0.0270995423
## 226                             D004_r1_Pazopanib  -0.587419452 -1.0504537565
## 227                         D004_r1_Pazopanib HCl   7.241411674  1.1117865785
## 228                             D004_r1_PD0325901  -6.094903305  1.8605450220
## 229                              D004_r1_PD168393   2.350245357  0.6378232237
## 230                              D004_r1_PD173955   1.971800934  0.1935366985
## 231                    D004_r1_PD184352 (CI-1040)   1.776991583  3.2914951432
## 232                              D004_r1_PD318088  -2.018745889  3.0409007537
## 233                               D004_r1_PD98059  -0.677422046  0.3241424713
## 234                   D004_r1_Pelitinib (EKB-569)   7.628585806  1.8484254897
## 235                           D004_r1_PF-00562271  -5.338395768  2.0309746057
## 236                           D004_r1_PF-04217903   0.709419051 -0.0800347645
## 237                           D004_r1_PF-04691502   6.490263089  4.3498253688
## 238                             D004_r1_PF-431396   1.882496781  3.1808666096
## 239                            D004_r1_PF-4708671  -3.251209224  0.4980951181
## 240                            D004_r1_PF-5274857   1.885861330  0.0843524986
## 241                             D004_r1_PF-562271  -7.929493452  3.8345165195
## 242                             D004_r1_PF-573228  -3.022559400  0.0091109930
## 243                             D004_r1_PH-797804   2.692166084  0.3952118233
## 244                            D004_r1_PHA-665752   1.744801646  0.4626939034
## 245                            D004_r1_PHA-680632   7.476519722  2.4868793213
## 246                            D004_r1_PHA-767491  -7.040555228  1.4747942278
## 247                            D004_r1_PHA-793887   2.168103224  0.4267294574
## 248                        D004_r1_Phenformin HCl   4.375712705 -0.1346302533
## 249                               D004_r1_PHT-427  16.546003935  3.8554012219
## 250                           D004_r1_Piceatannol   8.962708290  5.1771127139
## 251                               D004_r1_PIK-293  -2.786457342 -0.1067864365
## 252                               D004_r1_PIK-294   2.176583378  1.6017001672
## 253                                D004_r1_PIK-93   0.139839678  2.1316297155
## 254                D004_r1_Pimasertib (AS-703026)  -2.504815526  3.6407436341
## 255                           D004_r1_Pirfenidone   1.182367247 -0.1364052183
## 256                              D004_r1_PLX-4720  -0.816055207 -0.1710539079
## 257                               D004_r1_PLX7904   2.730099402 -0.3517023413
## 258                   D004_r1_Ponatinib (AP24534)   7.833021389  2.6735399667
## 259                                   D004_r1_PP1  -1.607812793  0.8130221757
## 260                                   D004_r1_PP2   0.255352482  0.5448456435
## 261                                 D004_r1_PP242  19.915131564 -1.2207425136
## 262                                D004_r1_PQ 401   4.015802473  1.3110580859
## 263                               D004_r1_PRI-724   1.422947847  0.2513615664
## 264      D004_r1_PRT062607 (P505-15, BIIB057) HCl   6.566457402  1.8992103764
## 265                          D004_r1_Purvalanol A   1.967913305  2.6650700987
## 266                             D004_r1_Quercetin   3.769653586  1.2199412470
## 267                   D004_r1_Quizartinib (AC220)  12.312535674  3.2094917801
## 268                                  D004_r1_R406   0.645260491  0.4749909981
## 269                      D004_r1_R406 (free base)   1.389846417  0.7551430439
## 270                                  D004_r1_R547  -6.710429478  3.4823179051
## 271                     D004_r1_RAF265 (CHIR-265)  -4.668538650  0.4049671023
## 272                 D004_r1_Rapamycin (Sirolimus)   7.481082316 -1.2704590868
## 273    D004_r1_Refametinib (RDEA119, Bay 86-9766)  -7.843442643  2.3563483560
## 274                                D004_r1_RepSox  -0.188612653  0.3947432276
## 275  D004_r1_Ridaforolimus (Deforolimus, MK-8669)   4.870642735  0.7300409183
## 276                 D004_r1_Rigosertib (ON-01910)  -3.799700090  2.9320900635
## 277                              D004_r1_RKI-1447   2.166532087  0.7201004723
## 278                                 D004_r1_RN486   3.207075286  0.9771514654
## 279                   D004_r1_Ro 31-8220 Mesylate  -0.766709151  1.5653768462
## 280                               D004_r1_Ro-3306   2.677388050  1.3559830818
## 281                                D004_r1_Ro3280  -9.029423905  2.7799287834
## 282                             D004_r1_RO4929097   3.519856788  0.6267815989
## 283       D004_r1_Roscovitine (Seliciclib,CYC202)  -5.465264589  0.6580044840
## 284              D004_r1_Ruxolitinib (INCB018424)  10.235302629  1.4692955238
## 285            D004_r1_S-Ruxolitinib (INCB018424)   2.827593504  0.4418493120
## 286                                D004_r1_SANT-1   2.715729515  0.3338014106
## 287                             D004_r1_SAR131675   2.383316867  2.0502409610
## 288                     D004_r1_SAR245409 (XL765)   3.306988628  2.1091123468
## 289                 D004_r1_Saracatinib (AZD0530)  15.227593820  2.6040511905
## 290                       D004_r1_SB202190 (FHPI)   1.526895721  0.5818658400
## 291                              D004_r1_SB203580   1.917557823  0.2267417431
## 292                              D004_r1_SB216763   4.041775491  1.5621826700
## 293                              D004_r1_SB239063   1.046787339  0.6460761094
## 294                              D004_r1_SB415286   1.656272919  0.5986206557
## 295                              D004_r1_SB431542   6.577634286  1.6324220919
## 296                              D004_r1_SB505124   5.366302429  0.6457727023
## 297                              D004_r1_SB525334   4.318912860  1.7608671237
## 298                              D004_r1_SB590885   0.297592462 -1.5233390203
## 299                                   D004_r1_SC1  -7.939554912  2.7716071277
## 300                 D004_r1_Schisandrin B (Sch B)   1.124425875  0.0956998039
## 301                 D004_r1_Selumetinib (AZD6244)   2.352049457  4.0012109794
## 302               D004_r1_Semagacestat (LY450139)   8.815909623  1.7033951340
## 303                    D004_r1_Semaxanib (SU5416)   2.389961305  1.6141548671
## 304                              D004_r1_SGI-7079  -4.178630332  4.1234960453
## 305                           D004_r1_Skepinone-L   3.340162542  0.1867847896
## 306                                D004_r1_SL-327  25.188682114  6.7783825773
## 307                  D004_r1_SNS-032 (BMS-387032)  -8.790407701  1.2077129189
## 308                      D004_r1_SNS-314 Mesylate  -7.521912904  0.5552754277
## 309                             D004_r1_Sorafenib   4.051213551  0.6286671970
## 310                    D004_r1_Sorafenib Tosylate   5.626943531  2.2034756852
## 311                          D004_r1_Sotrastaurin  -0.504476284  0.6964888163
## 312                              D004_r1_SP600125   2.906010753  1.6300476279
## 313                               D004_r1_SU11274  25.006279342  3.7647063247
## 314                                D004_r1_SU6656  -4.060240411  0.3865345429
## 315                                D004_r1_SU9516   2.792935012 -0.3474888809
## 316                      D004_r1_Sunitinib Malate  25.005885866  4.4426469566
## 317                   D004_r1_TAE226 (NVP-TAE226)   0.314895408  3.1925256326
## 318                               D004_r1_TAK-285   2.128440022  1.3887422858
## 319                               D004_r1_TAK-632   2.523478821  0.2381431505
## 320                               D004_r1_TAK-715   0.649706824  0.8470889300
## 321                               D004_r1_TAK-733 -11.519969459  2.1362833973
## 322                               D004_r1_TAK-901  -3.938263042  0.8840624742
## 323                 D004_r1_Taladegib (LY2940680)   4.138681962  1.2234869798
## 324                               D004_r1_TCS 359  -1.106561998  0.3001854347
## 325                                D004_r1_TDZD-8   3.762370289  0.4130041077
## 326                             D004_r1_Telatinib   2.967301524  1.7711438269
## 327    D004_r1_Temsirolimus (CCI-779, NSC 683864)  12.838298262  2.8635457825
## 328               D004_r1_Tepotinib (EMD 1214063)  -9.866287719  3.2248683352
## 329                                 D004_r1_TG003   3.771089808 -0.7647124491
## 330                             D004_r1_TG100-115   8.499347285  0.7949959299
## 331                              D004_r1_TG101209 -10.076679424  2.3049996928
## 332                  D004_r1_TG101348 (SAR302503)  -7.587621639  2.9307409629
## 333                               D004_r1_TGX-221  -0.617265868 -0.5372682794
## 334                          D004_r1_Theophylline   4.431992972  0.6783506995
## 335                           D004_r1_Thiazovivin   8.089242215  1.4071746310
## 336                        D004_r1_TIC10 Analogue   0.622055969  0.9489630357
## 337                            D004_r1_Tideglusib   2.065512763  1.3818619240
## 338                  D004_r1_Tivantinib (ARQ 197)  -7.623294387  1.0354986948
## 339                    D004_r1_Tivozanib (AV-951)  -3.901428888 -0.7837053395
## 340   D004_r1_Tofacitinib (CP-690550,Tasocitinib)   1.209725881 -0.0416742551
## 341       D004_r1_Tofacitinib (CP-690550) Citrate   1.526300135  0.2430005927
## 342                               D004_r1_Torin 2 -19.987232411  1.9207087394
## 343               D004_r1_Trametinib (GSK1120212) -15.120481282  2.6849250358
## 344                           D004_r1_Triciribine  -3.639522184  1.8109831642
## 345            D004_r1_TSU-68 (SU6668, Orantinib)   5.589619442  1.4278705165
## 346                                D004_r1_TWS119   6.807938385  1.7132252518
## 347                          D004_r1_Tyrphostin 9  -0.174861054  1.3884888768
## 348                    D004_r1_Tyrphostin AG 1296  -2.515549173 -0.0033459781
## 349                            D004_r1_U0126-EtOH  13.966461908  5.5524395841
## 350      D004_r1_Ulixertinib (BVD-523, VRT752271)  -5.146880114  2.5176911258
## 351               D004_r1_Uprosertib (GSK2141795)   5.247519359  0.6736988845
## 352                           D004_r1_Vacquinol-1   5.034244249  4.3499351830
## 353                            D004_r1_Varlitinib   1.728904103  0.5338900372
## 354               D004_r1_Vatalanib (PTK787) 2HCl  16.774218030  5.3769461628
## 355                                D004_r1_VE-821  18.706400472  3.2808991140
## 356                                D004_r1_VE-822  -4.182012724  1.6123651682
## 357         D004_r1_Vemurafenib (PLX4032, RG7204)   4.045072309  1.4389321608
## 358                 D004_r1_Vismodegib (GDC-0449)   2.195936629  0.7924975694
## 359                  D004_r1_Volasertib (BI 6727)   6.568997687  1.7940595084
## 360                             D004_r1_VPS34-IN1   2.292112010  1.1445246950
## 361                      D004_r1_VS-5584 (SB2343)   8.580340708  2.1915690536
## 362                                D004_r1_VX-11e   5.656688885  3.9299932457
## 363          D004_r1_VX-680 (Tozasertib, MK-0457)  -3.796186295  1.6472116704
## 364                                D004_r1_VX-702   1.937941117 -0.2164156675
## 365                                D004_r1_VX-745   5.113010077  0.9568419972
## 366                               D004_r1_WAY-600   4.844627126 -0.9065569439
## 367                              D004_r1_WH-4-023   7.494561189  1.3567031105
## 368                              D004_r1_WHI-P154   5.888073079  1.1099042697
## 369                                 D004_r1_WIKI4  -0.230344781  0.4895914198
## 370                         D004_r1_Wnt agonist 1  -7.750411478  1.1467437858
## 371                         D004_r1_Wnt-C59 (C59)  -0.549046158 -0.0547120132
## 372                                D004_r1_WP1066   1.152885950  0.3517706421
## 373                  D004_r1_WYE-125132 (WYE-132)  15.364365657  0.0249368082
## 374                               D004_r1_WYE-354  17.180892440 -0.1978375148
## 375                                D004_r1_WZ3146  -0.205939318 -0.0008560839
## 376                                D004_r1_WZ4002  -4.402851191 -0.0435689458
## 377                                D004_r1_WZ4003   3.534512459  0.7142447894
## 378                                D004_r1_WZ8040  18.729399764  2.8435364661
## 379                               D004_r1_XAV-939   4.552317446  1.1494010437
## 380                                 D004_r1_XL019   4.053301184  0.8557357238
## 381                               D004_r1_XMD8-92  -0.330510554  0.4362995446
## 382                          D004_r1_Y-27632 2HCl   8.361569510  0.9637640470
## 383                              D004_r1_YM201636  -6.181283774  0.6607480255
## 384                              D004_r1_YO-01027   3.418057288  0.5065570497
## 385                             D004_r1_ZM 306416   2.465984737 -0.1178977707
## 386                         D004_r1_ZM 323881 HCl   3.958687893 -0.6087032580
## 387                             D004_r1_ZM 336372   0.497478489  0.6563431384
## 388                          D004_r1_ZM 39923 HCl   1.883414211 -0.2965690475
## 389                             D004_r1_ZM 447439  -2.659423592  0.7954824319
## 390                  D004_r1_Zotarolimus(ABT-578)   6.061224054 -0.9922294699
## 391                               D004_r1_ZSTK474   7.393429427 -1.0804873156
## 392                      D004_r2_1-Azakenpaullone   2.024687512  1.3795545094
## 393                       D004_r2_3-Methyladenine  -0.329724708  0.9699969273
## 394                              D004_r2_A-674563 -10.875378047  0.9268372903
## 395                              D004_r2_A-769662   5.644868739 -0.2512062244
## 396                                   D004_r2_A66   5.480256664  0.4717459770
## 397                             D004_r2_Acadesine   3.215354601  1.1698922173
## 398                   D004_r2_AEE788 (NVP-AEE788)   4.729050248  1.2312464404
## 399         D004_r2_Afatinib (BIBW2992)_uncertain   5.064033331  0.5747968070
## 400                               D004_r2_AG-1024   2.204812885 -0.8325230104
## 401          D004_r2_AG-1478 (Tyrphostin AG-1478)   5.638312983  0.3919235892
## 402                                 D004_r2_AG-18   4.042386666  0.0289582820
## 403               D004_r2_AG-490 (Tyrphostin B42)   3.824645805 -0.1504002955
## 404                              D004_r2_Akti-1/2   4.083498800 -0.6033096428
## 405                   D004_r2_Alisertib (MLN8237)  -9.161618520  1.1502228406
## 406                               D004_r2_AMG 337   1.380914511 -0.2961125493
## 407                               D004_r2_AMG-458   0.339653073 -0.1111778391
## 408                               D004_r2_AMG-900  -6.135677832  0.1699045255
## 409                                D004_r2_AMG319   0.204449798 -0.3988249031
## 410                   D004_r2_Amuvatinib (MP-470)  -1.281578184 -0.6028043466
## 411                              D004_r2_Apatinib   3.627266558 -0.3609075265
## 412                            D004_r2_AR-A014418   2.988325528 -0.2103477909
## 413                             D004_r2_AS-252424   2.370139474  0.7971333938
## 414                             D004_r2_AS-604850   4.083003585 -0.7041927080
## 415                          D004_r2_Asiatic Acid   5.616145799  0.6781635099
## 416                              D004_r2_AST-1306   1.762426766  1.1754457208
## 417                               D004_r2_AT13148   1.564267373 -0.1918727087
## 418                                D004_r2_AT7519 -10.137959623  0.7009900787
## 419                                D004_r2_AT7867   2.893026076  1.1792899448
## 420                                D004_r2_AT9283 -12.693556089  0.3382002383
## 421                  D004_r2_Aurora A Inhibitor I  -3.874444507  0.0163861445
## 422              D004_r2_Avagacestat (BMS-708163)   2.181183488 -0.3740606077
## 423                               D004_r2_AVL-292  -0.358932106  0.1442082886
## 424                              D004_r2_Axitinib  -2.162500235  1.1024539603
## 425                              D004_r2_Axitinib  -2.162500235  1.1024539603
## 426                                D004_r2_AZ 628  -0.948038938 -0.1659607800
## 427                                D004_r2_AZ 960  -3.000269837  1.4358852195
## 428                                  D004_r2_AZ20   4.135741044  1.1798603881
## 429                               D004_r2_AZD1080  -5.520823510  1.6686973716
## 430                               D004_r2_AZD1480   0.884830822  1.9164750982
## 431                               D004_r2_AZD2014  10.299293906 -2.0126545449
## 432                               D004_r2_AZD2858  -3.229888022  1.5918738275
## 433                               D004_r2_AZD2932   5.679583614 -0.0078060038
## 434                               D004_r2_AZD3759  -1.373390631 -0.0452405889
## 435                               D004_r2_AZD5363   6.877637435 -1.5931238434
## 436                               D004_r2_AZD5438  -8.828762696 -0.5460676320
## 437                               D004_r2_AZD6482   6.235083739 -0.6382722978
## 438                               D004_r2_AZD6738  -6.617145020  1.5899943256
## 439                               D004_r2_AZD8055   8.445993811  0.0584528110
## 440                               D004_r2_AZD8330 -12.484304545  0.1820371214
## 441                   D004_r2_AZD8931 (Sapitinib)   3.914850152  0.0167212296
## 442                               D004_r2_AZD9291  -1.857448780  2.5549805458
## 443             D004_r2_Barasertib (AZD1152-HQPA)  -4.185258399  1.9456762809
## 444   D004_r2_Baricitinib (LY3009104, INCB028050)   6.139421145  0.4264812770
## 445                   D004_r2_BGT226 (NVP-BGT226)  13.130268160  4.4842895194
## 446                               D004_r2_BI 2536  -5.327634288  3.0335264446
## 447                               D004_r2_BI-78D3   3.129277270  0.3737222900
## 448                              D004_r2_BI-D1870  -2.052084667 -0.5006969025
## 449                               D004_r2_Bikinin  -0.351386033  0.2588369893
## 450                                   D004_r2_BIO   4.119362305  1.4390383789
## 451                D004_r2_BIRB 796 (Doramapimod)   1.457414203 -1.3402542974
## 452                             D004_r2_BIX 02188   3.491250443  0.0827708290
## 453                             D004_r2_BIX 02189   1.543214614  0.6053680253
## 454       D004_r2_BKM120 (NVP-BKM120, Buparlisib)  -7.491819129 -0.4063863829
## 455                            D004_r2_BMS-265246   4.479275417  1.2750842659
## 456                            D004_r2_BMS-536924  11.168206348  2.4241263442
## 457                            D004_r2_BMS-582949   1.131589594  0.0567346313
## 458                            D004_r2_BMS-754807 -10.176841641  1.4818291837
## 459                            D004_r2_BMS-777607  -0.093635871 -0.3617559773
## 460                            D004_r2_BMS-794833   2.502317527 -1.6709773370
## 461                            D004_r2_BMS-833923   5.424179298  0.2016463166
## 462                   D004_r2_Bosutinib (SKI-606)   8.247746116  2.4868408933
## 463                 D004_r2_Brivanib (BMS-540215)   1.956720391 -0.2603476613
## 464       D004_r2_Brivanib Alaninate (BMS-582664)   4.287418151 -0.0774664463
## 465                            D004_r2_BS-181 HCl   4.217242276  0.7375635272
## 466                                D004_r2_Butein   1.762116312  0.5946384623
## 467                                D004_r2_BYL719   8.682754249 -0.1160373482
## 468      D004_r2_Cabozantinib (XL184, BMS-907351)   2.933464488  0.8226614357
## 469           D004_r2_Cabozantinib malate (XL184)   2.874257228 -0.4211881985
## 470         D004_r2_CAL-101 (Idelalisib, GS-1101)   5.687208662  0.4418384604
## 471                              D004_r2_CAY10505   1.726840011  0.3294741159
## 472                                D004_r2_CC-223  15.007985853  0.2124644438
## 473                             D004_r2_CCT128930   5.000114101 -1.2149759594
## 474                   D004_r2_Cediranib (AZD2171)  -3.111007029  0.7753566351
## 475                             D004_r2_CEP-32496   5.101056683  0.7476539541
## 476                             D004_r2_CEP-33779   5.753103643  0.6690081487
## 477                               D004_r2_CGI1746   2.707435131 -0.4467269230
## 478                               D004_r2_CGK 733   6.326806172 -0.4391829377
## 479                             D004_r2_CH5132799  10.338977513  0.5965689374
## 480                            D004_r2_CHIR-98014 -10.454556680 -0.6778926862
## 481                  D004_r2_CHIR-99021 (CT99021)  -4.464229659  0.8523061129
## 482              D004_r2_CHIR-99021 (CT99021) HCl  -1.940309542  1.8128621189
## 483                     D004_r2_Chrysophanic Acid  -0.752989125 -0.7317485830
## 484                              D004_r2_CNX-2006   4.808800796  1.4043074152
## 485                               D004_r2_CNX-774   6.429239091  1.0869861449
## 486                     D004_r2_CO-1686 (AVL-301)   2.364430370 -1.8090720187
## 487        D004_r2_Cobimetinib (GDC-0973, RG7420) -11.216488411 -0.5109022145
## 488                             D004_r2_CP-673451  -1.277664840  1.9684668098
## 489                             D004_r2_CP-724714   1.037650075  0.4888748643
## 490                D004_r2_Crenolanib (CP-868596)   5.257312709  3.6839228821
## 491              D004_r2_Crizotinib (PF-02341066) -10.921941963  1.0537289045
## 492                                D004_r2_CYC116  -6.036892521  1.5324315073
## 493                                D004_r2_CYT387   5.973461243 -0.6567510089
## 494                              D004_r2_CZC24832   4.583425953  1.5943664217
## 495               D004_r2_Dabrafenib (GSK2118436)   0.490972126  0.3243954295
## 496         D004_r2_Dacomitinib (PF299804, PF299)   4.873281478  0.2204333220
## 497               D004_r2_Danusertib (PHA-739358)   2.521657530  2.6526916768
## 498                         D004_r2_DAPT (GSI-IX)   2.721565283 -0.3926104232
## 499                             D004_r2_Dasatinib   3.973717109  1.0979681406
## 500                 D004_r2_DCC-2036 (Rebastinib)  -1.331358157 -1.6918328555
## 501                 D004_r2_Decernotinib (VX-509)   4.116632180  0.0243181092
## 502                D004_r2_Dinaciclib (SCH727965)  -6.451856961  2.0776207576
## 503     D004_r2_Dovitinib (TKI-258) Dilactic Acid   6.656862255  3.3373436257
## 504                             D004_r2_ENMD-2076 -11.983834971  2.1669785989
## 505                D004_r2_Enzastaurin (LY317615)   0.019552379  0.2376551709
## 506                             D004_r2_ERK5-IN-1  -0.023205502  1.8418027927
## 507                              D004_r2_ETC-1002   2.908451930  0.6246492143
## 508                             D004_r2_ETP-46464   9.708488025 -0.4016605598
## 509                   D004_r2_Everolimus (RAD001)   9.511755055 -1.2129277929
## 510                 D004_r2_Fasudil (HA-1077) HCl   3.223550019  1.1024768556
## 511                                 D004_r2_FH535   4.346511982 -0.7824623408
## 512                 D004_r2_Filgotinib (GLPG0634)  -0.927968346  0.8034065306
## 513              D004_r2_Flavopiridol (Alvocidib)  -8.136165383  2.1257957381
## 514                      D004_r2_Flavopiridol HCl  -0.498480604  1.2941496734
## 515                D004_r2_Foretinib (GSK1363089)  -3.559227033 -0.3982157638
## 516                   D004_r2_Fostamatinib (R788)   4.555526595  3.1704258591
## 517                                 D004_r2_G-749   1.028164373 -0.4045641524
## 518                              D004_r2_GDC-0068   6.373819291 -1.8938300594
## 519                              D004_r2_GDC-0349   9.504280101 -2.0139205528
## 520                              D004_r2_GDC-0879   0.674681471  0.4505253259
## 521                              D004_r2_GDC-0941   2.976241159  0.1154531252
## 522                     D004_r2_GDC-0980 (RG7422)  10.163887645  0.1659085519
## 523                    D004_r2_Gefitinib (ZD1839)   8.331958068  2.1317085472
## 524                             D004_r2_Genistein  -2.774724096 -0.6680675237
## 525                             D004_r2_GF109203X   0.125009168  0.8119019845
## 526                                 D004_r2_GNF-2   5.278178478  1.1042868736
## 527                                 D004_r2_GNF-5   4.616802709 -0.1634523152
## 528                               D004_r2_Go 6983   0.448618121  1.2419704964
## 529                    D004_r2_Golvatinib (E7050)  -4.329646864  1.5757434103
## 530                           D004_r2_GSK1838705A  12.181129103  0.2703120508
## 531                           D004_r2_GSK1904529A   5.596583443  0.9869330173
## 532                   D004_r2_GSK2126458 (GSK458) -12.854947955  0.4432175255
## 533                            D004_r2_GSK2292767   5.047227269  1.7892174853
## 534                            D004_r2_GSK2636771   4.002470171 -0.1343413046
## 535                            D004_r2_GSK429286A   5.043655582  0.7730422860
## 536                             D004_r2_GSK461364 -11.293927175  0.5619344753
## 537                                D004_r2_GSK621  -0.452394978  0.2215899735
## 538                             D004_r2_GSK690693   2.212576391 -0.5656609503
## 539                                D004_r2_GW5074   4.214045590  1.9797529384
## 540                              D004_r2_GW788388   1.580058349 -0.6903750320
## 541                                D004_r2_GZD824   5.059449194  2.1677090877
## 542                             D004_r2_H 89 2HCl   1.776984715 -0.0548869066
## 543                            D004_r2_Hesperadin   1.035434915  1.4962062394
## 544                               D004_r2_HMN-214 -10.739861123  0.3774467916
## 545                              D004_r2_Honokiol   1.030502794  0.1132882791
## 546                                D004_r2_HS-173  -2.799252674  0.7796754097
## 547                            D004_r2_HTH-01-015  -4.842190911  1.3537553581
## 548                 D004_r2_Ibrutinib (PCI-32765)   2.061100657 -1.0522302537
## 549                               D004_r2_ICG-001   2.241141520 -0.5443029305
## 550                              D004_r2_Icotinib   2.598806469  0.9414142459
## 551                                 D004_r2_IM-12   2.197879574  0.7065271945
## 552            D004_r2_Imatinib Mesylate (STI571)   1.538971532  1.1531769684
## 553                             D004_r2_Indirubin   5.973166416  1.1338355541
## 554                     D004_r2_INK 128 (MLN0128)   7.721671221 -1.3613150028
## 555                     D004_r2_IPI-145 (INK1197)   0.647445123  1.5867337582
## 556                                D004_r2_IWP-L6   5.497186025  0.4058059028
## 557                            D004_r2_IWR-1-endo   2.539445240 -0.0487400677
## 558                          D004_r2_JNJ-38877605   3.018245270 -0.8106198957
## 559                           D004_r2_JNJ-7706621 -13.955147031  0.2915868959
## 560                      D004_r2_JNK Inhibitor IX  -4.601528992  2.9793030763
## 561                              D004_r2_JNK-IN-8  -0.170198762  1.8457721835
## 562                                D004_r2_K02288   0.737345838 -0.6654070163
## 563                                D004_r2_Ki8751   5.084566661 -0.6164424317
## 564                               D004_r2_KRN 633   0.834864848 -0.1896689036
## 565                            D004_r2_KU-0063794   6.480674779 -0.7447548299
## 566       D004_r2_KU-55933 (ATM Kinase Inhibitor)   4.874364793  1.4081753634
## 567                              D004_r2_KU-60019   0.597544627  1.3963129806
## 568                               D004_r2_KW-2449   1.243820839  2.7926937508
## 569                               D004_r2_KX2-391  -1.091891408  1.3318048133
## 570                               D004_r2_KY02111   1.450157571  0.4801287974
## 571                             D004_r2_Lapatinib  -1.327897157 -0.2066452915
## 572      D004_r2_Lapatinib (GW-572016) Ditosylate   2.269793369  1.5115207653
## 573                             D004_r2_LDC000067  -5.323338818  1.3354295945
## 574       D004_r2_LDE225 (NVP-LDE225,Erismodegib)   3.704922106  0.6589550601
## 575                            D004_r2_LDN-214117   4.951428467 -0.6812720400
## 576                    D004_r2_Lenvatinib (E7080)   2.311258821 -1.6573087384
## 577                               D004_r2_LFM-A13  -1.238417868  0.3266047306
## 578                               D004_r2_LGK-974   4.630582652  0.1064888177
## 579                   D004_r2_Linifanib (ABT-869)   4.140709454  1.5778412020
## 580                                D004_r2_LJH685   1.409867170  1.7708891296
## 581                                D004_r2_LJI308   2.475968412 -1.6317890150
## 582                D004_r2_Losmapimod (GW856553X)   1.437697872  0.5691600454
## 583                             D004_r2_LY2090314  -8.695087480  1.2422251316
## 584                             D004_r2_LY2157299   3.279052415 -0.0509717208
## 585                             D004_r2_LY2784544  -0.231138177  1.7270017348
## 586                             D004_r2_LY2835219  -3.807854184  1.5774609798
## 587                              D004_r2_LY294002   4.476644952  0.7546417844
## 588                             D004_r2_LY3023414 -10.027222291  1.2955978924
## 589                              D004_r2_LY411575   2.783235038  0.8263057082
## 590        D004_r2_MEK162 (ARRY-162, ARRY-438162)  -7.743493666  1.7199298015
## 591                              D004_r2_MGCD-265   0.636893971 -0.3959523489
## 592                D004_r2_Milciclib (PHA-848125)  -6.186061542  2.9359073563
## 593                               D004_r2_MK-0752   0.824281560 -0.7045035236
## 594                          D004_r2_MK-2206 2HCl   1.556797198 -1.3202063145
## 595                               D004_r2_MK-2461   1.093942078 -0.8461694265
## 596                      D004_r2_MK-5108 (VX-689)  -0.349666576  3.6420175100
## 597                               D004_r2_MK-8745  -1.299490038  2.6327896660
## 598                               D004_r2_MLN2480   2.925055438  0.2299852893
## 599                               D004_r2_MLN8054   0.804441545  0.0117707001
## 600       D004_r2_Motesanib Diphosphate (AMG-706)   2.268517865 -1.3416925391
## 601                   D004_r2_Nilotinib (AMN-107)   1.527007321  0.1242915278
## 602      D004_r2_Nintedanib (BIBF 1120)_uncertain   1.000853994  0.3913266925
## 603                                D004_r2_NU6027   1.220609692  0.5107328799
## 604                            D004_r2_NVP-AEW541   6.419270388  0.8460547664
## 605                            D004_r2_NVP-BHG712   2.233654741  0.5788615436
## 606                       D004_r2_NVP-BSK805 2HCl  -0.478767726  0.1224506859
## 607                            D004_r2_NVP-BVU972   0.288560104  0.1511441247
## 608                           D004_r2_Oclacitinib   5.888216776  0.8058810773
## 609       D004_r2_Olmutinib (HM61713, BI 1482694)   5.485044983  0.3794490486
## 610                              D004_r2_ONO-4059   1.189053485  0.0373067327
## 611                               D004_r2_OSI-027  11.756181464 -0.7571135256
## 612                               D004_r2_OSI-420   4.135057056  0.7307320771
## 613                  D004_r2_OSI-906 (Linsitinib)  12.669890548  1.5074248101
## 614                               D004_r2_P276-00  -7.113394176  1.0674068955
## 615                   D004_r2_Pacritinib (SB1518) -12.999749247  0.6017838982
## 616                    D004_r2_Palomid 529 (P529)   1.841779011  0.5547601996
## 617                             D004_r2_Pazopanib   4.186661920 -0.1991594182
## 618                         D004_r2_Pazopanib HCl   2.203860205  0.0306492732
## 619                             D004_r2_PD0325901  -9.270113432  1.0819085046
## 620                              D004_r2_PD168393   1.658813357  0.7825905605
## 621                              D004_r2_PD173955   7.256656816  0.6881377034
## 622                    D004_r2_PD184352 (CI-1040)   1.637936762  1.7061353389
## 623                              D004_r2_PD318088  -3.602502899  1.8019525645
## 624                               D004_r2_PD98059   3.698824819  0.3202031107
## 625                   D004_r2_Pelitinib (EKB-569)   3.417860056  0.2753603035
## 626                           D004_r2_PF-00562271  -6.140745782 -0.8140997893
## 627                           D004_r2_PF-04217903   8.067391077  0.4734002564
## 628                           D004_r2_PF-04691502   7.967693133  0.8382842918
## 629                             D004_r2_PF-431396  -0.766509254  2.5179281886
## 630                            D004_r2_PF-4708671  -4.451556212  0.8107961940
## 631                            D004_r2_PF-5274857   0.622467330 -0.0736553152
## 632                             D004_r2_PF-562271  -2.796717369  1.4723695917
## 633                             D004_r2_PF-573228   2.289890818  1.2935971636
## 634                             D004_r2_PH-797804   2.934761800 -0.7864972354
## 635                            D004_r2_PHA-665752   3.567028960  1.0718097127
## 636                            D004_r2_PHA-680632  -1.766195296  1.4022068550
## 637                            D004_r2_PHA-767491  -7.063581339  0.1966300608
## 638                            D004_r2_PHA-793887   1.631657696  0.7169724336
## 639                        D004_r2_Phenformin HCl   0.055279845  0.4339429390
## 640                               D004_r2_PHT-427   3.118308987 -0.6235656345
## 641                           D004_r2_Piceatannol   1.082623642  0.1849099493
## 642                               D004_r2_PIK-293   1.919033355  0.3440956861
## 643                               D004_r2_PIK-294   4.396010248  0.8906572231
## 644                                D004_r2_PIK-93  -1.726519948  1.6738670515
## 645                D004_r2_Pimasertib (AS-703026) -11.825211095 -0.4626027428
## 646                           D004_r2_Pirfenidone   1.452205360  0.1627789495
## 647                              D004_r2_PLX-4720   1.877029299 -0.1379769937
## 648                               D004_r2_PLX7904  -1.476445208 -0.2495691940
## 649                   D004_r2_Ponatinib (AP24534)   6.513648188  3.2320041272
## 650                                   D004_r2_PP1   3.906446132  0.7749957742
## 651                                   D004_r2_PP2   2.330417286  1.1873028574
## 652                                 D004_r2_PP242  20.311080193 -0.5644448084
## 653                                D004_r2_PQ 401   3.579393404 -0.3655514536
## 654                               D004_r2_PRI-724   4.776400352  1.0532834115
## 655      D004_r2_PRT062607 (P505-15, BIIB057) HCl   2.619538450  2.3479603712
## 656                          D004_r2_Purvalanol A   3.472406029  0.0523641764
## 657                             D004_r2_Quercetin   3.326944344 -0.0377284240
## 658                   D004_r2_Quizartinib (AC220)  -0.467053577 -0.2071679737
## 659                                  D004_r2_R406  -0.365367830  0.5939084512
## 660                      D004_r2_R406 (free base)   3.914918028  0.1167728652
## 661                                  D004_r2_R547 -14.126486398 -1.2991279300
## 662                     D004_r2_RAF265 (CHIR-265)  -9.783826178  0.6208765193
## 663                 D004_r2_Rapamycin (Sirolimus)   8.047267891  0.9852969796
## 664    D004_r2_Refametinib (RDEA119, Bay 86-9766) -11.470267130  0.1180249821
## 665                                D004_r2_RepSox   2.672465890  1.8659892489
## 666  D004_r2_Ridaforolimus (Deforolimus, MK-8669)   8.144411016 -1.4167271857
## 667                 D004_r2_Rigosertib (ON-01910) -12.269995942  0.3252076623
## 668                              D004_r2_RKI-1447   3.658162105  0.3809503403
## 669                                 D004_r2_RN486   0.238076674 -1.2052511533
## 670                   D004_r2_Ro 31-8220 Mesylate  -1.033757777  0.7565195244
## 671                               D004_r2_Ro-3306   1.460078644  0.6947445723
## 672                                D004_r2_Ro3280  -6.273556316  2.6549896884
## 673                             D004_r2_RO4929097   1.627037975  0.3977235859
## 674       D004_r2_Roscovitine (Seliciclib,CYC202)   4.396046946  2.1767152748
## 675              D004_r2_Ruxolitinib (INCB018424)   2.243869585  0.2423589704
## 676            D004_r2_S-Ruxolitinib (INCB018424)   0.859676106  0.3546998529
## 677                                D004_r2_SANT-1   2.868986475 -0.8448737993
## 678                             D004_r2_SAR131675   1.245941364  0.1193067961
## 679                     D004_r2_SAR245409 (XL765)   2.915290463 -0.5376672242
## 680                 D004_r2_Saracatinib (AZD0530)   6.146394435  0.3806040764
## 681                       D004_r2_SB202190 (FHPI)   3.681815925 -0.5546754172
## 682                              D004_r2_SB203580   0.857187411  1.2622478349
## 683                              D004_r2_SB216763   1.910049612  0.5801104280
## 684                              D004_r2_SB239063   0.716760487 -0.0230226461
## 685                              D004_r2_SB415286   2.967157059  1.5574990981
## 686                              D004_r2_SB431542   3.610668270 -0.0604624149
## 687                              D004_r2_SB505124   5.130318792 -0.1185226081
## 688                              D004_r2_SB525334   4.425569940  0.6149035351
## 689                              D004_r2_SB590885   1.955726291  0.3717089581
## 690                                   D004_r2_SC1  -8.967606792  0.0566946902
## 691                 D004_r2_Schisandrin B (Sch B)   1.150615506 -0.4509679649
## 692                 D004_r2_Selumetinib (AZD6244)  -5.187496885  2.5839237718
## 693               D004_r2_Semagacestat (LY450139)   4.234298096 -0.6679518688
## 694                    D004_r2_Semaxanib (SU5416)   6.990972807 -0.3814380697
## 695                              D004_r2_SGI-7079   1.800806374  1.7638299642
## 696                           D004_r2_Skepinone-L   2.944156577 -0.1903468346
## 697                                D004_r2_SL-327  -0.159894073  0.4253313431
## 698                  D004_r2_SNS-032 (BMS-387032) -11.666410403  0.4333111415
## 699                      D004_r2_SNS-314 Mesylate  -4.580941349  1.5366587768
## 700                             D004_r2_Sorafenib   4.983837083 -0.2441593393
## 701                    D004_r2_Sorafenib Tosylate   3.532360980  0.6461925461
## 702                          D004_r2_Sotrastaurin  -0.209438734  1.0611463672
## 703                              D004_r2_SP600125   2.783511051  0.8540694479
## 704                               D004_r2_SU11274   4.542700736 -1.2377586817
## 705                                D004_r2_SU6656  -4.426420121  1.1541447417
## 706                                D004_r2_SU9516   0.785936628  2.2756054501
## 707                      D004_r2_Sunitinib Malate   4.819315568 -1.0775744731
## 708                   D004_r2_TAE226 (NVP-TAE226)  -2.855215559  1.9864158546
## 709                               D004_r2_TAK-285   3.641781977  1.6765885453
## 710                               D004_r2_TAK-632   1.235283939  0.4230886642
## 711                               D004_r2_TAK-715   3.477902359  0.3697988864
## 712                               D004_r2_TAK-733 -13.943224772  0.2669788333
## 713                               D004_r2_TAK-901  -4.207733332  0.2145181139
## 714                 D004_r2_Taladegib (LY2940680)   5.431246423  0.7072523703
## 715                               D004_r2_TCS 359   5.359329163  0.7101311438
## 716                                D004_r2_TDZD-8   4.675284522  0.3418195570
## 717                             D004_r2_Telatinib   2.754540815 -0.7631988152
## 718    D004_r2_Temsirolimus (CCI-779, NSC 683864)   1.779999858 -1.5512025811
## 719               D004_r2_Tepotinib (EMD 1214063)  -6.911127295  2.5604144819
## 720                                 D004_r2_TG003   4.076829643 -1.1166204103
## 721                             D004_r2_TG100-115   3.211486453 -1.0987221675
## 722                              D004_r2_TG101209 -10.516329470  1.1370812963
## 723                  D004_r2_TG101348 (SAR302503) -13.514928804  1.0342892199
## 724                               D004_r2_TGX-221   2.088580682  0.0148094547
## 725                          D004_r2_Theophylline   4.887610237  0.1070671015
## 726                           D004_r2_Thiazovivin   4.382208523  0.1833871719
## 727                        D004_r2_TIC10 Analogue   3.262079136  0.9480837663
## 728                            D004_r2_Tideglusib   3.675371008  0.4467006417
## 729                  D004_r2_Tivantinib (ARQ 197)  -9.121594558  1.0706708635
## 730                    D004_r2_Tivozanib (AV-951)   4.304811287 -1.1607786018
## 731   D004_r2_Tofacitinib (CP-690550,Tasocitinib)   1.863043942  0.5786549900
## 732       D004_r2_Tofacitinib (CP-690550) Citrate   5.130926407  0.8375111889
## 733                               D004_r2_Torin 2 -15.109819794 -0.2285114218
## 734               D004_r2_Trametinib (GSK1120212) -10.932834574 -1.3718879194
## 735                           D004_r2_Triciribine  10.670758001  3.9740558637
## 736            D004_r2_TSU-68 (SU6668, Orantinib)   1.201845015  0.5852704249
## 737                                D004_r2_TWS119   0.636779007  0.0222235181
## 738                          D004_r2_Tyrphostin 9   3.909085081  0.9201314708
## 739                    D004_r2_Tyrphostin AG 1296   2.413599870  0.0672202533
## 740                            D004_r2_U0126-EtOH   2.707212702  1.3442635675
## 741      D004_r2_Ulixertinib (BVD-523, VRT752271)  -1.717737436  1.6089978264
## 742               D004_r2_Uprosertib (GSK2141795)   3.547504809 -0.2877735140
## 743                           D004_r2_Vacquinol-1   6.129098747  4.9450935751
## 744                            D004_r2_Varlitinib   1.066518706  0.0966943068
## 745               D004_r2_Vatalanib (PTK787) 2HCl   0.407745985  0.0297090476
## 746                                D004_r2_VE-821   1.955889831 -0.7586641021
## 747                                D004_r2_VE-822   1.388150677  1.4661667702
## 748         D004_r2_Vemurafenib (PLX4032, RG7204)   2.332566519  0.5301710322
## 749                 D004_r2_Vismodegib (GDC-0449)   4.149263220  0.5091524409
## 750                  D004_r2_Volasertib (BI 6727)   0.926554614  0.1431637114
## 751                             D004_r2_VPS34-IN1   2.722617452  0.3115024416
## 752                      D004_r2_VS-5584 (SB2343)  13.600203068  0.7126831951
## 753                                D004_r2_VX-11e -11.338558549 -1.1675621638
## 754          D004_r2_VX-680 (Tozasertib, MK-0457)  -3.106099962  1.7890786915
## 755                                D004_r2_VX-702   6.222109531  0.1763170599
## 756                                D004_r2_VX-745  -0.612462101 -0.8284596045
## 757                               D004_r2_WAY-600   3.895915668 -1.5246904350
## 758                              D004_r2_WH-4-023   8.936365826 -0.5723270355
## 759                              D004_r2_WHI-P154   1.425224637 -0.0418631001
## 760                                 D004_r2_WIKI4   5.575955043  0.6056881279
## 761                         D004_r2_Wnt agonist 1  -5.250466484  0.6009932569
## 762                         D004_r2_Wnt-C59 (C59)   4.214086225  0.7816349973
## 763                                D004_r2_WP1066   3.293676834  0.4920314661
## 764                  D004_r2_WYE-125132 (WYE-132)  10.263501660  0.0953281429
## 765                               D004_r2_WYE-354  10.488532660 -0.9330086851
## 766                                D004_r2_WZ3146   4.259751521  1.0009407769
## 767                                D004_r2_WZ4002   5.445128909  0.5830912537
## 768                                D004_r2_WZ4003   5.202256421 -0.0950680741
## 769                                D004_r2_WZ8040   1.014446393 -1.0405246755
## 770                               D004_r2_XAV-939   4.491787816  1.9553359523
## 771                                 D004_r2_XL019   6.163977352  1.0034656284
## 772                               D004_r2_XMD8-92   0.786208496  0.8218760714
## 773                          D004_r2_Y-27632 2HCl   2.642640092 -0.6551314239
## 774                              D004_r2_YM201636  -1.038530833  1.6065258254
## 775                              D004_r2_YO-01027   0.971053129 -0.0897683483
## 776                             D004_r2_ZM 306416   5.653261393  1.8377806994
## 777                         D004_r2_ZM 323881 HCl   1.404846172 -0.2734647274
## 778                             D004_r2_ZM 336372   1.567880063  0.2305711346
## 779                          D004_r2_ZM 39923 HCl   2.797609192  0.0700801995
## 780                             D004_r2_ZM 447439  -0.907797985  0.3156789723
## 781                  D004_r2_Zotarolimus(ABT-578)   2.378999541 -0.4093484840
## 782                               D004_r2_ZSTK474   5.492951436  1.2184856335
## 783                      D007_r1_1-Azakenpaullone  -5.320534899 -0.2273252968
## 784                       D007_r1_3-Methyladenine  -0.239470646 -1.1872711952
## 785                              D007_r1_A-674563  -2.970820461  0.9472083008
## 786                              D007_r1_A-769662   6.171948793 -2.3737373718
## 787                                   D007_r1_A66   4.369054642 -2.2513149615
## 788                             D007_r1_Acadesine   9.105469092 -2.2251293257
## 789                   D007_r1_AEE788 (NVP-AEE788)   4.127611816 -1.0146456595
## 790         D007_r1_Afatinib (BIBW2992)_uncertain   3.446052787 -1.0233592742
## 791                               D007_r1_AG-1024  11.747933347 -1.0526422919
## 792          D007_r1_AG-1478 (Tyrphostin AG-1478)   3.230696790 -1.5574184974
## 793                                 D007_r1_AG-18   7.752290603 -1.7416503867
## 794               D007_r1_AG-490 (Tyrphostin B42)   3.755995409 -2.0078835717
## 795                              D007_r1_Akti-1/2   6.822218046 -1.7651977757
## 796                   D007_r1_Alisertib (MLN8237)  -2.601892943 -0.0798452122
## 797                               D007_r1_AMG 337  -8.019814745 -1.4018305923
## 798                               D007_r1_AMG-458   5.577346232 -2.4734847006
## 799                               D007_r1_AMG-900   4.702671792 -1.7204419577
## 800                                D007_r1_AMG319   6.018759685 -2.1441227016
## 801                   D007_r1_Amuvatinib (MP-470)   8.099632245 -2.6300375970
## 802                              D007_r1_Apatinib   5.085973676 -2.9812449313
## 803                            D007_r1_AR-A014418   6.309924967 -1.8732875031
## 804                             D007_r1_AS-252424   7.138955843 -2.8341150810
## 805                             D007_r1_AS-604850   2.816585045 -1.8035139759
## 806                          D007_r1_Asiatic Acid  -5.331307878 -0.9085012298
## 807                              D007_r1_AST-1306   6.354511123 -0.8610649290
## 808                               D007_r1_AT13148   8.767492005 -2.0273513562
## 809                                D007_r1_AT7519  -3.178297317  1.2192716636
## 810                                D007_r1_AT7867  11.115018026 -2.8021548343
## 811                                D007_r1_AT9283 -11.563164525 -0.1197211536
## 812                  D007_r1_Aurora A Inhibitor I   5.611731680 -1.6570930095
## 813              D007_r1_Avagacestat (BMS-708163)   3.436375341 -1.6594358533
## 814                               D007_r1_AVL-292   3.811426652 -1.7149837632
## 815                              D007_r1_Axitinib   5.079015224 -1.0192307439
## 816                              D007_r1_Axitinib   5.079015224 -1.0192307439
## 817                                D007_r1_AZ 628   7.574724650 -3.4240841613
## 818                                D007_r1_AZ 960   3.501738786 -1.3162866918
## 819                                  D007_r1_AZ20  -0.561958273  0.9675552664
## 820                               D007_r1_AZD1080  -3.129857644 -0.2740873933
## 821                               D007_r1_AZD1480   1.090245901 -1.4043944241
## 822                               D007_r1_AZD2014   7.218283906 -0.6805275988
## 823                               D007_r1_AZD2858  -6.850877091 -0.2064662548
## 824                               D007_r1_AZD2932   1.844537896 -0.9204879771
## 825                               D007_r1_AZD3759   3.330442857 -1.5225880455
## 826                               D007_r1_AZD5363   4.901790140 -1.8482585337
## 827                               D007_r1_AZD5438  -5.281223543 -0.1793630734
## 828                               D007_r1_AZD6482   4.961857258 -1.6882586220
## 829                               D007_r1_AZD6738  -7.650432778  1.0309101990
## 830                               D007_r1_AZD8055   7.817759296 -1.0025970045
## 831                               D007_r1_AZD8330   3.437903725 -1.0967446410
## 832                   D007_r1_AZD8931 (Sapitinib)   6.529822045 -2.2671253131
## 833                               D007_r1_AZD9291   4.596275228 -3.0316057466
## 834             D007_r1_Barasertib (AZD1152-HQPA)   6.224434432 -1.8383934577
## 835   D007_r1_Baricitinib (LY3009104, INCB028050)   6.460732016 -1.6353230412
## 836                   D007_r1_BGT226 (NVP-BGT226) -16.344368610 -1.3718038967
## 837                               D007_r1_BI 2536  -7.283114094  2.1371216037
## 838                               D007_r1_BI-78D3   7.994723954 -2.1194062713
## 839                              D007_r1_BI-D1870   2.925758511 -1.9922427210
## 840                               D007_r1_Bikinin   9.671993570 -2.4189506174
## 841                                   D007_r1_BIO   1.455114227 -0.6738999155
## 842                D007_r1_BIRB 796 (Doramapimod)   8.724618437 -2.6155527738
## 843                             D007_r1_BIX 02188   8.408811700 -2.7819749118
## 844                             D007_r1_BIX 02189   7.871673257 -2.3299171562
## 845       D007_r1_BKM120 (NVP-BKM120, Buparlisib)  -6.898809516 -1.0216585313
## 846                            D007_r1_BMS-265246  10.641231717 -2.8062055494
## 847                            D007_r1_BMS-536924   1.373826349 -1.3912787550
## 848                            D007_r1_BMS-582949   0.717758998 -2.5629597156
## 849                            D007_r1_BMS-754807   0.507089794 -0.3105504618
## 850                            D007_r1_BMS-777607  10.055056081 -3.0073812943
## 851                            D007_r1_BMS-794833   8.269217107 -3.0446187025
## 852                            D007_r1_BMS-833923   6.023458809 -1.7503727388
## 853                   D007_r1_Bosutinib (SKI-606)   4.877612087 -1.5535948655
## 854                 D007_r1_Brivanib (BMS-540215)   6.824550704 -1.4287353784
## 855       D007_r1_Brivanib Alaninate (BMS-582664)   9.603456325 -1.7749484868
## 856                            D007_r1_BS-181 HCl   4.238512468 -2.1398021724
## 857                                D007_r1_Butein   5.776218773 -1.9981658071
## 858                                D007_r1_BYL719   4.150938190 -1.8543931005
## 859      D007_r1_Cabozantinib (XL184, BMS-907351)   6.915026271 -2.6650351511
## 860           D007_r1_Cabozantinib malate (XL184)   4.488507028 -1.9356116130
## 861         D007_r1_CAL-101 (Idelalisib, GS-1101)   7.175988132 -2.0281576658
## 862                              D007_r1_CAY10505   5.632313004 -2.6465620493
## 863                                D007_r1_CC-223   6.222645091 -1.1713606051
## 864                             D007_r1_CCT128930   5.283533354 -1.7717231003
## 865                   D007_r1_Cediranib (AZD2171)   6.347497043 -1.1840094232
## 866                             D007_r1_CEP-32496   5.226122637 -2.0061446970
## 867                             D007_r1_CEP-33779   5.448011771 -2.1862484362
## 868                               D007_r1_CGI1746   6.158713110 -2.0244219261
## 869                               D007_r1_CGK 733   5.668435086 -1.1534076607
## 870                             D007_r1_CH5132799   4.255421195 -0.8936845052
## 871                            D007_r1_CHIR-98014  -7.237544355 -0.2994771481
## 872                  D007_r1_CHIR-99021 (CT99021)  -5.803816051  0.0810013603
## 873              D007_r1_CHIR-99021 (CT99021) HCl  -4.260103498 -0.6459095059
## 874                     D007_r1_Chrysophanic Acid   5.535485181 -2.8083031342
## 875                              D007_r1_CNX-2006   6.836683089 -2.7580717330
## 876                               D007_r1_CNX-774   6.071635370 -2.5432514620
## 877                     D007_r1_CO-1686 (AVL-301)   9.882137861 -2.8906191552
## 878        D007_r1_Cobimetinib (GDC-0973, RG7420)   0.688777073 -1.3743212075
## 879                             D007_r1_CP-673451  10.090244511 -2.3951460336
## 880                             D007_r1_CP-724714  -6.882599733 -1.3480088200
## 881                D007_r1_Crenolanib (CP-868596)   7.387159064 -2.2122545558
## 882              D007_r1_Crizotinib (PF-02341066)   6.566001568 -2.2497290735
## 883                                D007_r1_CYC116   0.276789067 -2.3077951762
## 884                                D007_r1_CYT387   6.166436661 -1.6929907045
## 885                              D007_r1_CZC24832   3.510641530 -1.0974299909
## 886               D007_r1_Dabrafenib (GSK2118436)  -6.544061560 -0.6734908507
## 887         D007_r1_Dacomitinib (PF299804, PF299)   2.363168161 -1.5505190726
## 888               D007_r1_Danusertib (PHA-739358)   2.654618041 -1.1595287153
## 889                         D007_r1_DAPT (GSI-IX)   3.987404643 -1.7848734016
## 890                             D007_r1_Dasatinib   6.492460342 -3.0448000828
## 891                 D007_r1_DCC-2036 (Rebastinib)  -3.149672262 -1.1033644975
## 892                 D007_r1_Decernotinib (VX-509)   4.236603761 -2.3954672576
## 893                D007_r1_Dinaciclib (SCH727965)  -0.008524138  1.0193077428
## 894     D007_r1_Dovitinib (TKI-258) Dilactic Acid   3.085368693 -0.3449494079
## 895                             D007_r1_ENMD-2076  -5.032054311 -2.3687674883
## 896                D007_r1_Enzastaurin (LY317615)  -1.188443843 -1.1125077445
## 897                             D007_r1_ERK5-IN-1   2.217093275 -1.1055096985
## 898                              D007_r1_ETC-1002   5.791363749 -0.4707747084
## 899                             D007_r1_ETP-46464   4.123898408 -1.7605723566
## 900                   D007_r1_Everolimus (RAD001)   7.712802565 -2.2162975853
## 901                 D007_r1_Fasudil (HA-1077) HCl   7.348433524 -2.4361981382
## 902                                 D007_r1_FH535  -6.149636173 -2.1416446137
## 903                 D007_r1_Filgotinib (GLPG0634)   4.345063777 -1.6470243473
## 904              D007_r1_Flavopiridol (Alvocidib)   2.499376458 -0.0065817240
## 905                      D007_r1_Flavopiridol HCl  -0.229837822  1.2304920726
## 906                D007_r1_Foretinib (GSK1363089)   2.076387837 -2.0471296455
## 907                   D007_r1_Fostamatinib (R788)   0.797698183 -1.7453736019
## 908                                 D007_r1_G-749   9.235083380 -2.7090577099
## 909                              D007_r1_GDC-0068   4.909865438 -0.3789575083
## 910                              D007_r1_GDC-0349   7.518918985 -2.0459301221
## 911                              D007_r1_GDC-0879   8.404120391 -1.8650524797
## 912                              D007_r1_GDC-0941   5.687770586 -1.7752775834
## 913                     D007_r1_GDC-0980 (RG7422)   8.794529089  0.8419222964
## 914                    D007_r1_Gefitinib (ZD1839)   5.626420860 -1.6315658395
## 915                             D007_r1_Genistein   5.780394450 -1.7977442939
## 916                             D007_r1_GF109203X  -1.618042556 -1.7223014252
## 917                                 D007_r1_GNF-2   6.918929009 -2.1732789561
## 918                                 D007_r1_GNF-5  -0.611465342 -0.6358258799
## 919                               D007_r1_Go 6983   0.072345525 -1.7097647697
## 920                    D007_r1_Golvatinib (E7050)  -2.890610668  0.9416966390
## 921                           D007_r1_GSK1838705A   3.838449546 -1.6019096258
## 922                           D007_r1_GSK1904529A   6.769856585 -1.7171296422
## 923                   D007_r1_GSK2126458 (GSK458)   5.057006612  0.0411921186
## 924                            D007_r1_GSK2292767   2.342650575 -0.2445671655
## 925                            D007_r1_GSK2636771   2.063888871 -1.1463867867
## 926                            D007_r1_GSK429286A   6.818615463 -2.1692384834
## 927                             D007_r1_GSK461364 -11.262859286 -1.1770817514
## 928                                D007_r1_GSK621   8.058526240 -1.6067762528
## 929                             D007_r1_GSK690693   3.517547091 -1.9845364261
## 930                                D007_r1_GW5074   4.051343010 -2.4385407196
## 931                              D007_r1_GW788388   6.219558970 -1.9474827272
## 932                                D007_r1_GZD824  -2.384470669  0.7936006505
## 933                             D007_r1_H 89 2HCl  11.171777370 -3.6315323465
## 934                            D007_r1_Hesperadin   6.679209525 -1.6429111755
## 935                               D007_r1_HMN-214   3.512761599 -0.0799085243
## 936                              D007_r1_Honokiol  -1.940184889 -1.8141526513
## 937                                D007_r1_HS-173  -8.743778466  0.5925751710
## 938                            D007_r1_HTH-01-015   3.307664903 -0.8041545724
## 939                 D007_r1_Ibrutinib (PCI-32765)   4.433802495 -2.0427998214
## 940                               D007_r1_ICG-001   5.832780784 -1.6467652397
## 941                              D007_r1_Icotinib   3.502463403 -1.4371165188
## 942                                 D007_r1_IM-12   8.595468084 -2.2245113775
## 943            D007_r1_Imatinib Mesylate (STI571)   2.971388763 -1.4350093227
## 944                             D007_r1_Indirubin   1.234404016 -0.3036113906
## 945                     D007_r1_INK 128 (MLN0128)   6.876992395 -0.7466103129
## 946                     D007_r1_IPI-145 (INK1197)   3.853053942 -1.4866633046
## 947                                D007_r1_IWP-L6   6.594868025 -2.4823288435
## 948                            D007_r1_IWR-1-endo   5.781442818 -1.1367210940
## 949                          D007_r1_JNJ-38877605   4.631963099 -2.0284693590
## 950                           D007_r1_JNJ-7706621  -7.607759140  3.8011644246
## 951                      D007_r1_JNK Inhibitor IX  -0.141940772 -0.7420451212
## 952                              D007_r1_JNK-IN-8   1.209514336 -1.0112927769
## 953                                D007_r1_K02288   9.010651710 -2.2960939460
## 954                                D007_r1_Ki8751   5.484507741 -1.7184877895
## 955                               D007_r1_KRN 633   5.400202561 -1.8426921183
## 956                            D007_r1_KU-0063794  -0.601671734 -2.1449669664
## 957       D007_r1_KU-55933 (ATM Kinase Inhibitor)   6.905408281 -2.3638677933
## 958                              D007_r1_KU-60019   1.607630123 -0.6057159326
## 959                               D007_r1_KW-2449   1.995835419  0.3752054805
## 960                               D007_r1_KX2-391   4.312062105  0.5246136373
## 961                               D007_r1_KY02111   5.292447889 -2.2183539426
## 962                             D007_r1_Lapatinib   7.940465028 -1.8613036054
## 963      D007_r1_Lapatinib (GW-572016) Ditosylate   5.697442843 -1.6599738197
## 964                             D007_r1_LDC000067  -2.603699886  0.3629149099
## 965       D007_r1_LDE225 (NVP-LDE225,Erismodegib)   5.878141139 -2.4647442260
## 966                            D007_r1_LDN-214117   7.317739625 -2.4494637356
## 967                    D007_r1_Lenvatinib (E7080)   7.078455879 -1.5986634204
## 968                               D007_r1_LFM-A13   5.552449021 -2.1387486327
## 969                               D007_r1_LGK-974  -0.065010539 -2.1862645372
## 970                   D007_r1_Linifanib (ABT-869)   5.423175780 -0.9184253994
## 971                                D007_r1_LJH685   3.436540429 -2.0275773298
## 972                                D007_r1_LJI308   8.640638531 -1.8515908257
## 973                D007_r1_Losmapimod (GW856553X)   3.964867953 -2.2608087829
## 974                             D007_r1_LY2090314  -8.251151752 -0.3280919848
## 975                             D007_r1_LY2157299   6.117871087 -2.1998364095
## 976                             D007_r1_LY2784544  -3.206536421  0.1268474640
## 977                             D007_r1_LY2835219  -7.030755752 -1.0083555504
## 978                              D007_r1_LY294002   7.830104628 -2.6680299462
## 979                             D007_r1_LY3023414   4.875664893 -0.5401627412
## 980                              D007_r1_LY411575   2.167406660 -1.6456571622
## 981        D007_r1_MEK162 (ARRY-162, ARRY-438162)   1.159983220 -0.3915827132
## 982                              D007_r1_MGCD-265   6.523718810 -1.7248112478
## 983                D007_r1_Milciclib (PHA-848125)  -1.464906503 -1.1152328451
## 984                               D007_r1_MK-0752   3.165594983 -1.2243393316
## 985                          D007_r1_MK-2206 2HCl   5.550122966 -1.2463889414
## 986                               D007_r1_MK-2461   8.666825602 -2.3039481108
## 987                      D007_r1_MK-5108 (VX-689)   4.066043932 -2.4215317845
## 988                               D007_r1_MK-8745  -1.296562289 -1.1080038544
## 989                               D007_r1_MLN2480   0.773807060 -1.3693584725
## 990                               D007_r1_MLN8054   5.057444430 -1.0784737519
## 991       D007_r1_Motesanib Diphosphate (AMG-706)   8.444085960 -1.9176205200
## 992                   D007_r1_Nilotinib (AMN-107)   6.047365158 -2.4398357402
## 993      D007_r1_Nintedanib (BIBF 1120)_uncertain   5.344364475 -2.4027700198
## 994                                D007_r1_NU6027   5.021750489 -1.8589913210
## 995                            D007_r1_NVP-AEW541   7.255204141 -2.5490298420
## 996                            D007_r1_NVP-BHG712   1.189894701 -0.9521433566
## 997                       D007_r1_NVP-BSK805 2HCl   5.704993540 -1.5349904328
## 998                            D007_r1_NVP-BVU972   2.988716267 -1.5322568322
## 999                           D007_r1_Oclacitinib   1.857939553 -1.6622634686
## 1000      D007_r1_Olmutinib (HM61713, BI 1482694)   7.737557936 -2.6031743804
## 1001                             D007_r1_ONO-4059   6.517004475 -1.0943675053
## 1002                              D007_r1_OSI-027   4.627534601 -0.6740821700
## 1003                              D007_r1_OSI-420   6.557080515 -1.3440462716
## 1004                 D007_r1_OSI-906 (Linsitinib)   7.896544736 -1.9648363295
## 1005                              D007_r1_P276-00   0.343831957  0.9359760571
## 1006                  D007_r1_Pacritinib (SB1518)  -2.656460750  2.8997457546
## 1007                   D007_r1_Palomid 529 (P529)  -5.632806558 -0.9111434534
## 1008                            D007_r1_Pazopanib   4.483601135 -2.2438343986
## 1009                        D007_r1_Pazopanib HCl   7.879303471 -2.3539561763
## 1010                            D007_r1_PD0325901   4.207092914 -2.5947955627
## 1011                             D007_r1_PD168393   3.522024330 -1.8726802893
## 1012                             D007_r1_PD173955   5.173804343 -2.2955052354
## 1013                   D007_r1_PD184352 (CI-1040)   5.892540172 -1.8382042851
## 1014                             D007_r1_PD318088   5.777365075 -2.8667116388
## 1015                              D007_r1_PD98059   5.186381994 -1.6621322858
## 1016                  D007_r1_Pelitinib (EKB-569)   4.449882296 -0.9653734277
## 1017                          D007_r1_PF-00562271  -5.490528908  3.2610008271
## 1018                          D007_r1_PF-04217903   7.935467574 -2.2010972887
## 1019                          D007_r1_PF-04691502   7.515195297  0.8817457875
## 1020                            D007_r1_PF-431396   0.096485701  0.7139954378
## 1021                           D007_r1_PF-4708671   9.641280291 -1.8382602700
## 1022                           D007_r1_PF-5274857   5.289382677 -2.2249435606
## 1023                            D007_r1_PF-562271  -7.751593472  2.9052915730
## 1024                            D007_r1_PF-573228   4.690559664 -0.6093964464
## 1025                            D007_r1_PH-797804   0.752229975 -1.1164871210
## 1026                           D007_r1_PHA-665752   7.966203419 -1.5402478510
## 1027                           D007_r1_PHA-680632   3.221710034 -0.8895356150
## 1028                           D007_r1_PHA-767491   1.321372112  1.1691384251
## 1029                           D007_r1_PHA-793887   0.945167829 -1.3239274586
## 1030                       D007_r1_Phenformin HCl   7.177527855 -1.0281850205
## 1031                              D007_r1_PHT-427   7.530605140 -1.5942631912
## 1032                          D007_r1_Piceatannol   1.476647903  1.9464025885
## 1033                              D007_r1_PIK-293  10.616313635 -2.7114183878
## 1034                              D007_r1_PIK-294   5.159008386 -1.1508416299
## 1035                               D007_r1_PIK-93   1.617687345 -0.0520863918
## 1036               D007_r1_Pimasertib (AS-703026)   3.296205103 -1.7151627788
## 1037                          D007_r1_Pirfenidone   4.860207145 -2.2490265780
## 1038                             D007_r1_PLX-4720   5.765713716 -2.2154208097
## 1039                              D007_r1_PLX7904   5.225251955 -2.2482104144
## 1040                  D007_r1_Ponatinib (AP24534)   7.584076453 -2.7532914664
## 1041                                  D007_r1_PP1   4.763537629 -1.3371087329
## 1042                                  D007_r1_PP2   2.906042373 -2.3596350664
## 1043                                D007_r1_PP242  -3.433302380 -0.6568042225
## 1044                               D007_r1_PQ 401   5.839969648 -2.1759450999
## 1045                              D007_r1_PRI-724   1.877928548 -2.1421749117
## 1046     D007_r1_PRT062607 (P505-15, BIIB057) HCl   4.980425573 -1.4806325902
## 1047                         D007_r1_Purvalanol A  -0.453009505 -0.3886370152
## 1048                            D007_r1_Quercetin   6.206865808 -1.3672675898
## 1049                  D007_r1_Quizartinib (AC220)   5.522509601 -1.9605660151
## 1050                                 D007_r1_R406  -5.239835261 -1.9478246581
## 1051                     D007_r1_R406 (free base)   7.659610652 -2.4346064049
## 1052                                 D007_r1_R547  -0.307562225  1.4103391239
## 1053                    D007_r1_RAF265 (CHIR-265)   3.160424001 -0.2114229291
## 1054                D007_r1_Rapamycin (Sirolimus)   9.178370852 -2.8750420084
## 1055   D007_r1_Refametinib (RDEA119, Bay 86-9766)   5.304055594 -2.4424277619
## 1056                               D007_r1_RepSox   5.106803240 -2.1352557191
## 1057 D007_r1_Ridaforolimus (Deforolimus, MK-8669)  10.369548734 -3.3663502583
## 1058                D007_r1_Rigosertib (ON-01910)   6.080554776 -0.6284628695
## 1059                             D007_r1_RKI-1447   5.410356121 -2.1598879191
## 1060                                D007_r1_RN486   5.139497491 -1.4311122002
## 1061                  D007_r1_Ro 31-8220 Mesylate  -3.198688901  0.0911745405
## 1062                              D007_r1_Ro-3306   8.666250624 -1.9097441568
## 1063                               D007_r1_Ro3280  -9.582904051  1.2817577558
## 1064                            D007_r1_RO4929097   1.287104245 -1.1684967178
## 1065      D007_r1_Roscovitine (Seliciclib,CYC202)   6.225977867 -2.1276573509
## 1066             D007_r1_Ruxolitinib (INCB018424)   5.529223517 -1.6583245166
## 1067           D007_r1_S-Ruxolitinib (INCB018424)   6.678762036 -1.7481019607
## 1068                               D007_r1_SANT-1   3.036794569 -1.2096798803
## 1069                            D007_r1_SAR131675   6.318558828 -2.7556878848
## 1070                    D007_r1_SAR245409 (XL765)   8.578736510 -1.2819252817
## 1071                D007_r1_Saracatinib (AZD0530)   5.691628950 -3.0562386335
## 1072                      D007_r1_SB202190 (FHPI)   8.494277166 -3.0197746402
## 1073                             D007_r1_SB203580   6.407513604 -1.6795198733
## 1074                             D007_r1_SB216763  -0.517835874 -0.7120425538
## 1075                             D007_r1_SB239063   8.420454680 -2.0149638452
## 1076                             D007_r1_SB415286   5.551279299 -2.3116343380
## 1077                             D007_r1_SB431542   3.838716925 -1.1182204282
## 1078                             D007_r1_SB505124   4.886461686 -2.0503390855
## 1079                             D007_r1_SB525334   4.738941432 -2.3102242148
## 1080                             D007_r1_SB590885   3.208094733 -1.9022165870
## 1081                                  D007_r1_SC1  -4.961172249  0.6883540405
## 1082                D007_r1_Schisandrin B (Sch B)   4.543878350 -1.5371520590
## 1083                D007_r1_Selumetinib (AZD6244)   2.187057662 -1.4038314597
## 1084              D007_r1_Semagacestat (LY450139)   2.593920306 -1.5165966928
## 1085                   D007_r1_Semaxanib (SU5416)   1.310830698  0.2302669132
## 1086                             D007_r1_SGI-7079  -0.344327525  0.2807360403
## 1087                          D007_r1_Skepinone-L   5.095203563 -2.0813915124
## 1088                               D007_r1_SL-327   8.276696008 -2.9786531273
## 1089                 D007_r1_SNS-032 (BMS-387032)   3.244223108 -1.2788629184
## 1090                     D007_r1_SNS-314 Mesylate   3.919958160 -1.4367870198
## 1091                            D007_r1_Sorafenib   3.031836573 -2.5793102675
## 1092                   D007_r1_Sorafenib Tosylate   6.081483900 -2.3332785312
## 1093                         D007_r1_Sotrastaurin   2.103581345 -1.9571527257
## 1094                             D007_r1_SP600125   7.223254448 -2.1100955779
## 1095                              D007_r1_SU11274   6.430838215 -1.7554600246
## 1096                               D007_r1_SU6656   4.646502808 -1.4099207874
## 1097                               D007_r1_SU9516  -3.271613346 -0.7310396749
## 1098                     D007_r1_Sunitinib Malate   7.588553210 -1.5414077407
## 1099                  D007_r1_TAE226 (NVP-TAE226)   1.543454915 -1.0704928270
## 1100                              D007_r1_TAK-285   2.226308192 -0.7389839801
## 1101                              D007_r1_TAK-632   2.002776967 -1.3848538178
## 1102                              D007_r1_TAK-715   6.310905685 -2.7804626117
## 1103                              D007_r1_TAK-733   1.523038187 -0.6595848598
## 1104                              D007_r1_TAK-901   1.149888207 -0.6221452324
## 1105                D007_r1_Taladegib (LY2940680)   5.099551365 -1.9410628938
## 1106                              D007_r1_TCS 359   6.486754864 -3.0365456442
## 1107                               D007_r1_TDZD-8   3.189559512 -1.7297756929
## 1108                            D007_r1_Telatinib   7.945734998 -2.0650210933
## 1109   D007_r1_Temsirolimus (CCI-779, NSC 683864)   8.654908762 -2.2768220223
## 1110              D007_r1_Tepotinib (EMD 1214063)  -1.522698179  1.3147651208
## 1111                                D007_r1_TG003   6.612438328 -1.1773289858
## 1112                            D007_r1_TG100-115   5.416442952 -2.1479539526
## 1113                             D007_r1_TG101209   2.396266238 -0.9355653117
## 1114                 D007_r1_TG101348 (SAR302503)   4.620397693 -0.9134104094
## 1115                              D007_r1_TGX-221  -1.188928401 -1.6766673915
## 1116                         D007_r1_Theophylline   6.937428004 -2.0529668675
## 1117                          D007_r1_Thiazovivin   6.966803659 -3.2396375132
## 1118                       D007_r1_TIC10 Analogue   4.725019109 -1.8482773986
## 1119                           D007_r1_Tideglusib   4.162775120 -1.7680515889
## 1120                 D007_r1_Tivantinib (ARQ 197)  -1.653489926 -0.0350703519
## 1121                   D007_r1_Tivozanib (AV-951)  -3.987447276 -1.6472357092
## 1122  D007_r1_Tofacitinib (CP-690550,Tasocitinib)   5.939048603 -1.9466395779
## 1123      D007_r1_Tofacitinib (CP-690550) Citrate   6.223376582 -2.7155068946
## 1124                              D007_r1_Torin 2  -2.344100675  2.6474978156
## 1125              D007_r1_Trametinib (GSK1120212)   1.364227845  0.1856074417
## 1126                          D007_r1_Triciribine  -6.961028305  0.8233144235
## 1127           D007_r1_TSU-68 (SU6668, Orantinib)   7.427402414 -1.9438481082
## 1128                               D007_r1_TWS119   2.757328594 -1.4015815490
## 1129                         D007_r1_Tyrphostin 9  -1.336634192 -1.8522278132
## 1130                   D007_r1_Tyrphostin AG 1296   6.281942252 -1.4437361718
## 1131                           D007_r1_U0126-EtOH   6.249385595 -1.3011106765
## 1132     D007_r1_Ulixertinib (BVD-523, VRT752271)  -0.911719816 -0.6932752330
## 1133              D007_r1_Uprosertib (GSK2141795)   4.539315964 -2.0055626021
## 1134                          D007_r1_Vacquinol-1   3.424544922 -1.3526530982
## 1135                           D007_r1_Varlitinib   3.848355310 -1.6369647824
## 1136              D007_r1_Vatalanib (PTK787) 2HCl   7.994132493 -1.8377749864
## 1137                               D007_r1_VE-821   9.767729921 -2.9816565598
## 1138                               D007_r1_VE-822  -7.878452621  1.3248904186
## 1139        D007_r1_Vemurafenib (PLX4032, RG7204)   7.498082104 -1.4207165951
## 1140                D007_r1_Vismodegib (GDC-0449)   2.382249509 -0.2180720826
## 1141                 D007_r1_Volasertib (BI 6727)  -1.085981690 -1.1183821863
## 1142                            D007_r1_VPS34-IN1  -8.570942669 -0.8933827762
## 1143                     D007_r1_VS-5584 (SB2343)   6.454868557  0.6858604884
## 1144                               D007_r1_VX-11e   4.184705082 -1.4787611616
## 1145         D007_r1_VX-680 (Tozasertib, MK-0457)   5.784389913 -2.8496700409
## 1146                               D007_r1_VX-702   4.594262437 -1.5109121835
## 1147                               D007_r1_VX-745   9.420970066 -2.2546232333
## 1148                              D007_r1_WAY-600   2.601925434 -0.7026756038
## 1149                             D007_r1_WH-4-023   9.346421889 -1.9584563939
## 1150                             D007_r1_WHI-P154   4.318211399 -1.6949330628
## 1151                                D007_r1_WIKI4   0.608473480 -1.0070781764
## 1152                        D007_r1_Wnt agonist 1  -5.200729346 -0.1946960424
## 1153                        D007_r1_Wnt-C59 (C59)   6.458763728 -2.0273367282
## 1154                               D007_r1_WP1066   2.561255104 -1.4850910173
## 1155                 D007_r1_WYE-125132 (WYE-132)   7.046367414 -1.8245931995
## 1156                              D007_r1_WYE-354   5.501360091 -1.7115810809
## 1157                               D007_r1_WZ3146   5.998376214 -3.2607651235
## 1158                               D007_r1_WZ4002   6.116803091 -1.8888462013
## 1159                               D007_r1_WZ4003   3.376494040 -1.8133434129
## 1160                               D007_r1_WZ8040   8.911715500 -2.0323161630
## 1161                              D007_r1_XAV-939   3.594302743 -1.0011318095
## 1162                                D007_r1_XL019   7.370238553 -1.6621747899
## 1163                              D007_r1_XMD8-92   4.018600674 -2.1344878584
## 1164                         D007_r1_Y-27632 2HCl   5.548970725 -1.9985367798
## 1165                             D007_r1_YM201636  -5.500498305 -1.4564360189
## 1166                             D007_r1_YO-01027   3.699654941 -1.6753292361
## 1167                            D007_r1_ZM 306416   2.119483940 -0.3867141071
## 1168                        D007_r1_ZM 323881 HCl   1.598361406 -1.0108995289
## 1169                            D007_r1_ZM 336372   5.920610513 -2.0772062768
## 1170                         D007_r1_ZM 39923 HCl   3.916590780 -1.6704376004
## 1171                            D007_r1_ZM 447439   6.066382746 -1.9558512323
## 1172                 D007_r1_Zotarolimus(ABT-578)   7.489013336 -3.2907468142
## 1173                              D007_r1_ZSTK474   4.481015021 -1.9820463509
## 1174                     D007_r2_1-Azakenpaullone  -1.874177766 -2.0579303037
## 1175                      D007_r2_3-Methyladenine   8.899927448 -3.3322444285
## 1176                             D007_r2_A-674563   1.001316575 -0.8302049530
## 1177                             D007_r2_A-769662   6.805956718 -2.4373797795
## 1178                                  D007_r2_A66   7.890433604 -3.0930236445
## 1179                            D007_r2_Acadesine   6.615928433 -1.9417904957
## 1180                  D007_r2_AEE788 (NVP-AEE788)   2.628717103 -0.7451551609
## 1181        D007_r2_Afatinib (BIBW2992)_uncertain   3.856040984 -1.7497772179
## 1182                              D007_r2_AG-1024  14.928345567 -3.2614438108
## 1183         D007_r2_AG-1478 (Tyrphostin AG-1478)   4.735138743 -1.0771752128
## 1184                                D007_r2_AG-18   7.740523064 -1.9638858917
## 1185              D007_r2_AG-490 (Tyrphostin B42)   5.969995344 -1.8433312832
## 1186                             D007_r2_Akti-1/2   6.543658566 -2.1237781503
## 1187                  D007_r2_Alisertib (MLN8237)   1.729118137 -1.9763025577
## 1188                              D007_r2_AMG 337   6.633647096 -1.4200073502
## 1189                              D007_r2_AMG-458   6.636892916 -2.1440246893
## 1190                              D007_r2_AMG-900   7.610227741 -1.9622948702
## 1191                               D007_r2_AMG319   6.737876704 -3.0085801933
## 1192                  D007_r2_Amuvatinib (MP-470)   5.929784755 -3.0518460217
## 1193                             D007_r2_Apatinib   7.200860580 -2.4602801358
## 1194                           D007_r2_AR-A014418   9.531821561 -2.9071461401
## 1195                            D007_r2_AS-252424   7.621759263 -3.2158785501
## 1196                            D007_r2_AS-604850   7.834931347 -2.9330459467
## 1197                         D007_r2_Asiatic Acid   6.586878816 -2.5271846420
## 1198                             D007_r2_AST-1306   3.205971976 -2.0828512876
## 1199                              D007_r2_AT13148   6.604158098 -3.0443275007
## 1200                               D007_r2_AT7519  -1.671988562 -1.7432089297
## 1201                               D007_r2_AT7867  10.628405081 -2.2019715766
## 1202                               D007_r2_AT9283 -11.727046100 -0.4191393011
## 1203                 D007_r2_Aurora A Inhibitor I   7.380878766 -2.7940551361
## 1204             D007_r2_Avagacestat (BMS-708163)   5.001175768 -2.0806318695
## 1205                              D007_r2_AVL-292   3.842691885 -1.8421415024
## 1206                             D007_r2_Axitinib   7.156686103 -2.1485788531
## 1207                             D007_r2_Axitinib   7.156686103 -2.1485788531
## 1208                               D007_r2_AZ 628   7.675539488 -2.5277725689
## 1209                               D007_r2_AZ 960   3.901739932 -1.6202825172
## 1210                                 D007_r2_AZ20  -0.786740194  0.8934912652
## 1211                              D007_r2_AZD1080  -2.419895171 -0.4848408484
## 1212                              D007_r2_AZD1480   1.085451141 -1.4313193445
## 1213                              D007_r2_AZD2014   7.255192241 -1.7118892472
## 1214                              D007_r2_AZD2858  -6.546754964 -1.0256236963
## 1215                              D007_r2_AZD2932   5.979988196 -1.7226442345
## 1216                              D007_r2_AZD3759   5.185160127 -2.6569856682
## 1217                              D007_r2_AZD5363   3.955601729 -1.3307236459
## 1218                              D007_r2_AZD5438   1.102777130 -0.4154622135
## 1219                              D007_r2_AZD6482   0.805619138 -2.6189125576
## 1220                              D007_r2_AZD6738  -6.499909996 -0.6269417906
## 1221                              D007_r2_AZD8055   4.568912711 -2.4686368284
## 1222                              D007_r2_AZD8330   4.643072868 -2.3060338903
## 1223                  D007_r2_AZD8931 (Sapitinib)   1.346876025 -3.2715793864
## 1224                              D007_r2_AZD9291   8.828298170 -1.4810297453
## 1225            D007_r2_Barasertib (AZD1152-HQPA)   6.289691325 -2.2755019985
## 1226  D007_r2_Baricitinib (LY3009104, INCB028050)   8.798066060 -2.9856386799
## 1227                  D007_r2_BGT226 (NVP-BGT226) -11.915008529 -0.9537038623
## 1228                              D007_r2_BI 2536 -11.336166096 -2.6592258243
## 1229                              D007_r2_BI-78D3   6.117485438 -1.1852109261
## 1230                             D007_r2_BI-D1870   7.091763687 -2.5229777453
## 1231                              D007_r2_Bikinin   8.357956099 -3.4738888145
## 1232                                  D007_r2_BIO   5.464446621 -1.4911168876
## 1233               D007_r2_BIRB 796 (Doramapimod)   7.318635594 -3.2510425444
## 1234                            D007_r2_BIX 02188   5.569141814 -2.4415628517
## 1235                            D007_r2_BIX 02189   5.865143463 -2.0775501564
## 1236      D007_r2_BKM120 (NVP-BKM120, Buparlisib)   5.159312436  0.5028090644
## 1237                           D007_r2_BMS-265246  12.483909825 -3.6889236215
## 1238                           D007_r2_BMS-536924   2.190995444 -0.2842721979
## 1239                           D007_r2_BMS-582949   8.008842542 -2.5728188180
## 1240                           D007_r2_BMS-754807   2.740335542 -0.5304315581
## 1241                           D007_r2_BMS-777607   8.500356717 -3.3380798117
## 1242                           D007_r2_BMS-794833   5.628660888 -1.6890954827
## 1243                           D007_r2_BMS-833923   7.139754147 -2.2847033475
## 1244                  D007_r2_Bosutinib (SKI-606)   6.025882918 -1.4596556096
## 1245                D007_r2_Brivanib (BMS-540215)  11.193388476 -3.4094216414
## 1246      D007_r2_Brivanib Alaninate (BMS-582664)   7.303138862 -2.1522552612
## 1247                           D007_r2_BS-181 HCl   6.231791828 -2.6195134228
## 1248                               D007_r2_Butein   7.559959517 -3.2339875842
## 1249                               D007_r2_BYL719   7.647002793 -3.4446128883
## 1250     D007_r2_Cabozantinib (XL184, BMS-907351)   7.957627849 -2.6351914116
## 1251          D007_r2_Cabozantinib malate (XL184)   6.512800046 -2.1628637897
## 1252        D007_r2_CAL-101 (Idelalisib, GS-1101)   6.909526942 -2.3704777765
## 1253                             D007_r2_CAY10505   5.316154785 -1.6075224568
## 1254                               D007_r2_CC-223   8.953545903 -1.4233234139
## 1255                            D007_r2_CCT128930   6.349746008 -2.5303760166
## 1256                  D007_r2_Cediranib (AZD2171)   4.414067197 -2.0082638838
## 1257                            D007_r2_CEP-32496   6.880282301 -2.9032103448
## 1258                            D007_r2_CEP-33779   8.788147169 -2.7333897459
## 1259                              D007_r2_CGI1746   8.558725267 -2.2830327407
## 1260                              D007_r2_CGK 733   8.756778028 -2.5134401391
## 1261                            D007_r2_CH5132799   5.960180255 -3.6982598135
## 1262                           D007_r2_CHIR-98014  -5.549900227 -1.0434557254
## 1263                 D007_r2_CHIR-99021 (CT99021)  -3.236637456 -1.4744295978
## 1264             D007_r2_CHIR-99021 (CT99021) HCl  -3.426575762 -1.0911615048
## 1265                    D007_r2_Chrysophanic Acid   4.190253165 -1.5046164724
## 1266                             D007_r2_CNX-2006   2.669736816 -1.8827540065
## 1267                              D007_r2_CNX-774   8.832776242 -2.7299701509
## 1268                    D007_r2_CO-1686 (AVL-301)  10.457709936 -2.1085191866
## 1269       D007_r2_Cobimetinib (GDC-0973, RG7420)   4.307972995 -0.2338880901
## 1270                            D007_r2_CP-673451   5.200211230  0.4989236631
## 1271                            D007_r2_CP-724714   7.135055314 -1.1510110524
## 1272               D007_r2_Crenolanib (CP-868596)   8.262415111 -0.7649357427
## 1273             D007_r2_Crizotinib (PF-02341066)   5.302908577 -1.8760856350
## 1274                               D007_r2_CYC116   1.284263728 -1.8898860856
## 1275                               D007_r2_CYT387   9.126580559 -2.4889342032
## 1276                             D007_r2_CZC24832   6.995155602 -2.1545997822
## 1277              D007_r2_Dabrafenib (GSK2118436)   4.848775988 -2.0514269420
## 1278        D007_r2_Dacomitinib (PF299804, PF299)   7.366597195 -3.0472079626
## 1279              D007_r2_Danusertib (PHA-739358)   2.296481899 -0.8140603855
## 1280                        D007_r2_DAPT (GSI-IX)   5.333858505 -2.2566830870
## 1281                            D007_r2_Dasatinib   5.127583035 -2.1164087627
## 1282                D007_r2_DCC-2036 (Rebastinib)   2.051289279 -1.1719251230
## 1283                D007_r2_Decernotinib (VX-509)   8.347879512 -2.6139653824
## 1284               D007_r2_Dinaciclib (SCH727965)   2.392609482 -1.2492680238
## 1285    D007_r2_Dovitinib (TKI-258) Dilactic Acid   1.899685259 -0.4925535468
## 1286                            D007_r2_ENMD-2076   0.131123164 -1.6152085977
## 1287               D007_r2_Enzastaurin (LY317615)  -4.653629897 -2.3664342557
## 1288                            D007_r2_ERK5-IN-1   4.965810551 -1.5709047269
## 1289                             D007_r2_ETC-1002   5.200262130 -2.9855321166
## 1290                            D007_r2_ETP-46464   5.679445608 -2.9557740386
## 1291                  D007_r2_Everolimus (RAD001)   5.760066784 -3.3133429531
## 1292                D007_r2_Fasudil (HA-1077) HCl   7.397058884 -3.1495928763
## 1293                                D007_r2_FH535   9.660233660 -2.2329833364
## 1294                D007_r2_Filgotinib (GLPG0634)   7.671820599 -2.3984108849
## 1295             D007_r2_Flavopiridol (Alvocidib)   0.851367943 -1.1035010945
## 1296                     D007_r2_Flavopiridol HCl   2.852231954 -3.0871476742
## 1297               D007_r2_Foretinib (GSK1363089)   6.769253466 -2.0410966258
## 1298                  D007_r2_Fostamatinib (R788)   5.170574975  0.0334045396
## 1299                                D007_r2_G-749   6.528107562 -2.7769078781
## 1300                             D007_r2_GDC-0068   6.380210415 -1.1640512995
## 1301                             D007_r2_GDC-0349   9.805641077 -2.8524153563
## 1302                             D007_r2_GDC-0879   6.617357678 -2.3401034914
## 1303                             D007_r2_GDC-0941   4.837763321 -3.2571942590
## 1304                    D007_r2_GDC-0980 (RG7422)  12.886625333 -1.4402570286
## 1305                   D007_r2_Gefitinib (ZD1839)   4.757109544 -2.4729794697
## 1306                            D007_r2_Genistein   9.597888999 -2.2171268286
## 1307                            D007_r2_GF109203X  -2.897409775 -1.8835796815
## 1308                                D007_r2_GNF-2   9.233944679 -2.7305924569
## 1309                                D007_r2_GNF-5   6.277646721 -2.0797592680
## 1310                              D007_r2_Go 6983  -0.668730954 -1.3490040496
## 1311                   D007_r2_Golvatinib (E7050)   4.820802254 -0.2456282403
## 1312                          D007_r2_GSK1838705A   5.922608004 -1.9190086500
## 1313                          D007_r2_GSK1904529A   7.425887479 -2.0815178620
## 1314                  D007_r2_GSK2126458 (GSK458)  17.334690519  0.9425553414
## 1315                           D007_r2_GSK2292767   3.441584572 -2.1641007195
## 1316                           D007_r2_GSK2636771   6.755572114 -3.1351128056
## 1317                           D007_r2_GSK429286A  10.515659170 -2.8334924239
## 1318                            D007_r2_GSK461364 -12.468845561 -2.2778125858
## 1319                               D007_r2_GSK621   8.575097469 -3.0492884336
## 1320                            D007_r2_GSK690693   6.588393565 -1.6086727275
## 1321                               D007_r2_GW5074   7.782318890 -2.8348295221
## 1322                             D007_r2_GW788388   7.381912491 -2.0839540217
## 1323                               D007_r2_GZD824  10.422608790 -0.6323682356
## 1324                            D007_r2_H 89 2HCl   7.283357931 -0.9809123906
## 1325                           D007_r2_Hesperadin   1.597642490 -1.6525771387
## 1326                              D007_r2_HMN-214   0.922408645  0.0481782621
## 1327                             D007_r2_Honokiol   6.984593328 -2.7880632264
## 1328                               D007_r2_HS-173  -9.941841380  0.4429193135
## 1329                           D007_r2_HTH-01-015   3.158282290 -2.2155811441
## 1330                D007_r2_Ibrutinib (PCI-32765)   3.953693358 -1.8002188047
## 1331                              D007_r2_ICG-001   7.002093246 -2.0539274457
## 1332                             D007_r2_Icotinib   6.796862322 -1.5657163789
## 1333                                D007_r2_IM-12   5.809367468 -2.9477140468
## 1334           D007_r2_Imatinib Mesylate (STI571)   5.301762762 -2.5099125638
## 1335                            D007_r2_Indirubin   2.627250063 -1.2007071919
## 1336                    D007_r2_INK 128 (MLN0128)  13.162354811 -1.6122313140
## 1337                    D007_r2_IPI-145 (INK1197)   4.498778863 -2.7771575150
## 1338                               D007_r2_IWP-L6   8.145469134 -3.5176244081
## 1339                           D007_r2_IWR-1-endo   9.584465995 -0.3604243854
## 1340                         D007_r2_JNJ-38877605  10.146618549 -1.9813274096
## 1341                          D007_r2_JNJ-7706621  -4.572335928  1.3873534434
## 1342                     D007_r2_JNK Inhibitor IX   0.319703518 -0.3480648805
## 1343                             D007_r2_JNK-IN-8   5.415674911 -2.2627833155
## 1344                               D007_r2_K02288   7.944283302 -2.4154981870
## 1345                               D007_r2_Ki8751   6.489080710 -2.1309170669
## 1346                              D007_r2_KRN 633   7.014213477 -1.6357463669
## 1347                           D007_r2_KU-0063794   6.197294274 -2.4890059266
## 1348      D007_r2_KU-55933 (ATM Kinase Inhibitor)   3.425497350 -1.7163967251
## 1349                             D007_r2_KU-60019   3.919802405 -1.6548535000
## 1350                              D007_r2_KW-2449   7.340800197  0.2512909696
## 1351                              D007_r2_KX2-391   0.631675806  0.4137057966
## 1352                              D007_r2_KY02111  10.315323504 -2.3731113085
## 1353                            D007_r2_Lapatinib   4.703863163 -2.7105401288
## 1354     D007_r2_Lapatinib (GW-572016) Ditosylate   5.424185349 -1.9091939839
## 1355                            D007_r2_LDC000067  -0.632564542 -0.5956586215
## 1356      D007_r2_LDE225 (NVP-LDE225,Erismodegib)   9.358987751 -2.7914705422
## 1357                           D007_r2_LDN-214117   4.842450189 -3.8251193703
## 1358                   D007_r2_Lenvatinib (E7080)   6.230563832 -1.9587919392
## 1359                              D007_r2_LFM-A13   6.888811642 -3.0767331896
## 1360                              D007_r2_LGK-974   8.293655821 -2.7722399240
## 1361                  D007_r2_Linifanib (ABT-869)  10.023389070 -2.2593890205
## 1362                               D007_r2_LJH685   2.944617996 -2.9356273025
## 1363                               D007_r2_LJI308   6.994276484 -2.6637909547
## 1364               D007_r2_Losmapimod (GW856553X)   7.481867967 -2.9719590301
## 1365                            D007_r2_LY2090314  -4.270719494 -0.4041388356
## 1366                            D007_r2_LY2157299   5.385113735 -2.1740316923
## 1367                            D007_r2_LY2784544   1.114402786 -1.3111822091
## 1368                            D007_r2_LY2835219  -1.950443108 -0.8912884686
## 1369                             D007_r2_LY294002   5.770775212 -2.0718431852
## 1370                            D007_r2_LY3023414   4.656941748 -0.1588761604
## 1371                             D007_r2_LY411575   4.065617445 -0.9982778918
## 1372       D007_r2_MEK162 (ARRY-162, ARRY-438162)   6.245057641 -1.9287811249
## 1373                             D007_r2_MGCD-265   6.465278430 -3.6368918163
## 1374               D007_r2_Milciclib (PHA-848125)   0.120599870 -0.4351349714
## 1375                              D007_r2_MK-0752   5.847064361 -2.0486186555
## 1376                         D007_r2_MK-2206 2HCl   4.793470599 -3.2715967488
## 1377                              D007_r2_MK-2461   8.121164276 -2.4696894856
## 1378                     D007_r2_MK-5108 (VX-689)   8.434842380 -2.4094816231
## 1379                              D007_r2_MK-8745   1.872700631 -1.9208860727
## 1380                              D007_r2_MLN2480   4.893644914 -2.2165713169
## 1381                              D007_r2_MLN8054   6.251375084 -2.8417239775
## 1382      D007_r2_Motesanib Diphosphate (AMG-706)   6.370820848 -2.4951066237
## 1383                  D007_r2_Nilotinib (AMN-107)   9.885593072 -2.7003077982
## 1384     D007_r2_Nintedanib (BIBF 1120)_uncertain   2.895185151 -1.7064512717
## 1385                               D007_r2_NU6027   8.564731886 -1.5424134048
## 1386                           D007_r2_NVP-AEW541   5.348056306 -2.3242013263
## 1387                           D007_r2_NVP-BHG712   6.439156105 -1.2064647927
## 1388                      D007_r2_NVP-BSK805 2HCl   6.020360074 -2.6992714312
## 1389                           D007_r2_NVP-BVU972   9.472597947 -2.8922957940
## 1390                          D007_r2_Oclacitinib   9.582105866 -1.9960094571
## 1391      D007_r2_Olmutinib (HM61713, BI 1482694)   4.798708162 -0.8702669052
## 1392                             D007_r2_ONO-4059   3.887972109 -2.2187311011
## 1393                              D007_r2_OSI-027   4.957173532 -0.3244023117
## 1394                              D007_r2_OSI-420   5.497868984 -2.8750821129
## 1395                 D007_r2_OSI-906 (Linsitinib)  10.533417132 -2.6835775676
## 1396                              D007_r2_P276-00   1.908695377 -2.2612209995
## 1397                  D007_r2_Pacritinib (SB1518)   0.088922291  1.2590573766
## 1398                   D007_r2_Palomid 529 (P529)   9.547733769 -1.6430031493
## 1399                            D007_r2_Pazopanib   6.389971707 -2.3517426059
## 1400                        D007_r2_Pazopanib HCl   8.213482165 -2.0901503826
## 1401                            D007_r2_PD0325901   6.988229583 -2.3605151001
## 1402                             D007_r2_PD168393   7.730204477 -2.9278593993
## 1403                             D007_r2_PD173955   8.283291586 -2.8692024189
## 1404                   D007_r2_PD184352 (CI-1040)   4.048232869 -1.7960707350
## 1405                             D007_r2_PD318088   5.684789566 -2.0646031529
## 1406                              D007_r2_PD98059   2.916164480 -2.2008629977
## 1407                  D007_r2_Pelitinib (EKB-569)  -0.199276514 -3.1867351716
## 1408                          D007_r2_PF-00562271  -0.420141920 -0.0679029083
## 1409                          D007_r2_PF-04217903   4.568790105 -2.4120882094
## 1410                          D007_r2_PF-04691502   8.142770271 -1.5382737731
## 1411                            D007_r2_PF-431396   4.763162072  0.6337561368
## 1412                           D007_r2_PF-4708671  10.306841854 -1.6789682234
## 1413                           D007_r2_PF-5274857   5.565122266 -2.5196052244
## 1414                            D007_r2_PF-562271  -1.757616086 -0.1234730593
## 1415                            D007_r2_PF-573228   6.176790450 -1.8135190347
## 1416                            D007_r2_PH-797804   9.778184270 -4.5851319883
## 1417                           D007_r2_PHA-665752   6.956162979 -1.2199259322
## 1418                           D007_r2_PHA-680632   5.375711627 -1.5859343240
## 1419                           D007_r2_PHA-767491   2.326063159 -0.9940350139
## 1420                           D007_r2_PHA-793887  -1.613718637 -2.8685067201
## 1421                       D007_r2_Phenformin HCl  10.032101712 -3.3896234042
## 1422                              D007_r2_PHT-427   6.441426935 -2.1526725779
## 1423                          D007_r2_Piceatannol   6.289172756 -1.5364707573
## 1424                              D007_r2_PIK-293   6.349442746 -2.2223463175
## 1425                              D007_r2_PIK-294   4.906573799 -1.8772614550
## 1426                               D007_r2_PIK-93  -1.247635495 -1.1553899088
## 1427               D007_r2_Pimasertib (AS-703026)   3.848734562 -0.8540381250
## 1428                          D007_r2_Pirfenidone   6.040997873 -2.5535054698
## 1429                             D007_r2_PLX-4720   7.080611981 -2.4593759574
## 1430                              D007_r2_PLX7904   6.891282570 -2.6910252706
## 1431                  D007_r2_Ponatinib (AP24534)   8.311587369 -4.1799409952
## 1432                                  D007_r2_PP1   7.687008065 -2.2960799004
## 1433                                  D007_r2_PP2   9.111317924 -1.9308007438
## 1434                                D007_r2_PP242   8.892522200  1.7312739845
## 1435                               D007_r2_PQ 401   8.335916905 -2.6694278747
## 1436                              D007_r2_PRI-724   7.055332381 -2.0968824842
## 1437     D007_r2_PRT062607 (P505-15, BIIB057) HCl   4.677969177 -2.4078272497
## 1438                         D007_r2_Purvalanol A   8.007968098 -2.1093374558
## 1439                            D007_r2_Quercetin   5.588451845 -2.5311174142
## 1440                  D007_r2_Quizartinib (AC220)   6.376278161 -1.9277079860
## 1441                                 D007_r2_R406   7.606584967 -2.2932799728
## 1442                     D007_r2_R406 (free base)   5.978684243 -3.1299960231
## 1443                                 D007_r2_R547   3.931233370 -1.5285392620
## 1444                    D007_r2_RAF265 (CHIR-265)   9.547035753 -1.4870290792
## 1445                D007_r2_Rapamycin (Sirolimus)   5.714781209 -3.1239428565
## 1446   D007_r2_Refametinib (RDEA119, Bay 86-9766)   6.831806124 -1.2652335848
## 1447                               D007_r2_RepSox   8.144194049 -2.2412836910
## 1448 D007_r2_Ridaforolimus (Deforolimus, MK-8669)   9.658106119 -3.2254484699
## 1449                D007_r2_Rigosertib (ON-01910)  -7.023201917  0.1226204836
## 1450                             D007_r2_RKI-1447   8.315977531 -2.3893305650
## 1451                                D007_r2_RN486   6.388427632 -3.1613155877
## 1452                  D007_r2_Ro 31-8220 Mesylate  -0.744271362  0.3240497100
## 1453                              D007_r2_Ro-3306   6.944813813 -3.6089753689
## 1454                               D007_r2_Ro3280  -5.241000425  0.1496310446
## 1455                            D007_r2_RO4929097   4.724536672 -2.1321709483
## 1456      D007_r2_Roscovitine (Seliciclib,CYC202)   4.945388237 -1.0217914919
## 1457             D007_r2_Ruxolitinib (INCB018424)   7.842224303 -2.5363343853
## 1458           D007_r2_S-Ruxolitinib (INCB018424)   7.535581005 -2.2251664213
## 1459                               D007_r2_SANT-1   8.301703900 -1.8724975843
## 1460                            D007_r2_SAR131675   8.108627318 -2.3732861136
## 1461                    D007_r2_SAR245409 (XL765)   3.753116854 -2.8757994759
## 1462                D007_r2_Saracatinib (AZD0530)   2.690415358 -0.3027732085
## 1463                      D007_r2_SB202190 (FHPI)  10.097861214 -3.5659744253
## 1464                             D007_r2_SB203580   7.906604441 -2.4403699806
## 1465                             D007_r2_SB216763  -1.163796555 -1.5183167049
## 1466                             D007_r2_SB239063   5.556630542 -2.7769246740
## 1467                             D007_r2_SB415286   6.389757571 -2.0668593960
## 1468                             D007_r2_SB431542   7.655705974 -2.0684542017
## 1469                             D007_r2_SB505124   5.608353300 -2.7168812850
## 1470                             D007_r2_SB525334   6.416665300 -1.9091274131
## 1471                             D007_r2_SB590885   6.711979828 -1.9017894309
## 1472                                  D007_r2_SC1   3.049453554  0.6529224787
## 1473                D007_r2_Schisandrin B (Sch B)   9.726781616 -1.6827418083
## 1474                D007_r2_Selumetinib (AZD6244)   3.914682268 -2.1269960983
## 1475              D007_r2_Semagacestat (LY450139)   6.675229820 -2.3892308145
## 1476                   D007_r2_Semaxanib (SU5416)   6.291097194 -2.4809951902
## 1477                             D007_r2_SGI-7079   1.169217855 -0.5982551183
## 1478                          D007_r2_Skepinone-L   8.262387746 -2.2055492319
## 1479                               D007_r2_SL-327   6.799710738 -1.8387209109
## 1480                 D007_r2_SNS-032 (BMS-387032)   5.288138144  0.2343918909
## 1481                     D007_r2_SNS-314 Mesylate   1.490358158 -3.2308621385
## 1482                            D007_r2_Sorafenib  10.696247830 -3.7780632261
## 1483                   D007_r2_Sorafenib Tosylate   7.892162597 -3.7487488479
## 1484                         D007_r2_Sotrastaurin   2.544847877 -2.6229614307
## 1485                             D007_r2_SP600125   8.159550294 -2.3826019960
## 1486                              D007_r2_SU11274   8.157469088 -2.6927971910
## 1487                               D007_r2_SU6656   9.557636626 -4.0233560912
## 1488                               D007_r2_SU9516   3.806243403 -2.2520634994
## 1489                     D007_r2_Sunitinib Malate   9.553492157 -2.2783588163
## 1490                  D007_r2_TAE226 (NVP-TAE226)   6.490796674 -1.4116212213
## 1491                              D007_r2_TAK-285   8.807250027 -2.9073406586
## 1492                              D007_r2_TAK-632   6.437745990 -2.3379357977
## 1493                              D007_r2_TAK-715   6.841142704 -2.5838194013
## 1494                              D007_r2_TAK-733   6.808958825 -1.0902732688
## 1495                              D007_r2_TAK-901   3.994688723 -1.4688983473
## 1496                D007_r2_Taladegib (LY2940680)   6.456318061 -2.6394611061
## 1497                              D007_r2_TCS 359   6.816743325 -1.7830084142
## 1498                               D007_r2_TDZD-8   3.677137857 -1.4661051436
## 1499                            D007_r2_Telatinib   4.688654111 -2.5374790141
## 1500   D007_r2_Temsirolimus (CCI-779, NSC 683864)   6.364845849 -1.7366652921
## 1501              D007_r2_Tepotinib (EMD 1214063)   7.073730114  0.5336850205
## 1502                                D007_r2_TG003  11.301396568 -2.8282125578
## 1503                            D007_r2_TG100-115   7.129574553 -2.8420321954
## 1504                             D007_r2_TG101209   4.085184690 -1.7587780240
## 1505                 D007_r2_TG101348 (SAR302503)   4.262940248 -1.3818603273
## 1506                              D007_r2_TGX-221   7.720208637 -2.1275390958
## 1507                         D007_r2_Theophylline   5.160031986 -2.1402112146
## 1508                          D007_r2_Thiazovivin   7.594860913 -2.6959443327
## 1509                       D007_r2_TIC10 Analogue   6.356065536 -2.5168426050
## 1510                           D007_r2_Tideglusib   5.211409007 -3.0394738431
## 1511                 D007_r2_Tivantinib (ARQ 197)   3.819633986 -0.6877144519
## 1512                   D007_r2_Tivozanib (AV-951)   7.594663940 -2.2208324944
## 1513  D007_r2_Tofacitinib (CP-690550,Tasocitinib)   9.390753259 -2.5021741322
## 1514      D007_r2_Tofacitinib (CP-690550) Citrate   5.645759175 -2.3850254453
## 1515                              D007_r2_Torin 2   1.027674662  1.4450033302
## 1516              D007_r2_Trametinib (GSK1120212)   4.035247817 -1.1159544193
## 1517                          D007_r2_Triciribine  -4.620603634 -0.4125216085
## 1518           D007_r2_TSU-68 (SU6668, Orantinib)   6.231797389 -2.5437788262
## 1519                               D007_r2_TWS119   5.846895961 -2.1830936455
## 1520                         D007_r2_Tyrphostin 9   7.498372923 -1.7069090870
## 1521                   D007_r2_Tyrphostin AG 1296   8.156994966 -2.5388140508
## 1522                           D007_r2_U0126-EtOH  11.221141536 -2.5184786404
## 1523     D007_r2_Ulixertinib (BVD-523, VRT752271)   6.019372350 -1.7767914868
## 1524              D007_r2_Uprosertib (GSK2141795)   3.336157468 -0.9769517124
## 1525                          D007_r2_Vacquinol-1  -0.106609614 -1.3396853741
## 1526                           D007_r2_Varlitinib   8.024246205 -3.6151570184
## 1527              D007_r2_Vatalanib (PTK787) 2HCl   6.026651118 -2.4848613573
## 1528                               D007_r2_VE-821   6.492342768 -1.9400386279
## 1529                               D007_r2_VE-822  -6.126491097  0.5198023296
## 1530        D007_r2_Vemurafenib (PLX4032, RG7204)   6.062657194 -2.2670724070
## 1531                D007_r2_Vismodegib (GDC-0449)   6.280407782 -1.3511758712
## 1532                 D007_r2_Volasertib (BI 6727)   7.237408873 -2.5375326365
## 1533                            D007_r2_VPS34-IN1   3.761967773 -2.1958325537
## 1534                     D007_r2_VS-5584 (SB2343)  11.585019494  0.1998991795
## 1535                               D007_r2_VX-11e   6.750727487 -2.1551996754
## 1536         D007_r2_VX-680 (Tozasertib, MK-0457)   5.524209323 -2.6912475893
## 1537                               D007_r2_VX-702   6.616330461 -2.4951534778
## 1538                               D007_r2_VX-745   6.006862023 -2.1635701441
## 1539                              D007_r2_WAY-600   7.340497316 -2.4985002710
## 1540                             D007_r2_WH-4-023   6.275989962 -2.7124715280
## 1541                             D007_r2_WHI-P154   9.088232718 -2.8618697910
## 1542                                D007_r2_WIKI4   4.364255163 -1.3838075138
## 1543                        D007_r2_Wnt agonist 1   0.259568897  0.4592986222
## 1544                        D007_r2_Wnt-C59 (C59)   4.618042992 -3.0926639667
## 1545                               D007_r2_WP1066   7.393935167 -2.3876524034
## 1546                 D007_r2_WYE-125132 (WYE-132)   7.913769592 -1.8793100695
## 1547                              D007_r2_WYE-354   4.699548562 -2.3816686597
## 1548                               D007_r2_WZ3146   5.081111904 -2.1373912829
## 1549                               D007_r2_WZ4002   5.359167380 -2.1440956045
## 1550                               D007_r2_WZ4003   7.642242098 -1.1048200078
## 1551                               D007_r2_WZ8040   8.542546420 -2.1966308281
## 1552                              D007_r2_XAV-939   2.636190619 -1.4924312284
## 1553                                D007_r2_XL019  10.697390298 -2.4923791857
## 1554                              D007_r2_XMD8-92   2.989240120 -1.4599204595
## 1555                         D007_r2_Y-27632 2HCl   7.112927965 -3.0230252944
## 1556                             D007_r2_YM201636   3.897655987 -3.7005482059
## 1557                             D007_r2_YO-01027   6.342597892 -2.1716444112
## 1558                            D007_r2_ZM 306416   4.493175480 -3.6413219889
## 1559                        D007_r2_ZM 323881 HCl   9.375585650 -2.2644722203
## 1560                            D007_r2_ZM 336372   9.322616449 -2.2608229154
## 1561                         D007_r2_ZM 39923 HCl   7.612389119 -1.7175734904
## 1562                            D007_r2_ZM 447439   5.310921600 -2.6980291754
## 1563                 D007_r2_Zotarolimus(ABT-578)   7.870147790 -3.1566059525
## 1564                              D007_r2_ZSTK474   4.381854081 -2.3145920895
## 1565                     D010_r1_1-Azakenpaullone   4.309596659 -1.5997387868
## 1566                      D010_r1_3-Methyladenine   6.722156657 -2.3936875833
## 1567                             D010_r1_A-674563  -6.046198861 -0.7678566835
## 1568                             D010_r1_A-769662   4.201113680 -1.5251279804
## 1569                                  D010_r1_A66   5.678150008 -1.3513318360
## 1570                            D010_r1_Acadesine   6.396007140 -1.1517404157
## 1571                  D010_r1_AEE788 (NVP-AEE788)   7.583055325 -1.3694568301
## 1572        D010_r1_Afatinib (BIBW2992)_uncertain   8.789664902 -3.1458824414
## 1573                              D010_r1_AG-1024   7.270299583 -2.2154547988
## 1574         D010_r1_AG-1478 (Tyrphostin AG-1478)   3.726372318 -1.7130809588
## 1575                                D010_r1_AG-18  10.779572342 -1.7368957232
## 1576              D010_r1_AG-490 (Tyrphostin B42)   7.221597910 -2.0532505780
## 1577                             D010_r1_Akti-1/2   5.696335842 -2.5130915495
## 1578                  D010_r1_Alisertib (MLN8237)   2.657569093 -1.9552087116
## 1579                              D010_r1_AMG 337   8.234224035 -4.1222473333
## 1580                              D010_r1_AMG-458   6.830723297 -1.5834790471
## 1581                              D010_r1_AMG-900   1.331180087 -1.4152896915
## 1582                               D010_r1_AMG319   1.981673714 -1.8755640369
## 1583                  D010_r1_Amuvatinib (MP-470)   8.493925375 -2.1866443776
## 1584                             D010_r1_Apatinib   5.192566025 -2.3931852055
## 1585                           D010_r1_AR-A014418   5.283916468 -1.7606573463
## 1586                            D010_r1_AS-252424   3.611994505 -1.6275096547
## 1587                            D010_r1_AS-604850  10.529293021 -2.8503260303
## 1588                         D010_r1_Asiatic Acid   3.453975523 -1.7571729051
## 1589                             D010_r1_AST-1306   7.229945702 -1.2256253764
## 1590                              D010_r1_AT13148   6.886864579 -2.3910937795
## 1591                               D010_r1_AT7519  -5.368766747 -2.5029441290
## 1592                               D010_r1_AT7867   3.562322197  0.0273335714
## 1593                               D010_r1_AT9283  -4.575687345  0.0894809554
## 1594                 D010_r1_Aurora A Inhibitor I   5.113057673 -2.2612283472
## 1595             D010_r1_Avagacestat (BMS-708163)   6.286921786 -2.2843767219
## 1596                              D010_r1_AVL-292   5.962189286 -2.2490037857
## 1597                             D010_r1_Axitinib   4.259320287 -1.8794436644
## 1598                             D010_r1_Axitinib   4.259320287 -1.8794436644
## 1599                               D010_r1_AZ 628   4.924959827 -0.1247456094
## 1600                               D010_r1_AZ 960   3.937882305 -2.0452237703
## 1601                                 D010_r1_AZ20  -2.408008626 -1.4092206087
## 1602                              D010_r1_AZD1080  -0.874896691 -0.4410635996
## 1603                              D010_r1_AZD1480   2.442783183 -1.1314122487
## 1604                              D010_r1_AZD2014   1.823556195 -0.4346153530
## 1605                              D010_r1_AZD2858  -3.159478793 -0.5224429171
## 1606                              D010_r1_AZD2932   5.791746382 -2.4220552597
## 1607                              D010_r1_AZD3759   4.911637653 -1.3213025491
## 1608                              D010_r1_AZD5363   6.474999180 -2.9699007266
## 1609                              D010_r1_AZD5438  -5.967115255 -1.7790125378
## 1610                              D010_r1_AZD6482   4.894002389 -2.7519846580
## 1611                              D010_r1_AZD6738  -1.588510966 -2.1847544914
## 1612                              D010_r1_AZD8055   2.759268771 -1.2177183241
## 1613                              D010_r1_AZD8330  -5.374773415 -1.3559258178
## 1614                  D010_r1_AZD8931 (Sapitinib)   1.912263309 -0.3824939537
## 1615                              D010_r1_AZD9291   2.911684470 -1.2391353919
## 1616            D010_r1_Barasertib (AZD1152-HQPA)   6.760782438 -2.2399885482
## 1617  D010_r1_Baricitinib (LY3009104, INCB028050)   6.609389674 -2.0309431543
## 1618                  D010_r1_BGT226 (NVP-BGT226)   4.539503224  0.1658161354
## 1619                              D010_r1_BI 2536  -1.774941470 -1.3756422746
## 1620                              D010_r1_BI-78D3   5.403546034 -1.7591236379
## 1621                             D010_r1_BI-D1870   3.135188115 -1.3386738227
## 1622                              D010_r1_Bikinin   9.268153962 -2.7540431079
## 1623                                  D010_r1_BIO   0.023405964 -1.9228297905
## 1624               D010_r1_BIRB 796 (Doramapimod)   8.793309710 -2.1309633433
## 1625                            D010_r1_BIX 02188   7.066013589 -3.6032214120
## 1626                            D010_r1_BIX 02189   6.585132483 -0.9738217780
## 1627      D010_r1_BKM120 (NVP-BKM120, Buparlisib)  -4.015483699 -1.2365183044
## 1628                           D010_r1_BMS-265246   4.245008065 -1.4703574304
## 1629                           D010_r1_BMS-536924   3.286690384 -1.6222079559
## 1630                           D010_r1_BMS-582949   8.512292305 -1.0260838399
## 1631                           D010_r1_BMS-754807  -2.501763117 -1.3584268063
## 1632                           D010_r1_BMS-777607   7.498142498 -2.0843489997
## 1633                           D010_r1_BMS-794833   6.798230233 -2.8272092852
## 1634                           D010_r1_BMS-833923   7.029075582 -2.5433098633
## 1635                  D010_r1_Bosutinib (SKI-606)   5.894561147 -1.5205615783
## 1636                D010_r1_Brivanib (BMS-540215)  12.022368915 -2.6216545827
## 1637      D010_r1_Brivanib Alaninate (BMS-582664)  13.211641540 -2.1923486869
## 1638                           D010_r1_BS-181 HCl   2.134806027 -2.1394712290
## 1639                               D010_r1_Butein   9.040323807 -2.3933753773
## 1640                               D010_r1_BYL719   5.314812367 -2.9502565732
## 1641     D010_r1_Cabozantinib (XL184, BMS-907351)   6.072536301 -1.2144261068
## 1642          D010_r1_Cabozantinib malate (XL184)   9.181048924 -2.7577095009
## 1643        D010_r1_CAL-101 (Idelalisib, GS-1101)   7.903378533 -2.0594167174
## 1644                             D010_r1_CAY10505   4.757709267 -2.6219150022
## 1645                               D010_r1_CC-223   2.959263721 -2.4513705542
## 1646                            D010_r1_CCT128930  10.418129694 -2.1779290945
## 1647                  D010_r1_Cediranib (AZD2171)   5.267518453 -1.7223120550
## 1648                            D010_r1_CEP-32496   7.283338494 -1.8475795069
## 1649                            D010_r1_CEP-33779   7.220468518 -2.0924133370
## 1650                              D010_r1_CGI1746   3.527295495 -1.3496530910
## 1651                              D010_r1_CGK 733   4.952710503 -1.6071174414
## 1652                            D010_r1_CH5132799   7.341512724 -1.5412179829
## 1653                           D010_r1_CHIR-98014  -2.467273138 -0.2744002472
## 1654                 D010_r1_CHIR-99021 (CT99021)   3.067945118 -0.7232317540
## 1655             D010_r1_CHIR-99021 (CT99021) HCl   2.353376915 -1.1728706871
## 1656                    D010_r1_Chrysophanic Acid   7.945883391 -2.3736910887
## 1657                             D010_r1_CNX-2006   4.102902854 -2.0838127818
## 1658                              D010_r1_CNX-774   7.010940608 -2.0767220276
## 1659                    D010_r1_CO-1686 (AVL-301)   5.676436605 -2.0445232534
## 1660       D010_r1_Cobimetinib (GDC-0973, RG7420)  -5.346037252 -0.9258954318
## 1661                            D010_r1_CP-673451   5.806075090 -1.5558046788
## 1662                            D010_r1_CP-724714  13.059490373 -1.1532564238
## 1663               D010_r1_Crenolanib (CP-868596)   4.720952126 -2.3552460355
## 1664             D010_r1_Crizotinib (PF-02341066)   5.121424282 -1.2160729875
## 1665                               D010_r1_CYC116   2.799220797 -2.1237533098
## 1666                               D010_r1_CYT387   7.313057049 -2.3679665373
## 1667                             D010_r1_CZC24832   4.896755160 -1.4074545821
## 1668              D010_r1_Dabrafenib (GSK2118436)   5.450753895 -3.0923025734
## 1669        D010_r1_Dacomitinib (PF299804, PF299)   1.676494723  0.6174829172
## 1670              D010_r1_Danusertib (PHA-739358)   0.816781533 -3.5168587218
## 1671                        D010_r1_DAPT (GSI-IX)   7.223507282 -1.3956045357
## 1672                            D010_r1_Dasatinib  11.276182597 -0.1185843660
## 1673                D010_r1_DCC-2036 (Rebastinib)   5.772091173 -1.7473593273
## 1674                D010_r1_Decernotinib (VX-509)   8.583343666 -3.0822763055
## 1675               D010_r1_Dinaciclib (SCH727965)  -6.016362556 -1.3919243570
## 1676    D010_r1_Dovitinib (TKI-258) Dilactic Acid   1.555279235 -2.2945488010
## 1677                            D010_r1_ENMD-2076   3.526299217 -1.0216798992
## 1678               D010_r1_Enzastaurin (LY317615)   4.360428487 -1.2717032341
## 1679                            D010_r1_ERK5-IN-1   2.516209187 -0.5022944125
## 1680                             D010_r1_ETC-1002   6.311391489 -2.7644339446
## 1681                            D010_r1_ETP-46464   8.606180678 -2.0439925568
## 1682                  D010_r1_Everolimus (RAD001)   9.793393605 -1.9602028868
## 1683                D010_r1_Fasudil (HA-1077) HCl   6.704915960 -2.2755184476
## 1684                                D010_r1_FH535   5.095173412 -1.5380226421
## 1685                D010_r1_Filgotinib (GLPG0634)   5.818322123 -2.4846533984
## 1686             D010_r1_Flavopiridol (Alvocidib)  -7.288448287 -1.4523040485
## 1687                     D010_r1_Flavopiridol HCl  -6.481383879 -1.5367063954
## 1688               D010_r1_Foretinib (GSK1363089)   1.988649015 -2.8023558006
## 1689                  D010_r1_Fostamatinib (R788)  -5.674942759 -1.3390129772
## 1690                                D010_r1_G-749  10.489845804 -2.2687767158
## 1691                             D010_r1_GDC-0068   0.245572987 -1.4508570944
## 1692                             D010_r1_GDC-0349   5.595229971 -1.5101979274
## 1693                             D010_r1_GDC-0879   3.702210783 -1.7659715491
## 1694                             D010_r1_GDC-0941   4.401797448 -1.6570676043
## 1695                    D010_r1_GDC-0980 (RG7422)   0.888994892 -2.0912030184
## 1696                   D010_r1_Gefitinib (ZD1839)  10.570744015 -0.2472896542
## 1697                            D010_r1_Genistein   4.854821362 -2.2815566738
## 1698                            D010_r1_GF109203X   3.907554396 -1.4250506741
## 1699                                D010_r1_GNF-2   7.659676868 -3.3712874752
## 1700                                D010_r1_GNF-5   8.621511806 -2.3744695456
## 1701                              D010_r1_Go 6983   3.075657308 -1.2631810033
## 1702                   D010_r1_Golvatinib (E7050)  -0.527387020 -1.0562300910
## 1703                          D010_r1_GSK1838705A   3.369268845 -2.0720182076
## 1704                          D010_r1_GSK1904529A   6.067291157 -0.9893751545
## 1705                  D010_r1_GSK2126458 (GSK458)  -1.032092793 -1.1535214474
## 1706                           D010_r1_GSK2292767   1.579043270 -0.9390055257
## 1707                           D010_r1_GSK2636771   5.757222590 -3.1225460710
## 1708                           D010_r1_GSK429286A   9.261184387 -2.8815926489
## 1709                            D010_r1_GSK461364   1.006755670 -2.8818301516
## 1710                               D010_r1_GSK621   7.653562874 -2.4736361112
## 1711                            D010_r1_GSK690693   3.635967533 -1.1795870401
## 1712                               D010_r1_GW5074   5.898651381 -1.2491489721
## 1713                             D010_r1_GW788388  11.225500177 -1.7234633363
## 1714                               D010_r1_GZD824   9.027863600 -1.8797377018
## 1715                            D010_r1_H 89 2HCl   9.157653625 -3.4359985751
## 1716                           D010_r1_Hesperadin   1.428005339 -0.4224549320
## 1717                              D010_r1_HMN-214  -3.221853789 -2.5478441958
## 1718                             D010_r1_Honokiol  10.726143795 -0.8751661188
## 1719                               D010_r1_HS-173  -3.666495985 -1.2298331286
## 1720                           D010_r1_HTH-01-015   4.302979091 -2.1108654871
## 1721                D010_r1_Ibrutinib (PCI-32765)   3.667968434 -0.5478817786
## 1722                              D010_r1_ICG-001   8.564724922 -1.2113010489
## 1723                             D010_r1_Icotinib   5.841874966 -0.3824296598
## 1724                                D010_r1_IM-12   7.949015063 -2.5961370044
## 1725           D010_r1_Imatinib Mesylate (STI571)   5.714493769 -1.0551481674
## 1726                            D010_r1_Indirubin   2.681959728 -2.1633508256
## 1727                    D010_r1_INK 128 (MLN0128)   0.731704717 -0.8241618765
## 1728                    D010_r1_IPI-145 (INK1197)   5.218610700 -1.5728528635
## 1729                               D010_r1_IWP-L6   8.444360347 -1.6927207839
## 1730                           D010_r1_IWR-1-endo   7.636644566 -2.4240134321
## 1731                         D010_r1_JNJ-38877605   6.722326226 -1.2523808323
## 1732                          D010_r1_JNJ-7706621  -3.981846249 -0.8963031954
## 1733                     D010_r1_JNK Inhibitor IX  -0.602353577 -2.1762778941
## 1734                             D010_r1_JNK-IN-8   0.620594583 -1.8227858985
## 1735                               D010_r1_K02288  10.984173109 -2.3488385029
## 1736                               D010_r1_Ki8751   3.458034416 -2.0710091083
## 1737                              D010_r1_KRN 633   7.575648761 -3.0289482248
## 1738                           D010_r1_KU-0063794   8.690030169 -1.6315742758
## 1739      D010_r1_KU-55933 (ATM Kinase Inhibitor)   6.303696517 -1.9188152642
## 1740                             D010_r1_KU-60019   5.437295414 -2.4440264184
## 1741                              D010_r1_KW-2449   2.937626901 -0.4380931373
## 1742                              D010_r1_KX2-391  -2.447454630 -2.5797350423
## 1743                              D010_r1_KY02111   7.488499728 -2.1031526520
## 1744                            D010_r1_Lapatinib   3.311963510 -0.5837670830
## 1745     D010_r1_Lapatinib (GW-572016) Ditosylate   7.821050470 -1.7577797768
## 1746                            D010_r1_LDC000067   2.145530143 -1.6705857005
## 1747      D010_r1_LDE225 (NVP-LDE225,Erismodegib)   7.435612836 -1.6372649784
## 1748                           D010_r1_LDN-214117  11.236701310 -3.7062966384
## 1749                   D010_r1_Lenvatinib (E7080)   6.219360985 -2.3705233996
## 1750                              D010_r1_LFM-A13   4.517125880 -1.4395603819
## 1751                              D010_r1_LGK-974   6.956128856 -2.1591367741
## 1752                  D010_r1_Linifanib (ABT-869)   8.117350683 -0.9592691219
## 1753                               D010_r1_LJH685   6.433296222 -2.1334453325
## 1754                               D010_r1_LJI308   8.620801421 -2.0033219872
## 1755               D010_r1_Losmapimod (GW856553X)   4.644744638 -2.3720934905
## 1756                            D010_r1_LY2090314  -4.495309991 -0.7408324866
## 1757                            D010_r1_LY2157299   9.240886449 -2.2837947842
## 1758                            D010_r1_LY2784544   0.884933150 -2.2100472962
## 1759                            D010_r1_LY2835219   0.693055455 -1.6020316408
## 1760                             D010_r1_LY294002   7.626947345 -0.4200961391
## 1761                            D010_r1_LY3023414  -4.784597957 -1.6953279596
## 1762                             D010_r1_LY411575   7.792603814 -2.0101044928
## 1763       D010_r1_MEK162 (ARRY-162, ARRY-438162)  -2.269369451  0.6477233183
## 1764                             D010_r1_MGCD-265   7.385519540 -1.9984223485
## 1765               D010_r1_Milciclib (PHA-848125)  -4.143048250 -0.2745474933
## 1766                              D010_r1_MK-0752  10.614415627 -2.2243813263
## 1767                         D010_r1_MK-2206 2HCl   3.210567852 -1.0973060232
## 1768                              D010_r1_MK-2461   9.701911911 -3.1968742867
## 1769                     D010_r1_MK-5108 (VX-689)   0.328040447 -1.7028802908
## 1770                              D010_r1_MK-8745   0.211002104 -2.7472217018
## 1771                              D010_r1_MLN2480   5.387982760 -1.4701270777
## 1772                              D010_r1_MLN8054   7.326621334 -1.7182281220
## 1773      D010_r1_Motesanib Diphosphate (AMG-706)   3.323824097 -1.6500573114
## 1774                  D010_r1_Nilotinib (AMN-107)  11.752760169 -1.4084073810
## 1775     D010_r1_Nintedanib (BIBF 1120)_uncertain   9.922500530 -1.8815762525
## 1776                               D010_r1_NU6027   4.115031885 -2.5989417726
## 1777                           D010_r1_NVP-AEW541  -0.839465749 -1.0453557995
## 1778                           D010_r1_NVP-BHG712   4.488318932 -0.4973539366
## 1779                      D010_r1_NVP-BSK805 2HCl   8.105512881 -1.8021808795
## 1780                           D010_r1_NVP-BVU972   8.627678756 -2.1251096843
## 1781                          D010_r1_Oclacitinib   8.288353116 -2.6522541498
## 1782      D010_r1_Olmutinib (HM61713, BI 1482694)   2.063265942 -1.6180904797
## 1783                             D010_r1_ONO-4059   4.347923052 -0.5659707616
## 1784                              D010_r1_OSI-027   4.274144387 -2.1880790503
## 1785                              D010_r1_OSI-420   7.740547930 -0.6404176500
## 1786                 D010_r1_OSI-906 (Linsitinib)   4.584529384 -1.7293659086
## 1787                              D010_r1_P276-00  -6.143010408 -2.6929184652
## 1788                  D010_r1_Pacritinib (SB1518)  -4.202645196 -1.2632131891
## 1789                   D010_r1_Palomid 529 (P529)   9.016930864 -1.3036640849
## 1790                            D010_r1_Pazopanib   3.433144969 -3.2980390007
## 1791                        D010_r1_Pazopanib HCl   1.699682757 -1.1147044505
## 1792                            D010_r1_PD0325901  -3.716997560 -0.1423448185
## 1793                             D010_r1_PD168393   1.885711395 -0.9172006856
## 1794                             D010_r1_PD173955   5.431583535 -0.8420651454
## 1795                   D010_r1_PD184352 (CI-1040)  10.895896815 -0.2775840452
## 1796                             D010_r1_PD318088   0.771447297 -0.0002527474
## 1797                              D010_r1_PD98059   7.278377279 -2.2115994246
## 1798                  D010_r1_Pelitinib (EKB-569)   3.628011226 -1.6100588642
## 1799                          D010_r1_PF-00562271  -2.417388584 -1.8446049973
## 1800                          D010_r1_PF-04217903   7.203088522 -2.1599703348
## 1801                          D010_r1_PF-04691502  -1.007327750 -2.8727737510
## 1802                            D010_r1_PF-431396  -1.794710950 -1.1497545746
## 1803                           D010_r1_PF-4708671  -1.212753804 -0.9552102576
## 1804                           D010_r1_PF-5274857   6.881336018 -1.9028919740
## 1805                            D010_r1_PF-562271  -4.257176966 -1.4649119840
## 1806                            D010_r1_PF-573228   1.876862232 -0.3840237325
## 1807                            D010_r1_PH-797804   6.060742838 -2.1831178948
## 1808                           D010_r1_PHA-665752   9.543002174 -2.5190423761
## 1809                           D010_r1_PHA-680632   0.130002703 -2.3973818031
## 1810                           D010_r1_PHA-767491  -3.079968959 -1.1264445028
## 1811                           D010_r1_PHA-793887  -1.707349647 -0.5415923104
## 1812                       D010_r1_Phenformin HCl   6.556157960 -2.1170228080
## 1813                              D010_r1_PHT-427   8.693233487 -2.2812518201
## 1814                          D010_r1_Piceatannol   8.781067014 -2.2569302470
## 1815                              D010_r1_PIK-293   9.583007530 -3.3770325238
## 1816                              D010_r1_PIK-294   7.634455265 -2.1346510228
## 1817                               D010_r1_PIK-93  -3.986919811 -1.3347920243
## 1818               D010_r1_Pimasertib (AS-703026)  -5.674307620 -1.2587469461
## 1819                          D010_r1_Pirfenidone  13.226641125  0.5949058935
## 1820                             D010_r1_PLX-4720   9.714682386 -3.7022832554
## 1821                              D010_r1_PLX7904   7.157830873 -2.3160212860
## 1822                  D010_r1_Ponatinib (AP24534)   3.084310386 -1.9967429868
## 1823                                  D010_r1_PP1   8.829461511 -1.9767444783
## 1824                                  D010_r1_PP2   3.219345285 -1.8274225297
## 1825                                D010_r1_PP242   5.261082397 -1.6234867451
## 1826                               D010_r1_PQ 401   8.053978447 -2.7427717423
## 1827                              D010_r1_PRI-724   7.102337227 -2.2180217599
## 1828     D010_r1_PRT062607 (P505-15, BIIB057) HCl   2.673469405 -2.7045922759
## 1829                         D010_r1_Purvalanol A   1.008925973 -2.4838498494
## 1830                            D010_r1_Quercetin   6.793153279 -1.3832151448
## 1831                  D010_r1_Quizartinib (AC220)   6.147887780 -1.6448539708
## 1832                                 D010_r1_R406   4.566333444 -2.0041344578
## 1833                     D010_r1_R406 (free base)   6.532774147 -2.2350138476
## 1834                                 D010_r1_R547  -4.967610758 -1.1277539926
## 1835                    D010_r1_RAF265 (CHIR-265)  -2.128908050 -1.3056190785
## 1836                D010_r1_Rapamycin (Sirolimus)   9.436599136 -2.4462451486
## 1837   D010_r1_Refametinib (RDEA119, Bay 86-9766)  -5.321218029  0.3694718004
## 1838                               D010_r1_RepSox  10.416504910 -2.1232921463
## 1839 D010_r1_Ridaforolimus (Deforolimus, MK-8669)   7.587640459  0.0566591867
## 1840                D010_r1_Rigosertib (ON-01910)  -3.584124281 -2.8428700612
## 1841                             D010_r1_RKI-1447   6.053480102 -1.6941749814
## 1842                                D010_r1_RN486   9.188663200 -3.8976092156
## 1843                  D010_r1_Ro 31-8220 Mesylate  -2.279847685 -0.3724907484
## 1844                              D010_r1_Ro-3306   7.225987395 -2.7079237382
## 1845                               D010_r1_Ro3280  -1.405274617 -1.6513828968
## 1846                            D010_r1_RO4929097   5.892951286 -1.8881733218
## 1847      D010_r1_Roscovitine (Seliciclib,CYC202)   5.659740264 -2.2439755373
## 1848             D010_r1_Ruxolitinib (INCB018424)   7.405689726 -1.9738944540
## 1849           D010_r1_S-Ruxolitinib (INCB018424)   6.137865375 -2.2743731849
## 1850                               D010_r1_SANT-1   8.695345982 -2.0708668945
## 1851                            D010_r1_SAR131675   6.820253039 -2.1171917864
## 1852                    D010_r1_SAR245409 (XL765)  17.200938797 -2.5098286930
## 1853                D010_r1_Saracatinib (AZD0530)  12.880805729 -0.7944433402
## 1854                      D010_r1_SB202190 (FHPI)   9.204115208 -2.2585241752
## 1855                             D010_r1_SB203580   8.161961852 -1.2313463446
## 1856                             D010_r1_SB216763   7.597581617 -0.9000609535
## 1857                             D010_r1_SB239063   8.525615007 -1.9160190166
## 1858                             D010_r1_SB415286   5.937313872 -2.2853576682
## 1859                             D010_r1_SB431542   7.728677846 -1.3728178549
## 1860                             D010_r1_SB505124   3.415580919 -1.8649010541
## 1861                             D010_r1_SB525334   4.721054227 -1.3985786748
## 1862                             D010_r1_SB590885   7.159984985 -2.4656807262
## 1863                                  D010_r1_SC1  -0.383027953  0.8592505612
## 1864                D010_r1_Schisandrin B (Sch B)   8.916745754 -2.7408578043
## 1865                D010_r1_Selumetinib (AZD6244)   1.888718773  0.0825860452
## 1866              D010_r1_Semagacestat (LY450139)   4.606630549 -1.7513826751
## 1867                   D010_r1_Semaxanib (SU5416)   0.062650684 -2.5674216965
## 1868                             D010_r1_SGI-7079   0.365641791  0.8031333901
## 1869                          D010_r1_Skepinone-L   5.420921186 -1.3717409124
## 1870                               D010_r1_SL-327   7.202989264 -0.2505600103
## 1871                 D010_r1_SNS-032 (BMS-387032)  -5.808359421 -2.0712836662
## 1872                     D010_r1_SNS-314 Mesylate   1.257013089 -1.1247437515
## 1873                            D010_r1_Sorafenib   1.887376072 -1.5769314680
## 1874                   D010_r1_Sorafenib Tosylate   6.604310345 -1.2952810319
## 1875                         D010_r1_Sotrastaurin   5.038203455 -2.2427653640
## 1876                             D010_r1_SP600125   5.817503386 -1.6983205476
## 1877                              D010_r1_SU11274   8.656876679 -1.2753727282
## 1878                               D010_r1_SU6656  10.866038947 -2.9689839665
## 1879                               D010_r1_SU9516   2.950112351 -2.3352988674
## 1880                     D010_r1_Sunitinib Malate   7.198111918 -3.2146892233
## 1881                  D010_r1_TAE226 (NVP-TAE226)  -3.455869178 -2.0022462374
## 1882                              D010_r1_TAK-285   6.982530415 -1.1540930922
## 1883                              D010_r1_TAK-632   4.607651299  0.6426481506
## 1884                              D010_r1_TAK-715  10.327570750 -0.4278675873
## 1885                              D010_r1_TAK-733  -6.321919793 -1.4492585207
## 1886                              D010_r1_TAK-901   5.135592741 -1.3379536212
## 1887                D010_r1_Taladegib (LY2940680)   7.191335922 -1.4166507310
## 1888                              D010_r1_TCS 359   6.744721278 -3.0927923280
## 1889                               D010_r1_TDZD-8   3.045325034 -2.8175750880
## 1890                            D010_r1_Telatinib  12.930947756 -2.0056222143
## 1891   D010_r1_Temsirolimus (CCI-779, NSC 683864)   8.758833908 -1.7945348363
## 1892              D010_r1_Tepotinib (EMD 1214063)  -3.913755351 -0.5968712117
## 1893                                D010_r1_TG003   5.649343419 -1.5749111230
## 1894                            D010_r1_TG100-115   4.456259305 -0.9666198223
## 1895                             D010_r1_TG101209  -1.584051798 -1.8281274898
## 1896                 D010_r1_TG101348 (SAR302503)  -1.846247455 -1.8203919274
## 1897                              D010_r1_TGX-221   6.389368864 -1.7010378260
## 1898                         D010_r1_Theophylline   8.153558552 -1.9859794246
## 1899                          D010_r1_Thiazovivin   6.929238776 -2.0701053596
## 1900                       D010_r1_TIC10 Analogue   2.591496455 -1.7628474940
## 1901                           D010_r1_Tideglusib   3.977262938 -1.8781444822
## 1902                 D010_r1_Tivantinib (ARQ 197)  -2.577559560 -1.3751405074
## 1903                   D010_r1_Tivozanib (AV-951)   3.986882645 -2.4428669891
## 1904  D010_r1_Tofacitinib (CP-690550,Tasocitinib)   6.949020272 -1.7539279115
## 1905      D010_r1_Tofacitinib (CP-690550) Citrate   7.302654602 -1.8942960744
## 1906                              D010_r1_Torin 2 -10.096031239  0.0299461689
## 1907              D010_r1_Trametinib (GSK1120212)  -4.653874313 -0.6078333963
## 1908                          D010_r1_Triciribine  -0.910785539 -2.5972829082
## 1909           D010_r1_TSU-68 (SU6668, Orantinib)   4.538600215 -1.8259306432
## 1910                               D010_r1_TWS119   7.412365232 -2.2028580924
## 1911                         D010_r1_Tyrphostin 9  -0.609390355 -1.1972535301
## 1912                   D010_r1_Tyrphostin AG 1296   3.610245592 -2.2202366633
## 1913                           D010_r1_U0126-EtOH   7.556092083 -0.4940795936
## 1914     D010_r1_Ulixertinib (BVD-523, VRT752271)  -3.238950823 -0.7426729377
## 1915              D010_r1_Uprosertib (GSK2141795)   1.203241478 -1.2272973160
## 1916                          D010_r1_Vacquinol-1   6.436020028 -2.3683883995
## 1917                           D010_r1_Varlitinib   7.568272268 -1.4866963863
## 1918              D010_r1_Vatalanib (PTK787) 2HCl   6.412131108 -2.7804422025
## 1919                               D010_r1_VE-821   9.455372650 -3.0997739762
## 1920                               D010_r1_VE-822   0.718290723 -2.5632275465
## 1921        D010_r1_Vemurafenib (PLX4032, RG7204)   8.031600600 -2.6732738469
## 1922                D010_r1_Vismodegib (GDC-0449)   7.582348947 -2.5337564992
## 1923                 D010_r1_Volasertib (BI 6727)   5.672502100 -1.9429022517
## 1924                            D010_r1_VPS34-IN1  -0.622186010 -2.4236047356
## 1925                     D010_r1_VS-5584 (SB2343)  -3.999948380 -1.2595730897
## 1926                               D010_r1_VX-11e  -0.217738272 -1.1054640557
## 1927         D010_r1_VX-680 (Tozasertib, MK-0457)   7.786186020 -0.6287646914
## 1928                               D010_r1_VX-702   3.465144934 -1.6575484788
## 1929                               D010_r1_VX-745   8.265531522 -2.2374889347
## 1930                              D010_r1_WAY-600   5.417226600 -1.3400641855
## 1931                             D010_r1_WH-4-023  20.557819795 -0.4148361145
## 1932                             D010_r1_WHI-P154   7.212546673 -2.4784223673
## 1933                                D010_r1_WIKI4   6.019997554 -3.1314557086
## 1934                        D010_r1_Wnt agonist 1  -0.136152455 -2.1190327884
## 1935                        D010_r1_Wnt-C59 (C59)   8.761229357 -1.3556398852
## 1936                               D010_r1_WP1066   5.259896815 -1.9806843963
## 1937                 D010_r1_WYE-125132 (WYE-132)  -1.924907173  0.2934566884
## 1938                              D010_r1_WYE-354   9.048025077 -1.2598733941
## 1939                               D010_r1_WZ3146   2.213847499 -1.0946504833
## 1940                               D010_r1_WZ4002   5.497617662 -2.3634619255
## 1941                               D010_r1_WZ4003   6.529098663 -1.3789935752
## 1942                               D010_r1_WZ8040   9.835732989 -1.9357259301
## 1943                              D010_r1_XAV-939   2.475566465 -2.8479833523
## 1944                                D010_r1_XL019   3.687156101 -2.7760009007
## 1945                              D010_r1_XMD8-92   5.273732391 -2.4844176131
## 1946                         D010_r1_Y-27632 2HCl   9.763243265 -2.4793213063
## 1947                             D010_r1_YM201636   6.975241513 -1.2108180512
## 1948                             D010_r1_YO-01027   5.812616137 -1.9468014798
## 1949                            D010_r1_ZM 306416   4.331782432 -0.4917113706
## 1950                        D010_r1_ZM 323881 HCl   4.873502105 -1.4430927361
## 1951                            D010_r1_ZM 336372   6.688339232 -2.0041986374
## 1952                         D010_r1_ZM 39923 HCl   8.177920474 -2.3987454765
## 1953                            D010_r1_ZM 447439   3.490354153 -0.5792347343
## 1954                 D010_r1_Zotarolimus(ABT-578)   6.360716950 -1.5200167539
## 1955                              D010_r1_ZSTK474  10.191743696 -2.1165169309
## 1956                     D010_r2_1-Azakenpaullone   3.450098154 -1.9164023312
## 1957                      D010_r2_3-Methyladenine   5.549715541 -1.9580939235
## 1958                             D010_r2_A-674563  -7.525780774  0.2298748686
## 1959                             D010_r2_A-769662   7.464230222 -2.4583783684
## 1960                                  D010_r2_A66   5.759327824 -1.5819220145
## 1961                            D010_r2_Acadesine  10.293713350 -2.5303272282
## 1962                  D010_r2_AEE788 (NVP-AEE788)   0.700375836 -0.0812851998
## 1963        D010_r2_Afatinib (BIBW2992)_uncertain   7.993668683 -2.2531635837
## 1964                              D010_r2_AG-1024   9.623516816 -1.5221152388
## 1965         D010_r2_AG-1478 (Tyrphostin AG-1478)   4.387378261 -0.7626053215
## 1966                                D010_r2_AG-18   9.646751994 -2.1362883764
## 1967              D010_r2_AG-490 (Tyrphostin B42)   8.764246237 -2.2495507728
## 1968                             D010_r2_Akti-1/2   6.928754696 -2.3011720426
## 1969                  D010_r2_Alisertib (MLN8237)  -2.449885504 -1.7096641643
## 1970                              D010_r2_AMG 337   7.851631341 -0.7870390403
## 1971                              D010_r2_AMG-458   4.048919961 -1.7958161633
## 1972                              D010_r2_AMG-900   1.830637330 -2.4202611542
## 1973                               D010_r2_AMG319   4.508299910 -2.5490820907
## 1974                  D010_r2_Amuvatinib (MP-470)   3.510070193 -1.8844059073
## 1975                             D010_r2_Apatinib   2.796980667 -2.5832334203
## 1976                           D010_r2_AR-A014418   5.471366234 -1.9834550681
## 1977                            D010_r2_AS-252424   7.486326340 -2.0593893344
## 1978                            D010_r2_AS-604850   7.270881052 -1.4137552517
## 1979                         D010_r2_Asiatic Acid   8.923213072 -1.9149150774
## 1980                             D010_r2_AST-1306   5.830245517 -1.9050686644
## 1981                              D010_r2_AT13148   6.291820552 -1.6794558304
## 1982                               D010_r2_AT7519  -6.730030652  1.3328465353
## 1983                               D010_r2_AT7867   8.071379308 -1.1956319093
## 1984                               D010_r2_AT9283  -6.102017556  1.5735729958
## 1985                 D010_r2_Aurora A Inhibitor I   7.911577061 -2.7355431070
## 1986             D010_r2_Avagacestat (BMS-708163)  10.118720236 -1.5976743122
## 1987                              D010_r2_AVL-292   1.419010832 -2.0134964825
## 1988                             D010_r2_Axitinib   7.406948219 -0.5155653974
## 1989                             D010_r2_Axitinib   7.406948219 -0.5155653974
## 1990                               D010_r2_AZ 628   5.225672543 -0.9034390972
## 1991                               D010_r2_AZ 960   5.702159092 -1.6592276725
## 1992                                 D010_r2_AZ20  -0.319623080 -2.9398998948
## 1993                              D010_r2_AZD1080   0.117295505 -0.7594591022
## 1994                              D010_r2_AZD1480   0.400858448 -0.9447569420
## 1995                              D010_r2_AZD2014   0.233892136 -1.3083935534
## 1996                              D010_r2_AZD2858  -4.937092583 -0.2685500998
## 1997                              D010_r2_AZD2932   4.591603261 -1.2312319337
## 1998                              D010_r2_AZD3759   1.570605778 -0.3164473644
## 1999                              D010_r2_AZD5363   3.976510814 -0.9527658769
## 2000                              D010_r2_AZD5438  -5.737613946 -1.1802374218
## 2001                              D010_r2_AZD6482   5.840596609 -1.7978445309
## 2002                              D010_r2_AZD6738  -5.000406545 -1.2023381911
## 2003                              D010_r2_AZD8055  13.822171316 -0.7814368805
## 2004                              D010_r2_AZD8330  -1.052724610 -0.8147768423
## 2005                  D010_r2_AZD8931 (Sapitinib)   0.822852688  0.7605217947
## 2006                              D010_r2_AZD9291   5.494791805 -2.3973425884
## 2007            D010_r2_Barasertib (AZD1152-HQPA)   2.708688629 -2.0252023402
## 2008  D010_r2_Baricitinib (LY3009104, INCB028050)   4.901837440 -2.3929313475
## 2009                  D010_r2_BGT226 (NVP-BGT226)  -3.045126508 -1.8590926932
## 2010                              D010_r2_BI 2536  -5.851304260 -0.2027087340
## 2011                              D010_r2_BI-78D3   5.124950162 -1.3998810379
## 2012                             D010_r2_BI-D1870   4.997224555 -2.9574884686
## 2013                              D010_r2_Bikinin  10.939641640 -2.6745950891
## 2014                                  D010_r2_BIO   1.360879608 -2.1834948857
## 2015               D010_r2_BIRB 796 (Doramapimod)  13.050018633 -2.1233692342
## 2016                            D010_r2_BIX 02188   9.744410997 -1.9098670559
## 2017                            D010_r2_BIX 02189  10.641927410 -2.6553121283
## 2018      D010_r2_BKM120 (NVP-BKM120, Buparlisib)  -1.893070985 -1.7681850115
## 2019                           D010_r2_BMS-265246   6.885879325 -1.8687320984
## 2020                           D010_r2_BMS-536924  -1.356574897 -0.3196250975
## 2021                           D010_r2_BMS-582949  10.001629638 -1.0037101060
## 2022                           D010_r2_BMS-754807  -4.922686385 -1.2210539594
## 2023                           D010_r2_BMS-777607   6.163205941 -2.3605157369
## 2024                           D010_r2_BMS-794833   2.254677096 -2.6917136411
## 2025                           D010_r2_BMS-833923   6.866072347 -2.9674358720
## 2026                  D010_r2_Bosutinib (SKI-606)   3.213715557 -2.0280744052
## 2027                D010_r2_Brivanib (BMS-540215)  10.889720667 -2.5578761449
## 2028      D010_r2_Brivanib Alaninate (BMS-582664)   6.610734184 -0.8963077519
## 2029                           D010_r2_BS-181 HCl  -0.031671523 -2.3919058877
## 2030                               D010_r2_Butein   8.661409783 -2.8917079925
## 2031                               D010_r2_BYL719   1.140349586 -0.5029350155
## 2032     D010_r2_Cabozantinib (XL184, BMS-907351)   7.658502321 -1.6028668974
## 2033          D010_r2_Cabozantinib malate (XL184)   3.864493018 -1.7818342690
## 2034        D010_r2_CAL-101 (Idelalisib, GS-1101)  -0.678757138 -1.6644057690
## 2035                             D010_r2_CAY10505   5.178453943 -1.2972915516
## 2036                               D010_r2_CC-223   3.127868584 -2.1226154402
## 2037                            D010_r2_CCT128930   3.581778952 -3.0365533449
## 2038                  D010_r2_Cediranib (AZD2171)  16.229628805 -0.4029359502
## 2039                            D010_r2_CEP-32496   8.461155517 -1.1137944742
## 2040                            D010_r2_CEP-33779   5.522644709 -2.2365283936
## 2041                              D010_r2_CGI1746   6.714485472 -2.9457146810
## 2042                              D010_r2_CGK 733   4.585058900  0.0028650510
## 2043                            D010_r2_CH5132799   4.500631656 -0.6516214044
## 2044                           D010_r2_CHIR-98014  -0.388105843 -0.5028423487
## 2045                 D010_r2_CHIR-99021 (CT99021)   5.511596560 -1.5858307421
## 2046             D010_r2_CHIR-99021 (CT99021) HCl   0.211895922 -0.6305847567
## 2047                    D010_r2_Chrysophanic Acid   5.517045045 -2.4603739399
## 2048                             D010_r2_CNX-2006   5.212293267 -1.6531210635
## 2049                              D010_r2_CNX-774   8.842114802 -3.3229834256
## 2050                    D010_r2_CO-1686 (AVL-301)   0.639523826 -1.7347891085
## 2051       D010_r2_Cobimetinib (GDC-0973, RG7420)  -8.645072847 -0.3308094742
## 2052                            D010_r2_CP-673451  12.521158902 -0.6676105662
## 2053                            D010_r2_CP-724714  13.920896047 -1.9063403846
## 2054               D010_r2_Crenolanib (CP-868596)   6.880759940 -1.7877034432
## 2055             D010_r2_Crizotinib (PF-02341066)  -0.173476011 -0.7881917315
## 2056                               D010_r2_CYC116   0.823194589 -2.3733416962
## 2057                               D010_r2_CYT387   8.827564294 -2.3938280257
## 2058                             D010_r2_CZC24832   4.023837602 -1.6539898961
## 2059              D010_r2_Dabrafenib (GSK2118436)   5.013873880 -1.8631098926
## 2060        D010_r2_Dacomitinib (PF299804, PF299)  -0.428562114 -1.2017085302
## 2061              D010_r2_Danusertib (PHA-739358)  -1.089473678 -1.5922164110
## 2062                        D010_r2_DAPT (GSI-IX)   5.641349666 -2.1218717751
## 2063                            D010_r2_Dasatinib   2.435908184 -1.8380767217
## 2064                D010_r2_DCC-2036 (Rebastinib)   1.565160922 -2.3136570989
## 2065                D010_r2_Decernotinib (VX-509)   5.053738346 -2.0221419221
## 2066               D010_r2_Dinaciclib (SCH727965)  -8.682401694 -1.4733211571
## 2067    D010_r2_Dovitinib (TKI-258) Dilactic Acid   1.162641212 -0.1669772384
## 2068                            D010_r2_ENMD-2076   2.847504468 -1.8841432314
## 2069               D010_r2_Enzastaurin (LY317615)   4.969718955 -1.7429790499
## 2070                            D010_r2_ERK5-IN-1   1.152582971 -0.7480307016
## 2071                             D010_r2_ETC-1002   6.058528795 -3.0832102860
## 2072                            D010_r2_ETP-46464   5.651990044 -1.8572377865
## 2073                  D010_r2_Everolimus (RAD001)   6.354405111 -2.2007148502
## 2074                D010_r2_Fasudil (HA-1077) HCl   7.554763589 -2.8626340316
## 2075                                D010_r2_FH535   4.104465635 -1.2745200796
## 2076                D010_r2_Filgotinib (GLPG0634)   5.889323511 -1.7731637396
## 2077             D010_r2_Flavopiridol (Alvocidib)  -6.851300995 -0.8462024543
## 2078                     D010_r2_Flavopiridol HCl  -5.084107896 -0.8996095576
## 2079               D010_r2_Foretinib (GSK1363089)   6.782678346 -2.0357270174
## 2080                  D010_r2_Fostamatinib (R788)  -5.006761747  0.1217804822
## 2081                                D010_r2_G-749   7.613362659 -0.8605296376
## 2082                             D010_r2_GDC-0068   2.702053580 -1.0849293398
## 2083                             D010_r2_GDC-0349   5.052350633 -1.8170372170
## 2084                             D010_r2_GDC-0879   9.022891472 -2.1507058650
## 2085                             D010_r2_GDC-0941   2.283775759 -1.6453638583
## 2086                    D010_r2_GDC-0980 (RG7422)   1.813672169 -2.4897707083
## 2087                   D010_r2_Gefitinib (ZD1839)   4.496006349 -0.8071921691
## 2088                            D010_r2_Genistein   8.162678546 -2.0889992407
## 2089                            D010_r2_GF109203X   1.701707177 -1.1610057176
## 2090                                D010_r2_GNF-2   7.596745390 -2.8729308768
## 2091                                D010_r2_GNF-5   4.508694949 -1.8812408275
## 2092                              D010_r2_Go 6983   3.319000253 -1.4825657890
## 2093                   D010_r2_Golvatinib (E7050)  -4.405933397 -0.6343932589
## 2094                          D010_r2_GSK1838705A   3.557286378 -1.9831790138
## 2095                          D010_r2_GSK1904529A   4.359708282 -1.5101307706
## 2096                  D010_r2_GSK2126458 (GSK458)  -4.975995447 -2.3614487762
## 2097                           D010_r2_GSK2292767  -2.378689960 -2.2817294695
## 2098                           D010_r2_GSK2636771   5.737116134 -2.5578288962
## 2099                           D010_r2_GSK429286A   8.241578834 -2.6855301362
## 2100                            D010_r2_GSK461364   1.558490232 -1.6991967912
## 2101                               D010_r2_GSK621   4.056444951 -1.8245190746
## 2102                            D010_r2_GSK690693  11.106602772 -0.6665543800
## 2103                               D010_r2_GW5074   4.456125785 -0.7830993184
## 2104                             D010_r2_GW788388   9.606320331 -1.7401808590
## 2105                               D010_r2_GZD824   2.885664246 -0.4260890931
## 2106                            D010_r2_H 89 2HCl   9.157664498 -1.7378915970
## 2107                           D010_r2_Hesperadin   6.505128689 -1.2105466730
## 2108                              D010_r2_HMN-214  -4.553778271 -1.7251681995
## 2109                             D010_r2_Honokiol   5.305688962 -2.7913705821
## 2110                               D010_r2_HS-173  -5.298449659 -0.6760071962
## 2111                           D010_r2_HTH-01-015   4.792696149 -2.2864181702
## 2112                D010_r2_Ibrutinib (PCI-32765)   7.055506654 -1.4602865891
## 2113                              D010_r2_ICG-001   9.040625725 -1.8068621104
## 2114                             D010_r2_Icotinib   3.809533709 -1.1005014063
## 2115                                D010_r2_IM-12   7.310522166 -1.8216773465
## 2116           D010_r2_Imatinib Mesylate (STI571)   5.330648801 -1.2929950052
## 2117                            D010_r2_Indirubin   0.655256715 -3.1067388492
## 2118                    D010_r2_INK 128 (MLN0128)   0.678253398 -1.9450385333
## 2119                    D010_r2_IPI-145 (INK1197)   5.556699752 -0.9634172816
## 2120                               D010_r2_IWP-L6   7.389909735 -2.3332569779
## 2121                           D010_r2_IWR-1-endo   4.682019858 -1.7623040633
## 2122                         D010_r2_JNJ-38877605  11.199243364 -3.1822237143
## 2123                          D010_r2_JNJ-7706621  -3.561841112 -0.2155522811
## 2124                     D010_r2_JNK Inhibitor IX  -3.379360065 -1.7056418075
## 2125                             D010_r2_JNK-IN-8  -2.222074185 -1.1397225568
## 2126                               D010_r2_K02288  10.880717211 -1.1235684244
## 2127                               D010_r2_Ki8751   6.616262761 -3.5135023638
## 2128                              D010_r2_KRN 633   7.802723563 -1.5384505067
## 2129                           D010_r2_KU-0063794  10.708085706 -2.8141735896
## 2130      D010_r2_KU-55933 (ATM Kinase Inhibitor)   5.691448355 -2.8588167005
## 2131                             D010_r2_KU-60019   2.886511161 -2.8343142859
## 2132                              D010_r2_KW-2449   7.868810534  0.0414748446
## 2133                              D010_r2_KX2-391  -3.804357408 -2.1896463745
## 2134                              D010_r2_KY02111   7.950439165 -1.9772913731
## 2135                            D010_r2_Lapatinib   3.809311508 -1.6878803152
## 2136     D010_r2_Lapatinib (GW-572016) Ditosylate   7.158014000 -2.5570026636
## 2137                            D010_r2_LDC000067   1.768424473 -1.0640060808
## 2138      D010_r2_LDE225 (NVP-LDE225,Erismodegib)   8.167325956 -2.9676610745
## 2139                           D010_r2_LDN-214117  10.702482076 -3.6808626342
## 2140                   D010_r2_Lenvatinib (E7080)  15.862311503 -0.9710621865
## 2141                              D010_r2_LFM-A13   4.847002931 -2.5420018411
## 2142                              D010_r2_LGK-974   5.435207970 -2.4376110197
## 2143                  D010_r2_Linifanib (ABT-869)  18.003141136 -0.3800761568
## 2144                               D010_r2_LJH685   5.619446593 -1.2423674720
## 2145                               D010_r2_LJI308  10.881635456 -1.0511346788
## 2146               D010_r2_Losmapimod (GW856553X)   7.450850357 -1.3498079470
## 2147                            D010_r2_LY2090314  -3.844414291  0.2940772625
## 2148                            D010_r2_LY2157299  10.171346470 -3.3436411747
## 2149                            D010_r2_LY2784544   3.875254992 -1.6976107519
## 2150                            D010_r2_LY2835219   1.072229517 -0.2278246811
## 2151                             D010_r2_LY294002   4.909648229 -2.4516512852
## 2152                            D010_r2_LY3023414  -3.806871704 -0.8586531064
## 2153                             D010_r2_LY411575   6.508576702 -1.9635763461
## 2154       D010_r2_MEK162 (ARRY-162, ARRY-438162)   0.822691001  0.8921542377
## 2155                             D010_r2_MGCD-265   4.343190806 -2.1474616226
## 2156               D010_r2_Milciclib (PHA-848125)  -0.615315386 -1.5837564460
## 2157                              D010_r2_MK-0752   8.744046760 -1.6508808554
## 2158                         D010_r2_MK-2206 2HCl   5.995347974 -2.7884536916
## 2159                              D010_r2_MK-2461   5.494600153 -1.6592454346
## 2160                     D010_r2_MK-5108 (VX-689)   0.883107851 -0.2881042080
## 2161                              D010_r2_MK-8745   1.245821786 -2.7259461871
## 2162                              D010_r2_MLN2480   7.803177780 -2.0574887937
## 2163                              D010_r2_MLN8054   5.205135052 -2.5910509559
## 2164      D010_r2_Motesanib Diphosphate (AMG-706)  11.281255635 -1.7654164726
## 2165                  D010_r2_Nilotinib (AMN-107)  13.957241459 -2.1464391441
## 2166     D010_r2_Nintedanib (BIBF 1120)_uncertain   8.318051020 -1.4800170872
## 2167                               D010_r2_NU6027   7.472347933 -3.3263393134
## 2168                           D010_r2_NVP-AEW541  -0.944722850 -0.0963462389
## 2169                           D010_r2_NVP-BHG712   5.168974008 -1.6539353174
## 2170                      D010_r2_NVP-BSK805 2HCl   7.570589065 -2.5308217388
## 2171                           D010_r2_NVP-BVU972   4.079032582 -2.1580783510
## 2172                          D010_r2_Oclacitinib   9.992049334 -3.1057537898
## 2173      D010_r2_Olmutinib (HM61713, BI 1482694)   2.782567294 -1.6442030902
## 2174                             D010_r2_ONO-4059   8.458681355 -1.4031217684
## 2175                              D010_r2_OSI-027   7.358583569 -1.3720350520
## 2176                              D010_r2_OSI-420   7.581787031  0.3364473439
## 2177                 D010_r2_OSI-906 (Linsitinib)  -0.828337561 -1.3522486325
## 2178                              D010_r2_P276-00 -10.118537905  0.8840565777
## 2179                  D010_r2_Pacritinib (SB1518)  -3.011257128 -0.6538387970
## 2180                   D010_r2_Palomid 529 (P529)  11.193809543 -1.7306706954
## 2181                            D010_r2_Pazopanib   3.205254340 -1.8280975210
## 2182                        D010_r2_Pazopanib HCl   0.992302973 -1.7348674777
## 2183                            D010_r2_PD0325901  -5.406003986 -1.0102063718
## 2184                             D010_r2_PD168393   2.079265073 -0.5127768263
## 2185                             D010_r2_PD173955   3.498063224 -0.8713880539
## 2186                   D010_r2_PD184352 (CI-1040)  10.184125318 -0.2620705879
## 2187                             D010_r2_PD318088   0.209943993  0.0708668488
## 2188                              D010_r2_PD98059   5.765474126 -2.5214928579
## 2189                  D010_r2_Pelitinib (EKB-569)   1.948559348  1.3172779917
## 2190                          D010_r2_PF-00562271  -8.741704016 -1.7738204039
## 2191                          D010_r2_PF-04217903   8.562631394 -2.3855920900
## 2192                          D010_r2_PF-04691502   4.528418493 -2.8875517015
## 2193                            D010_r2_PF-431396  -0.423112740 -1.4558777400
## 2194                           D010_r2_PF-4708671  -1.867395362 -1.7454571506
## 2195                           D010_r2_PF-5274857   7.742454067 -2.6236348402
## 2196                            D010_r2_PF-562271  -6.860958193 -1.7470525731
## 2197                            D010_r2_PF-573228   3.703518899 -2.8334093288
## 2198                            D010_r2_PH-797804   6.365818986 -2.0350050494
## 2199                           D010_r2_PHA-665752   2.664514136 -1.6160470785
## 2200                           D010_r2_PHA-680632   1.539189360 -2.4915471262
## 2201                           D010_r2_PHA-767491  -4.543160368 -1.0707517709
## 2202                           D010_r2_PHA-793887   1.299018701 -2.1897620682
## 2203                       D010_r2_Phenformin HCl   5.210362371 -3.1916762570
## 2204                              D010_r2_PHT-427  11.074000870 -1.0460017244
## 2205                          D010_r2_Piceatannol   6.115987549 -1.4983739960
## 2206                              D010_r2_PIK-293   4.071715469 -2.2186788875
## 2207                              D010_r2_PIK-294   5.768154597 -1.7681645294
## 2208                               D010_r2_PIK-93  -4.651358334 -1.1716331598
## 2209               D010_r2_Pimasertib (AS-703026)   1.261832389  1.1404835365
## 2210                          D010_r2_Pirfenidone   7.530529962 -2.1976925796
## 2211                             D010_r2_PLX-4720   3.921944589 -2.9717357894
## 2212                              D010_r2_PLX7904   1.123377400 -1.0059454021
## 2213                  D010_r2_Ponatinib (AP24534)   3.183032035 -2.2939081887
## 2214                                  D010_r2_PP1   5.523481433 -2.4531992468
## 2215                                  D010_r2_PP2   6.107660732 -0.7390091539
## 2216                                D010_r2_PP242  12.330494657 -1.1937880603
## 2217                               D010_r2_PQ 401   2.774203790 -2.4924935559
## 2218                              D010_r2_PRI-724   5.399582942 -2.1569892257
## 2219     D010_r2_PRT062607 (P505-15, BIIB057) HCl   1.942945290 -1.5534303399
## 2220                         D010_r2_Purvalanol A  -0.160506041 -1.8127322127
## 2221                            D010_r2_Quercetin   5.335689651 -2.4030317389
## 2222                  D010_r2_Quizartinib (AC220)   6.359913244 -0.6657262531
## 2223                                 D010_r2_R406   7.188146439 -1.6355421418
## 2224                     D010_r2_R406 (free base)   5.398353489 -2.4163115010
## 2225                                 D010_r2_R547  -4.736308251 -0.7405393796
## 2226                    D010_r2_RAF265 (CHIR-265)  -0.386306283 -0.3002322942
## 2227                D010_r2_Rapamycin (Sirolimus)  12.144883520 -2.1024928179
## 2228   D010_r2_Refametinib (RDEA119, Bay 86-9766)  -2.719012127 -1.6708698744
## 2229                               D010_r2_RepSox   8.403980129 -2.0486747262
## 2230 D010_r2_Ridaforolimus (Deforolimus, MK-8669)  10.991488120 -1.9657905472
## 2231                D010_r2_Rigosertib (ON-01910)  -7.734265319 -0.9004571589
## 2232                             D010_r2_RKI-1447   9.339952865 -2.2891967284
## 2233                                D010_r2_RN486   7.300084492 -2.0934782686
## 2234                  D010_r2_Ro 31-8220 Mesylate  -0.763380785 -0.8905998471
## 2235                              D010_r2_Ro-3306   2.678070647 -2.4087866064
## 2236                               D010_r2_Ro3280  -6.211995462 -0.9001176281
## 2237                            D010_r2_RO4929097  -0.474802067 -2.1869629206
## 2238      D010_r2_Roscovitine (Seliciclib,CYC202)   6.887464157 -2.6263130671
## 2239             D010_r2_Ruxolitinib (INCB018424)   6.619231093 -2.3662813037
## 2240           D010_r2_S-Ruxolitinib (INCB018424)   7.358500927 -1.7266353807
## 2241                               D010_r2_SANT-1   5.459517415 -2.5715963533
## 2242                            D010_r2_SAR131675   7.998483392 -2.9757553384
## 2243                    D010_r2_SAR245409 (XL765)   3.362451680 -2.8593392304
## 2244                D010_r2_Saracatinib (AZD0530)  15.030323335 -1.1861682694
## 2245                      D010_r2_SB202190 (FHPI)   3.899575759 -2.7822009550
## 2246                             D010_r2_SB203580   2.579496742 -2.6884897821
## 2247                             D010_r2_SB216763   4.793953138 -1.9481959457
## 2248                             D010_r2_SB239063   6.795339988 -2.3697858866
## 2249                             D010_r2_SB415286   7.246972117 -2.4160340411
## 2250                             D010_r2_SB431542   8.220216808 -2.1263261374
## 2251                             D010_r2_SB505124   6.063529431 -2.9297934854
## 2252                             D010_r2_SB525334   6.338698126 -2.2824205375
## 2253                             D010_r2_SB590885   4.013502301 -1.7719673068
## 2254                                  D010_r2_SC1   0.300294724 -0.9857608923
## 2255                D010_r2_Schisandrin B (Sch B)   3.933482660 -4.0776266829
## 2256                D010_r2_Selumetinib (AZD6244)  15.157495226  1.0540790476
## 2257              D010_r2_Semagacestat (LY450139)   6.620719252 -2.2661201103
## 2258                   D010_r2_Semaxanib (SU5416)   2.266629818 -1.9420624953
## 2259                             D010_r2_SGI-7079   7.173481420  1.7458200651
## 2260                          D010_r2_Skepinone-L   2.584176929 -2.4349869933
## 2261                               D010_r2_SL-327  16.108042461 -1.1417215767
## 2262                 D010_r2_SNS-032 (BMS-387032)  -3.034716882 -1.6853443722
## 2263                     D010_r2_SNS-314 Mesylate  -1.296027858 -2.4780084119
## 2264                            D010_r2_Sorafenib   5.322202405 -1.4495540559
## 2265                   D010_r2_Sorafenib Tosylate   2.161550049 -1.5447888003
## 2266                         D010_r2_Sotrastaurin   3.049496644 -2.0944807630
## 2267                             D010_r2_SP600125   4.171860434 -1.5525926517
## 2268                              D010_r2_SU11274  13.094921071 -1.1369668109
## 2269                               D010_r2_SU6656   2.203953852 -1.3417735971
## 2270                               D010_r2_SU9516   4.442371808 -1.8351018311
## 2271                     D010_r2_Sunitinib Malate  11.135220847 -0.5329069768
## 2272                  D010_r2_TAE226 (NVP-TAE226)   1.594420659 -0.8042643947
## 2273                              D010_r2_TAK-285   4.110522432 -2.1969400946
## 2274                              D010_r2_TAK-632   2.914879351 -0.2729389396
## 2275                              D010_r2_TAK-715   8.142046976 -2.1008548618
## 2276                              D010_r2_TAK-733  -5.905771992 -0.0326905830
## 2277                              D010_r2_TAK-901   0.234494322 -2.0199918032
## 2278                D010_r2_Taladegib (LY2940680)   3.045620263 -2.2063530894
## 2279                              D010_r2_TCS 359   9.932928823 -4.0313927685
## 2280                               D010_r2_TDZD-8   5.235947700 -1.7466001168
## 2281                            D010_r2_Telatinib   3.839596920 -1.1028435795
## 2282   D010_r2_Temsirolimus (CCI-779, NSC 683864)  14.721026711 -2.1580307326
## 2283              D010_r2_Tepotinib (EMD 1214063)  -3.772865757 -1.0237570726
## 2284                                D010_r2_TG003   5.961143028 -2.3384271995
## 2285                            D010_r2_TG100-115   9.615718925 -2.7202455094
## 2286                             D010_r2_TG101209  -5.048425074 -1.5479395564
## 2287                 D010_r2_TG101348 (SAR302503)  -2.772291626 -1.9560387921
## 2288                              D010_r2_TGX-221   4.779388171 -2.4393380395
## 2289                         D010_r2_Theophylline   7.280331366 -2.0331806203
## 2290                          D010_r2_Thiazovivin   8.253916314 -2.5512576246
## 2291                       D010_r2_TIC10 Analogue   6.827221523 -2.7321754978
## 2292                           D010_r2_Tideglusib   8.703650156 -2.0435836563
## 2293                 D010_r2_Tivantinib (ARQ 197)  -1.411353474 -2.7901554861
## 2294                   D010_r2_Tivozanib (AV-951)   3.950731676 -2.4913475876
## 2295  D010_r2_Tofacitinib (CP-690550,Tasocitinib)   5.856600898 -2.1638173319
## 2296      D010_r2_Tofacitinib (CP-690550) Citrate   7.201266153 -2.0811947424
## 2297                              D010_r2_Torin 2  -4.760069081 -1.1226156172
## 2298              D010_r2_Trametinib (GSK1120212)  -7.514672707 -1.7278198171
## 2299                          D010_r2_Triciribine  -4.163752957 -1.6840504881
## 2300           D010_r2_TSU-68 (SU6668, Orantinib)   1.951664360 -3.2242607389
## 2301                               D010_r2_TWS119   9.332740607 -1.1210996014
## 2302                         D010_r2_Tyrphostin 9   3.106615654 -1.7458384268
## 2303                   D010_r2_Tyrphostin AG 1296   5.713769332 -2.5756070756
## 2304                           D010_r2_U0126-EtOH  15.054907907 -1.8034374050
## 2305     D010_r2_Ulixertinib (BVD-523, VRT752271)   0.020081694  1.0822420931
## 2306              D010_r2_Uprosertib (GSK2141795)   0.922426731 -1.3003151358
## 2307                          D010_r2_Vacquinol-1   4.338834407 -1.6869770518
## 2308                           D010_r2_Varlitinib   5.380308147 -1.5939623569
## 2309              D010_r2_Vatalanib (PTK787) 2HCl  10.551150360 -1.2970972852
## 2310                               D010_r2_VE-821  14.775466189 -0.5999524489
## 2311                               D010_r2_VE-822  -3.312693100 -3.0659840845
## 2312        D010_r2_Vemurafenib (PLX4032, RG7204)   2.279305144 -2.4294335193
## 2313                D010_r2_Vismodegib (GDC-0449)   4.458388891 -2.3157018341
## 2314                 D010_r2_Volasertib (BI 6727)  11.100301490 -1.1859075225
## 2315                            D010_r2_VPS34-IN1  -3.891346190 -1.4075732950
## 2316                     D010_r2_VS-5584 (SB2343)  -3.343995386 -1.8263612625
## 2317                               D010_r2_VX-11e   6.244995312 -0.2710552434
## 2318         D010_r2_VX-680 (Tozasertib, MK-0457)   2.054346161 -1.4828508128
## 2319                               D010_r2_VX-702   4.519676385 -2.8251736072
## 2320                               D010_r2_VX-745   5.554763505 -2.4160533811
## 2321                              D010_r2_WAY-600   5.437188206 -2.6602354702
## 2322                             D010_r2_WH-4-023   4.091532451 -1.0089185918
## 2323                             D010_r2_WHI-P154   8.538246004 -1.8621788774
## 2324                                D010_r2_WIKI4   2.243019710 -2.1298110146
## 2325                        D010_r2_Wnt agonist 1  -0.271146182 -2.2634583351
## 2326                        D010_r2_Wnt-C59 (C59)   3.790794910 -2.6802893300
## 2327                               D010_r2_WP1066   7.061085614 -1.7028449570
## 2328                 D010_r2_WYE-125132 (WYE-132)   4.588661562 -2.1576812658
## 2329                              D010_r2_WYE-354  18.018910640  0.5931151147
## 2330                               D010_r2_WZ3146   6.550283264 -1.4485274311
## 2331                               D010_r2_WZ4002   2.728679265 -2.2653888528
## 2332                               D010_r2_WZ4003   7.630341051 -2.6761913595
## 2333                               D010_r2_WZ8040  12.797723196 -1.2166063487
## 2334                              D010_r2_XAV-939   0.791897703 -2.5394478620
## 2335                                D010_r2_XL019   3.881859880 -2.0632326650
## 2336                              D010_r2_XMD8-92   2.444862574 -1.7419724272
## 2337                         D010_r2_Y-27632 2HCl  11.470472783 -2.2733863603
## 2338                             D010_r2_YM201636   8.116174963 -1.7494002146
## 2339                             D010_r2_YO-01027   5.637472935 -2.7465248472
## 2340                            D010_r2_ZM 306416   6.204111853 -0.9017330968
## 2341                        D010_r2_ZM 323881 HCl   7.776944081 -2.4247422635
## 2342                            D010_r2_ZM 336372   4.517812136 -3.2486083997
## 2343                         D010_r2_ZM 39923 HCl   6.288079470 -1.9624602977
## 2344                            D010_r2_ZM 447439   4.843765421 -2.1938264811
## 2345                 D010_r2_Zotarolimus(ABT-578)   9.489601614 -1.8132968257
## 2346                              D010_r2_ZSTK474   8.366063056 -1.1886207456
## 2347                     D013_r1_1-Azakenpaullone  -8.945514634  2.2194331639
## 2348                      D013_r1_3-Methyladenine  -5.168809117  0.6535806818
## 2349                             D013_r1_A-674563  -8.485389737  0.9652445250
## 2350                             D013_r1_A-769662  -5.372901829  0.2064718566
## 2351                                  D013_r1_A66  -9.802949813  1.5530581759
## 2352         D013_r1_AG-1478 (Tyrphostin AG-1478)  -6.967885273  3.1317434082
## 2353              D013_r1_AG-490 (Tyrphostin B42)  -4.790047935  0.1178865693
## 2354                             D013_r1_Akti-1/2  -9.806578749  1.4290759579
## 2355                              D013_r1_AMG-458  -3.953292202  0.4450020103
## 2356                              D013_r1_AMG-900 -11.568653237  0.1252390752
## 2357                               D013_r1_AMG319  -6.196923326  1.3287539261
## 2358                           D013_r1_AR-A014418  -6.434855923  0.2294662033
## 2359                            D013_r1_AS-252424  -4.270955248  0.3754415257
## 2360                            D013_r1_AS-604850  -5.732132011  1.0028836280
## 2361                               D013_r1_AT9283 -11.130839254  0.6738972209
## 2362             D013_r1_Avagacestat (BMS-708163)  -6.262567329  0.3031948027
## 2363                              D013_r1_AVL-292  -8.910129465  1.4986392070
## 2364                               D013_r1_AZ 628  -7.210425510  0.8988466818
## 2365                               D013_r1_AZ 960  -8.104644897  1.7493591917
## 2366                                 D013_r1_AZ20  -9.077288745  2.4935409115
## 2367                              D013_r1_AZD1080  -9.167029365  2.4867306754
## 2368                              D013_r1_AZD1480 -10.922543640  2.8754689749
## 2369                              D013_r1_AZD2014  -8.943902525  1.7842389930
## 2370                              D013_r1_AZD2858  -9.427129720  2.5595208411
## 2371                              D013_r1_AZD2932  -7.021963977  0.9240781761
## 2372                              D013_r1_AZD3759  -5.692961018  3.0274241849
## 2373                              D013_r1_AZD5438  -5.344679160  1.5981264934
## 2374                              D013_r1_AZD6738 -10.015609829  1.4631375258
## 2375                              D013_r1_AZD9291 -16.878550508  1.5570086047
## 2376  D013_r1_Baricitinib (LY3009104, INCB028050)  -7.594742583  1.0629076513
## 2377                  D013_r1_BGT226 (NVP-BGT226) -17.694576120  1.3344368974
## 2378                             D013_r1_BI-D1870  -7.916377970  0.4876620511
## 2379                                  D013_r1_BIO  -4.208816442 -0.4935700459
## 2380                           D013_r1_BMS-833923  -2.736492593 -0.3225831990
## 2381                               D013_r1_Butein  -7.479609351  0.7387862157
## 2382                               D013_r1_BYL719  -9.179798139  2.0656055950
## 2383          D013_r1_Cabozantinib malate (XL184)  -6.145057935  0.2216275996
## 2384                             D013_r1_CAY10505  -5.181842222  0.2001978965
## 2385                            D013_r1_CCT128930  -5.334037954 -0.8587643023
## 2386                            D013_r1_CEP-33779  -5.836753128  0.4007573637
## 2387                              D013_r1_CGI1746  -9.534015356  2.1197459265
## 2388                              D013_r1_CGK 733  -6.892785512  1.2081000905
## 2389                            D013_r1_CH5132799  -4.680168802  1.1181600525
## 2390                           D013_r1_CHIR-98014 -10.003160546  1.8039746988
## 2391             D013_r1_CHIR-99021 (CT99021) HCl  -9.634604963  1.8347798749
## 2392                    D013_r1_Chrysophanic Acid  -6.138966131  0.2686573941
## 2393                             D013_r1_CNX-2006 -13.990464152  2.8893590619
## 2394                              D013_r1_CNX-774 -12.573707948  2.0944701220
## 2395                    D013_r1_CO-1686 (AVL-301) -10.791119825  0.6018191522
## 2396       D013_r1_Cobimetinib (GDC-0973, RG7420)  -8.185625302  2.3141309596
## 2397               D013_r1_Crenolanib (CP-868596) -11.861576432  3.3302092121
## 2398                               D013_r1_CYT387  -7.512770141 -0.3270320732
## 2399                             D013_r1_CZC24832  -6.046336272  0.6990709055
## 2400              D013_r1_Dabrafenib (GSK2118436)  -9.784270121 -0.7952418395
## 2401        D013_r1_Dacomitinib (PF299804, PF299) -11.482860890  1.6327940242
## 2402                        D013_r1_DAPT (GSI-IX)  -9.544278635  0.9727980486
## 2403                D013_r1_DCC-2036 (Rebastinib)  -7.166711905  1.6007215246
## 2404                D013_r1_Decernotinib (VX-509)  -4.162485249 -0.4788011404
## 2405               D013_r1_Dinaciclib (SCH727965)  -7.925097821  2.1132705215
## 2406    D013_r1_Dovitinib (TKI-258) Dilactic Acid  -6.766517204  2.6126273604
## 2407               D013_r1_Enzastaurin (LY317615)  -9.393574308  0.2216224245
## 2408                            D013_r1_ERK5-IN-1  -5.178561006  1.9663274707
## 2409                            D013_r1_ETP-46464  -6.340254433  0.6682574642
## 2410                D013_r1_Fasudil (HA-1077) HCl  -7.443125099  0.1269645873
## 2411                                D013_r1_FH535  -2.534467228 -0.0518136211
## 2412                D013_r1_Filgotinib (GLPG0634)  -7.451183422  0.5721888376
## 2413                     D013_r1_Flavopiridol HCl  -6.373523195  1.5190033904
## 2414                  D013_r1_Fostamatinib (R788)  -9.165330061  1.6799055114
## 2415                             D013_r1_GDC-0068  -2.407928110 -1.0675457291
## 2416                             D013_r1_GDC-0349  -9.321303098  0.3431528805
## 2417                    D013_r1_GDC-0980 (RG7422)  -2.753724452  2.7368926592
## 2418                            D013_r1_GF109203X  -8.469825816  1.7917808667
## 2419                                D013_r1_GNF-2  -5.684016707  0.9961204980
## 2420                                D013_r1_GNF-5  -9.541557310  0.7513825970
## 2421                              D013_r1_Go 6983  -8.620307716  1.7251990387
## 2422                   D013_r1_Golvatinib (E7050)  -9.621823110  2.2681197542
## 2423                          D013_r1_GSK1838705A -10.216479339  4.3611443723
## 2424                  D013_r1_GSK2126458 (GSK458)  -3.643831564  2.1445266510
## 2425                           D013_r1_GSK2636771  -6.676549634  0.7622696543
## 2426                           D013_r1_GSK429286A  -7.160025786  0.8311271145
## 2427                               D013_r1_GW5074  -7.126985987  0.8988903685
## 2428                             D013_r1_GW788388  -5.898645474  0.0620409396
## 2429                               D013_r1_GZD824  -7.070736612  0.8093741987
## 2430                               D013_r1_HS-173 -10.368024182  2.8695250703
## 2431                           D013_r1_HTH-01-015 -13.057968815  1.8912722978
## 2432                D013_r1_Ibrutinib (PCI-32765)  -6.611469500  1.7729508677
## 2433                              D013_r1_ICG-001  -8.613363377  0.7843368352
## 2434                             D013_r1_Icotinib  -6.826588411  0.1078474944
## 2435                                D013_r1_IM-12  -8.137407766  0.5268163598
## 2436                            D013_r1_Indirubin  -1.939106863 -0.2806228638
## 2437                    D013_r1_INK 128 (MLN0128)  -3.644251057  1.7337121061
## 2438                    D013_r1_IPI-145 (INK1197)  -8.106730194  1.0495919260
## 2439                               D013_r1_IWP-L6  -5.812999073  0.7715164384
## 2440                           D013_r1_IWR-1-endo  -5.320542368 -0.2443673894
## 2441                     D013_r1_JNK Inhibitor IX  -8.287893904  1.6139521868
## 2442                             D013_r1_JNK-IN-8 -13.890125856  1.8625211491
## 2443                               D013_r1_K02288  -7.203096595  0.4208520935
## 2444                              D013_r1_KX2-391 -11.745606980  1.6435091293
## 2445                              D013_r1_KY02111  -7.489532056  0.7887969873
## 2446                            D013_r1_LDC000067  -7.667612620  0.4195688969
## 2447      D013_r1_LDE225 (NVP-LDE225,Erismodegib)  -7.689900005  0.7504453750
## 2448                           D013_r1_LDN-214117  -6.461939160  0.5829484551
## 2449                              D013_r1_LGK-974  -8.196539436  1.1383749099
## 2450                               D013_r1_LJH685  -9.427502244  1.5410425605
## 2451               D013_r1_Losmapimod (GW856553X)  -6.302310214 -0.0349526232
## 2452                            D013_r1_LY2090314  -8.833448635  1.6318948762
## 2453                            D013_r1_LY2157299  -6.546826627 -0.0344098911
## 2454                            D013_r1_LY2784544  -9.923521901  1.3364780691
## 2455                            D013_r1_LY2835219 -12.192685591  3.1134913354
## 2456                             D013_r1_LY411575  -5.731888540  0.6346804558
## 2457       D013_r1_MEK162 (ARRY-162, ARRY-438162)  -8.817414615  1.8190967787
## 2458               D013_r1_Milciclib (PHA-848125)  -9.679650661  1.6548287874
## 2459                              D013_r1_MK-0752  -5.932164980  0.6555981589
## 2460                              D013_r1_MK-2461  -8.639824998  1.1110026350
## 2461                     D013_r1_MK-5108 (VX-689)  -9.185997090  1.1584711663
## 2462                              D013_r1_MK-8745 -11.964258634  2.3123653497
## 2463                              D013_r1_MLN2480  -6.834182962 -0.3698047653
## 2464                               D013_r1_NU6027  -7.847941621  1.1851795468
## 2465                      D013_r1_NVP-BSK805 2HCl -10.464946924  1.4190073913
## 2466                           D013_r1_NVP-BVU972  -8.073227514  0.0176278131
## 2467                          D013_r1_Oclacitinib  -7.166234610  0.2967644362
## 2468                              D013_r1_OSI-027  -8.116341225  0.6101789840
## 2469                              D013_r1_P276-00  -4.181635758  1.1877990339
## 2470                  D013_r1_Pacritinib (SB1518)  -8.122033420  0.6397982255
## 2471                            D013_r1_Pazopanib  -7.474656898  1.3849242426
## 2472                             D013_r1_PD168393  -6.867958787  2.5496049667
## 2473                             D013_r1_PD173955 -10.465414231  2.4242116352
## 2474                          D013_r1_PF-00562271  -9.225548651  2.5349113494
## 2475                          D013_r1_PF-04691502  -4.110039117  2.0152148467
## 2476                            D013_r1_PF-431396  -8.159714925  2.7567867859
## 2477                           D013_r1_PF-5274857  -8.282931224  0.8196676904
## 2478                            D013_r1_PF-562271  -8.320968085  1.6473729483
## 2479                            D013_r1_PH-797804  -5.680394445  0.5938151679
## 2480                           D013_r1_PHA-767491  -8.922911813  1.8886269746
## 2481                       D013_r1_Phenformin HCl  -7.055524363  0.3871381011
## 2482                          D013_r1_Piceatannol  -9.159107996  1.9865766232
## 2483                          D013_r1_Pirfenidone  -7.804051005  0.5388527684
## 2484                              D013_r1_PLX7904  -8.062338029  0.2671916040
## 2485                                  D013_r1_PP1  -9.955756155  1.7108344816
## 2486                                  D013_r1_PP2  -8.996380097  2.5762988470
## 2487                               D013_r1_PQ 401  -6.353036936  0.7440884969
## 2488                              D013_r1_PRI-724  -6.044155011 -0.0048830000
## 2489                         D013_r1_Purvalanol A  -9.872966431  1.5783912834
## 2490                            D013_r1_Quercetin  -5.756648598 -0.5023209479
## 2491                                 D013_r1_R547   0.495671701  0.5604557773
## 2492                               D013_r1_RepSox  -8.352551215  1.6567429868
## 2493                             D013_r1_RKI-1447  -5.790467648  0.8480817816
## 2494                                D013_r1_RN486 -10.203575845  1.0288291423
## 2495                  D013_r1_Ro 31-8220 Mesylate  -0.043521693  0.9699069247
## 2496                               D013_r1_Ro3280  -9.039304973  2.8967505762
## 2497                            D013_r1_RO4929097  -6.823501337  1.1818791959
## 2498             D013_r1_Ruxolitinib (INCB018424)  -7.672120334  0.7494953457
## 2499           D013_r1_S-Ruxolitinib (INCB018424)  -7.686187793  0.7407995041
## 2500                               D013_r1_SANT-1  -6.978517159 -0.3261117633
## 2501                            D013_r1_SAR131675  -9.509023812  1.2855606186
## 2502                             D013_r1_SB216763 -10.122335394  1.2904343019
## 2503                             D013_r1_SB415286  -5.374954893  0.3267176140
## 2504                             D013_r1_SB431542  -6.604572645  0.2270780254
## 2505                             D013_r1_SB505124  -6.210586286  1.0703079305
## 2506                             D013_r1_SB525334  -6.122098212  0.5561699746
## 2507                                  D013_r1_SC1 -14.329883981  1.1350422518
## 2508                D013_r1_Schisandrin B (Sch B)  -7.676769749 -0.1182424365
## 2509              D013_r1_Semagacestat (LY450139)  -7.076576396 -0.0255980506
## 2510                   D013_r1_Semaxanib (SU5416)  -5.707473069  0.5229285562
## 2511                             D013_r1_SGI-7079  -5.740986121  1.2544691649
## 2512                          D013_r1_Skepinone-L  -4.821167879  0.4251619918
## 2513                            D013_r1_Sorafenib  -5.376176708  0.0256691004
## 2514                         D013_r1_Sotrastaurin  -6.446790796  0.0323816310
## 2515                               D013_r1_SU6656  -9.589869903  1.3684990558
## 2516                               D013_r1_SU9516  -8.516900559  2.1882496992
## 2517                  D013_r1_TAE226 (NVP-TAE226)  -6.515873140  2.8597316437
## 2518                              D013_r1_TAK-285  -7.515164720  1.7088169934
## 2519                              D013_r1_TAK-632  -8.789139237  2.2554521770
## 2520                              D013_r1_TAK-715  -7.696190160  0.3658280334
## 2521                              D013_r1_TAK-733  -8.692204501  2.0749797205
## 2522                              D013_r1_TAK-901 -11.640708616 -0.1706994641
## 2523                D013_r1_Taladegib (LY2940680)  -5.150480169 -0.6105307083
## 2524                               D013_r1_TDZD-8  -9.161659955  0.7166845455
## 2525              D013_r1_Tepotinib (EMD 1214063)  -6.227870918  1.0713319297
## 2526                                D013_r1_TG003  -6.354048284 -0.4628771051
## 2527                             D013_r1_TG101209 -12.045664340  2.1382617089
## 2528                 D013_r1_TG101348 (SAR302503) -11.591691293  1.2249730066
## 2529                         D013_r1_Theophylline  -6.759546374  1.0468240283
## 2530                          D013_r1_Thiazovivin  -8.683216782  0.8987764160
## 2531                       D013_r1_TIC10 Analogue  -4.480735344 -0.0063273431
## 2532                           D013_r1_Tideglusib  -8.735003883  0.7811362777
## 2533                 D013_r1_Tivantinib (ARQ 197) -12.070990054  1.5921408638
## 2534  D013_r1_Tofacitinib (CP-690550,Tasocitinib)  -7.201909629  0.3034867633
## 2535      D013_r1_Tofacitinib (CP-690550) Citrate  -8.809742665  1.1443576246
## 2536                              D013_r1_Torin 2  -8.114561113  3.4388956774
## 2537              D013_r1_Trametinib (GSK1120212)  -6.111293312  1.5418200321
## 2538                               D013_r1_TWS119  -6.812145808  0.4994341295
## 2539                         D013_r1_Tyrphostin 9  -9.742196127  0.1078477408
## 2540     D013_r1_Ulixertinib (BVD-523, VRT752271)  -7.473917501  1.6910356265
## 2541              D013_r1_Uprosertib (GSK2141795)  -8.062550485  0.5673364511
## 2542                           D013_r1_Varlitinib  -7.482433498  0.9722669550
## 2543                               D013_r1_VE-822 -11.462213919  1.3426279288
## 2544                D013_r1_Vismodegib (GDC-0449)  -7.410392597  0.6049414833
## 2545                            D013_r1_VPS34-IN1  -9.980544443  2.0178347724
## 2546                     D013_r1_VS-5584 (SB2343)  -0.273340246  1.2445966939
## 2547                               D013_r1_VX-702  -7.625667859  0.7464932967
## 2548                              D013_r1_WAY-600 -10.596768787  0.7103750631
## 2549                             D013_r1_WHI-P154  -6.892319139  0.2715547517
## 2550                                D013_r1_WIKI4  -7.473465033  1.2996726671
## 2551                        D013_r1_Wnt agonist 1 -10.896683236  2.1968711519
## 2552                        D013_r1_Wnt-C59 (C59)  -5.475077283  0.0774444269
## 2553                               D013_r1_WP1066  -7.559611632  0.8937741401
## 2554                 D013_r1_WYE-125132 (WYE-132)  -4.882670220  1.0222543818
## 2555                               D013_r1_WZ4003  -8.130049970  0.7497674225
## 2556                              D013_r1_XAV-939  -9.721574656  1.5846555532
## 2557                                D013_r1_XL019  -9.235148299  0.5732000458
## 2558                              D013_r1_XMD8-92  -9.017837699  1.0752594462
## 2559                         D013_r1_Y-27632 2HCl  -8.279751077  1.0100138795
## 2560                             D013_r1_YO-01027  -5.885316909  1.2521079849
## 2561                            D013_r1_ZM 306416  -7.609326025  1.0447264543
## 2562                        D013_r1_ZM 323881 HCl  -9.440151999  1.4656308120
## 2563                            D013_r1_ZM 336372  -8.025948047  1.6822645037
## 2564                         D013_r1_ZM 39923 HCl  -5.520588497  0.2463439608
## 2565                 D013_r1_Zotarolimus(ABT-578)  -5.754684232 -0.3076080376
## 2566                     D013_r2_1-Azakenpaullone  -8.749222327  0.1215931139
## 2567                      D013_r2_3-Methyladenine  -6.233050522  0.1467742637
## 2568                             D013_r2_A-674563  -6.576596158  0.5942925920
## 2569                             D013_r2_A-769662  -3.643173731 -0.7403378635
## 2570                                  D013_r2_A66  -7.075350358  0.7360736284
## 2571                            D013_r2_Acadesine  -8.292739919 -0.0213410218
## 2572                  D013_r2_AEE788 (NVP-AEE788)  -6.092059897 -0.3272036050
## 2573        D013_r2_Afatinib (BIBW2992)_uncertain  -6.923237052 -0.9767974313
## 2574                              D013_r2_AG-1024  -7.793949748 -0.6995409078
## 2575         D013_r2_AG-1478 (Tyrphostin AG-1478)  -0.006256273  1.7823640894
## 2576                                D013_r2_AG-18  -5.184112805 -0.3010481078
## 2577              D013_r2_AG-490 (Tyrphostin B42)  -0.781728164  0.2174678401
## 2578                             D013_r2_Akti-1/2  -4.414204477 -0.7755325784
## 2579                  D013_r2_Alisertib (MLN8237) -12.191456662 -0.4050215757
## 2580                              D013_r2_AMG 337  -4.102578953 -0.9048427517
## 2581                              D013_r2_AMG-458  -5.471531568  0.7203708466
## 2582                              D013_r2_AMG-900 -11.489136703  1.2329907626
## 2583                               D013_r2_AMG319  -1.421672997 -0.5468141297
## 2584                  D013_r2_Amuvatinib (MP-470)  -9.660851526  0.5415070526
## 2585                             D013_r2_Apatinib  -7.654788205 -0.5002922799
## 2586                           D013_r2_AR-A014418  -6.135482604 -0.6354601041
## 2587                            D013_r2_AS-252424  -6.742810529 -0.5833256085
## 2588                            D013_r2_AS-604850  -4.605752055 -0.6174179870
## 2589                         D013_r2_Asiatic Acid  -5.902579570 -0.4749552708
## 2590                             D013_r2_AST-1306 -17.429748721  2.8261846761
## 2591                              D013_r2_AT13148 -13.315372097 -0.1505394352
## 2592                               D013_r2_AT7519 -11.514947706 -2.7517914538
## 2593                               D013_r2_AT7867 -18.610662936  0.4699854186
## 2594                               D013_r2_AT9283 -13.512306530 -0.1935253738
## 2595                 D013_r2_Aurora A Inhibitor I  -7.488086560 -0.6367272015
## 2596             D013_r2_Avagacestat (BMS-708163)  -4.651127311 -0.9161920271
## 2597                              D013_r2_AVL-292  -4.398488853 -0.1854255304
## 2598                             D013_r2_Axitinib  -1.949432077 -0.8193892248
## 2599                             D013_r2_Axitinib  -1.949432077 -0.8193892248
## 2600                               D013_r2_AZ 628  -1.157553132 -0.5082766932
## 2601                               D013_r2_AZ 960  -6.547245809 -0.4450020807
## 2602                                 D013_r2_AZ20 -10.026413013  1.1237850060
## 2603                              D013_r2_AZD1080  -6.949636779 -0.0481356981
## 2604                              D013_r2_AZD1480 -13.613297091  0.8560778072
## 2605                              D013_r2_AZD2014  -3.335133282 -1.8654183469
## 2606                              D013_r2_AZD2858  -8.521922530  0.4830663763
## 2607                              D013_r2_AZD2932  -4.778164041  0.2892876779
## 2608                              D013_r2_AZD3759  -7.853985225  0.6655974332
## 2609                              D013_r2_AZD5363 -24.805932503  0.5883496762
## 2610                              D013_r2_AZD5438 -12.050889899  0.1297499187
## 2611                              D013_r2_AZD6482  -8.910982318 -0.8266803069
## 2612                              D013_r2_AZD6738  -9.286245867  3.2967668231
## 2613                              D013_r2_AZD8055 -13.098234204 -2.1837431204
## 2614                              D013_r2_AZD8330  -8.457743942  0.8215455744
## 2615                  D013_r2_AZD8931 (Sapitinib) -12.066572723 -1.3182448705
## 2616                              D013_r2_AZD9291 -10.576886588  1.5924938658
## 2617            D013_r2_Barasertib (AZD1152-HQPA) -13.069145734 -2.1629995248
## 2618  D013_r2_Baricitinib (LY3009104, INCB028050)  -6.347651420 -0.7527432869
## 2619                  D013_r2_BGT226 (NVP-BGT226)  -3.832156615  2.3057869268
## 2620                              D013_r2_BI 2536 -11.335436423  0.2820107320
## 2621                              D013_r2_BI-78D3  -6.204633078 -0.2488701444
## 2622                             D013_r2_BI-D1870  -6.669594932  0.1656731756
## 2623                              D013_r2_Bikinin  -4.164110638 -0.5528845249
## 2624                                  D013_r2_BIO  -6.449699404  0.3727050303
## 2625               D013_r2_BIRB 796 (Doramapimod)  -2.115910695 -0.0017923841
## 2626                            D013_r2_BIX 02188  -5.157508496 -0.6644610252
## 2627                            D013_r2_BIX 02189  -5.814763530  0.7230359826
## 2628      D013_r2_BKM120 (NVP-BKM120, Buparlisib) -14.082042919 -1.2167149277
## 2629                           D013_r2_BMS-265246  -7.311475394 -0.5829025630
## 2630                           D013_r2_BMS-536924  -5.537944046 -0.6241688332
## 2631                           D013_r2_BMS-582949  -5.854094413 -0.8993310352
## 2632                           D013_r2_BMS-754807  -9.268961719 -1.9423749248
## 2633                           D013_r2_BMS-777607  -4.877432518 -1.3347323763
## 2634                           D013_r2_BMS-794833  -7.612281177 -1.3973654502
## 2635                           D013_r2_BMS-833923  -1.969611752 -1.0079984093
## 2636                  D013_r2_Bosutinib (SKI-606) -13.255549286 -2.5480529512
## 2637                D013_r2_Brivanib (BMS-540215)  -3.711744895 -0.2982024230
## 2638      D013_r2_Brivanib Alaninate (BMS-582664)  -3.137747276 -0.0055256907
## 2639                           D013_r2_BS-181 HCl  -7.250663193 -1.3040098891
## 2640                               D013_r2_Butein  -2.390849514 -0.4126293212
## 2641                               D013_r2_BYL719  -7.868896801  0.6800434989
## 2642     D013_r2_Cabozantinib (XL184, BMS-907351)  -5.799460590 -1.0138574083
## 2643          D013_r2_Cabozantinib malate (XL184) -11.404108791  1.2326540955
## 2644        D013_r2_CAL-101 (Idelalisib, GS-1101)  -6.454388509 -0.8579510005
## 2645                             D013_r2_CAY10505  -4.607729850 -0.4008366065
## 2646                               D013_r2_CC-223  -8.908255342 -0.7285074746
## 2647                            D013_r2_CCT128930  -3.437877943  0.0715974277
## 2648                  D013_r2_Cediranib (AZD2171)   6.232315190 -2.2621669706
## 2649                            D013_r2_CEP-32496  -2.184798860 -1.3467679536
## 2650                            D013_r2_CEP-33779  -8.338706043  0.0176663112
## 2651                              D013_r2_CGI1746  -4.537519719 -0.9652788708
## 2652                              D013_r2_CGK 733  -3.539104226 -0.7892827945
## 2653                            D013_r2_CH5132799  -2.960217835 -1.3146723488
## 2654                           D013_r2_CHIR-98014  -8.460261002  0.1988952808
## 2655                 D013_r2_CHIR-99021 (CT99021)  -8.838672413 -0.8749004276
## 2656             D013_r2_CHIR-99021 (CT99021) HCl  -7.952989738  0.0954422832
## 2657                    D013_r2_Chrysophanic Acid  -6.594243440 -0.1969154895
## 2658                             D013_r2_CNX-2006  -8.867294727  1.4684103407
## 2659                              D013_r2_CNX-774  -8.355784509  1.3112937753
## 2660                    D013_r2_CO-1686 (AVL-301)  -5.066469598  0.7609439514
## 2661       D013_r2_Cobimetinib (GDC-0973, RG7420)  -7.087293046  0.8492234944
## 2662                            D013_r2_CP-673451 -12.771628165  1.0195667663
## 2663                            D013_r2_CP-724714  -7.236450948 -0.6965118171
## 2664               D013_r2_Crenolanib (CP-868596)  -8.169160999  1.2421054674
## 2665             D013_r2_Crizotinib (PF-02341066)  -6.092764569 -1.1567807711
## 2666                               D013_r2_CYC116 -14.250084692 -0.3694404536
## 2667                               D013_r2_CYT387  -4.888908896 -0.3414547007
## 2668                             D013_r2_CZC24832  -8.529297806  0.8432649044
## 2669              D013_r2_Dabrafenib (GSK2118436)  -9.811984002 -1.3117881781
## 2670        D013_r2_Dacomitinib (PF299804, PF299) -10.149289582  1.8676109211
## 2671              D013_r2_Danusertib (PHA-739358) -15.605851157 -0.7777794691
## 2672                        D013_r2_DAPT (GSI-IX)  -1.826437975 -1.0324716998
## 2673                            D013_r2_Dasatinib   4.071323362 -0.6486270747
## 2674                D013_r2_DCC-2036 (Rebastinib)  -9.323497487  0.2497595438
## 2675                D013_r2_Decernotinib (VX-509)  -5.234704541 -0.3737497512
## 2676               D013_r2_Dinaciclib (SCH727965) -11.750295723  1.0927302105
## 2677    D013_r2_Dovitinib (TKI-258) Dilactic Acid -11.441965251  1.1798873785
## 2678                            D013_r2_ENMD-2076 -13.135682673 -0.4706422407
## 2679               D013_r2_Enzastaurin (LY317615)  -7.021711310  0.0845401368
## 2680                            D013_r2_ERK5-IN-1  -6.029466259 -0.3240965232
## 2681                             D013_r2_ETC-1002  -8.521394496 -1.6712155765
## 2682                            D013_r2_ETP-46464  -8.594129333  0.2563031635
## 2683                  D013_r2_Everolimus (RAD001) -11.084419785  1.0548747561
## 2684                D013_r2_Fasudil (HA-1077) HCl  -7.204254566 -0.8037742927
## 2685                                D013_r2_FH535   7.765115968 -0.9642247269
## 2686                D013_r2_Filgotinib (GLPG0634)  -6.286053568 -0.2697938567
## 2687             D013_r2_Flavopiridol (Alvocidib) -13.699250044 -1.6248329848
## 2688                     D013_r2_Flavopiridol HCl  -4.669289623  1.3134434138
## 2689               D013_r2_Foretinib (GSK1363089) -14.732805045 -0.6145687941
## 2690                  D013_r2_Fostamatinib (R788)  -9.648591693  0.0131877592
## 2691                                D013_r2_G-749  -6.319266267 -0.9691027205
## 2692                             D013_r2_GDC-0068   0.427726501 -3.5759206321
## 2693                             D013_r2_GDC-0349  -6.165004560 -1.6614598016
## 2694                             D013_r2_GDC-0879   2.088151892 -1.0567048771
## 2695                             D013_r2_GDC-0941  -8.937956991 -1.8975751774
## 2696                    D013_r2_GDC-0980 (RG7422)  -1.617024753 -1.5104031876
## 2697                   D013_r2_Gefitinib (ZD1839)  -6.389923572  0.3419678056
## 2698                            D013_r2_Genistein  -5.322183720 -0.2180724685
## 2699                            D013_r2_GF109203X  -7.436826090  0.8511091797
## 2700                                D013_r2_GNF-2  -3.699401772  1.1468884465
## 2701                                D013_r2_GNF-5  -5.714675889  0.4414814302
## 2702                              D013_r2_Go 6983  -7.148592037  0.0624414260
## 2703                   D013_r2_Golvatinib (E7050)  -9.420058427  2.4041851917
## 2704                          D013_r2_GSK1838705A  -6.247882773 -1.0207305264
## 2705                          D013_r2_GSK1904529A  -5.306984865 -0.3487889478
## 2706                  D013_r2_GSK2126458 (GSK458)  -8.793395425  1.6007579113
## 2707                           D013_r2_GSK2292767 -17.229194359  0.8188209953
## 2708                           D013_r2_GSK2636771  -9.067225506  0.0533561271
## 2709                           D013_r2_GSK429286A  -5.139977131 -0.2464998913
## 2710                            D013_r2_GSK461364 -13.192178415 -0.8610570935
## 2711                               D013_r2_GSK621  -6.910744828  0.1747132145
## 2712                            D013_r2_GSK690693 -20.845039595  1.8331378239
## 2713                               D013_r2_GW5074  -8.642691630  0.7455483006
## 2714                             D013_r2_GW788388  -3.438094447 -0.1545506400
## 2715                               D013_r2_GZD824  -6.110300694  3.2891010086
## 2716                            D013_r2_H 89 2HCl  -6.932050043 -1.1323813983
## 2717                           D013_r2_Hesperadin -10.748909397 -0.5841197161
## 2718                              D013_r2_HMN-214 -17.895601245 -2.4537132246
## 2719                             D013_r2_Honokiol   2.462168517  1.3061494424
## 2720                               D013_r2_HS-173 -12.915044606  2.1348765441
## 2721                           D013_r2_HTH-01-015 -16.261788285  2.2319479653
## 2722                D013_r2_Ibrutinib (PCI-32765)  -6.984611323  1.1387330016
## 2723                              D013_r2_ICG-001  -4.966547303 -0.4104914149
## 2724                             D013_r2_Icotinib  -7.338477578  0.3901521727
## 2725                                D013_r2_IM-12  -7.281957819 -1.2994372055
## 2726           D013_r2_Imatinib Mesylate (STI571)  -6.461402995  1.4028437947
## 2727                            D013_r2_Indirubin  -2.827261577 -0.9584945226
## 2728                    D013_r2_INK 128 (MLN0128)  -0.199054009 -1.7319178011
## 2729                    D013_r2_IPI-145 (INK1197)  -8.074045339 -0.0030634659
## 2730                               D013_r2_IWP-L6  -9.608900348  0.1367890433
## 2731                           D013_r2_IWR-1-endo  -5.256726614 -0.1918421437
## 2732                         D013_r2_JNJ-38877605  -6.037778276 -0.5113252210
## 2733                          D013_r2_JNJ-7706621 -11.767888056  0.4264493782
## 2734                     D013_r2_JNK Inhibitor IX -14.888969022  1.9536107783
## 2735                             D013_r2_JNK-IN-8  -5.957853035  2.6039246320
## 2736                               D013_r2_K02288  -2.898829401 -0.7778761591
## 2737                               D013_r2_Ki8751 -10.657092284 -1.0229528280
## 2738                              D013_r2_KRN 633  -3.784878965 -1.1291013426
## 2739                           D013_r2_KU-0063794 -12.022321267  1.6625659947
## 2740      D013_r2_KU-55933 (ATM Kinase Inhibitor)  -4.392983676 -0.4010166769
## 2741                             D013_r2_KU-60019 -11.633585690 -0.5221139839
## 2742                              D013_r2_KW-2449   1.470268909  0.1121805684
## 2743                              D013_r2_KX2-391 -10.212572283  2.1381669524
## 2744                              D013_r2_KY02111  -4.314739925 -0.1764965579
## 2745                            D013_r2_Lapatinib -12.676133981 -1.2141910675
## 2746     D013_r2_Lapatinib (GW-572016) Ditosylate  -1.417801355 -2.3118580555
## 2747                            D013_r2_LDC000067  -4.934250502  0.3908012037
## 2748      D013_r2_LDE225 (NVP-LDE225,Erismodegib)  -2.621373818 -0.5664950772
## 2749                           D013_r2_LDN-214117  -5.821304765  1.4368754945
## 2750                   D013_r2_Lenvatinib (E7080)  -3.250761782 -0.9339108627
## 2751                              D013_r2_LFM-A13  -4.813516304 -1.3176737486
## 2752                              D013_r2_LGK-974  -4.649082679 -0.7789335680
## 2753                  D013_r2_Linifanib (ABT-869)  -5.070736126 -1.8426926553
## 2754                               D013_r2_LJH685  -4.424651049  0.0610006839
## 2755                               D013_r2_LJI308  -0.074764195 -1.7262106562
## 2756               D013_r2_Losmapimod (GW856553X)  -3.448135900 -0.1977875984
## 2757                            D013_r2_LY2090314  -6.142623944  2.7820563405
## 2758                            D013_r2_LY2157299  -0.979915821 -0.6417374081
## 2759                            D013_r2_LY2784544 -10.093763185 -0.6906317585
## 2760                            D013_r2_LY2835219 -10.527268075  1.3210952693
## 2761                             D013_r2_LY294002  -7.469723062 -0.6684262488
## 2762                            D013_r2_LY3023414  -9.032987760 -2.3045180395
## 2763                             D013_r2_LY411575  -5.689394393  0.3768119858
## 2764       D013_r2_MEK162 (ARRY-162, ARRY-438162)  -6.216113723 -0.1553432657
## 2765                             D013_r2_MGCD-265  -4.565785814 -0.5751031038
## 2766               D013_r2_Milciclib (PHA-848125) -10.536114276  0.5939719002
## 2767                              D013_r2_MK-0752  -3.638337108 -0.4128127086
## 2768                         D013_r2_MK-2206 2HCl -17.931709327 -0.2583941419
## 2769                              D013_r2_MK-2461  -7.291636366  0.2202758352
## 2770                     D013_r2_MK-5108 (VX-689) -10.124262061 -0.1150986108
## 2771                              D013_r2_MK-8745  -9.200942801  1.6701874266
## 2772                              D013_r2_MLN2480  -3.090143207 -1.5093183854
## 2773                              D013_r2_MLN8054  -5.330523112 -2.2604151752
## 2774      D013_r2_Motesanib Diphosphate (AMG-706)   7.324053191 -3.2011177641
## 2775                  D013_r2_Nilotinib (AMN-107)  -2.985364664 -0.7975487709
## 2776     D013_r2_Nintedanib (BIBF 1120)_uncertain  -6.571616236  0.7029846657
## 2777                               D013_r2_NU6027  -2.768029149 -0.7743920966
## 2778                           D013_r2_NVP-AEW541  -6.588797605 -0.4003236375
## 2779                           D013_r2_NVP-BHG712 -11.112335440 -1.8357193242
## 2780                      D013_r2_NVP-BSK805 2HCl  -5.296614859  0.3423806577
## 2781                           D013_r2_NVP-BVU972  -7.364915646 -0.1512739813
## 2782                          D013_r2_Oclacitinib  -4.244605282 -0.6358246731
## 2783      D013_r2_Olmutinib (HM61713, BI 1482694)  -7.747195416 -1.3365647937
## 2784                             D013_r2_ONO-4059  -8.618906300  1.5018716743
## 2785                              D013_r2_OSI-027   5.629131720  0.4942500368
## 2786                              D013_r2_OSI-420  -9.547699346 -0.3879680233
## 2787                 D013_r2_OSI-906 (Linsitinib) -12.130057820  1.1508897089
## 2788                              D013_r2_P276-00  -5.046594092  0.2227540956
## 2789                  D013_r2_Pacritinib (SB1518)  -6.459567391  0.3202626717
## 2790                   D013_r2_Palomid 529 (P529)  -5.538134406  0.3402790428
## 2791                            D013_r2_Pazopanib   1.556664556 -0.3260829277
## 2792                        D013_r2_Pazopanib HCl  -4.444065773 -0.1909637634
## 2793                            D013_r2_PD0325901  -7.391399316  1.7866721013
## 2794                             D013_r2_PD168393  -6.427135273  1.5159061701
## 2795                             D013_r2_PD173955  -3.567760072 -0.8954732508
## 2796                   D013_r2_PD184352 (CI-1040)  -6.314251579  1.0541062276
## 2797                             D013_r2_PD318088  -8.795852241  0.0903743262
## 2798                              D013_r2_PD98059  -7.512925292 -0.1630224904
## 2799                  D013_r2_Pelitinib (EKB-569) -11.148289638 -1.5289420057
## 2800                          D013_r2_PF-00562271 -12.292858055  0.7488625717
## 2801                          D013_r2_PF-04217903  -8.022146389 -0.7426241403
## 2802                          D013_r2_PF-04691502  -5.123647017 -0.7194196223
## 2803                            D013_r2_PF-431396 -11.474948305  1.7034453018
## 2804                           D013_r2_PF-4708671  -4.925438401 -1.9560218682
## 2805                           D013_r2_PF-5274857  -5.223530931 -1.0261117241
## 2806                            D013_r2_PF-562271 -13.543251415  1.2692198611
## 2807                            D013_r2_PF-573228  -9.852016890 -1.1022046501
## 2808                            D013_r2_PH-797804  -3.958057212 -0.9470582746
## 2809                           D013_r2_PHA-665752  -3.751657454  0.0757647313
## 2810                           D013_r2_PHA-680632  -8.510708870 -0.6488558673
## 2811                           D013_r2_PHA-767491 -10.936764617  1.3598825081
## 2812                           D013_r2_PHA-793887 -14.115823722  0.4193219421
## 2813                       D013_r2_Phenformin HCl  -3.819305544  0.0036146068
## 2814                              D013_r2_PHT-427  -7.406643966  0.4128020270
## 2815                          D013_r2_Piceatannol  -4.745033662  1.5346732526
## 2816                              D013_r2_PIK-293  -7.450659955 -0.7898429909
## 2817                              D013_r2_PIK-294  -8.925047122 -2.0260673047
## 2818                               D013_r2_PIK-93 -10.035489527  0.2062122380
## 2819               D013_r2_Pimasertib (AS-703026) -12.096748661  1.6770653819
## 2820                          D013_r2_Pirfenidone  -5.082566540 -0.4323507303
## 2821                             D013_r2_PLX-4720  -6.357082193 -1.0472147237
## 2822                              D013_r2_PLX7904  -5.643461661 -0.8319518867
## 2823                  D013_r2_Ponatinib (AP24534)  -7.284566415 -0.8891289960
## 2824                                  D013_r2_PP1  -8.793779569  0.0537359520
## 2825                                  D013_r2_PP2  -3.864798595  0.2602814793
## 2826                                D013_r2_PP242  -3.005246742 -0.8108305307
## 2827                               D013_r2_PQ 401  -3.368417571  0.0611188605
## 2828                              D013_r2_PRI-724  -6.186965604 -1.0532755138
## 2829     D013_r2_PRT062607 (P505-15, BIIB057) HCl -14.907924840 -0.6188532801
## 2830                         D013_r2_Purvalanol A  -3.740700454 -0.5573870416
## 2831                            D013_r2_Quercetin  -6.752090330 -0.8427166183
## 2832                  D013_r2_Quizartinib (AC220) -13.400156759  0.1473909302
## 2833                                 D013_r2_R406  -3.437479729 -0.1081615098
## 2834                     D013_r2_R406 (free base)  -6.275270172  0.0584316453
## 2835                                 D013_r2_R547  -6.970154257 -1.5498103590
## 2836                    D013_r2_RAF265 (CHIR-265) -11.495972337  1.3152940354
## 2837                D013_r2_Rapamycin (Sirolimus) -12.083369971  1.9364456961
## 2838   D013_r2_Refametinib (RDEA119, Bay 86-9766)  -8.985387572  0.7238924362
## 2839                               D013_r2_RepSox  -4.528897216 -0.4430826131
## 2840 D013_r2_Ridaforolimus (Deforolimus, MK-8669)  -8.510059265  0.9388465174
## 2841                D013_r2_Rigosertib (ON-01910) -14.837062291 -1.4951380030
## 2842                             D013_r2_RKI-1447  -6.912558657 -0.3761751276
## 2843                                D013_r2_RN486  -4.892871470  0.6341071441
## 2844                  D013_r2_Ro 31-8220 Mesylate  -8.125385059  0.1486994312
## 2845                              D013_r2_Ro-3306 -10.649012784 -1.8104487100
## 2846                               D013_r2_Ro3280  -9.577148685  0.5716876932
## 2847                            D013_r2_RO4929097  -6.129180339 -1.4398515309
## 2848      D013_r2_Roscovitine (Seliciclib,CYC202)  -7.673374188  0.0461388889
## 2849             D013_r2_Ruxolitinib (INCB018424)  -5.641601853  0.0883876106
## 2850           D013_r2_S-Ruxolitinib (INCB018424)  -4.693838427 -0.0436057698
## 2851                               D013_r2_SANT-1  -5.339786306 -0.5083257270
## 2852                            D013_r2_SAR131675  -3.582960917 -0.7180873466
## 2853                    D013_r2_SAR245409 (XL765)  -6.715371837  0.0040790147
## 2854                D013_r2_Saracatinib (AZD0530)  -6.663437989 -1.0443214770
## 2855                      D013_r2_SB202190 (FHPI)  -0.731365711  1.5344473363
## 2856                             D013_r2_SB203580  -3.242950506 -1.2236841139
## 2857                             D013_r2_SB216763  -6.845056575 -0.5867786395
## 2858                             D013_r2_SB239063  -2.091890395 -1.7667725310
## 2859                             D013_r2_SB415286  -3.871235996 -0.0459435059
## 2860                             D013_r2_SB431542  -5.151153115  0.1801171686
## 2861                             D013_r2_SB505124  -3.902503830 -0.8207322744
## 2862                             D013_r2_SB525334  -4.013627201 -0.3888637516
## 2863                             D013_r2_SB590885  -2.541870092 -0.9593474983
## 2864                                  D013_r2_SC1  -9.869385950  1.2337225681
## 2865                D013_r2_Schisandrin B (Sch B)  -3.818604745 -0.6960610528
## 2866                D013_r2_Selumetinib (AZD6244)  -3.558969789 -0.4097672337
## 2867              D013_r2_Semagacestat (LY450139)  -2.429352551 -0.7953766469
## 2868                   D013_r2_Semaxanib (SU5416)  -4.516162256 -0.5446816006
## 2869                             D013_r2_SGI-7079  -2.881867963  2.0262182938
## 2870                          D013_r2_Skepinone-L  -8.323682516  0.3758933544
## 2871                               D013_r2_SL-327  -2.520448809 -1.5884084631
## 2872                 D013_r2_SNS-032 (BMS-387032)  -9.724037376 -1.5772197811
## 2873                     D013_r2_SNS-314 Mesylate -16.944497480 -2.5872906672
## 2874                            D013_r2_Sorafenib  -2.008306966 -2.3057264504
## 2875                   D013_r2_Sorafenib Tosylate  -8.844316313  0.1436114256
## 2876                         D013_r2_Sotrastaurin  -4.928606970 -0.6224489942
## 2877                             D013_r2_SP600125  -1.408188939 -1.2253018931
## 2878                              D013_r2_SU11274  -3.118499112 -1.3131244422
## 2879                               D013_r2_SU6656  -9.198548744  1.4952016217
## 2880                               D013_r2_SU9516  -8.844002486  0.4676941702
## 2881                     D013_r2_Sunitinib Malate  -4.834251450  0.8966271113
## 2882                  D013_r2_TAE226 (NVP-TAE226)  -6.577515899  1.1116297371
## 2883                              D013_r2_TAK-285  -3.880131351  0.7965994948
## 2884                              D013_r2_TAK-632  -8.007760130 -0.2444240750
## 2885                              D013_r2_TAK-715  -2.937314064  0.0601998818
## 2886                              D013_r2_TAK-733  -2.195791747  1.2657044287
## 2887                              D013_r2_TAK-901 -13.054982493  1.4867490045
## 2888                D013_r2_Taladegib (LY2940680)  -6.574140595 -0.4921274250
## 2889                              D013_r2_TCS 359  -9.740294747 -0.2207905384
## 2890                               D013_r2_TDZD-8  -4.004699328 -0.2850588197
## 2891                            D013_r2_Telatinib  -7.812442122 -1.5505596331
## 2892   D013_r2_Temsirolimus (CCI-779, NSC 683864)  -7.209261314 -0.0588738330
## 2893              D013_r2_Tepotinib (EMD 1214063)  -6.864219594  1.9768516432
## 2894                                D013_r2_TG003  -0.865684991 -0.4950377485
## 2895                            D013_r2_TG100-115  -7.177378149 -1.2678476594
## 2896                             D013_r2_TG101209 -11.452196563  1.1737867443
## 2897                 D013_r2_TG101348 (SAR302503)  -9.771722530  1.1133166535
## 2898                              D013_r2_TGX-221  -8.964941580  0.7798101864
## 2899                         D013_r2_Theophylline  -1.038318516 -0.4454941368
## 2900                          D013_r2_Thiazovivin  -7.540621530 -0.3540939555
## 2901                       D013_r2_TIC10 Analogue  -3.686425103 -0.5365835213
## 2902                           D013_r2_Tideglusib  -0.610528728 -0.3883955247
## 2903                 D013_r2_Tivantinib (ARQ 197) -11.793000183  1.2176576387
## 2904                   D013_r2_Tivozanib (AV-951)  -6.142451301 -1.2891356591
## 2905  D013_r2_Tofacitinib (CP-690550,Tasocitinib)  -3.834384719 -0.0274612977
## 2906      D013_r2_Tofacitinib (CP-690550) Citrate  -6.004116771 -0.3944253673
## 2907                              D013_r2_Torin 2  -7.005523986  0.7481722354
## 2908              D013_r2_Trametinib (GSK1120212)  -9.444504933  1.1271244111
## 2909                          D013_r2_Triciribine  -8.403853739 -1.7959476055
## 2910           D013_r2_TSU-68 (SU6668, Orantinib)  -6.103009043 -1.2394356459
## 2911                               D013_r2_TWS119  -4.104664252 -0.4941198689
## 2912                         D013_r2_Tyrphostin 9  -5.567535216  0.6781596119
## 2913                   D013_r2_Tyrphostin AG 1296  -4.077933057 -1.8624031147
## 2914                           D013_r2_U0126-EtOH  -2.669048242 -0.2651393330
## 2915     D013_r2_Ulixertinib (BVD-523, VRT752271)  -8.272173137  0.3291985995
## 2916              D013_r2_Uprosertib (GSK2141795)  -7.193535541 -0.4927483688
## 2917                          D013_r2_Vacquinol-1 -11.830730551  0.1262377973
## 2918                           D013_r2_Varlitinib  -5.354084765  0.7833788935
## 2919              D013_r2_Vatalanib (PTK787) 2HCl  -7.265233855 -0.0706267676
## 2920                               D013_r2_VE-821  -5.423282327  0.8619908631
## 2921                               D013_r2_VE-822  -8.796004183  1.7157138785
## 2922        D013_r2_Vemurafenib (PLX4032, RG7204) -10.102026604 -1.3336395077
## 2923                D013_r2_Vismodegib (GDC-0449)  -3.883735868 -0.1448814420
## 2924                 D013_r2_Volasertib (BI 6727)  -4.226427540 -1.0873969220
## 2925                            D013_r2_VPS34-IN1  -6.371297002 -1.0349208590
## 2926                     D013_r2_VS-5584 (SB2343)  -3.870401143 -1.6671880582
## 2927                               D013_r2_VX-11e  -7.801360757 -0.2199054012
## 2928         D013_r2_VX-680 (Tozasertib, MK-0457) -10.939410930 -0.1058025701
## 2929                               D013_r2_VX-702  -5.457281933 -0.9091745712
## 2930                               D013_r2_VX-745  -5.603266982  0.1327978617
## 2931                              D013_r2_WAY-600  -4.380673107 -0.1794835048
## 2932                             D013_r2_WH-4-023  -1.648085113  0.2686125209
## 2933                             D013_r2_WHI-P154  -4.680481653 -0.4908727700
## 2934                                D013_r2_WIKI4  -4.687685781  0.2000444249
## 2935                        D013_r2_Wnt agonist 1 -15.360669594  0.0765605035
## 2936                        D013_r2_Wnt-C59 (C59)  -5.351867068 -0.1973548745
## 2937                               D013_r2_WP1066  -5.518890217 -0.6318869976
## 2938                 D013_r2_WYE-125132 (WYE-132)  -0.665298259 -1.8198225587
## 2939                              D013_r2_WYE-354 -12.322980536 -0.0219330376
## 2940                               D013_r2_WZ3146 -10.355975470  0.4043134895
## 2941                               D013_r2_WZ4002  -5.087459295  0.4522788857
## 2942                               D013_r2_WZ4003  -5.391060080 -0.1878159162
## 2943                               D013_r2_WZ8040 -11.763857544  0.5296352485
## 2944                              D013_r2_XAV-939  -6.466890970 -0.8525602482
## 2945                                D013_r2_XL019  -7.882455765  0.7444659979
## 2946                              D013_r2_XMD8-92  -1.991432554 -1.9614645289
## 2947                         D013_r2_Y-27632 2HCl  -3.848479711 -1.1943778928
## 2948                             D013_r2_YM201636 -11.810543284  1.4867764459
## 2949                             D013_r2_YO-01027  -1.984910961 -1.9275460754
## 2950                            D013_r2_ZM 306416  -5.638937635  0.0966924398
## 2951                        D013_r2_ZM 323881 HCl  -6.875226332 -0.3068150642
## 2952                            D013_r2_ZM 336372  -4.133997982  0.0306948468
## 2953                         D013_r2_ZM 39923 HCl  -5.155340647 -0.2498614841
## 2954                            D013_r2_ZM 447439 -12.999554806 -0.2655176833
## 2955                 D013_r2_Zotarolimus(ABT-578)  -8.742356932  0.6034184095
## 2956                              D013_r2_ZSTK474 -15.386021686  0.5355151151
## 2957                     D018_r1_1-Azakenpaullone   9.258594753  7.3783658567
## 2958                      D018_r1_3-Methyladenine   5.315456523  7.9971085393
## 2959                             D018_r1_A-674563  -7.071888625  3.5288264149
## 2960                             D018_r1_A-769662   7.861437215  7.1639186744
## 2961                                  D018_r1_A66   0.272045459  5.9851540219
## 2962                            D018_r1_Acadesine   2.552468817  4.8327834842
## 2963                  D018_r1_AEE788 (NVP-AEE788)  -1.918555453  6.9204120930
## 2964        D018_r1_Afatinib (BIBW2992)_uncertain  10.829152976  5.9381708246
## 2965                              D018_r1_AG-1024  11.063266611  6.7469750942
## 2966         D018_r1_AG-1478 (Tyrphostin AG-1478) -10.647795056  8.4691330221
## 2967                                D018_r1_AG-18   3.172098626  6.8260510286
## 2968              D018_r1_AG-490 (Tyrphostin B42)   4.578221780  6.8562152685
## 2969                             D018_r1_Akti-1/2   9.936208541  7.6132134840
## 2970                  D018_r1_Alisertib (MLN8237)   1.777621141  6.1398680314
## 2971                              D018_r1_AMG 337   4.936056651  7.0816216282
## 2972                              D018_r1_AMG-458   4.134523019  5.8010116157
## 2973                              D018_r1_AMG-900  -5.182890718  6.8392626488
## 2974                               D018_r1_AMG319  11.181181865  6.8837733529
## 2975                  D018_r1_Amuvatinib (MP-470)  10.851903544  6.6304805444
## 2976                             D018_r1_Apatinib   3.036986954  8.4733191009
## 2977                           D018_r1_AR-A014418  11.565578381  5.9772298221
## 2978                            D018_r1_AS-252424  -1.666370822  6.0583571970
## 2979                            D018_r1_AS-604850   7.968295939  6.9201922182
## 2980                         D018_r1_Asiatic Acid   1.997215333  7.2365808921
## 2981                             D018_r1_AST-1306  -9.446435836  7.3072502509
## 2982                              D018_r1_AT13148   0.179840315  6.2314613160
## 2983                               D018_r1_AT7519   0.857666540  4.1624690688
## 2984                               D018_r1_AT7867  12.330448291  6.3669434934
## 2985                               D018_r1_AT9283  -7.262892470  3.8477659420
## 2986                 D018_r1_Aurora A Inhibitor I   5.467735829  7.6896145204
## 2987             D018_r1_Avagacestat (BMS-708163)  16.325602551  6.5532615145
## 2988                              D018_r1_AVL-292   6.885616423  5.6460862081
## 2989                             D018_r1_Axitinib   2.688857600  7.1076344825
## 2990                             D018_r1_Axitinib   2.688857600  7.1076344825
## 2991                               D018_r1_AZ 628   0.681287128  9.2878438938
## 2992                               D018_r1_AZ 960  -0.384459965  4.1417372780
## 2993                                 D018_r1_AZ20   7.212323558  7.2972141136
## 2994                              D018_r1_AZD1080   7.771586216  7.2748573725
## 2995                              D018_r1_AZD1480  18.395438281  7.3656786061
## 2996                              D018_r1_AZD2014  21.315596850  7.5432558246
## 2997                              D018_r1_AZD2858  12.193401886  7.8819822850
## 2998                              D018_r1_AZD2932  10.750618533  6.0208618985
## 2999                              D018_r1_AZD3759  -5.362043517  5.0079620087
## 3000                              D018_r1_AZD5363  13.015101783  7.0392067074
## 3001                              D018_r1_AZD5438  -1.727286788  2.2651715748
## 3002                              D018_r1_AZD6482   3.111439797  6.0491527489
## 3003                              D018_r1_AZD6738   3.086656908  5.7803201035
## 3004                              D018_r1_AZD8055  18.222495737  6.9177532824
## 3005                              D018_r1_AZD8330 -14.046900500  8.1530891519
## 3006                  D018_r1_AZD8931 (Sapitinib) -10.681011159  6.4756721690
## 3007                              D018_r1_AZD9291  -8.237782762  4.7300892155
## 3008            D018_r1_Barasertib (AZD1152-HQPA)  -6.809699083  6.6759395354
## 3009  D018_r1_Baricitinib (LY3009104, INCB028050)  -1.986669378  6.6043953803
## 3010                  D018_r1_BGT226 (NVP-BGT226)  12.079816512  6.6750558272
## 3011                              D018_r1_BI 2536  -6.700078332  2.4312178596
## 3012                              D018_r1_BI-78D3   6.516234777  6.4581461899
## 3013                             D018_r1_BI-D1870   4.595567463  5.2767935813
## 3014                              D018_r1_Bikinin  12.092002291  6.1845547127
## 3015                                  D018_r1_BIO  21.006279936  6.5005511993
## 3016               D018_r1_BIRB 796 (Doramapimod)  10.743711717  5.8910839351
## 3017                            D018_r1_BIX 02188  10.049702440  7.7656679835
## 3018                            D018_r1_BIX 02189   9.376675253  7.2135238327
## 3019      D018_r1_BKM120 (NVP-BKM120, Buparlisib)  10.494800366  7.6560964513
## 3020                           D018_r1_BMS-265246  -6.123472951  7.2605093419
## 3021                           D018_r1_BMS-536924  -0.216623104  6.3595675819
## 3022                           D018_r1_BMS-582949  22.593201194  5.5333737909
## 3023                           D018_r1_BMS-754807  12.278714303  9.9057569543
## 3024                           D018_r1_BMS-777607   4.439161368  6.9634449182
## 3025                           D018_r1_BMS-794833   8.414159107  6.0587713245
## 3026                           D018_r1_BMS-833923  21.958722761  6.5597903456
## 3027                  D018_r1_Bosutinib (SKI-606)   0.935294868  6.3960371742
## 3028                D018_r1_Brivanib (BMS-540215)   2.704263966  6.9521904511
## 3029      D018_r1_Brivanib Alaninate (BMS-582664)  20.166991647  5.3489503283
## 3030                           D018_r1_BS-181 HCl   8.006392994  6.2414419754
## 3031                               D018_r1_Butein  12.526634118  6.0699823170
## 3032                               D018_r1_BYL719   3.681697095  7.2678035382
## 3033     D018_r1_Cabozantinib (XL184, BMS-907351)   3.026493108  6.5142214166
## 3034          D018_r1_Cabozantinib malate (XL184)   0.148263813  6.0370162679
## 3035        D018_r1_CAL-101 (Idelalisib, GS-1101)  -2.408122940  7.0608748672
## 3036                             D018_r1_CAY10505   3.203884799  5.7663536532
## 3037                               D018_r1_CC-223  17.757756203  6.7544781721
## 3038                            D018_r1_CCT128930   6.887134710  5.7171299432
## 3039                  D018_r1_Cediranib (AZD2171)   6.553391323  5.8474103215
## 3040                            D018_r1_CEP-32496   9.752991733  8.4300065432
## 3041                            D018_r1_CEP-33779   6.952303521  6.0555400999
## 3042                              D018_r1_CGI1746   4.568295672  7.5502123270
## 3043                              D018_r1_CGK 733  12.203876172  8.3622372696
## 3044                            D018_r1_CH5132799   3.866721014  7.0196520047
## 3045                           D018_r1_CHIR-98014   8.676402198  8.0070992080
## 3046                 D018_r1_CHIR-99021 (CT99021)  12.214261474  8.5067898290
## 3047             D018_r1_CHIR-99021 (CT99021) HCl  10.356561397  7.2441496347
## 3048                    D018_r1_Chrysophanic Acid   4.301057914  7.9364709589
## 3049                             D018_r1_CNX-2006  -1.212934881  4.7240785636
## 3050                              D018_r1_CNX-774   0.239918683  4.8386357185
## 3051                    D018_r1_CO-1686 (AVL-301)  -1.212345572  6.9572052040
## 3052       D018_r1_Cobimetinib (GDC-0973, RG7420) -13.023607978 10.1812345266
## 3053                            D018_r1_CP-673451  14.841438219  6.9480710782
## 3054                            D018_r1_CP-724714   6.322637381  6.4222637880
## 3055               D018_r1_Crenolanib (CP-868596)  13.788987216  6.0939905385
## 3056             D018_r1_Crizotinib (PF-02341066)  11.197483883  7.2294882582
## 3057                               D018_r1_CYC116  -2.900701255  6.1154222762
## 3058                               D018_r1_CYT387   1.874581169  7.2677036966
## 3059                             D018_r1_CZC24832   6.062313438  5.9839546460
## 3060              D018_r1_Dabrafenib (GSK2118436)  -3.599349627  6.5400299858
## 3061        D018_r1_Dacomitinib (PF299804, PF299)  -3.259568032  6.2100546372
## 3062              D018_r1_Danusertib (PHA-739358)   1.871123779  5.8830861861
## 3063                        D018_r1_DAPT (GSI-IX)  12.293155866  6.2717872858
## 3064                            D018_r1_Dasatinib -10.464714983  5.0652951996
## 3065                D018_r1_DCC-2036 (Rebastinib)   1.956936669  6.3149883622
## 3066                D018_r1_Decernotinib (VX-509)  11.704670525  6.3037092528
## 3067               D018_r1_Dinaciclib (SCH727965)  -1.801113591  5.0809041499
## 3068    D018_r1_Dovitinib (TKI-258) Dilactic Acid  11.823482474  7.1778028952
## 3069                            D018_r1_ENMD-2076   6.435999210  7.9097654201
## 3070               D018_r1_Enzastaurin (LY317615)   5.545757198  6.9712850029
## 3071                            D018_r1_ERK5-IN-1  14.182481641  6.0625611847
## 3072                             D018_r1_ETC-1002   3.665348963  6.9596936265
## 3073                            D018_r1_ETP-46464  14.764093848  7.6119731078
## 3074                  D018_r1_Everolimus (RAD001)   6.303367589  7.5595074335
## 3075                D018_r1_Fasudil (HA-1077) HCl   5.318771311  7.1874675467
## 3076                                D018_r1_FH535  -0.277600705  6.1844435032
## 3077                D018_r1_Filgotinib (GLPG0634)   2.472207798  7.2722007198
## 3078             D018_r1_Flavopiridol (Alvocidib)  -1.645296549  3.5988644720
## 3079                     D018_r1_Flavopiridol HCl   0.209624523  5.0658996235
## 3080               D018_r1_Foretinib (GSK1363089)  -8.354488573  6.3574278772
## 3081                  D018_r1_Fostamatinib (R788)   4.300421255  6.5796127676
## 3082                                D018_r1_G-749  10.031038273  6.7164362524
## 3083                             D018_r1_GDC-0068  21.515327911  7.1980662163
## 3084                             D018_r1_GDC-0349  24.211122202  6.4417120992
## 3085                             D018_r1_GDC-0879   6.160999956  6.8948534517
## 3086                             D018_r1_GDC-0941   0.495363780  6.2367271063
## 3087                    D018_r1_GDC-0980 (RG7422)  14.204768757  8.6929051553
## 3088                   D018_r1_Gefitinib (ZD1839) -14.754892992  5.1126696082
## 3089                            D018_r1_Genistein  13.917058995  4.9959569044
## 3090                            D018_r1_GF109203X  14.199094847  7.3538055180
## 3091                                D018_r1_GNF-2   0.958358320  6.7299664520
## 3092                                D018_r1_GNF-5   8.063286192  6.9974594876
## 3093                              D018_r1_Go 6983   7.330402911  6.7741384180
## 3094                   D018_r1_Golvatinib (E7050)  18.224529540  8.5480942356
## 3095                          D018_r1_GSK1838705A  -3.943340891  5.5512443782
## 3096                          D018_r1_GSK1904529A   8.875410961  7.5857477472
## 3097                  D018_r1_GSK2126458 (GSK458)   1.790897468  7.3824892575
## 3098                           D018_r1_GSK2292767  -1.310751719  5.6628938849
## 3099                           D018_r1_GSK2636771  19.257567044  7.3413594137
## 3100                           D018_r1_GSK429286A   7.744334772  6.5450891874
## 3101                            D018_r1_GSK461364  -2.243338824  2.6199984857
## 3102                               D018_r1_GSK621   3.693266974  7.3513285771
## 3103                            D018_r1_GSK690693   9.512585492  4.8054226261
## 3104                               D018_r1_GW5074   2.974857517  7.3696928853
## 3105                             D018_r1_GW788388   8.376009513  8.0418738501
## 3106                               D018_r1_GZD824   5.741321489  6.0566209149
## 3107                            D018_r1_H 89 2HCl   2.443265075  6.0485954368
## 3108                           D018_r1_Hesperadin  -0.148910408  5.6673616252
## 3109                              D018_r1_HMN-214   0.951281876  7.5404817419
## 3110                             D018_r1_Honokiol  -5.631826791  7.0244763010
## 3111                               D018_r1_HS-173   8.473639276  6.1870106377
## 3112                           D018_r1_HTH-01-015  -8.709692680  4.8969736178
## 3113                D018_r1_Ibrutinib (PCI-32765)  -7.993545944  7.4999509488
## 3114                              D018_r1_ICG-001  12.068901680  6.8352844158
## 3115                             D018_r1_Icotinib  -3.496052011  6.6128628783
## 3116                                D018_r1_IM-12  11.037241701  6.6706697332
## 3117           D018_r1_Imatinib Mesylate (STI571) -14.613126626  6.0108667314
## 3118                            D018_r1_Indirubin   8.310589832  5.0818640373
## 3119                    D018_r1_INK 128 (MLN0128)  28.905214949  6.6778112218
## 3120                    D018_r1_IPI-145 (INK1197)  -1.659397647  6.1132019278
## 3121                               D018_r1_IWP-L6   7.137322042  6.5087213873
## 3122                           D018_r1_IWR-1-endo   2.451182054  6.6620318210
## 3123                         D018_r1_JNJ-38877605   2.761255037  5.4679596464
## 3124                          D018_r1_JNJ-7706621  -5.084480675  3.9404952351
## 3125                     D018_r1_JNK Inhibitor IX   3.682263240  6.8701822701
## 3126                             D018_r1_JNK-IN-8   2.789077982  6.2551499255
## 3127                               D018_r1_K02288  15.417805335  6.5616147777
## 3128                               D018_r1_Ki8751  12.364985730  7.4371504464
## 3129                              D018_r1_KRN 633   5.628980383  7.1012237361
## 3130                           D018_r1_KU-0063794  14.738344160  5.9581921351
## 3131      D018_r1_KU-55933 (ATM Kinase Inhibitor)  12.753198235  6.3181784452
## 3132                             D018_r1_KU-60019   3.608282570  8.2144092683
## 3133                              D018_r1_KW-2449   3.578663506  6.8148064936
## 3134                              D018_r1_KX2-391   8.156505385  7.0172807366
## 3135                              D018_r1_KY02111   8.360755568  6.2538041559
## 3136                            D018_r1_Lapatinib  -0.204764522  6.8102818792
## 3137     D018_r1_Lapatinib (GW-572016) Ditosylate   5.631874545  8.2089752802
## 3138                            D018_r1_LDC000067  17.117277719  6.8036261682
## 3139      D018_r1_LDE225 (NVP-LDE225,Erismodegib)   4.757961726  6.9308538047
## 3140                           D018_r1_LDN-214117  29.405763122  8.9837838270
## 3141                   D018_r1_Lenvatinib (E7080)   8.943256967  6.1065296728
## 3142                              D018_r1_LFM-A13   6.487902202  6.9612412588
## 3143                              D018_r1_LGK-974  11.060438947  7.2477778519
## 3144                  D018_r1_Linifanib (ABT-869)  -0.227149604  5.5727452217
## 3145                               D018_r1_LJH685   2.036422466  6.0283460636
## 3146                               D018_r1_LJI308  -1.976482530  6.7855927560
## 3147               D018_r1_Losmapimod (GW856553X)   9.422082545  6.9619493805
## 3148                            D018_r1_LY2090314  10.099342291  6.8393719667
## 3149                            D018_r1_LY2157299  18.875246657  7.0421654232
## 3150                            D018_r1_LY2784544   6.847630975  6.6769429919
## 3151                            D018_r1_LY2835219  -1.660236251  6.4604995713
## 3152                             D018_r1_LY294002   4.452593572  9.0061446553
## 3153                            D018_r1_LY3023414  14.667981525  8.7929873607
## 3154                             D018_r1_LY411575  11.015408640  6.8534964489
## 3155       D018_r1_MEK162 (ARRY-162, ARRY-438162)  -9.729906763  9.0085567301
## 3156                             D018_r1_MGCD-265   8.022963520  6.2281616424
## 3157               D018_r1_Milciclib (PHA-848125)   3.779653157  5.8537758037
## 3158                              D018_r1_MK-0752   9.611172450  6.1376526359
## 3159                         D018_r1_MK-2206 2HCl  12.237253706  6.1774254270
## 3160                              D018_r1_MK-2461  11.653240762  6.5067646168
## 3161                     D018_r1_MK-5108 (VX-689)  -7.878214696  7.2644216393
## 3162                              D018_r1_MK-8745  -0.654437092  5.2106050448
## 3163                              D018_r1_MLN2480  11.145656969 10.1824764774
## 3164                              D018_r1_MLN8054   2.144184372  5.4646542831
## 3165      D018_r1_Motesanib Diphosphate (AMG-706)   3.397852497  6.0836625224
## 3166                  D018_r1_Nilotinib (AMN-107)   2.390269744  5.2153540207
## 3167     D018_r1_Nintedanib (BIBF 1120)_uncertain   3.611907827  5.0644775257
## 3168                               D018_r1_NU6027   6.866337491  6.3110517646
## 3169                           D018_r1_NVP-AEW541   5.336557424  5.3965650219
## 3170                           D018_r1_NVP-BHG712   9.159231391  6.8909967267
## 3171                      D018_r1_NVP-BSK805 2HCl   9.833909016  5.9289798625
## 3172                           D018_r1_NVP-BVU972   6.670813843  8.7296905628
## 3173                          D018_r1_Oclacitinib   2.312084987  7.3983414053
## 3174      D018_r1_Olmutinib (HM61713, BI 1482694)  -0.754640706  7.4876464588
## 3175                             D018_r1_ONO-4059 -14.781038416  7.3052233819
## 3176                              D018_r1_OSI-027  16.463138397  6.1570091312
## 3177                              D018_r1_OSI-420  -6.313731983  8.0909345706
## 3178                 D018_r1_OSI-906 (Linsitinib)  -4.278588264  6.5347786369
## 3179                              D018_r1_P276-00  -5.723992093  2.6753353272
## 3180                  D018_r1_Pacritinib (SB1518)  -3.439598917  3.0007627576
## 3181                   D018_r1_Palomid 529 (P529)   4.604100215  5.5573776059
## 3182                            D018_r1_Pazopanib   6.487478682  2.8399509927
## 3183                        D018_r1_Pazopanib HCl   8.423161237  5.3850799134
## 3184                            D018_r1_PD0325901 -13.841183119  7.0474561572
## 3185                             D018_r1_PD168393  -4.943870314  5.5884537126
## 3186                             D018_r1_PD173955  12.829363224  8.3586183508
## 3187                   D018_r1_PD184352 (CI-1040) -10.277011354  6.2988428707
## 3188                             D018_r1_PD318088  -6.366613902  7.6624346092
## 3189                              D018_r1_PD98059   6.501628133  6.7358093751
## 3190                  D018_r1_Pelitinib (EKB-569)  -1.413058548  3.6935598379
## 3191                          D018_r1_PF-00562271  -8.087717630  0.4288699425
## 3192                          D018_r1_PF-04217903  -2.190215433  6.9622757289
## 3193                          D018_r1_PF-04691502  20.832458678  7.6078169770
## 3194                            D018_r1_PF-431396  13.171572058  6.3064132930
## 3195                           D018_r1_PF-4708671   5.788475702  8.2349818601
## 3196                           D018_r1_PF-5274857   1.677210856  7.0782960357
## 3197                            D018_r1_PF-562271  -6.870702614  2.8314432495
## 3198                            D018_r1_PF-573228  -0.362299430  7.1431076020
## 3199                            D018_r1_PH-797804   7.529917127  6.5640971584
## 3200                           D018_r1_PHA-665752   5.332037940  7.7335795072
## 3201                           D018_r1_PHA-680632   9.648767011 11.1196101270
## 3202                           D018_r1_PHA-767491   3.784280166  5.2496295176
## 3203                           D018_r1_PHA-793887  -6.306390815  2.6062624790
## 3204                       D018_r1_Phenformin HCl  10.714305281  6.1375124521
## 3205                              D018_r1_PHT-427   3.166515379  6.0974818073
## 3206                          D018_r1_Piceatannol  11.793705304 10.1614806591
## 3207                              D018_r1_PIK-293   1.728063379  6.9237962848
## 3208                              D018_r1_PIK-294   4.790387600  7.6911254034
## 3209                               D018_r1_PIK-93  12.966975546  7.9733883652
## 3210               D018_r1_Pimasertib (AS-703026) -13.037520658  6.2880469484
## 3211                          D018_r1_Pirfenidone  10.030952322  7.0325067634
## 3212                             D018_r1_PLX-4720   3.356102536  6.5226898531
## 3213                              D018_r1_PLX7904   7.986863310  5.7653049729
## 3214                  D018_r1_Ponatinib (AP24534)  16.374401518  7.3430592063
## 3215                                  D018_r1_PP1  15.875926764  7.4250223660
## 3216                                  D018_r1_PP2  11.653799547  7.4456745855
## 3217                                D018_r1_PP242  32.834307235 10.9367750345
## 3218                               D018_r1_PQ 401  17.961149464  6.6708905047
## 3219                              D018_r1_PRI-724  11.497454357  5.1207325962
## 3220     D018_r1_PRT062607 (P505-15, BIIB057) HCl   5.496175477  6.6892579033
## 3221                         D018_r1_Purvalanol A   6.649901928  8.2139578635
## 3222                            D018_r1_Quercetin   6.245189209  6.9585617247
## 3223                  D018_r1_Quizartinib (AC220)   6.334018797  7.0806027673
## 3224                                 D018_r1_R406   6.742572631  7.3622004256
## 3225                     D018_r1_R406 (free base)   3.792849931  5.7464128639
## 3226                                 D018_r1_R547   0.778560855  4.3126118229
## 3227                    D018_r1_RAF265 (CHIR-265)  -9.419331524  9.9270844243
## 3228                D018_r1_Rapamycin (Sirolimus)   9.968872972  5.7612900614
## 3229   D018_r1_Refametinib (RDEA119, Bay 86-9766) -21.003863494  8.7046400667
## 3230                               D018_r1_RepSox   6.380940475  7.4958278108
## 3231 D018_r1_Ridaforolimus (Deforolimus, MK-8669)   5.623988458  6.6438183165
## 3232                D018_r1_Rigosertib (ON-01910)  12.568119867  9.5684050092
## 3233                             D018_r1_RKI-1447  12.413256112  6.8289899025
## 3234                                D018_r1_RN486   7.537308219  6.3905357124
## 3235                  D018_r1_Ro 31-8220 Mesylate   2.063961467  4.7701929767
## 3236                              D018_r1_Ro-3306   7.331680221  6.6783516590
## 3237                               D018_r1_Ro3280  15.563773339  8.8995855187
## 3238                            D018_r1_RO4929097  10.619698092  6.3650379336
## 3239      D018_r1_Roscovitine (Seliciclib,CYC202)  14.428847085  6.9768882312
## 3240             D018_r1_Ruxolitinib (INCB018424)   3.534495574  6.4670078212
## 3241           D018_r1_S-Ruxolitinib (INCB018424)   6.118018391  6.9677186302
## 3242                               D018_r1_SANT-1   5.337040034  6.0576457677
## 3243                            D018_r1_SAR131675   7.223214111  6.0786041647
## 3244                    D018_r1_SAR245409 (XL765)   9.699980633  6.5436672374
## 3245                D018_r1_Saracatinib (AZD0530)  -3.236589113  5.5323922206
## 3246                      D018_r1_SB202190 (FHPI)  10.232573698  6.4268465391
## 3247                             D018_r1_SB203580   9.452279347  5.8341553187
## 3248                             D018_r1_SB216763   5.248810966  6.7496102730
## 3249                             D018_r1_SB239063  15.768991380  7.8291245141
## 3250                             D018_r1_SB415286   4.921329398  6.4967345564
## 3251                             D018_r1_SB431542  10.021316015  7.1235788751
## 3252                             D018_r1_SB505124   7.391529668  5.8194091777
## 3253                             D018_r1_SB525334  10.273882836  4.7060951578
## 3254                             D018_r1_SB590885   9.955012779  7.4303431818
## 3255                                  D018_r1_SC1  -1.017562661  4.8008193430
## 3256                D018_r1_Schisandrin B (Sch B)  14.490131456  6.6743143665
## 3257                D018_r1_Selumetinib (AZD6244)  -2.852315392  5.5792908398
## 3258              D018_r1_Semagacestat (LY450139)  11.283861838  7.1224052171
## 3259                   D018_r1_Semaxanib (SU5416)   7.493201953  6.1068606055
## 3260                             D018_r1_SGI-7079  22.065831294 10.3223962206
## 3261                          D018_r1_Skepinone-L  -1.058681660  8.5783537665
## 3262                               D018_r1_SL-327   2.496854742  6.2691324013
## 3263                 D018_r1_SNS-032 (BMS-387032)  -4.020054990  3.2446810028
## 3264                     D018_r1_SNS-314 Mesylate   0.142645387  7.3536222322
## 3265                            D018_r1_Sorafenib   4.904444651  6.2465282864
## 3266                   D018_r1_Sorafenib Tosylate   9.574771492  5.7596512722
## 3267                         D018_r1_Sotrastaurin   6.101032103  6.0214385187
## 3268                             D018_r1_SP600125  11.403396366  7.8075665192
## 3269                              D018_r1_SU11274  10.675745718  5.5255446226
## 3270                               D018_r1_SU6656   7.463045619  5.6914895189
## 3271                               D018_r1_SU9516   9.321520926  6.8449743662
## 3272                     D018_r1_Sunitinib Malate  12.898524691  6.9714425843
## 3273                  D018_r1_TAE226 (NVP-TAE226)   7.886937869  6.1780867715
## 3274                              D018_r1_TAK-285   4.721730558  9.2612354453
## 3275                              D018_r1_TAK-632  11.898986134  9.4180319196
## 3276                              D018_r1_TAK-715   6.953783046  6.8191935916
## 3277                              D018_r1_TAK-733 -12.912553349  8.3770659048
## 3278                              D018_r1_TAK-901  22.731321730  9.1003716010
## 3279                D018_r1_Taladegib (LY2940680)   8.599278205  7.7993105529
## 3280                              D018_r1_TCS 359   1.029950911  7.5179676328
## 3281                               D018_r1_TDZD-8  12.313762741  6.4711032087
## 3282                            D018_r1_Telatinib   9.502871758  6.5850190048
## 3283   D018_r1_Temsirolimus (CCI-779, NSC 683864)   4.622359932  7.3599259795
## 3284              D018_r1_Tepotinib (EMD 1214063)  -0.468824891  7.7686343879
## 3285                                D018_r1_TG003  11.392551382  7.4228197175
## 3286                            D018_r1_TG100-115  14.924959934  7.0727298386
## 3287                             D018_r1_TG101209   1.151633513  5.8011901192
## 3288                 D018_r1_TG101348 (SAR302503)   5.314100399  6.2421611012
## 3289                              D018_r1_TGX-221   0.761601171  7.6398038417
## 3290                         D018_r1_Theophylline   8.942704356  7.1297599701
## 3291                          D018_r1_Thiazovivin  -0.966011118  7.3817248400
## 3292                       D018_r1_TIC10 Analogue   7.819352271  7.2012614349
## 3293                           D018_r1_Tideglusib   2.650496968  5.8098644631
## 3294                 D018_r1_Tivantinib (ARQ 197)  -0.795930680  5.7077252581
## 3295                   D018_r1_Tivozanib (AV-951)  21.918478453  7.6607635888
## 3296  D018_r1_Tofacitinib (CP-690550,Tasocitinib)   2.337876778  6.4122234783
## 3297      D018_r1_Tofacitinib (CP-690550) Citrate   4.791777779  6.8882010217
## 3298                              D018_r1_Torin 2   8.234267301  6.0883628813
## 3299              D018_r1_Trametinib (GSK1120212) -13.102454443  7.1559149930
## 3300                          D018_r1_Triciribine   5.075881601  7.6738992987
## 3301           D018_r1_TSU-68 (SU6668, Orantinib)  13.497938475  6.6811716916
## 3302                               D018_r1_TWS119  11.821759069  5.8548721595
## 3303                         D018_r1_Tyrphostin 9  25.077568363  9.2250322411
## 3304                   D018_r1_Tyrphostin AG 1296  10.460646602  6.8954458955
## 3305                           D018_r1_U0126-EtOH   4.124054621  7.1213751274
## 3306     D018_r1_Ulixertinib (BVD-523, VRT752271)  -5.970474728  6.5689119661
## 3307              D018_r1_Uprosertib (GSK2141795)  14.618765013  6.9056545060
## 3308                          D018_r1_Vacquinol-1   6.436242267  6.5541466459
## 3309                           D018_r1_Varlitinib   1.636773676  7.2241460295
## 3310              D018_r1_Vatalanib (PTK787) 2HCl   2.445258594  6.3853024904
## 3311                               D018_r1_VE-821  10.119267340  6.6659654907
## 3312                               D018_r1_VE-822  -0.193923535  6.1209323573
## 3313        D018_r1_Vemurafenib (PLX4032, RG7204)  10.929473679  7.0054167872
## 3314                D018_r1_Vismodegib (GDC-0449)   2.529658220  5.7955791963
## 3315                 D018_r1_Volasertib (BI 6727)  11.112683805  6.3262338480
## 3316                            D018_r1_VPS34-IN1   9.540424929  5.9063939772
## 3317                     D018_r1_VS-5584 (SB2343)  13.572327520  7.8078437956
## 3318                               D018_r1_VX-11e -12.217241693  8.1891422024
## 3319         D018_r1_VX-680 (Tozasertib, MK-0457)  -8.156826643  7.9046437891
## 3320                               D018_r1_VX-702   0.702418019  7.2756043940
## 3321                               D018_r1_VX-745   6.448257715  7.3699584927
## 3322                              D018_r1_WAY-600  10.102109241  6.4723022283
## 3323                             D018_r1_WH-4-023  22.474915662  8.5166577624
## 3324                             D018_r1_WHI-P154   5.894879308  5.7051602911
## 3325                                D018_r1_WIKI4   2.151853996  6.9721028007
## 3326                        D018_r1_Wnt agonist 1   7.405596805  7.9074294324
## 3327                        D018_r1_Wnt-C59 (C59)   5.540190139  6.3237817730
## 3328                               D018_r1_WP1066   4.633927113  7.2001453594
## 3329                 D018_r1_WYE-125132 (WYE-132)  17.638672748  7.3454175741
## 3330                              D018_r1_WYE-354  14.768457761  5.5481338767
## 3331                               D018_r1_WZ3146   0.146332886  6.9569374761
## 3332                               D018_r1_WZ4002   3.582954808  7.4099996322
## 3333                               D018_r1_WZ4003   6.833667303  6.3295404677
## 3334                               D018_r1_WZ8040   0.570016958  5.4847810535
## 3335                              D018_r1_XAV-939  -0.685519842  6.3492178799
## 3336                                D018_r1_XL019   9.766175439  6.6357412519
## 3337                              D018_r1_XMD8-92   8.343920247  3.5115116363
## 3338                         D018_r1_Y-27632 2HCl   4.351306242  5.8977534211
## 3339                             D018_r1_YM201636  -3.202536520  8.5706003026
## 3340                             D018_r1_YO-01027  11.345033522  7.4781758874
## 3341                            D018_r1_ZM 306416  -9.728320324  8.6375655993
## 3342                        D018_r1_ZM 323881 HCl  17.514515185  6.2212594671
## 3343                            D018_r1_ZM 336372  10.727722472  7.1142633338
## 3344                         D018_r1_ZM 39923 HCl   9.344671240  7.0684047832
## 3345                            D018_r1_ZM 447439  -1.641525453  8.5438293956
## 3346                 D018_r1_Zotarolimus(ABT-578)   6.579035399  8.3813107943
## 3347                              D018_r1_ZSTK474  10.322007432  7.8445363634
## 3348                     D018_r2_1-Azakenpaullone   4.368623343  7.3171609828
## 3349                      D018_r2_3-Methyladenine   2.930488431  6.8806983229
## 3350                             D018_r2_A-674563  -8.925001810  4.9221596016
## 3351                             D018_r2_A-769662   7.899882942  7.4065070057
## 3352                                  D018_r2_A66  -0.294171187  4.4506886470
## 3353                            D018_r2_Acadesine   7.311556577  6.3013745604
## 3354                  D018_r2_AEE788 (NVP-AEE788)   2.481371660  7.5713327552
## 3355        D018_r2_Afatinib (BIBW2992)_uncertain   4.507106262  6.0395735826
## 3356                              D018_r2_AG-1024  11.772949437  3.5590876114
## 3357         D018_r2_AG-1478 (Tyrphostin AG-1478)   1.763086274  7.4697591215
## 3358                                D018_r2_AG-18   9.336456717  8.0933864132
## 3359              D018_r2_AG-490 (Tyrphostin B42)   4.625168200  6.7782757782
## 3360                             D018_r2_Akti-1/2  15.177242981  6.3258273357
## 3361                  D018_r2_Alisertib (MLN8237)   4.994577633  6.8437168068
## 3362                              D018_r2_AMG 337   2.313091660  6.0234319625
## 3363                              D018_r2_AMG-458  10.827720756  6.7739612913
## 3364                              D018_r2_AMG-900  -0.869496152  8.5890309387
## 3365                               D018_r2_AMG319   9.123439203  7.5162199039
## 3366                  D018_r2_Amuvatinib (MP-470)  15.857134542  6.2008658895
## 3367                             D018_r2_Apatinib   5.325981609  5.6084048864
## 3368                           D018_r2_AR-A014418  11.552730317  5.8000394924
## 3369                            D018_r2_AS-252424   8.824288166  5.5922657039
## 3370                            D018_r2_AS-604850   3.238164682  7.4267049251
## 3371                         D018_r2_Asiatic Acid  11.052276268  7.6607508144
## 3372                             D018_r2_AST-1306   6.478748248  6.9989550917
## 3373                              D018_r2_AT13148   2.584576912  6.8588823858
## 3374                               D018_r2_AT7519   5.378002950  4.9620303625
## 3375                               D018_r2_AT7867  16.869668933  6.8380699663
## 3376                               D018_r2_AT9283   1.518307750  5.6929337939
## 3377                 D018_r2_Aurora A Inhibitor I   3.516521250  5.6493777862
## 3378             D018_r2_Avagacestat (BMS-708163)   9.503991312  6.7457809917
## 3379                              D018_r2_AVL-292   6.534967968  7.7599497794
## 3380                             D018_r2_Axitinib   5.526339256  7.0043469592
## 3381                             D018_r2_Axitinib   5.526339256  7.0043469592
## 3382                               D018_r2_AZ 628   1.291327292  8.3918960286
## 3383                               D018_r2_AZ 960   5.369795937  6.0361016506
## 3384                                 D018_r2_AZ20  16.796381386  6.7627774203
## 3385                              D018_r2_AZD1080   5.173847420  6.9754003085
## 3386                              D018_r2_AZD1480  15.044476388  6.5992563605
## 3387                              D018_r2_AZD2014  25.618132432  6.4828459103
## 3388                              D018_r2_AZD2858   9.062763543  8.2658732013
## 3389                              D018_r2_AZD2932   6.775082351  8.3713535199
## 3390                              D018_r2_AZD3759   0.156615551  7.7206153464
## 3391                              D018_r2_AZD5363  32.327977549  2.9507047780
## 3392                              D018_r2_AZD5438  -4.017399304  4.3566664644
## 3393                              D018_r2_AZD6482  10.315759151  6.2057195455
## 3394                              D018_r2_AZD6738   5.218660529  5.9934410049
## 3395                              D018_r2_AZD8055  30.148465866  4.6147455739
## 3396                              D018_r2_AZD8330  -9.150742114  8.3524237126
## 3397                  D018_r2_AZD8931 (Sapitinib)  -0.639498425  6.6695836818
## 3398                              D018_r2_AZD9291  -3.815893254  8.0031593332
## 3399            D018_r2_Barasertib (AZD1152-HQPA)   7.901913553  8.0618867148
## 3400  D018_r2_Baricitinib (LY3009104, INCB028050)   6.384253123  6.2341708558
## 3401                  D018_r2_BGT226 (NVP-BGT226)  -8.142622308  6.2606050952
## 3402                              D018_r2_BI 2536  10.096245070  6.2045291964
## 3403                              D018_r2_BI-78D3   4.032992604  7.8648279177
## 3404                             D018_r2_BI-D1870   7.245850640  6.5775024084
## 3405                              D018_r2_Bikinin   2.268502064  6.7927980406
## 3406                                  D018_r2_BIO  14.405212101  6.8150664444
## 3407               D018_r2_BIRB 796 (Doramapimod)   6.436201522  6.3590260536
## 3408                            D018_r2_BIX 02188  10.268798732  5.6853929152
## 3409                            D018_r2_BIX 02189  12.707856236  7.0201419541
## 3410      D018_r2_BKM120 (NVP-BKM120, Buparlisib)   9.764085315  6.1659228771
## 3411                           D018_r2_BMS-265246   1.999233779  7.1480630003
## 3412                           D018_r2_BMS-536924  16.983915853  6.3663431442
## 3413                           D018_r2_BMS-582949   3.770974718  7.6260631576
## 3414                           D018_r2_BMS-754807  15.548150363  7.8103252356
## 3415                           D018_r2_BMS-777607   8.924310725  6.8569667920
## 3416                           D018_r2_BMS-794833   9.123308962  6.7807280233
## 3417                           D018_r2_BMS-833923  14.656293600  5.3363222656
## 3418                  D018_r2_Bosutinib (SKI-606)  12.508707338  6.0811509795
## 3419                D018_r2_Brivanib (BMS-540215)   7.652116716  6.3679368038
## 3420      D018_r2_Brivanib Alaninate (BMS-582664)   2.886777011  6.6184685092
## 3421                           D018_r2_BS-181 HCl  12.745063724  7.1987246201
## 3422                               D018_r2_Butein  10.745963034  8.2818087274
## 3423                               D018_r2_BYL719  10.818288699  5.8314094304
## 3424     D018_r2_Cabozantinib (XL184, BMS-907351)   6.695402515  6.0845755011
## 3425          D018_r2_Cabozantinib malate (XL184)   5.943197392  5.8037708694
## 3426        D018_r2_CAL-101 (Idelalisib, GS-1101)   3.717226795  6.4672751169
## 3427                             D018_r2_CAY10505   5.666285969  6.8934078434
## 3428                               D018_r2_CC-223  23.128578619  5.7644144018
## 3429                            D018_r2_CCT128930  10.578299158  5.0112637871
## 3430                  D018_r2_Cediranib (AZD2171)   3.930821317  6.3861355775
## 3431                            D018_r2_CEP-32496  11.540240950  7.7625992326
## 3432                            D018_r2_CEP-33779   9.492008098  5.5777886121
## 3433                              D018_r2_CGI1746   8.403029081  6.1859336190
## 3434                              D018_r2_CGK 733  19.079355186  8.5944114914
## 3435                            D018_r2_CH5132799   9.167192753  5.7015064275
## 3436                           D018_r2_CHIR-98014   4.439165893  7.3791900807
## 3437                 D018_r2_CHIR-99021 (CT99021)   5.805788961  5.5531308553
## 3438             D018_r2_CHIR-99021 (CT99021) HCl   6.890375096  6.5655458923
## 3439                    D018_r2_Chrysophanic Acid  10.917498193  7.9482363690
## 3440                             D018_r2_CNX-2006   0.096406731  7.1362603646
## 3441                              D018_r2_CNX-774   2.803244379  4.9451131523
## 3442                    D018_r2_CO-1686 (AVL-301)  -3.411191483  8.2324330737
## 3443       D018_r2_Cobimetinib (GDC-0973, RG7420)   0.395752397  8.6686591091
## 3444                            D018_r2_CP-673451  26.404282992 10.3011954997
## 3445                            D018_r2_CP-724714  -1.818359547  7.9737165067
## 3446               D018_r2_Crenolanib (CP-868596)  15.382228665  6.9132169929
## 3447             D018_r2_Crizotinib (PF-02341066)  14.793734671  6.5756270043
## 3448                               D018_r2_CYC116  -0.314576412  6.5479235688
## 3449                               D018_r2_CYT387   5.541263051  6.2348887600
## 3450                             D018_r2_CZC24832   9.201309473  6.5677130910
## 3451              D018_r2_Dabrafenib (GSK2118436)   2.739954238  9.3637584039
## 3452        D018_r2_Dacomitinib (PF299804, PF299)  -1.144215949  5.6679866376
## 3453              D018_r2_Danusertib (PHA-739358)  12.413595235  6.8868280121
## 3454                        D018_r2_DAPT (GSI-IX)   6.471734667  5.9056559594
## 3455                            D018_r2_Dasatinib   7.864531715  6.2319272311
## 3456                D018_r2_DCC-2036 (Rebastinib)   8.912738672  8.4524568979
## 3457                D018_r2_Decernotinib (VX-509)   9.364546272  6.3432172662
## 3458               D018_r2_Dinaciclib (SCH727965)   0.224015716  4.8215761855
## 3459    D018_r2_Dovitinib (TKI-258) Dilactic Acid  18.306147278  6.2746201190
## 3460                            D018_r2_ENMD-2076   1.453000348  7.2148989831
## 3461               D018_r2_Enzastaurin (LY317615)   2.901838308  6.7257166620
## 3462                            D018_r2_ERK5-IN-1  11.392778133  6.7994856460
## 3463                             D018_r2_ETC-1002   7.765762427  6.1808668713
## 3464                            D018_r2_ETP-46464  19.909753392  4.5143378784
## 3465                  D018_r2_Everolimus (RAD001)   5.363765559  7.9307399485
## 3466                D018_r2_Fasudil (HA-1077) HCl   3.338410087  6.8033383849
## 3467                                D018_r2_FH535   3.526413654  5.3230547354
## 3468                D018_r2_Filgotinib (GLPG0634)   4.335433872  8.5133494930
## 3469             D018_r2_Flavopiridol (Alvocidib)  -1.790608084  4.0912101482
## 3470                     D018_r2_Flavopiridol HCl  -1.028944217  5.6250243933
## 3471               D018_r2_Foretinib (GSK1363089)   0.280612563  4.6327142907
## 3472                  D018_r2_Fostamatinib (R788)   3.340575562  6.3582717576
## 3473                                D018_r2_G-749   8.444820156  6.5795828167
## 3474                             D018_r2_GDC-0068  23.843894013  7.1949302659
## 3475                             D018_r2_GDC-0349  20.204732450  7.4738477720
## 3476                             D018_r2_GDC-0879   8.720118882  7.2744355710
## 3477                             D018_r2_GDC-0941   9.815013527  6.3534338184
## 3478                    D018_r2_GDC-0980 (RG7422)   7.409757721  7.1599071685
## 3479                   D018_r2_Gefitinib (ZD1839)   1.158351159  7.1632019242
## 3480                            D018_r2_Genistein   4.603615852  7.5355952168
## 3481                            D018_r2_GF109203X  10.638515568  7.4959449206
## 3482                                D018_r2_GNF-2   9.350362397  7.1096379280
## 3483                                D018_r2_GNF-5   9.976775469  6.5839481234
## 3484                              D018_r2_Go 6983   8.259524554  6.1224263110
## 3485                   D018_r2_Golvatinib (E7050)   8.031981542  6.8639879282
## 3486                          D018_r2_GSK1838705A   0.869791539  5.5702605686
## 3487                          D018_r2_GSK1904529A  11.544597044  5.7066122289
## 3488                  D018_r2_GSK2126458 (GSK458)   4.836664206  6.5989738618
## 3489                           D018_r2_GSK2292767   4.547735190  5.7966682865
## 3490                           D018_r2_GSK2636771  11.113904326  7.4758107027
## 3491                           D018_r2_GSK429286A   4.610435132  6.7115882596
## 3492                            D018_r2_GSK461364   4.100070938  5.4498867758
## 3493                               D018_r2_GSK621   9.152193885  7.1362647755
## 3494                            D018_r2_GSK690693  30.766784052  4.5172037952
## 3495                               D018_r2_GW5074   8.991407385  6.8340033240
## 3496                             D018_r2_GW788388   5.789554955  7.3607922631
## 3497                               D018_r2_GZD824  -2.325722674  4.6331604598
## 3498                            D018_r2_H 89 2HCl   3.994798853  7.1151753913
## 3499                           D018_r2_Hesperadin  12.250132981  7.2990132686
## 3500                              D018_r2_HMN-214   9.032067093  5.8330454639
## 3501                             D018_r2_Honokiol   3.884474108  5.5844364187
## 3502                               D018_r2_HS-173   1.833090202  6.7065986733
## 3503                           D018_r2_HTH-01-015   0.908225955  6.8122910700
## 3504                D018_r2_Ibrutinib (PCI-32765)   1.335384078  5.1683969834
## 3505                              D018_r2_ICG-001  17.986262720  5.9181333352
## 3506                             D018_r2_Icotinib   0.806173586  5.9094452048
## 3507                                D018_r2_IM-12   9.629588581  6.5726323696
## 3508           D018_r2_Imatinib Mesylate (STI571)  -5.649111438  9.4937193180
## 3509                            D018_r2_Indirubin  14.105652873  6.4309356658
## 3510                    D018_r2_INK 128 (MLN0128)  36.905379310  6.9251690284
## 3511                    D018_r2_IPI-145 (INK1197)   1.999948141  6.6901827680
## 3512                               D018_r2_IWP-L6   4.149121946  6.3665264128
## 3513                           D018_r2_IWR-1-endo   0.137026124  8.1453772474
## 3514                         D018_r2_JNJ-38877605   1.300680666  7.6541725965
## 3515                          D018_r2_JNJ-7706621   1.394689369  4.4850777273
## 3516                     D018_r2_JNK Inhibitor IX   3.534051126  5.9601766599
## 3517                             D018_r2_JNK-IN-8   1.253030011  7.2398447621
## 3518                               D018_r2_K02288  10.406797582  7.0796678811
## 3519                               D018_r2_Ki8751  14.941059606  6.1181123935
## 3520                              D018_r2_KRN 633   7.557262041  7.1999506939
## 3521                           D018_r2_KU-0063794  24.275296214  4.1733498029
## 3522      D018_r2_KU-55933 (ATM Kinase Inhibitor)   6.391307685  6.9582255437
## 3523                             D018_r2_KU-60019  11.315634472  6.8834348807
## 3524                              D018_r2_KW-2449  23.304587456  9.3205754210
## 3525                              D018_r2_KX2-391  18.809552075  7.8393589405
## 3526                              D018_r2_KY02111   8.149227380  6.5085733926
## 3527                            D018_r2_Lapatinib   7.291634404  8.5702910444
## 3528     D018_r2_Lapatinib (GW-572016) Ditosylate   2.391887837  6.1455591307
## 3529                            D018_r2_LDC000067   7.093472925  7.7092557597
## 3530      D018_r2_LDE225 (NVP-LDE225,Erismodegib)   6.863206308  7.2563552383
## 3531                           D018_r2_LDN-214117  11.118585250  7.1520114816
## 3532                   D018_r2_Lenvatinib (E7080)  13.475035310  6.3524913644
## 3533                              D018_r2_LFM-A13   3.765544206  5.9943997166
## 3534                              D018_r2_LGK-974   4.630109011  5.5356299723
## 3535                  D018_r2_Linifanib (ABT-869)   2.763917054  6.1218507203
## 3536                               D018_r2_LJH685   5.498764291  5.4255823694
## 3537                               D018_r2_LJI308   5.536932721  7.0495570037
## 3538               D018_r2_Losmapimod (GW856553X)   1.042931597  6.0357485343
## 3539                            D018_r2_LY2090314   5.974057288  6.5493199768
## 3540                            D018_r2_LY2157299  10.053708703  5.8486137715
## 3541                            D018_r2_LY2784544   6.493945806  6.2292071016
## 3542                            D018_r2_LY2835219  -1.678687323  5.8064329908
## 3543                             D018_r2_LY294002   4.880191289  6.3527552199
## 3544                            D018_r2_LY3023414  12.370405189  6.8804097725
## 3545                             D018_r2_LY411575   8.864175809  7.0180878787
## 3546       D018_r2_MEK162 (ARRY-162, ARRY-438162)  -3.942510663  7.5686500782
## 3547                             D018_r2_MGCD-265   5.886161988  6.8293861136
## 3548               D018_r2_Milciclib (PHA-848125)  12.130285117  5.7317587120
## 3549                              D018_r2_MK-0752  16.371329344  7.5468490998
## 3550                         D018_r2_MK-2206 2HCl  18.945174452  6.1822342687
## 3551                              D018_r2_MK-2461   4.305999138  7.2840578692
## 3552                     D018_r2_MK-5108 (VX-689)   2.634663880  5.7344413736
## 3553                              D018_r2_MK-8745   4.079561632  5.8558761851
## 3554                              D018_r2_MLN2480   0.675598077  7.1565047439
## 3555                              D018_r2_MLN8054   5.887160747  7.7096197460
## 3556      D018_r2_Motesanib Diphosphate (AMG-706)   7.359897821  4.8799750533
## 3557                  D018_r2_Nilotinib (AMN-107)   4.936443679  7.9670414294
## 3558     D018_r2_Nintedanib (BIBF 1120)_uncertain   1.850710890  5.2453309205
## 3559                               D018_r2_NU6027   2.530999120  6.5929608814
## 3560                           D018_r2_NVP-AEW541  14.564333630  6.2723767941
## 3561                           D018_r2_NVP-BHG712   4.149027665  5.5962165723
## 3562                      D018_r2_NVP-BSK805 2HCl   6.398202650  5.4918399458
## 3563                           D018_r2_NVP-BVU972   0.666824777  6.9449687287
## 3564                          D018_r2_Oclacitinib   3.660022485  6.4872449579
## 3565      D018_r2_Olmutinib (HM61713, BI 1482694)   8.875444855  8.6556088161
## 3566                             D018_r2_ONO-4059  -5.775547585  7.3765755209
## 3567                              D018_r2_OSI-027  25.728729570  2.4366776363
## 3568                              D018_r2_OSI-420   0.904970360  9.0593787775
## 3569                 D018_r2_OSI-906 (Linsitinib)  11.901810445  5.5272300485
## 3570                              D018_r2_P276-00  -4.557212170  4.9990270696
## 3571                  D018_r2_Pacritinib (SB1518)  -4.521064085  5.1696749509
## 3572                   D018_r2_Palomid 529 (P529)   9.293667902  7.9587935568
## 3573                            D018_r2_Pazopanib   3.741223846  4.8012060574
## 3574                        D018_r2_Pazopanib HCl   9.391476854  7.3776074603
## 3575                            D018_r2_PD0325901  -7.305540040  8.9059166146
## 3576                             D018_r2_PD168393  -4.972894703  9.6535603586
## 3577                             D018_r2_PD173955  13.530319150  7.6556686853
## 3578                   D018_r2_PD184352 (CI-1040)  -5.398136189  8.2587903182
## 3579                             D018_r2_PD318088  -5.528181487  9.2302636714
## 3580                              D018_r2_PD98059   9.955772206  7.6890513438
## 3581                  D018_r2_Pelitinib (EKB-569)   0.062597717  6.2496475748
## 3582                          D018_r2_PF-00562271   6.030974227  7.3574481516
## 3583                          D018_r2_PF-04217903   6.012364761  6.4445347062
## 3584                          D018_r2_PF-04691502  19.868094796  6.4223574023
## 3585                            D018_r2_PF-431396  15.554034594  7.3124438513
## 3586                           D018_r2_PF-4708671  13.308341631  6.6248492672
## 3587                           D018_r2_PF-5274857   5.653748208  6.8180090229
## 3588                            D018_r2_PF-562271  -2.660424847  5.8694624481
## 3589                            D018_r2_PF-573228  19.959628778  8.0908932349
## 3590                            D018_r2_PH-797804   6.357160297  6.9088760333
## 3591                           D018_r2_PHA-665752   6.001868276  6.2457075511
## 3592                           D018_r2_PHA-680632   7.192283517  6.5171997463
## 3593                           D018_r2_PHA-767491   6.292249184  6.8853744908
## 3594                           D018_r2_PHA-793887   1.365270290  3.3923102449
## 3595                       D018_r2_Phenformin HCl  11.251681278  7.9703593513
## 3596                              D018_r2_PHT-427   9.143557658  5.2114356723
## 3597                          D018_r2_Piceatannol  18.411766949 11.1605566201
## 3598                              D018_r2_PIK-293   6.753189947  6.5067688294
## 3599                              D018_r2_PIK-294   8.728570989  8.0438881764
## 3600                               D018_r2_PIK-93  11.052879078  8.8521317994
## 3601               D018_r2_Pimasertib (AS-703026)  -5.970484300  9.1617437518
## 3602                          D018_r2_Pirfenidone   3.741489208  6.4152222676
## 3603                             D018_r2_PLX-4720   5.960266984  6.9075917297
## 3604                              D018_r2_PLX7904   7.061800070  9.8679746225
## 3605                  D018_r2_Ponatinib (AP24534)  17.280774612  6.7542661759
## 3606                                  D018_r2_PP1   8.858015829  7.0178001558
## 3607                                  D018_r2_PP2   5.633481077  7.3571959883
## 3608                                D018_r2_PP242  40.858331646  4.2987642712
## 3609                               D018_r2_PQ 401  17.628690675  6.8777435186
## 3610                              D018_r2_PRI-724  16.030559338  5.4785557441
## 3611     D018_r2_PRT062607 (P505-15, BIIB057) HCl   8.735866958  4.9895243165
## 3612                         D018_r2_Purvalanol A   9.840839678  7.0438476959
## 3613                            D018_r2_Quercetin   9.838478592  7.6371729143
## 3614                  D018_r2_Quizartinib (AC220)   2.637457924  6.2240274764
## 3615                                 D018_r2_R406   5.766630657  7.2454949009
## 3616                     D018_r2_R406 (free base)   7.739576973  6.5602664641
## 3617                                 D018_r2_R547  11.904236220  8.0353440420
## 3618                    D018_r2_RAF265 (CHIR-265)  -0.009382290  8.6803248339
## 3619                D018_r2_Rapamycin (Sirolimus)  10.177268287  6.7748629279
## 3620   D018_r2_Refametinib (RDEA119, Bay 86-9766)  -6.026186785  8.7045676773
## 3621                               D018_r2_RepSox   4.216614799  6.3730789693
## 3622 D018_r2_Ridaforolimus (Deforolimus, MK-8669)   8.542734576  5.8986173656
## 3623                D018_r2_Rigosertib (ON-01910)  21.310758716  7.8737974335
## 3624                             D018_r2_RKI-1447  10.204402469  6.2677883862
## 3625                                D018_r2_RN486   4.395339830  8.5975095763
## 3626                  D018_r2_Ro 31-8220 Mesylate   3.002979759  5.2455008887
## 3627                              D018_r2_Ro-3306   7.737583000  5.6356434167
## 3628                               D018_r2_Ro3280   7.074058155  6.3121692311
## 3629                            D018_r2_RO4929097  11.419465455  6.1634159961
## 3630      D018_r2_Roscovitine (Seliciclib,CYC202)   7.805488438  7.4777543801
## 3631             D018_r2_Ruxolitinib (INCB018424)   4.563895601  6.4870235756
## 3632           D018_r2_S-Ruxolitinib (INCB018424)   6.889463377  6.0585146846
## 3633                               D018_r2_SANT-1  13.180936112  6.6824290250
## 3634                            D018_r2_SAR131675   8.552496625  7.5342983383
## 3635                    D018_r2_SAR245409 (XL765)   1.652896182  7.1118612049
## 3636                D018_r2_Saracatinib (AZD0530)  -1.712501600  5.0643403044
## 3637                      D018_r2_SB202190 (FHPI)  12.748523687  6.9284754433
## 3638                             D018_r2_SB203580  12.194688242  5.7341533881
## 3639                             D018_r2_SB216763   8.875960126  7.0115404207
## 3640                             D018_r2_SB239063  17.349272518  6.8012327220
## 3641                             D018_r2_SB415286   6.341704574  6.3557924459
## 3642                             D018_r2_SB431542   3.487695210  6.4735475321
## 3643                             D018_r2_SB505124  13.299707801  5.0227103607
## 3644                             D018_r2_SB525334  10.330441501  5.9995670488
## 3645                             D018_r2_SB590885  14.791215105  5.8068671882
## 3646                                  D018_r2_SC1   4.088859416  7.1076608270
## 3647                D018_r2_Schisandrin B (Sch B)  15.035353008  6.5574787098
## 3648                D018_r2_Selumetinib (AZD6244)  -5.955073226  7.3120857244
## 3649              D018_r2_Semagacestat (LY450139)  10.947594740  6.9492439003
## 3650                   D018_r2_Semaxanib (SU5416)  14.949698637  6.7836241889
## 3651                             D018_r2_SGI-7079  15.782976097  8.8918612528
## 3652                          D018_r2_Skepinone-L   1.813775798  5.8506465484
## 3653                               D018_r2_SL-327  -1.588005788  6.3556222670
## 3654                 D018_r2_SNS-032 (BMS-387032)   2.521163068  4.3742816833
## 3655                     D018_r2_SNS-314 Mesylate   7.707526590  5.5548289754
## 3656                            D018_r2_Sorafenib   7.197694434  4.7122866388
## 3657                   D018_r2_Sorafenib Tosylate  11.870668285  6.6596307926
## 3658                         D018_r2_Sotrastaurin   8.112634746  6.3056279126
## 3659                             D018_r2_SP600125  12.586986552  8.2004727967
## 3660                              D018_r2_SU11274   7.836128708  6.8588240657
## 3661                               D018_r2_SU6656  13.739797573  8.3716208328
## 3662                               D018_r2_SU9516   7.821870828  5.5401526000
## 3663                     D018_r2_Sunitinib Malate   9.426900508  4.7546966559
## 3664                  D018_r2_TAE226 (NVP-TAE226)  11.313190747  7.9884159508
## 3665                              D018_r2_TAK-285   0.144209610  6.4180827015
## 3666                              D018_r2_TAK-632  -0.487047888  9.0522755847
## 3667                              D018_r2_TAK-715   6.044782368  5.7465751158
## 3668                              D018_r2_TAK-733  -2.175143939  7.0809892679
## 3669                              D018_r2_TAK-901   5.562086959  7.1042321935
## 3670                D018_r2_Taladegib (LY2940680)   7.157545278  7.1746934228
## 3671                              D018_r2_TCS 359   8.821555941  8.1520541829
## 3672                               D018_r2_TDZD-8   4.978152362  5.1682758324
## 3673                            D018_r2_Telatinib   6.445155408  8.3144463278
## 3674   D018_r2_Temsirolimus (CCI-779, NSC 683864)   2.434943031  7.9854300513
## 3675              D018_r2_Tepotinib (EMD 1214063)   5.087362275  6.6037417273
## 3676                                D018_r2_TG003  12.363396900  8.0488690480
## 3677                            D018_r2_TG100-115   4.858352730  4.5720736169
## 3678                             D018_r2_TG101209  -0.354196145  5.1211744008
## 3679                 D018_r2_TG101348 (SAR302503)   8.666917122  6.7021886777
## 3680                              D018_r2_TGX-221   8.224230052  6.2436837525
## 3681                         D018_r2_Theophylline   8.255402345  6.1834993643
## 3682                          D018_r2_Thiazovivin  -0.898322824  7.3633274257
## 3683                       D018_r2_TIC10 Analogue   6.587905504  7.4487454527
## 3684                           D018_r2_Tideglusib   4.464186917  7.4773689509
## 3685                 D018_r2_Tivantinib (ARQ 197)  12.110205185  9.4269055325
## 3686                   D018_r2_Tivozanib (AV-951)  11.836138502  6.3814155596
## 3687  D018_r2_Tofacitinib (CP-690550,Tasocitinib)   4.648517090  6.7977068872
## 3688      D018_r2_Tofacitinib (CP-690550) Citrate   2.827541964  6.8867957454
## 3689                              D018_r2_Torin 2   2.881879085  5.7409579463
## 3690              D018_r2_Trametinib (GSK1120212)  -3.377007462 10.1982231597
## 3691                          D018_r2_Triciribine  11.656192246  8.0834288055
## 3692           D018_r2_TSU-68 (SU6668, Orantinib)   8.940909885  7.5629267964
## 3693                               D018_r2_TWS119   8.366367163  7.2544197202
## 3694                         D018_r2_Tyrphostin 9  14.597199799  6.2734188117
## 3695                   D018_r2_Tyrphostin AG 1296   3.138917728  6.0011789966
## 3696                           D018_r2_U0126-EtOH   5.028749035  7.7939201714
## 3697     D018_r2_Ulixertinib (BVD-523, VRT752271)  -3.435563346  6.6845728269
## 3698              D018_r2_Uprosertib (GSK2141795)  36.893350219  3.3433987027
## 3699                          D018_r2_Vacquinol-1   9.091213878  5.9950020990
## 3700                           D018_r2_Varlitinib   4.427310778  8.4519759141
## 3701              D018_r2_Vatalanib (PTK787) 2HCl  -1.715506414  5.4243656805
## 3702                               D018_r2_VE-821   2.358244034  7.7890391477
## 3703                               D018_r2_VE-822   4.991323234  5.3976896922
## 3704        D018_r2_Vemurafenib (PLX4032, RG7204)   8.916214278  6.9309864598
## 3705                D018_r2_Vismodegib (GDC-0449)   4.496796919  7.0978761367
## 3706                 D018_r2_Volasertib (BI 6727)   6.152800275  7.1260952449
## 3707                            D018_r2_VPS34-IN1   2.276394350  5.4055835271
## 3708                     D018_r2_VS-5584 (SB2343)  17.989960124  5.8405903458
## 3709                               D018_r2_VX-11e  -2.145139433  7.4483327383
## 3710         D018_r2_VX-680 (Tozasertib, MK-0457)  -5.186060549  6.0151107324
## 3711                               D018_r2_VX-702   0.595594463  5.1591872009
## 3712                               D018_r2_VX-745   4.985066458  6.3686058352
## 3713                              D018_r2_WAY-600   7.063232188  5.5390595017
## 3714                             D018_r2_WH-4-023  16.516938553  7.0732747410
## 3715                             D018_r2_WHI-P154   7.111315698  7.2496909634
## 3716                                D018_r2_WIKI4  -1.527619929  7.0617197147
## 3717                        D018_r2_Wnt agonist 1   9.028328947  6.9599080977
## 3718                        D018_r2_Wnt-C59 (C59)   6.874079574  6.0084147131
## 3719                               D018_r2_WP1066   4.743679679  6.6493169419
## 3720                 D018_r2_WYE-125132 (WYE-132)  28.550823767  5.2867680919
## 3721                              D018_r2_WYE-354  13.617992785  5.9910525777
## 3722                               D018_r2_WZ3146  -2.280630316  8.0879013584
## 3723                               D018_r2_WZ4002   6.946641879  6.5560930496
## 3724                               D018_r2_WZ4003   5.226951173  6.1886600648
## 3725                               D018_r2_WZ8040   0.843232431  7.8710946563
## 3726                              D018_r2_XAV-939   0.600040814  6.6189574541
## 3727                                D018_r2_XL019   8.735388524  5.8443369593
## 3728                              D018_r2_XMD8-92   5.626133957  5.7559175103
## 3729                         D018_r2_Y-27632 2HCl   5.975038566  6.6363963064
## 3730                             D018_r2_YM201636   4.465355678  7.0440564314
## 3731                             D018_r2_YO-01027   6.444172138  6.8931826297
## 3732                            D018_r2_ZM 306416  -4.851145475  7.1295576368
## 3733                        D018_r2_ZM 323881 HCl   7.760472072  6.5210334404
## 3734                            D018_r2_ZM 336372  13.253815141  5.9969820676
## 3735                         D018_r2_ZM 39923 HCl   5.156409117  5.9933139745
## 3736                            D018_r2_ZM 447439  -0.879968677  6.1938525839
## 3737                 D018_r2_Zotarolimus(ABT-578)  12.221024887  5.3598622416
## 3738                              D018_r2_ZSTK474  11.256288268  7.0341996070
## 3739                     D019_r1_1-Azakenpaullone   1.257559812 -1.6973562103
## 3740                      D019_r1_3-Methyladenine  -0.531341335 -0.0102827301
## 3741                             D019_r1_A-674563 -12.110557660  1.3541017021
## 3742                             D019_r1_A-769662   1.794097881 -3.0433015080
## 3743                                  D019_r1_A66   1.716303381 -0.5353014857
## 3744                            D019_r1_Acadesine  -1.315279864  0.7226309366
## 3745                  D019_r1_AEE788 (NVP-AEE788)   1.871329438 -1.9618948419
## 3746        D019_r1_Afatinib (BIBW2992)_uncertain   0.266408440 -0.1839082527
## 3747                              D019_r1_AG-1024  -1.964015257 -1.1375459456
## 3748         D019_r1_AG-1478 (Tyrphostin AG-1478)   1.109512656 -2.0578478750
## 3749                                D019_r1_AG-18   0.961065530 -0.8124590795
## 3750              D019_r1_AG-490 (Tyrphostin B42)   0.006250118 -0.1886428800
## 3751                             D019_r1_Akti-1/2   1.766971820  1.3318361859
## 3752                  D019_r1_Alisertib (MLN8237) -13.881458666  0.1250851006
## 3753                              D019_r1_AMG 337  -0.523169770 -0.4310997286
## 3754                              D019_r1_AMG-458   0.695229599 -0.8781228688
## 3755                              D019_r1_AMG-900 -10.361983253  3.0314158699
## 3756                               D019_r1_AMG319   1.322352702 -0.0424397269
## 3757                  D019_r1_Amuvatinib (MP-470)  -0.575436614 -1.8777936448
## 3758                             D019_r1_Apatinib   1.272640827 -0.7488563692
## 3759                           D019_r1_AR-A014418   0.582480720 -0.4537255270
## 3760                            D019_r1_AS-252424   1.843679826 -0.7223241178
## 3761                            D019_r1_AS-604850   0.734763048 -0.0508527331
## 3762                         D019_r1_Asiatic Acid   2.889519346  0.1077675501
## 3763                             D019_r1_AST-1306   1.592031244  0.4741053930
## 3764                              D019_r1_AT13148  -0.390524697  0.5210252637
## 3765                               D019_r1_AT7519  -4.415689374  2.0725894894
## 3766                               D019_r1_AT7867  -2.170517558  1.1925237671
## 3767                               D019_r1_AT9283 -18.106673002  2.5958193969
## 3768                 D019_r1_Aurora A Inhibitor I  -0.836709514 -1.8502748205
## 3769             D019_r1_Avagacestat (BMS-708163)   0.971777726 -0.4274028621
## 3770                              D019_r1_AVL-292  -0.240985930 -0.4737304404
## 3771                             D019_r1_Axitinib  -1.701505075 -0.0012792953
## 3772                             D019_r1_Axitinib  -1.701505075 -0.0012792953
## 3773                               D019_r1_AZ 628  -0.097447710  0.6660183568
## 3774                               D019_r1_AZ 960 -15.387875167  1.6402993472
## 3775                                 D019_r1_AZ20  -8.274747510  3.3785847030
## 3776                              D019_r1_AZD1080  -6.082673319 -0.8921134209
## 3777                              D019_r1_AZD1480  -9.780058790  1.9457373895
## 3778                              D019_r1_AZD2014  -2.854926297 -0.5291085920
## 3779                              D019_r1_AZD2858  -8.702203901 -0.1379702634
## 3780                              D019_r1_AZD2932   0.858768048 -0.5435573533
## 3781                              D019_r1_AZD3759   1.884852608 -0.3790975676
## 3782                              D019_r1_AZD5363  -5.203558927  0.4474663013
## 3783                              D019_r1_AZD5438  -6.774444926  3.5015753207
## 3784                              D019_r1_AZD6482   1.521696244 -0.7229383088
## 3785                              D019_r1_AZD6738  -8.233249771  2.6366793622
## 3786                              D019_r1_AZD8055  -7.133667825  0.3499005674
## 3787                              D019_r1_AZD8330  -3.384179504  3.1070625198
## 3788                  D019_r1_AZD8931 (Sapitinib)  -0.378112372 -0.6342182236
## 3789                              D019_r1_AZD9291  -0.813093058  0.6434179886
## 3790            D019_r1_Barasertib (AZD1152-HQPA)  -1.742866233 -1.1064958723
## 3791  D019_r1_Baricitinib (LY3009104, INCB028050)  -0.408204274  0.0259934095
## 3792                  D019_r1_BGT226 (NVP-BGT226)  -6.795618376  1.2809156277
## 3793                              D019_r1_BI 2536  -6.617330594  2.7164804798
## 3794                              D019_r1_BI-78D3   1.643276491 -1.3026603449
## 3795                             D019_r1_BI-D1870   1.961052881 -0.4209761995
## 3796                              D019_r1_Bikinin   0.490034760  0.0963724181
## 3797                                  D019_r1_BIO   1.778897215  0.1966878582
## 3798               D019_r1_BIRB 796 (Doramapimod)   0.723849757 -0.6367328026
## 3799                            D019_r1_BIX 02188   1.852914347 -0.4511512674
## 3800                            D019_r1_BIX 02189   1.549917466 -1.9464129851
## 3801      D019_r1_BKM120 (NVP-BKM120, Buparlisib)  -7.018773954  0.8220372304
## 3802                           D019_r1_BMS-265246  -2.401665189 -0.1454393902
## 3803                           D019_r1_BMS-536924  -3.770611604  0.3730577720
## 3804                           D019_r1_BMS-582949   2.632007160 -1.4457326542
## 3805                           D019_r1_BMS-754807  -5.962900652  3.2562082781
## 3806                           D019_r1_BMS-777607   0.174045521  0.4731864653
## 3807                           D019_r1_BMS-794833   0.577614579 -0.0356191220
## 3808                           D019_r1_BMS-833923   2.425785676 -1.2639951580
## 3809                  D019_r1_Bosutinib (SKI-606)   4.347627210 -1.4398492915
## 3810                D019_r1_Brivanib (BMS-540215)  -2.165612692 -0.5155909949
## 3811      D019_r1_Brivanib Alaninate (BMS-582664)   1.085449812 -0.7332931782
## 3812                           D019_r1_BS-181 HCl   2.113323977  0.3478982569
## 3813                               D019_r1_Butein   0.401093090 -0.0147406003
## 3814                               D019_r1_BYL719  -0.596965567  1.6261619121
## 3815     D019_r1_Cabozantinib (XL184, BMS-907351)   1.975041368  1.4780452452
## 3816          D019_r1_Cabozantinib malate (XL184)   1.161916731  0.5386541783
## 3817        D019_r1_CAL-101 (Idelalisib, GS-1101)  -0.488789191  0.0497230368
## 3818                             D019_r1_CAY10505   0.738641638  0.1849600698
## 3819                               D019_r1_CC-223   3.983141937  0.3514477477
## 3820                            D019_r1_CCT128930   1.022262507 -1.1554392593
## 3821                  D019_r1_Cediranib (AZD2171)   2.541852232 -1.1268707680
## 3822                            D019_r1_CEP-32496   3.179280641 -1.8842026994
## 3823                            D019_r1_CEP-33779  -0.362398268 -0.9616898107
## 3824                              D019_r1_CGI1746  -0.296204120  0.1903119345
## 3825                              D019_r1_CGK 733   0.624906351 -0.0488107455
## 3826                            D019_r1_CH5132799  -7.519470595 -0.2493573623
## 3827                           D019_r1_CHIR-98014  -7.738118439  0.2506491254
## 3828                 D019_r1_CHIR-99021 (CT99021)  -2.912600090  0.9615923999
## 3829             D019_r1_CHIR-99021 (CT99021) HCl  -3.277548237 -0.0173872411
## 3830                    D019_r1_Chrysophanic Acid  -1.434537038 -0.2510062012
## 3831                             D019_r1_CNX-2006  -0.568584049 -1.3475153063
## 3832                              D019_r1_CNX-774   1.062496946 -0.3211048674
## 3833                    D019_r1_CO-1686 (AVL-301)  -0.187692228  0.3562379586
## 3834       D019_r1_Cobimetinib (GDC-0973, RG7420)  -6.078515852  1.6480249578
## 3835                            D019_r1_CP-673451  -4.488385442  0.1194767153
## 3836                            D019_r1_CP-724714  -1.490674001 -2.1176686781
## 3837               D019_r1_Crenolanib (CP-868596)  -1.252380722  0.5819155302
## 3838             D019_r1_Crizotinib (PF-02341066)  -3.007380158  3.3287818387
## 3839                               D019_r1_CYC116 -18.202941556  1.1676524383
## 3840                               D019_r1_CYT387  -3.241813942  0.3467729836
## 3841                             D019_r1_CZC24832   2.188628641 -0.7867811091
## 3842              D019_r1_Dabrafenib (GSK2118436)  -2.116237262 -0.4729206772
## 3843        D019_r1_Dacomitinib (PF299804, PF299)   1.128043705 -1.1700202568
## 3844              D019_r1_Danusertib (PHA-739358) -12.313731545  1.5722048051
## 3845                        D019_r1_DAPT (GSI-IX)   2.603076383 -1.2839614563
## 3846                            D019_r1_Dasatinib   2.131020940  0.0469062942
## 3847                D019_r1_DCC-2036 (Rebastinib)  -3.132014727  0.4904499799
## 3848                D019_r1_Decernotinib (VX-509)   1.940339536 -0.5079846190
## 3849               D019_r1_Dinaciclib (SCH727965)  -4.737602169  2.4743640881
## 3850    D019_r1_Dovitinib (TKI-258) Dilactic Acid   1.450862168 -1.5590651452
## 3851                            D019_r1_ENMD-2076 -13.793988482  0.5530928771
## 3852               D019_r1_Enzastaurin (LY317615)  -0.962103076 -0.4050873456
## 3853                            D019_r1_ERK5-IN-1   3.702149493 -1.4427054039
## 3854                             D019_r1_ETC-1002   0.427366141 -0.0644548010
## 3855                            D019_r1_ETP-46464   0.051327469 -0.4612130465
## 3856                  D019_r1_Everolimus (RAD001)  -0.529671843  0.0175425044
## 3857                D019_r1_Fasudil (HA-1077) HCl  -0.645912653 -0.2251930533
## 3858                                D019_r1_FH535  -4.755630125 -1.1643425916
## 3859                D019_r1_Filgotinib (GLPG0634)   0.451192500  0.0123793479
## 3860             D019_r1_Flavopiridol (Alvocidib)  -8.299863365  2.8444683671
## 3861                     D019_r1_Flavopiridol HCl  -6.469111682  3.5580941897
## 3862               D019_r1_Foretinib (GSK1363089) -12.261246426  3.2701060956
## 3863                  D019_r1_Fostamatinib (R788)  -1.448745166 -0.9642030663
## 3864                                D019_r1_G-749   1.610155087 -0.4928077094
## 3865                             D019_r1_GDC-0068  -5.042370359  2.0533470195
## 3866                             D019_r1_GDC-0349  -0.174206494 -1.9931599016
## 3867                             D019_r1_GDC-0879  -1.793165672 -0.9511071475
## 3868                             D019_r1_GDC-0941   1.727895695 -1.6689313240
## 3869                    D019_r1_GDC-0980 (RG7422)  -5.955272042  0.4186500478
## 3870                   D019_r1_Gefitinib (ZD1839)   4.012782063  0.1246004469
## 3871                            D019_r1_Genistein   0.864652417 -1.3194518106
## 3872                            D019_r1_GF109203X   0.104334233 -0.2207933696
## 3873                                D019_r1_GNF-2   1.037261411 -0.6025469803
## 3874                                D019_r1_GNF-5  -0.897162878  0.9767974629
## 3875                              D019_r1_Go 6983   0.454784530  0.6547938332
## 3876                   D019_r1_Golvatinib (E7050) -13.176013979 -1.3966786035
## 3877                          D019_r1_GSK1838705A  -5.000182342  0.5404503263
## 3878                          D019_r1_GSK1904529A   1.007894815 -0.1709661725
## 3879                  D019_r1_GSK2126458 (GSK458) -12.494488251  2.1386874542
## 3880                           D019_r1_GSK2292767   0.793873903  0.1886260307
## 3881                           D019_r1_GSK2636771  -0.474421570 -0.3720064461
## 3882                           D019_r1_GSK429286A  -0.119602667 -0.7068819907
## 3883                            D019_r1_GSK461364 -12.230658349  3.2589377005
## 3884                               D019_r1_GSK621   0.299753617  0.1915638556
## 3885                            D019_r1_GSK690693   0.048441400 -0.3479495479
## 3886                               D019_r1_GW5074   0.696015007  0.2137475862
## 3887                             D019_r1_GW788388   1.080221862 -0.3244969832
## 3888                               D019_r1_GZD824   4.514502279  1.6664971405
## 3889                            D019_r1_H 89 2HCl   1.345682412 -0.6566274149
## 3890                           D019_r1_Hesperadin  -4.283168673  3.5480680556
## 3891                              D019_r1_HMN-214 -11.206186375  1.9340496778
## 3892                             D019_r1_Honokiol   1.384774834  0.0986736248
## 3893                               D019_r1_HS-173 -12.118926873  0.2603864889
## 3894                           D019_r1_HTH-01-015  -0.966410127 -1.0229612883
## 3895                D019_r1_Ibrutinib (PCI-32765)   3.515309510 -1.3409989058
## 3896                              D019_r1_ICG-001  -0.073026698 -0.0365414524
## 3897                             D019_r1_Icotinib  -0.753090266 -0.0245583809
## 3898                                D019_r1_IM-12  -0.118250196 -0.2754025426
## 3899           D019_r1_Imatinib Mesylate (STI571)   1.777362640 -0.7386387688
## 3900                            D019_r1_Indirubin   0.437582284  0.9268551978
## 3901                    D019_r1_INK 128 (MLN0128)  -5.607357958  0.2673176666
## 3902                    D019_r1_IPI-145 (INK1197)   1.172588982  0.5406480795
## 3903                               D019_r1_IWP-L6   1.436874610 -0.2798952415
## 3904                           D019_r1_IWR-1-endo  -0.482324272 -0.3743009587
## 3905                         D019_r1_JNJ-38877605   1.283808042 -0.2924922906
## 3906                          D019_r1_JNJ-7706621  -9.129069375  3.5645114995
## 3907                     D019_r1_JNK Inhibitor IX -14.031577170  0.6014211340
## 3908                             D019_r1_JNK-IN-8   2.287979399  0.4853540614
## 3909                               D019_r1_K02288   0.681569374 -0.5687064259
## 3910                               D019_r1_Ki8751   1.093233264 -0.4775387390
## 3911                              D019_r1_KRN 633   1.933132719 -0.6481901986
## 3912                           D019_r1_KU-0063794  -2.080524558 -0.9690443544
## 3913      D019_r1_KU-55933 (ATM Kinase Inhibitor)  -0.079059606  0.1531646565
## 3914                             D019_r1_KU-60019   1.819426665  0.9188823986
## 3915                              D019_r1_KW-2449   0.048326882  3.8238342620
## 3916                              D019_r1_KX2-391  -9.220697586  1.8188755613
## 3917                              D019_r1_KY02111   0.608642914  0.3461678343
## 3918                            D019_r1_Lapatinib   1.080066168 -0.0637396552
## 3919     D019_r1_Lapatinib (GW-572016) Ditosylate   3.147325769 -1.7996821061
## 3920                            D019_r1_LDC000067  -0.756301975 -0.8365982683
## 3921      D019_r1_LDE225 (NVP-LDE225,Erismodegib)   0.319970125 -1.1484411317
## 3922                           D019_r1_LDN-214117   1.407091096  1.0318749189
## 3923                   D019_r1_Lenvatinib (E7080)   0.402246903 -1.3400149067
## 3924                              D019_r1_LFM-A13   2.078192867 -0.2922429985
## 3925                              D019_r1_LGK-974  -0.442767643 -0.0117128899
## 3926                  D019_r1_Linifanib (ABT-869)   1.076397682 -1.2079163108
## 3927                               D019_r1_LJH685   3.295369089 -0.0305324762
## 3928                               D019_r1_LJI308   3.428701468 -0.0533854968
## 3929               D019_r1_Losmapimod (GW856553X)   0.006131379 -0.7137133572
## 3930                            D019_r1_LY2090314  -7.358434919  2.1801069044
## 3931                            D019_r1_LY2157299  -0.629181719  0.0660843074
## 3932                            D019_r1_LY2784544  -2.158145468 -0.3568845036
## 3933                            D019_r1_LY2835219  -8.442643104  0.2052984290
## 3934                             D019_r1_LY294002   0.582745690  1.1779579812
## 3935                            D019_r1_LY3023414  -0.932225887  2.9139508215
## 3936                             D019_r1_LY411575   1.424228157 -1.4719649948
## 3937       D019_r1_MEK162 (ARRY-162, ARRY-438162)  -3.379280490  2.5023995133
## 3938                             D019_r1_MGCD-265   0.901224621  0.2448138028
## 3939               D019_r1_Milciclib (PHA-848125)  -5.454908058  3.9469373327
## 3940                              D019_r1_MK-0752   2.249450402 -1.0853660798
## 3941                         D019_r1_MK-2206 2HCl  -0.635505905 -1.4234893092
## 3942                              D019_r1_MK-2461  -0.503772320 -1.6990040813
## 3943                     D019_r1_MK-5108 (VX-689)  -3.712501543 -0.7368390953
## 3944                              D019_r1_MK-8745  -6.598911585 -1.0549452523
## 3945                              D019_r1_MLN2480   1.163149787 -1.3668177097
## 3946                              D019_r1_MLN8054   1.731713995 -0.6118332921
## 3947      D019_r1_Motesanib Diphosphate (AMG-706)  -1.374158506 -0.4753947071
## 3948                  D019_r1_Nilotinib (AMN-107)   0.489260274 -1.1742383556
## 3949     D019_r1_Nintedanib (BIBF 1120)_uncertain   1.457012059 -1.7090269014
## 3950                               D019_r1_NU6027  -0.321891743  0.7177878117
## 3951                           D019_r1_NVP-AEW541   4.612606353  1.5452258319
## 3952                           D019_r1_NVP-BHG712  -0.205424585  0.8681410225
## 3953                      D019_r1_NVP-BSK805 2HCl  -0.551493596  0.7720322950
## 3954                           D019_r1_NVP-BVU972   1.641871511 -0.8390083180
## 3955                          D019_r1_Oclacitinib  -1.187970613  0.1973086877
## 3956      D019_r1_Olmutinib (HM61713, BI 1482694)   1.814050312  0.5266444050
## 3957                             D019_r1_ONO-4059   0.003171985 -1.4568886415
## 3958                              D019_r1_OSI-027  -1.682929865 -1.2096367056
## 3959                              D019_r1_OSI-420   1.934949887 -1.0494305239
## 3960                 D019_r1_OSI-906 (Linsitinib)  -5.167714083  0.8456602216
## 3961                              D019_r1_P276-00  -5.293295284  1.6439888004
## 3962                  D019_r1_Pacritinib (SB1518)  -9.537374816  2.0247908895
## 3963                   D019_r1_Palomid 529 (P529)  -0.419440303 -1.5648591339
## 3964                            D019_r1_Pazopanib   1.455658999 -0.6625851612
## 3965                        D019_r1_Pazopanib HCl  -2.753425876  0.8955744184
## 3966                            D019_r1_PD0325901  -4.286773736  2.5291853070
## 3967                             D019_r1_PD168393   0.786642619  0.2604626521
## 3968                             D019_r1_PD173955  -4.328814571 -0.6877358448
## 3969                   D019_r1_PD184352 (CI-1040)  -2.891211580  0.2864217065
## 3970                             D019_r1_PD318088  -7.088787940  0.9366837509
## 3971                              D019_r1_PD98059   1.885304260  1.0081799802
## 3972                  D019_r1_Pelitinib (EKB-569)   1.345464012 -0.6532592206
## 3973                          D019_r1_PF-00562271  -3.004046081  3.0544597458
## 3974                          D019_r1_PF-04217903  -1.600762684  0.9412530686
## 3975                          D019_r1_PF-04691502  -1.727756109  1.0980701819
## 3976                            D019_r1_PF-431396  -4.432413282  2.1699184586
## 3977                           D019_r1_PF-4708671  -5.621560410  3.5558708593
## 3978                           D019_r1_PF-5274857   0.559343243 -0.8260615667
## 3979                            D019_r1_PF-562271  -6.719624010  3.2380687945
## 3980                            D019_r1_PF-573228   3.520793490  0.7617579100
## 3981                            D019_r1_PH-797804  -1.200081011  0.1841252942
## 3982                           D019_r1_PHA-665752  -0.916718242  1.0809959179
## 3983                           D019_r1_PHA-680632  -0.887250706  0.7687385256
## 3984                           D019_r1_PHA-767491  -4.731608999  2.8445625673
## 3985                           D019_r1_PHA-793887  -3.628333225  1.5023534002
## 3986                       D019_r1_Phenformin HCl  -1.469458231 -1.4529778823
## 3987                              D019_r1_PHT-427   1.380058459 -0.5501080057
## 3988                          D019_r1_Piceatannol   3.444741126  2.7050051506
## 3989                              D019_r1_PIK-293   0.064645864 -0.8378852394
## 3990                              D019_r1_PIK-294  -2.084425784 -0.1686942220
## 3991                               D019_r1_PIK-93  -0.568206142  1.2952015004
## 3992               D019_r1_Pimasertib (AS-703026)  -4.492428945  3.1093628465
## 3993                          D019_r1_Pirfenidone   0.495087090  0.4823127539
## 3994                             D019_r1_PLX-4720  -0.325130787 -0.2420778254
## 3995                              D019_r1_PLX7904   1.091760041 -0.9699140755
## 3996                  D019_r1_Ponatinib (AP24534)   3.911485526 -0.6319738724
## 3997                                  D019_r1_PP1  -4.086124029 -0.2649187551
## 3998                                  D019_r1_PP2  -0.822398956 -0.8828175743
## 3999                                D019_r1_PP242  -0.344796601 -0.8682892433
## 4000                               D019_r1_PQ 401  -0.130404372 -0.6582293843
## 4001                              D019_r1_PRI-724   0.113974054 -1.0305919766
## 4002     D019_r1_PRT062607 (P505-15, BIIB057) HCl  -2.842480710  0.2054538141
## 4003                         D019_r1_Purvalanol A  -0.447587558 -1.0413267315
## 4004                            D019_r1_Quercetin   0.887369161 -0.4831386251
## 4005                  D019_r1_Quizartinib (AC220)   4.463523526  1.0020380468
## 4006                                 D019_r1_R406   0.467624033 -0.6564255861
## 4007                     D019_r1_R406 (free base)   0.950564816 -0.6176597020
## 4008                                 D019_r1_R547  -3.167982647  3.6505803445
## 4009                    D019_r1_RAF265 (CHIR-265)  -3.938404267  2.7812607591
## 4010                D019_r1_Rapamycin (Sirolimus)  -0.099965273 -0.8010643560
## 4011   D019_r1_Refametinib (RDEA119, Bay 86-9766)  -4.404287362  2.3808970451
## 4012                               D019_r1_RepSox  -0.718154766  1.4337269821
## 4013 D019_r1_Ridaforolimus (Deforolimus, MK-8669)  -0.833862390 -0.7058162053
## 4014                D019_r1_Rigosertib (ON-01910)  -8.296261464  2.1732715225
## 4015                             D019_r1_RKI-1447   1.383254236 -0.7009966159
## 4016                                D019_r1_RN486   3.493568740 -2.2820576493
## 4017                  D019_r1_Ro 31-8220 Mesylate   1.392136915  1.2947308978
## 4018                              D019_r1_Ro-3306   0.176771422 -1.4476566600
## 4019                               D019_r1_Ro3280  -8.033677105  3.1127158304
## 4020                            D019_r1_RO4929097   4.026781643 -0.9164040222
## 4021      D019_r1_Roscovitine (Seliciclib,CYC202)   0.349802221 -0.0806718393
## 4022             D019_r1_Ruxolitinib (INCB018424)   0.165991896  0.7816183753
## 4023           D019_r1_S-Ruxolitinib (INCB018424)  -0.217555562 -0.4784001024
## 4024                               D019_r1_SANT-1   3.137981657 -0.5491008013
## 4025                            D019_r1_SAR131675  -1.220725663  0.2503788186
## 4026                    D019_r1_SAR245409 (XL765)   1.484611178  1.6804651445
## 4027                D019_r1_Saracatinib (AZD0530)   5.093665681 -0.1620536240
## 4028                      D019_r1_SB202190 (FHPI)  -1.905195803  0.0585999071
## 4029                             D019_r1_SB203580   0.044063510 -0.1992506451
## 4030                             D019_r1_SB216763   0.547045351 -0.7269025733
## 4031                             D019_r1_SB239063   4.468417736  0.2772851087
## 4032                             D019_r1_SB415286   1.138720491 -1.0517780410
## 4033                             D019_r1_SB431542   1.861616451 -0.2061803353
## 4034                             D019_r1_SB505124   1.532627396 -1.9557089708
## 4035                             D019_r1_SB525334   1.437910020 -1.5563105976
## 4036                             D019_r1_SB590885   0.130909920  0.3273060179
## 4037                                  D019_r1_SC1  -6.243312887  2.6964398424
## 4038                D019_r1_Schisandrin B (Sch B)   1.452419195 -1.4191313124
## 4039                D019_r1_Selumetinib (AZD6244)  -2.047494761  0.9678511814
## 4040              D019_r1_Semagacestat (LY450139)   2.272265071  0.6700172290
## 4041                   D019_r1_Semaxanib (SU5416)  -0.341929452  0.9434827115
## 4042                             D019_r1_SGI-7079  -0.493599924  4.3700495312
## 4043                          D019_r1_Skepinone-L   0.566928139 -1.1766688122
## 4044                               D019_r1_SL-327   1.391318707 -1.2543371341
## 4045                 D019_r1_SNS-032 (BMS-387032)  -0.934548178  3.2659835623
## 4046                     D019_r1_SNS-314 Mesylate -16.731270630 -0.8190303684
## 4047                            D019_r1_Sorafenib  -0.543973498 -0.8412535235
## 4048                   D019_r1_Sorafenib Tosylate   1.311573450 -0.3544983529
## 4049                         D019_r1_Sotrastaurin   0.780106015  0.4095004689
## 4050                             D019_r1_SP600125   3.294112389 -1.5854649327
## 4051                              D019_r1_SU11274   2.835389674 -2.2674608518
## 4052                               D019_r1_SU6656   0.105459916 -0.6119470844
## 4053                               D019_r1_SU9516  -1.699525334  0.7836166158
## 4054                     D019_r1_Sunitinib Malate  -0.379378716 -0.0354115954
## 4055                  D019_r1_TAE226 (NVP-TAE226)  -3.530460100  3.3371308373
## 4056                              D019_r1_TAK-285   0.753034883 -0.9145368244
## 4057                              D019_r1_TAK-632  -1.333870905  0.7711109912
## 4058                              D019_r1_TAK-715   1.845488091 -1.1244777760
## 4059                              D019_r1_TAK-733  -3.963036733  2.5738250488
## 4060                              D019_r1_TAK-901  -0.852533155 -0.0224493666
## 4061                D019_r1_Taladegib (LY2940680)   1.628705440 -0.7435561715
## 4062                              D019_r1_TCS 359   0.270474469  0.4790242028
## 4063                               D019_r1_TDZD-8   0.149921072 -0.6790662461
## 4064                            D019_r1_Telatinib   1.200117301 -0.9050242079
## 4065   D019_r1_Temsirolimus (CCI-779, NSC 683864)   1.837489722 -2.2536337712
## 4066              D019_r1_Tepotinib (EMD 1214063) -14.315201807 -2.4295386955
## 4067                                D019_r1_TG003   2.276132400 -0.0036806122
## 4068                            D019_r1_TG100-115   2.180595391 -0.5880251875
## 4069                             D019_r1_TG101209  -4.025831612  3.7052960227
## 4070                 D019_r1_TG101348 (SAR302503)  -5.056840221  1.9629822834
## 4071                              D019_r1_TGX-221  -0.699431598 -2.2158349403
## 4072                         D019_r1_Theophylline  -0.037237916 -0.2076238826
## 4073                          D019_r1_Thiazovivin  -1.060009628  0.2298893780
## 4074                       D019_r1_TIC10 Analogue   0.654168879 -0.9185285973
## 4075                           D019_r1_Tideglusib   2.335918651  1.3674970814
## 4076                 D019_r1_Tivantinib (ARQ 197) -13.526091206  0.3316264088
## 4077                   D019_r1_Tivozanib (AV-951)  -1.511860940 -1.6087332108
## 4078  D019_r1_Tofacitinib (CP-690550,Tasocitinib)   0.632911018 -0.0200141650
## 4079      D019_r1_Tofacitinib (CP-690550) Citrate   0.898829759  0.3706085169
## 4080                              D019_r1_Torin 2 -10.698264749  1.7503742249
## 4081              D019_r1_Trametinib (GSK1120212)  -3.343378619  2.3793423007
## 4082                          D019_r1_Triciribine  -6.931711021  2.0209615913
## 4083           D019_r1_TSU-68 (SU6668, Orantinib)   2.029050270  0.7274763617
## 4084                               D019_r1_TWS119   1.002898372 -1.1883770258
## 4085                         D019_r1_Tyrphostin 9  -2.911438412  0.7239575684
## 4086                   D019_r1_Tyrphostin AG 1296   1.952467233  0.0686485363
## 4087                           D019_r1_U0126-EtOH   2.672682603 -0.2526390678
## 4088     D019_r1_Ulixertinib (BVD-523, VRT752271)  -6.250790647  1.6064655945
## 4089              D019_r1_Uprosertib (GSK2141795)  -4.239379257  0.6593533964
## 4090                          D019_r1_Vacquinol-1   2.571101827  2.3290712580
## 4091                           D019_r1_Varlitinib  -0.557926944  0.6603173476
## 4092              D019_r1_Vatalanib (PTK787) 2HCl   0.793153114 -0.5854959369
## 4093                               D019_r1_VE-821  -0.709938381 -0.7044762822
## 4094                               D019_r1_VE-822  -9.948272449  0.6649704229
## 4095        D019_r1_Vemurafenib (PLX4032, RG7204)   1.158595707 -0.9256757440
## 4096                D019_r1_Vismodegib (GDC-0449)   3.832874051 -1.2555100590
## 4097                 D019_r1_Volasertib (BI 6727)  -0.510678366 -1.0316478506
## 4098                            D019_r1_VPS34-IN1  -5.327612978  3.0214462188
## 4099                     D019_r1_VS-5584 (SB2343)  -5.429935616  1.0235469991
## 4100                               D019_r1_VX-11e  -4.067112279  1.2241161785
## 4101         D019_r1_VX-680 (Tozasertib, MK-0457) -14.494337349 -1.2816409664
## 4102                               D019_r1_VX-702   2.834123323 -1.1639763900
## 4103                               D019_r1_VX-745   1.043594690 -1.7076340801
## 4104                              D019_r1_WAY-600   1.704414167 -1.2985958059
## 4105                             D019_r1_WH-4-023   7.549751164 -1.2218629006
## 4106                             D019_r1_WHI-P154   1.809149182 -1.0556266610
## 4107                                D019_r1_WIKI4  -0.975332230 -0.3856729716
## 4108                        D019_r1_Wnt agonist 1 -10.097636505  2.5856333780
## 4109                        D019_r1_Wnt-C59 (C59)   1.806235164 -0.5130879291
## 4110                               D019_r1_WP1066   2.474945416 -0.9041823948
## 4111                 D019_r1_WYE-125132 (WYE-132)   1.584158950  0.9857751350
## 4112                              D019_r1_WYE-354  -3.922392240 -0.9178129701
## 4113                               D019_r1_WZ3146   1.589042787 -0.3081559000
## 4114                               D019_r1_WZ4002   0.041051731 -0.1614168384
## 4115                               D019_r1_WZ4003   2.288697917 -1.7339451750
## 4116                               D019_r1_WZ8040   2.056331216 -0.8595941071
## 4117                              D019_r1_XAV-939   1.252225656 -1.1145680216
## 4118                                D019_r1_XL019  -0.758909746 -0.2511866625
## 4119                              D019_r1_XMD8-92  -0.002975428 -1.8060312353
## 4120                         D019_r1_Y-27632 2HCl   1.909699568 -0.7796226824
## 4121                             D019_r1_YM201636   1.707736314 -2.3019494913
## 4122                             D019_r1_YO-01027  -0.193760612 -0.1728453782
## 4123                            D019_r1_ZM 306416  -0.499767231 -1.2704966854
## 4124                        D019_r1_ZM 323881 HCl  -1.288244045  0.4704000950
## 4125                            D019_r1_ZM 336372   0.496285841 -1.1981023554
## 4126                         D019_r1_ZM 39923 HCl  -0.783642631 -0.9848145503
## 4127                            D019_r1_ZM 447439   0.185612601 -0.2098528715
## 4128                 D019_r1_Zotarolimus(ABT-578)   1.778898278 -0.1964667273
## 4129                              D019_r1_ZSTK474  -5.699698005  0.5360739797
## 4130                     D019_r2_1-Azakenpaullone  -0.094496761  0.2722941813
## 4131                      D019_r2_3-Methyladenine   2.640506699 -1.3090031322
## 4132                             D019_r2_A-674563 -13.582060717  0.7948263840
## 4133                             D019_r2_A-769662   1.428738476 -0.9648424678
## 4134                                  D019_r2_A66  -0.312029793  1.1010230681
## 4135                            D019_r2_Acadesine   0.939720867 -0.0295928017
## 4136                  D019_r2_AEE788 (NVP-AEE788)   5.266108335  4.1503035362
## 4137        D019_r2_Afatinib (BIBW2992)_uncertain   0.855261168  0.5859030244
## 4138                              D019_r2_AG-1024  -0.440731003 -1.8804531481
## 4139         D019_r2_AG-1478 (Tyrphostin AG-1478)   0.949904933 -0.0622247764
## 4140                                D019_r2_AG-18   0.472894482  0.0788023799
## 4141              D019_r2_AG-490 (Tyrphostin B42)   0.584061321 -0.1068589843
## 4142                             D019_r2_Akti-1/2   2.909393067  0.2523608038
## 4143                  D019_r2_Alisertib (MLN8237)  -9.939710809  1.2632238158
## 4144                              D019_r2_AMG 337   0.940108877  0.4932688005
## 4145                              D019_r2_AMG-458   3.884920765  0.0744810799
## 4146                              D019_r2_AMG-900  -8.151173322  2.3443093643
## 4147                               D019_r2_AMG319  -0.200575928  0.1323839122
## 4148                  D019_r2_Amuvatinib (MP-470)  -1.345458948 -1.7216373820
## 4149                             D019_r2_Apatinib   1.507214545  0.7034361692
## 4150                           D019_r2_AR-A014418  -0.698922878 -0.4710161253
## 4151                            D019_r2_AS-252424  -0.617705866 -1.9631988549
## 4152                            D019_r2_AS-604850   1.469187737 -1.5064046010
## 4153                         D019_r2_Asiatic Acid   1.064366730 -0.4966580808
## 4154                             D019_r2_AST-1306   0.836213969 -0.9204056522
## 4155                              D019_r2_AT13148  -1.217039272  0.0075007759
## 4156                               D019_r2_AT7519  -7.945285473  2.0552627934
## 4157                               D019_r2_AT7867  -0.671608572  0.4538292969
## 4158                               D019_r2_AT9283 -12.204051000  3.2665304004
## 4159                 D019_r2_Aurora A Inhibitor I  -2.657766435 -0.9655106318
## 4160             D019_r2_Avagacestat (BMS-708163)   1.350604034 -1.1311727043
## 4161                              D019_r2_AVL-292  -0.259462362 -0.0425746395
## 4162                             D019_r2_Axitinib  -1.233039450 -0.8974404490
## 4163                             D019_r2_Axitinib  -1.233039450 -0.8974404490
## 4164                               D019_r2_AZ 628  -1.548692101  0.0559357963
## 4165                               D019_r2_AZ 960  -7.604933978  1.5619485739
## 4166                                 D019_r2_AZ20  -9.869455653  2.0494944503
## 4167                              D019_r2_AZD1080  -5.653194702  0.1609355759
## 4168                              D019_r2_AZD1480  -7.853373835  2.4937789931
## 4169                              D019_r2_AZD2014   1.828519741  1.5213455747
## 4170                              D019_r2_AZD2858  -8.519671068  1.6340880325
## 4171                              D019_r2_AZD2932   1.463384048 -0.2113459165
## 4172                              D019_r2_AZD3759   2.935366555  0.6367208819
## 4173                              D019_r2_AZD5363  -1.965782936  0.7188683505
## 4174                              D019_r2_AZD5438  -1.998233786  2.1917186690
## 4175                              D019_r2_AZD6482   0.627856747  1.3248231921
## 4176                              D019_r2_AZD6738  -9.008359434  1.5287536184
## 4177                              D019_r2_AZD8055  -9.665995130  0.3669986864
## 4178                              D019_r2_AZD8330  -3.165789866  1.8613539219
## 4179                  D019_r2_AZD8931 (Sapitinib)   0.754142412  0.4224763214
## 4180                              D019_r2_AZD9291   4.609058157  1.7217378236
## 4181            D019_r2_Barasertib (AZD1152-HQPA)  -4.305689694  0.7575244235
## 4182  D019_r2_Baricitinib (LY3009104, INCB028050)  -0.281458990 -1.8298032994
## 4183                  D019_r2_BGT226 (NVP-BGT226)  11.934077212  5.1879487677
## 4184                              D019_r2_BI 2536  -8.722377905  2.5573261677
## 4185                              D019_r2_BI-78D3   1.342667213 -0.4014346716
## 4186                             D019_r2_BI-D1870   0.728721611 -0.0472412055
## 4187                              D019_r2_Bikinin  -0.590159487 -0.2425735109
## 4188                                  D019_r2_BIO  -0.211894497  0.0728893006
## 4189               D019_r2_BIRB 796 (Doramapimod)   0.260689165 -1.0491015438
## 4190                            D019_r2_BIX 02188   1.976685971 -0.1822477176
## 4191                            D019_r2_BIX 02189   1.201286117 -0.2265441358
## 4192      D019_r2_BKM120 (NVP-BKM120, Buparlisib)  -4.479768675  2.7827298830
## 4193                           D019_r2_BMS-265246  -2.814090433 -0.1141102358
## 4194                           D019_r2_BMS-536924   1.824548132  2.7654218185
## 4195                           D019_r2_BMS-582949  -1.117079236 -0.5195470296
## 4196                           D019_r2_BMS-754807  -7.998237756  2.9345488092
## 4197                           D019_r2_BMS-777607   1.134589075 -0.2119516388
## 4198                           D019_r2_BMS-794833   0.154823561 -1.1058235032
## 4199                           D019_r2_BMS-833923   0.498467594 -1.3983854930
## 4200                  D019_r2_Bosutinib (SKI-606)   1.048438418 -0.1372542714
## 4201                D019_r2_Brivanib (BMS-540215)   2.374732135 -0.3471481481
## 4202      D019_r2_Brivanib Alaninate (BMS-582664)   1.331834058 -0.1540452087
## 4203                           D019_r2_BS-181 HCl  -0.159490474  0.1721720147
## 4204                               D019_r2_Butein  -0.245523442 -1.2567590576
## 4205                               D019_r2_BYL719   0.432172696  1.2748890153
## 4206     D019_r2_Cabozantinib (XL184, BMS-907351)   0.034387762  0.1919519179
## 4207          D019_r2_Cabozantinib malate (XL184)   1.407848229  0.7382736730
## 4208        D019_r2_CAL-101 (Idelalisib, GS-1101)   0.864929096 -0.1212149350
## 4209                             D019_r2_CAY10505  -0.141062993 -0.6597958382
## 4210                               D019_r2_CC-223  -1.558617874  1.6593923775
## 4211                            D019_r2_CCT128930   1.456983061  0.1296576726
## 4212                  D019_r2_Cediranib (AZD2171)  -0.573663422 -0.3848893498
## 4213                            D019_r2_CEP-32496   5.657579387 -0.0889504990
## 4214                            D019_r2_CEP-33779  -0.213009781 -1.1453787098
## 4215                              D019_r2_CGI1746  -0.607508986 -0.3630515200
## 4216                              D019_r2_CGK 733  -0.549846176  0.2244318326
## 4217                            D019_r2_CH5132799  -5.655117819  0.5471999024
## 4218                           D019_r2_CHIR-98014  -6.041914743  0.1202839772
## 4219                 D019_r2_CHIR-99021 (CT99021)  -1.605723856  0.6257543019
## 4220             D019_r2_CHIR-99021 (CT99021) HCl  -3.253004771  1.0481279536
## 4221                    D019_r2_Chrysophanic Acid  -1.246556277 -0.9357070135
## 4222                             D019_r2_CNX-2006  -1.205348907 -1.5701135163
## 4223                              D019_r2_CNX-774   1.224840615  0.1087726964
## 4224                    D019_r2_CO-1686 (AVL-301)   2.414810542 -1.0081949556
## 4225       D019_r2_Cobimetinib (GDC-0973, RG7420)  -9.642076170  1.3698918081
## 4226                            D019_r2_CP-673451  -1.009602432  1.7199475317
## 4227                            D019_r2_CP-724714   1.702743010 -0.4970018743
## 4228               D019_r2_Crenolanib (CP-868596)  -3.964588788  1.4211907037
## 4229             D019_r2_Crizotinib (PF-02341066)  -0.958259894  4.3329007057
## 4230                               D019_r2_CYC116 -10.456461764  2.2665748100
## 4231                               D019_r2_CYT387  -1.592053851  0.0375874436
## 4232                             D019_r2_CZC24832   2.325200904  0.1889205138
## 4233              D019_r2_Dabrafenib (GSK2118436)  -0.490660818 -2.0553794171
## 4234        D019_r2_Dacomitinib (PF299804, PF299)   0.950739921  0.4713653288
## 4235              D019_r2_Danusertib (PHA-739358)  -7.911096818  2.0619679492
## 4236                        D019_r2_DAPT (GSI-IX)   1.936989454 -0.2312631787
## 4237                            D019_r2_Dasatinib   3.752355097  2.3281870683
## 4238                D019_r2_DCC-2036 (Rebastinib)   1.230181205  1.0249360081
## 4239                D019_r2_Decernotinib (VX-509)   1.050190722  0.1219115742
## 4240               D019_r2_Dinaciclib (SCH727965)  -0.170825924  3.8643331601
## 4241    D019_r2_Dovitinib (TKI-258) Dilactic Acid   2.508707963  4.8996907826
## 4242                            D019_r2_ENMD-2076  -6.421379007  3.9501917582
## 4243               D019_r2_Enzastaurin (LY317615)  -3.707681048  0.1605919269
## 4244                            D019_r2_ERK5-IN-1   3.444159324  0.5826181735
## 4245                             D019_r2_ETC-1002  -0.245564619 -0.7431659262
## 4246                            D019_r2_ETP-46464   0.134862588  0.1939658146
## 4247                  D019_r2_Everolimus (RAD001)   3.015269315 -0.2715644852
## 4248                D019_r2_Fasudil (HA-1077) HCl   0.046667326 -0.6441706888
## 4249                                D019_r2_FH535  -4.782185900 -1.4001839929
## 4250                D019_r2_Filgotinib (GLPG0634)   1.148127596 -0.1876854382
## 4251             D019_r2_Flavopiridol (Alvocidib)  -5.276774105  1.6556581136
## 4252                     D019_r2_Flavopiridol HCl  -5.662310945  2.2306101905
## 4253               D019_r2_Foretinib (GSK1363089)   0.734707310 -1.9224590834
## 4254                  D019_r2_Fostamatinib (R788)  -7.348173868  1.3793516772
## 4255                                D019_r2_G-749   0.735100754 -1.7041595415
## 4256                             D019_r2_GDC-0068  -1.644563383 -0.4432445346
## 4257                             D019_r2_GDC-0349  -2.331151853  0.1425832043
## 4258                             D019_r2_GDC-0879  -0.893900959 -0.7561857998
## 4259                             D019_r2_GDC-0941  -0.101289746 -0.9547033617
## 4260                    D019_r2_GDC-0980 (RG7422) -12.006467422  0.3835973163
## 4261                   D019_r2_Gefitinib (ZD1839)   4.487165846  0.1628133835
## 4262                            D019_r2_Genistein   1.666166747 -0.0111937580
## 4263                            D019_r2_GF109203X  -1.209648721  1.4446175070
## 4264                                D019_r2_GNF-2  -0.279082450  0.7594346942
## 4265                                D019_r2_GNF-5   1.256274640  0.4549013877
## 4266                              D019_r2_Go 6983  -0.011735495  1.1832840175
## 4267                   D019_r2_Golvatinib (E7050)  -8.263341498  4.0631161335
## 4268                          D019_r2_GSK1838705A  -3.605091131  2.2358796623
## 4269                          D019_r2_GSK1904529A   2.739396018 -1.1774443856
## 4270                  D019_r2_GSK2126458 (GSK458)  -7.335636643  2.1363473215
## 4271                           D019_r2_GSK2292767  -2.089874624  1.3928254526
## 4272                           D019_r2_GSK2636771   0.518688466  0.3596727893
## 4273                           D019_r2_GSK429286A  -2.426158568 -0.0463502893
## 4274                            D019_r2_GSK461364  -4.298561781  2.6804164544
## 4275                               D019_r2_GSK621   2.769941665 -0.8616038044
## 4276                            D019_r2_GSK690693  -2.139149696 -0.0026183200
## 4277                               D019_r2_GW5074   1.427798545 -1.0545827689
## 4278                             D019_r2_GW788388   1.835098830  0.2093217234
## 4279                               D019_r2_GZD824   2.984128676  3.8839758519
## 4280                            D019_r2_H 89 2HCl   1.918852000  0.3316497650
## 4281                           D019_r2_Hesperadin  -2.696628724  4.6813672344
## 4282                              D019_r2_HMN-214  -8.548056698  1.9511874804
## 4283                             D019_r2_Honokiol   1.195968818 -0.1272662247
## 4284                               D019_r2_HS-173 -12.318072883  1.9831716786
## 4285                           D019_r2_HTH-01-015  -8.943709280  2.0171951391
## 4286                D019_r2_Ibrutinib (PCI-32765)  -0.183421290  1.5759459687
## 4287                              D019_r2_ICG-001  -0.622497646 -1.4858989804
## 4288                             D019_r2_Icotinib   1.171544686 -1.0915022170
## 4289                                D019_r2_IM-12   0.073984509 -0.7237102476
## 4290           D019_r2_Imatinib Mesylate (STI571)   2.633330381 -0.0611053237
## 4291                            D019_r2_Indirubin   0.659025067  0.5716790780
## 4292                    D019_r2_INK 128 (MLN0128)  -3.703642364  2.6192980457
## 4293                    D019_r2_IPI-145 (INK1197)  -1.653466991  0.3406272502
## 4294                               D019_r2_IWP-L6  -0.195601008 -1.1742419269
## 4295                           D019_r2_IWR-1-endo   1.360609951 -1.4110302698
## 4296                         D019_r2_JNJ-38877605   0.632442892 -0.4880779201
## 4297                          D019_r2_JNJ-7706621  -8.846103573  3.5244809880
## 4298                     D019_r2_JNK Inhibitor IX  -9.865949930  1.6421902277
## 4299                             D019_r2_JNK-IN-8   0.454600386  0.0841998172
## 4300                               D019_r2_K02288   0.245985791 -1.3504316677
## 4301                               D019_r2_Ki8751   1.829432159 -0.4183109176
## 4302                              D019_r2_KRN 633   2.599660811  2.2801847298
## 4303                           D019_r2_KU-0063794   0.077500708  0.2456451704
## 4304      D019_r2_KU-55933 (ATM Kinase Inhibitor)   0.563560943 -1.0115649184
## 4305                             D019_r2_KU-60019  -1.025391200  0.2400565323
## 4306                              D019_r2_KW-2449   1.948986028  5.4794461882
## 4307                              D019_r2_KX2-391  -7.883089120  2.4346805936
## 4308                              D019_r2_KY02111   2.644200305  0.2462513811
## 4309                            D019_r2_Lapatinib  -0.698038190 -1.2907744669
## 4310     D019_r2_Lapatinib (GW-572016) Ditosylate  -0.514002736 -0.0342892600
## 4311                            D019_r2_LDC000067   2.202174826  1.0955463679
## 4312      D019_r2_LDE225 (NVP-LDE225,Erismodegib)   1.112124956  0.0611757145
## 4313                           D019_r2_LDN-214117   2.085320477 -0.4016158728
## 4314                   D019_r2_Lenvatinib (E7080)   1.310370423 -1.2515024371
## 4315                              D019_r2_LFM-A13   1.494544141 -0.9097377369
## 4316                              D019_r2_LGK-974  -1.516624310 -1.3636487125
## 4317                  D019_r2_Linifanib (ABT-869)   4.314077639  1.7622250117
## 4318                               D019_r2_LJH685   2.024939586 -0.3275018868
## 4319                               D019_r2_LJI308  -0.438313068  0.3540267668
## 4320               D019_r2_Losmapimod (GW856553X)  -0.907357304 -1.4109512928
## 4321                            D019_r2_LY2090314  -4.444286901  1.4778847661
## 4322                            D019_r2_LY2157299  -0.185316470 -0.2724071666
## 4323                            D019_r2_LY2784544  -1.571973404  0.8729344292
## 4324                            D019_r2_LY2835219 -12.410877037 -0.4150791221
## 4325                             D019_r2_LY294002   2.124238774  0.7302371070
## 4326                            D019_r2_LY3023414  -2.524801630  1.6672174203
## 4327                             D019_r2_LY411575   3.129015655 -0.7503541936
## 4328       D019_r2_MEK162 (ARRY-162, ARRY-438162)  -8.963846636  1.3189261501
## 4329                             D019_r2_MGCD-265  -0.429912019  0.7792129100
## 4330               D019_r2_Milciclib (PHA-848125)  -2.793530258  3.5050717807
## 4331                              D019_r2_MK-0752   1.167724706  0.0998240175
## 4332                         D019_r2_MK-2206 2HCl  -2.121998798 -0.4326051808
## 4333                              D019_r2_MK-2461   0.247490825 -1.0139606130
## 4334                     D019_r2_MK-5108 (VX-689)  -2.896276726  0.9109410286
## 4335                              D019_r2_MK-8745  -6.553317235  0.5319025434
## 4336                              D019_r2_MLN2480   7.321916718  2.8620672898
## 4337                              D019_r2_MLN8054  -0.211680268 -0.1368574698
## 4338      D019_r2_Motesanib Diphosphate (AMG-706)  -0.451383140 -1.8919328526
## 4339                  D019_r2_Nilotinib (AMN-107)   0.893750593 -0.6118283784
## 4340     D019_r2_Nintedanib (BIBF 1120)_uncertain   1.673342560  0.3154046279
## 4341                               D019_r2_NU6027   2.435339241 -0.4428592446
## 4342                           D019_r2_NVP-AEW541   3.849667948  4.3359225375
## 4343                           D019_r2_NVP-BHG712  -1.898931804  0.1946284850
## 4344                      D019_r2_NVP-BSK805 2HCl   1.326191958  1.5836698624
## 4345                           D019_r2_NVP-BVU972   1.340446186  0.0270884911
## 4346                          D019_r2_Oclacitinib   1.554134700  0.1182157741
## 4347      D019_r2_Olmutinib (HM61713, BI 1482694)   2.368732531  0.5158753434
## 4348                             D019_r2_ONO-4059   0.560213958 -0.2826877670
## 4349                              D019_r2_OSI-027  -8.136550491 -0.0742263989
## 4350                              D019_r2_OSI-420   3.677326587  1.0447004166
## 4351                 D019_r2_OSI-906 (Linsitinib)   0.811992034  0.4709995036
## 4352                              D019_r2_P276-00 -10.883338572  1.8811956510
## 4353                  D019_r2_Pacritinib (SB1518) -10.121917129  1.5098243691
## 4354                   D019_r2_Palomid 529 (P529)   2.813816549 -0.2243537038
## 4355                            D019_r2_Pazopanib   0.594889573 -1.3438666177
## 4356                        D019_r2_Pazopanib HCl   0.811962651 -0.2057845670
## 4357                            D019_r2_PD0325901  -9.085573843  0.2531922837
## 4358                             D019_r2_PD168393   1.626547702 -0.2441291883
## 4359                             D019_r2_PD173955  -3.203880140  0.8038352182
## 4360                   D019_r2_PD184352 (CI-1040)  -3.400011839  1.7914032758
## 4361                             D019_r2_PD318088  -7.612643195  0.8868063591
## 4362                              D019_r2_PD98059  -0.226294144 -0.3220131533
## 4363                  D019_r2_Pelitinib (EKB-569)   1.869398224 -1.0685341005
## 4364                          D019_r2_PF-00562271  -1.196074417  3.1025922310
## 4365                          D019_r2_PF-04217903   0.273484903  0.4104549149
## 4366                          D019_r2_PF-04691502  -1.192097471  1.9723498482
## 4367                            D019_r2_PF-431396  -1.612508780  3.6809790918
## 4368                           D019_r2_PF-4708671  -2.042059202  1.9132379317
## 4369                           D019_r2_PF-5274857   1.152116577 -0.0178842047
## 4370                            D019_r2_PF-562271  -1.571526476  4.3889276987
## 4371                            D019_r2_PF-573228   1.367015149  1.0812794122
## 4372                            D019_r2_PH-797804  -0.890276522 -1.0989454608
## 4373                           D019_r2_PHA-665752   3.190967845  1.2654888957
## 4374                           D019_r2_PHA-680632  -3.007378809  0.9134991822
## 4375                           D019_r2_PHA-767491  -5.445900516  2.9450396093
## 4376                           D019_r2_PHA-793887  -2.603778739  0.9442469316
## 4377                       D019_r2_Phenformin HCl  -1.558486069 -1.1123353603
## 4378                              D019_r2_PHT-427   1.585782817 -0.0136840658
## 4379                          D019_r2_Piceatannol   3.575556788  0.4709594679
## 4380                              D019_r2_PIK-293   1.204638094  0.0266748993
## 4381                              D019_r2_PIK-294   0.412481161 -1.0990268618
## 4382                               D019_r2_PIK-93  -0.530384855  3.4117175847
## 4383               D019_r2_Pimasertib (AS-703026)  -7.989190573  2.1690178325
## 4384                          D019_r2_Pirfenidone   1.603240747  0.0833545029
## 4385                             D019_r2_PLX-4720   3.094626432 -0.3253192397
## 4386                              D019_r2_PLX7904   0.836819626 -0.1981487471
## 4387                  D019_r2_Ponatinib (AP24534)   4.959592824  0.1144176603
## 4388                                  D019_r2_PP1  -1.139114967 -0.2485750272
## 4389                                  D019_r2_PP2  -0.941441374  0.7296516934
## 4390                                D019_r2_PP242  -6.095756065  0.2555559408
## 4391                               D019_r2_PQ 401   0.108381477 -0.7988842833
## 4392                              D019_r2_PRI-724   0.597647149 -0.9409691682
## 4393     D019_r2_PRT062607 (P505-15, BIIB057) HCl   0.771544484  0.0263767011
## 4394                         D019_r2_Purvalanol A  -2.681587195 -0.0866239433
## 4395                            D019_r2_Quercetin   0.131538214 -0.5544525689
## 4396                  D019_r2_Quizartinib (AC220)   0.192688225  2.6677101609
## 4397                                 D019_r2_R406   1.233867838  0.1530469006
## 4398                     D019_r2_R406 (free base)  -0.165042006 -0.9012136250
## 4399                                 D019_r2_R547  -1.213248316  3.1295079031
## 4400                    D019_r2_RAF265 (CHIR-265)  -9.468544738  2.0552202109
## 4401                D019_r2_Rapamycin (Sirolimus)  -2.084492237 -0.5049683200
## 4402   D019_r2_Refametinib (RDEA119, Bay 86-9766)  -5.925387329  1.5358428505
## 4403                               D019_r2_RepSox   0.204513870  1.1005783965
## 4404 D019_r2_Ridaforolimus (Deforolimus, MK-8669)   2.445082288 -1.1084085714
## 4405                D019_r2_Rigosertib (ON-01910)  -9.494973221  1.5493170753
## 4406                             D019_r2_RKI-1447   0.486985856 -0.6117730751
## 4407                                D019_r2_RN486   0.849777938 -0.4673884697
## 4408                  D019_r2_Ro 31-8220 Mesylate  -0.240425906  2.0639141253
## 4409                              D019_r2_Ro-3306  -1.429795628 -1.6675247689
## 4410                               D019_r2_Ro3280  -3.747265972  2.6856105910
## 4411                            D019_r2_RO4929097   2.652812793 -2.5475953611
## 4412      D019_r2_Roscovitine (Seliciclib,CYC202)  -0.404578821 -0.2232151486
## 4413             D019_r2_Ruxolitinib (INCB018424)   2.341243825 -0.0734875542
## 4414           D019_r2_S-Ruxolitinib (INCB018424)   1.500770802 -0.1440411941
## 4415                               D019_r2_SANT-1   2.320287197  0.9081581802
## 4416                            D019_r2_SAR131675   1.601545849  0.2250837436
## 4417                    D019_r2_SAR245409 (XL765)  -0.037994586 -1.3058487759
## 4418                D019_r2_Saracatinib (AZD0530)   2.346990930  2.5578919985
## 4419                      D019_r2_SB202190 (FHPI)  -2.272032737 -1.2453614756
## 4420                             D019_r2_SB203580   2.434084349 -1.1302745965
## 4421                             D019_r2_SB216763  -1.723558751 -0.1462572803
## 4422                             D019_r2_SB239063   0.138491420 -1.2645492995
## 4423                             D019_r2_SB415286   0.520778762  0.3573762771
## 4424                             D019_r2_SB431542   1.458789469 -0.3047536967
## 4425                             D019_r2_SB505124   0.800229889 -2.2705547596
## 4426                             D019_r2_SB525334   0.861931853 -0.7014856888
## 4427                             D019_r2_SB590885   2.289297470 -0.9560731515
## 4428                                  D019_r2_SC1  -2.868639852  2.9990512836
## 4429                D019_r2_Schisandrin B (Sch B)   2.507498476 -0.1972808522
## 4430                D019_r2_Selumetinib (AZD6244)  -3.919442317  0.9347764744
## 4431              D019_r2_Semagacestat (LY450139)   3.314185290 -1.9105247131
## 4432                   D019_r2_Semaxanib (SU5416)   0.951536963 -0.5259801676
## 4433                             D019_r2_SGI-7079  -5.019639068  3.5628539824
## 4434                          D019_r2_Skepinone-L   2.887975694  0.7871664207
## 4435                               D019_r2_SL-327   1.292563146 -1.2989667020
## 4436                 D019_r2_SNS-032 (BMS-387032)  -1.652780973  2.6360077247
## 4437                     D019_r2_SNS-314 Mesylate -11.153223437 -0.0231605042
## 4438                            D019_r2_Sorafenib  -0.625907434 -1.1885138091
## 4439                   D019_r2_Sorafenib Tosylate   1.850522784 -1.7755264225
## 4440                         D019_r2_Sotrastaurin  -0.458450525 -0.7170915365
## 4441                             D019_r2_SP600125   2.349527394  0.2130114793
## 4442                              D019_r2_SU11274   0.960523481 -1.0023849222
## 4443                               D019_r2_SU6656  -1.917199771  0.5068949953
## 4444                               D019_r2_SU9516  -4.396851779  0.8890203382
## 4445                     D019_r2_Sunitinib Malate   1.739130469 -0.9907451663
## 4446                  D019_r2_TAE226 (NVP-TAE226)  -5.224084106  3.3499041717
## 4447                              D019_r2_TAK-285   2.288918260 -0.3896270196
## 4448                              D019_r2_TAK-632  -1.175482005  0.1379450185
## 4449                              D019_r2_TAK-715   0.608156266  0.2015113906
## 4450                              D019_r2_TAK-733  -5.907488938  2.7457479697
## 4451                              D019_r2_TAK-901  -2.797877885  0.9364217418
## 4452                D019_r2_Taladegib (LY2940680)   0.361113114 -1.2841847287
## 4453                              D019_r2_TCS 359  -0.436850957 -0.2877759780
## 4454                               D019_r2_TDZD-8   2.541713331  1.0718402720
## 4455                            D019_r2_Telatinib  -2.192911687 -2.2153762272
## 4456   D019_r2_Temsirolimus (CCI-779, NSC 683864)  -1.406809166 -0.3459329050
## 4457              D019_r2_Tepotinib (EMD 1214063) -11.822004630 -0.7687071749
## 4458                                D019_r2_TG003   3.688898612 -1.4601163852
## 4459                            D019_r2_TG100-115  -1.238235024 -0.0277123826
## 4460                             D019_r2_TG101209  -7.644175977  3.0093836452
## 4461                 D019_r2_TG101348 (SAR302503)  -4.777457155  2.3151854235
## 4462                              D019_r2_TGX-221   0.682952175 -0.8567021903
## 4463                         D019_r2_Theophylline   0.932412407  0.2210541491
## 4464                          D019_r2_Thiazovivin  -0.780486566  0.3037798901
## 4465                       D019_r2_TIC10 Analogue   1.260823652  0.6118206563
## 4466                           D019_r2_Tideglusib  -1.582456491 -0.7088768976
## 4467                 D019_r2_Tivantinib (ARQ 197) -10.694661485  1.5721691662
## 4468                   D019_r2_Tivozanib (AV-951)   0.836543925 -0.4499858367
## 4469  D019_r2_Tofacitinib (CP-690550,Tasocitinib)   2.125984779  0.0700559410
## 4470      D019_r2_Tofacitinib (CP-690550) Citrate   1.306793603  0.4924221262
## 4471                              D019_r2_Torin 2 -13.713675885  1.5419336756
## 4472              D019_r2_Trametinib (GSK1120212)  -7.344758792  2.1252541629
## 4473                          D019_r2_Triciribine  -1.408483473  1.6341704417
## 4474           D019_r2_TSU-68 (SU6668, Orantinib)   2.606421129 -1.1288327923
## 4475                               D019_r2_TWS119  -0.519420647 -0.9992712137
## 4476                         D019_r2_Tyrphostin 9  -3.796348456 -0.6768823499
## 4477                   D019_r2_Tyrphostin AG 1296  -0.279218662 -1.3717414700
## 4478                           D019_r2_U0126-EtOH   2.133512258  0.1264972758
## 4479     D019_r2_Ulixertinib (BVD-523, VRT752271)  -6.457550930  1.5611083110
## 4480              D019_r2_Uprosertib (GSK2141795)  -1.853946890  0.1505112459
## 4481                          D019_r2_Vacquinol-1  -9.693656098  1.7705537831
## 4482                           D019_r2_Varlitinib   1.067408049  0.0103553462
## 4483              D019_r2_Vatalanib (PTK787) 2HCl   0.878970800 -1.5014623169
## 4484                               D019_r2_VE-821   0.660748299 -0.4460469310
## 4485                               D019_r2_VE-822 -10.357510385  2.8891536836
## 4486        D019_r2_Vemurafenib (PLX4032, RG7204)  -2.032611524  0.2446806306
## 4487                D019_r2_Vismodegib (GDC-0449)   2.516793557  0.7306791099
## 4488                 D019_r2_Volasertib (BI 6727)   0.240785482 -0.0692336251
## 4489                            D019_r2_VPS34-IN1  -3.957206797  0.7611314223
## 4490                     D019_r2_VS-5584 (SB2343)  -7.951959163  1.7419062415
## 4491                               D019_r2_VX-11e  -5.403013315  2.4992354997
## 4492         D019_r2_VX-680 (Tozasertib, MK-0457) -10.389360619  1.8895446875
## 4493                               D019_r2_VX-702  -1.375201408 -1.1759634750
## 4494                               D019_r2_VX-745   3.297011831 -0.2824051959
## 4495                              D019_r2_WAY-600   1.683281015  2.5015708722
## 4496                             D019_r2_WH-4-023   4.054785546  0.2308895241
## 4497                             D019_r2_WHI-P154   1.527689625 -1.3034917736
## 4498                                D019_r2_WIKI4   0.662494215 -0.3177526369
## 4499                        D019_r2_Wnt agonist 1 -11.825003091  1.4647122207
## 4500                        D019_r2_Wnt-C59 (C59)   0.249604162 -0.9358673005
## 4501                               D019_r2_WP1066   0.551549807  0.2101822885
## 4502                 D019_r2_WYE-125132 (WYE-132)   2.076942214  0.8883636572
## 4503                              D019_r2_WYE-354  -6.098432842  1.1272991735
## 4504                               D019_r2_WZ3146   2.879414600  0.9842375964
## 4505                               D019_r2_WZ4002   1.598198657 -0.9782875516
## 4506                               D019_r2_WZ4003   3.725819384  1.7132996954
## 4507                               D019_r2_WZ8040   1.491543046 -0.5691212938
## 4508                              D019_r2_XAV-939  -0.049257515 -1.5000179417
## 4509                                D019_r2_XL019  -1.882539775 -0.4905720158
## 4510                              D019_r2_XMD8-92   0.371689170 -0.9508475643
## 4511                         D019_r2_Y-27632 2HCl   1.200144217 -1.1456309601
## 4512                             D019_r2_YM201636   0.519227592 -0.5013443260
## 4513                             D019_r2_YO-01027   1.916499486 -0.8545437521
## 4514                            D019_r2_ZM 306416   3.297255016 -0.2304684520
## 4515                        D019_r2_ZM 323881 HCl   1.851253170 -1.3802492424
## 4516                            D019_r2_ZM 336372   0.473648552 -0.6614289252
## 4517                         D019_r2_ZM 39923 HCl   0.829692505  0.0815834163
## 4518                            D019_r2_ZM 447439  -0.913143462 -0.8624666630
## 4519                 D019_r2_Zotarolimus(ABT-578)  -1.241191362  0.3498110696
## 4520                              D019_r2_ZSTK474   1.630743147 -0.7835341167
## 4521                     D020_r1_1-Azakenpaullone  -2.662038019 -0.9770759973
## 4522                      D020_r1_3-Methyladenine   1.761491240 -1.7738379975
## 4523                             D020_r1_A-674563  -8.983189654  0.1858468654
## 4524                             D020_r1_A-769662   0.538540447 -2.5051597184
## 4525                                  D020_r1_A66   1.014154166 -0.3702216217
## 4526                            D020_r1_Acadesine   0.360033845 -1.8895096754
## 4527                  D020_r1_AEE788 (NVP-AEE788)  -1.363780603 -0.1001744325
## 4528        D020_r1_Afatinib (BIBW2992)_uncertain  -1.065837709 -2.1330855831
## 4529                              D020_r1_AG-1024  -1.657200249 -2.6839432981
## 4530         D020_r1_AG-1478 (Tyrphostin AG-1478)   2.371593977 -0.8131956253
## 4531                                D020_r1_AG-18   0.632895575 -1.4475056731
## 4532              D020_r1_AG-490 (Tyrphostin B42)  -0.240244598 -1.9070008973
## 4533                             D020_r1_Akti-1/2   2.421889076 -0.9850188769
## 4534                  D020_r1_Alisertib (MLN8237)  -9.530663343 -0.1320884384
## 4535                              D020_r1_AMG 337  -2.181760278 -1.1493189028
## 4536                              D020_r1_AMG-458   0.241420119 -1.5640742279
## 4537                              D020_r1_AMG-900 -13.070549645  0.4579298187
## 4538                               D020_r1_AMG319   1.632748706 -0.9842082175
## 4539                  D020_r1_Amuvatinib (MP-470)  -0.912541852 -2.3305419862
## 4540                             D020_r1_Apatinib  -2.387537496 -1.5056075727
## 4541                           D020_r1_AR-A014418  -1.612569882 -1.1081197127
## 4542                            D020_r1_AS-252424  -0.923397325 -2.3679386558
## 4543                            D020_r1_AS-604850  -0.216621872 -2.2411685641
## 4544                         D020_r1_Asiatic Acid   0.426562958 -1.7019076453
## 4545                             D020_r1_AST-1306   3.425021955 -1.3316327135
## 4546                              D020_r1_AT13148   2.889390781 -1.5053722495
## 4547                               D020_r1_AT7519  -8.803414185  0.6595520898
## 4548                               D020_r1_AT7867   2.507997571  0.1027660938
## 4549                               D020_r1_AT9283  -9.887724734  0.3322287271
## 4550                 D020_r1_Aurora A Inhibitor I  -8.307331049  0.9095479341
## 4551             D020_r1_Avagacestat (BMS-708163)  -0.772114830 -2.1416763146
## 4552                              D020_r1_AVL-292  -0.785131973 -1.7566171035
## 4553                             D020_r1_Axitinib  -4.287044323 -0.4069361917
## 4554                             D020_r1_Axitinib  -4.287044323 -0.4069361917
## 4555                               D020_r1_AZ 628   1.276598471 -0.3018892228
## 4556                               D020_r1_AZ 960  -0.438418472 -2.2137561415
## 4557                                 D020_r1_AZ20  -8.190690537  0.4841585223
## 4558                              D020_r1_AZD1080  -2.291996980 -0.6779474858
## 4559                              D020_r1_AZD1480 -10.429099868  0.4181810132
## 4560                              D020_r1_AZD2014  -3.520687347  0.2269641545
## 4561                              D020_r1_AZD2858 -11.984923669  0.0011281963
## 4562                              D020_r1_AZD2932   1.805713069 -0.2733580913
## 4563                              D020_r1_AZD3759   1.642637734 -1.4363041841
## 4564                              D020_r1_AZD5363  -1.839833737 -1.3606907373
## 4565                              D020_r1_AZD5438  -8.294834119  0.3352517279
## 4566                              D020_r1_AZD6482   0.392526634 -1.8599630127
## 4567                              D020_r1_AZD6738  -9.433942511 -0.7430651906
## 4568                              D020_r1_AZD8055  -3.614160454  0.0214708344
## 4569                              D020_r1_AZD8330  -0.500253495 -1.0540973587
## 4570                  D020_r1_AZD8931 (Sapitinib)   2.688712563 -0.2986899201
## 4571                              D020_r1_AZD9291 -10.139828979  0.6386696357
## 4572            D020_r1_Barasertib (AZD1152-HQPA) -10.868606509  0.2115440311
## 4573  D020_r1_Baricitinib (LY3009104, INCB028050)   0.383203528 -2.0735841433
## 4574                  D020_r1_BGT226 (NVP-BGT226)   4.368124278  2.2441083456
## 4575                              D020_r1_BI 2536  -9.482022478  0.1955353949
## 4576                              D020_r1_BI-78D3  -1.851943225 -1.0216783704
## 4577                             D020_r1_BI-D1870  -1.010904633 -1.4856689215
## 4578                              D020_r1_Bikinin  -0.922337143 -0.7836251708
## 4579                                  D020_r1_BIO  -2.373366644 -0.7522027522
## 4580               D020_r1_BIRB 796 (Doramapimod)  -1.136428294 -1.8645848300
## 4581                            D020_r1_BIX 02188   1.726842025 -1.8542538620
## 4582                            D020_r1_BIX 02189  -0.101091818 -0.5460938655
## 4583      D020_r1_BKM120 (NVP-BKM120, Buparlisib) -10.038613150  0.3798674021
## 4584                           D020_r1_BMS-265246  -2.479601712 -1.3819562841
## 4585                           D020_r1_BMS-536924   1.220775722  0.7095956161
## 4586                           D020_r1_BMS-582949  -1.191182510 -1.3767327688
## 4587                           D020_r1_BMS-754807  -8.486433131  0.0079481368
## 4588                           D020_r1_BMS-777607   0.826548550 -1.5276939029
## 4589                           D020_r1_BMS-794833   0.975465161 -1.3498588392
## 4590                           D020_r1_BMS-833923  -1.126964843 -1.6932328143
## 4591                  D020_r1_Bosutinib (SKI-606)   6.871427442 -0.2674502450
## 4592                D020_r1_Brivanib (BMS-540215)   0.098623639 -2.1471415953
## 4593      D020_r1_Brivanib Alaninate (BMS-582664)  -1.499273762 -0.0772120805
## 4594                           D020_r1_BS-181 HCl  -1.592880029 -1.6678668294
## 4595                               D020_r1_Butein  -2.891459530 -1.0911255426
## 4596                               D020_r1_BYL719   1.104568916 -1.8636435196
## 4597     D020_r1_Cabozantinib (XL184, BMS-907351)  -0.623791491 -0.6021177111
## 4598          D020_r1_Cabozantinib malate (XL184)  -0.012026111 -2.3264642009
## 4599        D020_r1_CAL-101 (Idelalisib, GS-1101)  -1.234149837 -1.2404894922
## 4600                             D020_r1_CAY10505  -0.231361818 -1.7133425902
## 4601                               D020_r1_CC-223   0.342859564 -0.5189681411
## 4602                            D020_r1_CCT128930  -0.926796000 -0.9038048438
## 4603                  D020_r1_Cediranib (AZD2171)  -1.331305344 -0.4395108043
## 4604                            D020_r1_CEP-32496  -0.410003677 -1.7449836148
## 4605                            D020_r1_CEP-33779   0.023115628 -1.5184507526
## 4606                              D020_r1_CGI1746   0.079738085 -0.7359882515
## 4607                              D020_r1_CGK 733  -1.002943874 -1.8003214999
## 4608                            D020_r1_CH5132799  -4.382212760 -0.6193204294
## 4609                           D020_r1_CHIR-98014  -6.563930927 -0.5717140010
## 4610                 D020_r1_CHIR-99021 (CT99021)  -2.361320495 -0.1950834986
## 4611             D020_r1_CHIR-99021 (CT99021) HCl  -3.221140226 -0.7548573859
## 4612                    D020_r1_Chrysophanic Acid   0.157737380 -2.1997053737
## 4613                             D020_r1_CNX-2006   0.542769706 -0.0338584046
## 4614                              D020_r1_CNX-774  -0.291656406 -1.7747531102
## 4615                    D020_r1_CO-1686 (AVL-301)  -0.266679736 -1.4782608753
## 4616       D020_r1_Cobimetinib (GDC-0973, RG7420)  -3.534624169 -0.9111702051
## 4617                            D020_r1_CP-673451  -8.688809898  1.4043181553
## 4618                            D020_r1_CP-724714   0.075198766 -1.3393642395
## 4619               D020_r1_Crenolanib (CP-868596)  -9.754171596  0.7039829596
## 4620             D020_r1_Crizotinib (PF-02341066)  -8.903598253  0.9161390072
## 4621                               D020_r1_CYC116 -12.589416550  0.0989168443
## 4622                               D020_r1_CYT387  -1.348876066 -1.4025340778
## 4623                             D020_r1_CZC24832  -0.309100710 -2.2540048090
## 4624              D020_r1_Dabrafenib (GSK2118436)  -1.676638786 -2.4151847551
## 4625        D020_r1_Dacomitinib (PF299804, PF299)  -4.730786651  0.5519969560
## 4626              D020_r1_Danusertib (PHA-739358)  -9.330859654  0.9749945651
## 4627                        D020_r1_DAPT (GSI-IX)  -0.726248725 -0.7079550080
## 4628                            D020_r1_Dasatinib  -1.502594152 -0.8487720086
## 4629                D020_r1_DCC-2036 (Rebastinib)  -3.272352873  0.0870536267
## 4630                D020_r1_Decernotinib (VX-509)   1.316443348 -2.0082606860
## 4631               D020_r1_Dinaciclib (SCH727965) -10.343507742 -0.2194311701
## 4632    D020_r1_Dovitinib (TKI-258) Dilactic Acid  -8.435469857 -0.3611897861
## 4633                            D020_r1_ENMD-2076 -10.002371137  1.4237779306
## 4634               D020_r1_Enzastaurin (LY317615)  -1.144647131 -1.1369912424
## 4635                            D020_r1_ERK5-IN-1  -2.949392047  0.8584110583
## 4636                             D020_r1_ETC-1002  -1.138708464 -1.5167549670
## 4637                            D020_r1_ETP-46464   0.098440578 -1.3138785227
## 4638                  D020_r1_Everolimus (RAD001)  -1.109999953 -0.4974476804
## 4639                D020_r1_Fasudil (HA-1077) HCl   0.561894753 -1.9422288278
## 4640                                D020_r1_FH535   1.740038340 -2.2163822778
## 4641                D020_r1_Filgotinib (GLPG0634)  -1.590253928 -0.9757282715
## 4642             D020_r1_Flavopiridol (Alvocidib)  -7.880051889  0.7321629374
## 4643                     D020_r1_Flavopiridol HCl -11.353537939  0.4871344861
## 4644               D020_r1_Foretinib (GSK1363089)  -6.308473594 -1.0281349686
## 4645                  D020_r1_Fostamatinib (R788)  -6.938048302 -0.2567457119
## 4646                                D020_r1_G-749  -0.585886179 -1.7519493764
## 4647                             D020_r1_GDC-0068  -1.029683187 -1.2262001423
## 4648                             D020_r1_GDC-0349  -1.507829444 -1.2558165617
## 4649                             D020_r1_GDC-0879  -1.051856482 -1.0237829192
## 4650                             D020_r1_GDC-0941  -0.270726779 -2.1705659021
## 4651                    D020_r1_GDC-0980 (RG7422)  -2.428272795 -0.4322798305
## 4652                   D020_r1_Gefitinib (ZD1839)   1.981720863 -0.4481947338
## 4653                            D020_r1_Genistein   1.519119267 -2.7361733633
## 4654                            D020_r1_GF109203X  -3.459137050 -0.4079918234
## 4655                                D020_r1_GNF-2  -0.114628789 -1.8976482058
## 4656                                D020_r1_GNF-5  -0.469672979 -2.0227411116
## 4657                              D020_r1_Go 6983  -3.529750102  0.4573118923
## 4658                   D020_r1_Golvatinib (E7050) -11.853840073  0.7842869077
## 4659                          D020_r1_GSK1838705A   0.155992754 -0.0943428431
## 4660                          D020_r1_GSK1904529A   0.757043328  0.5703859341
## 4661                  D020_r1_GSK2126458 (GSK458)  -1.206734768 -0.3916402554
## 4662                           D020_r1_GSK2292767  -1.673496170  0.0616973571
## 4663                           D020_r1_GSK2636771  -2.497705707 -0.8837153879
## 4664                           D020_r1_GSK429286A   1.928321908 -1.4693854726
## 4665                            D020_r1_GSK461364  -9.844624694  0.4259667813
## 4666                               D020_r1_GSK621  -1.371399998 -1.9310731426
## 4667                            D020_r1_GSK690693  -3.651804384 -0.3493163070
## 4668                               D020_r1_GW5074   0.136767216 -2.2365622002
## 4669                             D020_r1_GW788388   1.080635997 -1.0715926455
## 4670                               D020_r1_GZD824   1.567724707 -0.7273352146
## 4671                            D020_r1_H 89 2HCl  -2.829752137 -0.2016413802
## 4672                           D020_r1_Hesperadin   1.707060669  1.3549019496
## 4673                              D020_r1_HMN-214 -11.146454163  1.2823823475
## 4674                             D020_r1_Honokiol   0.259654891 -1.7454700801
## 4675                               D020_r1_HS-173 -12.295883138 -0.1669580768
## 4676                           D020_r1_HTH-01-015  -9.063198486 -0.8543650254
## 4677                D020_r1_Ibrutinib (PCI-32765)   2.507662863 -1.7251380117
## 4678                              D020_r1_ICG-001   0.386645262 -0.9995596607
## 4679                             D020_r1_Icotinib   2.173674280 -1.5634035372
## 4680                                D020_r1_IM-12  -0.129828176 -2.0757038399
## 4681           D020_r1_Imatinib Mesylate (STI571)  -0.197205295 -0.9772748289
## 4682                            D020_r1_Indirubin  -0.363362348 -1.0834013089
## 4683                    D020_r1_INK 128 (MLN0128)  -1.563630848 -0.9766721433
## 4684                    D020_r1_IPI-145 (INK1197)  -0.970939228 -1.2824787419
## 4685                               D020_r1_IWP-L6   0.151481261 -1.6047107996
## 4686                           D020_r1_IWR-1-endo   0.059156624 -1.7436240641
## 4687                         D020_r1_JNJ-38877605  -1.417059655 -1.0513176292
## 4688                          D020_r1_JNJ-7706621  -5.949151958  0.8302269696
## 4689                     D020_r1_JNK Inhibitor IX -11.943909109 -0.7407639332
## 4690                             D020_r1_JNK-IN-8  -2.640154286  0.4298190088
## 4691                               D020_r1_K02288  -1.080384455 -0.9950887125
## 4692                               D020_r1_Ki8751  -2.176800481 -1.5350290913
## 4693                              D020_r1_KRN 633   1.140633884 -2.3733012374
## 4694                           D020_r1_KU-0063794  -1.624651642 -0.1706059474
## 4695      D020_r1_KU-55933 (ATM Kinase Inhibitor)  -0.505803447 -1.3854777286
## 4696                             D020_r1_KU-60019  -2.776350494  0.3106689085
## 4697                              D020_r1_KW-2449  -1.319078772  1.9166912221
## 4698                              D020_r1_KX2-391 -12.029494877  0.3753319843
## 4699                              D020_r1_KY02111   0.024425505 -1.6689034317
## 4700                            D020_r1_Lapatinib   0.342052152 -2.5465615839
## 4701     D020_r1_Lapatinib (GW-572016) Ditosylate   0.565123441 -2.3059102338
## 4702                            D020_r1_LDC000067  -7.948043245  0.7167609472
## 4703      D020_r1_LDE225 (NVP-LDE225,Erismodegib)   0.079737946 -1.1793921009
## 4704                           D020_r1_LDN-214117   0.541326347 -1.4244905092
## 4705                   D020_r1_Lenvatinib (E7080)  -2.304637787 -0.7750406583
## 4706                              D020_r1_LFM-A13   1.635951649 -1.9724421260
## 4707                              D020_r1_LGK-974   0.202369752 -2.3842732263
## 4708                  D020_r1_Linifanib (ABT-869)  -2.025163531 -0.9513562081
## 4709                               D020_r1_LJH685  -0.675084235 -1.5169245611
## 4710                               D020_r1_LJI308   0.416479981 -1.7805420562
## 4711               D020_r1_Losmapimod (GW856553X)  -1.635445843 -1.5348161375
## 4712                            D020_r1_LY2090314  -5.617043119 -0.9636995372
## 4713                            D020_r1_LY2157299   1.231406502 -1.3997983142
## 4714                            D020_r1_LY2784544  -5.887447658 -1.2162207097
## 4715                            D020_r1_LY2835219  -6.208620655  0.3369903314
## 4716                             D020_r1_LY294002   1.732009650 -1.7658150239
## 4717                            D020_r1_LY3023414  -3.350615992 -0.1080498809
## 4718                             D020_r1_LY411575  -1.038409838 -0.7705245729
## 4719       D020_r1_MEK162 (ARRY-162, ARRY-438162)  -0.017424640 -0.3681844479
## 4720                             D020_r1_MGCD-265  -0.172935766 -1.2002336667
## 4721               D020_r1_Milciclib (PHA-848125)  -7.312242818  0.4237298839
## 4722                              D020_r1_MK-0752  -1.080103620 -1.4991534041
## 4723                         D020_r1_MK-2206 2HCl  -1.025197688 -1.1460095537
## 4724                              D020_r1_MK-2461  -1.203152368 -1.6136269439
## 4725                     D020_r1_MK-5108 (VX-689) -11.541723930 -0.7991852673
## 4726                              D020_r1_MK-8745 -14.651079733 -1.1063860884
## 4727                              D020_r1_MLN2480   0.629843854 -1.3785746652
## 4728                              D020_r1_MLN8054   0.460646011 -2.3333741280
## 4729      D020_r1_Motesanib Diphosphate (AMG-706)  -1.221817419 -1.3014710979
## 4730                  D020_r1_Nilotinib (AMN-107)   1.123943235 -2.6324849035
## 4731     D020_r1_Nintedanib (BIBF 1120)_uncertain  -1.708818594 -1.4266351476
## 4732                               D020_r1_NU6027  -0.477413869 -1.5275882759
## 4733                           D020_r1_NVP-AEW541  -5.959227165  1.6607868900
## 4734                           D020_r1_NVP-BHG712  -2.015100618 -1.3276084870
## 4735                      D020_r1_NVP-BSK805 2HCl  -3.587636446 -0.8184911592
## 4736                           D020_r1_NVP-BVU972  -0.406108264 -1.6384019913
## 4737                          D020_r1_Oclacitinib   0.384933560 -1.9292551084
## 4738      D020_r1_Olmutinib (HM61713, BI 1482694)  -0.684451797 -1.3239525260
## 4739                             D020_r1_ONO-4059  -0.837012988 -0.8923483925
## 4740                              D020_r1_OSI-027   0.572431415 -0.7177090464
## 4741                              D020_r1_OSI-420   2.246426118 -0.5586923374
## 4742                 D020_r1_OSI-906 (Linsitinib)   0.396772739 -0.4801041901
## 4743                              D020_r1_P276-00  -4.515948735 -0.1504222095
## 4744                  D020_r1_Pacritinib (SB1518)  -7.395688731  0.8890538792
## 4745                   D020_r1_Palomid 529 (P529)  -0.126972627 -2.1761964036
## 4746                            D020_r1_Pazopanib  -3.090589023 -2.8235218238
## 4747                        D020_r1_Pazopanib HCl  -0.946882535 -1.2063119542
## 4748                            D020_r1_PD0325901   0.972709633 -0.2059865923
## 4749                             D020_r1_PD168393   1.357929865 -1.2767678933
## 4750                             D020_r1_PD173955  -5.792857770 -0.3082925915
## 4751                   D020_r1_PD184352 (CI-1040)   0.955037053 -0.8972919235
## 4752                             D020_r1_PD318088   3.932276314 -1.3771859620
## 4753                              D020_r1_PD98059  -0.038761815 -1.3335723982
## 4754                  D020_r1_Pelitinib (EKB-569)  -4.470267148 -0.1028703507
## 4755                          D020_r1_PF-00562271  -7.577756514  0.0821764644
## 4756                          D020_r1_PF-04217903  -0.901663530 -2.1190250542
## 4757                          D020_r1_PF-04691502   0.349706389 -0.8453918019
## 4758                            D020_r1_PF-431396  -7.809839985  0.9780930242
## 4759                           D020_r1_PF-4708671  -7.740858867  0.4261895392
## 4760                           D020_r1_PF-5274857  -1.938601707 -1.3621618598
## 4761                            D020_r1_PF-562271  -8.213666998  1.1570510246
## 4762                            D020_r1_PF-573228  -1.836770547 -1.3124082412
## 4763                            D020_r1_PH-797804  -1.527915450 -1.4084656305
## 4764                           D020_r1_PHA-665752  -1.026733851  0.5995391014
## 4765                           D020_r1_PHA-680632  -8.010972075 -0.1596898185
## 4766                           D020_r1_PHA-767491  -8.025044126 -0.0377562578
## 4767                           D020_r1_PHA-793887  -7.350404039  0.8188031863
## 4768                       D020_r1_Phenformin HCl  -2.138644204 -1.9019695551
## 4769                              D020_r1_PHT-427  -0.140600249 -1.8385155540
## 4770                          D020_r1_Piceatannol   0.186692908 -0.7186705884
## 4771                              D020_r1_PIK-293  -1.612322015 -1.0877330848
## 4772                              D020_r1_PIK-294   0.152084847 -3.6386740707
## 4773                               D020_r1_PIK-93  -2.334616257 -0.0473172999
## 4774               D020_r1_Pimasertib (AS-703026)  -0.928523779 -1.3785393026
## 4775                          D020_r1_Pirfenidone  -1.270241383 -0.9820710172
## 4776                             D020_r1_PLX-4720  -1.227014176 -0.8637216180
## 4777                              D020_r1_PLX7904  -0.924159600 -1.5231712241
## 4778                  D020_r1_Ponatinib (AP24534)   2.550396933 -1.3642021731
## 4779                                  D020_r1_PP1   0.112144068 -2.3273787043
## 4780                                  D020_r1_PP2  -2.062477803 -3.0163847454
## 4781                                D020_r1_PP242  -1.194502709 -1.2624087042
## 4782                               D020_r1_PQ 401   0.171809142 -1.5576890164
## 4783                              D020_r1_PRI-724  -0.004665216 -1.7231595612
## 4784     D020_r1_PRT062607 (P505-15, BIIB057) HCl  -2.782867929  1.2175443575
## 4785                         D020_r1_Purvalanol A  -3.321632246 -1.2255719061
## 4786                            D020_r1_Quercetin   1.145528851 -2.5771145355
## 4787                  D020_r1_Quizartinib (AC220)  -5.630465249  0.9768808366
## 4788                                 D020_r1_R406  -3.246398009 -0.8823366007
## 4789                     D020_r1_R406 (free base)  -2.027332931 -1.7175259550
## 4790                                 D020_r1_R547  -8.246519507 -0.6665969645
## 4791                    D020_r1_RAF265 (CHIR-265)   2.064658732 -1.1350783097
## 4792                D020_r1_Rapamycin (Sirolimus)   0.157525432 -1.6404258065
## 4793   D020_r1_Refametinib (RDEA119, Bay 86-9766)   0.403215217 -0.7353991504
## 4794                               D020_r1_RepSox   1.301077519 -2.3067974944
## 4795 D020_r1_Ridaforolimus (Deforolimus, MK-8669)   0.053343516 -0.9656570673
## 4796                D020_r1_Rigosertib (ON-01910)  -8.814166235  0.8163605908
## 4797                             D020_r1_RKI-1447   0.630036699 -1.2260708296
## 4798                                D020_r1_RN486  -3.364452945 -1.8512042478
## 4799                  D020_r1_Ro 31-8220 Mesylate  -2.987288367  0.6092923542
## 4800                              D020_r1_Ro-3306  -1.181278029 -2.5001638422
## 4801                               D020_r1_Ro3280 -10.365387568 -0.3146804564
## 4802                            D020_r1_RO4929097   0.896872657 -2.1119784665
## 4803      D020_r1_Roscovitine (Seliciclib,CYC202)  -1.592493031 -1.9336166005
## 4804             D020_r1_Ruxolitinib (INCB018424)   0.494550407 -2.2359420983
## 4805           D020_r1_S-Ruxolitinib (INCB018424)  -1.639460957 -1.3644643903
## 4806                               D020_r1_SANT-1  -0.798107855 -2.0378673347
## 4807                            D020_r1_SAR131675   0.130513255 -2.2987097177
## 4808                    D020_r1_SAR245409 (XL765)   1.467955443 -3.1113545260
## 4809                D020_r1_Saracatinib (AZD0530)  -0.343330241  0.2467451628
## 4810                      D020_r1_SB202190 (FHPI)  -0.654036503 -1.5658390530
## 4811                             D020_r1_SB203580  -2.745230185 -1.6177440105
## 4812                             D020_r1_SB216763  -1.838486299 -0.8641804363
## 4813                             D020_r1_SB239063   0.257536271 -1.3498569833
## 4814                             D020_r1_SB415286  -0.850338578 -1.1336580381
## 4815                             D020_r1_SB431542   0.190077611 -1.4325482388
## 4816                             D020_r1_SB505124   0.667875348 -1.8562900857
## 4817                             D020_r1_SB525334  -0.755144535 -1.9443533188
## 4818                             D020_r1_SB590885  -2.144493783 -1.3125411459
## 4819                                  D020_r1_SC1  -3.424300757 -0.3564949087
## 4820                D020_r1_Schisandrin B (Sch B)  -2.479728727 -0.5469508567
## 4821                D020_r1_Selumetinib (AZD6244)   3.636859464 -0.0789377908
## 4822              D020_r1_Semagacestat (LY450139)   0.410417415 -1.3359316702
## 4823                   D020_r1_Semaxanib (SU5416)  -0.677181234 -0.2914097085
## 4824                             D020_r1_SGI-7079  -4.620214079  0.7298624120
## 4825                          D020_r1_Skepinone-L  -2.044351805 -1.5539946033
## 4826                               D020_r1_SL-327   2.438614153 -1.9144813604
## 4827                 D020_r1_SNS-032 (BMS-387032)  -7.373739782 -0.2223783820
## 4828                     D020_r1_SNS-314 Mesylate  -9.724090390 -1.7111012820
## 4829                            D020_r1_Sorafenib  -0.114455128 -3.0417485734
## 4830                   D020_r1_Sorafenib Tosylate  -0.409175314 -1.9268692305
## 4831                         D020_r1_Sotrastaurin  -0.032702872 -1.2347004115
## 4832                             D020_r1_SP600125  -1.343807424 -1.1855600464
## 4833                              D020_r1_SU11274   0.208437207 -1.6812805196
## 4834                               D020_r1_SU6656  -5.405630347  0.1249845473
## 4835                               D020_r1_SU9516  -6.624744483  0.3314346444
## 4836                     D020_r1_Sunitinib Malate   3.255605375 -0.2879299188
## 4837                  D020_r1_TAE226 (NVP-TAE226)  -6.363837636 -0.0978572940
## 4838                              D020_r1_TAK-285   1.067079921 -0.7854390155
## 4839                              D020_r1_TAK-632  -3.374760857 -1.0067856208
## 4840                              D020_r1_TAK-715  -1.067710537 -2.1480640357
## 4841                              D020_r1_TAK-733  -0.997491108 -0.3002882708
## 4842                              D020_r1_TAK-901  -9.771573812  0.4534459017
## 4843                D020_r1_Taladegib (LY2940680)  -0.613004786 -1.5536496104
## 4844                              D020_r1_TCS 359  -1.485985098 -2.2363925496
## 4845                               D020_r1_TDZD-8  -0.658681385 -1.9103474344
## 4846                            D020_r1_Telatinib  -1.066173719 -2.1770902752
## 4847   D020_r1_Temsirolimus (CCI-779, NSC 683864)   1.089739684 -0.9344864605
## 4848              D020_r1_Tepotinib (EMD 1214063)  -7.312097509  1.3318901679
## 4849                                D020_r1_TG003   1.816267671 -2.1061424274
## 4850                            D020_r1_TG100-115  -0.562015855 -1.3416629981
## 4851                             D020_r1_TG101209 -13.939880557 -0.3419317998
## 4852                 D020_r1_TG101348 (SAR302503) -12.008196854  0.8080909344
## 4853                              D020_r1_TGX-221   0.976699792 -0.8462424287
## 4854                         D020_r1_Theophylline  -0.605427411 -1.4340704889
## 4855                          D020_r1_Thiazovivin   1.161501642 -0.9977399622
## 4856                       D020_r1_TIC10 Analogue  -0.445056181 -1.6920951024
## 4857                           D020_r1_Tideglusib  -0.875970589 -2.1786421463
## 4858                 D020_r1_Tivantinib (ARQ 197) -13.422206050 -1.1200224848
## 4859                   D020_r1_Tivozanib (AV-951)  -1.583410786 -1.3007596930
## 4860  D020_r1_Tofacitinib (CP-690550,Tasocitinib)   0.141236048 -1.4167034352
## 4861      D020_r1_Tofacitinib (CP-690550) Citrate   0.200405831 -1.9506037111
## 4862                              D020_r1_Torin 2  -4.618423777  0.1286037154
## 4863              D020_r1_Trametinib (GSK1120212)   0.181768537 -0.8876384839
## 4864                          D020_r1_Triciribine  -0.561810696  0.3560529350
## 4865           D020_r1_TSU-68 (SU6668, Orantinib)  -0.437733165 -1.9094656259
## 4866                               D020_r1_TWS119  -0.397127303 -1.5968754830
## 4867                         D020_r1_Tyrphostin 9  -1.815988033 -1.2146450481
## 4868                   D020_r1_Tyrphostin AG 1296  -1.398295127 -2.3154087836
## 4869                           D020_r1_U0126-EtOH   0.017714402 -0.0752877811
## 4870     D020_r1_Ulixertinib (BVD-523, VRT752271)  -1.498112848 -0.6401914384
## 4871              D020_r1_Uprosertib (GSK2141795)  -3.304933827 -1.0187987695
## 4872                          D020_r1_Vacquinol-1  -5.711600625  1.4296321910
## 4873                           D020_r1_Varlitinib   0.511122291 -1.8908250159
## 4874              D020_r1_Vatalanib (PTK787) 2HCl  -2.895984885 -1.9758365370
## 4875                               D020_r1_VE-821  -1.243929222 -2.3614654786
## 4876                               D020_r1_VE-822  -8.090898682 -1.1656940859
## 4877        D020_r1_Vemurafenib (PLX4032, RG7204)  -0.008584104 -2.1905196181
## 4878                D020_r1_Vismodegib (GDC-0449)  -0.044472216 -1.1160657202
## 4879                 D020_r1_Volasertib (BI 6727)  -1.460606583 -1.0127432028
## 4880                            D020_r1_VPS34-IN1  -4.409565460 -1.1013096925
## 4881                     D020_r1_VS-5584 (SB2343)  -2.090255239 -0.7470808435
## 4882                               D020_r1_VX-11e   1.148011308 -1.0916476015
## 4883         D020_r1_VX-680 (Tozasertib, MK-0457) -10.852757448  1.4608133528
## 4884                               D020_r1_VX-702   0.096854617 -1.8016526436
## 4885                               D020_r1_VX-745   0.588395408 -2.0584783866
## 4886                              D020_r1_WAY-600  -4.343006430 -1.5677645410
## 4887                             D020_r1_WH-4-023  -0.937387139 -2.4561078383
## 4888                             D020_r1_WHI-P154  -0.099386727 -2.0341929116
## 4889                                D020_r1_WIKI4  -0.187411028 -1.4711662538
## 4890                        D020_r1_Wnt agonist 1 -12.493472811  0.0589622940
## 4891                        D020_r1_Wnt-C59 (C59)   0.286678879 -2.1257023553
## 4892                               D020_r1_WP1066  -1.101760124 -1.1611902491
## 4893                 D020_r1_WYE-125132 (WYE-132)  -2.819006036 -0.6853043437
## 4894                              D020_r1_WYE-354   2.382154440 -0.5112629142
## 4895                               D020_r1_WZ3146  -2.548810876 -0.1921899945
## 4896                               D020_r1_WZ4002   0.258002146 -2.2232308495
## 4897                               D020_r1_WZ4003  -0.427420088 -0.8956011321
## 4898                               D020_r1_WZ8040   1.505155832 -1.7772211038
## 4899                              D020_r1_XAV-939  -3.052906944 -1.8965782763
## 4900                                D020_r1_XL019  -1.996386339 -2.0578369144
## 4901                              D020_r1_XMD8-92  -1.799870146 -0.6292654468
## 4902                         D020_r1_Y-27632 2HCl  -0.335777592 -1.9592402275
## 4903                             D020_r1_YM201636   1.065317004 -0.4569206604
## 4904                             D020_r1_YO-01027  -0.889271395 -1.0477798091
## 4905                            D020_r1_ZM 306416   2.998114902 -1.4773153579
## 4906                        D020_r1_ZM 323881 HCl   1.964607243 -1.7726432849
## 4907                            D020_r1_ZM 336372  -0.807889780 -1.5104787391
## 4908                         D020_r1_ZM 39923 HCl   0.401345323 -1.6288578011
## 4909                            D020_r1_ZM 447439  -7.006643903  1.2052692456
## 4910                 D020_r1_Zotarolimus(ABT-578)   1.251159944 -1.7199770139
## 4911                              D020_r1_ZSTK474   0.093241809 -0.5103938579
## 4912                     D020_r2_1-Azakenpaullone  -1.983651006 -0.8387338215
## 4913                      D020_r2_3-Methyladenine  -1.707275295 -0.6093017318
## 4914                             D020_r2_A-674563 -10.276942828 -2.3346601181
## 4915                             D020_r2_A-769662   1.373138420 -1.5386283814
## 4916                                  D020_r2_A66   1.917552627 -2.0324511441
## 4917                            D020_r2_Acadesine  -0.861867086 -1.8702126331
## 4918                  D020_r2_AEE788 (NVP-AEE788)  -3.167006430 -0.8678408664
## 4919        D020_r2_Afatinib (BIBW2992)_uncertain  -0.473817049 -1.9349385458
## 4920                              D020_r2_AG-1024  -0.256315922 -1.3355107067
## 4921         D020_r2_AG-1478 (Tyrphostin AG-1478)   2.952728373 -1.2079349936
## 4922                                D020_r2_AG-18  -0.127803016 -1.8779711016
## 4923              D020_r2_AG-490 (Tyrphostin B42)  -0.520119357 -1.8052319132
## 4924                             D020_r2_Akti-1/2   3.689381850 -0.8109341441
## 4925                  D020_r2_Alisertib (MLN8237)  -9.610048589  0.9059966723
## 4926                              D020_r2_AMG 337  -2.352876434 -2.1550805170
## 4927                              D020_r2_AMG-458   1.811605193 -0.8803538080
## 4928                              D020_r2_AMG-900  -8.595519940 -1.6310085794
## 4929                               D020_r2_AMG319   0.493320726 -2.0829523451
## 4930                  D020_r2_Amuvatinib (MP-470)  -0.983021136 -2.1790475648
## 4931                             D020_r2_Apatinib  -1.011055962 -1.3336729638
## 4932                           D020_r2_AR-A014418   0.977269314 -1.3434588182
## 4933                            D020_r2_AS-252424  -0.140407991 -0.5662923476
## 4934                            D020_r2_AS-604850   0.431602053 -1.9170069864
## 4935                         D020_r2_Asiatic Acid  -0.546800079 -1.2050836951
## 4936                             D020_r2_AST-1306   0.304141117 -1.2244084390
## 4937                              D020_r2_AT13148  -0.357680861 -0.6343243506
## 4938                               D020_r2_AT7519  -8.037077859 -1.2890363867
## 4939                               D020_r2_AT7867   1.994846235  0.3848231079
## 4940                               D020_r2_AT9283  -7.264455571  0.5383588166
## 4941                 D020_r2_Aurora A Inhibitor I  -8.746409394 -0.5751242053
## 4942             D020_r2_Avagacestat (BMS-708163)   0.268754340 -2.2684789254
## 4943                              D020_r2_AVL-292   4.348072864 -3.6918684796
## 4944                             D020_r2_Axitinib  -1.768804939  0.1637246413
## 4945                             D020_r2_Axitinib  -1.768804939  0.1637246413
## 4946                               D020_r2_AZ 628   2.408255320 -0.8121186238
## 4947                               D020_r2_AZ 960   0.740817365 -2.6776756382
## 4948                                 D020_r2_AZ20  -7.046498576 -1.2961867449
## 4949                              D020_r2_AZD1080  -4.055621286 -0.3192620646
## 4950                              D020_r2_AZD1480  -8.143840157  0.4213470660
## 4951                              D020_r2_AZD2014  -4.894055191 -2.6730943000
## 4952                              D020_r2_AZD2858  -9.596050957 -0.1432882686
## 4953                              D020_r2_AZD2932  -1.846869742 -0.7713234428
## 4954                              D020_r2_AZD3759   2.842771234 -2.7147327837
## 4955                              D020_r2_AZD5363  -1.131599409 -1.3504155086
## 4956                              D020_r2_AZD5438  -5.148470643 -1.0862842223
## 4957                              D020_r2_AZD6482   0.377142111 -1.6360300915
## 4958                              D020_r2_AZD6738  -8.755721845 -0.4899715943
## 4959                              D020_r2_AZD8055   0.656732732 -0.9320687981
## 4960                              D020_r2_AZD8330   0.302732806 -1.2691822435
## 4961                  D020_r2_AZD8931 (Sapitinib)  -1.398711947 -0.8280761479
## 4962                              D020_r2_AZD9291  -2.062838218  0.8085492954
## 4963            D020_r2_Barasertib (AZD1152-HQPA)  -8.821846082 -1.0317979847
## 4964  D020_r2_Baricitinib (LY3009104, INCB028050)   0.179847083 -2.3679315629
## 4965                  D020_r2_BGT226 (NVP-BGT226)   9.732899648  1.0550525572
## 4966                              D020_r2_BI 2536 -11.123098629 -0.9787506213
## 4967                              D020_r2_BI-78D3  -0.197028136 -2.0211114189
## 4968                             D020_r2_BI-D1870   2.124096858 -2.4108311576
## 4969                              D020_r2_Bikinin  -0.007341893 -1.8896525625
## 4970                                  D020_r2_BIO  -0.646743168 -1.9981598556
## 4971               D020_r2_BIRB 796 (Doramapimod)   0.024507027 -1.6594776881
## 4972                            D020_r2_BIX 02188   0.575102730 -1.6862898718
## 4973                            D020_r2_BIX 02189  -0.030384503 -1.6659677283
## 4974      D020_r2_BKM120 (NVP-BKM120, Buparlisib) -10.997698220 -0.0083743679
## 4975                           D020_r2_BMS-265246  -1.195604681 -2.5094333466
## 4976                           D020_r2_BMS-536924  -1.565128975 -0.1659552712
## 4977                           D020_r2_BMS-582949  -0.107988971 -1.9391695064
## 4978                           D020_r2_BMS-754807  -7.090705632 -0.0732145862
## 4979                           D020_r2_BMS-777607  -0.442845524 -1.9191055761
## 4980                           D020_r2_BMS-794833   0.519020791 -2.2023663428
## 4981                           D020_r2_BMS-833923  -0.606520254 -1.4398544887
## 4982                  D020_r2_Bosutinib (SKI-606)   0.850786071 -0.1755469769
## 4983                D020_r2_Brivanib (BMS-540215)  -1.019025475 -0.9827318835
## 4984      D020_r2_Brivanib Alaninate (BMS-582664)  -2.203505395 -0.7737728427
## 4985                           D020_r2_BS-181 HCl  -2.196494377 -2.1662398716
## 4986                               D020_r2_Butein   1.345296736 -1.5750801358
## 4987                               D020_r2_BYL719  -1.250497653 -2.4135190827
## 4988     D020_r2_Cabozantinib (XL184, BMS-907351)  -0.800357412 -1.2668928146
## 4989          D020_r2_Cabozantinib malate (XL184)   0.206572505 -0.6350798313
## 4990        D020_r2_CAL-101 (Idelalisib, GS-1101)  -0.306274814 -1.2645675752
## 4991                             D020_r2_CAY10505   1.539819541 -1.4338157603
## 4992                               D020_r2_CC-223  -0.502425536 -1.5263539961
## 4993                            D020_r2_CCT128930  -4.173608114 -0.8532715185
## 4994                  D020_r2_Cediranib (AZD2171)  -0.842408631 -1.5391259149
## 4995                            D020_r2_CEP-32496  -0.418708405 -2.3302466558
## 4996                            D020_r2_CEP-33779  -0.942679273 -0.6437918123
## 4997                              D020_r2_CGI1746   2.294004201 -2.8370326815
## 4998                              D020_r2_CGK 733   0.062162565 -1.1069090342
## 4999                            D020_r2_CH5132799  -0.668303602  0.2715738424
## 5000                           D020_r2_CHIR-98014  -7.410867851  0.1420316272
## 5001                 D020_r2_CHIR-99021 (CT99021)  -2.180864233 -0.6481320540
## 5002             D020_r2_CHIR-99021 (CT99021) HCl  -2.550231082 -1.3547714157
## 5003                    D020_r2_Chrysophanic Acid  -0.891458278 -0.7374880978
## 5004                             D020_r2_CNX-2006  -1.417639917 -0.5813226609
## 5005                              D020_r2_CNX-774   0.747901573 -2.1397919136
## 5006                    D020_r2_CO-1686 (AVL-301)   0.135997512 -1.0366760114
## 5007       D020_r2_Cobimetinib (GDC-0973, RG7420)  -1.962649729 -0.9643935418
## 5008                            D020_r2_CP-673451  -9.822533888  0.2560725250
## 5009                            D020_r2_CP-724714  -0.344050494 -2.0745624676
## 5010               D020_r2_Crenolanib (CP-868596)  -7.793785065  1.1526372356
## 5011             D020_r2_Crizotinib (PF-02341066)  -6.056808086  1.0798614095
## 5012                               D020_r2_CYC116  -8.857952917 -1.6986367675
## 5013                               D020_r2_CYT387  -1.995353420 -1.3981799099
## 5014                             D020_r2_CZC24832   2.261546795 -1.7156953511
## 5015              D020_r2_Dabrafenib (GSK2118436)   4.721376944 -3.1365254218
## 5016        D020_r2_Dacomitinib (PF299804, PF299)  -0.934759957 -0.1359135402
## 5017              D020_r2_Danusertib (PHA-739358)  -8.028441455 -0.3328091294
## 5018                        D020_r2_DAPT (GSI-IX)  -1.127696727 -1.5911937142
## 5019                            D020_r2_Dasatinib   1.092036406 -0.9668328038
## 5020                D020_r2_DCC-2036 (Rebastinib)  -1.845712965 -1.6137557015
## 5021                D020_r2_Decernotinib (VX-509)   0.432139575 -1.9131301909
## 5022               D020_r2_Dinaciclib (SCH727965)  -6.980701756 -2.5667188296
## 5023    D020_r2_Dovitinib (TKI-258) Dilactic Acid  -2.115905232 -1.8635753482
## 5024                            D020_r2_ENMD-2076  -7.845916566 -0.2266172382
## 5025               D020_r2_Enzastaurin (LY317615)  -1.957368504 -1.5630967601
## 5026                            D020_r2_ERK5-IN-1  -3.505027022  0.2454489192
## 5027                             D020_r2_ETC-1002  -2.177980318 -2.3957609694
## 5028                            D020_r2_ETP-46464  -0.860476246 -1.7005561527
## 5029                  D020_r2_Everolimus (RAD001)  -1.437156260 -1.0832602931
## 5030                D020_r2_Fasudil (HA-1077) HCl  -0.298570165 -2.3624906852
## 5031                                D020_r2_FH535   0.116297753 -1.3811714511
## 5032                D020_r2_Filgotinib (GLPG0634)  -1.673536843 -1.7282331377
## 5033             D020_r2_Flavopiridol (Alvocidib)  -6.515646035 -0.7320167941
## 5034                     D020_r2_Flavopiridol HCl  -8.016294895  0.0865685546
## 5035               D020_r2_Foretinib (GSK1363089)  -7.834218611 -0.3986001447
## 5036                  D020_r2_Fostamatinib (R788)  -6.972701788 -0.4466255931
## 5037                                D020_r2_G-749   0.321500040 -0.7515838217
## 5038                             D020_r2_GDC-0068  -4.653678798 -0.8820793470
## 5039                             D020_r2_GDC-0349  -1.496845982 -1.3847849643
## 5040                             D020_r2_GDC-0879  -1.460116513 -0.9472479934
## 5041                             D020_r2_GDC-0941  -2.093740058 -1.3190713754
## 5042                    D020_r2_GDC-0980 (RG7422)  -3.682157297 -0.6163755852
## 5043                   D020_r2_Gefitinib (ZD1839)   3.985180742 -1.9492498869
## 5044                            D020_r2_Genistein  -0.945487375 -1.2785459288
## 5045                            D020_r2_GF109203X  -0.712226173 -0.6153649027
## 5046                                D020_r2_GNF-2  -0.709115599 -1.8985044540
## 5047                                D020_r2_GNF-5  -0.969507515 -2.3141929533
## 5048                              D020_r2_Go 6983  -0.417097035 -0.2820236289
## 5049                   D020_r2_Golvatinib (E7050)  -7.852508164 -0.9737047374
## 5050                          D020_r2_GSK1838705A  -3.792921549 -1.3134598435
## 5051                          D020_r2_GSK1904529A   0.216966331 -1.7817229791
## 5052                  D020_r2_GSK2126458 (GSK458)  -4.237212816  0.3373559502
## 5053                           D020_r2_GSK2292767  -4.653564038 -0.7197129227
## 5054                           D020_r2_GSK2636771   5.022532080 -1.9612785511
## 5055                           D020_r2_GSK429286A   1.929447498 -1.7896464288
## 5056                            D020_r2_GSK461364 -10.897065007 -0.4647605072
## 5057                               D020_r2_GSK621  -1.627557740 -1.4892173995
## 5058                            D020_r2_GSK690693   0.136996193 -1.5846806432
## 5059                               D020_r2_GW5074   2.244528306 -2.6265223297
## 5060                             D020_r2_GW788388   0.284880903 -1.9086261606
## 5061                               D020_r2_GZD824   8.749186934  0.1315753371
## 5062                            D020_r2_H 89 2HCl  -1.965392000 -1.0585516055
## 5063                           D020_r2_Hesperadin   2.901007488 -0.0627464034
## 5064                              D020_r2_HMN-214 -10.717295533 -0.4879878353
## 5065                             D020_r2_Honokiol  -1.962970926 -2.2354988472
## 5066                               D020_r2_HS-173 -10.306151324  0.0067960335
## 5067                           D020_r2_HTH-01-015  -5.946276345 -2.0002601296
## 5068                D020_r2_Ibrutinib (PCI-32765)   3.542793372 -0.0085592644
## 5069                              D020_r2_ICG-001  -0.385630490 -0.9336913603
## 5070                             D020_r2_Icotinib   2.178131188 -0.3777204517
## 5071                                D020_r2_IM-12  -0.090739776 -2.6397678239
## 5072           D020_r2_Imatinib Mesylate (STI571)   0.132479900 -1.4293815342
## 5073                            D020_r2_Indirubin  -2.040858479 -0.8907203305
## 5074                    D020_r2_INK 128 (MLN0128)  -6.607117024 -1.4514511725
## 5075                    D020_r2_IPI-145 (INK1197)  -2.199860029 -0.1292741140
## 5076                               D020_r2_IWP-L6   0.342677185 -2.5540807296
## 5077                           D020_r2_IWR-1-endo   0.182970120 -2.8222196672
## 5078                         D020_r2_JNJ-38877605  -0.359508324 -1.8686632760
## 5079                          D020_r2_JNJ-7706621  -9.208685913 -0.1450188706
## 5080                     D020_r2_JNK Inhibitor IX  -9.857367735 -0.3481216119
## 5081                             D020_r2_JNK-IN-8   1.685748358 -0.1140264414
## 5082                               D020_r2_K02288   3.061629881 -2.4571419590
## 5083                               D020_r2_Ki8751  -3.706153998 -1.5180256331
## 5084                              D020_r2_KRN 633  -0.187362925 -1.5436063992
## 5085                           D020_r2_KU-0063794  -0.983763084 -1.4865590863
## 5086      D020_r2_KU-55933 (ATM Kinase Inhibitor)  -1.224842690 -1.7172737875
## 5087                             D020_r2_KU-60019  -3.441785755 -0.5581504129
## 5088                              D020_r2_KW-2449  -4.036435842 -0.5756289254
## 5089                              D020_r2_KX2-391  -7.226052539 -1.5575388397
## 5090                              D020_r2_KY02111   0.188397018 -1.7748486529
## 5091                            D020_r2_Lapatinib  -2.003574188 -1.5513895829
## 5092     D020_r2_Lapatinib (GW-572016) Ditosylate   2.543381108 -2.6583055204
## 5093                            D020_r2_LDC000067  -8.298420347  0.4536242915
## 5094      D020_r2_LDE225 (NVP-LDE225,Erismodegib)  -0.452313723 -2.0591053058
## 5095                           D020_r2_LDN-214117   2.116737530 -2.2669471766
## 5096                   D020_r2_Lenvatinib (E7080)   2.269598254 -1.7861954117
## 5097                              D020_r2_LFM-A13   0.244564430 -1.6608414785
## 5098                              D020_r2_LGK-974  -0.014556951 -1.9418371769
## 5099                  D020_r2_Linifanib (ABT-869)   2.679029572 -2.0020954434
## 5100                               D020_r2_LJH685   0.875560954 -1.7101079250
## 5101                               D020_r2_LJI308  -0.713253518 -1.2137032079
## 5102               D020_r2_Losmapimod (GW856553X)  -1.112170933 -2.4595296905
## 5103                            D020_r2_LY2090314  -3.071587836 -0.9014687546
## 5104                            D020_r2_LY2157299   1.357955909 -2.9376280761
## 5105                            D020_r2_LY2784544  -3.898530383 -0.2622954607
## 5106                            D020_r2_LY2835219  -4.563098005 -0.3997650766
## 5107                             D020_r2_LY294002  -0.827020528 -0.7627626547
## 5108                            D020_r2_LY3023414  -5.469594724 -0.5789835444
## 5109                             D020_r2_LY411575  -1.178432182 -2.0357238271
## 5110       D020_r2_MEK162 (ARRY-162, ARRY-438162)  -5.375146822 -1.2557289344
## 5111                             D020_r2_MGCD-265   0.688731231  0.6733602409
## 5112               D020_r2_Milciclib (PHA-848125)  -6.770069204 -1.2853436286
## 5113                              D020_r2_MK-0752   0.264740145 -2.4598165848
## 5114                         D020_r2_MK-2206 2HCl  -4.874930714 -0.3406734116
## 5115                              D020_r2_MK-2461   1.502856756 -3.1709250735
## 5116                     D020_r2_MK-5108 (VX-689)  -9.474352079  0.2528625073
## 5117                              D020_r2_MK-8745 -10.375549055 -1.4250218982
## 5118                              D020_r2_MLN2480  -0.362801590 -1.6400173014
## 5119                              D020_r2_MLN8054  -0.294669026 -2.4924056895
## 5120      D020_r2_Motesanib Diphosphate (AMG-706)   1.269433403 -1.9142465924
## 5121                  D020_r2_Nilotinib (AMN-107)   1.545638478 -1.2126357780
## 5122     D020_r2_Nintedanib (BIBF 1120)_uncertain  -1.019192513 -2.5315512781
## 5123                               D020_r2_NU6027   0.908422306 -3.1949712993
## 5124                           D020_r2_NVP-AEW541  -2.890918003  0.2473117398
## 5125                           D020_r2_NVP-BHG712  -1.362452904 -2.3535331498
## 5126                      D020_r2_NVP-BSK805 2HCl   0.075494267 -2.6875104589
## 5127                           D020_r2_NVP-BVU972   3.845435892 -1.7529022780
## 5128                          D020_r2_Oclacitinib   0.046062268 -2.5759289290
## 5129      D020_r2_Olmutinib (HM61713, BI 1482694)  -1.680315849 -1.2235578124
## 5130                             D020_r2_ONO-4059  -1.374888691 -0.2713298510
## 5131                              D020_r2_OSI-027  -1.200626859 -0.3480558185
## 5132                              D020_r2_OSI-420   1.156188133 -0.4071202976
## 5133                 D020_r2_OSI-906 (Linsitinib)   0.787114391  0.3734619120
## 5134                              D020_r2_P276-00  -9.358785416 -1.1010356157
## 5135                  D020_r2_Pacritinib (SB1518)  -4.316831736 -1.2283247095
## 5136                   D020_r2_Palomid 529 (P529)  -0.413935570 -2.0085660109
## 5137                            D020_r2_Pazopanib  -1.931341849 -2.1822129150
## 5138                        D020_r2_Pazopanib HCl  -1.011023197 -2.9502840497
## 5139                            D020_r2_PD0325901  -2.500640346 -1.4639347027
## 5140                             D020_r2_PD168393   5.834280614 -1.2098164454
## 5141                             D020_r2_PD173955  -2.888575172 -0.6536502656
## 5142                   D020_r2_PD184352 (CI-1040)  -0.801090049 -1.2954509359
## 5143                             D020_r2_PD318088  -1.623991701 -0.7262390430
## 5144                              D020_r2_PD98059  -1.284842107 -0.5666180919
## 5145                  D020_r2_Pelitinib (EKB-569)  -3.417922719 -0.8777001547
## 5146                          D020_r2_PF-00562271  -8.616566006 -1.8365125742
## 5147                          D020_r2_PF-04217903  -1.460224866 -1.7024291908
## 5148                          D020_r2_PF-04691502   3.508178281 -2.3327470883
## 5149                            D020_r2_PF-431396  -5.347757255  0.4910311456
## 5150                           D020_r2_PF-4708671  -4.926967731 -0.3375017183
## 5151                           D020_r2_PF-5274857  -1.473019486 -1.3591933307
## 5152                            D020_r2_PF-562271   5.131254740  2.6855444901
## 5153                            D020_r2_PF-573228  -0.279813524  0.0124046997
## 5154                            D020_r2_PH-797804  -1.544159307 -1.3441165071
## 5155                           D020_r2_PHA-665752   1.380702674 -0.0078578723
## 5156                           D020_r2_PHA-680632  -5.193978484  0.3011598276
## 5157                           D020_r2_PHA-767491  -3.875993880 -1.4279822102
## 5158                           D020_r2_PHA-793887  -4.504083754  0.2209731158
## 5159                       D020_r2_Phenformin HCl  -0.905860655 -0.7350111652
## 5160                              D020_r2_PHT-427   1.127098187 -2.3240696247
## 5161                          D020_r2_Piceatannol   1.447108358 -1.2455582664
## 5162                              D020_r2_PIK-293  -1.232104600 -2.5160265875
## 5163                              D020_r2_PIK-294   0.597463718 -2.8523231846
## 5164                               D020_r2_PIK-93  -2.837797850 -0.9127312790
## 5165               D020_r2_Pimasertib (AS-703026)   0.975528887 -0.9220416049
## 5166                          D020_r2_Pirfenidone  -0.700018303 -0.9182576562
## 5167                             D020_r2_PLX-4720   0.138820259 -2.3052943160
## 5168                              D020_r2_PLX7904  -0.815671054 -1.9611106494
## 5169                  D020_r2_Ponatinib (AP24534)  -1.253607254 -0.6079259942
## 5170                                  D020_r2_PP1   2.199336516 -2.8639552296
## 5171                                  D020_r2_PP2   2.373073021 -1.1930141013
## 5172                                D020_r2_PP242  -3.286119588 -1.2250989378
## 5173                               D020_r2_PQ 401   0.994861356 -1.2532334780
## 5174                              D020_r2_PRI-724  -0.240097312 -1.9723947319
## 5175     D020_r2_PRT062607 (P505-15, BIIB057) HCl  -2.859466962 -1.1256875895
## 5176                         D020_r2_Purvalanol A   0.229991499 -0.4909330510
## 5177                            D020_r2_Quercetin  -0.798139485 -1.4826299833
## 5178                  D020_r2_Quizartinib (AC220)  -2.409857385 -0.2867320772
## 5179                                 D020_r2_R406  -2.416720471 -1.3483803369
## 5180                     D020_r2_R406 (free base)  -3.258782944 -1.0435871920
## 5181                                 D020_r2_R547  -4.463912880 -1.4860525563
## 5182                    D020_r2_RAF265 (CHIR-265)  -3.525937698 -1.4405047712
## 5183                D020_r2_Rapamycin (Sirolimus)   0.949720512 -1.1265095215
## 5184   D020_r2_Refametinib (RDEA119, Bay 86-9766)  -2.949578017 -1.0835833030
## 5185                               D020_r2_RepSox   2.073102921 -1.2234492940
## 5186 D020_r2_Ridaforolimus (Deforolimus, MK-8669)  -0.859735924 -1.0858571521
## 5187                D020_r2_Rigosertib (ON-01910)  -7.620611263  0.8129234135
## 5188                             D020_r2_RKI-1447  -2.723175527 -1.9432397622
## 5189                                D020_r2_RN486  -2.407779730 -1.2968068752
## 5190                  D020_r2_Ro 31-8220 Mesylate  -6.230783767  0.1545788969
## 5191                              D020_r2_Ro-3306   0.092623566 -2.4237891241
## 5192                               D020_r2_Ro3280  -7.427430037  0.3342362878
## 5193                            D020_r2_RO4929097  -0.419914508 -2.2886517655
## 5194      D020_r2_Roscovitine (Seliciclib,CYC202)  -2.233420386 -1.3874521498
## 5195             D020_r2_Ruxolitinib (INCB018424)  -0.686644569 -1.9325256990
## 5196           D020_r2_S-Ruxolitinib (INCB018424)   0.050657352 -2.1345265619
## 5197                               D020_r2_SANT-1   0.309337322 -0.9411746486
## 5198                            D020_r2_SAR131675  -0.062063818 -1.0758441448
## 5199                    D020_r2_SAR245409 (XL765)  -1.896940345 -2.1386563255
## 5200                D020_r2_Saracatinib (AZD0530)   2.039330763 -0.2691012802
## 5201                      D020_r2_SB202190 (FHPI)  -2.988733248 -1.3321034756
## 5202                             D020_r2_SB203580  -2.055180757 -2.4976419901
## 5203                             D020_r2_SB216763  -3.536052319 -0.4714739226
## 5204                             D020_r2_SB239063   1.469555630 -1.6543194729
## 5205                             D020_r2_SB415286  -1.356976810 -2.6111151417
## 5206                             D020_r2_SB431542   0.944094554 -1.3613026965
## 5207                             D020_r2_SB505124  -2.120069834 -1.3974608922
## 5208                             D020_r2_SB525334   0.410855863 -1.7068484606
## 5209                             D020_r2_SB590885  -1.991386286 -1.2131186766
## 5210                                  D020_r2_SC1  -2.056320488 -1.4060394597
## 5211                D020_r2_Schisandrin B (Sch B)  -3.358705210 -0.8142154876
## 5212                D020_r2_Selumetinib (AZD6244)  -0.018000180 -0.4709037780
## 5213              D020_r2_Semagacestat (LY450139)  -0.193468870 -1.9597138055
## 5214                   D020_r2_Semaxanib (SU5416)   1.467004204 -0.9500781784
## 5215                             D020_r2_SGI-7079  -5.093644614 -1.5890059601
## 5216                          D020_r2_Skepinone-L   1.936381398 -2.8334035489
## 5217                               D020_r2_SL-327   0.935550257 -2.7710067256
## 5218                 D020_r2_SNS-032 (BMS-387032)   0.892372789  0.1123126977
## 5219                     D020_r2_SNS-314 Mesylate  -9.266140157 -0.1877628733
## 5220                            D020_r2_Sorafenib   1.789261263 -2.9869045286
## 5221                   D020_r2_Sorafenib Tosylate  -3.518539415 -1.5619685944
## 5222                         D020_r2_Sotrastaurin  -1.032547860 -1.3084457175
## 5223                             D020_r2_SP600125  -0.230017966 -3.1600271068
## 5224                              D020_r2_SU11274  -0.752237431 -0.6663810668
## 5225                               D020_r2_SU6656   1.883072658 -0.4904161751
## 5226                               D020_r2_SU9516  -4.162485118 -0.2207009135
## 5227                     D020_r2_Sunitinib Malate   2.914909900 -1.2437011560
## 5228                  D020_r2_TAE226 (NVP-TAE226)  -3.161593860 -0.0205080262
## 5229                              D020_r2_TAK-285   3.369397721 -1.4519303797
## 5230                              D020_r2_TAK-632  -2.785609470 -0.9680503249
## 5231                              D020_r2_TAK-715   1.662626179 -1.9797206761
## 5232                              D020_r2_TAK-733   3.328946330 -0.2238729623
## 5233                              D020_r2_TAK-901  -6.417402440 -2.2150172966
## 5234                D020_r2_Taladegib (LY2940680)  -1.275360139 -1.9794410348
## 5235                              D020_r2_TCS 359  -1.045346224 -1.0820416368
## 5236                               D020_r2_TDZD-8  -0.478440652 -1.2788038767
## 5237                            D020_r2_Telatinib  -1.151616455 -1.5212987517
## 5238   D020_r2_Temsirolimus (CCI-779, NSC 683864)   1.442480583 -1.3072286348
## 5239              D020_r2_Tepotinib (EMD 1214063)  -7.637778241 -1.5283997262
## 5240                                D020_r2_TG003   2.761385556 -2.2600513200
## 5241                            D020_r2_TG100-115   0.120038032 -1.3124296266
## 5242                             D020_r2_TG101209  -8.533398051 -0.1178550446
## 5243                 D020_r2_TG101348 (SAR302503)  -8.290424594 -0.0288545959
## 5244                              D020_r2_TGX-221  -1.212010095 -1.4330198935
## 5245                         D020_r2_Theophylline   0.775029792 -1.5690896775
## 5246                          D020_r2_Thiazovivin   0.863259867 -0.1946126211
## 5247                       D020_r2_TIC10 Analogue   3.010020323  0.6887139425
## 5248                           D020_r2_Tideglusib   1.351532391 -1.1073421141
## 5249                 D020_r2_Tivantinib (ARQ 197) -10.020431295 -1.2875763432
## 5250                   D020_r2_Tivozanib (AV-951)   0.043588209 -2.3220207385
## 5251  D020_r2_Tofacitinib (CP-690550,Tasocitinib)  -1.363708636 -1.6681089398
## 5252      D020_r2_Tofacitinib (CP-690550) Citrate  -1.611537134 -1.2378259775
## 5253                              D020_r2_Torin 2  -9.119361639 -1.2040140858
## 5254              D020_r2_Trametinib (GSK1120212)  -2.101685396 -2.4455323033
## 5255                          D020_r2_Triciribine  -1.853972679  0.3494978015
## 5256           D020_r2_TSU-68 (SU6668, Orantinib)  -1.274230055 -1.0949077955
## 5257                               D020_r2_TWS119  -0.276910783 -1.7952906006
## 5258                         D020_r2_Tyrphostin 9  -4.598523861 -1.2439958236
## 5259                   D020_r2_Tyrphostin AG 1296  -1.188790965 -2.5625741052
## 5260                           D020_r2_U0126-EtOH   0.428374742 -0.7195228718
## 5261     D020_r2_Ulixertinib (BVD-523, VRT752271)  -0.595060812 -0.8466259404
## 5262              D020_r2_Uprosertib (GSK2141795)  -5.247842554 -0.8823786171
## 5263                          D020_r2_Vacquinol-1  -3.096340626  0.1533892172
## 5264                           D020_r2_Varlitinib  -0.660194291 -1.0073018913
## 5265              D020_r2_Vatalanib (PTK787) 2HCl  -0.370844225 -2.0876639841
## 5266                               D020_r2_VE-821  -1.580584585 -1.6149067791
## 5267                               D020_r2_VE-822  -9.651300261 -0.4535343828
## 5268        D020_r2_Vemurafenib (PLX4032, RG7204)   0.038209812 -2.3387110640
## 5269                D020_r2_Vismodegib (GDC-0449)   2.225784379 -3.2153763062
## 5270                 D020_r2_Volasertib (BI 6727)   1.285429827 -1.1739747217
## 5271                            D020_r2_VPS34-IN1  -6.798622633 -0.7539060917
## 5272                     D020_r2_VS-5584 (SB2343)  -5.368176614 -0.5238774560
## 5273                               D020_r2_VX-11e   1.363301698 -0.9270627632
## 5274         D020_r2_VX-680 (Tozasertib, MK-0457)  -7.917888523  1.3679266576
## 5275                               D020_r2_VX-702  -0.323459530 -1.6676335918
## 5276                               D020_r2_VX-745  -0.594013468 -0.8567336306
## 5277                              D020_r2_WAY-600  -2.170006291 -0.8393966818
## 5278                             D020_r2_WH-4-023   0.083729962 -2.5496693242
## 5279                             D020_r2_WHI-P154   1.344598113 -2.5596186981
## 5280                                D020_r2_WIKI4   0.454971422 -1.4002628303
## 5281                        D020_r2_Wnt agonist 1  -9.589426445 -0.8860076539
## 5282                        D020_r2_Wnt-C59 (C59)  -0.093480918 -2.1718893930
## 5283                               D020_r2_WP1066  -0.874760498 -1.3205461162
## 5284                 D020_r2_WYE-125132 (WYE-132)  -1.056254927 -0.8114780701
## 5285                              D020_r2_WYE-354  -1.855734507 -1.6560687519
## 5286                               D020_r2_WZ3146   1.484743865 -0.7880068303
## 5287                               D020_r2_WZ4002   0.090833098 -2.1849833962
## 5288                               D020_r2_WZ4003   0.102584997 -2.1068791621
## 5289                               D020_r2_WZ8040   1.656305383 -3.0215041391
## 5290                              D020_r2_XAV-939  -1.460110498 -2.3481519651
## 5291                                D020_r2_XL019  -2.242675605 -1.4948675316
## 5292                              D020_r2_XMD8-92  -1.460983597 -0.1988014451
## 5293                         D020_r2_Y-27632 2HCl   1.435668727 -2.1740020603
## 5294                             D020_r2_YM201636  -4.230356391  0.7794036102
## 5295                             D020_r2_YO-01027  -0.393065625 -1.1368697381
## 5296                            D020_r2_ZM 306416   3.649177837 -2.7053464531
## 5297                        D020_r2_ZM 323881 HCl   2.512954662 -2.0703206347
## 5298                            D020_r2_ZM 336372   0.807597277 -1.6667967491
## 5299                         D020_r2_ZM 39923 HCl   0.173671576 -1.4583367307
## 5300                            D020_r2_ZM 447439  -6.347095179 -0.1705584021
## 5301                 D020_r2_Zotarolimus(ABT-578)   3.242833103 -0.4145039314
## 5302                              D020_r2_ZSTK474  -3.297997315 -0.5403422213
## 5303                     D022_r1_1-Azakenpaullone  -6.349019186  1.6835578703
## 5304                      D022_r1_3-Methyladenine  -8.788605742  0.1874467021
## 5305                             D022_r1_A-674563 -30.205354590  3.3120034301
## 5306                             D022_r1_A-769662  -4.900440134  1.0091668066
## 5307                                  D022_r1_A66  -3.106055880  2.7876229423
## 5308                            D022_r1_Acadesine  -3.362798098  0.8689693480
## 5309                  D022_r1_AEE788 (NVP-AEE788) -12.692124399  2.4932648347
## 5310        D022_r1_Afatinib (BIBW2992)_uncertain  -4.309613944 -0.2714054898
## 5311                              D022_r1_AG-1024  -5.416407982  1.0684665756
## 5312         D022_r1_AG-1478 (Tyrphostin AG-1478)  -2.345993755  0.5214762341
## 5313                                D022_r1_AG-18  -3.769552466  1.4254216545
## 5314              D022_r1_AG-490 (Tyrphostin B42)  -4.478497503 -0.3538771316
## 5315                             D022_r1_Akti-1/2   0.162486809  3.0832251250
## 5316                  D022_r1_Alisertib (MLN8237) -26.701072998  2.6697506895
## 5317                              D022_r1_AMG 337  -7.949226359  2.0281576317
## 5318                              D022_r1_AMG-458  -4.917348785  1.3814717536
## 5319                              D022_r1_AMG-900 -32.198783953  4.0971621547
## 5320                               D022_r1_AMG319  -4.037659810  1.3609915380
## 5321                  D022_r1_Amuvatinib (MP-470)  -4.662902011  0.8023272972
## 5322                             D022_r1_Apatinib  -3.536526015  2.1228031531
## 5323                           D022_r1_AR-A014418  -4.358276245  0.6894291211
## 5324                            D022_r1_AS-252424  -7.065636939  0.4065594300
## 5325                            D022_r1_AS-604850  -2.546483483  0.9443859166
## 5326                         D022_r1_Asiatic Acid  -7.180711182  0.2349914065
## 5327                             D022_r1_AST-1306   0.933362978  1.7710229013
## 5328                              D022_r1_AT13148  -0.981227145  3.2180819799
## 5329                               D022_r1_AT7519 -28.446649210  2.3620469984
## 5330                               D022_r1_AT7867   1.920108511  3.9884052883
## 5331                               D022_r1_AT9283 -33.798959487  3.2058181441
## 5332                 D022_r1_Aurora A Inhibitor I -24.764896797  3.7320045475
## 5333             D022_r1_Avagacestat (BMS-708163)  -4.495009669  1.2120558762
## 5334                              D022_r1_AVL-292  -7.236850917  1.2674308193
## 5335                             D022_r1_Axitinib  -7.130850053  2.2808857584
## 5336                             D022_r1_Axitinib  -7.130850053  2.2808857584
## 5337                               D022_r1_AZ 628  -5.688356404  2.2052833840
## 5338                               D022_r1_AZ 960  -8.472543592  0.4159518471
## 5339                                 D022_r1_AZ20 -17.576512597  5.4092245994
## 5340                              D022_r1_AZD1080  -6.993332810  0.2064119108
## 5341                              D022_r1_AZD1480 -26.736947305  2.2925297314
## 5342                              D022_r1_AZD2014   2.667907119  2.0675221192
## 5343                              D022_r1_AZD2858 -19.528184041  1.9095616406
## 5344                              D022_r1_AZD2932  -5.791619254  0.6928530403
## 5345                              D022_r1_AZD3759  -3.131799262  2.1409907505
## 5346                              D022_r1_AZD5363  -0.278156670  2.1592004705
## 5347                              D022_r1_AZD5438 -18.613981618  5.1190484615
## 5348                              D022_r1_AZD6482  -4.735089693 -0.6186786174
## 5349                              D022_r1_AZD6738 -24.480574782  3.5371468225
## 5350                              D022_r1_AZD8055   1.683691276  4.2083778967
## 5351                              D022_r1_AZD8330   2.291466449  1.7544739032
## 5352                  D022_r1_AZD8931 (Sapitinib)   0.731733254  4.1234792596
## 5353                              D022_r1_AZD9291 -19.934884020  6.1888827235
## 5354            D022_r1_Barasertib (AZD1152-HQPA) -26.541125564  3.1983099994
## 5355  D022_r1_Baricitinib (LY3009104, INCB028050)  -4.428902104  1.3267574537
## 5356                  D022_r1_BGT226 (NVP-BGT226) -35.519546932  3.7193657865
## 5357                              D022_r1_BI 2536 -33.104423226  3.2386886246
## 5358                              D022_r1_BI-78D3  -7.862422620  1.0450920160
## 5359                             D022_r1_BI-D1870  -8.041105298  1.6198416362
## 5360                              D022_r1_Bikinin  -4.456377666  1.1330946101
## 5361                                  D022_r1_BIO  -6.438071316  0.9983708809
## 5362               D022_r1_BIRB 796 (Doramapimod)  -7.524484551  0.4542192661
## 5363                            D022_r1_BIX 02188  -4.587929759 -0.1490964088
## 5364                            D022_r1_BIX 02189  -5.965483165  0.3230978794
## 5365      D022_r1_BKM120 (NVP-BKM120, Buparlisib) -22.851574214  4.3885254783
## 5366                           D022_r1_BMS-265246  -5.075403949  2.6132870670
## 5367                           D022_r1_BMS-536924  -7.884027333  3.4659286095
## 5368                           D022_r1_BMS-582949  -4.262606486 -0.3538493212
## 5369                           D022_r1_BMS-754807 -10.442085242  4.6892145153
## 5370                           D022_r1_BMS-777607  -2.552222121  0.1579368012
## 5371                           D022_r1_BMS-794833  -5.523357740  1.7566338218
## 5372                           D022_r1_BMS-833923  -3.795922519  0.3595019323
## 5373                  D022_r1_Bosutinib (SKI-606)   3.621643528  3.8083130331
## 5374                D022_r1_Brivanib (BMS-540215)  -7.898918149  1.8926572975
## 5375      D022_r1_Brivanib Alaninate (BMS-582664)  -2.442239753  1.3658103023
## 5376                           D022_r1_BS-181 HCl  -8.675151396  1.1209452984
## 5377                               D022_r1_Butein  -6.285536574  0.6761833838
## 5378                               D022_r1_BYL719   1.546042319  2.7751098382
## 5379     D022_r1_Cabozantinib (XL184, BMS-907351)  -6.563487298  1.7957461159
## 5380          D022_r1_Cabozantinib malate (XL184)  -6.795819827  1.2275430021
## 5381        D022_r1_CAL-101 (Idelalisib, GS-1101)  -1.099129928  0.5529509840
## 5382                             D022_r1_CAY10505  -5.009577488 -0.3279466410
## 5383                               D022_r1_CC-223   2.962274686  1.8219824601
## 5384                            D022_r1_CCT128930  -1.952120327  2.0095572885
## 5385                  D022_r1_Cediranib (AZD2171)  -6.845806492  3.1385799271
## 5386                            D022_r1_CEP-32496  -0.618769524 -0.7786336070
## 5387                            D022_r1_CEP-33779  -4.317183182  0.5476071791
## 5388                              D022_r1_CGI1746  -4.912036684  1.9851465618
## 5389                              D022_r1_CGK 733  -4.043755601  1.0017260874
## 5390                            D022_r1_CH5132799   0.720444323  0.9154594429
## 5391                           D022_r1_CHIR-98014 -12.712710585  2.1129876104
## 5392                 D022_r1_CHIR-99021 (CT99021)  -5.471349602  1.0962766051
## 5393             D022_r1_CHIR-99021 (CT99021) HCl  -5.428769551  1.9167676231
## 5394                    D022_r1_Chrysophanic Acid  -7.993653585  0.6909418738
## 5395                             D022_r1_CNX-2006   1.971143826  5.4480837396
## 5396                              D022_r1_CNX-774  -7.432820892 -0.8197890273
## 5397                    D022_r1_CO-1686 (AVL-301)  -5.823960368  1.5730127468
## 5398       D022_r1_Cobimetinib (GDC-0973, RG7420)  -0.340194206  4.6843957158
## 5399                            D022_r1_CP-673451 -14.259876630  5.5143443459
## 5400                            D022_r1_CP-724714  -3.868196841  1.5957561853
## 5401               D022_r1_Crenolanib (CP-868596) -15.844504956  4.7344089511
## 5402             D022_r1_Crizotinib (PF-02341066) -36.642985213  3.3300048141
## 5403                               D022_r1_CYC116 -19.041782379  4.0107671147
## 5404                               D022_r1_CYT387  -3.604115847  0.0468298362
## 5405                             D022_r1_CZC24832  -3.711258903  0.4783837092
## 5406              D022_r1_Dabrafenib (GSK2118436)  -9.987546665  0.2648618431
## 5407        D022_r1_Dacomitinib (PF299804, PF299)  -8.013344062  5.7274608144
## 5408              D022_r1_Danusertib (PHA-739358) -25.549231232  3.4500693283
## 5409                        D022_r1_DAPT (GSI-IX)  -4.247419944  1.2814575087
## 5410                            D022_r1_Dasatinib  -4.909306794 -0.4374746699
## 5411                D022_r1_DCC-2036 (Rebastinib)  -7.126423673  2.6783406638
## 5412                D022_r1_Decernotinib (VX-509)  -5.924855893  0.4129580020
## 5413               D022_r1_Dinaciclib (SCH727965) -32.146787154  4.6882253047
## 5414    D022_r1_Dovitinib (TKI-258) Dilactic Acid -41.021575440  5.2663237930
## 5415                            D022_r1_ENMD-2076 -15.330359410  2.5396259422
## 5416               D022_r1_Enzastaurin (LY317615)  -7.911624885  0.4517593949
## 5417                            D022_r1_ERK5-IN-1  -5.130730128  6.6840876888
## 5418                             D022_r1_ETC-1002  -6.371928371 -0.3923615653
## 5419                            D022_r1_ETP-46464  -3.463139584  1.2651835693
## 5420                  D022_r1_Everolimus (RAD001)  -1.068048630  0.5413883023
## 5421                D022_r1_Fasudil (HA-1077) HCl  -3.147518415 -0.3123922789
## 5422                                D022_r1_FH535  -0.444562024  0.8575552489
## 5423                D022_r1_Filgotinib (GLPG0634)  -6.179548572  1.6384222536
## 5424             D022_r1_Flavopiridol (Alvocidib) -35.771692123  3.0072733048
## 5425                     D022_r1_Flavopiridol HCl -30.573449523  2.8225590352
## 5426               D022_r1_Foretinib (GSK1363089) -11.933582833 -0.2100269816
## 5427                  D022_r1_Fostamatinib (R788) -12.054469329 -0.0328369748
## 5428                                D022_r1_G-749  -6.946302028  1.4755469198
## 5429                             D022_r1_GDC-0068  -3.994181469  2.8936948867
## 5430                             D022_r1_GDC-0349   0.230179916  0.1167773991
## 5431                             D022_r1_GDC-0879  -6.505153106  1.7737114705
## 5432                             D022_r1_GDC-0941  -2.334194335  1.0936242724
## 5433                    D022_r1_GDC-0980 (RG7422)   3.008756368  4.2972983781
## 5434                   D022_r1_Gefitinib (ZD1839)   3.694482583  1.7387009357
## 5435                            D022_r1_Genistein  -2.381642596 -2.0057773084
## 5436                            D022_r1_GF109203X  -5.807157665  1.3923899018
## 5437                                D022_r1_GNF-2  -9.070014336 -0.2097707197
## 5438                                D022_r1_GNF-5  -5.142245107  0.9633925369
## 5439                              D022_r1_Go 6983  -4.800286164  4.1942172819
## 5440                   D022_r1_Golvatinib (E7050) -33.753485452  5.0594238120
## 5441                          D022_r1_GSK1838705A  -0.271274392  5.2556668039
## 5442                          D022_r1_GSK1904529A  -1.825476791 -0.5318480297
## 5443                  D022_r1_GSK2126458 (GSK458)   0.740078928  3.9354943973
## 5444                           D022_r1_GSK2292767  -4.084021043  3.4939834043
## 5445                           D022_r1_GSK2636771  -9.397521592  1.3272214708
## 5446                           D022_r1_GSK429286A  -2.906894498  1.8077761011
## 5447                            D022_r1_GSK461364 -26.287168049  2.2444721304
## 5448                               D022_r1_GSK621  -4.500452454  0.0835730332
## 5449                            D022_r1_GSK690693  -5.197660618  2.1965292397
## 5450                               D022_r1_GW5074  -4.495091603 -0.8310706871
## 5451                             D022_r1_GW788388  -4.423836183  0.4884320989
## 5452                               D022_r1_GZD824  -6.933393008  2.7936101111
## 5453                            D022_r1_H 89 2HCl  -4.475868466 -0.0854147522
## 5454                           D022_r1_Hesperadin   2.451529352  5.5914442804
## 5455                              D022_r1_HMN-214 -21.817892876  0.7629539860
## 5456                             D022_r1_Honokiol  -5.620788476  0.6029280944
## 5457                               D022_r1_HS-173 -23.460614382  4.4231185987
## 5458                           D022_r1_HTH-01-015 -26.770232758  2.0879464829
## 5459                D022_r1_Ibrutinib (PCI-32765)  -1.266954090  0.8230903926
## 5460                              D022_r1_ICG-001  -3.669068569  1.5529764588
## 5461                             D022_r1_Icotinib  -7.104208595  0.6795812626
## 5462                                D022_r1_IM-12  -5.876170123 -0.1421349603
## 5463           D022_r1_Imatinib Mesylate (STI571)  -3.717223603  1.5920268880
## 5464                            D022_r1_Indirubin  -5.652517785  1.6713527983
## 5465                    D022_r1_INK 128 (MLN0128)   6.611405642  2.9300870309
## 5466                    D022_r1_IPI-145 (INK1197)  -3.758464166 -0.4851833820
## 5467                               D022_r1_IWP-L6  -5.588184365  0.3384942312
## 5468                           D022_r1_IWR-1-endo  -9.533679099  1.2333829498
## 5469                         D022_r1_JNJ-38877605  -1.539047873 -0.7873442785
## 5470                          D022_r1_JNJ-7706621 -20.408740166  6.8357661670
## 5471                     D022_r1_JNK Inhibitor IX -29.258841224  2.5264556151
## 5472                             D022_r1_JNK-IN-8  -9.257022066  3.5414729281
## 5473                               D022_r1_K02288  -4.775687905  0.2782003443
## 5474                               D022_r1_Ki8751  -5.346234638  1.9558050256
## 5475                              D022_r1_KRN 633  -2.190397575  0.3379316558
## 5476                           D022_r1_KU-0063794   2.463778632  0.5587186000
## 5477      D022_r1_KU-55933 (ATM Kinase Inhibitor)  -5.049836986  0.7709405886
## 5478                             D022_r1_KU-60019  -7.761264996  2.9319556247
## 5479                              D022_r1_KW-2449 -12.648366088  4.1561753320
## 5480                              D022_r1_KX2-391 -28.167494001  4.5213015008
## 5481                              D022_r1_KY02111  -5.493076699  1.2267868587
## 5482                            D022_r1_Lapatinib  -5.004450621  0.8581514273
## 5483     D022_r1_Lapatinib (GW-572016) Ditosylate  -6.224299473  0.5113900493
## 5484                            D022_r1_LDC000067 -17.190366120  3.1757303975
## 5485      D022_r1_LDE225 (NVP-LDE225,Erismodegib)  -2.367479539  0.3459533051
## 5486                           D022_r1_LDN-214117  -9.635848243  0.2484601850
## 5487                   D022_r1_Lenvatinib (E7080)  -3.990875988  0.2380310530
## 5488                              D022_r1_LFM-A13  -4.055878833  0.6569028363
## 5489                              D022_r1_LGK-974  -4.885784483  0.7621604359
## 5490                  D022_r1_Linifanib (ABT-869)  -4.246099882  0.4702072963
## 5491                               D022_r1_LJH685  -7.643757195  1.3110245006
## 5492                               D022_r1_LJI308  -6.327325326  1.0640789978
## 5493               D022_r1_Losmapimod (GW856553X)  -6.043126627  1.0277883642
## 5494                            D022_r1_LY2090314  -5.964543003  2.4561741628
## 5495                            D022_r1_LY2157299  -3.820210665  0.9378162855
## 5496                            D022_r1_LY2784544 -13.832388730  2.7570871861
## 5497                            D022_r1_LY2835219  -9.314306192  4.0578922827
## 5498                             D022_r1_LY294002  -3.915595127  0.6397651254
## 5499                            D022_r1_LY3023414  -0.315581903  3.2309408696
## 5500                             D022_r1_LY411575  -2.390298089  0.4083464209
## 5501       D022_r1_MEK162 (ARRY-162, ARRY-438162)   0.103389313  3.1033741067
## 5502                             D022_r1_MGCD-265  -3.897670457  0.9357565310
## 5503               D022_r1_Milciclib (PHA-848125) -41.640994436  5.1909290404
## 5504                              D022_r1_MK-0752  -4.077303239  1.2240545905
## 5505                         D022_r1_MK-2206 2HCl  -2.362629476  3.7046211906
## 5506                              D022_r1_MK-2461  -7.353153755  1.3690275435
## 5507                     D022_r1_MK-5108 (VX-689) -28.081649546  3.8039331555
## 5508                              D022_r1_MK-8745 -26.263248368  2.1524498259
## 5509                              D022_r1_MLN2480  -5.372725311  1.2735527867
## 5510                              D022_r1_MLN8054  -3.033266892 -0.5677799720
## 5511      D022_r1_Motesanib Diphosphate (AMG-706)  -5.522330430  0.9322351365
## 5512                  D022_r1_Nilotinib (AMN-107)  -6.237614763  1.1255144719
## 5513     D022_r1_Nintedanib (BIBF 1120)_uncertain  -8.458645061  1.7355821680
## 5514                               D022_r1_NU6027  -6.830324580  0.7508339144
## 5515                           D022_r1_NVP-AEW541 -27.903867017  3.2630922158
## 5516                           D022_r1_NVP-BHG712  -7.409419815  0.3537626383
## 5517                      D022_r1_NVP-BSK805 2HCl  -6.927997753  2.6722171161
## 5518                           D022_r1_NVP-BVU972  -5.755687378  0.4346761931
## 5519                          D022_r1_Oclacitinib  -5.467054524  0.0031645394
## 5520      D022_r1_Olmutinib (HM61713, BI 1482694)  -7.271254891  1.6047335899
## 5521                             D022_r1_ONO-4059  -3.073770293  1.4669008120
## 5522                              D022_r1_OSI-027   0.827926017  1.9642606850
## 5523                              D022_r1_OSI-420   8.808171628  2.2740958846
## 5524                 D022_r1_OSI-906 (Linsitinib)   2.649791015  2.8975093897
## 5525                              D022_r1_P276-00 -25.322067014  4.2376687975
## 5526                  D022_r1_Pacritinib (SB1518) -38.401608215  3.3218039867
## 5527                   D022_r1_Palomid 529 (P529)  -3.288092351  2.4721730281
## 5528                            D022_r1_Pazopanib -13.766232721  0.1617706401
## 5529                        D022_r1_Pazopanib HCl  -3.711881250 -0.0596709732
## 5530                            D022_r1_PD0325901   2.629371984  4.0763551706
## 5531                             D022_r1_PD168393  -4.019570344  2.4211013657
## 5532                             D022_r1_PD173955 -11.851810688  0.1529986575
## 5533                   D022_r1_PD184352 (CI-1040)  -3.197179215  1.1547603493
## 5534                             D022_r1_PD318088  -1.456894311  3.0337115540
## 5535                              D022_r1_PD98059  -1.857006400  0.6793267134
## 5536                  D022_r1_Pelitinib (EKB-569)  -6.798142651  2.9306931537
## 5537                          D022_r1_PF-00562271 -22.131271038  6.0425209003
## 5538                          D022_r1_PF-04217903  -7.146455766  0.9992837663
## 5539                          D022_r1_PF-04691502   4.443698273  1.8939978260
## 5540                            D022_r1_PF-431396 -19.287600383  5.0963828264
## 5541                           D022_r1_PF-4708671 -21.968645286  2.3319574588
## 5542                           D022_r1_PF-5274857  -7.504635708  1.5937337403
## 5543                            D022_r1_PF-562271 -15.950719729  5.6306337437
## 5544                            D022_r1_PF-573228  -0.003030485  1.6809405286
## 5545                            D022_r1_PH-797804  -2.803194759 -0.1788726823
## 5546                           D022_r1_PHA-665752  -6.062314988  2.5692103802
## 5547                           D022_r1_PHA-680632 -25.376415183  3.9925428812
## 5548                           D022_r1_PHA-767491 -22.606164834  4.9861622255
## 5549                           D022_r1_PHA-793887 -15.683294167  5.1935021264
## 5550                       D022_r1_Phenformin HCl  -2.681277662  0.4906161565
## 5551                              D022_r1_PHT-427  -2.836945956 -0.1853108910
## 5552                          D022_r1_Piceatannol  -0.719457758  1.2948725660
## 5553                              D022_r1_PIK-293  -1.221664887  1.8113402454
## 5554                              D022_r1_PIK-294  -9.013023354  0.3779629960
## 5555                               D022_r1_PIK-93  -3.694594528  2.5565101649
## 5556               D022_r1_Pimasertib (AS-703026)   4.361421464  4.6896166486
## 5557                          D022_r1_Pirfenidone  -2.322479322  0.8712873470
## 5558                             D022_r1_PLX-4720  -3.611389774  0.3586969214
## 5559                              D022_r1_PLX7904  -7.191228958  0.7755608649
## 5560                  D022_r1_Ponatinib (AP24534)  -1.808942839  2.4973363659
## 5561                                  D022_r1_PP1  -9.294239808 -0.1123256491
## 5562                                  D022_r1_PP2  -9.914361129 -0.0402419118
## 5563                                D022_r1_PP242   0.459704811  0.6268174780
## 5564                               D022_r1_PQ 401  -3.333840969  1.5524118392
## 5565                              D022_r1_PRI-724  -3.597806408  0.3120126735
## 5566     D022_r1_PRT062607 (P505-15, BIIB057) HCl  -2.898450536  3.9973020647
## 5567                         D022_r1_Purvalanol A  -8.434326849  3.1906686209
## 5568                            D022_r1_Quercetin  -7.319327445  0.0153535036
## 5569                  D022_r1_Quizartinib (AC220) -14.666655956  2.8201503383
## 5570                                 D022_r1_R406  -1.024934141 -0.2027099594
## 5571                     D022_r1_R406 (free base)  -3.867007846 -1.3538672410
## 5572                                 D022_r1_R547 -16.063739608  3.7613758506
## 5573                    D022_r1_RAF265 (CHIR-265)   2.153559352  3.5064289466
## 5574                D022_r1_Rapamycin (Sirolimus)  -4.039385337  0.0067946523
## 5575   D022_r1_Refametinib (RDEA119, Bay 86-9766)   1.933200012  1.5984597866
## 5576                               D022_r1_RepSox  -4.408508052  1.6057759039
## 5577 D022_r1_Ridaforolimus (Deforolimus, MK-8669)   1.944842782  2.2734761433
## 5578                D022_r1_Rigosertib (ON-01910) -24.768596767  4.6324284283
## 5579                             D022_r1_RKI-1447  -5.279675253  0.5805036393
## 5580                                D022_r1_RN486  -7.971767678  0.0697342449
## 5581                  D022_r1_Ro 31-8220 Mesylate  -3.777906073  4.1029311769
## 5582                              D022_r1_Ro-3306  -3.683404466  0.0644223080
## 5583                               D022_r1_Ro3280 -15.995447784  3.7016568893
## 5584                            D022_r1_RO4929097  -3.649226311  0.7643285575
## 5585      D022_r1_Roscovitine (Seliciclib,CYC202)  -3.461902977  1.2783794174
## 5586             D022_r1_Ruxolitinib (INCB018424)  -3.419532106  0.4335505725
## 5587           D022_r1_S-Ruxolitinib (INCB018424)  -4.737419215  1.1422126201
## 5588                               D022_r1_SANT-1  -3.266018128  1.4007664407
## 5589                            D022_r1_SAR131675  -4.684025082  0.4318635018
## 5590                    D022_r1_SAR245409 (XL765)  -4.767842150  0.2485885846
## 5591                D022_r1_Saracatinib (AZD0530)   6.828171468  4.3361652338
## 5592                      D022_r1_SB202190 (FHPI)  -5.019213477  1.3204501524
## 5593                             D022_r1_SB203580  -4.538674492  1.0681920645
## 5594                             D022_r1_SB216763  -5.697165807  1.6823958743
## 5595                             D022_r1_SB239063  -7.473868510  1.1813443714
## 5596                             D022_r1_SB415286  -4.892091405  0.4505537367
## 5597                             D022_r1_SB431542  -5.183905879 -0.1140932374
## 5598                             D022_r1_SB505124  -7.799039213  1.3454937237
## 5599                             D022_r1_SB525334  -3.919429992  0.1968191733
## 5600                             D022_r1_SB590885  -7.400643833  1.4609530388
## 5601                                  D022_r1_SC1  -2.625706867  3.3238385039
## 5602                D022_r1_Schisandrin B (Sch B)  -5.049006544 -0.4037558793
## 5603                D022_r1_Selumetinib (AZD6244)   1.091338262  4.0268780721
## 5604              D022_r1_Semagacestat (LY450139)  -4.931360008  0.2657723989
## 5605                   D022_r1_Semaxanib (SU5416) -11.095541576  1.4862438512
## 5606                             D022_r1_SGI-7079 -14.743495137  3.8192645000
## 5607                          D022_r1_Skepinone-L  -3.900583544  0.0731011134
## 5608                               D022_r1_SL-327  -6.018228543  2.3681398705
## 5609                 D022_r1_SNS-032 (BMS-387032) -29.699053083  3.8658393356
## 5610                     D022_r1_SNS-314 Mesylate -27.783656502  3.4627054697
## 5611                            D022_r1_Sorafenib  -9.693483968  0.7257275907
## 5612                   D022_r1_Sorafenib Tosylate  -4.442176887  0.7689622147
## 5613                         D022_r1_Sotrastaurin  -3.345628255  0.5151366944
## 5614                             D022_r1_SP600125  -3.902708081  2.1784124164
## 5615                              D022_r1_SU11274  -9.578414309  2.1258677683
## 5616                               D022_r1_SU6656 -21.030223211  3.3727849008
## 5617                               D022_r1_SU9516 -13.850125590  3.9410504475
## 5618                     D022_r1_Sunitinib Malate  -0.240978415  2.4154511862
## 5619                  D022_r1_TAE226 (NVP-TAE226) -15.815419063  5.3181824852
## 5620                              D022_r1_TAK-285  -4.818590935  1.8099160121
## 5621                              D022_r1_TAK-632  -9.806709838  4.0033668013
## 5622                              D022_r1_TAK-715  -7.690159059  0.0803638323
## 5623                              D022_r1_TAK-733  -0.144600894  3.4312142528
## 5624                              D022_r1_TAK-901 -18.429163240  1.0921707580
## 5625                D022_r1_Taladegib (LY2940680)  -5.175216467  0.8901508794
## 5626                              D022_r1_TCS 359  -5.290535802  1.9614851519
## 5627                               D022_r1_TDZD-8 -11.240440791  0.5303569571
## 5628                            D022_r1_Telatinib  -7.377214243  0.2685591832
## 5629   D022_r1_Temsirolimus (CCI-779, NSC 683864)  -3.683541716  2.1252328155
## 5630              D022_r1_Tepotinib (EMD 1214063) -34.212991402  2.9299992799
## 5631                                D022_r1_TG003  -7.227486366  0.6099704398
## 5632                            D022_r1_TG100-115  -5.109778667  0.3681350966
## 5633                             D022_r1_TG101209 -35.923076783  2.8007511227
## 5634                 D022_r1_TG101348 (SAR302503) -31.876441757  3.5782039682
## 5635                              D022_r1_TGX-221  -1.475252358  3.3164164154
## 5636                         D022_r1_Theophylline  -4.511513654  0.6417477318
## 5637                          D022_r1_Thiazovivin  -1.218363746  1.3433070516
## 5638                       D022_r1_TIC10 Analogue  -4.564412349  0.7410038158
## 5639                           D022_r1_Tideglusib  -4.667235641 -0.2049992766
## 5640                 D022_r1_Tivantinib (ARQ 197) -27.222128744  2.3407588674
## 5641                   D022_r1_Tivozanib (AV-951)  -7.671340410  0.9169570378
## 5642  D022_r1_Tofacitinib (CP-690550,Tasocitinib)  -6.554334577  0.3855375221
## 5643      D022_r1_Tofacitinib (CP-690550) Citrate  -4.596001820  0.0038904743
## 5644                              D022_r1_Torin 2  -2.023200706  2.7027096990
## 5645              D022_r1_Trametinib (GSK1120212)   0.475842839  2.3250723229
## 5646                          D022_r1_Triciribine  -3.006160458  3.1983362853
## 5647           D022_r1_TSU-68 (SU6668, Orantinib)  -7.139427691  0.7848851894
## 5648                               D022_r1_TWS119  -4.586485114  0.7540287839
## 5649                         D022_r1_Tyrphostin 9  -8.577132645  1.5736369616
## 5650                   D022_r1_Tyrphostin AG 1296  -4.322558407  0.4820022901
## 5651                           D022_r1_U0126-EtOH  -1.111056612 -0.1488880733
## 5652     D022_r1_Ulixertinib (BVD-523, VRT752271)  -2.196895211  2.0317527194
## 5653              D022_r1_Uprosertib (GSK2141795)  -4.920143494  2.8342301435
## 5654                          D022_r1_Vacquinol-1 -21.542247616  3.8268779634
## 5655                           D022_r1_Varlitinib  -2.304172192  0.4090159366
## 5656              D022_r1_Vatalanib (PTK787) 2HCl  -5.694677154  0.6555598972
## 5657                               D022_r1_VE-821  -2.741777760  0.4855770239
## 5658                               D022_r1_VE-822 -21.617628384  4.0118758129
## 5659        D022_r1_Vemurafenib (PLX4032, RG7204)  -7.524400069  0.5921655101
## 5660                D022_r1_Vismodegib (GDC-0449)  -4.608075773 -0.5249985390
## 5661                 D022_r1_Volasertib (BI 6727)  -5.434689143  1.5975793711
## 5662                            D022_r1_VPS34-IN1  -6.220797200  3.4245363554
## 5663                     D022_r1_VS-5584 (SB2343)   4.560244449  3.2543706956
## 5664                               D022_r1_VX-11e   3.986417776  3.0562991018
## 5665         D022_r1_VX-680 (Tozasertib, MK-0457) -23.697376256  3.0060978955
## 5666                               D022_r1_VX-702  -4.755572390 -0.1268316257
## 5667                               D022_r1_VX-745  -3.564320250 -0.3529000822
## 5668                              D022_r1_WAY-600  -6.400508019  1.2630101725
## 5669                             D022_r1_WH-4-023  -7.630796119  0.0458521564
## 5670                             D022_r1_WHI-P154  -3.880123201  0.4740307618
## 5671                                D022_r1_WIKI4  -5.402237180  0.8656447873
## 5672                        D022_r1_Wnt agonist 1 -33.053820088  2.8689861687
## 5673                        D022_r1_Wnt-C59 (C59)  -4.038165768  0.4654989422
## 5674                               D022_r1_WP1066  -5.434771284  1.3588230437
## 5675                 D022_r1_WYE-125132 (WYE-132)   7.749922110  3.3542977460
## 5676                              D022_r1_WYE-354   3.941478438 -0.1057269229
## 5677                               D022_r1_WZ3146  -8.175495096  4.5576086720
## 5678                               D022_r1_WZ4002  -4.985733188 -0.2652216793
## 5679                               D022_r1_WZ4003  -5.402338701  0.2699488351
## 5680                               D022_r1_WZ8040  -7.940046004  1.3106930104
## 5681                              D022_r1_XAV-939  -7.727461258  1.6844546288
## 5682                                D022_r1_XL019  -9.070179163  0.8962617823
## 5683                              D022_r1_XMD8-92  -7.150662147  2.0553257159
## 5684                         D022_r1_Y-27632 2HCl  -7.428822780  0.2922155165
## 5685                             D022_r1_YM201636  -8.246501659  1.6273773244
## 5686                             D022_r1_YO-01027  -3.074742563  1.0341177609
## 5687                            D022_r1_ZM 306416  -4.249646807  0.9809213731
## 5688                        D022_r1_ZM 323881 HCl  -4.626596512  0.8711927711
## 5689                            D022_r1_ZM 336372  -3.525895656  0.9262320499
## 5690                         D022_r1_ZM 39923 HCl  -5.623691191  0.5389936161
## 5691                            D022_r1_ZM 447439 -15.043032597 -0.2416172517
## 5692                 D022_r1_Zotarolimus(ABT-578)  -2.565496616  2.1133300649
## 5693                              D022_r1_ZSTK474  -2.306088977  2.7153810412
## 5694                     D022_r2_1-Azakenpaullone  -9.771100098  0.0941922716
## 5695                      D022_r2_3-Methyladenine  -4.965197582  0.1660358259
## 5696                             D022_r2_A-674563 -13.355195974 -1.0521073570
## 5697                             D022_r2_A-769662  -5.819036672  0.7345263667
## 5698                                  D022_r2_A66  -4.754296239  1.1103211108
## 5699                            D022_r2_Acadesine  -5.633693927  0.5999308554
## 5700                  D022_r2_AEE788 (NVP-AEE788) -11.223051162  1.5238653729
## 5701        D022_r2_Afatinib (BIBW2992)_uncertain  -7.544791029 -0.2405135154
## 5702                              D022_r2_AG-1024  -5.508448066  0.2527302982
## 5703         D022_r2_AG-1478 (Tyrphostin AG-1478)  -4.818188424  0.8223996153
## 5704                                D022_r2_AG-18  -3.376834639 -1.2757474449
## 5705              D022_r2_AG-490 (Tyrphostin B42)  -4.459114979 -0.0475881561
## 5706                             D022_r2_Akti-1/2  -4.650960213  1.5309273106
## 5707                  D022_r2_Alisertib (MLN8237) -17.217022720 -0.1277404890
## 5708                              D022_r2_AMG 337  -8.275230363  0.3858889798
## 5709                              D022_r2_AMG-458  -3.051945896  0.4349706700
## 5710                              D022_r2_AMG-900 -13.390751504  0.6022985034
## 5711                               D022_r2_AMG319  -5.259332553  1.7095694354
## 5712                  D022_r2_Amuvatinib (MP-470)  -6.764783063 -1.0212730092
## 5713                             D022_r2_Apatinib  -4.983136860 -0.5618155174
## 5714                           D022_r2_AR-A014418  -3.786326390  0.6832481254
## 5715                            D022_r2_AS-252424  -5.751946681 -0.8434750546
## 5716                            D022_r2_AS-604850  -1.117885314  0.1012452432
## 5717                         D022_r2_Asiatic Acid  -3.667453880  1.5863000856
## 5718                             D022_r2_AST-1306  -4.694603947  1.3928650463
## 5719                              D022_r2_AT13148  -1.209114532 -0.0803895884
## 5720                               D022_r2_AT7519 -15.865156512  0.2196515238
## 5721                               D022_r2_AT7867  -2.125303155  0.6933483991
## 5722                               D022_r2_AT9283 -15.586234960  0.1452747740
## 5723                 D022_r2_Aurora A Inhibitor I -17.461282195 -0.1044645714
## 5724             D022_r2_Avagacestat (BMS-708163)  -5.720733520 -0.8345266568
## 5725                              D022_r2_AVL-292  -5.384709164  0.5937459311
## 5726                             D022_r2_Axitinib  -9.992110724 -0.1144683076
## 5727                             D022_r2_Axitinib  -9.992110724 -0.1144683076
## 5728                               D022_r2_AZ 628  -4.857980751  0.4489236398
## 5729                               D022_r2_AZ 960  -5.345345932 -0.2416023448
## 5730                                 D022_r2_AZ20  -9.635023985  1.0894475925
## 5731                              D022_r2_AZD1080 -11.064736608 -0.0366229790
## 5732                              D022_r2_AZD1480 -15.037400316  0.6831996536
## 5733                              D022_r2_AZD2014  -4.473968764  1.1226982086
## 5734                              D022_r2_AZD2858 -13.454140092  0.8366858167
## 5735                              D022_r2_AZD2932  -3.432550728  1.3763781277
## 5736                              D022_r2_AZD3759  -4.806788222  1.0217903722
## 5737                              D022_r2_AZD5363  -3.064570821  0.4384761735
## 5738                              D022_r2_AZD5438 -10.748888500 -0.7673615206
## 5739                              D022_r2_AZD6482  -1.963494008 -0.6338747730
## 5740                              D022_r2_AZD6738 -10.591467071 -0.6702450694
## 5741                              D022_r2_AZD8055  -6.461973193 -0.1176412506
## 5742                              D022_r2_AZD8330 -11.401608405  0.2280869867
## 5743                  D022_r2_AZD8931 (Sapitinib)  -3.683648143  0.9194591541
## 5744                              D022_r2_AZD9291  -7.655678837  0.7551331343
## 5745            D022_r2_Barasertib (AZD1152-HQPA) -17.055710670  1.6675425515
## 5746  D022_r2_Baricitinib (LY3009104, INCB028050)  -1.843786549 -0.7283540988
## 5747                  D022_r2_BGT226 (NVP-BGT226)  -5.575953054  0.2097324030
## 5748                              D022_r2_BI 2536 -14.082129000  0.5421461445
## 5749                              D022_r2_BI-78D3  -5.711189202  1.1566496271
## 5750                             D022_r2_BI-D1870  -4.951518538  0.3941913896
## 5751                              D022_r2_Bikinin  -2.152064189  0.1339788061
## 5752                                  D022_r2_BIO  -6.752219775 -0.0762247005
## 5753               D022_r2_BIRB 796 (Doramapimod)  -5.513060269 -1.1572981556
## 5754                            D022_r2_BIX 02188  -2.456427385  1.3403877935
## 5755                            D022_r2_BIX 02189  -0.899144811 -0.3197204727
## 5756      D022_r2_BKM120 (NVP-BKM120, Buparlisib) -15.054115122  0.3772331802
## 5757                           D022_r2_BMS-265246  -9.827272522  1.7690640426
## 5758                           D022_r2_BMS-536924 -13.497949045  0.1320294443
## 5759                           D022_r2_BMS-582949  -7.631207335 -0.1229294350
## 5760                           D022_r2_BMS-754807 -20.204083685  0.8007847470
## 5761                           D022_r2_BMS-777607  -2.126074578 -0.2497633625
## 5762                           D022_r2_BMS-794833  -3.947732657 -0.6344639163
## 5763                           D022_r2_BMS-833923  -5.295246244 -0.3928472875
## 5764                  D022_r2_Bosutinib (SKI-606)  -1.010506293  0.2960970333
## 5765                D022_r2_Brivanib (BMS-540215)  -4.996416421 -0.6039621697
## 5766      D022_r2_Brivanib Alaninate (BMS-582664)  -7.117810159  0.7618554714
## 5767                           D022_r2_BS-181 HCl  -7.118241514  0.8299650281
## 5768                               D022_r2_Butein  -0.798954192  1.2227892037
## 5769                               D022_r2_BYL719  -5.416192058  0.6075880015
## 5770     D022_r2_Cabozantinib (XL184, BMS-907351)  -5.090531467  0.1727906762
## 5771          D022_r2_Cabozantinib malate (XL184)  -8.661398772  1.1947547844
## 5772        D022_r2_CAL-101 (Idelalisib, GS-1101)  -5.353985852 -0.1050814127
## 5773                             D022_r2_CAY10505  -4.422648907 -0.1002718672
## 5774                               D022_r2_CC-223  -1.806284889  0.0067230639
## 5775                            D022_r2_CCT128930  -5.092518291  1.6652221706
## 5776                  D022_r2_Cediranib (AZD2171)  -9.147321173 -0.9073767725
## 5777                            D022_r2_CEP-32496  -2.756324199 -0.0335684649
## 5778                            D022_r2_CEP-33779  -5.328140191 -0.4763169023
## 5779                              D022_r2_CGI1746  -3.726858019  1.4087402693
## 5780                              D022_r2_CGK 733  -5.853324666  0.7021655979
## 5781                            D022_r2_CH5132799  -3.223570426  1.0017282700
## 5782                           D022_r2_CHIR-98014  -9.048308939  0.2813689061
## 5783                 D022_r2_CHIR-99021 (CT99021)  -9.236891615  0.5575665048
## 5784             D022_r2_CHIR-99021 (CT99021) HCl  -8.817928672  0.4613465615
## 5785                    D022_r2_Chrysophanic Acid  -4.992425161 -0.1059034945
## 5786                             D022_r2_CNX-2006  -1.732904185 -0.7922837780
## 5787                              D022_r2_CNX-774  -0.997083210 -1.2788060783
## 5788                    D022_r2_CO-1686 (AVL-301)  -5.722845132  2.2697533219
## 5789       D022_r2_Cobimetinib (GDC-0973, RG7420)  -4.047948437  0.8191894847
## 5790                            D022_r2_CP-673451 -15.786120135  1.1762122753
## 5791                            D022_r2_CP-724714  -5.762400852  0.5351492977
## 5792               D022_r2_Crenolanib (CP-868596)  -9.784793559  0.2685105844
## 5793             D022_r2_Crizotinib (PF-02341066) -16.328740723  1.0039720489
## 5794                               D022_r2_CYC116 -16.900893943  2.8234092500
## 5795                               D022_r2_CYT387  -5.146051475  0.9533995586
## 5796                             D022_r2_CZC24832  -3.036271127 -1.0479257485
## 5797              D022_r2_Dabrafenib (GSK2118436)  -2.630876461 -0.2416929982
## 5798        D022_r2_Dacomitinib (PF299804, PF299)  -4.687180458 -0.1119951658
## 5799              D022_r2_Danusertib (PHA-739358) -20.259927226  0.1144577400
## 5800                        D022_r2_DAPT (GSI-IX)  -4.467159579 -0.9119085179
## 5801                            D022_r2_Dasatinib  -6.663028752  1.3622315653
## 5802                D022_r2_DCC-2036 (Rebastinib) -10.065250555  1.3725294753
## 5803                D022_r2_Decernotinib (VX-509)  -5.305807751 -0.0204469148
## 5804               D022_r2_Dinaciclib (SCH727965) -11.279690537  0.7780671886
## 5805    D022_r2_Dovitinib (TKI-258) Dilactic Acid  -5.925580523 -0.1148176036
## 5806                            D022_r2_ENMD-2076 -17.501625276  1.6209940334
## 5807               D022_r2_Enzastaurin (LY317615)  -7.823390300  1.2926428028
## 5808                            D022_r2_ERK5-IN-1  -9.227368713  1.1659587026
## 5809                             D022_r2_ETC-1002  -5.303072262  1.3260115223
## 5810                            D022_r2_ETP-46464  -7.149835793  1.6874438813
## 5811                  D022_r2_Everolimus (RAD001)  -1.700847202  0.3566119208
## 5812                D022_r2_Fasudil (HA-1077) HCl  -3.955913109  0.0207277787
## 5813                                D022_r2_FH535  -3.595631333  0.4518917699
## 5814                D022_r2_Filgotinib (GLPG0634)  -9.119587913  0.9164838894
## 5815             D022_r2_Flavopiridol (Alvocidib)  -8.798003907 -0.7619747582
## 5816                     D022_r2_Flavopiridol HCl -10.996374478  0.2400178949
## 5817               D022_r2_Foretinib (GSK1363089) -14.181429563  0.6553539645
## 5818                  D022_r2_Fostamatinib (R788) -10.149228362 -0.7755681154
## 5819                                D022_r2_G-749  -5.202134367  0.2444546791
## 5820                             D022_r2_GDC-0068  -2.875181521  1.6648397969
## 5821                             D022_r2_GDC-0349  -2.507297594  1.5162689769
## 5822                             D022_r2_GDC-0879  -3.431947397 -0.8314959742
## 5823                             D022_r2_GDC-0941  -3.145658591  0.9707559473
## 5824                    D022_r2_GDC-0980 (RG7422)  -5.400456674  1.1026339303
## 5825                   D022_r2_Gefitinib (ZD1839)  -2.443547929  1.5647932019
## 5826                            D022_r2_Genistein  -4.353061496 -1.1599146268
## 5827                            D022_r2_GF109203X  -7.193399454  1.3022256082
## 5828                                D022_r2_GNF-2  -5.674027044  0.6120850339
## 5829                                D022_r2_GNF-5  -6.791688208  0.6298534326
## 5830                              D022_r2_Go 6983  -7.398374152  0.6367443487
## 5831                   D022_r2_Golvatinib (E7050) -10.576408196  0.0709254950
## 5832                          D022_r2_GSK1838705A  -7.195479488  0.1225130275
## 5833                          D022_r2_GSK1904529A  -6.749516838  1.1773295045
## 5834                  D022_r2_GSK2126458 (GSK458)  -8.641694509  0.0882165197
## 5835                           D022_r2_GSK2292767 -11.546360577  1.8596984948
## 5836                           D022_r2_GSK2636771  -4.595668525  0.8200634880
## 5837                           D022_r2_GSK429286A  -2.816614600  0.2822672758
## 5838                            D022_r2_GSK461364 -16.287859648  0.9819431241
## 5839                               D022_r2_GSK621  -6.704126152  0.3105268785
## 5840                            D022_r2_GSK690693  -8.546774070  0.6092398479
## 5841                               D022_r2_GW5074  -2.577776430 -0.9535254017
## 5842                             D022_r2_GW788388  -3.988163775 -0.0559918383
## 5843                               D022_r2_GZD824  -6.311712403  0.8730735028
## 5844                            D022_r2_H 89 2HCl  -4.127458509  0.2613646595
## 5845                           D022_r2_Hesperadin  -6.639776613  1.0819925735
## 5846                              D022_r2_HMN-214 -17.414225149  0.5968929890
## 5847                             D022_r2_Honokiol  -7.419279269 -0.4896315819
## 5848                               D022_r2_HS-173 -12.462219730  0.4477382508
## 5849                           D022_r2_HTH-01-015 -10.632855909 -1.0456501317
## 5850                D022_r2_Ibrutinib (PCI-32765)  -2.730401833  1.6351531679
## 5851                              D022_r2_ICG-001  -4.220520546  0.7891810009
## 5852                             D022_r2_Icotinib  -3.194503170 -2.1173404963
## 5853                                D022_r2_IM-12  -2.475025074 -0.3240313565
## 5854           D022_r2_Imatinib Mesylate (STI571)  -8.300706058  1.5065882526
## 5855                            D022_r2_Indirubin  -7.551760603  0.1053433730
## 5856                    D022_r2_INK 128 (MLN0128)  -7.782991500  0.4417551993
## 5857                    D022_r2_IPI-145 (INK1197)  -3.341593664 -1.2558856828
## 5858                               D022_r2_IWP-L6  -4.578684989 -1.3077072789
## 5859                           D022_r2_IWR-1-endo  -5.105676164 -0.8881928137
## 5860                         D022_r2_JNJ-38877605  -2.989901494 -1.0932548983
## 5861                          D022_r2_JNJ-7706621 -15.086361050  1.7155879389
## 5862                     D022_r2_JNK Inhibitor IX -10.923077832 -0.9082889660
## 5863                             D022_r2_JNK-IN-8  -5.777228293  1.4591795244
## 5864                               D022_r2_K02288  -6.454724732  0.3327317127
## 5865                               D022_r2_Ki8751 -12.682512802  0.8139730932
## 5866                              D022_r2_KRN 633  -7.245232807 -0.6218819463
## 5867                           D022_r2_KU-0063794  -7.103623523  0.7882831056
## 5868      D022_r2_KU-55933 (ATM Kinase Inhibitor)  -2.812520767  0.3009824241
## 5869                             D022_r2_KU-60019 -10.838302274  0.6858632926
## 5870                              D022_r2_KW-2449 -12.692023523  0.6268003232
## 5871                              D022_r2_KX2-391 -11.601316591  0.2643304410
## 5872                              D022_r2_KY02111  -3.346945993 -0.3307485898
## 5873                            D022_r2_Lapatinib  -2.888222453  0.9850617582
## 5874     D022_r2_Lapatinib (GW-572016) Ditosylate  -4.530935017  1.1214190750
## 5875                            D022_r2_LDC000067  -8.524934559  0.8119710452
## 5876      D022_r2_LDE225 (NVP-LDE225,Erismodegib)  -5.289419717  0.3131604734
## 5877                           D022_r2_LDN-214117  -2.429780323 -0.0340970233
## 5878                   D022_r2_Lenvatinib (E7080)  -9.567662980 -0.9040725588
## 5879                              D022_r2_LFM-A13  -5.493321711  0.6788031319
## 5880                              D022_r2_LGK-974  -4.267375065  0.1389176960
## 5881                  D022_r2_Linifanib (ABT-869)  -9.308907902 -0.9073851739
## 5882                               D022_r2_LJH685  -4.241906140 -1.1380097917
## 5883                               D022_r2_LJI308  -7.052374737  0.5897753142
## 5884               D022_r2_Losmapimod (GW856553X)  -2.207815312  0.3999364620
## 5885                            D022_r2_LY2090314  -9.472308636 -0.3328746931
## 5886                            D022_r2_LY2157299  -0.962282420 -0.2044697024
## 5887                            D022_r2_LY2784544 -14.099285580 -0.3277904684
## 5888                            D022_r2_LY2835219  -7.378878257 -0.5438479223
## 5889                             D022_r2_LY294002  -6.065926475  1.4457221521
## 5890                            D022_r2_LY3023414  -8.681401025  0.3976221132
## 5891                             D022_r2_LY411575  -5.351645932  0.0557336653
## 5892       D022_r2_MEK162 (ARRY-162, ARRY-438162)  -6.742697740  0.6649926070
## 5893                             D022_r2_MGCD-265  -1.122560038 -0.5618726568
## 5894               D022_r2_Milciclib (PHA-848125) -11.361622110 -0.9959920881
## 5895                              D022_r2_MK-0752  -7.114123397 -0.2992386003
## 5896                         D022_r2_MK-2206 2HCl  -5.313456676  1.0551891899
## 5897                              D022_r2_MK-2461  -0.774170126 -0.2234046658
## 5898                     D022_r2_MK-5108 (VX-689) -11.224218294 -0.7533934549
## 5899                              D022_r2_MK-8745 -10.733975397 -0.4949411359
## 5900                              D022_r2_MLN2480  -4.341995649  0.7954790526
## 5901                              D022_r2_MLN8054  -1.157859903 -0.4519100042
## 5902      D022_r2_Motesanib Diphosphate (AMG-706)  -9.849765801 -0.0945850866
## 5903                  D022_r2_Nilotinib (AMN-107)  -7.984113334 -0.4252855999
## 5904     D022_r2_Nintedanib (BIBF 1120)_uncertain  -7.242849590  0.2339512615
## 5905                               D022_r2_NU6027  -1.685232819  0.5965540412
## 5906                           D022_r2_NVP-AEW541 -14.018505873  1.7467393959
## 5907                           D022_r2_NVP-BHG712  -7.399175841  0.7970165035
## 5908                      D022_r2_NVP-BSK805 2HCl  -3.730471654 -1.1061585490
## 5909                           D022_r2_NVP-BVU972  -1.855966875  0.2607550931
## 5910                          D022_r2_Oclacitinib  -5.026031326 -0.4313132872
## 5911      D022_r2_Olmutinib (HM61713, BI 1482694)  -1.900411419 -0.3885718633
## 5912                             D022_r2_ONO-4059  -2.145497744  0.2398101611
## 5913                              D022_r2_OSI-027  -3.879304877 -1.9870044371
## 5914                              D022_r2_OSI-420  -2.205096729  1.9084688760
## 5915                 D022_r2_OSI-906 (Linsitinib)  -4.883972546  2.1563672675
## 5916                              D022_r2_P276-00 -11.852169022 -0.9053373731
## 5917                  D022_r2_Pacritinib (SB1518) -12.116716233 -0.1762658904
## 5918                   D022_r2_Palomid 529 (P529)  -5.179805567 -1.0904916012
## 5919                            D022_r2_Pazopanib  -4.235978260 -1.5892450532
## 5920                        D022_r2_Pazopanib HCl  -8.498933458  0.4053205600
## 5921                            D022_r2_PD0325901  -9.313831717  1.3875226821
## 5922                             D022_r2_PD168393  -4.657233625  1.8882704793
## 5923                             D022_r2_PD173955  -6.311144375 -1.1936498270
## 5924                   D022_r2_PD184352 (CI-1040)  -2.286786938  1.2686892127
## 5925                             D022_r2_PD318088  -5.172247785  0.8467463836
## 5926                              D022_r2_PD98059  -4.657888753  0.3697587609
## 5927                  D022_r2_Pelitinib (EKB-569)  -6.120756819  1.8355806546
## 5928                          D022_r2_PF-00562271  -7.987852173 -0.0316391507
## 5929                          D022_r2_PF-04217903  -6.979316422 -0.5708629417
## 5930                          D022_r2_PF-04691502  -3.708893601  1.5284999861
## 5931                            D022_r2_PF-431396 -10.439644508 -0.9838960202
## 5932                           D022_r2_PF-4708671 -14.675240771  0.8635752287
## 5933                           D022_r2_PF-5274857  -4.983226572  0.0868943494
## 5934                            D022_r2_PF-562271 -10.928889948 -0.3351175017
## 5935                            D022_r2_PF-573228  -6.406738844  1.8392161744
## 5936                            D022_r2_PH-797804  -4.685952801  0.6457688557
## 5937                           D022_r2_PHA-665752  -9.214388159  0.9611379607
## 5938                           D022_r2_PHA-680632 -13.547728898  2.3694418919
## 5939                           D022_r2_PHA-767491  -6.582831336  1.0463229229
## 5940                           D022_r2_PHA-793887 -14.749401180  1.3247274194
## 5941                       D022_r2_Phenformin HCl  -5.403357618 -0.0851334118
## 5942                              D022_r2_PHT-427  -7.430536543  0.2612349677
## 5943                          D022_r2_Piceatannol  -3.080293245  1.7942454321
## 5944                              D022_r2_PIK-293  -4.309726153  0.6516435117
## 5945                              D022_r2_PIK-294  -4.083803446 -0.0508324616
## 5946                               D022_r2_PIK-93 -10.685813653  1.2178252770
## 5947               D022_r2_Pimasertib (AS-703026) -10.602269988  1.8126141561
## 5948                          D022_r2_Pirfenidone  -1.274409445  0.6345266486
## 5949                             D022_r2_PLX-4720  -7.819974937 -0.2055297659
## 5950                              D022_r2_PLX7904  -3.922829070  0.4748118379
## 5951                  D022_r2_Ponatinib (AP24534)  -4.836277739 -0.4308818341
## 5952                                  D022_r2_PP1  -4.750682501  0.8760758522
## 5953                                  D022_r2_PP2  -4.221325695  1.1131498029
## 5954                                D022_r2_PP242  -4.023032551 -0.0255124500
## 5955                               D022_r2_PQ 401  -1.897821819  0.0479212310
## 5956                              D022_r2_PRI-724  -6.908583162  0.0541115061
## 5957     D022_r2_PRT062607 (P505-15, BIIB057) HCl  -6.121187019  2.7161987327
## 5958                         D022_r2_Purvalanol A  -6.775390257  1.1406565514
## 5959                            D022_r2_Quercetin  -4.919206939  0.4978916382
## 5960                  D022_r2_Quizartinib (AC220) -12.228426379  0.7427167785
## 5961                                 D022_r2_R406  -5.604273642  0.4178061627
## 5962                     D022_r2_R406 (free base)  -4.510713247  0.0412773879
## 5963                                 D022_r2_R547  -9.355289947  0.9711984133
## 5964                    D022_r2_RAF265 (CHIR-265)  -6.581863949  1.7501212519
## 5965                D022_r2_Rapamycin (Sirolimus)  -8.098590889  0.8239617667
## 5966   D022_r2_Refametinib (RDEA119, Bay 86-9766)  -8.715763553  0.8169096957
## 5967                               D022_r2_RepSox  -2.986416955  0.2168324317
## 5968 D022_r2_Ridaforolimus (Deforolimus, MK-8669)  -7.129098299  0.7366639942
## 5969                D022_r2_Rigosertib (ON-01910) -17.788561946 -0.0669685732
## 5970                             D022_r2_RKI-1447  -3.917161911  0.1628740610
## 5971                                D022_r2_RN486  -2.720944923  0.0281346708
## 5972                  D022_r2_Ro 31-8220 Mesylate -13.449289931  0.9712664796
## 5973                              D022_r2_Ro-3306  -3.822762007  0.4348871365
## 5974                               D022_r2_Ro3280 -11.350452232  0.0766835296
## 5975                            D022_r2_RO4929097  -4.851161253 -0.8112345915
## 5976      D022_r2_Roscovitine (Seliciclib,CYC202)  -6.310637858  0.0634858148
## 5977             D022_r2_Ruxolitinib (INCB018424)  -5.903689803  0.2692956952
## 5978           D022_r2_S-Ruxolitinib (INCB018424)  -5.436810670 -0.0253240352
## 5979                               D022_r2_SANT-1  -5.470264758 -0.3887381325
## 5980                            D022_r2_SAR131675  -2.437151398  0.5287270141
## 5981                    D022_r2_SAR245409 (XL765)  -0.600997091 -0.2352252319
## 5982                D022_r2_Saracatinib (AZD0530)  -3.018869293  2.0354184392
## 5983                      D022_r2_SB202190 (FHPI)  -5.348632686  1.0444352530
## 5984                             D022_r2_SB203580  -7.951758917  0.6949876568
## 5985                             D022_r2_SB216763  -7.281459161  0.1760243810
## 5986                             D022_r2_SB239063  -6.301873575  0.6625966132
## 5987                             D022_r2_SB415286  -6.364813239 -0.3505962281
## 5988                             D022_r2_SB431542  -3.976232044  0.0860289668
## 5989                             D022_r2_SB505124  -1.865811104 -0.4185627225
## 5990                             D022_r2_SB525334  -6.071379109 -0.1736730312
## 5991                             D022_r2_SB590885  -1.679615280 -0.8795249755
## 5992                                  D022_r2_SC1  -9.512166312  0.8236481450
## 5993                D022_r2_Schisandrin B (Sch B)  -3.659759398  1.0135931011
## 5994                D022_r2_Selumetinib (AZD6244)  -7.561601890  2.0115890623
## 5995              D022_r2_Semagacestat (LY450139)  -6.064598970  0.5874644689
## 5996                   D022_r2_Semaxanib (SU5416)  -6.406066975  0.1401127684
## 5997                             D022_r2_SGI-7079 -10.181998218 -1.0017970597
## 5998                          D022_r2_Skepinone-L  -2.053935261 -0.6832616228
## 5999                               D022_r2_SL-327  -6.959218284  0.1036580438
## 6000                 D022_r2_SNS-032 (BMS-387032) -12.995369152  1.5519014963
## 6001                     D022_r2_SNS-314 Mesylate -17.638115313  2.0193970113
## 6002                            D022_r2_Sorafenib  -4.584533140 -1.2531548602
## 6003                   D022_r2_Sorafenib Tosylate  -1.590943716  0.5331354676
## 6004                         D022_r2_Sotrastaurin  -5.201582736  0.5785737190
## 6005                             D022_r2_SP600125  -5.728842641 -0.2681247453
## 6006                              D022_r2_SU11274  -6.677853572 -0.4474618469
## 6007                               D022_r2_SU6656 -10.671166145  1.4918304331
## 6008                               D022_r2_SU9516  -9.417405534  1.0392978228
## 6009                     D022_r2_Sunitinib Malate  -3.230255738 -1.1434591962
## 6010                  D022_r2_TAE226 (NVP-TAE226) -10.351703965 -0.2512585060
## 6011                              D022_r2_TAK-285  -3.226815079  0.9893318004
## 6012                              D022_r2_TAK-632  -0.465423527 -0.4416840807
## 6013                              D022_r2_TAK-715  -3.028273058 -2.2816606006
## 6014                              D022_r2_TAK-733  -8.707085577 -0.6263106037
## 6015                              D022_r2_TAK-901 -10.020967580  1.4511052986
## 6016                D022_r2_Taladegib (LY2940680)  -3.575058095  0.1072296560
## 6017                              D022_r2_TCS 359  -5.404877587  0.9528768958
## 6018                               D022_r2_TDZD-8  -3.925492059 -1.1522387753
## 6019                            D022_r2_Telatinib  -1.753418400 -0.3886789438
## 6020   D022_r2_Temsirolimus (CCI-779, NSC 683864)  -4.065477678 -0.3475391426
## 6021              D022_r2_Tepotinib (EMD 1214063) -12.937608548 -0.7894966341
## 6022                                D022_r2_TG003  -3.351266101  0.4700622709
## 6023                            D022_r2_TG100-115  -5.982752580 -1.0716140456
## 6024                             D022_r2_TG101209 -15.297874002  0.1819585715
## 6025                 D022_r2_TG101348 (SAR302503) -14.858266146  0.0088664951
## 6026                              D022_r2_TGX-221  -6.099098697  0.8451749070
## 6027                         D022_r2_Theophylline  -4.623922266  0.9006400099
## 6028                          D022_r2_Thiazovivin  -2.882382754  0.2332380942
## 6029                       D022_r2_TIC10 Analogue  -4.668035359 -0.2250410030
## 6030                           D022_r2_Tideglusib  -1.550797302 -1.3034115087
## 6031                 D022_r2_Tivantinib (ARQ 197) -13.104949174 -0.6934977254
## 6032                   D022_r2_Tivozanib (AV-951)  -5.293098536 -0.0087533842
## 6033  D022_r2_Tofacitinib (CP-690550,Tasocitinib)  -5.191418993  0.8672952345
## 6034      D022_r2_Tofacitinib (CP-690550) Citrate  -2.859160962  0.0878776386
## 6035                              D022_r2_Torin 2  -8.590930237 -0.1873540856
## 6036              D022_r2_Trametinib (GSK1120212)  -8.387799952  0.5463095368
## 6037                          D022_r2_Triciribine -10.938347425  1.2345577011
## 6038           D022_r2_TSU-68 (SU6668, Orantinib)  -5.199068233  0.2836749037
## 6039                               D022_r2_TWS119  -5.562808430 -0.0358544578
## 6040                         D022_r2_Tyrphostin 9  -7.017850064 -0.0775504899
## 6041                   D022_r2_Tyrphostin AG 1296  -6.122074809  0.1600051007
## 6042                           D022_r2_U0126-EtOH  -6.764028438  0.8465308407
## 6043     D022_r2_Ulixertinib (BVD-523, VRT752271)  -5.771780957 -0.1534414692
## 6044              D022_r2_Uprosertib (GSK2141795)  -8.692846775 -0.4088482933
## 6045                          D022_r2_Vacquinol-1 -14.036803695  0.6242422310
## 6046                           D022_r2_Varlitinib  -6.083444811  0.4851189463
## 6047              D022_r2_Vatalanib (PTK787) 2HCl  -8.604895103 -0.2797857121
## 6048                               D022_r2_VE-821  -8.712952991 -0.4199869824
## 6049                               D022_r2_VE-822  -8.889163027 -1.7658614349
## 6050        D022_r2_Vemurafenib (PLX4032, RG7204)  -5.547225489 -0.5320178888
## 6051                D022_r2_Vismodegib (GDC-0449)  -5.305336710 -0.9356717335
## 6052                 D022_r2_Volasertib (BI 6727)  -7.052694742 -0.6849917713
## 6053                            D022_r2_VPS34-IN1  -6.030324129  1.5613622658
## 6054                     D022_r2_VS-5584 (SB2343)  -4.990203719  0.2382899605
## 6055                               D022_r2_VX-11e  -9.706328989  0.8016567333
## 6056         D022_r2_VX-680 (Tozasertib, MK-0457) -16.404849828  0.2838517905
## 6057                               D022_r2_VX-702  -2.078391551 -1.6829513575
## 6058                               D022_r2_VX-745  -3.944476354 -0.0634383107
## 6059                              D022_r2_WAY-600  -7.130834477  1.1213237550
## 6060                             D022_r2_WH-4-023  -3.128168880  0.6349045915
## 6061                             D022_r2_WHI-P154  -4.410652435 -0.1727186376
## 6062                                D022_r2_WIKI4  -7.425692539  0.6259992475
## 6063                        D022_r2_Wnt agonist 1 -15.701047892 -0.4387070281
## 6064                        D022_r2_Wnt-C59 (C59)  -1.884817148 -0.7263411457
## 6065                               D022_r2_WP1066  -6.277850896  0.2533441915
## 6066                 D022_r2_WYE-125132 (WYE-132)  -4.545351092  0.1667533236
## 6067                              D022_r2_WYE-354  -6.378103640  0.6873567150
## 6068                               D022_r2_WZ3146  -5.574352142  0.5561562515
## 6069                               D022_r2_WZ4002  -3.247041523  0.6905174607
## 6070                               D022_r2_WZ4003  -6.414449082  0.9013813342
## 6071                               D022_r2_WZ8040  -5.488941283 -0.4476975968
## 6072                              D022_r2_XAV-939  -5.641057816 -0.8859463184
## 6073                                D022_r2_XL019  -6.705067339 -0.2532018568
## 6074                              D022_r2_XMD8-92  -8.446521328 -0.6934365867
## 6075                         D022_r2_Y-27632 2HCl  -5.901913835  0.0481849323
## 6076                             D022_r2_YM201636  -7.503432052  2.2717114464
## 6077                             D022_r2_YO-01027  -4.835896578  0.4294158931
## 6078                            D022_r2_ZM 306416  -4.065334581  0.7000773304
## 6079                        D022_r2_ZM 323881 HCl  -5.510476793  0.4625332379
## 6080                            D022_r2_ZM 336372  -5.508637227  0.4405904206
## 6081                         D022_r2_ZM 39923 HCl  -5.041685659  0.0104488088
## 6082                            D022_r2_ZM 447439 -14.778040704  1.7734724140
## 6083                 D022_r2_Zotarolimus(ABT-578)  -1.552838237  0.1853451833
## 6084                              D022_r2_ZSTK474  -6.416247676  2.1369594078
## 6085                     D027_r1_1-Azakenpaullone -12.665206099  2.1149624838
## 6086                      D027_r1_3-Methyladenine  -8.897423820  1.5492525318
## 6087                             D027_r1_A-674563  -9.885106774  1.4582985979
## 6088                             D027_r1_A-769662  -5.669532016  0.1328252916
## 6089                                  D027_r1_A66  -8.245884753  0.8844405410
## 6090                            D027_r1_Acadesine  -3.539028375  0.1022518811
## 6091                  D027_r1_AEE788 (NVP-AEE788) -19.584837720  2.5123819567
## 6092        D027_r1_Afatinib (BIBW2992)_uncertain  -7.346951299  0.9276426020
## 6093                              D027_r1_AG-1024  -5.915039260  0.4734145235
## 6094         D027_r1_AG-1478 (Tyrphostin AG-1478) -11.225238334  1.8308439822
## 6095                                D027_r1_AG-18  -7.433287752  1.2488775277
## 6096              D027_r1_AG-490 (Tyrphostin B42)  -5.548387776  0.4546374976
## 6097                             D027_r1_Akti-1/2  -6.272761218  1.1158560681
## 6098                  D027_r1_Alisertib (MLN8237)  -9.729942827  0.1543094463
## 6099                              D027_r1_AMG 337  -7.118095860  0.0801572478
## 6100                              D027_r1_AMG-458  -8.653642089  1.8143872140
## 6101                              D027_r1_AMG-900 -13.806561404  2.0209368376
## 6102                               D027_r1_AMG319  -5.871350423  0.2376482450
## 6103                  D027_r1_Amuvatinib (MP-470)  -6.375523008  0.6766124734
## 6104                             D027_r1_Apatinib  -6.948231983 -0.4823627735
## 6105                           D027_r1_AR-A014418  -7.329217976  1.4125261574
## 6106                            D027_r1_AS-252424  -7.977229472  0.6121396266
## 6107                            D027_r1_AS-604850  -8.681690975  1.5893395496
## 6108                         D027_r1_Asiatic Acid  -8.218170836  0.8282005136
## 6109                             D027_r1_AST-1306  -8.777389669  3.2263775945
## 6110                              D027_r1_AT13148  -5.409244834 -0.6899458654
## 6111                               D027_r1_AT7519 -14.124688163  3.1535881733
## 6112                               D027_r1_AT7867  -1.282227307 -0.1586886706
## 6113                               D027_r1_AT9283 -16.778124720  1.8036796970
## 6114                 D027_r1_Aurora A Inhibitor I -10.392307434  2.2223130422
## 6115             D027_r1_Avagacestat (BMS-708163)  -7.857458552  0.6884452377
## 6116                              D027_r1_AVL-292  -6.658151672  0.1207333120
## 6117                             D027_r1_Axitinib  -6.879397497  0.6709207284
## 6118                             D027_r1_Axitinib  -6.879397497  0.6709207284
## 6119                               D027_r1_AZ 628  -5.978063739  1.0589224947
## 6120                               D027_r1_AZ 960  -8.164446905  1.2291808596
## 6121                                 D027_r1_AZ20  -9.540533800  2.3544279382
## 6122                              D027_r1_AZD1080 -11.222331543  1.3170807295
## 6123                              D027_r1_AZD1480 -14.547465995  1.9015259146
## 6124                              D027_r1_AZD2014  -5.733324332  1.2767540835
## 6125                              D027_r1_AZD2858 -14.037866272  2.1708369468
## 6126                              D027_r1_AZD2932  -8.180509694  0.5812467992
## 6127                              D027_r1_AZD3759  -8.864546700  1.7009615792
## 6128                              D027_r1_AZD5363  -6.552716068  0.1821345347
## 6129                              D027_r1_AZD5438  -8.022468354  2.0132944764
## 6130                              D027_r1_AZD6482  -7.994478403  0.8879976354
## 6131                              D027_r1_AZD6738 -11.081047891  0.4651974300
## 6132                              D027_r1_AZD8055  -2.885209424  1.2359387189
## 6133                              D027_r1_AZD8330 -10.882671322  0.9593327175
## 6134                  D027_r1_AZD8931 (Sapitinib)  -9.924778810 -0.2211829728
## 6135                              D027_r1_AZD9291 -15.629694527  2.4739457589
## 6136            D027_r1_Barasertib (AZD1152-HQPA) -12.342942631  1.5467446871
## 6137  D027_r1_Baricitinib (LY3009104, INCB028050)  -6.032036110  0.9612885154
## 6138                  D027_r1_BGT226 (NVP-BGT226) -15.746776160  2.7912902010
## 6139                              D027_r1_BI 2536 -20.388219825  1.9921852468
## 6140                              D027_r1_BI-78D3  -8.748382144  1.9128396431
## 6141                             D027_r1_BI-D1870  -7.926647232  1.2080598592
## 6142                              D027_r1_Bikinin  -6.712457694  1.4817970975
## 6143                                  D027_r1_BIO -11.585849519  1.6824999545
## 6144               D027_r1_BIRB 796 (Doramapimod)  -3.562349442  0.6140721521
## 6145                            D027_r1_BIX 02188  -8.580380862  0.9392778171
## 6146                            D027_r1_BIX 02189  -6.129204706  0.5912602685
## 6147      D027_r1_BKM120 (NVP-BKM120, Buparlisib)  -8.080152560  3.4838414828
## 6148                           D027_r1_BMS-265246 -10.263188120  1.4745472676
## 6149                           D027_r1_BMS-536924  -9.706433311  2.2547089615
## 6150                           D027_r1_BMS-582949  -7.078260005  1.1349714908
## 6151                           D027_r1_BMS-754807 -16.130703043  2.0292011095
## 6152                           D027_r1_BMS-777607  -6.603799499  0.5409819532
## 6153                           D027_r1_BMS-794833  -6.210655975  1.0362888975
## 6154                           D027_r1_BMS-833923  -6.931535363  1.0709580215
## 6155                  D027_r1_Bosutinib (SKI-606)  -7.467326885  3.6972076374
## 6156                D027_r1_Brivanib (BMS-540215)  -7.337374032  1.3426903733
## 6157      D027_r1_Brivanib Alaninate (BMS-582664)  -5.896557543  0.9031682991
## 6158                           D027_r1_BS-181 HCl  -4.854308339  0.1635858635
## 6159                               D027_r1_Butein  -7.817818310  1.0526284759
## 6160                               D027_r1_BYL719  -7.336594649  1.0442720819
## 6161     D027_r1_Cabozantinib (XL184, BMS-907351)  -7.060725145  0.5419368807
## 6162          D027_r1_Cabozantinib malate (XL184)  -4.510460102 -0.0920251365
## 6163        D027_r1_CAL-101 (Idelalisib, GS-1101)  -9.420832112  0.8078568573
## 6164                             D027_r1_CAY10505  -5.171537941 -0.7201200233
## 6165                               D027_r1_CC-223  -7.039008406  0.5934870818
## 6166                            D027_r1_CCT128930  -7.116589130  1.0273898265
## 6167                  D027_r1_Cediranib (AZD2171) -10.555858302  2.8433277526
## 6168                            D027_r1_CEP-32496  -6.738361959  0.5622056440
## 6169                            D027_r1_CEP-33779  -4.342426108  0.3734640442
## 6170                              D027_r1_CGI1746  -7.998240818  1.4956764509
## 6171                              D027_r1_CGK 733  -6.302475245  0.8955068060
## 6172                            D027_r1_CH5132799  -7.029327078  0.9039885313
## 6173                           D027_r1_CHIR-98014 -13.336658705  0.7198531250
## 6174                 D027_r1_CHIR-99021 (CT99021) -14.808208805  2.5764008683
## 6175             D027_r1_CHIR-99021 (CT99021) HCl -13.897234084  2.1331925765
## 6176                    D027_r1_Chrysophanic Acid  -7.063667077  1.2344215989
## 6177                             D027_r1_CNX-2006  -8.532341528  1.3641206319
## 6178                              D027_r1_CNX-774  -8.311402259  0.9979964514
## 6179                    D027_r1_CO-1686 (AVL-301)  -6.563087024 -0.0156220819
## 6180       D027_r1_Cobimetinib (GDC-0973, RG7420)  -9.299119900  2.2188282292
## 6181                            D027_r1_CP-673451  -8.530683261  1.0215169816
## 6182                            D027_r1_CP-724714  -7.700825489  0.7391322105
## 6183               D027_r1_Crenolanib (CP-868596)  -7.884092008  3.0541833007
## 6184             D027_r1_Crizotinib (PF-02341066) -17.703357716  1.4825192414
## 6185                               D027_r1_CYC116 -12.406871791  1.2736841146
## 6186                               D027_r1_CYT387  -6.322560274  0.5398526164
## 6187                             D027_r1_CZC24832  -4.744406488 -1.0297709801
## 6188              D027_r1_Dabrafenib (GSK2118436)  -7.876343507 -0.5697451749
## 6189        D027_r1_Dacomitinib (PF299804, PF299) -13.060201760  2.6154738157
## 6190              D027_r1_Danusertib (PHA-739358) -12.827848119  2.6680153726
## 6191                        D027_r1_DAPT (GSI-IX) -10.051661693  2.0619065419
## 6192                            D027_r1_Dasatinib  -9.472485173  1.1801434890
## 6193                D027_r1_DCC-2036 (Rebastinib) -10.443359468  1.9116033434
## 6194                D027_r1_Decernotinib (VX-509)  -5.092722925  0.7240366255
## 6195               D027_r1_Dinaciclib (SCH727965)  -9.943115231  2.1346103594
## 6196    D027_r1_Dovitinib (TKI-258) Dilactic Acid -18.187633352  1.7064124022
## 6197                            D027_r1_ENMD-2076 -10.472872820  3.6548633657
## 6198               D027_r1_Enzastaurin (LY317615) -12.862587399  1.1223154394
## 6199                            D027_r1_ERK5-IN-1 -11.757154472  3.6010356555
## 6200                             D027_r1_ETC-1002 -10.536767804  1.1816840542
## 6201                            D027_r1_ETP-46464  -3.577683372 -0.3607801893
## 6202                  D027_r1_Everolimus (RAD001)  -7.473483617 -0.0058871768
## 6203                D027_r1_Fasudil (HA-1077) HCl  -6.679700960  0.5575338018
## 6204                                D027_r1_FH535  -6.348024023  0.4377941282
## 6205                D027_r1_Filgotinib (GLPG0634)  -8.824819193  0.7933354340
## 6206             D027_r1_Flavopiridol (Alvocidib)  -8.307028828  0.7346890569
## 6207                     D027_r1_Flavopiridol HCl -10.615011743  2.0676859886
## 6208               D027_r1_Foretinib (GSK1363089)  -8.662823952  0.4208046078
## 6209                  D027_r1_Fostamatinib (R788)  -9.893328424  1.9757886283
## 6210                                D027_r1_G-749  -5.658413590  0.8835726082
## 6211                             D027_r1_GDC-0068  -6.324757578  0.6976751298
## 6212                             D027_r1_GDC-0349  -6.033642772  0.6026646861
## 6213                             D027_r1_GDC-0879  -4.012910180  1.2205365695
## 6214                             D027_r1_GDC-0941  -6.683328529  1.0659505235
## 6215                    D027_r1_GDC-0980 (RG7422)  -4.078724855  2.3481437786
## 6216                   D027_r1_Gefitinib (ZD1839)  -8.609825546  2.5521511284
## 6217                            D027_r1_Genistein  -7.320187136  0.4192567535
## 6218                            D027_r1_GF109203X  -7.425705137  1.3083502710
## 6219                                D027_r1_GNF-2  -5.742491683  0.9437591632
## 6220                                D027_r1_GNF-5  -8.466102471  0.9047687854
## 6221                              D027_r1_Go 6983  -9.285063173  1.5866827176
## 6222                   D027_r1_Golvatinib (E7050) -22.874464190  1.6686341978
## 6223                          D027_r1_GSK1838705A  -5.364167339 -0.6169307590
## 6224                          D027_r1_GSK1904529A  -8.375130354  0.8816632804
## 6225                  D027_r1_GSK2126458 (GSK458) -10.445806484  1.8645418330
## 6226                           D027_r1_GSK2292767  -9.335520081  1.8232605184
## 6227                           D027_r1_GSK2636771 -10.334002113  0.4678692093
## 6228                           D027_r1_GSK429286A  -4.251934055  0.2820915716
## 6229                            D027_r1_GSK461364 -17.560046815  2.9699521406
## 6230                               D027_r1_GSK621  -6.367975931  0.1376912463
## 6231                            D027_r1_GSK690693  -7.405388504  0.6520813514
## 6232                               D027_r1_GW5074  -6.821932554  0.5908836571
## 6233                             D027_r1_GW788388  -5.669093783  0.9586967076
## 6234                               D027_r1_GZD824  -6.890778794  1.1706942659
## 6235                            D027_r1_H 89 2HCl  -4.561963889  0.1417696654
## 6236                           D027_r1_Hesperadin  -9.312061541  3.7204186478
## 6237                              D027_r1_HMN-214 -13.725183826  1.3830103440
## 6238                             D027_r1_Honokiol  -8.097076230  0.7148134100
## 6239                               D027_r1_HS-173 -13.255000765  1.2943266783
## 6240                           D027_r1_HTH-01-015 -17.883783144  1.4308314433
## 6241                D027_r1_Ibrutinib (PCI-32765)  -7.099910723  1.8440484514
## 6242                              D027_r1_ICG-001  -6.938775953  0.8989619975
## 6243                             D027_r1_Icotinib  -9.310248215  1.8589095916
## 6244                                D027_r1_IM-12  -6.651107931  0.9832087000
## 6245           D027_r1_Imatinib Mesylate (STI571)  -9.071536842  1.5567602932
## 6246                            D027_r1_Indirubin  -7.339281796  0.6773967251
## 6247                    D027_r1_INK 128 (MLN0128)  -6.124267842  2.0066378312
## 6248                    D027_r1_IPI-145 (INK1197)  -8.298712327  1.7791131581
## 6249                               D027_r1_IWP-L6  -5.707412613  0.1527738946
## 6250                           D027_r1_IWR-1-endo  -6.771627245  0.5985413704
## 6251                         D027_r1_JNJ-38877605  -7.099847970  0.9217880714
## 6252                          D027_r1_JNJ-7706621  -7.700653036  2.0404357590
## 6253                     D027_r1_JNK Inhibitor IX -12.441679473  2.4917159993
## 6254                             D027_r1_JNK-IN-8  -7.012119076  0.1727321264
## 6255                               D027_r1_K02288  -9.394922062  0.6819997367
## 6256                               D027_r1_Ki8751  -4.692838850 -0.4226255952
## 6257                              D027_r1_KRN 633  -8.725607054  1.4142995014
## 6258                           D027_r1_KU-0063794  -5.354875242  0.3396995038
## 6259      D027_r1_KU-55933 (ATM Kinase Inhibitor)  -8.210077856  0.8242135158
## 6260                             D027_r1_KU-60019  -5.113141532  1.2884758192
## 6261                              D027_r1_KW-2449  -8.639702127  4.5338483391
## 6262                              D027_r1_KX2-391  -9.998319519  1.2547884245
## 6263                              D027_r1_KY02111  -6.969091596  0.5059583797
## 6264                            D027_r1_Lapatinib  -8.223358840  1.8475343351
## 6265     D027_r1_Lapatinib (GW-572016) Ditosylate  -7.885051594  0.8458809589
## 6266                            D027_r1_LDC000067  -8.072233152  1.1314915072
## 6267      D027_r1_LDE225 (NVP-LDE225,Erismodegib)  -7.064503510  1.1411089273
## 6268                           D027_r1_LDN-214117  -9.850168656  0.8188118281
## 6269                   D027_r1_Lenvatinib (E7080)  -3.255566916 -0.5213807542
## 6270                              D027_r1_LFM-A13  -6.489549238  0.2216722130
## 6271                              D027_r1_LGK-974  -5.582240636  0.0755690672
## 6272                  D027_r1_Linifanib (ABT-869)  -8.964131041  1.5133348666
## 6273                               D027_r1_LJH685  -6.408834093  0.9002361173
## 6274                               D027_r1_LJI308  -6.290532767  0.4485548896
## 6275               D027_r1_Losmapimod (GW856553X)  -8.556307450  0.9499058443
## 6276                            D027_r1_LY2090314 -14.603103796  1.6696463058
## 6277                            D027_r1_LY2157299  -6.677523724  0.8969670306
## 6278                            D027_r1_LY2784544  -9.865915961  1.1860631516
## 6279                            D027_r1_LY2835219 -10.227329212  3.3153020851
## 6280                             D027_r1_LY294002  -8.252023262  0.5760949968
## 6281                            D027_r1_LY3023414  -9.113978225  2.4336421396
## 6282                             D027_r1_LY411575  -6.544989009  0.4622384589
## 6283       D027_r1_MEK162 (ARRY-162, ARRY-438162)  -8.879618562  3.3580546123
## 6284                             D027_r1_MGCD-265  -9.362834450  0.5894309663
## 6285               D027_r1_Milciclib (PHA-848125) -12.906472234  3.2819975550
## 6286                              D027_r1_MK-0752  -8.811845495  0.9686420702
## 6287                         D027_r1_MK-2206 2HCl  -7.013166072  0.7269217878
## 6288                              D027_r1_MK-2461  -7.863518266 -0.1140806797
## 6289                     D027_r1_MK-5108 (VX-689) -11.226649995  2.7050246343
## 6290                              D027_r1_MK-8745  -9.689082604  0.7982303937
## 6291                              D027_r1_MLN2480  -7.936031874  1.3327397892
## 6292                              D027_r1_MLN8054  -3.804110604 -0.4607651188
## 6293      D027_r1_Motesanib Diphosphate (AMG-706)  -9.772228814  1.2145725949
## 6294                  D027_r1_Nilotinib (AMN-107)  -2.606950450 -0.2260092165
## 6295     D027_r1_Nintedanib (BIBF 1120)_uncertain  -9.410054277  0.6226498621
## 6296                               D027_r1_NU6027  -6.401147198  2.0413790780
## 6297                           D027_r1_NVP-AEW541 -14.784478709  4.6388244505
## 6298                           D027_r1_NVP-BHG712 -10.496014143  2.4290031897
## 6299                      D027_r1_NVP-BSK805 2HCl -10.383770843  0.8631284676
## 6300                           D027_r1_NVP-BVU972  -6.902406709  1.1761985772
## 6301                          D027_r1_Oclacitinib  -6.189856720  1.1577757706
## 6302      D027_r1_Olmutinib (HM61713, BI 1482694)  -9.367349804  1.8119509920
## 6303                             D027_r1_ONO-4059  -9.615296110  4.1843237743
## 6304                              D027_r1_OSI-027  -8.574538461  1.4008319326
## 6305                              D027_r1_OSI-420  -7.257360918  1.3064352632
## 6306                 D027_r1_OSI-906 (Linsitinib)  -6.049537387  1.8179711447
## 6307                              D027_r1_P276-00  -5.735450270  1.8648021223
## 6308                  D027_r1_Pacritinib (SB1518) -13.379058545  1.3017359679
## 6309                   D027_r1_Palomid 529 (P529)  -7.534308093  1.4028187570
## 6310                            D027_r1_Pazopanib  -9.467660557  0.6336780881
## 6311                        D027_r1_Pazopanib HCl  -7.311122137  1.0843187441
## 6312                            D027_r1_PD0325901  -9.106679020  2.2026996005
## 6313                             D027_r1_PD168393 -10.296562970  3.6498309457
## 6314                             D027_r1_PD173955 -11.980366838  0.3356573309
## 6315                   D027_r1_PD184352 (CI-1040)  -8.712334851  2.2533377882
## 6316                             D027_r1_PD318088  -6.086777350  3.5575333396
## 6317                              D027_r1_PD98059  -8.357464263  1.2831869835
## 6318                  D027_r1_Pelitinib (EKB-569) -11.896790040  1.5724173619
## 6319                          D027_r1_PF-00562271 -12.109238137  1.7514713237
## 6320                          D027_r1_PF-04217903  -8.162032543  1.5355184957
## 6321                          D027_r1_PF-04691502  -9.416921480  1.1714484665
## 6322                            D027_r1_PF-431396  -9.925740740  1.9856669945
## 6323                           D027_r1_PF-4708671 -17.264465509  2.2251771343
## 6324                           D027_r1_PF-5274857  -7.285622968  1.6851405327
## 6325                            D027_r1_PF-562271 -16.491872086  4.1488704970
## 6326                            D027_r1_PF-573228  -9.688225377  1.8042698119
## 6327                            D027_r1_PH-797804  -7.056839878  1.8393624552
## 6328                           D027_r1_PHA-665752 -10.820907175  3.6759106860
## 6329                           D027_r1_PHA-680632 -10.564862154  1.9874095111
## 6330                           D027_r1_PHA-767491  -5.324118004  2.6191797431
## 6331                           D027_r1_PHA-793887  -6.681516028  3.0603837943
## 6332                       D027_r1_Phenformin HCl  -9.234024692  1.0598654211
## 6333                              D027_r1_PHT-427  -5.425562363  1.7572274262
## 6334                          D027_r1_Piceatannol  -5.407510519  3.5328813215
## 6335                              D027_r1_PIK-293  -8.266800559  0.3562338954
## 6336                              D027_r1_PIK-294  -7.098550310 -0.0432524314
## 6337                               D027_r1_PIK-93 -11.706353065  2.5251134969
## 6338               D027_r1_Pimasertib (AS-703026) -10.331702928  4.0872981489
## 6339                          D027_r1_Pirfenidone  -8.703837610  0.8455317462
## 6340                             D027_r1_PLX-4720  -5.012551618  0.2567401335
## 6341                              D027_r1_PLX7904  -6.242547694  0.5352443040
## 6342                  D027_r1_Ponatinib (AP24534)  -7.952362358  1.2020301500
## 6343                                  D027_r1_PP1  -7.793044433  0.2969980962
## 6344                                  D027_r1_PP2  -7.405176199  0.4731287139
## 6345                                D027_r1_PP242  -0.791054786  0.8533734273
## 6346                               D027_r1_PQ 401  -5.347601248  1.1901264383
## 6347                              D027_r1_PRI-724  -9.058016672  1.6888634428
## 6348     D027_r1_PRT062607 (P505-15, BIIB057) HCl  -9.056315525  1.6818806368
## 6349                         D027_r1_Purvalanol A -10.470768724  0.4407921109
## 6350                            D027_r1_Quercetin  -7.303766246 -0.2600322427
## 6351                  D027_r1_Quizartinib (AC220) -14.586000906  1.9613685607
## 6352                                 D027_r1_R406  -5.466015378  0.6771873409
## 6353                     D027_r1_R406 (free base)  -3.066245948 -0.5307220157
## 6354                                 D027_r1_R547  -4.496992722  1.2456648493
## 6355                    D027_r1_RAF265 (CHIR-265) -11.651026643  3.1385985614
## 6356                D027_r1_Rapamycin (Sirolimus)  -5.884783856  1.1866270243
## 6357   D027_r1_Refametinib (RDEA119, Bay 86-9766)  -9.373171317  1.9797968886
## 6358                               D027_r1_RepSox  -7.148825505  1.3904401211
## 6359 D027_r1_Ridaforolimus (Deforolimus, MK-8669)  -4.224264261 -0.3480078730
## 6360                D027_r1_Rigosertib (ON-01910)  -9.252867526  3.6316859386
## 6361                             D027_r1_RKI-1447  -8.031786866  1.0551166559
## 6362                                D027_r1_RN486  -9.526385890  1.4577624243
## 6363                  D027_r1_Ro 31-8220 Mesylate  -9.778485484  2.3828153499
## 6364                              D027_r1_Ro-3306  -6.170421015  0.3771001993
## 6365                               D027_r1_Ro3280 -15.812163809  2.9914513307
## 6366                            D027_r1_RO4929097  -7.475706150  0.4651586662
## 6367      D027_r1_Roscovitine (Seliciclib,CYC202)  -8.689298595  0.3168783432
## 6368             D027_r1_Ruxolitinib (INCB018424)  -7.426846851  1.2254462871
## 6369           D027_r1_S-Ruxolitinib (INCB018424)  -7.740086217  0.7546390683
## 6370                               D027_r1_SANT-1  -6.649364861  0.2609507508
## 6371                            D027_r1_SAR131675  -5.398757314  0.7098541792
## 6372                    D027_r1_SAR245409 (XL765)  -7.606153446 -0.0056170622
## 6373                D027_r1_Saracatinib (AZD0530) -14.553671524  2.9051328906
## 6374                      D027_r1_SB202190 (FHPI)  -4.616210607  0.1513881647
## 6375                             D027_r1_SB203580  -8.335475233  0.9719726810
## 6376                             D027_r1_SB216763  -9.650178423  1.1952165948
## 6377                             D027_r1_SB239063  -6.433236761  0.0795911056
## 6378                             D027_r1_SB415286  -9.112972698  0.4311234208
## 6379                             D027_r1_SB431542  -8.146138768  0.6344061320
## 6380                             D027_r1_SB505124  -7.019346960  0.0131107812
## 6381                             D027_r1_SB525334  -8.530275865  0.6258812047
## 6382                             D027_r1_SB590885  -7.226898554  1.2161687013
## 6383                                  D027_r1_SC1 -15.438293182  2.0378621634
## 6384                D027_r1_Schisandrin B (Sch B)  -6.346717761  1.2707348502
## 6385                D027_r1_Selumetinib (AZD6244)  -8.268820622  3.7391600082
## 6386              D027_r1_Semagacestat (LY450139)  -4.805729363 -0.3204513606
## 6387                   D027_r1_Semaxanib (SU5416)  -9.992367624  1.8200003394
## 6388                             D027_r1_SGI-7079  -9.656757205  1.2614562714
## 6389                          D027_r1_Skepinone-L  -5.324547089  0.5172833209
## 6390                               D027_r1_SL-327 -10.930723641  2.7447529892
## 6391                 D027_r1_SNS-032 (BMS-387032)  -9.734435091  2.9157717819
## 6392                     D027_r1_SNS-314 Mesylate -15.312154933  1.7497161928
## 6393                            D027_r1_Sorafenib  -6.302618563  0.6804254523
## 6394                   D027_r1_Sorafenib Tosylate  -7.734977856  0.4705819180
## 6395                         D027_r1_Sotrastaurin  -7.757007633  1.2413776250
## 6396                             D027_r1_SP600125  -6.391924436  0.2457023416
## 6397                              D027_r1_SU11274  -6.501049667  1.2207865775
## 6398                               D027_r1_SU6656  -8.175663584  1.3296087489
## 6399                               D027_r1_SU9516  -9.740883349  1.2540373023
## 6400                     D027_r1_Sunitinib Malate  -5.053950636  2.6875371553
## 6401                  D027_r1_TAE226 (NVP-TAE226) -10.364776495  2.5552221150
## 6402                              D027_r1_TAK-285  -9.043491023  1.7067705056
## 6403                              D027_r1_TAK-632  -8.800380223  2.3124528004
## 6404                              D027_r1_TAK-715  -8.901416638  0.3761516411
## 6405                              D027_r1_TAK-733 -10.931412904  3.0531468641
## 6406                              D027_r1_TAK-901 -11.115282173  2.6348105425
## 6407                D027_r1_Taladegib (LY2940680)  -7.187532475  0.7240770587
## 6408                              D027_r1_TCS 359  -4.013401244 -0.6091096250
## 6409                               D027_r1_TDZD-8  -8.502627216  0.4721398002
## 6410                            D027_r1_Telatinib  -5.349930377 -0.2954694231
## 6411   D027_r1_Temsirolimus (CCI-779, NSC 683864)  -6.899618608  1.3879633777
## 6412              D027_r1_Tepotinib (EMD 1214063) -19.427979441  2.2741602738
## 6413                                D027_r1_TG003  -4.976181025  0.3828694705
## 6414                            D027_r1_TG100-115  -8.639422822  1.0757551622
## 6415                             D027_r1_TG101209 -15.733712556  2.4289415163
## 6416                 D027_r1_TG101348 (SAR302503) -17.590388230  1.5659985597
## 6417                              D027_r1_TGX-221  -6.498911267  0.1734435610
## 6418                         D027_r1_Theophylline  -6.095784223  0.5284359480
## 6419                          D027_r1_Thiazovivin  -4.213110828 -0.1232676102
## 6420                       D027_r1_TIC10 Analogue  -8.715899413  0.9831302748
## 6421                           D027_r1_Tideglusib  -8.811568562  1.5121733489
## 6422                 D027_r1_Tivantinib (ARQ 197) -11.292683048  2.5302220587
## 6423                   D027_r1_Tivozanib (AV-951)  -3.910651810 -0.9336021561
## 6424  D027_r1_Tofacitinib (CP-690550,Tasocitinib)  -7.441045471  1.1463651307
## 6425      D027_r1_Tofacitinib (CP-690550) Citrate  -6.951056073  1.2156017612
## 6426                              D027_r1_Torin 2  -8.878049353  3.0316016000
## 6427              D027_r1_Trametinib (GSK1120212) -11.946815975  2.4954446355
## 6428                          D027_r1_Triciribine -11.913011586  2.2994738241
## 6429           D027_r1_TSU-68 (SU6668, Orantinib)  -5.611695438  0.8533240255
## 6430                               D027_r1_TWS119  -7.809271525  0.4582364517
## 6431                         D027_r1_Tyrphostin 9  -5.708973077  1.2489338987
## 6432                   D027_r1_Tyrphostin AG 1296  -5.714215458  1.2162065422
## 6433                           D027_r1_U0126-EtOH  -9.285491393  3.1503018298
## 6434     D027_r1_Ulixertinib (BVD-523, VRT752271)  -8.298461343  2.2135227283
## 6435              D027_r1_Uprosertib (GSK2141795)  -8.179605810  0.9541445894
## 6436                          D027_r1_Vacquinol-1 -13.071224877  2.5530078352
## 6437                           D027_r1_Varlitinib  -6.168292054  0.4536750587
## 6438              D027_r1_Vatalanib (PTK787) 2HCl  -5.912231569  0.9541394232
## 6439                               D027_r1_VE-821  -6.457395943  1.8444923399
## 6440                               D027_r1_VE-822  -9.025773851  0.3723983993
## 6441        D027_r1_Vemurafenib (PLX4032, RG7204)  -8.964813509  0.7949898556
## 6442                D027_r1_Vismodegib (GDC-0449)  -7.441674895  1.1478256444
## 6443                 D027_r1_Volasertib (BI 6727)  -8.600055874  1.3255479107
## 6444                            D027_r1_VPS34-IN1 -11.352658776  0.8769959677
## 6445                     D027_r1_VS-5584 (SB2343)  -5.900408469  2.0209252227
## 6446                               D027_r1_VX-11e -11.079361849  2.1982789063
## 6447         D027_r1_VX-680 (Tozasertib, MK-0457) -12.503622205  2.1554679017
## 6448                               D027_r1_VX-702  -5.420226515  0.2350843427
## 6449                               D027_r1_VX-745  -7.308754882  0.5509678439
## 6450                              D027_r1_WAY-600 -12.057129684  2.1890166993
## 6451                             D027_r1_WH-4-023  -4.545616807  0.0045626657
## 6452                             D027_r1_WHI-P154  -7.552552033  0.9491749785
## 6453                                D027_r1_WIKI4  -6.202415623  0.6721312637
## 6454                        D027_r1_Wnt agonist 1 -15.733337861  3.2876973296
## 6455                        D027_r1_Wnt-C59 (C59)  -5.807799397 -0.1511435278
## 6456                               D027_r1_WP1066  -5.448177842  0.8229405159
## 6457                 D027_r1_WYE-125132 (WYE-132)  -3.972582717 -0.7996901353
## 6458                              D027_r1_WYE-354  -4.041444450  0.7564270821
## 6459                               D027_r1_WZ3146  -9.012871315  4.0759785412
## 6460                               D027_r1_WZ4002  -5.811733767  0.4321596084
## 6461                               D027_r1_WZ4003  -6.641412739 -0.0891581453
## 6462                               D027_r1_WZ8040  -7.811718999  2.3641726551
## 6463                              D027_r1_XAV-939  -7.321157329  0.4035266428
## 6464                                D027_r1_XL019 -12.520658414  0.3000591828
## 6465                              D027_r1_XMD8-92 -11.148600942  1.5445981574
## 6466                         D027_r1_Y-27632 2HCl  -5.532522169  0.8589185394
## 6467                             D027_r1_YM201636 -12.249217894  2.6374757009
## 6468                             D027_r1_YO-01027  -6.747316910  1.1659237885
## 6469                            D027_r1_ZM 306416  -7.169025683  1.8944244757
## 6470                        D027_r1_ZM 323881 HCl  -6.318067210  0.8620601181
## 6471                            D027_r1_ZM 336372  -7.417414952 -0.2234723170
## 6472                         D027_r1_ZM 39923 HCl  -6.974136185  1.0374943630
## 6473                            D027_r1_ZM 447439 -11.361396131  2.3028979406
## 6474                 D027_r1_Zotarolimus(ABT-578)  -5.289862318  1.0189127275
## 6475                              D027_r1_ZSTK474  -8.754830504  2.9243202605
## 6476                     D027_r2_1-Azakenpaullone  -5.644440925  1.6263416817
## 6477                            D027_r2_Acadesine  -5.592011191  1.0824286201
## 6478                  D027_r2_AEE788 (NVP-AEE788)  -8.102415859 -0.3978064968
## 6479        D027_r2_Afatinib (BIBW2992)_uncertain  -3.800579108 -1.1509525200
## 6480                              D027_r2_AG-1024  -2.384926114  2.3708261675
## 6481                                D027_r2_AG-18  -3.222942198  0.9405415094
## 6482              D027_r2_AG-490 (Tyrphostin B42)  -6.741381920  0.9102357719
## 6483                  D027_r2_Alisertib (MLN8237) -13.096680386  0.7478975523
## 6484                              D027_r2_AMG 337  -4.812514249  0.9816445692
## 6485                  D027_r2_Amuvatinib (MP-470)  -4.953140055 -0.1057094704
## 6486                             D027_r2_Apatinib  -6.757293644  2.4614879157
## 6487                           D027_r2_AR-A014418  -3.441782895  0.9525504619
## 6488                         D027_r2_Asiatic Acid  -4.783914683  1.3511991209
## 6489                             D027_r2_AST-1306  -7.669947016  1.6141271683
## 6490                              D027_r2_AT13148  -8.889075690  0.7071531188
## 6491                               D027_r2_AT7519 -10.264792420  1.8623389999
## 6492                               D027_r2_AT7867  -5.304601836  3.0744794546
## 6493                               D027_r2_AT9283 -13.039446235  0.7942607060
## 6494                 D027_r2_Aurora A Inhibitor I  -6.217587840  1.1762592892
## 6495             D027_r2_Avagacestat (BMS-708163)  -5.930326469 -0.7194512916
## 6496                             D027_r2_Axitinib  -5.398300632 -0.4409727501
## 6497                             D027_r2_Axitinib  -5.398300632 -0.4409727501
## 6498                               D027_r2_AZ 960  -6.462031600  0.0692324429
## 6499                              D027_r2_AZD1080 -10.747213822  0.8994276473
## 6500                              D027_r2_AZD1480 -11.843824861  1.4462765830
## 6501                              D027_r2_AZD2858 -12.128245251  0.1841295630
## 6502                              D027_r2_AZD5363  -6.988564201  0.6370249456
## 6503                              D027_r2_AZD6482  -6.087376645  0.2529166336
## 6504                              D027_r2_AZD8055  -7.463804543 -1.5614062886
## 6505                              D027_r2_AZD8330  -7.386933182  1.4470008171
## 6506                  D027_r2_AZD8931 (Sapitinib)  -8.565015570  0.3526279710
## 6507            D027_r2_Barasertib (AZD1152-HQPA)  -7.753569342  2.0336900238
## 6508  D027_r2_Baricitinib (LY3009104, INCB028050)  -6.543917436 -0.0527159804
## 6509                              D027_r2_BI 2536 -12.252631736  0.4956750434
## 6510                              D027_r2_BI-78D3  -3.147360275  0.8277484857
## 6511                              D027_r2_Bikinin  -7.055160252  1.6233596902
## 6512                                  D027_r2_BIO  -8.523731610  0.0736483918
## 6513               D027_r2_BIRB 796 (Doramapimod)  -4.963239708  0.8017046622
## 6514                            D027_r2_BIX 02188  -3.519190775  0.4525904295
## 6515                            D027_r2_BIX 02189  -3.622990557  0.5555903355
## 6516      D027_r2_BKM120 (NVP-BKM120, Buparlisib) -10.397167315 -0.3659040356
## 6517                           D027_r2_BMS-265246  -4.611527924  1.0683360268
## 6518                           D027_r2_BMS-536924 -11.305482366  1.7366272438
## 6519                           D027_r2_BMS-582949  -3.918650233  0.2442237119
## 6520                           D027_r2_BMS-754807 -10.867302939  0.2544578927
## 6521                           D027_r2_BMS-777607  -6.793648282  3.5690933123
## 6522                           D027_r2_BMS-794833  -6.538264581  1.1168507732
## 6523                           D027_r2_BMS-833923  -6.972857803  0.9002923521
## 6524                  D027_r2_Bosutinib (SKI-606)  -8.392393289  0.2519841468
## 6525                D027_r2_Brivanib (BMS-540215)  -7.599077292  2.0158566336
## 6526      D027_r2_Brivanib Alaninate (BMS-582664)  -4.668804188 -0.3140880766
## 6527                           D027_r2_BS-181 HCl  -5.775352034  1.1816241129
## 6528     D027_r2_Cabozantinib (XL184, BMS-907351)  -6.788431154  0.4660655652
## 6529        D027_r2_CAL-101 (Idelalisib, GS-1101)  -6.387383640  1.9059882967
## 6530                               D027_r2_CC-223  -4.759263332 -0.3553612630
## 6531                  D027_r2_Cediranib (AZD2171)  -5.125655592 -0.8169981602
## 6532                            D027_r2_CEP-32496  -7.205738745 -0.8266921446
## 6533                            D027_r2_CEP-33779  -7.813358851  0.9582763986
## 6534                           D027_r2_CHIR-98014  -8.344593786  0.6544403562
## 6535                 D027_r2_CHIR-99021 (CT99021) -12.036878362  0.7894289963
## 6536             D027_r2_CHIR-99021 (CT99021) HCl -10.686692844  1.9855417099
## 6537                            D027_r2_CP-673451  -8.961705060  2.8841412153
## 6538                            D027_r2_CP-724714  -7.392781451  0.6485466845
## 6539             D027_r2_Crizotinib (PF-02341066) -13.275408357  1.0407292570
## 6540                               D027_r2_CYC116 -10.442448595  0.7039738428
## 6541                               D027_r2_CYT387  -7.002695145  0.5938984760
## 6542              D027_r2_Danusertib (PHA-739358) -11.268060704  0.3559426987
## 6543                        D027_r2_DAPT (GSI-IX)  -4.051449616  0.5077258589
## 6544                            D027_r2_Dasatinib  -9.157305264  0.6527515268
## 6545                D027_r2_Decernotinib (VX-509)  -4.032480995 -0.0200569675
## 6546                            D027_r2_ENMD-2076  -9.303347048  1.2257107155
## 6547               D027_r2_Enzastaurin (LY317615)  -8.425466923  0.5207558407
## 6548                             D027_r2_ETC-1002  -9.911987390  0.4607381766
## 6549                  D027_r2_Everolimus (RAD001)  -4.002203334 -0.6483695134
## 6550                D027_r2_Fasudil (HA-1077) HCl  -6.959433346  0.3816527075
## 6551                                D027_r2_FH535  -0.097736566  0.6888087496
## 6552                D027_r2_Filgotinib (GLPG0634)  -4.897676754  0.1426913878
## 6553             D027_r2_Flavopiridol (Alvocidib)  -6.759500561 -0.4840245835
## 6554               D027_r2_Foretinib (GSK1363089) -10.148278004  1.3133841715
## 6555                                D027_r2_G-749  -6.770419233 -0.4975073158
## 6556                             D027_r2_GDC-0879  -6.028027951  2.3610927304
## 6557                             D027_r2_GDC-0941  -5.212320510  0.2177418424
## 6558                   D027_r2_Gefitinib (ZD1839)  -7.614158679 -0.4913346024
## 6559                            D027_r2_Genistein  -5.779865606  0.9292384010
## 6560                            D027_r2_GF109203X  -5.146263878  0.7696614354
## 6561                                D027_r2_GNF-5  -5.954887516  1.4276225616
## 6562                              D027_r2_Go 6983  -7.200437556  0.7965311258
## 6563                          D027_r2_GSK1904529A  -7.801431248  0.6538619561
## 6564                           D027_r2_GSK2292767  -9.179335682  0.7543603548
## 6565                           D027_r2_GSK429286A  -6.022120852  1.2871054444
## 6566                            D027_r2_GSK461364 -10.040044179  1.2191700861
## 6567                               D027_r2_GSK621  -7.705284138  0.1438426510
## 6568                            D027_r2_GSK690693  -8.844594707  0.9883342652
## 6569                             D027_r2_GW788388  -5.225489207 -0.3932719817
## 6570                            D027_r2_H 89 2HCl  -5.825915627  1.3849143471
## 6571                           D027_r2_Hesperadin  -8.671277453  2.7882779033
## 6572                              D027_r2_HMN-214 -13.087691818  1.4852773773
## 6573                             D027_r2_Honokiol  -9.312884446  2.4298195210
## 6574                              D027_r2_ICG-001  -5.307514025  0.9263013822
## 6575                                D027_r2_IM-12  -3.845003937  0.9088810212
## 6576           D027_r2_Imatinib Mesylate (STI571) -11.087696884  0.6111172202
## 6577                            D027_r2_Indirubin  -8.658866746  0.7565849787
## 6578                               D027_r2_IWP-L6  -4.050682386  0.8244654352
## 6579                           D027_r2_IWR-1-endo  -5.639089653  0.1921889389
## 6580                         D027_r2_JNJ-38877605  -5.918795151  1.0192405077
## 6581                          D027_r2_JNJ-7706621 -10.812710643  1.8878094005
## 6582                               D027_r2_K02288  -5.956329899  0.7682026376
## 6583                               D027_r2_Ki8751  -6.134978420  1.2471459512
## 6584                              D027_r2_KRN 633  -6.410858479  2.0812426807
## 6585                           D027_r2_KU-0063794  -6.791674371  1.3313908295
## 6586      D027_r2_KU-55933 (ATM Kinase Inhibitor)  -7.969017216  0.1638588386
## 6587                             D027_r2_KU-60019  -7.976146608  0.2943777354
## 6588                              D027_r2_KW-2449  -5.803344500  3.3872660676
## 6589                              D027_r2_KY02111  -4.646001281  0.5948397211
## 6590                            D027_r2_Lapatinib  -5.953858330  1.0723919609
## 6591     D027_r2_Lapatinib (GW-572016) Ditosylate  -4.727442251  0.4529659435
## 6592      D027_r2_LDE225 (NVP-LDE225,Erismodegib)  -1.674103402 -1.3977914429
## 6593                   D027_r2_Lenvatinib (E7080)  -6.015028876  0.3274166792
## 6594                              D027_r2_LFM-A13  -7.264456885 -0.0042208578
## 6595                              D027_r2_LGK-974  -3.450892077  0.4392574918
## 6596                  D027_r2_Linifanib (ABT-869)  -3.260814417  0.8871762294
## 6597                               D027_r2_LJI308  -4.883882727 -0.5093614562
## 6598                            D027_r2_LY2157299  -2.392615909  1.7583933582
## 6599                            D027_r2_LY2784544  -9.705863382  1.5432053447
## 6600                             D027_r2_LY294002  -6.900522840  1.3234174106
## 6601                            D027_r2_LY3023414  -9.824047071  0.4767929607
## 6602                             D027_r2_LY411575  -8.779236291  0.7804768449
## 6603                             D027_r2_MGCD-265  -6.096266591  1.3494679156
## 6604                              D027_r2_MK-0752  -3.801999315 -0.3451880979
## 6605                         D027_r2_MK-2206 2HCl  -6.184036926 -0.6563531780
## 6606                              D027_r2_MLN8054  -8.096811141  0.2710950069
## 6607      D027_r2_Motesanib Diphosphate (AMG-706)  -6.894021629 -0.5546872884
## 6608                  D027_r2_Nilotinib (AMN-107)  -5.860073285  1.4095619231
## 6609     D027_r2_Nintedanib (BIBF 1120)_uncertain  -4.936117913 -0.3588991097
## 6610                           D027_r2_NVP-AEW541   1.344442971  1.8315128408
## 6611                           D027_r2_NVP-BHG712  -8.929428936  1.4294406826
## 6612                      D027_r2_NVP-BSK805 2HCl  -6.867681166  0.2769037540
## 6613                          D027_r2_Oclacitinib  -4.249824046  0.4730481674
## 6614      D027_r2_Olmutinib (HM61713, BI 1482694)  -6.706370826 -0.1698931841
## 6615                             D027_r2_ONO-4059  -7.750721341  3.0300048292
## 6616                              D027_r2_OSI-420  -7.156107040  2.2332778580
## 6617                 D027_r2_OSI-906 (Linsitinib)  -9.806662273  2.0458248656
## 6618                  D027_r2_Pacritinib (SB1518)  -8.616796297 -0.3293202890
## 6619                   D027_r2_Palomid 529 (P529)  -6.867563838  0.7016280217
## 6620                        D027_r2_Pazopanib HCl  -7.804475324  1.3773328169
## 6621                            D027_r2_PD0325901  -9.846350840  1.3728165206
## 6622                             D027_r2_PD173955  -6.529304550  1.9616142840
## 6623                   D027_r2_PD184352 (CI-1040)  -6.736325395  1.4706584190
## 6624                             D027_r2_PD318088  -7.994773005  2.0728500335
## 6625                              D027_r2_PD98059  -5.031583313  2.2947138453
## 6626                  D027_r2_Pelitinib (EKB-569)  -7.044203146 -1.7041126230
## 6627                          D027_r2_PF-04217903  -3.161167131  0.4849821558
## 6628                           D027_r2_PF-4708671 -10.590208195 -0.1381529093
## 6629                           D027_r2_PF-5274857  -7.047874144  0.7262665392
## 6630                            D027_r2_PF-573228  -7.650699213  2.2451796882
## 6631                           D027_r2_PHA-665752  -3.528962294 -0.5685789356
## 6632                           D027_r2_PHA-680632 -13.146077636  1.1677981291
## 6633                           D027_r2_PHA-793887  -8.692670548  2.9418808449
## 6634                              D027_r2_PHT-427  -3.412388361  0.4403376067
## 6635                              D027_r2_PIK-293  -2.717871077 -1.1752535354
## 6636                              D027_r2_PIK-294  -5.056111055  1.3829452963
## 6637                               D027_r2_PIK-93 -13.187409474  1.3278387587
## 6638               D027_r2_Pimasertib (AS-703026)  -6.911537765  1.4827921346
## 6639                          D027_r2_Pirfenidone  -7.148546065  0.2359524548
## 6640                             D027_r2_PLX-4720  -6.447101750  0.3891022838
## 6641                  D027_r2_Ponatinib (AP24534)  -3.622643641  1.0916172699
## 6642                                D027_r2_PP242   2.154945939  0.1293476111
## 6643                              D027_r2_PRI-724  -6.732538038  1.2352660612
## 6644     D027_r2_PRT062607 (P505-15, BIIB057) HCl -11.501043935  1.9974913879
## 6645                            D027_r2_Quercetin  -3.977884382  1.2716481181
## 6646                  D027_r2_Quizartinib (AC220)  -7.606683058  0.2532972246
## 6647                                 D027_r2_R406  -7.066417348  2.0643482026
## 6648                     D027_r2_R406 (free base)  -7.456521691  1.2771762996
## 6649                    D027_r2_RAF265 (CHIR-265)  -5.770349988  0.7067543111
## 6650                D027_r2_Rapamycin (Sirolimus)  -6.572179859 -0.7444908685
## 6651   D027_r2_Refametinib (RDEA119, Bay 86-9766)  -8.789204936  1.4633581528
## 6652                               D027_r2_RepSox  -4.879686740 -0.2868561827
## 6653 D027_r2_Ridaforolimus (Deforolimus, MK-8669)  -5.587265572  0.4613518181
## 6654                D027_r2_Rigosertib (ON-01910)  -9.979725728  1.6066143444
## 6655                             D027_r2_RKI-1447  -1.850370710 -0.6688665574
## 6656                  D027_r2_Ro 31-8220 Mesylate  -8.034678898  2.1555283419
## 6657                              D027_r2_Ro-3306  -4.267448410 -0.3494050724
## 6658                            D027_r2_RO4929097  -7.241548990  0.2128155354
## 6659      D027_r2_Roscovitine (Seliciclib,CYC202)  -5.416715735  1.2654164467
## 6660             D027_r2_Ruxolitinib (INCB018424)  -6.631522975  0.7585946317
## 6661           D027_r2_S-Ruxolitinib (INCB018424)  -2.773599759  0.8049428149
## 6662                               D027_r2_SANT-1  -2.751234372 -0.0778911000
## 6663                    D027_r2_SAR245409 (XL765)  -5.626367476  1.6005790060
## 6664                D027_r2_Saracatinib (AZD0530)  -4.094400722  0.7515996492
## 6665                      D027_r2_SB202190 (FHPI)  -7.440855881  1.4635225497
## 6666                             D027_r2_SB203580  -5.686572000  1.1131515012
## 6667                             D027_r2_SB216763  -8.898524920  1.5320597277
## 6668                             D027_r2_SB239063  -5.129497663  0.6222935798
## 6669                             D027_r2_SB415286  -9.083122330  2.1270705383
## 6670                             D027_r2_SB431542  -5.195527213  1.9465925105
## 6671                             D027_r2_SB505124  -4.900374278  1.1628603911
## 6672                             D027_r2_SB525334  -8.155437522 -0.3317035512
## 6673                             D027_r2_SB590885  -4.292481352  1.5144635417
## 6674                D027_r2_Selumetinib (AZD6244)  -4.804467654  1.8111437221
## 6675              D027_r2_Semagacestat (LY450139)  -3.089300053  0.4086305840
## 6676                               D027_r2_SL-327  -4.558648251 -0.2785103424
## 6677                 D027_r2_SNS-032 (BMS-387032)  -8.397194938  1.8410945341
## 6678                     D027_r2_SNS-314 Mesylate -14.062627631  1.4958568723
## 6679                   D027_r2_Sorafenib Tosylate  -7.864434596  0.1164267311
## 6680                         D027_r2_Sotrastaurin  -9.057137141  0.9556802969
## 6681                             D027_r2_SP600125  -4.214469906  1.0747045672
## 6682                              D027_r2_SU11274  -8.410604961 -0.2496008325
## 6683                     D027_r2_Sunitinib Malate  -4.372828198  0.4010767356
## 6684                D027_r2_Taladegib (LY2940680)  -4.312891973  0.7064546033
## 6685                              D027_r2_TCS 359  -6.789749734  0.9147758676
## 6686                            D027_r2_Telatinib  -6.541983808 -0.5682784995
## 6687   D027_r2_Temsirolimus (CCI-779, NSC 683864)  -5.292784000  1.4110785778
## 6688                            D027_r2_TG100-115  -7.701011213  0.9350962874
## 6689                             D027_r2_TG101209 -14.523395865  1.7516547956
## 6690                 D027_r2_TG101348 (SAR302503)  -8.746019431  0.7759777319
## 6691                              D027_r2_TGX-221  -9.217281936 -0.4867668746
## 6692                         D027_r2_Theophylline  -5.831334553  0.3680971884
## 6693                          D027_r2_Thiazovivin  -6.178897077  1.2495253670
## 6694                   D027_r2_Tivozanib (AV-951)  -3.491803953 -0.5121433073
## 6695  D027_r2_Tofacitinib (CP-690550,Tasocitinib)  -5.009719456 -0.0539925843
## 6696      D027_r2_Tofacitinib (CP-690550) Citrate  -4.353668193  2.0390308542
## 6697                          D027_r2_Triciribine  -9.723537685  1.5191695844
## 6698           D027_r2_TSU-68 (SU6668, Orantinib)  -6.235941125  1.4686807350
## 6699                               D027_r2_TWS119  -4.743596251  0.0721216706
## 6700                   D027_r2_Tyrphostin AG 1296  -7.299734406  1.7141427014
## 6701                           D027_r2_U0126-EtOH  -3.315049863  0.8348229178
## 6702                          D027_r2_Vacquinol-1  -8.470323430  2.5090115585
## 6703              D027_r2_Vatalanib (PTK787) 2HCl  -5.171228628 -0.9996977093
## 6704                               D027_r2_VE-821  -7.172495139  0.4989319539
## 6705        D027_r2_Vemurafenib (PLX4032, RG7204)  -6.196131790  0.2431440832
## 6706                D027_r2_Vismodegib (GDC-0449)  -7.081539215  0.6460534494
## 6707                 D027_r2_Volasertib (BI 6727)  -3.604711768  0.5384065113
## 6708                               D027_r2_VX-11e  -7.836385000  2.2096393117
## 6709         D027_r2_VX-680 (Tozasertib, MK-0457) -12.322180304  1.0409119447
## 6710                               D027_r2_VX-745  -5.144741005  0.6566763519
## 6711                             D027_r2_WH-4-023   0.401263763  0.1706339807
## 6712                             D027_r2_WHI-P154  -4.691337513  1.1476953057
## 6713                                D027_r2_WIKI4  -2.832242697 -1.2814016300
## 6714                        D027_r2_Wnt agonist 1 -11.480204278  2.0332318827
## 6715                        D027_r2_Wnt-C59 (C59)  -3.820649513  0.4375937858
## 6716                               D027_r2_WP1066  -4.238195287  2.2420644228
## 6717                              D027_r2_WYE-354  -1.961329096 -1.8357986998
## 6718                               D027_r2_WZ3146  -5.323422115  3.3622813011
## 6719                               D027_r2_WZ4002  -0.053534295  3.6778920355
## 6720                               D027_r2_WZ8040  -7.136599105  1.4254047656
## 6721                              D027_r2_XAV-939  -5.113707942  0.5837103353
## 6722                                D027_r2_XL019 -11.239372881  2.0300642640
## 6723                         D027_r2_Y-27632 2HCl  -5.865199422  1.2475475336
## 6724                             D027_r2_YM201636 -10.484748501  0.7913534124
## 6725                             D027_r2_YO-01027  -6.377204656  0.5117849198
## 6726                         D027_r2_ZM 39923 HCl  -5.248530234  1.4706979115
## 6727                            D027_r2_ZM 447439  -7.224747381  0.8459302697
## 6728                              D027_r2_ZSTK474  -7.272103484 -0.7261581042
## 6729                     D030_r1_1-Azakenpaullone  -9.768769060  0.5103994188
## 6730                      D030_r1_3-Methyladenine -10.455405913  0.7705945439
## 6731                             D030_r1_A-674563 -18.354419081  0.4246785667
## 6732                             D030_r1_A-769662  -7.081832294  0.2480082323
## 6733                                  D030_r1_A66  -7.867919429  2.8398703683
## 6734                            D030_r1_Acadesine  -7.361768313  0.4871587260
## 6735                  D030_r1_AEE788 (NVP-AEE788)  -5.271060198 -0.1878227277
## 6736        D030_r1_Afatinib (BIBW2992)_uncertain  -9.732035503  1.0272618676
## 6737                              D030_r1_AG-1024  -2.864812674 -1.0517879122
## 6738         D030_r1_AG-1478 (Tyrphostin AG-1478)  -7.937589759  0.3792971579
## 6739                                D030_r1_AG-18  -9.225786695  0.3187114069
## 6740              D030_r1_AG-490 (Tyrphostin B42)  -7.291989292  0.2351439509
## 6741                             D030_r1_Akti-1/2  -9.682822309  1.5635095908
## 6742                  D030_r1_Alisertib (MLN8237) -15.393091760  4.3974602434
## 6743                              D030_r1_AMG 337  -8.540849349  0.0762822456
## 6744                              D030_r1_AMG-458  -8.860189975  1.1694259166
## 6745                              D030_r1_AMG-900 -16.833899231  2.8348113452
## 6746                               D030_r1_AMG319  -7.105972874  0.3362785853
## 6747                  D030_r1_Amuvatinib (MP-470)  -9.337107101 -0.1930498374
## 6748                             D030_r1_Apatinib  -6.320976840 -0.4547464177
## 6749                           D030_r1_AR-A014418  -8.613295730  1.1387411672
## 6750                            D030_r1_AS-252424  -9.834010187  0.3986363288
## 6751                            D030_r1_AS-604850  -7.440857751  0.8142406458
## 6752                         D030_r1_Asiatic Acid  -8.519385905  0.4460205981
## 6753                             D030_r1_AST-1306  -8.979362142  1.7842853500
## 6754                              D030_r1_AT13148  -6.666593951 -0.4305446170
## 6755                               D030_r1_AT7519 -12.381662796  0.9809391492
## 6756                               D030_r1_AT7867  -3.904947267  0.4415355220
## 6757                               D030_r1_AT9283 -15.826847778  0.7110087993
## 6758                 D030_r1_Aurora A Inhibitor I  -8.174160873  1.0830153669
## 6759             D030_r1_Avagacestat (BMS-708163)  -8.739034388  0.8554814766
## 6760                              D030_r1_AVL-292  -8.997837665  2.0428250504
## 6761                             D030_r1_Axitinib  -9.808713601  0.8527594767
## 6762                             D030_r1_Axitinib  -9.808713601  0.8527594767
## 6763                               D030_r1_AZ 628  -9.315169619  2.7528750987
## 6764                               D030_r1_AZ 960 -10.982178283  0.3398879183
## 6765                                 D030_r1_AZ20  -8.825153582  4.0400929902
## 6766                              D030_r1_AZD1080 -10.421023737 -0.8444067428
## 6767                              D030_r1_AZD1480 -17.226481210  1.4717857888
## 6768                              D030_r1_AZD2014  -1.972642776  1.8381055632
## 6769                              D030_r1_AZD2858 -12.363443417 -0.3270786513
## 6770                              D030_r1_AZD2932 -10.474487177  0.4748436625
## 6771                              D030_r1_AZD3759  -8.246443752  1.8848746210
## 6772                              D030_r1_AZD5363  -9.523732754  1.3805558708
## 6773                              D030_r1_AZD5438 -16.009339989  1.7950434400
## 6774                              D030_r1_AZD6482  -7.885675249  0.6237153651
## 6775                              D030_r1_AZD6738 -10.106500034  2.3704010754
## 6776                              D030_r1_AZD8055  -5.378917068  3.7603119257
## 6777                              D030_r1_AZD8330  -3.025712419 -0.2416977088
## 6778                  D030_r1_AZD8931 (Sapitinib)  -9.232997483  0.2305751731
## 6779                              D030_r1_AZD9291  -9.456785234  3.2370583425
## 6780            D030_r1_Barasertib (AZD1152-HQPA) -17.910375697  2.1284788889
## 6781  D030_r1_Baricitinib (LY3009104, INCB028050)  -6.426612214  0.0259064190
## 6782                  D030_r1_BGT226 (NVP-BGT226)  -9.415391809  3.1100834724
## 6783                              D030_r1_BI 2536  -9.737068754  3.0935294487
## 6784                              D030_r1_BI-78D3  -7.358635031 -0.1288684259
## 6785                             D030_r1_BI-D1870 -10.580860459  0.2264032016
## 6786                              D030_r1_Bikinin  -7.410997467  0.1060237951
## 6787                                  D030_r1_BIO  -9.845614235  1.7724895662
## 6788               D030_r1_BIRB 796 (Doramapimod)  -6.777178803 -0.3487198927
## 6789                            D030_r1_BIX 02188  -8.361910911  0.5222170542
## 6790                            D030_r1_BIX 02189  -7.866240125 -0.9147947234
## 6791      D030_r1_BKM120 (NVP-BKM120, Buparlisib) -10.114253187  3.5040861777
## 6792                           D030_r1_BMS-265246  -7.459677689  1.7696477820
## 6793                           D030_r1_BMS-536924  -6.044227935  3.2402860735
## 6794                           D030_r1_BMS-582949  -8.791251937  1.3434685524
## 6795                           D030_r1_BMS-754807 -12.059680386  5.8923395988
## 6796                           D030_r1_BMS-777607  -8.001482824  0.5900544101
## 6797                           D030_r1_BMS-794833  -6.743861013  0.0060514363
## 6798                           D030_r1_BMS-833923  -8.085526804  0.0365091618
## 6799                  D030_r1_Bosutinib (SKI-606)  -5.603845005  0.3343505727
## 6800                D030_r1_Brivanib (BMS-540215)  -6.173418653 -0.0527581782
## 6801      D030_r1_Brivanib Alaninate (BMS-582664)  -4.640158003  0.4826264921
## 6802                           D030_r1_BS-181 HCl -10.297341981  1.2929669469
## 6803                               D030_r1_Butein  -9.459736645  0.5486373637
## 6804                               D030_r1_BYL719  -7.516895786  3.5376019403
## 6805     D030_r1_Cabozantinib (XL184, BMS-907351)  -9.109791082  1.3717037187
## 6806          D030_r1_Cabozantinib malate (XL184)  -9.962479082  1.2299908682
## 6807        D030_r1_CAL-101 (Idelalisib, GS-1101)  -9.146325985  0.9846405813
## 6808                             D030_r1_CAY10505  -8.179830101  0.1086957002
## 6809                               D030_r1_CC-223  -2.741059104  0.2525807200
## 6810                            D030_r1_CCT128930  -9.484189052  2.2902701625
## 6811                  D030_r1_Cediranib (AZD2171)  -9.156477497  0.5943924115
## 6812                            D030_r1_CEP-32496  -7.251666854 -0.0215284367
## 6813                            D030_r1_CEP-33779  -7.305332320 -0.2321176411
## 6814                              D030_r1_CGI1746  -7.079597793  2.0740032560
## 6815                              D030_r1_CGK 733  -7.791078113  0.8959205678
## 6816                            D030_r1_CH5132799  -7.155654867  2.9917049800
## 6817                           D030_r1_CHIR-98014 -11.734041084 -0.3038563183
## 6818                 D030_r1_CHIR-99021 (CT99021) -15.380177490  1.7516763816
## 6819             D030_r1_CHIR-99021 (CT99021) HCl -11.113131887  0.6997968329
## 6820                    D030_r1_Chrysophanic Acid  -9.123796479  0.1115288210
## 6821                             D030_r1_CNX-2006 -10.533953626  0.7543943969
## 6822                              D030_r1_CNX-774  -7.852684836 -0.0304295352
## 6823                    D030_r1_CO-1686 (AVL-301) -11.620075449  2.5205615635
## 6824       D030_r1_Cobimetinib (GDC-0973, RG7420)  -4.861676752  4.5401512256
## 6825                            D030_r1_CP-673451 -15.204840131  3.4209114906
## 6826                            D030_r1_CP-724714  -7.165229974  0.4240383974
## 6827               D030_r1_Crenolanib (CP-868596) -10.538985027 -0.1090204363
## 6828             D030_r1_Crizotinib (PF-02341066) -12.943801859  3.5608819549
## 6829                               D030_r1_CYC116 -12.653283541  1.9693145350
## 6830                               D030_r1_CYT387  -7.671358525  0.1933334330
## 6831                             D030_r1_CZC24832  -8.129702666 -0.3386036182
## 6832              D030_r1_Dabrafenib (GSK2118436) -10.571967793 -0.6818526936
## 6833        D030_r1_Dacomitinib (PF299804, PF299)  -8.880609544  1.8819133068
## 6834              D030_r1_Danusertib (PHA-739358) -10.121559797  1.0574947846
## 6835                        D030_r1_DAPT (GSI-IX)  -8.953986722  0.2288927295
## 6836                            D030_r1_Dasatinib  -8.348525373 -0.2265070668
## 6837                D030_r1_DCC-2036 (Rebastinib) -12.370659588  0.9226602875
## 6838                D030_r1_Decernotinib (VX-509)  -6.840271964  0.0256607432
## 6839               D030_r1_Dinaciclib (SCH727965) -15.213777901  1.5271982203
## 6840    D030_r1_Dovitinib (TKI-258) Dilactic Acid -11.070923903  1.8669084435
## 6841                            D030_r1_ENMD-2076 -15.937079548  2.0351251141
## 6842               D030_r1_Enzastaurin (LY317615) -15.585717223 -0.2205668818
## 6843                            D030_r1_ERK5-IN-1  -6.794322754  1.6016426473
## 6844                             D030_r1_ETC-1002  -6.444853838  0.4619422619
## 6845                            D030_r1_ETP-46464  -7.046215035  0.5232575499
## 6846                  D030_r1_Everolimus (RAD001)  -6.269832581  0.7213395849
## 6847                D030_r1_Fasudil (HA-1077) HCl  -8.173996436  0.5168230652
## 6848                                D030_r1_FH535   0.196917515 -1.1563360620
## 6849                D030_r1_Filgotinib (GLPG0634)  -8.414757567  0.7893015009
## 6850             D030_r1_Flavopiridol (Alvocidib) -12.627986018  0.3777095466
## 6851                     D030_r1_Flavopiridol HCl -13.697052660  2.2375993672
## 6852               D030_r1_Foretinib (GSK1363089) -11.797435638  0.5109048326
## 6853                  D030_r1_Fostamatinib (R788) -15.519483725  0.0312936837
## 6854                                D030_r1_G-749  -9.731154878  0.8857374549
## 6855                             D030_r1_GDC-0068  -9.148451118  1.7218542463
## 6856                             D030_r1_GDC-0349  -7.102952050  1.0709397637
## 6857                             D030_r1_GDC-0879  -4.433214044  0.7768777202
## 6858                             D030_r1_GDC-0941 -10.727589012  2.2868887759
## 6859                    D030_r1_GDC-0980 (RG7422)   6.756385889  9.1079753816
## 6860                   D030_r1_Gefitinib (ZD1839)  -8.841179847  2.2091373588
## 6861                            D030_r1_Genistein  -7.126403791  1.3304078967
## 6862                            D030_r1_GF109203X  -8.413084260 -0.1900970659
## 6863                                D030_r1_GNF-2  -8.518629112  0.5398129152
## 6864                                D030_r1_GNF-5  -9.568716985  0.5189884738
## 6865                              D030_r1_Go 6983  -7.244467136  0.0896885718
## 6866                   D030_r1_Golvatinib (E7050) -18.602888449  2.1915531754
## 6867                          D030_r1_GSK1838705A  -6.845879710  0.5837775764
## 6868                          D030_r1_GSK1904529A  -5.972588587 -0.0361697358
## 6869                  D030_r1_GSK2126458 (GSK458)  -9.999270730  3.9630004999
## 6870                           D030_r1_GSK2292767  -6.275342273  4.3312592334
## 6871                           D030_r1_GSK2636771 -11.243981200 -0.2245193092
## 6872                           D030_r1_GSK429286A  -5.743861353  0.8166982304
## 6873                            D030_r1_GSK461364 -12.029009913  0.6473108054
## 6874                               D030_r1_GSK621  -9.468979849  0.3028665836
## 6875                            D030_r1_GSK690693  -9.480682308  1.4419071863
## 6876                               D030_r1_GW5074  -6.811489377  0.1402827837
## 6877                             D030_r1_GW788388  -8.653305662  1.0540098984
## 6878                               D030_r1_GZD824  -5.271132229  2.3869816766
## 6879                            D030_r1_H 89 2HCl  -7.286999206  0.7114470952
## 6880                           D030_r1_Hesperadin  -8.225454383  4.8281216830
## 6881                              D030_r1_HMN-214 -14.311415711  0.8290915149
## 6882                             D030_r1_Honokiol  -9.670326707  0.9063875544
## 6883                               D030_r1_HS-173 -14.233401638  1.6571614330
## 6884                           D030_r1_HTH-01-015 -13.177267319  0.5780348565
## 6885                D030_r1_Ibrutinib (PCI-32765)  -7.853100098  0.9316329758
## 6886                              D030_r1_ICG-001  -8.226193129  1.0893597490
## 6887                             D030_r1_Icotinib -10.181142558  0.5167278483
## 6888                                D030_r1_IM-12 -10.099059407  0.3575507202
## 6889           D030_r1_Imatinib Mesylate (STI571)  -8.294657168  2.5269965293
## 6890                            D030_r1_Indirubin  -7.499373055  1.1246008218
## 6891                    D030_r1_INK 128 (MLN0128)  -4.813501638  4.9896394163
## 6892                    D030_r1_IPI-145 (INK1197) -11.917823173  1.4307727747
## 6893                               D030_r1_IWP-L6  -7.148548451  0.3621423963
## 6894                           D030_r1_IWR-1-endo  -9.250204492  0.2431347620
## 6895                         D030_r1_JNJ-38877605  -9.796817273 -0.2771213734
## 6896                          D030_r1_JNJ-7706621 -12.258508783  6.0678483426
## 6897                     D030_r1_JNK Inhibitor IX -15.253608122 -0.3125842959
## 6898                             D030_r1_JNK-IN-8 -11.905215989  1.3762896446
## 6899                               D030_r1_K02288  -9.973450991  0.8269495999
## 6900                               D030_r1_Ki8751  -8.257883467  0.1192733200
## 6901                              D030_r1_KRN 633  -5.872228729  0.2068113472
## 6902                           D030_r1_KU-0063794  -5.795143024 -0.7690737912
## 6903      D030_r1_KU-55933 (ATM Kinase Inhibitor)  -7.282255259  0.5967951476
## 6904                             D030_r1_KU-60019  -5.568097458  0.5353193212
## 6905                              D030_r1_KW-2449  -7.747754452  3.6970096746
## 6906                              D030_r1_KX2-391 -15.525359874 -0.4825880626
## 6907                              D030_r1_KY02111  -8.309565191  0.1649647801
## 6908                            D030_r1_Lapatinib -10.403722603  0.8540708506
## 6909     D030_r1_Lapatinib (GW-572016) Ditosylate  -7.790959287  0.6475265331
## 6910                            D030_r1_LDC000067 -11.420877505  2.5869303106
## 6911      D030_r1_LDE225 (NVP-LDE225,Erismodegib)  -6.558959217  0.5979771233
## 6912                           D030_r1_LDN-214117  -7.866680748  0.7138922044
## 6913                   D030_r1_Lenvatinib (E7080) -10.416022878  0.5246594013
## 6914                              D030_r1_LFM-A13  -7.993660203  0.8032615134
## 6915                              D030_r1_LGK-974  -5.503844691 -0.5526765567
## 6916                  D030_r1_Linifanib (ABT-869) -11.960605256  0.9941820840
## 6917                               D030_r1_LJH685  -7.871809713 -0.3858973135
## 6918                               D030_r1_LJI308  -8.898406209  0.4927908821
## 6919               D030_r1_Losmapimod (GW856553X)  -8.711975764  1.5374271149
## 6920                            D030_r1_LY2090314 -11.266033162 -3.0552301325
## 6921                            D030_r1_LY2157299  -6.545848534  0.7289061801
## 6922                            D030_r1_LY2784544 -11.327590227  1.5217983555
## 6923                            D030_r1_LY2835219 -10.325154219 -0.0621334764
## 6924                             D030_r1_LY294002  -7.514392420  0.9213143252
## 6925                            D030_r1_LY3023414  -8.272072737  4.6890347247
## 6926                             D030_r1_LY411575  -7.889821442  0.0033246353
## 6927       D030_r1_MEK162 (ARRY-162, ARRY-438162)  -5.329049278  2.0439138622
## 6928                             D030_r1_MGCD-265  -6.793521220  0.0907857625
## 6929               D030_r1_Milciclib (PHA-848125) -16.102526227  1.1413744227
## 6930                              D030_r1_MK-0752  -7.667841341  1.0539633442
## 6931                         D030_r1_MK-2206 2HCl  -8.413506968  1.3935441585
## 6932                              D030_r1_MK-2461  -7.530096981  0.2033234163
## 6933                     D030_r1_MK-5108 (VX-689)  -8.451201043  0.0652566935
## 6934                              D030_r1_MK-8745  -8.369415347  0.2877117108
## 6935                              D030_r1_MLN2480  -9.714188638  1.8300720652
## 6936                              D030_r1_MLN8054  -6.851761906 -0.2259374001
## 6937      D030_r1_Motesanib Diphosphate (AMG-706)  -8.093425254  0.1867904923
## 6938                  D030_r1_Nilotinib (AMN-107)  -8.962463816  0.7444673221
## 6939     D030_r1_Nintedanib (BIBF 1120)_uncertain -10.361322491  2.5874756507
## 6940                               D030_r1_NU6027 -10.502340584  1.1406862922
## 6941                           D030_r1_NVP-AEW541  -6.277645456  2.3250840168
## 6942                           D030_r1_NVP-BHG712  -8.922630159  1.4202878268
## 6943                      D030_r1_NVP-BSK805 2HCl  -8.075808802 -0.1117548616
## 6944                           D030_r1_NVP-BVU972 -12.083322793  1.4204834933
## 6945                          D030_r1_Oclacitinib  -7.891691836  1.0094148754
## 6946      D030_r1_Olmutinib (HM61713, BI 1482694)  -6.451179552  0.5161907372
## 6947                             D030_r1_ONO-4059  -7.493928773  1.4872832138
## 6948                              D030_r1_OSI-027  -6.151167730  1.5408875808
## 6949                              D030_r1_OSI-420  -6.332776134  2.9970895514
## 6950                 D030_r1_OSI-906 (Linsitinib)  -2.232427666 -1.2242160111
## 6951                              D030_r1_P276-00 -14.297274015 -0.4961062691
## 6952                  D030_r1_Pacritinib (SB1518) -15.559141065  1.1516356135
## 6953                   D030_r1_Palomid 529 (P529)  -7.538689171  0.0970155530
## 6954                            D030_r1_Pazopanib  -7.333063386 -0.9105658261
## 6955                        D030_r1_Pazopanib HCl  -6.231273329 -0.1791698953
## 6956                            D030_r1_PD0325901  -6.144744433  3.8672189082
## 6957                             D030_r1_PD168393  -7.358029527  1.2118971709
## 6958                             D030_r1_PD173955 -12.505057675  0.7000461887
## 6959                   D030_r1_PD184352 (CI-1040)  -8.446202119  1.1410999628
## 6960                             D030_r1_PD318088  -4.966234399  1.1889717275
## 6961                              D030_r1_PD98059  -9.230806286  1.1872446595
## 6962                  D030_r1_Pelitinib (EKB-569)  -8.248655786  3.7816023360
## 6963                          D030_r1_PF-00562271 -12.067150786  0.7011180449
## 6964                          D030_r1_PF-04217903  -6.815679062 -0.2337219115
## 6965                          D030_r1_PF-04691502  -5.130170966  4.1694343104
## 6966                            D030_r1_PF-431396 -15.697319403  1.7387990493
## 6967                           D030_r1_PF-4708671 -11.167303457  1.4754796429
## 6968                           D030_r1_PF-5274857  -8.323043694  0.6367577566
## 6969                            D030_r1_PF-562271 -12.282410455  3.3479758262
## 6970                            D030_r1_PF-573228  -8.806287565  1.6829411722
## 6971                            D030_r1_PH-797804  -8.179619883  0.6120207390
## 6972                           D030_r1_PHA-665752  -9.039500715  0.8772462700
## 6973                           D030_r1_PHA-680632 -12.139652216  2.8194530570
## 6974                           D030_r1_PHA-767491 -14.406282881  2.2679802271
## 6975                           D030_r1_PHA-793887  -8.976277695  1.6194157101
## 6976                       D030_r1_Phenformin HCl  -7.856412309 -0.1727155465
## 6977                              D030_r1_PHT-427  -9.927270527  1.9206238443
## 6978                          D030_r1_Piceatannol  -8.175087206  1.6137230715
## 6979                              D030_r1_PIK-293  -8.746200355 -0.1944333411
## 6980                              D030_r1_PIK-294 -10.701366679  0.9883171085
## 6981                               D030_r1_PIK-93  -9.463698938  2.2509054696
## 6982               D030_r1_Pimasertib (AS-703026)  -6.716913170  2.0939478913
## 6983                          D030_r1_Pirfenidone  -9.931289343  0.7487008581
## 6984                             D030_r1_PLX-4720  -8.171098118  1.3787491540
## 6985                              D030_r1_PLX7904  -9.325119047 -0.6532953107
## 6986                  D030_r1_Ponatinib (AP24534)  -6.391569985  2.0246106280
## 6987                                  D030_r1_PP1 -10.838632484  1.1577024112
## 6988                                  D030_r1_PP2 -10.205145215  1.8470404871
## 6989                                D030_r1_PP242  -3.578532857  2.1192537726
## 6990                               D030_r1_PQ 401  -9.842382215  1.1015384925
## 6991                              D030_r1_PRI-724  -6.990471309  0.4008846992
## 6992     D030_r1_PRT062607 (P505-15, BIIB057) HCl -11.000515238  2.0003157250
## 6993                         D030_r1_Purvalanol A -11.642115659  1.6575399760
## 6994                            D030_r1_Quercetin  -8.297806272  0.2661241621
## 6995                  D030_r1_Quizartinib (AC220)  -8.028814306 -0.1252790489
## 6996                                 D030_r1_R406  -7.762214821  0.8754398494
## 6997                     D030_r1_R406 (free base)  -6.849387381  0.9528180334
## 6998                                 D030_r1_R547  -5.891171757  1.2181794014
## 6999                    D030_r1_RAF265 (CHIR-265)  -7.972129986  3.7946674499
## 7000                D030_r1_Rapamycin (Sirolimus)  -5.752912456  1.2104445571
## 7001   D030_r1_Refametinib (RDEA119, Bay 86-9766)  -6.103224683  3.7753697047
## 7002                               D030_r1_RepSox -10.399760743  1.2582687604
## 7003 D030_r1_Ridaforolimus (Deforolimus, MK-8669)  -6.323022853  0.9264621544
## 7004                D030_r1_Rigosertib (ON-01910) -20.156477981  2.4025072560
## 7005                             D030_r1_RKI-1447  -8.075234205 -0.2375199080
## 7006                                D030_r1_RN486  -5.973447971 -0.3643209386
## 7007                  D030_r1_Ro 31-8220 Mesylate -12.138962115  1.1869688135
## 7008                              D030_r1_Ro-3306  -6.526170775  0.2019434601
## 7009                               D030_r1_Ro3280 -13.284385718  1.7445593778
## 7010                            D030_r1_RO4929097  -8.145921669 -0.2004797554
## 7011      D030_r1_Roscovitine (Seliciclib,CYC202)  -8.573578809  0.3756362809
## 7012             D030_r1_Ruxolitinib (INCB018424)  -7.509023126  0.4597649158
## 7013           D030_r1_S-Ruxolitinib (INCB018424)  -8.510278728  0.0549257236
## 7014                               D030_r1_SANT-1  -7.004793023  0.5035865259
## 7015                            D030_r1_SAR131675  -9.978148065  1.1431171174
## 7016                    D030_r1_SAR245409 (XL765)  -9.269696209  0.8031110128
## 7017                D030_r1_Saracatinib (AZD0530)  -7.197170878  2.9935786926
## 7018                      D030_r1_SB202190 (FHPI)  -9.374354623  0.4627436646
## 7019                             D030_r1_SB203580  -6.892279687  0.6156451595
## 7020                             D030_r1_SB216763 -10.331747548  0.8778080218
## 7021                             D030_r1_SB239063  -7.239892023  0.8033819054
## 7022                             D030_r1_SB415286  -7.584382101  0.4915585356
## 7023                             D030_r1_SB431542  -8.758633906  1.2117387344
## 7024                             D030_r1_SB505124  -7.692813584 -0.3962017343
## 7025                             D030_r1_SB525334  -7.467231824 -0.0020563637
## 7026                             D030_r1_SB590885  -6.510687337 -0.6284664985
## 7027                                  D030_r1_SC1 -16.988506192  0.0489765532
## 7028                D030_r1_Schisandrin B (Sch B)  -5.858278545 -0.2636845838
## 7029                D030_r1_Selumetinib (AZD6244)  -7.627266573  3.6585635066
## 7030              D030_r1_Semagacestat (LY450139)  -8.221683141  0.2761605672
## 7031                   D030_r1_Semaxanib (SU5416)  -9.488051669  2.6303699686
## 7032                             D030_r1_SGI-7079 -14.175187979  3.0631097600
## 7033                          D030_r1_Skepinone-L  -6.326420479  0.4320728097
## 7034                               D030_r1_SL-327 -11.439500740  1.4738138785
## 7035                 D030_r1_SNS-032 (BMS-387032) -13.924000992  2.5989195338
## 7036                     D030_r1_SNS-314 Mesylate -15.683412434  2.9552522313
## 7037                            D030_r1_Sorafenib  -9.255822573 -1.1156905714
## 7038                   D030_r1_Sorafenib Tosylate -10.353953784 -0.3333945923
## 7039                         D030_r1_Sotrastaurin  -9.985026442  0.6659655969
## 7040                             D030_r1_SP600125  -8.027364013  0.9140848257
## 7041                              D030_r1_SU11274  -8.212230608  0.3174488170
## 7042                               D030_r1_SU6656 -18.899211766  2.4456457719
## 7043                               D030_r1_SU9516 -12.454544973  1.2071568086
## 7044                     D030_r1_Sunitinib Malate -13.100613756  3.5737319403
## 7045                  D030_r1_TAE226 (NVP-TAE226) -15.090907708  1.4147009106
## 7046                              D030_r1_TAK-285  -9.290540835  1.1711995494
## 7047                              D030_r1_TAK-632  -7.576925413 -0.0297908487
## 7048                              D030_r1_TAK-715  -7.958661570  0.6434869048
## 7049                              D030_r1_TAK-733  -7.218518065  3.5615017806
## 7050                              D030_r1_TAK-901 -14.205485270 -1.4259092664
## 7051                D030_r1_Taladegib (LY2940680)  -7.463421104  0.0666788211
## 7052                              D030_r1_TCS 359  -6.716982104  0.6706505508
## 7053                               D030_r1_TDZD-8  -8.151296608 -0.3822537355
## 7054                            D030_r1_Telatinib -10.372473946  0.4188710491
## 7055   D030_r1_Temsirolimus (CCI-779, NSC 683864)  -3.718921599  0.5748039187
## 7056              D030_r1_Tepotinib (EMD 1214063)  -4.754928046 -1.7581459876
## 7057                                D030_r1_TG003  -9.556149730  0.6643299855
## 7058                            D030_r1_TG100-115  -8.849064124 -0.0981670935
## 7059                             D030_r1_TG101209 -17.417986708  1.4034183830
## 7060                 D030_r1_TG101348 (SAR302503) -15.291544895  0.8666495613
## 7061                              D030_r1_TGX-221  -8.721914498  0.5901930138
## 7062                         D030_r1_Theophylline  -7.862177753  0.5959607664
## 7063                          D030_r1_Thiazovivin  -8.162489090  0.8089066167
## 7064                       D030_r1_TIC10 Analogue  -8.033667713 -0.2539117946
## 7065                           D030_r1_Tideglusib  -6.519565023  0.3342450963
## 7066                 D030_r1_Tivantinib (ARQ 197) -14.351985768 -1.4227310950
## 7067                   D030_r1_Tivozanib (AV-951)  -5.209400571 -0.2467036979
## 7068  D030_r1_Tofacitinib (CP-690550,Tasocitinib)  -8.893917100  1.0340749501
## 7069      D030_r1_Tofacitinib (CP-690550) Citrate  -9.887555275  1.0087286254
## 7070                              D030_r1_Torin 2  -9.120230254  4.5690570519
## 7071              D030_r1_Trametinib (GSK1120212)  -6.812892010  1.3597206897
## 7072                          D030_r1_Triciribine  -8.104397095  2.3112130920
## 7073           D030_r1_TSU-68 (SU6668, Orantinib)  -7.101241007 -0.3208648199
## 7074                               D030_r1_TWS119  -8.865930519  0.4717812619
## 7075                         D030_r1_Tyrphostin 9  -8.608733375  1.8011248069
## 7076                   D030_r1_Tyrphostin AG 1296  -7.179535014  0.6602635239
## 7077                           D030_r1_U0126-EtOH  -9.170247992  1.8133712769
## 7078     D030_r1_Ulixertinib (BVD-523, VRT752271) -10.950513974 -0.0954809873
## 7079              D030_r1_Uprosertib (GSK2141795) -12.882885353  1.7172905580
## 7080                          D030_r1_Vacquinol-1 -10.450775963  1.7235272812
## 7081                           D030_r1_Varlitinib  -9.122086872  1.5042434777
## 7082              D030_r1_Vatalanib (PTK787) 2HCl -10.655725119  0.4827721922
## 7083                               D030_r1_VE-821  -6.537475898  0.0791888526
## 7084                               D030_r1_VE-822 -13.705122439  1.3413501561
## 7085        D030_r1_Vemurafenib (PLX4032, RG7204)  -7.703958709  0.1906688839
## 7086                D030_r1_Vismodegib (GDC-0449)  -8.273353251  0.3923107494
## 7087                 D030_r1_Volasertib (BI 6727)  -5.945911961  1.4447812347
## 7088                            D030_r1_VPS34-IN1  -4.454869762  0.1711696595
## 7089                     D030_r1_VS-5584 (SB2343)  -0.947884845  3.9291944715
## 7090                               D030_r1_VX-11e  -8.644412771  2.2404366474
## 7091         D030_r1_VX-680 (Tozasertib, MK-0457) -13.063692080  1.8416734364
## 7092                               D030_r1_VX-702  -8.851799220  0.2715068410
## 7093                               D030_r1_VX-745  -7.549001789  0.7532679696
## 7094                              D030_r1_WAY-600 -11.407154435  0.8444021829
## 7095                             D030_r1_WH-4-023  -7.856219718  0.0609815103
## 7096                             D030_r1_WHI-P154  -8.910629325  0.0122791737
## 7097                                D030_r1_WIKI4  -6.281593641  1.0229661272
## 7098                        D030_r1_Wnt agonist 1 -16.002714917  2.6629823841
## 7099                        D030_r1_Wnt-C59 (C59)  -8.234034620 -0.1462389551
## 7100                               D030_r1_WP1066  -7.063043723  0.4045061757
## 7101                 D030_r1_WYE-125132 (WYE-132)  -5.867257530  2.1307311112
## 7102                              D030_r1_WYE-354  -6.425328009  1.4137201310
## 7103                               D030_r1_WZ3146  -8.603795396  2.3182523778
## 7104                               D030_r1_WZ4002  -6.020651121  0.2523212298
## 7105                               D030_r1_WZ4003 -10.173478101  1.4447897981
## 7106                               D030_r1_WZ8040 -10.081897054 -0.0859423624
## 7107                              D030_r1_XAV-939 -10.490018897  0.3267076777
## 7108                                D030_r1_XL019  -5.342735357  0.4773266349
## 7109                              D030_r1_XMD8-92  -6.518300954  0.2692565859
## 7110                         D030_r1_Y-27632 2HCl  -6.992701590  0.3307842194
## 7111                             D030_r1_YM201636  -9.048191572  0.3946312123
## 7112                             D030_r1_YO-01027  -7.417633948 -0.2429869219
## 7113                            D030_r1_ZM 306416  -9.787792101  1.5438001780
## 7114                        D030_r1_ZM 323881 HCl  -8.485831581  0.9919151830
## 7115                            D030_r1_ZM 336372  -8.303208072 -0.1987235266
## 7116                         D030_r1_ZM 39923 HCl  -9.472833159  0.8405792999
## 7117                            D030_r1_ZM 447439 -10.797939595 -0.1961942565
## 7118                 D030_r1_Zotarolimus(ABT-578)  -6.849613769  0.6655529078
## 7119                              D030_r1_ZSTK474  -5.781420257  2.7068130534
## 7120                     D030_r2_1-Azakenpaullone  -7.742899502  0.6750719585
## 7121                      D030_r2_3-Methyladenine  -8.121557071  1.8829874355
## 7122                             D030_r2_A-674563   5.657775478  3.4214493245
## 7123                             D030_r2_A-769662  -8.670038954  3.1437779574
## 7124                                  D030_r2_A66  -3.165664959  1.3886117013
## 7125                            D030_r2_Acadesine  -6.117790725 -0.0608560183
## 7126                  D030_r2_AEE788 (NVP-AEE788)  -5.556132429 -0.9376058586
## 7127        D030_r2_Afatinib (BIBW2992)_uncertain -11.514031593 -0.7065248942
## 7128                              D030_r2_AG-1024  -2.765519083 -1.4796341087
## 7129         D030_r2_AG-1478 (Tyrphostin AG-1478)  -6.587276125 -0.0792674521
## 7130                                D030_r2_AG-18  -3.826546482 -0.9050105584
## 7131              D030_r2_AG-490 (Tyrphostin B42)  -4.122548758  0.0414073758
## 7132                             D030_r2_Akti-1/2  -6.413623213  2.0162644036
## 7133                  D030_r2_Alisertib (MLN8237) -12.079499534 -1.6205487332
## 7134                              D030_r2_AMG 337  -7.338567808 -0.6717421470
## 7135                              D030_r2_AMG-458  -8.822864136  1.8314661291
## 7136                              D030_r2_AMG-900  -6.845491332  2.6239356336
## 7137                               D030_r2_AMG319  -7.834755692  2.3990322816
## 7138                  D030_r2_Amuvatinib (MP-470) -11.613223433  0.4933741273
## 7139                             D030_r2_Apatinib  -5.359644854  0.1732118845
## 7140                           D030_r2_AR-A014418  -5.399890802  0.8218768996
## 7141                            D030_r2_AS-252424  -5.548613151  0.9878008032
## 7142                            D030_r2_AS-604850  -5.841780268  1.9431150455
## 7143                         D030_r2_Asiatic Acid  -5.862127494  0.6896122954
## 7144                             D030_r2_AST-1306  -6.131489711 -1.0732101222
## 7145                              D030_r2_AT13148 -12.131214806  1.2293586765
## 7146                               D030_r2_AT7519  -8.845033419 -1.8943074878
## 7147                               D030_r2_AT7867  -4.368845271  1.9925003321
## 7148                               D030_r2_AT9283  -4.768551775 -0.1677815376
## 7149                 D030_r2_Aurora A Inhibitor I  -7.491353176  0.1821853380
## 7150             D030_r2_Avagacestat (BMS-708163)  -9.110201143  0.2465187491
## 7151                              D030_r2_AVL-292  -8.055189707  1.8634710935
## 7152                             D030_r2_Axitinib  -8.400507094  0.1422176238
## 7153                             D030_r2_Axitinib  -8.400507094  0.1422176238
## 7154                               D030_r2_AZ 628  -2.780067096  1.9698156663
## 7155                               D030_r2_AZ 960  -9.061642741  0.0799490953
## 7156                                 D030_r2_AZ20  -5.008340462  3.4520081411
## 7157                              D030_r2_AZD1080  -7.634769128  0.3082156963
## 7158                              D030_r2_AZD1480  -9.951666739  0.4065085095
## 7159                              D030_r2_AZD2014  -5.447393601  0.8704337245
## 7160                              D030_r2_AZD2858  -7.015728332 -0.0752262406
## 7161                              D030_r2_AZD2932  -7.248005828  1.8584192504
## 7162                              D030_r2_AZD3759  -4.684442260  2.0514092017
## 7163                              D030_r2_AZD5363  -8.503168764 -0.4295075183
## 7164                              D030_r2_AZD5438   0.936551970  3.2666620261
## 7165                              D030_r2_AZD6482  -6.757442968 -1.2073058618
## 7166                              D030_r2_AZD6738  -5.641947929  2.0946735778
## 7167                              D030_r2_AZD8055  -6.892652448  0.3462700736
## 7168                              D030_r2_AZD8330  -4.282414867 -1.4718180412
## 7169                  D030_r2_AZD8931 (Sapitinib)  -5.034683317 -1.4256607928
## 7170                              D030_r2_AZD9291  -3.024563087  3.7263591357
## 7171            D030_r2_Barasertib (AZD1152-HQPA) -13.701506379  0.0495976349
## 7172  D030_r2_Baricitinib (LY3009104, INCB028050)  -3.802386749 -0.0762050730
## 7173                  D030_r2_BGT226 (NVP-BGT226)   7.549439135  5.1366977265
## 7174                              D030_r2_BI 2536 -11.287080257 -2.2396702437
## 7175                              D030_r2_BI-78D3  -7.046974696 -0.3681725811
## 7176                             D030_r2_BI-D1870 -10.802493605  2.8394089564
## 7177                              D030_r2_Bikinin  -9.669136439 -0.2426945964
## 7178                                  D030_r2_BIO  -5.428517411  1.9065415644
## 7179               D030_r2_BIRB 796 (Doramapimod)  -5.061483933 -0.1520926483
## 7180                            D030_r2_BIX 02188  -7.085961980 -1.3038620037
## 7181                            D030_r2_BIX 02189  -9.324404421 -0.2690102109
## 7182      D030_r2_BKM120 (NVP-BKM120, Buparlisib)  -8.567334344 -0.3613334379
## 7183                           D030_r2_BMS-265246  -9.072306480  0.0509703153
## 7184                           D030_r2_BMS-536924  -7.722636644 -1.5162542153
## 7185                           D030_r2_BMS-582949  -8.809469022 -0.1662371259
## 7186                           D030_r2_BMS-754807 -12.610591059  0.0040515698
## 7187                           D030_r2_BMS-777607  -6.700738094  0.1244922796
## 7188                           D030_r2_BMS-794833 -11.017694790  1.4831423348
## 7189                           D030_r2_BMS-833923  -6.692717896  1.4206814358
## 7190                  D030_r2_Bosutinib (SKI-606)  -4.763764880 -1.1795524059
## 7191                D030_r2_Brivanib (BMS-540215)  -6.579689979  0.2054905671
## 7192      D030_r2_Brivanib Alaninate (BMS-582664)  -5.511552848  0.7099761073
## 7193                           D030_r2_BS-181 HCl  -7.157929434 -0.7976756590
## 7194                               D030_r2_Butein -10.522288392  2.0234876989
## 7195                               D030_r2_BYL719  -6.267569307  1.3111691975
## 7196     D030_r2_Cabozantinib (XL184, BMS-907351)  -4.416784143 -1.0975785927
## 7197          D030_r2_Cabozantinib malate (XL184)  -6.400204517  1.1875189543
## 7198        D030_r2_CAL-101 (Idelalisib, GS-1101)  -8.110282056  1.0873032586
## 7199                             D030_r2_CAY10505  -6.736602671  2.3868823878
## 7200                               D030_r2_CC-223  -2.910324619 -1.2322219822
## 7201                            D030_r2_CCT128930  -4.552003940  0.9974095690
## 7202                  D030_r2_Cediranib (AZD2171)  -7.928846985 -1.5377024400
## 7203                            D030_r2_CEP-32496  -6.403720378 -1.0350452485
## 7204                            D030_r2_CEP-33779  -7.394644143  0.8400763766
## 7205                              D030_r2_CGI1746  -6.012439972  1.6826480923
## 7206                              D030_r2_CGK 733  -8.319458410  2.7992682239
## 7207                            D030_r2_CH5132799   0.092382927  1.8204018800
## 7208                           D030_r2_CHIR-98014  -6.173827823  0.4214026016
## 7209                 D030_r2_CHIR-99021 (CT99021)  -8.026509899 -0.6327067339
## 7210             D030_r2_CHIR-99021 (CT99021) HCl  -3.690744170  0.8298653415
## 7211                    D030_r2_Chrysophanic Acid  -0.879382831 -0.2430296791
## 7212                             D030_r2_CNX-2006  -7.492787501  1.5433560652
## 7213                              D030_r2_CNX-774  -7.038893610  0.2350900693
## 7214                    D030_r2_CO-1686 (AVL-301)  -5.485719442  1.3225628063
## 7215       D030_r2_Cobimetinib (GDC-0973, RG7420)   2.146945102  3.1228105995
## 7216                            D030_r2_CP-673451  -9.999637040 -0.4337808073
## 7217                            D030_r2_CP-724714  -6.496140312 -0.3166158436
## 7218               D030_r2_Crenolanib (CP-868596)  -7.987056026  2.1073234704
## 7219             D030_r2_Crizotinib (PF-02341066)  -8.060645268  0.5219169837
## 7220                               D030_r2_CYC116 -15.574047852  0.4480622640
## 7221                               D030_r2_CYT387  -7.927240041  1.0837814811
## 7222                             D030_r2_CZC24832  -4.347156820  0.0215798442
## 7223              D030_r2_Dabrafenib (GSK2118436)   0.608705553  1.8478103642
## 7224        D030_r2_Dacomitinib (PF299804, PF299)  -7.090949444  1.5897198100
## 7225              D030_r2_Danusertib (PHA-739358) -12.095933655  1.1124228693
## 7226                        D030_r2_DAPT (GSI-IX)  -6.999833637  0.7351244323
## 7227                            D030_r2_Dasatinib  -6.346929487 -0.9439828615
## 7228                D030_r2_DCC-2036 (Rebastinib)  -6.881265633  1.3315162778
## 7229                D030_r2_Decernotinib (VX-509)  -5.497841973 -0.2097183795
## 7230               D030_r2_Dinaciclib (SCH727965)  -2.083789989  3.2029287976
## 7231    D030_r2_Dovitinib (TKI-258) Dilactic Acid  -6.565434730  1.2859402378
## 7232                            D030_r2_ENMD-2076 -10.306705215 -1.4804812122
## 7233               D030_r2_Enzastaurin (LY317615)  -8.052193741 -0.2055077290
## 7234                            D030_r2_ERK5-IN-1  -6.665740238  1.6577769258
## 7235                             D030_r2_ETC-1002  -3.891959366 -0.0887330151
## 7236                            D030_r2_ETP-46464  -3.797636222  2.3571492319
## 7237                  D030_r2_Everolimus (RAD001)  -3.310155070 -0.6097254688
## 7238                D030_r2_Fasudil (HA-1077) HCl  -6.469180223  0.6189669399
## 7239                                D030_r2_FH535   0.653198918 -0.9543572061
## 7240                D030_r2_Filgotinib (GLPG0634)  -7.732339925  0.7437009375
## 7241             D030_r2_Flavopiridol (Alvocidib)  -3.879474912 -1.2024569226
## 7242                     D030_r2_Flavopiridol HCl  -3.323716550  3.2933769240
## 7243               D030_r2_Foretinib (GSK1363089) -13.354928774 -1.7579592212
## 7244                  D030_r2_Fostamatinib (R788)   9.077235887  3.0412176517
## 7245                                D030_r2_G-749 -10.533349660 -1.3419781174
## 7246                             D030_r2_GDC-0068  -3.635998892  2.4665629908
## 7247                             D030_r2_GDC-0349   0.207338450  2.9272749804
## 7248                             D030_r2_GDC-0879  -8.839732700  0.3814078725
## 7249                             D030_r2_GDC-0941  -6.536485472 -0.3375881182
## 7250                    D030_r2_GDC-0980 (RG7422)  -5.879114012  2.7844926504
## 7251                   D030_r2_Gefitinib (ZD1839)  -3.727605063 -1.7288553158
## 7252                            D030_r2_Genistein  -8.272171063  0.7160139396
## 7253                            D030_r2_GF109203X  -7.021931360  1.2318788998
## 7254                                D030_r2_GNF-2  -5.543631132  0.9147626720
## 7255                                D030_r2_GNF-5  -6.658825633  0.5795747088
## 7256                              D030_r2_Go 6983  -4.280044486  1.1285898204
## 7257                   D030_r2_Golvatinib (E7050)   4.373609239  4.7749513665
## 7258                          D030_r2_GSK1838705A  -3.572499736  2.1682495023
## 7259                          D030_r2_GSK1904529A  -8.451582731 -0.1723669682
## 7260                  D030_r2_GSK2126458 (GSK458)  -4.619028295  3.7389683300
## 7261                           D030_r2_GSK2292767  -8.459975021 -0.2758660256
## 7262                           D030_r2_GSK2636771  -7.656030701  1.9909532907
## 7263                           D030_r2_GSK429286A  -5.142894137  0.9804458945
## 7264                            D030_r2_GSK461364 -13.261569995  0.4459024259
## 7265                               D030_r2_GSK621  -6.637618743 -0.8000956155
## 7266                            D030_r2_GSK690693  -8.205095005  0.1929450312
## 7267                               D030_r2_GW5074  -4.494334397  0.9630095100
## 7268                             D030_r2_GW788388  -8.948615367  1.4068196990
## 7269                               D030_r2_GZD824  -1.305350459  4.7812618441
## 7270                            D030_r2_H 89 2HCl  -9.897165175  0.3368335202
## 7271                           D030_r2_Hesperadin  -8.977564134  0.2935796044
## 7272                              D030_r2_HMN-214 -11.599540156 -0.2649492513
## 7273                             D030_r2_Honokiol  -6.446083284 -0.1748279574
## 7274                               D030_r2_HS-173  -7.043810413  2.6612124892
## 7275                           D030_r2_HTH-01-015  -9.366893335  1.3467209712
## 7276                D030_r2_Ibrutinib (PCI-32765)  -5.334514361  1.5376461474
## 7277                              D030_r2_ICG-001  -9.467375936  1.7545757026
## 7278                             D030_r2_Icotinib   2.249487849  0.6861507675
## 7279                                D030_r2_IM-12  -8.477668323  0.6934187113
## 7280           D030_r2_Imatinib Mesylate (STI571)  -7.496881015 -1.5935801104
## 7281                            D030_r2_Indirubin  -6.303773450  0.4255138446
## 7282                    D030_r2_INK 128 (MLN0128) -10.032124256  1.1658706125
## 7283                    D030_r2_IPI-145 (INK1197)  -2.861638511  1.5506590445
## 7284                               D030_r2_IWP-L6  -8.736130931  1.0167195830
## 7285                           D030_r2_IWR-1-endo  -6.914161729  0.8955483483
## 7286                         D030_r2_JNJ-38877605  -5.854893938  0.0344386934
## 7287                          D030_r2_JNJ-7706621 -11.484006919 -0.4106135259
## 7288                     D030_r2_JNK Inhibitor IX  -9.685672466  1.5557366763
## 7289                             D030_r2_JNK-IN-8  -5.381511615  2.0427155903
## 7290                               D030_r2_K02288  -6.107230238  0.1326284031
## 7291                               D030_r2_Ki8751  -9.338039810  0.4626228443
## 7292                              D030_r2_KRN 633  -5.818534071  0.5058394501
## 7293                           D030_r2_KU-0063794  -6.248171896  0.0972862478
## 7294      D030_r2_KU-55933 (ATM Kinase Inhibitor)  -6.371411385 -0.2750167301
## 7295                             D030_r2_KU-60019  -6.187122636 -0.2956125077
## 7296                              D030_r2_KW-2449  -5.050579608  0.8762409959
## 7297                              D030_r2_KX2-391  -8.930018700  2.9246814209
## 7298                              D030_r2_KY02111  -7.289839747  0.7635955025
## 7299                            D030_r2_Lapatinib  -5.186491082 -1.2170837112
## 7300     D030_r2_Lapatinib (GW-572016) Ditosylate -10.270072676  0.2490724400
## 7301                            D030_r2_LDC000067   1.195452872  1.7323192227
## 7302      D030_r2_LDE225 (NVP-LDE225,Erismodegib)  -4.355892268  0.4598272590
## 7303                           D030_r2_LDN-214117  -1.498926705  1.3161739277
## 7304                   D030_r2_Lenvatinib (E7080)  -3.679737816 -0.4107888064
## 7305                              D030_r2_LFM-A13  -5.034450781  0.3998174024
## 7306                              D030_r2_LGK-974  -0.189614872  0.1206091917
## 7307                  D030_r2_Linifanib (ABT-869)  -5.678914040 -0.3322804288
## 7308                               D030_r2_LJH685  -5.763608914  0.9868483630
## 7309                               D030_r2_LJI308  -9.359152666  0.2444151214
## 7310               D030_r2_Losmapimod (GW856553X)  -6.001803052  2.3987716077
## 7311                            D030_r2_LY2090314  -3.133610337  2.2723404807
## 7312                            D030_r2_LY2157299  -8.786754748  1.6749447959
## 7313                            D030_r2_LY2784544  -8.659445782  0.2732642953
## 7314                            D030_r2_LY2835219  -5.726367711  2.2914511443
## 7315                             D030_r2_LY294002  -9.017732390 -0.3648467167
## 7316                            D030_r2_LY3023414  -6.377408270 -0.5098453284
## 7317                             D030_r2_LY411575  -7.468563139 -0.2532550552
## 7318       D030_r2_MEK162 (ARRY-162, ARRY-438162)   1.504585665  2.5708206555
## 7319                             D030_r2_MGCD-265  -7.730498995  0.8557878533
## 7320               D030_r2_Milciclib (PHA-848125)  -8.042035718  2.4595392695
## 7321                              D030_r2_MK-0752  -7.044004118  0.8821079573
## 7322                         D030_r2_MK-2206 2HCl -11.324406458 -0.0082361061
## 7323                              D030_r2_MK-2461  -6.129155733  3.3437522917
## 7324                     D030_r2_MK-5108 (VX-689)  -7.075887255  1.2589292560
## 7325                              D030_r2_MK-8745  -2.446893883  1.5209523449
## 7326                              D030_r2_MLN2480  -7.720579334  1.0355308865
## 7327                              D030_r2_MLN8054  -9.332707416 -0.9413293110
## 7328      D030_r2_Motesanib Diphosphate (AMG-706)  -9.569590261  0.5442691470
## 7329                  D030_r2_Nilotinib (AMN-107)  -5.043034490 -0.0332194240
## 7330     D030_r2_Nintedanib (BIBF 1120)_uncertain  -9.001007394 -1.5784727849
## 7331                               D030_r2_NU6027  -6.755203963  1.6195315627
## 7332                           D030_r2_NVP-AEW541  -2.153405606 -0.4616713309
## 7333                           D030_r2_NVP-BHG712  -5.745717814 -0.9817668838
## 7334                      D030_r2_NVP-BSK805 2HCl  -6.607922411  0.5404397023
## 7335                           D030_r2_NVP-BVU972  -8.536722824  2.6554496661
## 7336                          D030_r2_Oclacitinib  -7.029693563  0.4143873826
## 7337      D030_r2_Olmutinib (HM61713, BI 1482694)  -8.773681968 -0.5598622257
## 7338                             D030_r2_ONO-4059 -10.385161607 -0.2749992454
## 7339                              D030_r2_OSI-027   9.321368830 -0.1476942566
## 7340                              D030_r2_OSI-420  -9.891104852 -0.1807179501
## 7341                 D030_r2_OSI-906 (Linsitinib)  -6.817431106  0.1870686162
## 7342                              D030_r2_P276-00  -1.143915719  2.7684093686
## 7343                  D030_r2_Pacritinib (SB1518)  -4.742986456  0.5347855526
## 7344                   D030_r2_Palomid 529 (P529)  -6.853685789 -0.1454345960
## 7345                            D030_r2_Pazopanib  -0.993970073 -0.2194466936
## 7346                        D030_r2_Pazopanib HCl -11.174617783  0.6630045237
## 7347                            D030_r2_PD0325901  -2.828718088 -0.8899785435
## 7348                             D030_r2_PD168393  -1.487388640  1.2800660498
## 7349                             D030_r2_PD173955  -6.844607431  1.1463921575
## 7350                   D030_r2_PD184352 (CI-1040)  -7.393502802  0.5763962357
## 7351                             D030_r2_PD318088  -5.460095214  0.1949327094
## 7352                              D030_r2_PD98059  -9.497356937 -0.5609398527
## 7353                  D030_r2_Pelitinib (EKB-569)  -7.827449148 -0.4056279668
## 7354                          D030_r2_PF-00562271  -1.685411554  3.2793452932
## 7355                          D030_r2_PF-04217903  -9.082586584  0.0239390847
## 7356                          D030_r2_PF-04691502  -2.540150281  3.1862989455
## 7357                            D030_r2_PF-431396   4.035986735  3.3155297058
## 7358                           D030_r2_PF-4708671  -5.317881618 -1.0051605617
## 7359                           D030_r2_PF-5274857  -8.031659132  0.8985754271
## 7360                            D030_r2_PF-562271  -4.859969130  3.0070478405
## 7361                            D030_r2_PF-573228  -8.485891726  0.2247272538
## 7362                            D030_r2_PH-797804  -7.705386603  1.5654461828
## 7363                           D030_r2_PHA-665752 -10.058942510  0.0945594486
## 7364                           D030_r2_PHA-680632  -9.882432492  1.5281857881
## 7365                           D030_r2_PHA-767491  -1.990049485  2.8361076251
## 7366                           D030_r2_PHA-793887 -11.680919067  0.7680487560
## 7367                       D030_r2_Phenformin HCl  -0.342281572 -0.7415754677
## 7368                              D030_r2_PHT-427  -8.555423709  0.9629093616
## 7369                          D030_r2_Piceatannol  -2.099234899  3.2018857049
## 7370                              D030_r2_PIK-293  -0.861752045 -0.8330180950
## 7371                              D030_r2_PIK-294  -7.839156592  0.5918878880
## 7372                               D030_r2_PIK-93  -9.734384008  0.9029157495
## 7373               D030_r2_Pimasertib (AS-703026)  -4.848311782  0.1101708864
## 7374                          D030_r2_Pirfenidone  -8.139984009  1.0837907974
## 7375                             D030_r2_PLX-4720  -7.027626463  1.1328384651
## 7376                              D030_r2_PLX7904  -8.747068659  1.2034059579
## 7377                  D030_r2_Ponatinib (AP24534)  -8.854566570 -1.2032688317
## 7378                                  D030_r2_PP1  -5.140246689  2.0935821132
## 7379                                  D030_r2_PP2  -6.528458241  1.3176870731
## 7380                                D030_r2_PP242  -4.474118014  0.3813892558
## 7381                               D030_r2_PQ 401  -8.159472707  2.4800751652
## 7382                              D030_r2_PRI-724  -8.950124484  0.3104346738
## 7383     D030_r2_PRT062607 (P505-15, BIIB057) HCl  -7.555141930 -0.6230758119
## 7384                         D030_r2_Purvalanol A  -6.983353129  1.5947300642
## 7385                            D030_r2_Quercetin  -5.118927477  0.6576163466
## 7386                  D030_r2_Quizartinib (AC220) -10.621281968 -0.6280736977
## 7387                                 D030_r2_R406  -4.882234502  0.1947573183
## 7388                     D030_r2_R406 (free base) -10.349215008 -0.0156354311
## 7389                                 D030_r2_R547   4.958996954  3.9165113868
## 7390                    D030_r2_RAF265 (CHIR-265)  -5.622861470 -1.1107446168
## 7391                D030_r2_Rapamycin (Sirolimus)  -7.964385139 -0.8207719622
## 7392   D030_r2_Refametinib (RDEA119, Bay 86-9766)  -5.317775033 -0.9648439449
## 7393                               D030_r2_RepSox  -7.344251617  0.9314121862
## 7394 D030_r2_Ridaforolimus (Deforolimus, MK-8669)  -5.830814776 -0.4279315121
## 7395                D030_r2_Rigosertib (ON-01910) -10.045252889 -1.9389502205
## 7396                             D030_r2_RKI-1447  -7.600232753  1.5585862962
## 7397                                D030_r2_RN486  -7.763158879  1.3574087306
## 7398                  D030_r2_Ro 31-8220 Mesylate  -3.869672284  1.1397868008
## 7399                              D030_r2_Ro-3306  -9.698503602  0.8737456373
## 7400                               D030_r2_Ro3280  -5.461424838  2.2211830524
## 7401                            D030_r2_RO4929097  -5.090716423 -0.5069085985
## 7402      D030_r2_Roscovitine (Seliciclib,CYC202)  -6.808677013 -0.2439008716
## 7403             D030_r2_Ruxolitinib (INCB018424)  -6.555699750  1.1441802913
## 7404           D030_r2_S-Ruxolitinib (INCB018424)  -7.586951901  1.3137728615
## 7405                               D030_r2_SANT-1  -7.076197090  0.4719719316
## 7406                            D030_r2_SAR131675  -8.860818492  1.4750043229
## 7407                    D030_r2_SAR245409 (XL765)  -3.690109422 -0.6743435919
## 7408                D030_r2_Saracatinib (AZD0530)  -4.137901815 -0.1073750571
## 7409                      D030_r2_SB202190 (FHPI)  -7.037777188 -0.9205241264
## 7410                             D030_r2_SB203580  -9.328572977  0.8764583140
## 7411                             D030_r2_SB216763  -8.584933754  0.2323204151
## 7412                             D030_r2_SB239063  -6.714452178 -0.6186531540
## 7413                             D030_r2_SB415286  -7.582570858  0.5358559982
## 7414                             D030_r2_SB431542  -9.466646027  1.9655013305
## 7415                             D030_r2_SB505124  -4.407124267 -0.1618235003
## 7416                             D030_r2_SB525334  -8.618947149  0.2465009218
## 7417                             D030_r2_SB590885  -8.997132868  0.8886007655
## 7418                                  D030_r2_SC1  -9.223832140  2.1628073298
## 7419                D030_r2_Schisandrin B (Sch B)  -4.895697262  0.2247843425
## 7420                D030_r2_Selumetinib (AZD6244)  -7.316364650 -0.5156555046
## 7421              D030_r2_Semagacestat (LY450139)  -4.787757815 -0.0917837774
## 7422                   D030_r2_Semaxanib (SU5416)  -7.257690018  2.5739019055
## 7423                             D030_r2_SGI-7079  -0.015602340  4.6818504006
## 7424                          D030_r2_Skepinone-L  -7.546219136  0.9586023072
## 7425                               D030_r2_SL-327  -5.182523449 -1.0501547123
## 7426                 D030_r2_SNS-032 (BMS-387032)  -8.425775641 -2.2183974501
## 7427                     D030_r2_SNS-314 Mesylate -10.987108342 -0.1106500501
## 7428                            D030_r2_Sorafenib  -7.019997893 -0.1296453116
## 7429                   D030_r2_Sorafenib Tosylate -10.660479193 -1.0326704846
## 7430                         D030_r2_Sotrastaurin  -8.721821414  0.7830661370
## 7431                             D030_r2_SP600125  -7.215684515 -1.6343811367
## 7432                              D030_r2_SU11274  -9.180933558 -1.3791564194
## 7433                               D030_r2_SU6656  -8.535263614  1.3558007625
## 7434                               D030_r2_SU9516  11.696885044  4.5232091589
## 7435                     D030_r2_Sunitinib Malate  -7.893823762 -0.2445244203
## 7436                  D030_r2_TAE226 (NVP-TAE226)  -5.584107743  2.3028417869
## 7437                              D030_r2_TAK-285  -8.032604915  2.0293468985
## 7438                              D030_r2_TAK-632  -2.848582065  0.7851585059
## 7439                              D030_r2_TAK-715  -3.638590037 -1.0406335183
## 7440                              D030_r2_TAK-733  12.307777332  4.2283972801
## 7441                              D030_r2_TAK-901  -7.033215168  2.0858290772
## 7442                D030_r2_Taladegib (LY2940680)  -8.905724163 -0.0068528018
## 7443                              D030_r2_TCS 359  -8.044545619  0.1962015226
## 7444                               D030_r2_TDZD-8  -2.009000744  0.4687472838
## 7445                            D030_r2_Telatinib  -5.127965050 -1.9356592590
## 7446   D030_r2_Temsirolimus (CCI-779, NSC 683864)  -6.372202838 -0.6265776872
## 7447              D030_r2_Tepotinib (EMD 1214063)  13.309644323  5.6876707226
## 7448                                D030_r2_TG003  -2.979044478  1.6903785407
## 7449                            D030_r2_TG100-115  -5.718409567 -1.3866002659
## 7450                             D030_r2_TG101209  -6.035914470  1.3248794008
## 7451                 D030_r2_TG101348 (SAR302503)  -4.491537705  1.9327571822
## 7452                              D030_r2_TGX-221  -4.948558817 -1.1983859843
## 7453                         D030_r2_Theophylline  -7.149148885  0.2925707613
## 7454                          D030_r2_Thiazovivin  -4.386942471 -0.5838106274
## 7455                       D030_r2_TIC10 Analogue  -9.010746626  2.1998540227
## 7456                           D030_r2_Tideglusib  -4.858114947  0.9812490871
## 7457                 D030_r2_Tivantinib (ARQ 197) -13.230732905  0.5511140684
## 7458                   D030_r2_Tivozanib (AV-951)  -8.035498281  0.3120831153
## 7459  D030_r2_Tofacitinib (CP-690550,Tasocitinib)  -9.886626631  1.9439428312
## 7460      D030_r2_Tofacitinib (CP-690550) Citrate  -7.772005137  1.0692909913
## 7461                              D030_r2_Torin 2  -6.630286024  2.2513396534
## 7462              D030_r2_Trametinib (GSK1120212)   5.864333546  4.0367343221
## 7463                          D030_r2_Triciribine  -7.206296611 -0.2786974819
## 7464           D030_r2_TSU-68 (SU6668, Orantinib) -10.377635848 -0.1622504309
## 7465                               D030_r2_TWS119  -7.581373729 -0.2110702212
## 7466                         D030_r2_Tyrphostin 9  -3.536289712  1.4105272803
## 7467                   D030_r2_Tyrphostin AG 1296  -8.370809058  0.2566354348
## 7468                           D030_r2_U0126-EtOH  -8.153627696  0.0117862241
## 7469     D030_r2_Ulixertinib (BVD-523, VRT752271)   1.359481856  2.0431489565
## 7470              D030_r2_Uprosertib (GSK2141795)  -5.816643206  1.4114933510
## 7471                          D030_r2_Vacquinol-1 -12.108545906 -1.4327856631
## 7472                           D030_r2_Varlitinib -10.305228747  2.0013307139
## 7473              D030_r2_Vatalanib (PTK787) 2HCl  -6.117247048 -0.3804536453
## 7474                               D030_r2_VE-821  -7.075221867 -0.6739221555
## 7475                               D030_r2_VE-822  -8.036127738  2.0297086556
## 7476        D030_r2_Vemurafenib (PLX4032, RG7204)  -3.715355093  0.2670450113
## 7477                D030_r2_Vismodegib (GDC-0449)  -4.852528396 -0.0106108616
## 7478                 D030_r2_Volasertib (BI 6727)  -8.717269282  0.7214160451
## 7479                            D030_r2_VPS34-IN1  -3.295153125  2.5619426612
## 7480                     D030_r2_VS-5584 (SB2343)  -4.365790362  2.8424105340
## 7481                               D030_r2_VX-11e  -8.395888530 -0.3890567003
## 7482         D030_r2_VX-680 (Tozasertib, MK-0457) -11.843689362  0.1254583154
## 7483                               D030_r2_VX-702   0.506406233  0.5111744131
## 7484                               D030_r2_VX-745  -7.779807573 -1.0431393301
## 7485                              D030_r2_WAY-600  -2.681906921  1.4124344608
## 7486                             D030_r2_WH-4-023  -4.174156632 -0.8657815015
## 7487                             D030_r2_WHI-P154  -6.484631739  1.5334182428
## 7488                                D030_r2_WIKI4  -6.145506592  0.7068959681
## 7489                        D030_r2_Wnt agonist 1  -9.223177551  0.5532479240
## 7490                        D030_r2_Wnt-C59 (C59)  -9.220843046  0.7101439175
## 7491                               D030_r2_WP1066  -9.238206284  1.6712839151
## 7492                 D030_r2_WYE-125132 (WYE-132)   3.228536326  2.6719160986
## 7493                              D030_r2_WYE-354  -9.626111893 -2.2776566798
## 7494                               D030_r2_WZ3146  -7.625007576 -0.9368836580
## 7495                               D030_r2_WZ4002  -4.159794556 -0.4254388377
## 7496                               D030_r2_WZ4003  -7.863859236  0.9684473595
## 7497                               D030_r2_WZ8040  -7.608399542  0.1029053831
## 7498                              D030_r2_XAV-939  -4.322647937  0.0507331777
## 7499                                D030_r2_XL019  -3.344789950  0.4045440426
## 7500                              D030_r2_XMD8-92  -7.947264830  1.6460818808
## 7501                         D030_r2_Y-27632 2HCl  -2.908208653  0.0436404844
## 7502                             D030_r2_YM201636  -9.475286504 -0.5425602803
## 7503                             D030_r2_YO-01027  -7.300746440  0.1210277226
## 7504                            D030_r2_ZM 306416  -2.824680270  0.3466607598
## 7505                        D030_r2_ZM 323881 HCl  -6.940655232  0.7545594832
## 7506                            D030_r2_ZM 336372  -7.970832508  2.8860536149
## 7507                         D030_r2_ZM 39923 HCl  -6.191539749  0.4744738658
## 7508                            D030_r2_ZM 447439  -9.239851312 -0.6859806369
## 7509                 D030_r2_Zotarolimus(ABT-578)  -7.955741028  1.3106848477
## 7510                              D030_r2_ZSTK474  -7.886573561  0.0070619166
## 7511                     D046_r1_1-Azakenpaullone  10.471191687 -0.6216156911
## 7512                      D046_r1_3-Methyladenine  17.878336003 -0.2778840104
## 7513                             D046_r1_A-674563  -1.862596103 -1.1074729613
## 7514                             D046_r1_A-769662  17.843644741 -0.7414436607
## 7515                                  D046_r1_A66  17.207662660 -1.3926083877
## 7516                            D046_r1_Acadesine  16.421550653 -0.2014117259
## 7517                  D046_r1_AEE788 (NVP-AEE788)  14.584087062 -1.9993828706
## 7518        D046_r1_Afatinib (BIBW2992)_uncertain  16.151921233 -2.6283370314
## 7519                              D046_r1_AG-1024  12.080923655 -2.7661023886
## 7520         D046_r1_AG-1478 (Tyrphostin AG-1478)  13.368888832 -0.6996275741
## 7521                                D046_r1_AG-18  16.078909087 -1.3417947351
## 7522              D046_r1_AG-490 (Tyrphostin B42)  15.403522340 -1.6312619323
## 7523                             D046_r1_Akti-1/2  15.671920460  0.4429191810
## 7524                  D046_r1_Alisertib (MLN8237)   3.175896285  1.2515542240
## 7525                              D046_r1_AMG 337  17.538715635 -3.1614851115
## 7526                              D046_r1_AMG-458  16.045556760 -1.7468156004
## 7527                              D046_r1_AMG-900   3.398591952 -0.4003896714
## 7528                               D046_r1_AMG319  14.732939886 -0.7937907525
## 7529                  D046_r1_Amuvatinib (MP-470)   8.391048209 -2.3550175464
## 7530                             D046_r1_Apatinib  19.847309860 -4.2891056051
## 7531                           D046_r1_AR-A014418  13.912291119 -0.7380894036
## 7532                            D046_r1_AS-252424  14.544920576 -1.0503305823
## 7533                            D046_r1_AS-604850  16.323061425 -0.9812152552
## 7534                         D046_r1_Asiatic Acid  14.027995694 -0.8013312671
## 7535                             D046_r1_AST-1306  21.799337381 -0.6964999925
## 7536                              D046_r1_AT13148  20.585414733 -1.9651084490
## 7537                               D046_r1_AT7519  -4.719762311  1.9619586060
## 7538                               D046_r1_AT7867  15.142669381 -1.6031295757
## 7539                               D046_r1_AT9283  -2.783583195  0.8639494302
## 7540                 D046_r1_Aurora A Inhibitor I  16.507314855 -0.6138780952
## 7541             D046_r1_Avagacestat (BMS-708163)  18.006383295 -2.8816810518
## 7542                              D046_r1_AVL-292  16.041146038 -0.9902768933
## 7543                             D046_r1_Axitinib   7.505506195  0.3423305442
## 7544                             D046_r1_Axitinib   7.505506195  0.3423305442
## 7545                               D046_r1_AZ 628  16.291526995  0.7199474283
## 7546                               D046_r1_AZ 960   9.361938904 -0.6642602725
## 7547                                 D046_r1_AZ20   6.000601865 -0.0413054173
## 7548                              D046_r1_AZD1080  10.109466576 -0.2012929948
## 7549                              D046_r1_AZD1480   9.115209478  1.7022777252
## 7550                              D046_r1_AZD2014  13.382636707  0.5539370557
## 7551                              D046_r1_AZD2858   3.840030474 -0.3353654597
## 7552                              D046_r1_AZD2932  13.366871409 -3.3606057672
## 7553                              D046_r1_AZD3759  17.579842037 -2.9768589831
## 7554                              D046_r1_AZD5363  10.264992088 -0.1987237058
## 7555                              D046_r1_AZD5438   1.130421661  0.1212239498
## 7556                              D046_r1_AZD6482  17.666556171 -0.0854782302
## 7557                              D046_r1_AZD6738   7.153733030  0.1795077879
## 7558                              D046_r1_AZD8055  13.828841303  0.4905400764
## 7559                              D046_r1_AZD8330   2.072933899 -0.6472713874
## 7560                  D046_r1_AZD8931 (Sapitinib)  15.725146358 -0.8345019099
## 7561                              D046_r1_AZD9291  15.755800386 -2.1076141894
## 7562            D046_r1_Barasertib (AZD1152-HQPA)  10.409037857 -0.4608680519
## 7563  D046_r1_Baricitinib (LY3009104, INCB028050)  21.297589007 -2.0675440638
## 7564                  D046_r1_BGT226 (NVP-BGT226)  13.788007812  1.1386052702
## 7565                              D046_r1_BI 2536   1.413777586  1.8404047498
## 7566                              D046_r1_BI-78D3  15.569536718 -1.3443696635
## 7567                             D046_r1_BI-D1870  13.659684469 -1.1353428010
## 7568                              D046_r1_Bikinin  16.420562377 -1.4079691947
## 7569                                  D046_r1_BIO  18.816379367 -0.5352759260
## 7570               D046_r1_BIRB 796 (Doramapimod)  12.533367605 -1.2617886214
## 7571                            D046_r1_BIX 02188  18.973583579 -1.5443754802
## 7572                            D046_r1_BIX 02189  16.018877553 -1.1711506788
## 7573      D046_r1_BKM120 (NVP-BKM120, Buparlisib)   0.533821846  1.7650699838
## 7574                           D046_r1_BMS-265246  14.824810195  0.8994098099
## 7575                           D046_r1_BMS-536924  31.344615806  1.4272870546
## 7576                           D046_r1_BMS-582949  13.809194368 -1.5296991225
## 7577                           D046_r1_BMS-754807   6.652959131  0.9702346650
## 7578                           D046_r1_BMS-777607  18.539878747 -1.5180557210
## 7579                           D046_r1_BMS-794833  17.198064993 -2.2344129405
## 7580                           D046_r1_BMS-833923  16.300779054 -2.0692881451
## 7581                  D046_r1_Bosutinib (SKI-606)  18.761970586 -1.1622700726
## 7582                D046_r1_Brivanib (BMS-540215)  18.737872718 -0.6076154968
## 7583      D046_r1_Brivanib Alaninate (BMS-582664)  16.650334875 -2.5125680263
## 7584                           D046_r1_BS-181 HCl  16.727460845 -0.2868344429
## 7585                               D046_r1_Butein  19.089582949 -1.5426778551
## 7586                               D046_r1_BYL719  17.552937474 -0.0474756336
## 7587     D046_r1_Cabozantinib (XL184, BMS-907351)  15.997341257 -1.3301185427
## 7588          D046_r1_Cabozantinib malate (XL184)  16.859942960 -1.9404026149
## 7589        D046_r1_CAL-101 (Idelalisib, GS-1101)  18.233567763 -0.6073053174
## 7590                             D046_r1_CAY10505  15.951049200 -1.7732795448
## 7591                               D046_r1_CC-223  21.845201407 -0.1788447672
## 7592                            D046_r1_CCT128930  16.551719024 -0.2370466038
## 7593                  D046_r1_Cediranib (AZD2171)  20.252348065 -2.7092913262
## 7594                            D046_r1_CEP-32496  15.656469296 -0.9336309675
## 7595                            D046_r1_CEP-33779  18.633087155 -2.1659845147
## 7596                              D046_r1_CGI1746  16.780976220 -1.6319321423
## 7597                              D046_r1_CGK 733  15.298517506 -0.8628166391
## 7598                            D046_r1_CH5132799  17.392492415 -0.5659200745
## 7599                           D046_r1_CHIR-98014   4.242835042  0.1171144465
## 7600                 D046_r1_CHIR-99021 (CT99021)   5.983382007 -1.3710908563
## 7601             D046_r1_CHIR-99021 (CT99021) HCl   9.061253526 -0.0475734525
## 7602                    D046_r1_Chrysophanic Acid  17.664306580 -2.4184008671
## 7603                             D046_r1_CNX-2006  19.425945958 -1.1126848847
## 7604                              D046_r1_CNX-774  16.176857105 -2.7893233293
## 7605                    D046_r1_CO-1686 (AVL-301)  19.581629617 -1.1766450269
## 7606       D046_r1_Cobimetinib (GDC-0973, RG7420)   3.719307925 -0.2856534562
## 7607                            D046_r1_CP-673451  12.451461974  1.2730337206
## 7608                            D046_r1_CP-724714  17.827652882 -1.1466015718
## 7609               D046_r1_Crenolanib (CP-868596)  10.951881659  0.6441939993
## 7610             D046_r1_Crizotinib (PF-02341066)   7.746605317 -0.6557542494
## 7611                               D046_r1_CYC116   6.735714786  0.3622962232
## 7612                               D046_r1_CYT387  16.729064538 -1.7263558770
## 7613                             D046_r1_CZC24832  16.985457586 -0.5233621360
## 7614              D046_r1_Dabrafenib (GSK2118436)  19.463553604 -1.8454358227
## 7615        D046_r1_Dacomitinib (PF299804, PF299)  14.507818489 -2.5267610699
## 7616              D046_r1_Danusertib (PHA-739358)  12.890625205  1.8429600297
## 7617                        D046_r1_DAPT (GSI-IX)  16.035824467 -0.8542386293
## 7618                            D046_r1_Dasatinib  15.116854363 -1.6199413170
## 7619                D046_r1_DCC-2036 (Rebastinib)  22.585119169 -2.4006480683
## 7620                D046_r1_Decernotinib (VX-509)  18.919078421 -2.0309735803
## 7621               D046_r1_Dinaciclib (SCH727965)   1.163380582  0.4988239887
## 7622    D046_r1_Dovitinib (TKI-258) Dilactic Acid   7.880999154  0.1190072489
## 7623                            D046_r1_ENMD-2076   0.503136910 -1.7732906144
## 7624               D046_r1_Enzastaurin (LY317615)  15.344599575 -2.4984006184
## 7625                            D046_r1_ERK5-IN-1  11.152847378 -0.3022243264
## 7626                             D046_r1_ETC-1002  22.226409114 -1.5954744957
## 7627                            D046_r1_ETP-46464  17.907844920 -0.1421664882
## 7628                  D046_r1_Everolimus (RAD001)  18.227837888 -0.0168471452
## 7629                D046_r1_Fasudil (HA-1077) HCl  16.210369131 -1.8503486869
## 7630                                D046_r1_FH535  10.922460935 -0.7212030014
## 7631                D046_r1_Filgotinib (GLPG0634)  13.507710397 -1.0654258820
## 7632             D046_r1_Flavopiridol (Alvocidib)   3.942095963  0.2826122562
## 7633                     D046_r1_Flavopiridol HCl  -0.109663954  0.5580603920
## 7634               D046_r1_Foretinib (GSK1363089)   6.593246399 -0.0209248543
## 7635                  D046_r1_Fostamatinib (R788)   9.548153086  0.5140416297
## 7636                                D046_r1_G-749  17.998337120 -1.3503183151
## 7637                             D046_r1_GDC-0068  10.644101938 -0.0475628515
## 7638                             D046_r1_GDC-0349  16.186987926 -1.2461480158
## 7639                             D046_r1_GDC-0879  15.291543813 -3.3100390028
## 7640                             D046_r1_GDC-0941  17.499290886 -1.0731207758
## 7641                    D046_r1_GDC-0980 (RG7422)  11.670436889  0.4886213306
## 7642                   D046_r1_Gefitinib (ZD1839)  18.143401239 -1.9674524803
## 7643                            D046_r1_Genistein  20.175450085 -2.3058786357
## 7644                            D046_r1_GF109203X  12.687962065 -1.4730127854
## 7645                                D046_r1_GNF-2  15.341722197 -1.9965122760
## 7646                                D046_r1_GNF-5  13.787766900 -1.0381873284
## 7647                              D046_r1_Go 6983  10.737257053 -1.2868880834
## 7648                   D046_r1_Golvatinib (E7050)   1.167092196 -0.1316120332
## 7649                          D046_r1_GSK1838705A  17.629801423 -2.5428961287
## 7650                          D046_r1_GSK1904529A  16.791341793 -0.7587418318
## 7651                  D046_r1_GSK2126458 (GSK458)   0.889530571 -1.6340274248
## 7652                           D046_r1_GSK2292767  21.461284967  1.9109064775
## 7653                           D046_r1_GSK2636771  13.792954978 -2.6116096750
## 7654                           D046_r1_GSK429286A  21.040012022 -1.6696617012
## 7655                            D046_r1_GSK461364  -4.767126519 -1.2266093709
## 7656                               D046_r1_GSK621  16.919025084 -2.0405130090
## 7657                            D046_r1_GSK690693   9.149769640 -1.4660969400
## 7658                               D046_r1_GW5074  18.812015348 -1.4492257383
## 7659                             D046_r1_GW788388  17.558713905 -2.5493553190
## 7660                               D046_r1_GZD824  18.738259516 -2.3320898567
## 7661                            D046_r1_H 89 2HCl  14.178166584 -2.3712068596
## 7662                           D046_r1_Hesperadin  14.737490149  2.2296650082
## 7663                              D046_r1_HMN-214   1.363456079  1.6104397386
## 7664                             D046_r1_Honokiol  18.647905682 -1.5127592003
## 7665                               D046_r1_HS-173  -0.813369795 -0.1661350180
## 7666                           D046_r1_HTH-01-015   7.752897892 -1.0364895296
## 7667                D046_r1_Ibrutinib (PCI-32765)  19.917416968 -2.2955882475
## 7668                              D046_r1_ICG-001  15.597841912 -2.9710710934
## 7669                             D046_r1_Icotinib  17.528649026 -1.2514636350
## 7670                                D046_r1_IM-12  19.280305261 -2.7295494008
## 7671           D046_r1_Imatinib Mesylate (STI571)  15.179997820 -2.5328116970
## 7672                            D046_r1_Indirubin  21.321563807 -0.2918571600
## 7673                    D046_r1_INK 128 (MLN0128)  11.424533661  0.4311185908
## 7674                    D046_r1_IPI-145 (INK1197)  20.625665873 -1.0660451707
## 7675                               D046_r1_IWP-L6  18.625818756 -2.0556222780
## 7676                           D046_r1_IWR-1-endo  16.900631472 -1.0732377433
## 7677                         D046_r1_JNJ-38877605  21.230708830 -2.1499002950
## 7678                          D046_r1_JNJ-7706621  -5.815752500  0.0210494521
## 7679                     D046_r1_JNK Inhibitor IX   2.062547941  1.2098242046
## 7680                             D046_r1_JNK-IN-8  12.249390743 -0.6549388303
## 7681                               D046_r1_K02288  14.121305769 -1.6751105667
## 7682                               D046_r1_Ki8751  19.278511847 -1.9601655441
## 7683                              D046_r1_KRN 633  17.618824577 -3.5669314781
## 7684                           D046_r1_KU-0063794  16.215539479 -1.0268006498
## 7685      D046_r1_KU-55933 (ATM Kinase Inhibitor)  20.849243517 -0.7708661614
## 7686                             D046_r1_KU-60019  16.309240671  0.1957683016
## 7687                              D046_r1_KW-2449  21.397564894  0.4819237267
## 7688                              D046_r1_KX2-391  -3.172081557  1.1445944395
## 7689                              D046_r1_KY02111  17.341080740 -2.3545242995
## 7690                            D046_r1_Lapatinib  19.780861744 -2.3688524484
## 7691     D046_r1_Lapatinib (GW-572016) Ditosylate  19.522973056 -2.7148181512
## 7692                            D046_r1_LDC000067   6.733669646 -2.6285462322
## 7693      D046_r1_LDE225 (NVP-LDE225,Erismodegib)  16.301273074 -1.6271760190
## 7694                           D046_r1_LDN-214117  16.554910427 -2.5621352872
## 7695                   D046_r1_Lenvatinib (E7080)  11.543892512 -1.8720822395
## 7696                              D046_r1_LFM-A13  14.760066032 -1.6892532007
## 7697                              D046_r1_LGK-974  14.537789903 -0.8567413353
## 7698                  D046_r1_Linifanib (ABT-869)  10.187823001 -2.3739693521
## 7699                               D046_r1_LJH685  19.537021379 -0.1159853740
## 7700                               D046_r1_LJI308  18.261821024 -1.6073619927
## 7701               D046_r1_Losmapimod (GW856553X)  15.472795580 -1.8199769806
## 7702                            D046_r1_LY2090314   3.540191658  0.3574473025
## 7703                            D046_r1_LY2157299  15.559390830 -2.2689106283
## 7704                            D046_r1_LY2784544  12.434823795 -0.8675351686
## 7705                            D046_r1_LY2835219   3.088871962  0.9193688203
## 7706                             D046_r1_LY294002  17.233770058 -0.3448495933
## 7707                            D046_r1_LY3023414  11.774839785 -0.4687320793
## 7708                             D046_r1_LY411575  15.780700601 -0.8940712651
## 7709       D046_r1_MEK162 (ARRY-162, ARRY-438162)   3.250567031  1.5563379291
## 7710                             D046_r1_MGCD-265  19.567535933  0.5197440019
## 7711               D046_r1_Milciclib (PHA-848125)  -1.451215548 -0.8753125717
## 7712                              D046_r1_MK-0752  13.929911207 -2.3436692196
## 7713                         D046_r1_MK-2206 2HCl  13.851531099 -0.1244771535
## 7714                              D046_r1_MK-2461  17.037666166 -1.0781030346
## 7715                     D046_r1_MK-5108 (VX-689)   9.889478670 -1.1844820639
## 7716                              D046_r1_MK-8745   8.676415306  2.2685649619
## 7717                              D046_r1_MLN2480  18.475627036 -0.4143746369
## 7718                              D046_r1_MLN8054  20.877232076 -1.0279522018
## 7719      D046_r1_Motesanib Diphosphate (AMG-706)  16.053358630 -2.4530669185
## 7720                  D046_r1_Nilotinib (AMN-107)  17.280847962 -1.2171692213
## 7721     D046_r1_Nintedanib (BIBF 1120)_uncertain  16.953512134 -2.4423697881
## 7722                               D046_r1_NU6027  15.482696267 -0.4688877492
## 7723                           D046_r1_NVP-AEW541  10.700424577 -0.6453070799
## 7724                           D046_r1_NVP-BHG712   9.634347777 -0.0731462795
## 7725                      D046_r1_NVP-BSK805 2HCl  17.999600399 -3.0134560176
## 7726                           D046_r1_NVP-BVU972  18.550933995 -1.5787620744
## 7727                          D046_r1_Oclacitinib  18.399411412 -2.6045034793
## 7728      D046_r1_Olmutinib (HM61713, BI 1482694)  18.202651736 -1.2502414750
## 7729                             D046_r1_ONO-4059  17.925786552 -0.5717325729
## 7730                              D046_r1_OSI-027  10.248909988  0.2471452254
## 7731                              D046_r1_OSI-420  19.164944799 -1.8308254940
## 7732                 D046_r1_OSI-906 (Linsitinib)  22.181494986 -0.0430315372
## 7733                              D046_r1_P276-00  -2.301981355  0.1725448392
## 7734                  D046_r1_Pacritinib (SB1518)  -2.223221567 -0.9016422183
## 7735                   D046_r1_Palomid 529 (P529)  18.605824670 -1.0178762634
## 7736                            D046_r1_Pazopanib  16.996773956 -1.8037481674
## 7737                        D046_r1_Pazopanib HCl  11.698338167 -1.8940582951
## 7738                            D046_r1_PD0325901   3.859080502  1.1510080519
## 7739                             D046_r1_PD168393  13.600658870  0.0578748174
## 7740                             D046_r1_PD173955  13.413316497 -1.7658915562
## 7741                   D046_r1_PD184352 (CI-1040)  13.297125699 -0.1251844284
## 7742                             D046_r1_PD318088  11.846725488  3.4183297083
## 7743                              D046_r1_PD98059  18.494500609 -1.8391076247
## 7744                  D046_r1_Pelitinib (EKB-569)  14.848523903 -0.2142839614
## 7745                          D046_r1_PF-00562271   1.601583355 -0.6113269858
## 7746                          D046_r1_PF-04217903  17.312963468 -0.9242454668
## 7747                          D046_r1_PF-04691502  16.896502387  1.1127940279
## 7748                            D046_r1_PF-431396  10.075104121  1.4965151602
## 7749                           D046_r1_PF-4708671   4.508315975  0.6047707264
## 7750                           D046_r1_PF-5274857  19.514461664 -1.9217740023
## 7751                            D046_r1_PF-562271  -1.160316022  0.4451799346
## 7752                            D046_r1_PF-573228  18.226060172  2.3555271877
## 7753                            D046_r1_PH-797804  11.558058842 -1.1594828473
## 7754                           D046_r1_PHA-665752  19.561058956 -1.5333185064
## 7755                           D046_r1_PHA-680632   5.377028974  1.7381978509
## 7756                           D046_r1_PHA-767491  -2.215630921 -0.7689914485
## 7757                           D046_r1_PHA-793887  13.495158633 -0.4281205638
## 7758                       D046_r1_Phenformin HCl  12.839789410 -1.6614682984
## 7759                              D046_r1_PHT-427  18.997763685 -2.0634448735
## 7760                          D046_r1_Piceatannol  17.128795006 -1.5946058650
## 7761                              D046_r1_PIK-293  16.887867539 -0.1170319513
## 7762                              D046_r1_PIK-294  17.077673615 -1.7765171003
## 7763                               D046_r1_PIK-93  14.816506078 -0.9051716484
## 7764               D046_r1_Pimasertib (AS-703026)   5.103324931  0.5714091756
## 7765                          D046_r1_Pirfenidone  14.944466775 -1.3268581975
## 7766                             D046_r1_PLX-4720  13.439993165 -1.4818834629
## 7767                              D046_r1_PLX7904  15.893150897 -1.4835663131
## 7768                  D046_r1_Ponatinib (AP24534)  25.368311310 -1.5511546317
## 7769                                  D046_r1_PP1  18.733286441 -1.1164436382
## 7770                                  D046_r1_PP2  11.720215489 -0.5097790559
## 7771                                D046_r1_PP242  13.787508267 -1.1406379001
## 7772                               D046_r1_PQ 401  13.838078144 -0.4180049766
## 7773                              D046_r1_PRI-724  15.503973289 -1.4998572185
## 7774     D046_r1_PRT062607 (P505-15, BIIB057) HCl  16.374065018 -0.5124225019
## 7775                         D046_r1_Purvalanol A  14.468321799 -0.6377277612
## 7776                            D046_r1_Quercetin  19.145475381 -0.9428169046
## 7777                  D046_r1_Quizartinib (AC220)  10.570620017 -1.8390639884
## 7778                                 D046_r1_R406  13.590229862 -1.6259077242
## 7779                     D046_r1_R406 (free base)  13.098750898 -1.6598055991
## 7780                                 D046_r1_R547  -2.367684579 -0.5958432967
## 7781                    D046_r1_RAF265 (CHIR-265)   5.200117355  1.8192266460
## 7782                D046_r1_Rapamycin (Sirolimus)  23.843284458 -1.0712265827
## 7783   D046_r1_Refametinib (RDEA119, Bay 86-9766)   6.331987480  0.2288474440
## 7784                               D046_r1_RepSox  15.235401202 -2.2031502979
## 7785 D046_r1_Ridaforolimus (Deforolimus, MK-8669)  17.031327535 -1.9234989086
## 7786                D046_r1_Rigosertib (ON-01910)  -1.302134236  1.3265880089
## 7787                             D046_r1_RKI-1447  17.440377957 -1.4711431194
## 7788                                D046_r1_RN486  13.082246687 -2.9088952979
## 7789                  D046_r1_Ro 31-8220 Mesylate   4.530757426  1.0559590936
## 7790                              D046_r1_Ro-3306  17.647211498 -2.2157785200
## 7791                               D046_r1_Ro3280  -1.717140350 -0.9649423868
## 7792                            D046_r1_RO4929097  15.137766787 -1.4556314149
## 7793      D046_r1_Roscovitine (Seliciclib,CYC202)  19.918369378 -0.7297507914
## 7794             D046_r1_Ruxolitinib (INCB018424)  16.950329003 -1.5921689748
## 7795           D046_r1_S-Ruxolitinib (INCB018424)  16.313284189 -1.3050134673
## 7796                               D046_r1_SANT-1  18.918715958 -1.2085170847
## 7797                            D046_r1_SAR131675  16.164615022 -0.5032857442
## 7798                    D046_r1_SAR245409 (XL765)  18.808570039 -1.6899873363
## 7799                D046_r1_Saracatinib (AZD0530)  21.170792006 -3.1399279223
## 7800                      D046_r1_SB202190 (FHPI)  17.461331529 -1.5631144659
## 7801                             D046_r1_SB203580  14.036782619 -1.8642170887
## 7802                             D046_r1_SB216763  14.422753438 -1.8551965600
## 7803                             D046_r1_SB239063  14.477193518 -1.1814665015
## 7804                             D046_r1_SB415286  14.565876847 -1.0092392208
## 7805                             D046_r1_SB431542  15.560513653 -1.6961964735
## 7806                             D046_r1_SB505124  14.317235920 -1.6054413914
## 7807                             D046_r1_SB525334  17.260055797 -1.6455424960
## 7808                             D046_r1_SB590885  18.647385854 -1.4136519068
## 7809                                  D046_r1_SC1   2.887281890 -0.1305903475
## 7810                D046_r1_Schisandrin B (Sch B)  22.185562037 -0.1539990640
## 7811                D046_r1_Selumetinib (AZD6244)   3.410741993  1.9909131014
## 7812              D046_r1_Semagacestat (LY450139)  16.878455131 -1.7958034189
## 7813                   D046_r1_Semaxanib (SU5416)  16.912859318 -0.1720598163
## 7814                             D046_r1_SGI-7079   8.181025971  0.6700922092
## 7815                          D046_r1_Skepinone-L  13.438231663 -1.1122293648
## 7816                               D046_r1_SL-327  14.942393896 -0.3424104596
## 7817                 D046_r1_SNS-032 (BMS-387032)  -3.020338324  0.1714215228
## 7818                     D046_r1_SNS-314 Mesylate   9.111459213 -1.7733966303
## 7819                            D046_r1_Sorafenib  18.519249747 -2.4016069765
## 7820                   D046_r1_Sorafenib Tosylate  14.396548991 -3.1737377920
## 7821                         D046_r1_Sotrastaurin  12.863252275 -0.5721492056
## 7822                             D046_r1_SP600125  29.907197000 -9.1922857840
## 7823                              D046_r1_SU11274  11.323564548 -1.3222857599
## 7824                               D046_r1_SU6656  10.283671978 -0.6635161372
## 7825                               D046_r1_SU9516  15.248334587 -2.3293144343
## 7826                     D046_r1_Sunitinib Malate  16.303191927 -0.5784170749
## 7827                  D046_r1_TAE226 (NVP-TAE226)   6.308915111  0.6318168856
## 7828                              D046_r1_TAK-285  18.152912866 -2.0195930826
## 7829                              D046_r1_TAK-632  11.252140195  1.0476699013
## 7830                              D046_r1_TAK-715  14.200734324 -0.4775223433
## 7831                              D046_r1_TAK-733   3.553582375 -0.0629037626
## 7832                              D046_r1_TAK-901   2.759647609 -0.4870971895
## 7833                D046_r1_Taladegib (LY2940680)  17.683166745 -1.9902098387
## 7834                              D046_r1_TCS 359  17.452503075 -1.2979878198
## 7835                               D046_r1_TDZD-8  12.403143678 -0.9948141392
## 7836                            D046_r1_Telatinib  16.730047106 -1.7889756395
## 7837   D046_r1_Temsirolimus (CCI-779, NSC 683864)  16.426747960 -1.2421977465
## 7838              D046_r1_Tepotinib (EMD 1214063)  -1.575911741 -0.4342906014
## 7839                                D046_r1_TG003  14.671694328 -1.3392123140
## 7840                            D046_r1_TG100-115  15.892484556 -2.4004919319
## 7841                             D046_r1_TG101209   2.546987103  0.0206567515
## 7842                 D046_r1_TG101348 (SAR302503)   1.663879805 -0.1072885452
## 7843                              D046_r1_TGX-221  11.100549842 -1.0366408036
## 7844                         D046_r1_Theophylline  17.905229995 -1.8279398808
## 7845                          D046_r1_Thiazovivin  17.398770960 -1.9632344253
## 7846                       D046_r1_TIC10 Analogue  17.688125980 -1.4617185668
## 7847                           D046_r1_Tideglusib  16.686595369 -0.9364443874
## 7848                 D046_r1_Tivantinib (ARQ 197)  -2.645997883  0.4482581222
## 7849                   D046_r1_Tivozanib (AV-951)  16.318841953 -2.1301336436
## 7850  D046_r1_Tofacitinib (CP-690550,Tasocitinib)  15.564417896 -1.1924698293
## 7851      D046_r1_Tofacitinib (CP-690550) Citrate  19.480251481 -1.5355588033
## 7852                              D046_r1_Torin 2   1.668054503  0.9862956046
## 7853              D046_r1_Trametinib (GSK1120212)   3.721685375 -1.1535789323
## 7854                          D046_r1_Triciribine  20.535820045  0.5837449553
## 7855           D046_r1_TSU-68 (SU6668, Orantinib)  18.922108229 -1.9246605607
## 7856                               D046_r1_TWS119  16.203083799 -1.9975098265
## 7857                         D046_r1_Tyrphostin 9  10.319952185 -1.8167446304
## 7858                   D046_r1_Tyrphostin AG 1296  16.955357798 -0.1098635862
## 7859                           D046_r1_U0126-EtOH  18.982402019 -0.8253791602
## 7860     D046_r1_Ulixertinib (BVD-523, VRT752271)   9.990551205  1.7434374246
## 7861              D046_r1_Uprosertib (GSK2141795)  12.417774091 -0.9201638756
## 7862                          D046_r1_Vacquinol-1  18.448350258 -3.6760028240
## 7863                           D046_r1_Varlitinib  17.649507577 -1.0947821157
## 7864              D046_r1_Vatalanib (PTK787) 2HCl  16.040648765 -2.3356472935
## 7865                               D046_r1_VE-821  13.244659159 -1.9592719212
## 7866                               D046_r1_VE-822   3.021686533 -0.9758687395
## 7867        D046_r1_Vemurafenib (PLX4032, RG7204)  16.085116686 -1.9750188988
## 7868                D046_r1_Vismodegib (GDC-0449)  16.755532534 -0.9987355012
## 7869                 D046_r1_Volasertib (BI 6727)  15.782635286 -1.8617398510
## 7870                            D046_r1_VPS34-IN1   6.909238017 -0.4206239941
## 7871                     D046_r1_VS-5584 (SB2343)   9.663511532 -0.2158386107
## 7872                               D046_r1_VX-11e   7.535429361  1.6462022509
## 7873         D046_r1_VX-680 (Tozasertib, MK-0457)  11.849757697 -2.4273554723
## 7874                               D046_r1_VX-702  17.433700952 -1.9070395852
## 7875                               D046_r1_VX-745  13.288427060 -1.5041731337
## 7876                              D046_r1_WAY-600   6.737409303 -3.2448299932
## 7877                             D046_r1_WH-4-023  17.758513598 -1.6889578457
## 7878                             D046_r1_WHI-P154  17.202456239 -2.1153135373
## 7879                                D046_r1_WIKI4  20.390295011 -1.3721161466
## 7880                        D046_r1_Wnt agonist 1   0.504506781  1.8002324498
## 7881                        D046_r1_Wnt-C59 (C59)  15.561170806 -0.8150611012
## 7882                               D046_r1_WP1066  16.325393867 -1.5899377254
## 7883                 D046_r1_WYE-125132 (WYE-132)  14.493427475  1.0252317291
## 7884                              D046_r1_WYE-354  16.745791330 -1.6584538135
## 7885                               D046_r1_WZ3146  11.274060241 -1.1473288403
## 7886                               D046_r1_WZ4002  18.005472351 -0.6612709082
## 7887                               D046_r1_WZ4003  17.953107704 -1.6188752252
## 7888                               D046_r1_WZ8040  15.928896117 -1.5366802456
## 7889                              D046_r1_XAV-939  19.117225891 -1.6278866137
## 7890                                D046_r1_XL019  16.898535946 -1.9728625684
## 7891                              D046_r1_XMD8-92  12.094456245 -0.2135290147
## 7892                         D046_r1_Y-27632 2HCl  15.763893218 -1.5618063721
## 7893                             D046_r1_YM201636  11.709420821 -2.1072046157
## 7894                             D046_r1_YO-01027  15.922023881 -0.7009470609
## 7895                            D046_r1_ZM 306416  18.306508496 -1.1489471712
## 7896                        D046_r1_ZM 323881 HCl  16.602399846 -2.0895030966
## 7897                            D046_r1_ZM 336372  19.217106573 -3.2721586088
## 7898                         D046_r1_ZM 39923 HCl  15.463503693 -1.3064271823
## 7899                            D046_r1_ZM 447439  16.843247616 -2.3792739524
## 7900                 D046_r1_Zotarolimus(ABT-578)  17.169197031 -0.7062773415
## 7901                              D046_r1_ZSTK474  20.378981030 -4.3210731948
## 7902                     D046_r2_1-Azakenpaullone  15.772176278 -0.9891978238
## 7903                      D046_r2_3-Methyladenine  20.467635423 -2.0906919733
## 7904                             D046_r2_A-674563   0.650997135 -1.3799405134
## 7905                             D046_r2_A-769662  21.115818337 -2.5901708504
## 7906                                  D046_r2_A66  19.701700715 -1.5700360617
## 7907                            D046_r2_Acadesine  14.471910175 -2.2870284705
## 7908                  D046_r2_AEE788 (NVP-AEE788)  12.627080321 -1.4382025242
## 7909        D046_r2_Afatinib (BIBW2992)_uncertain  13.512316773 -1.4412779522
## 7910                              D046_r2_AG-1024  10.840742911 -2.0509325371
## 7911         D046_r2_AG-1478 (Tyrphostin AG-1478)  17.869412952 -0.9004365151
## 7912                                D046_r2_AG-18  15.383030019 -1.0997305845
## 7913              D046_r2_AG-490 (Tyrphostin B42)  17.002802291 -1.6814742158
## 7914                             D046_r2_Akti-1/2  17.756723738 -1.9976876923
## 7915                  D046_r2_Alisertib (MLN8237)  44.062324794  6.6115005760
## 7916                              D046_r2_AMG 337  17.445478205 -2.1629327446
## 7917                              D046_r2_AMG-458  17.780406156 -2.9898287035
## 7918                              D046_r2_AMG-900   6.039932671 -0.9354890510
## 7919                               D046_r2_AMG319  16.435567926 -0.4703439420
## 7920                  D046_r2_Amuvatinib (MP-470)  12.604581510 -0.1771263859
## 7921                             D046_r2_Apatinib  18.997853722 -1.9131427354
## 7922                           D046_r2_AR-A014418  12.601295738 -0.6365665459
## 7923                            D046_r2_AS-252424  20.100974382 -2.1040561786
## 7924                            D046_r2_AS-604850  16.574059073 -0.7413794071
## 7925                         D046_r2_Asiatic Acid  26.554977084  0.6194133691
## 7926                             D046_r2_AST-1306  15.459506589 -1.3630665943
## 7927                              D046_r2_AT13148  14.615166128 -1.4161855239
## 7928                               D046_r2_AT7519  -0.659367823  0.9255038527
## 7929                               D046_r2_AT7867  24.006330980 -1.9767413116
## 7930                               D046_r2_AT9283  -2.125850705  1.3422185829
## 7931                 D046_r2_Aurora A Inhibitor I  12.379658669 -1.8825069750
## 7932             D046_r2_Avagacestat (BMS-708163)  14.387192822 -1.9710100294
## 7933                              D046_r2_AVL-292  17.360013025 -1.8339427548
## 7934                             D046_r2_Axitinib  15.386765431 -1.5481512000
## 7935                             D046_r2_Axitinib  15.386765431 -1.5481512000
## 7936                               D046_r2_AZ 628  14.817403330 -0.6704689248
## 7937                               D046_r2_AZ 960  15.112435023 -1.9152869243
## 7938                                 D046_r2_AZ20   7.978025933  1.1753418589
## 7939                              D046_r2_AZD1080   7.773385474 -0.8815280361
## 7940                              D046_r2_AZD1480  14.871368389  0.8434618006
## 7941                              D046_r2_AZD2014  14.543781514 -0.7015769360
## 7942                              D046_r2_AZD2858   5.747186827 -1.5148435139
## 7943                              D046_r2_AZD2932  18.863338347 -1.8938159045
## 7944                              D046_r2_AZD3759  20.242772113 -1.3368435071
## 7945                              D046_r2_AZD5363  12.598821211  0.5428973953
## 7946                              D046_r2_AZD5438   8.210350019  1.4133084531
## 7947                              D046_r2_AZD6482  19.133439329 -2.4971460244
## 7948                              D046_r2_AZD6738   7.030872872 -0.6935169697
## 7949                              D046_r2_AZD8055  21.675848015  1.2994953076
## 7950                              D046_r2_AZD8330   4.720183645  0.3310643847
## 7951                  D046_r2_AZD8931 (Sapitinib)  10.716285406 -0.7120815043
## 7952                              D046_r2_AZD9291  15.398745254 -1.1977229908
## 7953            D046_r2_Barasertib (AZD1152-HQPA)   9.579630151  0.4030911053
## 7954  D046_r2_Baricitinib (LY3009104, INCB028050)  22.140659902 -2.0583031453
## 7955                  D046_r2_BGT226 (NVP-BGT226)  14.812864948  0.6592895191
## 7956                              D046_r2_BI 2536   6.719147739 -0.2856491501
## 7957                              D046_r2_BI-78D3  13.022874178 -0.1640490962
## 7958                             D046_r2_BI-D1870  16.990183636 -1.8505382175
## 7959                              D046_r2_Bikinin  18.314583364 -3.3109305522
## 7960                                  D046_r2_BIO  18.958068731 -0.4405040996
## 7961               D046_r2_BIRB 796 (Doramapimod)  12.814859327 -1.5199271770
## 7962                            D046_r2_BIX 02188  14.416678936 -1.3914836817
## 7963                            D046_r2_BIX 02189  15.580245541 -1.7616384724
## 7964      D046_r2_BKM120 (NVP-BKM120, Buparlisib)   7.773932539  0.8043648725
## 7965                           D046_r2_BMS-265246  13.276254085 -0.0166298415
## 7966                           D046_r2_BMS-536924  25.337922764  3.3603744550
## 7967                           D046_r2_BMS-582949  14.059396205 -0.8803860515
## 7968                           D046_r2_BMS-754807   7.246946535  1.9908986148
## 7969                           D046_r2_BMS-777607  16.698986254 -1.4713694077
## 7970                           D046_r2_BMS-794833  15.713843586 -2.6410963855
## 7971                           D046_r2_BMS-833923  13.154738228 -0.6863499649
## 7972                  D046_r2_Bosutinib (SKI-606)  15.489374863  0.4847065343
## 7973                D046_r2_Brivanib (BMS-540215)  17.372223457 -3.0225341478
## 7974      D046_r2_Brivanib Alaninate (BMS-582664)  16.270425506 -1.7850051239
## 7975                           D046_r2_BS-181 HCl  16.097360492 -1.2358841399
## 7976                               D046_r2_Butein  17.817744197 -3.0180003236
## 7977                               D046_r2_BYL719  15.754779011  1.4175471990
## 7978     D046_r2_Cabozantinib (XL184, BMS-907351)  15.768843918 -1.2062692224
## 7979          D046_r2_Cabozantinib malate (XL184)  17.022977973 -1.4727137776
## 7980        D046_r2_CAL-101 (Idelalisib, GS-1101)  12.867928372 -0.7879565544
## 7981                             D046_r2_CAY10505  17.673536918 -2.5627768177
## 7982                               D046_r2_CC-223  19.282771040 -0.0971749664
## 7983                            D046_r2_CCT128930  20.319011772 -2.1799931852
## 7984                  D046_r2_Cediranib (AZD2171)  18.670841675 -2.7446323871
## 7985                            D046_r2_CEP-32496  17.466459949 -1.2965469517
## 7986                            D046_r2_CEP-33779  19.564910695 -1.3493354349
## 7987                              D046_r2_CGI1746  17.516805852 -3.1457324676
## 7988                              D046_r2_CGK 733  17.628539054 -1.6056177299
## 7989                            D046_r2_CH5132799  13.866711760 -0.9695795272
## 7990                           D046_r2_CHIR-98014   4.671303463 -1.3549808525
## 7991                 D046_r2_CHIR-99021 (CT99021)  12.008684595 -2.2046881642
## 7992             D046_r2_CHIR-99021 (CT99021) HCl   9.498405609 -1.5131759319
## 7993                    D046_r2_Chrysophanic Acid  18.321341323 -1.0109508546
## 7994                             D046_r2_CNX-2006  14.040536605 -1.5241339672
## 7995                              D046_r2_CNX-774  18.249152221 -3.2727245164
## 7996                    D046_r2_CO-1686 (AVL-301)  15.067833327 -2.3933390364
## 7997       D046_r2_Cobimetinib (GDC-0973, RG7420)   2.094392699  1.3814990868
## 7998                            D046_r2_CP-673451  14.573748755 -1.8000981503
## 7999                            D046_r2_CP-724714  15.537457481 -1.5706234210
## 8000               D046_r2_Crenolanib (CP-868596)  10.547907808 -2.1303397559
## 8001             D046_r2_Crizotinib (PF-02341066)  10.265518452 -1.2068517684
## 8002                               D046_r2_CYC116  10.245664170  0.2322068039
## 8003                               D046_r2_CYT387  15.942369402 -1.5308734496
## 8004                             D046_r2_CZC24832  22.754400201 -2.3221526163
## 8005              D046_r2_Dabrafenib (GSK2118436)  15.118974544 -0.2040387778
## 8006        D046_r2_Dacomitinib (PF299804, PF299)  18.616211089 -3.4132529462
## 8007              D046_r2_Danusertib (PHA-739358)  14.966466215 -0.3709451650
## 8008                        D046_r2_DAPT (GSI-IX)  15.907443844 -1.9389242053
## 8009                            D046_r2_Dasatinib  20.502319877 -1.9786826070
## 8010                D046_r2_DCC-2036 (Rebastinib)  16.224212758 -1.8820585339
## 8011                D046_r2_Decernotinib (VX-509)  19.033578193 -2.3166896050
## 8012               D046_r2_Dinaciclib (SCH727965)   3.290263722  0.8813094644
## 8013    D046_r2_Dovitinib (TKI-258) Dilactic Acid  10.876190125  0.2955362814
## 8014                            D046_r2_ENMD-2076   6.759906750 -0.1082960018
## 8015               D046_r2_Enzastaurin (LY317615)  12.649085162 -1.4581948132
## 8016                            D046_r2_ERK5-IN-1  12.908947393 -0.4079588302
## 8017                             D046_r2_ETC-1002  16.131128119 -1.9356779491
## 8018                            D046_r2_ETP-46464  18.772626994 -1.8325357296
## 8019                  D046_r2_Everolimus (RAD001)  19.642917944 -1.6745813399
## 8020                D046_r2_Fasudil (HA-1077) HCl  14.679081809 -2.1493829319
## 8021                                D046_r2_FH535  14.222854337 -0.8552504990
## 8022                D046_r2_Filgotinib (GLPG0634)  14.060929346 -1.2011419333
## 8023             D046_r2_Flavopiridol (Alvocidib)   0.090208004  1.0205490517
## 8024                     D046_r2_Flavopiridol HCl   1.836979503 -0.6615574657
## 8025               D046_r2_Foretinib (GSK1363089)   9.299379534 -1.7451623167
## 8026                  D046_r2_Fostamatinib (R788)  12.959348418 -0.1846657426
## 8027                                D046_r2_G-749  14.610849477 -1.9960701733
## 8028                             D046_r2_GDC-0068  11.891388913 -0.5602227409
## 8029                             D046_r2_GDC-0349  15.463610483 -0.6373240771
## 8030                             D046_r2_GDC-0879  19.402027874 -2.6794755257
## 8031                             D046_r2_GDC-0941  19.723614717 -1.9771976729
## 8032                    D046_r2_GDC-0980 (RG7422)  12.040254542  0.1385909697
## 8033                   D046_r2_Gefitinib (ZD1839)   9.856467972 -0.3126170806
## 8034                            D046_r2_Genistein  18.645849091 -4.2256274738
## 8035                            D046_r2_GF109203X  10.534555207 -1.3190350382
## 8036                                D046_r2_GNF-2  18.442321730 -0.9841875997
## 8037                                D046_r2_GNF-5  15.905237802 -0.6468617850
## 8038                              D046_r2_Go 6983   9.646700492 -1.1088111733
## 8039                   D046_r2_Golvatinib (E7050)   5.676847817  0.9947748611
## 8040                          D046_r2_GSK1838705A  18.008738323 -0.5466221732
## 8041                          D046_r2_GSK1904529A  12.282979165 -0.6486043685
## 8042                  D046_r2_GSK2126458 (GSK458)  -0.152082132 -1.9224162272
## 8043                           D046_r2_GSK2292767  20.553975158  0.3870761251
## 8044                           D046_r2_GSK2636771  16.818750972 -0.4193592733
## 8045                           D046_r2_GSK429286A  20.602221246 -1.2670224027
## 8046                            D046_r2_GSK461364  -0.063123660 -0.9018071251
## 8047                               D046_r2_GSK621  16.054854462 -1.1595909079
## 8048                            D046_r2_GSK690693  12.002672023 -1.1328147154
## 8049                               D046_r2_GW5074  19.502789816 -2.0571618017
## 8050                             D046_r2_GW788388  14.795737382 -1.8061575314
## 8051                               D046_r2_GZD824  20.461213493  0.6931642866
## 8052                            D046_r2_H 89 2HCl  18.684551769 -1.6470690279
## 8053                           D046_r2_Hesperadin  19.332170848  3.4320022275
## 8054                              D046_r2_HMN-214   7.029985908  0.2262013845
## 8055                             D046_r2_Honokiol  17.037184246 -2.0377631475
## 8056                               D046_r2_HS-173   1.905525166  0.2999898521
## 8057                           D046_r2_HTH-01-015  13.264456534 -1.8123714400
## 8058                D046_r2_Ibrutinib (PCI-32765)  15.122485304 -2.8102185987
## 8059                              D046_r2_ICG-001  16.526550904 -1.4127953128
## 8060                             D046_r2_Icotinib  14.330503116 -0.5351640074
## 8061                                D046_r2_IM-12  18.451782395 -2.6317422337
## 8062           D046_r2_Imatinib Mesylate (STI571)  14.713900452 -1.2453284377
## 8063                            D046_r2_Indirubin  20.755790654 -1.4048455989
## 8064                    D046_r2_INK 128 (MLN0128)  15.226107172  0.1684741012
## 8065                    D046_r2_IPI-145 (INK1197)  18.843678157 -2.4370437986
## 8066                               D046_r2_IWP-L6  21.703715046 -2.0165334362
## 8067                           D046_r2_IWR-1-endo  16.547594979 -1.8735546334
## 8068                         D046_r2_JNJ-38877605  15.954964332 -1.4012062879
## 8069                          D046_r2_JNJ-7706621  -0.298618117  0.2527655880
## 8070                     D046_r2_JNK Inhibitor IX   9.357678816 -0.0659347749
## 8071                             D046_r2_JNK-IN-8  12.355392925 -0.7880631529
## 8072                               D046_r2_K02288  17.129746050 -2.4457031275
## 8073                               D046_r2_Ki8751  13.546589514 -1.0972727694
## 8074                              D046_r2_KRN 633  19.299967716 -2.2324259006
## 8075                           D046_r2_KU-0063794  15.088439180 -0.1032167595
## 8076      D046_r2_KU-55933 (ATM Kinase Inhibitor)  10.817644837 -0.6971462169
## 8077                             D046_r2_KU-60019  18.110707104 -0.8675964980
## 8078                              D046_r2_KW-2449  25.812124771  1.2855311287
## 8079                              D046_r2_KX2-391   3.262708252 -0.8099446628
## 8080                              D046_r2_KY02111  17.625110950 -1.2293558129
## 8081                            D046_r2_Lapatinib  11.551106761 -0.0719761714
## 8082     D046_r2_Lapatinib (GW-572016) Ditosylate  14.836618581 -1.1538872996
## 8083                            D046_r2_LDC000067   6.707083134 -0.5821393121
## 8084      D046_r2_LDE225 (NVP-LDE225,Erismodegib)  18.219968565 -0.9915131094
## 8085                           D046_r2_LDN-214117  17.245407436 -3.7808444280
## 8086                   D046_r2_Lenvatinib (E7080)  12.698792884 -1.6108845237
## 8087                              D046_r2_LFM-A13  13.302519467 -1.7982815754
## 8088                              D046_r2_LGK-974  15.580100150 -2.1529535151
## 8089                  D046_r2_Linifanib (ABT-869)  12.248378028 -2.1372257971
## 8090                               D046_r2_LJH685  18.276529748 -1.4413729732
## 8091                               D046_r2_LJI308  17.549289451 -2.1440730256
## 8092               D046_r2_Losmapimod (GW856553X)  18.924210548 -2.4310390128
## 8093                            D046_r2_LY2090314   5.727895663 -0.2095942000
## 8094                            D046_r2_LY2157299  14.604792867 -2.1547357119
## 8095                            D046_r2_LY2784544  17.812995387 -2.1865446777
## 8096                            D046_r2_LY2835219   5.910019135  0.1838686936
## 8097                             D046_r2_LY294002  14.920336737 -0.5534349698
## 8098                            D046_r2_LY3023414  17.627197648  1.0363280877
## 8099                             D046_r2_LY411575  13.335356484 -0.6196333931
## 8100       D046_r2_MEK162 (ARRY-162, ARRY-438162)   5.517252656  1.0033584133
## 8101                             D046_r2_MGCD-265  18.458209781 -2.8246242764
## 8102               D046_r2_Milciclib (PHA-848125)   6.457776842 -0.0374958505
## 8103                              D046_r2_MK-0752  13.272058754 -1.1933485249
## 8104                         D046_r2_MK-2206 2HCl  16.445176253  2.0576073256
## 8105                              D046_r2_MK-2461  14.547452914 -2.3597803631
## 8106                     D046_r2_MK-5108 (VX-689)  12.817498701 -2.0451796638
## 8107                              D046_r2_MK-8745  16.769751841 -0.2689987891
## 8108                              D046_r2_MLN2480  13.204317450 -0.9488551739
## 8109                              D046_r2_MLN8054  14.437847607 -1.0315628274
## 8110      D046_r2_Motesanib Diphosphate (AMG-706)  13.866075560 -2.7158907496
## 8111                  D046_r2_Nilotinib (AMN-107)  18.148494224 -1.2900816920
## 8112     D046_r2_Nintedanib (BIBF 1120)_uncertain  18.030443866 -3.5933155223
## 8113                               D046_r2_NU6027  15.929022782 -2.2015170293
## 8114                           D046_r2_NVP-AEW541   6.558654447  1.4463117003
## 8115                           D046_r2_NVP-BHG712  18.212692081  1.5019903877
## 8116                      D046_r2_NVP-BSK805 2HCl  19.584486448 -2.6142205957
## 8117                           D046_r2_NVP-BVU972  18.354762174 -0.8060370707
## 8118                          D046_r2_Oclacitinib  17.384345796 -1.1092099140
## 8119      D046_r2_Olmutinib (HM61713, BI 1482694)  16.003098469 -2.3042158387
## 8120                             D046_r2_ONO-4059  14.395343092 -1.5044038049
## 8121                              D046_r2_OSI-027  12.274403782 -0.6949858994
## 8122                              D046_r2_OSI-420  19.578602874 -1.3079092606
## 8123                 D046_r2_OSI-906 (Linsitinib)  22.053201852  0.4806952606
## 8124                              D046_r2_P276-00  -1.896421961 -0.5602549221
## 8125                  D046_r2_Pacritinib (SB1518)  -0.515204733 -0.4036194227
## 8126                   D046_r2_Palomid 529 (P529)  17.432493396 -2.8389221043
## 8127                            D046_r2_Pazopanib  18.805153813 -1.4298381789
## 8128                        D046_r2_Pazopanib HCl  12.131851242 -2.1818147988
## 8129                            D046_r2_PD0325901   1.451157145  0.9904994726
## 8130                             D046_r2_PD168393  16.418275845 -2.1740313497
## 8131                             D046_r2_PD173955  12.782995275  0.0297638901
## 8132                   D046_r2_PD184352 (CI-1040)  13.824308327  0.9703146559
## 8133                             D046_r2_PD318088  12.035772214  3.2178618088
## 8134                              D046_r2_PD98059  16.414324975 -0.7965593143
## 8135                  D046_r2_Pelitinib (EKB-569)  14.493425766 -0.4488392031
## 8136                          D046_r2_PF-00562271  -1.641919842  0.5361265436
## 8137                          D046_r2_PF-04217903  16.190522534 -2.2906355413
## 8138                          D046_r2_PF-04691502  18.798451828 -1.2814291765
## 8139                            D046_r2_PF-431396  16.844178600  0.7542695594
## 8140                           D046_r2_PF-4708671   5.757158024  0.9229287749
## 8141                           D046_r2_PF-5274857  17.021742322 -1.5379683815
## 8142                            D046_r2_PF-562271   4.418050645  0.7233221823
## 8143                            D046_r2_PF-573228  16.058669469  0.2619730087
## 8144                            D046_r2_PH-797804  15.420997409 -1.4873455272
## 8145                           D046_r2_PHA-665752  21.158312349  0.9552955505
## 8146                           D046_r2_PHA-680632  13.902328180 -0.5093939428
## 8147                           D046_r2_PHA-767491   3.585250415  0.0674581482
## 8148                           D046_r2_PHA-793887   8.417137045  0.3829819080
## 8149                       D046_r2_Phenformin HCl   9.968752077 -0.9950767238
## 8150                              D046_r2_PHT-427  14.283946040 -3.8188032062
## 8151                          D046_r2_Piceatannol  14.517045258 -0.7144224199
## 8152                              D046_r2_PIK-293  16.786023001 -1.0366988141
## 8153                              D046_r2_PIK-294  15.408200864 -1.0999436591
## 8154                               D046_r2_PIK-93  15.887059980 -0.3712392452
## 8155               D046_r2_Pimasertib (AS-703026)   2.893010489  2.8068437827
## 8156                          D046_r2_Pirfenidone  15.404409856 -0.6196442240
## 8157                             D046_r2_PLX-4720  16.906069396 -2.7773096039
## 8158                              D046_r2_PLX7904  15.292165906 -0.5763404020
## 8159                  D046_r2_Ponatinib (AP24534)  14.851969764 -2.1056408115
## 8160                                  D046_r2_PP1  15.020439451 -1.1862821303
## 8161                                  D046_r2_PP2  12.677354726 -1.8316595571
## 8162                                D046_r2_PP242   8.709061707  0.2378078026
## 8163                               D046_r2_PQ 401  17.395709283 -1.4379278567
## 8164                              D046_r2_PRI-724  20.410104073 -0.6226937846
## 8165     D046_r2_PRT062607 (P505-15, BIIB057) HCl  18.356438866 -0.2015241389
## 8166                         D046_r2_Purvalanol A  16.320085751 -1.1409768177
## 8167                            D046_r2_Quercetin  18.079525552 -1.3208919392
## 8168                  D046_r2_Quizartinib (AC220)  12.711207071 -3.3348724214
## 8169                                 D046_r2_R406  17.477725819 -1.7717683853
## 8170                     D046_r2_R406 (free base)  17.179203850 -1.0898294826
## 8171                                 D046_r2_R547   2.410180229 -0.7551604237
## 8172                    D046_r2_RAF265 (CHIR-265)   4.159011639  1.5435643164
## 8173                D046_r2_Rapamycin (Sirolimus)  19.688576642 -3.4265445205
## 8174   D046_r2_Refametinib (RDEA119, Bay 86-9766)   0.444207510  0.1445532885
## 8175                               D046_r2_RepSox  14.994230411 -1.0886549699
## 8176 D046_r2_Ridaforolimus (Deforolimus, MK-8669)  19.167205097 -1.8648418493
## 8177                D046_r2_Rigosertib (ON-01910)  -8.279780758 -0.6866282932
## 8178                             D046_r2_RKI-1447  15.617903085 -1.1323463606
## 8179                                D046_r2_RN486  18.688792139 -2.3615416300
## 8180                  D046_r2_Ro 31-8220 Mesylate   4.751263496  0.1185326998
## 8181                              D046_r2_Ro-3306  14.775074732 -1.5393714845
## 8182                               D046_r2_Ro3280   2.425857888 -1.5705940527
## 8183                            D046_r2_RO4929097  17.502612631 -1.3165653306
## 8184      D046_r2_Roscovitine (Seliciclib,CYC202)  11.560801245 -0.3158621479
## 8185             D046_r2_Ruxolitinib (INCB018424)  20.004103817 -2.7365423184
## 8186           D046_r2_S-Ruxolitinib (INCB018424)  15.890860158 -1.3047590344
## 8187                               D046_r2_SANT-1  15.573043708 -1.3502867963
## 8188                            D046_r2_SAR131675  18.297193012 -2.2750510904
## 8189                    D046_r2_SAR245409 (XL765)  18.391124179 -3.0176397460
## 8190                D046_r2_Saracatinib (AZD0530)  17.315279527  0.2970840448
## 8191                      D046_r2_SB202190 (FHPI)  14.086865859 -1.1538135961
## 8192                             D046_r2_SB203580  17.826040937 -2.8643286088
## 8193                             D046_r2_SB216763  13.162638923 -0.8368244375
## 8194                             D046_r2_SB239063  16.046822319 -1.4494726863
## 8195                             D046_r2_SB415286  17.024403943 -1.0171101726
## 8196                             D046_r2_SB431542  15.363252619 -1.5163053811
## 8197                             D046_r2_SB505124  16.339563076 -1.8164685895
## 8198                             D046_r2_SB525334  19.112786730 -1.2352226782
## 8199                             D046_r2_SB590885  14.095289407  2.0784471679
## 8200                                  D046_r2_SC1   7.654982962 -0.4395286230
## 8201                D046_r2_Schisandrin B (Sch B)  18.235900768 -1.7212757555
## 8202                D046_r2_Selumetinib (AZD6244)   7.952285504  1.9747526735
## 8203              D046_r2_Semagacestat (LY450139)  15.347408753 -1.2250828082
## 8204                   D046_r2_Semaxanib (SU5416)  26.076872301 -0.9043354457
## 8205                             D046_r2_SGI-7079   8.989790871  1.2197068137
## 8206                          D046_r2_Skepinone-L  12.618033157 -1.2499709560
## 8207                               D046_r2_SL-327  10.984255339 -1.4245901895
## 8208                 D046_r2_SNS-032 (BMS-387032)   2.839477643  1.2396396753
## 8209                     D046_r2_SNS-314 Mesylate   7.523089324  0.1307353737
## 8210                            D046_r2_Sorafenib  14.443391070 -2.0729079282
## 8211                   D046_r2_Sorafenib Tosylate  12.223553042 -2.3135503164
## 8212                         D046_r2_Sotrastaurin  13.930597858 -1.9474885233
## 8213                             D046_r2_SP600125  17.814408285 -1.6409424097
## 8214                              D046_r2_SU11274  16.769979079 -4.0819090529
## 8215                               D046_r2_SU6656  14.386003740 -0.6883949181
## 8216                               D046_r2_SU9516  11.277181437 -0.4270044191
## 8217                     D046_r2_Sunitinib Malate  16.054990639 -0.3841740184
## 8218                  D046_r2_TAE226 (NVP-TAE226)   9.986037050  0.4113500962
## 8219                              D046_r2_TAK-285  21.628878449 -2.5375375978
## 8220                              D046_r2_TAK-632  15.422185796 -0.1401221581
## 8221                              D046_r2_TAK-715  20.538363357 -1.0575350895
## 8222                              D046_r2_TAK-733   3.606644823 -0.4678375870
## 8223                              D046_r2_TAK-901  10.294904073 -1.5181513149
## 8224                D046_r2_Taladegib (LY2940680)  13.541339336 -2.0412499000
## 8225                              D046_r2_TCS 359  16.263202876 -1.7180743129
## 8226                               D046_r2_TDZD-8  15.442212151 -0.8668767966
## 8227                            D046_r2_Telatinib  17.528314972 -1.6902057148
## 8228   D046_r2_Temsirolimus (CCI-779, NSC 683864)  13.404961766 -1.7176884882
## 8229              D046_r2_Tepotinib (EMD 1214063)  -0.978588579 -0.6949553397
## 8230                                D046_r2_TG003  16.712827768 -0.9290344539
## 8231                            D046_r2_TG100-115  17.567252871 -2.1173489933
## 8232                             D046_r2_TG101209  14.157921745 -0.3584727882
## 8233                 D046_r2_TG101348 (SAR302503)  16.765878452 -0.2520611942
## 8234                              D046_r2_TGX-221  24.789754181 -5.4431057539
## 8235                         D046_r2_Theophylline  16.083502918 -1.8246004512
## 8236                          D046_r2_Thiazovivin  16.910337708 -2.3616903820
## 8237                       D046_r2_TIC10 Analogue  17.420073535 -0.3853540037
## 8238                           D046_r2_Tideglusib  15.855633200 -1.7680930818
## 8239                 D046_r2_Tivantinib (ARQ 197)   4.381922943 -0.2843492290
## 8240                   D046_r2_Tivozanib (AV-951)  20.103484802 -2.7165273592
## 8241  D046_r2_Tofacitinib (CP-690550,Tasocitinib)  16.032824895 -1.6235364414
## 8242      D046_r2_Tofacitinib (CP-690550) Citrate  17.975719148 -1.4893683578
## 8243                              D046_r2_Torin 2   8.106523407 -1.1325565707
## 8244              D046_r2_Trametinib (GSK1120212)  -3.284449518 -1.0456897686
## 8245                          D046_r2_Triciribine  17.573831280  0.7560820599
## 8246           D046_r2_TSU-68 (SU6668, Orantinib)  18.997617273 -2.1099167109
## 8247                               D046_r2_TWS119  16.175844258 -1.6019321905
## 8248                         D046_r2_Tyrphostin 9  13.322641322  0.6390825839
## 8249                   D046_r2_Tyrphostin AG 1296  13.373042533 -0.9245948352
## 8250                           D046_r2_U0126-EtOH  17.847137938 -2.3296122049
## 8251     D046_r2_Ulixertinib (BVD-523, VRT752271)  10.169135540  1.7053131504
## 8252              D046_r2_Uprosertib (GSK2141795)  14.443333171 -0.7464639790
## 8253                          D046_r2_Vacquinol-1  11.060344034 -1.8975389401
## 8254                           D046_r2_Varlitinib  21.689337209 -3.4432187223
## 8255              D046_r2_Vatalanib (PTK787) 2HCl  15.535168313 -2.5730385993
## 8256                               D046_r2_VE-821   9.996645140 -1.3100523836
## 8257                               D046_r2_VE-822   7.001801483  0.8640856367
## 8258        D046_r2_Vemurafenib (PLX4032, RG7204)  13.365238435 -2.5967897517
## 8259                D046_r2_Vismodegib (GDC-0449)  13.613110413 -1.4330634920
## 8260                 D046_r2_Volasertib (BI 6727)  13.327586636 -1.8030664510
## 8261                            D046_r2_VPS34-IN1  12.843377596 -0.4638714752
## 8262                     D046_r2_VS-5584 (SB2343)  13.071344569 -0.6277447977
## 8263                               D046_r2_VX-11e  13.742287821  2.3044600781
## 8264         D046_r2_VX-680 (Tozasertib, MK-0457)  10.000624725  0.0382530615
## 8265                               D046_r2_VX-702  18.882854108 -1.8505295349
## 8266                               D046_r2_VX-745  15.724718990 -1.4550651887
## 8267                              D046_r2_WAY-600   8.003527202 -1.0464672023
## 8268                             D046_r2_WH-4-023  17.596174049 -3.3826176414
## 8269                             D046_r2_WHI-P154  17.177627315 -1.2638705367
## 8270                                D046_r2_WIKI4  15.367037281 -1.1560279797
## 8271                        D046_r2_Wnt agonist 1   6.294147248 -0.3383390540
## 8272                        D046_r2_Wnt-C59 (C59)  15.721724460 -1.5083426706
## 8273                               D046_r2_WP1066  16.353253765 -2.3427475373
## 8274                 D046_r2_WYE-125132 (WYE-132)  17.598610874  1.0474818152
## 8275                              D046_r2_WYE-354  20.344346335  1.4087080646
## 8276                               D046_r2_WZ3146  15.142761031 -1.5131969830
## 8277                               D046_r2_WZ4002  16.964700869 -1.1847023809
## 8278                               D046_r2_WZ4003  18.651213214 -1.6942484681
## 8279                               D046_r2_WZ8040  13.516489198 -0.9569765062
## 8280                              D046_r2_XAV-939  18.863004121 -2.2708030797
## 8281                                D046_r2_XL019  14.600575755 -2.2900107531
## 8282                              D046_r2_XMD8-92  18.202743709  0.2535590434
## 8283                         D046_r2_Y-27632 2HCl  17.429007989 -1.7309430039
## 8284                             D046_r2_YM201636  12.280128868 -0.1654197707
## 8285                             D046_r2_YO-01027  15.554554328 -1.4578636099
## 8286                            D046_r2_ZM 306416  16.362940946 -1.3666665545
## 8287                        D046_r2_ZM 323881 HCl  18.399477499 -0.9347406149
## 8288                            D046_r2_ZM 336372  20.547882805 -4.7084169073
## 8289                         D046_r2_ZM 39923 HCl  15.773252925 -1.0281041181
## 8290                            D046_r2_ZM 447439  12.776217747 -1.8334836213
## 8291                 D046_r2_Zotarolimus(ABT-578)  23.212960845 -1.9757888413
## 8292                              D046_r2_ZSTK474  14.150569670 -0.4420212513
##                 V3                                 drug      id
## 1     1.470161e+00                     1-Azakenpaullone D004_r1
## 2     1.569017e+00                      3-Methyladenine D004_r1
## 3     3.893268e+00                             A-674563 D004_r1
## 4     1.454402e+00                             A-769662 D004_r1
## 5     1.646895e+00                                  A66 D004_r1
## 6     6.657757e-01                            Acadesine D004_r1
## 7     1.367418e+00                  AEE788 (NVP-AEE788) D004_r1
## 8     9.951474e-01        Afatinib (BIBW2992)_uncertain D004_r1
## 9     2.680892e+00                              AG-1024 D004_r1
## 10    2.972165e+00         AG-1478 (Tyrphostin AG-1478) D004_r1
## 11    2.249399e+00                                AG-18 D004_r1
## 12    1.029235e+00              AG-490 (Tyrphostin B42) D004_r1
## 13    1.256966e+00                             Akti-1/2 D004_r1
## 14    5.164589e-02                  Alisertib (MLN8237) D004_r1
## 15    1.152488e+00                              AMG 337 D004_r1
## 16    1.370578e+00                              AMG-458 D004_r1
## 17    3.056167e+00                              AMG-900 D004_r1
## 18    2.121270e-01                               AMG319 D004_r1
## 19    1.637931e+00                  Amuvatinib (MP-470) D004_r1
## 20    4.713673e-01                             Apatinib D004_r1
## 21    1.645729e+00                           AR-A014418 D004_r1
## 22    1.915561e+00                            AS-252424 D004_r1
## 23   -9.683376e-02                            AS-604850 D004_r1
## 24    6.989285e-01                         Asiatic Acid D004_r1
## 25    6.275537e-01                             AST-1306 D004_r1
## 26    1.582160e+00                              AT13148 D004_r1
## 27    2.133390e+00                               AT7519 D004_r1
## 28    2.897469e-01                               AT7867 D004_r1
## 29    4.425380e+00                               AT9283 D004_r1
## 30    3.150674e+00                 Aurora A Inhibitor I D004_r1
## 31    1.724889e+00             Avagacestat (BMS-708163) D004_r1
## 32    7.943582e-01                              AVL-292 D004_r1
## 33    3.907214e+00                             Axitinib D004_r1
## 34    3.907214e+00                             Axitinib D004_r1
## 35    3.683315e+00                               AZ 628 D004_r1
## 36    2.930928e+00                               AZ 960 D004_r1
## 37    2.108028e+00                                 AZ20 D004_r1
## 38    2.598361e+00                              AZD1080 D004_r1
## 39    1.829066e+00                              AZD1480 D004_r1
## 40    2.405675e+00                              AZD2014 D004_r1
## 41    3.278781e+00                              AZD2858 D004_r1
## 42   -3.274798e-01                              AZD2932 D004_r1
## 43    8.418968e-01                              AZD3759 D004_r1
## 44   -2.973514e-01                              AZD5363 D004_r1
## 45    2.184836e+00                              AZD5438 D004_r1
## 46    1.168897e-01                              AZD6482 D004_r1
## 47    1.390485e+00                              AZD6738 D004_r1
## 48    3.219707e+00                              AZD8055 D004_r1
## 49    5.337087e+00                              AZD8330 D004_r1
## 50    2.265770e+00                  AZD8931 (Sapitinib) D004_r1
## 51    3.921592e+00                              AZD9291 D004_r1
## 52    6.885383e-01            Barasertib (AZD1152-HQPA) D004_r1
## 53    1.634426e-02  Baricitinib (LY3009104, INCB028050) D004_r1
## 54   -2.221380e-01                  BGT226 (NVP-BGT226) D004_r1
## 55    1.239426e+00                              BI 2536 D004_r1
## 56    8.765624e-01                              BI-78D3 D004_r1
## 57    1.500237e+00                             BI-D1870 D004_r1
## 58    1.003750e+00                              Bikinin D004_r1
## 59    7.472606e-01                                  BIO D004_r1
## 60    1.763410e-02               BIRB 796 (Doramapimod) D004_r1
## 61    1.118792e+00                            BIX 02188 D004_r1
## 62   -3.681186e-01                            BIX 02189 D004_r1
## 63   -4.216208e-01      BKM120 (NVP-BKM120, Buparlisib) D004_r1
## 64    2.900221e-01                           BMS-265246 D004_r1
## 65    1.528684e+00                           BMS-536924 D004_r1
## 66    1.111979e+00                           BMS-582949 D004_r1
## 67    1.180547e-01                           BMS-754807 D004_r1
## 68    1.227733e+00                           BMS-777607 D004_r1
## 69    5.908569e-01                           BMS-794833 D004_r1
## 70    9.051947e-01                           BMS-833923 D004_r1
## 71    1.629544e+00                  Bosutinib (SKI-606) D004_r1
## 72    1.730439e+00                Brivanib (BMS-540215) D004_r1
## 73    1.623883e+00      Brivanib Alaninate (BMS-582664) D004_r1
## 74   -4.437208e-01                           BS-181 HCl D004_r1
## 75    3.498320e-01                               Butein D004_r1
## 76    8.741788e-01                               BYL719 D004_r1
## 77    3.691435e-01     Cabozantinib (XL184, BMS-907351) D004_r1
## 78    8.972400e-01          Cabozantinib malate (XL184) D004_r1
## 79    3.869729e-01        CAL-101 (Idelalisib, GS-1101) D004_r1
## 80   -1.140159e+00                             CAY10505 D004_r1
## 81    2.215050e-01                               CC-223 D004_r1
## 82    1.713331e+00                            CCT128930 D004_r1
## 83    3.767673e+00                  Cediranib (AZD2171) D004_r1
## 84    1.301441e+00                            CEP-32496 D004_r1
## 85    4.046173e-01                            CEP-33779 D004_r1
## 86    5.869037e-01                              CGI1746 D004_r1
## 87    1.499666e+00                              CGK 733 D004_r1
## 88    2.642580e+00                            CH5132799 D004_r1
## 89    4.026983e+00                           CHIR-98014 D004_r1
## 90    2.787625e+00                 CHIR-99021 (CT99021) D004_r1
## 91    2.373125e+00             CHIR-99021 (CT99021) HCl D004_r1
## 92   -9.184061e-01                    Chrysophanic Acid D004_r1
## 93    4.297772e+00                             CNX-2006 D004_r1
## 94    5.163404e-01                              CNX-774 D004_r1
## 95   -4.200394e-01                    CO-1686 (AVL-301) D004_r1
## 96    3.962909e+00       Cobimetinib (GDC-0973, RG7420) D004_r1
## 97    1.990121e+00                            CP-673451 D004_r1
## 98    1.631408e+00                            CP-724714 D004_r1
## 99    2.693292e+00               Crenolanib (CP-868596) D004_r1
## 100   5.499185e-01             Crizotinib (PF-02341066) D004_r1
## 101   1.272303e+00                               CYC116 D004_r1
## 102   9.981521e-01                               CYT387 D004_r1
## 103   1.598674e+00                             CZC24832 D004_r1
## 104   7.462058e-01              Dabrafenib (GSK2118436) D004_r1
## 105   1.585317e+00        Dacomitinib (PF299804, PF299) D004_r1
## 106   2.926102e-01              Danusertib (PHA-739358) D004_r1
## 107   2.224453e+00                        DAPT (GSI-IX) D004_r1
## 108   1.258698e-02                            Dasatinib D004_r1
## 109  -3.552980e+00                DCC-2036 (Rebastinib) D004_r1
## 110   6.217911e-01                Decernotinib (VX-509) D004_r1
## 111   3.684790e+00               Dinaciclib (SCH727965) D004_r1
## 112   8.644770e-01    Dovitinib (TKI-258) Dilactic Acid D004_r1
## 113   2.630459e+00                            ENMD-2076 D004_r1
## 114   2.222124e+00               Enzastaurin (LY317615) D004_r1
## 115  -1.884339e-01                            ERK5-IN-1 D004_r1
## 116   1.150016e+00                             ETC-1002 D004_r1
## 117   1.045656e+00                            ETP-46464 D004_r1
## 118   4.723118e-02                  Everolimus (RAD001) D004_r1
## 119   1.334858e+00                Fasudil (HA-1077) HCl D004_r1
## 120   1.660643e+00                                FH535 D004_r1
## 121  -1.082879e-01                Filgotinib (GLPG0634) D004_r1
## 122   8.059152e-01             Flavopiridol (Alvocidib) D004_r1
## 123   3.482738e+00                     Flavopiridol HCl D004_r1
## 124   3.647301e+00               Foretinib (GSK1363089) D004_r1
## 125  -5.525749e-01                  Fostamatinib (R788) D004_r1
## 126   1.034255e+00                                G-749 D004_r1
## 127   2.071051e+00                             GDC-0068 D004_r1
## 128   1.720949e+00                             GDC-0349 D004_r1
## 129   8.678323e-01                             GDC-0879 D004_r1
## 130   2.575860e+00                             GDC-0941 D004_r1
## 131   1.528518e+00                    GDC-0980 (RG7422) D004_r1
## 132   2.134519e+00                   Gefitinib (ZD1839) D004_r1
## 133   2.035674e+00                            Genistein D004_r1
## 134   3.815548e+00                            GF109203X D004_r1
## 135   3.254898e-01                                GNF-2 D004_r1
## 136   5.060756e-01                                GNF-5 D004_r1
## 137   3.271320e+00                              Go 6983 D004_r1
## 138   9.462593e-01                   Golvatinib (E7050) D004_r1
## 139   1.543765e+00                          GSK1838705A D004_r1
## 140  -3.130955e-01                          GSK1904529A D004_r1
## 141   1.554574e+00                  GSK2126458 (GSK458) D004_r1
## 142   1.236882e-01                           GSK2292767 D004_r1
## 143  -1.313637e+00                           GSK2636771 D004_r1
## 144  -4.680370e-01                           GSK429286A D004_r1
## 145   3.174889e+00                            GSK461364 D004_r1
## 146   6.488731e-01                               GSK621 D004_r1
## 147   1.021389e+00                            GSK690693 D004_r1
## 148  -1.503974e-01                               GW5074 D004_r1
## 149   7.826684e-01                             GW788388 D004_r1
## 150   2.621261e+00                               GZD824 D004_r1
## 151   1.200486e+00                            H 89 2HCl D004_r1
## 152  -2.434081e-02                           Hesperadin D004_r1
## 153   2.411647e+00                              HMN-214 D004_r1
## 154   1.548474e-01                             Honokiol D004_r1
## 155   1.737830e+00                               HS-173 D004_r1
## 156   5.073785e-01                           HTH-01-015 D004_r1
## 157   1.653564e+00                Ibrutinib (PCI-32765) D004_r1
## 158   6.006221e-01                              ICG-001 D004_r1
## 159   1.392231e+00                             Icotinib D004_r1
## 160   9.740023e-01                                IM-12 D004_r1
## 161   2.349742e+00           Imatinib Mesylate (STI571) D004_r1
## 162  -1.180540e+00                            Indirubin D004_r1
## 163   3.461376e+00                    INK 128 (MLN0128) D004_r1
## 164  -8.463669e-01                    IPI-145 (INK1197) D004_r1
## 165   1.093121e-01                               IWP-L6 D004_r1
## 166   1.529676e+00                           IWR-1-endo D004_r1
## 167   1.083731e+00                         JNJ-38877605 D004_r1
## 168   4.170938e+00                          JNJ-7706621 D004_r1
## 169   1.103921e+00                     JNK Inhibitor IX D004_r1
## 170   6.387188e-01                             JNK-IN-8 D004_r1
## 171   1.890390e+00                               K02288 D004_r1
## 172   3.231627e-01                               Ki8751 D004_r1
## 173   1.802616e+00                              KRN 633 D004_r1
## 174   1.247077e-01                           KU-0063794 D004_r1
## 175   5.840769e-01      KU-55933 (ATM Kinase Inhibitor) D004_r1
## 176  -1.465824e-01                             KU-60019 D004_r1
## 177  -4.136771e-01                              KW-2449 D004_r1
## 178   1.955965e+00                              KX2-391 D004_r1
## 179   1.098915e+00                              KY02111 D004_r1
## 180   2.212224e+00                            Lapatinib D004_r1
## 181   2.920535e+00     Lapatinib (GW-572016) Ditosylate D004_r1
## 182   2.173536e+00                            LDC000067 D004_r1
## 183   1.010405e+00      LDE225 (NVP-LDE225,Erismodegib) D004_r1
## 184   7.307076e-01                           LDN-214117 D004_r1
## 185   2.064886e+00                   Lenvatinib (E7080) D004_r1
## 186   6.561207e-01                              LFM-A13 D004_r1
## 187   7.653177e-01                              LGK-974 D004_r1
## 188   1.661053e+00                  Linifanib (ABT-869) D004_r1
## 189   1.357761e+00                               LJH685 D004_r1
## 190   1.249590e+00                               LJI308 D004_r1
## 191   5.250815e-01               Losmapimod (GW856553X) D004_r1
## 192   2.778806e+00                            LY2090314 D004_r1
## 193   9.825464e-01                            LY2157299 D004_r1
## 194   5.646129e-02                            LY2784544 D004_r1
## 195   3.456397e+00                            LY2835219 D004_r1
## 196   3.235909e-01                             LY294002 D004_r1
## 197  -6.658815e-01                            LY3023414 D004_r1
## 198   1.198882e+00                             LY411575 D004_r1
## 199   3.858581e+00       MEK162 (ARRY-162, ARRY-438162) D004_r1
## 200   1.026068e+00                             MGCD-265 D004_r1
## 201   4.716577e+00               Milciclib (PHA-848125) D004_r1
## 202   3.593635e-01                              MK-0752 D004_r1
## 203   1.702685e+00                         MK-2206 2HCl D004_r1
## 204   8.162852e-01                              MK-2461 D004_r1
## 205   5.486183e-01                     MK-5108 (VX-689) D004_r1
## 206   2.004508e+00                              MK-8745 D004_r1
## 207   1.793127e+00                              MLN2480 D004_r1
## 208   3.233247e-01                              MLN8054 D004_r1
## 209   2.381343e+00      Motesanib Diphosphate (AMG-706) D004_r1
## 210   2.562968e+00                  Nilotinib (AMN-107) D004_r1
## 211   1.939671e+00     Nintedanib (BIBF 1120)_uncertain D004_r1
## 212  -3.884921e-01                               NU6027 D004_r1
## 213   1.405644e+00                           NVP-AEW541 D004_r1
## 214   1.421952e-01                           NVP-BHG712 D004_r1
## 215   1.815346e+00                      NVP-BSK805 2HCl D004_r1
## 216   1.754209e+00                           NVP-BVU972 D004_r1
## 217   1.121468e+00                          Oclacitinib D004_r1
## 218   3.850436e-01      Olmutinib (HM61713, BI 1482694) D004_r1
## 219   2.087230e+00                             ONO-4059 D004_r1
## 220   1.765988e+00                              OSI-027 D004_r1
## 221   9.231055e-01                              OSI-420 D004_r1
## 222   4.299633e-01                 OSI-906 (Linsitinib) D004_r1
## 223   3.222384e+00                              P276-00 D004_r1
## 224   2.579626e+00                  Pacritinib (SB1518) D004_r1
## 225   1.130084e+00                   Palomid 529 (P529) D004_r1
## 226  -1.089004e+00                            Pazopanib D004_r1
## 227   1.449806e+00                        Pazopanib HCl D004_r1
## 228   2.692263e+00                            PD0325901 D004_r1
## 229   2.582617e+00                             PD168393 D004_r1
## 230  -2.602685e-01                             PD173955 D004_r1
## 231   3.938552e+00                   PD184352 (CI-1040) D004_r1
## 232   2.742710e+00                             PD318088 D004_r1
## 233   2.334661e-02                              PD98059 D004_r1
## 234   2.921905e+00                  Pelitinib (EKB-569) D004_r1
## 235   2.013246e+00                          PF-00562271 D004_r1
## 236  -7.895853e-01                          PF-04217903 D004_r1
## 237   9.943712e-01                          PF-04691502 D004_r1
## 238   2.800013e+00                            PF-431396 D004_r1
## 239   4.459736e-01                           PF-4708671 D004_r1
## 240   9.051586e-01                           PF-5274857 D004_r1
## 241   2.643276e+00                            PF-562271 D004_r1
## 242   4.084460e-01                            PF-573228 D004_r1
## 243   1.090069e+00                            PH-797804 D004_r1
## 244   1.286130e+00                           PHA-665752 D004_r1
## 245   1.030343e+00                           PHA-680632 D004_r1
## 246   3.847571e+00                           PHA-767491 D004_r1
## 247   2.876051e-01                           PHA-793887 D004_r1
## 248  -3.659741e-01                       Phenformin HCl D004_r1
## 249   3.772918e+00                              PHT-427 D004_r1
## 250   6.389243e+00                          Piceatannol D004_r1
## 251  -5.115483e-02                              PIK-293 D004_r1
## 252  -3.487892e-01                              PIK-294 D004_r1
## 253   2.148688e+00                               PIK-93 D004_r1
## 254   4.810932e+00               Pimasertib (AS-703026) D004_r1
## 255   9.413481e-01                          Pirfenidone D004_r1
## 256  -3.002914e-01                             PLX-4720 D004_r1
## 257   8.293959e-01                              PLX7904 D004_r1
## 258   1.623794e+00                  Ponatinib (AP24534) D004_r1
## 259   9.760714e-01                                  PP1 D004_r1
## 260   3.465521e-01                                  PP2 D004_r1
## 261  -9.751273e-01                                PP242 D004_r1
## 262   1.793589e+00                               PQ 401 D004_r1
## 263  -5.110830e-01                              PRI-724 D004_r1
## 264   1.005342e+00     PRT062607 (P505-15, BIIB057) HCl D004_r1
## 265   1.992559e+00                         Purvalanol A D004_r1
## 266   1.757547e+00                            Quercetin D004_r1
## 267   1.125944e+00                  Quizartinib (AC220) D004_r1
## 268   2.061924e+00                                 R406 D004_r1
## 269   6.594590e-01                     R406 (free base) D004_r1
## 270   3.126257e+00                                 R547 D004_r1
## 271   1.614054e+00                    RAF265 (CHIR-265) D004_r1
## 272  -4.705535e-01                Rapamycin (Sirolimus) D004_r1
## 273   2.755500e+00   Refametinib (RDEA119, Bay 86-9766) D004_r1
## 274   9.626079e-01                               RepSox D004_r1
## 275   3.010851e-01 Ridaforolimus (Deforolimus, MK-8669) D004_r1
## 276   1.637482e+00                Rigosertib (ON-01910) D004_r1
## 277   9.563186e-01                             RKI-1447 D004_r1
## 278   7.951880e-01                                RN486 D004_r1
## 279   3.153957e+00                  Ro 31-8220 Mesylate D004_r1
## 280   1.008149e+00                              Ro-3306 D004_r1
## 281   3.264680e+00                               Ro3280 D004_r1
## 282   7.732136e-01                            RO4929097 D004_r1
## 283   1.252062e-01      Roscovitine (Seliciclib,CYC202) D004_r1
## 284   5.410362e-01             Ruxolitinib (INCB018424) D004_r1
## 285   6.184801e-01           S-Ruxolitinib (INCB018424) D004_r1
## 286   5.226437e-01                               SANT-1 D004_r1
## 287   6.695779e-01                            SAR131675 D004_r1
## 288   4.544131e-01                    SAR245409 (XL765) D004_r1
## 289   2.573758e+00                Saracatinib (AZD0530) D004_r1
## 290  -1.009629e-01                      SB202190 (FHPI) D004_r1
## 291  -7.111482e-01                             SB203580 D004_r1
## 292   1.741508e+00                             SB216763 D004_r1
## 293   9.794631e-01                             SB239063 D004_r1
## 294   1.466194e+00                             SB415286 D004_r1
## 295   1.776634e+00                             SB431542 D004_r1
## 296   6.498249e-01                             SB505124 D004_r1
## 297   3.770215e-01                             SB525334 D004_r1
## 298   7.175338e-01                             SB590885 D004_r1
## 299   1.660492e+00                                  SC1 D004_r1
## 300  -2.045911e-01                Schisandrin B (Sch B) D004_r1
## 301   3.877021e+00                Selumetinib (AZD6244) D004_r1
## 302   2.239821e+00              Semagacestat (LY450139) D004_r1
## 303  -6.215045e-02                   Semaxanib (SU5416) D004_r1
## 304   3.511766e+00                             SGI-7079 D004_r1
## 305  -2.097676e-01                          Skepinone-L D004_r1
## 306   5.104108e+00                               SL-327 D004_r1
## 307   1.662809e+00                 SNS-032 (BMS-387032) D004_r1
## 308   8.577743e-01                     SNS-314 Mesylate D004_r1
## 309   1.119824e+00                            Sorafenib D004_r1
## 310   2.558495e+00                   Sorafenib Tosylate D004_r1
## 311   2.877138e+00                         Sotrastaurin D004_r1
## 312   3.086283e-01                             SP600125 D004_r1
## 313   3.969867e+00                              SU11274 D004_r1
## 314   3.760512e-01                               SU6656 D004_r1
## 315  -9.709495e-01                               SU9516 D004_r1
## 316   3.361603e+00                     Sunitinib Malate D004_r1
## 317   2.631021e+00                  TAE226 (NVP-TAE226) D004_r1
## 318   7.540281e-01                              TAK-285 D004_r1
## 319   1.199475e+00                              TAK-632 D004_r1
## 320   1.085547e+00                              TAK-715 D004_r1
## 321   2.960441e+00                              TAK-733 D004_r1
## 322   3.568237e-01                              TAK-901 D004_r1
## 323   1.047004e+00                Taladegib (LY2940680) D004_r1
## 324   6.511774e-01                              TCS 359 D004_r1
## 325   3.971976e-02                               TDZD-8 D004_r1
## 326   8.080548e-01                            Telatinib D004_r1
## 327   3.137994e+00   Temsirolimus (CCI-779, NSC 683864) D004_r1
## 328   1.906438e+00              Tepotinib (EMD 1214063) D004_r1
## 329  -5.109877e-01                                TG003 D004_r1
## 330   1.628671e+00                            TG100-115 D004_r1
## 331   2.367670e+00                             TG101209 D004_r1
## 332   1.635036e+00                 TG101348 (SAR302503) D004_r1
## 333   1.342725e+00                              TGX-221 D004_r1
## 334   1.149632e+00                         Theophylline D004_r1
## 335   9.641993e-02                          Thiazovivin D004_r1
## 336   1.147331e-01                       TIC10 Analogue D004_r1
## 337   8.346788e-02                           Tideglusib D004_r1
## 338  -1.316553e-01                 Tivantinib (ARQ 197) D004_r1
## 339   7.680432e-01                   Tivozanib (AV-951) D004_r1
## 340   1.241978e+00  Tofacitinib (CP-690550,Tasocitinib) D004_r1
## 341   7.522191e-01      Tofacitinib (CP-690550) Citrate D004_r1
## 342   1.133025e+00                              Torin 2 D004_r1
## 343   3.625672e+00              Trametinib (GSK1120212) D004_r1
## 344   2.671765e-01                          Triciribine D004_r1
## 345  -2.428037e-01           TSU-68 (SU6668, Orantinib) D004_r1
## 346   1.973085e+00                               TWS119 D004_r1
## 347   3.445881e+00                         Tyrphostin 9 D004_r1
## 348   1.797863e-01                   Tyrphostin AG 1296 D004_r1
## 349   4.913655e+00                           U0126-EtOH D004_r1
## 350   3.551548e+00     Ulixertinib (BVD-523, VRT752271) D004_r1
## 351   2.578197e+00              Uprosertib (GSK2141795) D004_r1
## 352  -3.914461e+00                          Vacquinol-1 D004_r1
## 353   8.430649e-01                           Varlitinib D004_r1
## 354   2.923046e+00              Vatalanib (PTK787) 2HCl D004_r1
## 355   2.747731e+00                               VE-821 D004_r1
## 356   5.949639e-01                               VE-822 D004_r1
## 357   1.101951e+00        Vemurafenib (PLX4032, RG7204) D004_r1
## 358   3.975105e-01                Vismodegib (GDC-0449) D004_r1
## 359   1.319823e+00                 Volasertib (BI 6727) D004_r1
## 360  -4.000609e-01                            VPS34-IN1 D004_r1
## 361   1.987526e+00                     VS-5584 (SB2343) D004_r1
## 362   5.572038e+00                               VX-11e D004_r1
## 363   2.861220e+00         VX-680 (Tozasertib, MK-0457) D004_r1
## 364  -4.002863e-01                               VX-702 D004_r1
## 365   9.600987e-01                               VX-745 D004_r1
## 366   1.264687e+00                              WAY-600 D004_r1
## 367  -6.559585e-01                             WH-4-023 D004_r1
## 368   7.124757e-01                             WHI-P154 D004_r1
## 369  -1.956041e-01                                WIKI4 D004_r1
## 370  -2.115791e-01                        Wnt agonist 1 D004_r1
## 371   2.152766e-02                        Wnt-C59 (C59) D004_r1
## 372   1.036571e+00                               WP1066 D004_r1
## 373   2.021438e+00                 WYE-125132 (WYE-132) D004_r1
## 374   2.604072e+00                              WYE-354 D004_r1
## 375   8.956736e-01                               WZ3146 D004_r1
## 376   7.194295e-01                               WZ4002 D004_r1
## 377   1.260999e+00                               WZ4003 D004_r1
## 378   2.936262e+00                               WZ8040 D004_r1
## 379   6.086144e-01                              XAV-939 D004_r1
## 380   3.728090e-01                                XL019 D004_r1
## 381   2.046900e+00                              XMD8-92 D004_r1
## 382   6.291966e-01                         Y-27632 2HCl D004_r1
## 383  -3.413101e-03                             YM201636 D004_r1
## 384   6.381745e-01                             YO-01027 D004_r1
## 385   3.202164e+00                            ZM 306416 D004_r1
## 386  -5.654196e-01                        ZM 323881 HCl D004_r1
## 387  -6.538619e-01                            ZM 336372 D004_r1
## 388   7.079312e-01                         ZM 39923 HCl D004_r1
## 389   1.875301e+00                            ZM 447439 D004_r1
## 390   8.435131e-01                 Zotarolimus(ABT-578) D004_r1
## 391   1.057548e+00                              ZSTK474 D004_r1
## 392   3.573038e+00                     1-Azakenpaullone D004_r2
## 393   1.311463e+00                      3-Methyladenine D004_r2
## 394   4.508446e+00                             A-674563 D004_r2
## 395   1.026606e+00                             A-769662 D004_r2
## 396   2.984839e+00                                  A66 D004_r2
## 397   1.477426e+00                            Acadesine D004_r2
## 398   3.254357e+00                  AEE788 (NVP-AEE788) D004_r2
## 399   1.212972e+00        Afatinib (BIBW2992)_uncertain D004_r2
## 400   8.023595e-01                              AG-1024 D004_r2
## 401   1.802801e+00         AG-1478 (Tyrphostin AG-1478) D004_r2
## 402   5.490566e-01                                AG-18 D004_r2
## 403   5.707983e-01              AG-490 (Tyrphostin B42) D004_r2
## 404   1.946587e+00                             Akti-1/2 D004_r2
## 405   3.749768e+00                  Alisertib (MLN8237) D004_r2
## 406  -1.499441e-01                              AMG 337 D004_r2
## 407   8.565068e-01                              AMG-458 D004_r2
## 408   2.931998e+00                              AMG-900 D004_r2
## 409   1.375570e+00                               AMG319 D004_r2
## 410   4.253100e-01                  Amuvatinib (MP-470) D004_r2
## 411   3.011791e-01                             Apatinib D004_r2
## 412   1.473370e+00                           AR-A014418 D004_r2
## 413   2.114607e+00                            AS-252424 D004_r2
## 414   8.877988e-01                            AS-604850 D004_r2
## 415   1.739398e+00                         Asiatic Acid D004_r2
## 416   4.380719e+00                             AST-1306 D004_r2
## 417   1.872569e+00                              AT13148 D004_r2
## 418   4.647977e+00                               AT7519 D004_r2
## 419   2.208006e+00                               AT7867 D004_r2
## 420   5.588277e+00                               AT9283 D004_r2
## 421   1.530961e+00                 Aurora A Inhibitor I D004_r2
## 422   2.939158e-01             Avagacestat (BMS-708163) D004_r2
## 423   2.477489e+00                              AVL-292 D004_r2
## 424   8.603356e-02                             Axitinib D004_r2
## 425   8.603356e-02                             Axitinib D004_r2
## 426   2.462444e+00                               AZ 628 D004_r2
## 427   1.962352e+00                               AZ 960 D004_r2
## 428   4.053747e+00                                 AZ20 D004_r2
## 429   4.765287e+00                              AZD1080 D004_r2
## 430   2.363932e+00                              AZD1480 D004_r2
## 431   3.362759e+00                              AZD2014 D004_r2
## 432   4.485272e+00                              AZD2858 D004_r2
## 433   9.479875e-01                              AZD2932 D004_r2
## 434   2.007836e+00                              AZD3759 D004_r2
## 435   2.545933e+00                              AZD5363 D004_r2
## 436   3.609687e+00                              AZD5438 D004_r2
## 437   8.998567e-01                              AZD6482 D004_r2
## 438   5.306456e+00                              AZD6738 D004_r2
## 439   3.334833e+00                              AZD8055 D004_r2
## 440   4.090244e+00                              AZD8330 D004_r2
## 441   2.113113e+00                  AZD8931 (Sapitinib) D004_r2
## 442   5.290871e+00                              AZD9291 D004_r2
## 443   2.869967e+00            Barasertib (AZD1152-HQPA) D004_r2
## 444  -2.934056e-01  Baricitinib (LY3009104, INCB028050) D004_r2
## 445  -8.204597e+00                  BGT226 (NVP-BGT226) D004_r2
## 446  -2.985123e+00                              BI 2536 D004_r2
## 447  -3.696780e-01                              BI-78D3 D004_r2
## 448   6.658601e-01                             BI-D1870 D004_r2
## 449   1.638232e+00                              Bikinin D004_r2
## 450  -2.328786e-01                                  BIO D004_r2
## 451  -9.114416e-01               BIRB 796 (Doramapimod) D004_r2
## 452   3.823969e-02                            BIX 02188 D004_r2
## 453   9.044309e-01                            BIX 02189 D004_r2
## 454   3.591736e+00      BKM120 (NVP-BKM120, Buparlisib) D004_r2
## 455   2.369576e+00                           BMS-265246 D004_r2
## 456   2.102098e+00                           BMS-536924 D004_r2
## 457   1.760318e-01                           BMS-582949 D004_r2
## 458   4.194373e+00                           BMS-754807 D004_r2
## 459   1.036988e+00                           BMS-777607 D004_r2
## 460  -1.105463e-01                           BMS-794833 D004_r2
## 461   1.548600e+00                           BMS-833923 D004_r2
## 462  -1.217718e-01                  Bosutinib (SKI-606) D004_r2
## 463  -6.060167e-01                Brivanib (BMS-540215) D004_r2
## 464   8.867843e-01      Brivanib Alaninate (BMS-582664) D004_r2
## 465   1.058631e+00                           BS-181 HCl D004_r2
## 466  -6.391610e-02                               Butein D004_r2
## 467   3.518447e+00                               BYL719 D004_r2
## 468  -4.206145e-02     Cabozantinib (XL184, BMS-907351) D004_r2
## 469   5.109385e-01          Cabozantinib malate (XL184) D004_r2
## 470  -7.206219e-02        CAL-101 (Idelalisib, GS-1101) D004_r2
## 471   1.054526e+00                             CAY10505 D004_r2
## 472   1.146766e+00                               CC-223 D004_r2
## 473   2.762413e+00                            CCT128930 D004_r2
## 474   2.788479e+00                  Cediranib (AZD2171) D004_r2
## 475   1.917598e+00                            CEP-32496 D004_r2
## 476   1.995852e+00                            CEP-33779 D004_r2
## 477   1.507603e+00                              CGI1746 D004_r2
## 478   7.745732e-01                              CGK 733 D004_r2
## 479   3.804423e+00                            CH5132799 D004_r2
## 480   3.460009e+00                           CHIR-98014 D004_r2
## 481   3.355495e+00                 CHIR-99021 (CT99021) D004_r2
## 482   3.815499e+00             CHIR-99021 (CT99021) HCl D004_r2
## 483  -1.186096e+00                    Chrysophanic Acid D004_r2
## 484   3.501266e+00                             CNX-2006 D004_r2
## 485   2.247095e+00                              CNX-774 D004_r2
## 486  -7.193438e-01                    CO-1686 (AVL-301) D004_r2
## 487   5.312965e+00       Cobimetinib (GDC-0973, RG7420) D004_r2
## 488   3.220742e+00                            CP-673451 D004_r2
## 489   6.776669e-01                            CP-724714 D004_r2
## 490   3.079194e+00               Crenolanib (CP-868596) D004_r2
## 491   1.227245e+00             Crizotinib (PF-02341066) D004_r2
## 492   4.731880e+00                               CYC116 D004_r2
## 493  -7.407324e-01                               CYT387 D004_r2
## 494   1.972478e+00                             CZC24832 D004_r2
## 495   1.303042e+00              Dabrafenib (GSK2118436) D004_r2
## 496   1.865721e+00        Dacomitinib (PF299804, PF299) D004_r2
## 497   2.445793e+00              Danusertib (PHA-739358) D004_r2
## 498   7.632104e-01                        DAPT (GSI-IX) D004_r2
## 499   5.435260e-01                            Dasatinib D004_r2
## 500  -3.543689e-01                DCC-2036 (Rebastinib) D004_r2
## 501   1.971415e+00                Decernotinib (VX-509) D004_r2
## 502   4.730179e+00               Dinaciclib (SCH727965) D004_r2
## 503   2.607491e+00    Dovitinib (TKI-258) Dilactic Acid D004_r2
## 504   3.847003e+00                            ENMD-2076 D004_r2
## 505   2.283755e+00               Enzastaurin (LY317615) D004_r2
## 506   2.136299e+00                            ERK5-IN-1 D004_r2
## 507   2.092490e+00                             ETC-1002 D004_r2
## 508   2.998864e+00                            ETP-46464 D004_r2
## 509   8.553664e-01                  Everolimus (RAD001) D004_r2
## 510   1.683845e+00                Fasudil (HA-1077) HCl D004_r2
## 511   1.545530e+00                                FH535 D004_r2
## 512   1.498680e-01                Filgotinib (GLPG0634) D004_r2
## 513   4.659613e+00             Flavopiridol (Alvocidib) D004_r2
## 514   3.070362e+00                     Flavopiridol HCl D004_r2
## 515  -8.017065e-02               Foretinib (GSK1363089) D004_r2
## 516   1.878582e+00                  Fostamatinib (R788) D004_r2
## 517   2.627470e+00                                G-749 D004_r2
## 518   2.537459e+00                             GDC-0068 D004_r2
## 519   2.521456e+00                             GDC-0349 D004_r2
## 520   6.729805e-01                             GDC-0879 D004_r2
## 521   2.890901e+00                             GDC-0941 D004_r2
## 522   9.007440e-01                    GDC-0980 (RG7422) D004_r2
## 523   5.556986e+00                   Gefitinib (ZD1839) D004_r2
## 524   1.678052e+00                            Genistein D004_r2
## 525   3.747914e+00                            GF109203X D004_r2
## 526   1.990551e+00                                GNF-2 D004_r2
## 527   2.345661e-01                                GNF-5 D004_r2
## 528   4.001712e+00                              Go 6983 D004_r2
## 529   1.769342e+00                   Golvatinib (E7050) D004_r2
## 530   2.489515e+00                          GSK1838705A D004_r2
## 531   9.197816e-01                          GSK1904529A D004_r2
## 532   2.581751e+00                  GSK2126458 (GSK458) D004_r2
## 533   9.755844e-01                           GSK2292767 D004_r2
## 534   4.602735e-01                           GSK2636771 D004_r2
## 535  -3.144476e-02                           GSK429286A D004_r2
## 536   2.282041e+00                            GSK461364 D004_r2
## 537   3.196275e+00                               GSK621 D004_r2
## 538   1.539353e+00                            GSK690693 D004_r2
## 539   3.100325e+00                               GW5074 D004_r2
## 540   1.327212e-01                             GW788388 D004_r2
## 541   2.581993e+00                               GZD824 D004_r2
## 542   6.817644e-01                            H 89 2HCl D004_r2
## 543   2.804648e+00                           Hesperadin D004_r2
## 544   2.856263e+00                              HMN-214 D004_r2
## 545   1.197173e+00                             Honokiol D004_r2
## 546   3.016612e-01                               HS-173 D004_r2
## 547   2.680747e+00                           HTH-01-015 D004_r2
## 548   3.485283e-02                Ibrutinib (PCI-32765) D004_r2
## 549  -1.342923e-01                              ICG-001 D004_r2
## 550   1.038649e+00                             Icotinib D004_r2
## 551   1.924461e+00                                IM-12 D004_r2
## 552   2.356051e+00           Imatinib Mesylate (STI571) D004_r2
## 553  -1.570504e+00                            Indirubin D004_r2
## 554   1.862653e+00                    INK 128 (MLN0128) D004_r2
## 555   1.908746e+00                    IPI-145 (INK1197) D004_r2
## 556   1.792493e+00                               IWP-L6 D004_r2
## 557   1.082418e-01                           IWR-1-endo D004_r2
## 558   1.954029e+00                         JNJ-38877605 D004_r2
## 559   3.639632e+00                          JNJ-7706621 D004_r2
## 560   2.828139e+00                     JNK Inhibitor IX D004_r2
## 561   1.173903e+00                             JNK-IN-8 D004_r2
## 562   1.278780e-01                               K02288 D004_r2
## 563   1.525145e+00                               Ki8751 D004_r2
## 564   2.704114e-01                              KRN 633 D004_r2
## 565   3.961880e+00                           KU-0063794 D004_r2
## 566   2.266839e+00      KU-55933 (ATM Kinase Inhibitor) D004_r2
## 567   7.258343e-01                             KU-60019 D004_r2
## 568   7.706798e-01                              KW-2449 D004_r2
## 569   2.096724e+00                              KX2-391 D004_r2
## 570   1.496259e+00                              KY02111 D004_r2
## 571   2.677742e+00                            Lapatinib D004_r2
## 572   3.626765e+00     Lapatinib (GW-572016) Ditosylate D004_r2
## 573   3.576963e+00                            LDC000067 D004_r2
## 574   1.242393e-01      LDE225 (NVP-LDE225,Erismodegib) D004_r2
## 575   2.167097e+00                           LDN-214117 D004_r2
## 576  -1.241908e+00                   Lenvatinib (E7080) D004_r2
## 577   2.010396e+00                              LFM-A13 D004_r2
## 578   1.753593e+00                              LGK-974 D004_r2
## 579  -2.407979e+00                  Linifanib (ABT-869) D004_r2
## 580   2.996353e+00                               LJH685 D004_r2
## 581   7.828314e-02                               LJI308 D004_r2
## 582   5.355598e-01               Losmapimod (GW856553X) D004_r2
## 583   3.378849e+00                            LY2090314 D004_r2
## 584   1.074217e+00                            LY2157299 D004_r2
## 585   1.865291e+00                            LY2784544 D004_r2
## 586   3.294331e+00                            LY2835219 D004_r2
## 587   8.765118e-01                             LY294002 D004_r2
## 588   3.930139e+00                            LY3023414 D004_r2
## 589   2.806133e+00                             LY411575 D004_r2
## 590   5.445359e+00       MEK162 (ARRY-162, ARRY-438162) D004_r2
## 591   1.515155e+00                             MGCD-265 D004_r2
## 592   5.177095e+00               Milciclib (PHA-848125) D004_r2
## 593  -3.341714e-02                              MK-0752 D004_r2
## 594   1.618489e+00                         MK-2206 2HCl D004_r2
## 595   4.600099e-01                              MK-2461 D004_r2
## 596   2.839265e+00                     MK-5108 (VX-689) D004_r2
## 597   3.519320e+00                              MK-8745 D004_r2
## 598   2.349293e+00                              MLN2480 D004_r2
## 599  -2.028156e-01                              MLN8054 D004_r2
## 600  -2.747946e+00      Motesanib Diphosphate (AMG-706) D004_r2
## 601  -8.436568e-01                  Nilotinib (AMN-107) D004_r2
## 602   1.792495e+00     Nintedanib (BIBF 1120)_uncertain D004_r2
## 603   9.074369e-01                               NU6027 D004_r2
## 604   2.541450e+00                           NVP-AEW541 D004_r2
## 605   1.878537e+00                           NVP-BHG712 D004_r2
## 606   2.146527e+00                      NVP-BSK805 2HCl D004_r2
## 607   3.104568e-02                           NVP-BVU972 D004_r2
## 608   1.167880e+00                          Oclacitinib D004_r2
## 609   1.122280e+00      Olmutinib (HM61713, BI 1482694) D004_r2
## 610   2.054409e+00                             ONO-4059 D004_r2
## 611   5.070358e+00                              OSI-027 D004_r2
## 612   4.325891e+00                              OSI-420 D004_r2
## 613   2.354399e+00                 OSI-906 (Linsitinib) D004_r2
## 614   4.138329e+00                              P276-00 D004_r2
## 615   4.701805e+00                  Pacritinib (SB1518) D004_r2
## 616   5.004907e-01                   Palomid 529 (P529) D004_r2
## 617  -7.128035e-01                            Pazopanib D004_r2
## 618   1.722101e+00                        Pazopanib HCl D004_r2
## 619   5.413166e+00                            PD0325901 D004_r2
## 620   1.449727e+00                             PD168393 D004_r2
## 621  -4.470653e-01                             PD173955 D004_r2
## 622   5.029383e+00                   PD184352 (CI-1040) D004_r2
## 623   4.663065e+00                             PD318088 D004_r2
## 624   1.936293e+00                              PD98059 D004_r2
## 625   3.054954e+00                  Pelitinib (EKB-569) D004_r2
## 626   1.399986e+00                          PF-00562271 D004_r2
## 627   1.832749e+00                          PF-04217903 D004_r2
## 628   1.393323e+00                          PF-04691502 D004_r2
## 629   3.891680e+00                            PF-431396 D004_r2
## 630   3.856049e+00                           PF-4708671 D004_r2
## 631   1.408106e+00                           PF-5274857 D004_r2
## 632   2.438891e+00                            PF-562271 D004_r2
## 633   9.305844e-01                            PF-573228 D004_r2
## 634   1.120407e+00                            PH-797804 D004_r2
## 635   1.917204e+00                           PHA-665752 D004_r2
## 636   1.937269e+00                           PHA-680632 D004_r2
## 637   4.608241e+00                           PHA-767491 D004_r2
## 638   9.885165e-01                           PHA-793887 D004_r2
## 639   3.932112e-01                       Phenformin HCl D004_r2
## 640  -6.776881e-01                              PHT-427 D004_r2
## 641  -7.469636e-01                          Piceatannol D004_r2
## 642   2.685332e+00                              PIK-293 D004_r2
## 643   1.362690e+00                              PIK-294 D004_r2
## 644   3.209252e+00                               PIK-93 D004_r2
## 645   4.072153e+00               Pimasertib (AS-703026) D004_r2
## 646   1.239166e+00                          Pirfenidone D004_r2
## 647  -2.707212e-02                             PLX-4720 D004_r2
## 648   1.596192e+00                              PLX7904 D004_r2
## 649   3.394121e+00                  Ponatinib (AP24534) D004_r2
## 650   8.019042e-01                                  PP1 D004_r2
## 651   1.137674e+00                                  PP2 D004_r2
## 652   1.038618e+00                                PP242 D004_r2
## 653   2.212774e+00                               PQ 401 D004_r2
## 654   1.772566e+00                              PRI-724 D004_r2
## 655   3.202935e+00     PRT062607 (P505-15, BIIB057) HCl D004_r2
## 656  -1.787783e-02                         Purvalanol A D004_r2
## 657   1.161887e+00                            Quercetin D004_r2
## 658   1.509612e+00                  Quizartinib (AC220) D004_r2
## 659   4.534864e-02                                 R406 D004_r2
## 660   1.278839e+00                     R406 (free base) D004_r2
## 661   3.327197e+00                                 R547 D004_r2
## 662   4.842885e+00                    RAF265 (CHIR-265) D004_r2
## 663   1.805958e+00                Rapamycin (Sirolimus) D004_r2
## 664   4.630943e+00   Refametinib (RDEA119, Bay 86-9766) D004_r2
## 665   9.508273e-01                               RepSox D004_r2
## 666   8.848484e-01 Ridaforolimus (Deforolimus, MK-8669) D004_r2
## 667   2.965207e+00                Rigosertib (ON-01910) D004_r2
## 668   2.359465e-01                             RKI-1447 D004_r2
## 669  -1.502617e+00                                RN486 D004_r2
## 670   4.160074e+00                  Ro 31-8220 Mesylate D004_r2
## 671   1.604043e+00                              Ro-3306 D004_r2
## 672   4.499217e+00                               Ro3280 D004_r2
## 673   1.609456e+00                            RO4929097 D004_r2
## 674   2.467080e+00      Roscovitine (Seliciclib,CYC202) D004_r2
## 675   1.422544e-01             Ruxolitinib (INCB018424) D004_r2
## 676   4.690535e-01           S-Ruxolitinib (INCB018424) D004_r2
## 677  -9.148033e-01                               SANT-1 D004_r2
## 678   4.728473e-01                            SAR131675 D004_r2
## 679   2.493687e+00                    SAR245409 (XL765) D004_r2
## 680   2.423136e+00                Saracatinib (AZD0530) D004_r2
## 681   8.800906e-01                      SB202190 (FHPI) D004_r2
## 682   1.751320e+00                             SB203580 D004_r2
## 683   1.986454e+00                             SB216763 D004_r2
## 684   2.078530e+00                             SB239063 D004_r2
## 685   1.966819e+00                             SB415286 D004_r2
## 686   3.126966e-01                             SB431542 D004_r2
## 687   1.119811e+00                             SB505124 D004_r2
## 688   1.226467e+00                             SB525334 D004_r2
## 689  -7.610074e-01                             SB590885 D004_r2
## 690   3.202355e+00                                  SC1 D004_r2
## 691   7.544405e-01                Schisandrin B (Sch B) D004_r2
## 692   6.361974e+00                Selumetinib (AZD6244) D004_r2
## 693   1.096817e+00              Semagacestat (LY450139) D004_r2
## 694  -1.729225e+00                   Semaxanib (SU5416) D004_r2
## 695   3.594231e+00                             SGI-7079 D004_r2
## 696   2.669587e-01                          Skepinone-L D004_r2
## 697   1.712313e+00                               SL-327 D004_r2
## 698   3.825496e+00                 SNS-032 (BMS-387032) D004_r2
## 699   2.893268e+00                     SNS-314 Mesylate D004_r2
## 700   7.534066e-01                            Sorafenib D004_r2
## 701   8.300201e-01                   Sorafenib Tosylate D004_r2
## 702   4.754366e+00                         Sotrastaurin D004_r2
## 703   2.192880e+00                             SP600125 D004_r2
## 704  -1.003326e+00                              SU11274 D004_r2
## 705   2.494636e+00                               SU6656 D004_r2
## 706   4.115448e+00                               SU9516 D004_r2
## 707   4.066107e-01                     Sunitinib Malate D004_r2
## 708   3.261399e+00                  TAE226 (NVP-TAE226) D004_r2
## 709   1.499675e+00                              TAK-285 D004_r2
## 710   3.524773e+00                              TAK-632 D004_r2
## 711   1.481245e+00                              TAK-715 D004_r2
## 712   4.868328e+00                              TAK-733 D004_r2
## 713   8.249882e-01                              TAK-901 D004_r2
## 714   1.561565e+00                Taladegib (LY2940680) D004_r2
## 715   4.527757e-01                              TCS 359 D004_r2
## 716   2.415146e+00                               TDZD-8 D004_r2
## 717   3.914928e-01                            Telatinib D004_r2
## 718   1.028804e+00   Temsirolimus (CCI-779, NSC 683864) D004_r2
## 719   2.884025e+00              Tepotinib (EMD 1214063) D004_r2
## 720  -1.509389e-01                                TG003 D004_r2
## 721   1.291721e+00                            TG100-115 D004_r2
## 722   3.610489e+00                             TG101209 D004_r2
## 723   2.575481e+00                 TG101348 (SAR302503) D004_r2
## 724   4.953085e-01                              TGX-221 D004_r2
## 725   9.123907e-01                         Theophylline D004_r2
## 726   5.893301e-01                          Thiazovivin D004_r2
## 727  -4.974149e-01                       TIC10 Analogue D004_r2
## 728   2.276381e+00                           Tideglusib D004_r2
## 729   2.056086e+00                 Tivantinib (ARQ 197) D004_r2
## 730  -1.725559e+00                   Tivozanib (AV-951) D004_r2
## 731   1.455512e+00  Tofacitinib (CP-690550,Tasocitinib) D004_r2
## 732   1.542858e+00      Tofacitinib (CP-690550) Citrate D004_r2
## 733   3.292468e+00                              Torin 2 D004_r2
## 734   2.949584e+00              Trametinib (GSK1120212) D004_r2
## 735   2.357294e-01                          Triciribine D004_r2
## 736   1.673306e+00           TSU-68 (SU6668, Orantinib) D004_r2
## 737   8.933687e-01                               TWS119 D004_r2
## 738   3.747696e+00                         Tyrphostin 9 D004_r2
## 739   1.854637e+00                   Tyrphostin AG 1296 D004_r2
## 740   3.818463e+00                           U0126-EtOH D004_r2
## 741   4.858317e+00     Ulixertinib (BVD-523, VRT752271) D004_r2
## 742   3.634528e+00              Uprosertib (GSK2141795) D004_r2
## 743  -7.600308e+00                          Vacquinol-1 D004_r2
## 744   1.778964e-01                           Varlitinib D004_r2
## 745   4.372030e-01              Vatalanib (PTK787) 2HCl D004_r2
## 746   4.590085e-02                               VE-821 D004_r2
## 747   1.110602e+00                               VE-822 D004_r2
## 748   2.617149e+00        Vemurafenib (PLX4032, RG7204) D004_r2
## 749  -6.195150e-01                Vismodegib (GDC-0449) D004_r2
## 750  -2.357966e-01                 Volasertib (BI 6727) D004_r2
## 751   5.627971e-01                            VPS34-IN1 D004_r2
## 752   2.800460e+00                     VS-5584 (SB2343) D004_r2
## 753   4.015976e+00                               VX-11e D004_r2
## 754   3.174891e+00         VX-680 (Tozasertib, MK-0457) D004_r2
## 755   9.126739e-01                               VX-702 D004_r2
## 756   1.245836e+00                               VX-745 D004_r2
## 757  -2.043440e-01                              WAY-600 D004_r2
## 758   9.870296e-01                             WH-4-023 D004_r2
## 759   1.440450e+00                             WHI-P154 D004_r2
## 760   8.148050e-01                                WIKI4 D004_r2
## 761   5.449391e-01                        Wnt agonist 1 D004_r2
## 762   1.492359e+00                        Wnt-C59 (C59) D004_r2
## 763   1.889102e+00                               WP1066 D004_r2
## 764   4.742769e+00                 WYE-125132 (WYE-132) D004_r2
## 765   5.313925e+00                              WYE-354 D004_r2
## 766   2.147316e+00                               WZ3146 D004_r2
## 767   6.888799e-01                               WZ4002 D004_r2
## 768   1.641113e+00                               WZ4003 D004_r2
## 769  -5.624239e-01                               WZ8040 D004_r2
## 770   1.756682e-01                              XAV-939 D004_r2
## 771   1.284494e+00                                XL019 D004_r2
## 772   3.055323e+00                              XMD8-92 D004_r2
## 773  -2.260060e-02                         Y-27632 2HCl D004_r2
## 774   7.783105e-01                             YM201636 D004_r2
## 775   1.084048e+00                             YO-01027 D004_r2
## 776   3.657576e+00                            ZM 306416 D004_r2
## 777   6.357258e-01                        ZM 323881 HCl D004_r2
## 778  -3.730626e-02                            ZM 336372 D004_r2
## 779   7.434517e-01                         ZM 39923 HCl D004_r2
## 780   1.630618e+00                            ZM 447439 D004_r2
## 781   1.473172e+00                 Zotarolimus(ABT-578) D004_r2
## 782   4.230277e+00                              ZSTK474 D004_r2
## 783  -3.670741e+00                     1-Azakenpaullone D007_r1
## 784  -5.728555e+00                      3-Methyladenine D007_r1
## 785   2.974707e+00                             A-674563 D007_r1
## 786  -8.208321e+00                             A-769662 D007_r1
## 787  -7.989503e+00                                  A66 D007_r1
## 788  -8.830684e+00                            Acadesine D007_r1
## 789  -2.380388e+00                  AEE788 (NVP-AEE788) D007_r1
## 790  -7.123689e+00        Afatinib (BIBW2992)_uncertain D007_r1
## 791  -1.083608e+01                              AG-1024 D007_r1
## 792  -2.542734e+00         AG-1478 (Tyrphostin AG-1478) D007_r1
## 793  -8.543150e+00                                AG-18 D007_r1
## 794  -6.971481e+00              AG-490 (Tyrphostin B42) D007_r1
## 795  -7.720721e+00                             Akti-1/2 D007_r1
## 796  -2.961429e+00                  Alisertib (MLN8237) D007_r1
## 797  -3.245189e+00                              AMG 337 D007_r1
## 798  -7.343404e+00                              AMG-458 D007_r1
## 799  -7.270372e+00                              AMG-900 D007_r1
## 800  -7.654698e+00                               AMG319 D007_r1
## 801  -9.190435e+00                  Amuvatinib (MP-470) D007_r1
## 802  -6.731694e+00                             Apatinib D007_r1
## 803  -7.070852e+00                           AR-A014418 D007_r1
## 804  -7.065826e+00                            AS-252424 D007_r1
## 805  -6.752646e+00                            AS-604850 D007_r1
## 806  -4.989098e+00                         Asiatic Acid D007_r1
## 807  -3.403977e+00                             AST-1306 D007_r1
## 808  -8.225911e+00                              AT13148 D007_r1
## 809   1.487101e+00                               AT7519 D007_r1
## 810  -8.988739e+00                               AT7867 D007_r1
## 811   3.375698e+00                               AT9283 D007_r1
## 812  -7.875837e+00                 Aurora A Inhibitor I D007_r1
## 813  -7.654660e+00             Avagacestat (BMS-708163) D007_r1
## 814  -7.152892e+00                              AVL-292 D007_r1
## 815  -9.440387e+00                             Axitinib D007_r1
## 816  -9.440387e+00                             Axitinib D007_r1
## 817  -6.735223e+00                               AZ 628 D007_r1
## 818  -6.885279e+00                               AZ 960 D007_r1
## 819  -5.960536e+00                                 AZ20 D007_r1
## 820  -6.628423e+00                              AZD1080 D007_r1
## 821  -4.109990e+00                              AZD1480 D007_r1
## 822  -5.975545e+00                              AZD2014 D007_r1
## 823  -2.165991e+00                              AZD2858 D007_r1
## 824  -6.091298e+00                              AZD2932 D007_r1
## 825  -3.771439e+00                              AZD3759 D007_r1
## 826  -5.236541e+00                              AZD5363 D007_r1
## 827  -7.537428e-01                              AZD5438 D007_r1
## 828  -6.781997e+00                              AZD6482 D007_r1
## 829  -2.912910e+00                              AZD6738 D007_r1
## 830  -5.318771e+00                              AZD8055 D007_r1
## 831  -1.760059e+00                              AZD8330 D007_r1
## 832  -1.295068e+00                  AZD8931 (Sapitinib) D007_r1
## 833  -5.402967e+00                              AZD9291 D007_r1
## 834  -7.376306e+00            Barasertib (AZD1152-HQPA) D007_r1
## 835  -7.927906e+00  Baricitinib (LY3009104, INCB028050) D007_r1
## 836   4.123103e+00                  BGT226 (NVP-BGT226) D007_r1
## 837   6.839498e-01                              BI 2536 D007_r1
## 838  -8.244438e+00                              BI-78D3 D007_r1
## 839  -7.160402e+00                             BI-D1870 D007_r1
## 840  -8.705079e+00                              Bikinin D007_r1
## 841  -7.092190e+00                                  BIO D007_r1
## 842  -9.061415e+00               BIRB 796 (Doramapimod) D007_r1
## 843  -7.883829e+00                            BIX 02188 D007_r1
## 844  -6.792340e+00                            BIX 02189 D007_r1
## 845  -3.544736e+00      BKM120 (NVP-BKM120, Buparlisib) D007_r1
## 846  -7.324079e+00                           BMS-265246 D007_r1
## 847  -6.569120e+00                           BMS-536924 D007_r1
## 848  -6.517837e+00                           BMS-582949 D007_r1
## 849  -5.956883e+00                           BMS-754807 D007_r1
## 850  -8.039670e+00                           BMS-777607 D007_r1
## 851  -8.333755e+00                           BMS-794833 D007_r1
## 852  -8.474364e+00                           BMS-833923 D007_r1
## 853  -6.641134e+00                  Bosutinib (SKI-606) D007_r1
## 854  -9.019720e+00                Brivanib (BMS-540215) D007_r1
## 855  -9.693004e+00      Brivanib Alaninate (BMS-582664) D007_r1
## 856  -6.101075e+00                           BS-181 HCl D007_r1
## 857  -8.474628e+00                               Butein D007_r1
## 858  -5.999611e+00                               BYL719 D007_r1
## 859  -7.259039e+00     Cabozantinib (XL184, BMS-907351) D007_r1
## 860  -6.671457e+00          Cabozantinib malate (XL184) D007_r1
## 861  -6.686432e+00        CAL-101 (Idelalisib, GS-1101) D007_r1
## 862  -7.986016e+00                             CAY10505 D007_r1
## 863  -5.727534e+00                               CC-223 D007_r1
## 864  -7.831046e+00                            CCT128930 D007_r1
## 865  -8.439082e+00                  Cediranib (AZD2171) D007_r1
## 866  -6.383183e+00                            CEP-32496 D007_r1
## 867  -7.559208e+00                            CEP-33779 D007_r1
## 868  -6.818115e+00                              CGI1746 D007_r1
## 869  -8.154170e+00                              CGK 733 D007_r1
## 870  -3.934169e+00                            CH5132799 D007_r1
## 871  -4.409699e+00                           CHIR-98014 D007_r1
## 872  -1.781101e+00                 CHIR-99021 (CT99021) D007_r1
## 873  -3.982486e+00             CHIR-99021 (CT99021) HCl D007_r1
## 874  -8.083227e+00                    Chrysophanic Acid D007_r1
## 875  -6.455046e+00                             CNX-2006 D007_r1
## 876  -7.388718e+00                              CNX-774 D007_r1
## 877  -8.610192e+00                    CO-1686 (AVL-301) D007_r1
## 878  -4.188268e+00       Cobimetinib (GDC-0973, RG7420) D007_r1
## 879  -3.836372e+00                            CP-673451 D007_r1
## 880  -3.655104e+00                            CP-724714 D007_r1
## 881  -5.123846e+00               Crenolanib (CP-868596) D007_r1
## 882  -7.827470e+00             Crizotinib (PF-02341066) D007_r1
## 883  -5.388778e+00                               CYC116 D007_r1
## 884  -8.050915e+00                               CYT387 D007_r1
## 885  -6.214542e+00                             CZC24832 D007_r1
## 886  -3.124615e+00              Dabrafenib (GSK2118436) D007_r1
## 887  -1.652142e+00        Dacomitinib (PF299804, PF299) D007_r1
## 888  -5.405407e+00              Danusertib (PHA-739358) D007_r1
## 889  -7.035000e+00                        DAPT (GSI-IX) D007_r1
## 890  -5.210362e+00                            Dasatinib D007_r1
## 891  -6.251029e+00                DCC-2036 (Rebastinib) D007_r1
## 892  -6.516825e+00                Decernotinib (VX-509) D007_r1
## 893   1.248608e+00               Dinaciclib (SCH727965) D007_r1
## 894  -6.004996e+00    Dovitinib (TKI-258) Dilactic Acid D007_r1
## 895  -4.212800e+00                            ENMD-2076 D007_r1
## 896  -4.494976e+00               Enzastaurin (LY317615) D007_r1
## 897  -5.674355e+00                            ERK5-IN-1 D007_r1
## 898  -6.955396e+00                             ETC-1002 D007_r1
## 899  -7.661636e+00                            ETP-46464 D007_r1
## 900  -7.287969e+00                  Everolimus (RAD001) D007_r1
## 901  -7.489901e+00                Fasudil (HA-1077) HCl D007_r1
## 902  -4.099073e+00                                FH535 D007_r1
## 903  -7.598623e+00                Filgotinib (GLPG0634) D007_r1
## 904   3.341498e-01             Flavopiridol (Alvocidib) D007_r1
## 905   2.815710e+00                     Flavopiridol HCl D007_r1
## 906  -6.939706e+00               Foretinib (GSK1363089) D007_r1
## 907  -6.798164e+00                  Fostamatinib (R788) D007_r1
## 908  -8.226354e+00                                G-749 D007_r1
## 909  -5.969792e+00                             GDC-0068 D007_r1
## 910  -6.760505e+00                             GDC-0349 D007_r1
## 911  -8.167303e+00                             GDC-0879 D007_r1
## 912  -7.105867e+00                             GDC-0941 D007_r1
## 913  -3.310726e+00                    GDC-0980 (RG7422) D007_r1
## 914  -1.993056e+00                   Gefitinib (ZD1839) D007_r1
## 915  -8.018091e+00                            Genistein D007_r1
## 916  -4.201725e+00                            GF109203X D007_r1
## 917  -8.067851e+00                                GNF-2 D007_r1
## 918  -5.396846e+00                                GNF-5 D007_r1
## 919  -5.430157e+00                              Go 6983 D007_r1
## 920  -3.246321e+00                   Golvatinib (E7050) D007_r1
## 921  -7.104380e+00                          GSK1838705A D007_r1
## 922  -7.413927e+00                          GSK1904529A D007_r1
## 923  -6.214556e+00                  GSK2126458 (GSK458) D007_r1
## 924  -5.503006e+00                           GSK2292767 D007_r1
## 925  -7.630606e+00                           GSK2636771 D007_r1
## 926  -8.517559e+00                           GSK429286A D007_r1
## 927  -4.462900e-01                            GSK461364 D007_r1
## 928  -8.645645e+00                               GSK621 D007_r1
## 929  -8.712829e+00                            GSK690693 D007_r1
## 930  -7.254246e+00                               GW5074 D007_r1
## 931  -8.481826e+00                             GW788388 D007_r1
## 932  -2.857324e+00                               GZD824 D007_r1
## 933  -8.271118e+00                            H 89 2HCl D007_r1
## 934  -8.762164e+00                           Hesperadin D007_r1
## 935  -5.016903e+00                              HMN-214 D007_r1
## 936  -5.989217e+00                             Honokiol D007_r1
## 937  -1.485614e+00                               HS-173 D007_r1
## 938  -7.041562e+00                           HTH-01-015 D007_r1
## 939  -4.358733e+00                Ibrutinib (PCI-32765) D007_r1
## 940  -8.253763e+00                              ICG-001 D007_r1
## 941  -4.395002e+00                             Icotinib D007_r1
## 942  -7.011974e+00                                IM-12 D007_r1
## 943  -4.466950e+00           Imatinib Mesylate (STI571) D007_r1
## 944  -7.478737e+00                            Indirubin D007_r1
## 945  -3.375262e+00                    INK 128 (MLN0128) D007_r1
## 946  -7.240517e+00                    IPI-145 (INK1197) D007_r1
## 947  -7.570058e+00                               IWP-L6 D007_r1
## 948  -8.380350e+00                           IWR-1-endo D007_r1
## 949  -7.821026e+00                         JNJ-38877605 D007_r1
## 950   5.176501e+00                          JNJ-7706621 D007_r1
## 951  -5.224721e+00                     JNK Inhibitor IX D007_r1
## 952  -5.808185e+00                             JNK-IN-8 D007_r1
## 953  -7.989533e+00                               K02288 D007_r1
## 954  -5.988003e+00                               Ki8751 D007_r1
## 955  -7.475341e+00                              KRN 633 D007_r1
## 956  -6.226930e+00                           KU-0063794 D007_r1
## 957  -8.028217e+00      KU-55933 (ATM Kinase Inhibitor) D007_r1
## 958  -4.457168e+00                             KU-60019 D007_r1
## 959  -8.824693e+00                              KW-2449 D007_r1
## 960  -3.954990e+00                              KX2-391 D007_r1
## 961  -7.881311e+00                              KY02111 D007_r1
## 962  -6.524852e+00                            Lapatinib D007_r1
## 963  -5.128976e+00     Lapatinib (GW-572016) Ditosylate D007_r1
## 964  -1.777631e+00                            LDC000067 D007_r1
## 965  -7.973416e+00      LDE225 (NVP-LDE225,Erismodegib) D007_r1
## 966  -7.218708e+00                           LDN-214117 D007_r1
## 967  -9.044841e+00                   Lenvatinib (E7080) D007_r1
## 968  -7.527829e+00                              LFM-A13 D007_r1
## 969  -6.617747e+00                              LGK-974 D007_r1
## 970  -9.158919e+00                  Linifanib (ABT-869) D007_r1
## 971  -6.653070e+00                               LJH685 D007_r1
## 972  -8.353715e+00                               LJI308 D007_r1
## 973  -5.531944e+00               Losmapimod (GW856553X) D007_r1
## 974  -4.218382e+00                            LY2090314 D007_r1
## 975  -8.154275e+00                            LY2157299 D007_r1
## 976  -4.854103e+00                            LY2784544 D007_r1
## 977  -3.821671e+00                            LY2835219 D007_r1
## 978  -8.657349e+00                             LY294002 D007_r1
## 979  -3.077432e+00                            LY3023414 D007_r1
## 980  -5.706126e+00                             LY411575 D007_r1
## 981  -1.994116e+00       MEK162 (ARRY-162, ARRY-438162) D007_r1
## 982  -6.882551e+00                             MGCD-265 D007_r1
## 983  -2.740100e+00               Milciclib (PHA-848125) D007_r1
## 984  -6.875406e+00                              MK-0752 D007_r1
## 985  -7.286481e+00                         MK-2206 2HCl D007_r1
## 986  -8.535403e+00                              MK-2461 D007_r1
## 987  -7.405044e+00                     MK-5108 (VX-689) D007_r1
## 988  -5.693191e+00                              MK-8745 D007_r1
## 989  -3.299888e+00                              MLN2480 D007_r1
## 990  -5.861463e+00                              MLN8054 D007_r1
## 991  -9.070560e+00      Motesanib Diphosphate (AMG-706) D007_r1
## 992  -7.587291e+00                  Nilotinib (AMN-107) D007_r1
## 993  -7.414360e+00     Nintedanib (BIBF 1120)_uncertain D007_r1
## 994  -7.915599e+00                               NU6027 D007_r1
## 995  -8.148699e+00                           NVP-AEW541 D007_r1
## 996  -5.675610e+00                           NVP-BHG712 D007_r1
## 997  -7.731681e+00                      NVP-BSK805 2HCl D007_r1
## 998  -6.682009e+00                           NVP-BVU972 D007_r1
## 999  -6.697578e+00                          Oclacitinib D007_r1
## 1000 -7.460545e+00      Olmutinib (HM61713, BI 1482694) D007_r1
## 1001 -6.017745e+00                             ONO-4059 D007_r1
## 1002 -5.403931e+00                              OSI-027 D007_r1
## 1003 -1.002214e+00                              OSI-420 D007_r1
## 1004 -8.059617e+00                 OSI-906 (Linsitinib) D007_r1
## 1005  2.562351e+00                              P276-00 D007_r1
## 1006  2.582223e+00                  Pacritinib (SB1518) D007_r1
## 1007 -4.752982e+00                   Palomid 529 (P529) D007_r1
## 1008 -7.312664e+00                            Pazopanib D007_r1
## 1009 -8.452509e+00                        Pazopanib HCl D007_r1
## 1010 -4.810752e+00                            PD0325901 D007_r1
## 1011 -5.142603e+00                             PD168393 D007_r1
## 1012 -7.102079e+00                             PD173955 D007_r1
## 1013 -7.204855e+00                   PD184352 (CI-1040) D007_r1
## 1014 -5.239258e+00                             PD318088 D007_r1
## 1015 -6.060336e+00                              PD98059 D007_r1
## 1016 -5.280988e-01                  Pelitinib (EKB-569) D007_r1
## 1017 -2.724344e-01                          PF-00562271 D007_r1
## 1018 -7.677826e+00                          PF-04217903 D007_r1
## 1019 -4.051579e+00                          PF-04691502 D007_r1
## 1020 -8.804118e+00                            PF-431396 D007_r1
## 1021 -7.559467e+00                           PF-4708671 D007_r1
## 1022 -7.775787e+00                           PF-5274857 D007_r1
## 1023  1.166300e+00                            PF-562271 D007_r1
## 1024 -7.734688e+00                            PF-573228 D007_r1
## 1025 -4.269604e+00                            PH-797804 D007_r1
## 1026 -9.083714e+00                           PHA-665752 D007_r1
## 1027 -6.406398e+00                           PHA-680632 D007_r1
## 1028  1.444900e+00                           PHA-767491 D007_r1
## 1029 -5.857105e+00                           PHA-793887 D007_r1
## 1030 -1.060767e+01                       Phenformin HCl D007_r1
## 1031 -8.925180e+00                              PHT-427 D007_r1
## 1032 -1.967380e+00                          Piceatannol D007_r1
## 1033 -8.655045e+00                              PIK-293 D007_r1
## 1034 -6.843745e+00                              PIK-294 D007_r1
## 1035 -2.511446e+00                               PIK-93 D007_r1
## 1036 -4.468871e+00               Pimasertib (AS-703026) D007_r1
## 1037 -7.404296e+00                          Pirfenidone D007_r1
## 1038 -6.830825e+00                             PLX-4720 D007_r1
## 1039 -6.637631e+00                              PLX7904 D007_r1
## 1040 -6.714745e+00                  Ponatinib (AP24534) D007_r1
## 1041 -4.221334e+00                                  PP1 D007_r1
## 1042 -6.399373e+00                                  PP2 D007_r1
## 1043 -5.407466e+00                                PP242 D007_r1
## 1044 -8.360754e+00                               PQ 401 D007_r1
## 1045 -6.508994e+00                              PRI-724 D007_r1
## 1046 -6.324958e+00     PRT062607 (P505-15, BIIB057) HCl D007_r1
## 1047 -5.093977e+00                         Purvalanol A D007_r1
## 1048 -6.123265e+00                            Quercetin D007_r1
## 1049 -8.809028e+00                  Quizartinib (AC220) D007_r1
## 1050 -4.298903e+00                                 R406 D007_r1
## 1051 -7.640576e+00                     R406 (free base) D007_r1
## 1052  2.449056e+00                                 R547 D007_r1
## 1053 -2.220588e-01                    RAF265 (CHIR-265) D007_r1
## 1054 -7.959465e+00                Rapamycin (Sirolimus) D007_r1
## 1055 -6.159604e+00   Refametinib (RDEA119, Bay 86-9766) D007_r1
## 1056 -7.384893e+00                               RepSox D007_r1
## 1057 -8.694133e+00 Ridaforolimus (Deforolimus, MK-8669) D007_r1
## 1058 -4.198850e+00                Rigosertib (ON-01910) D007_r1
## 1059 -7.211232e+00                             RKI-1447 D007_r1
## 1060 -8.138043e+00                                RN486 D007_r1
## 1061 -2.400059e+00                  Ro 31-8220 Mesylate D007_r1
## 1062 -6.964468e+00                              Ro-3306 D007_r1
## 1063 -2.717508e-01                               Ro3280 D007_r1
## 1064 -6.163324e+00                            RO4929097 D007_r1
## 1065 -6.664025e+00      Roscovitine (Seliciclib,CYC202) D007_r1
## 1066 -7.635406e+00             Ruxolitinib (INCB018424) D007_r1
## 1067 -8.869595e+00           S-Ruxolitinib (INCB018424) D007_r1
## 1068 -7.188426e+00                               SANT-1 D007_r1
## 1069 -7.466282e+00                            SAR131675 D007_r1
## 1070 -8.918014e+00                    SAR245409 (XL765) D007_r1
## 1071 -4.097902e+00                Saracatinib (AZD0530) D007_r1
## 1072 -7.354592e+00                      SB202190 (FHPI) D007_r1
## 1073 -7.468801e+00                             SB203580 D007_r1
## 1074 -6.432767e+00                             SB216763 D007_r1
## 1075 -7.487426e+00                             SB239063 D007_r1
## 1076 -7.528924e+00                             SB415286 D007_r1
## 1077 -8.402583e+00                             SB431542 D007_r1
## 1078 -8.040043e+00                             SB505124 D007_r1
## 1079 -6.925385e+00                             SB525334 D007_r1
## 1080 -7.804017e+00                             SB590885 D007_r1
## 1081  4.791362e-01                                  SC1 D007_r1
## 1082 -7.133546e+00                Schisandrin B (Sch B) D007_r1
## 1083 -3.169788e+00                Selumetinib (AZD6244) D007_r1
## 1084 -7.379154e+00              Semagacestat (LY450139) D007_r1
## 1085 -6.935615e+00                   Semaxanib (SU5416) D007_r1
## 1086 -2.377227e+00                             SGI-7079 D007_r1
## 1087 -7.147460e+00                          Skepinone-L D007_r1
## 1088 -8.399630e+00                               SL-327 D007_r1
## 1089 -3.811883e+00                 SNS-032 (BMS-387032) D007_r1
## 1090 -6.111161e+00                     SNS-314 Mesylate D007_r1
## 1091 -6.039049e+00                            Sorafenib D007_r1
## 1092 -6.476027e+00                   Sorafenib Tosylate D007_r1
## 1093 -6.821531e+00                         Sotrastaurin D007_r1
## 1094 -7.817454e+00                             SP600125 D007_r1
## 1095 -8.901913e+00                              SU11274 D007_r1
## 1096 -7.631543e+00                               SU6656 D007_r1
## 1097 -6.115095e+00                               SU9516 D007_r1
## 1098 -9.909971e+00                     Sunitinib Malate D007_r1
## 1099 -7.018221e+00                  TAE226 (NVP-TAE226) D007_r1
## 1100 -4.822922e+00                              TAK-285 D007_r1
## 1101 -4.672307e+00                              TAK-632 D007_r1
## 1102 -7.469746e+00                              TAK-715 D007_r1
## 1103 -1.856021e+00                              TAK-733 D007_r1
## 1104 -6.080386e+00                              TAK-901 D007_r1
## 1105 -7.440971e+00                Taladegib (LY2940680) D007_r1
## 1106 -6.907584e+00                              TCS 359 D007_r1
## 1107 -6.602099e+00                               TDZD-8 D007_r1
## 1108 -7.747287e+00                            Telatinib D007_r1
## 1109 -9.206633e+00   Temsirolimus (CCI-779, NSC 683864) D007_r1
## 1110 -2.620288e+00              Tepotinib (EMD 1214063) D007_r1
## 1111 -8.550536e+00                                TG003 D007_r1
## 1112 -8.305730e+00                            TG100-115 D007_r1
## 1113 -6.236738e+00                             TG101209 D007_r1
## 1114 -6.912015e+00                 TG101348 (SAR302503) D007_r1
## 1115 -6.409172e+00                              TGX-221 D007_r1
## 1116 -8.189025e+00                         Theophylline D007_r1
## 1117 -7.460348e+00                          Thiazovivin D007_r1
## 1118 -6.872459e+00                       TIC10 Analogue D007_r1
## 1119 -6.996259e+00                           Tideglusib D007_r1
## 1120 -4.828432e+00                 Tivantinib (ARQ 197) D007_r1
## 1121 -4.764278e+00                   Tivozanib (AV-951) D007_r1
## 1122 -7.123415e+00  Tofacitinib (CP-690550,Tasocitinib) D007_r1
## 1123 -7.720690e+00      Tofacitinib (CP-690550) Citrate D007_r1
## 1124 -4.341090e-01                              Torin 2 D007_r1
## 1125 -1.748632e+00              Trametinib (GSK1120212) D007_r1
## 1126 -3.284644e+00                          Triciribine D007_r1
## 1127 -7.126305e+00           TSU-68 (SU6668, Orantinib) D007_r1
## 1128 -7.043152e+00                               TWS119 D007_r1
## 1129 -5.291106e+00                         Tyrphostin 9 D007_r1
## 1130 -6.975329e+00                   Tyrphostin AG 1296 D007_r1
## 1131 -7.456579e+00                           U0126-EtOH D007_r1
## 1132 -4.996496e+00     Ulixertinib (BVD-523, VRT752271) D007_r1
## 1133 -5.547842e+00              Uprosertib (GSK2141795) D007_r1
## 1134 -6.544513e+00                          Vacquinol-1 D007_r1
## 1135 -6.202093e+00                           Varlitinib D007_r1
## 1136 -8.505436e+00              Vatalanib (PTK787) 2HCl D007_r1
## 1137 -9.708048e+00                               VE-821 D007_r1
## 1138 -3.487758e+00                               VE-822 D007_r1
## 1139 -7.164463e+00        Vemurafenib (PLX4032, RG7204) D007_r1
## 1140 -6.075869e+00                Vismodegib (GDC-0449) D007_r1
## 1141 -6.399870e+00                 Volasertib (BI 6727) D007_r1
## 1142 -2.332185e+00                            VPS34-IN1 D007_r1
## 1143 -4.070319e+00                     VS-5584 (SB2343) D007_r1
## 1144 -6.303197e+00                               VX-11e D007_r1
## 1145 -8.378222e+00         VX-680 (Tozasertib, MK-0457) D007_r1
## 1146 -6.872199e+00                               VX-702 D007_r1
## 1147 -8.914356e+00                               VX-745 D007_r1
## 1148 -7.579085e+00                              WAY-600 D007_r1
## 1149 -5.920599e+00                             WH-4-023 D007_r1
## 1150 -7.211314e+00                             WHI-P154 D007_r1
## 1151 -5.890958e+00                                WIKI4 D007_r1
## 1152 -3.108559e+00                        Wnt agonist 1 D007_r1
## 1153 -7.125492e+00                        Wnt-C59 (C59) D007_r1
## 1154 -6.475928e+00                               WP1066 D007_r1
## 1155 -7.334806e+00                 WYE-125132 (WYE-132) D007_r1
## 1156 -6.727249e+00                              WYE-354 D007_r1
## 1157 -6.528305e+00                               WZ3146 D007_r1
## 1158 -7.469467e+00                               WZ4002 D007_r1
## 1159 -5.798471e+00                               WZ4003 D007_r1
## 1160 -8.608324e+00                               WZ8040 D007_r1
## 1161 -7.289346e+00                              XAV-939 D007_r1
## 1162 -9.097660e+00                                XL019 D007_r1
## 1163 -7.608145e+00                              XMD8-92 D007_r1
## 1164 -8.304604e+00                         Y-27632 2HCl D007_r1
## 1165 -3.955462e+00                             YM201636 D007_r1
## 1166 -6.375530e+00                             YO-01027 D007_r1
## 1167 -1.317012e+00                            ZM 306416 D007_r1
## 1168 -6.092759e+00                        ZM 323881 HCl D007_r1
## 1169 -7.178069e+00                            ZM 336372 D007_r1
## 1170 -7.847857e+00                         ZM 39923 HCl D007_r1
## 1171 -8.625194e+00                            ZM 447439 D007_r1
## 1172 -7.768573e+00                 Zotarolimus(ABT-578) D007_r1
## 1173 -5.980063e+00                              ZSTK474 D007_r1
## 1174 -5.146722e+00                     1-Azakenpaullone D007_r2
## 1175 -7.841257e+00                      3-Methyladenine D007_r2
## 1176  7.850813e-01                             A-674563 D007_r2
## 1177 -7.943171e+00                             A-769662 D007_r2
## 1178 -7.040339e+00                                  A66 D007_r2
## 1179 -7.873293e+00                            Acadesine D007_r2
## 1180  3.880173e-01                  AEE788 (NVP-AEE788) D007_r2
## 1181 -7.419207e+00        Afatinib (BIBW2992)_uncertain D007_r2
## 1182 -1.101593e+01                              AG-1024 D007_r2
## 1183  8.229888e-02         AG-1478 (Tyrphostin AG-1478) D007_r2
## 1184 -9.421305e+00                                AG-18 D007_r2
## 1185 -8.057362e+00              AG-490 (Tyrphostin B42) D007_r2
## 1186 -8.650373e+00                             Akti-1/2 D007_r2
## 1187 -8.216676e+00                  Alisertib (MLN8237) D007_r2
## 1188 -8.243858e+00                              AMG 337 D007_r2
## 1189 -8.352080e+00                              AMG-458 D007_r2
## 1190 -8.955655e+00                              AMG-900 D007_r2
## 1191 -8.028183e+00                               AMG319 D007_r2
## 1192 -8.312440e+00                  Amuvatinib (MP-470) D007_r2
## 1193 -8.459661e+00                             Apatinib D007_r2
## 1194 -4.776361e+00                           AR-A014418 D007_r2
## 1195 -6.631200e+00                            AS-252424 D007_r2
## 1196 -7.990510e+00                            AS-604850 D007_r2
## 1197 -6.920595e+00                         Asiatic Acid D007_r2
## 1198 -1.906842e+00                             AST-1306 D007_r2
## 1199 -8.706025e+00                              AT13148 D007_r2
## 1200 -1.760639e+00                               AT7519 D007_r2
## 1201 -1.042749e+01                               AT7867 D007_r2
## 1202  3.053558e+00                               AT9283 D007_r2
## 1203 -9.030462e+00                 Aurora A Inhibitor I D007_r2
## 1204 -7.830022e+00             Avagacestat (BMS-708163) D007_r2
## 1205 -7.262995e+00                              AVL-292 D007_r2
## 1206 -9.300744e+00                             Axitinib D007_r2
## 1207 -9.300744e+00                             Axitinib D007_r2
## 1208 -5.401687e+00                               AZ 628 D007_r2
## 1209 -7.076809e+00                               AZ 960 D007_r2
## 1210 -3.722755e+00                                 AZ20 D007_r2
## 1211 -4.828944e+00                              AZD1080 D007_r2
## 1212 -4.021984e+00                              AZD1480 D007_r2
## 1213 -6.264897e+00                              AZD2014 D007_r2
## 1214 -1.577043e+00                              AZD2858 D007_r2
## 1215 -6.832455e+00                              AZD2932 D007_r2
## 1216 -2.130866e-01                              AZD3759 D007_r2
## 1217 -4.835044e+00                              AZD5363 D007_r2
## 1218 -2.847868e-01                              AZD5438 D007_r2
## 1219 -4.161758e+00                              AZD6482 D007_r2
## 1220 -2.898497e+00                              AZD6738 D007_r2
## 1221 -3.987074e+00                              AZD8055 D007_r2
## 1222 -1.537935e+00                              AZD8330 D007_r2
## 1223  1.634085e+00                  AZD8931 (Sapitinib) D007_r2
## 1224 -1.562181e+00                              AZD9291 D007_r2
## 1225 -9.334338e+00            Barasertib (AZD1152-HQPA) D007_r2
## 1226 -8.851664e+00  Baricitinib (LY3009104, INCB028050) D007_r2
## 1227  2.682777e+00                  BGT226 (NVP-BGT226) D007_r2
## 1228 -2.254965e+00                              BI 2536 D007_r2
## 1229 -8.386203e+00                              BI-78D3 D007_r2
## 1230 -8.821719e+00                             BI-D1870 D007_r2
## 1231 -8.611897e+00                              Bikinin D007_r2
## 1232 -8.367699e+00                                  BIO D007_r2
## 1233 -7.685567e+00               BIRB 796 (Doramapimod) D007_r2
## 1234 -8.640959e+00                            BIX 02188 D007_r2
## 1235 -8.138842e+00                            BIX 02189 D007_r2
## 1236 -5.371235e+00      BKM120 (NVP-BKM120, Buparlisib) D007_r2
## 1237 -7.372708e+00                           BMS-265246 D007_r2
## 1238 -9.592244e+00                           BMS-536924 D007_r2
## 1239 -7.671201e+00                           BMS-582949 D007_r2
## 1240 -6.745204e+00                           BMS-754807 D007_r2
## 1241 -8.070265e+00                           BMS-777607 D007_r2
## 1242 -8.260184e+00                           BMS-794833 D007_r2
## 1243 -8.874440e+00                           BMS-833923 D007_r2
## 1244 -9.107072e+00                  Bosutinib (SKI-606) D007_r2
## 1245 -1.008184e+01                Brivanib (BMS-540215) D007_r2
## 1246 -9.562402e+00      Brivanib Alaninate (BMS-582664) D007_r2
## 1247 -8.148110e+00                           BS-181 HCl D007_r2
## 1248 -7.834399e+00                               Butein D007_r2
## 1249 -5.855357e+00                               BYL719 D007_r2
## 1250 -7.914399e+00     Cabozantinib (XL184, BMS-907351) D007_r2
## 1251 -7.593184e+00          Cabozantinib malate (XL184) D007_r2
## 1252 -8.674545e+00        CAL-101 (Idelalisib, GS-1101) D007_r2
## 1253 -7.882141e+00                             CAY10505 D007_r2
## 1254 -6.767461e+00                               CC-223 D007_r2
## 1255 -7.729466e+00                            CCT128930 D007_r2
## 1256 -6.615370e+00                  Cediranib (AZD2171) D007_r2
## 1257 -7.780849e+00                            CEP-32496 D007_r2
## 1258 -9.266290e+00                            CEP-33779 D007_r2
## 1259 -8.160308e+00                              CGI1746 D007_r2
## 1260 -8.467641e+00                              CGK 733 D007_r2
## 1261 -7.340033e+00                            CH5132799 D007_r2
## 1262 -2.460619e+00                           CHIR-98014 D007_r2
## 1263 -4.720335e+00                 CHIR-99021 (CT99021) D007_r2
## 1264 -3.538046e+00             CHIR-99021 (CT99021) HCl D007_r2
## 1265 -8.607892e+00                    Chrysophanic Acid D007_r2
## 1266 -3.538520e+00                             CNX-2006 D007_r2
## 1267 -9.156783e+00                              CNX-774 D007_r2
## 1268 -7.594671e+00                    CO-1686 (AVL-301) D007_r2
## 1269  2.065029e+00       Cobimetinib (GDC-0973, RG7420) D007_r2
## 1270  1.293499e-01                            CP-673451 D007_r2
## 1271 -6.629515e+00                            CP-724714 D007_r2
## 1272 -3.140823e+00               Crenolanib (CP-868596) D007_r2
## 1273 -7.308264e+00             Crizotinib (PF-02341066) D007_r2
## 1274 -7.877510e+00                               CYC116 D007_r2
## 1275 -9.453292e+00                               CYT387 D007_r2
## 1276 -8.624468e+00                             CZC24832 D007_r2
## 1277 -7.357756e+00              Dabrafenib (GSK2118436) D007_r2
## 1278  4.036206e-01        Dacomitinib (PF299804, PF299) D007_r2
## 1279 -7.084903e+00              Danusertib (PHA-739358) D007_r2
## 1280 -7.572867e+00                        DAPT (GSI-IX) D007_r2
## 1281 -3.981359e+00                            Dasatinib D007_r2
## 1282 -8.424124e+00                DCC-2036 (Rebastinib) D007_r2
## 1283 -8.350292e+00                Decernotinib (VX-509) D007_r2
## 1284 -8.316453e-02               Dinaciclib (SCH727965) D007_r2
## 1285 -6.643583e+00    Dovitinib (TKI-258) Dilactic Acid D007_r2
## 1286 -3.825095e+00                            ENMD-2076 D007_r2
## 1287 -2.344848e+00               Enzastaurin (LY317615) D007_r2
## 1288 -6.477870e+00                            ERK5-IN-1 D007_r2
## 1289 -6.956108e+00                             ETC-1002 D007_r2
## 1290 -6.894337e+00                            ETP-46464 D007_r2
## 1291 -7.882029e+00                  Everolimus (RAD001) D007_r2
## 1292 -7.264426e+00                Fasudil (HA-1077) HCl D007_r2
## 1293 -9.798405e+00                                FH535 D007_r2
## 1294 -7.858434e+00                Filgotinib (GLPG0634) D007_r2
## 1295 -1.494468e+00             Flavopiridol (Alvocidib) D007_r2
## 1296  4.718548e-01                     Flavopiridol HCl D007_r2
## 1297 -9.050188e+00               Foretinib (GSK1363089) D007_r2
## 1298 -5.041625e+00                  Fostamatinib (R788) D007_r2
## 1299 -8.205147e+00                                G-749 D007_r2
## 1300 -8.378688e+00                             GDC-0068 D007_r2
## 1301 -9.157583e+00                             GDC-0349 D007_r2
## 1302 -7.154872e+00                             GDC-0879 D007_r2
## 1303 -6.768283e+00                             GDC-0941 D007_r2
## 1304 -5.576209e+00                    GDC-0980 (RG7422) D007_r2
## 1305 -9.537301e-01                   Gefitinib (ZD1839) D007_r2
## 1306 -9.904430e+00                            Genistein D007_r2
## 1307 -2.762747e+00                            GF109203X D007_r2
## 1308 -9.206236e+00                                GNF-2 D007_r2
## 1309 -8.034193e+00                                GNF-5 D007_r2
## 1310 -4.397581e+00                              Go 6983 D007_r2
## 1311 -6.312832e+00                   Golvatinib (E7050) D007_r2
## 1312 -7.302834e+00                          GSK1838705A D007_r2
## 1313 -8.656944e+00                          GSK1904529A D007_r2
## 1314 -5.787102e+00                  GSK2126458 (GSK458) D007_r2
## 1315 -8.250685e+00                           GSK2292767 D007_r2
## 1316 -7.298672e+00                           GSK2636771 D007_r2
## 1317 -8.124378e+00                           GSK429286A D007_r2
## 1318 -2.630140e-01                            GSK461364 D007_r2
## 1319 -8.744081e+00                               GSK621 D007_r2
## 1320 -8.273346e+00                            GSK690693 D007_r2
## 1321 -7.723859e+00                               GW5074 D007_r2
## 1322 -8.439076e+00                             GW788388 D007_r2
## 1323 -5.054833e+00                               GZD824 D007_r2
## 1324 -9.566426e+00                            H 89 2HCl D007_r2
## 1325 -5.102610e+00                           Hesperadin D007_r2
## 1326 -5.396019e+00                              HMN-214 D007_r2
## 1327 -8.059144e+00                             Honokiol D007_r2
## 1328 -2.195786e-01                               HS-173 D007_r2
## 1329 -8.083917e+00                           HTH-01-015 D007_r2
## 1330 -2.791608e+00                Ibrutinib (PCI-32765) D007_r2
## 1331 -8.869476e+00                              ICG-001 D007_r2
## 1332 -4.586072e+00                             Icotinib D007_r2
## 1333 -6.194686e+00                                IM-12 D007_r2
## 1334 -6.423029e+00           Imatinib Mesylate (STI571) D007_r2
## 1335 -8.456561e+00                            Indirubin D007_r2
## 1336 -4.323659e+00                    INK 128 (MLN0128) D007_r2
## 1337 -6.112301e+00                    IPI-145 (INK1197) D007_r2
## 1338 -8.371330e+00                               IWP-L6 D007_r2
## 1339 -9.634054e+00                           IWR-1-endo D007_r2
## 1340 -1.052429e+01                         JNJ-38877605 D007_r2
## 1341  2.574355e-01                          JNJ-7706621 D007_r2
## 1342 -5.110511e+00                     JNK Inhibitor IX D007_r2
## 1343 -8.221248e+00                             JNK-IN-8 D007_r2
## 1344 -6.286380e+00                               K02288 D007_r2
## 1345 -8.678831e+00                               Ki8751 D007_r2
## 1346 -8.730813e+00                              KRN 633 D007_r2
## 1347 -7.645815e+00                           KU-0063794 D007_r2
## 1348 -6.984787e+00      KU-55933 (ATM Kinase Inhibitor) D007_r2
## 1349 -8.052452e+00                             KU-60019 D007_r2
## 1350 -7.674152e+00                              KW-2449 D007_r2
## 1351 -2.417478e+00                              KX2-391 D007_r2
## 1352 -8.851678e+00                              KY02111 D007_r2
## 1353 -3.967521e+00                            Lapatinib D007_r2
## 1354 -6.918793e+00     Lapatinib (GW-572016) Ditosylate D007_r2
## 1355 -1.788275e+00                            LDC000067 D007_r2
## 1356 -1.004542e+01      LDE225 (NVP-LDE225,Erismodegib) D007_r2
## 1357 -5.263348e+00                           LDN-214117 D007_r2
## 1358 -8.247264e+00                   Lenvatinib (E7080) D007_r2
## 1359 -9.178036e+00                              LFM-A13 D007_r2
## 1360 -8.721109e+00                              LGK-974 D007_r2
## 1361 -1.043849e+01                  Linifanib (ABT-869) D007_r2
## 1362 -5.338412e+00                               LJH685 D007_r2
## 1363 -7.486398e+00                               LJI308 D007_r2
## 1364 -6.690626e+00               Losmapimod (GW856553X) D007_r2
## 1365 -4.526041e+00                            LY2090314 D007_r2
## 1366 -7.338471e+00                            LY2157299 D007_r2
## 1367 -6.909033e+00                            LY2784544 D007_r2
## 1368 -2.464153e+00                            LY2835219 D007_r2
## 1369 -8.492954e+00                             LY294002 D007_r2
## 1370 -3.616018e+00                            LY3023414 D007_r2
## 1371 -7.565770e+00                             LY411575 D007_r2
## 1372 -3.709624e+00       MEK162 (ARRY-162, ARRY-438162) D007_r2
## 1373 -8.363135e+00                             MGCD-265 D007_r2
## 1374 -1.716027e+00               Milciclib (PHA-848125) D007_r2
## 1375 -7.540808e+00                              MK-0752 D007_r2
## 1376 -8.281939e+00                         MK-2206 2HCl D007_r2
## 1377 -8.634756e+00                              MK-2461 D007_r2
## 1378 -8.927101e+00                     MK-5108 (VX-689) D007_r2
## 1379 -6.757692e+00                              MK-8745 D007_r2
## 1380 -4.965165e+00                              MLN2480 D007_r2
## 1381 -8.857352e+00                              MLN8054 D007_r2
## 1382 -8.413301e+00      Motesanib Diphosphate (AMG-706) D007_r2
## 1383 -1.017076e+01                  Nilotinib (AMN-107) D007_r2
## 1384 -6.377106e+00     Nintedanib (BIBF 1120)_uncertain D007_r2
## 1385 -8.859532e+00                               NU6027 D007_r2
## 1386 -7.731582e+00                           NVP-AEW541 D007_r2
## 1387 -8.545299e+00                           NVP-BHG712 D007_r2
## 1388 -7.193507e+00                      NVP-BSK805 2HCl D007_r2
## 1389 -9.131304e+00                           NVP-BVU972 D007_r2
## 1390 -8.837207e+00                          Oclacitinib D007_r2
## 1391 -7.343308e+00      Olmutinib (HM61713, BI 1482694) D007_r2
## 1392 -4.202383e+00                             ONO-4059 D007_r2
## 1393 -6.680663e+00                              OSI-027 D007_r2
## 1394 -6.712487e-01                              OSI-420 D007_r2
## 1395 -8.850973e+00                 OSI-906 (Linsitinib) D007_r2
## 1396 -1.219183e+00                              P276-00 D007_r2
## 1397  9.040764e-01                  Pacritinib (SB1518) D007_r2
## 1398 -9.274611e+00                   Palomid 529 (P529) D007_r2
## 1399 -8.424509e+00                            Pazopanib D007_r2
## 1400 -9.436988e+00                        Pazopanib HCl D007_r2
## 1401 -2.196248e+00                            PD0325901 D007_r2
## 1402 -5.133821e+00                             PD168393 D007_r2
## 1403 -6.945490e+00                             PD173955 D007_r2
## 1404 -5.192040e+00                   PD184352 (CI-1040) D007_r2
## 1405 -3.677719e+00                             PD318088 D007_r2
## 1406 -5.273714e+00                              PD98059 D007_r2
## 1407  7.125922e-01                  Pelitinib (EKB-569) D007_r2
## 1408 -2.752621e+00                          PF-00562271 D007_r2
## 1409 -6.916507e+00                          PF-04217903 D007_r2
## 1410 -5.145791e+00                          PF-04691502 D007_r2
## 1411 -6.431528e+00                            PF-431396 D007_r2
## 1412 -7.095688e+00                           PF-4708671 D007_r2
## 1413 -7.880922e+00                           PF-5274857 D007_r2
## 1414 -2.881228e+00                            PF-562271 D007_r2
## 1415 -7.613981e+00                            PF-573228 D007_r2
## 1416 -7.811657e+00                            PH-797804 D007_r2
## 1417 -8.004243e+00                           PHA-665752 D007_r2
## 1418 -8.095730e+00                           PHA-680632 D007_r2
## 1419  3.341786e-01                           PHA-767491 D007_r2
## 1420 -3.471273e+00                           PHA-793887 D007_r2
## 1421 -9.329329e+00                       Phenformin HCl D007_r2
## 1422 -8.363933e+00                              PHT-427 D007_r2
## 1423 -7.528029e+00                          Piceatannol D007_r2
## 1424 -7.207337e+00                              PIK-293 D007_r2
## 1425 -8.060795e+00                              PIK-294 D007_r2
## 1426 -3.886377e+00                               PIK-93 D007_r2
## 1427 -1.613100e+00               Pimasertib (AS-703026) D007_r2
## 1428 -7.159272e+00                          Pirfenidone D007_r2
## 1429 -9.998356e+00                             PLX-4720 D007_r2
## 1430 -7.885425e+00                              PLX7904 D007_r2
## 1431 -6.096546e+00                  Ponatinib (AP24534) D007_r2
## 1432 -7.112296e+00                                  PP1 D007_r2
## 1433 -6.892122e+00                                  PP2 D007_r2
## 1434 -6.370867e+00                                PP242 D007_r2
## 1435 -8.471896e+00                               PQ 401 D007_r2
## 1436 -8.059807e+00                              PRI-724 D007_r2
## 1437 -7.393741e+00     PRT062607 (P505-15, BIIB057) HCl D007_r2
## 1438 -8.740367e+00                         Purvalanol A D007_r2
## 1439 -7.216017e+00                            Quercetin D007_r2
## 1440 -8.949734e+00                  Quizartinib (AC220) D007_r2
## 1441 -9.347213e+00                                 R406 D007_r2
## 1442 -7.730253e+00                     R406 (free base) D007_r2
## 1443  1.965291e-01                                 R547 D007_r2
## 1444 -1.737137e+00                    RAF265 (CHIR-265) D007_r2
## 1445 -7.725678e+00                Rapamycin (Sirolimus) D007_r2
## 1446 -2.981589e+00   Refametinib (RDEA119, Bay 86-9766) D007_r2
## 1447 -7.624123e+00                               RepSox D007_r2
## 1448 -9.940045e+00 Ridaforolimus (Deforolimus, MK-8669) D007_r2
## 1449 -1.023652e+00                Rigosertib (ON-01910) D007_r2
## 1450 -8.622556e+00                             RKI-1447 D007_r2
## 1451 -7.096786e+00                                RN486 D007_r2
## 1452  5.219361e-01                  Ro 31-8220 Mesylate D007_r2
## 1453 -7.682188e+00                              Ro-3306 D007_r2
## 1454 -2.815850e+00                               Ro3280 D007_r2
## 1455 -6.814531e+00                            RO4929097 D007_r2
## 1456 -6.129808e+00      Roscovitine (Seliciclib,CYC202) D007_r2
## 1457 -8.411811e+00             Ruxolitinib (INCB018424) D007_r2
## 1458 -8.499543e+00           S-Ruxolitinib (INCB018424) D007_r2
## 1459 -8.712174e+00                               SANT-1 D007_r2
## 1460 -8.466955e+00                            SAR131675 D007_r2
## 1461 -6.549191e+00                    SAR245409 (XL765) D007_r2
## 1462  1.082694e+00                Saracatinib (AZD0530) D007_r2
## 1463 -8.526328e+00                      SB202190 (FHPI) D007_r2
## 1464 -9.485272e+00                             SB203580 D007_r2
## 1465 -6.081059e+00                             SB216763 D007_r2
## 1466 -7.628708e+00                             SB239063 D007_r2
## 1467 -8.445286e+00                             SB415286 D007_r2
## 1468 -9.440351e+00                             SB431542 D007_r2
## 1469 -8.347206e+00                             SB505124 D007_r2
## 1470 -8.853388e+00                             SB525334 D007_r2
## 1471 -1.027104e+01                             SB590885 D007_r2
## 1472  1.702766e-01                                  SC1 D007_r2
## 1473 -8.592543e+00                Schisandrin B (Sch B) D007_r2
## 1474 -4.957488e+00                Selumetinib (AZD6244) D007_r2
## 1475 -8.816942e+00              Semagacestat (LY450139) D007_r2
## 1476 -8.855783e+00                   Semaxanib (SU5416) D007_r2
## 1477 -1.353290e+00                             SGI-7079 D007_r2
## 1478 -7.730553e+00                          Skepinone-L D007_r2
## 1479 -7.077611e+00                               SL-327 D007_r2
## 1480 -2.329314e+00                 SNS-032 (BMS-387032) D007_r2
## 1481 -6.509771e+00                     SNS-314 Mesylate D007_r2
## 1482 -7.394384e+00                            Sorafenib D007_r2
## 1483 -7.490492e+00                   Sorafenib Tosylate D007_r2
## 1484 -5.935849e+00                         Sotrastaurin D007_r2
## 1485 -9.830218e+00                             SP600125 D007_r2
## 1486 -1.089054e+01                              SU11274 D007_r2
## 1487 -9.703366e+00                               SU6656 D007_r2
## 1488 -8.414722e+00                               SU9516 D007_r2
## 1489 -1.014263e+01                     Sunitinib Malate D007_r2
## 1490 -5.825394e+00                  TAE226 (NVP-TAE226) D007_r2
## 1491 -6.350689e+00                              TAK-285 D007_r2
## 1492 -5.552638e+00                              TAK-632 D007_r2
## 1493 -6.569117e+00                              TAK-715 D007_r2
## 1494 -8.986133e-01                              TAK-733 D007_r2
## 1495 -6.741811e+00                              TAK-901 D007_r2
## 1496 -8.407751e+00                Taladegib (LY2940680) D007_r2
## 1497 -8.127947e+00                              TCS 359 D007_r2
## 1498 -7.304774e+00                               TDZD-8 D007_r2
## 1499 -7.290766e+00                            Telatinib D007_r2
## 1500 -9.286825e+00   Temsirolimus (CCI-779, NSC 683864) D007_r2
## 1501 -7.566299e+00              Tepotinib (EMD 1214063) D007_r2
## 1502 -9.306926e+00                                TG003 D007_r2
## 1503 -8.204363e+00                            TG100-115 D007_r2
## 1504 -5.259607e+00                             TG101209 D007_r2
## 1505 -5.818715e+00                 TG101348 (SAR302503) D007_r2
## 1506 -8.208259e+00                              TGX-221 D007_r2
## 1507 -7.346299e+00                         Theophylline D007_r2
## 1508 -7.692564e+00                          Thiazovivin D007_r2
## 1509 -8.659218e+00                       TIC10 Analogue D007_r2
## 1510 -6.929106e+00                           Tideglusib D007_r2
## 1511 -6.392811e+00                 Tivantinib (ARQ 197) D007_r2
## 1512 -8.026538e+00                   Tivozanib (AV-951) D007_r2
## 1513 -9.149674e+00  Tofacitinib (CP-690550,Tasocitinib) D007_r2
## 1514 -7.536813e+00      Tofacitinib (CP-690550) Citrate D007_r2
## 1515 -4.733463e-01                              Torin 2 D007_r2
## 1516  3.968762e-01              Trametinib (GSK1120212) D007_r2
## 1517 -7.724524e+00                          Triciribine D007_r2
## 1518 -7.440354e+00           TSU-68 (SU6668, Orantinib) D007_r2
## 1519 -7.464953e+00                               TWS119 D007_r2
## 1520 -7.391748e+00                         Tyrphostin 9 D007_r2
## 1521 -9.328677e+00                   Tyrphostin AG 1296 D007_r2
## 1522 -8.049805e+00                           U0126-EtOH D007_r2
## 1523 -5.150707e+00     Ulixertinib (BVD-523, VRT752271) D007_r2
## 1524 -6.755159e+00              Uprosertib (GSK2141795) D007_r2
## 1525 -5.192065e+00                          Vacquinol-1 D007_r2
## 1526 -6.191216e+00                           Varlitinib D007_r2
## 1527 -5.621462e+00              Vatalanib (PTK787) 2HCl D007_r2
## 1528 -8.453098e+00                               VE-821 D007_r2
## 1529 -4.171018e+00                               VE-822 D007_r2
## 1530 -8.423067e+00        Vemurafenib (PLX4032, RG7204) D007_r2
## 1531 -8.823025e+00                Vismodegib (GDC-0449) D007_r2
## 1532 -9.140982e+00                 Volasertib (BI 6727) D007_r2
## 1533 -6.808284e+00                            VPS34-IN1 D007_r2
## 1534 -5.779015e+00                     VS-5584 (SB2343) D007_r2
## 1535 -5.509707e+00                               VX-11e D007_r2
## 1536 -9.028106e+00         VX-680 (Tozasertib, MK-0457) D007_r2
## 1537 -7.491948e+00                               VX-702 D007_r2
## 1538 -7.008301e+00                               VX-745 D007_r2
## 1539 -8.834958e+00                              WAY-600 D007_r2
## 1540 -6.405273e+00                             WH-4-023 D007_r2
## 1541 -7.819392e+00                             WHI-P154 D007_r2
## 1542 -8.087146e+00                                WIKI4 D007_r2
## 1543 -4.080142e+00                        Wnt agonist 1 D007_r2
## 1544 -7.798024e+00                        Wnt-C59 (C59) D007_r2
## 1545 -9.255457e+00                               WP1066 D007_r2
## 1546 -5.947181e+00                 WYE-125132 (WYE-132) D007_r2
## 1547 -5.872464e+00                              WYE-354 D007_r2
## 1548 -6.072900e+00                               WZ3146 D007_r2
## 1549 -6.832722e+00                               WZ4002 D007_r2
## 1550 -7.479514e+00                               WZ4003 D007_r2
## 1551 -8.201417e+00                               WZ8040 D007_r2
## 1552 -7.833746e+00                              XAV-939 D007_r2
## 1553 -9.685518e+00                                XL019 D007_r2
## 1554 -5.215101e+00                              XMD8-92 D007_r2
## 1555 -8.037961e+00                         Y-27632 2HCl D007_r2
## 1556 -7.686154e+00                             YM201636 D007_r2
## 1557 -8.278583e+00                             YO-01027 D007_r2
## 1558 -2.159318e+00                            ZM 306416 D007_r2
## 1559 -7.911066e+00                        ZM 323881 HCl D007_r2
## 1560 -8.291353e+00                            ZM 336372 D007_r2
## 1561 -8.511486e+00                         ZM 39923 HCl D007_r2
## 1562 -7.600324e+00                            ZM 447439 D007_r2
## 1563 -8.252005e+00                 Zotarolimus(ABT-578) D007_r2
## 1564 -6.553339e+00                              ZSTK474 D007_r2
## 1565 -3.274982e+00                     1-Azakenpaullone D010_r1
## 1566 -4.096827e+00                      3-Methyladenine D010_r1
## 1567  2.652573e+00                             A-674563 D010_r1
## 1568 -3.562152e+00                             A-769662 D010_r1
## 1569 -3.689605e+00                                  A66 D010_r1
## 1570 -4.079864e+00                            Acadesine D010_r1
## 1571 -2.436200e+00                  AEE788 (NVP-AEE788) D010_r1
## 1572 -4.802148e+00        Afatinib (BIBW2992)_uncertain D010_r1
## 1573 -6.068614e+00                              AG-1024 D010_r1
## 1574 -2.515128e+00         AG-1478 (Tyrphostin AG-1478) D010_r1
## 1575 -5.192628e+00                                AG-18 D010_r1
## 1576 -4.168705e+00              AG-490 (Tyrphostin B42) D010_r1
## 1577 -2.851017e+00                             Akti-1/2 D010_r1
## 1578 -4.114048e+00                  Alisertib (MLN8237) D010_r1
## 1579 -6.560281e+00                              AMG 337 D010_r1
## 1580 -5.128862e+00                              AMG-458 D010_r1
## 1581 -2.634123e+00                              AMG-900 D010_r1
## 1582 -3.357234e+00                               AMG319 D010_r1
## 1583 -6.044126e+00                  Amuvatinib (MP-470) D010_r1
## 1584 -4.910954e+00                             Apatinib D010_r1
## 1585 -3.450777e+00                           AR-A014418 D010_r1
## 1586 -3.669290e+00                            AS-252424 D010_r1
## 1587 -5.549090e+00                            AS-604850 D010_r1
## 1588 -3.259131e+00                         Asiatic Acid D010_r1
## 1589 -2.366140e+00                             AST-1306 D010_r1
## 1590 -2.206171e+00                              AT13148 D010_r1
## 1591  3.603146e-01                               AT7519 D010_r1
## 1592 -2.812723e-01                               AT7867 D010_r1
## 1593  5.818571e-01                               AT9283 D010_r1
## 1594 -4.769101e+00                 Aurora A Inhibitor I D010_r1
## 1595 -4.971443e+00             Avagacestat (BMS-708163) D010_r1
## 1596 -4.283423e+00                              AVL-292 D010_r1
## 1597 -4.510786e+00                             Axitinib D010_r1
## 1598 -4.510786e+00                             Axitinib D010_r1
## 1599 -2.030562e+00                               AZ 628 D010_r1
## 1600 -4.695400e+00                               AZ 960 D010_r1
## 1601 -2.197376e+00                                 AZ20 D010_r1
## 1602 -1.518657e+00                              AZD1080 D010_r1
## 1603 -4.025781e+00                              AZD1480 D010_r1
## 1604 -7.168295e-01                              AZD2014 D010_r1
## 1605 -9.463343e-01                              AZD2858 D010_r1
## 1606 -4.822886e+00                              AZD2932 D010_r1
## 1607 -1.647178e+00                              AZD3759 D010_r1
## 1608 -2.140494e+00                              AZD5363 D010_r1
## 1609  5.534727e-01                              AZD5438 D010_r1
## 1610 -4.127680e+00                              AZD6482 D010_r1
## 1611 -3.062292e+00                              AZD6738 D010_r1
## 1612 -1.876509e-03                              AZD8055 D010_r1
## 1613 -9.657556e-01                              AZD8330 D010_r1
## 1614 -1.435359e+00                  AZD8931 (Sapitinib) D010_r1
## 1615 -1.968611e+00                              AZD9291 D010_r1
## 1616 -3.492556e+00            Barasertib (AZD1152-HQPA) D010_r1
## 1617 -4.805151e+00  Baricitinib (LY3009104, INCB028050) D010_r1
## 1618 -8.540527e+00                  BGT226 (NVP-BGT226) D010_r1
## 1619 -1.689302e+00                              BI 2536 D010_r1
## 1620 -4.692506e+00                              BI-78D3 D010_r1
## 1621 -3.236975e+00                             BI-D1870 D010_r1
## 1622 -4.293342e+00                              Bikinin D010_r1
## 1623 -4.393796e+00                                  BIO D010_r1
## 1624 -5.153143e+00               BIRB 796 (Doramapimod) D010_r1
## 1625 -5.708412e+00                            BIX 02188 D010_r1
## 1626 -2.439982e+00                            BIX 02189 D010_r1
## 1627 -1.118643e+00      BKM120 (NVP-BKM120, Buparlisib) D010_r1
## 1628 -2.293719e+00                           BMS-265246 D010_r1
## 1629 -2.777313e+00                           BMS-536924 D010_r1
## 1630 -5.861241e+00                           BMS-582949 D010_r1
## 1631 -1.632099e+00                           BMS-754807 D010_r1
## 1632 -4.240446e+00                           BMS-777607 D010_r1
## 1633 -4.836837e+00                           BMS-794833 D010_r1
## 1634 -4.181196e+00                           BMS-833923 D010_r1
## 1635 -4.691682e+00                  Bosutinib (SKI-606) D010_r1
## 1636 -5.045281e+00                Brivanib (BMS-540215) D010_r1
## 1637 -4.978317e+00      Brivanib Alaninate (BMS-582664) D010_r1
## 1638 -3.183528e+00                           BS-181 HCl D010_r1
## 1639 -6.623132e+00                               Butein D010_r1
## 1640 -5.346791e+00                               BYL719 D010_r1
## 1641 -3.138557e+00     Cabozantinib (XL184, BMS-907351) D010_r1
## 1642 -6.788253e+00          Cabozantinib malate (XL184) D010_r1
## 1643 -4.905125e+00        CAL-101 (Idelalisib, GS-1101) D010_r1
## 1644 -3.297766e+00                             CAY10505 D010_r1
## 1645 -3.451871e+00                               CC-223 D010_r1
## 1646 -2.084243e+00                            CCT128930 D010_r1
## 1647 -4.404834e+00                  Cediranib (AZD2171) D010_r1
## 1648 -2.894677e+00                            CEP-32496 D010_r1
## 1649 -4.683787e+00                            CEP-33779 D010_r1
## 1650 -5.121552e+00                              CGI1746 D010_r1
## 1651 -2.068294e+00                              CGK 733 D010_r1
## 1652 -2.925637e+00                            CH5132799 D010_r1
## 1653 -1.472953e+00                           CHIR-98014 D010_r1
## 1654 -1.563838e+00                 CHIR-99021 (CT99021) D010_r1
## 1655 -1.673786e+00             CHIR-99021 (CT99021) HCl D010_r1
## 1656 -5.206486e+00                    Chrysophanic Acid D010_r1
## 1657 -3.640191e+00                             CNX-2006 D010_r1
## 1658 -4.909324e+00                              CNX-774 D010_r1
## 1659 -4.250868e+00                    CO-1686 (AVL-301) D010_r1
## 1660  1.153004e+00       Cobimetinib (GDC-0973, RG7420) D010_r1
## 1661 -1.747351e+00                            CP-673451 D010_r1
## 1662 -4.985910e+00                            CP-724714 D010_r1
## 1663 -2.629986e+00               Crenolanib (CP-868596) D010_r1
## 1664 -2.897562e+00             Crizotinib (PF-02341066) D010_r1
## 1665 -3.995542e+00                               CYC116 D010_r1
## 1666 -4.338362e+00                               CYT387 D010_r1
## 1667 -4.602307e+00                             CZC24832 D010_r1
## 1668 -3.387894e+00              Dabrafenib (GSK2118436) D010_r1
## 1669 -8.110846e-02        Dacomitinib (PF299804, PF299) D010_r1
## 1670 -5.131382e+00              Danusertib (PHA-739358) D010_r1
## 1671 -4.526242e+00                        DAPT (GSI-IX) D010_r1
## 1672 -4.764363e+00                            Dasatinib D010_r1
## 1673 -4.798753e+00                DCC-2036 (Rebastinib) D010_r1
## 1674 -4.434030e+00                Decernotinib (VX-509) D010_r1
## 1675  7.833606e-01               Dinaciclib (SCH727965) D010_r1
## 1676 -3.969177e+00    Dovitinib (TKI-258) Dilactic Acid D010_r1
## 1677 -3.243693e+00                            ENMD-2076 D010_r1
## 1678 -1.721597e+00               Enzastaurin (LY317615) D010_r1
## 1679 -1.811598e+00                            ERK5-IN-1 D010_r1
## 1680 -4.879051e+00                             ETC-1002 D010_r1
## 1681 -4.450043e+00                            ETP-46464 D010_r1
## 1682 -2.681828e+00                  Everolimus (RAD001) D010_r1
## 1683 -4.498023e+00                Fasudil (HA-1077) HCl D010_r1
## 1684 -3.612376e+00                                FH535 D010_r1
## 1685 -4.877280e+00                Filgotinib (GLPG0634) D010_r1
## 1686  1.302019e+00             Flavopiridol (Alvocidib) D010_r1
## 1687  1.497413e+00                     Flavopiridol HCl D010_r1
## 1688 -4.694073e+00               Foretinib (GSK1363089) D010_r1
## 1689 -1.683752e+00                  Fostamatinib (R788) D010_r1
## 1690 -2.630237e+00                                G-749 D010_r1
## 1691 -6.292669e-01                             GDC-0068 D010_r1
## 1692 -2.571837e+00                             GDC-0349 D010_r1
## 1693 -3.790021e+00                             GDC-0879 D010_r1
## 1694 -3.566214e+00                             GDC-0941 D010_r1
## 1695 -1.288974e+00                    GDC-0980 (RG7422) D010_r1
## 1696 -1.003425e+00                   Gefitinib (ZD1839) D010_r1
## 1697 -4.144104e+00                            Genistein D010_r1
## 1698 -1.431522e+00                            GF109203X D010_r1
## 1699 -6.400321e+00                                GNF-2 D010_r1
## 1700 -5.202278e+00                                GNF-5 D010_r1
## 1701 -1.699208e+00                              Go 6983 D010_r1
## 1702 -1.577577e+00                   Golvatinib (E7050) D010_r1
## 1703 -1.939255e+00                          GSK1838705A D010_r1
## 1704 -2.896910e+00                          GSK1904529A D010_r1
## 1705 -1.289119e+00                  GSK2126458 (GSK458) D010_r1
## 1706 -2.177072e+00                           GSK2292767 D010_r1
## 1707 -5.116466e+00                           GSK2636771 D010_r1
## 1708 -5.044360e+00                           GSK429286A D010_r1
## 1709 -4.646290e+00                            GSK461364 D010_r1
## 1710 -4.654458e+00                               GSK621 D010_r1
## 1711 -2.116081e+00                            GSK690693 D010_r1
## 1712 -4.896914e+00                               GW5074 D010_r1
## 1713 -4.800922e+00                             GW788388 D010_r1
## 1714 -4.628873e+00                               GZD824 D010_r1
## 1715 -4.332438e+00                            H 89 2HCl D010_r1
## 1716 -2.680617e+00                           Hesperadin D010_r1
## 1717 -3.958788e+00                              HMN-214 D010_r1
## 1718 -4.569562e+00                             Honokiol D010_r1
## 1719 -3.723058e+00                               HS-173 D010_r1
## 1720 -5.853489e+00                           HTH-01-015 D010_r1
## 1721 -3.290174e+00                Ibrutinib (PCI-32765) D010_r1
## 1722 -4.172555e+00                              ICG-001 D010_r1
## 1723 -2.866419e+00                             Icotinib D010_r1
## 1724 -4.980894e+00                                IM-12 D010_r1
## 1725 -1.528016e+00           Imatinib Mesylate (STI571) D010_r1
## 1726 -4.766423e+00                            Indirubin D010_r1
## 1727  3.261741e-01                    INK 128 (MLN0128) D010_r1
## 1728 -5.473341e+00                    IPI-145 (INK1197) D010_r1
## 1729 -3.279526e+00                               IWP-L6 D010_r1
## 1730 -5.680245e+00                           IWR-1-endo D010_r1
## 1731 -3.767979e+00                         JNJ-38877605 D010_r1
## 1732 -7.385848e-01                          JNJ-7706621 D010_r1
## 1733 -5.575030e+00                     JNK Inhibitor IX D010_r1
## 1734 -5.016594e+00                             JNK-IN-8 D010_r1
## 1735 -5.071008e+00                               K02288 D010_r1
## 1736 -3.985419e+00                               Ki8751 D010_r1
## 1737 -4.996458e+00                              KRN 633 D010_r1
## 1738 -2.568268e+00                           KU-0063794 D010_r1
## 1739 -2.864574e+00      KU-55933 (ATM Kinase Inhibitor) D010_r1
## 1740 -5.012581e+00                             KU-60019 D010_r1
## 1741 -2.511914e+00                              KW-2449 D010_r1
## 1742 -4.327502e+00                              KX2-391 D010_r1
## 1743 -4.666918e+00                              KY02111 D010_r1
## 1744 -3.139482e+00                            Lapatinib D010_r1
## 1745 -3.797869e+00     Lapatinib (GW-572016) Ditosylate D010_r1
## 1746 -2.835159e+00                            LDC000067 D010_r1
## 1747 -3.908154e+00      LDE225 (NVP-LDE225,Erismodegib) D010_r1
## 1748 -4.706528e+00                           LDN-214117 D010_r1
## 1749 -3.455462e+00                   Lenvatinib (E7080) D010_r1
## 1750 -3.704385e+00                              LFM-A13 D010_r1
## 1751 -4.597145e+00                              LGK-974 D010_r1
## 1752 -5.702749e+00                  Linifanib (ABT-869) D010_r1
## 1753 -5.059705e+00                               LJH685 D010_r1
## 1754 -4.428674e+00                               LJI308 D010_r1
## 1755 -4.514061e+00               Losmapimod (GW856553X) D010_r1
## 1756 -8.236065e-01                            LY2090314 D010_r1
## 1757 -5.291491e+00                            LY2157299 D010_r1
## 1758 -4.017785e+00                            LY2784544 D010_r1
## 1759 -1.087114e+00                            LY2835219 D010_r1
## 1760 -4.004557e+00                             LY294002 D010_r1
## 1761 -1.621520e+00                            LY3023414 D010_r1
## 1762 -3.044227e+00                             LY411575 D010_r1
## 1763  1.358855e+00       MEK162 (ARRY-162, ARRY-438162) D010_r1
## 1764 -4.503767e+00                             MGCD-265 D010_r1
## 1765 -8.789252e-01               Milciclib (PHA-848125) D010_r1
## 1766 -5.714820e+00                              MK-0752 D010_r1
## 1767 -1.160188e+00                         MK-2206 2HCl D010_r1
## 1768 -5.657508e+00                              MK-2461 D010_r1
## 1769 -4.354866e+00                     MK-5108 (VX-689) D010_r1
## 1770 -4.485668e+00                              MK-8745 D010_r1
## 1771 -2.124907e+00                              MLN2480 D010_r1
## 1772 -4.339720e+00                              MLN8054 D010_r1
## 1773 -4.599301e+00      Motesanib Diphosphate (AMG-706) D010_r1
## 1774 -5.526121e+00                  Nilotinib (AMN-107) D010_r1
## 1775 -2.812822e+00     Nintedanib (BIBF 1120)_uncertain D010_r1
## 1776 -4.423022e+00                               NU6027 D010_r1
## 1777 -1.342417e+00                           NVP-AEW541 D010_r1
## 1778 -3.133523e+00                           NVP-BHG712 D010_r1
## 1779 -4.393859e+00                      NVP-BSK805 2HCl D010_r1
## 1780 -4.827684e+00                           NVP-BVU972 D010_r1
## 1781 -5.387547e+00                          Oclacitinib D010_r1
## 1782 -3.347421e+00      Olmutinib (HM61713, BI 1482694) D010_r1
## 1783 -3.885470e+00                             ONO-4059 D010_r1
## 1784 -2.243984e+00                              OSI-027 D010_r1
## 1785 -2.054458e+00                              OSI-420 D010_r1
## 1786 -2.151559e+00                 OSI-906 (Linsitinib) D010_r1
## 1787  1.108402e+00                              P276-00 D010_r1
## 1788 -4.695875e-01                  Pacritinib (SB1518) D010_r1
## 1789 -4.767881e+00                   Palomid 529 (P529) D010_r1
## 1790 -6.246287e+00                            Pazopanib D010_r1
## 1791 -3.507316e+00                        Pazopanib HCl D010_r1
## 1792  1.768441e+00                            PD0325901 D010_r1
## 1793 -3.216983e+00                             PD168393 D010_r1
## 1794 -4.077749e+00                             PD173955 D010_r1
## 1795 -6.396492e-01                   PD184352 (CI-1040) D010_r1
## 1796  4.968645e-01                             PD318088 D010_r1
## 1797 -3.790232e+00                              PD98059 D010_r1
## 1798 -1.544525e+00                  Pelitinib (EKB-569) D010_r1
## 1799 -2.713665e+00                          PF-00562271 D010_r1
## 1800 -3.550617e+00                          PF-04217903 D010_r1
## 1801 -2.221390e+00                          PF-04691502 D010_r1
## 1802 -3.559679e+00                            PF-431396 D010_r1
## 1803 -8.360192e-01                           PF-4708671 D010_r1
## 1804 -4.164531e+00                           PF-5274857 D010_r1
## 1805 -1.297030e+00                            PF-562271 D010_r1
## 1806 -3.298356e+00                            PF-573228 D010_r1
## 1807 -5.053489e+00                            PH-797804 D010_r1
## 1808 -4.414135e+00                           PHA-665752 D010_r1
## 1809 -5.554983e+00                           PHA-680632 D010_r1
## 1810 -7.693362e-03                           PHA-767491 D010_r1
## 1811 -1.945412e+00                           PHA-793887 D010_r1
## 1812 -5.139572e+00                       Phenformin HCl D010_r1
## 1813 -5.088829e+00                              PHT-427 D010_r1
## 1814 -3.704838e+00                          Piceatannol D010_r1
## 1815 -5.401476e+00                              PIK-293 D010_r1
## 1816 -4.114456e+00                              PIK-294 D010_r1
## 1817 -2.598684e+00                               PIK-93 D010_r1
## 1818 -2.802473e-01               Pimasertib (AS-703026) D010_r1
## 1819 -6.191340e+00                          Pirfenidone D010_r1
## 1820 -5.431249e+00                             PLX-4720 D010_r1
## 1821 -4.072768e+00                              PLX7904 D010_r1
## 1822 -4.420471e+00                  Ponatinib (AP24534) D010_r1
## 1823 -2.483597e+00                                  PP1 D010_r1
## 1824 -2.998963e+00                                  PP2 D010_r1
## 1825 -1.522974e+00                                PP242 D010_r1
## 1826 -4.492194e+00                               PQ 401 D010_r1
## 1827 -4.775969e+00                              PRI-724 D010_r1
## 1828 -4.149756e+00     PRT062607 (P505-15, BIIB057) HCl D010_r1
## 1829 -3.749664e+00                         Purvalanol A D010_r1
## 1830 -3.582553e+00                            Quercetin D010_r1
## 1831 -3.278856e+00                  Quizartinib (AC220) D010_r1
## 1832 -3.818466e+00                                 R406 D010_r1
## 1833 -4.141464e+00                     R406 (free base) D010_r1
## 1834  7.438027e-01                                 R547 D010_r1
## 1835  4.475632e-01                    RAF265 (CHIR-265) D010_r1
## 1836 -3.126117e+00                Rapamycin (Sirolimus) D010_r1
## 1837  3.126894e-01   Refametinib (RDEA119, Bay 86-9766) D010_r1
## 1838 -4.813048e+00                               RepSox D010_r1
## 1839 -1.386883e+00 Ridaforolimus (Deforolimus, MK-8669) D010_r1
## 1840 -3.758784e+00                Rigosertib (ON-01910) D010_r1
## 1841 -3.634262e+00                             RKI-1447 D010_r1
## 1842 -5.546160e+00                                RN486 D010_r1
## 1843  1.710439e+00                  Ro 31-8220 Mesylate D010_r1
## 1844 -4.691970e+00                              Ro-3306 D010_r1
## 1845 -2.834695e+00                               Ro3280 D010_r1
## 1846 -5.037284e+00                            RO4929097 D010_r1
## 1847 -3.566657e+00      Roscovitine (Seliciclib,CYC202) D010_r1
## 1848 -5.316427e+00             Ruxolitinib (INCB018424) D010_r1
## 1849 -4.312451e+00           S-Ruxolitinib (INCB018424) D010_r1
## 1850 -4.838227e+00                               SANT-1 D010_r1
## 1851 -4.017095e+00                            SAR131675 D010_r1
## 1852 -6.802916e+00                    SAR245409 (XL765) D010_r1
## 1853 -2.922867e+00                Saracatinib (AZD0530) D010_r1
## 1854 -3.254011e+00                      SB202190 (FHPI) D010_r1
## 1855 -3.803578e+00                             SB203580 D010_r1
## 1856 -2.358958e+00                             SB216763 D010_r1
## 1857 -4.648597e+00                             SB239063 D010_r1
## 1858 -4.081189e+00                             SB415286 D010_r1
## 1859 -3.473934e+00                             SB431542 D010_r1
## 1860 -4.870993e+00                             SB505124 D010_r1
## 1861 -3.301128e+00                             SB525334 D010_r1
## 1862 -7.110283e+00                             SB590885 D010_r1
## 1863 -6.163196e-01                                  SC1 D010_r1
## 1864 -5.838123e+00                Schisandrin B (Sch B) D010_r1
## 1865  6.908678e-01                Selumetinib (AZD6244) D010_r1
## 1866 -3.517839e+00              Semagacestat (LY450139) D010_r1
## 1867 -4.401714e+00                   Semaxanib (SU5416) D010_r1
## 1868 -2.102110e+00                             SGI-7079 D010_r1
## 1869 -5.004745e+00                          Skepinone-L D010_r1
## 1870 -4.203002e+00                               SL-327 D010_r1
## 1871  1.263123e-01                 SNS-032 (BMS-387032) D010_r1
## 1872 -3.200950e+00                     SNS-314 Mesylate D010_r1
## 1873 -3.215168e+00                            Sorafenib D010_r1
## 1874 -2.171087e+00                   Sorafenib Tosylate D010_r1
## 1875 -2.406227e+00                         Sotrastaurin D010_r1
## 1876 -4.565076e+00                             SP600125 D010_r1
## 1877 -4.060778e+00                              SU11274 D010_r1
## 1878 -5.506997e+00                               SU6656 D010_r1
## 1879 -3.347089e+00                               SU9516 D010_r1
## 1880 -4.418569e+00                     Sunitinib Malate D010_r1
## 1881 -1.775080e+00                  TAE226 (NVP-TAE226) D010_r1
## 1882 -4.509803e+00                              TAK-285 D010_r1
## 1883 -3.031673e+00                              TAK-632 D010_r1
## 1884 -5.626202e+00                              TAK-715 D010_r1
## 1885 -7.727974e-02                              TAK-733 D010_r1
## 1886 -4.452802e+00                              TAK-901 D010_r1
## 1887 -3.623764e+00                Taladegib (LY2940680) D010_r1
## 1888 -4.884587e+00                              TCS 359 D010_r1
## 1889 -3.964539e+00                               TDZD-8 D010_r1
## 1890 -6.441349e+00                            Telatinib D010_r1
## 1891 -2.780623e+00   Temsirolimus (CCI-779, NSC 683864) D010_r1
## 1892 -1.528894e+00              Tepotinib (EMD 1214063) D010_r1
## 1893 -5.511793e+00                                TG003 D010_r1
## 1894 -3.169291e+00                            TG100-115 D010_r1
## 1895 -2.694364e+00                             TG101209 D010_r1
## 1896 -1.974651e+00                 TG101348 (SAR302503) D010_r1
## 1897 -3.690757e+00                              TGX-221 D010_r1
## 1898 -4.876954e+00                         Theophylline D010_r1
## 1899 -3.443135e+00                          Thiazovivin D010_r1
## 1900 -3.392425e+00                       TIC10 Analogue D010_r1
## 1901 -4.000816e+00                           Tideglusib D010_r1
## 1902 -4.760096e+00                 Tivantinib (ARQ 197) D010_r1
## 1903 -4.276934e+00                   Tivozanib (AV-951) D010_r1
## 1904 -4.192312e+00  Tofacitinib (CP-690550,Tasocitinib) D010_r1
## 1905 -4.093127e+00      Tofacitinib (CP-690550) Citrate D010_r1
## 1906 -3.814558e-01                              Torin 2 D010_r1
## 1907 -2.689241e-01              Trametinib (GSK1120212) D010_r1
## 1908 -2.658439e+00                          Triciribine D010_r1
## 1909 -4.396891e+00           TSU-68 (SU6668, Orantinib) D010_r1
## 1910 -4.310704e+00                               TWS119 D010_r1
## 1911 -1.052504e+00                         Tyrphostin 9 D010_r1
## 1912 -3.570103e+00                   Tyrphostin AG 1296 D010_r1
## 1913 -3.894619e+00                           U0126-EtOH D010_r1
## 1914 -1.958314e-02     Ulixertinib (BVD-523, VRT752271) D010_r1
## 1915 -3.602810e-01              Uprosertib (GSK2141795) D010_r1
## 1916 -4.507114e+00                          Vacquinol-1 D010_r1
## 1917 -3.768845e+00                           Varlitinib D010_r1
## 1918 -5.763884e+00              Vatalanib (PTK787) 2HCl D010_r1
## 1919 -5.303696e+00                               VE-821 D010_r1
## 1920 -3.863265e+00                               VE-822 D010_r1
## 1921 -6.809602e+00        Vemurafenib (PLX4032, RG7204) D010_r1
## 1922 -4.783157e+00                Vismodegib (GDC-0449) D010_r1
## 1923 -5.511571e+00                 Volasertib (BI 6727) D010_r1
## 1924 -2.510075e+00                            VPS34-IN1 D010_r1
## 1925 -3.115361e-01                     VS-5584 (SB2343) D010_r1
## 1926  5.340110e-02                               VX-11e D010_r1
## 1927 -4.688806e+00         VX-680 (Tozasertib, MK-0457) D010_r1
## 1928 -4.390838e+00                               VX-702 D010_r1
## 1929 -6.172789e+00                               VX-745 D010_r1
## 1930 -2.993899e+00                              WAY-600 D010_r1
## 1931 -6.341645e+00                             WH-4-023 D010_r1
## 1932 -4.227584e+00                             WHI-P154 D010_r1
## 1933 -5.023471e+00                                WIKI4 D010_r1
## 1934 -4.736294e+00                        Wnt agonist 1 D010_r1
## 1935 -4.311804e+00                        Wnt-C59 (C59) D010_r1
## 1936 -3.487148e+00                               WP1066 D010_r1
## 1937 -6.764391e-01                 WYE-125132 (WYE-132) D010_r1
## 1938 -4.420117e+00                              WYE-354 D010_r1
## 1939 -2.907853e+00                               WZ3146 D010_r1
## 1940 -3.319537e+00                               WZ4002 D010_r1
## 1941 -4.390512e+00                               WZ4003 D010_r1
## 1942 -4.438634e+00                               WZ8040 D010_r1
## 1943 -4.658605e+00                              XAV-939 D010_r1
## 1944 -4.179649e+00                                XL019 D010_r1
## 1945 -2.328529e+00                              XMD8-92 D010_r1
## 1946 -4.546861e+00                         Y-27632 2HCl D010_r1
## 1947 -2.971749e+00                             YM201636 D010_r1
## 1948 -4.034034e+00                             YO-01027 D010_r1
## 1949 -2.664815e+00                            ZM 306416 D010_r1
## 1950 -2.673838e+00                        ZM 323881 HCl D010_r1
## 1951 -5.404926e+00                            ZM 336372 D010_r1
## 1952 -4.367727e+00                         ZM 39923 HCl D010_r1
## 1953 -3.671727e+00                            ZM 447439 D010_r1
## 1954 -4.135019e+00                 Zotarolimus(ABT-578) D010_r1
## 1955 -3.621163e+00                              ZSTK474 D010_r1
## 1956 -2.777732e+00                     1-Azakenpaullone D010_r2
## 1957 -4.992033e+00                      3-Methyladenine D010_r2
## 1958  3.756180e+00                             A-674563 D010_r2
## 1959 -5.234492e+00                             A-769662 D010_r2
## 1960 -3.734070e+00                                  A66 D010_r2
## 1961 -4.555260e+00                            Acadesine D010_r2
## 1962 -1.162745e+00                  AEE788 (NVP-AEE788) D010_r2
## 1963 -4.614927e+00        Afatinib (BIBW2992)_uncertain D010_r2
## 1964 -4.619043e+00                              AG-1024 D010_r2
## 1965 -2.105697e+00         AG-1478 (Tyrphostin AG-1478) D010_r2
## 1966 -5.100065e+00                                AG-18 D010_r2
## 1967 -3.946376e+00              AG-490 (Tyrphostin B42) D010_r2
## 1968 -4.569156e+00                             Akti-1/2 D010_r2
## 1969 -3.241865e+00                  Alisertib (MLN8237) D010_r2
## 1970 -5.980507e+00                              AMG 337 D010_r2
## 1971 -4.550467e+00                              AMG-458 D010_r2
## 1972 -3.844009e+00                              AMG-900 D010_r2
## 1973 -4.275713e+00                               AMG319 D010_r2
## 1974 -3.653860e+00                  Amuvatinib (MP-470) D010_r2
## 1975 -3.457127e+00                             Apatinib D010_r2
## 1976 -2.753541e+00                           AR-A014418 D010_r2
## 1977 -5.829002e+00                            AS-252424 D010_r2
## 1978 -4.473546e+00                            AS-604850 D010_r2
## 1979 -3.088879e+00                         Asiatic Acid D010_r2
## 1980 -4.532424e+00                             AST-1306 D010_r2
## 1981 -2.700321e+00                              AT13148 D010_r2
## 1982  1.282603e+00                               AT7519 D010_r2
## 1983 -1.241741e+00                               AT7867 D010_r2
## 1984  1.632063e+00                               AT9283 D010_r2
## 1985 -4.387659e+00                 Aurora A Inhibitor I D010_r2
## 1986 -5.441793e+00             Avagacestat (BMS-708163) D010_r2
## 1987 -3.648136e+00                              AVL-292 D010_r2
## 1988 -3.762988e+00                             Axitinib D010_r2
## 1989 -3.762988e+00                             Axitinib D010_r2
## 1990 -1.935434e+00                               AZ 628 D010_r2
## 1991 -4.367730e+00                               AZ 960 D010_r2
## 1992 -3.620949e+00                                 AZ20 D010_r2
## 1993 -1.512039e+00                              AZD1080 D010_r2
## 1994 -2.902337e+00                              AZD1480 D010_r2
## 1995 -2.718499e-01                              AZD2014 D010_r2
## 1996 -1.026615e+00                              AZD2858 D010_r2
## 1997 -4.762757e+00                              AZD2932 D010_r2
## 1998 -1.301462e+00                              AZD3759 D010_r2
## 1999 -5.258968e-01                              AZD5363 D010_r2
## 2000  2.325448e+00                              AZD5438 D010_r2
## 2001 -3.916977e+00                              AZD6482 D010_r2
## 2002 -2.536428e+00                              AZD6738 D010_r2
## 2003 -2.083806e+00                              AZD8055 D010_r2
## 2004  1.352198e+00                              AZD8330 D010_r2
## 2005 -1.268051e+00                  AZD8931 (Sapitinib) D010_r2
## 2006 -2.614072e+00                              AZD9291 D010_r2
## 2007 -3.306638e+00            Barasertib (AZD1152-HQPA) D010_r2
## 2008 -4.210703e+00  Baricitinib (LY3009104, INCB028050) D010_r2
## 2009 -4.152683e+00                  BGT226 (NVP-BGT226) D010_r2
## 2010 -1.125883e+00                              BI 2536 D010_r2
## 2011 -3.243813e+00                              BI-78D3 D010_r2
## 2012 -4.946170e+00                             BI-D1870 D010_r2
## 2013 -4.542033e+00                              Bikinin D010_r2
## 2014 -4.283710e+00                                  BIO D010_r2
## 2015 -5.574526e+00               BIRB 796 (Doramapimod) D010_r2
## 2016 -3.709471e+00                            BIX 02188 D010_r2
## 2017 -3.120275e+00                            BIX 02189 D010_r2
## 2018 -2.085385e+00      BKM120 (NVP-BKM120, Buparlisib) D010_r2
## 2019 -2.734231e+00                           BMS-265246 D010_r2
## 2020 -3.006063e+00                           BMS-536924 D010_r2
## 2021 -3.271333e+00                           BMS-582949 D010_r2
## 2022 -2.710500e+00                           BMS-754807 D010_r2
## 2023 -4.005539e+00                           BMS-777607 D010_r2
## 2024 -3.665980e+00                           BMS-794833 D010_r2
## 2025 -4.681003e+00                           BMS-833923 D010_r2
## 2026 -2.824418e+00                  Bosutinib (SKI-606) D010_r2
## 2027 -4.600122e+00                Brivanib (BMS-540215) D010_r2
## 2028 -2.398291e+00      Brivanib Alaninate (BMS-582664) D010_r2
## 2029 -3.661891e+00                           BS-181 HCl D010_r2
## 2030 -5.478902e+00                               Butein D010_r2
## 2031 -2.850197e+00                               BYL719 D010_r2
## 2032 -2.895391e+00     Cabozantinib (XL184, BMS-907351) D010_r2
## 2033 -4.223035e+00          Cabozantinib malate (XL184) D010_r2
## 2034 -2.948942e+00        CAL-101 (Idelalisib, GS-1101) D010_r2
## 2035 -4.258936e+00                             CAY10505 D010_r2
## 2036 -2.754247e+00                               CC-223 D010_r2
## 2037 -2.501948e+00                            CCT128930 D010_r2
## 2038 -5.017021e+00                  Cediranib (AZD2171) D010_r2
## 2039 -2.614305e+00                            CEP-32496 D010_r2
## 2040 -4.453041e+00                            CEP-33779 D010_r2
## 2041 -4.454126e+00                              CGI1746 D010_r2
## 2042 -4.135120e+00                              CGK 733 D010_r2
## 2043 -1.321216e+00                            CH5132799 D010_r2
## 2044 -1.963902e+00                           CHIR-98014 D010_r2
## 2045 -3.160776e+00                 CHIR-99021 (CT99021) D010_r2
## 2046 -8.446017e-01             CHIR-99021 (CT99021) HCl D010_r2
## 2047 -5.341982e+00                    Chrysophanic Acid D010_r2
## 2048 -2.304317e+00                             CNX-2006 D010_r2
## 2049 -6.093727e+00                              CNX-774 D010_r2
## 2050 -2.536244e+00                    CO-1686 (AVL-301) D010_r2
## 2051  1.530985e+00       Cobimetinib (GDC-0973, RG7420) D010_r2
## 2052 -1.848606e+00                            CP-673451 D010_r2
## 2053 -4.428782e+00                            CP-724714 D010_r2
## 2054 -2.981658e+00               Crenolanib (CP-868596) D010_r2
## 2055 -1.585005e+00             Crizotinib (PF-02341066) D010_r2
## 2056 -4.748428e+00                               CYC116 D010_r2
## 2057 -4.020365e+00                               CYT387 D010_r2
## 2058 -3.852440e+00                             CZC24832 D010_r2
## 2059 -2.871976e+00              Dabrafenib (GSK2118436) D010_r2
## 2060 -2.027884e+00        Dacomitinib (PF299804, PF299) D010_r2
## 2061 -4.559286e+00              Danusertib (PHA-739358) D010_r2
## 2062 -4.692260e+00                        DAPT (GSI-IX) D010_r2
## 2063 -2.782262e+00                            Dasatinib D010_r2
## 2064 -3.872512e+00                DCC-2036 (Rebastinib) D010_r2
## 2065 -4.660072e+00                Decernotinib (VX-509) D010_r2
## 2066  1.987901e+00               Dinaciclib (SCH727965) D010_r2
## 2067 -1.816092e+00    Dovitinib (TKI-258) Dilactic Acid D010_r2
## 2068 -2.995463e+00                            ENMD-2076 D010_r2
## 2069 -2.997382e+00               Enzastaurin (LY317615) D010_r2
## 2070 -1.829237e+00                            ERK5-IN-1 D010_r2
## 2071 -4.014085e+00                             ETC-1002 D010_r2
## 2072 -3.762115e+00                            ETP-46464 D010_r2
## 2073 -3.188878e+00                  Everolimus (RAD001) D010_r2
## 2074 -5.214079e+00                Fasudil (HA-1077) HCl D010_r2
## 2075 -2.452329e+00                                FH535 D010_r2
## 2076 -4.295835e+00                Filgotinib (GLPG0634) D010_r2
## 2077  1.628702e+00             Flavopiridol (Alvocidib) D010_r2
## 2078  2.131394e+00                     Flavopiridol HCl D010_r2
## 2079 -3.939538e+00               Foretinib (GSK1363089) D010_r2
## 2080 -4.371323e-01                  Fostamatinib (R788) D010_r2
## 2081 -3.208873e+00                                G-749 D010_r2
## 2082 -9.384820e-01                             GDC-0068 D010_r2
## 2083 -2.959629e+00                             GDC-0349 D010_r2
## 2084 -4.205830e+00                             GDC-0879 D010_r2
## 2085 -3.130487e+00                             GDC-0941 D010_r2
## 2086 -2.807986e+00                    GDC-0980 (RG7422) D010_r2
## 2087 -1.423776e+00                   Gefitinib (ZD1839) D010_r2
## 2088 -3.860770e+00                            Genistein D010_r2
## 2089 -2.082002e+00                            GF109203X D010_r2
## 2090 -5.351245e+00                                GNF-2 D010_r2
## 2091 -4.766564e+00                                GNF-5 D010_r2
## 2092 -2.553293e+00                              Go 6983 D010_r2
## 2093 -1.897091e+00                   Golvatinib (E7050) D010_r2
## 2094 -2.580098e+00                          GSK1838705A D010_r2
## 2095 -3.645032e+00                          GSK1904529A D010_r2
## 2096 -8.701650e-01                  GSK2126458 (GSK458) D010_r2
## 2097 -2.273805e+00                           GSK2292767 D010_r2
## 2098 -2.962805e+00                           GSK2636771 D010_r2
## 2099 -4.339833e+00                           GSK429286A D010_r2
## 2100 -2.181254e+00                            GSK461364 D010_r2
## 2101 -2.166595e+00                               GSK621 D010_r2
## 2102 -2.634465e+00                            GSK690693 D010_r2
## 2103 -4.439724e+00                               GW5074 D010_r2
## 2104 -4.843962e+00                             GW788388 D010_r2
## 2105 -2.110553e+00                               GZD824 D010_r2
## 2106 -3.059751e+00                            H 89 2HCl D010_r2
## 2107 -2.230541e+00                           Hesperadin D010_r2
## 2108 -3.055367e+00                              HMN-214 D010_r2
## 2109 -4.124287e+00                             Honokiol D010_r2
## 2110 -3.401131e+00                               HS-173 D010_r2
## 2111 -5.058804e+00                           HTH-01-015 D010_r2
## 2112 -4.551287e+00                Ibrutinib (PCI-32765) D010_r2
## 2113 -4.878533e+00                              ICG-001 D010_r2
## 2114 -3.254863e+00                             Icotinib D010_r2
## 2115 -3.848118e+00                                IM-12 D010_r2
## 2116 -2.128833e+00           Imatinib Mesylate (STI571) D010_r2
## 2117 -5.037772e+00                            Indirubin D010_r2
## 2118 -2.633940e-01                    INK 128 (MLN0128) D010_r2
## 2119 -2.984596e+00                    IPI-145 (INK1197) D010_r2
## 2120 -5.157354e+00                               IWP-L6 D010_r2
## 2121 -4.760124e+00                           IWR-1-endo D010_r2
## 2122 -5.774842e+00                         JNJ-38877605 D010_r2
## 2123 -5.186562e-01                          JNJ-7706621 D010_r2
## 2124 -3.398585e+00                     JNK Inhibitor IX D010_r2
## 2125 -3.505400e+00                             JNK-IN-8 D010_r2
## 2126 -4.476708e+00                               K02288 D010_r2
## 2127 -5.831968e+00                               Ki8751 D010_r2
## 2128 -4.278429e+00                              KRN 633 D010_r2
## 2129 -2.958347e+00                           KU-0063794 D010_r2
## 2130 -3.667642e+00      KU-55933 (ATM Kinase Inhibitor) D010_r2
## 2131 -4.315656e+00                             KU-60019 D010_r2
## 2132 -2.373408e+00                              KW-2449 D010_r2
## 2133 -4.052281e+00                              KX2-391 D010_r2
## 2134 -5.112955e+00                              KY02111 D010_r2
## 2135 -3.728571e+00                            Lapatinib D010_r2
## 2136 -6.352544e+00     Lapatinib (GW-572016) Ditosylate D010_r2
## 2137 -1.457691e+00                            LDC000067 D010_r2
## 2138 -5.028675e+00      LDE225 (NVP-LDE225,Erismodegib) D010_r2
## 2139 -5.975678e+00                           LDN-214117 D010_r2
## 2140 -6.213249e+00                   Lenvatinib (E7080) D010_r2
## 2141 -2.821136e+00                              LFM-A13 D010_r2
## 2142 -4.514462e+00                              LGK-974 D010_r2
## 2143 -5.455419e+00                  Linifanib (ABT-869) D010_r2
## 2144 -3.841757e+00                               LJH685 D010_r2
## 2145 -3.582764e+00                               LJI308 D010_r2
## 2146 -4.430560e+00               Losmapimod (GW856553X) D010_r2
## 2147 -1.897640e+00                            LY2090314 D010_r2
## 2148 -5.186068e+00                            LY2157299 D010_r2
## 2149 -3.825278e+00                            LY2784544 D010_r2
## 2150  6.040727e-01                            LY2835219 D010_r2
## 2151 -3.682018e+00                             LY294002 D010_r2
## 2152 -2.565391e-01                            LY3023414 D010_r2
## 2153 -3.838962e+00                             LY411575 D010_r2
## 2154  1.179065e+00       MEK162 (ARRY-162, ARRY-438162) D010_r2
## 2155 -2.378290e+00                             MGCD-265 D010_r2
## 2156 -2.060426e+00               Milciclib (PHA-848125) D010_r2
## 2157 -4.269789e+00                              MK-0752 D010_r2
## 2158 -2.103721e+00                         MK-2206 2HCl D010_r2
## 2159 -4.122899e+00                              MK-2461 D010_r2
## 2160 -3.554222e+00                     MK-5108 (VX-689) D010_r2
## 2161 -4.967433e+00                              MK-8745 D010_r2
## 2162 -4.851367e+00                              MLN2480 D010_r2
## 2163 -4.146231e+00                              MLN8054 D010_r2
## 2164 -5.073210e+00      Motesanib Diphosphate (AMG-706) D010_r2
## 2165 -5.385984e+00                  Nilotinib (AMN-107) D010_r2
## 2166 -3.185375e+00     Nintedanib (BIBF 1120)_uncertain D010_r2
## 2167 -6.746252e+00                               NU6027 D010_r2
## 2168 -3.074720e-01                           NVP-AEW541 D010_r2
## 2169 -3.554560e+00                           NVP-BHG712 D010_r2
## 2170 -3.717049e+00                      NVP-BSK805 2HCl D010_r2
## 2171 -4.340022e+00                           NVP-BVU972 D010_r2
## 2172 -4.884251e+00                          Oclacitinib D010_r2
## 2173 -4.066991e+00      Olmutinib (HM61713, BI 1482694) D010_r2
## 2174 -3.016262e+00                             ONO-4059 D010_r2
## 2175 -1.034902e+00                              OSI-027 D010_r2
## 2176 -1.617519e+00                              OSI-420 D010_r2
## 2177 -2.128714e+00                 OSI-906 (Linsitinib) D010_r2
## 2178  3.618764e+00                              P276-00 D010_r2
## 2179  2.147703e+00                  Pacritinib (SB1518) D010_r2
## 2180 -3.927047e+00                   Palomid 529 (P529) D010_r2
## 2181 -4.556187e+00                            Pazopanib D010_r2
## 2182 -3.520435e+00                        Pazopanib HCl D010_r2
## 2183  1.804842e+00                            PD0325901 D010_r2
## 2184 -2.184266e+00                             PD168393 D010_r2
## 2185 -3.732175e+00                             PD173955 D010_r2
## 2186 -1.681753e+00                   PD184352 (CI-1040) D010_r2
## 2187  2.585403e-01                             PD318088 D010_r2
## 2188 -4.076076e+00                              PD98059 D010_r2
## 2189 -4.370772e-01                  Pelitinib (EKB-569) D010_r2
## 2190 -3.276106e-01                          PF-00562271 D010_r2
## 2191 -4.203199e+00                          PF-04217903 D010_r2
## 2192 -3.907380e+00                          PF-04691502 D010_r2
## 2193 -3.250642e+00                            PF-431396 D010_r2
## 2194 -5.185667e-01                           PF-4708671 D010_r2
## 2195 -5.427887e+00                           PF-5274857 D010_r2
## 2196 -6.519435e-02                            PF-562271 D010_r2
## 2197 -4.351076e+00                            PF-573228 D010_r2
## 2198 -4.929983e+00                            PH-797804 D010_r2
## 2199 -3.292496e+00                           PHA-665752 D010_r2
## 2200 -3.462439e+00                           PHA-680632 D010_r2
## 2201  1.646148e+00                           PHA-767491 D010_r2
## 2202 -1.529508e+00                           PHA-793887 D010_r2
## 2203 -4.885914e+00                       Phenformin HCl D010_r2
## 2204 -4.835743e+00                              PHT-427 D010_r2
## 2205 -3.422668e+00                          Piceatannol D010_r2
## 2206 -3.400464e+00                              PIK-293 D010_r2
## 2207 -4.354433e+00                              PIK-294 D010_r2
## 2208 -2.215800e+00                               PIK-93 D010_r2
## 2209  6.922769e-01               Pimasertib (AS-703026) D010_r2
## 2210 -4.487279e+00                          Pirfenidone D010_r2
## 2211 -3.475391e+00                             PLX-4720 D010_r2
## 2212 -2.411299e+00                              PLX7904 D010_r2
## 2213 -2.763250e+00                  Ponatinib (AP24534) D010_r2
## 2214 -1.967027e+00                                  PP1 D010_r2
## 2215 -2.290513e+00                                  PP2 D010_r2
## 2216 -3.139906e+00                                PP242 D010_r2
## 2217 -5.250517e+00                               PQ 401 D010_r2
## 2218 -3.578831e+00                              PRI-724 D010_r2
## 2219 -2.458280e+00     PRT062607 (P505-15, BIIB057) HCl D010_r2
## 2220 -3.303050e+00                         Purvalanol A D010_r2
## 2221 -3.388312e+00                            Quercetin D010_r2
## 2222 -2.020474e+00                  Quizartinib (AC220) D010_r2
## 2223 -4.387003e+00                                 R406 D010_r2
## 2224 -4.502666e+00                     R406 (free base) D010_r2
## 2225  1.342716e+00                                 R547 D010_r2
## 2226  8.015479e-01                    RAF265 (CHIR-265) D010_r2
## 2227 -3.470580e+00                Rapamycin (Sirolimus) D010_r2
## 2228  7.551946e-01   Refametinib (RDEA119, Bay 86-9766) D010_r2
## 2229 -4.719856e+00                               RepSox D010_r2
## 2230 -4.259278e+00 Ridaforolimus (Deforolimus, MK-8669) D010_r2
## 2231 -1.755407e+00                Rigosertib (ON-01910) D010_r2
## 2232 -4.125590e+00                             RKI-1447 D010_r2
## 2233 -3.947372e+00                                RN486 D010_r2
## 2234  1.702624e+00                  Ro 31-8220 Mesylate D010_r2
## 2235 -3.973775e+00                              Ro-3306 D010_r2
## 2236 -1.870796e+00                               Ro3280 D010_r2
## 2237 -3.166144e+00                            RO4929097 D010_r2
## 2238 -3.944371e+00      Roscovitine (Seliciclib,CYC202) D010_r2
## 2239 -4.832032e+00             Ruxolitinib (INCB018424) D010_r2
## 2240 -4.551588e+00           S-Ruxolitinib (INCB018424) D010_r2
## 2241 -4.061262e+00                               SANT-1 D010_r2
## 2242 -6.906101e+00                            SAR131675 D010_r2
## 2243 -4.819262e+00                    SAR245409 (XL765) D010_r2
## 2244 -9.984201e-01                Saracatinib (AZD0530) D010_r2
## 2245 -3.455137e+00                      SB202190 (FHPI) D010_r2
## 2246 -4.299736e+00                             SB203580 D010_r2
## 2247 -2.245406e+00                             SB216763 D010_r2
## 2248 -3.457229e+00                             SB239063 D010_r2
## 2249 -5.066183e+00                             SB415286 D010_r2
## 2250 -4.544294e+00                             SB431542 D010_r2
## 2251 -4.245440e+00                             SB505124 D010_r2
## 2252 -4.295249e+00                             SB525334 D010_r2
## 2253 -5.165399e+00                             SB590885 D010_r2
## 2254 -1.854138e+00                                  SC1 D010_r2
## 2255 -6.001743e+00                Schisandrin B (Sch B) D010_r2
## 2256 -1.783861e+00                Selumetinib (AZD6244) D010_r2
## 2257 -4.046999e+00              Semagacestat (LY450139) D010_r2
## 2258 -3.724958e+00                   Semaxanib (SU5416) D010_r2
## 2259 -1.103725e+00                             SGI-7079 D010_r2
## 2260 -5.331761e+00                          Skepinone-L D010_r2
## 2261 -6.140516e+00                               SL-327 D010_r2
## 2262  1.020254e+00                 SNS-032 (BMS-387032) D010_r2
## 2263 -2.869314e+00                     SNS-314 Mesylate D010_r2
## 2264 -1.396408e+00                            Sorafenib D010_r2
## 2265 -3.847284e+00                   Sorafenib Tosylate D010_r2
## 2266 -2.720063e+00                         Sotrastaurin D010_r2
## 2267 -3.431865e+00                             SP600125 D010_r2
## 2268 -4.667413e+00                              SU11274 D010_r2
## 2269 -5.460074e+00                               SU6656 D010_r2
## 2270 -4.332583e+00                               SU9516 D010_r2
## 2271 -4.682351e+00                     Sunitinib Malate D010_r2
## 2272 -2.222793e+00                  TAE226 (NVP-TAE226) D010_r2
## 2273 -3.138180e+00                              TAK-285 D010_r2
## 2274 -1.616489e+00                              TAK-632 D010_r2
## 2275 -3.972054e+00                              TAK-715 D010_r2
## 2276  1.299850e+00                              TAK-733 D010_r2
## 2277 -4.892278e+00                              TAK-901 D010_r2
## 2278 -4.594502e+00                Taladegib (LY2940680) D010_r2
## 2279 -5.493044e+00                              TCS 359 D010_r2
## 2280 -4.641363e+00                               TDZD-8 D010_r2
## 2281 -3.825742e+00                            Telatinib D010_r2
## 2282 -3.925123e+00   Temsirolimus (CCI-779, NSC 683864) D010_r2
## 2283 -2.028255e+00              Tepotinib (EMD 1214063) D010_r2
## 2284 -4.767350e+00                                TG003 D010_r2
## 2285 -5.493049e+00                            TG100-115 D010_r2
## 2286 -1.733434e+00                             TG101209 D010_r2
## 2287 -2.577298e+00                 TG101348 (SAR302503) D010_r2
## 2288 -4.236540e+00                              TGX-221 D010_r2
## 2289 -4.808197e+00                         Theophylline D010_r2
## 2290 -3.399490e+00                          Thiazovivin D010_r2
## 2291 -4.575967e+00                       TIC10 Analogue D010_r2
## 2292 -5.428790e+00                           Tideglusib D010_r2
## 2293 -4.995133e+00                 Tivantinib (ARQ 197) D010_r2
## 2294 -3.679918e+00                   Tivozanib (AV-951) D010_r2
## 2295 -4.470639e+00  Tofacitinib (CP-690550,Tasocitinib) D010_r2
## 2296 -4.527815e+00      Tofacitinib (CP-690550) Citrate D010_r2
## 2297  9.651777e-02                              Torin 2 D010_r2
## 2298  5.773882e-01              Trametinib (GSK1120212) D010_r2
## 2299 -2.327649e+00                          Triciribine D010_r2
## 2300 -4.381787e+00           TSU-68 (SU6668, Orantinib) D010_r2
## 2301 -4.838864e+00                               TWS119 D010_r2
## 2302 -1.874639e+00                         Tyrphostin 9 D010_r2
## 2303 -4.562168e+00                   Tyrphostin AG 1296 D010_r2
## 2304 -4.857219e+00                           U0126-EtOH D010_r2
## 2305  1.066670e+00     Ulixertinib (BVD-523, VRT752271) D010_r2
## 2306 -9.174298e-01              Uprosertib (GSK2141795) D010_r2
## 2307 -3.619082e+00                          Vacquinol-1 D010_r2
## 2308 -4.384515e+00                           Varlitinib D010_r2
## 2309 -3.572069e+00              Vatalanib (PTK787) 2HCl D010_r2
## 2310 -5.893181e+00                               VE-821 D010_r2
## 2311 -4.674590e+00                               VE-822 D010_r2
## 2312 -3.280503e+00        Vemurafenib (PLX4032, RG7204) D010_r2
## 2313 -4.591747e+00                Vismodegib (GDC-0449) D010_r2
## 2314 -5.044325e+00                 Volasertib (BI 6727) D010_r2
## 2315 -2.115233e+00                            VPS34-IN1 D010_r2
## 2316 -7.616878e-01                     VS-5584 (SB2343) D010_r2
## 2317 -1.802911e+00                               VX-11e D010_r2
## 2318 -3.331373e+00         VX-680 (Tozasertib, MK-0457) D010_r2
## 2319 -4.649143e+00                               VX-702 D010_r2
## 2320 -4.123563e+00                               VX-745 D010_r2
## 2321 -4.085288e+00                              WAY-600 D010_r2
## 2322 -3.336343e+00                             WH-4-023 D010_r2
## 2323 -3.671060e+00                             WHI-P154 D010_r2
## 2324 -4.794265e+00                                WIKI4 D010_r2
## 2325 -4.180692e+00                        Wnt agonist 1 D010_r2
## 2326 -4.750442e+00                        Wnt-C59 (C59) D010_r2
## 2327 -4.733671e+00                               WP1066 D010_r2
## 2328 -2.534766e+00                 WYE-125132 (WYE-132) D010_r2
## 2329 -5.095281e+00                              WYE-354 D010_r2
## 2330 -2.640817e+00                               WZ3146 D010_r2
## 2331 -2.675605e+00                               WZ4002 D010_r2
## 2332 -5.689395e+00                               WZ4003 D010_r2
## 2333 -4.860626e+00                               WZ8040 D010_r2
## 2334 -4.356279e+00                              XAV-939 D010_r2
## 2335 -4.362591e+00                                XL019 D010_r2
## 2336 -2.858580e+00                              XMD8-92 D010_r2
## 2337 -5.459882e+00                         Y-27632 2HCl D010_r2
## 2338 -2.292147e+00                             YM201636 D010_r2
## 2339 -4.120494e+00                             YO-01027 D010_r2
## 2340 -1.434385e+00                            ZM 306416 D010_r2
## 2341 -5.001299e+00                        ZM 323881 HCl D010_r2
## 2342 -6.680170e+00                            ZM 336372 D010_r2
## 2343 -4.765833e+00                         ZM 39923 HCl D010_r2
## 2344 -4.026331e+00                            ZM 447439 D010_r2
## 2345 -3.218160e+00                 Zotarolimus(ABT-578) D010_r2
## 2346 -3.902508e+00                              ZSTK474 D010_r2
## 2347 -1.938027e+00                     1-Azakenpaullone D013_r1
## 2348 -4.492328e+00                      3-Methyladenine D013_r1
## 2349  2.373529e+00                             A-674563 D013_r1
## 2350 -3.429049e+00                             A-769662 D013_r1
## 2351 -2.575498e+00                                  A66 D013_r1
## 2352  1.361172e+00         AG-1478 (Tyrphostin AG-1478) D013_r1
## 2353 -3.267117e+00              AG-490 (Tyrphostin B42) D013_r1
## 2354 -2.989116e+00                             Akti-1/2 D013_r1
## 2355 -4.213290e+00                              AMG-458 D013_r1
## 2356 -2.648507e+00                              AMG-900 D013_r1
## 2357 -3.495014e+00                               AMG319 D013_r1
## 2358 -2.588803e+00                           AR-A014418 D013_r1
## 2359 -3.863793e+00                            AS-252424 D013_r1
## 2360 -4.125261e+00                            AS-604850 D013_r1
## 2361  2.707720e+00                               AT9283 D013_r1
## 2362 -2.256981e+00             Avagacestat (BMS-708163) D013_r1
## 2363 -2.405229e+00                              AVL-292 D013_r1
## 2364 -2.760793e+00                               AZ 628 D013_r1
## 2365 -2.655880e+00                               AZ 960 D013_r1
## 2366  1.395692e+00                                 AZ20 D013_r1
## 2367 -1.143338e+00                              AZD1080 D013_r1
## 2368  1.183902e+00                              AZD1480 D013_r1
## 2369 -2.398207e-01                              AZD2014 D013_r1
## 2370  6.336464e-01                              AZD2858 D013_r1
## 2371 -4.692672e+00                              AZD2932 D013_r1
## 2372  3.364727e-01                              AZD3759 D013_r1
## 2373  2.874618e+00                              AZD5438 D013_r1
## 2374  1.970670e+00                              AZD6738 D013_r1
## 2375  2.720756e+00                              AZD9291 D013_r1
## 2376 -3.924146e+00  Baricitinib (LY3009104, INCB028050) D013_r1
## 2377  3.885811e+00                  BGT226 (NVP-BGT226) D013_r1
## 2378 -4.089542e+00                             BI-D1870 D013_r1
## 2379 -2.533940e+00                                  BIO D013_r1
## 2380 -2.849939e+00                           BMS-833923 D013_r1
## 2381 -3.995028e+00                               Butein D013_r1
## 2382 -1.964624e+00                               BYL719 D013_r1
## 2383 -3.732310e+00          Cabozantinib malate (XL184) D013_r1
## 2384 -4.491588e+00                             CAY10505 D013_r1
## 2385 -3.361030e+00                            CCT128930 D013_r1
## 2386 -3.752235e+00                            CEP-33779 D013_r1
## 2387 -3.046337e+00                              CGI1746 D013_r1
## 2388 -2.538985e+00                              CGK 733 D013_r1
## 2389 -1.653642e+00                            CH5132799 D013_r1
## 2390  1.028427e+00                           CHIR-98014 D013_r1
## 2391 -1.627808e+00             CHIR-99021 (CT99021) HCl D013_r1
## 2392 -3.961782e+00                    Chrysophanic Acid D013_r1
## 2393  2.180031e+00                             CNX-2006 D013_r1
## 2394 -2.959610e+00                              CNX-774 D013_r1
## 2395 -2.786220e+00                    CO-1686 (AVL-301) D013_r1
## 2396  2.089264e-01       Cobimetinib (GDC-0973, RG7420) D013_r1
## 2397  6.946967e-01               Crenolanib (CP-868596) D013_r1
## 2398 -2.988355e+00                               CYT387 D013_r1
## 2399 -3.449333e+00                             CZC24832 D013_r1
## 2400 -3.489353e+00              Dabrafenib (GSK2118436) D013_r1
## 2401  2.665644e+00        Dacomitinib (PF299804, PF299) D013_r1
## 2402 -2.389537e+00                        DAPT (GSI-IX) D013_r1
## 2403 -2.496389e+00                DCC-2036 (Rebastinib) D013_r1
## 2404 -3.367454e+00                Decernotinib (VX-509) D013_r1
## 2405  3.421872e+00               Dinaciclib (SCH727965) D013_r1
## 2406  5.446813e-02    Dovitinib (TKI-258) Dilactic Acid D013_r1
## 2407 -3.122866e+00               Enzastaurin (LY317615) D013_r1
## 2408  2.290014e-01                            ERK5-IN-1 D013_r1
## 2409 -3.361310e+00                            ETP-46464 D013_r1
## 2410 -4.139922e+00                Fasudil (HA-1077) HCl D013_r1
## 2411 -2.158832e+00                                FH535 D013_r1
## 2412 -2.986806e+00                Filgotinib (GLPG0634) D013_r1
## 2413  2.691689e+00                     Flavopiridol HCl D013_r1
## 2414 -2.266445e+00                  Fostamatinib (R788) D013_r1
## 2415 -2.674780e+00                             GDC-0068 D013_r1
## 2416 -1.607913e+00                             GDC-0349 D013_r1
## 2417  1.473094e+00                    GDC-0980 (RG7422) D013_r1
## 2418 -9.973265e-01                            GF109203X D013_r1
## 2419 -3.747894e+00                                GNF-2 D013_r1
## 2420 -3.396019e+00                                GNF-5 D013_r1
## 2421 -1.650167e+00                              Go 6983 D013_r1
## 2422  8.282412e-01                   Golvatinib (E7050) D013_r1
## 2423  9.840264e-01                          GSK1838705A D013_r1
## 2424  3.162204e-01                  GSK2126458 (GSK458) D013_r1
## 2425 -4.717036e+00                           GSK2636771 D013_r1
## 2426 -3.979517e+00                           GSK429286A D013_r1
## 2427 -2.975382e+00                               GW5074 D013_r1
## 2428 -3.791052e+00                             GW788388 D013_r1
## 2429 -1.916636e+00                               GZD824 D013_r1
## 2430  1.501624e+00                               HS-173 D013_r1
## 2431 -3.243087e-01                           HTH-01-015 D013_r1
## 2432 -3.412276e-01                Ibrutinib (PCI-32765) D013_r1
## 2433 -3.500629e+00                              ICG-001 D013_r1
## 2434 -3.700270e+00                             Icotinib D013_r1
## 2435 -3.541639e+00                                IM-12 D013_r1
## 2436 -2.364728e+00                            Indirubin D013_r1
## 2437  2.023246e+00                    INK 128 (MLN0128) D013_r1
## 2438 -2.898551e+00                    IPI-145 (INK1197) D013_r1
## 2439 -3.298028e+00                               IWP-L6 D013_r1
## 2440 -3.310357e+00                           IWR-1-endo D013_r1
## 2441  3.392146e-01                     JNK Inhibitor IX D013_r1
## 2442 -1.223733e+00                             JNK-IN-8 D013_r1
## 2443 -3.678953e+00                               K02288 D013_r1
## 2444  2.640269e+00                              KX2-391 D013_r1
## 2445 -2.266626e+00                              KY02111 D013_r1
## 2446 -1.817790e+00                            LDC000067 D013_r1
## 2447 -3.579851e+00      LDE225 (NVP-LDE225,Erismodegib) D013_r1
## 2448 -3.758294e+00                           LDN-214117 D013_r1
## 2449 -3.624116e+00                              LGK-974 D013_r1
## 2450 -2.809871e+00                               LJH685 D013_r1
## 2451 -3.349276e+00               Losmapimod (GW856553X) D013_r1
## 2452  2.124304e+00                            LY2090314 D013_r1
## 2453 -3.029222e+00                            LY2157299 D013_r1
## 2454 -3.265783e+00                            LY2784544 D013_r1
## 2455  4.212884e-01                            LY2835219 D013_r1
## 2456 -3.290703e+00                             LY411575 D013_r1
## 2457 -8.755401e-01       MEK162 (ARRY-162, ARRY-438162) D013_r1
## 2458  2.168763e+00               Milciclib (PHA-848125) D013_r1
## 2459 -2.536480e+00                              MK-0752 D013_r1
## 2460 -3.902952e+00                              MK-2461 D013_r1
## 2461 -1.690743e+00                     MK-5108 (VX-689) D013_r1
## 2462 -7.777693e-01                              MK-8745 D013_r1
## 2463 -3.130080e+00                              MLN2480 D013_r1
## 2464 -3.137290e+00                               NU6027 D013_r1
## 2465 -2.747645e+00                      NVP-BSK805 2HCl D013_r1
## 2466 -2.773753e+00                           NVP-BVU972 D013_r1
## 2467 -3.070487e+00                          Oclacitinib D013_r1
## 2468 -1.127866e+00                              OSI-027 D013_r1
## 2469  2.545546e+00                              P276-00 D013_r1
## 2470  2.375590e+00                  Pacritinib (SB1518) D013_r1
## 2471 -3.345606e+00                            Pazopanib D013_r1
## 2472  9.865275e-01                             PD168393 D013_r1
## 2473  7.027262e-01                             PD173955 D013_r1
## 2474  1.753082e+00                          PF-00562271 D013_r1
## 2475 -2.982230e-01                          PF-04691502 D013_r1
## 2476 -1.845309e-01                            PF-431396 D013_r1
## 2477 -2.830371e+00                           PF-5274857 D013_r1
## 2478  3.914251e-01                            PF-562271 D013_r1
## 2479 -4.122354e+00                            PH-797804 D013_r1
## 2480  6.294903e-01                           PHA-767491 D013_r1
## 2481 -3.060379e+00                       Phenformin HCl D013_r1
## 2482 -1.524340e+00                          Piceatannol D013_r1
## 2483 -4.243524e+00                          Pirfenidone D013_r1
## 2484 -3.407928e+00                              PLX7904 D013_r1
## 2485 -3.697758e+00                                  PP1 D013_r1
## 2486 -3.787304e+00                                  PP2 D013_r1
## 2487 -3.933847e+00                               PQ 401 D013_r1
## 2488 -3.498077e+00                              PRI-724 D013_r1
## 2489 -3.000860e+00                         Purvalanol A D013_r1
## 2490 -3.352483e+00                            Quercetin D013_r1
## 2491  1.689627e+00                                 R547 D013_r1
## 2492 -2.838940e+00                               RepSox D013_r1
## 2493 -2.285620e+00                             RKI-1447 D013_r1
## 2494 -2.672157e+00                                RN486 D013_r1
## 2495  1.942448e+00                  Ro 31-8220 Mesylate D013_r1
## 2496  1.366780e+00                               Ro3280 D013_r1
## 2497 -3.009693e+00                            RO4929097 D013_r1
## 2498 -3.265855e+00             Ruxolitinib (INCB018424) D013_r1
## 2499 -3.179016e+00           S-Ruxolitinib (INCB018424) D013_r1
## 2500 -2.931445e+00                               SANT-1 D013_r1
## 2501 -3.209023e+00                            SAR131675 D013_r1
## 2502 -2.157641e+00                             SB216763 D013_r1
## 2503 -3.472469e+00                             SB415286 D013_r1
## 2504 -4.118352e+00                             SB431542 D013_r1
## 2505 -3.411994e+00                             SB505124 D013_r1
## 2506 -3.114885e+00                             SB525334 D013_r1
## 2507  2.639887e+00                                  SC1 D013_r1
## 2508 -3.249618e+00                Schisandrin B (Sch B) D013_r1
## 2509 -2.183097e+00              Semagacestat (LY450139) D013_r1
## 2510 -2.814793e+00                   Semaxanib (SU5416) D013_r1
## 2511  2.734986e-01                             SGI-7079 D013_r1
## 2512 -3.912736e+00                          Skepinone-L D013_r1
## 2513 -2.356729e+00                            Sorafenib D013_r1
## 2514 -3.212101e+00                         Sotrastaurin D013_r1
## 2515 -1.735706e+00                               SU6656 D013_r1
## 2516 -3.093963e+00                               SU9516 D013_r1
## 2517  2.472846e+00                  TAE226 (NVP-TAE226) D013_r1
## 2518 -3.855266e+00                              TAK-285 D013_r1
## 2519 -1.636889e+00                              TAK-632 D013_r1
## 2520 -2.939067e+00                              TAK-715 D013_r1
## 2521  1.554224e+00                              TAK-733 D013_r1
## 2522  1.192065e+00                              TAK-901 D013_r1
## 2523 -3.721347e+00                Taladegib (LY2940680) D013_r1
## 2524 -3.564215e+00                               TDZD-8 D013_r1
## 2525 -2.797902e+00              Tepotinib (EMD 1214063) D013_r1
## 2526 -2.188243e+00                                TG003 D013_r1
## 2527  1.910295e+00                             TG101209 D013_r1
## 2528  1.567925e+00                 TG101348 (SAR302503) D013_r1
## 2529 -2.309008e+00                         Theophylline D013_r1
## 2530 -3.623100e+00                          Thiazovivin D013_r1
## 2531 -4.140022e+00                       TIC10 Analogue D013_r1
## 2532 -2.317265e+00                           Tideglusib D013_r1
## 2533  4.664958e-01                 Tivantinib (ARQ 197) D013_r1
## 2534 -3.107662e+00  Tofacitinib (CP-690550,Tasocitinib) D013_r1
## 2535 -3.345020e+00      Tofacitinib (CP-690550) Citrate D013_r1
## 2536  2.337669e+00                              Torin 2 D013_r1
## 2537 -3.600022e-01              Trametinib (GSK1120212) D013_r1
## 2538 -3.019978e+00                               TWS119 D013_r1
## 2539 -1.928551e+00                         Tyrphostin 9 D013_r1
## 2540 -2.119989e+00     Ulixertinib (BVD-523, VRT752271) D013_r1
## 2541 -1.271014e+00              Uprosertib (GSK2141795) D013_r1
## 2542 -4.016949e+00                           Varlitinib D013_r1
## 2543  1.738857e+00                               VE-822 D013_r1
## 2544 -3.544440e+00                Vismodegib (GDC-0449) D013_r1
## 2545 -6.349741e-01                            VPS34-IN1 D013_r1
## 2546  1.516001e+00                     VS-5584 (SB2343) D013_r1
## 2547 -3.323988e+00                               VX-702 D013_r1
## 2548 -2.463852e+00                              WAY-600 D013_r1
## 2549 -3.289527e+00                             WHI-P154 D013_r1
## 2550 -2.529205e+00                                WIKI4 D013_r1
## 2551  1.106738e+00                        Wnt agonist 1 D013_r1
## 2552 -2.861646e+00                        Wnt-C59 (C59) D013_r1
## 2553 -3.584075e+00                               WP1066 D013_r1
## 2554 -6.536007e-01                 WYE-125132 (WYE-132) D013_r1
## 2555 -1.298570e+00                               WZ4003 D013_r1
## 2556 -3.100417e+00                              XAV-939 D013_r1
## 2557 -3.034317e+00                                XL019 D013_r1
## 2558 -2.860523e+00                              XMD8-92 D013_r1
## 2559 -3.052781e+00                         Y-27632 2HCl D013_r1
## 2560 -2.614635e+00                             YO-01027 D013_r1
## 2561 -2.622510e+00                            ZM 306416 D013_r1
## 2562 -2.246542e+00                        ZM 323881 HCl D013_r1
## 2563 -4.189669e+00                            ZM 336372 D013_r1
## 2564 -3.668913e+00                         ZM 39923 HCl D013_r1
## 2565 -4.265447e+00                 Zotarolimus(ABT-578) D013_r1
## 2566  7.710473e-01                     1-Azakenpaullone D013_r2
## 2567 -1.427310e+00                      3-Methyladenine D013_r2
## 2568  4.555066e+00                             A-674563 D013_r2
## 2569 -2.157873e+00                             A-769662 D013_r2
## 2570 -5.944173e-01                                  A66 D013_r2
## 2571 -2.002036e+00                            Acadesine D013_r2
## 2572 -2.563589e+00                  AEE788 (NVP-AEE788) D013_r2
## 2573 -3.097535e+00        Afatinib (BIBW2992)_uncertain D013_r2
## 2574 -2.807169e-01                              AG-1024 D013_r2
## 2575 -3.449291e+00         AG-1478 (Tyrphostin AG-1478) D013_r2
## 2576 -3.884108e+00                                AG-18 D013_r2
## 2577 -3.165367e+00              AG-490 (Tyrphostin B42) D013_r2
## 2578 -2.757888e+00                             Akti-1/2 D013_r2
## 2579 -7.179943e-01                  Alisertib (MLN8237) D013_r2
## 2580 -3.836436e+00                              AMG 337 D013_r2
## 2581  1.013829e-01                              AMG-458 D013_r2
## 2582  3.307566e+00                              AMG-900 D013_r2
## 2583 -3.021090e+00                               AMG319 D013_r2
## 2584 -3.950778e+00                  Amuvatinib (MP-470) D013_r2
## 2585 -3.531935e+00                             Apatinib D013_r2
## 2586  1.333894e+00                           AR-A014418 D013_r2
## 2587 -4.312034e-01                            AS-252424 D013_r2
## 2588 -1.725264e+00                            AS-604850 D013_r2
## 2589 -2.207274e+00                         Asiatic Acid D013_r2
## 2590 -1.031880e+00                             AST-1306 D013_r2
## 2591 -4.898769e+00                              AT13148 D013_r2
## 2592 -1.503372e+00                               AT7519 D013_r2
## 2593 -3.838884e+00                               AT7867 D013_r2
## 2594  1.509162e+00                               AT9283 D013_r2
## 2595 -2.515568e+00                 Aurora A Inhibitor I D013_r2
## 2596 -1.423634e+00             Avagacestat (BMS-708163) D013_r2
## 2597 -8.748214e-01                              AVL-292 D013_r2
## 2598 -3.527280e+00                             Axitinib D013_r2
## 2599 -3.527280e+00                             Axitinib D013_r2
## 2600 -1.725263e+00                               AZ 628 D013_r2
## 2601 -2.728110e+00                               AZ 960 D013_r2
## 2602  4.309581e+00                                 AZ20 D013_r2
## 2603 -4.777368e-01                              AZD1080 D013_r2
## 2604  1.735110e+00                              AZD1480 D013_r2
## 2605 -1.244062e+00                              AZD2014 D013_r2
## 2606  5.062493e-01                              AZD2858 D013_r2
## 2607 -5.850073e-01                              AZD2932 D013_r2
## 2608 -5.041958e-01                              AZD3759 D013_r2
## 2609 -1.620846e+00                              AZD5363 D013_r2
## 2610  3.884499e+00                              AZD5438 D013_r2
## 2611 -1.452199e+00                              AZD6482 D013_r2
## 2612  4.900134e+00                              AZD6738 D013_r2
## 2613 -1.658126e+00                              AZD8055 D013_r2
## 2614 -4.640174e-01                              AZD8330 D013_r2
## 2615 -1.652521e+00                  AZD8931 (Sapitinib) D013_r2
## 2616  1.321023e-01                              AZD9291 D013_r2
## 2617 -4.295659e-01            Barasertib (AZD1152-HQPA) D013_r2
## 2618 -2.629917e+00  Baricitinib (LY3009104, INCB028050) D013_r2
## 2619  2.596098e+00                  BGT226 (NVP-BGT226) D013_r2
## 2620 -1.249269e+00                              BI 2536 D013_r2
## 2621 -2.190311e+00                              BI-78D3 D013_r2
## 2622  6.123230e-01                             BI-D1870 D013_r2
## 2623 -3.234462e+00                              Bikinin D013_r2
## 2624  2.684827e-02                                  BIO D013_r2
## 2625 -4.045069e+00               BIRB 796 (Doramapimod) D013_r2
## 2626 -3.252109e+00                            BIX 02188 D013_r2
## 2627 -4.157331e+00                            BIX 02189 D013_r2
## 2628  4.574306e-01      BKM120 (NVP-BKM120, Buparlisib) D013_r2
## 2629 -2.902381e+00                           BMS-265246 D013_r2
## 2630 -7.345855e-02                           BMS-536924 D013_r2
## 2631 -3.335983e+00                           BMS-582949 D013_r2
## 2632  2.081812e-01                           BMS-754807 D013_r2
## 2633 -2.231865e+00                           BMS-777607 D013_r2
## 2634 -1.997304e+00                           BMS-794833 D013_r2
## 2635 -1.807432e+00                           BMS-833923 D013_r2
## 2636  2.361655e-01                  Bosutinib (SKI-606) D013_r2
## 2637 -1.845216e+00                Brivanib (BMS-540215) D013_r2
## 2638 -4.787025e+00      Brivanib Alaninate (BMS-582664) D013_r2
## 2639 -3.253788e+00                           BS-181 HCl D013_r2
## 2640 -1.698305e+00                               Butein D013_r2
## 2641 -1.778688e+00                               BYL719 D013_r2
## 2642 -2.996728e+00     Cabozantinib (XL184, BMS-907351) D013_r2
## 2643  3.531751e+00          Cabozantinib malate (XL184) D013_r2
## 2644 -2.819828e+00        CAL-101 (Idelalisib, GS-1101) D013_r2
## 2645 -5.161027e-02                             CAY10505 D013_r2
## 2646 -1.091425e+00                               CC-223 D013_r2
## 2647 -4.832450e+00                            CCT128930 D013_r2
## 2648 -6.436297e+00                  Cediranib (AZD2171) D013_r2
## 2649 -2.978526e+00                            CEP-32496 D013_r2
## 2650 -2.327542e+00                            CEP-33779 D013_r2
## 2651  2.937996e-01                              CGI1746 D013_r2
## 2652 -1.746310e+00                              CGK 733 D013_r2
## 2653 -3.348654e+00                            CH5132799 D013_r2
## 2654  8.489290e-01                           CHIR-98014 D013_r2
## 2655 -2.584525e+00                 CHIR-99021 (CT99021) D013_r2
## 2656  5.474351e-01             CHIR-99021 (CT99021) HCl D013_r2
## 2657 -1.107999e+00                    Chrysophanic Acid D013_r2
## 2658  1.514507e+00                             CNX-2006 D013_r2
## 2659 -3.952669e-01                              CNX-774 D013_r2
## 2660 -1.727465e+00                    CO-1686 (AVL-301) D013_r2
## 2661 -9.660245e-01       Cobimetinib (GDC-0973, RG7420) D013_r2
## 2662 -2.962193e+00                            CP-673451 D013_r2
## 2663 -2.517650e+00                            CP-724714 D013_r2
## 2664 -4.915828e-01               Crenolanib (CP-868596) D013_r2
## 2665 -2.209556e+00             Crizotinib (PF-02341066) D013_r2
## 2666 -5.736837e-01                               CYC116 D013_r2
## 2667 -2.580835e+00                               CYT387 D013_r2
## 2668 -7.828931e-01                             CZC24832 D013_r2
## 2669  1.102826e-01              Dabrafenib (GSK2118436) D013_r2
## 2670  1.506864e+00        Dacomitinib (PF299804, PF299) D013_r2
## 2671  2.292124e-01              Danusertib (PHA-739358) D013_r2
## 2672 -2.432669e+00                        DAPT (GSI-IX) D013_r2
## 2673 -3.522518e+00                            Dasatinib D013_r2
## 2674  1.334086e+00                DCC-2036 (Rebastinib) D013_r2
## 2675 -2.870762e+00                Decernotinib (VX-509) D013_r2
## 2676  4.788407e+00               Dinaciclib (SCH727965) D013_r2
## 2677  3.406005e+00    Dovitinib (TKI-258) Dilactic Acid D013_r2
## 2678 -1.988445e+00                            ENMD-2076 D013_r2
## 2679 -1.167589e+00               Enzastaurin (LY317615) D013_r2
## 2680 -6.627865e-02                            ERK5-IN-1 D013_r2
## 2681 -4.243097e+00                             ETC-1002 D013_r2
## 2682 -2.110056e+00                            ETP-46464 D013_r2
## 2683 -2.707420e+00                  Everolimus (RAD001) D013_r2
## 2684 -1.729711e+00                Fasudil (HA-1077) HCl D013_r2
## 2685 -5.009738e+00                                FH535 D013_r2
## 2686 -1.209974e+00                Filgotinib (GLPG0634) D013_r2
## 2687  1.884438e+00             Flavopiridol (Alvocidib) D013_r2
## 2688  4.132505e+00                     Flavopiridol HCl D013_r2
## 2689 -3.759801e-01               Foretinib (GSK1363089) D013_r2
## 2690  3.252335e+00                  Fostamatinib (R788) D013_r2
## 2691 -3.354069e+00                                G-749 D013_r2
## 2692 -2.444861e+00                             GDC-0068 D013_r2
## 2693 -1.203168e+00                             GDC-0349 D013_r2
## 2694 -4.795068e+00                             GDC-0879 D013_r2
## 2695 -1.587491e+00                             GDC-0941 D013_r2
## 2696  2.495946e+00                    GDC-0980 (RG7422) D013_r2
## 2697 -3.608040e+00                   Gefitinib (ZD1839) D013_r2
## 2698 -2.555752e+00                            Genistein D013_r2
## 2699 -3.201825e-01                            GF109203X D013_r2
## 2700 -9.467117e-01                                GNF-2 D013_r2
## 2701 -2.201361e+00                                GNF-5 D013_r2
## 2702 -1.768970e-01                              Go 6983 D013_r2
## 2703  2.620014e+00                   Golvatinib (E7050) D013_r2
## 2704  7.082390e-01                          GSK1838705A D013_r2
## 2705 -2.602127e+00                          GSK1904529A D013_r2
## 2706  4.178142e+00                  GSK2126458 (GSK458) D013_r2
## 2707 -1.260210e+00                           GSK2292767 D013_r2
## 2708  9.009723e-01                           GSK2636771 D013_r2
## 2709 -3.405391e+00                           GSK429286A D013_r2
## 2710  4.007154e-01                            GSK461364 D013_r2
## 2711 -1.841073e+00                               GSK621 D013_r2
## 2712 -1.832611e+00                            GSK690693 D013_r2
## 2713 -9.939976e-02                               GW5074 D013_r2
## 2714 -1.961506e+00                             GW788388 D013_r2
## 2715  2.139485e+00                               GZD824 D013_r2
## 2716 -2.811174e+00                            H 89 2HCl D013_r2
## 2717 -1.955201e-01                           Hesperadin D013_r2
## 2718  8.385197e-01                              HMN-214 D013_r2
## 2719 -4.562335e+00                             Honokiol D013_r2
## 2720  4.611287e+00                               HS-173 D013_r2
## 2721  5.366259e+00                           HTH-01-015 D013_r2
## 2722 -1.073107e+00                Ibrutinib (PCI-32765) D013_r2
## 2723 -1.792565e+00                              ICG-001 D013_r2
## 2724 -1.531242e+00                             Icotinib D013_r2
## 2725 -2.965042e+00                                IM-12 D013_r2
## 2726 -5.636486e-01           Imatinib Mesylate (STI571) D013_r2
## 2727 -2.352621e+00                            Indirubin D013_r2
## 2728 -6.974014e-01                    INK 128 (MLN0128) D013_r2
## 2729 -5.134135e-01                    IPI-145 (INK1197) D013_r2
## 2730 -1.444804e+00                               IWP-L6 D013_r2
## 2731 -1.393818e+00                           IWR-1-endo D013_r2
## 2732 -1.968569e+00                         JNJ-38877605 D013_r2
## 2733 -2.624690e+00                          JNJ-7706621 D013_r2
## 2734  5.985477e+00                     JNK Inhibitor IX D013_r2
## 2735  9.482602e-01                             JNK-IN-8 D013_r2
## 2736 -2.484266e+00                               K02288 D013_r2
## 2737 -1.229207e+00                               Ki8751 D013_r2
## 2738 -3.335323e+00                              KRN 633 D013_r2
## 2739 -2.156509e+00                           KU-0063794 D013_r2
## 2740 -2.780043e+00      KU-55933 (ATM Kinase Inhibitor) D013_r2
## 2741 -2.213650e+00                             KU-60019 D013_r2
## 2742 -4.146787e+00                              KW-2449 D013_r2
## 2743  4.713649e+00                              KX2-391 D013_r2
## 2744 -1.694343e+00                              KY02111 D013_r2
## 2745 -2.069881e+00                            Lapatinib D013_r2
## 2746 -3.877188e+00     Lapatinib (GW-572016) Ditosylate D013_r2
## 2747 -2.219581e+00                            LDC000067 D013_r2
## 2748 -2.036077e+00      LDE225 (NVP-LDE225,Erismodegib) D013_r2
## 2749 -2.500697e+00                           LDN-214117 D013_r2
## 2750 -6.542989e+00                   Lenvatinib (E7080) D013_r2
## 2751 -3.573575e+00                              LFM-A13 D013_r2
## 2752 -2.475535e+00                              LGK-974 D013_r2
## 2753 -3.684193e+00                  Linifanib (ABT-869) D013_r2
## 2754 -8.314087e-01                               LJH685 D013_r2
## 2755 -6.269350e+00                               LJI308 D013_r2
## 2756 -1.884595e+00               Losmapimod (GW856553X) D013_r2
## 2757  3.026600e+00                            LY2090314 D013_r2
## 2758 -2.857855e+00                            LY2157299 D013_r2
## 2759 -7.537710e-01                            LY2784544 D013_r2
## 2760 -3.875706e-01                            LY2835219 D013_r2
## 2761 -2.106568e+00                             LY294002 D013_r2
## 2762 -7.236494e-01                            LY3023414 D013_r2
## 2763 -1.435005e+00                             LY411575 D013_r2
## 2764  4.930611e-01       MEK162 (ARRY-162, ARRY-438162) D013_r2
## 2765 -3.106631e+00                             MGCD-265 D013_r2
## 2766  2.883137e+00               Milciclib (PHA-848125) D013_r2
## 2767 -1.637671e+00                              MK-0752 D013_r2
## 2768 -1.015326e+00                         MK-2206 2HCl D013_r2
## 2769 -6.428966e-01                              MK-2461 D013_r2
## 2770  1.513976e+00                     MK-5108 (VX-689) D013_r2
## 2771  1.739133e+00                              MK-8745 D013_r2
## 2772 -4.931692e-02                              MLN2480 D013_r2
## 2773 -2.020893e+00                              MLN8054 D013_r2
## 2774 -7.503620e+00      Motesanib Diphosphate (AMG-706) D013_r2
## 2775 -3.433100e+00                  Nilotinib (AMN-107) D013_r2
## 2776 -3.835408e+00     Nintedanib (BIBF 1120)_uncertain D013_r2
## 2777 -2.508146e+00                               NU6027 D013_r2
## 2778 -3.745431e+00                           NVP-AEW541 D013_r2
## 2779 -1.294103e+00                           NVP-BHG712 D013_r2
## 2780 -7.491540e-01                      NVP-BSK805 2HCl D013_r2
## 2781 -5.944951e-01                           NVP-BVU972 D013_r2
## 2782 -2.877813e+00                          Oclacitinib D013_r2
## 2783 -1.458253e+00      Olmutinib (HM61713, BI 1482694) D013_r2
## 2784 -2.777192e+00                             ONO-4059 D013_r2
## 2785 -6.301476e+00                              OSI-027 D013_r2
## 2786  4.095975e-02                              OSI-420 D013_r2
## 2787  1.274870e+00                 OSI-906 (Linsitinib) D013_r2
## 2788  4.345827e+00                              P276-00 D013_r2
## 2789  2.559205e+00                  Pacritinib (SB1518) D013_r2
## 2790 -1.883381e+00                   Palomid 529 (P529) D013_r2
## 2791 -5.891396e+00                            Pazopanib D013_r2
## 2792 -3.701369e+00                        Pazopanib HCl D013_r2
## 2793 -7.802449e-01                            PD0325901 D013_r2
## 2794  2.540250e-01                             PD168393 D013_r2
## 2795 -9.644813e-01                             PD173955 D013_r2
## 2796 -4.373768e-01                   PD184352 (CI-1040) D013_r2
## 2797  1.110583e+00                             PD318088 D013_r2
## 2798 -1.854425e+00                              PD98059 D013_r2
## 2799 -1.130962e+00                  Pelitinib (EKB-569) D013_r2
## 2800  3.826611e+00                          PF-00562271 D013_r2
## 2801 -1.154718e-01                          PF-04217903 D013_r2
## 2802  7.375393e-04                          PF-04691502 D013_r2
## 2803  3.224600e+00                            PF-431396 D013_r2
## 2804 -2.011153e+00                           PF-4708671 D013_r2
## 2805 -1.119552e+00                           PF-5274857 D013_r2
## 2806  4.256920e+00                            PF-562271 D013_r2
## 2807 -2.313661e+00                            PF-573228 D013_r2
## 2808 -1.352607e+00                            PH-797804 D013_r2
## 2809 -1.083676e+00                           PHA-665752 D013_r2
## 2810 -1.085996e+00                           PHA-680632 D013_r2
## 2811  2.911679e+00                           PHA-767491 D013_r2
## 2812 -1.554492e-01                           PHA-793887 D013_r2
## 2813 -2.657070e+00                       Phenformin HCl D013_r2
## 2814 -1.874732e+00                              PHT-427 D013_r2
## 2815 -1.519889e-01                          Piceatannol D013_r2
## 2816 -2.025944e+00                              PIK-293 D013_r2
## 2817 -1.186989e+00                              PIK-294 D013_r2
## 2818 -1.913636e+00                               PIK-93 D013_r2
## 2819 -8.372453e-01               Pimasertib (AS-703026) D013_r2
## 2820 -2.053119e+00                          Pirfenidone D013_r2
## 2821 -1.406962e+00                             PLX-4720 D013_r2
## 2822  2.286007e-02                              PLX7904 D013_r2
## 2823 -1.394855e+00                  Ponatinib (AP24534) D013_r2
## 2824 -5.351355e-01                                  PP1 D013_r2
## 2825 -2.390841e+00                                  PP2 D013_r2
## 2826 -6.031194e-01                                PP242 D013_r2
## 2827 -6.060661e-01                               PQ 401 D013_r2
## 2828 -2.146740e+00                              PRI-724 D013_r2
## 2829 -1.021351e+00     PRT062607 (P505-15, BIIB057) HCl D013_r2
## 2830  1.633170e-01                         Purvalanol A D013_r2
## 2831 -1.755281e+00                            Quercetin D013_r2
## 2832  2.087117e-01                  Quizartinib (AC220) D013_r2
## 2833 -3.585362e+00                                 R406 D013_r2
## 2834 -3.320715e+00                     R406 (free base) D013_r2
## 2835  3.505016e+00                                 R547 D013_r2
## 2836 -2.852143e-02                    RAF265 (CHIR-265) D013_r2
## 2837 -3.207670e+00                Rapamycin (Sirolimus) D013_r2
## 2838 -7.693064e-01   Refametinib (RDEA119, Bay 86-9766) D013_r2
## 2839 -1.192155e+00                               RepSox D013_r2
## 2840 -1.153117e+00 Ridaforolimus (Deforolimus, MK-8669) D013_r2
## 2841 -4.404274e-01                Rigosertib (ON-01910) D013_r2
## 2842 -1.799779e+00                             RKI-1447 D013_r2
## 2843 -5.977841e-01                                RN486 D013_r2
## 2844  1.945604e+00                  Ro 31-8220 Mesylate D013_r2
## 2845 -2.436430e+00                              Ro-3306 D013_r2
## 2846  3.159141e+00                               Ro3280 D013_r2
## 2847 -1.499019e+00                            RO4929097 D013_r2
## 2848 -1.513324e+00      Roscovitine (Seliciclib,CYC202) D013_r2
## 2849 -2.710530e+00             Ruxolitinib (INCB018424) D013_r2
## 2850 -2.236929e+00           S-Ruxolitinib (INCB018424) D013_r2
## 2851 -2.048132e+00                               SANT-1 D013_r2
## 2852 -1.265010e+00                            SAR131675 D013_r2
## 2853 -3.422559e+00                    SAR245409 (XL765) D013_r2
## 2854  1.510915e-01                Saracatinib (AZD0530) D013_r2
## 2855 -4.564343e+00                      SB202190 (FHPI) D013_r2
## 2856 -2.753644e+00                             SB203580 D013_r2
## 2857 -7.222774e-01                             SB216763 D013_r2
## 2858 -5.030261e+00                             SB239063 D013_r2
## 2859 -2.185055e+00                             SB415286 D013_r2
## 2860 -2.000531e+00                             SB431542 D013_r2
## 2861 -2.346466e+00                             SB505124 D013_r2
## 2862 -1.890625e+00                             SB525334 D013_r2
## 2863 -3.792569e+00                             SB590885 D013_r2
## 2864  3.315728e+00                                  SC1 D013_r2
## 2865 -2.524774e+00                Schisandrin B (Sch B) D013_r2
## 2866 -2.953700e+00                Selumetinib (AZD6244) D013_r2
## 2867 -2.001854e+00              Semagacestat (LY450139) D013_r2
## 2868  2.271057e-01                   Semaxanib (SU5416) D013_r2
## 2869  3.759497e-01                             SGI-7079 D013_r2
## 2870  4.854666e-01                          Skepinone-L D013_r2
## 2871 -2.534685e+00                               SL-327 D013_r2
## 2872  4.209959e-01                 SNS-032 (BMS-387032) D013_r2
## 2873  6.235872e-01                     SNS-314 Mesylate D013_r2
## 2874 -3.164750e+00                            Sorafenib D013_r2
## 2875 -1.024775e+00                   Sorafenib Tosylate D013_r2
## 2876 -4.717086e-01                         Sotrastaurin D013_r2
## 2877 -4.301369e+00                             SP600125 D013_r2
## 2878 -3.088318e+00                              SU11274 D013_r2
## 2879  2.129963e+00                               SU6656 D013_r2
## 2880 -9.946635e-01                               SU9516 D013_r2
## 2881 -2.530922e+00                     Sunitinib Malate D013_r2
## 2882  3.448019e+00                  TAE226 (NVP-TAE226) D013_r2
## 2883  3.232161e-02                              TAK-285 D013_r2
## 2884 -4.590651e-01                              TAK-632 D013_r2
## 2885 -3.964374e+00                              TAK-715 D013_r2
## 2886 -3.157528e+00                              TAK-733 D013_r2
## 2887  4.791397e+00                              TAK-901 D013_r2
## 2888 -2.355515e+00                Taladegib (LY2940680) D013_r2
## 2889 -2.742580e+00                              TCS 359 D013_r2
## 2890 -3.371984e+00                               TDZD-8 D013_r2
## 2891 -3.204486e+00                            Telatinib D013_r2
## 2892 -2.221050e+00   Temsirolimus (CCI-779, NSC 683864) D013_r2
## 2893  2.775064e+00              Tepotinib (EMD 1214063) D013_r2
## 2894 -2.074391e+00                                TG003 D013_r2
## 2895 -2.061732e+00                            TG100-115 D013_r2
## 2896  1.196124e+00                             TG101209 D013_r2
## 2897  1.593336e+00                 TG101348 (SAR302503) D013_r2
## 2898 -2.687086e+00                              TGX-221 D013_r2
## 2899 -2.016378e+00                         Theophylline D013_r2
## 2900 -2.174434e+00                          Thiazovivin D013_r2
## 2901 -1.691978e+00                       TIC10 Analogue D013_r2
## 2902 -2.897252e+00                           Tideglusib D013_r2
## 2903  4.055252e+00                 Tivantinib (ARQ 197) D013_r2
## 2904 -2.745481e+00                   Tivozanib (AV-951) D013_r2
## 2905 -1.615863e+00  Tofacitinib (CP-690550,Tasocitinib) D013_r2
## 2906  3.232510e-02      Tofacitinib (CP-690550) Citrate D013_r2
## 2907  2.965929e+00                              Torin 2 D013_r2
## 2908  4.236763e-01              Trametinib (GSK1120212) D013_r2
## 2909 -1.203176e+00                          Triciribine D013_r2
## 2910 -1.728800e+00           TSU-68 (SU6668, Orantinib) D013_r2
## 2911 -2.533400e+00                               TWS119 D013_r2
## 2912 -2.840534e-01                         Tyrphostin 9 D013_r2
## 2913 -4.275793e+00                   Tyrphostin AG 1296 D013_r2
## 2914 -1.792940e+00                           U0126-EtOH D013_r2
## 2915 -1.434094e+00     Ulixertinib (BVD-523, VRT752271) D013_r2
## 2916 -1.164140e+00              Uprosertib (GSK2141795) D013_r2
## 2917 -7.235772e-01                          Vacquinol-1 D013_r2
## 2918 -7.530853e-01                           Varlitinib D013_r2
## 2919 -4.223838e+00              Vatalanib (PTK787) 2HCl D013_r2
## 2920 -3.581594e+00                               VE-821 D013_r2
## 2921  4.120956e+00                               VE-822 D013_r2
## 2922 -2.472973e+00        Vemurafenib (PLX4032, RG7204) D013_r2
## 2923 -2.061951e+00                Vismodegib (GDC-0449) D013_r2
## 2924 -3.065176e+00                 Volasertib (BI 6727) D013_r2
## 2925  2.852511e+00                            VPS34-IN1 D013_r2
## 2926  9.299148e-01                     VS-5584 (SB2343) D013_r2
## 2927 -8.314873e-01                               VX-11e D013_r2
## 2928 -1.165476e+00         VX-680 (Tozasertib, MK-0457) D013_r2
## 2929 -1.257495e+00                               VX-702 D013_r2
## 2930 -3.022954e+00                               VX-745 D013_r2
## 2931 -2.990571e+00                              WAY-600 D013_r2
## 2932 -5.873655e+00                             WH-4-023 D013_r2
## 2933 -1.271444e+00                             WHI-P154 D013_r2
## 2934 -2.760412e+00                                WIKI4 D013_r2
## 2935  2.341238e+00                        Wnt agonist 1 D013_r2
## 2936 -2.387699e+00                        Wnt-C59 (C59) D013_r2
## 2937 -1.817036e+00                               WP1066 D013_r2
## 2938 -1.314046e+00                 WYE-125132 (WYE-132) D013_r2
## 2939 -4.168250e+00                              WYE-354 D013_r2
## 2940 -1.182291e+00                               WZ3146 D013_r2
## 2941 -2.536227e+00                               WZ4002 D013_r2
## 2942 -6.846473e-02                               WZ4003 D013_r2
## 2943 -2.464276e+00                               WZ8040 D013_r2
## 2944 -1.889650e+00                              XAV-939 D013_r2
## 2945 -2.291659e+00                                XL019 D013_r2
## 2946 -6.024065e-01                              XMD8-92 D013_r2
## 2947 -1.215317e+00                         Y-27632 2HCl D013_r2
## 2948 -1.822900e+00                             YM201636 D013_r2
## 2949 -2.927025e+00                             YO-01027 D013_r2
## 2950 -6.065274e-01                            ZM 306416 D013_r2
## 2951  2.979443e-01                        ZM 323881 HCl D013_r2
## 2952 -1.452287e+00                            ZM 336372 D013_r2
## 2953 -1.784398e+00                         ZM 39923 HCl D013_r2
## 2954  1.961155e-01                            ZM 447439 D013_r2
## 2955 -8.892810e-01                 Zotarolimus(ABT-578) D013_r2
## 2956 -2.429591e+00                              ZSTK474 D013_r2
## 2957  3.603617e+00                     1-Azakenpaullone D018_r1
## 2958  3.087915e+00                      3-Methyladenine D018_r1
## 2959  7.902725e+00                             A-674563 D018_r1
## 2960  1.791362e+00                             A-769662 D018_r1
## 2961 -1.611894e-01                                  A66 D018_r1
## 2962  7.176090e-01                            Acadesine D018_r1
## 2963  4.125270e+00                  AEE788 (NVP-AEE788) D018_r1
## 2964 -1.450693e+00        Afatinib (BIBW2992)_uncertain D018_r1
## 2965 -9.473564e-01                              AG-1024 D018_r1
## 2966  3.159117e+00         AG-1478 (Tyrphostin AG-1478) D018_r1
## 2967  6.324285e-01                                AG-18 D018_r1
## 2968 -3.032321e-01              AG-490 (Tyrphostin B42) D018_r1
## 2969  2.551543e+00                             Akti-1/2 D018_r1
## 2970  3.462642e+00                  Alisertib (MLN8237) D018_r1
## 2971  5.099667e-01                              AMG 337 D018_r1
## 2972  1.204536e+00                              AMG-458 D018_r1
## 2973  5.085684e+00                              AMG-900 D018_r1
## 2974  2.440470e+00                               AMG319 D018_r1
## 2975  2.127520e+00                  Amuvatinib (MP-470) D018_r1
## 2976  3.619657e+00                             Apatinib D018_r1
## 2977  2.838400e-01                           AR-A014418 D018_r1
## 2978  8.843726e-01                            AS-252424 D018_r1
## 2979  8.865556e-01                            AS-604850 D018_r1
## 2980  8.140079e-01                         Asiatic Acid D018_r1
## 2981  1.485983e-01                             AST-1306 D018_r1
## 2982  2.564163e+00                              AT13148 D018_r1
## 2983  8.166765e+00                               AT7519 D018_r1
## 2984  1.650496e+00                               AT7867 D018_r1
## 2985  7.931156e+00                               AT9283 D018_r1
## 2986  1.114578e+00                 Aurora A Inhibitor I D018_r1
## 2987  1.452448e-01             Avagacestat (BMS-708163) D018_r1
## 2988  2.232725e-01                              AVL-292 D018_r1
## 2989  1.107080e+00                             Axitinib D018_r1
## 2990  1.107080e+00                             Axitinib D018_r1
## 2991 -1.635081e+00                               AZ 628 D018_r1
## 2992  7.041760e+00                               AZ 960 D018_r1
## 2993  3.814031e+00                                 AZ20 D018_r1
## 2994  5.788854e+00                              AZD1080 D018_r1
## 2995  2.978997e+00                              AZD1480 D018_r1
## 2996  3.693756e+00                              AZD2014 D018_r1
## 2997  5.064169e+00                              AZD2858 D018_r1
## 2998 -8.592205e-01                              AZD2932 D018_r1
## 2999  2.530175e+00                              AZD3759 D018_r1
## 3000  4.682246e+00                              AZD5363 D018_r1
## 3001  8.530079e+00                              AZD5438 D018_r1
## 3002  2.667092e+00                              AZD6482 D018_r1
## 3003 -9.091748e-02                              AZD6738 D018_r1
## 3004  5.137804e+00                              AZD8055 D018_r1
## 3005  3.359029e-01                              AZD8330 D018_r1
## 3006  1.427543e+00                  AZD8931 (Sapitinib) D018_r1
## 3007  4.549919e+00                              AZD9291 D018_r1
## 3008  2.152812e+00            Barasertib (AZD1152-HQPA) D018_r1
## 3009  1.740942e+00  Baricitinib (LY3009104, INCB028050) D018_r1
## 3010  7.336009e+00                  BGT226 (NVP-BGT226) D018_r1
## 3011  4.906754e+00                              BI 2536 D018_r1
## 3012 -1.213907e+00                              BI-78D3 D018_r1
## 3013 -3.094755e-01                             BI-D1870 D018_r1
## 3014 -7.514154e-01                              Bikinin D018_r1
## 3015  3.646461e+00                                  BIO D018_r1
## 3016  6.115131e-01               BIRB 796 (Doramapimod) D018_r1
## 3017 -3.328510e-01                            BIX 02188 D018_r1
## 3018  2.088847e+00                            BIX 02189 D018_r1
## 3019  4.126634e+00      BKM120 (NVP-BKM120, Buparlisib) D018_r1
## 3020  2.245478e+00                           BMS-265246 D018_r1
## 3021  3.021949e+00                           BMS-536924 D018_r1
## 3022 -3.895394e+00                           BMS-582949 D018_r1
## 3023  5.496055e+00                           BMS-754807 D018_r1
## 3024  1.623504e+00                           BMS-777607 D018_r1
## 3025  2.479041e+00                           BMS-794833 D018_r1
## 3026  1.233110e+00                           BMS-833923 D018_r1
## 3027 -3.657727e-01                  Bosutinib (SKI-606) D018_r1
## 3028  3.575659e+00                Brivanib (BMS-540215) D018_r1
## 3029 -1.313949e+00      Brivanib Alaninate (BMS-582664) D018_r1
## 3030  2.402328e+00                           BS-181 HCl D018_r1
## 3031  1.212414e+00                               Butein D018_r1
## 3032 -1.605342e-01                               BYL719 D018_r1
## 3033  6.382764e-01     Cabozantinib (XL184, BMS-907351) D018_r1
## 3034  3.237220e+00          Cabozantinib malate (XL184) D018_r1
## 3035 -3.998133e-01        CAL-101 (Idelalisib, GS-1101) D018_r1
## 3036  2.163912e+00                             CAY10505 D018_r1
## 3037  3.478084e+00                               CC-223 D018_r1
## 3038  1.333041e+00                            CCT128930 D018_r1
## 3039  1.533042e+00                  Cediranib (AZD2171) D018_r1
## 3040  7.979475e-01                            CEP-32496 D018_r1
## 3041  2.636980e+00                            CEP-33779 D018_r1
## 3042  7.184744e-01                              CGI1746 D018_r1
## 3043  1.048414e+00                              CGK 733 D018_r1
## 3044  2.526801e+00                            CH5132799 D018_r1
## 3045  8.598886e+00                           CHIR-98014 D018_r1
## 3046  2.633762e+00                 CHIR-99021 (CT99021) D018_r1
## 3047  3.141685e+00             CHIR-99021 (CT99021) HCl D018_r1
## 3048  6.863116e-02                    Chrysophanic Acid D018_r1
## 3049  3.443013e+00                             CNX-2006 D018_r1
## 3050  7.694948e-01                              CNX-774 D018_r1
## 3051  2.216644e+00                    CO-1686 (AVL-301) D018_r1
## 3052  6.377500e-01       Cobimetinib (GDC-0973, RG7420) D018_r1
## 3053  6.002103e+00                            CP-673451 D018_r1
## 3054 -1.419685e+00                            CP-724714 D018_r1
## 3055  6.339320e+00               Crenolanib (CP-868596) D018_r1
## 3056  3.321669e+00             Crizotinib (PF-02341066) D018_r1
## 3057  1.556935e+00                               CYC116 D018_r1
## 3058  2.638491e+00                               CYT387 D018_r1
## 3059 -1.718349e-01                             CZC24832 D018_r1
## 3060  1.724163e+00              Dabrafenib (GSK2118436) D018_r1
## 3061  4.237441e+00        Dacomitinib (PF299804, PF299) D018_r1
## 3062  8.164865e+00              Danusertib (PHA-739358) D018_r1
## 3063  8.430472e-01                        DAPT (GSI-IX) D018_r1
## 3064  4.508018e+00                            Dasatinib D018_r1
## 3065  1.540667e+00                DCC-2036 (Rebastinib) D018_r1
## 3066  7.945779e-01                Decernotinib (VX-509) D018_r1
## 3067  8.151757e+00               Dinaciclib (SCH727965) D018_r1
## 3068  3.417961e+00    Dovitinib (TKI-258) Dilactic Acid D018_r1
## 3069  2.452088e+00                            ENMD-2076 D018_r1
## 3070  3.123814e+00               Enzastaurin (LY317615) D018_r1
## 3071  3.331981e+00                            ERK5-IN-1 D018_r1
## 3072 -3.937513e-01                             ETC-1002 D018_r1
## 3073  2.711013e+00                            ETP-46464 D018_r1
## 3074  1.219764e+00                  Everolimus (RAD001) D018_r1
## 3075 -3.578782e-01                Fasudil (HA-1077) HCl D018_r1
## 3076  6.825270e+00                                FH535 D018_r1
## 3077  1.909502e+00                Filgotinib (GLPG0634) D018_r1
## 3078  8.089051e+00             Flavopiridol (Alvocidib) D018_r1
## 3079  7.698289e+00                     Flavopiridol HCl D018_r1
## 3080  2.759328e+00               Foretinib (GSK1363089) D018_r1
## 3081  4.384078e+00                  Fostamatinib (R788) D018_r1
## 3082  1.155147e+00                                G-749 D018_r1
## 3083  5.944454e+00                             GDC-0068 D018_r1
## 3084  3.200451e+00                             GDC-0349 D018_r1
## 3085  1.654867e+00                             GDC-0879 D018_r1
## 3086  5.053313e-01                             GDC-0941 D018_r1
## 3087  1.736653e+00                    GDC-0980 (RG7422) D018_r1
## 3088  2.621630e+00                   Gefitinib (ZD1839) D018_r1
## 3089 -1.235117e+00                            Genistein D018_r1
## 3090  4.000988e+00                            GF109203X D018_r1
## 3091  3.563199e-01                                GNF-2 D018_r1
## 3092  3.196237e+00                                GNF-5 D018_r1
## 3093  2.525997e+00                              Go 6983 D018_r1
## 3094  2.548734e+00                   Golvatinib (E7050) D018_r1
## 3095  4.716890e-01                          GSK1838705A D018_r1
## 3096  4.196730e+00                          GSK1904529A D018_r1
## 3097  5.820621e+00                  GSK2126458 (GSK458) D018_r1
## 3098  5.312375e-01                           GSK2292767 D018_r1
## 3099  1.120482e+00                           GSK2636771 D018_r1
## 3100  4.607997e-01                           GSK429286A D018_r1
## 3101  4.068933e+00                            GSK461364 D018_r1
## 3102  6.835108e-01                               GSK621 D018_r1
## 3103  2.243148e+00                            GSK690693 D018_r1
## 3104  3.408845e-01                               GW5074 D018_r1
## 3105  6.781150e-02                             GW788388 D018_r1
## 3106  5.837370e+00                               GZD824 D018_r1
## 3107  3.226700e+00                            H 89 2HCl D018_r1
## 3108  5.835389e+00                           Hesperadin D018_r1
## 3109  6.342356e+00                              HMN-214 D018_r1
## 3110  5.918309e-01                             Honokiol D018_r1
## 3111  2.404957e+00                               HS-173 D018_r1
## 3112  1.256953e+00                           HTH-01-015 D018_r1
## 3113  2.920041e+00                Ibrutinib (PCI-32765) D018_r1
## 3114  1.682013e+00                              ICG-001 D018_r1
## 3115 -1.218680e+00                             Icotinib D018_r1
## 3116 -1.256480e+00                                IM-12 D018_r1
## 3117  1.873118e+00           Imatinib Mesylate (STI571) D018_r1
## 3118  4.383204e+00                            Indirubin D018_r1
## 3119  2.942347e+00                    INK 128 (MLN0128) D018_r1
## 3120  1.768374e+00                    IPI-145 (INK1197) D018_r1
## 3121  3.621621e-01                               IWP-L6 D018_r1
## 3122 -4.206399e-02                           IWR-1-endo D018_r1
## 3123 -1.712488e+00                         JNJ-38877605 D018_r1
## 3124  6.546742e+00                          JNJ-7706621 D018_r1
## 3125  4.970766e+00                     JNK Inhibitor IX D018_r1
## 3126  6.987961e+00                             JNK-IN-8 D018_r1
## 3127 -1.955339e+00                               K02288 D018_r1
## 3128  2.177459e+00                               Ki8751 D018_r1
## 3129  1.462788e+00                              KRN 633 D018_r1
## 3130  1.501847e+00                           KU-0063794 D018_r1
## 3131 -1.164354e+00      KU-55933 (ATM Kinase Inhibitor) D018_r1
## 3132  1.270004e+00                             KU-60019 D018_r1
## 3133  6.299017e+00                              KW-2449 D018_r1
## 3134  5.000241e+00                              KX2-391 D018_r1
## 3135  9.829721e-01                              KY02111 D018_r1
## 3136 -3.019817e-01                            Lapatinib D018_r1
## 3137 -8.918335e-01     Lapatinib (GW-572016) Ditosylate D018_r1
## 3138  6.391094e+00                            LDC000067 D018_r1
## 3139  8.091775e-01      LDE225 (NVP-LDE225,Erismodegib) D018_r1
## 3140  1.540079e+00                           LDN-214117 D018_r1
## 3141  3.259451e+00                   Lenvatinib (E7080) D018_r1
## 3142 -4.375745e-01                              LFM-A13 D018_r1
## 3143 -9.679589e-01                              LGK-974 D018_r1
## 3144  4.734113e-01                  Linifanib (ABT-869) D018_r1
## 3145  2.148624e+00                               LJH685 D018_r1
## 3146  1.462578e+00                               LJI308 D018_r1
## 3147  2.171764e+00               Losmapimod (GW856553X) D018_r1
## 3148  5.723893e+00                            LY2090314 D018_r1
## 3149  3.108909e-01                            LY2157299 D018_r1
## 3150  1.539792e+00                            LY2784544 D018_r1
## 3151  2.539230e+00                            LY2835219 D018_r1
## 3152  2.294821e+00                             LY294002 D018_r1
## 3153  4.900913e+00                            LY3023414 D018_r1
## 3154  1.737756e+00                             LY411575 D018_r1
## 3155 -2.041087e-01       MEK162 (ARRY-162, ARRY-438162) D018_r1
## 3156 -2.603230e-01                             MGCD-265 D018_r1
## 3157  4.581459e+00               Milciclib (PHA-848125) D018_r1
## 3158  8.413818e-01                              MK-0752 D018_r1
## 3159  2.151996e+00                         MK-2206 2HCl D018_r1
## 3160  1.654318e-01                              MK-2461 D018_r1
## 3161  4.477131e+00                     MK-5108 (VX-689) D018_r1
## 3162  4.754726e+00                              MK-8745 D018_r1
## 3163  6.038423e-01                              MLN2480 D018_r1
## 3164  8.430886e-01                              MLN8054 D018_r1
## 3165  2.531207e+00      Motesanib Diphosphate (AMG-706) D018_r1
## 3166  2.580335e+00                  Nilotinib (AMN-107) D018_r1
## 3167 -4.992425e-01     Nintedanib (BIBF 1120)_uncertain D018_r1
## 3168 -1.694756e-01                               NU6027 D018_r1
## 3169  4.387169e+00                           NVP-AEW541 D018_r1
## 3170  4.536139e-01                           NVP-BHG712 D018_r1
## 3171  1.297321e+00                      NVP-BSK805 2HCl D018_r1
## 3172  1.188819e-01                           NVP-BVU972 D018_r1
## 3173  6.384790e-01                          Oclacitinib D018_r1
## 3174  5.443577e-01      Olmutinib (HM61713, BI 1482694) D018_r1
## 3175  3.193651e+00                             ONO-4059 D018_r1
## 3176  2.022345e+00                              OSI-027 D018_r1
## 3177  1.023075e+00                              OSI-420 D018_r1
## 3178  3.554151e+00                 OSI-906 (Linsitinib) D018_r1
## 3179  7.870301e+00                              P276-00 D018_r1
## 3180  6.012621e+00                  Pacritinib (SB1518) D018_r1
## 3181  1.197936e+00                   Palomid 529 (P529) D018_r1
## 3182 -9.651572e-01                            Pazopanib D018_r1
## 3183  1.199033e+00                        Pazopanib HCl D018_r1
## 3184  2.591403e+00                            PD0325901 D018_r1
## 3185  2.865278e+00                             PD168393 D018_r1
## 3186  3.768068e+00                             PD173955 D018_r1
## 3187  1.808417e-01                   PD184352 (CI-1040) D018_r1
## 3188 -1.430639e+00                             PD318088 D018_r1
## 3189 -6.872424e-02                              PD98059 D018_r1
## 3190  1.962660e+00                  Pelitinib (EKB-569) D018_r1
## 3191  6.560025e+00                          PF-00562271 D018_r1
## 3192  2.708283e+00                          PF-04217903 D018_r1
## 3193  6.701647e+00                          PF-04691502 D018_r1
## 3194  6.062071e+00                            PF-431396 D018_r1
## 3195  7.345780e+00                           PF-4708671 D018_r1
## 3196  2.369868e+00                           PF-5274857 D018_r1
## 3197  8.095119e+00                            PF-562271 D018_r1
## 3198  2.486004e+00                            PF-573228 D018_r1
## 3199  4.537256e-01                            PH-797804 D018_r1
## 3200  1.883797e+00                           PHA-665752 D018_r1
## 3201  4.595322e+00                           PHA-680632 D018_r1
## 3202  9.187643e+00                           PHA-767491 D018_r1
## 3203  7.577666e+00                           PHA-793887 D018_r1
## 3204 -1.226155e-01                       Phenformin HCl D018_r1
## 3205  1.827272e-01                              PHT-427 D018_r1
## 3206  4.225913e+00                          Piceatannol D018_r1
## 3207 -3.713103e-01                              PIK-293 D018_r1
## 3208  2.663634e-01                              PIK-294 D018_r1
## 3209  7.193016e+00                               PIK-93 D018_r1
## 3210 -8.206210e-01               Pimasertib (AS-703026) D018_r1
## 3211  9.386452e-01                          Pirfenidone D018_r1
## 3212  3.715839e+00                             PLX-4720 D018_r1
## 3213 -1.314938e+00                              PLX7904 D018_r1
## 3214  1.484656e+00                  Ponatinib (AP24534) D018_r1
## 3215  3.557990e+00                                  PP1 D018_r1
## 3216  3.017860e+00                                  PP2 D018_r1
## 3217  1.758990e+00                                PP242 D018_r1
## 3218  4.582686e+00                               PQ 401 D018_r1
## 3219  5.406493e-01                              PRI-724 D018_r1
## 3220  6.382939e+00     PRT062607 (P505-15, BIIB057) HCl D018_r1
## 3221  5.441032e+00                         Purvalanol A D018_r1
## 3222  5.221800e-01                            Quercetin D018_r1
## 3223  2.711529e+00                  Quizartinib (AC220) D018_r1
## 3224  1.570043e+00                                 R406 D018_r1
## 3225  4.142507e+00                     R406 (free base) D018_r1
## 3226  8.248057e+00                                 R547 D018_r1
## 3227  2.197229e+00                    RAF265 (CHIR-265) D018_r1
## 3228  1.044114e+00                Rapamycin (Sirolimus) D018_r1
## 3229  3.151601e+00   Refametinib (RDEA119, Bay 86-9766) D018_r1
## 3230  8.195835e-01                               RepSox D018_r1
## 3231  2.024925e+00 Ridaforolimus (Deforolimus, MK-8669) D018_r1
## 3232  4.826469e+00                Rigosertib (ON-01910) D018_r1
## 3233  1.035810e+00                             RKI-1447 D018_r1
## 3234  1.200115e+00                                RN486 D018_r1
## 3235  9.779089e+00                  Ro 31-8220 Mesylate D018_r1
## 3236  8.575826e-02                              Ro-3306 D018_r1
## 3237  3.921414e+00                               Ro3280 D018_r1
## 3238  6.614206e-02                            RO4929097 D018_r1
## 3239  1.299649e+00      Roscovitine (Seliciclib,CYC202) D018_r1
## 3240  2.956273e+00             Ruxolitinib (INCB018424) D018_r1
## 3241  1.911464e-01           S-Ruxolitinib (INCB018424) D018_r1
## 3242  2.909771e+00                               SANT-1 D018_r1
## 3243  2.475808e-01                            SAR131675 D018_r1
## 3244 -7.630540e-01                    SAR245409 (XL765) D018_r1
## 3245  5.582066e+00                Saracatinib (AZD0530) D018_r1
## 3246  1.701111e+00                      SB202190 (FHPI) D018_r1
## 3247  1.358537e+00                             SB203580 D018_r1
## 3248  1.966535e+00                             SB216763 D018_r1
## 3249  3.724066e+00                             SB239063 D018_r1
## 3250  3.198165e-01                             SB415286 D018_r1
## 3251  3.027901e-01                             SB431542 D018_r1
## 3252  2.201766e+00                             SB505124 D018_r1
## 3253  1.359262e+00                             SB525334 D018_r1
## 3254  9.022284e-01                             SB590885 D018_r1
## 3255  7.306135e+00                                  SC1 D018_r1
## 3256  5.395864e-01                Schisandrin B (Sch B) D018_r1
## 3257 -2.949941e+00                Selumetinib (AZD6244) D018_r1
## 3258  5.809104e-01              Semagacestat (LY450139) D018_r1
## 3259  3.336724e+00                   Semaxanib (SU5416) D018_r1
## 3260  1.568782e+00                             SGI-7079 D018_r1
## 3261  3.152211e-02                          Skepinone-L D018_r1
## 3262  5.405627e-01                               SL-327 D018_r1
## 3263  1.073725e+01                 SNS-032 (BMS-387032) D018_r1
## 3264  4.072932e+00                     SNS-314 Mesylate D018_r1
## 3265  1.546680e-01                            Sorafenib D018_r1
## 3266  2.142834e+00                   Sorafenib Tosylate D018_r1
## 3267  2.851465e+00                         Sotrastaurin D018_r1
## 3268  3.287619e+00                             SP600125 D018_r1
## 3269 -1.603824e+00                              SU11274 D018_r1
## 3270  3.362705e+00                               SU6656 D018_r1
## 3271  4.022338e+00                               SU9516 D018_r1
## 3272  2.619933e+00                     Sunitinib Malate D018_r1
## 3273  3.263341e+00                  TAE226 (NVP-TAE226) D018_r1
## 3274  2.263731e-01                              TAK-285 D018_r1
## 3275  2.889169e-01                              TAK-632 D018_r1
## 3276 -2.511594e-01                              TAK-715 D018_r1
## 3277 -2.177534e-01                              TAK-733 D018_r1
## 3278  3.335873e+00                              TAK-901 D018_r1
## 3279 -8.761709e-01                Taladegib (LY2940680) D018_r1
## 3280  6.392484e-01                              TCS 359 D018_r1
## 3281  9.396792e-01                               TDZD-8 D018_r1
## 3282  6.241454e-02                            Telatinib D018_r1
## 3283  1.356569e+00   Temsirolimus (CCI-779, NSC 683864) D018_r1
## 3284  3.619670e+00              Tepotinib (EMD 1214063) D018_r1
## 3285  2.122859e-01                                TG003 D018_r1
## 3286  1.729206e+00                            TG100-115 D018_r1
## 3287  5.845557e+00                             TG101209 D018_r1
## 3288  4.487269e+00                 TG101348 (SAR302503) D018_r1
## 3289  3.070541e+00                              TGX-221 D018_r1
## 3290 -8.327994e-01                         Theophylline D018_r1
## 3291  6.265571e-01                          Thiazovivin D018_r1
## 3292  7.017015e-01                       TIC10 Analogue D018_r1
## 3293 -3.957463e-01                           Tideglusib D018_r1
## 3294  2.345480e+00                 Tivantinib (ARQ 197) D018_r1
## 3295  1.022163e+00                   Tivozanib (AV-951) D018_r1
## 3296 -3.313777e-01  Tofacitinib (CP-690550,Tasocitinib) D018_r1
## 3297  2.075971e-01      Tofacitinib (CP-690550) Citrate D018_r1
## 3298  6.708016e+00                              Torin 2 D018_r1
## 3299  6.184229e-01              Trametinib (GSK1120212) D018_r1
## 3300  4.052512e+00                          Triciribine D018_r1
## 3301 -3.915838e-01           TSU-68 (SU6668, Orantinib) D018_r1
## 3302 -7.674843e-02                               TWS119 D018_r1
## 3303  3.181333e+00                         Tyrphostin 9 D018_r1
## 3304  4.307872e-01                   Tyrphostin AG 1296 D018_r1
## 3305  5.955632e-01                           U0126-EtOH D018_r1
## 3306 -1.862962e+00     Ulixertinib (BVD-523, VRT752271) D018_r1
## 3307  6.711315e+00              Uprosertib (GSK2141795) D018_r1
## 3308  4.083619e+00                          Vacquinol-1 D018_r1
## 3309  8.415386e-01                           Varlitinib D018_r1
## 3310  3.402022e+00              Vatalanib (PTK787) 2HCl D018_r1
## 3311 -1.823925e+00                               VE-821 D018_r1
## 3312  2.588360e+00                               VE-822 D018_r1
## 3313 -1.829345e+00        Vemurafenib (PLX4032, RG7204) D018_r1
## 3314  1.023062e+00                Vismodegib (GDC-0449) D018_r1
## 3315  9.669953e-01                 Volasertib (BI 6727) D018_r1
## 3316  6.525054e+00                            VPS34-IN1 D018_r1
## 3317  3.985050e+00                     VS-5584 (SB2343) D018_r1
## 3318  1.232013e+00                               VX-11e D018_r1
## 3319  3.113365e-01         VX-680 (Tozasertib, MK-0457) D018_r1
## 3320 -6.447585e-01                               VX-702 D018_r1
## 3321  2.871353e+00                               VX-745 D018_r1
## 3322  2.527764e+00                              WAY-600 D018_r1
## 3323  1.536023e+00                             WH-4-023 D018_r1
## 3324  5.657826e-01                             WHI-P154 D018_r1
## 3325  8.722649e-01                                WIKI4 D018_r1
## 3326  3.372266e+00                        Wnt agonist 1 D018_r1
## 3327 -1.047827e+00                        Wnt-C59 (C59) D018_r1
## 3328  1.623813e+00                               WP1066 D018_r1
## 3329  3.008860e+00                 WYE-125132 (WYE-132) D018_r1
## 3330  4.924999e-01                              WYE-354 D018_r1
## 3331  1.372252e-02                               WZ3146 D018_r1
## 3332  9.300405e-01                               WZ4002 D018_r1
## 3333 -2.326941e-01                               WZ4003 D018_r1
## 3334 -1.864864e+00                               WZ8040 D018_r1
## 3335  1.976882e-01                              XAV-939 D018_r1
## 3336  2.040191e+00                                XL019 D018_r1
## 3337 -1.720136e+00                              XMD8-92 D018_r1
## 3338  5.736970e-01                         Y-27632 2HCl D018_r1
## 3339  2.352972e+00                             YM201636 D018_r1
## 3340  8.334479e-01                             YO-01027 D018_r1
## 3341  2.550482e+00                            ZM 306416 D018_r1
## 3342  1.202863e-01                        ZM 323881 HCl D018_r1
## 3343  1.039732e+00                            ZM 336372 D018_r1
## 3344  6.332191e-02                         ZM 39923 HCl D018_r1
## 3345  2.248494e+00                            ZM 447439 D018_r1
## 3346  1.232190e+00                 Zotarolimus(ABT-578) D018_r1
## 3347  2.177469e+00                              ZSTK474 D018_r1
## 3348  3.833040e-01                     1-Azakenpaullone D018_r2
## 3349  8.170803e-01                      3-Methyladenine D018_r2
## 3350  2.549872e+00                             A-674563 D018_r2
## 3351  7.862236e-02                             A-769662 D018_r2
## 3352  3.139209e+00                                  A66 D018_r2
## 3353  4.578753e-01                            Acadesine D018_r2
## 3354  9.708590e-01                  AEE788 (NVP-AEE788) D018_r2
## 3355 -4.347750e-01        Afatinib (BIBW2992)_uncertain D018_r2
## 3356 -7.308607e-01                              AG-1024 D018_r2
## 3357 -5.718700e-01         AG-1478 (Tyrphostin AG-1478) D018_r2
## 3358  6.437393e-01                                AG-18 D018_r2
## 3359 -7.741636e-01              AG-490 (Tyrphostin B42) D018_r2
## 3360 -8.100210e-01                             Akti-1/2 D018_r2
## 3361  7.158617e-01                  Alisertib (MLN8237) D018_r2
## 3362 -1.149537e+00                              AMG 337 D018_r2
## 3363  4.867391e-01                              AMG-458 D018_r2
## 3364  2.274716e+00                              AMG-900 D018_r2
## 3365  5.897566e-01                               AMG319 D018_r2
## 3366 -1.823146e+00                  Amuvatinib (MP-470) D018_r2
## 3367 -2.889761e-01                             Apatinib D018_r2
## 3368  3.383542e-01                           AR-A014418 D018_r2
## 3369 -1.716630e+00                            AS-252424 D018_r2
## 3370  1.467465e+00                            AS-604850 D018_r2
## 3371  7.734508e-01                         Asiatic Acid D018_r2
## 3372 -1.055590e+00                             AST-1306 D018_r2
## 3373 -1.413039e-01                              AT13148 D018_r2
## 3374  2.989907e+00                               AT7519 D018_r2
## 3375 -1.760896e+00                               AT7867 D018_r2
## 3376  3.189378e+00                               AT9283 D018_r2
## 3377  7.661344e-01                 Aurora A Inhibitor I D018_r2
## 3378  1.835563e-01             Avagacestat (BMS-708163) D018_r2
## 3379  7.203934e-01                              AVL-292 D018_r2
## 3380  1.312794e-01                             Axitinib D018_r2
## 3381  1.312794e-01                             Axitinib D018_r2
## 3382 -1.924052e+00                               AZ 628 D018_r2
## 3383  9.963991e-01                               AZ 960 D018_r2
## 3384  2.082384e+00                                 AZ20 D018_r2
## 3385  2.217334e+00                              AZD1080 D018_r2
## 3386  6.664548e-01                              AZD1480 D018_r2
## 3387  2.715287e+00                              AZD2014 D018_r2
## 3388  1.917037e+00                              AZD2858 D018_r2
## 3389  8.712232e-01                              AZD2932 D018_r2
## 3390 -1.565260e+00                              AZD3759 D018_r2
## 3391 -1.995509e-02                              AZD5363 D018_r2
## 3392  3.507476e+00                              AZD5438 D018_r2
## 3393  1.781671e+00                              AZD6482 D018_r2
## 3394 -4.557614e-01                              AZD6738 D018_r2
## 3395  2.463497e+00                              AZD8055 D018_r2
## 3396 -1.502718e+00                              AZD8330 D018_r2
## 3397  4.280125e-01                  AZD8931 (Sapitinib) D018_r2
## 3398  8.636513e-01                              AZD9291 D018_r2
## 3399 -7.801776e-01            Barasertib (AZD1152-HQPA) D018_r2
## 3400 -9.537827e-01  Baricitinib (LY3009104, INCB028050) D018_r2
## 3401 -1.133539e+00                  BGT226 (NVP-BGT226) D018_r2
## 3402 -1.110401e+00                              BI 2536 D018_r2
## 3403  4.071927e-03                              BI-78D3 D018_r2
## 3404 -2.064020e+00                             BI-D1870 D018_r2
## 3405 -7.786694e-01                              Bikinin D018_r2
## 3406  7.384320e-01                                  BIO D018_r2
## 3407 -7.947065e-01               BIRB 796 (Doramapimod) D018_r2
## 3408  3.965570e-01                            BIX 02188 D018_r2
## 3409 -5.521190e-01                            BIX 02189 D018_r2
## 3410  2.172821e+00      BKM120 (NVP-BKM120, Buparlisib) D018_r2
## 3411 -5.318924e-01                           BMS-265246 D018_r2
## 3412 -3.435706e-01                           BMS-536924 D018_r2
## 3413 -4.417093e-01                           BMS-582949 D018_r2
## 3414  1.861363e+00                           BMS-754807 D018_r2
## 3415  2.528732e-01                           BMS-777607 D018_r2
## 3416 -5.702829e-01                           BMS-794833 D018_r2
## 3417 -7.905939e-02                           BMS-833923 D018_r2
## 3418 -3.458944e-01                  Bosutinib (SKI-606) D018_r2
## 3419 -2.372891e+00                Brivanib (BMS-540215) D018_r2
## 3420 -9.932720e-01      Brivanib Alaninate (BMS-582664) D018_r2
## 3421  1.474998e-01                           BS-181 HCl D018_r2
## 3422 -1.583037e-01                               Butein D018_r2
## 3423  3.942034e-01                               BYL719 D018_r2
## 3424 -4.097821e-01     Cabozantinib (XL184, BMS-907351) D018_r2
## 3425  2.623788e-01          Cabozantinib malate (XL184) D018_r2
## 3426  1.194495e+00        CAL-101 (Idelalisib, GS-1101) D018_r2
## 3427  6.056217e-01                             CAY10505 D018_r2
## 3428  1.501657e+00                               CC-223 D018_r2
## 3429 -1.011548e+00                            CCT128930 D018_r2
## 3430 -1.426415e+00                  Cediranib (AZD2171) D018_r2
## 3431 -1.177435e+00                            CEP-32496 D018_r2
## 3432  7.252059e-01                            CEP-33779 D018_r2
## 3433 -1.037949e+00                              CGI1746 D018_r2
## 3434  2.491560e+00                              CGK 733 D018_r2
## 3435  2.015274e+00                            CH5132799 D018_r2
## 3436  3.648949e+00                           CHIR-98014 D018_r2
## 3437  4.965745e-01                 CHIR-99021 (CT99021) D018_r2
## 3438  1.364460e+00             CHIR-99021 (CT99021) HCl D018_r2
## 3439 -9.193943e-01                    Chrysophanic Acid D018_r2
## 3440  1.354282e-01                             CNX-2006 D018_r2
## 3441 -5.128451e-01                              CNX-774 D018_r2
## 3442  5.217153e-01                    CO-1686 (AVL-301) D018_r2
## 3443 -1.613368e+00       Cobimetinib (GDC-0973, RG7420) D018_r2
## 3444  2.143938e+00                            CP-673451 D018_r2
## 3445 -1.291311e+00                            CP-724714 D018_r2
## 3446  2.036258e+00               Crenolanib (CP-868596) D018_r2
## 3447  3.413432e-01             Crizotinib (PF-02341066) D018_r2
## 3448  3.358232e-01                               CYC116 D018_r2
## 3449  7.504221e-01                               CYT387 D018_r2
## 3450  6.484689e-02                             CZC24832 D018_r2
## 3451  1.875053e+00              Dabrafenib (GSK2118436) D018_r2
## 3452  1.297713e+00        Dacomitinib (PF299804, PF299) D018_r2
## 3453  1.093624e+00              Danusertib (PHA-739358) D018_r2
## 3454  6.014885e-01                        DAPT (GSI-IX) D018_r2
## 3455  1.766430e+00                            Dasatinib D018_r2
## 3456  1.066768e+00                DCC-2036 (Rebastinib) D018_r2
## 3457 -5.782377e-02                Decernotinib (VX-509) D018_r2
## 3458  3.237220e+00               Dinaciclib (SCH727965) D018_r2
## 3459  3.006482e+00    Dovitinib (TKI-258) Dilactic Acid D018_r2
## 3460  1.085214e+00                            ENMD-2076 D018_r2
## 3461  1.010717e+00               Enzastaurin (LY317615) D018_r2
## 3462  2.561571e-01                            ERK5-IN-1 D018_r2
## 3463 -5.170868e-01                             ETC-1002 D018_r2
## 3464  2.594363e-01                            ETP-46464 D018_r2
## 3465  8.711325e-01                  Everolimus (RAD001) D018_r2
## 3466 -3.534984e-01                Fasudil (HA-1077) HCl D018_r2
## 3467  2.529295e+00                                FH535 D018_r2
## 3468  1.863215e+00                Filgotinib (GLPG0634) D018_r2
## 3469  2.738138e+00             Flavopiridol (Alvocidib) D018_r2
## 3470  3.371919e+00                     Flavopiridol HCl D018_r2
## 3471 -1.407705e+00               Foretinib (GSK1363089) D018_r2
## 3472  2.275233e+00                  Fostamatinib (R788) D018_r2
## 3473  1.837738e+00                                G-749 D018_r2
## 3474  1.920117e+00                             GDC-0068 D018_r2
## 3475  3.179300e+00                             GDC-0349 D018_r2
## 3476 -1.440945e+00                             GDC-0879 D018_r2
## 3477 -1.544813e+00                             GDC-0941 D018_r2
## 3478  2.302529e+00                    GDC-0980 (RG7422) D018_r2
## 3479 -6.166205e-01                   Gefitinib (ZD1839) D018_r2
## 3480  4.572749e-01                            Genistein D018_r2
## 3481  1.243067e+00                            GF109203X D018_r2
## 3482  1.144951e+00                                GNF-2 D018_r2
## 3483  6.701398e-01                                GNF-5 D018_r2
## 3484  5.703298e-01                              Go 6983 D018_r2
## 3485  1.783543e+00                   Golvatinib (E7050) D018_r2
## 3486 -8.555719e-02                          GSK1838705A D018_r2
## 3487  1.808543e+00                          GSK1904529A D018_r2
## 3488  1.531042e+00                  GSK2126458 (GSK458) D018_r2
## 3489 -3.617414e-01                           GSK2292767 D018_r2
## 3490 -1.302882e+00                           GSK2636771 D018_r2
## 3491 -1.643875e+00                           GSK429286A D018_r2
## 3492 -5.707926e-01                            GSK461364 D018_r2
## 3493 -1.085586e+00                               GSK621 D018_r2
## 3494  1.609665e-01                            GSK690693 D018_r2
## 3495 -1.386073e-01                               GW5074 D018_r2
## 3496 -1.302933e+00                             GW788388 D018_r2
## 3497  3.070914e+00                               GZD824 D018_r2
## 3498 -4.724670e-01                            H 89 2HCl D018_r2
## 3499  6.678290e-01                           Hesperadin D018_r2
## 3500  9.829917e-01                              HMN-214 D018_r2
## 3501 -1.663862e+00                             Honokiol D018_r2
## 3502  1.539625e+00                               HS-173 D018_r2
## 3503 -5.284850e-01                           HTH-01-015 D018_r2
## 3504 -1.275857e+00                Ibrutinib (PCI-32765) D018_r2
## 3505  3.329903e-03                              ICG-001 D018_r2
## 3506 -1.148060e+00                             Icotinib D018_r2
## 3507 -4.069261e-01                                IM-12 D018_r2
## 3508 -2.460919e+00           Imatinib Mesylate (STI571) D018_r2
## 3509 -4.909228e-01                            Indirubin D018_r2
## 3510  2.858159e+00                    INK 128 (MLN0128) D018_r2
## 3511 -8.853728e-01                    IPI-145 (INK1197) D018_r2
## 3512  2.609990e-02                               IWP-L6 D018_r2
## 3513 -1.173312e-01                           IWR-1-endo D018_r2
## 3514 -3.180075e+00                         JNJ-38877605 D018_r2
## 3515  2.417014e+00                          JNJ-7706621 D018_r2
## 3516 -5.264114e-01                     JNK Inhibitor IX D018_r2
## 3517  8.459973e-01                             JNK-IN-8 D018_r2
## 3518  6.382969e-01                               K02288 D018_r2
## 3519  2.719512e+00                               Ki8751 D018_r2
## 3520  8.807206e-02                              KRN 633 D018_r2
## 3521  1.944389e+00                           KU-0063794 D018_r2
## 3522 -1.174123e+00      KU-55933 (ATM Kinase Inhibitor) D018_r2
## 3523 -7.591610e-02                             KU-60019 D018_r2
## 3524  1.101751e+00                              KW-2449 D018_r2
## 3525  9.704798e-01                              KX2-391 D018_r2
## 3526  9.265673e-03                              KY02111 D018_r2
## 3527 -1.682622e+00                            Lapatinib D018_r2
## 3528 -1.067761e+00     Lapatinib (GW-572016) Ditosylate D018_r2
## 3529  4.003611e+00                            LDC000067 D018_r2
## 3530 -1.197907e-01      LDE225 (NVP-LDE225,Erismodegib) D018_r2
## 3531  5.006014e-01                           LDN-214117 D018_r2
## 3532 -1.574757e+00                   Lenvatinib (E7080) D018_r2
## 3533  4.197232e-01                              LFM-A13 D018_r2
## 3534  2.409960e+00                              LGK-974 D018_r2
## 3535 -3.007002e+00                  Linifanib (ABT-869) D018_r2
## 3536 -1.980644e+00                               LJH685 D018_r2
## 3537 -1.291649e+00                               LJI308 D018_r2
## 3538  1.837887e+00               Losmapimod (GW856553X) D018_r2
## 3539  2.873013e+00                            LY2090314 D018_r2
## 3540 -1.192570e+00                            LY2157299 D018_r2
## 3541 -4.691390e-01                            LY2784544 D018_r2
## 3542 -6.941181e-01                            LY2835219 D018_r2
## 3543  1.370343e-01                             LY294002 D018_r2
## 3544  7.649561e-01                            LY3023414 D018_r2
## 3545  1.043488e+00                             LY411575 D018_r2
## 3546 -1.363624e+00       MEK162 (ARRY-162, ARRY-438162) D018_r2
## 3547 -1.657376e+00                             MGCD-265 D018_r2
## 3548  9.438550e-01               Milciclib (PHA-848125) D018_r2
## 3549 -3.827528e-01                              MK-0752 D018_r2
## 3550  1.311069e+00                         MK-2206 2HCl D018_r2
## 3551  2.399517e+00                              MK-2461 D018_r2
## 3552 -1.809763e-01                     MK-5108 (VX-689) D018_r2
## 3553 -1.037957e-02                              MK-8745 D018_r2
## 3554  6.528617e-01                              MLN2480 D018_r2
## 3555 -8.637201e-01                              MLN8054 D018_r2
## 3556 -1.435972e+00      Motesanib Diphosphate (AMG-706) D018_r2
## 3557  1.238447e-01                  Nilotinib (AMN-107) D018_r2
## 3558 -3.627461e-01     Nintedanib (BIBF 1120)_uncertain D018_r2
## 3559  2.003455e+00                               NU6027 D018_r2
## 3560  1.740591e+00                           NVP-AEW541 D018_r2
## 3561  7.340230e-01                           NVP-BHG712 D018_r2
## 3562  6.646768e-01                      NVP-BSK805 2HCl D018_r2
## 3563  5.631890e-01                           NVP-BVU972 D018_r2
## 3564 -3.731317e-01                          Oclacitinib D018_r2
## 3565  1.656049e+00      Olmutinib (HM61713, BI 1482694) D018_r2
## 3566 -1.818877e+00                             ONO-4059 D018_r2
## 3567  6.972926e-01                              OSI-027 D018_r2
## 3568 -9.606721e-01                              OSI-420 D018_r2
## 3569 -9.473139e-01                 OSI-906 (Linsitinib) D018_r2
## 3570  3.096087e+00                              P276-00 D018_r2
## 3571  3.431276e+00                  Pacritinib (SB1518) D018_r2
## 3572 -1.795855e-02                   Palomid 529 (P529) D018_r2
## 3573 -4.264472e-01                            Pazopanib D018_r2
## 3574  5.534435e-01                        Pazopanib HCl D018_r2
## 3575 -2.594683e+00                            PD0325901 D018_r2
## 3576  2.728777e+00                             PD168393 D018_r2
## 3577  1.327064e+00                             PD173955 D018_r2
## 3578 -1.430570e+00                   PD184352 (CI-1040) D018_r2
## 3579 -1.790932e+00                             PD318088 D018_r2
## 3580 -2.160230e-01                              PD98059 D018_r2
## 3581  5.308963e-01                  Pelitinib (EKB-569) D018_r2
## 3582  4.572787e+00                          PF-00562271 D018_r2
## 3583 -1.602745e+00                          PF-04217903 D018_r2
## 3584  3.886429e+00                          PF-04691502 D018_r2
## 3585  9.312424e-01                            PF-431396 D018_r2
## 3586  2.035817e+00                           PF-4708671 D018_r2
## 3587 -1.146289e+00                           PF-5274857 D018_r2
## 3588  3.305162e+00                            PF-562271 D018_r2
## 3589  6.739436e-01                            PF-573228 D018_r2
## 3590 -2.615762e-01                            PH-797804 D018_r2
## 3591 -2.215498e+00                           PHA-665752 D018_r2
## 3592  4.227996e-01                           PHA-680632 D018_r2
## 3593  3.776937e+00                           PHA-767491 D018_r2
## 3594  2.255127e+00                           PHA-793887 D018_r2
## 3595  4.011361e-01                       Phenformin HCl D018_r2
## 3596  1.374074e+00                              PHT-427 D018_r2
## 3597  3.547392e+00                          Piceatannol D018_r2
## 3598  1.183944e+00                              PIK-293 D018_r2
## 3599  1.259527e-01                              PIK-294 D018_r2
## 3600  4.338310e+00                               PIK-93 D018_r2
## 3601 -2.294629e+00               Pimasertib (AS-703026) D018_r2
## 3602 -1.534294e-01                          Pirfenidone D018_r2
## 3603  2.596789e-01                             PLX-4720 D018_r2
## 3604  1.174039e-01                              PLX7904 D018_r2
## 3605  1.550994e+00                  Ponatinib (AP24534) D018_r2
## 3606  2.481527e+00                                  PP1 D018_r2
## 3607  8.150347e-01                                  PP2 D018_r2
## 3608  1.541327e+00                                PP242 D018_r2
## 3609  5.705460e-01                               PQ 401 D018_r2
## 3610 -2.481477e-01                              PRI-724 D018_r2
## 3611  8.695931e-01     PRT062607 (P505-15, BIIB057) HCl D018_r2
## 3612  2.179980e+00                         Purvalanol A D018_r2
## 3613 -1.170415e-01                            Quercetin D018_r2
## 3614 -1.678390e-01                  Quizartinib (AC220) D018_r2
## 3615  6.513598e-01                                 R406 D018_r2
## 3616  1.351878e+00                     R406 (free base) D018_r2
## 3617  4.024650e+00                                 R547 D018_r2
## 3618 -2.751646e+00                    RAF265 (CHIR-265) D018_r2
## 3619  8.108221e-01                Rapamycin (Sirolimus) D018_r2
## 3620 -9.656859e-01   Refametinib (RDEA119, Bay 86-9766) D018_r2
## 3621 -1.118467e+00                               RepSox D018_r2
## 3622  3.540237e-01 Ridaforolimus (Deforolimus, MK-8669) D018_r2
## 3623  1.329919e-01                Rigosertib (ON-01910) D018_r2
## 3624  6.277475e-02                             RKI-1447 D018_r2
## 3625  9.736046e-01                                RN486 D018_r2
## 3626  3.702022e+00                  Ro 31-8220 Mesylate D018_r2
## 3627 -6.784052e-01                              Ro-3306 D018_r2
## 3628  4.983983e-01                               Ro3280 D018_r2
## 3629  5.742039e-01                            RO4929097 D018_r2
## 3630  6.103083e-01      Roscovitine (Seliciclib,CYC202) D018_r2
## 3631 -1.514306e-02             Ruxolitinib (INCB018424) D018_r2
## 3632 -8.554775e-01           S-Ruxolitinib (INCB018424) D018_r2
## 3633  3.199018e-02                               SANT-1 D018_r2
## 3634  7.932701e-01                            SAR131675 D018_r2
## 3635 -4.469085e-01                    SAR245409 (XL765) D018_r2
## 3636  1.156758e+00                Saracatinib (AZD0530) D018_r2
## 3637 -5.311983e-01                      SB202190 (FHPI) D018_r2
## 3638  9.633354e-02                             SB203580 D018_r2
## 3639  9.795188e-01                             SB216763 D018_r2
## 3640 -1.824247e-01                             SB239063 D018_r2
## 3641 -8.522942e-01                             SB415286 D018_r2
## 3642 -3.221178e-01                             SB431542 D018_r2
## 3643 -4.679182e-01                             SB505124 D018_r2
## 3644 -4.639366e-01                             SB525334 D018_r2
## 3645 -1.549190e+00                             SB590885 D018_r2
## 3646  4.136813e+00                                  SC1 D018_r2
## 3647 -7.273524e-01                Schisandrin B (Sch B) D018_r2
## 3648 -1.308780e+00                Selumetinib (AZD6244) D018_r2
## 3649 -4.789518e-01              Semagacestat (LY450139) D018_r2
## 3650 -6.237319e-01                   Semaxanib (SU5416) D018_r2
## 3651  1.042831e+00                             SGI-7079 D018_r2
## 3652 -8.323882e-01                          Skepinone-L D018_r2
## 3653 -1.032660e-01                               SL-327 D018_r2
## 3654  2.919214e+00                 SNS-032 (BMS-387032) D018_r2
## 3655 -8.991357e-01                     SNS-314 Mesylate D018_r2
## 3656 -3.448935e-01                            Sorafenib D018_r2
## 3657  8.773357e-01                   Sorafenib Tosylate D018_r2
## 3658  7.711535e-01                         Sotrastaurin D018_r2
## 3659 -3.769411e-01                             SP600125 D018_r2
## 3660 -9.522902e-01                              SU11274 D018_r2
## 3661  1.879364e+00                               SU6656 D018_r2
## 3662 -9.621090e-02                               SU9516 D018_r2
## 3663  8.733497e-01                     Sunitinib Malate D018_r2
## 3664  2.663234e-01                  TAE226 (NVP-TAE226) D018_r2
## 3665 -4.718634e-01                              TAK-285 D018_r2
## 3666 -2.013151e-01                              TAK-632 D018_r2
## 3667 -1.365934e+00                              TAK-715 D018_r2
## 3668 -6.912971e-01                              TAK-733 D018_r2
## 3669  4.076479e+00                              TAK-901 D018_r2
## 3670  3.571243e-01                Taladegib (LY2940680) D018_r2
## 3671  9.757246e-01                              TCS 359 D018_r2
## 3672 -1.134101e-01                               TDZD-8 D018_r2
## 3673  6.269666e-01                            Telatinib D018_r2
## 3674  4.687918e-01   Temsirolimus (CCI-779, NSC 683864) D018_r2
## 3675  1.607517e+00              Tepotinib (EMD 1214063) D018_r2
## 3676  8.617345e-02                                TG003 D018_r2
## 3677  1.584859e+00                            TG100-115 D018_r2
## 3678  1.793988e+00                             TG101209 D018_r2
## 3679  1.997902e+00                 TG101348 (SAR302503) D018_r2
## 3680  4.383952e-01                              TGX-221 D018_r2
## 3681  3.524224e-01                         Theophylline D018_r2
## 3682 -9.739333e-01                          Thiazovivin D018_r2
## 3683  8.252061e-01                       TIC10 Analogue D018_r2
## 3684 -1.260695e+00                           Tideglusib D018_r2
## 3685  1.037720e+00                 Tivantinib (ARQ 197) D018_r2
## 3686 -1.359466e-01                   Tivozanib (AV-951) D018_r2
## 3687 -6.596131e-01  Tofacitinib (CP-690550,Tasocitinib) D018_r2
## 3688  3.569873e-01      Tofacitinib (CP-690550) Citrate D018_r2
## 3689  7.748710e-01                              Torin 2 D018_r2
## 3690  2.938239e-01              Trametinib (GSK1120212) D018_r2
## 3691  6.056987e-01                          Triciribine D018_r2
## 3692 -1.453326e-01           TSU-68 (SU6668, Orantinib) D018_r2
## 3693 -8.443164e-01                               TWS119 D018_r2
## 3694  4.621068e-01                         Tyrphostin 9 D018_r2
## 3695  1.449297e+00                   Tyrphostin AG 1296 D018_r2
## 3696 -1.017644e-01                           U0126-EtOH D018_r2
## 3697 -2.000487e+00     Ulixertinib (BVD-523, VRT752271) D018_r2
## 3698  1.420175e+00              Uprosertib (GSK2141795) D018_r2
## 3699  3.400579e-01                          Vacquinol-1 D018_r2
## 3700 -2.255469e-01                           Varlitinib D018_r2
## 3701  1.003409e+00              Vatalanib (PTK787) 2HCl D018_r2
## 3702 -1.571549e+00                               VE-821 D018_r2
## 3703  9.143282e-01                               VE-822 D018_r2
## 3704 -1.027394e+00        Vemurafenib (PLX4032, RG7204) D018_r2
## 3705  4.936538e-01                Vismodegib (GDC-0449) D018_r2
## 3706 -1.649402e-01                 Volasertib (BI 6727) D018_r2
## 3707  1.323800e+00                            VPS34-IN1 D018_r2
## 3708  2.296137e+00                     VS-5584 (SB2343) D018_r2
## 3709 -1.279422e+00                               VX-11e D018_r2
## 3710  1.177863e+00         VX-680 (Tozasertib, MK-0457) D018_r2
## 3711 -1.963017e-01                               VX-702 D018_r2
## 3712  1.000661e+00                               VX-745 D018_r2
## 3713  5.408094e-01                              WAY-600 D018_r2
## 3714 -4.811580e-01                             WH-4-023 D018_r2
## 3715 -2.128356e-01                             WHI-P154 D018_r2
## 3716  6.454714e-01                                WIKI4 D018_r2
## 3717  4.589877e-01                        Wnt agonist 1 D018_r2
## 3718 -3.715192e-01                        Wnt-C59 (C59) D018_r2
## 3719 -4.786053e-01                               WP1066 D018_r2
## 3720  4.107275e-01                 WYE-125132 (WYE-132) D018_r2
## 3721  4.155410e-01                              WYE-354 D018_r2
## 3722  6.795787e-01                               WZ3146 D018_r2
## 3723 -1.398401e+00                               WZ4002 D018_r2
## 3724 -3.202404e-01                               WZ4003 D018_r2
## 3725 -8.299158e-01                               WZ8040 D018_r2
## 3726 -3.361608e-01                              XAV-939 D018_r2
## 3727 -2.426404e-01                                XL019 D018_r2
## 3728 -3.937006e-01                              XMD8-92 D018_r2
## 3729 -1.400112e+00                         Y-27632 2HCl D018_r2
## 3730  6.703268e-01                             YM201636 D018_r2
## 3731  1.933858e+00                             YO-01027 D018_r2
## 3732  1.210254e+00                            ZM 306416 D018_r2
## 3733 -5.181511e-01                        ZM 323881 HCl D018_r2
## 3734 -1.565784e+00                            ZM 336372 D018_r2
## 3735 -8.069797e-01                         ZM 39923 HCl D018_r2
## 3736  4.195450e-01                            ZM 447439 D018_r2
## 3737 -9.061637e-01                 Zotarolimus(ABT-578) D018_r2
## 3738  5.578338e-01                              ZSTK474 D018_r2
## 3739  8.911419e-01                     1-Azakenpaullone D019_r1
## 3740  4.083427e+00                      3-Methyladenine D019_r1
## 3741  3.408323e+00                             A-674563 D019_r1
## 3742  6.257919e-02                             A-769662 D019_r1
## 3743  1.658723e+00                                  A66 D019_r1
## 3744  5.080655e+00                            Acadesine D019_r1
## 3745  1.282659e+00                  AEE788 (NVP-AEE788) D019_r1
## 3746  2.045428e+00        Afatinib (BIBW2992)_uncertain D019_r1
## 3747  3.015385e+00                              AG-1024 D019_r1
## 3748  1.934952e+00         AG-1478 (Tyrphostin AG-1478) D019_r1
## 3749  3.489781e+00                                AG-18 D019_r1
## 3750  2.590163e+00              AG-490 (Tyrphostin B42) D019_r1
## 3751  2.023916e+00                             Akti-1/2 D019_r1
## 3752  3.594201e+00                  Alisertib (MLN8237) D019_r1
## 3753  2.523960e+00                              AMG 337 D019_r1
## 3754  1.912816e+00                              AMG-458 D019_r1
## 3755  4.272607e+00                              AMG-900 D019_r1
## 3756  3.007786e+00                               AMG319 D019_r1
## 3757  1.595922e+00                  Amuvatinib (MP-470) D019_r1
## 3758  3.757276e+00                             Apatinib D019_r1
## 3759  1.750105e+00                           AR-A014418 D019_r1
## 3760  4.176485e-01                            AS-252424 D019_r1
## 3761  3.490654e+00                            AS-604850 D019_r1
## 3762  3.618474e+00                         Asiatic Acid D019_r1
## 3763  4.017334e+00                             AST-1306 D019_r1
## 3764  1.773559e+00                              AT13148 D019_r1
## 3765  5.175677e+00                               AT7519 D019_r1
## 3766  2.338281e+00                               AT7867 D019_r1
## 3767  5.994531e+00                               AT9283 D019_r1
## 3768  1.790543e+00                 Aurora A Inhibitor I D019_r1
## 3769  2.813860e+00             Avagacestat (BMS-708163) D019_r1
## 3770  3.228850e+00                              AVL-292 D019_r1
## 3771  3.564372e+00                             Axitinib D019_r1
## 3772  3.564372e+00                             Axitinib D019_r1
## 3773  4.457717e+00                               AZ 628 D019_r1
## 3774  4.873546e+00                               AZ 960 D019_r1
## 3775  5.550052e+00                                 AZ20 D019_r1
## 3776  1.401471e+00                              AZD1080 D019_r1
## 3777  4.252658e+00                              AZD1480 D019_r1
## 3778  2.221156e+00                              AZD2014 D019_r1
## 3779  3.332362e+00                              AZD2858 D019_r1
## 3780  1.757456e+00                              AZD2932 D019_r1
## 3781  3.059496e+00                              AZD3759 D019_r1
## 3782  3.049121e+00                              AZD5363 D019_r1
## 3783  3.571206e+00                              AZD5438 D019_r1
## 3784  2.702133e+00                              AZD6482 D019_r1
## 3785  4.453845e+00                              AZD6738 D019_r1
## 3786  4.871149e+00                              AZD8055 D019_r1
## 3787  5.854723e+00                              AZD8330 D019_r1
## 3788  2.914546e+00                  AZD8931 (Sapitinib) D019_r1
## 3789  3.496525e+00                              AZD9291 D019_r1
## 3790  1.358235e+00            Barasertib (AZD1152-HQPA) D019_r1
## 3791  1.944065e+00  Baricitinib (LY3009104, INCB028050) D019_r1
## 3792 -4.350838e+00                  BGT226 (NVP-BGT226) D019_r1
## 3793  5.361688e+00                              BI 2536 D019_r1
## 3794  2.598233e+00                              BI-78D3 D019_r1
## 3795  4.389395e-01                             BI-D1870 D019_r1
## 3796  2.682588e+00                              Bikinin D019_r1
## 3797  3.656423e+00                                  BIO D019_r1
## 3798  1.767692e+00               BIRB 796 (Doramapimod) D019_r1
## 3799  1.974775e+00                            BIX 02188 D019_r1
## 3800  1.359601e+00                            BIX 02189 D019_r1
## 3801 -9.925572e-02      BKM120 (NVP-BKM120, Buparlisib) D019_r1
## 3802  1.727832e+00                           BMS-265246 D019_r1
## 3803  2.940757e+00                           BMS-536924 D019_r1
## 3804  1.971819e+00                           BMS-582949 D019_r1
## 3805  4.204404e+00                           BMS-754807 D019_r1
## 3806  4.677741e+00                           BMS-777607 D019_r1
## 3807  2.914256e+00                           BMS-794833 D019_r1
## 3808  2.356868e+00                           BMS-833923 D019_r1
## 3809  3.359808e-01                  Bosutinib (SKI-606) D019_r1
## 3810  4.477844e+00                Brivanib (BMS-540215) D019_r1
## 3811  2.971355e+00      Brivanib Alaninate (BMS-582664) D019_r1
## 3812  3.613759e+00                           BS-181 HCl D019_r1
## 3813  2.381467e+00                               Butein D019_r1
## 3814  3.647328e+00                               BYL719 D019_r1
## 3815  4.073318e+00     Cabozantinib (XL184, BMS-907351) D019_r1
## 3816  3.295452e+00          Cabozantinib malate (XL184) D019_r1
## 3817  3.501621e+00        CAL-101 (Idelalisib, GS-1101) D019_r1
## 3818  2.587141e+00                             CAY10505 D019_r1
## 3819  4.925029e+00                               CC-223 D019_r1
## 3820 -5.933746e-01                            CCT128930 D019_r1
## 3821  1.316345e+00                  Cediranib (AZD2171) D019_r1
## 3822  1.450795e+00                            CEP-32496 D019_r1
## 3823  2.599037e+00                            CEP-33779 D019_r1
## 3824  3.515890e+00                              CGI1746 D019_r1
## 3825  2.384901e+00                              CGK 733 D019_r1
## 3826  2.862397e+00                            CH5132799 D019_r1
## 3827  3.450385e+00                           CHIR-98014 D019_r1
## 3828  4.450256e+00                 CHIR-99021 (CT99021) D019_r1
## 3829  3.013995e+00             CHIR-99021 (CT99021) HCl D019_r1
## 3830  2.020979e+00                    Chrysophanic Acid D019_r1
## 3831  2.596632e+00                             CNX-2006 D019_r1
## 3832  2.913639e+00                              CNX-774 D019_r1
## 3833  3.654528e+00                    CO-1686 (AVL-301) D019_r1
## 3834  5.424133e+00       Cobimetinib (GDC-0973, RG7420) D019_r1
## 3835  9.939284e-01                            CP-673451 D019_r1
## 3836  1.834762e+00                            CP-724714 D019_r1
## 3837  7.684562e-01               Crenolanib (CP-868596) D019_r1
## 3838  3.899494e+00             Crizotinib (PF-02341066) D019_r1
## 3839  5.144823e+00                               CYC116 D019_r1
## 3840  2.791678e+00                               CYT387 D019_r1
## 3841  3.113651e+00                             CZC24832 D019_r1
## 3842  3.406439e+00              Dabrafenib (GSK2118436) D019_r1
## 3843  1.515218e+00        Dacomitinib (PF299804, PF299) D019_r1
## 3844  4.871048e+00              Danusertib (PHA-739358) D019_r1
## 3845  2.730788e+00                        DAPT (GSI-IX) D019_r1
## 3846  3.724309e+00                            Dasatinib D019_r1
## 3847  1.557455e+00                DCC-2036 (Rebastinib) D019_r1
## 3848  2.660537e+00                Decernotinib (VX-509) D019_r1
## 3849  3.080318e+00               Dinaciclib (SCH727965) D019_r1
## 3850  4.803455e-01    Dovitinib (TKI-258) Dilactic Acid D019_r1
## 3851  2.241476e+00                            ENMD-2076 D019_r1
## 3852  4.318243e+00               Enzastaurin (LY317615) D019_r1
## 3853  1.890248e+00                            ERK5-IN-1 D019_r1
## 3854  2.137040e+00                             ETC-1002 D019_r1
## 3855  2.338711e+00                            ETP-46464 D019_r1
## 3856  2.735657e+00                  Everolimus (RAD001) D019_r1
## 3857  3.293688e+00                Fasudil (HA-1077) HCl D019_r1
## 3858  2.429350e+00                                FH535 D019_r1
## 3859  2.499030e+00                Filgotinib (GLPG0634) D019_r1
## 3860  4.279438e+00             Flavopiridol (Alvocidib) D019_r1
## 3861  4.749685e+00                     Flavopiridol HCl D019_r1
## 3862  6.080887e+00               Foretinib (GSK1363089) D019_r1
## 3863  1.542241e+00                  Fostamatinib (R788) D019_r1
## 3864  1.249975e+00                                G-749 D019_r1
## 3865  2.807296e+00                             GDC-0068 D019_r1
## 3866  1.675839e+00                             GDC-0349 D019_r1
## 3867  1.875352e+00                             GDC-0879 D019_r1
## 3868 -1.106874e-01                             GDC-0941 D019_r1
## 3869  2.382100e+00                    GDC-0980 (RG7422) D019_r1
## 3870  3.944829e+00                   Gefitinib (ZD1839) D019_r1
## 3871  3.091351e+00                            Genistein D019_r1
## 3872  1.885784e+00                            GF109203X D019_r1
## 3873  1.956845e+00                                GNF-2 D019_r1
## 3874  4.320417e+00                                GNF-5 D019_r1
## 3875  3.243714e+00                              Go 6983 D019_r1
## 3876  1.218940e+00                   Golvatinib (E7050) D019_r1
## 3877  2.203104e+00                          GSK1838705A D019_r1
## 3878  2.880203e+00                          GSK1904529A D019_r1
## 3879  3.234177e+00                  GSK2126458 (GSK458) D019_r1
## 3880  3.496117e+00                           GSK2292767 D019_r1
## 3881  1.444797e+00                           GSK2636771 D019_r1
## 3882  1.151832e+00                           GSK429286A D019_r1
## 3883  4.825948e+00                            GSK461364 D019_r1
## 3884  3.592076e+00                               GSK621 D019_r1
## 3885  2.884902e+00                            GSK690693 D019_r1
## 3886  3.556439e+00                               GW5074 D019_r1
## 3887  2.651766e+00                             GW788388 D019_r1
## 3888  2.585437e+00                               GZD824 D019_r1
## 3889  2.248989e+00                            H 89 2HCl D019_r1
## 3890  5.075373e+00                           Hesperadin D019_r1
## 3891  4.174891e+00                              HMN-214 D019_r1
## 3892  2.645656e+00                             Honokiol D019_r1
## 3893  1.984309e+00                               HS-173 D019_r1
## 3894  3.026507e-01                           HTH-01-015 D019_r1
## 3895  1.159866e+00                Ibrutinib (PCI-32765) D019_r1
## 3896  2.891968e+00                              ICG-001 D019_r1
## 3897  3.380252e+00                             Icotinib D019_r1
## 3898  2.463756e+00                                IM-12 D019_r1
## 3899  1.796158e+00           Imatinib Mesylate (STI571) D019_r1
## 3900  4.043835e+00                            Indirubin D019_r1
## 3901  5.209136e+00                    INK 128 (MLN0128) D019_r1
## 3902  4.426932e+00                    IPI-145 (INK1197) D019_r1
## 3903  2.839304e+00                               IWP-L6 D019_r1
## 3904  2.903204e+00                           IWR-1-endo D019_r1
## 3905  2.975380e+00                         JNJ-38877605 D019_r1
## 3906  5.655783e+00                          JNJ-7706621 D019_r1
## 3907  2.950005e+00                     JNK Inhibitor IX D019_r1
## 3908  3.270305e+00                             JNK-IN-8 D019_r1
## 3909  1.489556e+00                               K02288 D019_r1
## 3910  2.736740e+00                               Ki8751 D019_r1
## 3911  1.941751e+00                              KRN 633 D019_r1
## 3912  2.491473e+00                           KU-0063794 D019_r1
## 3913  2.245321e+00      KU-55933 (ATM Kinase Inhibitor) D019_r1
## 3914  3.829907e+00                             KU-60019 D019_r1
## 3915  4.829011e+00                              KW-2449 D019_r1
## 3916  2.161717e+00                              KX2-391 D019_r1
## 3917  3.428222e+00                              KY02111 D019_r1
## 3918  3.688711e+00                            Lapatinib D019_r1
## 3919  4.868095e-01     Lapatinib (GW-572016) Ditosylate D019_r1
## 3920  2.565701e+00                            LDC000067 D019_r1
## 3921  2.043446e+00      LDE225 (NVP-LDE225,Erismodegib) D019_r1
## 3922  2.137927e+00                           LDN-214117 D019_r1
## 3923  1.873264e+00                   Lenvatinib (E7080) D019_r1
## 3924  3.658392e+00                              LFM-A13 D019_r1
## 3925  4.038837e+00                              LGK-974 D019_r1
## 3926 -8.204302e-01                  Linifanib (ABT-869) D019_r1
## 3927  9.095826e-01                               LJH685 D019_r1
## 3928  2.683204e+00                               LJI308 D019_r1
## 3929  2.594742e+00               Losmapimod (GW856553X) D019_r1
## 3930  3.944180e+00                            LY2090314 D019_r1
## 3931  3.658020e+00                            LY2157299 D019_r1
## 3932  1.645094e+00                            LY2784544 D019_r1
## 3933  3.797504e+00                            LY2835219 D019_r1
## 3934  4.275597e+00                             LY294002 D019_r1
## 3935  5.068655e+00                            LY3023414 D019_r1
## 3936  2.628041e+00                             LY411575 D019_r1
## 3937  5.527440e+00       MEK162 (ARRY-162, ARRY-438162) D019_r1
## 3938  3.396068e+00                             MGCD-265 D019_r1
## 3939  5.147382e+00               Milciclib (PHA-848125) D019_r1
## 3940  1.635151e+00                              MK-0752 D019_r1
## 3941 -2.578022e-01                         MK-2206 2HCl D019_r1
## 3942  1.145734e+00                              MK-2461 D019_r1
## 3943  1.291346e+00                     MK-5108 (VX-689) D019_r1
## 3944  1.286417e+00                              MK-8745 D019_r1
## 3945  2.299564e+00                              MLN2480 D019_r1
## 3946  2.581445e+00                              MLN8054 D019_r1
## 3947  2.294244e+00      Motesanib Diphosphate (AMG-706) D019_r1
## 3948  2.740587e+00                  Nilotinib (AMN-107) D019_r1
## 3949  9.734180e-01     Nintedanib (BIBF 1120)_uncertain D019_r1
## 3950  3.762153e+00                               NU6027 D019_r1
## 3951  3.292677e+00                           NVP-AEW541 D019_r1
## 3952  4.057231e+00                           NVP-BHG712 D019_r1
## 3953  2.834268e+00                      NVP-BSK805 2HCl D019_r1
## 3954  3.222575e-01                           NVP-BVU972 D019_r1
## 3955  2.905571e+00                          Oclacitinib D019_r1
## 3956  3.352078e+00      Olmutinib (HM61713, BI 1482694) D019_r1
## 3957  1.868972e+00                             ONO-4059 D019_r1
## 3958  2.889697e+00                              OSI-027 D019_r1
## 3959  2.811542e+00                              OSI-420 D019_r1
## 3960  2.429652e+00                 OSI-906 (Linsitinib) D019_r1
## 3961  3.104653e+00                              P276-00 D019_r1
## 3962  3.481442e+00                  Pacritinib (SB1518) D019_r1
## 3963  1.031802e+00                   Palomid 529 (P529) D019_r1
## 3964  1.119836e+00                            Pazopanib D019_r1
## 3965  3.660743e+00                        Pazopanib HCl D019_r1
## 3966  6.693715e+00                            PD0325901 D019_r1
## 3967  3.685247e+00                             PD168393 D019_r1
## 3968  1.143476e+00                             PD173955 D019_r1
## 3969  3.577185e+00                   PD184352 (CI-1040) D019_r1
## 3970  5.101640e+00                             PD318088 D019_r1
## 3971  3.637205e+00                              PD98059 D019_r1
## 3972  3.080978e+00                  Pelitinib (EKB-569) D019_r1
## 3973  4.255765e+00                          PF-00562271 D019_r1
## 3974  3.593398e+00                          PF-04217903 D019_r1
## 3975  3.587225e+00                          PF-04691502 D019_r1
## 3976  2.739354e+00                            PF-431396 D019_r1
## 3977  5.060969e+00                           PF-4708671 D019_r1
## 3978  2.908068e+00                           PF-5274857 D019_r1
## 3979  5.801937e+00                            PF-562271 D019_r1
## 3980  2.020924e+00                            PF-573228 D019_r1
## 3981  2.002307e+00                            PH-797804 D019_r1
## 3982  3.585524e+00                           PHA-665752 D019_r1
## 3983  3.733790e+00                           PHA-680632 D019_r1
## 3984  3.287481e+00                           PHA-767491 D019_r1
## 3985  3.505084e+00                           PHA-793887 D019_r1
## 3986  2.850421e+00                       Phenformin HCl D019_r1
## 3987  3.084608e+00                              PHT-427 D019_r1
## 3988  5.591377e+00                          Piceatannol D019_r1
## 3989  3.232581e+00                              PIK-293 D019_r1
## 3990  3.734430e+00                              PIK-294 D019_r1
## 3991  5.809926e+00                               PIK-93 D019_r1
## 3992  6.242800e+00               Pimasertib (AS-703026) D019_r1
## 3993  3.623952e+00                          Pirfenidone D019_r1
## 3994  1.903547e+00                             PLX-4720 D019_r1
## 3995  2.194705e+00                              PLX7904 D019_r1
## 3996  4.947341e+00                  Ponatinib (AP24534) D019_r1
## 3997  1.492795e+00                                  PP1 D019_r1
## 3998 -1.789952e-01                                  PP2 D019_r1
## 3999  6.640130e-01                                PP242 D019_r1
## 4000  2.862883e+00                               PQ 401 D019_r1
## 4001  1.385736e+00                              PRI-724 D019_r1
## 4002  3.246441e+00     PRT062607 (P505-15, BIIB057) HCl D019_r1
## 4003  1.987983e+00                         Purvalanol A D019_r1
## 4004  2.885155e+00                            Quercetin D019_r1
## 4005  4.105848e+00                  Quizartinib (AC220) D019_r1
## 4006  3.169417e+00                                 R406 D019_r1
## 4007  2.662933e+00                     R406 (free base) D019_r1
## 4008  3.602019e+00                                 R547 D019_r1
## 4009  7.284090e+00                    RAF265 (CHIR-265) D019_r1
## 4010  2.580147e+00                Rapamycin (Sirolimus) D019_r1
## 4011  5.527539e+00   Refametinib (RDEA119, Bay 86-9766) D019_r1
## 4012  3.455854e+00                               RepSox D019_r1
## 4013  1.726198e+00 Ridaforolimus (Deforolimus, MK-8669) D019_r1
## 4014  2.784848e+00                Rigosertib (ON-01910) D019_r1
## 4015  1.967802e+00                             RKI-1447 D019_r1
## 4016 -1.401566e+00                                RN486 D019_r1
## 4017  3.359751e+00                  Ro 31-8220 Mesylate D019_r1
## 4018  2.044693e+00                              Ro-3306 D019_r1
## 4019  4.329939e+00                               Ro3280 D019_r1
## 4020  2.623129e+00                            RO4929097 D019_r1
## 4021  4.253156e+00      Roscovitine (Seliciclib,CYC202) D019_r1
## 4022  3.065649e+00             Ruxolitinib (INCB018424) D019_r1
## 4023  2.241399e+00           S-Ruxolitinib (INCB018424) D019_r1
## 4024  2.736046e+00                               SANT-1 D019_r1
## 4025  3.883994e+00                            SAR131675 D019_r1
## 4026  2.649899e+00                    SAR245409 (XL765) D019_r1
## 4027  2.042767e+00                Saracatinib (AZD0530) D019_r1
## 4028  2.021059e+00                      SB202190 (FHPI) D019_r1
## 4029  1.277290e+00                             SB203580 D019_r1
## 4030  2.211814e+00                             SB216763 D019_r1
## 4031  3.405921e+00                             SB239063 D019_r1
## 4032  2.385819e+00                             SB415286 D019_r1
## 4033  2.690027e+00                             SB431542 D019_r1
## 4034  1.905018e+00                             SB505124 D019_r1
## 4035  1.826747e+00                             SB525334 D019_r1
## 4036  1.810008e+00                             SB590885 D019_r1
## 4037  3.185482e+00                                  SC1 D019_r1
## 4038  9.061094e-01                Schisandrin B (Sch B) D019_r1
## 4039  4.568358e+00                Selumetinib (AZD6244) D019_r1
## 4040  3.583808e+00              Semagacestat (LY450139) D019_r1
## 4041  3.389838e+00                   Semaxanib (SU5416) D019_r1
## 4042  3.770306e+00                             SGI-7079 D019_r1
## 4043  4.754666e-02                          Skepinone-L D019_r1
## 4044  2.477725e+00                               SL-327 D019_r1
## 4045  6.320446e+00                 SNS-032 (BMS-387032) D019_r1
## 4046  4.156008e+00                     SNS-314 Mesylate D019_r1
## 4047  2.915842e+00                            Sorafenib D019_r1
## 4048  2.357646e+00                   Sorafenib Tosylate D019_r1
## 4049  4.020025e+00                         Sotrastaurin D019_r1
## 4050  1.222186e+00                             SP600125 D019_r1
## 4051  1.620093e+00                              SU11274 D019_r1
## 4052  1.887668e+00                               SU6656 D019_r1
## 4053  1.697022e+00                               SU9516 D019_r1
## 4054  3.158658e+00                     Sunitinib Malate D019_r1
## 4055  2.821873e+00                  TAE226 (NVP-TAE226) D019_r1
## 4056  2.803223e+00                              TAK-285 D019_r1
## 4057  3.821306e+00                              TAK-632 D019_r1
## 4058  1.026485e+00                              TAK-715 D019_r1
## 4059  5.532538e+00                              TAK-733 D019_r1
## 4060  1.869770e+00                              TAK-901 D019_r1
## 4061  2.223828e+00                Taladegib (LY2940680) D019_r1
## 4062  3.883734e+00                              TCS 359 D019_r1
## 4063  3.110516e+00                               TDZD-8 D019_r1
## 4064  2.660558e+00                            Telatinib D019_r1
## 4065  4.038645e-01   Temsirolimus (CCI-779, NSC 683864) D019_r1
## 4066  1.520621e+00              Tepotinib (EMD 1214063) D019_r1
## 4067  2.734938e+00                                TG003 D019_r1
## 4068  3.748149e+00                            TG100-115 D019_r1
## 4069  3.718652e+00                             TG101209 D019_r1
## 4070  3.033663e+00                 TG101348 (SAR302503) D019_r1
## 4071  5.224991e-01                              TGX-221 D019_r1
## 4072  2.698948e+00                         Theophylline D019_r1
## 4073  2.087156e+00                          Thiazovivin D019_r1
## 4074  1.227143e+00                       TIC10 Analogue D019_r1
## 4075  3.170687e+00                           Tideglusib D019_r1
## 4076  2.620736e+00                 Tivantinib (ARQ 197) D019_r1
## 4077 -4.721360e-01                   Tivozanib (AV-951) D019_r1
## 4078  2.363113e+00  Tofacitinib (CP-690550,Tasocitinib) D019_r1
## 4079  2.173322e+00      Tofacitinib (CP-690550) Citrate D019_r1
## 4080  3.233151e+00                              Torin 2 D019_r1
## 4081  5.707278e+00              Trametinib (GSK1120212) D019_r1
## 4082  4.243878e+00                          Triciribine D019_r1
## 4083  3.547990e+00           TSU-68 (SU6668, Orantinib) D019_r1
## 4084  9.731294e-01                               TWS119 D019_r1
## 4085  4.158810e+00                         Tyrphostin 9 D019_r1
## 4086  4.258803e+00                   Tyrphostin AG 1296 D019_r1
## 4087  3.715759e+00                           U0126-EtOH D019_r1
## 4088  3.821133e+00     Ulixertinib (BVD-523, VRT752271) D019_r1
## 4089  3.258661e+00              Uprosertib (GSK2141795) D019_r1
## 4090  5.241992e+00                          Vacquinol-1 D019_r1
## 4091  3.475972e+00                           Varlitinib D019_r1
## 4092  2.820891e+00              Vatalanib (PTK787) 2HCl D019_r1
## 4093  2.003906e+00                               VE-821 D019_r1
## 4094  2.654066e+00                               VE-822 D019_r1
## 4095  4.861799e-01        Vemurafenib (PLX4032, RG7204) D019_r1
## 4096  5.664475e-01                Vismodegib (GDC-0449) D019_r1
## 4097  6.300639e-01                 Volasertib (BI 6727) D019_r1
## 4098  4.564428e+00                            VPS34-IN1 D019_r1
## 4099  4.281767e+00                     VS-5584 (SB2343) D019_r1
## 4100  4.374692e+00                               VX-11e D019_r1
## 4101  3.374486e+00         VX-680 (Tozasertib, MK-0457) D019_r1
## 4102  2.017434e+00                               VX-702 D019_r1
## 4103  1.578129e+00                               VX-745 D019_r1
## 4104 -2.840611e-01                              WAY-600 D019_r1
## 4105  1.438638e+00                             WH-4-023 D019_r1
## 4106  1.997023e+00                             WHI-P154 D019_r1
## 4107  2.768686e+00                                WIKI4 D019_r1
## 4108  2.494757e+00                        Wnt agonist 1 D019_r1
## 4109  2.775850e+00                        Wnt-C59 (C59) D019_r1
## 4110  2.113364e+00                               WP1066 D019_r1
## 4111  2.613707e+00                 WYE-125132 (WYE-132) D019_r1
## 4112  2.288528e+00                              WYE-354 D019_r1
## 4113  3.639295e+00                               WZ3146 D019_r1
## 4114  3.032555e+00                               WZ4002 D019_r1
## 4115  2.023245e+00                               WZ4003 D019_r1
## 4116  2.655559e+00                               WZ8040 D019_r1
## 4117  1.897750e+00                              XAV-939 D019_r1
## 4118  2.181117e+00                                XL019 D019_r1
## 4119  3.280646e+00                              XMD8-92 D019_r1
## 4120  1.403449e+00                         Y-27632 2HCl D019_r1
## 4121  3.556609e-01                             YM201636 D019_r1
## 4122  3.940184e+00                             YO-01027 D019_r1
## 4123  3.175633e+00                            ZM 306416 D019_r1
## 4124  3.150100e+00                        ZM 323881 HCl D019_r1
## 4125  6.548481e-01                            ZM 336372 D019_r1
## 4126  1.885673e+00                         ZM 39923 HCl D019_r1
## 4127  2.042982e+00                            ZM 447439 D019_r1
## 4128  2.224513e+00                 Zotarolimus(ABT-578) D019_r1
## 4129  1.562601e+00                              ZSTK474 D019_r1
## 4130  3.361794e+00                     1-Azakenpaullone D019_r2
## 4131  1.433108e+00                      3-Methyladenine D019_r2
## 4132  4.509564e+00                             A-674563 D019_r2
## 4133  2.605623e+00                             A-769662 D019_r2
## 4134  3.981870e+00                                  A66 D019_r2
## 4135  3.435561e+00                            Acadesine D019_r2
## 4136  5.993564e+00                  AEE788 (NVP-AEE788) D019_r2
## 4137  3.640663e+00        Afatinib (BIBW2992)_uncertain D019_r2
## 4138  1.473454e+00                              AG-1024 D019_r2
## 4139  4.227519e+00         AG-1478 (Tyrphostin AG-1478) D019_r2
## 4140  3.698179e+00                                AG-18 D019_r2
## 4141  2.621031e+00              AG-490 (Tyrphostin B42) D019_r2
## 4142  2.225871e+00                             Akti-1/2 D019_r2
## 4143  3.714951e+00                  Alisertib (MLN8237) D019_r2
## 4144  2.704976e+00                              AMG 337 D019_r2
## 4145  2.648811e+00                              AMG-458 D019_r2
## 4146  5.708415e+00                              AMG-900 D019_r2
## 4147  3.393330e+00                               AMG319 D019_r2
## 4148  1.615827e+00                  Amuvatinib (MP-470) D019_r2
## 4149  3.494647e+00                             Apatinib D019_r2
## 4150  2.924845e+00                           AR-A014418 D019_r2
## 4151  2.369446e+00                            AS-252424 D019_r2
## 4152  2.313144e+00                            AS-604850 D019_r2
## 4153  2.949631e+00                         Asiatic Acid D019_r2
## 4154  2.981244e+00                             AST-1306 D019_r2
## 4155  5.738117e-01                              AT13148 D019_r2
## 4156  4.467279e+00                               AT7519 D019_r2
## 4157  2.075022e+00                               AT7867 D019_r2
## 4158  5.442500e+00                               AT9283 D019_r2
## 4159  2.022373e+00                 Aurora A Inhibitor I D019_r2
## 4160  2.820304e+00             Avagacestat (BMS-708163) D019_r2
## 4161  4.116009e+00                              AVL-292 D019_r2
## 4162  2.111683e+00                             Axitinib D019_r2
## 4163  2.111683e+00                             Axitinib D019_r2
## 4164  3.613376e+00                               AZ 628 D019_r2
## 4165  3.798908e+00                               AZ 960 D019_r2
## 4166  4.986587e+00                                 AZ20 D019_r2
## 4167  2.760485e+00                              AZD1080 D019_r2
## 4168  4.362247e+00                              AZD1480 D019_r2
## 4169  4.307797e+00                              AZD2014 D019_r2
## 4170  4.675353e+00                              AZD2858 D019_r2
## 4171  3.134537e+00                              AZD2932 D019_r2
## 4172  4.054162e+00                              AZD3759 D019_r2
## 4173  2.758496e+00                              AZD5363 D019_r2
## 4174  9.421833e-02                              AZD5438 D019_r2
## 4175  3.551299e+00                              AZD6482 D019_r2
## 4176  6.003680e+00                              AZD6738 D019_r2
## 4177  3.808692e+00                              AZD8055 D019_r2
## 4178  4.621222e+00                              AZD8330 D019_r2
## 4179  5.910053e+00                  AZD8931 (Sapitinib) D019_r2
## 4180  3.583958e+00                              AZD9291 D019_r2
## 4181  4.134890e+00            Barasertib (AZD1152-HQPA) D019_r2
## 4182  6.163256e-01  Baricitinib (LY3009104, INCB028050) D019_r2
## 4183 -7.661054e+00                  BGT226 (NVP-BGT226) D019_r2
## 4184  3.979200e+00                              BI 2536 D019_r2
## 4185  3.093032e+00                              BI-78D3 D019_r2
## 4186  2.392792e+00                             BI-D1870 D019_r2
## 4187  3.329309e+00                              Bikinin D019_r2
## 4188  3.690464e+00                                  BIO D019_r2
## 4189  2.509194e+00               BIRB 796 (Doramapimod) D019_r2
## 4190  2.484266e+00                            BIX 02188 D019_r2
## 4191  2.408654e+00                            BIX 02189 D019_r2
## 4192  3.586039e+00      BKM120 (NVP-BKM120, Buparlisib) D019_r2
## 4193  1.900369e+00                           BMS-265246 D019_r2
## 4194  3.568516e+00                           BMS-536924 D019_r2
## 4195  3.082019e+00                           BMS-582949 D019_r2
## 4196  4.880853e+00                           BMS-754807 D019_r2
## 4197  2.321479e+00                           BMS-777607 D019_r2
## 4198  1.461676e+00                           BMS-794833 D019_r2
## 4199  2.084708e+00                           BMS-833923 D019_r2
## 4200  9.594133e-01                  Bosutinib (SKI-606) D019_r2
## 4201  3.705491e+00                Brivanib (BMS-540215) D019_r2
## 4202  2.691334e+00      Brivanib Alaninate (BMS-582664) D019_r2
## 4203  3.404729e+00                           BS-181 HCl D019_r2
## 4204  1.191158e+00                               Butein D019_r2
## 4205  2.490402e+00                               BYL719 D019_r2
## 4206  3.041932e+00     Cabozantinib (XL184, BMS-907351) D019_r2
## 4207  2.784678e+00          Cabozantinib malate (XL184) D019_r2
## 4208  2.896192e+00        CAL-101 (Idelalisib, GS-1101) D019_r2
## 4209  1.561118e+00                             CAY10505 D019_r2
## 4210  4.994413e+00                               CC-223 D019_r2
## 4211  2.764702e+00                            CCT128930 D019_r2
## 4212  2.263684e+00                  Cediranib (AZD2171) D019_r2
## 4213  3.121550e+00                            CEP-32496 D019_r2
## 4214  2.989884e+00                            CEP-33779 D019_r2
## 4215  3.388862e+00                              CGI1746 D019_r2
## 4216  2.569097e+00                              CGK 733 D019_r2
## 4217  1.941206e+00                            CH5132799 D019_r2
## 4218  3.267842e+00                           CHIR-98014 D019_r2
## 4219  3.618173e+00                 CHIR-99021 (CT99021) D019_r2
## 4220  4.504228e+00             CHIR-99021 (CT99021) HCl D019_r2
## 4221  2.469227e+00                    Chrysophanic Acid D019_r2
## 4222  3.996477e+00                             CNX-2006 D019_r2
## 4223  3.631027e+00                              CNX-774 D019_r2
## 4224  1.352333e+00                    CO-1686 (AVL-301) D019_r2
## 4225  4.934527e+00       Cobimetinib (GDC-0973, RG7420) D019_r2
## 4226  2.431602e+00                            CP-673451 D019_r2
## 4227  3.515729e+00                            CP-724714 D019_r2
## 4228  3.517213e+00               Crenolanib (CP-868596) D019_r2
## 4229  4.008559e+00             Crizotinib (PF-02341066) D019_r2
## 4230  4.932977e+00                               CYC116 D019_r2
## 4231  1.802195e+00                               CYT387 D019_r2
## 4232  2.051740e+00                             CZC24832 D019_r2
## 4233  1.343112e+00              Dabrafenib (GSK2118436) D019_r2
## 4234  4.381937e+00        Dacomitinib (PF299804, PF299) D019_r2
## 4235  4.751963e+00              Danusertib (PHA-739358) D019_r2
## 4236  3.850868e+00                        DAPT (GSI-IX) D019_r2
## 4237  4.590077e+00                            Dasatinib D019_r2
## 4238  3.042923e+00                DCC-2036 (Rebastinib) D019_r2
## 4239  2.016455e+00                Decernotinib (VX-509) D019_r2
## 4240  2.056641e+00               Dinaciclib (SCH727965) D019_r2
## 4241  6.506513e+00    Dovitinib (TKI-258) Dilactic Acid D019_r2
## 4242  4.567895e+00                            ENMD-2076 D019_r2
## 4243  5.015028e+00               Enzastaurin (LY317615) D019_r2
## 4244  4.554242e+00                            ERK5-IN-1 D019_r2
## 4245  2.415871e+00                             ETC-1002 D019_r2
## 4246  2.477621e+00                            ETP-46464 D019_r2
## 4247  2.175754e+00                  Everolimus (RAD001) D019_r2
## 4248  2.739548e+00                Fasudil (HA-1077) HCl D019_r2
## 4249  2.074033e+00                                FH535 D019_r2
## 4250  2.762566e+00                Filgotinib (GLPG0634) D019_r2
## 4251  2.306096e+00             Flavopiridol (Alvocidib) D019_r2
## 4252  3.464232e+00                     Flavopiridol HCl D019_r2
## 4253 -2.040391e-01               Foretinib (GSK1363089) D019_r2
## 4254  3.697343e+00                  Fostamatinib (R788) D019_r2
## 4255  1.253074e+00                                G-749 D019_r2
## 4256  2.980032e+00                             GDC-0068 D019_r2
## 4257  3.703664e+00                             GDC-0349 D019_r2
## 4258  1.771348e+00                             GDC-0879 D019_r2
## 4259  2.422572e+00                             GDC-0941 D019_r2
## 4260  4.418670e+00                    GDC-0980 (RG7422) D019_r2
## 4261  5.128703e+00                   Gefitinib (ZD1839) D019_r2
## 4262  2.989783e+00                            Genistein D019_r2
## 4263  4.327178e+00                            GF109203X D019_r2
## 4264  2.931892e+00                                GNF-2 D019_r2
## 4265  3.359165e+00                                GNF-5 D019_r2
## 4266  4.495963e+00                              Go 6983 D019_r2
## 4267  4.399949e+00                   Golvatinib (E7050) D019_r2
## 4268  2.157169e+00                          GSK1838705A D019_r2
## 4269  2.277433e+00                          GSK1904529A D019_r2
## 4270  3.025050e+00                  GSK2126458 (GSK458) D019_r2
## 4271  3.570793e+00                           GSK2292767 D019_r2
## 4272  3.318410e+00                           GSK2636771 D019_r2
## 4273  2.126118e+00                           GSK429286A D019_r2
## 4274  2.730841e+00                            GSK461364 D019_r2
## 4275  1.740878e+00                               GSK621 D019_r2
## 4276  3.687209e+00                            GSK690693 D019_r2
## 4277  2.089763e+00                               GW5074 D019_r2
## 4278  3.647004e+00                             GW788388 D019_r2
## 4279  4.610566e+00                               GZD824 D019_r2
## 4280  3.525813e+00                            H 89 2HCl D019_r2
## 4281  4.810112e+00                           Hesperadin D019_r2
## 4282  3.419606e+00                              HMN-214 D019_r2
## 4283  2.681557e+00                             Honokiol D019_r2
## 4284  4.859318e+00                               HS-173 D019_r2
## 4285  4.852481e+00                           HTH-01-015 D019_r2
## 4286  2.664174e+00                Ibrutinib (PCI-32765) D019_r2
## 4287  1.965905e+00                              ICG-001 D019_r2
## 4288  2.295308e+00                             Icotinib D019_r2
## 4289  2.555106e+00                                IM-12 D019_r2
## 4290  3.168218e+00           Imatinib Mesylate (STI571) D019_r2
## 4291  3.375507e+00                            Indirubin D019_r2
## 4292  6.481075e+00                    INK 128 (MLN0128) D019_r2
## 4293  2.746432e+00                    IPI-145 (INK1197) D019_r2
## 4294  2.516281e+00                               IWP-L6 D019_r2
## 4295  1.705688e+00                           IWR-1-endo D019_r2
## 4296  3.385648e+00                         JNJ-38877605 D019_r2
## 4297  4.312810e+00                          JNJ-7706621 D019_r2
## 4298  4.541281e+00                     JNK Inhibitor IX D019_r2
## 4299  2.848747e+00                             JNK-IN-8 D019_r2
## 4300  1.503589e+00                               K02288 D019_r2
## 4301  1.748725e+00                               Ki8751 D019_r2
## 4302  4.926980e+00                              KRN 633 D019_r2
## 4303  1.763779e+00                           KU-0063794 D019_r2
## 4304  2.478796e+00      KU-55933 (ATM Kinase Inhibitor) D019_r2
## 4305  3.507645e+00                             KU-60019 D019_r2
## 4306  5.124995e+00                              KW-2449 D019_r2
## 4307  3.781130e+00                              KX2-391 D019_r2
## 4308  2.455111e+00                              KY02111 D019_r2
## 4309  3.024372e+00                            Lapatinib D019_r2
## 4310  3.500251e+00     Lapatinib (GW-572016) Ditosylate D019_r2
## 4311  4.176434e+00                            LDC000067 D019_r2
## 4312  3.083408e+00      LDE225 (NVP-LDE225,Erismodegib) D019_r2
## 4313  2.036599e+00                           LDN-214117 D019_r2
## 4314  2.796039e+00                   Lenvatinib (E7080) D019_r2
## 4315  2.353991e+00                              LFM-A13 D019_r2
## 4316  2.785513e+00                              LGK-974 D019_r2
## 4317  1.734373e+00                  Linifanib (ABT-869) D019_r2
## 4318  8.545544e-01                               LJH685 D019_r2
## 4319  3.076171e+00                               LJI308 D019_r2
## 4320  3.238955e+00               Losmapimod (GW856553X) D019_r2
## 4321  2.849538e+00                            LY2090314 D019_r2
## 4322  2.253255e+00                            LY2157299 D019_r2
## 4323  3.137211e+00                            LY2784544 D019_r2
## 4324  3.071409e+00                            LY2835219 D019_r2
## 4325  3.658421e+00                             LY294002 D019_r2
## 4326  3.484888e+00                            LY3023414 D019_r2
## 4327  3.526997e+00                             LY411575 D019_r2
## 4328  3.902284e+00       MEK162 (ARRY-162, ARRY-438162) D019_r2
## 4329  2.803426e+00                             MGCD-265 D019_r2
## 4330  5.990781e+00               Milciclib (PHA-848125) D019_r2
## 4331  4.031403e+00                              MK-0752 D019_r2
## 4332  2.019524e+00                         MK-2206 2HCl D019_r2
## 4333  1.485275e+00                              MK-2461 D019_r2
## 4334  2.559351e+00                     MK-5108 (VX-689) D019_r2
## 4335  3.998822e+00                              MK-8745 D019_r2
## 4336  4.388435e+00                              MLN2480 D019_r2
## 4337  2.118286e+00                              MLN8054 D019_r2
## 4338  1.310713e+00      Motesanib Diphosphate (AMG-706) D019_r2
## 4339  2.253972e+00                  Nilotinib (AMN-107) D019_r2
## 4340  2.018710e+00     Nintedanib (BIBF 1120)_uncertain D019_r2
## 4341  3.309664e+00                               NU6027 D019_r2
## 4342  4.759184e+00                           NVP-AEW541 D019_r2
## 4343  3.362809e+00                           NVP-BHG712 D019_r2
## 4344  3.200393e+00                      NVP-BSK805 2HCl D019_r2
## 4345  3.042275e+00                           NVP-BVU972 D019_r2
## 4346  2.346270e+00                          Oclacitinib D019_r2
## 4347  3.547500e+00      Olmutinib (HM61713, BI 1482694) D019_r2
## 4348  2.779423e+00                             ONO-4059 D019_r2
## 4349  2.894884e+00                              OSI-027 D019_r2
## 4350  5.548414e+00                              OSI-420 D019_r2
## 4351  1.560167e+00                 OSI-906 (Linsitinib) D019_r2
## 4352  4.582802e+00                              P276-00 D019_r2
## 4353  3.442940e+00                  Pacritinib (SB1518) D019_r2
## 4354  2.325764e+00                   Palomid 529 (P529) D019_r2
## 4355  2.427148e+00                            Pazopanib D019_r2
## 4356  2.757867e+00                        Pazopanib HCl D019_r2
## 4357  3.149933e+00                            PD0325901 D019_r2
## 4358  2.849302e+00                             PD168393 D019_r2
## 4359  2.687397e+00                             PD173955 D019_r2
## 4360  3.147922e+00                   PD184352 (CI-1040) D019_r2
## 4361  4.142955e+00                             PD318088 D019_r2
## 4362  3.537180e+00                              PD98059 D019_r2
## 4363  2.210648e+00                  Pelitinib (EKB-569) D019_r2
## 4364  4.256497e+00                          PF-00562271 D019_r2
## 4365  3.531312e+00                          PF-04217903 D019_r2
## 4366  4.478965e+00                          PF-04691502 D019_r2
## 4367  3.158075e+00                            PF-431396 D019_r2
## 4368  3.039093e+00                           PF-4708671 D019_r2
## 4369  3.032809e+00                           PF-5274857 D019_r2
## 4370  5.251874e+00                            PF-562271 D019_r2
## 4371  3.722069e+00                            PF-573228 D019_r2
## 4372  2.329283e+00                            PH-797804 D019_r2
## 4373  3.064344e+00                           PHA-665752 D019_r2
## 4374  2.551299e+00                           PHA-680632 D019_r2
## 4375  3.485896e+00                           PHA-767491 D019_r2
## 4376  2.940214e+00                           PHA-793887 D019_r2
## 4377  1.459223e+00                       Phenformin HCl D019_r2
## 4378  3.574255e+00                              PHT-427 D019_r2
## 4379  3.382984e+00                          Piceatannol D019_r2
## 4380  3.357536e+00                              PIK-293 D019_r2
## 4381  2.559774e+00                              PIK-294 D019_r2
## 4382  5.237393e+00                               PIK-93 D019_r2
## 4383  4.858357e+00               Pimasertib (AS-703026) D019_r2
## 4384  4.179660e+00                          Pirfenidone D019_r2
## 4385  1.805003e+00                             PLX-4720 D019_r2
## 4386  2.657791e+00                              PLX7904 D019_r2
## 4387  4.447928e+00                  Ponatinib (AP24534) D019_r2
## 4388  2.205457e+00                                  PP1 D019_r2
## 4389  2.580227e+00                                  PP2 D019_r2
## 4390  2.940956e+00                                PP242 D019_r2
## 4391  3.316489e+00                               PQ 401 D019_r2
## 4392  9.812788e-01                              PRI-724 D019_r2
## 4393  3.424809e+00     PRT062607 (P505-15, BIIB057) HCl D019_r2
## 4394  3.768301e+00                         Purvalanol A D019_r2
## 4395  3.005531e+00                            Quercetin D019_r2
## 4396  5.091409e+00                  Quizartinib (AC220) D019_r2
## 4397  4.443598e+00                                 R406 D019_r2
## 4398  1.867293e+00                     R406 (free base) D019_r2
## 4399  3.636814e+00                                 R547 D019_r2
## 4400  5.051158e+00                    RAF265 (CHIR-265) D019_r2
## 4401  3.730027e+00                Rapamycin (Sirolimus) D019_r2
## 4402  3.696853e+00   Refametinib (RDEA119, Bay 86-9766) D019_r2
## 4403  3.052709e+00                               RepSox D019_r2
## 4404  1.278108e+00 Ridaforolimus (Deforolimus, MK-8669) D019_r2
## 4405  3.301561e+00                Rigosertib (ON-01910) D019_r2
## 4406  2.099132e+00                             RKI-1447 D019_r2
## 4407  2.969747e+00                                RN486 D019_r2
## 4408  5.150967e+00                  Ro 31-8220 Mesylate D019_r2
## 4409  2.252795e+00                              Ro-3306 D019_r2
## 4410  4.546160e+00                               Ro3280 D019_r2
## 4411  1.707545e+00                            RO4929097 D019_r2
## 4412  3.689497e+00      Roscovitine (Seliciclib,CYC202) D019_r2
## 4413  2.155367e+00             Ruxolitinib (INCB018424) D019_r2
## 4414  2.800154e+00           S-Ruxolitinib (INCB018424) D019_r2
## 4415  4.457763e+00                               SANT-1 D019_r2
## 4416  2.648669e+00                            SAR131675 D019_r2
## 4417  2.980300e+00                    SAR245409 (XL765) D019_r2
## 4418  3.155079e+00                Saracatinib (AZD0530) D019_r2
## 4419  1.800651e+00                      SB202190 (FHPI) D019_r2
## 4420  1.191783e+00                             SB203580 D019_r2
## 4421  2.641237e+00                             SB216763 D019_r2
## 4422  2.277559e+00                             SB239063 D019_r2
## 4423  3.172517e+00                             SB415286 D019_r2
## 4424  2.138962e+00                             SB431542 D019_r2
## 4425  1.607937e+00                             SB505124 D019_r2
## 4426  2.153223e+00                             SB525334 D019_r2
## 4427  1.018410e+00                             SB590885 D019_r2
## 4428  4.795565e+00                                  SC1 D019_r2
## 4429  2.744424e+00                Schisandrin B (Sch B) D019_r2
## 4430  4.153442e+00                Selumetinib (AZD6244) D019_r2
## 4431  2.052898e+00              Semagacestat (LY450139) D019_r2
## 4432  2.609658e+00                   Semaxanib (SU5416) D019_r2
## 4433  5.853290e+00                             SGI-7079 D019_r2
## 4434  1.575866e+00                          Skepinone-L D019_r2
## 4435  2.833765e+00                               SL-327 D019_r2
## 4436  3.710481e+00                 SNS-032 (BMS-387032) D019_r2
## 4437  3.690722e+00                     SNS-314 Mesylate D019_r2
## 4438  4.096810e+00                            Sorafenib D019_r2
## 4439  2.265474e+00                   Sorafenib Tosylate D019_r2
## 4440  3.358443e+00                         Sotrastaurin D019_r2
## 4441  2.831961e+00                             SP600125 D019_r2
## 4442  1.269366e+00                              SU11274 D019_r2
## 4443  3.273799e+00                               SU6656 D019_r2
## 4444  3.020931e+00                               SU9516 D019_r2
## 4445  1.893101e+00                     Sunitinib Malate D019_r2
## 4446  3.725298e+00                  TAE226 (NVP-TAE226) D019_r2
## 4447  4.080022e+00                              TAK-285 D019_r2
## 4448  4.661664e+00                              TAK-632 D019_r2
## 4449  2.176804e+00                              TAK-715 D019_r2
## 4450  5.839263e+00                              TAK-733 D019_r2
## 4451  1.949433e+00                              TAK-901 D019_r2
## 4452  2.545497e+00                Taladegib (LY2940680) D019_r2
## 4453  2.900602e+00                              TCS 359 D019_r2
## 4454  2.708177e+00                               TDZD-8 D019_r2
## 4455  1.676802e+00                            Telatinib D019_r2
## 4456  3.334757e+00   Temsirolimus (CCI-779, NSC 683864) D019_r2
## 4457  1.854321e+00              Tepotinib (EMD 1214063) D019_r2
## 4458  1.746013e+00                                TG003 D019_r2
## 4459  2.469539e+00                            TG100-115 D019_r2
## 4460  4.553421e+00                             TG101209 D019_r2
## 4461  1.968850e+00                 TG101348 (SAR302503) D019_r2
## 4462  2.224185e+00                              TGX-221 D019_r2
## 4463  2.777637e+00                         Theophylline D019_r2
## 4464  1.837880e+00                          Thiazovivin D019_r2
## 4465  3.572777e+00                       TIC10 Analogue D019_r2
## 4466  3.466858e+00                           Tideglusib D019_r2
## 4467  5.411567e+00                 Tivantinib (ARQ 197) D019_r2
## 4468  9.165745e-01                   Tivozanib (AV-951) D019_r2
## 4469  3.077031e+00  Tofacitinib (CP-690550,Tasocitinib) D019_r2
## 4470  2.632497e+00      Tofacitinib (CP-690550) Citrate D019_r2
## 4471  4.080184e+00                              Torin 2 D019_r2
## 4472  6.108397e+00              Trametinib (GSK1120212) D019_r2
## 4473  2.243134e+00                          Triciribine D019_r2
## 4474  2.737503e+00           TSU-68 (SU6668, Orantinib) D019_r2
## 4475  2.142217e+00                               TWS119 D019_r2
## 4476  4.058074e+00                         Tyrphostin 9 D019_r2
## 4477  1.949751e+00                   Tyrphostin AG 1296 D019_r2
## 4478  5.001344e+00                           U0126-EtOH D019_r2
## 4479  4.539157e+00     Ulixertinib (BVD-523, VRT752271) D019_r2
## 4480  1.787282e+00              Uprosertib (GSK2141795) D019_r2
## 4481  3.891507e+00                          Vacquinol-1 D019_r2
## 4482  3.874495e+00                           Varlitinib D019_r2
## 4483  6.495298e-01              Vatalanib (PTK787) 2HCl D019_r2
## 4484  2.703140e+00                               VE-821 D019_r2
## 4485  5.947404e+00                               VE-822 D019_r2
## 4486  2.491567e+00        Vemurafenib (PLX4032, RG7204) D019_r2
## 4487  2.383135e+00                Vismodegib (GDC-0449) D019_r2
## 4488  2.839696e+00                 Volasertib (BI 6727) D019_r2
## 4489  4.832704e+00                            VPS34-IN1 D019_r2
## 4490  6.279529e+00                     VS-5584 (SB2343) D019_r2
## 4491  5.641767e+00                               VX-11e D019_r2
## 4492  4.487825e+00         VX-680 (Tozasertib, MK-0457) D019_r2
## 4493  1.288347e+00                               VX-702 D019_r2
## 4494  3.130256e+00                               VX-745 D019_r2
## 4495  3.821469e+00                              WAY-600 D019_r2
## 4496  1.144438e+00                             WH-4-023 D019_r2
## 4497  1.810798e+00                             WHI-P154 D019_r2
## 4498  3.448511e+00                                WIKI4 D019_r2
## 4499  4.081874e+00                        Wnt agonist 1 D019_r2
## 4500  2.548938e+00                        Wnt-C59 (C59) D019_r2
## 4501  2.842536e+00                               WP1066 D019_r2
## 4502  1.946733e+00                 WYE-125132 (WYE-132) D019_r2
## 4503  3.970331e+00                              WYE-354 D019_r2
## 4504  4.247855e+00                               WZ3146 D019_r2
## 4505  2.769891e+00                               WZ4002 D019_r2
## 4506  3.384882e+00                               WZ4003 D019_r2
## 4507  2.881792e+00                               WZ8040 D019_r2
## 4508  1.594535e+00                              XAV-939 D019_r2
## 4509  2.161723e+00                                XL019 D019_r2
## 4510  2.737548e+00                              XMD8-92 D019_r2
## 4511  1.276145e+00                         Y-27632 2HCl D019_r2
## 4512  3.538634e+00                             YM201636 D019_r2
## 4513  3.401907e+00                             YO-01027 D019_r2
## 4514  3.067578e+00                            ZM 306416 D019_r2
## 4515  1.973075e+00                        ZM 323881 HCl D019_r2
## 4516  1.076342e+00                            ZM 336372 D019_r2
## 4517  3.043948e+00                         ZM 39923 HCl D019_r2
## 4518  2.091679e+00                            ZM 447439 D019_r2
## 4519  1.655864e+00                 Zotarolimus(ABT-578) D019_r2
## 4520  2.082477e+00                              ZSTK474 D019_r2
## 4521  2.260343e+00                     1-Azakenpaullone D020_r1
## 4522  1.734081e+00                      3-Methyladenine D020_r1
## 4523 -5.021060e-01                             A-674563 D020_r1
## 4524  9.138053e-01                             A-769662 D020_r1
## 4525  4.780884e+00                                  A66 D020_r1
## 4526  2.221225e+00                            Acadesine D020_r1
## 4527  5.496074e+00                  AEE788 (NVP-AEE788) D020_r1
## 4528  8.687840e-01        Afatinib (BIBW2992)_uncertain D020_r1
## 4529  9.015505e-01                              AG-1024 D020_r1
## 4530  6.092905e+00         AG-1478 (Tyrphostin AG-1478) D020_r1
## 4531  1.446272e+00                                AG-18 D020_r1
## 4532  1.843272e+00              AG-490 (Tyrphostin B42) D020_r1
## 4533  2.460856e+00                             Akti-1/2 D020_r1
## 4534  1.107210e+00                  Alisertib (MLN8237) D020_r1
## 4535  1.395297e+00                              AMG 337 D020_r1
## 4536  1.478287e+00                              AMG-458 D020_r1
## 4537  2.273384e+00                              AMG-900 D020_r1
## 4538  2.702574e+00                               AMG319 D020_r1
## 4539  1.202347e+00                  Amuvatinib (MP-470) D020_r1
## 4540  8.684453e-01                             Apatinib D020_r1
## 4541  2.413532e+00                           AR-A014418 D020_r1
## 4542  9.767476e-01                            AS-252424 D020_r1
## 4543  1.718303e+00                            AS-604850 D020_r1
## 4544  2.347846e+00                         Asiatic Acid D020_r1
## 4545  4.979942e+00                             AST-1306 D020_r1
## 4546  9.255753e-01                              AT13148 D020_r1
## 4547  9.100146e-01                               AT7519 D020_r1
## 4548  1.188067e+00                               AT7867 D020_r1
## 4549 -5.287874e-01                               AT9283 D020_r1
## 4550  1.893216e+00                 Aurora A Inhibitor I D020_r1
## 4551  2.157611e+00             Avagacestat (BMS-708163) D020_r1
## 4552  2.568575e+00                              AVL-292 D020_r1
## 4553  2.527220e+00                             Axitinib D020_r1
## 4554  2.527220e+00                             Axitinib D020_r1
## 4555  4.592317e+00                               AZ 628 D020_r1
## 4556  1.004032e+00                               AZ 960 D020_r1
## 4557  1.663484e+00                                 AZ20 D020_r1
## 4558  2.682620e+00                              AZD1080 D020_r1
## 4559  1.091584e+00                              AZD1480 D020_r1
## 4560  5.807597e+00                              AZD2014 D020_r1
## 4561  2.608290e+00                              AZD2858 D020_r1
## 4562  8.177272e-01                              AZD2932 D020_r1
## 4563  5.668607e+00                              AZD3759 D020_r1
## 4564  3.262893e+00                              AZD5363 D020_r1
## 4565  6.745718e-01                              AZD5438 D020_r1
## 4566  1.815215e+00                              AZD6482 D020_r1
## 4567  6.546320e-01                              AZD6738 D020_r1
## 4568  6.955030e+00                              AZD8055 D020_r1
## 4569  4.548224e+00                              AZD8330 D020_r1
## 4570  6.351848e+00                  AZD8931 (Sapitinib) D020_r1
## 4571  3.413618e-01                              AZD9291 D020_r1
## 4572  1.826794e+00            Barasertib (AZD1152-HQPA) D020_r1
## 4573  1.229148e+00  Baricitinib (LY3009104, INCB028050) D020_r1
## 4574 -9.288082e+00                  BGT226 (NVP-BGT226) D020_r1
## 4575 -4.560806e-01                              BI 2536 D020_r1
## 4576  2.736349e+00                              BI-78D3 D020_r1
## 4577  1.744314e+00                             BI-D1870 D020_r1
## 4578  1.938679e+00                              Bikinin D020_r1
## 4579  9.695471e-01                                  BIO D020_r1
## 4580  7.787247e-01               BIRB 796 (Doramapimod) D020_r1
## 4581  5.061886e-01                            BIX 02188 D020_r1
## 4582  2.788028e+00                            BIX 02189 D020_r1
## 4583  1.077612e+00      BKM120 (NVP-BKM120, Buparlisib) D020_r1
## 4584  9.317943e-01                           BMS-265246 D020_r1
## 4585  2.225624e+00                           BMS-536924 D020_r1
## 4586  1.754206e+00                           BMS-582949 D020_r1
## 4587  1.891674e+00                           BMS-754807 D020_r1
## 4588  1.599353e+00                           BMS-777607 D020_r1
## 4589  1.254188e+00                           BMS-794833 D020_r1
## 4590  1.205547e+00                           BMS-833923 D020_r1
## 4591  2.592886e+00                  Bosutinib (SKI-606) D020_r1
## 4592  2.008127e+00                Brivanib (BMS-540215) D020_r1
## 4593  2.772097e+00      Brivanib Alaninate (BMS-582664) D020_r1
## 4594  1.112580e+00                           BS-181 HCl D020_r1
## 4595  1.623487e+00                               Butein D020_r1
## 4596  3.810755e+00                               BYL719 D020_r1
## 4597  2.521363e+00     Cabozantinib (XL184, BMS-907351) D020_r1
## 4598  8.720529e-01          Cabozantinib malate (XL184) D020_r1
## 4599  2.551876e+00        CAL-101 (Idelalisib, GS-1101) D020_r1
## 4600  2.004035e+00                             CAY10505 D020_r1
## 4601  3.981981e+00                               CC-223 D020_r1
## 4602  3.965342e+00                            CCT128930 D020_r1
## 4603  9.763056e-01                  Cediranib (AZD2171) D020_r1
## 4604  1.333095e+00                            CEP-32496 D020_r1
## 4605  2.775769e+00                            CEP-33779 D020_r1
## 4606  2.551355e+00                              CGI1746 D020_r1
## 4607  2.016177e+00                              CGK 733 D020_r1
## 4608  5.195227e+00                            CH5132799 D020_r1
## 4609  3.136941e+00                           CHIR-98014 D020_r1
## 4610  2.877569e+00                 CHIR-99021 (CT99021) D020_r1
## 4611  2.956794e+00             CHIR-99021 (CT99021) HCl D020_r1
## 4612  2.195131e+00                    Chrysophanic Acid D020_r1
## 4613  6.246058e+00                             CNX-2006 D020_r1
## 4614  1.805398e+00                              CNX-774 D020_r1
## 4615  3.156515e+00                    CO-1686 (AVL-301) D020_r1
## 4616  3.866557e+00       Cobimetinib (GDC-0973, RG7420) D020_r1
## 4617  1.943045e+00                            CP-673451 D020_r1
## 4618  2.135144e+00                            CP-724714 D020_r1
## 4619  1.039344e-01               Crenolanib (CP-868596) D020_r1
## 4620  7.246098e-01             Crizotinib (PF-02341066) D020_r1
## 4621  2.204375e+00                               CYC116 D020_r1
## 4622  2.100642e+00                               CYT387 D020_r1
## 4623  8.238271e-01                             CZC24832 D020_r1
## 4624  1.473361e+00              Dabrafenib (GSK2118436) D020_r1
## 4625  3.692665e+00        Dacomitinib (PF299804, PF299) D020_r1
## 4626  7.760071e-01              Danusertib (PHA-739358) D020_r1
## 4627  3.536683e+00                        DAPT (GSI-IX) D020_r1
## 4628  3.812024e+00                            Dasatinib D020_r1
## 4629  2.371658e+00                DCC-2036 (Rebastinib) D020_r1
## 4630  7.535047e-01                Decernotinib (VX-509) D020_r1
## 4631 -5.628997e-01               Dinaciclib (SCH727965) D020_r1
## 4632  1.549042e+00    Dovitinib (TKI-258) Dilactic Acid D020_r1
## 4633  3.083457e+00                            ENMD-2076 D020_r1
## 4634  2.632868e+00               Enzastaurin (LY317615) D020_r1
## 4635  2.476046e+00                            ERK5-IN-1 D020_r1
## 4636  2.101946e+00                             ETC-1002 D020_r1
## 4637  3.576038e+00                            ETP-46464 D020_r1
## 4638  3.190576e+00                  Everolimus (RAD001) D020_r1
## 4639  2.060966e+00                Fasudil (HA-1077) HCl D020_r1
## 4640  2.072285e+00                                FH535 D020_r1
## 4641  2.497790e+00                Filgotinib (GLPG0634) D020_r1
## 4642  1.859261e-01             Flavopiridol (Alvocidib) D020_r1
## 4643 -6.509898e-02                     Flavopiridol HCl D020_r1
## 4644  7.078303e-01               Foretinib (GSK1363089) D020_r1
## 4645  2.345264e+00                  Fostamatinib (R788) D020_r1
## 4646  2.888141e+00                                G-749 D020_r1
## 4647  3.501979e+00                             GDC-0068 D020_r1
## 4648  5.250802e+00                             GDC-0349 D020_r1
## 4649  7.729807e-01                             GDC-0879 D020_r1
## 4650  3.453518e+00                             GDC-0941 D020_r1
## 4651  4.928535e+00                    GDC-0980 (RG7422) D020_r1
## 4652  6.094143e+00                   Gefitinib (ZD1839) D020_r1
## 4653  1.128047e+00                            Genistein D020_r1
## 4654  4.422781e+00                            GF109203X D020_r1
## 4655  1.843550e+00                                GNF-2 D020_r1
## 4656  1.553516e+00                                GNF-5 D020_r1
## 4657  4.199919e+00                              Go 6983 D020_r1
## 4658  7.420815e-01                   Golvatinib (E7050) D020_r1
## 4659  4.657529e+00                          GSK1838705A D020_r1
## 4660  3.072965e+00                          GSK1904529A D020_r1
## 4661  2.825635e+00                  GSK2126458 (GSK458) D020_r1
## 4662  3.853172e+00                           GSK2292767 D020_r1
## 4663  1.200198e+00                           GSK2636771 D020_r1
## 4664 -2.328616e-02                           GSK429286A D020_r1
## 4665  1.342080e+00                            GSK461364 D020_r1
## 4666  9.749073e-01                               GSK621 D020_r1
## 4667  2.957782e+00                            GSK690693 D020_r1
## 4668  1.563714e+00                               GW5074 D020_r1
## 4669  1.955842e+00                             GW788388 D020_r1
## 4670  9.101853e-01                               GZD824 D020_r1
## 4671  2.342131e+00                            H 89 2HCl D020_r1
## 4672  6.006167e-01                           Hesperadin D020_r1
## 4673  1.285366e+00                              HMN-214 D020_r1
## 4674  1.937113e+00                             Honokiol D020_r1
## 4675  1.429353e+00                               HS-173 D020_r1
## 4676  9.484889e-01                           HTH-01-015 D020_r1
## 4677  4.119958e+00                Ibrutinib (PCI-32765) D020_r1
## 4678  1.988775e+00                              ICG-001 D020_r1
## 4679  3.142219e+00                             Icotinib D020_r1
## 4680  1.773438e+00                                IM-12 D020_r1
## 4681  5.437872e+00           Imatinib Mesylate (STI571) D020_r1
## 4682  6.616151e-01                            Indirubin D020_r1
## 4683  4.975831e+00                    INK 128 (MLN0128) D020_r1
## 4684  3.703914e+00                    IPI-145 (INK1197) D020_r1
## 4685  2.590580e+00                               IWP-L6 D020_r1
## 4686  7.130598e-01                           IWR-1-endo D020_r1
## 4687  1.941979e+00                         JNJ-38877605 D020_r1
## 4688  2.646964e+00                          JNJ-7706621 D020_r1
## 4689  1.387238e-01                     JNK Inhibitor IX D020_r1
## 4690  3.517726e+00                             JNK-IN-8 D020_r1
## 4691  1.973633e+00                               K02288 D020_r1
## 4692  1.287608e+00                               Ki8751 D020_r1
## 4693  5.099610e-01                              KRN 633 D020_r1
## 4694  4.174022e+00                           KU-0063794 D020_r1
## 4695  1.859465e+00      KU-55933 (ATM Kinase Inhibitor) D020_r1
## 4696  1.416188e+00                             KU-60019 D020_r1
## 4697  2.902913e+00                              KW-2449 D020_r1
## 4698  9.408997e-01                              KX2-391 D020_r1
## 4699  9.365297e-01                              KY02111 D020_r1
## 4700  1.339334e+00                            Lapatinib D020_r1
## 4701  2.136852e+00     Lapatinib (GW-572016) Ditosylate D020_r1
## 4702  4.300570e+00                            LDC000067 D020_r1
## 4703  2.045451e+00      LDE225 (NVP-LDE225,Erismodegib) D020_r1
## 4704  2.429852e+00                           LDN-214117 D020_r1
## 4705  1.543496e+00                   Lenvatinib (E7080) D020_r1
## 4706  1.007253e+00                              LFM-A13 D020_r1
## 4707  1.891442e+00                              LGK-974 D020_r1
## 4708  8.449194e-01                  Linifanib (ABT-869) D020_r1
## 4709  2.126971e+00                               LJH685 D020_r1
## 4710  1.590486e+00                               LJI308 D020_r1
## 4711  1.625190e+00               Losmapimod (GW856553X) D020_r1
## 4712  1.697140e+00                            LY2090314 D020_r1
## 4713  1.294517e+00                            LY2157299 D020_r1
## 4714  4.163868e-02                            LY2784544 D020_r1
## 4715  5.013863e+00                            LY2835219 D020_r1
## 4716  2.866619e+00                             LY294002 D020_r1
## 4717  3.902142e+00                            LY3023414 D020_r1
## 4718  2.671862e+00                             LY411575 D020_r1
## 4719  5.531869e+00       MEK162 (ARRY-162, ARRY-438162) D020_r1
## 4720  1.901001e+00                             MGCD-265 D020_r1
## 4721  8.665717e-01               Milciclib (PHA-848125) D020_r1
## 4722  2.209421e+00                              MK-0752 D020_r1
## 4723  5.404026e+00                         MK-2206 2HCl D020_r1
## 4724  1.813765e+00                              MK-2461 D020_r1
## 4725  8.193480e-01                     MK-5108 (VX-689) D020_r1
## 4726  1.075616e+00                              MK-8745 D020_r1
## 4727  2.231676e+00                              MLN2480 D020_r1
## 4728  1.286800e+00                              MLN8054 D020_r1
## 4729  5.660577e-01      Motesanib Diphosphate (AMG-706) D020_r1
## 4730 -4.541129e-01                  Nilotinib (AMN-107) D020_r1
## 4731  2.324857e+00     Nintedanib (BIBF 1120)_uncertain D020_r1
## 4732  1.392422e+00                               NU6027 D020_r1
## 4733  1.220717e+00                           NVP-AEW541 D020_r1
## 4734  1.275195e+00                           NVP-BHG712 D020_r1
## 4735  1.403050e+00                      NVP-BSK805 2HCl D020_r1
## 4736  1.350323e+00                           NVP-BVU972 D020_r1
## 4737  1.601950e+00                          Oclacitinib D020_r1
## 4738  2.779022e+00      Olmutinib (HM61713, BI 1482694) D020_r1
## 4739  4.421983e+00                             ONO-4059 D020_r1
## 4740  5.675671e+00                              OSI-027 D020_r1
## 4741  5.573313e+00                              OSI-420 D020_r1
## 4742  4.062128e+00                 OSI-906 (Linsitinib) D020_r1
## 4743 -5.730753e-01                              P276-00 D020_r1
## 4744 -4.470117e+00                  Pacritinib (SB1518) D020_r1
## 4745  1.863345e+00                   Palomid 529 (P529) D020_r1
## 4746  1.069523e+00                            Pazopanib D020_r1
## 4747  1.637425e+00                        Pazopanib HCl D020_r1
## 4748  5.062142e+00                            PD0325901 D020_r1
## 4749  4.504681e+00                             PD168393 D020_r1
## 4750  7.482683e-01                             PD173955 D020_r1
## 4751  5.016450e+00                   PD184352 (CI-1040) D020_r1
## 4752  4.857013e+00                             PD318088 D020_r1
## 4753  2.355968e+00                              PD98059 D020_r1
## 4754  4.364705e+00                  Pelitinib (EKB-569) D020_r1
## 4755  1.788211e+00                          PF-00562271 D020_r1
## 4756  1.562011e+00                          PF-04217903 D020_r1
## 4757  4.169809e+00                          PF-04691502 D020_r1
## 4758  1.626615e+00                            PF-431396 D020_r1
## 4759  9.512893e-01                           PF-4708671 D020_r1
## 4760  2.188822e+00                           PF-5274857 D020_r1
## 4761  2.394319e+00                            PF-562271 D020_r1
## 4762  2.228794e+00                            PF-573228 D020_r1
## 4763  1.486453e+00                            PH-797804 D020_r1
## 4764  1.857858e+00                           PHA-665752 D020_r1
## 4765  1.681000e+00                           PHA-680632 D020_r1
## 4766  1.086174e+00                           PHA-767491 D020_r1
## 4767  2.030425e+00                           PHA-793887 D020_r1
## 4768  1.732400e+00                       Phenformin HCl D020_r1
## 4769  1.080519e+00                              PHT-427 D020_r1
## 4770  3.068601e+00                          Piceatannol D020_r1
## 4771  2.510853e+00                              PIK-293 D020_r1
## 4772 -2.866784e-01                              PIK-294 D020_r1
## 4773  4.477776e+00                               PIK-93 D020_r1
## 4774  3.947098e+00               Pimasertib (AS-703026) D020_r1
## 4775  2.149196e+00                          Pirfenidone D020_r1
## 4776  1.880811e+00                             PLX-4720 D020_r1
## 4777  1.511075e+00                              PLX7904 D020_r1
## 4778  3.368349e+00                  Ponatinib (AP24534) D020_r1
## 4779  1.507495e+00                                  PP1 D020_r1
## 4780  2.669176e-01                                  PP2 D020_r1
## 4781  3.201751e+00                                PP242 D020_r1
## 4782  1.964729e+00                               PQ 401 D020_r1
## 4783  1.928615e+00                              PRI-724 D020_r1
## 4784  4.719686e+00     PRT062607 (P505-15, BIIB057) HCl D020_r1
## 4785  1.648659e+00                         Purvalanol A D020_r1
## 4786  1.184626e+00                            Quercetin D020_r1
## 4787  4.336565e+00                  Quizartinib (AC220) D020_r1
## 4788  2.456996e+00                                 R406 D020_r1
## 4789  2.650584e+00                     R406 (free base) D020_r1
## 4790 -3.777375e-02                                 R547 D020_r1
## 4791  5.658751e+00                    RAF265 (CHIR-265) D020_r1
## 4792  2.774637e+00                Rapamycin (Sirolimus) D020_r1
## 4793  3.937663e+00   Refametinib (RDEA119, Bay 86-9766) D020_r1
## 4794 -6.117539e-01                               RepSox D020_r1
## 4795  2.815795e+00 Ridaforolimus (Deforolimus, MK-8669) D020_r1
## 4796  1.738266e-01                Rigosertib (ON-01910) D020_r1
## 4797  2.556172e+00                             RKI-1447 D020_r1
## 4798  1.963010e+00                                RN486 D020_r1
## 4799  1.843953e+00                  Ro 31-8220 Mesylate D020_r1
## 4800  6.226115e-01                              Ro-3306 D020_r1
## 4801  7.295227e-01                               Ro3280 D020_r1
## 4802  1.135631e+00                            RO4929097 D020_r1
## 4803  1.614289e+00      Roscovitine (Seliciclib,CYC202) D020_r1
## 4804  5.336508e-01             Ruxolitinib (INCB018424) D020_r1
## 4805  2.228579e+00           S-Ruxolitinib (INCB018424) D020_r1
## 4806  1.588717e+00                               SANT-1 D020_r1
## 4807  9.096541e-01                            SAR131675 D020_r1
## 4808  1.783372e-01                    SAR245409 (XL765) D020_r1
## 4809  4.640096e+00                Saracatinib (AZD0530) D020_r1
## 4810  1.761040e+00                      SB202190 (FHPI) D020_r1
## 4811  1.881849e-01                             SB203580 D020_r1
## 4812  2.863330e+00                             SB216763 D020_r1
## 4813  2.170121e-01                             SB239063 D020_r1
## 4814  2.783332e+00                             SB415286 D020_r1
## 4815  2.353369e+00                             SB431542 D020_r1
## 4816  1.059492e+00                             SB505124 D020_r1
## 4817  1.859921e+00                             SB525334 D020_r1
## 4818  2.035117e+00                             SB590885 D020_r1
## 4819  8.975839e-01                                  SC1 D020_r1
## 4820  1.818685e+00                Schisandrin B (Sch B) D020_r1
## 4821  5.667002e+00                Selumetinib (AZD6244) D020_r1
## 4822  2.759748e+00              Semagacestat (LY450139) D020_r1
## 4823  1.859447e+00                   Semaxanib (SU5416) D020_r1
## 4824  1.825401e+00                             SGI-7079 D020_r1
## 4825  1.404799e+00                          Skepinone-L D020_r1
## 4826  3.224986e+00                               SL-327 D020_r1
## 4827 -6.961811e-01                 SNS-032 (BMS-387032) D020_r1
## 4828  3.627001e-01                     SNS-314 Mesylate D020_r1
## 4829  3.233139e-01                            Sorafenib D020_r1
## 4830  1.373725e+00                   Sorafenib Tosylate D020_r1
## 4831  2.401708e+00                         Sotrastaurin D020_r1
## 4832  2.337613e+00                             SP600125 D020_r1
## 4833  1.513110e+00                              SU11274 D020_r1
## 4834  1.417171e+00                               SU6656 D020_r1
## 4835  2.059154e+00                               SU9516 D020_r1
## 4836  3.085034e+00                     Sunitinib Malate D020_r1
## 4837  1.774017e+00                  TAE226 (NVP-TAE226) D020_r1
## 4838  3.094739e+00                              TAK-285 D020_r1
## 4839  1.784654e+00                              TAK-632 D020_r1
## 4840  1.742015e+00                              TAK-715 D020_r1
## 4841  4.959271e+00                              TAK-733 D020_r1
## 4842  1.288885e+00                              TAK-901 D020_r1
## 4843  2.324407e+00                Taladegib (LY2940680) D020_r1
## 4844  1.636493e+00                              TCS 359 D020_r1
## 4845  2.162241e+00                               TDZD-8 D020_r1
## 4846  1.204043e+00                            Telatinib D020_r1
## 4847  3.042103e+00   Temsirolimus (CCI-779, NSC 683864) D020_r1
## 4848  1.011222e+00              Tepotinib (EMD 1214063) D020_r1
## 4849  1.767068e+00                                TG003 D020_r1
## 4850  2.139505e+00                            TG100-115 D020_r1
## 4851  6.228714e-01                             TG101209 D020_r1
## 4852 -4.218933e-01                 TG101348 (SAR302503) D020_r1
## 4853  2.948063e+00                              TGX-221 D020_r1
## 4854  2.023041e+00                         Theophylline D020_r1
## 4855  1.327141e+00                          Thiazovivin D020_r1
## 4856  2.448470e+00                       TIC10 Analogue D020_r1
## 4857  1.829633e+00                           Tideglusib D020_r1
## 4858  2.181451e-01                 Tivantinib (ARQ 197) D020_r1
## 4859  4.360455e-01                   Tivozanib (AV-951) D020_r1
## 4860  1.674140e+00  Tofacitinib (CP-690550,Tasocitinib) D020_r1
## 4861  2.133482e+00      Tofacitinib (CP-690550) Citrate D020_r1
## 4862  3.505766e+00                              Torin 2 D020_r1
## 4863  5.250345e+00              Trametinib (GSK1120212) D020_r1
## 4864  2.831276e+00                          Triciribine D020_r1
## 4865  6.627122e-01           TSU-68 (SU6668, Orantinib) D020_r1
## 4866  9.326773e-01                               TWS119 D020_r1
## 4867  3.332725e+00                         Tyrphostin 9 D020_r1
## 4868  1.550642e+00                   Tyrphostin AG 1296 D020_r1
## 4869  2.621905e+00                           U0126-EtOH D020_r1
## 4870  5.187049e+00     Ulixertinib (BVD-523, VRT752271) D020_r1
## 4871  4.707477e+00              Uprosertib (GSK2141795) D020_r1
## 4872 -3.155214e+00                          Vacquinol-1 D020_r1
## 4873  1.098697e+00                           Varlitinib D020_r1
## 4874  9.737009e-01              Vatalanib (PTK787) 2HCl D020_r1
## 4875 -3.081914e-01                               VE-821 D020_r1
## 4876  6.494969e-01                               VE-822 D020_r1
## 4877  1.468599e+00        Vemurafenib (PLX4032, RG7204) D020_r1
## 4878  3.260784e+00                Vismodegib (GDC-0449) D020_r1
## 4879  1.630486e+00                 Volasertib (BI 6727) D020_r1
## 4880  2.160558e+00                            VPS34-IN1 D020_r1
## 4881  5.319688e+00                     VS-5584 (SB2343) D020_r1
## 4882  5.024686e+00                               VX-11e D020_r1
## 4883  1.665108e+00         VX-680 (Tozasertib, MK-0457) D020_r1
## 4884  2.289357e+00                               VX-702 D020_r1
## 4885  1.629650e+00                               VX-745 D020_r1
## 4886  4.352420e+00                              WAY-600 D020_r1
## 4887  8.681620e-01                             WH-4-023 D020_r1
## 4888  1.105284e+00                             WHI-P154 D020_r1
## 4889  1.165246e+00                                WIKI4 D020_r1
## 4890  6.388046e-01                        Wnt agonist 1 D020_r1
## 4891  2.108629e+00                        Wnt-C59 (C59) D020_r1
## 4892  2.689551e+00                               WP1066 D020_r1
## 4893  5.640993e+00                 WYE-125132 (WYE-132) D020_r1
## 4894  5.157759e+00                              WYE-354 D020_r1
## 4895  4.692831e+00                               WZ3146 D020_r1
## 4896  2.542781e+00                               WZ4002 D020_r1
## 4897  3.387364e+00                               WZ4003 D020_r1
## 4898  3.524828e+00                               WZ8040 D020_r1
## 4899  1.217397e+00                              XAV-939 D020_r1
## 4900  1.504816e+00                                XL019 D020_r1
## 4901  4.128442e+00                              XMD8-92 D020_r1
## 4902  9.685745e-01                         Y-27632 2HCl D020_r1
## 4903  2.731713e+00                             YM201636 D020_r1
## 4904  3.001809e+00                             YO-01027 D020_r1
## 4905  3.797700e+00                            ZM 306416 D020_r1
## 4906  2.400057e+00                        ZM 323881 HCl D020_r1
## 4907  5.907661e-01                            ZM 336372 D020_r1
## 4908  2.101796e+00                         ZM 39923 HCl D020_r1
## 4909  3.246434e+00                            ZM 447439 D020_r1
## 4910  3.100048e+00                 Zotarolimus(ABT-578) D020_r1
## 4911  4.744053e+00                              ZSTK474 D020_r1
## 4912  2.878870e+00                     1-Azakenpaullone D020_r2
## 4913  2.462794e+00                      3-Methyladenine D020_r2
## 4914 -4.730878e-01                             A-674563 D020_r2
## 4915  2.772310e+00                             A-769662 D020_r2
## 4916  3.014954e+00                                  A66 D020_r2
## 4917  2.560800e+00                            Acadesine D020_r2
## 4918  4.826307e+00                  AEE788 (NVP-AEE788) D020_r2
## 4919  9.217742e-01        Afatinib (BIBW2992)_uncertain D020_r2
## 4920  1.946715e+00                              AG-1024 D020_r2
## 4921  3.947389e+00         AG-1478 (Tyrphostin AG-1478) D020_r2
## 4922  1.825942e+00                                AG-18 D020_r2
## 4923  1.959152e+00              AG-490 (Tyrphostin B42) D020_r2
## 4924  3.500268e+00                             Akti-1/2 D020_r2
## 4925  2.522349e+00                  Alisertib (MLN8237) D020_r2
## 4926  1.819649e+00                              AMG 337 D020_r2
## 4927  3.396069e+00                              AMG-458 D020_r2
## 4928 -4.316041e-01                              AMG-900 D020_r2
## 4929  1.883939e+00                               AMG319 D020_r2
## 4930  1.429722e+00                  Amuvatinib (MP-470) D020_r2
## 4931  2.735976e+00                             Apatinib D020_r2
## 4932  1.939408e+00                           AR-A014418 D020_r2
## 4933  3.066869e+00                            AS-252424 D020_r2
## 4934  1.581854e+00                            AS-604850 D020_r2
## 4935  1.790877e+00                         Asiatic Acid D020_r2
## 4936  4.552884e+00                             AST-1306 D020_r2
## 4937  2.260971e+00                              AT13148 D020_r2
## 4938 -2.851552e-01                               AT7519 D020_r2
## 4939  1.122748e+00                               AT7867 D020_r2
## 4940 -1.331350e+00                               AT9283 D020_r2
## 4941  3.389095e-01                 Aurora A Inhibitor I D020_r2
## 4942  8.944373e-01             Avagacestat (BMS-708163) D020_r2
## 4943 -9.430402e-01                              AVL-292 D020_r2
## 4944  1.992012e+00                             Axitinib D020_r2
## 4945  1.992012e+00                             Axitinib D020_r2
## 4946  3.317241e+00                               AZ 628 D020_r2
## 4947  5.841690e-01                               AZ 960 D020_r2
## 4948  1.675406e+00                                 AZ20 D020_r2
## 4949  2.097314e+00                              AZD1080 D020_r2
## 4950  3.536136e-01                              AZD1480 D020_r2
## 4951  4.492535e+00                              AZD2014 D020_r2
## 4952  1.666778e+00                              AZD2858 D020_r2
## 4953  1.195964e+00                              AZD2932 D020_r2
## 4954  2.445756e+00                              AZD3759 D020_r2
## 4955  3.172321e+00                              AZD5363 D020_r2
## 4956  1.230818e+00                              AZD5438 D020_r2
## 4957  2.667780e+00                              AZD6482 D020_r2
## 4958  1.828500e+00                              AZD6738 D020_r2
## 4959  3.434721e+00                              AZD8055 D020_r2
## 4960  3.721748e+00                              AZD8330 D020_r2
## 4961  4.478247e+00                  AZD8931 (Sapitinib) D020_r2
## 4962  2.789746e+00                              AZD9291 D020_r2
## 4963  8.164001e-01            Barasertib (AZD1152-HQPA) D020_r2
## 4964  6.156066e-01  Baricitinib (LY3009104, INCB028050) D020_r2
## 4965 -9.677279e+00                  BGT226 (NVP-BGT226) D020_r2
## 4966  3.710808e-02                              BI 2536 D020_r2
## 4967  2.467974e+00                              BI-78D3 D020_r2
## 4968  8.634357e-01                             BI-D1870 D020_r2
## 4969  2.346139e+00                              Bikinin D020_r2
## 4970 -2.954465e-01                                  BIO D020_r2
## 4971  8.070234e-01               BIRB 796 (Doramapimod) D020_r2
## 4972  1.409481e+00                            BIX 02188 D020_r2
## 4973  2.383998e+00                            BIX 02189 D020_r2
## 4974  1.211282e+00      BKM120 (NVP-BKM120, Buparlisib) D020_r2
## 4975 -4.056321e-01                           BMS-265246 D020_r2
## 4976  9.370776e-01                           BMS-536924 D020_r2
## 4977  1.235117e+00                           BMS-582949 D020_r2
## 4978  1.223092e+00                           BMS-754807 D020_r2
## 4979  3.020409e+00                           BMS-777607 D020_r2
## 4980  1.762766e+00                           BMS-794833 D020_r2
## 4981  2.622715e+00                           BMS-833923 D020_r2
## 4982  1.400274e-01                  Bosutinib (SKI-606) D020_r2
## 4983  2.389320e+00                Brivanib (BMS-540215) D020_r2
## 4984  2.508407e+00      Brivanib Alaninate (BMS-582664) D020_r2
## 4985  1.708550e+00                           BS-181 HCl D020_r2
## 4986  1.137160e+00                               Butein D020_r2
## 4987  2.688483e+00                               BYL719 D020_r2
## 4988  3.016925e+00     Cabozantinib (XL184, BMS-907351) D020_r2
## 4989  2.782125e+00          Cabozantinib malate (XL184) D020_r2
## 4990  2.958314e+00        CAL-101 (Idelalisib, GS-1101) D020_r2
## 4991  3.056285e+00                             CAY10505 D020_r2
## 4992  2.359887e+00                               CC-223 D020_r2
## 4993  3.399729e+00                            CCT128930 D020_r2
## 4994 -9.034160e-01                  Cediranib (AZD2171) D020_r2
## 4995  1.760322e+00                            CEP-32496 D020_r2
## 4996  3.100382e+00                            CEP-33779 D020_r2
## 4997  1.686562e+00                              CGI1746 D020_r2
## 4998  3.296881e+00                              CGK 733 D020_r2
## 4999  6.022553e+00                            CH5132799 D020_r2
## 5000  2.541860e+00                           CHIR-98014 D020_r2
## 5001  2.191145e+00                 CHIR-99021 (CT99021) D020_r2
## 5002  2.416723e+00             CHIR-99021 (CT99021) HCl D020_r2
## 5003  2.616660e+00                    Chrysophanic Acid D020_r2
## 5004  5.212304e+00                             CNX-2006 D020_r2
## 5005  1.724280e+00                              CNX-774 D020_r2
## 5006  5.017258e+00                    CO-1686 (AVL-301) D020_r2
## 5007  4.170159e+00       Cobimetinib (GDC-0973, RG7420) D020_r2
## 5008  2.057590e+00                            CP-673451 D020_r2
## 5009  9.672186e-01                            CP-724714 D020_r2
## 5010  2.094358e+00               Crenolanib (CP-868596) D020_r2
## 5011  9.826678e-01             Crizotinib (PF-02341066) D020_r2
## 5012  1.830609e-01                               CYC116 D020_r2
## 5013  2.230732e+00                               CYT387 D020_r2
## 5014  2.458372e+00                             CZC24832 D020_r2
## 5015  2.233622e-01              Dabrafenib (GSK2118436) D020_r2
## 5016  3.184280e+00        Dacomitinib (PF299804, PF299) D020_r2
## 5017 -3.047681e-01              Danusertib (PHA-739358) D020_r2
## 5018  2.049724e+00                        DAPT (GSI-IX) D020_r2
## 5019  2.255341e+00                            Dasatinib D020_r2
## 5020  2.265055e+00                DCC-2036 (Rebastinib) D020_r2
## 5021  2.059859e+00                Decernotinib (VX-509) D020_r2
## 5022  7.472446e-02               Dinaciclib (SCH727965) D020_r2
## 5023  2.449328e+00    Dovitinib (TKI-258) Dilactic Acid D020_r2
## 5024  1.119202e+00                            ENMD-2076 D020_r2
## 5025  1.658680e+00               Enzastaurin (LY317615) D020_r2
## 5026  2.309992e+00                            ERK5-IN-1 D020_r2
## 5027  2.231306e+00                             ETC-1002 D020_r2
## 5028  1.806027e+00                            ETP-46464 D020_r2
## 5029  3.394790e+00                  Everolimus (RAD001) D020_r2
## 5030  1.793822e+00                Fasudil (HA-1077) HCl D020_r2
## 5031  1.404309e+00                                FH535 D020_r2
## 5032  1.784173e+00                Filgotinib (GLPG0634) D020_r2
## 5033 -1.898619e+00             Flavopiridol (Alvocidib) D020_r2
## 5034  5.826231e-01                     Flavopiridol HCl D020_r2
## 5035  9.468396e-01               Foretinib (GSK1363089) D020_r2
## 5036  3.447576e+00                  Fostamatinib (R788) D020_r2
## 5037  2.902599e+00                                G-749 D020_r2
## 5038  3.479340e+00                             GDC-0068 D020_r2
## 5039  4.039971e+00                             GDC-0349 D020_r2
## 5040  8.981117e-01                             GDC-0879 D020_r2
## 5041  3.841332e+00                             GDC-0941 D020_r2
## 5042  4.573067e+00                    GDC-0980 (RG7422) D020_r2
## 5043  3.862951e+00                   Gefitinib (ZD1839) D020_r2
## 5044  1.565614e+00                            Genistein D020_r2
## 5045  2.140999e+00                            GF109203X D020_r2
## 5046  2.471836e+00                                GNF-2 D020_r2
## 5047  1.805610e+00                                GNF-5 D020_r2
## 5048  2.950093e+00                              Go 6983 D020_r2
## 5049  5.144084e-01                   Golvatinib (E7050) D020_r2
## 5050  4.114860e+00                          GSK1838705A D020_r2
## 5051  2.330569e+00                          GSK1904529A D020_r2
## 5052  2.696158e+00                  GSK2126458 (GSK458) D020_r2
## 5053  3.390079e+00                           GSK2292767 D020_r2
## 5054  1.093408e+00                           GSK2636771 D020_r2
## 5055 -7.787096e-01                           GSK429286A D020_r2
## 5056  8.308040e-01                            GSK461364 D020_r2
## 5057  2.183675e+00                               GSK621 D020_r2
## 5058  2.548306e+00                            GSK690693 D020_r2
## 5059  1.262347e+00                               GW5074 D020_r2
## 5060  1.724433e+00                             GW788388 D020_r2
## 5061  2.640942e+00                               GZD824 D020_r2
## 5062  2.179744e+00                            H 89 2HCl D020_r2
## 5063 -3.497857e-01                           Hesperadin D020_r2
## 5064  2.793594e-01                              HMN-214 D020_r2
## 5065  2.107047e+00                             Honokiol D020_r2
## 5066  1.321289e+00                               HS-173 D020_r2
## 5067  8.751808e-02                           HTH-01-015 D020_r2
## 5068  5.133385e+00                Ibrutinib (PCI-32765) D020_r2
## 5069  2.681071e+00                              ICG-001 D020_r2
## 5070  3.848505e+00                             Icotinib D020_r2
## 5071  1.997391e+00                                IM-12 D020_r2
## 5072  4.697480e+00           Imatinib Mesylate (STI571) D020_r2
## 5073  9.524801e-01                            Indirubin D020_r2
## 5074  4.445783e+00                    INK 128 (MLN0128) D020_r2
## 5075  4.199155e+00                    IPI-145 (INK1197) D020_r2
## 5076  2.466297e+00                               IWP-L6 D020_r2
## 5077  6.828377e-01                           IWR-1-endo D020_r2
## 5078  2.349112e+00                         JNJ-38877605 D020_r2
## 5079  2.108984e+00                          JNJ-7706621 D020_r2
## 5080 -3.935047e-01                     JNK Inhibitor IX D020_r2
## 5081  3.540044e+00                             JNK-IN-8 D020_r2
## 5082  8.348680e-01                               K02288 D020_r2
## 5083  6.767489e-01                               Ki8751 D020_r2
## 5084  1.841107e+00                              KRN 633 D020_r2
## 5085  4.334371e+00                           KU-0063794 D020_r2
## 5086  2.261565e+00      KU-55933 (ATM Kinase Inhibitor) D020_r2
## 5087  2.554203e+00                             KU-60019 D020_r2
## 5088  2.056967e+00                              KW-2449 D020_r2
## 5089 -1.261941e+00                              KX2-391 D020_r2
## 5090  2.399680e+00                              KY02111 D020_r2
## 5091  1.840508e+00                            Lapatinib D020_r2
## 5092  1.719494e+00     Lapatinib (GW-572016) Ditosylate D020_r2
## 5093  4.922036e+00                            LDC000067 D020_r2
## 5094  1.859840e+00      LDE225 (NVP-LDE225,Erismodegib) D020_r2
## 5095  2.268427e+00                           LDN-214117 D020_r2
## 5096 -1.457548e-01                   Lenvatinib (E7080) D020_r2
## 5097  3.083152e+00                              LFM-A13 D020_r2
## 5098  3.087436e+00                              LGK-974 D020_r2
## 5099  2.746549e-01                  Linifanib (ABT-869) D020_r2
## 5100  3.510768e+00                               LJH685 D020_r2
## 5101  2.239690e+00                               LJI308 D020_r2
## 5102  1.182319e+00               Losmapimod (GW856553X) D020_r2
## 5103  1.719054e+00                            LY2090314 D020_r2
## 5104 -1.662227e-01                            LY2157299 D020_r2
## 5105  1.056610e+00                            LY2784544 D020_r2
## 5106  4.628182e+00                            LY2835219 D020_r2
## 5107  3.722952e+00                             LY294002 D020_r2
## 5108  2.674346e+00                            LY3023414 D020_r2
## 5109  1.692814e+00                             LY411575 D020_r2
## 5110  4.242927e+00       MEK162 (ARRY-162, ARRY-438162) D020_r2
## 5111  1.416549e+00                             MGCD-265 D020_r2
## 5112  1.548033e+00               Milciclib (PHA-848125) D020_r2
## 5113  1.164902e+00                              MK-0752 D020_r2
## 5114  4.402317e+00                         MK-2206 2HCl D020_r2
## 5115  2.533511e-01                              MK-2461 D020_r2
## 5116  2.548901e+00                     MK-5108 (VX-689) D020_r2
## 5117  8.977816e-01                              MK-8745 D020_r2
## 5118  3.750284e+00                              MLN2480 D020_r2
## 5119  1.619899e+00                              MLN8054 D020_r2
## 5120 -6.787817e-01      Motesanib Diphosphate (AMG-706) D020_r2
## 5121  1.606473e+00                  Nilotinib (AMN-107) D020_r2
## 5122  1.196650e+00     Nintedanib (BIBF 1120)_uncertain D020_r2
## 5123  1.755070e+00                               NU6027 D020_r2
## 5124 -1.486248e-01                           NVP-AEW541 D020_r2
## 5125  2.036467e+00                           NVP-BHG712 D020_r2
## 5126  1.627767e+00                      NVP-BSK805 2HCl D020_r2
## 5127  1.977056e+00                           NVP-BVU972 D020_r2
## 5128  1.902011e+00                          Oclacitinib D020_r2
## 5129  3.157863e+00      Olmutinib (HM61713, BI 1482694) D020_r2
## 5130  4.451779e+00                             ONO-4059 D020_r2
## 5131  6.078350e+00                              OSI-027 D020_r2
## 5132  5.133151e+00                              OSI-420 D020_r2
## 5133  3.917066e+00                 OSI-906 (Linsitinib) D020_r2
## 5134  1.025189e+00                              P276-00 D020_r2
## 5135 -4.766458e+00                  Pacritinib (SB1518) D020_r2
## 5136  2.376584e+00                   Palomid 529 (P529) D020_r2
## 5137  2.623417e+00                            Pazopanib D020_r2
## 5138  3.401861e-01                        Pazopanib HCl D020_r2
## 5139  3.952367e+00                            PD0325901 D020_r2
## 5140  3.999494e+00                             PD168393 D020_r2
## 5141  3.005985e-01                             PD173955 D020_r2
## 5142  4.068754e+00                   PD184352 (CI-1040) D020_r2
## 5143  4.367958e+00                             PD318088 D020_r2
## 5144  3.886341e+00                              PD98059 D020_r2
## 5145  4.028027e+00                  Pelitinib (EKB-569) D020_r2
## 5146  1.079405e+00                          PF-00562271 D020_r2
## 5147  2.532759e+00                          PF-04217903 D020_r2
## 5148  1.437044e-01                          PF-04691502 D020_r2
## 5149  3.503626e+00                            PF-431396 D020_r2
## 5150  2.940661e-01                           PF-4708671 D020_r2
## 5151  1.899301e+00                           PF-5274857 D020_r2
## 5152  2.402461e+00                            PF-562271 D020_r2
## 5153  3.299142e+00                            PF-573228 D020_r2
## 5154  1.875271e+00                            PH-797804 D020_r2
## 5155  3.014682e+00                           PHA-665752 D020_r2
## 5156  1.977062e+00                           PHA-680632 D020_r2
## 5157  1.301862e-01                           PHA-767491 D020_r2
## 5158  2.478587e+00                           PHA-793887 D020_r2
## 5159  6.806318e-01                       Phenformin HCl D020_r2
## 5160  1.043557e+00                              PHT-427 D020_r2
## 5161  1.336582e+00                          Piceatannol D020_r2
## 5162  1.842662e+00                              PIK-293 D020_r2
## 5163  2.156351e+00                              PIK-294 D020_r2
## 5164  3.967503e+00                               PIK-93 D020_r2
## 5165  4.391951e+00               Pimasertib (AS-703026) D020_r2
## 5166  2.307657e+00                          Pirfenidone D020_r2
## 5167  5.034188e-01                             PLX-4720 D020_r2
## 5168  2.622084e+00                              PLX7904 D020_r2
## 5169  3.552848e+00                  Ponatinib (AP24534) D020_r2
## 5170  2.659739e+00                                  PP1 D020_r2
## 5171  2.671409e+00                                  PP2 D020_r2
## 5172  2.787227e+00                                PP242 D020_r2
## 5173  2.633758e+00                               PQ 401 D020_r2
## 5174  2.008117e+00                              PRI-724 D020_r2
## 5175  2.564617e+00     PRT062607 (P505-15, BIIB057) HCl D020_r2
## 5176  2.555841e+00                         Purvalanol A D020_r2
## 5177  2.430687e+00                            Quercetin D020_r2
## 5178  4.621399e+00                  Quizartinib (AC220) D020_r2
## 5179  3.794194e+00                                 R406 D020_r2
## 5180  3.515604e+00                     R406 (free base) D020_r2
## 5181 -3.314947e-01                                 R547 D020_r2
## 5182  3.763011e+00                    RAF265 (CHIR-265) D020_r2
## 5183  3.680128e+00                Rapamycin (Sirolimus) D020_r2
## 5184  4.043552e+00   Refametinib (RDEA119, Bay 86-9766) D020_r2
## 5185  7.566745e-01                               RepSox D020_r2
## 5186  2.212731e+00 Ridaforolimus (Deforolimus, MK-8669) D020_r2
## 5187 -8.659675e-01                Rigosertib (ON-01910) D020_r2
## 5188  2.357766e+00                             RKI-1447 D020_r2
## 5189  1.754434e+00                                RN486 D020_r2
## 5190  1.119889e+00                  Ro 31-8220 Mesylate D020_r2
## 5191  1.563696e+00                              Ro-3306 D020_r2
## 5192  1.902727e+00                               Ro3280 D020_r2
## 5193  2.375199e+00                            RO4929097 D020_r2
## 5194  2.914469e+00      Roscovitine (Seliciclib,CYC202) D020_r2
## 5195  2.060186e+00             Ruxolitinib (INCB018424) D020_r2
## 5196  1.739734e+00           S-Ruxolitinib (INCB018424) D020_r2
## 5197  2.684508e+00                               SANT-1 D020_r2
## 5198  2.612969e+00                            SAR131675 D020_r2
## 5199  3.571457e-01                    SAR245409 (XL765) D020_r2
## 5200  4.802095e+00                Saracatinib (AZD0530) D020_r2
## 5201  1.776728e+00                      SB202190 (FHPI) D020_r2
## 5202  6.274794e-01                             SB203580 D020_r2
## 5203  2.711163e+00                             SB216763 D020_r2
## 5204  5.519534e-01                             SB239063 D020_r2
## 5205  1.649024e+00                             SB415286 D020_r2
## 5206  2.229757e+00                             SB431542 D020_r2
## 5207  1.425666e+00                             SB505124 D020_r2
## 5208  1.883025e+00                             SB525334 D020_r2
## 5209  1.582768e+00                             SB590885 D020_r2
## 5210  2.412327e+00                                  SC1 D020_r2
## 5211  3.519939e+00                Schisandrin B (Sch B) D020_r2
## 5212  4.152056e+00                Selumetinib (AZD6244) D020_r2
## 5213  1.740557e+00              Semagacestat (LY450139) D020_r2
## 5214  1.376134e+00                   Semaxanib (SU5416) D020_r2
## 5215  1.954717e+00                             SGI-7079 D020_r2
## 5216  1.274685e+00                          Skepinone-L D020_r2
## 5217  5.883882e-01                               SL-327 D020_r2
## 5218 -2.487584e+00                 SNS-032 (BMS-387032) D020_r2
## 5219  2.152719e+00                     SNS-314 Mesylate D020_r2
## 5220  1.557221e+00                            Sorafenib D020_r2
## 5221  2.400543e+00                   Sorafenib Tosylate D020_r2
## 5222  7.768983e-01                         Sotrastaurin D020_r2
## 5223  1.682708e+00                             SP600125 D020_r2
## 5224  1.380222e+00                              SU11274 D020_r2
## 5225 -6.249854e-01                               SU6656 D020_r2
## 5226  1.442747e+00                               SU9516 D020_r2
## 5227  1.814211e+00                     Sunitinib Malate D020_r2
## 5228  4.142133e+00                  TAE226 (NVP-TAE226) D020_r2
## 5229  1.812588e+00                              TAK-285 D020_r2
## 5230  3.296928e+00                              TAK-632 D020_r2
## 5231  2.145377e+00                              TAK-715 D020_r2
## 5232  4.296514e+00                              TAK-733 D020_r2
## 5233 -1.050109e+00                              TAK-901 D020_r2
## 5234  1.592959e+00                Taladegib (LY2940680) D020_r2
## 5235  3.623056e+00                              TCS 359 D020_r2
## 5236  2.798115e+00                               TDZD-8 D020_r2
## 5237  2.083242e+00                            Telatinib D020_r2
## 5238  2.255807e+00   Temsirolimus (CCI-779, NSC 683864) D020_r2
## 5239  4.588983e-01              Tepotinib (EMD 1214063) D020_r2
## 5240  2.046168e+00                                TG003 D020_r2
## 5241  1.661959e+00                            TG100-115 D020_r2
## 5242 -4.104428e-02                             TG101209 D020_r2
## 5243 -8.434342e-01                 TG101348 (SAR302503) D020_r2
## 5244  2.851913e+00                              TGX-221 D020_r2
## 5245  1.808946e+00                         Theophylline D020_r2
## 5246  1.450974e+00                          Thiazovivin D020_r2
## 5247  2.211386e+00                       TIC10 Analogue D020_r2
## 5248  1.299278e+00                           Tideglusib D020_r2
## 5249 -8.248112e-01                 Tivantinib (ARQ 197) D020_r2
## 5250  7.993233e-01                   Tivozanib (AV-951) D020_r2
## 5251  2.157282e+00  Tofacitinib (CP-690550,Tasocitinib) D020_r2
## 5252  2.889041e+00      Tofacitinib (CP-690550) Citrate D020_r2
## 5253  2.070505e+00                              Torin 2 D020_r2
## 5254  3.189923e+00              Trametinib (GSK1120212) D020_r2
## 5255  3.111388e+00                          Triciribine D020_r2
## 5256  3.240138e+00           TSU-68 (SU6668, Orantinib) D020_r2
## 5257  2.107075e+00                               TWS119 D020_r2
## 5258  3.643049e+00                         Tyrphostin 9 D020_r2
## 5259  1.759523e+00                   Tyrphostin AG 1296 D020_r2
## 5260  1.821993e+00                           U0126-EtOH D020_r2
## 5261  4.322574e+00     Ulixertinib (BVD-523, VRT752271) D020_r2
## 5262  3.877592e+00              Uprosertib (GSK2141795) D020_r2
## 5263  2.681887e+00                          Vacquinol-1 D020_r2
## 5264  8.423340e-01                           Varlitinib D020_r2
## 5265  1.699927e+00              Vatalanib (PTK787) 2HCl D020_r2
## 5266  3.304613e+00                               VE-821 D020_r2
## 5267  1.679969e+00                               VE-822 D020_r2
## 5268  1.464199e+00        Vemurafenib (PLX4032, RG7204) D020_r2
## 5269  1.707789e-01                Vismodegib (GDC-0449) D020_r2
## 5270  1.179942e+00                 Volasertib (BI 6727) D020_r2
## 5271  1.233649e+00                            VPS34-IN1 D020_r2
## 5272  4.625342e+00                     VS-5584 (SB2343) D020_r2
## 5273  4.583164e+00                               VX-11e D020_r2
## 5274  7.303661e-01         VX-680 (Tozasertib, MK-0457) D020_r2
## 5275  2.869352e+00                               VX-702 D020_r2
## 5276  2.117606e+00                               VX-745 D020_r2
## 5277  4.530192e+00                              WAY-600 D020_r2
## 5278  1.310462e+00                             WH-4-023 D020_r2
## 5279  1.725985e+00                             WHI-P154 D020_r2
## 5280  1.570733e+00                                WIKI4 D020_r2
## 5281 -1.375506e+00                        Wnt agonist 1 D020_r2
## 5282  2.341954e+00                        Wnt-C59 (C59) D020_r2
## 5283  2.101635e+00                               WP1066 D020_r2
## 5284  4.962040e+00                 WYE-125132 (WYE-132) D020_r2
## 5285  3.684615e+00                              WYE-354 D020_r2
## 5286  4.921409e+00                               WZ3146 D020_r2
## 5287  3.544517e+00                               WZ4002 D020_r2
## 5288  3.881516e+00                               WZ4003 D020_r2
## 5289  1.643829e+00                               WZ8040 D020_r2
## 5290  1.070958e+00                              XAV-939 D020_r2
## 5291  3.052232e+00                                XL019 D020_r2
## 5292  2.245991e+00                              XMD8-92 D020_r2
## 5293  1.509070e+00                         Y-27632 2HCl D020_r2
## 5294  4.065662e+00                             YM201636 D020_r2
## 5295  3.274384e+00                             YO-01027 D020_r2
## 5296  2.491941e+00                            ZM 306416 D020_r2
## 5297  3.109100e+00                        ZM 323881 HCl D020_r2
## 5298  2.052395e+00                            ZM 336372 D020_r2
## 5299  2.294309e+00                         ZM 39923 HCl D020_r2
## 5300  1.998489e+00                            ZM 447439 D020_r2
## 5301  3.361708e+00                 Zotarolimus(ABT-578) D020_r2
## 5302  3.413063e+00                              ZSTK474 D020_r2
## 5303  3.617717e+00                     1-Azakenpaullone D022_r1
## 5304  4.437470e+00                      3-Methyladenine D022_r1
## 5305  3.073886e+00                             A-674563 D022_r1
## 5306  4.179030e+00                             A-769662 D022_r1
## 5307  7.969715e+00                                  A66 D022_r1
## 5308  4.235472e+00                            Acadesine D022_r1
## 5309  7.749445e+00                  AEE788 (NVP-AEE788) D022_r1
## 5310  3.027656e+00        Afatinib (BIBW2992)_uncertain D022_r1
## 5311  3.992371e+00                              AG-1024 D022_r1
## 5312  7.191815e+00         AG-1478 (Tyrphostin AG-1478) D022_r1
## 5313  3.256255e+00                                AG-18 D022_r1
## 5314  2.294853e+00              AG-490 (Tyrphostin B42) D022_r1
## 5315  6.062853e+00                             Akti-1/2 D022_r1
## 5316  4.679025e+00                  Alisertib (MLN8237) D022_r1
## 5317  4.315931e+00                              AMG 337 D022_r1
## 5318  4.694830e+00                              AMG-458 D022_r1
## 5319  6.076502e+00                              AMG-900 D022_r1
## 5320  4.495040e+00                               AMG319 D022_r1
## 5321  4.106965e+00                  Amuvatinib (MP-470) D022_r1
## 5322  4.602605e+00                             Apatinib D022_r1
## 5323  2.921235e+00                           AR-A014418 D022_r1
## 5324  2.401805e+00                            AS-252424 D022_r1
## 5325  3.684645e+00                            AS-604850 D022_r1
## 5326  3.801993e+00                         Asiatic Acid D022_r1
## 5327  8.900595e+00                             AST-1306 D022_r1
## 5328  4.496957e+00                              AT13148 D022_r1
## 5329  3.548828e+00                               AT7519 D022_r1
## 5330  4.461162e+00                               AT7867 D022_r1
## 5331  2.838559e+00                               AT9283 D022_r1
## 5332  3.758780e+00                 Aurora A Inhibitor I D022_r1
## 5333  4.489934e+00             Avagacestat (BMS-708163) D022_r1
## 5334  4.004088e+00                              AVL-292 D022_r1
## 5335  3.569758e+00                             Axitinib D022_r1
## 5336  3.569758e+00                             Axitinib D022_r1
## 5337  5.449410e+00                               AZ 628 D022_r1
## 5338  3.426435e+00                               AZ 960 D022_r1
## 5339  5.157065e+00                                 AZ20 D022_r1
## 5340  3.808746e+00                              AZD1080 D022_r1
## 5341  5.206172e+00                              AZD1480 D022_r1
## 5342  8.367061e+00                              AZD2014 D022_r1
## 5343  5.782720e+00                              AZD2858 D022_r1
## 5344  2.223963e+00                              AZD2932 D022_r1
## 5345  8.636043e+00                              AZD3759 D022_r1
## 5346  5.860272e+00                              AZD5363 D022_r1
## 5347  5.167537e+00                              AZD5438 D022_r1
## 5348  3.624750e+00                              AZD6482 D022_r1
## 5349  4.702481e+00                              AZD6738 D022_r1
## 5350  9.699609e+00                              AZD8055 D022_r1
## 5351  6.953242e+00                              AZD8330 D022_r1
## 5352  9.598796e+00                  AZD8931 (Sapitinib) D022_r1
## 5353  5.447272e+00                              AZD9291 D022_r1
## 5354  5.609528e+00            Barasertib (AZD1152-HQPA) D022_r1
## 5355  3.544969e+00  Baricitinib (LY3009104, INCB028050) D022_r1
## 5356 -2.973149e+00                  BGT226 (NVP-BGT226) D022_r1
## 5357  2.957161e+00                              BI 2536 D022_r1
## 5358  4.141218e+00                              BI-78D3 D022_r1
## 5359  4.457284e+00                             BI-D1870 D022_r1
## 5360  3.928037e+00                              Bikinin D022_r1
## 5361  1.137534e+00                                  BIO D022_r1
## 5362  3.538688e+00               BIRB 796 (Doramapimod) D022_r1
## 5363  2.312493e+00                            BIX 02188 D022_r1
## 5364  3.335704e+00                            BIX 02189 D022_r1
## 5365  4.647709e+00      BKM120 (NVP-BKM120, Buparlisib) D022_r1
## 5366  3.288537e+00                           BMS-265246 D022_r1
## 5367  4.704664e+00                           BMS-536924 D022_r1
## 5368  1.587060e+00                           BMS-582949 D022_r1
## 5369  4.098264e+00                           BMS-754807 D022_r1
## 5370  3.910891e+00                           BMS-777607 D022_r1
## 5371  2.172072e+00                           BMS-794833 D022_r1
## 5372  3.190835e+00                           BMS-833923 D022_r1
## 5373  4.268244e+00                  Bosutinib (SKI-606) D022_r1
## 5374  4.110013e+00                Brivanib (BMS-540215) D022_r1
## 5375  3.307908e+00      Brivanib Alaninate (BMS-582664) D022_r1
## 5376  4.635533e+00                           BS-181 HCl D022_r1
## 5377  3.615733e+00                               Butein D022_r1
## 5378  7.627625e+00                               BYL719 D022_r1
## 5379  4.341816e+00     Cabozantinib (XL184, BMS-907351) D022_r1
## 5380  4.630445e+00          Cabozantinib malate (XL184) D022_r1
## 5381  4.640135e+00        CAL-101 (Idelalisib, GS-1101) D022_r1
## 5382  3.286559e+00                             CAY10505 D022_r1
## 5383  5.061958e+00                               CC-223 D022_r1
## 5384  6.120285e+00                            CCT128930 D022_r1
## 5385  3.139155e+00                  Cediranib (AZD2171) D022_r1
## 5386  2.319361e+00                            CEP-32496 D022_r1
## 5387  3.802776e+00                            CEP-33779 D022_r1
## 5388  4.238028e+00                              CGI1746 D022_r1
## 5389  4.161770e+00                              CGK 733 D022_r1
## 5390  5.897535e+00                            CH5132799 D022_r1
## 5391  5.338510e+00                           CHIR-98014 D022_r1
## 5392  4.653938e+00                 CHIR-99021 (CT99021) D022_r1
## 5393  4.881823e+00             CHIR-99021 (CT99021) HCl D022_r1
## 5394  3.057472e+00                    Chrysophanic Acid D022_r1
## 5395  1.305561e+01                             CNX-2006 D022_r1
## 5396  3.112268e+00                              CNX-774 D022_r1
## 5397  4.975728e+00                    CO-1686 (AVL-301) D022_r1
## 5398  8.662639e+00       Cobimetinib (GDC-0973, RG7420) D022_r1
## 5399  2.401574e+00                            CP-673451 D022_r1
## 5400  4.461494e+00                            CP-724714 D022_r1
## 5401  4.917761e+00               Crenolanib (CP-868596) D022_r1
## 5402  3.066849e+00             Crizotinib (PF-02341066) D022_r1
## 5403  5.766250e+00                               CYC116 D022_r1
## 5404  2.320742e+00                               CYT387 D022_r1
## 5405  3.311658e+00                             CZC24832 D022_r1
## 5406  4.163917e+00              Dabrafenib (GSK2118436) D022_r1
## 5407  7.275625e+00        Dacomitinib (PF299804, PF299) D022_r1
## 5408  5.221587e+00              Danusertib (PHA-739358) D022_r1
## 5409  3.409272e+00                        DAPT (GSI-IX) D022_r1
## 5410  5.678802e+00                            Dasatinib D022_r1
## 5411  3.700991e+00                DCC-2036 (Rebastinib) D022_r1
## 5412  2.493066e+00                Decernotinib (VX-509) D022_r1
## 5413  2.683076e+00               Dinaciclib (SCH727965) D022_r1
## 5414  4.680702e+00    Dovitinib (TKI-258) Dilactic Acid D022_r1
## 5415  3.571153e+00                            ENMD-2076 D022_r1
## 5416  5.163710e+00               Enzastaurin (LY317615) D022_r1
## 5417  6.948525e+00                            ERK5-IN-1 D022_r1
## 5418  2.734800e+00                             ETC-1002 D022_r1
## 5419  5.500701e+00                            ETP-46464 D022_r1
## 5420  3.262748e+00                  Everolimus (RAD001) D022_r1
## 5421  2.939659e+00                Fasudil (HA-1077) HCl D022_r1
## 5422  2.744584e+00                                FH535 D022_r1
## 5423  4.392274e+00                Filgotinib (GLPG0634) D022_r1
## 5424  2.914848e+00             Flavopiridol (Alvocidib) D022_r1
## 5425  3.225056e+00                     Flavopiridol HCl D022_r1
## 5426  2.363928e+00               Foretinib (GSK1363089) D022_r1
## 5427  2.933752e+00                  Fostamatinib (R788) D022_r1
## 5428  4.094495e+00                                G-749 D022_r1
## 5429  5.292573e+00                             GDC-0068 D022_r1
## 5430  7.766509e+00                             GDC-0349 D022_r1
## 5431  1.991202e+00                             GDC-0879 D022_r1
## 5432  4.644146e+00                             GDC-0941 D022_r1
## 5433  1.005087e+01                    GDC-0980 (RG7422) D022_r1
## 5434  9.697013e+00                   Gefitinib (ZD1839) D022_r1
## 5435  1.653507e+00                            Genistein D022_r1
## 5436  5.641839e+00                            GF109203X D022_r1
## 5437  3.306880e+00                                GNF-2 D022_r1
## 5438  4.631536e+00                                GNF-5 D022_r1
## 5439  8.106421e+00                              Go 6983 D022_r1
## 5440  3.295113e+00                   Golvatinib (E7050) D022_r1
## 5441  8.924252e+00                          GSK1838705A D022_r1
## 5442  1.502360e+00                          GSK1904529A D022_r1
## 5443  5.289003e+00                  GSK2126458 (GSK458) D022_r1
## 5444  6.885849e+00                           GSK2292767 D022_r1
## 5445  2.345732e+00                           GSK2636771 D022_r1
## 5446  1.621825e+00                           GSK429286A D022_r1
## 5447  4.058701e+00                            GSK461364 D022_r1
## 5448  2.897046e+00                               GSK621 D022_r1
## 5449  4.791670e+00                            GSK690693 D022_r1
## 5450  1.409582e+00                               GW5074 D022_r1
## 5451  2.708046e+00                             GW788388 D022_r1
## 5452  4.640289e+00                               GZD824 D022_r1
## 5453  2.192593e+00                            H 89 2HCl D022_r1
## 5454  9.206702e-01                           Hesperadin D022_r1
## 5455  3.126714e+00                              HMN-214 D022_r1
## 5456  3.528224e+00                             Honokiol D022_r1
## 5457  3.846322e+00                               HS-173 D022_r1
## 5458  4.950012e+00                           HTH-01-015 D022_r1
## 5459  5.829342e+00                Ibrutinib (PCI-32765) D022_r1
## 5460  3.338443e+00                              ICG-001 D022_r1
## 5461  5.550997e+00                             Icotinib D022_r1
## 5462  3.430393e+00                                IM-12 D022_r1
## 5463  8.917733e+00           Imatinib Mesylate (STI571) D022_r1
## 5464  2.415442e+00                            Indirubin D022_r1
## 5465  8.983061e+00                    INK 128 (MLN0128) D022_r1
## 5466  4.376809e+00                    IPI-145 (INK1197) D022_r1
## 5467  3.668280e+00                               IWP-L6 D022_r1
## 5468  3.555597e+00                           IWR-1-endo D022_r1
## 5469  1.193713e+00                         JNJ-38877605 D022_r1
## 5470  6.476926e+00                          JNJ-7706621 D022_r1
## 5471  4.068445e+00                     JNK Inhibitor IX D022_r1
## 5472  7.021522e+00                             JNK-IN-8 D022_r1
## 5473  2.687977e+00                               K02288 D022_r1
## 5474  4.342658e+00                               Ki8751 D022_r1
## 5475  1.877698e+00                              KRN 633 D022_r1
## 5476  6.099352e+00                           KU-0063794 D022_r1
## 5477  4.305227e+00      KU-55933 (ATM Kinase Inhibitor) D022_r1
## 5478  4.091566e+00                             KU-60019 D022_r1
## 5479  3.522743e+00                              KW-2449 D022_r1
## 5480  3.300146e+00                              KX2-391 D022_r1
## 5481  4.003936e+00                              KY02111 D022_r1
## 5482  3.657165e+00                            Lapatinib D022_r1
## 5483  3.584094e+00     Lapatinib (GW-572016) Ditosylate D022_r1
## 5484  5.570736e+00                            LDC000067 D022_r1
## 5485  3.577846e+00      LDE225 (NVP-LDE225,Erismodegib) D022_r1
## 5486  2.733277e+00                           LDN-214117 D022_r1
## 5487  2.340536e+00                   Lenvatinib (E7080) D022_r1
## 5488  4.511668e+00                              LFM-A13 D022_r1
## 5489  4.199422e+00                              LGK-974 D022_r1
## 5490  2.328196e+00                  Linifanib (ABT-869) D022_r1
## 5491  4.030969e+00                               LJH685 D022_r1
## 5492  3.718452e+00                               LJI308 D022_r1
## 5493  3.749400e+00               Losmapimod (GW856553X) D022_r1
## 5494  3.782100e+00                            LY2090314 D022_r1
## 5495  1.896039e+00                            LY2157299 D022_r1
## 5496  3.790207e+00                            LY2784544 D022_r1
## 5497  8.304987e+00                            LY2835219 D022_r1
## 5498  4.436591e+00                             LY294002 D022_r1
## 5499  5.403082e+00                            LY3023414 D022_r1
## 5500  4.243153e+00                             LY411575 D022_r1
## 5501  9.102962e+00       MEK162 (ARRY-162, ARRY-438162) D022_r1
## 5502  2.932529e+00                             MGCD-265 D022_r1
## 5503  2.669883e+00               Milciclib (PHA-848125) D022_r1
## 5504  3.784122e+00                              MK-0752 D022_r1
## 5505  9.204576e+00                         MK-2206 2HCl D022_r1
## 5506  3.207292e+00                              MK-2461 D022_r1
## 5507  5.262131e+00                     MK-5108 (VX-689) D022_r1
## 5508  5.248445e+00                              MK-8745 D022_r1
## 5509  4.400015e+00                              MLN2480 D022_r1
## 5510  3.397674e+00                              MLN8054 D022_r1
## 5511  1.772670e+00      Motesanib Diphosphate (AMG-706) D022_r1
## 5512  2.037910e+00                  Nilotinib (AMN-107) D022_r1
## 5513  3.145311e+00     Nintedanib (BIBF 1120)_uncertain D022_r1
## 5514  3.721375e+00                               NU6027 D022_r1
## 5515  2.215211e+00                           NVP-AEW541 D022_r1
## 5516  3.038631e+00                           NVP-BHG712 D022_r1
## 5517  7.682529e+00                      NVP-BSK805 2HCl D022_r1
## 5518  3.083935e+00                           NVP-BVU972 D022_r1
## 5519  3.527528e+00                          Oclacitinib D022_r1
## 5520  6.442522e+00      Olmutinib (HM61713, BI 1482694) D022_r1
## 5521  6.339813e+00                             ONO-4059 D022_r1
## 5522  8.091613e+00                              OSI-027 D022_r1
## 5523  1.005349e+01                              OSI-420 D022_r1
## 5524  5.749415e+00                 OSI-906 (Linsitinib) D022_r1
## 5525  4.611860e+00                              P276-00 D022_r1
## 5526  5.623738e-01                  Pacritinib (SB1518) D022_r1
## 5527  3.788057e+00                   Palomid 529 (P529) D022_r1
## 5528  2.804732e+00                            Pazopanib D022_r1
## 5529  1.594825e+00                        Pazopanib HCl D022_r1
## 5530  8.643066e+00                            PD0325901 D022_r1
## 5531  8.652148e+00                             PD168393 D022_r1
## 5532  1.834579e+00                             PD173955 D022_r1
## 5533  6.573899e+00                   PD184352 (CI-1040) D022_r1
## 5534  8.314706e+00                             PD318088 D022_r1
## 5535  3.194033e+00                              PD98059 D022_r1
## 5536  6.770814e+00                  Pelitinib (EKB-569) D022_r1
## 5537  4.701942e+00                          PF-00562271 D022_r1
## 5538  3.857372e+00                          PF-04217903 D022_r1
## 5539  7.546793e+00                          PF-04691502 D022_r1
## 5540  5.559152e+00                            PF-431396 D022_r1
## 5541  2.803015e+00                           PF-4708671 D022_r1
## 5542  3.693357e+00                           PF-5274857 D022_r1
## 5543  4.845651e+00                            PF-562271 D022_r1
## 5544  5.287806e+00                            PF-573228 D022_r1
## 5545  2.549569e+00                            PH-797804 D022_r1
## 5546  3.844371e+00                           PHA-665752 D022_r1
## 5547  5.229984e+00                           PHA-680632 D022_r1
## 5548  2.711941e+00                           PHA-767491 D022_r1
## 5549  4.774245e+00                           PHA-793887 D022_r1
## 5550  2.711988e+00                       Phenformin HCl D022_r1
## 5551  2.931272e+00                              PHT-427 D022_r1
## 5552  4.508317e+00                          Piceatannol D022_r1
## 5553  2.939120e+00                              PIK-293 D022_r1
## 5554  3.755821e+00                              PIK-294 D022_r1
## 5555  7.058042e+00                               PIK-93 D022_r1
## 5556  8.464333e+00               Pimasertib (AS-703026) D022_r1
## 5557  3.480057e+00                          Pirfenidone D022_r1
## 5558  2.738621e-02                             PLX-4720 D022_r1
## 5559  3.249498e+00                              PLX7904 D022_r1
## 5560  7.694463e+00                  Ponatinib (AP24534) D022_r1
## 5561  3.444887e+00                                  PP1 D022_r1
## 5562  3.528322e+00                                  PP2 D022_r1
## 5563  5.060994e+00                                PP242 D022_r1
## 5564  3.620717e+00                               PQ 401 D022_r1
## 5565  2.651922e+00                              PRI-724 D022_r1
## 5566  7.288063e+00     PRT062607 (P505-15, BIIB057) HCl D022_r1
## 5567  5.114634e+00                         Purvalanol A D022_r1
## 5568  3.288005e+00                            Quercetin D022_r1
## 5569  4.608237e+00                  Quizartinib (AC220) D022_r1
## 5570  2.128557e+00                                 R406 D022_r1
## 5571  2.507484e+00                     R406 (free base) D022_r1
## 5572  3.513167e+00                                 R547 D022_r1
## 5573  1.024363e+01                    RAF265 (CHIR-265) D022_r1
## 5574  3.115001e+00                Rapamycin (Sirolimus) D022_r1
## 5575  6.391071e+00   Refametinib (RDEA119, Bay 86-9766) D022_r1
## 5576  3.278141e+00                               RepSox D022_r1
## 5577  4.845633e+00 Ridaforolimus (Deforolimus, MK-8669) D022_r1
## 5578  2.121799e+00                Rigosertib (ON-01910) D022_r1
## 5579  3.624142e+00                             RKI-1447 D022_r1
## 5580  4.857201e+00                                RN486 D022_r1
## 5581  3.163947e+00                  Ro 31-8220 Mesylate D022_r1
## 5582  2.141385e+00                              Ro-3306 D022_r1
## 5583  3.963204e+00                               Ro3280 D022_r1
## 5584  4.511263e+00                            RO4929097 D022_r1
## 5585  3.731716e+00      Roscovitine (Seliciclib,CYC202) D022_r1
## 5586  3.171996e+00             Ruxolitinib (INCB018424) D022_r1
## 5587  3.607726e+00           S-Ruxolitinib (INCB018424) D022_r1
## 5588  3.374893e+00                               SANT-1 D022_r1
## 5589  2.511317e+00                            SAR131675 D022_r1
## 5590  3.859218e+00                    SAR245409 (XL765) D022_r1
## 5591  8.622927e+00                Saracatinib (AZD0530) D022_r1
## 5592  1.741458e+00                      SB202190 (FHPI) D022_r1
## 5593  1.352517e+00                             SB203580 D022_r1
## 5594  4.252018e+00                             SB216763 D022_r1
## 5595  1.202239e+00                             SB239063 D022_r1
## 5596  4.509053e+00                             SB415286 D022_r1
## 5597  2.410198e+00                             SB431542 D022_r1
## 5598  3.620441e+00                             SB505124 D022_r1
## 5599  2.906731e+00                             SB525334 D022_r1
## 5600  4.076350e+00                             SB590885 D022_r1
## 5601  4.735546e+00                                  SC1 D022_r1
## 5602  2.879584e+00                Schisandrin B (Sch B) D022_r1
## 5603  8.510349e+00                Selumetinib (AZD6244) D022_r1
## 5604  4.001544e+00              Semagacestat (LY450139) D022_r1
## 5605  3.064809e+00                   Semaxanib (SU5416) D022_r1
## 5606  4.689893e+00                             SGI-7079 D022_r1
## 5607  2.954058e+00                          Skepinone-L D022_r1
## 5608  6.317759e+00                               SL-327 D022_r1
## 5609  3.487072e+00                 SNS-032 (BMS-387032) D022_r1
## 5610  5.168771e+00                     SNS-314 Mesylate D022_r1
## 5611  2.687153e+00                            Sorafenib D022_r1
## 5612  3.700002e+00                   Sorafenib Tosylate D022_r1
## 5613  2.995577e+00                         Sotrastaurin D022_r1
## 5614  5.083341e+00                             SP600125 D022_r1
## 5615  3.761534e+00                              SU11274 D022_r1
## 5616  4.962502e+00                               SU6656 D022_r1
## 5617  3.387497e+00                               SU9516 D022_r1
## 5618  3.134522e+00                     Sunitinib Malate D022_r1
## 5619  4.139941e+00                  TAE226 (NVP-TAE226) D022_r1
## 5620  4.809396e+00                              TAK-285 D022_r1
## 5621  5.160790e+00                              TAK-632 D022_r1
## 5622  3.567238e+00                              TAK-715 D022_r1
## 5623  9.292582e+00                              TAK-733 D022_r1
## 5624  3.832414e+00                              TAK-901 D022_r1
## 5625  4.437042e+00                Taladegib (LY2940680) D022_r1
## 5626  4.657972e+00                              TCS 359 D022_r1
## 5627  5.062570e+00                               TDZD-8 D022_r1
## 5628  2.632312e+00                            Telatinib D022_r1
## 5629  4.351753e+00   Temsirolimus (CCI-779, NSC 683864) D022_r1
## 5630  5.356182e+00              Tepotinib (EMD 1214063) D022_r1
## 5631  4.226576e+00                                TG003 D022_r1
## 5632  3.772770e+00                            TG100-115 D022_r1
## 5633  3.087517e+00                             TG101209 D022_r1
## 5634  2.999690e+00                 TG101348 (SAR302503) D022_r1
## 5635  4.388314e+00                              TGX-221 D022_r1
## 5636  3.574915e+00                         Theophylline D022_r1
## 5637  3.434757e+00                          Thiazovivin D022_r1
## 5638  3.909533e+00                       TIC10 Analogue D022_r1
## 5639  3.892529e+00                           Tideglusib D022_r1
## 5640  3.074959e+00                 Tivantinib (ARQ 197) D022_r1
## 5641  1.565010e+00                   Tivozanib (AV-951) D022_r1
## 5642  4.111778e+00  Tofacitinib (CP-690550,Tasocitinib) D022_r1
## 5643  3.488490e+00      Tofacitinib (CP-690550) Citrate D022_r1
## 5644  5.977977e+00                              Torin 2 D022_r1
## 5645  7.967774e+00              Trametinib (GSK1120212) D022_r1
## 5646  4.109232e+00                          Triciribine D022_r1
## 5647  2.922224e+00           TSU-68 (SU6668, Orantinib) D022_r1
## 5648  2.976983e+00                               TWS119 D022_r1
## 5649  4.380139e+00                         Tyrphostin 9 D022_r1
## 5650  3.350474e+00                   Tyrphostin AG 1296 D022_r1
## 5651  2.366935e+00                           U0126-EtOH D022_r1
## 5652  8.862569e+00     Ulixertinib (BVD-523, VRT752271) D022_r1
## 5653  7.137169e+00              Uprosertib (GSK2141795) D022_r1
## 5654  3.156130e+00                          Vacquinol-1 D022_r1
## 5655  3.469802e+00                           Varlitinib D022_r1
## 5656  3.683326e+00              Vatalanib (PTK787) 2HCl D022_r1
## 5657  3.788138e+00                               VE-821 D022_r1
## 5658  5.678321e+00                               VE-822 D022_r1
## 5659  3.120985e+00        Vemurafenib (PLX4032, RG7204) D022_r1
## 5660  2.850852e+00                Vismodegib (GDC-0449) D022_r1
## 5661  2.518781e+00                 Volasertib (BI 6727) D022_r1
## 5662  4.933374e+00                            VPS34-IN1 D022_r1
## 5663  9.516785e+00                     VS-5584 (SB2343) D022_r1
## 5664  9.200262e+00                               VX-11e D022_r1
## 5665  5.109208e+00         VX-680 (Tozasertib, MK-0457) D022_r1
## 5666  3.743989e+00                               VX-702 D022_r1
## 5667  2.014899e+00                               VX-745 D022_r1
## 5668  6.885333e+00                              WAY-600 D022_r1
## 5669  3.732817e+00                             WH-4-023 D022_r1
## 5670  3.413617e+00                             WHI-P154 D022_r1
## 5671  2.283892e+00                                WIKI4 D022_r1
## 5672  4.041197e+00                        Wnt agonist 1 D022_r1
## 5673  4.524373e+00                        Wnt-C59 (C59) D022_r1
## 5674  3.419011e+00                               WP1066 D022_r1
## 5675  9.696544e+00                 WYE-125132 (WYE-132) D022_r1
## 5676  6.946160e+00                              WYE-354 D022_r1
## 5677  9.747394e+00                               WZ3146 D022_r1
## 5678  4.725969e+00                               WZ4002 D022_r1
## 5679  3.908180e+00                               WZ4003 D022_r1
## 5680  4.661600e+00                               WZ8040 D022_r1
## 5681  3.348002e+00                              XAV-939 D022_r1
## 5682  4.148407e+00                                XL019 D022_r1
## 5683  5.137431e+00                              XMD8-92 D022_r1
## 5684  3.159199e+00                         Y-27632 2HCl D022_r1
## 5685  4.462787e+00                             YM201636 D022_r1
## 5686  4.325689e+00                             YO-01027 D022_r1
## 5687  7.853270e+00                            ZM 306416 D022_r1
## 5688  3.782104e+00                        ZM 323881 HCl D022_r1
## 5689  3.039053e+00                            ZM 336372 D022_r1
## 5690  3.560443e+00                         ZM 39923 HCl D022_r1
## 5691  2.790460e+00                            ZM 447439 D022_r1
## 5692  4.690982e+00                 Zotarolimus(ABT-578) D022_r1
## 5693  8.498522e+00                              ZSTK474 D022_r1
## 5694  4.995414e+00                     1-Azakenpaullone D022_r2
## 5695  4.742290e+00                      3-Methyladenine D022_r2
## 5696  1.433967e+00                             A-674563 D022_r2
## 5697  4.948262e+00                             A-769662 D022_r2
## 5698  5.172621e+00                                  A66 D022_r2
## 5699  4.801415e+00                            Acadesine D022_r2
## 5700  7.696407e+00                  AEE788 (NVP-AEE788) D022_r2
## 5701  3.925363e+00        Afatinib (BIBW2992)_uncertain D022_r2
## 5702  3.003108e+00                              AG-1024 D022_r2
## 5703  4.243437e+00         AG-1478 (Tyrphostin AG-1478) D022_r2
## 5704  2.873612e+00                                AG-18 D022_r2
## 5705  4.187456e+00              AG-490 (Tyrphostin B42) D022_r2
## 5706  4.741017e+00                             Akti-1/2 D022_r2
## 5707  5.709307e+00                  Alisertib (MLN8237) D022_r2
## 5708  5.396590e+00                              AMG 337 D022_r2
## 5709  4.131100e+00                              AMG-458 D022_r2
## 5710  3.573399e+00                              AMG-900 D022_r2
## 5711  4.568831e+00                               AMG319 D022_r2
## 5712  4.114901e+00                  Amuvatinib (MP-470) D022_r2
## 5713  4.950660e+00                             Apatinib D022_r2
## 5714  4.512639e+00                           AR-A014418 D022_r2
## 5715  3.034139e+00                            AS-252424 D022_r2
## 5716  3.808650e+00                            AS-604850 D022_r2
## 5717  4.687891e+00                         Asiatic Acid D022_r2
## 5718  7.154446e+00                             AST-1306 D022_r2
## 5719  3.675872e+00                              AT13148 D022_r2
## 5720  2.595064e+00                               AT7519 D022_r2
## 5721  3.314390e+00                               AT7867 D022_r2
## 5722  2.943059e+00                               AT9283 D022_r2
## 5723  5.620653e+00                 Aurora A Inhibitor I D022_r2
## 5724  4.506272e+00             Avagacestat (BMS-708163) D022_r2
## 5725  4.695472e+00                              AVL-292 D022_r2
## 5726  5.446112e+00                             Axitinib D022_r2
## 5727  5.446112e+00                             Axitinib D022_r2
## 5728  4.407180e+00                               AZ 628 D022_r2
## 5729  4.326085e+00                               AZ 960 D022_r2
## 5730  3.738843e+00                                 AZ20 D022_r2
## 5731  3.870038e+00                              AZD1080 D022_r2
## 5732  4.657753e+00                              AZD1480 D022_r2
## 5733  5.287988e+00                              AZD2014 D022_r2
## 5734  4.499082e+00                              AZD2858 D022_r2
## 5735  4.961692e+00                              AZD2932 D022_r2
## 5736  5.754380e+00                              AZD3759 D022_r2
## 5737  4.739853e+00                              AZD5363 D022_r2
## 5738  6.955676e-01                              AZD5438 D022_r2
## 5739  4.552900e+00                              AZD6482 D022_r2
## 5740  2.083646e+00                              AZD6738 D022_r2
## 5741  5.566349e+00                              AZD8055 D022_r2
## 5742  7.496910e+00                              AZD8330 D022_r2
## 5743  4.163738e+00                  AZD8931 (Sapitinib) D022_r2
## 5744  2.804885e+00                              AZD9291 D022_r2
## 5745  6.270099e+00            Barasertib (AZD1152-HQPA) D022_r2
## 5746  3.479002e+00  Baricitinib (LY3009104, INCB028050) D022_r2
## 5747 -4.839254e+00                  BGT226 (NVP-BGT226) D022_r2
## 5748  3.065385e+00                              BI 2536 D022_r2
## 5749  4.935703e+00                              BI-78D3 D022_r2
## 5750  4.012393e+00                             BI-D1870 D022_r2
## 5751  3.358229e+00                              Bikinin D022_r2
## 5752  3.859290e+00                                  BIO D022_r2
## 5753  3.523283e+00               BIRB 796 (Doramapimod) D022_r2
## 5754  3.990416e+00                            BIX 02188 D022_r2
## 5755  3.786770e+00                            BIX 02189 D022_r2
## 5756  4.995626e+00      BKM120 (NVP-BKM120, Buparlisib) D022_r2
## 5757  5.291963e+00                           BMS-265246 D022_r2
## 5758  4.343854e+00                           BMS-536924 D022_r2
## 5759  5.022579e+00                           BMS-582949 D022_r2
## 5760  4.872348e+00                           BMS-754807 D022_r2
## 5761  4.939850e+00                           BMS-777607 D022_r2
## 5762  3.190114e+00                           BMS-794833 D022_r2
## 5763  4.284088e+00                           BMS-833923 D022_r2
## 5764  2.418678e+00                  Bosutinib (SKI-606) D022_r2
## 5765  5.244194e+00                Brivanib (BMS-540215) D022_r2
## 5766  5.008393e+00      Brivanib Alaninate (BMS-582664) D022_r2
## 5767  6.282925e+00                           BS-181 HCl D022_r2
## 5768  6.200703e+00                               Butein D022_r2
## 5769  4.502306e+00                               BYL719 D022_r2
## 5770  5.340670e+00     Cabozantinib (XL184, BMS-907351) D022_r2
## 5771  4.814623e+00          Cabozantinib malate (XL184) D022_r2
## 5772  5.534535e+00        CAL-101 (Idelalisib, GS-1101) D022_r2
## 5773  3.608404e+00                             CAY10505 D022_r2
## 5774  5.803461e+00                               CC-223 D022_r2
## 5775  5.397378e+00                            CCT128930 D022_r2
## 5776  2.235589e+00                  Cediranib (AZD2171) D022_r2
## 5777  3.955885e+00                            CEP-32496 D022_r2
## 5778  3.881996e+00                            CEP-33779 D022_r2
## 5779  5.034973e+00                              CGI1746 D022_r2
## 5780  5.037945e+00                              CGK 733 D022_r2
## 5781  5.249474e+00                            CH5132799 D022_r2
## 5782  3.791082e+00                           CHIR-98014 D022_r2
## 5783  5.237074e+00                 CHIR-99021 (CT99021) D022_r2
## 5784  4.029421e+00             CHIR-99021 (CT99021) HCl D022_r2
## 5785  3.001947e+00                    Chrysophanic Acid D022_r2
## 5786  6.629377e+00                             CNX-2006 D022_r2
## 5787  4.170456e+00                              CNX-774 D022_r2
## 5788  5.297263e+00                    CO-1686 (AVL-301) D022_r2
## 5789  4.097152e+00       Cobimetinib (GDC-0973, RG7420) D022_r2
## 5790  5.295062e+00                            CP-673451 D022_r2
## 5791  3.896635e+00                            CP-724714 D022_r2
## 5792  2.821087e+00               Crenolanib (CP-868596) D022_r2
## 5793  5.533069e+00             Crizotinib (PF-02341066) D022_r2
## 5794  5.711089e+00                               CYC116 D022_r2
## 5795  4.557320e+00                               CYT387 D022_r2
## 5796  3.201034e+00                             CZC24832 D022_r2
## 5797  3.951618e+00              Dabrafenib (GSK2118436) D022_r2
## 5798  5.367789e+00        Dacomitinib (PF299804, PF299) D022_r2
## 5799  5.617515e+00              Danusertib (PHA-739358) D022_r2
## 5800  3.416674e+00                        DAPT (GSI-IX) D022_r2
## 5801  4.619551e+00                            Dasatinib D022_r2
## 5802  3.293260e+00                DCC-2036 (Rebastinib) D022_r2
## 5803  4.028224e+00                Decernotinib (VX-509) D022_r2
## 5804  1.519562e+00               Dinaciclib (SCH727965) D022_r2
## 5805  2.488507e+00    Dovitinib (TKI-258) Dilactic Acid D022_r2
## 5806  6.594158e+00                            ENMD-2076 D022_r2
## 5807  4.756709e+00               Enzastaurin (LY317615) D022_r2
## 5808  3.377395e+00                            ERK5-IN-1 D022_r2
## 5809  4.755135e+00                             ETC-1002 D022_r2
## 5810  5.057716e+00                            ETP-46464 D022_r2
## 5811  4.761382e+00                  Everolimus (RAD001) D022_r2
## 5812  4.035130e+00                Fasudil (HA-1077) HCl D022_r2
## 5813  3.330654e+00                                FH535 D022_r2
## 5814  4.837240e+00                Filgotinib (GLPG0634) D022_r2
## 5815 -4.900605e+00             Flavopiridol (Alvocidib) D022_r2
## 5816  6.889884e-01                     Flavopiridol HCl D022_r2
## 5817  5.526433e+00               Foretinib (GSK1363089) D022_r2
## 5818  2.348777e+00                  Fostamatinib (R788) D022_r2
## 5819  4.123717e+00                                G-749 D022_r2
## 5820  6.476957e+00                             GDC-0068 D022_r2
## 5821  5.191733e+00                             GDC-0349 D022_r2
## 5822  2.478339e+00                             GDC-0879 D022_r2
## 5823  5.106278e+00                             GDC-0941 D022_r2
## 5824  4.926958e+00                    GDC-0980 (RG7422) D022_r2
## 5825  6.755967e+00                   Gefitinib (ZD1839) D022_r2
## 5826  3.425860e+00                            Genistein D022_r2
## 5827  5.207937e+00                            GF109203X D022_r2
## 5828  3.495598e+00                                GNF-2 D022_r2
## 5829  4.670852e+00                                GNF-5 D022_r2
## 5830  4.320125e+00                              Go 6983 D022_r2
## 5831  1.178280e+00                   Golvatinib (E7050) D022_r2
## 5832  4.182690e+00                          GSK1838705A D022_r2
## 5833  4.498151e+00                          GSK1904529A D022_r2
## 5834  2.424726e+00                  GSK2126458 (GSK458) D022_r2
## 5835  6.268120e+00                           GSK2292767 D022_r2
## 5836  3.974010e+00                           GSK2636771 D022_r2
## 5837  3.154136e+00                           GSK429286A D022_r2
## 5838  4.804304e+00                            GSK461364 D022_r2
## 5839  5.145877e+00                               GSK621 D022_r2
## 5840  6.112562e+00                            GSK690693 D022_r2
## 5841  3.136966e+00                               GW5074 D022_r2
## 5842  4.440708e+00                             GW788388 D022_r2
## 5843  2.156298e+00                               GZD824 D022_r2
## 5844  4.661013e+00                            H 89 2HCl D022_r2
## 5845  3.501207e+00                           Hesperadin D022_r2
## 5846  4.675667e+00                              HMN-214 D022_r2
## 5847  4.955561e+00                             Honokiol D022_r2
## 5848  2.679477e+00                               HS-173 D022_r2
## 5849  1.987797e+00                           HTH-01-015 D022_r2
## 5850  6.379061e+00                Ibrutinib (PCI-32765) D022_r2
## 5851  4.282581e+00                              ICG-001 D022_r2
## 5852  2.827821e+00                             Icotinib D022_r2
## 5853  4.259132e+00                                IM-12 D022_r2
## 5854  7.006562e+00           Imatinib Mesylate (STI571) D022_r2
## 5855  3.589421e+00                            Indirubin D022_r2
## 5856  4.269761e+00                    INK 128 (MLN0128) D022_r2
## 5857  3.646292e+00                    IPI-145 (INK1197) D022_r2
## 5858  3.787656e+00                               IWP-L6 D022_r2
## 5859  2.963689e+00                           IWR-1-endo D022_r2
## 5860  3.093156e+00                         JNJ-38877605 D022_r2
## 5861  5.083410e+00                          JNJ-7706621 D022_r2
## 5862  1.573812e+00                     JNK Inhibitor IX D022_r2
## 5863  5.179301e+00                             JNK-IN-8 D022_r2
## 5864  4.701025e+00                               K02288 D022_r2
## 5865  5.919858e+00                               Ki8751 D022_r2
## 5866  4.705802e+00                              KRN 633 D022_r2
## 5867  6.621176e+00                           KU-0063794 D022_r2
## 5868  4.670701e+00      KU-55933 (ATM Kinase Inhibitor) D022_r2
## 5869  5.888075e+00                             KU-60019 D022_r2
## 5870  5.718598e+00                              KW-2449 D022_r2
## 5871  1.730631e+00                              KX2-391 D022_r2
## 5872  4.358923e+00                              KY02111 D022_r2
## 5873  4.097645e+00                            Lapatinib D022_r2
## 5874  5.514223e+00     Lapatinib (GW-572016) Ditosylate D022_r2
## 5875  3.373236e+00                            LDC000067 D022_r2
## 5876  4.651114e+00      LDE225 (NVP-LDE225,Erismodegib) D022_r2
## 5877  4.937372e+00                           LDN-214117 D022_r2
## 5878  2.151867e+00                   Lenvatinib (E7080) D022_r2
## 5879  5.160952e+00                              LFM-A13 D022_r2
## 5880  5.007171e+00                              LGK-974 D022_r2
## 5881  3.008626e+00                  Linifanib (ABT-869) D022_r2
## 5882  2.797493e+00                               LJH685 D022_r2
## 5883  3.998588e+00                               LJI308 D022_r2
## 5884  5.202757e+00               Losmapimod (GW856553X) D022_r2
## 5885  3.133870e+00                            LY2090314 D022_r2
## 5886  3.607779e+00                            LY2157299 D022_r2
## 5887  4.393952e+00                            LY2784544 D022_r2
## 5888  3.252768e+00                            LY2835219 D022_r2
## 5889  6.068132e+00                             LY294002 D022_r2
## 5890  6.353417e+00                            LY3023414 D022_r2
## 5891  4.247970e+00                             LY411575 D022_r2
## 5892  5.214947e+00       MEK162 (ARRY-162, ARRY-438162) D022_r2
## 5893  3.004592e+00                             MGCD-265 D022_r2
## 5894  1.408901e+00               Milciclib (PHA-848125) D022_r2
## 5895  3.719089e+00                              MK-0752 D022_r2
## 5896  6.005245e+00                         MK-2206 2HCl D022_r2
## 5897  4.057275e+00                              MK-2461 D022_r2
## 5898  2.421129e+00                     MK-5108 (VX-689) D022_r2
## 5899  2.619264e+00                              MK-8745 D022_r2
## 5900  4.434388e+00                              MLN2480 D022_r2
## 5901  4.326861e+00                              MLN8054 D022_r2
## 5902  3.536485e+00      Motesanib Diphosphate (AMG-706) D022_r2
## 5903  4.014866e+00                  Nilotinib (AMN-107) D022_r2
## 5904  5.004672e+00     Nintedanib (BIBF 1120)_uncertain D022_r2
## 5905  5.506065e+00                               NU6027 D022_r2
## 5906  6.035771e+00                           NVP-AEW541 D022_r2
## 5907  4.434975e+00                           NVP-BHG712 D022_r2
## 5908  3.577977e+00                      NVP-BSK805 2HCl D022_r2
## 5909  4.407763e+00                           NVP-BVU972 D022_r2
## 5910  4.460875e+00                          Oclacitinib D022_r2
## 5911  5.756459e+00      Olmutinib (HM61713, BI 1482694) D022_r2
## 5912  5.452150e+00                             ONO-4059 D022_r2
## 5913  3.730339e+00                              OSI-027 D022_r2
## 5914  5.996766e+00                              OSI-420 D022_r2
## 5915  6.998297e+00                 OSI-906 (Linsitinib) D022_r2
## 5916  1.381124e+00                              P276-00 D022_r2
## 5917  1.581942e-01                  Pacritinib (SB1518) D022_r2
## 5918  4.892805e+00                   Palomid 529 (P529) D022_r2
## 5919  2.185115e+00                            Pazopanib D022_r2
## 5920  4.372786e+00                        Pazopanib HCl D022_r2
## 5921  8.052372e+00                            PD0325901 D022_r2
## 5922  5.616641e+00                             PD168393 D022_r2
## 5923  1.889194e+00                             PD173955 D022_r2
## 5924  6.078720e+00                   PD184352 (CI-1040) D022_r2
## 5925  7.773155e+00                             PD318088 D022_r2
## 5926  4.369887e+00                              PD98059 D022_r2
## 5927  6.352440e+00                  Pelitinib (EKB-569) D022_r2
## 5928  1.831942e+00                          PF-00562271 D022_r2
## 5929  4.780349e+00                          PF-04217903 D022_r2
## 5930  5.315848e+00                          PF-04691502 D022_r2
## 5931  1.862392e+00                            PF-431396 D022_r2
## 5932  5.948889e+00                           PF-4708671 D022_r2
## 5933  4.694198e+00                           PF-5274857 D022_r2
## 5934  2.899783e+00                            PF-562271 D022_r2
## 5935  5.236633e+00                            PF-573228 D022_r2
## 5936  4.149528e+00                            PH-797804 D022_r2
## 5937  5.395782e+00                           PHA-665752 D022_r2
## 5938  5.571832e+00                           PHA-680632 D022_r2
## 5939  1.045717e-01                           PHA-767491 D022_r2
## 5940  7.099107e+00                           PHA-793887 D022_r2
## 5941  4.198380e+00                       Phenformin HCl D022_r2
## 5942  4.591955e+00                              PHT-427 D022_r2
## 5943  5.800644e+00                          Piceatannol D022_r2
## 5944  5.398147e+00                              PIK-293 D022_r2
## 5945  3.522082e+00                              PIK-294 D022_r2
## 5946  6.296202e+00                               PIK-93 D022_r2
## 5947  7.292115e+00               Pimasertib (AS-703026) D022_r2
## 5948  5.026423e+00                          Pirfenidone D022_r2
## 5949  5.223742e+00                             PLX-4720 D022_r2
## 5950  4.732008e+00                              PLX7904 D022_r2
## 5951  5.771542e+00                  Ponatinib (AP24534) D022_r2
## 5952  5.167313e+00                                  PP1 D022_r2
## 5953  5.202158e+00                                  PP2 D022_r2
## 5954  4.615096e+00                                PP242 D022_r2
## 5955  4.615821e+00                               PQ 401 D022_r2
## 5956  3.496153e+00                              PRI-724 D022_r2
## 5957  5.334157e+00     PRT062607 (P505-15, BIIB057) HCl D022_r2
## 5958  4.420859e+00                         Purvalanol A D022_r2
## 5959  3.911277e+00                            Quercetin D022_r2
## 5960  5.826723e+00                  Quizartinib (AC220) D022_r2
## 5961  5.344035e+00                                 R406 D022_r2
## 5962  5.023060e+00                     R406 (free base) D022_r2
## 5963  9.251243e-01                                 R547 D022_r2
## 5964  7.801564e+00                    RAF265 (CHIR-265) D022_r2
## 5965  5.804443e+00                Rapamycin (Sirolimus) D022_r2
## 5966  7.495260e+00   Refametinib (RDEA119, Bay 86-9766) D022_r2
## 5967  4.398396e+00                               RepSox D022_r2
## 5968  5.312017e+00 Ridaforolimus (Deforolimus, MK-8669) D022_r2
## 5969  5.336656e+00                Rigosertib (ON-01910) D022_r2
## 5970  4.121588e+00                             RKI-1447 D022_r2
## 5971  5.750740e+00                                RN486 D022_r2
## 5972  4.672642e+00                  Ro 31-8220 Mesylate D022_r2
## 5973  3.878913e+00                              Ro-3306 D022_r2
## 5974  2.500941e+00                               Ro3280 D022_r2
## 5975  4.488792e+00                            RO4929097 D022_r2
## 5976  5.895365e+00      Roscovitine (Seliciclib,CYC202) D022_r2
## 5977  4.393853e+00             Ruxolitinib (INCB018424) D022_r2
## 5978  3.791789e+00           S-Ruxolitinib (INCB018424) D022_r2
## 5979  4.389271e+00                               SANT-1 D022_r2
## 5980  4.312351e+00                            SAR131675 D022_r2
## 5981  4.489350e+00                    SAR245409 (XL765) D022_r2
## 5982  7.025090e+00                Saracatinib (AZD0530) D022_r2
## 5983  2.593563e+00                      SB202190 (FHPI) D022_r2
## 5984  2.668950e+00                             SB203580 D022_r2
## 5985  4.451313e+00                             SB216763 D022_r2
## 5986  3.556974e+00                             SB239063 D022_r2
## 5987  4.152953e+00                             SB415286 D022_r2
## 5988  3.852042e+00                             SB431542 D022_r2
## 5989  3.389050e+00                             SB505124 D022_r2
## 5990  4.575261e+00                             SB525334 D022_r2
## 5991  2.971681e+00                             SB590885 D022_r2
## 5992  1.791123e+00                                  SC1 D022_r2
## 5993  5.389071e+00                Schisandrin B (Sch B) D022_r2
## 5994  8.161479e+00                Selumetinib (AZD6244) D022_r2
## 5995  5.424281e+00              Semagacestat (LY450139) D022_r2
## 5996  4.159424e+00                   Semaxanib (SU5416) D022_r2
## 5997  1.521884e+00                             SGI-7079 D022_r2
## 5998  2.901159e+00                          Skepinone-L D022_r2
## 5999  5.780467e+00                               SL-327 D022_r2
## 6000  1.632509e+00                 SNS-032 (BMS-387032) D022_r2
## 6001  6.147501e+00                     SNS-314 Mesylate D022_r2
## 6002  2.405633e+00                            Sorafenib D022_r2
## 6003  5.811931e+00                   Sorafenib Tosylate D022_r2
## 6004  3.801881e+00                         Sotrastaurin D022_r2
## 6005  5.174791e+00                             SP600125 D022_r2
## 6006  4.703527e+00                              SU11274 D022_r2
## 6007  3.761564e+00                               SU6656 D022_r2
## 6008  2.857631e+00                               SU9516 D022_r2
## 6009  3.541562e+00                     Sunitinib Malate D022_r2
## 6010  2.385099e+00                  TAE226 (NVP-TAE226) D022_r2
## 6011  4.814395e+00                              TAK-285 D022_r2
## 6012  3.146993e+00                              TAK-632 D022_r2
## 6013  1.606245e+00                              TAK-715 D022_r2
## 6014  3.631256e+00                              TAK-733 D022_r2
## 6015  3.099190e+00                              TAK-901 D022_r2
## 6016  4.470689e+00                Taladegib (LY2940680) D022_r2
## 6017  5.172528e+00                              TCS 359 D022_r2
## 6018  3.042877e+00                               TDZD-8 D022_r2
## 6019  3.644491e+00                            Telatinib D022_r2
## 6020  4.521171e+00   Temsirolimus (CCI-779, NSC 683864) D022_r2
## 6021  1.358576e+00              Tepotinib (EMD 1214063) D022_r2
## 6022  5.137484e+00                                TG003 D022_r2
## 6023  4.090458e+00                            TG100-115 D022_r2
## 6024  3.901752e+00                             TG101209 D022_r2
## 6025  3.559123e+00                 TG101348 (SAR302503) D022_r2
## 6026  5.508622e+00                              TGX-221 D022_r2
## 6027  4.933709e+00                         Theophylline D022_r2
## 6028  3.654529e+00                          Thiazovivin D022_r2
## 6029  3.966275e+00                       TIC10 Analogue D022_r2
## 6030  2.646511e+00                           Tideglusib D022_r2
## 6031  2.818084e+00                 Tivantinib (ARQ 197) D022_r2
## 6032  3.619049e+00                   Tivozanib (AV-951) D022_r2
## 6033  4.904552e+00  Tofacitinib (CP-690550,Tasocitinib) D022_r2
## 6034  4.109396e+00      Tofacitinib (CP-690550) Citrate D022_r2
## 6035  3.054097e+00                              Torin 2 D022_r2
## 6036  4.626891e+00              Trametinib (GSK1120212) D022_r2
## 6037  4.927754e+00                          Triciribine D022_r2
## 6038  5.348572e+00           TSU-68 (SU6668, Orantinib) D022_r2
## 6039  4.214534e+00                               TWS119 D022_r2
## 6040  4.269891e+00                         Tyrphostin 9 D022_r2
## 6041  4.835772e+00                   Tyrphostin AG 1296 D022_r2
## 6042  5.250842e+00                           U0126-EtOH D022_r2
## 6043  4.211832e+00     Ulixertinib (BVD-523, VRT752271) D022_r2
## 6044  3.750054e+00              Uprosertib (GSK2141795) D022_r2
## 6045  5.891021e+00                          Vacquinol-1 D022_r2
## 6046  4.899434e+00                           Varlitinib D022_r2
## 6047  4.572308e+00              Vatalanib (PTK787) 2HCl D022_r2
## 6048  4.509896e+00                               VE-821 D022_r2
## 6049  1.053783e+00                               VE-822 D022_r2
## 6050  5.051328e+00        Vemurafenib (PLX4032, RG7204) D022_r2
## 6051  3.896456e+00                Vismodegib (GDC-0449) D022_r2
## 6052  3.599676e+00                 Volasertib (BI 6727) D022_r2
## 6053  4.379184e+00                            VPS34-IN1 D022_r2
## 6054  4.250401e+00                     VS-5584 (SB2343) D022_r2
## 6055  7.828052e+00                               VX-11e D022_r2
## 6056  5.639743e+00         VX-680 (Tozasertib, MK-0457) D022_r2
## 6057  2.447019e+00                               VX-702 D022_r2
## 6058  4.290434e+00                               VX-745 D022_r2
## 6059  3.989556e+00                              WAY-600 D022_r2
## 6060  4.090944e+00                             WH-4-023 D022_r2
## 6061  3.740769e+00                             WHI-P154 D022_r2
## 6062  4.414113e+00                                WIKI4 D022_r2
## 6063  3.859299e+00                        Wnt agonist 1 D022_r2
## 6064  3.742512e+00                        Wnt-C59 (C59) D022_r2
## 6065  4.628324e+00                               WP1066 D022_r2
## 6066  3.801351e+00                 WYE-125132 (WYE-132) D022_r2
## 6067  4.721855e+00                              WYE-354 D022_r2
## 6068  7.303542e+00                               WZ3146 D022_r2
## 6069  4.407135e+00                               WZ4002 D022_r2
## 6070  4.170247e+00                               WZ4003 D022_r2
## 6071  4.153060e+00                               WZ8040 D022_r2
## 6072  3.637715e+00                              XAV-939 D022_r2
## 6073  4.953154e+00                                XL019 D022_r2
## 6074  2.632628e+00                              XMD8-92 D022_r2
## 6075  4.980457e+00                         Y-27632 2HCl D022_r2
## 6076  6.119428e+00                             YM201636 D022_r2
## 6077  4.126432e+00                             YO-01027 D022_r2
## 6078  5.476072e+00                            ZM 306416 D022_r2
## 6079  3.959179e+00                        ZM 323881 HCl D022_r2
## 6080  4.560625e+00                            ZM 336372 D022_r2
## 6081  4.236116e+00                         ZM 39923 HCl D022_r2
## 6082  6.522911e+00                            ZM 447439 D022_r2
## 6083  4.074236e+00                 Zotarolimus(ABT-578) D022_r2
## 6084  5.696359e+00                              ZSTK474 D022_r2
## 6085  7.721318e-01                     1-Azakenpaullone D027_r1
## 6086  1.876229e-01                      3-Methyladenine D027_r1
## 6087  2.516270e+00                             A-674563 D027_r1
## 6088 -8.533548e-01                             A-769662 D027_r1
## 6089  1.538773e+00                                  A66 D027_r1
## 6090 -1.187445e-01                            Acadesine D027_r1
## 6091  3.312730e+00                  AEE788 (NVP-AEE788) D027_r1
## 6092  1.171511e-01        Afatinib (BIBW2992)_uncertain D027_r1
## 6093 -1.545918e+00                              AG-1024 D027_r1
## 6094  3.919891e+00         AG-1478 (Tyrphostin AG-1478) D027_r1
## 6095  3.331643e-01                                AG-18 D027_r1
## 6096 -1.085891e+00              AG-490 (Tyrphostin B42) D027_r1
## 6097  3.522019e-01                             Akti-1/2 D027_r1
## 6098 -1.275766e+00                  Alisertib (MLN8237) D027_r1
## 6099 -6.433497e-01                              AMG 337 D027_r1
## 6100  8.534682e-01                              AMG-458 D027_r1
## 6101  1.162304e+00                              AMG-900 D027_r1
## 6102 -5.876081e-01                               AMG319 D027_r1
## 6103 -1.857453e+00                  Amuvatinib (MP-470) D027_r1
## 6104 -1.798854e+00                             Apatinib D027_r1
## 6105 -7.449678e-02                           AR-A014418 D027_r1
## 6106 -6.785447e-01                            AS-252424 D027_r1
## 6107 -9.436461e-01                            AS-604850 D027_r1
## 6108 -1.366894e+00                         Asiatic Acid D027_r1
## 6109  3.112320e+00                             AST-1306 D027_r1
## 6110 -7.698887e-01                              AT13148 D027_r1
## 6111  3.172973e+00                               AT7519 D027_r1
## 6112 -2.398136e+00                               AT7867 D027_r1
## 6113  3.223631e+00                               AT9283 D027_r1
## 6114 -1.240642e+00                 Aurora A Inhibitor I D027_r1
## 6115 -4.064340e-01             Avagacestat (BMS-708163) D027_r1
## 6116 -1.141479e+00                              AVL-292 D027_r1
## 6117 -1.602130e+00                             Axitinib D027_r1
## 6118 -1.602130e+00                             Axitinib D027_r1
## 6119 -2.063834e-01                               AZ 628 D027_r1
## 6120 -5.074731e-01                               AZ 960 D027_r1
## 6121  2.064755e+00                                 AZ20 D027_r1
## 6122  1.183424e+00                              AZD1080 D027_r1
## 6123  1.061485e+00                              AZD1480 D027_r1
## 6124  2.561638e+00                              AZD2014 D027_r1
## 6125  2.115781e+00                              AZD2858 D027_r1
## 6126 -1.848099e+00                              AZD2932 D027_r1
## 6127  1.928619e+00                              AZD3759 D027_r1
## 6128  7.929612e-01                              AZD5363 D027_r1
## 6129  2.377145e+00                              AZD5438 D027_r1
## 6130 -2.418403e-01                              AZD6482 D027_r1
## 6131  3.057999e-01                              AZD6738 D027_r1
## 6132  3.631686e+00                              AZD8055 D027_r1
## 6133  1.706626e+00                              AZD8330 D027_r1
## 6134  7.833433e-01                  AZD8931 (Sapitinib) D027_r1
## 6135  1.790196e+00                              AZD9291 D027_r1
## 6136  3.990212e-01            Barasertib (AZD1152-HQPA) D027_r1
## 6137 -6.072917e-01  Baricitinib (LY3009104, INCB028050) D027_r1
## 6138 -2.269377e+00                  BGT226 (NVP-BGT226) D027_r1
## 6139  2.812078e+00                              BI 2536 D027_r1
## 6140 -8.524540e-01                              BI-78D3 D027_r1
## 6141 -8.428823e-01                             BI-D1870 D027_r1
## 6142 -1.148790e+00                              Bikinin D027_r1
## 6143 -1.022323e-01                                  BIO D027_r1
## 6144 -2.092185e+00               BIRB 796 (Doramapimod) D027_r1
## 6145 -9.343606e-02                            BIX 02188 D027_r1
## 6146 -1.510917e-01                            BIX 02189 D027_r1
## 6147  2.484966e+00      BKM120 (NVP-BKM120, Buparlisib) D027_r1
## 6148 -1.341140e+00                           BMS-265246 D027_r1
## 6149  1.656460e+00                           BMS-536924 D027_r1
## 6150 -1.081099e-01                           BMS-582949 D027_r1
## 6151  1.477068e+00                           BMS-754807 D027_r1
## 6152 -3.365749e-01                           BMS-777607 D027_r1
## 6153 -1.469462e+00                           BMS-794833 D027_r1
## 6154 -8.057183e-01                           BMS-833923 D027_r1
## 6155  1.552635e+00                  Bosutinib (SKI-606) D027_r1
## 6156 -6.229935e-01                Brivanib (BMS-540215) D027_r1
## 6157 -1.503438e+00      Brivanib Alaninate (BMS-582664) D027_r1
## 6158 -6.242412e-01                           BS-181 HCl D027_r1
## 6159 -1.693551e-01                               Butein D027_r1
## 6160  1.423370e+00                               BYL719 D027_r1
## 6161 -2.786125e+00     Cabozantinib (XL184, BMS-907351) D027_r1
## 6162 -1.689163e+00          Cabozantinib malate (XL184) D027_r1
## 6163 -6.128879e-01        CAL-101 (Idelalisib, GS-1101) D027_r1
## 6164 -1.757467e+00                             CAY10505 D027_r1
## 6165  4.978317e-01                               CC-223 D027_r1
## 6166  2.206475e+00                            CCT128930 D027_r1
## 6167  6.055641e-01                  Cediranib (AZD2171) D027_r1
## 6168 -1.161161e+00                            CEP-32496 D027_r1
## 6169 -1.734911e+00                            CEP-33779 D027_r1
## 6170  3.790574e-01                              CGI1746 D027_r1
## 6171 -1.146596e+00                              CGK 733 D027_r1
## 6172  2.272303e+00                            CH5132799 D027_r1
## 6173  2.099394e+00                           CHIR-98014 D027_r1
## 6174  2.957180e+00                 CHIR-99021 (CT99021) D027_r1
## 6175  1.563041e+00             CHIR-99021 (CT99021) HCl D027_r1
## 6176 -5.472262e-01                    Chrysophanic Acid D027_r1
## 6177  1.768003e+00                             CNX-2006 D027_r1
## 6178  1.396240e+00                              CNX-774 D027_r1
## 6179 -3.720778e-01                    CO-1686 (AVL-301) D027_r1
## 6180  3.245435e+00       Cobimetinib (GDC-0973, RG7420) D027_r1
## 6181 -1.293430e+00                            CP-673451 D027_r1
## 6182 -1.101769e+00                            CP-724714 D027_r1
## 6183  6.307852e-01               Crenolanib (CP-868596) D027_r1
## 6184  1.992156e+00             Crizotinib (PF-02341066) D027_r1
## 6185 -3.030775e-01                               CYC116 D027_r1
## 6186 -1.414976e+00                               CYT387 D027_r1
## 6187 -1.720139e+00                             CZC24832 D027_r1
## 6188 -9.519449e-01              Dabrafenib (GSK2118436) D027_r1
## 6189  2.532190e+00        Dacomitinib (PF299804, PF299) D027_r1
## 6190  1.901601e-01              Danusertib (PHA-739358) D027_r1
## 6191  5.412028e-01                        DAPT (GSI-IX) D027_r1
## 6192  4.772364e-02                            Dasatinib D027_r1
## 6193 -1.460428e+00                DCC-2036 (Rebastinib) D027_r1
## 6194 -1.152947e+00                Decernotinib (VX-509) D027_r1
## 6195  2.685942e+00               Dinaciclib (SCH727965) D027_r1
## 6196  2.724352e+00    Dovitinib (TKI-258) Dilactic Acid D027_r1
## 6197  1.019950e+00                            ENMD-2076 D027_r1
## 6198  2.550755e+00               Enzastaurin (LY317615) D027_r1
## 6199  9.531794e-01                            ERK5-IN-1 D027_r1
## 6200  5.174517e-01                             ETC-1002 D027_r1
## 6201  5.265375e-02                            ETP-46464 D027_r1
## 6202  3.844622e-01                  Everolimus (RAD001) D027_r1
## 6203 -5.653786e-01                Fasudil (HA-1077) HCl D027_r1
## 6204 -5.995235e-01                                FH535 D027_r1
## 6205 -7.143135e-01                Filgotinib (GLPG0634) D027_r1
## 6206  1.600897e+00             Flavopiridol (Alvocidib) D027_r1
## 6207  1.310434e+00                     Flavopiridol HCl D027_r1
## 6208 -5.128678e-01               Foretinib (GSK1363089) D027_r1
## 6209  8.530738e-01                  Fostamatinib (R788) D027_r1
## 6210 -1.059156e+00                                G-749 D027_r1
## 6211  1.740010e+00                             GDC-0068 D027_r1
## 6212  1.637272e+00                             GDC-0349 D027_r1
## 6213 -2.359316e+00                             GDC-0879 D027_r1
## 6214  1.016691e+00                             GDC-0941 D027_r1
## 6215  3.344913e+00                    GDC-0980 (RG7422) D027_r1
## 6216  3.348212e+00                   Gefitinib (ZD1839) D027_r1
## 6217 -3.963857e-01                            Genistein D027_r1
## 6218  6.887691e-01                            GF109203X D027_r1
## 6219 -3.797487e-01                                GNF-2 D027_r1
## 6220 -5.084398e-01                                GNF-5 D027_r1
## 6221  7.586262e-01                              Go 6983 D027_r1
## 6222  1.993775e+00                   Golvatinib (E7050) D027_r1
## 6223 -2.942428e-01                          GSK1838705A D027_r1
## 6224 -6.069278e-02                          GSK1904529A D027_r1
## 6225  4.908939e-01                  GSK2126458 (GSK458) D027_r1
## 6226  4.135118e-01                           GSK2292767 D027_r1
## 6227 -1.189166e+00                           GSK2636771 D027_r1
## 6228 -1.862189e+00                           GSK429286A D027_r1
## 6229  2.423361e+00                            GSK461364 D027_r1
## 6230 -1.336459e+00                               GSK621 D027_r1
## 6231  9.109470e-01                            GSK690693 D027_r1
## 6232 -1.301999e+00                               GW5074 D027_r1
## 6233 -5.382248e-01                             GW788388 D027_r1
## 6234 -6.221659e-01                               GZD824 D027_r1
## 6235 -7.574641e-01                            H 89 2HCl D027_r1
## 6236  1.147421e-01                           Hesperadin D027_r1
## 6237  1.287376e+00                              HMN-214 D027_r1
## 6238 -4.668462e-01                             Honokiol D027_r1
## 6239  6.002993e-01                               HS-173 D027_r1
## 6240  1.973733e+00                           HTH-01-015 D027_r1
## 6241  1.289110e+00                Ibrutinib (PCI-32765) D027_r1
## 6242 -1.379021e+00                              ICG-001 D027_r1
## 6243 -5.196595e-01                             Icotinib D027_r1
## 6244 -2.056883e-01                                IM-12 D027_r1
## 6245  3.187674e+00           Imatinib Mesylate (STI571) D027_r1
## 6246 -1.896482e+00                            Indirubin D027_r1
## 6247  2.657002e+00                    INK 128 (MLN0128) D027_r1
## 6248  1.043731e+00                    IPI-145 (INK1197) D027_r1
## 6249 -7.516360e-01                               IWP-L6 D027_r1
## 6250 -2.026191e+00                           IWR-1-endo D027_r1
## 6251 -2.125135e-01                         JNJ-38877605 D027_r1
## 6252 -3.739448e-01                          JNJ-7706621 D027_r1
## 6253  1.058197e+00                     JNK Inhibitor IX D027_r1
## 6254 -2.022470e+00                             JNK-IN-8 D027_r1
## 6255 -1.162344e+00                               K02288 D027_r1
## 6256 -1.814443e+00                               Ki8751 D027_r1
## 6257 -1.748907e-01                              KRN 633 D027_r1
## 6258  1.640501e+00                           KU-0063794 D027_r1
## 6259  3.596248e-01      KU-55933 (ATM Kinase Inhibitor) D027_r1
## 6260 -1.933535e+00                             KU-60019 D027_r1
## 6261 -7.069294e-02                              KW-2449 D027_r1
## 6262 -3.197988e-01                              KX2-391 D027_r1
## 6263 -4.606365e-01                              KY02111 D027_r1
## 6264  3.700462e-01                            Lapatinib D027_r1
## 6265 -3.086292e-01     Lapatinib (GW-572016) Ditosylate D027_r1
## 6266 -6.163951e-01                            LDC000067 D027_r1
## 6267 -3.939496e-01      LDE225 (NVP-LDE225,Erismodegib) D027_r1
## 6268  2.410667e-01                           LDN-214117 D027_r1
## 6269 -2.883172e+00                   Lenvatinib (E7080) D027_r1
## 6270 -1.355190e-01                              LFM-A13 D027_r1
## 6271 -1.069361e+00                              LGK-974 D027_r1
## 6272 -7.332014e-01                  Linifanib (ABT-869) D027_r1
## 6273  1.911405e-01                               LJH685 D027_r1
## 6274 -8.226906e-01                               LJI308 D027_r1
## 6275 -1.617137e-01               Losmapimod (GW856553X) D027_r1
## 6276  2.813028e+00                            LY2090314 D027_r1
## 6277 -1.265679e+00                            LY2157299 D027_r1
## 6278 -1.820104e+00                            LY2784544 D027_r1
## 6279  1.702083e+00                            LY2835219 D027_r1
## 6280 -4.317046e-01                             LY294002 D027_r1
## 6281  1.584601e+00                            LY3023414 D027_r1
## 6282 -4.481650e-01                             LY411575 D027_r1
## 6283  2.700120e+00       MEK162 (ARRY-162, ARRY-438162) D027_r1
## 6284  1.497491e-01                             MGCD-265 D027_r1
## 6285  1.226114e+00               Milciclib (PHA-848125) D027_r1
## 6286  4.985276e-01                              MK-0752 D027_r1
## 6287  2.919927e-01                         MK-2206 2HCl D027_r1
## 6288 -5.038819e-01                              MK-2461 D027_r1
## 6289  8.130989e-01                     MK-5108 (VX-689) D027_r1
## 6290 -1.832495e+00                              MK-8745 D027_r1
## 6291  4.279185e-01                              MLN2480 D027_r1
## 6292 -1.403199e+00                              MLN8054 D027_r1
## 6293 -4.789876e-01      Motesanib Diphosphate (AMG-706) D027_r1
## 6294 -3.421368e+00                  Nilotinib (AMN-107) D027_r1
## 6295  2.072120e-02     Nintedanib (BIBF 1120)_uncertain D027_r1
## 6296 -6.840370e-01                               NU6027 D027_r1
## 6297 -5.660210e-01                           NVP-AEW541 D027_r1
## 6298 -8.853923e-01                           NVP-BHG712 D027_r1
## 6299 -7.017347e-01                      NVP-BSK805 2HCl D027_r1
## 6300 -1.159455e+00                           NVP-BVU972 D027_r1
## 6301 -8.463409e-01                          Oclacitinib D027_r1
## 6302  7.656532e-01      Olmutinib (HM61713, BI 1482694) D027_r1
## 6303  2.318157e+00                             ONO-4059 D027_r1
## 6304  2.405470e+00                              OSI-027 D027_r1
## 6305  2.614559e+00                              OSI-420 D027_r1
## 6306  1.557638e+00                 OSI-906 (Linsitinib) D027_r1
## 6307  1.675654e+00                              P276-00 D027_r1
## 6308  1.639894e+00                  Pacritinib (SB1518) D027_r1
## 6309 -4.023578e-01                   Palomid 529 (P529) D027_r1
## 6310 -7.513890e-01                            Pazopanib D027_r1
## 6311 -8.016453e-01                        Pazopanib HCl D027_r1
## 6312  2.841612e+00                            PD0325901 D027_r1
## 6313  3.652933e+00                             PD168393 D027_r1
## 6314 -5.251943e-01                             PD173955 D027_r1
## 6315  1.519671e+00                   PD184352 (CI-1040) D027_r1
## 6316  3.888848e+00                             PD318088 D027_r1
## 6317 -4.033862e-02                              PD98059 D027_r1
## 6318  2.094133e+00                  Pelitinib (EKB-569) D027_r1
## 6319 -8.268588e-01                          PF-00562271 D027_r1
## 6320 -2.357420e-01                          PF-04217903 D027_r1
## 6321  1.229039e+00                          PF-04691502 D027_r1
## 6322 -2.187392e-01                            PF-431396 D027_r1
## 6323  1.646979e+00                           PF-4708671 D027_r1
## 6324 -6.765773e-01                           PF-5274857 D027_r1
## 6325  1.833645e+00                            PF-562271 D027_r1
## 6326 -1.134603e+00                            PF-573228 D027_r1
## 6327 -1.432880e+00                            PH-797804 D027_r1
## 6328  1.025467e+00                           PHA-665752 D027_r1
## 6329  1.127261e-01                           PHA-680632 D027_r1
## 6330  1.846560e+00                           PHA-767491 D027_r1
## 6331 -7.192035e-01                           PHA-793887 D027_r1
## 6332 -5.902249e-01                       Phenformin HCl D027_r1
## 6333 -6.250035e-01                              PHT-427 D027_r1
## 6334  1.796904e+00                          Piceatannol D027_r1
## 6335 -6.041792e-01                              PIK-293 D027_r1
## 6336 -1.547500e+00                              PIK-294 D027_r1
## 6337  1.133026e+00                               PIK-93 D027_r1
## 6338  2.931345e+00               Pimasertib (AS-703026) D027_r1
## 6339 -7.388797e-01                          Pirfenidone D027_r1
## 6340 -1.842081e+00                             PLX-4720 D027_r1
## 6341 -1.419772e+00                              PLX7904 D027_r1
## 6342  3.882065e-01                  Ponatinib (AP24534) D027_r1
## 6343 -1.203327e-02                                  PP1 D027_r1
## 6344 -4.145309e-01                                  PP2 D027_r1
## 6345 -9.539335e-01                                PP242 D027_r1
## 6346 -9.237166e-01                               PQ 401 D027_r1
## 6347 -2.395972e-01                              PRI-724 D027_r1
## 6348 -8.267917e-01     PRT062607 (P505-15, BIIB057) HCl D027_r1
## 6349 -1.094748e+00                         Purvalanol A D027_r1
## 6350 -8.182419e-01                            Quercetin D027_r1
## 6351  2.570640e+00                  Quizartinib (AC220) D027_r1
## 6352 -2.818633e+00                                 R406 D027_r1
## 6353 -2.418118e+00                     R406 (free base) D027_r1
## 6354  6.209905e-01                                 R547 D027_r1
## 6355  3.473359e+00                    RAF265 (CHIR-265) D027_r1
## 6356  9.746046e-01                Rapamycin (Sirolimus) D027_r1
## 6357  2.062856e+00   Refametinib (RDEA119, Bay 86-9766) D027_r1
## 6358 -1.571305e+00                               RepSox D027_r1
## 6359 -9.718131e-03 Ridaforolimus (Deforolimus, MK-8669) D027_r1
## 6360  1.345586e+00                Rigosertib (ON-01910) D027_r1
## 6361  3.506592e-01                             RKI-1447 D027_r1
## 6362  2.303605e-01                                RN486 D027_r1
## 6363  2.780872e+00                  Ro 31-8220 Mesylate D027_r1
## 6364 -4.803314e-01                              Ro-3306 D027_r1
## 6365  2.090778e+00                               Ro3280 D027_r1
## 6366 -2.111874e-01                            RO4929097 D027_r1
## 6367 -5.460799e-01      Roscovitine (Seliciclib,CYC202) D027_r1
## 6368 -7.902159e-01             Ruxolitinib (INCB018424) D027_r1
## 6369 -1.328526e+00           S-Ruxolitinib (INCB018424) D027_r1
## 6370 -6.590432e-01                               SANT-1 D027_r1
## 6371 -1.342951e+00                            SAR131675 D027_r1
## 6372 -4.396960e-01                    SAR245409 (XL765) D027_r1
## 6373  3.014796e+00                Saracatinib (AZD0530) D027_r1
## 6374 -1.841473e+00                      SB202190 (FHPI) D027_r1
## 6375 -9.376326e-01                             SB203580 D027_r1
## 6376 -1.117400e-01                             SB216763 D027_r1
## 6377 -1.489303e+00                             SB239063 D027_r1
## 6378 -5.774023e-01                             SB415286 D027_r1
## 6379 -4.762542e-01                             SB431542 D027_r1
## 6380 -9.971975e-01                             SB505124 D027_r1
## 6381 -9.169885e-01                             SB525334 D027_r1
## 6382 -2.247572e+00                             SB590885 D027_r1
## 6383  1.099775e+00                                  SC1 D027_r1
## 6384 -5.385669e-01                Schisandrin B (Sch B) D027_r1
## 6385  3.169921e+00                Selumetinib (AZD6244) D027_r1
## 6386 -9.909208e-01              Semagacestat (LY450139) D027_r1
## 6387 -9.431752e-01                   Semaxanib (SU5416) D027_r1
## 6388  3.240026e-01                             SGI-7079 D027_r1
## 6389 -5.936220e-01                          Skepinone-L D027_r1
## 6390  1.380376e+00                               SL-327 D027_r1
## 6391  2.418664e+00                 SNS-032 (BMS-387032) D027_r1
## 6392  9.205791e-01                     SNS-314 Mesylate D027_r1
## 6393  2.679246e-01                            Sorafenib D027_r1
## 6394 -7.179316e-01                   Sorafenib Tosylate D027_r1
## 6395 -1.013990e-02                         Sotrastaurin D027_r1
## 6396 -1.629761e+00                             SP600125 D027_r1
## 6397 -6.296304e-01                              SU11274 D027_r1
## 6398 -1.524189e+00                               SU6656 D027_r1
## 6399 -2.173816e+00                               SU9516 D027_r1
## 6400 -1.372468e-01                     Sunitinib Malate D027_r1
## 6401  6.756139e-01                  TAE226 (NVP-TAE226) D027_r1
## 6402  8.356296e-01                              TAK-285 D027_r1
## 6403  1.961866e+00                              TAK-632 D027_r1
## 6404 -7.188776e-01                              TAK-715 D027_r1
## 6405  2.429658e+00                              TAK-733 D027_r1
## 6406  6.881037e-01                              TAK-901 D027_r1
## 6407 -2.348332e-01                Taladegib (LY2940680) D027_r1
## 6408 -1.415785e+00                              TCS 359 D027_r1
## 6409 -6.484295e-01                               TDZD-8 D027_r1
## 6410 -1.436669e+00                            Telatinib D027_r1
## 6411 -1.839265e-01   Temsirolimus (CCI-779, NSC 683864) D027_r1
## 6412  2.424047e+00              Tepotinib (EMD 1214063) D027_r1
## 6413 -5.403001e-01                                TG003 D027_r1
## 6414 -8.433750e-01                            TG100-115 D027_r1
## 6415  1.885616e+00                             TG101209 D027_r1
## 6416  1.867310e+00                 TG101348 (SAR302503) D027_r1
## 6417 -1.920775e+00                              TGX-221 D027_r1
## 6418 -1.219880e+00                         Theophylline D027_r1
## 6419 -1.619857e+00                          Thiazovivin D027_r1
## 6420 -2.108991e-01                       TIC10 Analogue D027_r1
## 6421  8.896379e-01                           Tideglusib D027_r1
## 6422  6.121336e-02                 Tivantinib (ARQ 197) D027_r1
## 6423 -2.625166e+00                   Tivozanib (AV-951) D027_r1
## 6424 -3.397328e-01  Tofacitinib (CP-690550,Tasocitinib) D027_r1
## 6425 -6.410392e-01      Tofacitinib (CP-690550) Citrate D027_r1
## 6426  2.479895e+00                              Torin 2 D027_r1
## 6427  2.324963e+00              Trametinib (GSK1120212) D027_r1
## 6428 -2.459601e-01                          Triciribine D027_r1
## 6429 -9.500278e-01           TSU-68 (SU6668, Orantinib) D027_r1
## 6430 -9.736919e-01                               TWS119 D027_r1
## 6431 -7.940615e-01                         Tyrphostin 9 D027_r1
## 6432 -1.028412e+00                   Tyrphostin AG 1296 D027_r1
## 6433  1.355861e+00                           U0126-EtOH D027_r1
## 6434  1.564160e+00     Ulixertinib (BVD-523, VRT752271) D027_r1
## 6435  1.515818e+00              Uprosertib (GSK2141795) D027_r1
## 6436  1.569046e+00                          Vacquinol-1 D027_r1
## 6437 -2.411906e+00                           Varlitinib D027_r1
## 6438  9.717988e-02              Vatalanib (PTK787) 2HCl D027_r1
## 6439 -3.640013e-01                               VE-821 D027_r1
## 6440 -1.789194e-03                               VE-822 D027_r1
## 6441 -9.262637e-01        Vemurafenib (PLX4032, RG7204) D027_r1
## 6442 -3.598935e-01                Vismodegib (GDC-0449) D027_r1
## 6443 -4.859067e-01                 Volasertib (BI 6727) D027_r1
## 6444 -4.295767e-01                            VPS34-IN1 D027_r1
## 6445  3.660064e+00                     VS-5584 (SB2343) D027_r1
## 6446  2.608905e+00                               VX-11e D027_r1
## 6447 -3.473374e-01         VX-680 (Tozasertib, MK-0457) D027_r1
## 6448  5.177485e-01                               VX-702 D027_r1
## 6449 -2.110931e+00                               VX-745 D027_r1
## 6450  2.404809e+00                              WAY-600 D027_r1
## 6451 -1.879332e+00                             WH-4-023 D027_r1
## 6452 -1.023861e+00                             WHI-P154 D027_r1
## 6453 -2.964937e+00                                WIKI4 D027_r1
## 6454  2.059908e+00                        Wnt agonist 1 D027_r1
## 6455 -1.366503e+00                        Wnt-C59 (C59) D027_r1
## 6456 -7.853148e-01                               WP1066 D027_r1
## 6457  8.264677e-01                 WYE-125132 (WYE-132) D027_r1
## 6458  1.614085e+00                              WYE-354 D027_r1
## 6459  3.725048e+00                               WZ3146 D027_r1
## 6460  1.493922e-01                               WZ4002 D027_r1
## 6461 -8.977287e-01                               WZ4003 D027_r1
## 6462  2.874653e-01                               WZ8040 D027_r1
## 6463 -1.133231e+00                              XAV-939 D027_r1
## 6464 -1.085126e+00                                XL019 D027_r1
## 6465  1.965752e+00                              XMD8-92 D027_r1
## 6466 -3.760687e-01                         Y-27632 2HCl D027_r1
## 6467  8.122979e-01                             YM201636 D027_r1
## 6468  4.073010e-01                             YO-01027 D027_r1
## 6469  1.893906e+00                            ZM 306416 D027_r1
## 6470 -6.803437e-01                        ZM 323881 HCl D027_r1
## 6471 -2.028357e+00                            ZM 336372 D027_r1
## 6472 -6.135212e-01                         ZM 39923 HCl D027_r1
## 6473  1.035269e-01                            ZM 447439 D027_r1
## 6474  1.102455e+00                 Zotarolimus(ABT-578) D027_r1
## 6475  3.633583e+00                              ZSTK474 D027_r1
## 6476 -8.486904e-01                     1-Azakenpaullone D027_r2
## 6477 -3.359108e-01                            Acadesine D027_r2
## 6478 -2.075592e+00                  AEE788 (NVP-AEE788) D027_r2
## 6479 -1.467937e+00        Afatinib (BIBW2992)_uncertain D027_r2
## 6480 -1.678678e+00                              AG-1024 D027_r2
## 6481 -2.842095e-01                                AG-18 D027_r2
## 6482 -8.890248e-02              AG-490 (Tyrphostin B42) D027_r2
## 6483 -1.050063e+00                  Alisertib (MLN8237) D027_r2
## 6484 -4.807801e-01                              AMG 337 D027_r2
## 6485  1.514725e-01                  Amuvatinib (MP-470) D027_r2
## 6486  9.041428e-01                             Apatinib D027_r2
## 6487 -1.332661e+00                           AR-A014418 D027_r2
## 6488 -1.694114e-01                         Asiatic Acid D027_r2
## 6489  1.194688e+00                             AST-1306 D027_r2
## 6490  1.876543e+00                              AT13148 D027_r2
## 6491  5.779581e-01                               AT7519 D027_r2
## 6492  1.273865e+00                               AT7867 D027_r2
## 6493 -4.981079e-01                               AT9283 D027_r2
## 6494 -1.772910e+00                 Aurora A Inhibitor I D027_r2
## 6495  2.181050e-01             Avagacestat (BMS-708163) D027_r2
## 6496 -1.042746e+00                             Axitinib D027_r2
## 6497 -1.042746e+00                             Axitinib D027_r2
## 6498 -6.918778e-01                               AZ 960 D027_r2
## 6499 -5.165822e-01                              AZD1080 D027_r2
## 6500 -1.532672e+00                              AZD1480 D027_r2
## 6501 -3.606739e-01                              AZD2858 D027_r2
## 6502  2.306489e+00                              AZD5363 D027_r2
## 6503 -9.008360e-01                              AZD6482 D027_r2
## 6504  5.941843e-01                              AZD8055 D027_r2
## 6505  5.222815e-01                              AZD8330 D027_r2
## 6506  2.165999e-01                  AZD8931 (Sapitinib) D027_r2
## 6507 -3.615966e-02            Barasertib (AZD1152-HQPA) D027_r2
## 6508  7.502760e-02  Baricitinib (LY3009104, INCB028050) D027_r2
## 6509 -1.350375e+00                              BI 2536 D027_r2
## 6510 -7.904167e-01                              BI-78D3 D027_r2
## 6511 -3.764167e-01                              Bikinin D027_r2
## 6512 -1.927716e+00                                  BIO D027_r2
## 6513 -6.367206e-01               BIRB 796 (Doramapimod) D027_r2
## 6514 -1.336756e+00                            BIX 02188 D027_r2
## 6515 -3.246893e-01                            BIX 02189 D027_r2
## 6516 -8.524176e-01      BKM120 (NVP-BKM120, Buparlisib) D027_r2
## 6517 -2.737083e+00                           BMS-265246 D027_r2
## 6518  5.207992e-02                           BMS-536924 D027_r2
## 6519 -5.195546e-01                           BMS-582949 D027_r2
## 6520 -1.370286e+00                           BMS-754807 D027_r2
## 6521  7.112169e-01                           BMS-777607 D027_r2
## 6522 -2.455732e+00                           BMS-794833 D027_r2
## 6523 -1.561459e+00                           BMS-833923 D027_r2
## 6524 -2.154730e+00                  Bosutinib (SKI-606) D027_r2
## 6525 -3.379861e-01                Brivanib (BMS-540215) D027_r2
## 6526  6.992245e-01      Brivanib Alaninate (BMS-582664) D027_r2
## 6527  4.207848e-01                           BS-181 HCl D027_r2
## 6528 -2.467072e-01     Cabozantinib (XL184, BMS-907351) D027_r2
## 6529  2.544941e-02        CAL-101 (Idelalisib, GS-1101) D027_r2
## 6530 -2.333943e+00                               CC-223 D027_r2
## 6531 -4.056017e+00                  Cediranib (AZD2171) D027_r2
## 6532 -7.897041e-01                            CEP-32496 D027_r2
## 6533 -1.410874e+00                            CEP-33779 D027_r2
## 6534 -2.217527e-01                           CHIR-98014 D027_r2
## 6535 -1.183504e-01                 CHIR-99021 (CT99021) D027_r2
## 6536  3.236593e-01             CHIR-99021 (CT99021) HCl D027_r2
## 6537 -7.186991e-01                            CP-673451 D027_r2
## 6538 -1.051094e+00                            CP-724714 D027_r2
## 6539 -1.605351e+00             Crizotinib (PF-02341066) D027_r2
## 6540 -2.563906e+00                               CYC116 D027_r2
## 6541 -6.630785e-01                               CYT387 D027_r2
## 6542 -2.113226e+00              Danusertib (PHA-739358) D027_r2
## 6543 -4.618733e-01                        DAPT (GSI-IX) D027_r2
## 6544 -1.564834e+00                            Dasatinib D027_r2
## 6545 -1.211854e+00                Decernotinib (VX-509) D027_r2
## 6546 -3.159395e+00                            ENMD-2076 D027_r2
## 6547  8.957234e-02               Enzastaurin (LY317615) D027_r2
## 6548  4.453705e-02                             ETC-1002 D027_r2
## 6549 -6.441165e-01                  Everolimus (RAD001) D027_r2
## 6550 -5.906956e-01                Fasudil (HA-1077) HCl D027_r2
## 6551 -2.249831e+00                                FH535 D027_r2
## 6552 -1.428782e+00                Filgotinib (GLPG0634) D027_r2
## 6553 -6.340247e-01             Flavopiridol (Alvocidib) D027_r2
## 6554 -1.436398e+00               Foretinib (GSK1363089) D027_r2
## 6555  7.499624e-01                                G-749 D027_r2
## 6556  6.169464e-01                             GDC-0879 D027_r2
## 6557  7.534543e-01                             GDC-0941 D027_r2
## 6558  3.321098e-02                   Gefitinib (ZD1839) D027_r2
## 6559 -7.490060e-01                            Genistein D027_r2
## 6560  8.443711e-01                            GF109203X D027_r2
## 6561 -7.860068e-01                                GNF-5 D027_r2
## 6562  4.992064e-01                              Go 6983 D027_r2
## 6563 -3.917215e-01                          GSK1904529A D027_r2
## 6564 -1.516294e+00                           GSK2292767 D027_r2
## 6565 -2.713420e+00                           GSK429286A D027_r2
## 6566 -1.608571e+00                            GSK461364 D027_r2
## 6567 -3.102178e-01                               GSK621 D027_r2
## 6568  1.235461e+00                            GSK690693 D027_r2
## 6569 -1.650209e-01                             GW788388 D027_r2
## 6570  1.646364e-01                            H 89 2HCl D027_r2
## 6571 -2.740973e+00                           Hesperadin D027_r2
## 6572 -1.051377e-01                              HMN-214 D027_r2
## 6573  4.124549e-01                             Honokiol D027_r2
## 6574 -9.874616e-01                              ICG-001 D027_r2
## 6575 -1.565778e+00                                IM-12 D027_r2
## 6576  1.449039e+00           Imatinib Mesylate (STI571) D027_r2
## 6577 -5.280111e-01                            Indirubin D027_r2
## 6578 -2.540877e+00                               IWP-L6 D027_r2
## 6579 -1.558153e+00                           IWR-1-endo D027_r2
## 6580 -6.957343e-01                         JNJ-38877605 D027_r2
## 6581 -1.010184e+00                          JNJ-7706621 D027_r2
## 6582 -1.495512e+00                               K02288 D027_r2
## 6583 -1.000906e+00                               Ki8751 D027_r2
## 6584  3.690410e-01                              KRN 633 D027_r2
## 6585  1.662421e+00                           KU-0063794 D027_r2
## 6586 -5.109077e-01      KU-55933 (ATM Kinase Inhibitor) D027_r2
## 6587 -1.045319e+00                             KU-60019 D027_r2
## 6588 -2.357149e+00                              KW-2449 D027_r2
## 6589  2.894619e-01                              KY02111 D027_r2
## 6590 -5.050823e-01                            Lapatinib D027_r2
## 6591 -5.860847e-01     Lapatinib (GW-572016) Ditosylate D027_r2
## 6592 -1.760246e+00      LDE225 (NVP-LDE225,Erismodegib) D027_r2
## 6593 -2.752637e-01                   Lenvatinib (E7080) D027_r2
## 6594 -2.267650e-01                              LFM-A13 D027_r2
## 6595  1.429035e-01                              LGK-974 D027_r2
## 6596 -2.752984e+00                  Linifanib (ABT-869) D027_r2
## 6597 -7.993386e-01                               LJI308 D027_r2
## 6598 -1.242853e+00                            LY2157299 D027_r2
## 6599 -1.797692e+00                            LY2784544 D027_r2
## 6600  1.805839e+00                             LY294002 D027_r2
## 6601  8.206529e-01                            LY3023414 D027_r2
## 6602  5.463436e-01                             LY411575 D027_r2
## 6603  4.052488e-01                             MGCD-265 D027_r2
## 6604 -2.761020e-02                              MK-0752 D027_r2
## 6605 -8.857994e-01                         MK-2206 2HCl D027_r2
## 6606 -1.178428e-02                              MLN8054 D027_r2
## 6607 -2.212066e+00      Motesanib Diphosphate (AMG-706) D027_r2
## 6608 -3.924750e-01                  Nilotinib (AMN-107) D027_r2
## 6609 -2.002471e+00     Nintedanib (BIBF 1120)_uncertain D027_r2
## 6610 -9.464080e+00                           NVP-AEW541 D027_r2
## 6611 -8.348902e-01                           NVP-BHG712 D027_r2
## 6612 -3.029828e+00                      NVP-BSK805 2HCl D027_r2
## 6613 -5.599267e-02                          Oclacitinib D027_r2
## 6614 -2.434408e-01      Olmutinib (HM61713, BI 1482694) D027_r2
## 6615  2.236362e+00                             ONO-4059 D027_r2
## 6616  4.432528e-01                              OSI-420 D027_r2
## 6617  1.775649e+00                 OSI-906 (Linsitinib) D027_r2
## 6618 -1.921257e+00                  Pacritinib (SB1518) D027_r2
## 6619 -8.094799e-01                   Palomid 529 (P529) D027_r2
## 6620 -3.958467e-01                        Pazopanib HCl D027_r2
## 6621  2.627782e+00                            PD0325901 D027_r2
## 6622 -1.718991e+00                             PD173955 D027_r2
## 6623  1.044878e+00                   PD184352 (CI-1040) D027_r2
## 6624  1.877844e+00                             PD318088 D027_r2
## 6625 -1.208813e-01                              PD98059 D027_r2
## 6626 -2.870721e+00                  Pelitinib (EKB-569) D027_r2
## 6627 -4.493022e-01                          PF-04217903 D027_r2
## 6628 -2.804055e+00                           PF-4708671 D027_r2
## 6629 -1.953553e-01                           PF-5274857 D027_r2
## 6630 -1.458011e+00                            PF-573228 D027_r2
## 6631 -2.383616e+00                           PHA-665752 D027_r2
## 6632  5.869596e-01                           PHA-680632 D027_r2
## 6633 -3.870233e-01                           PHA-793887 D027_r2
## 6634 -8.990363e-01                              PHT-427 D027_r2
## 6635 -1.203980e+00                              PIK-293 D027_r2
## 6636 -6.592797e-01                              PIK-294 D027_r2
## 6637  7.470640e-01                               PIK-93 D027_r2
## 6638 -2.918992e-01               Pimasertib (AS-703026) D027_r2
## 6639 -2.441658e-01                          Pirfenidone D027_r2
## 6640  5.561784e-02                             PLX-4720 D027_r2
## 6641 -2.447763e+00                  Ponatinib (AP24534) D027_r2
## 6642  1.052574e+00                                PP242 D027_r2
## 6643 -6.128348e-01                              PRI-724 D027_r2
## 6644 -1.322665e+00     PRT062607 (P505-15, BIIB057) HCl D027_r2
## 6645 -1.490182e-01                            Quercetin D027_r2
## 6646 -9.196043e-01                  Quizartinib (AC220) D027_r2
## 6647  5.903886e-01                                 R406 D027_r2
## 6648 -5.309521e-03                     R406 (free base) D027_r2
## 6649 -1.565406e+00                    RAF265 (CHIR-265) D027_r2
## 6650  7.484558e-01                Rapamycin (Sirolimus) D027_r2
## 6651  1.553893e+00   Refametinib (RDEA119, Bay 86-9766) D027_r2
## 6652 -1.614615e+00                               RepSox D027_r2
## 6653  8.939542e-01 Ridaforolimus (Deforolimus, MK-8669) D027_r2
## 6654 -1.586250e+00                Rigosertib (ON-01910) D027_r2
## 6655 -2.250093e+00                             RKI-1447 D027_r2
## 6656  1.670198e+00                  Ro 31-8220 Mesylate D027_r2
## 6657 -1.419809e+00                              Ro-3306 D027_r2
## 6658 -6.430579e-01                            RO4929097 D027_r2
## 6659 -9.473041e-01      Roscovitine (Seliciclib,CYC202) D027_r2
## 6660 -1.559049e-01             Ruxolitinib (INCB018424) D027_r2
## 6661 -1.267416e+00           S-Ruxolitinib (INCB018424) D027_r2
## 6662 -1.651591e+00                               SANT-1 D027_r2
## 6663 -1.202484e-01                    SAR245409 (XL765) D027_r2
## 6664 -2.842281e+00                Saracatinib (AZD0530) D027_r2
## 6665  9.618691e-01                      SB202190 (FHPI) D027_r2
## 6666 -5.117891e-01                             SB203580 D027_r2
## 6667  1.345788e-01                             SB216763 D027_r2
## 6668 -2.877123e-01                             SB239063 D027_r2
## 6669  5.027774e-01                             SB415286 D027_r2
## 6670 -8.953810e-01                             SB431542 D027_r2
## 6671 -1.775952e+00                             SB505124 D027_r2
## 6672  8.228075e-03                             SB525334 D027_r2
## 6673 -6.012116e-01                             SB590885 D027_r2
## 6674 -6.403778e-01                Selumetinib (AZD6244) D027_r2
## 6675 -1.263146e+00              Semagacestat (LY450139) D027_r2
## 6676  2.076496e-01                               SL-327 D027_r2
## 6677  9.933751e-01                 SNS-032 (BMS-387032) D027_r2
## 6678 -3.928864e-01                     SNS-314 Mesylate D027_r2
## 6679 -4.294760e-01                   Sorafenib Tosylate D027_r2
## 6680  6.848452e-01                         Sotrastaurin D027_r2
## 6681 -1.513450e+00                             SP600125 D027_r2
## 6682  2.062037e-01                              SU11274 D027_r2
## 6683 -1.326741e+00                     Sunitinib Malate D027_r2
## 6684 -3.658133e-01                Taladegib (LY2940680) D027_r2
## 6685  4.181263e-01                              TCS 359 D027_r2
## 6686 -6.697690e-01                            Telatinib D027_r2
## 6687  1.017686e+00   Temsirolimus (CCI-779, NSC 683864) D027_r2
## 6688 -4.851092e-01                            TG100-115 D027_r2
## 6689 -5.706942e-01                             TG101209 D027_r2
## 6690 -1.256759e+00                 TG101348 (SAR302503) D027_r2
## 6691 -5.070831e-01                              TGX-221 D027_r2
## 6692 -9.391693e-01                         Theophylline D027_r2
## 6693  6.534963e-01                          Thiazovivin D027_r2
## 6694 -2.111200e+00                   Tivozanib (AV-951) D027_r2
## 6695  3.170559e-01  Tofacitinib (CP-690550,Tasocitinib) D027_r2
## 6696 -3.079777e-01      Tofacitinib (CP-690550) Citrate D027_r2
## 6697 -1.217136e+00                          Triciribine D027_r2
## 6698  2.608633e-01           TSU-68 (SU6668, Orantinib) D027_r2
## 6699 -8.873412e-01                               TWS119 D027_r2
## 6700  4.632195e-01                   Tyrphostin AG 1296 D027_r2
## 6701  5.813552e-01                           U0126-EtOH D027_r2
## 6702 -1.449082e+00                          Vacquinol-1 D027_r2
## 6703 -2.042426e+00              Vatalanib (PTK787) 2HCl D027_r2
## 6704 -5.126524e-01                               VE-821 D027_r2
## 6705 -9.135445e-01        Vemurafenib (PLX4032, RG7204) D027_r2
## 6706 -8.746667e-01                Vismodegib (GDC-0449) D027_r2
## 6707  9.186703e-02                 Volasertib (BI 6727) D027_r2
## 6708  1.535626e+00                               VX-11e D027_r2
## 6709 -1.354608e+00         VX-680 (Tozasertib, MK-0457) D027_r2
## 6710 -1.122205e+00                               VX-745 D027_r2
## 6711 -3.569537e+00                             WH-4-023 D027_r2
## 6712 -1.753709e+00                             WHI-P154 D027_r2
## 6713 -5.455293e+00                                WIKI4 D027_r2
## 6714 -2.585862e+00                        Wnt agonist 1 D027_r2
## 6715 -9.206841e-01                        Wnt-C59 (C59) D027_r2
## 6716 -1.529098e+00                               WP1066 D027_r2
## 6717  3.020755e-01                              WYE-354 D027_r2
## 6718  3.089135e+00                               WZ3146 D027_r2
## 6719 -1.121116e+00                               WZ4002 D027_r2
## 6720  1.830153e+00                               WZ8040 D027_r2
## 6721 -7.095690e-01                              XAV-939 D027_r2
## 6722  3.849381e-02                                XL019 D027_r2
## 6723 -9.620268e-01                         Y-27632 2HCl D027_r2
## 6724  3.894106e-01                             YM201636 D027_r2
## 6725  5.902699e-02                             YO-01027 D027_r2
## 6726  9.150987e-01                         ZM 39923 HCl D027_r2
## 6727 -1.515899e-01                            ZM 447439 D027_r2
## 6728  2.232805e+00                              ZSTK474 D027_r2
## 6729 -8.064151e-01                     1-Azakenpaullone D030_r1
## 6730 -2.993038e+00                      3-Methyladenine D030_r1
## 6731  1.283601e+00                             A-674563 D030_r1
## 6732 -4.502343e+00                             A-769662 D030_r1
## 6733  1.443767e+00                                  A66 D030_r1
## 6734 -3.562399e+00                            Acadesine D030_r1
## 6735 -3.762800e-01                  AEE788 (NVP-AEE788) D030_r1
## 6736 -4.030907e+00        Afatinib (BIBW2992)_uncertain D030_r1
## 6737 -3.652341e+00                              AG-1024 D030_r1
## 6738  3.371194e-01         AG-1478 (Tyrphostin AG-1478) D030_r1
## 6739 -3.007773e+00                                AG-18 D030_r1
## 6740 -4.026151e+00              AG-490 (Tyrphostin B42) D030_r1
## 6741 -1.692616e+00                             Akti-1/2 D030_r1
## 6742  2.536226e+00                  Alisertib (MLN8237) D030_r1
## 6743 -3.538756e+00                              AMG 337 D030_r1
## 6744 -2.840088e+00                              AMG-458 D030_r1
## 6745  1.227447e+00                              AMG-900 D030_r1
## 6746 -3.830675e+00                               AMG319 D030_r1
## 6747 -3.204448e+00                  Amuvatinib (MP-470) D030_r1
## 6748 -4.429914e+00                             Apatinib D030_r1
## 6749 -2.778472e+00                           AR-A014418 D030_r1
## 6750 -2.614165e+00                            AS-252424 D030_r1
## 6751 -4.667408e+00                            AS-604850 D030_r1
## 6752 -2.852314e+00                         Asiatic Acid D030_r1
## 6753  7.311990e-01                             AST-1306 D030_r1
## 6754 -5.509837e+00                              AT13148 D030_r1
## 6755  2.836412e+00                               AT7519 D030_r1
## 6756 -6.039444e+00                               AT7867 D030_r1
## 6757  2.850985e+00                               AT9283 D030_r1
## 6758 -2.973578e+00                 Aurora A Inhibitor I D030_r1
## 6759 -3.043185e+00             Avagacestat (BMS-708163) D030_r1
## 6760 -3.479805e+00                              AVL-292 D030_r1
## 6761 -4.209753e+00                             Axitinib D030_r1
## 6762 -4.209753e+00                             Axitinib D030_r1
## 6763  1.020215e+00                               AZ 628 D030_r1
## 6764 -2.420777e+00                               AZ 960 D030_r1
## 6765  1.337362e+00                                 AZ20 D030_r1
## 6766  3.244344e-01                              AZD1080 D030_r1
## 6767  3.753499e+00                              AZD1480 D030_r1
## 6768  1.909898e+00                              AZD2014 D030_r1
## 6769  1.641453e+00                              AZD2858 D030_r1
## 6770 -2.847357e+00                              AZD2932 D030_r1
## 6771  8.462317e-01                              AZD3759 D030_r1
## 6772 -2.426107e+00                              AZD5363 D030_r1
## 6773  1.832337e+00                              AZD5438 D030_r1
## 6774 -3.100096e+00                              AZD6482 D030_r1
## 6775 -4.896444e-01                              AZD6738 D030_r1
## 6776  5.473377e+00                              AZD8055 D030_r1
## 6777  2.008315e-02                              AZD8330 D030_r1
## 6778  9.628947e-01                  AZD8931 (Sapitinib) D030_r1
## 6779  9.328259e-01                              AZD9291 D030_r1
## 6780  1.908265e+00            Barasertib (AZD1152-HQPA) D030_r1
## 6781 -5.327082e+00  Baricitinib (LY3009104, INCB028050) D030_r1
## 6782 -7.411175e+00                  BGT226 (NVP-BGT226) D030_r1
## 6783  2.809754e+00                              BI 2536 D030_r1
## 6784 -4.567851e+00                              BI-78D3 D030_r1
## 6785 -2.831339e+00                             BI-D1870 D030_r1
## 6786 -3.637968e+00                              Bikinin D030_r1
## 6787 -2.962705e+00                                  BIO D030_r1
## 6788 -3.953628e+00               BIRB 796 (Doramapimod) D030_r1
## 6789 -3.506570e+00                            BIX 02188 D030_r1
## 6790 -1.823108e+00                            BIX 02189 D030_r1
## 6791  3.337882e+00      BKM120 (NVP-BKM120, Buparlisib) D030_r1
## 6792 -3.102036e+00                           BMS-265246 D030_r1
## 6793  2.782372e+00                           BMS-536924 D030_r1
## 6794 -3.328929e+00                           BMS-582949 D030_r1
## 6795  5.588992e+00                           BMS-754807 D030_r1
## 6796 -3.123111e+00                           BMS-777607 D030_r1
## 6797 -5.692786e+00                           BMS-794833 D030_r1
## 6798 -3.147364e+00                           BMS-833923 D030_r1
## 6799 -1.359332e+00                  Bosutinib (SKI-606) D030_r1
## 6800 -4.347238e+00                Brivanib (BMS-540215) D030_r1
## 6801 -5.078579e+00      Brivanib Alaninate (BMS-582664) D030_r1
## 6802 -1.377100e+00                           BS-181 HCl D030_r1
## 6803 -3.658258e+00                               Butein D030_r1
## 6804  2.847242e+00                               BYL719 D030_r1
## 6805 -2.865753e+00     Cabozantinib (XL184, BMS-907351) D030_r1
## 6806 -3.478982e+00          Cabozantinib malate (XL184) D030_r1
## 6807 -2.817751e+00        CAL-101 (Idelalisib, GS-1101) D030_r1
## 6808 -3.526152e+00                             CAY10505 D030_r1
## 6809  4.013662e-01                               CC-223 D030_r1
## 6810 -1.508234e+00                            CCT128930 D030_r1
## 6811 -6.561277e-01                  Cediranib (AZD2171) D030_r1
## 6812 -2.842987e+00                            CEP-32496 D030_r1
## 6813 -4.262675e+00                            CEP-33779 D030_r1
## 6814 -3.109974e+00                              CGI1746 D030_r1
## 6815 -3.648238e+00                              CGK 733 D030_r1
## 6816  4.021609e+00                            CH5132799 D030_r1
## 6817  1.844763e+00                           CHIR-98014 D030_r1
## 6818  1.754903e+00                 CHIR-99021 (CT99021) D030_r1
## 6819  3.380766e-01             CHIR-99021 (CT99021) HCl D030_r1
## 6820 -4.491134e+00                    Chrysophanic Acid D030_r1
## 6821 -9.175602e-02                             CNX-2006 D030_r1
## 6822 -3.867791e+00                              CNX-774 D030_r1
## 6823 -8.800096e-01                    CO-1686 (AVL-301) D030_r1
## 6824  4.217806e+00       Cobimetinib (GDC-0973, RG7420) D030_r1
## 6825  3.187112e+00                            CP-673451 D030_r1
## 6826 -3.077946e+00                            CP-724714 D030_r1
## 6827  1.261743e-01               Crenolanib (CP-868596) D030_r1
## 6828  4.715258e+00             Crizotinib (PF-02341066) D030_r1
## 6829  3.729712e-03                               CYC116 D030_r1
## 6830 -4.219902e+00                               CYT387 D030_r1
## 6831 -3.662584e+00                             CZC24832 D030_r1
## 6832  4.671123e-01              Dabrafenib (GSK2118436) D030_r1
## 6833  2.052197e+00        Dacomitinib (PF299804, PF299) D030_r1
## 6834 -7.406977e-01              Danusertib (PHA-739358) D030_r1
## 6835 -2.453705e+00                        DAPT (GSI-IX) D030_r1
## 6836  1.481577e+00                            Dasatinib D030_r1
## 6837 -4.198882e-02                DCC-2036 (Rebastinib) D030_r1
## 6838 -4.107100e+00                Decernotinib (VX-509) D030_r1
## 6839  1.580044e+00               Dinaciclib (SCH727965) D030_r1
## 6840  6.518469e-01    Dovitinib (TKI-258) Dilactic Acid D030_r1
## 6841  3.270315e+00                            ENMD-2076 D030_r1
## 6842  2.013653e+00               Enzastaurin (LY317615) D030_r1
## 6843  1.225833e+00                            ERK5-IN-1 D030_r1
## 6844 -4.943350e+00                             ETC-1002 D030_r1
## 6845 -2.907758e-01                            ETP-46464 D030_r1
## 6846 -2.569165e+00                  Everolimus (RAD001) D030_r1
## 6847 -3.759946e+00                Fasudil (HA-1077) HCl D030_r1
## 6848 -2.817659e+00                                FH535 D030_r1
## 6849 -3.440828e+00                Filgotinib (GLPG0634) D030_r1
## 6850  1.800370e+00             Flavopiridol (Alvocidib) D030_r1
## 6851  1.645786e+00                     Flavopiridol HCl D030_r1
## 6852 -6.006260e-01               Foretinib (GSK1363089) D030_r1
## 6853  1.841220e+00                  Fostamatinib (R788) D030_r1
## 6854 -3.107018e+00                                G-749 D030_r1
## 6855 -1.463403e+00                             GDC-0068 D030_r1
## 6856  3.795821e-01                             GDC-0349 D030_r1
## 6857 -5.762195e+00                             GDC-0879 D030_r1
## 6858 -5.396773e-01                             GDC-0941 D030_r1
## 6859  4.194185e+00                    GDC-0980 (RG7422) D030_r1
## 6860  2.591869e+00                   Gefitinib (ZD1839) D030_r1
## 6861 -3.394522e+00                            Genistein D030_r1
## 6862  1.049138e+00                            GF109203X D030_r1
## 6863 -3.119489e+00                                GNF-2 D030_r1
## 6864 -2.189138e+00                                GNF-5 D030_r1
## 6865 -1.456865e+00                              Go 6983 D030_r1
## 6866  2.365200e+00                   Golvatinib (E7050) D030_r1
## 6867 -3.582306e-01                          GSK1838705A D030_r1
## 6868 -2.880328e+00                          GSK1904529A D030_r1
## 6869  3.490834e+00                  GSK2126458 (GSK458) D030_r1
## 6870  3.895301e+00                           GSK2292767 D030_r1
## 6871 -2.264712e+00                           GSK2636771 D030_r1
## 6872 -6.682754e+00                           GSK429286A D030_r1
## 6873 -2.932410e-01                            GSK461364 D030_r1
## 6874 -3.409386e+00                               GSK621 D030_r1
## 6875 -1.882934e-01                            GSK690693 D030_r1
## 6876 -3.245199e+00                               GW5074 D030_r1
## 6877 -3.314761e+00                             GW788388 D030_r1
## 6878  2.592140e+00                               GZD824 D030_r1
## 6879 -3.844055e+00                            H 89 2HCl D030_r1
## 6880  3.200794e+00                           Hesperadin D030_r1
## 6881  1.896458e+00                              HMN-214 D030_r1
## 6882 -3.589391e+00                             Honokiol D030_r1
## 6883  1.482705e+00                               HS-173 D030_r1
## 6884 -3.917792e-01                           HTH-01-015 D030_r1
## 6885 -2.852730e+00                Ibrutinib (PCI-32765) D030_r1
## 6886 -3.376509e+00                              ICG-001 D030_r1
## 6887 -2.505515e+00                             Icotinib D030_r1
## 6888 -2.946488e+00                                IM-12 D030_r1
## 6889  1.785512e+00           Imatinib Mesylate (STI571) D030_r1
## 6890 -3.932996e+00                            Indirubin D030_r1
## 6891  5.660868e+00                    INK 128 (MLN0128) D030_r1
## 6892  4.463858e-01                    IPI-145 (INK1197) D030_r1
## 6893 -4.049130e+00                               IWP-L6 D030_r1
## 6894 -4.152544e+00                           IWR-1-endo D030_r1
## 6895 -2.631073e+00                         JNJ-38877605 D030_r1
## 6896  5.636767e+00                          JNJ-7706621 D030_r1
## 6897  1.821448e+00                     JNK Inhibitor IX D030_r1
## 6898 -1.589001e+00                             JNK-IN-8 D030_r1
## 6899 -3.845299e+00                               K02288 D030_r1
## 6900 -4.423936e+00                               Ki8751 D030_r1
## 6901 -4.945013e+00                              KRN 633 D030_r1
## 6902 -3.423525e+00                           KU-0063794 D030_r1
## 6903 -4.798340e+00      KU-55933 (ATM Kinase Inhibitor) D030_r1
## 6904 -5.017972e+00                             KU-60019 D030_r1
## 6905  1.660241e+00                              KW-2449 D030_r1
## 6906  1.116865e+00                              KX2-391 D030_r1
## 6907 -3.670696e+00                              KY02111 D030_r1
## 6908 -1.806268e+00                            Lapatinib D030_r1
## 6909 -3.928730e+00     Lapatinib (GW-572016) Ditosylate D030_r1
## 6910 -1.421446e+00                            LDC000067 D030_r1
## 6911 -3.577199e+00      LDE225 (NVP-LDE225,Erismodegib) D030_r1
## 6912 -4.273391e+00                           LDN-214117 D030_r1
## 6913 -3.696375e+00                   Lenvatinib (E7080) D030_r1
## 6914 -3.453714e+00                              LFM-A13 D030_r1
## 6915 -4.245574e+00                              LGK-974 D030_r1
## 6916 -2.307328e+00                  Linifanib (ABT-869) D030_r1
## 6917 -3.195474e+00                               LJH685 D030_r1
## 6918 -3.412083e+00                               LJI308 D030_r1
## 6919 -2.897535e+00               Losmapimod (GW856553X) D030_r1
## 6920  3.224105e-01                            LY2090314 D030_r1
## 6921 -4.380367e+00                            LY2157299 D030_r1
## 6922 -2.229457e+00                            LY2784544 D030_r1
## 6923  1.283663e+00                            LY2835219 D030_r1
## 6924 -2.788758e+00                             LY294002 D030_r1
## 6925  4.467049e+00                            LY3023414 D030_r1
## 6926 -3.014655e+00                             LY411575 D030_r1
## 6927  2.017137e+00       MEK162 (ARRY-162, ARRY-438162) D030_r1
## 6928 -4.914694e+00                             MGCD-265 D030_r1
## 6929  1.393132e+00               Milciclib (PHA-848125) D030_r1
## 6930 -4.326047e+00                              MK-0752 D030_r1
## 6931 -1.780829e+00                         MK-2206 2HCl D030_r1
## 6932 -4.732684e+00                              MK-2461 D030_r1
## 6933 -4.130714e+00                     MK-5108 (VX-689) D030_r1
## 6934 -3.177026e+00                              MK-8745 D030_r1
## 6935 -6.979205e-01                              MLN2480 D030_r1
## 6936 -4.733324e+00                              MLN8054 D030_r1
## 6937 -4.864341e+00      Motesanib Diphosphate (AMG-706) D030_r1
## 6938 -2.784798e+00                  Nilotinib (AMN-107) D030_r1
## 6939 -1.027665e+00     Nintedanib (BIBF 1120)_uncertain D030_r1
## 6940 -3.031968e+00                               NU6027 D030_r1
## 6941  2.789873e+00                           NVP-AEW541 D030_r1
## 6942 -4.025719e+00                           NVP-BHG712 D030_r1
## 6943 -3.628827e+00                      NVP-BSK805 2HCl D030_r1
## 6944 -2.208548e+00                           NVP-BVU972 D030_r1
## 6945 -3.661249e+00                          Oclacitinib D030_r1
## 6946 -2.353410e+00      Olmutinib (HM61713, BI 1482694) D030_r1
## 6947 -2.573828e+00                             ONO-4059 D030_r1
## 6948  2.634656e-01                              OSI-027 D030_r1
## 6949  2.017246e+00                              OSI-420 D030_r1
## 6950 -3.076749e+00                 OSI-906 (Linsitinib) D030_r1
## 6951  7.764166e-01                              P276-00 D030_r1
## 6952  2.047734e-01                  Pacritinib (SB1518) D030_r1
## 6953 -4.188033e+00                   Palomid 529 (P529) D030_r1
## 6954 -3.483780e+00                            Pazopanib D030_r1
## 6955 -5.007651e+00                        Pazopanib HCl D030_r1
## 6956  5.894426e+00                            PD0325901 D030_r1
## 6957  5.647142e-01                             PD168393 D030_r1
## 6958  1.755654e+00                             PD173955 D030_r1
## 6959 -8.191419e-01                   PD184352 (CI-1040) D030_r1
## 6960  8.647700e-01                             PD318088 D030_r1
## 6961 -2.548051e+00                              PD98059 D030_r1
## 6962  3.996876e+00                  Pelitinib (EKB-569) D030_r1
## 6963  1.944398e+00                          PF-00562271 D030_r1
## 6964 -4.459911e+00                          PF-04217903 D030_r1
## 6965  4.436068e+00                          PF-04691502 D030_r1
## 6966  3.040081e+00                            PF-431396 D030_r1
## 6967  1.765498e+00                           PF-4708671 D030_r1
## 6968 -3.712825e+00                           PF-5274857 D030_r1
## 6969  3.892095e+00                            PF-562271 D030_r1
## 6970 -3.193055e+00                            PF-573228 D030_r1
## 6971 -4.030804e+00                            PH-797804 D030_r1
## 6972 -1.508008e+00                           PHA-665752 D030_r1
## 6973  5.096749e-01                           PHA-680632 D030_r1
## 6974  2.259857e+00                           PHA-767491 D030_r1
## 6975 -9.497246e-01                           PHA-793887 D030_r1
## 6976 -4.734795e+00                       Phenformin HCl D030_r1
## 6977 -2.478411e+00                              PHT-427 D030_r1
## 6978 -2.558005e+00                          Piceatannol D030_r1
## 6979 -3.255803e+00                              PIK-293 D030_r1
## 6980 -2.835132e+00                              PIK-294 D030_r1
## 6981  2.843879e+00                               PIK-93 D030_r1
## 6982  2.897266e+00               Pimasertib (AS-703026) D030_r1
## 6983 -2.647066e+00                          Pirfenidone D030_r1
## 6984 -4.665582e+00                             PLX-4720 D030_r1
## 6985 -2.415945e+00                              PLX7904 D030_r1
## 6986  1.652735e+00                  Ponatinib (AP24534) D030_r1
## 6987  1.280660e+00                                  PP1 D030_r1
## 6988  1.529574e+00                                  PP2 D030_r1
## 6989  1.228617e+00                                PP242 D030_r1
## 6990 -2.845518e+00                               PQ 401 D030_r1
## 6991 -3.018780e+00                              PRI-724 D030_r1
## 6992  6.954062e-01     PRT062607 (P505-15, BIIB057) HCl D030_r1
## 6993  6.723949e-01                         Purvalanol A D030_r1
## 6994 -3.935852e+00                            Quercetin D030_r1
## 6995 -9.383710e-01                  Quizartinib (AC220) D030_r1
## 6996 -4.912417e+00                                 R406 D030_r1
## 6997 -3.982141e+00                     R406 (free base) D030_r1
## 6998 -1.914574e+00                                 R547 D030_r1
## 6999  4.765713e+00                    RAF265 (CHIR-265) D030_r1
## 7000 -2.576695e+00                Rapamycin (Sirolimus) D030_r1
## 7001  4.876892e+00   Refametinib (RDEA119, Bay 86-9766) D030_r1
## 7002 -1.673554e+00                               RepSox D030_r1
## 7003 -2.515051e+00 Ridaforolimus (Deforolimus, MK-8669) D030_r1
## 7004  4.289964e+00                Rigosertib (ON-01910) D030_r1
## 7005 -3.706200e+00                             RKI-1447 D030_r1
## 7006 -3.685186e+00                                RN486 D030_r1
## 7007  2.537817e+00                  Ro 31-8220 Mesylate D030_r1
## 7008 -4.158394e+00                              Ro-3306 D030_r1
## 7009  1.571392e+00                               Ro3280 D030_r1
## 7010 -3.311038e+00                            RO4929097 D030_r1
## 7011 -3.388628e+00      Roscovitine (Seliciclib,CYC202) D030_r1
## 7012 -4.455693e+00             Ruxolitinib (INCB018424) D030_r1
## 7013 -3.730247e+00           S-Ruxolitinib (INCB018424) D030_r1
## 7014 -4.234659e+00                               SANT-1 D030_r1
## 7015 -3.312847e+00                            SAR131675 D030_r1
## 7016 -3.515371e+00                    SAR245409 (XL765) D030_r1
## 7017  4.509626e+00                Saracatinib (AZD0530) D030_r1
## 7018 -3.322959e+00                      SB202190 (FHPI) D030_r1
## 7019 -4.946628e+00                             SB203580 D030_r1
## 7020 -1.182876e+00                             SB216763 D030_r1
## 7021 -4.373035e+00                             SB239063 D030_r1
## 7022 -3.761356e+00                             SB415286 D030_r1
## 7023 -3.097352e+00                             SB431542 D030_r1
## 7024 -3.172574e+00                             SB505124 D030_r1
## 7025 -3.903847e+00                             SB525334 D030_r1
## 7026 -4.588129e+00                             SB590885 D030_r1
## 7027  6.073628e-01                                  SC1 D030_r1
## 7028 -5.059956e+00                Schisandrin B (Sch B) D030_r1
## 7029  5.503197e+00                Selumetinib (AZD6244) D030_r1
## 7030 -3.584001e+00              Semagacestat (LY450139) D030_r1
## 7031 -2.551716e+00                   Semaxanib (SU5416) D030_r1
## 7032  2.334235e+00                             SGI-7079 D030_r1
## 7033 -3.098714e+00                          Skepinone-L D030_r1
## 7034 -3.246743e-01                               SL-327 D030_r1
## 7035  4.254277e+00                 SNS-032 (BMS-387032) D030_r1
## 7036  1.572850e+00                     SNS-314 Mesylate D030_r1
## 7037 -1.583029e+00                            Sorafenib D030_r1
## 7038 -8.337210e-01                   Sorafenib Tosylate D030_r1
## 7039 -2.190050e+00                         Sotrastaurin D030_r1
## 7040 -3.047786e+00                             SP600125 D030_r1
## 7041 -4.113465e+00                              SU11274 D030_r1
## 7042  1.133968e+00                               SU6656 D030_r1
## 7043 -1.136156e+00                               SU9516 D030_r1
## 7044 -7.583128e-01                     Sunitinib Malate D030_r1
## 7045  2.158912e+00                  TAE226 (NVP-TAE226) D030_r1
## 7046 -1.570166e+00                              TAK-285 D030_r1
## 7047 -1.011212e+00                              TAK-632 D030_r1
## 7048 -4.696982e+00                              TAK-715 D030_r1
## 7049  4.036028e+00                              TAK-733 D030_r1
## 7050  1.040504e+00                              TAK-901 D030_r1
## 7051 -3.750121e+00                Taladegib (LY2940680) D030_r1
## 7052 -3.396431e+00                              TCS 359 D030_r1
## 7053 -4.456480e+00                               TDZD-8 D030_r1
## 7054 -2.506139e+00                            Telatinib D030_r1
## 7055 -4.602390e+00   Temsirolimus (CCI-779, NSC 683864) D030_r1
## 7056 -3.568669e+00              Tepotinib (EMD 1214063) D030_r1
## 7057 -3.684070e+00                                TG003 D030_r1
## 7058 -3.842331e+00                            TG100-115 D030_r1
## 7059  3.317052e+00                             TG101209 D030_r1
## 7060  2.365851e+00                 TG101348 (SAR302503) D030_r1
## 7061 -2.767254e+00                              TGX-221 D030_r1
## 7062 -3.590832e+00                         Theophylline D030_r1
## 7063 -4.988399e+00                          Thiazovivin D030_r1
## 7064 -3.568704e+00                       TIC10 Analogue D030_r1
## 7065 -4.472337e+00                           Tideglusib D030_r1
## 7066  1.133969e+00                 Tivantinib (ARQ 197) D030_r1
## 7067 -4.669049e+00                   Tivozanib (AV-951) D030_r1
## 7068 -3.110414e+00  Tofacitinib (CP-690550,Tasocitinib) D030_r1
## 7069 -2.901594e+00      Tofacitinib (CP-690550) Citrate D030_r1
## 7070  2.723234e+00                              Torin 2 D030_r1
## 7071  2.837891e+00              Trametinib (GSK1120212) D030_r1
## 7072 -3.924375e+00                          Triciribine D030_r1
## 7073 -3.728656e+00           TSU-68 (SU6668, Orantinib) D030_r1
## 7074 -3.750650e+00                               TWS119 D030_r1
## 7075 -1.181165e+00                         Tyrphostin 9 D030_r1
## 7076 -4.448556e+00                   Tyrphostin AG 1296 D030_r1
## 7077 -2.059164e+00                           U0126-EtOH D030_r1
## 7078  1.305008e+00     Ulixertinib (BVD-523, VRT752271) D030_r1
## 7079 -9.660020e-01              Uprosertib (GSK2141795) D030_r1
## 7080 -1.473189e+00                          Vacquinol-1 D030_r1
## 7081 -1.450179e+00                           Varlitinib D030_r1
## 7082 -2.952695e+00              Vatalanib (PTK787) 2HCl D030_r1
## 7083 -4.507955e+00                               VE-821 D030_r1
## 7084 -4.141432e-01                               VE-822 D030_r1
## 7085 -4.274123e+00        Vemurafenib (PLX4032, RG7204) D030_r1
## 7086 -3.386971e+00                Vismodegib (GDC-0449) D030_r1
## 7087 -4.136290e+00                 Volasertib (BI 6727) D030_r1
## 7088 -2.687745e+00                            VPS34-IN1 D030_r1
## 7089  2.265856e+00                     VS-5584 (SB2343) D030_r1
## 7090  3.531866e+00                               VX-11e D030_r1
## 7091  2.560151e-01         VX-680 (Tozasertib, MK-0457) D030_r1
## 7092 -2.938285e+00                               VX-702 D030_r1
## 7093 -3.904518e+00                               VX-745 D030_r1
## 7094  1.818731e+00                              WAY-600 D030_r1
## 7095 -1.888180e+00                             WH-4-023 D030_r1
## 7096 -3.623175e+00                             WHI-P154 D030_r1
## 7097 -4.523870e+00                                WIKI4 D030_r1
## 7098  3.149239e+00                        Wnt agonist 1 D030_r1
## 7099 -3.684943e+00                        Wnt-C59 (C59) D030_r1
## 7100 -3.731678e+00                               WP1066 D030_r1
## 7101  2.846027e+00                 WYE-125132 (WYE-132) D030_r1
## 7102  3.412438e+00                              WYE-354 D030_r1
## 7103  9.629713e-01                               WZ3146 D030_r1
## 7104 -3.464373e+00                               WZ4002 D030_r1
## 7105 -1.364638e+00                               WZ4003 D030_r1
## 7106 -2.284119e+00                               WZ8040 D030_r1
## 7107 -2.654662e+00                              XAV-939 D030_r1
## 7108 -5.848537e+00                                XL019 D030_r1
## 7109 -2.349725e+00                              XMD8-92 D030_r1
## 7110 -4.452834e+00                         Y-27632 2HCl D030_r1
## 7111 -2.614513e+00                             YM201636 D030_r1
## 7112 -4.154709e+00                             YO-01027 D030_r1
## 7113 -8.121303e-01                            ZM 306416 D030_r1
## 7114 -3.839736e+00                        ZM 323881 HCl D030_r1
## 7115 -4.371011e+00                            ZM 336372 D030_r1
## 7116 -3.213674e+00                         ZM 39923 HCl D030_r1
## 7117 -1.323784e+00                            ZM 447439 D030_r1
## 7118 -2.828814e+00                 Zotarolimus(ABT-578) D030_r1
## 7119  2.596913e+00                              ZSTK474 D030_r1
## 7120 -1.078188e+00                     1-Azakenpaullone D030_r2
## 7121 -3.753134e+00                      3-Methyladenine D030_r2
## 7122 -8.231122e+00                             A-674563 D030_r2
## 7123 -3.525576e+00                             A-769662 D030_r2
## 7124 -3.293518e+00                                  A66 D030_r2
## 7125 -5.724462e+00                            Acadesine D030_r2
## 7126 -9.655259e-02                  AEE788 (NVP-AEE788) D030_r2
## 7127 -3.568712e+00        Afatinib (BIBW2992)_uncertain D030_r2
## 7128 -4.248451e+00                              AG-1024 D030_r2
## 7129 -1.840468e+00         AG-1478 (Tyrphostin AG-1478) D030_r2
## 7130 -5.551399e+00                                AG-18 D030_r2
## 7131 -4.598945e+00              AG-490 (Tyrphostin B42) D030_r2
## 7132 -4.454879e+00                             Akti-1/2 D030_r2
## 7133 -2.489589e+00                  Alisertib (MLN8237) D030_r2
## 7134 -3.606511e+00                              AMG 337 D030_r2
## 7135 -1.984211e+00                              AMG-458 D030_r2
## 7136 -1.482345e+00                              AMG-900 D030_r2
## 7137 -3.173331e+00                               AMG319 D030_r2
## 7138 -2.589359e+00                  Amuvatinib (MP-470) D030_r2
## 7139 -5.101808e+00                             Apatinib D030_r2
## 7140 -3.521078e+00                           AR-A014418 D030_r2
## 7141 -2.930555e+00                            AS-252424 D030_r2
## 7142 -4.221741e+00                            AS-604850 D030_r2
## 7143 -5.281507e+00                         Asiatic Acid D030_r2
## 7144 -1.976016e+00                             AST-1306 D030_r2
## 7145 -3.363448e+00                              AT13148 D030_r2
## 7146 -2.572367e+00                               AT7519 D030_r2
## 7147 -7.239236e+00                               AT7867 D030_r2
## 7148 -6.429277e+00                               AT9283 D030_r2
## 7149 -2.810111e+00                 Aurora A Inhibitor I D030_r2
## 7150 -2.734760e+00             Avagacestat (BMS-708163) D030_r2
## 7151 -2.669109e+00                              AVL-292 D030_r2
## 7152 -3.236970e+00                             Axitinib D030_r2
## 7153 -3.236970e+00                             Axitinib D030_r2
## 7154 -3.915986e+00                               AZ 628 D030_r2
## 7155 -3.348654e+00                               AZ 960 D030_r2
## 7156 -2.201917e+00                                 AZ20 D030_r2
## 7157 -8.281905e-01                              AZD1080 D030_r2
## 7158 -1.785111e-01                              AZD1480 D030_r2
## 7159 -1.924517e+00                              AZD2014 D030_r2
## 7160 -5.911979e-01                              AZD2858 D030_r2
## 7161 -2.798941e+00                              AZD2932 D030_r2
## 7162 -2.949325e+00                              AZD3759 D030_r2
## 7163 -4.477776e+00                              AZD5363 D030_r2
## 7164 -6.296830e+00                              AZD5438 D030_r2
## 7165 -3.607689e+00                              AZD6482 D030_r2
## 7166 -2.035427e+00                              AZD6738 D030_r2
## 7167  1.363096e-01                              AZD8055 D030_r2
## 7168 -2.655057e+00                              AZD8330 D030_r2
## 7169 -8.341265e-01                  AZD8931 (Sapitinib) D030_r2
## 7170 -4.048300e+00                              AZD9291 D030_r2
## 7171 -1.883003e+00            Barasertib (AZD1152-HQPA) D030_r2
## 7172 -5.089028e+00  Baricitinib (LY3009104, INCB028050) D030_r2
## 7173 -7.261684e+00                  BGT226 (NVP-BGT226) D030_r2
## 7174 -2.176741e+00                              BI 2536 D030_r2
## 7175 -4.651455e+00                              BI-78D3 D030_r2
## 7176 -2.331485e+00                             BI-D1870 D030_r2
## 7177 -2.308568e+00                              Bikinin D030_r2
## 7178 -3.156113e+00                                  BIO D030_r2
## 7179 -3.614735e+00               BIRB 796 (Doramapimod) D030_r2
## 7180 -3.419898e+00                            BIX 02188 D030_r2
## 7181 -2.371960e+00                            BIX 02189 D030_r2
## 7182 -2.380411e+00      BKM120 (NVP-BKM120, Buparlisib) D030_r2
## 7183 -3.672887e+00                           BMS-265246 D030_r2
## 7184 -3.310665e-01                           BMS-536924 D030_r2
## 7185 -2.031984e+00                           BMS-582949 D030_r2
## 7186 -9.099112e-01                           BMS-754807 D030_r2
## 7187 -4.891489e+00                           BMS-777607 D030_r2
## 7188 -4.635439e+00                           BMS-794833 D030_r2
## 7189 -3.960818e+00                           BMS-833923 D030_r2
## 7190 -3.346424e+00                  Bosutinib (SKI-606) D030_r2
## 7191 -3.589006e+00                Brivanib (BMS-540215) D030_r2
## 7192 -3.546715e+00      Brivanib Alaninate (BMS-582664) D030_r2
## 7193 -3.820269e+00                           BS-181 HCl D030_r2
## 7194 -2.403458e+00                               Butein D030_r2
## 7195 -2.188219e+00                               BYL719 D030_r2
## 7196 -4.642697e+00     Cabozantinib (XL184, BMS-907351) D030_r2
## 7197 -3.326442e+00          Cabozantinib malate (XL184) D030_r2
## 7198 -2.437433e+00        CAL-101 (Idelalisib, GS-1101) D030_r2
## 7199 -3.920988e+00                             CAY10505 D030_r2
## 7200 -2.136807e+00                               CC-223 D030_r2
## 7201 -5.162929e+00                            CCT128930 D030_r2
## 7202 -2.319829e+00                  Cediranib (AZD2171) D030_r2
## 7203 -2.494451e+00                            CEP-32496 D030_r2
## 7204 -3.678504e+00                            CEP-33779 D030_r2
## 7205 -3.391881e+00                              CGI1746 D030_r2
## 7206 -2.547890e+00                              CGK 733 D030_r2
## 7207 -9.556589e-01                            CH5132799 D030_r2
## 7208 -5.707280e-01                           CHIR-98014 D030_r2
## 7209 -1.516209e+00                 CHIR-99021 (CT99021) D030_r2
## 7210 -2.199549e+00             CHIR-99021 (CT99021) HCl D030_r2
## 7211 -6.609989e+00                    Chrysophanic Acid D030_r2
## 7212 -2.296252e+00                             CNX-2006 D030_r2
## 7213 -3.928563e+00                              CNX-774 D030_r2
## 7214 -4.836726e+00                    CO-1686 (AVL-301) D030_r2
## 7215 -1.590039e+00       Cobimetinib (GDC-0973, RG7420) D030_r2
## 7216 -1.101733e+00                            CP-673451 D030_r2
## 7217 -2.124449e+00                            CP-724714 D030_r2
## 7218  1.484301e-01               Crenolanib (CP-868596) D030_r2
## 7219 -2.010889e+00             Crizotinib (PF-02341066) D030_r2
## 7220 -1.867381e+00                               CYC116 D030_r2
## 7221 -4.904117e+00                               CYT387 D030_r2
## 7222 -3.030733e+00                             CZC24832 D030_r2
## 7223 -1.097311e+00              Dabrafenib (GSK2118436) D030_r2
## 7224 -1.978738e+00        Dacomitinib (PF299804, PF299) D030_r2
## 7225 -6.997068e-01              Danusertib (PHA-739358) D030_r2
## 7226 -3.508213e+00                        DAPT (GSI-IX) D030_r2
## 7227  1.796805e-01                            Dasatinib D030_r2
## 7228 -2.079434e+00                DCC-2036 (Rebastinib) D030_r2
## 7229 -4.243836e+00                Decernotinib (VX-509) D030_r2
## 7230 -5.346844e+00               Dinaciclib (SCH727965) D030_r2
## 7231 -1.135898e+00    Dovitinib (TKI-258) Dilactic Acid D030_r2
## 7232 -3.790341e+00                            ENMD-2076 D030_r2
## 7233 -1.472708e+00               Enzastaurin (LY317615) D030_r2
## 7234 -1.599390e+00                            ERK5-IN-1 D030_r2
## 7235 -5.274058e+00                             ETC-1002 D030_r2
## 7236 -2.996823e+00                            ETP-46464 D030_r2
## 7237 -3.792760e+00                  Everolimus (RAD001) D030_r2
## 7238 -4.326448e+00                Fasudil (HA-1077) HCl D030_r2
## 7239 -2.981197e+00                                FH535 D030_r2
## 7240 -3.590976e+00                Filgotinib (GLPG0634) D030_r2
## 7241 -5.847967e+00             Flavopiridol (Alvocidib) D030_r2
## 7242 -5.176764e+00                     Flavopiridol HCl D030_r2
## 7243 -1.551375e+00               Foretinib (GSK1363089) D030_r2
## 7244 -2.674853e+00                  Fostamatinib (R788) D030_r2
## 7245 -2.975628e+00                                G-749 D030_r2
## 7246 -4.103783e+00                             GDC-0068 D030_r2
## 7247 -1.709795e+00                             GDC-0349 D030_r2
## 7248 -3.856285e+00                             GDC-0879 D030_r2
## 7249 -2.031388e+00                             GDC-0941 D030_r2
## 7250  1.039214e+00                    GDC-0980 (RG7422) D030_r2
## 7251 -2.353132e+00                   Gefitinib (ZD1839) D030_r2
## 7252 -3.065290e+00                            Genistein D030_r2
## 7253 -3.512833e-01                            GF109203X D030_r2
## 7254 -4.184860e+00                                GNF-2 D030_r2
## 7255 -3.893779e+00                                GNF-5 D030_r2
## 7256 -2.327272e+00                              Go 6983 D030_r2
## 7257 -2.463798e+00                   Golvatinib (E7050) D030_r2
## 7258 -3.289433e+00                          GSK1838705A D030_r2
## 7259 -1.997900e+00                          GSK1904529A D030_r2
## 7260 -2.398901e+00                  GSK2126458 (GSK458) D030_r2
## 7261 -8.422984e-01                           GSK2292767 D030_r2
## 7262 -3.442018e+00                           GSK2636771 D030_r2
## 7263 -6.782044e+00                           GSK429286A D030_r2
## 7264 -9.169029e-01                            GSK461364 D030_r2
## 7265 -4.590737e+00                               GSK621 D030_r2
## 7266 -1.630638e+00                            GSK690693 D030_r2
## 7267 -3.546884e+00                               GW5074 D030_r2
## 7268 -3.397263e+00                             GW788388 D030_r2
## 7269 -4.042960e+00                               GZD824 D030_r2
## 7270 -3.191724e+00                            H 89 2HCl D030_r2
## 7271 -2.244546e+00                           Hesperadin D030_r2
## 7272 -1.983510e+00                              HMN-214 D030_r2
## 7273 -4.195183e+00                             Honokiol D030_r2
## 7274 -4.451164e-01                               HS-173 D030_r2
## 7275 -1.579939e+00                           HTH-01-015 D030_r2
## 7276 -3.338849e+00                Ibrutinib (PCI-32765) D030_r2
## 7277 -2.922776e+00                              ICG-001 D030_r2
## 7278 -2.573131e+00                             Icotinib D030_r2
## 7279 -3.468277e+00                                IM-12 D030_r2
## 7280 -7.180986e-01           Imatinib Mesylate (STI571) D030_r2
## 7281 -4.061591e+00                            Indirubin D030_r2
## 7282 -3.388436e-01                    INK 128 (MLN0128) D030_r2
## 7283 -3.135444e+00                    IPI-145 (INK1197) D030_r2
## 7284 -2.197290e+00                               IWP-L6 D030_r2
## 7285 -5.290138e+00                           IWR-1-endo D030_r2
## 7286 -4.505069e+00                         JNJ-38877605 D030_r2
## 7287 -1.711186e+00                          JNJ-7706621 D030_r2
## 7288  7.292701e-01                     JNK Inhibitor IX D030_r2
## 7289 -4.221202e+00                             JNK-IN-8 D030_r2
## 7290 -3.383193e+00                               K02288 D030_r2
## 7291 -3.362212e+00                               Ki8751 D030_r2
## 7292 -3.919116e+00                              KRN 633 D030_r2
## 7293 -3.453897e-01                           KU-0063794 D030_r2
## 7294 -3.930768e+00      KU-55933 (ATM Kinase Inhibitor) D030_r2
## 7295 -4.293337e+00                             KU-60019 D030_r2
## 7296 -3.259953e+00                              KW-2449 D030_r2
## 7297 -4.327492e-01                              KX2-391 D030_r2
## 7298 -3.857361e+00                              KY02111 D030_r2
## 7299 -3.899815e+00                            Lapatinib D030_r2
## 7300 -1.914617e+00     Lapatinib (GW-572016) Ditosylate D030_r2
## 7301 -7.879034e+00                            LDC000067 D030_r2
## 7302 -4.624659e+00      LDE225 (NVP-LDE225,Erismodegib) D030_r2
## 7303 -6.166968e+00                           LDN-214117 D030_r2
## 7304 -5.439985e+00                   Lenvatinib (E7080) D030_r2
## 7305 -5.099830e+00                              LFM-A13 D030_r2
## 7306 -3.923332e+00                              LGK-974 D030_r2
## 7307 -4.959040e+00                  Linifanib (ABT-869) D030_r2
## 7308 -2.814770e+00                               LJH685 D030_r2
## 7309 -2.332812e+00                               LJI308 D030_r2
## 7310 -4.648396e+00               Losmapimod (GW856553X) D030_r2
## 7311 -1.667073e+00                            LY2090314 D030_r2
## 7312 -2.643727e+00                            LY2157299 D030_r2
## 7313 -2.530528e+00                            LY2784544 D030_r2
## 7314 -3.320822e-01                            LY2835219 D030_r2
## 7315 -2.578497e+00                             LY294002 D030_r2
## 7316 -2.038349e+00                            LY3023414 D030_r2
## 7317 -3.492564e+00                             LY411575 D030_r2
## 7318 -2.114304e+00       MEK162 (ARRY-162, ARRY-438162) D030_r2
## 7319 -4.411189e+00                             MGCD-265 D030_r2
## 7320 -4.994271e-01               Milciclib (PHA-848125) D030_r2
## 7321 -3.411341e+00                              MK-0752 D030_r2
## 7322 -2.065241e+00                         MK-2206 2HCl D030_r2
## 7323 -4.892481e+00                              MK-2461 D030_r2
## 7324 -2.310984e+00                     MK-5108 (VX-689) D030_r2
## 7325 -3.404551e+00                              MK-8745 D030_r2
## 7326 -1.535903e+00                              MLN2480 D030_r2
## 7327 -3.394177e+00                              MLN8054 D030_r2
## 7328 -4.096093e+00      Motesanib Diphosphate (AMG-706) D030_r2
## 7329 -3.523900e+00                  Nilotinib (AMN-107) D030_r2
## 7330 -2.315795e+00     Nintedanib (BIBF 1120)_uncertain D030_r2
## 7331 -3.283138e+00                               NU6027 D030_r2
## 7332 -1.205681e+00                           NVP-AEW541 D030_r2
## 7333 -4.485448e+00                           NVP-BHG712 D030_r2
## 7334 -3.412626e+00                      NVP-BSK805 2HCl D030_r2
## 7335 -3.533433e+00                           NVP-BVU972 D030_r2
## 7336 -4.873707e+00                          Oclacitinib D030_r2
## 7337 -2.381534e+00      Olmutinib (HM61713, BI 1482694) D030_r2
## 7338 -5.046526e-01                             ONO-4059 D030_r2
## 7339 -5.692080e+00                              OSI-027 D030_r2
## 7340  5.768562e-01                              OSI-420 D030_r2
## 7341 -1.185696e-01                 OSI-906 (Linsitinib) D030_r2
## 7342 -5.022068e+00                              P276-00 D030_r2
## 7343 -5.190334e+00                  Pacritinib (SB1518) D030_r2
## 7344 -4.073808e+00                   Palomid 529 (P529) D030_r2
## 7345 -3.590207e+00                            Pazopanib D030_r2
## 7346 -2.081072e+00                        Pazopanib HCl D030_r2
## 7347 -2.981644e+00                            PD0325901 D030_r2
## 7348 -4.217174e+00                             PD168393 D030_r2
## 7349 -5.558667e-01                             PD173955 D030_r2
## 7350 -2.004166e+00                   PD184352 (CI-1040) D030_r2
## 7351 -1.677187e+00                             PD318088 D030_r2
## 7352 -3.432395e+00                              PD98059 D030_r2
## 7353 -1.737977e+00                  Pelitinib (EKB-569) D030_r2
## 7354 -3.159909e+00                          PF-00562271 D030_r2
## 7355 -2.740382e+00                          PF-04217903 D030_r2
## 7356 -6.332495e-01                          PF-04691502 D030_r2
## 7357 -3.509549e+00                            PF-431396 D030_r2
## 7358 -4.132930e+00                           PF-4708671 D030_r2
## 7359 -2.934071e+00                           PF-5274857 D030_r2
## 7360 -1.573604e+00                            PF-562271 D030_r2
## 7361 -3.001624e+00                            PF-573228 D030_r2
## 7362 -4.257110e+00                            PH-797804 D030_r2
## 7363 -2.843496e+00                           PHA-665752 D030_r2
## 7364 -1.412668e+00                           PHA-680632 D030_r2
## 7365 -3.845546e+00                           PHA-767491 D030_r2
## 7366 -1.079987e+00                           PHA-793887 D030_r2
## 7367 -4.951823e+00                       Phenformin HCl D030_r2
## 7368 -2.367530e+00                              PHT-427 D030_r2
## 7369 -3.097352e+00                          Piceatannol D030_r2
## 7370 -6.202203e+00                              PIK-293 D030_r2
## 7371 -4.272418e+00                              PIK-294 D030_r2
## 7372  1.045293e+00                               PIK-93 D030_r2
## 7373 -1.377572e+00               Pimasertib (AS-703026) D030_r2
## 7374 -3.471529e+00                          Pirfenidone D030_r2
## 7375 -4.890460e+00                             PLX-4720 D030_r2
## 7376 -1.558548e+00                              PLX7904 D030_r2
## 7377  5.568569e-01                  Ponatinib (AP24534) D030_r2
## 7378 -2.556208e+00                                  PP1 D030_r2
## 7379 -1.024832e+00                                  PP2 D030_r2
## 7380 -7.189698e-01                                PP242 D030_r2
## 7381 -1.566007e+00                               PQ 401 D030_r2
## 7382 -3.714382e+00                              PRI-724 D030_r2
## 7383 -1.084490e+00     PRT062607 (P505-15, BIIB057) HCl D030_r2
## 7384 -2.386899e+00                         Purvalanol A D030_r2
## 7385 -3.209673e+00                            Quercetin D030_r2
## 7386 -1.841255e+00                  Quizartinib (AC220) D030_r2
## 7387 -4.922080e+00                                 R406 D030_r2
## 7388 -2.823658e+00                     R406 (free base) D030_r2
## 7389 -6.373429e+00                                 R547 D030_r2
## 7390 -1.499708e+00                    RAF265 (CHIR-265) D030_r2
## 7391 -2.614329e+00                Rapamycin (Sirolimus) D030_r2
## 7392 -1.660533e+00   Refametinib (RDEA119, Bay 86-9766) D030_r2
## 7393 -3.475886e+00                               RepSox D030_r2
## 7394 -4.851227e+00 Ridaforolimus (Deforolimus, MK-8669) D030_r2
## 7395 -2.592447e+00                Rigosertib (ON-01910) D030_r2
## 7396 -4.366171e+00                             RKI-1447 D030_r2
## 7397 -3.222549e+00                                RN486 D030_r2
## 7398 -3.108159e+00                  Ro 31-8220 Mesylate D030_r2
## 7399 -4.322713e+00                              Ro-3306 D030_r2
## 7400 -2.820058e+00                               Ro3280 D030_r2
## 7401 -3.236676e+00                            RO4929097 D030_r2
## 7402 -4.366709e+00      Roscovitine (Seliciclib,CYC202) D030_r2
## 7403 -5.120653e+00             Ruxolitinib (INCB018424) D030_r2
## 7404 -3.973797e+00           S-Ruxolitinib (INCB018424) D030_r2
## 7405 -3.516703e+00                               SANT-1 D030_r2
## 7406 -3.761238e+00                            SAR131675 D030_r2
## 7407 -5.367106e+00                    SAR245409 (XL765) D030_r2
## 7408 -1.054477e+00                Saracatinib (AZD0530) D030_r2
## 7409 -4.227253e+00                      SB202190 (FHPI) D030_r2
## 7410 -3.406097e+00                             SB203580 D030_r2
## 7411 -1.016184e+00                             SB216763 D030_r2
## 7412 -5.490570e+00                             SB239063 D030_r2
## 7413 -3.476888e+00                             SB415286 D030_r2
## 7414 -3.893881e+00                             SB431542 D030_r2
## 7415 -3.773453e+00                             SB505124 D030_r2
## 7416 -3.674743e+00                             SB525334 D030_r2
## 7417 -2.413784e+00                             SB590885 D030_r2
## 7418  4.797207e-01                                  SC1 D030_r2
## 7419 -4.740613e+00                Schisandrin B (Sch B) D030_r2
## 7420 -1.724339e+00                Selumetinib (AZD6244) D030_r2
## 7421 -4.428661e+00              Semagacestat (LY450139) D030_r2
## 7422 -2.511307e+00                   Semaxanib (SU5416) D030_r2
## 7423 -2.868606e+00                             SGI-7079 D030_r2
## 7424 -3.440423e+00                          Skepinone-L D030_r2
## 7425 -2.445575e+00                               SL-327 D030_r2
## 7426 -2.962670e+00                 SNS-032 (BMS-387032) D030_r2
## 7427 -4.701712e+00                     SNS-314 Mesylate D030_r2
## 7428 -4.234201e+00                            Sorafenib D030_r2
## 7429 -1.011397e+00                   Sorafenib Tosylate D030_r2
## 7430 -2.040394e+00                         Sotrastaurin D030_r2
## 7431 -4.503276e+00                             SP600125 D030_r2
## 7432 -3.078738e+00                              SU11274 D030_r2
## 7433 -2.125183e+00                               SU6656 D030_r2
## 7434 -7.858808e+00                               SU9516 D030_r2
## 7435 -3.017663e+00                     Sunitinib Malate D030_r2
## 7436 -6.931654e-01                  TAE226 (NVP-TAE226) D030_r2
## 7437 -2.374020e+00                              TAK-285 D030_r2
## 7438 -4.692362e+00                              TAK-632 D030_r2
## 7439 -3.277395e+00                              TAK-715 D030_r2
## 7440 -6.925977e+00                              TAK-733 D030_r2
## 7441  7.610460e-01                              TAK-901 D030_r2
## 7442 -3.485506e+00                Taladegib (LY2940680) D030_r2
## 7443 -3.834358e+00                              TCS 359 D030_r2
## 7444 -2.003442e+00                               TDZD-8 D030_r2
## 7445 -3.124903e+00                            Telatinib D030_r2
## 7446 -3.788104e+00   Temsirolimus (CCI-779, NSC 683864) D030_r2
## 7447 -4.169858e+00              Tepotinib (EMD 1214063) D030_r2
## 7448 -5.621626e+00                                TG003 D030_r2
## 7449 -4.095744e+00                            TG100-115 D030_r2
## 7450 -1.712395e+00                             TG101209 D030_r2
## 7451 -2.815890e+00                 TG101348 (SAR302503) D030_r2
## 7452 -4.231573e+00                              TGX-221 D030_r2
## 7453 -3.194258e+00                         Theophylline D030_r2
## 7454 -4.826812e+00                          Thiazovivin D030_r2
## 7455 -8.556180e-01                       TIC10 Analogue D030_r2
## 7456 -4.648191e+00                           Tideglusib D030_r2
## 7457  5.482199e-01                 Tivantinib (ARQ 197) D030_r2
## 7458 -4.328551e+00                   Tivozanib (AV-951) D030_r2
## 7459 -2.594847e+00  Tofacitinib (CP-690550,Tasocitinib) D030_r2
## 7460 -4.017832e+00      Tofacitinib (CP-690550) Citrate D030_r2
## 7461  1.876518e-01                              Torin 2 D030_r2
## 7462 -4.228525e+00              Trametinib (GSK1120212) D030_r2
## 7463 -5.554340e+00                          Triciribine D030_r2
## 7464 -3.330954e+00           TSU-68 (SU6668, Orantinib) D030_r2
## 7465 -3.621372e+00                               TWS119 D030_r2
## 7466 -5.560130e+00                         Tyrphostin 9 D030_r2
## 7467 -2.733619e+00                   Tyrphostin AG 1296 D030_r2
## 7468 -2.507799e+00                           U0126-EtOH D030_r2
## 7469 -3.448742e-01     Ulixertinib (BVD-523, VRT752271) D030_r2
## 7470 -4.147839e+00              Uprosertib (GSK2141795) D030_r2
## 7471 -1.255326e+00                          Vacquinol-1 D030_r2
## 7472 -9.438709e-01                           Varlitinib D030_r2
## 7473 -3.468288e+00              Vatalanib (PTK787) 2HCl D030_r2
## 7474 -3.511424e+00                               VE-821 D030_r2
## 7475 -1.533042e+00                               VE-822 D030_r2
## 7476 -6.072839e+00        Vemurafenib (PLX4032, RG7204) D030_r2
## 7477 -3.559684e+00                Vismodegib (GDC-0449) D030_r2
## 7478 -3.087107e+00                 Volasertib (BI 6727) D030_r2
## 7479 -3.438174e+00                            VPS34-IN1 D030_r2
## 7480 -1.240667e+00                     VS-5584 (SB2343) D030_r2
## 7481 -6.479650e-01                               VX-11e D030_r2
## 7482 -2.520154e+00         VX-680 (Tozasertib, MK-0457) D030_r2
## 7483 -4.893069e+00                               VX-702 D030_r2
## 7484 -3.694064e+00                               VX-745 D030_r2
## 7485 -1.064912e+00                              WAY-600 D030_r2
## 7486 -2.142889e+00                             WH-4-023 D030_r2
## 7487 -3.734156e+00                             WHI-P154 D030_r2
## 7488 -4.803534e+00                                WIKI4 D030_r2
## 7489 -1.371409e+00                        Wnt agonist 1 D030_r2
## 7490 -2.794987e+00                        Wnt-C59 (C59) D030_r2
## 7491 -2.768818e+00                               WP1066 D030_r2
## 7492 -4.093060e+00                 WYE-125132 (WYE-132) D030_r2
## 7493 -3.690941e-01                              WYE-354 D030_r2
## 7494 -7.345837e-01                               WZ3146 D030_r2
## 7495 -4.542635e+00                               WZ4002 D030_r2
## 7496 -2.913508e+00                               WZ4003 D030_r2
## 7497 -2.167890e+00                               WZ8040 D030_r2
## 7498 -3.072652e+00                              XAV-939 D030_r2
## 7499 -5.469022e+00                                XL019 D030_r2
## 7500 -8.570031e-01                              XMD8-92 D030_r2
## 7501 -5.715091e+00                         Y-27632 2HCl D030_r2
## 7502 -2.742566e+00                             YM201636 D030_r2
## 7503 -3.326992e+00                             YO-01027 D030_r2
## 7504 -3.519189e+00                            ZM 306416 D030_r2
## 7505 -4.309000e+00                        ZM 323881 HCl D030_r2
## 7506 -4.668612e+00                            ZM 336372 D030_r2
## 7507 -3.411980e+00                         ZM 39923 HCl D030_r2
## 7508 -1.988971e+00                            ZM 447439 D030_r2
## 7509 -3.154935e+00                 Zotarolimus(ABT-578) D030_r2
## 7510 -7.224986e-01                              ZSTK474 D030_r2
## 7511  3.406815e+00                     1-Azakenpaullone D046_r1
## 7512  3.140334e+00                      3-Methyladenine D046_r1
## 7513  2.978238e+00                             A-674563 D046_r1
## 7514  1.674752e+00                             A-769662 D046_r1
## 7515  3.998165e+00                                  A66 D046_r1
## 7516  3.523425e+00                            Acadesine D046_r1
## 7517  4.095382e+00                  AEE788 (NVP-AEE788) D046_r1
## 7518  7.007553e-01        Afatinib (BIBW2992)_uncertain D046_r1
## 7519  7.585014e-01                              AG-1024 D046_r1
## 7520  2.851931e+00         AG-1478 (Tyrphostin AG-1478) D046_r1
## 7521  1.014605e+00                                AG-18 D046_r1
## 7522  1.567676e+00              AG-490 (Tyrphostin B42) D046_r1
## 7523  5.339983e+00                             Akti-1/2 D046_r1
## 7524  2.228656e+00                  Alisertib (MLN8237) D046_r1
## 7525  6.432705e-01                              AMG 337 D046_r1
## 7526  2.347467e+00                              AMG-458 D046_r1
## 7527  2.711076e+00                              AMG-900 D046_r1
## 7528  2.787210e+00                               AMG319 D046_r1
## 7529  1.065316e+00                  Amuvatinib (MP-470) D046_r1
## 7530 -1.257731e+00                             Apatinib D046_r1
## 7531  3.284331e+00                           AR-A014418 D046_r1
## 7532  2.128536e+00                            AS-252424 D046_r1
## 7533  3.591873e+00                            AS-604850 D046_r1
## 7534  2.972357e+00                         Asiatic Acid D046_r1
## 7535  4.271692e+00                             AST-1306 D046_r1
## 7536  2.978023e+00                              AT13148 D046_r1
## 7537  3.891268e+00                               AT7519 D046_r1
## 7538  3.826494e+00                               AT7867 D046_r1
## 7539  3.008796e+00                               AT9283 D046_r1
## 7540 -6.247600e-01                 Aurora A Inhibitor I D046_r1
## 7541  2.917135e-01             Avagacestat (BMS-708163) D046_r1
## 7542  1.223156e+00                              AVL-292 D046_r1
## 7543  8.958537e-01                             Axitinib D046_r1
## 7544  8.958537e-01                             Axitinib D046_r1
## 7545  6.057972e+00                               AZ 628 D046_r1
## 7546  1.147474e+00                               AZ 960 D046_r1
## 7547  4.138136e+00                                 AZ20 D046_r1
## 7548  3.009087e+00                              AZD1080 D046_r1
## 7549  3.447385e+00                              AZD1480 D046_r1
## 7550  5.503887e+00                              AZD2014 D046_r1
## 7551  3.551901e+00                              AZD2858 D046_r1
## 7552 -7.178045e-01                              AZD2932 D046_r1
## 7553  7.821544e-01                              AZD3759 D046_r1
## 7554  6.821781e+00                              AZD5363 D046_r1
## 7555  2.026599e+00                              AZD5438 D046_r1
## 7556  3.874798e+00                              AZD6482 D046_r1
## 7557  3.374831e+00                              AZD6738 D046_r1
## 7558  5.652703e+00                              AZD8055 D046_r1
## 7559  2.900312e+00                              AZD8330 D046_r1
## 7560  3.791843e+00                  AZD8931 (Sapitinib) D046_r1
## 7561  1.260969e+00                              AZD9291 D046_r1
## 7562  2.342778e+00            Barasertib (AZD1152-HQPA) D046_r1
## 7563 -2.676309e-01  Baricitinib (LY3009104, INCB028050) D046_r1
## 7564 -7.709975e+00                  BGT226 (NVP-BGT226) D046_r1
## 7565  1.276177e+00                              BI 2536 D046_r1
## 7566  1.274714e+00                              BI-78D3 D046_r1
## 7567  1.622876e+00                             BI-D1870 D046_r1
## 7568  1.737904e+00                              Bikinin D046_r1
## 7569  1.086980e+00                                  BIO D046_r1
## 7570  1.241797e+00               BIRB 796 (Doramapimod) D046_r1
## 7571  2.622576e+00                            BIX 02188 D046_r1
## 7572  3.468289e+00                            BIX 02189 D046_r1
## 7573  4.251757e+00      BKM120 (NVP-BKM120, Buparlisib) D046_r1
## 7574  4.709985e+00                           BMS-265246 D046_r1
## 7575  5.781787e+00                           BMS-536924 D046_r1
## 7576  1.686152e+00                           BMS-582949 D046_r1
## 7577  2.974588e+00                           BMS-754807 D046_r1
## 7578  2.164180e+00                           BMS-777607 D046_r1
## 7579  3.378085e+00                           BMS-794833 D046_r1
## 7580  1.679767e+00                           BMS-833923 D046_r1
## 7581 -1.251160e+00                  Bosutinib (SKI-606) D046_r1
## 7582  2.867119e+00                Brivanib (BMS-540215) D046_r1
## 7583  2.929798e-01      Brivanib Alaninate (BMS-582664) D046_r1
## 7584  2.674531e+00                           BS-181 HCl D046_r1
## 7585  1.309302e+00                               Butein D046_r1
## 7586  4.381865e+00                               BYL719 D046_r1
## 7587  3.086540e+00     Cabozantinib (XL184, BMS-907351) D046_r1
## 7588  1.579505e+00          Cabozantinib malate (XL184) D046_r1
## 7589  3.423193e+00        CAL-101 (Idelalisib, GS-1101) D046_r1
## 7590  1.222296e+00                             CAY10505 D046_r1
## 7591  4.810800e+00                               CC-223 D046_r1
## 7592  4.560206e+00                            CCT128930 D046_r1
## 7593  1.358408e-01                  Cediranib (AZD2171) D046_r1
## 7594  1.290715e+00                            CEP-32496 D046_r1
## 7595  5.803087e-01                            CEP-33779 D046_r1
## 7596  2.310088e+00                              CGI1746 D046_r1
## 7597  4.862244e+00                              CGK 733 D046_r1
## 7598  4.949930e+00                            CH5132799 D046_r1
## 7599  3.570852e+00                           CHIR-98014 D046_r1
## 7600  3.157219e+00                 CHIR-99021 (CT99021) D046_r1
## 7601  4.511984e+00             CHIR-99021 (CT99021) HCl D046_r1
## 7602  8.499994e-01                    Chrysophanic Acid D046_r1
## 7603  5.335833e+00                             CNX-2006 D046_r1
## 7604  9.736202e-01                              CNX-774 D046_r1
## 7605  1.951094e+00                    CO-1686 (AVL-301) D046_r1
## 7606  2.949105e+00       Cobimetinib (GDC-0973, RG7420) D046_r1
## 7607  5.761970e+00                            CP-673451 D046_r1
## 7608  2.279349e+00                            CP-724714 D046_r1
## 7609  3.661766e+00               Crenolanib (CP-868596) D046_r1
## 7610  8.091909e-01             Crizotinib (PF-02341066) D046_r1
## 7611  2.670257e+00                               CYC116 D046_r1
## 7612  1.439122e+00                               CYT387 D046_r1
## 7613  2.551528e+00                             CZC24832 D046_r1
## 7614  2.767341e+00              Dabrafenib (GSK2118436) D046_r1
## 7615  1.545768e+00        Dacomitinib (PF299804, PF299) D046_r1
## 7616  6.161749e-01              Danusertib (PHA-739358) D046_r1
## 7617  2.337119e+00                        DAPT (GSI-IX) D046_r1
## 7618 -4.797058e-01                            Dasatinib D046_r1
## 7619 -3.459506e+00                DCC-2036 (Rebastinib) D046_r1
## 7620  2.211497e+00                Decernotinib (VX-509) D046_r1
## 7621  1.182855e+00               Dinaciclib (SCH727965) D046_r1
## 7622  3.697870e+00    Dovitinib (TKI-258) Dilactic Acid D046_r1
## 7623  2.009817e+00                            ENMD-2076 D046_r1
## 7624  1.571861e+00               Enzastaurin (LY317615) D046_r1
## 7625  4.548074e+00                            ERK5-IN-1 D046_r1
## 7626  1.700800e+00                             ETC-1002 D046_r1
## 7627  5.963524e+00                            ETP-46464 D046_r1
## 7628  4.324192e+00                  Everolimus (RAD001) D046_r1
## 7629  2.323149e+00                Fasudil (HA-1077) HCl D046_r1
## 7630  1.551851e+00                                FH535 D046_r1
## 7631  1.190507e+00                Filgotinib (GLPG0634) D046_r1
## 7632  1.377793e+00             Flavopiridol (Alvocidib) D046_r1
## 7633  2.235838e+00                     Flavopiridol HCl D046_r1
## 7634  6.923048e-01               Foretinib (GSK1363089) D046_r1
## 7635  1.977331e+00                  Fostamatinib (R788) D046_r1
## 7636  4.257144e+00                                G-749 D046_r1
## 7637  5.686254e+00                             GDC-0068 D046_r1
## 7638  3.960946e+00                             GDC-0349 D046_r1
## 7639 -3.814356e-01                             GDC-0879 D046_r1
## 7640  3.739174e+00                             GDC-0941 D046_r1
## 7641  3.340199e+00                    GDC-0980 (RG7422) D046_r1
## 7642  2.840107e+00                   Gefitinib (ZD1839) D046_r1
## 7643  1.002923e+00                            Genistein D046_r1
## 7644  3.496019e+00                            GF109203X D046_r1
## 7645  2.741568e+00                                GNF-2 D046_r1
## 7646  3.027667e+00                                GNF-5 D046_r1
## 7647  3.530164e+00                              Go 6983 D046_r1
## 7648 -2.136570e-01                   Golvatinib (E7050) D046_r1
## 7649  2.347393e+00                          GSK1838705A D046_r1
## 7650  2.342333e+00                          GSK1904529A D046_r1
## 7651 -7.066349e-01                  GSK2126458 (GSK458) D046_r1
## 7652  4.630484e+00                           GSK2292767 D046_r1
## 7653  1.758694e+00                           GSK2636771 D046_r1
## 7654 -3.638110e-01                           GSK429286A D046_r1
## 7655 -1.891221e-01                            GSK461364 D046_r1
## 7656  1.100085e+00                               GSK621 D046_r1
## 7657  4.361156e+00                            GSK690693 D046_r1
## 7658  1.680912e+00                               GW5074 D046_r1
## 7659  2.125781e-01                             GW788388 D046_r1
## 7660 -7.100027e-01                               GZD824 D046_r1
## 7661  1.514977e+00                            H 89 2HCl D046_r1
## 7662  1.525783e+00                           Hesperadin D046_r1
## 7663  1.744303e+00                              HMN-214 D046_r1
## 7664  2.165664e+00                             Honokiol D046_r1
## 7665 -1.485667e-01                               HS-173 D046_r1
## 7666  1.300953e-01                           HTH-01-015 D046_r1
## 7667  1.465259e+00                Ibrutinib (PCI-32765) D046_r1
## 7668  8.646929e-01                              ICG-001 D046_r1
## 7669  2.276554e+00                             Icotinib D046_r1
## 7670  1.876346e+00                                IM-12 D046_r1
## 7671  2.683932e+00           Imatinib Mesylate (STI571) D046_r1
## 7672  8.962610e-01                            Indirubin D046_r1
## 7673  5.690619e+00                    INK 128 (MLN0128) D046_r1
## 7674  3.397305e+00                    IPI-145 (INK1197) D046_r1
## 7675  1.016141e+00                               IWP-L6 D046_r1
## 7676  9.110545e-01                           IWR-1-endo D046_r1
## 7677  1.466478e+00                         JNJ-38877605 D046_r1
## 7678  3.153361e+00                          JNJ-7706621 D046_r1
## 7679  1.472266e+00                     JNK Inhibitor IX D046_r1
## 7680  1.841846e+00                             JNK-IN-8 D046_r1
## 7681  2.955218e+00                               K02288 D046_r1
## 7682  1.606329e+00                               Ki8751 D046_r1
## 7683 -4.313198e-01                              KRN 633 D046_r1
## 7684  5.425478e+00                           KU-0063794 D046_r1
## 7685  3.238191e+00      KU-55933 (ATM Kinase Inhibitor) D046_r1
## 7686  3.061822e+00                             KU-60019 D046_r1
## 7687  3.392439e-01                              KW-2449 D046_r1
## 7688 -6.899214e-02                              KX2-391 D046_r1
## 7689  5.738663e-01                              KY02111 D046_r1
## 7690  2.122897e+00                            Lapatinib D046_r1
## 7691  9.620432e-01     Lapatinib (GW-572016) Ditosylate D046_r1
## 7692  2.778915e+00                            LDC000067 D046_r1
## 7693  2.426161e+00      LDE225 (NVP-LDE225,Erismodegib) D046_r1
## 7694  2.350162e+00                           LDN-214117 D046_r1
## 7695  1.782733e+00                   Lenvatinib (E7080) D046_r1
## 7696  2.485409e+00                              LFM-A13 D046_r1
## 7697  3.475289e+00                              LGK-974 D046_r1
## 7698  5.191621e-01                  Linifanib (ABT-869) D046_r1
## 7699  3.544637e+00                               LJH685 D046_r1
## 7700  2.536225e+00                               LJI308 D046_r1
## 7701  1.516165e+00               Losmapimod (GW856553X) D046_r1
## 7702  3.082014e+00                            LY2090314 D046_r1
## 7703  1.258923e+00                            LY2157299 D046_r1
## 7704  3.214973e+00                            LY2784544 D046_r1
## 7705  5.455162e+00                            LY2835219 D046_r1
## 7706  5.256165e+00                             LY294002 D046_r1
## 7707  3.959626e+00                            LY3023414 D046_r1
## 7708  2.742547e+00                             LY411575 D046_r1
## 7709  4.704995e+00       MEK162 (ARRY-162, ARRY-438162) D046_r1
## 7710  6.378293e-02                             MGCD-265 D046_r1
## 7711  2.034134e+00               Milciclib (PHA-848125) D046_r1
## 7712  3.581606e-01                              MK-0752 D046_r1
## 7713  6.839345e+00                         MK-2206 2HCl D046_r1
## 7714  2.865174e+00                              MK-2461 D046_r1
## 7715  5.417491e-01                     MK-5108 (VX-689) D046_r1
## 7716  9.308600e-01                              MK-8745 D046_r1
## 7717  3.267602e+00                              MLN2480 D046_r1
## 7718  3.609618e+00                              MLN8054 D046_r1
## 7719 -4.730814e-01      Motesanib Diphosphate (AMG-706) D046_r1
## 7720  1.950700e+00                  Nilotinib (AMN-107) D046_r1
## 7721  1.639272e+00     Nintedanib (BIBF 1120)_uncertain D046_r1
## 7722  3.612444e+00                               NU6027 D046_r1
## 7723  2.064308e+00                           NVP-AEW541 D046_r1
## 7724  1.378127e+00                           NVP-BHG712 D046_r1
## 7725  1.388663e+00                      NVP-BSK805 2HCl D046_r1
## 7726  2.202052e+00                           NVP-BVU972 D046_r1
## 7727  6.293197e-01                          Oclacitinib D046_r1
## 7728  2.986745e+00      Olmutinib (HM61713, BI 1482694) D046_r1
## 7729  2.614296e+00                             ONO-4059 D046_r1
## 7730  6.260871e+00                              OSI-027 D046_r1
## 7731  1.273325e+00                              OSI-420 D046_r1
## 7732  3.833163e+00                 OSI-906 (Linsitinib) D046_r1
## 7733  2.703982e+00                              P276-00 D046_r1
## 7734  6.743582e-01                  Pacritinib (SB1518) D046_r1
## 7735  2.102371e+00                   Palomid 529 (P529) D046_r1
## 7736  2.675217e+00                            Pazopanib D046_r1
## 7737  1.503654e+00                        Pazopanib HCl D046_r1
## 7738  4.550266e+00                            PD0325901 D046_r1
## 7739  3.138104e+00                             PD168393 D046_r1
## 7740 -3.565474e-01                             PD173955 D046_r1
## 7741  5.418318e+00                   PD184352 (CI-1040) D046_r1
## 7742  6.983392e+00                             PD318088 D046_r1
## 7743  1.069665e+00                              PD98059 D046_r1
## 7744  2.565541e+00                  Pelitinib (EKB-569) D046_r1
## 7745  8.658108e-02                          PF-00562271 D046_r1
## 7746  2.479475e+00                          PF-04217903 D046_r1
## 7747  4.332214e+00                          PF-04691502 D046_r1
## 7748  4.271663e+00                            PF-431396 D046_r1
## 7749  5.738335e+00                           PF-4708671 D046_r1
## 7750  8.174588e-01                           PF-5274857 D046_r1
## 7751  2.727408e+00                            PF-562271 D046_r1
## 7752  2.986692e+00                            PF-573228 D046_r1
## 7753  2.643546e+00                            PH-797804 D046_r1
## 7754  1.678104e+00                           PHA-665752 D046_r1
## 7755  3.439167e+00                           PHA-680632 D046_r1
## 7756  2.297668e+00                           PHA-767491 D046_r1
## 7757  3.148287e+00                           PHA-793887 D046_r1
## 7758  3.808833e+00                       Phenformin HCl D046_r1
## 7759  5.106735e-01                              PHT-427 D046_r1
## 7760  1.831140e+00                          Piceatannol D046_r1
## 7761  3.675831e+00                              PIK-293 D046_r1
## 7762  1.685917e+00                              PIK-294 D046_r1
## 7763  5.456048e+00                               PIK-93 D046_r1
## 7764  3.401019e+00               Pimasertib (AS-703026) D046_r1
## 7765  1.726972e+00                          Pirfenidone D046_r1
## 7766  2.095309e+00                             PLX-4720 D046_r1
## 7767  1.818953e+00                              PLX7904 D046_r1
## 7768  5.825912e-01                  Ponatinib (AP24534) D046_r1
## 7769  4.689677e+00                                  PP1 D046_r1
## 7770  3.176911e+00                                  PP2 D046_r1
## 7771  5.378266e+00                                PP242 D046_r1
## 7772  3.481669e+00                               PQ 401 D046_r1
## 7773  2.654747e+00                              PRI-724 D046_r1
## 7774  3.459316e+00     PRT062607 (P505-15, BIIB057) HCl D046_r1
## 7775  1.966004e+00                         Purvalanol A D046_r1
## 7776  2.514801e+00                            Quercetin D046_r1
## 7777  1.600528e+00                  Quizartinib (AC220) D046_r1
## 7778  2.448603e+00                                 R406 D046_r1
## 7779  1.774488e+00                     R406 (free base) D046_r1
## 7780  1.933380e+00                                 R547 D046_r1
## 7781  4.697884e+00                    RAF265 (CHIR-265) D046_r1
## 7782  3.919801e+00                Rapamycin (Sirolimus) D046_r1
## 7783  2.983338e+00   Refametinib (RDEA119, Bay 86-9766) D046_r1
## 7784  2.457400e+00                               RepSox D046_r1
## 7785  2.543017e+00 Ridaforolimus (Deforolimus, MK-8669) D046_r1
## 7786  1.474262e+00                Rigosertib (ON-01910) D046_r1
## 7787  1.540677e+00                             RKI-1447 D046_r1
## 7788  4.904921e-01                                RN486 D046_r1
## 7789  5.340131e+00                  Ro 31-8220 Mesylate D046_r1
## 7790  4.747602e-01                              Ro-3306 D046_r1
## 7791  1.877368e+00                               Ro3280 D046_r1
## 7792  1.908972e+00                            RO4929097 D046_r1
## 7793  3.093417e+00      Roscovitine (Seliciclib,CYC202) D046_r1
## 7794  1.203319e+00             Ruxolitinib (INCB018424) D046_r1
## 7795  1.494083e+00           S-Ruxolitinib (INCB018424) D046_r1
## 7796  2.159792e+00                               SANT-1 D046_r1
## 7797  1.845003e+00                            SAR131675 D046_r1
## 7798  2.098501e+00                    SAR245409 (XL765) D046_r1
## 7799  1.632850e+00                Saracatinib (AZD0530) D046_r1
## 7800  1.822035e+00                      SB202190 (FHPI) D046_r1
## 7801  3.060337e+00                             SB203580 D046_r1
## 7802  2.486991e+00                             SB216763 D046_r1
## 7803  2.359968e+00                             SB239063 D046_r1
## 7804  3.051590e+00                             SB415286 D046_r1
## 7805  2.105948e+00                             SB431542 D046_r1
## 7806  2.562101e+00                             SB505124 D046_r1
## 7807  1.818086e+00                             SB525334 D046_r1
## 7808  2.829283e+00                             SB590885 D046_r1
## 7809  1.454914e+00                                  SC1 D046_r1
## 7810  3.301808e+00                Schisandrin B (Sch B) D046_r1
## 7811  5.493384e+00                Selumetinib (AZD6244) D046_r1
## 7812  1.643007e+00              Semagacestat (LY450139) D046_r1
## 7813  9.068414e-01                   Semaxanib (SU5416) D046_r1
## 7814  3.369009e+00                             SGI-7079 D046_r1
## 7815  3.189222e+00                          Skepinone-L D046_r1
## 7816  3.436116e+00                               SL-327 D046_r1
## 7817  4.163714e+00                 SNS-032 (BMS-387032) D046_r1
## 7818  1.250067e+00                     SNS-314 Mesylate D046_r1
## 7819  2.066725e+00                            Sorafenib D046_r1
## 7820  2.213692e+00                   Sorafenib Tosylate D046_r1
## 7821  4.504200e+00                         Sotrastaurin D046_r1
## 7822 -7.832270e+00                             SP600125 D046_r1
## 7823  2.005372e+00                              SU11274 D046_r1
## 7824  9.620435e-01                               SU6656 D046_r1
## 7825  1.531939e+00                               SU9516 D046_r1
## 7826  2.169320e+00                     Sunitinib Malate D046_r1
## 7827  1.607331e+00                  TAE226 (NVP-TAE226) D046_r1
## 7828  1.661261e+00                              TAK-285 D046_r1
## 7829  3.340034e+00                              TAK-632 D046_r1
## 7830  2.818614e+00                              TAK-715 D046_r1
## 7831  2.416588e+00                              TAK-733 D046_r1
## 7832  1.805409e+00                              TAK-901 D046_r1
## 7833  2.526095e+00                Taladegib (LY2940680) D046_r1
## 7834  2.973014e+00                              TCS 359 D046_r1
## 7835  2.929323e+00                               TDZD-8 D046_r1
## 7836  1.747378e+00                            Telatinib D046_r1
## 7837  2.771878e+00   Temsirolimus (CCI-779, NSC 683864) D046_r1
## 7838 -3.299761e-01              Tepotinib (EMD 1214063) D046_r1
## 7839  1.942416e+00                                TG003 D046_r1
## 7840  2.153914e+00                            TG100-115 D046_r1
## 7841  1.267004e+00                             TG101209 D046_r1
## 7842  1.709090e+00                 TG101348 (SAR302503) D046_r1
## 7843  2.353847e+00                              TGX-221 D046_r1
## 7844  1.313060e+00                         Theophylline D046_r1
## 7845  1.036928e+00                          Thiazovivin D046_r1
## 7846  1.985152e+00                       TIC10 Analogue D046_r1
## 7847  2.754651e+00                           Tideglusib D046_r1
## 7848  1.380638e+00                 Tivantinib (ARQ 197) D046_r1
## 7849  1.446319e+00                   Tivozanib (AV-951) D046_r1
## 7850  1.965069e+00  Tofacitinib (CP-690550,Tasocitinib) D046_r1
## 7851  1.907436e+00      Tofacitinib (CP-690550) Citrate D046_r1
## 7852  1.106148e+00                              Torin 2 D046_r1
## 7853  2.122487e+00              Trametinib (GSK1120212) D046_r1
## 7854  2.071038e+00                          Triciribine D046_r1
## 7855 -3.106429e-01           TSU-68 (SU6668, Orantinib) D046_r1
## 7856  6.183962e-01                               TWS119 D046_r1
## 7857  3.833222e+00                         Tyrphostin 9 D046_r1
## 7858  3.787954e+00                   Tyrphostin AG 1296 D046_r1
## 7859  2.028322e+00                           U0126-EtOH D046_r1
## 7860  4.782393e+00     Ulixertinib (BVD-523, VRT752271) D046_r1
## 7861  6.602029e+00              Uprosertib (GSK2141795) D046_r1
## 7862 -1.427963e-01                          Vacquinol-1 D046_r1
## 7863  2.443326e+00                           Varlitinib D046_r1
## 7864  1.449557e+00              Vatalanib (PTK787) 2HCl D046_r1
## 7865  2.449068e+00                               VE-821 D046_r1
## 7866  2.310811e+00                               VE-822 D046_r1
## 7867  2.773474e+00        Vemurafenib (PLX4032, RG7204) D046_r1
## 7868  2.756991e+00                Vismodegib (GDC-0449) D046_r1
## 7869  1.880603e+00                 Volasertib (BI 6727) D046_r1
## 7870  1.130624e+00                            VPS34-IN1 D046_r1
## 7871  4.403268e+00                     VS-5584 (SB2343) D046_r1
## 7872  5.457403e+00                               VX-11e D046_r1
## 7873 -2.154991e+00         VX-680 (Tozasertib, MK-0457) D046_r1
## 7874  1.060980e+00                               VX-702 D046_r1
## 7875  3.062069e+00                               VX-745 D046_r1
## 7876  9.249428e-01                              WAY-600 D046_r1
## 7877  1.729120e+00                             WH-4-023 D046_r1
## 7878  1.335213e+00                             WHI-P154 D046_r1
## 7879  1.248636e+00                                WIKI4 D046_r1
## 7880  2.603041e+00                        Wnt agonist 1 D046_r1
## 7881  2.774412e+00                        Wnt-C59 (C59) D046_r1
## 7882  2.073441e+00                               WP1066 D046_r1
## 7883  6.010741e+00                 WYE-125132 (WYE-132) D046_r1
## 7884  3.675103e+00                              WYE-354 D046_r1
## 7885  2.235250e+00                               WZ3146 D046_r1
## 7886  2.708769e+00                               WZ4002 D046_r1
## 7887  2.303491e+00                               WZ4003 D046_r1
## 7888  1.977977e+00                               WZ8040 D046_r1
## 7889  4.802083e-01                              XAV-939 D046_r1
## 7890  2.047762e+00                                XL019 D046_r1
## 7891  4.646679e+00                              XMD8-92 D046_r1
## 7892  8.057541e-01                         Y-27632 2HCl D046_r1
## 7893  8.579250e-01                             YM201636 D046_r1
## 7894  3.546874e+00                             YO-01027 D046_r1
## 7895  2.749773e+00                            ZM 306416 D046_r1
## 7896  1.497638e+00                        ZM 323881 HCl D046_r1
## 7897  5.620690e-01                            ZM 336372 D046_r1
## 7898  1.824861e+00                         ZM 39923 HCl D046_r1
## 7899 -1.848360e+00                            ZM 447439 D046_r1
## 7900  3.163860e+00                 Zotarolimus(ABT-578) D046_r1
## 7901 -8.296570e-01                              ZSTK474 D046_r1
## 7902  1.779620e+00                     1-Azakenpaullone D046_r2
## 7903  1.691562e+00                      3-Methyladenine D046_r2
## 7904  4.113017e+00                             A-674563 D046_r2
## 7905  4.501723e-01                             A-769662 D046_r2
## 7906  2.872621e+00                                  A66 D046_r2
## 7907  1.032066e+00                            Acadesine D046_r2
## 7908  4.005001e+00                  AEE788 (NVP-AEE788) D046_r2
## 7909  1.764172e+00        Afatinib (BIBW2992)_uncertain D046_r2
## 7910  2.257415e+00                              AG-1024 D046_r2
## 7911  3.144183e+00         AG-1478 (Tyrphostin AG-1478) D046_r2
## 7912  3.016061e+00                                AG-18 D046_r2
## 7913  1.609698e+00              AG-490 (Tyrphostin B42) D046_r2
## 7914  2.852373e+00                             Akti-1/2 D046_r2
## 7915 -5.411970e+00                  Alisertib (MLN8237) D046_r2
## 7916  1.691819e+00                              AMG 337 D046_r2
## 7917  3.320900e-01                              AMG-458 D046_r2
## 7918  2.266852e+00                              AMG-900 D046_r2
## 7919  2.629231e+00                               AMG319 D046_r2
## 7920  8.562351e-01                  Amuvatinib (MP-470) D046_r2
## 7921  2.216970e+00                             Apatinib D046_r2
## 7922  2.111666e+00                           AR-A014418 D046_r2
## 7923  2.580078e+00                            AS-252424 D046_r2
## 7924  1.729760e+00                            AS-604850 D046_r2
## 7925 -6.273536e-01                         Asiatic Acid D046_r2
## 7926  2.426114e+00                             AST-1306 D046_r2
## 7927  3.161387e+00                              AT13148 D046_r2
## 7928  6.336458e+00                               AT7519 D046_r2
## 7929  1.568241e+00                               AT7867 D046_r2
## 7930  4.965112e+00                               AT9283 D046_r2
## 7931  1.280713e+00                 Aurora A Inhibitor I D046_r2
## 7932  1.508508e+00             Avagacestat (BMS-708163) D046_r2
## 7933  1.162433e+00                              AVL-292 D046_r2
## 7934  7.731851e-01                             Axitinib D046_r2
## 7935  7.731851e-01                             Axitinib D046_r2
## 7936  4.077759e+00                               AZ 628 D046_r2
## 7937  1.358238e+00                               AZ 960 D046_r2
## 7938  5.267103e+00                                 AZ20 D046_r2
## 7939  1.810837e+00                              AZD1080 D046_r2
## 7940  3.608746e+00                              AZD1480 D046_r2
## 7941  5.371932e+00                              AZD2014 D046_r2
## 7942  2.957225e+00                              AZD2858 D046_r2
## 7943  1.737447e+00                              AZD2932 D046_r2
## 7944  2.637941e+00                              AZD3759 D046_r2
## 7945  5.631332e+00                              AZD5363 D046_r2
## 7946  3.950570e+00                              AZD5438 D046_r2
## 7947  4.444055e-01                              AZD6482 D046_r2
## 7948  1.833540e+00                              AZD6738 D046_r2
## 7949  7.124455e+00                              AZD8055 D046_r2
## 7950  4.465008e+00                              AZD8330 D046_r2
## 7951  4.199577e+00                  AZD8931 (Sapitinib) D046_r2
## 7952  1.344670e+00                              AZD9291 D046_r2
## 7953  2.506039e+00            Barasertib (AZD1152-HQPA) D046_r2
## 7954  1.226928e+00  Baricitinib (LY3009104, INCB028050) D046_r2
## 7955 -4.010260e+00                  BGT226 (NVP-BGT226) D046_r2
## 7956  4.607871e+00                              BI 2536 D046_r2
## 7957  2.859608e+00                              BI-78D3 D046_r2
## 7958  1.734028e+00                             BI-D1870 D046_r2
## 7959 -2.631109e-01                              Bikinin D046_r2
## 7960 -3.657653e-02                                  BIO D046_r2
## 7961  7.701328e-01               BIRB 796 (Doramapimod) D046_r2
## 7962  2.453828e+00                            BIX 02188 D046_r2
## 7963  2.708173e+00                            BIX 02189 D046_r2
## 7964  5.275349e+00      BKM120 (NVP-BKM120, Buparlisib) D046_r2
## 7965  3.609814e+00                           BMS-265246 D046_r2
## 7966  5.348192e+00                           BMS-536924 D046_r2
## 7967  2.975992e+00                           BMS-582949 D046_r2
## 7968  4.279672e+00                           BMS-754807 D046_r2
## 7969  2.154421e+00                           BMS-777607 D046_r2
## 7970  4.828580e-01                           BMS-794833 D046_r2
## 7971  2.181443e+00                           BMS-833923 D046_r2
## 7972  2.156327e+00                  Bosutinib (SKI-606) D046_r2
## 7973  3.662769e-01                Brivanib (BMS-540215) D046_r2
## 7974  1.934187e+00      Brivanib Alaninate (BMS-582664) D046_r2
## 7975  2.435261e+00                           BS-181 HCl D046_r2
## 7976  7.099450e-01                               Butein D046_r2
## 7977  4.771216e+00                               BYL719 D046_r2
## 7978  5.355865e-01     Cabozantinib (XL184, BMS-907351) D046_r2
## 7979  1.874834e+00          Cabozantinib malate (XL184) D046_r2
## 7980  2.631868e+00        CAL-101 (Idelalisib, GS-1101) D046_r2
## 7981  1.078772e+00                             CAY10505 D046_r2
## 7982  5.027065e+00                               CC-223 D046_r2
## 7983  3.141475e+00                            CCT128930 D046_r2
## 7984  4.717118e-01                  Cediranib (AZD2171) D046_r2
## 7985  2.812227e+00                            CEP-32496 D046_r2
## 7986  2.243164e+00                            CEP-33779 D046_r2
## 7987  5.772518e-01                              CGI1746 D046_r2
## 7988  2.516490e+00                              CGK 733 D046_r2
## 7989  4.135411e+00                            CH5132799 D046_r2
## 7990  3.118874e+00                           CHIR-98014 D046_r2
## 7991  1.929474e+00                 CHIR-99021 (CT99021) D046_r2
## 7992  2.204625e+00             CHIR-99021 (CT99021) HCl D046_r2
## 7993  2.571886e+00                    Chrysophanic Acid D046_r2
## 7994  3.534485e+00                             CNX-2006 D046_r2
## 7995  9.187266e-01                              CNX-774 D046_r2
## 7996  2.108952e+00                    CO-1686 (AVL-301) D046_r2
## 7997  5.627280e+00       Cobimetinib (GDC-0973, RG7420) D046_r2
## 7998  2.082924e+00                            CP-673451 D046_r2
## 7999  2.732822e+00                            CP-724714 D046_r2
## 8000  8.279172e-02               Crenolanib (CP-868596) D046_r2
## 8001  3.006413e+00             Crizotinib (PF-02341066) D046_r2
## 8002  3.664986e+00                               CYC116 D046_r2
## 8003  1.652287e+00                               CYT387 D046_r2
## 8004  1.325108e+00                             CZC24832 D046_r2
## 8005  3.936018e+00              Dabrafenib (GSK2118436) D046_r2
## 8006 -1.969239e-01        Dacomitinib (PF299804, PF299) D046_r2
## 8007  1.170979e+00              Danusertib (PHA-739358) D046_r2
## 8008  1.334337e+00                        DAPT (GSI-IX) D046_r2
## 8009  8.205280e-01                            Dasatinib D046_r2
## 8010 -2.142982e+00                DCC-2036 (Rebastinib) D046_r2
## 8011  1.989350e+00                Decernotinib (VX-509) D046_r2
## 8012  3.751486e+00               Dinaciclib (SCH727965) D046_r2
## 8013  2.730091e+00    Dovitinib (TKI-258) Dilactic Acid D046_r2
## 8014  3.898594e+00                            ENMD-2076 D046_r2
## 8015  2.808760e+00               Enzastaurin (LY317615) D046_r2
## 8016  4.869037e+00                            ERK5-IN-1 D046_r2
## 8017  2.104307e+00                             ETC-1002 D046_r2
## 8018  2.857914e+00                            ETP-46464 D046_r2
## 8019  2.825237e+00                  Everolimus (RAD001) D046_r2
## 8020  1.950897e+00                Fasudil (HA-1077) HCl D046_r2
## 8021  7.967853e-02                                FH535 D046_r2
## 8022  1.223598e+00                Filgotinib (GLPG0634) D046_r2
## 8023  5.909179e+00             Flavopiridol (Alvocidib) D046_r2
## 8024  2.776867e+00                     Flavopiridol HCl D046_r2
## 8025 -5.198174e-01               Foretinib (GSK1363089) D046_r2
## 8026  2.798214e+00                  Fostamatinib (R788) D046_r2
## 8027  2.247774e+00                                G-749 D046_r2
## 8028  5.403466e+00                             GDC-0068 D046_r2
## 8029  5.085374e+00                             GDC-0349 D046_r2
## 8030  1.824097e+00                             GDC-0879 D046_r2
## 8031  1.834459e+00                             GDC-0941 D046_r2
## 8032  4.482716e+00                    GDC-0980 (RG7422) D046_r2
## 8033  3.074065e+00                   Gefitinib (ZD1839) D046_r2
## 8034 -1.009221e+00                            Genistein D046_r2
## 8035  3.184468e+00                            GF109203X D046_r2
## 8036  2.498007e+00                                GNF-2 D046_r2
## 8037  2.798838e+00                                GNF-5 D046_r2
## 8038  3.263637e+00                              Go 6983 D046_r2
## 8039  2.568278e+00                   Golvatinib (E7050) D046_r2
## 8040  4.619502e+00                          GSK1838705A D046_r2
## 8041  2.314942e+00                          GSK1904529A D046_r2
## 8042 -7.771914e-01                  GSK2126458 (GSK458) D046_r2
## 8043  2.560087e+00                           GSK2292767 D046_r2
## 8044  3.478051e+00                           GSK2636771 D046_r2
## 8045  8.167787e-01                           GSK429286A D046_r2
## 8046  6.206527e-01                            GSK461364 D046_r2
## 8047  2.532794e+00                               GSK621 D046_r2
## 8048  4.029325e+00                            GSK690693 D046_r2
## 8049  2.271155e+00                               GW5074 D046_r2
## 8050  1.979257e+00                             GW788388 D046_r2
## 8051  2.901019e+00                               GZD824 D046_r2
## 8052  1.789990e+00                            H 89 2HCl D046_r2
## 8053  2.916316e+00                           Hesperadin D046_r2
## 8054  1.806829e+00                              HMN-214 D046_r2
## 8055  7.812169e-01                             Honokiol D046_r2
## 8056  1.705883e+00                               HS-173 D046_r2
## 8057  2.745069e+00                           HTH-01-015 D046_r2
## 8058 -6.469826e-03                Ibrutinib (PCI-32765) D046_r2
## 8059  1.683909e+00                              ICG-001 D046_r2
## 8060  3.374074e+00                             Icotinib D046_r2
## 8061  1.414151e+00                                IM-12 D046_r2
## 8062  2.928438e+00           Imatinib Mesylate (STI571) D046_r2
## 8063  4.456679e-01                            Indirubin D046_r2
## 8064  6.118521e+00                    INK 128 (MLN0128) D046_r2
## 8065  1.761981e+00                    IPI-145 (INK1197) D046_r2
## 8066  2.404274e+00                               IWP-L6 D046_r2
## 8067  8.230130e-01                           IWR-1-endo D046_r2
## 8068  1.676336e+00                         JNJ-38877605 D046_r2
## 8069  5.612534e+00                          JNJ-7706621 D046_r2
## 8070  8.793252e-01                     JNK Inhibitor IX D046_r2
## 8071  1.595610e+00                             JNK-IN-8 D046_r2
## 8072  2.348963e+00                               K02288 D046_r2
## 8073  1.512086e+00                               Ki8751 D046_r2
## 8074  4.118014e-01                              KRN 633 D046_r2
## 8075  5.623994e+00                           KU-0063794 D046_r2
## 8076  2.942611e+00      KU-55933 (ATM Kinase Inhibitor) D046_r2
## 8077  1.995974e+00                             KU-60019 D046_r2
## 8078  2.312771e+00                              KW-2449 D046_r2
## 8079 -1.970572e-01                              KX2-391 D046_r2
## 8080  2.160269e+00                              KY02111 D046_r2
## 8081  1.860343e+00                            Lapatinib D046_r2
## 8082  2.110011e+00     Lapatinib (GW-572016) Ditosylate D046_r2
## 8083  4.414689e+00                            LDC000067 D046_r2
## 8084  2.836679e+00      LDE225 (NVP-LDE225,Erismodegib) D046_r2
## 8085  3.342859e+00                           LDN-214117 D046_r2
## 8086  1.936899e+00                   Lenvatinib (E7080) D046_r2
## 8087  2.495518e+00                              LFM-A13 D046_r2
## 8088  3.552216e+00                              LGK-974 D046_r2
## 8089  1.012221e+00                  Linifanib (ABT-869) D046_r2
## 8090  2.949666e+00                               LJH685 D046_r2
## 8091  9.308956e-01                               LJI308 D046_r2
## 8092  1.415026e-01               Losmapimod (GW856553X) D046_r2
## 8093  1.924361e+00                            LY2090314 D046_r2
## 8094  1.832953e+00                            LY2157299 D046_r2
## 8095  2.224911e+00                            LY2784544 D046_r2
## 8096  4.591976e+00                            LY2835219 D046_r2
## 8097  3.124400e+00                             LY294002 D046_r2
## 8098  6.143776e+00                            LY3023414 D046_r2
## 8099  3.059870e+00                             LY411575 D046_r2
## 8100  5.365263e+00       MEK162 (ARRY-162, ARRY-438162) D046_r2
## 8101  1.119928e+00                             MGCD-265 D046_r2
## 8102  1.877671e+00               Milciclib (PHA-848125) D046_r2
## 8103  2.749773e+00                              MK-0752 D046_r2
## 8104  4.661284e+00                         MK-2206 2HCl D046_r2
## 8105  2.076968e+00                              MK-2461 D046_r2
## 8106  3.216051e-01                     MK-5108 (VX-689) D046_r2
## 8107  2.802131e+00                              MK-8745 D046_r2
## 8108  1.575050e+00                              MLN2480 D046_r2
## 8109  2.202196e+00                              MLN8054 D046_r2
## 8110  1.235552e+00      Motesanib Diphosphate (AMG-706) D046_r2
## 8111  1.538754e+00                  Nilotinib (AMN-107) D046_r2
## 8112  1.373104e+00     Nintedanib (BIBF 1120)_uncertain D046_r2
## 8113  1.946575e+00                               NU6027 D046_r2
## 8114  3.413241e+00                           NVP-AEW541 D046_r2
## 8115 -1.257633e+00                           NVP-BHG712 D046_r2
## 8116  2.074006e+00                      NVP-BSK805 2HCl D046_r2
## 8117  1.580633e+00                           NVP-BVU972 D046_r2
## 8118  3.038137e+00                          Oclacitinib D046_r2
## 8119  1.830232e+00      Olmutinib (HM61713, BI 1482694) D046_r2
## 8120  2.287601e+00                             ONO-4059 D046_r2
## 8121  5.467326e+00                              OSI-027 D046_r2
## 8122  2.884132e+00                              OSI-420 D046_r2
## 8123  4.905296e+00                 OSI-906 (Linsitinib) D046_r2
## 8124  3.561043e+00                              P276-00 D046_r2
## 8125  3.697593e+00                  Pacritinib (SB1518) D046_r2
## 8126  5.195241e-01                   Palomid 529 (P529) D046_r2
## 8127  2.424800e+00                            Pazopanib D046_r2
## 8128  2.432548e+00                        Pazopanib HCl D046_r2
## 8129  4.963272e+00                            PD0325901 D046_r2
## 8130  2.365668e+00                             PD168393 D046_r2
## 8131  7.251484e-01                             PD173955 D046_r2
## 8132  6.049624e+00                   PD184352 (CI-1040) D046_r2
## 8133  8.267176e+00                             PD318088 D046_r2
## 8134  2.515681e+00                              PD98059 D046_r2
## 8135  2.935615e+00                  Pelitinib (EKB-569) D046_r2
## 8136  2.670247e+00                          PF-00562271 D046_r2
## 8137  1.489752e+00                          PF-04217903 D046_r2
## 8138  1.456427e+00                          PF-04691502 D046_r2
## 8139  4.469095e+00                            PF-431396 D046_r2
## 8140  4.883422e+00                           PF-4708671 D046_r2
## 8141  1.745057e+00                           PF-5274857 D046_r2
## 8142  3.644794e+00                            PF-562271 D046_r2
## 8143  1.972709e+00                            PF-573228 D046_r2
## 8144  2.257279e+00                            PH-797804 D046_r2
## 8145  4.849972e+00                           PHA-665752 D046_r2
## 8146  1.158910e+00                           PHA-680632 D046_r2
## 8147  4.619951e+00                           PHA-767491 D046_r2
## 8148  3.987510e+00                           PHA-793887 D046_r2
## 8149  2.388733e+00                       Phenformin HCl D046_r2
## 8150 -7.440293e-01                              PHT-427 D046_r2
## 8151  2.067775e+00                          Piceatannol D046_r2
## 8152  3.485830e+00                              PIK-293 D046_r2
## 8153  1.125776e+00                              PIK-294 D046_r2
## 8154  5.027967e+00                               PIK-93 D046_r2
## 8155  6.284591e+00               Pimasertib (AS-703026) D046_r2
## 8156  2.435112e+00                          Pirfenidone D046_r2
## 8157  1.284448e+00                             PLX-4720 D046_r2
## 8158  3.430692e+00                              PLX7904 D046_r2
## 8159 -6.758194e-01                  Ponatinib (AP24534) D046_r2
## 8160  2.535111e+00                                  PP1 D046_r2
## 8161  1.778776e+00                                  PP2 D046_r2
## 8162  5.304898e+00                                PP242 D046_r2
## 8163  3.545897e+00                               PQ 401 D046_r2
## 8164  2.687755e+00                              PRI-724 D046_r2
## 8165  4.262794e+00     PRT062607 (P505-15, BIIB057) HCl D046_r2
## 8166 -3.924294e-01                         Purvalanol A D046_r2
## 8167  2.390935e+00                            Quercetin D046_r2
## 8168  8.431294e-01                  Quizartinib (AC220) D046_r2
## 8169  2.589093e+00                                 R406 D046_r2
## 8170  2.115502e+00                     R406 (free base) D046_r2
## 8171  2.442085e+00                                 R547 D046_r2
## 8172  5.574612e+00                    RAF265 (CHIR-265) D046_r2
## 8173  6.080452e-01                Rapamycin (Sirolimus) D046_r2
## 8174  4.028306e+00   Refametinib (RDEA119, Bay 86-9766) D046_r2
## 8175  3.368307e+00                               RepSox D046_r2
## 8176  1.359091e+00 Ridaforolimus (Deforolimus, MK-8669) D046_r2
## 8177  2.121209e+00                Rigosertib (ON-01910) D046_r2
## 8178  1.854618e+00                             RKI-1447 D046_r2
## 8179  2.043352e-01                                RN486 D046_r2
## 8180  5.369716e+00                  Ro 31-8220 Mesylate D046_r2
## 8181  5.148905e-01                              Ro-3306 D046_r2
## 8182  3.097163e+00                               Ro3280 D046_r2
## 8183  2.377475e+00                            RO4929097 D046_r2
## 8184  2.720317e+00      Roscovitine (Seliciclib,CYC202) D046_r2
## 8185  4.507117e-01             Ruxolitinib (INCB018424) D046_r2
## 8186  1.529948e+00           S-Ruxolitinib (INCB018424) D046_r2
## 8187  1.947237e+00                               SANT-1 D046_r2
## 8188  9.379239e-01                            SAR131675 D046_r2
## 8189 -1.766239e-01                    SAR245409 (XL765) D046_r2
## 8190  2.165092e+00                Saracatinib (AZD0530) D046_r2
## 8191  1.778193e+00                      SB202190 (FHPI) D046_r2
## 8192  1.175468e+00                             SB203580 D046_r2
## 8193  2.647552e+00                             SB216763 D046_r2
## 8194  2.048009e+00                             SB239063 D046_r2
## 8195  1.820440e+00                             SB415286 D046_r2
## 8196  2.294886e+00                             SB431542 D046_r2
## 8197  3.394996e+00                             SB505124 D046_r2
## 8198  2.556414e+00                             SB525334 D046_r2
## 8199  2.670450e-01                             SB590885 D046_r2
## 8200  1.760883e+00                                  SC1 D046_r2
## 8201  2.048127e+00                Schisandrin B (Sch B) D046_r2
## 8202  7.340612e+00                Selumetinib (AZD6244) D046_r2
## 8203  2.228604e+00              Semagacestat (LY450139) D046_r2
## 8204  1.150344e-01                   Semaxanib (SU5416) D046_r2
## 8205  4.489667e+00                             SGI-7079 D046_r2
## 8206  3.109373e+00                          Skepinone-L D046_r2
## 8207  4.911226e-01                               SL-327 D046_r2
## 8208  6.676567e+00                 SNS-032 (BMS-387032) D046_r2
## 8209  4.389005e+00                     SNS-314 Mesylate D046_r2
## 8210  2.659719e+00                            Sorafenib D046_r2
## 8211  2.701565e+00                   Sorafenib Tosylate D046_r2
## 8212  3.499181e+00                         Sotrastaurin D046_r2
## 8213  2.645687e+00                             SP600125 D046_r2
## 8214  1.507655e-01                              SU11274 D046_r2
## 8215  5.488515e-01                               SU6656 D046_r2
## 8216  3.088651e-01                               SU9516 D046_r2
## 8217  2.682225e+00                     Sunitinib Malate D046_r2
## 8218  1.377733e+00                  TAE226 (NVP-TAE226) D046_r2
## 8219  6.848320e-01                              TAK-285 D046_r2
## 8220  2.588481e+00                              TAK-632 D046_r2
## 8221  2.135053e+00                              TAK-715 D046_r2
## 8222  3.487900e+00                              TAK-733 D046_r2
## 8223  4.861152e-02                              TAK-901 D046_r2
## 8224  2.313294e+00                Taladegib (LY2940680) D046_r2
## 8225  2.366559e+00                              TCS 359 D046_r2
## 8226  7.979323e-01                               TDZD-8 D046_r2
## 8227  1.535874e+00                            Telatinib D046_r2
## 8228  2.487104e+00   Temsirolimus (CCI-779, NSC 683864) D046_r2
## 8229  1.638222e+00              Tepotinib (EMD 1214063) D046_r2
## 8230  2.696442e+00                                TG003 D046_r2
## 8231  1.012269e+00                            TG100-115 D046_r2
## 8232  3.207725e+00                             TG101209 D046_r2
## 8233  4.764185e+00                 TG101348 (SAR302503) D046_r2
## 8234 -4.006985e+00                              TGX-221 D046_r2
## 8235  1.379303e+00                         Theophylline D046_r2
## 8236  1.786529e+00                          Thiazovivin D046_r2
## 8237  2.435415e+00                       TIC10 Analogue D046_r2
## 8238  1.619263e+00                           Tideglusib D046_r2
## 8239  7.611012e-01                 Tivantinib (ARQ 197) D046_r2
## 8240  2.144208e+00                   Tivozanib (AV-951) D046_r2
## 8241  1.647826e+00  Tofacitinib (CP-690550,Tasocitinib) D046_r2
## 8242  1.932500e+00      Tofacitinib (CP-690550) Citrate D046_r2
## 8243  2.167231e+00                              Torin 2 D046_r2
## 8244  2.761318e+00              Trametinib (GSK1120212) D046_r2
## 8245  1.788431e+00                          Triciribine D046_r2
## 8246  1.641619e+00           TSU-68 (SU6668, Orantinib) D046_r2
## 8247  1.500585e+00                               TWS119 D046_r2
## 8248  9.113740e-01                         Tyrphostin 9 D046_r2
## 8249  3.103437e+00                   Tyrphostin AG 1296 D046_r2
## 8250  1.049937e+00                           U0126-EtOH D046_r2
## 8251  5.579835e+00     Ulixertinib (BVD-523, VRT752271) D046_r2
## 8252  5.994447e+00              Uprosertib (GSK2141795) D046_r2
## 8253  1.329683e+00                          Vacquinol-1 D046_r2
## 8254 -2.904327e-01                           Varlitinib D046_r2
## 8255  2.003098e+00              Vatalanib (PTK787) 2HCl D046_r2
## 8256  2.891017e+00                               VE-821 D046_r2
## 8257  3.611939e+00                               VE-822 D046_r2
## 8258  1.452326e+00        Vemurafenib (PLX4032, RG7204) D046_r2
## 8259  2.648051e+00                Vismodegib (GDC-0449) D046_r2
## 8260  2.081226e+00                 Volasertib (BI 6727) D046_r2
## 8261  7.370043e-01                            VPS34-IN1 D046_r2
## 8262  4.368065e+00                     VS-5584 (SB2343) D046_r2
## 8263  5.896082e+00                               VX-11e D046_r2
## 8264  1.827214e+00         VX-680 (Tozasertib, MK-0457) D046_r2
## 8265  1.908209e+00                               VX-702 D046_r2
## 8266  1.048491e+00                               VX-745 D046_r2
## 8267  3.581587e+00                              WAY-600 D046_r2
## 8268  3.599670e-01                             WH-4-023 D046_r2
## 8269  2.294108e+00                             WHI-P154 D046_r2
## 8270  1.138685e+00                                WIKI4 D046_r2
## 8271  8.357442e-01                        Wnt agonist 1 D046_r2
## 8272  2.632397e+00                        Wnt-C59 (C59) D046_r2
## 8273  7.457732e-01                               WP1066 D046_r2
## 8274  5.808393e+00                 WYE-125132 (WYE-132) D046_r2
## 8275  6.254635e+00                              WYE-354 D046_r2
## 8276  1.999640e+00                               WZ3146 D046_r2
## 8277  2.310205e+00                               WZ4002 D046_r2
## 8278  6.854645e-01                               WZ4003 D046_r2
## 8279  2.065616e+00                               WZ8040 D046_r2
## 8280  5.948859e-01                              XAV-939 D046_r2
## 8281  1.618386e+00                                XL019 D046_r2
## 8282  5.146390e+00                              XMD8-92 D046_r2
## 8283  2.326700e+00                         Y-27632 2HCl D046_r2
## 8284  3.988483e+00                             YM201636 D046_r2
## 8285  2.472159e+00                             YO-01027 D046_r2
## 8286  2.863717e+00                            ZM 306416 D046_r2
## 8287  2.323386e+00                        ZM 323881 HCl D046_r2
## 8288 -1.454626e+00                            ZM 336372 D046_r2
## 8289  2.317548e+00                         ZM 39923 HCl D046_r2
## 8290  1.245941e+00                            ZM 447439 D046_r2
## 8291  2.078172e+00                 Zotarolimus(ABT-578) D046_r2
## 8292  3.643173e+00                              ZSTK474 D046_r2
##                   target line
## 1                  GSK-3 D004
## 2                   PI3K D004
## 3                    Akt D004
## 4                   AMPK D004
## 5                   PI3K D004
## 6                   AMPK D004
## 7                   EGFR D004
## 8                   &lt;NA&gt; D004
## 9                 IGF-1R D004
## 10                  EGFR D004
## 11                  EGFR D004
## 12                   JAK D004
## 13                   Akt D004
## 14         Aurora Kinase D004
## 15                 c-Met D004
## 16                 c-Met D004
## 17         Aurora Kinase D004
## 18                  PI3K D004
## 19                 c-Met D004
## 20                 VEGFR D004
## 21                 GSK-3 D004
## 22                  PI3K D004
## 23                  PI3K D004
## 24              p38 MAPK D004
## 25                  EGFR D004
## 26                   Akt D004
## 27                   CDK D004
## 28                   Akt D004
## 29               Bcr-Abl D004
## 30         Aurora Kinase D004
## 31       Gamma-secretase D004
## 32                   BTK D004
## 33                 VEGFR D004
## 34                 PDGFR D004
## 35                   Raf D004
## 36                   JAK D004
## 37               ATM/ATR D004
## 38                 GSK-3 D004
## 39                   JAK D004
## 40                  mTOR D004
## 41                 GSK-3 D004
## 42                 PDGFR D004
## 43                  EGFR D004
## 44                   Akt D004
## 45                   CDK D004
## 46                  PI3K D004
## 47               ATM/ATR D004
## 48                  mTOR D004
## 49                   MEK D004
## 50                  EGFR D004
## 51                  EGFR D004
## 52         Aurora Kinase D004
## 53                   JAK D004
## 54                  PI3K D004
## 55                   PLK D004
## 56                   JNK D004
## 57             S6 Kinase D004
## 58                 GSK-3 D004
## 59                 GSK-3 D004
## 60              p38 MAPK D004
## 61                   MEK D004
## 62                  &lt;NA&gt; D004
## 63                  PI3K D004
## 64                   CDK D004
## 65                IGF-1R D004
## 66              p38 MAPK D004
## 67                IGF-1R D004
## 68                 c-Met D004
## 69                 c-Met D004
## 70   Hedgehog/Smoothened D004
## 71                   Src D004
## 72                 VEGFR D004
## 73                 VEGFR D004
## 74                   CDK D004
## 75                  EGFR D004
## 76                  PI3K D004
## 77                 VEGFR D004
## 78                  &lt;NA&gt; D004
## 79                  PI3K D004
## 80                  PI3K D004
## 81                  mTOR D004
## 82                   Akt D004
## 83                 VEGFR D004
## 84                   Raf D004
## 85                   JAK D004
## 86                   BTK D004
## 87               ATM/ATR D004
## 88                  PI3K D004
## 89                 GSK-3 D004
## 90                 GSK-3 D004
## 91                  &lt;NA&gt; D004
## 92                  EGFR D004
## 93                  EGFR D004
## 94                   BTK D004
## 95                  EGFR D004
## 96                   MEK D004
## 97                 PDGFR D004
## 98                  EGFR D004
## 99                 PDGFR D004
## 100                c-Met D004
## 101        Aurora Kinase D004
## 102                  JAK D004
## 103                 PI3K D004
## 104                  Raf D004
## 105                 EGFR D004
## 106        Aurora Kinase D004
## 107      Gamma-secretase D004
## 108                  Src D004
## 109              Bcr-Abl D004
## 110                  JAK D004
## 111                  CDK D004
## 112                 &lt;NA&gt; D004
## 113        Aurora Kinase D004
## 114                  PKC D004
## 115                  ERK D004
## 116                 AMPK D004
## 117                 mTOR D004
## 118                 mTOR D004
## 119                 ROCK D004
## 120     Wnt/beta-catenin D004
## 121                  JAK D004
## 122                  CDK D004
## 123                 &lt;NA&gt; D004
## 124                c-Met D004
## 125                  Syk D004
## 126                 FLT3 D004
## 127                  Akt D004
## 128                 mTOR D004
## 129                  Raf D004
## 130                 PI3K D004
## 131                 mTOR D004
## 132                 EGFR D004
## 133                 EGFR D004
## 134                  PKC D004
## 135              Bcr-Abl D004
## 136              Bcr-Abl D004
## 137                  PKC D004
## 138                c-Met D004
## 139               IGF-1R D004
## 140               IGF-1R D004
## 141                 PI3K D004
## 142                 PI3K D004
## 143                 PI3K D004
## 144                 ROCK D004
## 145                  PLK D004
## 146                 AMPK D004
## 147                  Akt D004
## 148                  Raf D004
## 149        TGF-beta/Smad D004
## 150              Bcr-Abl D004
## 151            S6 Kinase D004
## 152        Aurora Kinase D004
## 153                  PLK D004
## 154                  Akt D004
## 155                 PI3K D004
## 156                 AMPK D004
## 157                  Src D004
## 158     Wnt/beta-catenin D004
## 159                 EGFR D004
## 160                GSK-3 D004
## 161                PDGFR D004
## 162                GSK-3 D004
## 163                 mTOR D004
## 164                 PI3K D004
## 165     Wnt/beta-catenin D004
## 166     Wnt/beta-catenin D004
## 167                c-Met D004
## 168                  CDK D004
## 169                  JNK D004
## 170                  JNK D004
## 171        TGF-beta/Smad D004
## 172                VEGFR D004
## 173                VEGFR D004
## 174                 mTOR D004
## 175              ATM/ATR D004
## 176              ATM/ATR D004
## 177                 FLT3 D004
## 178                  Src D004
## 179     Wnt/beta-catenin D004
## 180                 EGFR D004
## 181                 EGFR D004
## 182                  CDK D004
## 183  Hedgehog/Smoothened D004
## 184        TGF-beta/Smad D004
## 185                VEGFR D004
## 186                  BTK D004
## 187     Wnt/beta-catenin D004
## 188                PDGFR D004
## 189            S6 Kinase D004
## 190            S6 Kinase D004
## 191             p38 MAPK D004
## 192                GSK-3 D004
## 193        TGF-beta/Smad D004
## 194                  JAK D004
## 195                  CDK D004
## 196                 PI3K D004
## 197                  Akt D004
## 198      Gamma-secretase D004
## 199                  MEK D004
## 200                c-Met D004
## 201                  CDK D004
## 202      Gamma-secretase D004
## 203                  Akt D004
## 204                c-Met D004
## 205        Aurora Kinase D004
## 206        Aurora Kinase D004
## 207                  Raf D004
## 208        Aurora Kinase D004
## 209                VEGFR D004
## 210              Bcr-Abl D004
## 211                VEGFR D004
## 212                  CDK D004
## 213               IGF-1R D004
## 214                VEGFR D004
## 215                  JAK D004
## 216                c-Met D004
## 217                  JAK D004
## 218                 EGFR D004
## 219                  BTK D004
## 220                 mTOR D004
## 221                 EGFR D004
## 222               IGF-1R D004
## 223                  CDK D004
## 224                  JAK D004
## 225                 mTOR D004
## 226                VEGFR D004
## 227                VEGFR D004
## 228                  MEK D004
## 229                 EGFR D004
## 230              Bcr-Abl D004
## 231                  MEK D004
## 232                  MEK D004
## 233                  MEK D004
## 234                 EGFR D004
## 235                  FAK D004
## 236                c-Met D004
## 237                 mTOR D004
## 238                  FAK D004
## 239            S6 Kinase D004
## 240  Hedgehog/Smoothened D004
## 241                  FAK D004
## 242                  FAK D004
## 243             p38 MAPK D004
## 244                c-Met D004
## 245        Aurora Kinase D004
## 246                  CDK D004
## 247                  CDK D004
## 248                 AMPK D004
## 249                  Akt D004
## 250                  Syk D004
## 251                 PI3K D004
## 252                 PI3K D004
## 253                 PI3K D004
## 254                  MEK D004
## 255        TGF-beta/Smad D004
## 256                  Raf D004
## 257                  Raf D004
## 258              Bcr-Abl D004
## 259                  Src D004
## 260                  Src D004
## 261                 mTOR D004
## 262               IGF-1R D004
## 263     Wnt/beta-catenin D004
## 264                  Syk D004
## 265                  CDK D004
## 266                 PI3K D004
## 267                 FLT3 D004
## 268                  Syk D004
## 269                  Syk D004
## 270                  CDK D004
## 271                  Raf D004
## 272                 mTOR D004
## 273                  MEK D004
## 274        TGF-beta/Smad D004
## 275                 mTOR D004
## 276                  PLK D004
## 277                 ROCK D004
## 278                  BTK D004
## 279                  PKC D004
## 280                  CDK D004
## 281                  PLK D004
## 282      Gamma-secretase D004
## 283                  CDK D004
## 284                  JAK D004
## 285                  JAK D004
## 286  Hedgehog/Smoothened D004
## 287                VEGFR D004
## 288                 PI3K D004
## 289                  Src D004
## 290             p38 MAPK D004
## 291             p38 MAPK D004
## 292                GSK-3 D004
## 293             p38 MAPK D004
## 294                GSK-3 D004
## 295        TGF-beta/Smad D004
## 296        TGF-beta/Smad D004
## 297        TGF-beta/Smad D004
## 298                  Raf D004
## 299                  ERK D004
## 300              ATM/ATR D004
## 301                  MEK D004
## 302      Gamma-secretase D004
## 303                VEGFR D004
## 304                VEGFR D004
## 305             p38 MAPK D004
## 306                  MEK D004
## 307                  CDK D004
## 308        Aurora Kinase D004
## 309                  Raf D004
## 310                 &lt;NA&gt; D004
## 311                  PKC D004
## 312                  JNK D004
## 313                c-Met D004
## 314                  Src D004
## 315                  CDK D004
## 316                VEGFR D004
## 317                  FAK D004
## 318                 EGFR D004
## 319                  Raf D004
## 320             p38 MAPK D004
## 321                  MEK D004
## 322        Aurora Kinase D004
## 323  Hedgehog/Smoothened D004
## 324                 FLT3 D004
## 325                GSK-3 D004
## 326                VEGFR D004
## 327                 mTOR D004
## 328                c-Met D004
## 329                  CDK D004
## 330                 PI3K D004
## 331                 FLT3 D004
## 332                  JAK D004
## 333                 PI3K D004
## 334        TGF-beta/Smad D004
## 335                 ROCK D004
## 336                  Akt D004
## 337                GSK-3 D004
## 338                c-Met D004
## 339                VEGFR D004
## 340                  JAK D004
## 341                  JAK D004
## 342                 mTOR D004
## 343                  MEK D004
## 344                  Akt D004
## 345                VEGFR D004
## 346                GSK-3 D004
## 347                 EGFR D004
## 348                PDGFR D004
## 349                  MEK D004
## 350                  ERK D004
## 351                  Akt D004
## 352                  JNK D004
## 353                 EGFR D004
## 354                VEGFR D004
## 355              ATM/ATR D004
## 356              ATM/ATR D004
## 357                  Raf D004
## 358  Hedgehog/Smoothened D004
## 359                  PLK D004
## 360                 PI3K D004
## 361                 PI3K D004
## 362                  ERK D004
## 363        Aurora Kinase D004
## 364             p38 MAPK D004
## 365             p38 MAPK D004
## 366                 mTOR D004
## 367                  Src D004
## 368                  JAK D004
## 369     Wnt/beta-catenin D004
## 370     Wnt/beta-catenin D004
## 371     Wnt/beta-catenin D004
## 372                  JAK D004
## 373                 mTOR D004
## 374                 mTOR D004
## 375                 EGFR D004
## 376                 EGFR D004
## 377                 AMPK D004
## 378                 EGFR D004
## 379     Wnt/beta-catenin D004
## 380                  JAK D004
## 381                  ERK D004
## 382                 ROCK D004
## 383                 PI3K D004
## 384      Gamma-secretase D004
## 385                VEGFR D004
## 386                VEGFR D004
## 387                  Raf D004
## 388                  JAK D004
## 389        Aurora Kinase D004
## 390                 mTOR D004
## 391                 PI3K D004
## 392                GSK-3 D004
## 393                 PI3K D004
## 394                  Akt D004
## 395                 AMPK D004
## 396                 PI3K D004
## 397                 AMPK D004
## 398                 EGFR D004
## 399                 &lt;NA&gt; D004
## 400               IGF-1R D004
## 401                 EGFR D004
## 402                 EGFR D004
## 403                  JAK D004
## 404                  Akt D004
## 405        Aurora Kinase D004
## 406                c-Met D004
## 407                c-Met D004
## 408        Aurora Kinase D004
## 409                 PI3K D004
## 410                c-Met D004
## 411                VEGFR D004
## 412                GSK-3 D004
## 413                 PI3K D004
## 414                 PI3K D004
## 415             p38 MAPK D004
## 416                 EGFR D004
## 417                  Akt D004
## 418                  CDK D004
## 419                  Akt D004
## 420              Bcr-Abl D004
## 421        Aurora Kinase D004
## 422      Gamma-secretase D004
## 423                  BTK D004
## 424                VEGFR D004
## 425                PDGFR D004
## 426                  Raf D004
## 427                  JAK D004
## 428              ATM/ATR D004
## 429                GSK-3 D004
## 430                  JAK D004
## 431                 mTOR D004
## 432                GSK-3 D004
## 433                PDGFR D004
## 434                 EGFR D004
## 435                  Akt D004
## 436                  CDK D004
## 437                 PI3K D004
## 438              ATM/ATR D004
## 439                 mTOR D004
## 440                  MEK D004
## 441                 EGFR D004
## 442                 EGFR D004
## 443        Aurora Kinase D004
## 444                  JAK D004
## 445                 PI3K D004
## 446                  PLK D004
## 447                  JNK D004
## 448            S6 Kinase D004
## 449                GSK-3 D004
## 450                GSK-3 D004
## 451             p38 MAPK D004
## 452                  MEK D004
## 453                 &lt;NA&gt; D004
## 454                 PI3K D004
## 455                  CDK D004
## 456               IGF-1R D004
## 457             p38 MAPK D004
## 458               IGF-1R D004
## 459                c-Met D004
## 460                c-Met D004
## 461  Hedgehog/Smoothened D004
## 462                  Src D004
## 463                VEGFR D004
## 464                VEGFR D004
## 465                  CDK D004
## 466                 EGFR D004
## 467                 PI3K D004
## 468                VEGFR D004
## 469                 &lt;NA&gt; D004
## 470                 PI3K D004
## 471                 PI3K D004
## 472                 mTOR D004
## 473                  Akt D004
## 474                VEGFR D004
## 475                  Raf D004
## 476                  JAK D004
## 477                  BTK D004
## 478              ATM/ATR D004
## 479                 PI3K D004
## 480                GSK-3 D004
## 481                GSK-3 D004
## 482                 &lt;NA&gt; D004
## 483                 EGFR D004
## 484                 EGFR D004
## 485                  BTK D004
## 486                 EGFR D004
## 487                  MEK D004
## 488                PDGFR D004
## 489                 EGFR D004
## 490                PDGFR D004
## 491                c-Met D004
## 492        Aurora Kinase D004
## 493                  JAK D004
## 494                 PI3K D004
## 495                  Raf D004
## 496                 EGFR D004
## 497        Aurora Kinase D004
## 498      Gamma-secretase D004
## 499                  Src D004
## 500              Bcr-Abl D004
## 501                  JAK D004
## 502                  CDK D004
## 503                 &lt;NA&gt; D004
## 504        Aurora Kinase D004
## 505                  PKC D004
## 506                  ERK D004
## 507                 AMPK D004
## 508                 mTOR D004
## 509                 mTOR D004
## 510                 ROCK D004
## 511     Wnt/beta-catenin D004
## 512                  JAK D004
## 513                  CDK D004
## 514                 &lt;NA&gt; D004
## 515                c-Met D004
## 516                  Syk D004
## 517                 FLT3 D004
## 518                  Akt D004
## 519                 mTOR D004
## 520                  Raf D004
## 521                 PI3K D004
## 522                 mTOR D004
## 523                 EGFR D004
## 524                 EGFR D004
## 525                  PKC D004
## 526              Bcr-Abl D004
## 527              Bcr-Abl D004
## 528                  PKC D004
## 529                c-Met D004
## 530               IGF-1R D004
## 531               IGF-1R D004
## 532                 PI3K D004
## 533                 PI3K D004
## 534                 PI3K D004
## 535                 ROCK D004
## 536                  PLK D004
## 537                 AMPK D004
## 538                  Akt D004
## 539                  Raf D004
## 540        TGF-beta/Smad D004
## 541              Bcr-Abl D004
## 542            S6 Kinase D004
## 543        Aurora Kinase D004
## 544                  PLK D004
## 545                  Akt D004
## 546                 PI3K D004
## 547                 AMPK D004
## 548                  Src D004
## 549     Wnt/beta-catenin D004
## 550                 EGFR D004
## 551                GSK-3 D004
## 552                PDGFR D004
## 553                GSK-3 D004
## 554                 mTOR D004
## 555                 PI3K D004
## 556     Wnt/beta-catenin D004
## 557     Wnt/beta-catenin D004
## 558                c-Met D004
## 559                  CDK D004
## 560                  JNK D004
## 561                  JNK D004
## 562        TGF-beta/Smad D004
## 563                VEGFR D004
## 564                VEGFR D004
## 565                 mTOR D004
## 566              ATM/ATR D004
## 567              ATM/ATR D004
## 568                 FLT3 D004
## 569                  Src D004
## 570     Wnt/beta-catenin D004
## 571                 EGFR D004
## 572                 EGFR D004
## 573                  CDK D004
## 574  Hedgehog/Smoothened D004
## 575        TGF-beta/Smad D004
## 576                VEGFR D004
## 577                  BTK D004
## 578     Wnt/beta-catenin D004
## 579                PDGFR D004
## 580            S6 Kinase D004
## 581            S6 Kinase D004
## 582             p38 MAPK D004
## 583                GSK-3 D004
## 584        TGF-beta/Smad D004
## 585                  JAK D004
## 586                  CDK D004
## 587                 PI3K D004
## 588                  Akt D004
## 589      Gamma-secretase D004
## 590                  MEK D004
## 591                c-Met D004
## 592                  CDK D004
## 593      Gamma-secretase D004
## 594                  Akt D004
## 595                c-Met D004
## 596        Aurora Kinase D004
## 597        Aurora Kinase D004
## 598                  Raf D004
## 599        Aurora Kinase D004
## 600                VEGFR D004
## 601              Bcr-Abl D004
## 602                VEGFR D004
## 603                  CDK D004
## 604               IGF-1R D004
## 605                VEGFR D004
## 606                  JAK D004
## 607                c-Met D004
## 608                  JAK D004
## 609                 EGFR D004
## 610                  BTK D004
## 611                 mTOR D004
## 612                 EGFR D004
## 613               IGF-1R D004
## 614                  CDK D004
## 615                  JAK D004
## 616                 mTOR D004
## 617                VEGFR D004
## 618                VEGFR D004
## 619                  MEK D004
## 620                 EGFR D004
## 621              Bcr-Abl D004
## 622                  MEK D004
## 623                  MEK D004
## 624                  MEK D004
## 625                 EGFR D004
## 626                  FAK D004
## 627                c-Met D004
## 628                 mTOR D004
## 629                  FAK D004
## 630            S6 Kinase D004
## 631  Hedgehog/Smoothened D004
## 632                  FAK D004
## 633                  FAK D004
## 634             p38 MAPK D004
## 635                c-Met D004
## 636        Aurora Kinase D004
## 637                  CDK D004
## 638                  CDK D004
## 639                 AMPK D004
## 640                  Akt D004
## 641                  Syk D004
## 642                 PI3K D004
## 643                 PI3K D004
## 644                 PI3K D004
## 645                  MEK D004
## 646        TGF-beta/Smad D004
## 647                  Raf D004
## 648                  Raf D004
## 649              Bcr-Abl D004
## 650                  Src D004
## 651                  Src D004
## 652                 mTOR D004
## 653               IGF-1R D004
## 654     Wnt/beta-catenin D004
## 655                  Syk D004
## 656                  CDK D004
## 657                 PI3K D004
## 658                 FLT3 D004
## 659                  Syk D004
## 660                  Syk D004
## 661                  CDK D004
## 662                  Raf D004
## 663                 mTOR D004
## 664                  MEK D004
## 665        TGF-beta/Smad D004
## 666                 mTOR D004
## 667                  PLK D004
## 668                 ROCK D004
## 669                  BTK D004
## 670                  PKC D004
## 671                  CDK D004
## 672                  PLK D004
## 673      Gamma-secretase D004
## 674                  CDK D004
## 675                  JAK D004
## 676                  JAK D004
## 677  Hedgehog/Smoothened D004
## 678                VEGFR D004
## 679                 PI3K D004
## 680                  Src D004
## 681             p38 MAPK D004
## 682             p38 MAPK D004
## 683                GSK-3 D004
## 684             p38 MAPK D004
## 685                GSK-3 D004
## 686        TGF-beta/Smad D004
## 687        TGF-beta/Smad D004
## 688        TGF-beta/Smad D004
## 689                  Raf D004
## 690                  ERK D004
## 691              ATM/ATR D004
## 692                  MEK D004
## 693      Gamma-secretase D004
## 694                VEGFR D004
## 695                VEGFR D004
## 696             p38 MAPK D004
## 697                  MEK D004
## 698                  CDK D004
## 699        Aurora Kinase D004
## 700                  Raf D004
## 701                 &lt;NA&gt; D004
## 702                  PKC D004
## 703                  JNK D004
## 704                c-Met D004
## 705                  Src D004
## 706                  CDK D004
## 707                VEGFR D004
## 708                  FAK D004
## 709                 EGFR D004
## 710                  Raf D004
## 711             p38 MAPK D004
## 712                  MEK D004
## 713        Aurora Kinase D004
## 714  Hedgehog/Smoothened D004
## 715                 FLT3 D004
## 716                GSK-3 D004
## 717                VEGFR D004
## 718                 mTOR D004
## 719                c-Met D004
## 720                  CDK D004
## 721                 PI3K D004
## 722                 FLT3 D004
## 723                  JAK D004
## 724                 PI3K D004
## 725        TGF-beta/Smad D004
## 726                 ROCK D004
## 727                  Akt D004
## 728                GSK-3 D004
## 729                c-Met D004
## 730                VEGFR D004
## 731                  JAK D004
## 732                  JAK D004
## 733                 mTOR D004
## 734                  MEK D004
## 735                  Akt D004
## 736                VEGFR D004
## 737                GSK-3 D004
## 738                 EGFR D004
## 739                PDGFR D004
## 740                  MEK D004
## 741                  ERK D004
## 742                  Akt D004
## 743                  JNK D004
## 744                 EGFR D004
## 745                VEGFR D004
## 746              ATM/ATR D004
## 747              ATM/ATR D004
## 748                  Raf D004
## 749  Hedgehog/Smoothened D004
## 750                  PLK D004
## 751                 PI3K D004
## 752                 PI3K D004
## 753                  ERK D004
## 754        Aurora Kinase D004
## 755             p38 MAPK D004
## 756             p38 MAPK D004
## 757                 mTOR D004
## 758                  Src D004
## 759                  JAK D004
## 760     Wnt/beta-catenin D004
## 761     Wnt/beta-catenin D004
## 762     Wnt/beta-catenin D004
## 763                  JAK D004
## 764                 mTOR D004
## 765                 mTOR D004
## 766                 EGFR D004
## 767                 EGFR D004
## 768                 AMPK D004
## 769                 EGFR D004
## 770     Wnt/beta-catenin D004
## 771                  JAK D004
## 772                  ERK D004
## 773                 ROCK D004
## 774                 PI3K D004
## 775      Gamma-secretase D004
## 776                VEGFR D004
## 777                VEGFR D004
## 778                  Raf D004
## 779                  JAK D004
## 780        Aurora Kinase D004
## 781                 mTOR D004
## 782                 PI3K D004
## 783                GSK-3 D007
## 784                 PI3K D007
## 785                  Akt D007
## 786                 AMPK D007
## 787                 PI3K D007
## 788                 AMPK D007
## 789                 EGFR D007
## 790                 &lt;NA&gt; D007
## 791               IGF-1R D007
## 792                 EGFR D007
## 793                 EGFR D007
## 794                  JAK D007
## 795                  Akt D007
## 796        Aurora Kinase D007
## 797                c-Met D007
## 798                c-Met D007
## 799        Aurora Kinase D007
## 800                 PI3K D007
## 801                c-Met D007
## 802                VEGFR D007
## 803                GSK-3 D007
## 804                 PI3K D007
## 805                 PI3K D007
## 806             p38 MAPK D007
## 807                 EGFR D007
## 808                  Akt D007
## 809                  CDK D007
## 810                  Akt D007
## 811              Bcr-Abl D007
## 812        Aurora Kinase D007
## 813      Gamma-secretase D007
## 814                  BTK D007
## 815                VEGFR D007
## 816                PDGFR D007
## 817                  Raf D007
## 818                  JAK D007
## 819              ATM/ATR D007
## 820                GSK-3 D007
## 821                  JAK D007
## 822                 mTOR D007
## 823                GSK-3 D007
## 824                PDGFR D007
## 825                 EGFR D007
## 826                  Akt D007
## 827                  CDK D007
## 828                 PI3K D007
## 829              ATM/ATR D007
## 830                 mTOR D007
## 831                  MEK D007
## 832                 EGFR D007
## 833                 EGFR D007
## 834        Aurora Kinase D007
## 835                  JAK D007
## 836                 PI3K D007
## 837                  PLK D007
## 838                  JNK D007
## 839            S6 Kinase D007
## 840                GSK-3 D007
## 841                GSK-3 D007
## 842             p38 MAPK D007
## 843                  MEK D007
## 844                 &lt;NA&gt; D007
## 845                 PI3K D007
## 846                  CDK D007
## 847               IGF-1R D007
## 848             p38 MAPK D007
## 849               IGF-1R D007
## 850                c-Met D007
## 851                c-Met D007
## 852  Hedgehog/Smoothened D007
## 853                  Src D007
## 854                VEGFR D007
## 855                VEGFR D007
## 856                  CDK D007
## 857                 EGFR D007
## 858                 PI3K D007
## 859                VEGFR D007
## 860                 &lt;NA&gt; D007
## 861                 PI3K D007
## 862                 PI3K D007
## 863                 mTOR D007
## 864                  Akt D007
## 865                VEGFR D007
## 866                  Raf D007
## 867                  JAK D007
## 868                  BTK D007
## 869              ATM/ATR D007
## 870                 PI3K D007
## 871                GSK-3 D007
## 872                GSK-3 D007
## 873                 &lt;NA&gt; D007
## 874                 EGFR D007
## 875                 EGFR D007
## 876                  BTK D007
## 877                 EGFR D007
## 878                  MEK D007
## 879                PDGFR D007
## 880                 EGFR D007
## 881                PDGFR D007
## 882                c-Met D007
## 883        Aurora Kinase D007
## 884                  JAK D007
## 885                 PI3K D007
## 886                  Raf D007
## 887                 EGFR D007
## 888        Aurora Kinase D007
## 889      Gamma-secretase D007
## 890                  Src D007
## 891              Bcr-Abl D007
## 892                  JAK D007
## 893                  CDK D007
## 894                 &lt;NA&gt; D007
## 895        Aurora Kinase D007
## 896                  PKC D007
## 897                  ERK D007
## 898                 AMPK D007
## 899                 mTOR D007
## 900                 mTOR D007
## 901                 ROCK D007
## 902     Wnt/beta-catenin D007
## 903                  JAK D007
## 904                  CDK D007
## 905                 &lt;NA&gt; D007
## 906                c-Met D007
## 907                  Syk D007
## 908                 FLT3 D007
## 909                  Akt D007
## 910                 mTOR D007
## 911                  Raf D007
## 912                 PI3K D007
## 913                 mTOR D007
## 914                 EGFR D007
## 915                 EGFR D007
## 916                  PKC D007
## 917              Bcr-Abl D007
## 918              Bcr-Abl D007
## 919                  PKC D007
## 920                c-Met D007
## 921               IGF-1R D007
## 922               IGF-1R D007
## 923                 PI3K D007
## 924                 PI3K D007
## 925                 PI3K D007
## 926                 ROCK D007
## 927                  PLK D007
## 928                 AMPK D007
## 929                  Akt D007
## 930                  Raf D007
## 931        TGF-beta/Smad D007
## 932              Bcr-Abl D007
## 933            S6 Kinase D007
## 934        Aurora Kinase D007
## 935                  PLK D007
## 936                  Akt D007
## 937                 PI3K D007
## 938                 AMPK D007
## 939                  Src D007
## 940     Wnt/beta-catenin D007
## 941                 EGFR D007
## 942                GSK-3 D007
## 943                PDGFR D007
## 944                GSK-3 D007
## 945                 mTOR D007
## 946                 PI3K D007
## 947     Wnt/beta-catenin D007
## 948     Wnt/beta-catenin D007
## 949                c-Met D007
## 950                  CDK D007
## 951                  JNK D007
## 952                  JNK D007
## 953        TGF-beta/Smad D007
## 954                VEGFR D007
## 955                VEGFR D007
## 956                 mTOR D007
## 957              ATM/ATR D007
## 958              ATM/ATR D007
## 959                 FLT3 D007
## 960                  Src D007
## 961     Wnt/beta-catenin D007
## 962                 EGFR D007
## 963                 EGFR D007
## 964                  CDK D007
## 965  Hedgehog/Smoothened D007
## 966        TGF-beta/Smad D007
## 967                VEGFR D007
## 968                  BTK D007
## 969     Wnt/beta-catenin D007
## 970                PDGFR D007
## 971            S6 Kinase D007
## 972            S6 Kinase D007
## 973             p38 MAPK D007
## 974                GSK-3 D007
## 975        TGF-beta/Smad D007
## 976                  JAK D007
## 977                  CDK D007
## 978                 PI3K D007
## 979                  Akt D007
## 980      Gamma-secretase D007
## 981                  MEK D007
## 982                c-Met D007
## 983                  CDK D007
## 984      Gamma-secretase D007
## 985                  Akt D007
## 986                c-Met D007
## 987        Aurora Kinase D007
## 988        Aurora Kinase D007
## 989                  Raf D007
## 990        Aurora Kinase D007
## 991                VEGFR D007
## 992              Bcr-Abl D007
## 993                VEGFR D007
## 994                  CDK D007
## 995               IGF-1R D007
## 996                VEGFR D007
## 997                  JAK D007
## 998                c-Met D007
## 999                  JAK D007
## 1000                EGFR D007
## 1001                 BTK D007
## 1002                mTOR D007
## 1003                EGFR D007
## 1004              IGF-1R D007
## 1005                 CDK D007
## 1006                 JAK D007
## 1007                mTOR D007
## 1008               VEGFR D007
## 1009               VEGFR D007
## 1010                 MEK D007
## 1011                EGFR D007
## 1012             Bcr-Abl D007
## 1013                 MEK D007
## 1014                 MEK D007
## 1015                 MEK D007
## 1016                EGFR D007
## 1017                 FAK D007
## 1018               c-Met D007
## 1019                mTOR D007
## 1020                 FAK D007
## 1021           S6 Kinase D007
## 1022 Hedgehog/Smoothened D007
## 1023                 FAK D007
## 1024                 FAK D007
## 1025            p38 MAPK D007
## 1026               c-Met D007
## 1027       Aurora Kinase D007
## 1028                 CDK D007
## 1029                 CDK D007
## 1030                AMPK D007
## 1031                 Akt D007
## 1032                 Syk D007
## 1033                PI3K D007
## 1034                PI3K D007
## 1035                PI3K D007
## 1036                 MEK D007
## 1037       TGF-beta/Smad D007
## 1038                 Raf D007
## 1039                 Raf D007
## 1040             Bcr-Abl D007
## 1041                 Src D007
## 1042                 Src D007
## 1043                mTOR D007
## 1044              IGF-1R D007
## 1045    Wnt/beta-catenin D007
## 1046                 Syk D007
## 1047                 CDK D007
## 1048                PI3K D007
## 1049                FLT3 D007
## 1050                 Syk D007
## 1051                 Syk D007
## 1052                 CDK D007
## 1053                 Raf D007
## 1054                mTOR D007
## 1055                 MEK D007
## 1056       TGF-beta/Smad D007
## 1057                mTOR D007
## 1058                 PLK D007
## 1059                ROCK D007
## 1060                 BTK D007
## 1061                 PKC D007
## 1062                 CDK D007
## 1063                 PLK D007
## 1064     Gamma-secretase D007
## 1065                 CDK D007
## 1066                 JAK D007
## 1067                 JAK D007
## 1068 Hedgehog/Smoothened D007
## 1069               VEGFR D007
## 1070                PI3K D007
## 1071                 Src D007
## 1072            p38 MAPK D007
## 1073            p38 MAPK D007
## 1074               GSK-3 D007
## 1075            p38 MAPK D007
## 1076               GSK-3 D007
## 1077       TGF-beta/Smad D007
## 1078       TGF-beta/Smad D007
## 1079       TGF-beta/Smad D007
## 1080                 Raf D007
## 1081                 ERK D007
## 1082             ATM/ATR D007
## 1083                 MEK D007
## 1084     Gamma-secretase D007
## 1085               VEGFR D007
## 1086               VEGFR D007
## 1087            p38 MAPK D007
## 1088                 MEK D007
## 1089                 CDK D007
## 1090       Aurora Kinase D007
## 1091                 Raf D007
## 1092                &lt;NA&gt; D007
## 1093                 PKC D007
## 1094                 JNK D007
## 1095               c-Met D007
## 1096                 Src D007
## 1097                 CDK D007
## 1098               VEGFR D007
## 1099                 FAK D007
## 1100                EGFR D007
## 1101                 Raf D007
## 1102            p38 MAPK D007
## 1103                 MEK D007
## 1104       Aurora Kinase D007
## 1105 Hedgehog/Smoothened D007
## 1106                FLT3 D007
## 1107               GSK-3 D007
## 1108               VEGFR D007
## 1109                mTOR D007
## 1110               c-Met D007
## 1111                 CDK D007
## 1112                PI3K D007
## 1113                FLT3 D007
## 1114                 JAK D007
## 1115                PI3K D007
## 1116       TGF-beta/Smad D007
## 1117                ROCK D007
## 1118                 Akt D007
## 1119               GSK-3 D007
## 1120               c-Met D007
## 1121               VEGFR D007
## 1122                 JAK D007
## 1123                 JAK D007
## 1124                mTOR D007
## 1125                 MEK D007
## 1126                 Akt D007
## 1127               VEGFR D007
## 1128               GSK-3 D007
## 1129                EGFR D007
## 1130               PDGFR D007
## 1131                 MEK D007
## 1132                 ERK D007
## 1133                 Akt D007
## 1134                 JNK D007
## 1135                EGFR D007
## 1136               VEGFR D007
## 1137             ATM/ATR D007
## 1138             ATM/ATR D007
## 1139                 Raf D007
## 1140 Hedgehog/Smoothened D007
## 1141                 PLK D007
## 1142                PI3K D007
## 1143                PI3K D007
## 1144                 ERK D007
## 1145       Aurora Kinase D007
## 1146            p38 MAPK D007
## 1147            p38 MAPK D007
## 1148                mTOR D007
## 1149                 Src D007
## 1150                 JAK D007
## 1151    Wnt/beta-catenin D007
## 1152    Wnt/beta-catenin D007
## 1153    Wnt/beta-catenin D007
## 1154                 JAK D007
## 1155                mTOR D007
## 1156                mTOR D007
## 1157                EGFR D007
## 1158                EGFR D007
## 1159                AMPK D007
## 1160                EGFR D007
## 1161    Wnt/beta-catenin D007
## 1162                 JAK D007
## 1163                 ERK D007
## 1164                ROCK D007
## 1165                PI3K D007
## 1166     Gamma-secretase D007
## 1167               VEGFR D007
## 1168               VEGFR D007
## 1169                 Raf D007
## 1170                 JAK D007
## 1171       Aurora Kinase D007
## 1172                mTOR D007
## 1173                PI3K D007
## 1174               GSK-3 D007
## 1175                PI3K D007
## 1176                 Akt D007
## 1177                AMPK D007
## 1178                PI3K D007
## 1179                AMPK D007
## 1180                EGFR D007
## 1181                &lt;NA&gt; D007
## 1182              IGF-1R D007
## 1183                EGFR D007
## 1184                EGFR D007
## 1185                 JAK D007
## 1186                 Akt D007
## 1187       Aurora Kinase D007
## 1188               c-Met D007
## 1189               c-Met D007
## 1190       Aurora Kinase D007
## 1191                PI3K D007
## 1192               c-Met D007
## 1193               VEGFR D007
## 1194               GSK-3 D007
## 1195                PI3K D007
## 1196                PI3K D007
## 1197            p38 MAPK D007
## 1198                EGFR D007
## 1199                 Akt D007
## 1200                 CDK D007
## 1201                 Akt D007
## 1202             Bcr-Abl D007
## 1203       Aurora Kinase D007
## 1204     Gamma-secretase D007
## 1205                 BTK D007
## 1206               VEGFR D007
## 1207               PDGFR D007
## 1208                 Raf D007
## 1209                 JAK D007
## 1210             ATM/ATR D007
## 1211               GSK-3 D007
## 1212                 JAK D007
## 1213                mTOR D007
## 1214               GSK-3 D007
## 1215               PDGFR D007
## 1216                EGFR D007
## 1217                 Akt D007
## 1218                 CDK D007
## 1219                PI3K D007
## 1220             ATM/ATR D007
## 1221                mTOR D007
## 1222                 MEK D007
## 1223                EGFR D007
## 1224                EGFR D007
## 1225       Aurora Kinase D007
## 1226                 JAK D007
## 1227                PI3K D007
## 1228                 PLK D007
## 1229                 JNK D007
## 1230           S6 Kinase D007
## 1231               GSK-3 D007
## 1232               GSK-3 D007
## 1233            p38 MAPK D007
## 1234                 MEK D007
## 1235                &lt;NA&gt; D007
## 1236                PI3K D007
## 1237                 CDK D007
## 1238              IGF-1R D007
## 1239            p38 MAPK D007
## 1240              IGF-1R D007
## 1241               c-Met D007
## 1242               c-Met D007
## 1243 Hedgehog/Smoothened D007
## 1244                 Src D007
## 1245               VEGFR D007
## 1246               VEGFR D007
## 1247                 CDK D007
## 1248                EGFR D007
## 1249                PI3K D007
## 1250               VEGFR D007
## 1251                &lt;NA&gt; D007
## 1252                PI3K D007
## 1253                PI3K D007
## 1254                mTOR D007
## 1255                 Akt D007
## 1256               VEGFR D007
## 1257                 Raf D007
## 1258                 JAK D007
## 1259                 BTK D007
## 1260             ATM/ATR D007
## 1261                PI3K D007
## 1262               GSK-3 D007
## 1263               GSK-3 D007
## 1264                &lt;NA&gt; D007
## 1265                EGFR D007
## 1266                EGFR D007
## 1267                 BTK D007
## 1268                EGFR D007
## 1269                 MEK D007
## 1270               PDGFR D007
## 1271                EGFR D007
## 1272               PDGFR D007
## 1273               c-Met D007
## 1274       Aurora Kinase D007
## 1275                 JAK D007
## 1276                PI3K D007
## 1277                 Raf D007
## 1278                EGFR D007
## 1279       Aurora Kinase D007
## 1280     Gamma-secretase D007
## 1281                 Src D007
## 1282             Bcr-Abl D007
## 1283                 JAK D007
## 1284                 CDK D007
## 1285                &lt;NA&gt; D007
## 1286       Aurora Kinase D007
## 1287                 PKC D007
## 1288                 ERK D007
## 1289                AMPK D007
## 1290                mTOR D007
## 1291                mTOR D007
## 1292                ROCK D007
## 1293    Wnt/beta-catenin D007
## 1294                 JAK D007
## 1295                 CDK D007
## 1296                &lt;NA&gt; D007
## 1297               c-Met D007
## 1298                 Syk D007
## 1299                FLT3 D007
## 1300                 Akt D007
## 1301                mTOR D007
## 1302                 Raf D007
## 1303                PI3K D007
## 1304                mTOR D007
## 1305                EGFR D007
## 1306                EGFR D007
## 1307                 PKC D007
## 1308             Bcr-Abl D007
## 1309             Bcr-Abl D007
## 1310                 PKC D007
## 1311               c-Met D007
## 1312              IGF-1R D007
## 1313              IGF-1R D007
## 1314                PI3K D007
## 1315                PI3K D007
## 1316                PI3K D007
## 1317                ROCK D007
## 1318                 PLK D007
## 1319                AMPK D007
## 1320                 Akt D007
## 1321                 Raf D007
## 1322       TGF-beta/Smad D007
## 1323             Bcr-Abl D007
## 1324           S6 Kinase D007
## 1325       Aurora Kinase D007
## 1326                 PLK D007
## 1327                 Akt D007
## 1328                PI3K D007
## 1329                AMPK D007
## 1330                 Src D007
## 1331    Wnt/beta-catenin D007
## 1332                EGFR D007
## 1333               GSK-3 D007
## 1334               PDGFR D007
## 1335               GSK-3 D007
## 1336                mTOR D007
## 1337                PI3K D007
## 1338    Wnt/beta-catenin D007
## 1339    Wnt/beta-catenin D007
## 1340               c-Met D007
## 1341                 CDK D007
## 1342                 JNK D007
## 1343                 JNK D007
## 1344       TGF-beta/Smad D007
## 1345               VEGFR D007
## 1346               VEGFR D007
## 1347                mTOR D007
## 1348             ATM/ATR D007
## 1349             ATM/ATR D007
## 1350                FLT3 D007
## 1351                 Src D007
## 1352    Wnt/beta-catenin D007
## 1353                EGFR D007
## 1354                EGFR D007
## 1355                 CDK D007
## 1356 Hedgehog/Smoothened D007
## 1357       TGF-beta/Smad D007
## 1358               VEGFR D007
## 1359                 BTK D007
## 1360    Wnt/beta-catenin D007
## 1361               PDGFR D007
## 1362           S6 Kinase D007
## 1363           S6 Kinase D007
## 1364            p38 MAPK D007
## 1365               GSK-3 D007
## 1366       TGF-beta/Smad D007
## 1367                 JAK D007
## 1368                 CDK D007
## 1369                PI3K D007
## 1370                 Akt D007
## 1371     Gamma-secretase D007
## 1372                 MEK D007
## 1373               c-Met D007
## 1374                 CDK D007
## 1375     Gamma-secretase D007
## 1376                 Akt D007
## 1377               c-Met D007
## 1378       Aurora Kinase D007
## 1379       Aurora Kinase D007
## 1380                 Raf D007
## 1381       Aurora Kinase D007
## 1382               VEGFR D007
## 1383             Bcr-Abl D007
## 1384               VEGFR D007
## 1385                 CDK D007
## 1386              IGF-1R D007
## 1387               VEGFR D007
## 1388                 JAK D007
## 1389               c-Met D007
## 1390                 JAK D007
## 1391                EGFR D007
## 1392                 BTK D007
## 1393                mTOR D007
## 1394                EGFR D007
## 1395              IGF-1R D007
## 1396                 CDK D007
## 1397                 JAK D007
## 1398                mTOR D007
## 1399               VEGFR D007
## 1400               VEGFR D007
## 1401                 MEK D007
## 1402                EGFR D007
## 1403             Bcr-Abl D007
## 1404                 MEK D007
## 1405                 MEK D007
## 1406                 MEK D007
## 1407                EGFR D007
## 1408                 FAK D007
## 1409               c-Met D007
## 1410                mTOR D007
## 1411                 FAK D007
## 1412           S6 Kinase D007
## 1413 Hedgehog/Smoothened D007
## 1414                 FAK D007
## 1415                 FAK D007
## 1416            p38 MAPK D007
## 1417               c-Met D007
## 1418       Aurora Kinase D007
## 1419                 CDK D007
## 1420                 CDK D007
## 1421                AMPK D007
## 1422                 Akt D007
## 1423                 Syk D007
## 1424                PI3K D007
## 1425                PI3K D007
## 1426                PI3K D007
## 1427                 MEK D007
## 1428       TGF-beta/Smad D007
## 1429                 Raf D007
## 1430                 Raf D007
## 1431             Bcr-Abl D007
## 1432                 Src D007
## 1433                 Src D007
## 1434                mTOR D007
## 1435              IGF-1R D007
## 1436    Wnt/beta-catenin D007
## 1437                 Syk D007
## 1438                 CDK D007
## 1439                PI3K D007
## 1440                FLT3 D007
## 1441                 Syk D007
## 1442                 Syk D007
## 1443                 CDK D007
## 1444                 Raf D007
## 1445                mTOR D007
## 1446                 MEK D007
## 1447       TGF-beta/Smad D007
## 1448                mTOR D007
## 1449                 PLK D007
## 1450                ROCK D007
## 1451                 BTK D007
## 1452                 PKC D007
## 1453                 CDK D007
## 1454                 PLK D007
## 1455     Gamma-secretase D007
## 1456                 CDK D007
## 1457                 JAK D007
## 1458                 JAK D007
## 1459 Hedgehog/Smoothened D007
## 1460               VEGFR D007
## 1461                PI3K D007
## 1462                 Src D007
## 1463            p38 MAPK D007
## 1464            p38 MAPK D007
## 1465               GSK-3 D007
## 1466            p38 MAPK D007
## 1467               GSK-3 D007
## 1468       TGF-beta/Smad D007
## 1469       TGF-beta/Smad D007
## 1470       TGF-beta/Smad D007
## 1471                 Raf D007
## 1472                 ERK D007
## 1473             ATM/ATR D007
## 1474                 MEK D007
## 1475     Gamma-secretase D007
## 1476               VEGFR D007
## 1477               VEGFR D007
## 1478            p38 MAPK D007
## 1479                 MEK D007
## 1480                 CDK D007
## 1481       Aurora Kinase D007
## 1482                 Raf D007
## 1483                &lt;NA&gt; D007
## 1484                 PKC D007
## 1485                 JNK D007
## 1486               c-Met D007
## 1487                 Src D007
## 1488                 CDK D007
## 1489               VEGFR D007
## 1490                 FAK D007
## 1491                EGFR D007
## 1492                 Raf D007
## 1493            p38 MAPK D007
## 1494                 MEK D007
## 1495       Aurora Kinase D007
## 1496 Hedgehog/Smoothened D007
## 1497                FLT3 D007
## 1498               GSK-3 D007
## 1499               VEGFR D007
## 1500                mTOR D007
## 1501               c-Met D007
## 1502                 CDK D007
## 1503                PI3K D007
## 1504                FLT3 D007
## 1505                 JAK D007
## 1506                PI3K D007
## 1507       TGF-beta/Smad D007
## 1508                ROCK D007
## 1509                 Akt D007
## 1510               GSK-3 D007
## 1511               c-Met D007
## 1512               VEGFR D007
## 1513                 JAK D007
## 1514                 JAK D007
## 1515                mTOR D007
## 1516                 MEK D007
## 1517                 Akt D007
## 1518               VEGFR D007
## 1519               GSK-3 D007
## 1520                EGFR D007
## 1521               PDGFR D007
## 1522                 MEK D007
## 1523                 ERK D007
## 1524                 Akt D007
## 1525                 JNK D007
## 1526                EGFR D007
## 1527               VEGFR D007
## 1528             ATM/ATR D007
## 1529             ATM/ATR D007
## 1530                 Raf D007
## 1531 Hedgehog/Smoothened D007
## 1532                 PLK D007
## 1533                PI3K D007
## 1534                PI3K D007
## 1535                 ERK D007
## 1536       Aurora Kinase D007
## 1537            p38 MAPK D007
## 1538            p38 MAPK D007
## 1539                mTOR D007
## 1540                 Src D007
## 1541                 JAK D007
## 1542    Wnt/beta-catenin D007
## 1543    Wnt/beta-catenin D007
## 1544    Wnt/beta-catenin D007
## 1545                 JAK D007
## 1546                mTOR D007
## 1547                mTOR D007
## 1548                EGFR D007
## 1549                EGFR D007
## 1550                AMPK D007
## 1551                EGFR D007
## 1552    Wnt/beta-catenin D007
## 1553                 JAK D007
## 1554                 ERK D007
## 1555                ROCK D007
## 1556                PI3K D007
## 1557     Gamma-secretase D007
## 1558               VEGFR D007
## 1559               VEGFR D007
## 1560                 Raf D007
## 1561                 JAK D007
## 1562       Aurora Kinase D007
## 1563                mTOR D007
## 1564                PI3K D007
## 1565               GSK-3 D010
## 1566                PI3K D010
## 1567                 Akt D010
## 1568                AMPK D010
## 1569                PI3K D010
## 1570                AMPK D010
## 1571                EGFR D010
## 1572                &lt;NA&gt; D010
## 1573              IGF-1R D010
## 1574                EGFR D010
## 1575                EGFR D010
## 1576                 JAK D010
## 1577                 Akt D010
## 1578       Aurora Kinase D010
## 1579               c-Met D010
## 1580               c-Met D010
## 1581       Aurora Kinase D010
## 1582                PI3K D010
## 1583               c-Met D010
## 1584               VEGFR D010
## 1585               GSK-3 D010
## 1586                PI3K D010
## 1587                PI3K D010
## 1588            p38 MAPK D010
## 1589                EGFR D010
## 1590                 Akt D010
## 1591                 CDK D010
## 1592                 Akt D010
## 1593             Bcr-Abl D010
## 1594       Aurora Kinase D010
## 1595     Gamma-secretase D010
## 1596                 BTK D010
## 1597               VEGFR D010
## 1598               PDGFR D010
## 1599                 Raf D010
## 1600                 JAK D010
## 1601             ATM/ATR D010
## 1602               GSK-3 D010
## 1603                 JAK D010
## 1604                mTOR D010
## 1605               GSK-3 D010
## 1606               PDGFR D010
## 1607                EGFR D010
## 1608                 Akt D010
## 1609                 CDK D010
## 1610                PI3K D010
## 1611             ATM/ATR D010
## 1612                mTOR D010
## 1613                 MEK D010
## 1614                EGFR D010
## 1615                EGFR D010
## 1616       Aurora Kinase D010
## 1617                 JAK D010
## 1618                PI3K D010
## 1619                 PLK D010
## 1620                 JNK D010
## 1621           S6 Kinase D010
## 1622               GSK-3 D010
## 1623               GSK-3 D010
## 1624            p38 MAPK D010
## 1625                 MEK D010
## 1626                &lt;NA&gt; D010
## 1627                PI3K D010
## 1628                 CDK D010
## 1629              IGF-1R D010
## 1630            p38 MAPK D010
## 1631              IGF-1R D010
## 1632               c-Met D010
## 1633               c-Met D010
## 1634 Hedgehog/Smoothened D010
## 1635                 Src D010
## 1636               VEGFR D010
## 1637               VEGFR D010
## 1638                 CDK D010
## 1639                EGFR D010
## 1640                PI3K D010
## 1641               VEGFR D010
## 1642                &lt;NA&gt; D010
## 1643                PI3K D010
## 1644                PI3K D010
## 1645                mTOR D010
## 1646                 Akt D010
## 1647               VEGFR D010
## 1648                 Raf D010
## 1649                 JAK D010
## 1650                 BTK D010
## 1651             ATM/ATR D010
## 1652                PI3K D010
## 1653               GSK-3 D010
## 1654               GSK-3 D010
## 1655                &lt;NA&gt; D010
## 1656                EGFR D010
## 1657                EGFR D010
## 1658                 BTK D010
## 1659                EGFR D010
## 1660                 MEK D010
## 1661               PDGFR D010
## 1662                EGFR D010
## 1663               PDGFR D010
## 1664               c-Met D010
## 1665       Aurora Kinase D010
## 1666                 JAK D010
## 1667                PI3K D010
## 1668                 Raf D010
## 1669                EGFR D010
## 1670       Aurora Kinase D010
## 1671     Gamma-secretase D010
## 1672                 Src D010
## 1673             Bcr-Abl D010
## 1674                 JAK D010
## 1675                 CDK D010
## 1676                &lt;NA&gt; D010
## 1677       Aurora Kinase D010
## 1678                 PKC D010
## 1679                 ERK D010
## 1680                AMPK D010
## 1681                mTOR D010
## 1682                mTOR D010
## 1683                ROCK D010
## 1684    Wnt/beta-catenin D010
## 1685                 JAK D010
## 1686                 CDK D010
## 1687                &lt;NA&gt; D010
## 1688               c-Met D010
## 1689                 Syk D010
## 1690                FLT3 D010
## 1691                 Akt D010
## 1692                mTOR D010
## 1693                 Raf D010
## 1694                PI3K D010
## 1695                mTOR D010
## 1696                EGFR D010
## 1697                EGFR D010
## 1698                 PKC D010
## 1699             Bcr-Abl D010
## 1700             Bcr-Abl D010
## 1701                 PKC D010
## 1702               c-Met D010
## 1703              IGF-1R D010
## 1704              IGF-1R D010
## 1705                PI3K D010
## 1706                PI3K D010
## 1707                PI3K D010
## 1708                ROCK D010
## 1709                 PLK D010
## 1710                AMPK D010
## 1711                 Akt D010
## 1712                 Raf D010
## 1713       TGF-beta/Smad D010
## 1714             Bcr-Abl D010
## 1715           S6 Kinase D010
## 1716       Aurora Kinase D010
## 1717                 PLK D010
## 1718                 Akt D010
## 1719                PI3K D010
## 1720                AMPK D010
## 1721                 Src D010
## 1722    Wnt/beta-catenin D010
## 1723                EGFR D010
## 1724               GSK-3 D010
## 1725               PDGFR D010
## 1726               GSK-3 D010
## 1727                mTOR D010
## 1728                PI3K D010
## 1729    Wnt/beta-catenin D010
## 1730    Wnt/beta-catenin D010
## 1731               c-Met D010
## 1732                 CDK D010
## 1733                 JNK D010
## 1734                 JNK D010
## 1735       TGF-beta/Smad D010
## 1736               VEGFR D010
## 1737               VEGFR D010
## 1738                mTOR D010
## 1739             ATM/ATR D010
## 1740             ATM/ATR D010
## 1741                FLT3 D010
## 1742                 Src D010
## 1743    Wnt/beta-catenin D010
## 1744                EGFR D010
## 1745                EGFR D010
## 1746                 CDK D010
## 1747 Hedgehog/Smoothened D010
## 1748       TGF-beta/Smad D010
## 1749               VEGFR D010
## 1750                 BTK D010
## 1751    Wnt/beta-catenin D010
## 1752               PDGFR D010
## 1753           S6 Kinase D010
## 1754           S6 Kinase D010
## 1755            p38 MAPK D010
## 1756               GSK-3 D010
## 1757       TGF-beta/Smad D010
## 1758                 JAK D010
## 1759                 CDK D010
## 1760                PI3K D010
## 1761                 Akt D010
## 1762     Gamma-secretase D010
## 1763                 MEK D010
## 1764               c-Met D010
## 1765                 CDK D010
## 1766     Gamma-secretase D010
## 1767                 Akt D010
## 1768               c-Met D010
## 1769       Aurora Kinase D010
## 1770       Aurora Kinase D010
## 1771                 Raf D010
## 1772       Aurora Kinase D010
## 1773               VEGFR D010
## 1774             Bcr-Abl D010
## 1775               VEGFR D010
## 1776                 CDK D010
## 1777              IGF-1R D010
## 1778               VEGFR D010
## 1779                 JAK D010
## 1780               c-Met D010
## 1781                 JAK D010
## 1782                EGFR D010
## 1783                 BTK D010
## 1784                mTOR D010
## 1785                EGFR D010
## 1786              IGF-1R D010
## 1787                 CDK D010
## 1788                 JAK D010
## 1789                mTOR D010
## 1790               VEGFR D010
## 1791               VEGFR D010
## 1792                 MEK D010
## 1793                EGFR D010
## 1794             Bcr-Abl D010
## 1795                 MEK D010
## 1796                 MEK D010
## 1797                 MEK D010
## 1798                EGFR D010
## 1799                 FAK D010
## 1800               c-Met D010
## 1801                mTOR D010
## 1802                 FAK D010
## 1803           S6 Kinase D010
## 1804 Hedgehog/Smoothened D010
## 1805                 FAK D010
## 1806                 FAK D010
## 1807            p38 MAPK D010
## 1808               c-Met D010
## 1809       Aurora Kinase D010
## 1810                 CDK D010
## 1811                 CDK D010
## 1812                AMPK D010
## 1813                 Akt D010
## 1814                 Syk D010
## 1815                PI3K D010
## 1816                PI3K D010
## 1817                PI3K D010
## 1818                 MEK D010
## 1819       TGF-beta/Smad D010
## 1820                 Raf D010
## 1821                 Raf D010
## 1822             Bcr-Abl D010
## 1823                 Src D010
## 1824                 Src D010
## 1825                mTOR D010
## 1826              IGF-1R D010
## 1827    Wnt/beta-catenin D010
## 1828                 Syk D010
## 1829                 CDK D010
## 1830                PI3K D010
## 1831                FLT3 D010
## 1832                 Syk D010
## 1833                 Syk D010
## 1834                 CDK D010
## 1835                 Raf D010
## 1836                mTOR D010
## 1837                 MEK D010
## 1838       TGF-beta/Smad D010
## 1839                mTOR D010
## 1840                 PLK D010
## 1841                ROCK D010
## 1842                 BTK D010
## 1843                 PKC D010
## 1844                 CDK D010
## 1845                 PLK D010
## 1846     Gamma-secretase D010
## 1847                 CDK D010
## 1848                 JAK D010
## 1849                 JAK D010
## 1850 Hedgehog/Smoothened D010
## 1851               VEGFR D010
## 1852                PI3K D010
## 1853                 Src D010
## 1854            p38 MAPK D010
## 1855            p38 MAPK D010
## 1856               GSK-3 D010
## 1857            p38 MAPK D010
## 1858               GSK-3 D010
## 1859       TGF-beta/Smad D010
## 1860       TGF-beta/Smad D010
## 1861       TGF-beta/Smad D010
## 1862                 Raf D010
## 1863                 ERK D010
## 1864             ATM/ATR D010
## 1865                 MEK D010
## 1866     Gamma-secretase D010
## 1867               VEGFR D010
## 1868               VEGFR D010
## 1869            p38 MAPK D010
## 1870                 MEK D010
## 1871                 CDK D010
## 1872       Aurora Kinase D010
## 1873                 Raf D010
## 1874                &lt;NA&gt; D010
## 1875                 PKC D010
## 1876                 JNK D010
## 1877               c-Met D010
## 1878                 Src D010
## 1879                 CDK D010
## 1880               VEGFR D010
## 1881                 FAK D010
## 1882                EGFR D010
## 1883                 Raf D010
## 1884            p38 MAPK D010
## 1885                 MEK D010
## 1886       Aurora Kinase D010
## 1887 Hedgehog/Smoothened D010
## 1888                FLT3 D010
## 1889               GSK-3 D010
## 1890               VEGFR D010
## 1891                mTOR D010
## 1892               c-Met D010
## 1893                 CDK D010
## 1894                PI3K D010
## 1895                FLT3 D010
## 1896                 JAK D010
## 1897                PI3K D010
## 1898       TGF-beta/Smad D010
## 1899                ROCK D010
## 1900                 Akt D010
## 1901               GSK-3 D010
## 1902               c-Met D010
## 1903               VEGFR D010
## 1904                 JAK D010
## 1905                 JAK D010
## 1906                mTOR D010
## 1907                 MEK D010
## 1908                 Akt D010
## 1909               VEGFR D010
## 1910               GSK-3 D010
## 1911                EGFR D010
## 1912               PDGFR D010
## 1913                 MEK D010
## 1914                 ERK D010
## 1915                 Akt D010
## 1916                 JNK D010
## 1917                EGFR D010
## 1918               VEGFR D010
## 1919             ATM/ATR D010
## 1920             ATM/ATR D010
## 1921                 Raf D010
## 1922 Hedgehog/Smoothened D010
## 1923                 PLK D010
## 1924                PI3K D010
## 1925                PI3K D010
## 1926                 ERK D010
## 1927       Aurora Kinase D010
## 1928            p38 MAPK D010
## 1929            p38 MAPK D010
## 1930                mTOR D010
## 1931                 Src D010
## 1932                 JAK D010
## 1933    Wnt/beta-catenin D010
## 1934    Wnt/beta-catenin D010
## 1935    Wnt/beta-catenin D010
## 1936                 JAK D010
## 1937                mTOR D010
## 1938                mTOR D010
## 1939                EGFR D010
## 1940                EGFR D010
## 1941                AMPK D010
## 1942                EGFR D010
## 1943    Wnt/beta-catenin D010
## 1944                 JAK D010
## 1945                 ERK D010
## 1946                ROCK D010
## 1947                PI3K D010
## 1948     Gamma-secretase D010
## 1949               VEGFR D010
## 1950               VEGFR D010
## 1951                 Raf D010
## 1952                 JAK D010
## 1953       Aurora Kinase D010
## 1954                mTOR D010
## 1955                PI3K D010
## 1956               GSK-3 D010
## 1957                PI3K D010
## 1958                 Akt D010
## 1959                AMPK D010
## 1960                PI3K D010
## 1961                AMPK D010
## 1962                EGFR D010
## 1963                &lt;NA&gt; D010
## 1964              IGF-1R D010
## 1965                EGFR D010
## 1966                EGFR D010
## 1967                 JAK D010
## 1968                 Akt D010
## 1969       Aurora Kinase D010
## 1970               c-Met D010
## 1971               c-Met D010
## 1972       Aurora Kinase D010
## 1973                PI3K D010
## 1974               c-Met D010
## 1975               VEGFR D010
## 1976               GSK-3 D010
## 1977                PI3K D010
## 1978                PI3K D010
## 1979            p38 MAPK D010
## 1980                EGFR D010
## 1981                 Akt D010
## 1982                 CDK D010
## 1983                 Akt D010
## 1984             Bcr-Abl D010
## 1985       Aurora Kinase D010
## 1986     Gamma-secretase D010
## 1987                 BTK D010
## 1988               VEGFR D010
## 1989               PDGFR D010
## 1990                 Raf D010
## 1991                 JAK D010
## 1992             ATM/ATR D010
## 1993               GSK-3 D010
## 1994                 JAK D010
## 1995                mTOR D010
## 1996               GSK-3 D010
## 1997               PDGFR D010
## 1998                EGFR D010
## 1999                 Akt D010
## 2000                 CDK D010
## 2001                PI3K D010
## 2002             ATM/ATR D010
## 2003                mTOR D010
## 2004                 MEK D010
## 2005                EGFR D010
## 2006                EGFR D010
## 2007       Aurora Kinase D010
## 2008                 JAK D010
## 2009                PI3K D010
## 2010                 PLK D010
## 2011                 JNK D010
## 2012           S6 Kinase D010
## 2013               GSK-3 D010
## 2014               GSK-3 D010
## 2015            p38 MAPK D010
## 2016                 MEK D010
## 2017                &lt;NA&gt; D010
## 2018                PI3K D010
## 2019                 CDK D010
## 2020              IGF-1R D010
## 2021            p38 MAPK D010
## 2022              IGF-1R D010
## 2023               c-Met D010
## 2024               c-Met D010
## 2025 Hedgehog/Smoothened D010
## 2026                 Src D010
## 2027               VEGFR D010
## 2028               VEGFR D010
## 2029                 CDK D010
## 2030                EGFR D010
## 2031                PI3K D010
## 2032               VEGFR D010
## 2033                &lt;NA&gt; D010
## 2034                PI3K D010
## 2035                PI3K D010
## 2036                mTOR D010
## 2037                 Akt D010
## 2038               VEGFR D010
## 2039                 Raf D010
## 2040                 JAK D010
## 2041                 BTK D010
## 2042             ATM/ATR D010
## 2043                PI3K D010
## 2044               GSK-3 D010
## 2045               GSK-3 D010
## 2046                &lt;NA&gt; D010
## 2047                EGFR D010
## 2048                EGFR D010
## 2049                 BTK D010
## 2050                EGFR D010
## 2051                 MEK D010
## 2052               PDGFR D010
## 2053                EGFR D010
## 2054               PDGFR D010
## 2055               c-Met D010
## 2056       Aurora Kinase D010
## 2057                 JAK D010
## 2058                PI3K D010
## 2059                 Raf D010
## 2060                EGFR D010
## 2061       Aurora Kinase D010
## 2062     Gamma-secretase D010
## 2063                 Src D010
## 2064             Bcr-Abl D010
## 2065                 JAK D010
## 2066                 CDK D010
## 2067                &lt;NA&gt; D010
## 2068       Aurora Kinase D010
## 2069                 PKC D010
## 2070                 ERK D010
## 2071                AMPK D010
## 2072                mTOR D010
## 2073                mTOR D010
## 2074                ROCK D010
## 2075    Wnt/beta-catenin D010
## 2076                 JAK D010
## 2077                 CDK D010
## 2078                &lt;NA&gt; D010
## 2079               c-Met D010
## 2080                 Syk D010
## 2081                FLT3 D010
## 2082                 Akt D010
## 2083                mTOR D010
## 2084                 Raf D010
## 2085                PI3K D010
## 2086                mTOR D010
## 2087                EGFR D010
## 2088                EGFR D010
## 2089                 PKC D010
## 2090             Bcr-Abl D010
## 2091             Bcr-Abl D010
## 2092                 PKC D010
## 2093               c-Met D010
## 2094              IGF-1R D010
## 2095              IGF-1R D010
## 2096                PI3K D010
## 2097                PI3K D010
## 2098                PI3K D010
## 2099                ROCK D010
## 2100                 PLK D010
## 2101                AMPK D010
## 2102                 Akt D010
## 2103                 Raf D010
## 2104       TGF-beta/Smad D010
## 2105             Bcr-Abl D010
## 2106           S6 Kinase D010
## 2107       Aurora Kinase D010
## 2108                 PLK D010
## 2109                 Akt D010
## 2110                PI3K D010
## 2111                AMPK D010
## 2112                 Src D010
## 2113    Wnt/beta-catenin D010
## 2114                EGFR D010
## 2115               GSK-3 D010
## 2116               PDGFR D010
## 2117               GSK-3 D010
## 2118                mTOR D010
## 2119                PI3K D010
## 2120    Wnt/beta-catenin D010
## 2121    Wnt/beta-catenin D010
## 2122               c-Met D010
## 2123                 CDK D010
## 2124                 JNK D010
## 2125                 JNK D010
## 2126       TGF-beta/Smad D010
## 2127               VEGFR D010
## 2128               VEGFR D010
## 2129                mTOR D010
## 2130             ATM/ATR D010
## 2131             ATM/ATR D010
## 2132                FLT3 D010
## 2133                 Src D010
## 2134    Wnt/beta-catenin D010
## 2135                EGFR D010
## 2136                EGFR D010
## 2137                 CDK D010
## 2138 Hedgehog/Smoothened D010
## 2139       TGF-beta/Smad D010
## 2140               VEGFR D010
## 2141                 BTK D010
## 2142    Wnt/beta-catenin D010
## 2143               PDGFR D010
## 2144           S6 Kinase D010
## 2145           S6 Kinase D010
## 2146            p38 MAPK D010
## 2147               GSK-3 D010
## 2148       TGF-beta/Smad D010
## 2149                 JAK D010
## 2150                 CDK D010
## 2151                PI3K D010
## 2152                 Akt D010
## 2153     Gamma-secretase D010
## 2154                 MEK D010
## 2155               c-Met D010
## 2156                 CDK D010
## 2157     Gamma-secretase D010
## 2158                 Akt D010
## 2159               c-Met D010
## 2160       Aurora Kinase D010
## 2161       Aurora Kinase D010
## 2162                 Raf D010
## 2163       Aurora Kinase D010
## 2164               VEGFR D010
## 2165             Bcr-Abl D010
## 2166               VEGFR D010
## 2167                 CDK D010
## 2168              IGF-1R D010
## 2169               VEGFR D010
## 2170                 JAK D010
## 2171               c-Met D010
## 2172                 JAK D010
## 2173                EGFR D010
## 2174                 BTK D010
## 2175                mTOR D010
## 2176                EGFR D010
## 2177              IGF-1R D010
## 2178                 CDK D010
## 2179                 JAK D010
## 2180                mTOR D010
## 2181               VEGFR D010
## 2182               VEGFR D010
## 2183                 MEK D010
## 2184                EGFR D010
## 2185             Bcr-Abl D010
## 2186                 MEK D010
## 2187                 MEK D010
## 2188                 MEK D010
## 2189                EGFR D010
## 2190                 FAK D010
## 2191               c-Met D010
## 2192                mTOR D010
## 2193                 FAK D010
## 2194           S6 Kinase D010
## 2195 Hedgehog/Smoothened D010
## 2196                 FAK D010
## 2197                 FAK D010
## 2198            p38 MAPK D010
## 2199               c-Met D010
## 2200       Aurora Kinase D010
## 2201                 CDK D010
## 2202                 CDK D010
## 2203                AMPK D010
## 2204                 Akt D010
## 2205                 Syk D010
## 2206                PI3K D010
## 2207                PI3K D010
## 2208                PI3K D010
## 2209                 MEK D010
## 2210       TGF-beta/Smad D010
## 2211                 Raf D010
## 2212                 Raf D010
## 2213             Bcr-Abl D010
## 2214                 Src D010
## 2215                 Src D010
## 2216                mTOR D010
## 2217              IGF-1R D010
## 2218    Wnt/beta-catenin D010
## 2219                 Syk D010
## 2220                 CDK D010
## 2221                PI3K D010
## 2222                FLT3 D010
## 2223                 Syk D010
## 2224                 Syk D010
## 2225                 CDK D010
## 2226                 Raf D010
## 2227                mTOR D010
## 2228                 MEK D010
## 2229       TGF-beta/Smad D010
## 2230                mTOR D010
## 2231                 PLK D010
## 2232                ROCK D010
## 2233                 BTK D010
## 2234                 PKC D010
## 2235                 CDK D010
## 2236                 PLK D010
## 2237     Gamma-secretase D010
## 2238                 CDK D010
## 2239                 JAK D010
## 2240                 JAK D010
## 2241 Hedgehog/Smoothened D010
## 2242               VEGFR D010
## 2243                PI3K D010
## 2244                 Src D010
## 2245            p38 MAPK D010
## 2246            p38 MAPK D010
## 2247               GSK-3 D010
## 2248            p38 MAPK D010
## 2249               GSK-3 D010
## 2250       TGF-beta/Smad D010
## 2251       TGF-beta/Smad D010
## 2252       TGF-beta/Smad D010
## 2253                 Raf D010
## 2254                 ERK D010
## 2255             ATM/ATR D010
## 2256                 MEK D010
## 2257     Gamma-secretase D010
## 2258               VEGFR D010
## 2259               VEGFR D010
## 2260            p38 MAPK D010
## 2261                 MEK D010
## 2262                 CDK D010
## 2263       Aurora Kinase D010
## 2264                 Raf D010
## 2265                &lt;NA&gt; D010
## 2266                 PKC D010
## 2267                 JNK D010
## 2268               c-Met D010
## 2269                 Src D010
## 2270                 CDK D010
## 2271               VEGFR D010
## 2272                 FAK D010
## 2273                EGFR D010
## 2274                 Raf D010
## 2275            p38 MAPK D010
## 2276                 MEK D010
## 2277       Aurora Kinase D010
## 2278 Hedgehog/Smoothened D010
## 2279                FLT3 D010
## 2280               GSK-3 D010
## 2281               VEGFR D010
## 2282                mTOR D010
## 2283               c-Met D010
## 2284                 CDK D010
## 2285                PI3K D010
## 2286                FLT3 D010
## 2287                 JAK D010
## 2288                PI3K D010
## 2289       TGF-beta/Smad D010
## 2290                ROCK D010
## 2291                 Akt D010
## 2292               GSK-3 D010
## 2293               c-Met D010
## 2294               VEGFR D010
## 2295                 JAK D010
## 2296                 JAK D010
## 2297                mTOR D010
## 2298                 MEK D010
## 2299                 Akt D010
## 2300               VEGFR D010
## 2301               GSK-3 D010
## 2302                EGFR D010
## 2303               PDGFR D010
## 2304                 MEK D010
## 2305                 ERK D010
## 2306                 Akt D010
## 2307                 JNK D010
## 2308                EGFR D010
## 2309               VEGFR D010
## 2310             ATM/ATR D010
## 2311             ATM/ATR D010
## 2312                 Raf D010
## 2313 Hedgehog/Smoothened D010
## 2314                 PLK D010
## 2315                PI3K D010
## 2316                PI3K D010
## 2317                 ERK D010
## 2318       Aurora Kinase D010
## 2319            p38 MAPK D010
## 2320            p38 MAPK D010
## 2321                mTOR D010
## 2322                 Src D010
## 2323                 JAK D010
## 2324    Wnt/beta-catenin D010
## 2325    Wnt/beta-catenin D010
## 2326    Wnt/beta-catenin D010
## 2327                 JAK D010
## 2328                mTOR D010
## 2329                mTOR D010
## 2330                EGFR D010
## 2331                EGFR D010
## 2332                AMPK D010
## 2333                EGFR D010
## 2334    Wnt/beta-catenin D010
## 2335                 JAK D010
## 2336                 ERK D010
## 2337                ROCK D010
## 2338                PI3K D010
## 2339     Gamma-secretase D010
## 2340               VEGFR D010
## 2341               VEGFR D010
## 2342                 Raf D010
## 2343                 JAK D010
## 2344       Aurora Kinase D010
## 2345                mTOR D010
## 2346                PI3K D010
## 2347               GSK-3 D013
## 2348                PI3K D013
## 2349                 Akt D013
## 2350                AMPK D013
## 2351                PI3K D013
## 2352                EGFR D013
## 2353                 JAK D013
## 2354                 Akt D013
## 2355               c-Met D013
## 2356       Aurora Kinase D013
## 2357                PI3K D013
## 2358               GSK-3 D013
## 2359                PI3K D013
## 2360                PI3K D013
## 2361             Bcr-Abl D013
## 2362     Gamma-secretase D013
## 2363                 BTK D013
## 2364                 Raf D013
## 2365                 JAK D013
## 2366             ATM/ATR D013
## 2367               GSK-3 D013
## 2368                 JAK D013
## 2369                mTOR D013
## 2370               GSK-3 D013
## 2371               PDGFR D013
## 2372                EGFR D013
## 2373                 CDK D013
## 2374             ATM/ATR D013
## 2375                EGFR D013
## 2376                 JAK D013
## 2377                PI3K D013
## 2378           S6 Kinase D013
## 2379               GSK-3 D013
## 2380 Hedgehog/Smoothened D013
## 2381                EGFR D013
## 2382                PI3K D013
## 2383                &lt;NA&gt; D013
## 2384                PI3K D013
## 2385                 Akt D013
## 2386                 JAK D013
## 2387                 BTK D013
## 2388             ATM/ATR D013
## 2389                PI3K D013
## 2390               GSK-3 D013
## 2391                &lt;NA&gt; D013
## 2392                EGFR D013
## 2393                EGFR D013
## 2394                 BTK D013
## 2395                EGFR D013
## 2396                 MEK D013
## 2397               PDGFR D013
## 2398                 JAK D013
## 2399                PI3K D013
## 2400                 Raf D013
## 2401                EGFR D013
## 2402     Gamma-secretase D013
## 2403             Bcr-Abl D013
## 2404                 JAK D013
## 2405                 CDK D013
## 2406                &lt;NA&gt; D013
## 2407                 PKC D013
## 2408                 ERK D013
## 2409                mTOR D013
## 2410                ROCK D013
## 2411    Wnt/beta-catenin D013
## 2412                 JAK D013
## 2413                &lt;NA&gt; D013
## 2414                 Syk D013
## 2415                 Akt D013
## 2416                mTOR D013
## 2417                mTOR D013
## 2418                 PKC D013
## 2419             Bcr-Abl D013
## 2420             Bcr-Abl D013
## 2421                 PKC D013
## 2422               c-Met D013
## 2423              IGF-1R D013
## 2424                PI3K D013
## 2425                PI3K D013
## 2426                ROCK D013
## 2427                 Raf D013
## 2428       TGF-beta/Smad D013
## 2429             Bcr-Abl D013
## 2430                PI3K D013
## 2431                AMPK D013
## 2432                 Src D013
## 2433    Wnt/beta-catenin D013
## 2434                EGFR D013
## 2435               GSK-3 D013
## 2436               GSK-3 D013
## 2437                mTOR D013
## 2438                PI3K D013
## 2439    Wnt/beta-catenin D013
## 2440    Wnt/beta-catenin D013
## 2441                 JNK D013
## 2442                 JNK D013
## 2443       TGF-beta/Smad D013
## 2444                 Src D013
## 2445    Wnt/beta-catenin D013
## 2446                 CDK D013
## 2447 Hedgehog/Smoothened D013
## 2448       TGF-beta/Smad D013
## 2449    Wnt/beta-catenin D013
## 2450           S6 Kinase D013
## 2451            p38 MAPK D013
## 2452               GSK-3 D013
## 2453       TGF-beta/Smad D013
## 2454                 JAK D013
## 2455                 CDK D013
## 2456     Gamma-secretase D013
## 2457                 MEK D013
## 2458                 CDK D013
## 2459     Gamma-secretase D013
## 2460               c-Met D013
## 2461       Aurora Kinase D013
## 2462       Aurora Kinase D013
## 2463                 Raf D013
## 2464                 CDK D013
## 2465                 JAK D013
## 2466               c-Met D013
## 2467                 JAK D013
## 2468                mTOR D013
## 2469                 CDK D013
## 2470                 JAK D013
## 2471               VEGFR D013
## 2472                EGFR D013
## 2473             Bcr-Abl D013
## 2474                 FAK D013
## 2475                mTOR D013
## 2476                 FAK D013
## 2477 Hedgehog/Smoothened D013
## 2478                 FAK D013
## 2479            p38 MAPK D013
## 2480                 CDK D013
## 2481                AMPK D013
## 2482                 Syk D013
## 2483       TGF-beta/Smad D013
## 2484                 Raf D013
## 2485                 Src D013
## 2486                 Src D013
## 2487              IGF-1R D013
## 2488    Wnt/beta-catenin D013
## 2489                 CDK D013
## 2490                PI3K D013
## 2491                 CDK D013
## 2492       TGF-beta/Smad D013
## 2493                ROCK D013
## 2494                 BTK D013
## 2495                 PKC D013
## 2496                 PLK D013
## 2497     Gamma-secretase D013
## 2498                 JAK D013
## 2499                 JAK D013
## 2500 Hedgehog/Smoothened D013
## 2501               VEGFR D013
## 2502               GSK-3 D013
## 2503               GSK-3 D013
## 2504       TGF-beta/Smad D013
## 2505       TGF-beta/Smad D013
## 2506       TGF-beta/Smad D013
## 2507                 ERK D013
## 2508             ATM/ATR D013
## 2509     Gamma-secretase D013
## 2510               VEGFR D013
## 2511               VEGFR D013
## 2512            p38 MAPK D013
## 2513                 Raf D013
## 2514                 PKC D013
## 2515                 Src D013
## 2516                 CDK D013
## 2517                 FAK D013
## 2518                EGFR D013
## 2519                 Raf D013
## 2520            p38 MAPK D013
## 2521                 MEK D013
## 2522       Aurora Kinase D013
## 2523 Hedgehog/Smoothened D013
## 2524               GSK-3 D013
## 2525               c-Met D013
## 2526                 CDK D013
## 2527                FLT3 D013
## 2528                 JAK D013
## 2529       TGF-beta/Smad D013
## 2530                ROCK D013
## 2531                 Akt D013
## 2532               GSK-3 D013
## 2533               c-Met D013
## 2534                 JAK D013
## 2535                 JAK D013
## 2536                mTOR D013
## 2537                 MEK D013
## 2538               GSK-3 D013
## 2539                EGFR D013
## 2540                 ERK D013
## 2541                 Akt D013
## 2542                EGFR D013
## 2543             ATM/ATR D013
## 2544 Hedgehog/Smoothened D013
## 2545                PI3K D013
## 2546                PI3K D013
## 2547            p38 MAPK D013
## 2548                mTOR D013
## 2549                 JAK D013
## 2550    Wnt/beta-catenin D013
## 2551    Wnt/beta-catenin D013
## 2552    Wnt/beta-catenin D013
## 2553                 JAK D013
## 2554                mTOR D013
## 2555                AMPK D013
## 2556    Wnt/beta-catenin D013
## 2557                 JAK D013
## 2558                 ERK D013
## 2559                ROCK D013
## 2560     Gamma-secretase D013
## 2561               VEGFR D013
## 2562               VEGFR D013
## 2563                 Raf D013
## 2564                 JAK D013
## 2565                mTOR D013
## 2566               GSK-3 D013
## 2567                PI3K D013
## 2568                 Akt D013
## 2569                AMPK D013
## 2570                PI3K D013
## 2571                AMPK D013
## 2572                EGFR D013
## 2573                &lt;NA&gt; D013
## 2574              IGF-1R D013
## 2575                EGFR D013
## 2576                EGFR D013
## 2577                 JAK D013
## 2578                 Akt D013
## 2579       Aurora Kinase D013
## 2580               c-Met D013
## 2581               c-Met D013
## 2582       Aurora Kinase D013
## 2583                PI3K D013
## 2584               c-Met D013
## 2585               VEGFR D013
## 2586               GSK-3 D013
## 2587                PI3K D013
## 2588                PI3K D013
## 2589            p38 MAPK D013
## 2590                EGFR D013
## 2591                 Akt D013
## 2592                 CDK D013
## 2593                 Akt D013
## 2594             Bcr-Abl D013
## 2595       Aurora Kinase D013
## 2596     Gamma-secretase D013
## 2597                 BTK D013
## 2598               VEGFR D013
## 2599               PDGFR D013
## 2600                 Raf D013
## 2601                 JAK D013
## 2602             ATM/ATR D013
## 2603               GSK-3 D013
## 2604                 JAK D013
## 2605                mTOR D013
## 2606               GSK-3 D013
## 2607               PDGFR D013
## 2608                EGFR D013
## 2609                 Akt D013
## 2610                 CDK D013
## 2611                PI3K D013
## 2612             ATM/ATR D013
## 2613                mTOR D013
## 2614                 MEK D013
## 2615                EGFR D013
## 2616                EGFR D013
## 2617       Aurora Kinase D013
## 2618                 JAK D013
## 2619                PI3K D013
## 2620                 PLK D013
## 2621                 JNK D013
## 2622           S6 Kinase D013
## 2623               GSK-3 D013
## 2624               GSK-3 D013
## 2625            p38 MAPK D013
## 2626                 MEK D013
## 2627                &lt;NA&gt; D013
## 2628                PI3K D013
## 2629                 CDK D013
## 2630              IGF-1R D013
## 2631            p38 MAPK D013
## 2632              IGF-1R D013
## 2633               c-Met D013
## 2634               c-Met D013
## 2635 Hedgehog/Smoothened D013
## 2636                 Src D013
## 2637               VEGFR D013
## 2638               VEGFR D013
## 2639                 CDK D013
## 2640                EGFR D013
## 2641                PI3K D013
## 2642               VEGFR D013
## 2643                &lt;NA&gt; D013
## 2644                PI3K D013
## 2645                PI3K D013
## 2646                mTOR D013
## 2647                 Akt D013
## 2648               VEGFR D013
## 2649                 Raf D013
## 2650                 JAK D013
## 2651                 BTK D013
## 2652             ATM/ATR D013
## 2653                PI3K D013
## 2654               GSK-3 D013
## 2655               GSK-3 D013
## 2656                &lt;NA&gt; D013
## 2657                EGFR D013
## 2658                EGFR D013
## 2659                 BTK D013
## 2660                EGFR D013
## 2661                 MEK D013
## 2662               PDGFR D013
## 2663                EGFR D013
## 2664               PDGFR D013
## 2665               c-Met D013
## 2666       Aurora Kinase D013
## 2667                 JAK D013
## 2668                PI3K D013
## 2669                 Raf D013
## 2670                EGFR D013
## 2671       Aurora Kinase D013
## 2672     Gamma-secretase D013
## 2673                 Src D013
## 2674             Bcr-Abl D013
## 2675                 JAK D013
## 2676                 CDK D013
## 2677                &lt;NA&gt; D013
## 2678       Aurora Kinase D013
## 2679                 PKC D013
## 2680                 ERK D013
## 2681                AMPK D013
## 2682                mTOR D013
## 2683                mTOR D013
## 2684                ROCK D013
## 2685    Wnt/beta-catenin D013
## 2686                 JAK D013
## 2687                 CDK D013
## 2688                &lt;NA&gt; D013
## 2689               c-Met D013
## 2690                 Syk D013
## 2691                FLT3 D013
## 2692                 Akt D013
## 2693                mTOR D013
## 2694                 Raf D013
## 2695                PI3K D013
## 2696                mTOR D013
## 2697                EGFR D013
## 2698                EGFR D013
## 2699                 PKC D013
## 2700             Bcr-Abl D013
## 2701             Bcr-Abl D013
## 2702                 PKC D013
## 2703               c-Met D013
## 2704              IGF-1R D013
## 2705              IGF-1R D013
## 2706                PI3K D013
## 2707                PI3K D013
## 2708                PI3K D013
## 2709                ROCK D013
## 2710                 PLK D013
## 2711                AMPK D013
## 2712                 Akt D013
## 2713                 Raf D013
## 2714       TGF-beta/Smad D013
## 2715             Bcr-Abl D013
## 2716           S6 Kinase D013
## 2717       Aurora Kinase D013
## 2718                 PLK D013
## 2719                 Akt D013
## 2720                PI3K D013
## 2721                AMPK D013
## 2722                 Src D013
## 2723    Wnt/beta-catenin D013
## 2724                EGFR D013
## 2725               GSK-3 D013
## 2726               PDGFR D013
## 2727               GSK-3 D013
## 2728                mTOR D013
## 2729                PI3K D013
## 2730    Wnt/beta-catenin D013
## 2731    Wnt/beta-catenin D013
## 2732               c-Met D013
## 2733                 CDK D013
## 2734                 JNK D013
## 2735                 JNK D013
## 2736       TGF-beta/Smad D013
## 2737               VEGFR D013
## 2738               VEGFR D013
## 2739                mTOR D013
## 2740             ATM/ATR D013
## 2741             ATM/ATR D013
## 2742                FLT3 D013
## 2743                 Src D013
## 2744    Wnt/beta-catenin D013
## 2745                EGFR D013
## 2746                EGFR D013
## 2747                 CDK D013
## 2748 Hedgehog/Smoothened D013
## 2749       TGF-beta/Smad D013
## 2750               VEGFR D013
## 2751                 BTK D013
## 2752    Wnt/beta-catenin D013
## 2753               PDGFR D013
## 2754           S6 Kinase D013
## 2755           S6 Kinase D013
## 2756            p38 MAPK D013
## 2757               GSK-3 D013
## 2758       TGF-beta/Smad D013
## 2759                 JAK D013
## 2760                 CDK D013
## 2761                PI3K D013
## 2762                 Akt D013
## 2763     Gamma-secretase D013
## 2764                 MEK D013
## 2765               c-Met D013
## 2766                 CDK D013
## 2767     Gamma-secretase D013
## 2768                 Akt D013
## 2769               c-Met D013
## 2770       Aurora Kinase D013
## 2771       Aurora Kinase D013
## 2772                 Raf D013
## 2773       Aurora Kinase D013
## 2774               VEGFR D013
## 2775             Bcr-Abl D013
## 2776               VEGFR D013
## 2777                 CDK D013
## 2778              IGF-1R D013
## 2779               VEGFR D013
## 2780                 JAK D013
## 2781               c-Met D013
## 2782                 JAK D013
## 2783                EGFR D013
## 2784                 BTK D013
## 2785                mTOR D013
## 2786                EGFR D013
## 2787              IGF-1R D013
## 2788                 CDK D013
## 2789                 JAK D013
## 2790                mTOR D013
## 2791               VEGFR D013
## 2792               VEGFR D013
## 2793                 MEK D013
## 2794                EGFR D013
## 2795             Bcr-Abl D013
## 2796                 MEK D013
## 2797                 MEK D013
## 2798                 MEK D013
## 2799                EGFR D013
## 2800                 FAK D013
## 2801               c-Met D013
## 2802                mTOR D013
## 2803                 FAK D013
## 2804           S6 Kinase D013
## 2805 Hedgehog/Smoothened D013
## 2806                 FAK D013
## 2807                 FAK D013
## 2808            p38 MAPK D013
## 2809               c-Met D013
## 2810       Aurora Kinase D013
## 2811                 CDK D013
## 2812                 CDK D013
## 2813                AMPK D013
## 2814                 Akt D013
## 2815                 Syk D013
## 2816                PI3K D013
## 2817                PI3K D013
## 2818                PI3K D013
## 2819                 MEK D013
## 2820       TGF-beta/Smad D013
## 2821                 Raf D013
## 2822                 Raf D013
## 2823             Bcr-Abl D013
## 2824                 Src D013
## 2825                 Src D013
## 2826                mTOR D013
## 2827              IGF-1R D013
## 2828    Wnt/beta-catenin D013
## 2829                 Syk D013
## 2830                 CDK D013
## 2831                PI3K D013
## 2832                FLT3 D013
## 2833                 Syk D013
## 2834                 Syk D013
## 2835                 CDK D013
## 2836                 Raf D013
## 2837                mTOR D013
## 2838                 MEK D013
## 2839       TGF-beta/Smad D013
## 2840                mTOR D013
## 2841                 PLK D013
## 2842                ROCK D013
## 2843                 BTK D013
## 2844                 PKC D013
## 2845                 CDK D013
## 2846                 PLK D013
## 2847     Gamma-secretase D013
## 2848                 CDK D013
## 2849                 JAK D013
## 2850                 JAK D013
## 2851 Hedgehog/Smoothened D013
## 2852               VEGFR D013
## 2853                PI3K D013
## 2854                 Src D013
## 2855            p38 MAPK D013
## 2856            p38 MAPK D013
## 2857               GSK-3 D013
## 2858            p38 MAPK D013
## 2859               GSK-3 D013
## 2860       TGF-beta/Smad D013
## 2861       TGF-beta/Smad D013
## 2862       TGF-beta/Smad D013
## 2863                 Raf D013
## 2864                 ERK D013
## 2865             ATM/ATR D013
## 2866                 MEK D013
## 2867     Gamma-secretase D013
## 2868               VEGFR D013
## 2869               VEGFR D013
## 2870            p38 MAPK D013
## 2871                 MEK D013
## 2872                 CDK D013
## 2873       Aurora Kinase D013
## 2874                 Raf D013
## 2875                &lt;NA&gt; D013
## 2876                 PKC D013
## 2877                 JNK D013
## 2878               c-Met D013
## 2879                 Src D013
## 2880                 CDK D013
## 2881               VEGFR D013
## 2882                 FAK D013
## 2883                EGFR D013
## 2884                 Raf D013
## 2885            p38 MAPK D013
## 2886                 MEK D013
## 2887       Aurora Kinase D013
## 2888 Hedgehog/Smoothened D013
## 2889                FLT3 D013
## 2890               GSK-3 D013
## 2891               VEGFR D013
## 2892                mTOR D013
## 2893               c-Met D013
## 2894                 CDK D013
## 2895                PI3K D013
## 2896                FLT3 D013
## 2897                 JAK D013
## 2898                PI3K D013
## 2899       TGF-beta/Smad D013
## 2900                ROCK D013
## 2901                 Akt D013
## 2902               GSK-3 D013
## 2903               c-Met D013
## 2904               VEGFR D013
## 2905                 JAK D013
## 2906                 JAK D013
## 2907                mTOR D013
## 2908                 MEK D013
## 2909                 Akt D013
## 2910               VEGFR D013
## 2911               GSK-3 D013
## 2912                EGFR D013
## 2913               PDGFR D013
## 2914                 MEK D013
## 2915                 ERK D013
## 2916                 Akt D013
## 2917                 JNK D013
## 2918                EGFR D013
## 2919               VEGFR D013
## 2920             ATM/ATR D013
## 2921             ATM/ATR D013
## 2922                 Raf D013
## 2923 Hedgehog/Smoothened D013
## 2924                 PLK D013
## 2925                PI3K D013
## 2926                PI3K D013
## 2927                 ERK D013
## 2928       Aurora Kinase D013
## 2929            p38 MAPK D013
## 2930            p38 MAPK D013
## 2931                mTOR D013
## 2932                 Src D013
## 2933                 JAK D013
## 2934    Wnt/beta-catenin D013
## 2935    Wnt/beta-catenin D013
## 2936    Wnt/beta-catenin D013
## 2937                 JAK D013
## 2938                mTOR D013
## 2939                mTOR D013
## 2940                EGFR D013
## 2941                EGFR D013
## 2942                AMPK D013
## 2943                EGFR D013
## 2944    Wnt/beta-catenin D013
## 2945                 JAK D013
## 2946                 ERK D013
## 2947                ROCK D013
## 2948                PI3K D013
## 2949     Gamma-secretase D013
## 2950               VEGFR D013
## 2951               VEGFR D013
## 2952                 Raf D013
## 2953                 JAK D013
## 2954       Aurora Kinase D013
## 2955                mTOR D013
## 2956                PI3K D013
## 2957               GSK-3 D018
## 2958                PI3K D018
## 2959                 Akt D018
## 2960                AMPK D018
## 2961                PI3K D018
## 2962                AMPK D018
## 2963                EGFR D018
## 2964                &lt;NA&gt; D018
## 2965              IGF-1R D018
## 2966                EGFR D018
## 2967                EGFR D018
## 2968                 JAK D018
## 2969                 Akt D018
## 2970       Aurora Kinase D018
## 2971               c-Met D018
## 2972               c-Met D018
## 2973       Aurora Kinase D018
## 2974                PI3K D018
## 2975               c-Met D018
## 2976               VEGFR D018
## 2977               GSK-3 D018
## 2978                PI3K D018
## 2979                PI3K D018
## 2980            p38 MAPK D018
## 2981                EGFR D018
## 2982                 Akt D018
## 2983                 CDK D018
## 2984                 Akt D018
## 2985             Bcr-Abl D018
## 2986       Aurora Kinase D018
## 2987     Gamma-secretase D018
## 2988                 BTK D018
## 2989               VEGFR D018
## 2990               PDGFR D018
## 2991                 Raf D018
## 2992                 JAK D018
## 2993             ATM/ATR D018
## 2994               GSK-3 D018
## 2995                 JAK D018
## 2996                mTOR D018
## 2997               GSK-3 D018
## 2998               PDGFR D018
## 2999                EGFR D018
## 3000                 Akt D018
## 3001                 CDK D018
## 3002                PI3K D018
## 3003             ATM/ATR D018
## 3004                mTOR D018
## 3005                 MEK D018
## 3006                EGFR D018
## 3007                EGFR D018
## 3008       Aurora Kinase D018
## 3009                 JAK D018
## 3010                PI3K D018
## 3011                 PLK D018
## 3012                 JNK D018
## 3013           S6 Kinase D018
## 3014               GSK-3 D018
## 3015               GSK-3 D018
## 3016            p38 MAPK D018
## 3017                 MEK D018
## 3018                &lt;NA&gt; D018
## 3019                PI3K D018
## 3020                 CDK D018
## 3021              IGF-1R D018
## 3022            p38 MAPK D018
## 3023              IGF-1R D018
## 3024               c-Met D018
## 3025               c-Met D018
## 3026 Hedgehog/Smoothened D018
## 3027                 Src D018
## 3028               VEGFR D018
## 3029               VEGFR D018
## 3030                 CDK D018
## 3031                EGFR D018
## 3032                PI3K D018
## 3033               VEGFR D018
## 3034                &lt;NA&gt; D018
## 3035                PI3K D018
## 3036                PI3K D018
## 3037                mTOR D018
## 3038                 Akt D018
## 3039               VEGFR D018
## 3040                 Raf D018
## 3041                 JAK D018
## 3042                 BTK D018
## 3043             ATM/ATR D018
## 3044                PI3K D018
## 3045               GSK-3 D018
## 3046               GSK-3 D018
## 3047                &lt;NA&gt; D018
## 3048                EGFR D018
## 3049                EGFR D018
## 3050                 BTK D018
## 3051                EGFR D018
## 3052                 MEK D018
## 3053               PDGFR D018
## 3054                EGFR D018
## 3055               PDGFR D018
## 3056               c-Met D018
## 3057       Aurora Kinase D018
## 3058                 JAK D018
## 3059                PI3K D018
## 3060                 Raf D018
## 3061                EGFR D018
## 3062       Aurora Kinase D018
## 3063     Gamma-secretase D018
## 3064                 Src D018
## 3065             Bcr-Abl D018
## 3066                 JAK D018
## 3067                 CDK D018
## 3068                &lt;NA&gt; D018
## 3069       Aurora Kinase D018
## 3070                 PKC D018
## 3071                 ERK D018
## 3072                AMPK D018
## 3073                mTOR D018
## 3074                mTOR D018
## 3075                ROCK D018
## 3076    Wnt/beta-catenin D018
## 3077                 JAK D018
## 3078                 CDK D018
## 3079                &lt;NA&gt; D018
## 3080               c-Met D018
## 3081                 Syk D018
## 3082                FLT3 D018
## 3083                 Akt D018
## 3084                mTOR D018
## 3085                 Raf D018
## 3086                PI3K D018
## 3087                mTOR D018
## 3088                EGFR D018
## 3089                EGFR D018
## 3090                 PKC D018
## 3091             Bcr-Abl D018
## 3092             Bcr-Abl D018
## 3093                 PKC D018
## 3094               c-Met D018
## 3095              IGF-1R D018
## 3096              IGF-1R D018
## 3097                PI3K D018
## 3098                PI3K D018
## 3099                PI3K D018
## 3100                ROCK D018
## 3101                 PLK D018
## 3102                AMPK D018
## 3103                 Akt D018
## 3104                 Raf D018
## 3105       TGF-beta/Smad D018
## 3106             Bcr-Abl D018
## 3107           S6 Kinase D018
## 3108       Aurora Kinase D018
## 3109                 PLK D018
## 3110                 Akt D018
## 3111                PI3K D018
## 3112                AMPK D018
## 3113                 Src D018
## 3114    Wnt/beta-catenin D018
## 3115                EGFR D018
## 3116               GSK-3 D018
## 3117               PDGFR D018
## 3118               GSK-3 D018
## 3119                mTOR D018
## 3120                PI3K D018
## 3121    Wnt/beta-catenin D018
## 3122    Wnt/beta-catenin D018
## 3123               c-Met D018
## 3124                 CDK D018
## 3125                 JNK D018
## 3126                 JNK D018
## 3127       TGF-beta/Smad D018
## 3128               VEGFR D018
## 3129               VEGFR D018
## 3130                mTOR D018
## 3131             ATM/ATR D018
## 3132             ATM/ATR D018
## 3133                FLT3 D018
## 3134                 Src D018
## 3135    Wnt/beta-catenin D018
## 3136                EGFR D018
## 3137                EGFR D018
## 3138                 CDK D018
## 3139 Hedgehog/Smoothened D018
## 3140       TGF-beta/Smad D018
## 3141               VEGFR D018
## 3142                 BTK D018
## 3143    Wnt/beta-catenin D018
## 3144               PDGFR D018
## 3145           S6 Kinase D018
## 3146           S6 Kinase D018
## 3147            p38 MAPK D018
## 3148               GSK-3 D018
## 3149       TGF-beta/Smad D018
## 3150                 JAK D018
## 3151                 CDK D018
## 3152                PI3K D018
## 3153                 Akt D018
## 3154     Gamma-secretase D018
## 3155                 MEK D018
## 3156               c-Met D018
## 3157                 CDK D018
## 3158     Gamma-secretase D018
## 3159                 Akt D018
## 3160               c-Met D018
## 3161       Aurora Kinase D018
## 3162       Aurora Kinase D018
## 3163                 Raf D018
## 3164       Aurora Kinase D018
## 3165               VEGFR D018
## 3166             Bcr-Abl D018
## 3167               VEGFR D018
## 3168                 CDK D018
## 3169              IGF-1R D018
## 3170               VEGFR D018
## 3171                 JAK D018
## 3172               c-Met D018
## 3173                 JAK D018
## 3174                EGFR D018
## 3175                 BTK D018
## 3176                mTOR D018
## 3177                EGFR D018
## 3178              IGF-1R D018
## 3179                 CDK D018
## 3180                 JAK D018
## 3181                mTOR D018
## 3182               VEGFR D018
## 3183               VEGFR D018
## 3184                 MEK D018
## 3185                EGFR D018
## 3186             Bcr-Abl D018
## 3187                 MEK D018
## 3188                 MEK D018
## 3189                 MEK D018
## 3190                EGFR D018
## 3191                 FAK D018
## 3192               c-Met D018
## 3193                mTOR D018
## 3194                 FAK D018
## 3195           S6 Kinase D018
## 3196 Hedgehog/Smoothened D018
## 3197                 FAK D018
## 3198                 FAK D018
## 3199            p38 MAPK D018
## 3200               c-Met D018
## 3201       Aurora Kinase D018
## 3202                 CDK D018
## 3203                 CDK D018
## 3204                AMPK D018
## 3205                 Akt D018
## 3206                 Syk D018
## 3207                PI3K D018
## 3208                PI3K D018
## 3209                PI3K D018
## 3210                 MEK D018
## 3211       TGF-beta/Smad D018
## 3212                 Raf D018
## 3213                 Raf D018
## 3214             Bcr-Abl D018
## 3215                 Src D018
## 3216                 Src D018
## 3217                mTOR D018
## 3218              IGF-1R D018
## 3219    Wnt/beta-catenin D018
## 3220                 Syk D018
## 3221                 CDK D018
## 3222                PI3K D018
## 3223                FLT3 D018
## 3224                 Syk D018
## 3225                 Syk D018
## 3226                 CDK D018
## 3227                 Raf D018
## 3228                mTOR D018
## 3229                 MEK D018
## 3230       TGF-beta/Smad D018
## 3231                mTOR D018
## 3232                 PLK D018
## 3233                ROCK D018
## 3234                 BTK D018
## 3235                 PKC D018
## 3236                 CDK D018
## 3237                 PLK D018
## 3238     Gamma-secretase D018
## 3239                 CDK D018
## 3240                 JAK D018
## 3241                 JAK D018
## 3242 Hedgehog/Smoothened D018
## 3243               VEGFR D018
## 3244                PI3K D018
## 3245                 Src D018
## 3246            p38 MAPK D018
## 3247            p38 MAPK D018
## 3248               GSK-3 D018
## 3249            p38 MAPK D018
## 3250               GSK-3 D018
## 3251       TGF-beta/Smad D018
## 3252       TGF-beta/Smad D018
## 3253       TGF-beta/Smad D018
## 3254                 Raf D018
## 3255                 ERK D018
## 3256             ATM/ATR D018
## 3257                 MEK D018
## 3258     Gamma-secretase D018
## 3259               VEGFR D018
## 3260               VEGFR D018
## 3261            p38 MAPK D018
## 3262                 MEK D018
## 3263                 CDK D018
## 3264       Aurora Kinase D018
## 3265                 Raf D018
## 3266                &lt;NA&gt; D018
## 3267                 PKC D018
## 3268                 JNK D018
## 3269               c-Met D018
## 3270                 Src D018
## 3271                 CDK D018
## 3272               VEGFR D018
## 3273                 FAK D018
## 3274                EGFR D018
## 3275                 Raf D018
## 3276            p38 MAPK D018
## 3277                 MEK D018
## 3278       Aurora Kinase D018
## 3279 Hedgehog/Smoothened D018
## 3280                FLT3 D018
## 3281               GSK-3 D018
## 3282               VEGFR D018
## 3283                mTOR D018
## 3284               c-Met D018
## 3285                 CDK D018
## 3286                PI3K D018
## 3287                FLT3 D018
## 3288                 JAK D018
## 3289                PI3K D018
## 3290       TGF-beta/Smad D018
## 3291                ROCK D018
## 3292                 Akt D018
## 3293               GSK-3 D018
## 3294               c-Met D018
## 3295               VEGFR D018
## 3296                 JAK D018
## 3297                 JAK D018
## 3298                mTOR D018
## 3299                 MEK D018
## 3300                 Akt D018
## 3301               VEGFR D018
## 3302               GSK-3 D018
## 3303                EGFR D018
## 3304               PDGFR D018
## 3305                 MEK D018
## 3306                 ERK D018
## 3307                 Akt D018
## 3308                 JNK D018
## 3309                EGFR D018
## 3310               VEGFR D018
## 3311             ATM/ATR D018
## 3312             ATM/ATR D018
## 3313                 Raf D018
## 3314 Hedgehog/Smoothened D018
## 3315                 PLK D018
## 3316                PI3K D018
## 3317                PI3K D018
## 3318                 ERK D018
## 3319       Aurora Kinase D018
## 3320            p38 MAPK D018
## 3321            p38 MAPK D018
## 3322                mTOR D018
## 3323                 Src D018
## 3324                 JAK D018
## 3325    Wnt/beta-catenin D018
## 3326    Wnt/beta-catenin D018
## 3327    Wnt/beta-catenin D018
## 3328                 JAK D018
## 3329                mTOR D018
## 3330                mTOR D018
## 3331                EGFR D018
## 3332                EGFR D018
## 3333                AMPK D018
## 3334                EGFR D018
## 3335    Wnt/beta-catenin D018
## 3336                 JAK D018
## 3337                 ERK D018
## 3338                ROCK D018
## 3339                PI3K D018
## 3340     Gamma-secretase D018
## 3341               VEGFR D018
## 3342               VEGFR D018
## 3343                 Raf D018
## 3344                 JAK D018
## 3345       Aurora Kinase D018
## 3346                mTOR D018
## 3347                PI3K D018
## 3348               GSK-3 D018
## 3349                PI3K D018
## 3350                 Akt D018
## 3351                AMPK D018
## 3352                PI3K D018
## 3353                AMPK D018
## 3354                EGFR D018
## 3355                &lt;NA&gt; D018
## 3356              IGF-1R D018
## 3357                EGFR D018
## 3358                EGFR D018
## 3359                 JAK D018
## 3360                 Akt D018
## 3361       Aurora Kinase D018
## 3362               c-Met D018
## 3363               c-Met D018
## 3364       Aurora Kinase D018
## 3365                PI3K D018
## 3366               c-Met D018
## 3367               VEGFR D018
## 3368               GSK-3 D018
## 3369                PI3K D018
## 3370                PI3K D018
## 3371            p38 MAPK D018
## 3372                EGFR D018
## 3373                 Akt D018
## 3374                 CDK D018
## 3375                 Akt D018
## 3376             Bcr-Abl D018
## 3377       Aurora Kinase D018
## 3378     Gamma-secretase D018
## 3379                 BTK D018
## 3380               VEGFR D018
## 3381               PDGFR D018
## 3382                 Raf D018
## 3383                 JAK D018
## 3384             ATM/ATR D018
## 3385               GSK-3 D018
## 3386                 JAK D018
## 3387                mTOR D018
## 3388               GSK-3 D018
## 3389               PDGFR D018
## 3390                EGFR D018
## 3391                 Akt D018
## 3392                 CDK D018
## 3393                PI3K D018
## 3394             ATM/ATR D018
## 3395                mTOR D018
## 3396                 MEK D018
## 3397                EGFR D018
## 3398                EGFR D018
## 3399       Aurora Kinase D018
## 3400                 JAK D018
## 3401                PI3K D018
## 3402                 PLK D018
## 3403                 JNK D018
## 3404           S6 Kinase D018
## 3405               GSK-3 D018
## 3406               GSK-3 D018
## 3407            p38 MAPK D018
## 3408                 MEK D018
## 3409                &lt;NA&gt; D018
## 3410                PI3K D018
## 3411                 CDK D018
## 3412              IGF-1R D018
## 3413            p38 MAPK D018
## 3414              IGF-1R D018
## 3415               c-Met D018
## 3416               c-Met D018
## 3417 Hedgehog/Smoothened D018
## 3418                 Src D018
## 3419               VEGFR D018
## 3420               VEGFR D018
## 3421                 CDK D018
## 3422                EGFR D018
## 3423                PI3K D018
## 3424               VEGFR D018
## 3425                &lt;NA&gt; D018
## 3426                PI3K D018
## 3427                PI3K D018
## 3428                mTOR D018
## 3429                 Akt D018
## 3430               VEGFR D018
## 3431                 Raf D018
## 3432                 JAK D018
## 3433                 BTK D018
## 3434             ATM/ATR D018
## 3435                PI3K D018
## 3436               GSK-3 D018
## 3437               GSK-3 D018
## 3438                &lt;NA&gt; D018
## 3439                EGFR D018
## 3440                EGFR D018
## 3441                 BTK D018
## 3442                EGFR D018
## 3443                 MEK D018
## 3444               PDGFR D018
## 3445                EGFR D018
## 3446               PDGFR D018
## 3447               c-Met D018
## 3448       Aurora Kinase D018
## 3449                 JAK D018
## 3450                PI3K D018
## 3451                 Raf D018
## 3452                EGFR D018
## 3453       Aurora Kinase D018
## 3454     Gamma-secretase D018
## 3455                 Src D018
## 3456             Bcr-Abl D018
## 3457                 JAK D018
## 3458                 CDK D018
## 3459                &lt;NA&gt; D018
## 3460       Aurora Kinase D018
## 3461                 PKC D018
## 3462                 ERK D018
## 3463                AMPK D018
## 3464                mTOR D018
## 3465                mTOR D018
## 3466                ROCK D018
## 3467    Wnt/beta-catenin D018
## 3468                 JAK D018
## 3469                 CDK D018
## 3470                &lt;NA&gt; D018
## 3471               c-Met D018
## 3472                 Syk D018
## 3473                FLT3 D018
## 3474                 Akt D018
## 3475                mTOR D018
## 3476                 Raf D018
## 3477                PI3K D018
## 3478                mTOR D018
## 3479                EGFR D018
## 3480                EGFR D018
## 3481                 PKC D018
## 3482             Bcr-Abl D018
## 3483             Bcr-Abl D018
## 3484                 PKC D018
## 3485               c-Met D018
## 3486              IGF-1R D018
## 3487              IGF-1R D018
## 3488                PI3K D018
## 3489                PI3K D018
## 3490                PI3K D018
## 3491                ROCK D018
## 3492                 PLK D018
## 3493                AMPK D018
## 3494                 Akt D018
## 3495                 Raf D018
## 3496       TGF-beta/Smad D018
## 3497             Bcr-Abl D018
## 3498           S6 Kinase D018
## 3499       Aurora Kinase D018
## 3500                 PLK D018
## 3501                 Akt D018
## 3502                PI3K D018
## 3503                AMPK D018
## 3504                 Src D018
## 3505    Wnt/beta-catenin D018
## 3506                EGFR D018
## 3507               GSK-3 D018
## 3508               PDGFR D018
## 3509               GSK-3 D018
## 3510                mTOR D018
## 3511                PI3K D018
## 3512    Wnt/beta-catenin D018
## 3513    Wnt/beta-catenin D018
## 3514               c-Met D018
## 3515                 CDK D018
## 3516                 JNK D018
## 3517                 JNK D018
## 3518       TGF-beta/Smad D018
## 3519               VEGFR D018
## 3520               VEGFR D018
## 3521                mTOR D018
## 3522             ATM/ATR D018
## 3523             ATM/ATR D018
## 3524                FLT3 D018
## 3525                 Src D018
## 3526    Wnt/beta-catenin D018
## 3527                EGFR D018
## 3528                EGFR D018
## 3529                 CDK D018
## 3530 Hedgehog/Smoothened D018
## 3531       TGF-beta/Smad D018
## 3532               VEGFR D018
## 3533                 BTK D018
## 3534    Wnt/beta-catenin D018
## 3535               PDGFR D018
## 3536           S6 Kinase D018
## 3537           S6 Kinase D018
## 3538            p38 MAPK D018
## 3539               GSK-3 D018
## 3540       TGF-beta/Smad D018
## 3541                 JAK D018
## 3542                 CDK D018
## 3543                PI3K D018
## 3544                 Akt D018
## 3545     Gamma-secretase D018
## 3546                 MEK D018
## 3547               c-Met D018
## 3548                 CDK D018
## 3549     Gamma-secretase D018
## 3550                 Akt D018
## 3551               c-Met D018
## 3552       Aurora Kinase D018
## 3553       Aurora Kinase D018
## 3554                 Raf D018
## 3555       Aurora Kinase D018
## 3556               VEGFR D018
## 3557             Bcr-Abl D018
## 3558               VEGFR D018
## 3559                 CDK D018
## 3560              IGF-1R D018
## 3561               VEGFR D018
## 3562                 JAK D018
## 3563               c-Met D018
## 3564                 JAK D018
## 3565                EGFR D018
## 3566                 BTK D018
## 3567                mTOR D018
## 3568                EGFR D018
## 3569              IGF-1R D018
## 3570                 CDK D018
## 3571                 JAK D018
## 3572                mTOR D018
## 3573               VEGFR D018
## 3574               VEGFR D018
## 3575                 MEK D018
## 3576                EGFR D018
## 3577             Bcr-Abl D018
## 3578                 MEK D018
## 3579                 MEK D018
## 3580                 MEK D018
## 3581                EGFR D018
## 3582                 FAK D018
## 3583               c-Met D018
## 3584                mTOR D018
## 3585                 FAK D018
## 3586           S6 Kinase D018
## 3587 Hedgehog/Smoothened D018
## 3588                 FAK D018
## 3589                 FAK D018
## 3590            p38 MAPK D018
## 3591               c-Met D018
## 3592       Aurora Kinase D018
## 3593                 CDK D018
## 3594                 CDK D018
## 3595                AMPK D018
## 3596                 Akt D018
## 3597                 Syk D018
## 3598                PI3K D018
## 3599                PI3K D018
## 3600                PI3K D018
## 3601                 MEK D018
## 3602       TGF-beta/Smad D018
## 3603                 Raf D018
## 3604                 Raf D018
## 3605             Bcr-Abl D018
## 3606                 Src D018
## 3607                 Src D018
## 3608                mTOR D018
## 3609              IGF-1R D018
## 3610    Wnt/beta-catenin D018
## 3611                 Syk D018
## 3612                 CDK D018
## 3613                PI3K D018
## 3614                FLT3 D018
## 3615                 Syk D018
## 3616                 Syk D018
## 3617                 CDK D018
## 3618                 Raf D018
## 3619                mTOR D018
## 3620                 MEK D018
## 3621       TGF-beta/Smad D018
## 3622                mTOR D018
## 3623                 PLK D018
## 3624                ROCK D018
## 3625                 BTK D018
## 3626                 PKC D018
## 3627                 CDK D018
## 3628                 PLK D018
## 3629     Gamma-secretase D018
## 3630                 CDK D018
## 3631                 JAK D018
## 3632                 JAK D018
## 3633 Hedgehog/Smoothened D018
## 3634               VEGFR D018
## 3635                PI3K D018
## 3636                 Src D018
## 3637            p38 MAPK D018
## 3638            p38 MAPK D018
## 3639               GSK-3 D018
## 3640            p38 MAPK D018
## 3641               GSK-3 D018
## 3642       TGF-beta/Smad D018
## 3643       TGF-beta/Smad D018
## 3644       TGF-beta/Smad D018
## 3645                 Raf D018
## 3646                 ERK D018
## 3647             ATM/ATR D018
## 3648                 MEK D018
## 3649     Gamma-secretase D018
## 3650               VEGFR D018
## 3651               VEGFR D018
## 3652            p38 MAPK D018
## 3653                 MEK D018
## 3654                 CDK D018
## 3655       Aurora Kinase D018
## 3656                 Raf D018
## 3657                &lt;NA&gt; D018
## 3658                 PKC D018
## 3659                 JNK D018
## 3660               c-Met D018
## 3661                 Src D018
## 3662                 CDK D018
## 3663               VEGFR D018
## 3664                 FAK D018
## 3665                EGFR D018
## 3666                 Raf D018
## 3667            p38 MAPK D018
## 3668                 MEK D018
## 3669       Aurora Kinase D018
## 3670 Hedgehog/Smoothened D018
## 3671                FLT3 D018
## 3672               GSK-3 D018
## 3673               VEGFR D018
## 3674                mTOR D018
## 3675               c-Met D018
## 3676                 CDK D018
## 3677                PI3K D018
## 3678                FLT3 D018
## 3679                 JAK D018
## 3680                PI3K D018
## 3681       TGF-beta/Smad D018
## 3682                ROCK D018
## 3683                 Akt D018
## 3684               GSK-3 D018
## 3685               c-Met D018
## 3686               VEGFR D018
## 3687                 JAK D018
## 3688                 JAK D018
## 3689                mTOR D018
## 3690                 MEK D018
## 3691                 Akt D018
## 3692               VEGFR D018
## 3693               GSK-3 D018
## 3694                EGFR D018
## 3695               PDGFR D018
## 3696                 MEK D018
## 3697                 ERK D018
## 3698                 Akt D018
## 3699                 JNK D018
## 3700                EGFR D018
## 3701               VEGFR D018
## 3702             ATM/ATR D018
## 3703             ATM/ATR D018
## 3704                 Raf D018
## 3705 Hedgehog/Smoothened D018
## 3706                 PLK D018
## 3707                PI3K D018
## 3708                PI3K D018
## 3709                 ERK D018
## 3710       Aurora Kinase D018
## 3711            p38 MAPK D018
## 3712            p38 MAPK D018
## 3713                mTOR D018
## 3714                 Src D018
## 3715                 JAK D018
## 3716    Wnt/beta-catenin D018
## 3717    Wnt/beta-catenin D018
## 3718    Wnt/beta-catenin D018
## 3719                 JAK D018
## 3720                mTOR D018
## 3721                mTOR D018
## 3722                EGFR D018
## 3723                EGFR D018
## 3724                AMPK D018
## 3725                EGFR D018
## 3726    Wnt/beta-catenin D018
## 3727                 JAK D018
## 3728                 ERK D018
## 3729                ROCK D018
## 3730                PI3K D018
## 3731     Gamma-secretase D018
## 3732               VEGFR D018
## 3733               VEGFR D018
## 3734                 Raf D018
## 3735                 JAK D018
## 3736       Aurora Kinase D018
## 3737                mTOR D018
## 3738                PI3K D018
## 3739               GSK-3 D019
## 3740                PI3K D019
## 3741                 Akt D019
## 3742                AMPK D019
## 3743                PI3K D019
## 3744                AMPK D019
## 3745                EGFR D019
## 3746                &lt;NA&gt; D019
## 3747              IGF-1R D019
## 3748                EGFR D019
## 3749                EGFR D019
## 3750                 JAK D019
## 3751                 Akt D019
## 3752       Aurora Kinase D019
## 3753               c-Met D019
## 3754               c-Met D019
## 3755       Aurora Kinase D019
## 3756                PI3K D019
## 3757               c-Met D019
## 3758               VEGFR D019
## 3759               GSK-3 D019
## 3760                PI3K D019
## 3761                PI3K D019
## 3762            p38 MAPK D019
## 3763                EGFR D019
## 3764                 Akt D019
## 3765                 CDK D019
## 3766                 Akt D019
## 3767             Bcr-Abl D019
## 3768       Aurora Kinase D019
## 3769     Gamma-secretase D019
## 3770                 BTK D019
## 3771               VEGFR D019
## 3772               PDGFR D019
## 3773                 Raf D019
## 3774                 JAK D019
## 3775             ATM/ATR D019
## 3776               GSK-3 D019
## 3777                 JAK D019
## 3778                mTOR D019
## 3779               GSK-3 D019
## 3780               PDGFR D019
## 3781                EGFR D019
## 3782                 Akt D019
## 3783                 CDK D019
## 3784                PI3K D019
## 3785             ATM/ATR D019
## 3786                mTOR D019
## 3787                 MEK D019
## 3788                EGFR D019
## 3789                EGFR D019
## 3790       Aurora Kinase D019
## 3791                 JAK D019
## 3792                PI3K D019
## 3793                 PLK D019
## 3794                 JNK D019
## 3795           S6 Kinase D019
## 3796               GSK-3 D019
## 3797               GSK-3 D019
## 3798            p38 MAPK D019
## 3799                 MEK D019
## 3800                &lt;NA&gt; D019
## 3801                PI3K D019
## 3802                 CDK D019
## 3803              IGF-1R D019
## 3804            p38 MAPK D019
## 3805              IGF-1R D019
## 3806               c-Met D019
## 3807               c-Met D019
## 3808 Hedgehog/Smoothened D019
## 3809                 Src D019
## 3810               VEGFR D019
## 3811               VEGFR D019
## 3812                 CDK D019
## 3813                EGFR D019
## 3814                PI3K D019
## 3815               VEGFR D019
## 3816                &lt;NA&gt; D019
## 3817                PI3K D019
## 3818                PI3K D019
## 3819                mTOR D019
## 3820                 Akt D019
## 3821               VEGFR D019
## 3822                 Raf D019
## 3823                 JAK D019
## 3824                 BTK D019
## 3825             ATM/ATR D019
## 3826                PI3K D019
## 3827               GSK-3 D019
## 3828               GSK-3 D019
## 3829                &lt;NA&gt; D019
## 3830                EGFR D019
## 3831                EGFR D019
## 3832                 BTK D019
## 3833                EGFR D019
## 3834                 MEK D019
## 3835               PDGFR D019
## 3836                EGFR D019
## 3837               PDGFR D019
## 3838               c-Met D019
## 3839       Aurora Kinase D019
## 3840                 JAK D019
## 3841                PI3K D019
## 3842                 Raf D019
## 3843                EGFR D019
## 3844       Aurora Kinase D019
## 3845     Gamma-secretase D019
## 3846                 Src D019
## 3847             Bcr-Abl D019
## 3848                 JAK D019
## 3849                 CDK D019
## 3850                &lt;NA&gt; D019
## 3851       Aurora Kinase D019
## 3852                 PKC D019
## 3853                 ERK D019
## 3854                AMPK D019
## 3855                mTOR D019
## 3856                mTOR D019
## 3857                ROCK D019
## 3858    Wnt/beta-catenin D019
## 3859                 JAK D019
## 3860                 CDK D019
## 3861                &lt;NA&gt; D019
## 3862               c-Met D019
## 3863                 Syk D019
## 3864                FLT3 D019
## 3865                 Akt D019
## 3866                mTOR D019
## 3867                 Raf D019
## 3868                PI3K D019
## 3869                mTOR D019
## 3870                EGFR D019
## 3871                EGFR D019
## 3872                 PKC D019
## 3873             Bcr-Abl D019
## 3874             Bcr-Abl D019
## 3875                 PKC D019
## 3876               c-Met D019
## 3877              IGF-1R D019
## 3878              IGF-1R D019
## 3879                PI3K D019
## 3880                PI3K D019
## 3881                PI3K D019
## 3882                ROCK D019
## 3883                 PLK D019
## 3884                AMPK D019
## 3885                 Akt D019
## 3886                 Raf D019
## 3887       TGF-beta/Smad D019
## 3888             Bcr-Abl D019
## 3889           S6 Kinase D019
## 3890       Aurora Kinase D019
## 3891                 PLK D019
## 3892                 Akt D019
## 3893                PI3K D019
## 3894                AMPK D019
## 3895                 Src D019
## 3896    Wnt/beta-catenin D019
## 3897                EGFR D019
## 3898               GSK-3 D019
## 3899               PDGFR D019
## 3900               GSK-3 D019
## 3901                mTOR D019
## 3902                PI3K D019
## 3903    Wnt/beta-catenin D019
## 3904    Wnt/beta-catenin D019
## 3905               c-Met D019
## 3906                 CDK D019
## 3907                 JNK D019
## 3908                 JNK D019
## 3909       TGF-beta/Smad D019
## 3910               VEGFR D019
## 3911               VEGFR D019
## 3912                mTOR D019
## 3913             ATM/ATR D019
## 3914             ATM/ATR D019
## 3915                FLT3 D019
## 3916                 Src D019
## 3917    Wnt/beta-catenin D019
## 3918                EGFR D019
## 3919                EGFR D019
## 3920                 CDK D019
## 3921 Hedgehog/Smoothened D019
## 3922       TGF-beta/Smad D019
## 3923               VEGFR D019
## 3924                 BTK D019
## 3925    Wnt/beta-catenin D019
## 3926               PDGFR D019
## 3927           S6 Kinase D019
## 3928           S6 Kinase D019
## 3929            p38 MAPK D019
## 3930               GSK-3 D019
## 3931       TGF-beta/Smad D019
## 3932                 JAK D019
## 3933                 CDK D019
## 3934                PI3K D019
## 3935                 Akt D019
## 3936     Gamma-secretase D019
## 3937                 MEK D019
## 3938               c-Met D019
## 3939                 CDK D019
## 3940     Gamma-secretase D019
## 3941                 Akt D019
## 3942               c-Met D019
## 3943       Aurora Kinase D019
## 3944       Aurora Kinase D019
## 3945                 Raf D019
## 3946       Aurora Kinase D019
## 3947               VEGFR D019
## 3948             Bcr-Abl D019
## 3949               VEGFR D019
## 3950                 CDK D019
## 3951              IGF-1R D019
## 3952               VEGFR D019
## 3953                 JAK D019
## 3954               c-Met D019
## 3955                 JAK D019
## 3956                EGFR D019
## 3957                 BTK D019
## 3958                mTOR D019
## 3959                EGFR D019
## 3960              IGF-1R D019
## 3961                 CDK D019
## 3962                 JAK D019
## 3963                mTOR D019
## 3964               VEGFR D019
## 3965               VEGFR D019
## 3966                 MEK D019
## 3967                EGFR D019
## 3968             Bcr-Abl D019
## 3969                 MEK D019
## 3970                 MEK D019
## 3971                 MEK D019
## 3972                EGFR D019
## 3973                 FAK D019
## 3974               c-Met D019
## 3975                mTOR D019
## 3976                 FAK D019
## 3977           S6 Kinase D019
## 3978 Hedgehog/Smoothened D019
## 3979                 FAK D019
## 3980                 FAK D019
## 3981            p38 MAPK D019
## 3982               c-Met D019
## 3983       Aurora Kinase D019
## 3984                 CDK D019
## 3985                 CDK D019
## 3986                AMPK D019
## 3987                 Akt D019
## 3988                 Syk D019
## 3989                PI3K D019
## 3990                PI3K D019
## 3991                PI3K D019
## 3992                 MEK D019
## 3993       TGF-beta/Smad D019
## 3994                 Raf D019
## 3995                 Raf D019
## 3996             Bcr-Abl D019
## 3997                 Src D019
## 3998                 Src D019
## 3999                mTOR D019
## 4000              IGF-1R D019
## 4001    Wnt/beta-catenin D019
## 4002                 Syk D019
## 4003                 CDK D019
## 4004                PI3K D019
## 4005                FLT3 D019
## 4006                 Syk D019
## 4007                 Syk D019
## 4008                 CDK D019
## 4009                 Raf D019
## 4010                mTOR D019
## 4011                 MEK D019
## 4012       TGF-beta/Smad D019
## 4013                mTOR D019
## 4014                 PLK D019
## 4015                ROCK D019
## 4016                 BTK D019
## 4017                 PKC D019
## 4018                 CDK D019
## 4019                 PLK D019
## 4020     Gamma-secretase D019
## 4021                 CDK D019
## 4022                 JAK D019
## 4023                 JAK D019
## 4024 Hedgehog/Smoothened D019
## 4025               VEGFR D019
## 4026                PI3K D019
## 4027                 Src D019
## 4028            p38 MAPK D019
## 4029            p38 MAPK D019
## 4030               GSK-3 D019
## 4031            p38 MAPK D019
## 4032               GSK-3 D019
## 4033       TGF-beta/Smad D019
## 4034       TGF-beta/Smad D019
## 4035       TGF-beta/Smad D019
## 4036                 Raf D019
## 4037                 ERK D019
## 4038             ATM/ATR D019
## 4039                 MEK D019
## 4040     Gamma-secretase D019
## 4041               VEGFR D019
## 4042               VEGFR D019
## 4043            p38 MAPK D019
## 4044                 MEK D019
## 4045                 CDK D019
## 4046       Aurora Kinase D019
## 4047                 Raf D019
## 4048                &lt;NA&gt; D019
## 4049                 PKC D019
## 4050                 JNK D019
## 4051               c-Met D019
## 4052                 Src D019
## 4053                 CDK D019
## 4054               VEGFR D019
## 4055                 FAK D019
## 4056                EGFR D019
## 4057                 Raf D019
## 4058            p38 MAPK D019
## 4059                 MEK D019
## 4060       Aurora Kinase D019
## 4061 Hedgehog/Smoothened D019
## 4062                FLT3 D019
## 4063               GSK-3 D019
## 4064               VEGFR D019
## 4065                mTOR D019
## 4066               c-Met D019
## 4067                 CDK D019
## 4068                PI3K D019
## 4069                FLT3 D019
## 4070                 JAK D019
## 4071                PI3K D019
## 4072       TGF-beta/Smad D019
## 4073                ROCK D019
## 4074                 Akt D019
## 4075               GSK-3 D019
## 4076               c-Met D019
## 4077               VEGFR D019
## 4078                 JAK D019
## 4079                 JAK D019
## 4080                mTOR D019
## 4081                 MEK D019
## 4082                 Akt D019
## 4083               VEGFR D019
## 4084               GSK-3 D019
## 4085                EGFR D019
## 4086               PDGFR D019
## 4087                 MEK D019
## 4088                 ERK D019
## 4089                 Akt D019
## 4090                 JNK D019
## 4091                EGFR D019
## 4092               VEGFR D019
## 4093             ATM/ATR D019
## 4094             ATM/ATR D019
## 4095                 Raf D019
## 4096 Hedgehog/Smoothened D019
## 4097                 PLK D019
## 4098                PI3K D019
## 4099                PI3K D019
## 4100                 ERK D019
## 4101       Aurora Kinase D019
## 4102            p38 MAPK D019
## 4103            p38 MAPK D019
## 4104                mTOR D019
## 4105                 Src D019
## 4106                 JAK D019
## 4107    Wnt/beta-catenin D019
## 4108    Wnt/beta-catenin D019
## 4109    Wnt/beta-catenin D019
## 4110                 JAK D019
## 4111                mTOR D019
## 4112                mTOR D019
## 4113                EGFR D019
## 4114                EGFR D019
## 4115                AMPK D019
## 4116                EGFR D019
## 4117    Wnt/beta-catenin D019
## 4118                 JAK D019
## 4119                 ERK D019
## 4120                ROCK D019
## 4121                PI3K D019
## 4122     Gamma-secretase D019
## 4123               VEGFR D019
## 4124               VEGFR D019
## 4125                 Raf D019
## 4126                 JAK D019
## 4127       Aurora Kinase D019
## 4128                mTOR D019
## 4129                PI3K D019
## 4130               GSK-3 D019
## 4131                PI3K D019
## 4132                 Akt D019
## 4133                AMPK D019
## 4134                PI3K D019
## 4135                AMPK D019
## 4136                EGFR D019
## 4137                &lt;NA&gt; D019
## 4138              IGF-1R D019
## 4139                EGFR D019
## 4140                EGFR D019
## 4141                 JAK D019
## 4142                 Akt D019
## 4143       Aurora Kinase D019
## 4144               c-Met D019
## 4145               c-Met D019
## 4146       Aurora Kinase D019
## 4147                PI3K D019
## 4148               c-Met D019
## 4149               VEGFR D019
## 4150               GSK-3 D019
## 4151                PI3K D019
## 4152                PI3K D019
## 4153            p38 MAPK D019
## 4154                EGFR D019
## 4155                 Akt D019
## 4156                 CDK D019
## 4157                 Akt D019
## 4158             Bcr-Abl D019
## 4159       Aurora Kinase D019
## 4160     Gamma-secretase D019
## 4161                 BTK D019
## 4162               VEGFR D019
## 4163               PDGFR D019
## 4164                 Raf D019
## 4165                 JAK D019
## 4166             ATM/ATR D019
## 4167               GSK-3 D019
## 4168                 JAK D019
## 4169                mTOR D019
## 4170               GSK-3 D019
## 4171               PDGFR D019
## 4172                EGFR D019
## 4173                 Akt D019
## 4174                 CDK D019
## 4175                PI3K D019
## 4176             ATM/ATR D019
## 4177                mTOR D019
## 4178                 MEK D019
## 4179                EGFR D019
## 4180                EGFR D019
## 4181       Aurora Kinase D019
## 4182                 JAK D019
## 4183                PI3K D019
## 4184                 PLK D019
## 4185                 JNK D019
## 4186           S6 Kinase D019
## 4187               GSK-3 D019
## 4188               GSK-3 D019
## 4189            p38 MAPK D019
## 4190                 MEK D019
## 4191                &lt;NA&gt; D019
## 4192                PI3K D019
## 4193                 CDK D019
## 4194              IGF-1R D019
## 4195            p38 MAPK D019
## 4196              IGF-1R D019
## 4197               c-Met D019
## 4198               c-Met D019
## 4199 Hedgehog/Smoothened D019
## 4200                 Src D019
## 4201               VEGFR D019
## 4202               VEGFR D019
## 4203                 CDK D019
## 4204                EGFR D019
## 4205                PI3K D019
## 4206               VEGFR D019
## 4207                &lt;NA&gt; D019
## 4208                PI3K D019
## 4209                PI3K D019
## 4210                mTOR D019
## 4211                 Akt D019
## 4212               VEGFR D019
## 4213                 Raf D019
## 4214                 JAK D019
## 4215                 BTK D019
## 4216             ATM/ATR D019
## 4217                PI3K D019
## 4218               GSK-3 D019
## 4219               GSK-3 D019
## 4220                &lt;NA&gt; D019
## 4221                EGFR D019
## 4222                EGFR D019
## 4223                 BTK D019
## 4224                EGFR D019
## 4225                 MEK D019
## 4226               PDGFR D019
## 4227                EGFR D019
## 4228               PDGFR D019
## 4229               c-Met D019
## 4230       Aurora Kinase D019
## 4231                 JAK D019
## 4232                PI3K D019
## 4233                 Raf D019
## 4234                EGFR D019
## 4235       Aurora Kinase D019
## 4236     Gamma-secretase D019
## 4237                 Src D019
## 4238             Bcr-Abl D019
## 4239                 JAK D019
## 4240                 CDK D019
## 4241                &lt;NA&gt; D019
## 4242       Aurora Kinase D019
## 4243                 PKC D019
## 4244                 ERK D019
## 4245                AMPK D019
## 4246                mTOR D019
## 4247                mTOR D019
## 4248                ROCK D019
## 4249    Wnt/beta-catenin D019
## 4250                 JAK D019
## 4251                 CDK D019
## 4252                &lt;NA&gt; D019
## 4253               c-Met D019
## 4254                 Syk D019
## 4255                FLT3 D019
## 4256                 Akt D019
## 4257                mTOR D019
## 4258                 Raf D019
## 4259                PI3K D019
## 4260                mTOR D019
## 4261                EGFR D019
## 4262                EGFR D019
## 4263                 PKC D019
## 4264             Bcr-Abl D019
## 4265             Bcr-Abl D019
## 4266                 PKC D019
## 4267               c-Met D019
## 4268              IGF-1R D019
## 4269              IGF-1R D019
## 4270                PI3K D019
## 4271                PI3K D019
## 4272                PI3K D019
## 4273                ROCK D019
## 4274                 PLK D019
## 4275                AMPK D019
## 4276                 Akt D019
## 4277                 Raf D019
## 4278       TGF-beta/Smad D019
## 4279             Bcr-Abl D019
## 4280           S6 Kinase D019
## 4281       Aurora Kinase D019
## 4282                 PLK D019
## 4283                 Akt D019
## 4284                PI3K D019
## 4285                AMPK D019
## 4286                 Src D019
## 4287    Wnt/beta-catenin D019
## 4288                EGFR D019
## 4289               GSK-3 D019
## 4290               PDGFR D019
## 4291               GSK-3 D019
## 4292                mTOR D019
## 4293                PI3K D019
## 4294    Wnt/beta-catenin D019
## 4295    Wnt/beta-catenin D019
## 4296               c-Met D019
## 4297                 CDK D019
## 4298                 JNK D019
## 4299                 JNK D019
## 4300       TGF-beta/Smad D019
## 4301               VEGFR D019
## 4302               VEGFR D019
## 4303                mTOR D019
## 4304             ATM/ATR D019
## 4305             ATM/ATR D019
## 4306                FLT3 D019
## 4307                 Src D019
## 4308    Wnt/beta-catenin D019
## 4309                EGFR D019
## 4310                EGFR D019
## 4311                 CDK D019
## 4312 Hedgehog/Smoothened D019
## 4313       TGF-beta/Smad D019
## 4314               VEGFR D019
## 4315                 BTK D019
## 4316    Wnt/beta-catenin D019
## 4317               PDGFR D019
## 4318           S6 Kinase D019
## 4319           S6 Kinase D019
## 4320            p38 MAPK D019
## 4321               GSK-3 D019
## 4322       TGF-beta/Smad D019
## 4323                 JAK D019
## 4324                 CDK D019
## 4325                PI3K D019
## 4326                 Akt D019
## 4327     Gamma-secretase D019
## 4328                 MEK D019
## 4329               c-Met D019
## 4330                 CDK D019
## 4331     Gamma-secretase D019
## 4332                 Akt D019
## 4333               c-Met D019
## 4334       Aurora Kinase D019
## 4335       Aurora Kinase D019
## 4336                 Raf D019
## 4337       Aurora Kinase D019
## 4338               VEGFR D019
## 4339             Bcr-Abl D019
## 4340               VEGFR D019
## 4341                 CDK D019
## 4342              IGF-1R D019
## 4343               VEGFR D019
## 4344                 JAK D019
## 4345               c-Met D019
## 4346                 JAK D019
## 4347                EGFR D019
## 4348                 BTK D019
## 4349                mTOR D019
## 4350                EGFR D019
## 4351              IGF-1R D019
## 4352                 CDK D019
## 4353                 JAK D019
## 4354                mTOR D019
## 4355               VEGFR D019
## 4356               VEGFR D019
## 4357                 MEK D019
## 4358                EGFR D019
## 4359             Bcr-Abl D019
## 4360                 MEK D019
## 4361                 MEK D019
## 4362                 MEK D019
## 4363                EGFR D019
## 4364                 FAK D019
## 4365               c-Met D019
## 4366                mTOR D019
## 4367                 FAK D019
## 4368           S6 Kinase D019
## 4369 Hedgehog/Smoothened D019
## 4370                 FAK D019
## 4371                 FAK D019
## 4372            p38 MAPK D019
## 4373               c-Met D019
## 4374       Aurora Kinase D019
## 4375                 CDK D019
## 4376                 CDK D019
## 4377                AMPK D019
## 4378                 Akt D019
## 4379                 Syk D019
## 4380                PI3K D019
## 4381                PI3K D019
## 4382                PI3K D019
## 4383                 MEK D019
## 4384       TGF-beta/Smad D019
## 4385                 Raf D019
## 4386                 Raf D019
## 4387             Bcr-Abl D019
## 4388                 Src D019
## 4389                 Src D019
## 4390                mTOR D019
## 4391              IGF-1R D019
## 4392    Wnt/beta-catenin D019
## 4393                 Syk D019
## 4394                 CDK D019
## 4395                PI3K D019
## 4396                FLT3 D019
## 4397                 Syk D019
## 4398                 Syk D019
## 4399                 CDK D019
## 4400                 Raf D019
## 4401                mTOR D019
## 4402                 MEK D019
## 4403       TGF-beta/Smad D019
## 4404                mTOR D019
## 4405                 PLK D019
## 4406                ROCK D019
## 4407                 BTK D019
## 4408                 PKC D019
## 4409                 CDK D019
## 4410                 PLK D019
## 4411     Gamma-secretase D019
## 4412                 CDK D019
## 4413                 JAK D019
## 4414                 JAK D019
## 4415 Hedgehog/Smoothened D019
## 4416               VEGFR D019
## 4417                PI3K D019
## 4418                 Src D019
## 4419            p38 MAPK D019
## 4420            p38 MAPK D019
## 4421               GSK-3 D019
## 4422            p38 MAPK D019
## 4423               GSK-3 D019
## 4424       TGF-beta/Smad D019
## 4425       TGF-beta/Smad D019
## 4426       TGF-beta/Smad D019
## 4427                 Raf D019
## 4428                 ERK D019
## 4429             ATM/ATR D019
## 4430                 MEK D019
## 4431     Gamma-secretase D019
## 4432               VEGFR D019
## 4433               VEGFR D019
## 4434            p38 MAPK D019
## 4435                 MEK D019
## 4436                 CDK D019
## 4437       Aurora Kinase D019
## 4438                 Raf D019
## 4439                &lt;NA&gt; D019
## 4440                 PKC D019
## 4441                 JNK D019
## 4442               c-Met D019
## 4443                 Src D019
## 4444                 CDK D019
## 4445               VEGFR D019
## 4446                 FAK D019
## 4447                EGFR D019
## 4448                 Raf D019
## 4449            p38 MAPK D019
## 4450                 MEK D019
## 4451       Aurora Kinase D019
## 4452 Hedgehog/Smoothened D019
## 4453                FLT3 D019
## 4454               GSK-3 D019
## 4455               VEGFR D019
## 4456                mTOR D019
## 4457               c-Met D019
## 4458                 CDK D019
## 4459                PI3K D019
## 4460                FLT3 D019
## 4461                 JAK D019
## 4462                PI3K D019
## 4463       TGF-beta/Smad D019
## 4464                ROCK D019
## 4465                 Akt D019
## 4466               GSK-3 D019
## 4467               c-Met D019
## 4468               VEGFR D019
## 4469                 JAK D019
## 4470                 JAK D019
## 4471                mTOR D019
## 4472                 MEK D019
## 4473                 Akt D019
## 4474               VEGFR D019
## 4475               GSK-3 D019
## 4476                EGFR D019
## 4477               PDGFR D019
## 4478                 MEK D019
## 4479                 ERK D019
## 4480                 Akt D019
## 4481                 JNK D019
## 4482                EGFR D019
## 4483               VEGFR D019
## 4484             ATM/ATR D019
## 4485             ATM/ATR D019
## 4486                 Raf D019
## 4487 Hedgehog/Smoothened D019
## 4488                 PLK D019
## 4489                PI3K D019
## 4490                PI3K D019
## 4491                 ERK D019
## 4492       Aurora Kinase D019
## 4493            p38 MAPK D019
## 4494            p38 MAPK D019
## 4495                mTOR D019
## 4496                 Src D019
## 4497                 JAK D019
## 4498    Wnt/beta-catenin D019
## 4499    Wnt/beta-catenin D019
## 4500    Wnt/beta-catenin D019
## 4501                 JAK D019
## 4502                mTOR D019
## 4503                mTOR D019
## 4504                EGFR D019
## 4505                EGFR D019
## 4506                AMPK D019
## 4507                EGFR D019
## 4508    Wnt/beta-catenin D019
## 4509                 JAK D019
## 4510                 ERK D019
## 4511                ROCK D019
## 4512                PI3K D019
## 4513     Gamma-secretase D019
## 4514               VEGFR D019
## 4515               VEGFR D019
## 4516                 Raf D019
## 4517                 JAK D019
## 4518       Aurora Kinase D019
## 4519                mTOR D019
## 4520                PI3K D019
## 4521               GSK-3 D020
## 4522                PI3K D020
## 4523                 Akt D020
## 4524                AMPK D020
## 4525                PI3K D020
## 4526                AMPK D020
## 4527                EGFR D020
## 4528                &lt;NA&gt; D020
## 4529              IGF-1R D020
## 4530                EGFR D020
## 4531                EGFR D020
## 4532                 JAK D020
## 4533                 Akt D020
## 4534       Aurora Kinase D020
## 4535               c-Met D020
## 4536               c-Met D020
## 4537       Aurora Kinase D020
## 4538                PI3K D020
## 4539               c-Met D020
## 4540               VEGFR D020
## 4541               GSK-3 D020
## 4542                PI3K D020
## 4543                PI3K D020
## 4544            p38 MAPK D020
## 4545                EGFR D020
## 4546                 Akt D020
## 4547                 CDK D020
## 4548                 Akt D020
## 4549             Bcr-Abl D020
## 4550       Aurora Kinase D020
## 4551     Gamma-secretase D020
## 4552                 BTK D020
## 4553               VEGFR D020
## 4554               PDGFR D020
## 4555                 Raf D020
## 4556                 JAK D020
## 4557             ATM/ATR D020
## 4558               GSK-3 D020
## 4559                 JAK D020
## 4560                mTOR D020
## 4561               GSK-3 D020
## 4562               PDGFR D020
## 4563                EGFR D020
## 4564                 Akt D020
## 4565                 CDK D020
## 4566                PI3K D020
## 4567             ATM/ATR D020
## 4568                mTOR D020
## 4569                 MEK D020
## 4570                EGFR D020
## 4571                EGFR D020
## 4572       Aurora Kinase D020
## 4573                 JAK D020
## 4574                PI3K D020
## 4575                 PLK D020
## 4576                 JNK D020
## 4577           S6 Kinase D020
## 4578               GSK-3 D020
## 4579               GSK-3 D020
## 4580            p38 MAPK D020
## 4581                 MEK D020
## 4582                &lt;NA&gt; D020
## 4583                PI3K D020
## 4584                 CDK D020
## 4585              IGF-1R D020
## 4586            p38 MAPK D020
## 4587              IGF-1R D020
## 4588               c-Met D020
## 4589               c-Met D020
## 4590 Hedgehog/Smoothened D020
## 4591                 Src D020
## 4592               VEGFR D020
## 4593               VEGFR D020
## 4594                 CDK D020
## 4595                EGFR D020
## 4596                PI3K D020
## 4597               VEGFR D020
## 4598                &lt;NA&gt; D020
## 4599                PI3K D020
## 4600                PI3K D020
## 4601                mTOR D020
## 4602                 Akt D020
## 4603               VEGFR D020
## 4604                 Raf D020
## 4605                 JAK D020
## 4606                 BTK D020
## 4607             ATM/ATR D020
## 4608                PI3K D020
## 4609               GSK-3 D020
## 4610               GSK-3 D020
## 4611                &lt;NA&gt; D020
## 4612                EGFR D020
## 4613                EGFR D020
## 4614                 BTK D020
## 4615                EGFR D020
## 4616                 MEK D020
## 4617               PDGFR D020
## 4618                EGFR D020
## 4619               PDGFR D020
## 4620               c-Met D020
## 4621       Aurora Kinase D020
## 4622                 JAK D020
## 4623                PI3K D020
## 4624                 Raf D020
## 4625                EGFR D020
## 4626       Aurora Kinase D020
## 4627     Gamma-secretase D020
## 4628                 Src D020
## 4629             Bcr-Abl D020
## 4630                 JAK D020
## 4631                 CDK D020
## 4632                &lt;NA&gt; D020
## 4633       Aurora Kinase D020
## 4634                 PKC D020
## 4635                 ERK D020
## 4636                AMPK D020
## 4637                mTOR D020
## 4638                mTOR D020
## 4639                ROCK D020
## 4640    Wnt/beta-catenin D020
## 4641                 JAK D020
## 4642                 CDK D020
## 4643                &lt;NA&gt; D020
## 4644               c-Met D020
## 4645                 Syk D020
## 4646                FLT3 D020
## 4647                 Akt D020
## 4648                mTOR D020
## 4649                 Raf D020
## 4650                PI3K D020
## 4651                mTOR D020
## 4652                EGFR D020
## 4653                EGFR D020
## 4654                 PKC D020
## 4655             Bcr-Abl D020
## 4656             Bcr-Abl D020
## 4657                 PKC D020
## 4658               c-Met D020
## 4659              IGF-1R D020
## 4660              IGF-1R D020
## 4661                PI3K D020
## 4662                PI3K D020
## 4663                PI3K D020
## 4664                ROCK D020
## 4665                 PLK D020
## 4666                AMPK D020
## 4667                 Akt D020
## 4668                 Raf D020
## 4669       TGF-beta/Smad D020
## 4670             Bcr-Abl D020
## 4671           S6 Kinase D020
## 4672       Aurora Kinase D020
## 4673                 PLK D020
## 4674                 Akt D020
## 4675                PI3K D020
## 4676                AMPK D020
## 4677                 Src D020
## 4678    Wnt/beta-catenin D020
## 4679                EGFR D020
## 4680               GSK-3 D020
## 4681               PDGFR D020
## 4682               GSK-3 D020
## 4683                mTOR D020
## 4684                PI3K D020
## 4685    Wnt/beta-catenin D020
## 4686    Wnt/beta-catenin D020
## 4687               c-Met D020
## 4688                 CDK D020
## 4689                 JNK D020
## 4690                 JNK D020
## 4691       TGF-beta/Smad D020
## 4692               VEGFR D020
## 4693               VEGFR D020
## 4694                mTOR D020
## 4695             ATM/ATR D020
## 4696             ATM/ATR D020
## 4697                FLT3 D020
## 4698                 Src D020
## 4699    Wnt/beta-catenin D020
## 4700                EGFR D020
## 4701                EGFR D020
## 4702                 CDK D020
## 4703 Hedgehog/Smoothened D020
## 4704       TGF-beta/Smad D020
## 4705               VEGFR D020
## 4706                 BTK D020
## 4707    Wnt/beta-catenin D020
## 4708               PDGFR D020
## 4709           S6 Kinase D020
## 4710           S6 Kinase D020
## 4711            p38 MAPK D020
## 4712               GSK-3 D020
## 4713       TGF-beta/Smad D020
## 4714                 JAK D020
## 4715                 CDK D020
## 4716                PI3K D020
## 4717                 Akt D020
## 4718     Gamma-secretase D020
## 4719                 MEK D020
## 4720               c-Met D020
## 4721                 CDK D020
## 4722     Gamma-secretase D020
## 4723                 Akt D020
## 4724               c-Met D020
## 4725       Aurora Kinase D020
## 4726       Aurora Kinase D020
## 4727                 Raf D020
## 4728       Aurora Kinase D020
## 4729               VEGFR D020
## 4730             Bcr-Abl D020
## 4731               VEGFR D020
## 4732                 CDK D020
## 4733              IGF-1R D020
## 4734               VEGFR D020
## 4735                 JAK D020
## 4736               c-Met D020
## 4737                 JAK D020
## 4738                EGFR D020
## 4739                 BTK D020
## 4740                mTOR D020
## 4741                EGFR D020
## 4742              IGF-1R D020
## 4743                 CDK D020
## 4744                 JAK D020
## 4745                mTOR D020
## 4746               VEGFR D020
## 4747               VEGFR D020
## 4748                 MEK D020
## 4749                EGFR D020
## 4750             Bcr-Abl D020
## 4751                 MEK D020
## 4752                 MEK D020
## 4753                 MEK D020
## 4754                EGFR D020
## 4755                 FAK D020
## 4756               c-Met D020
## 4757                mTOR D020
## 4758                 FAK D020
## 4759           S6 Kinase D020
## 4760 Hedgehog/Smoothened D020
## 4761                 FAK D020
## 4762                 FAK D020
## 4763            p38 MAPK D020
## 4764               c-Met D020
## 4765       Aurora Kinase D020
## 4766                 CDK D020
## 4767                 CDK D020
## 4768                AMPK D020
## 4769                 Akt D020
## 4770                 Syk D020
## 4771                PI3K D020
## 4772                PI3K D020
## 4773                PI3K D020
## 4774                 MEK D020
## 4775       TGF-beta/Smad D020
## 4776                 Raf D020
## 4777                 Raf D020
## 4778             Bcr-Abl D020
## 4779                 Src D020
## 4780                 Src D020
## 4781                mTOR D020
## 4782              IGF-1R D020
## 4783    Wnt/beta-catenin D020
## 4784                 Syk D020
## 4785                 CDK D020
## 4786                PI3K D020
## 4787                FLT3 D020
## 4788                 Syk D020
## 4789                 Syk D020
## 4790                 CDK D020
## 4791                 Raf D020
## 4792                mTOR D020
## 4793                 MEK D020
## 4794       TGF-beta/Smad D020
## 4795                mTOR D020
## 4796                 PLK D020
## 4797                ROCK D020
## 4798                 BTK D020
## 4799                 PKC D020
## 4800                 CDK D020
## 4801                 PLK D020
## 4802     Gamma-secretase D020
## 4803                 CDK D020
## 4804                 JAK D020
## 4805                 JAK D020
## 4806 Hedgehog/Smoothened D020
## 4807               VEGFR D020
## 4808                PI3K D020
## 4809                 Src D020
## 4810            p38 MAPK D020
## 4811            p38 MAPK D020
## 4812               GSK-3 D020
## 4813            p38 MAPK D020
## 4814               GSK-3 D020
## 4815       TGF-beta/Smad D020
## 4816       TGF-beta/Smad D020
## 4817       TGF-beta/Smad D020
## 4818                 Raf D020
## 4819                 ERK D020
## 4820             ATM/ATR D020
## 4821                 MEK D020
## 4822     Gamma-secretase D020
## 4823               VEGFR D020
## 4824               VEGFR D020
## 4825            p38 MAPK D020
## 4826                 MEK D020
## 4827                 CDK D020
## 4828       Aurora Kinase D020
## 4829                 Raf D020
## 4830                &lt;NA&gt; D020
## 4831                 PKC D020
## 4832                 JNK D020
## 4833               c-Met D020
## 4834                 Src D020
## 4835                 CDK D020
## 4836               VEGFR D020
## 4837                 FAK D020
## 4838                EGFR D020
## 4839                 Raf D020
## 4840            p38 MAPK D020
## 4841                 MEK D020
## 4842       Aurora Kinase D020
## 4843 Hedgehog/Smoothened D020
## 4844                FLT3 D020
## 4845               GSK-3 D020
## 4846               VEGFR D020
## 4847                mTOR D020
## 4848               c-Met D020
## 4849                 CDK D020
## 4850                PI3K D020
## 4851                FLT3 D020
## 4852                 JAK D020
## 4853                PI3K D020
## 4854       TGF-beta/Smad D020
## 4855                ROCK D020
## 4856                 Akt D020
## 4857               GSK-3 D020
## 4858               c-Met D020
## 4859               VEGFR D020
## 4860                 JAK D020
## 4861                 JAK D020
## 4862                mTOR D020
## 4863                 MEK D020
## 4864                 Akt D020
## 4865               VEGFR D020
## 4866               GSK-3 D020
## 4867                EGFR D020
## 4868               PDGFR D020
## 4869                 MEK D020
## 4870                 ERK D020
## 4871                 Akt D020
## 4872                 JNK D020
## 4873                EGFR D020
## 4874               VEGFR D020
## 4875             ATM/ATR D020
## 4876             ATM/ATR D020
## 4877                 Raf D020
## 4878 Hedgehog/Smoothened D020
## 4879                 PLK D020
## 4880                PI3K D020
## 4881                PI3K D020
## 4882                 ERK D020
## 4883       Aurora Kinase D020
## 4884            p38 MAPK D020
## 4885            p38 MAPK D020
## 4886                mTOR D020
## 4887                 Src D020
## 4888                 JAK D020
## 4889    Wnt/beta-catenin D020
## 4890    Wnt/beta-catenin D020
## 4891    Wnt/beta-catenin D020
## 4892                 JAK D020
## 4893                mTOR D020
## 4894                mTOR D020
## 4895                EGFR D020
## 4896                EGFR D020
## 4897                AMPK D020
## 4898                EGFR D020
## 4899    Wnt/beta-catenin D020
## 4900                 JAK D020
## 4901                 ERK D020
## 4902                ROCK D020
## 4903                PI3K D020
## 4904     Gamma-secretase D020
## 4905               VEGFR D020
## 4906               VEGFR D020
## 4907                 Raf D020
## 4908                 JAK D020
## 4909       Aurora Kinase D020
## 4910                mTOR D020
## 4911                PI3K D020
## 4912               GSK-3 D020
## 4913                PI3K D020
## 4914                 Akt D020
## 4915                AMPK D020
## 4916                PI3K D020
## 4917                AMPK D020
## 4918                EGFR D020
## 4919                &lt;NA&gt; D020
## 4920              IGF-1R D020
## 4921                EGFR D020
## 4922                EGFR D020
## 4923                 JAK D020
## 4924                 Akt D020
## 4925       Aurora Kinase D020
## 4926               c-Met D020
## 4927               c-Met D020
## 4928       Aurora Kinase D020
## 4929                PI3K D020
## 4930               c-Met D020
## 4931               VEGFR D020
## 4932               GSK-3 D020
## 4933                PI3K D020
## 4934                PI3K D020
## 4935            p38 MAPK D020
## 4936                EGFR D020
## 4937                 Akt D020
## 4938                 CDK D020
## 4939                 Akt D020
## 4940             Bcr-Abl D020
## 4941       Aurora Kinase D020
## 4942     Gamma-secretase D020
## 4943                 BTK D020
## 4944               VEGFR D020
## 4945               PDGFR D020
## 4946                 Raf D020
## 4947                 JAK D020
## 4948             ATM/ATR D020
## 4949               GSK-3 D020
## 4950                 JAK D020
## 4951                mTOR D020
## 4952               GSK-3 D020
## 4953               PDGFR D020
## 4954                EGFR D020
## 4955                 Akt D020
## 4956                 CDK D020
## 4957                PI3K D020
## 4958             ATM/ATR D020
## 4959                mTOR D020
## 4960                 MEK D020
## 4961                EGFR D020
## 4962                EGFR D020
## 4963       Aurora Kinase D020
## 4964                 JAK D020
## 4965                PI3K D020
## 4966                 PLK D020
## 4967                 JNK D020
## 4968           S6 Kinase D020
## 4969               GSK-3 D020
## 4970               GSK-3 D020
## 4971            p38 MAPK D020
## 4972                 MEK D020
## 4973                &lt;NA&gt; D020
## 4974                PI3K D020
## 4975                 CDK D020
## 4976              IGF-1R D020
## 4977            p38 MAPK D020
## 4978              IGF-1R D020
## 4979               c-Met D020
## 4980               c-Met D020
## 4981 Hedgehog/Smoothened D020
## 4982                 Src D020
## 4983               VEGFR D020
## 4984               VEGFR D020
## 4985                 CDK D020
## 4986                EGFR D020
## 4987                PI3K D020
## 4988               VEGFR D020
## 4989                &lt;NA&gt; D020
## 4990                PI3K D020
## 4991                PI3K D020
## 4992                mTOR D020
## 4993                 Akt D020
## 4994               VEGFR D020
## 4995                 Raf D020
## 4996                 JAK D020
## 4997                 BTK D020
## 4998             ATM/ATR D020
## 4999                PI3K D020
## 5000               GSK-3 D020
## 5001               GSK-3 D020
## 5002                &lt;NA&gt; D020
## 5003                EGFR D020
## 5004                EGFR D020
## 5005                 BTK D020
## 5006                EGFR D020
## 5007                 MEK D020
## 5008               PDGFR D020
## 5009                EGFR D020
## 5010               PDGFR D020
## 5011               c-Met D020
## 5012       Aurora Kinase D020
## 5013                 JAK D020
## 5014                PI3K D020
## 5015                 Raf D020
## 5016                EGFR D020
## 5017       Aurora Kinase D020
## 5018     Gamma-secretase D020
## 5019                 Src D020
## 5020             Bcr-Abl D020
## 5021                 JAK D020
## 5022                 CDK D020
## 5023                &lt;NA&gt; D020
## 5024       Aurora Kinase D020
## 5025                 PKC D020
## 5026                 ERK D020
## 5027                AMPK D020
## 5028                mTOR D020
## 5029                mTOR D020
## 5030                ROCK D020
## 5031    Wnt/beta-catenin D020
## 5032                 JAK D020
## 5033                 CDK D020
## 5034                &lt;NA&gt; D020
## 5035               c-Met D020
## 5036                 Syk D020
## 5037                FLT3 D020
## 5038                 Akt D020
## 5039                mTOR D020
## 5040                 Raf D020
## 5041                PI3K D020
## 5042                mTOR D020
## 5043                EGFR D020
## 5044                EGFR D020
## 5045                 PKC D020
## 5046             Bcr-Abl D020
## 5047             Bcr-Abl D020
## 5048                 PKC D020
## 5049               c-Met D020
## 5050              IGF-1R D020
## 5051              IGF-1R D020
## 5052                PI3K D020
## 5053                PI3K D020
## 5054                PI3K D020
## 5055                ROCK D020
## 5056                 PLK D020
## 5057                AMPK D020
## 5058                 Akt D020
## 5059                 Raf D020
## 5060       TGF-beta/Smad D020
## 5061             Bcr-Abl D020
## 5062           S6 Kinase D020
## 5063       Aurora Kinase D020
## 5064                 PLK D020
## 5065                 Akt D020
## 5066                PI3K D020
## 5067                AMPK D020
## 5068                 Src D020
## 5069    Wnt/beta-catenin D020
## 5070                EGFR D020
## 5071               GSK-3 D020
## 5072               PDGFR D020
## 5073               GSK-3 D020
## 5074                mTOR D020
## 5075                PI3K D020
## 5076    Wnt/beta-catenin D020
## 5077    Wnt/beta-catenin D020
## 5078               c-Met D020
## 5079                 CDK D020
## 5080                 JNK D020
## 5081                 JNK D020
## 5082       TGF-beta/Smad D020
## 5083               VEGFR D020
## 5084               VEGFR D020
## 5085                mTOR D020
## 5086             ATM/ATR D020
## 5087             ATM/ATR D020
## 5088                FLT3 D020
## 5089                 Src D020
## 5090    Wnt/beta-catenin D020
## 5091                EGFR D020
## 5092                EGFR D020
## 5093                 CDK D020
## 5094 Hedgehog/Smoothened D020
## 5095       TGF-beta/Smad D020
## 5096               VEGFR D020
## 5097                 BTK D020
## 5098    Wnt/beta-catenin D020
## 5099               PDGFR D020
## 5100           S6 Kinase D020
## 5101           S6 Kinase D020
## 5102            p38 MAPK D020
## 5103               GSK-3 D020
## 5104       TGF-beta/Smad D020
## 5105                 JAK D020
## 5106                 CDK D020
## 5107                PI3K D020
## 5108                 Akt D020
## 5109     Gamma-secretase D020
## 5110                 MEK D020
## 5111               c-Met D020
## 5112                 CDK D020
## 5113     Gamma-secretase D020
## 5114                 Akt D020
## 5115               c-Met D020
## 5116       Aurora Kinase D020
## 5117       Aurora Kinase D020
## 5118                 Raf D020
## 5119       Aurora Kinase D020
## 5120               VEGFR D020
## 5121             Bcr-Abl D020
## 5122               VEGFR D020
## 5123                 CDK D020
## 5124              IGF-1R D020
## 5125               VEGFR D020
## 5126                 JAK D020
## 5127               c-Met D020
## 5128                 JAK D020
## 5129                EGFR D020
## 5130                 BTK D020
## 5131                mTOR D020
## 5132                EGFR D020
## 5133              IGF-1R D020
## 5134                 CDK D020
## 5135                 JAK D020
## 5136                mTOR D020
## 5137               VEGFR D020
## 5138               VEGFR D020
## 5139                 MEK D020
## 5140                EGFR D020
## 5141             Bcr-Abl D020
## 5142                 MEK D020
## 5143                 MEK D020
## 5144                 MEK D020
## 5145                EGFR D020
## 5146                 FAK D020
## 5147               c-Met D020
## 5148                mTOR D020
## 5149                 FAK D020
## 5150           S6 Kinase D020
## 5151 Hedgehog/Smoothened D020
## 5152                 FAK D020
## 5153                 FAK D020
## 5154            p38 MAPK D020
## 5155               c-Met D020
## 5156       Aurora Kinase D020
## 5157                 CDK D020
## 5158                 CDK D020
## 5159                AMPK D020
## 5160                 Akt D020
## 5161                 Syk D020
## 5162                PI3K D020
## 5163                PI3K D020
## 5164                PI3K D020
## 5165                 MEK D020
## 5166       TGF-beta/Smad D020
## 5167                 Raf D020
## 5168                 Raf D020
## 5169             Bcr-Abl D020
## 5170                 Src D020
## 5171                 Src D020
## 5172                mTOR D020
## 5173              IGF-1R D020
## 5174    Wnt/beta-catenin D020
## 5175                 Syk D020
## 5176                 CDK D020
## 5177                PI3K D020
## 5178                FLT3 D020
## 5179                 Syk D020
## 5180                 Syk D020
## 5181                 CDK D020
## 5182                 Raf D020
## 5183                mTOR D020
## 5184                 MEK D020
## 5185       TGF-beta/Smad D020
## 5186                mTOR D020
## 5187                 PLK D020
## 5188                ROCK D020
## 5189                 BTK D020
## 5190                 PKC D020
## 5191                 CDK D020
## 5192                 PLK D020
## 5193     Gamma-secretase D020
## 5194                 CDK D020
## 5195                 JAK D020
## 5196                 JAK D020
## 5197 Hedgehog/Smoothened D020
## 5198               VEGFR D020
## 5199                PI3K D020
## 5200                 Src D020
## 5201            p38 MAPK D020
## 5202            p38 MAPK D020
## 5203               GSK-3 D020
## 5204            p38 MAPK D020
## 5205               GSK-3 D020
## 5206       TGF-beta/Smad D020
## 5207       TGF-beta/Smad D020
## 5208       TGF-beta/Smad D020
## 5209                 Raf D020
## 5210                 ERK D020
## 5211             ATM/ATR D020
## 5212                 MEK D020
## 5213     Gamma-secretase D020
## 5214               VEGFR D020
## 5215               VEGFR D020
## 5216            p38 MAPK D020
## 5217                 MEK D020
## 5218                 CDK D020
## 5219       Aurora Kinase D020
## 5220                 Raf D020
## 5221                &lt;NA&gt; D020
## 5222                 PKC D020
## 5223                 JNK D020
## 5224               c-Met D020
## 5225                 Src D020
## 5226                 CDK D020
## 5227               VEGFR D020
## 5228                 FAK D020
## 5229                EGFR D020
## 5230                 Raf D020
## 5231            p38 MAPK D020
## 5232                 MEK D020
## 5233       Aurora Kinase D020
## 5234 Hedgehog/Smoothened D020
## 5235                FLT3 D020
## 5236               GSK-3 D020
## 5237               VEGFR D020
## 5238                mTOR D020
## 5239               c-Met D020
## 5240                 CDK D020
## 5241                PI3K D020
## 5242                FLT3 D020
## 5243                 JAK D020
## 5244                PI3K D020
## 5245       TGF-beta/Smad D020
## 5246                ROCK D020
## 5247                 Akt D020
## 5248               GSK-3 D020
## 5249               c-Met D020
## 5250               VEGFR D020
## 5251                 JAK D020
## 5252                 JAK D020
## 5253                mTOR D020
## 5254                 MEK D020
## 5255                 Akt D020
## 5256               VEGFR D020
## 5257               GSK-3 D020
## 5258                EGFR D020
## 5259               PDGFR D020
## 5260                 MEK D020
## 5261                 ERK D020
## 5262                 Akt D020
## 5263                 JNK D020
## 5264                EGFR D020
## 5265               VEGFR D020
## 5266             ATM/ATR D020
## 5267             ATM/ATR D020
## 5268                 Raf D020
## 5269 Hedgehog/Smoothened D020
## 5270                 PLK D020
## 5271                PI3K D020
## 5272                PI3K D020
## 5273                 ERK D020
## 5274       Aurora Kinase D020
## 5275            p38 MAPK D020
## 5276            p38 MAPK D020
## 5277                mTOR D020
## 5278                 Src D020
## 5279                 JAK D020
## 5280    Wnt/beta-catenin D020
## 5281    Wnt/beta-catenin D020
## 5282    Wnt/beta-catenin D020
## 5283                 JAK D020
## 5284                mTOR D020
## 5285                mTOR D020
## 5286                EGFR D020
## 5287                EGFR D020
## 5288                AMPK D020
## 5289                EGFR D020
## 5290    Wnt/beta-catenin D020
## 5291                 JAK D020
## 5292                 ERK D020
## 5293                ROCK D020
## 5294                PI3K D020
## 5295     Gamma-secretase D020
## 5296               VEGFR D020
## 5297               VEGFR D020
## 5298                 Raf D020
## 5299                 JAK D020
## 5300       Aurora Kinase D020
## 5301                mTOR D020
## 5302                PI3K D020
## 5303               GSK-3 D022
## 5304                PI3K D022
## 5305                 Akt D022
## 5306                AMPK D022
## 5307                PI3K D022
## 5308                AMPK D022
## 5309                EGFR D022
## 5310                &lt;NA&gt; D022
## 5311              IGF-1R D022
## 5312                EGFR D022
## 5313                EGFR D022
## 5314                 JAK D022
## 5315                 Akt D022
## 5316       Aurora Kinase D022
## 5317               c-Met D022
## 5318               c-Met D022
## 5319       Aurora Kinase D022
## 5320                PI3K D022
## 5321               c-Met D022
## 5322               VEGFR D022
## 5323               GSK-3 D022
## 5324                PI3K D022
## 5325                PI3K D022
## 5326            p38 MAPK D022
## 5327                EGFR D022
## 5328                 Akt D022
## 5329                 CDK D022
## 5330                 Akt D022
## 5331             Bcr-Abl D022
## 5332       Aurora Kinase D022
## 5333     Gamma-secretase D022
## 5334                 BTK D022
## 5335               VEGFR D022
## 5336               PDGFR D022
## 5337                 Raf D022
## 5338                 JAK D022
## 5339             ATM/ATR D022
## 5340               GSK-3 D022
## 5341                 JAK D022
## 5342                mTOR D022
## 5343               GSK-3 D022
## 5344               PDGFR D022
## 5345                EGFR D022
## 5346                 Akt D022
## 5347                 CDK D022
## 5348                PI3K D022
## 5349             ATM/ATR D022
## 5350                mTOR D022
## 5351                 MEK D022
## 5352                EGFR D022
## 5353                EGFR D022
## 5354       Aurora Kinase D022
## 5355                 JAK D022
## 5356                PI3K D022
## 5357                 PLK D022
## 5358                 JNK D022
## 5359           S6 Kinase D022
## 5360               GSK-3 D022
## 5361               GSK-3 D022
## 5362            p38 MAPK D022
## 5363                 MEK D022
## 5364                &lt;NA&gt; D022
## 5365                PI3K D022
## 5366                 CDK D022
## 5367              IGF-1R D022
## 5368            p38 MAPK D022
## 5369              IGF-1R D022
## 5370               c-Met D022
## 5371               c-Met D022
## 5372 Hedgehog/Smoothened D022
## 5373                 Src D022
## 5374               VEGFR D022
## 5375               VEGFR D022
## 5376                 CDK D022
## 5377                EGFR D022
## 5378                PI3K D022
## 5379               VEGFR D022
## 5380                &lt;NA&gt; D022
## 5381                PI3K D022
## 5382                PI3K D022
## 5383                mTOR D022
## 5384                 Akt D022
## 5385               VEGFR D022
## 5386                 Raf D022
## 5387                 JAK D022
## 5388                 BTK D022
## 5389             ATM/ATR D022
## 5390                PI3K D022
## 5391               GSK-3 D022
## 5392               GSK-3 D022
## 5393                &lt;NA&gt; D022
## 5394                EGFR D022
## 5395                EGFR D022
## 5396                 BTK D022
## 5397                EGFR D022
## 5398                 MEK D022
## 5399               PDGFR D022
## 5400                EGFR D022
## 5401               PDGFR D022
## 5402               c-Met D022
## 5403       Aurora Kinase D022
## 5404                 JAK D022
## 5405                PI3K D022
## 5406                 Raf D022
## 5407                EGFR D022
## 5408       Aurora Kinase D022
## 5409     Gamma-secretase D022
## 5410                 Src D022
## 5411             Bcr-Abl D022
## 5412                 JAK D022
## 5413                 CDK D022
## 5414                &lt;NA&gt; D022
## 5415       Aurora Kinase D022
## 5416                 PKC D022
## 5417                 ERK D022
## 5418                AMPK D022
## 5419                mTOR D022
## 5420                mTOR D022
## 5421                ROCK D022
## 5422    Wnt/beta-catenin D022
## 5423                 JAK D022
## 5424                 CDK D022
## 5425                &lt;NA&gt; D022
## 5426               c-Met D022
## 5427                 Syk D022
## 5428                FLT3 D022
## 5429                 Akt D022
## 5430                mTOR D022
## 5431                 Raf D022
## 5432                PI3K D022
## 5433                mTOR D022
## 5434                EGFR D022
## 5435                EGFR D022
## 5436                 PKC D022
## 5437             Bcr-Abl D022
## 5438             Bcr-Abl D022
## 5439                 PKC D022
## 5440               c-Met D022
## 5441              IGF-1R D022
## 5442              IGF-1R D022
## 5443                PI3K D022
## 5444                PI3K D022
## 5445                PI3K D022
## 5446                ROCK D022
## 5447                 PLK D022
## 5448                AMPK D022
## 5449                 Akt D022
## 5450                 Raf D022
## 5451       TGF-beta/Smad D022
## 5452             Bcr-Abl D022
## 5453           S6 Kinase D022
## 5454       Aurora Kinase D022
## 5455                 PLK D022
## 5456                 Akt D022
## 5457                PI3K D022
## 5458                AMPK D022
## 5459                 Src D022
## 5460    Wnt/beta-catenin D022
## 5461                EGFR D022
## 5462               GSK-3 D022
## 5463               PDGFR D022
## 5464               GSK-3 D022
## 5465                mTOR D022
## 5466                PI3K D022
## 5467    Wnt/beta-catenin D022
## 5468    Wnt/beta-catenin D022
## 5469               c-Met D022
## 5470                 CDK D022
## 5471                 JNK D022
## 5472                 JNK D022
## 5473       TGF-beta/Smad D022
## 5474               VEGFR D022
## 5475               VEGFR D022
## 5476                mTOR D022
## 5477             ATM/ATR D022
## 5478             ATM/ATR D022
## 5479                FLT3 D022
## 5480                 Src D022
## 5481    Wnt/beta-catenin D022
## 5482                EGFR D022
## 5483                EGFR D022
## 5484                 CDK D022
## 5485 Hedgehog/Smoothened D022
## 5486       TGF-beta/Smad D022
## 5487               VEGFR D022
## 5488                 BTK D022
## 5489    Wnt/beta-catenin D022
## 5490               PDGFR D022
## 5491           S6 Kinase D022
## 5492           S6 Kinase D022
## 5493            p38 MAPK D022
## 5494               GSK-3 D022
## 5495       TGF-beta/Smad D022
## 5496                 JAK D022
## 5497                 CDK D022
## 5498                PI3K D022
## 5499                 Akt D022
## 5500     Gamma-secretase D022
## 5501                 MEK D022
## 5502               c-Met D022
## 5503                 CDK D022
## 5504     Gamma-secretase D022
## 5505                 Akt D022
## 5506               c-Met D022
## 5507       Aurora Kinase D022
## 5508       Aurora Kinase D022
## 5509                 Raf D022
## 5510       Aurora Kinase D022
## 5511               VEGFR D022
## 5512             Bcr-Abl D022
## 5513               VEGFR D022
## 5514                 CDK D022
## 5515              IGF-1R D022
## 5516               VEGFR D022
## 5517                 JAK D022
## 5518               c-Met D022
## 5519                 JAK D022
## 5520                EGFR D022
## 5521                 BTK D022
## 5522                mTOR D022
## 5523                EGFR D022
## 5524              IGF-1R D022
## 5525                 CDK D022
## 5526                 JAK D022
## 5527                mTOR D022
## 5528               VEGFR D022
## 5529               VEGFR D022
## 5530                 MEK D022
## 5531                EGFR D022
## 5532             Bcr-Abl D022
## 5533                 MEK D022
## 5534                 MEK D022
## 5535                 MEK D022
## 5536                EGFR D022
## 5537                 FAK D022
## 5538               c-Met D022
## 5539                mTOR D022
## 5540                 FAK D022
## 5541           S6 Kinase D022
## 5542 Hedgehog/Smoothened D022
## 5543                 FAK D022
## 5544                 FAK D022
## 5545            p38 MAPK D022
## 5546               c-Met D022
## 5547       Aurora Kinase D022
## 5548                 CDK D022
## 5549                 CDK D022
## 5550                AMPK D022
## 5551                 Akt D022
## 5552                 Syk D022
## 5553                PI3K D022
## 5554                PI3K D022
## 5555                PI3K D022
## 5556                 MEK D022
## 5557       TGF-beta/Smad D022
## 5558                 Raf D022
## 5559                 Raf D022
## 5560             Bcr-Abl D022
## 5561                 Src D022
## 5562                 Src D022
## 5563                mTOR D022
## 5564              IGF-1R D022
## 5565    Wnt/beta-catenin D022
## 5566                 Syk D022
## 5567                 CDK D022
## 5568                PI3K D022
## 5569                FLT3 D022
## 5570                 Syk D022
## 5571                 Syk D022
## 5572                 CDK D022
## 5573                 Raf D022
## 5574                mTOR D022
## 5575                 MEK D022
## 5576       TGF-beta/Smad D022
## 5577                mTOR D022
## 5578                 PLK D022
## 5579                ROCK D022
## 5580                 BTK D022
## 5581                 PKC D022
## 5582                 CDK D022
## 5583                 PLK D022
## 5584     Gamma-secretase D022
## 5585                 CDK D022
## 5586                 JAK D022
## 5587                 JAK D022
## 5588 Hedgehog/Smoothened D022
## 5589               VEGFR D022
## 5590                PI3K D022
## 5591                 Src D022
## 5592            p38 MAPK D022
## 5593            p38 MAPK D022
## 5594               GSK-3 D022
## 5595            p38 MAPK D022
## 5596               GSK-3 D022
## 5597       TGF-beta/Smad D022
## 5598       TGF-beta/Smad D022
## 5599       TGF-beta/Smad D022
## 5600                 Raf D022
## 5601                 ERK D022
## 5602             ATM/ATR D022
## 5603                 MEK D022
## 5604     Gamma-secretase D022
## 5605               VEGFR D022
## 5606               VEGFR D022
## 5607            p38 MAPK D022
## 5608                 MEK D022
## 5609                 CDK D022
## 5610       Aurora Kinase D022
## 5611                 Raf D022
## 5612                &lt;NA&gt; D022
## 5613                 PKC D022
## 5614                 JNK D022
## 5615               c-Met D022
## 5616                 Src D022
## 5617                 CDK D022
## 5618               VEGFR D022
## 5619                 FAK D022
## 5620                EGFR D022
## 5621                 Raf D022
## 5622            p38 MAPK D022
## 5623                 MEK D022
## 5624       Aurora Kinase D022
## 5625 Hedgehog/Smoothened D022
## 5626                FLT3 D022
## 5627               GSK-3 D022
## 5628               VEGFR D022
## 5629                mTOR D022
## 5630               c-Met D022
## 5631                 CDK D022
## 5632                PI3K D022
## 5633                FLT3 D022
## 5634                 JAK D022
## 5635                PI3K D022
## 5636       TGF-beta/Smad D022
## 5637                ROCK D022
## 5638                 Akt D022
## 5639               GSK-3 D022
## 5640               c-Met D022
## 5641               VEGFR D022
## 5642                 JAK D022
## 5643                 JAK D022
## 5644                mTOR D022
## 5645                 MEK D022
## 5646                 Akt D022
## 5647               VEGFR D022
## 5648               GSK-3 D022
## 5649                EGFR D022
## 5650               PDGFR D022
## 5651                 MEK D022
## 5652                 ERK D022
## 5653                 Akt D022
## 5654                 JNK D022
## 5655                EGFR D022
## 5656               VEGFR D022
## 5657             ATM/ATR D022
## 5658             ATM/ATR D022
## 5659                 Raf D022
## 5660 Hedgehog/Smoothened D022
## 5661                 PLK D022
## 5662                PI3K D022
## 5663                PI3K D022
## 5664                 ERK D022
## 5665       Aurora Kinase D022
## 5666            p38 MAPK D022
## 5667            p38 MAPK D022
## 5668                mTOR D022
## 5669                 Src D022
## 5670                 JAK D022
## 5671    Wnt/beta-catenin D022
## 5672    Wnt/beta-catenin D022
## 5673    Wnt/beta-catenin D022
## 5674                 JAK D022
## 5675                mTOR D022
## 5676                mTOR D022
## 5677                EGFR D022
## 5678                EGFR D022
## 5679                AMPK D022
## 5680                EGFR D022
## 5681    Wnt/beta-catenin D022
## 5682                 JAK D022
## 5683                 ERK D022
## 5684                ROCK D022
## 5685                PI3K D022
## 5686     Gamma-secretase D022
## 5687               VEGFR D022
## 5688               VEGFR D022
## 5689                 Raf D022
## 5690                 JAK D022
## 5691       Aurora Kinase D022
## 5692                mTOR D022
## 5693                PI3K D022
## 5694               GSK-3 D022
## 5695                PI3K D022
## 5696                 Akt D022
## 5697                AMPK D022
## 5698                PI3K D022
## 5699                AMPK D022
## 5700                EGFR D022
## 5701                &lt;NA&gt; D022
## 5702              IGF-1R D022
## 5703                EGFR D022
## 5704                EGFR D022
## 5705                 JAK D022
## 5706                 Akt D022
## 5707       Aurora Kinase D022
## 5708               c-Met D022
## 5709               c-Met D022
## 5710       Aurora Kinase D022
## 5711                PI3K D022
## 5712               c-Met D022
## 5713               VEGFR D022
## 5714               GSK-3 D022
## 5715                PI3K D022
## 5716                PI3K D022
## 5717            p38 MAPK D022
## 5718                EGFR D022
## 5719                 Akt D022
## 5720                 CDK D022
## 5721                 Akt D022
## 5722             Bcr-Abl D022
## 5723       Aurora Kinase D022
## 5724     Gamma-secretase D022
## 5725                 BTK D022
## 5726               VEGFR D022
## 5727               PDGFR D022
## 5728                 Raf D022
## 5729                 JAK D022
## 5730             ATM/ATR D022
## 5731               GSK-3 D022
## 5732                 JAK D022
## 5733                mTOR D022
## 5734               GSK-3 D022
## 5735               PDGFR D022
## 5736                EGFR D022
## 5737                 Akt D022
## 5738                 CDK D022
## 5739                PI3K D022
## 5740             ATM/ATR D022
## 5741                mTOR D022
## 5742                 MEK D022
## 5743                EGFR D022
## 5744                EGFR D022
## 5745       Aurora Kinase D022
## 5746                 JAK D022
## 5747                PI3K D022
## 5748                 PLK D022
## 5749                 JNK D022
## 5750           S6 Kinase D022
## 5751               GSK-3 D022
## 5752               GSK-3 D022
## 5753            p38 MAPK D022
## 5754                 MEK D022
## 5755                &lt;NA&gt; D022
## 5756                PI3K D022
## 5757                 CDK D022
## 5758              IGF-1R D022
## 5759            p38 MAPK D022
## 5760              IGF-1R D022
## 5761               c-Met D022
## 5762               c-Met D022
## 5763 Hedgehog/Smoothened D022
## 5764                 Src D022
## 5765               VEGFR D022
## 5766               VEGFR D022
## 5767                 CDK D022
## 5768                EGFR D022
## 5769                PI3K D022
## 5770               VEGFR D022
## 5771                &lt;NA&gt; D022
## 5772                PI3K D022
## 5773                PI3K D022
## 5774                mTOR D022
## 5775                 Akt D022
## 5776               VEGFR D022
## 5777                 Raf D022
## 5778                 JAK D022
## 5779                 BTK D022
## 5780             ATM/ATR D022
## 5781                PI3K D022
## 5782               GSK-3 D022
## 5783               GSK-3 D022
## 5784                &lt;NA&gt; D022
## 5785                EGFR D022
## 5786                EGFR D022
## 5787                 BTK D022
## 5788                EGFR D022
## 5789                 MEK D022
## 5790               PDGFR D022
## 5791                EGFR D022
## 5792               PDGFR D022
## 5793               c-Met D022
## 5794       Aurora Kinase D022
## 5795                 JAK D022
## 5796                PI3K D022
## 5797                 Raf D022
## 5798                EGFR D022
## 5799       Aurora Kinase D022
## 5800     Gamma-secretase D022
## 5801                 Src D022
## 5802             Bcr-Abl D022
## 5803                 JAK D022
## 5804                 CDK D022
## 5805                &lt;NA&gt; D022
## 5806       Aurora Kinase D022
## 5807                 PKC D022
## 5808                 ERK D022
## 5809                AMPK D022
## 5810                mTOR D022
## 5811                mTOR D022
## 5812                ROCK D022
## 5813    Wnt/beta-catenin D022
## 5814                 JAK D022
## 5815                 CDK D022
## 5816                &lt;NA&gt; D022
## 5817               c-Met D022
## 5818                 Syk D022
## 5819                FLT3 D022
## 5820                 Akt D022
## 5821                mTOR D022
## 5822                 Raf D022
## 5823                PI3K D022
## 5824                mTOR D022
## 5825                EGFR D022
## 5826                EGFR D022
## 5827                 PKC D022
## 5828             Bcr-Abl D022
## 5829             Bcr-Abl D022
## 5830                 PKC D022
## 5831               c-Met D022
## 5832              IGF-1R D022
## 5833              IGF-1R D022
## 5834                PI3K D022
## 5835                PI3K D022
## 5836                PI3K D022
## 5837                ROCK D022
## 5838                 PLK D022
## 5839                AMPK D022
## 5840                 Akt D022
## 5841                 Raf D022
## 5842       TGF-beta/Smad D022
## 5843             Bcr-Abl D022
## 5844           S6 Kinase D022
## 5845       Aurora Kinase D022
## 5846                 PLK D022
## 5847                 Akt D022
## 5848                PI3K D022
## 5849                AMPK D022
## 5850                 Src D022
## 5851    Wnt/beta-catenin D022
## 5852                EGFR D022
## 5853               GSK-3 D022
## 5854               PDGFR D022
## 5855               GSK-3 D022
## 5856                mTOR D022
## 5857                PI3K D022
## 5858    Wnt/beta-catenin D022
## 5859    Wnt/beta-catenin D022
## 5860               c-Met D022
## 5861                 CDK D022
## 5862                 JNK D022
## 5863                 JNK D022
## 5864       TGF-beta/Smad D022
## 5865               VEGFR D022
## 5866               VEGFR D022
## 5867                mTOR D022
## 5868             ATM/ATR D022
## 5869             ATM/ATR D022
## 5870                FLT3 D022
## 5871                 Src D022
## 5872    Wnt/beta-catenin D022
## 5873                EGFR D022
## 5874                EGFR D022
## 5875                 CDK D022
## 5876 Hedgehog/Smoothened D022
## 5877       TGF-beta/Smad D022
## 5878               VEGFR D022
## 5879                 BTK D022
## 5880    Wnt/beta-catenin D022
## 5881               PDGFR D022
## 5882           S6 Kinase D022
## 5883           S6 Kinase D022
## 5884            p38 MAPK D022
## 5885               GSK-3 D022
## 5886       TGF-beta/Smad D022
## 5887                 JAK D022
## 5888                 CDK D022
## 5889                PI3K D022
## 5890                 Akt D022
## 5891     Gamma-secretase D022
## 5892                 MEK D022
## 5893               c-Met D022
## 5894                 CDK D022
## 5895     Gamma-secretase D022
## 5896                 Akt D022
## 5897               c-Met D022
## 5898       Aurora Kinase D022
## 5899       Aurora Kinase D022
## 5900                 Raf D022
## 5901       Aurora Kinase D022
## 5902               VEGFR D022
## 5903             Bcr-Abl D022
## 5904               VEGFR D022
## 5905                 CDK D022
## 5906              IGF-1R D022
## 5907               VEGFR D022
## 5908                 JAK D022
## 5909               c-Met D022
## 5910                 JAK D022
## 5911                EGFR D022
## 5912                 BTK D022
## 5913                mTOR D022
## 5914                EGFR D022
## 5915              IGF-1R D022
## 5916                 CDK D022
## 5917                 JAK D022
## 5918                mTOR D022
## 5919               VEGFR D022
## 5920               VEGFR D022
## 5921                 MEK D022
## 5922                EGFR D022
## 5923             Bcr-Abl D022
## 5924                 MEK D022
## 5925                 MEK D022
## 5926                 MEK D022
## 5927                EGFR D022
## 5928                 FAK D022
## 5929               c-Met D022
## 5930                mTOR D022
## 5931                 FAK D022
## 5932           S6 Kinase D022
## 5933 Hedgehog/Smoothened D022
## 5934                 FAK D022
## 5935                 FAK D022
## 5936            p38 MAPK D022
## 5937               c-Met D022
## 5938       Aurora Kinase D022
## 5939                 CDK D022
## 5940                 CDK D022
## 5941                AMPK D022
## 5942                 Akt D022
## 5943                 Syk D022
## 5944                PI3K D022
## 5945                PI3K D022
## 5946                PI3K D022
## 5947                 MEK D022
## 5948       TGF-beta/Smad D022
## 5949                 Raf D022
## 5950                 Raf D022
## 5951             Bcr-Abl D022
## 5952                 Src D022
## 5953                 Src D022
## 5954                mTOR D022
## 5955              IGF-1R D022
## 5956    Wnt/beta-catenin D022
## 5957                 Syk D022
## 5958                 CDK D022
## 5959                PI3K D022
## 5960                FLT3 D022
## 5961                 Syk D022
## 5962                 Syk D022
## 5963                 CDK D022
## 5964                 Raf D022
## 5965                mTOR D022
## 5966                 MEK D022
## 5967       TGF-beta/Smad D022
## 5968                mTOR D022
## 5969                 PLK D022
## 5970                ROCK D022
## 5971                 BTK D022
## 5972                 PKC D022
## 5973                 CDK D022
## 5974                 PLK D022
## 5975     Gamma-secretase D022
## 5976                 CDK D022
## 5977                 JAK D022
## 5978                 JAK D022
## 5979 Hedgehog/Smoothened D022
## 5980               VEGFR D022
## 5981                PI3K D022
## 5982                 Src D022
## 5983            p38 MAPK D022
## 5984            p38 MAPK D022
## 5985               GSK-3 D022
## 5986            p38 MAPK D022
## 5987               GSK-3 D022
## 5988       TGF-beta/Smad D022
## 5989       TGF-beta/Smad D022
## 5990       TGF-beta/Smad D022
## 5991                 Raf D022
## 5992                 ERK D022
## 5993             ATM/ATR D022
## 5994                 MEK D022
## 5995     Gamma-secretase D022
## 5996               VEGFR D022
## 5997               VEGFR D022
## 5998            p38 MAPK D022
## 5999                 MEK D022
## 6000                 CDK D022
## 6001       Aurora Kinase D022
## 6002                 Raf D022
## 6003                &lt;NA&gt; D022
## 6004                 PKC D022
## 6005                 JNK D022
## 6006               c-Met D022
## 6007                 Src D022
## 6008                 CDK D022
## 6009               VEGFR D022
## 6010                 FAK D022
## 6011                EGFR D022
## 6012                 Raf D022
## 6013            p38 MAPK D022
## 6014                 MEK D022
## 6015       Aurora Kinase D022
## 6016 Hedgehog/Smoothened D022
## 6017                FLT3 D022
## 6018               GSK-3 D022
## 6019               VEGFR D022
## 6020                mTOR D022
## 6021               c-Met D022
## 6022                 CDK D022
## 6023                PI3K D022
## 6024                FLT3 D022
## 6025                 JAK D022
## 6026                PI3K D022
## 6027       TGF-beta/Smad D022
## 6028                ROCK D022
## 6029                 Akt D022
## 6030               GSK-3 D022
## 6031               c-Met D022
## 6032               VEGFR D022
## 6033                 JAK D022
## 6034                 JAK D022
## 6035                mTOR D022
## 6036                 MEK D022
## 6037                 Akt D022
## 6038               VEGFR D022
## 6039               GSK-3 D022
## 6040                EGFR D022
## 6041               PDGFR D022
## 6042                 MEK D022
## 6043                 ERK D022
## 6044                 Akt D022
## 6045                 JNK D022
## 6046                EGFR D022
## 6047               VEGFR D022
## 6048             ATM/ATR D022
## 6049             ATM/ATR D022
## 6050                 Raf D022
## 6051 Hedgehog/Smoothened D022
## 6052                 PLK D022
## 6053                PI3K D022
## 6054                PI3K D022
## 6055                 ERK D022
## 6056       Aurora Kinase D022
## 6057            p38 MAPK D022
## 6058            p38 MAPK D022
## 6059                mTOR D022
## 6060                 Src D022
## 6061                 JAK D022
## 6062    Wnt/beta-catenin D022
## 6063    Wnt/beta-catenin D022
## 6064    Wnt/beta-catenin D022
## 6065                 JAK D022
## 6066                mTOR D022
## 6067                mTOR D022
## 6068                EGFR D022
## 6069                EGFR D022
## 6070                AMPK D022
## 6071                EGFR D022
## 6072    Wnt/beta-catenin D022
## 6073                 JAK D022
## 6074                 ERK D022
## 6075                ROCK D022
## 6076                PI3K D022
## 6077     Gamma-secretase D022
## 6078               VEGFR D022
## 6079               VEGFR D022
## 6080                 Raf D022
## 6081                 JAK D022
## 6082       Aurora Kinase D022
## 6083                mTOR D022
## 6084                PI3K D022
## 6085               GSK-3 D027
## 6086                PI3K D027
## 6087                 Akt D027
## 6088                AMPK D027
## 6089                PI3K D027
## 6090                AMPK D027
## 6091                EGFR D027
## 6092                &lt;NA&gt; D027
## 6093              IGF-1R D027
## 6094                EGFR D027
## 6095                EGFR D027
## 6096                 JAK D027
## 6097                 Akt D027
## 6098       Aurora Kinase D027
## 6099               c-Met D027
## 6100               c-Met D027
## 6101       Aurora Kinase D027
## 6102                PI3K D027
## 6103               c-Met D027
## 6104               VEGFR D027
## 6105               GSK-3 D027
## 6106                PI3K D027
## 6107                PI3K D027
## 6108            p38 MAPK D027
## 6109                EGFR D027
## 6110                 Akt D027
## 6111                 CDK D027
## 6112                 Akt D027
## 6113             Bcr-Abl D027
## 6114       Aurora Kinase D027
## 6115     Gamma-secretase D027
## 6116                 BTK D027
## 6117               VEGFR D027
## 6118               PDGFR D027
## 6119                 Raf D027
## 6120                 JAK D027
## 6121             ATM/ATR D027
## 6122               GSK-3 D027
## 6123                 JAK D027
## 6124                mTOR D027
## 6125               GSK-3 D027
## 6126               PDGFR D027
## 6127                EGFR D027
## 6128                 Akt D027
## 6129                 CDK D027
## 6130                PI3K D027
## 6131             ATM/ATR D027
## 6132                mTOR D027
## 6133                 MEK D027
## 6134                EGFR D027
## 6135                EGFR D027
## 6136       Aurora Kinase D027
## 6137                 JAK D027
## 6138                PI3K D027
## 6139                 PLK D027
## 6140                 JNK D027
## 6141           S6 Kinase D027
## 6142               GSK-3 D027
## 6143               GSK-3 D027
## 6144            p38 MAPK D027
## 6145                 MEK D027
## 6146                &lt;NA&gt; D027
## 6147                PI3K D027
## 6148                 CDK D027
## 6149              IGF-1R D027
## 6150            p38 MAPK D027
## 6151              IGF-1R D027
## 6152               c-Met D027
## 6153               c-Met D027
## 6154 Hedgehog/Smoothened D027
## 6155                 Src D027
## 6156               VEGFR D027
## 6157               VEGFR D027
## 6158                 CDK D027
## 6159                EGFR D027
## 6160                PI3K D027
## 6161               VEGFR D027
## 6162                &lt;NA&gt; D027
## 6163                PI3K D027
## 6164                PI3K D027
## 6165                mTOR D027
## 6166                 Akt D027
## 6167               VEGFR D027
## 6168                 Raf D027
## 6169                 JAK D027
## 6170                 BTK D027
## 6171             ATM/ATR D027
## 6172                PI3K D027
## 6173               GSK-3 D027
## 6174               GSK-3 D027
## 6175                &lt;NA&gt; D027
## 6176                EGFR D027
## 6177                EGFR D027
## 6178                 BTK D027
## 6179                EGFR D027
## 6180                 MEK D027
## 6181               PDGFR D027
## 6182                EGFR D027
## 6183               PDGFR D027
## 6184               c-Met D027
## 6185       Aurora Kinase D027
## 6186                 JAK D027
## 6187                PI3K D027
## 6188                 Raf D027
## 6189                EGFR D027
## 6190       Aurora Kinase D027
## 6191     Gamma-secretase D027
## 6192                 Src D027
## 6193             Bcr-Abl D027
## 6194                 JAK D027
## 6195                 CDK D027
## 6196                &lt;NA&gt; D027
## 6197       Aurora Kinase D027
## 6198                 PKC D027
## 6199                 ERK D027
## 6200                AMPK D027
## 6201                mTOR D027
## 6202                mTOR D027
## 6203                ROCK D027
## 6204    Wnt/beta-catenin D027
## 6205                 JAK D027
## 6206                 CDK D027
## 6207                &lt;NA&gt; D027
## 6208               c-Met D027
## 6209                 Syk D027
## 6210                FLT3 D027
## 6211                 Akt D027
## 6212                mTOR D027
## 6213                 Raf D027
## 6214                PI3K D027
## 6215                mTOR D027
## 6216                EGFR D027
## 6217                EGFR D027
## 6218                 PKC D027
## 6219             Bcr-Abl D027
## 6220             Bcr-Abl D027
## 6221                 PKC D027
## 6222               c-Met D027
## 6223              IGF-1R D027
## 6224              IGF-1R D027
## 6225                PI3K D027
## 6226                PI3K D027
## 6227                PI3K D027
## 6228                ROCK D027
## 6229                 PLK D027
## 6230                AMPK D027
## 6231                 Akt D027
## 6232                 Raf D027
## 6233       TGF-beta/Smad D027
## 6234             Bcr-Abl D027
## 6235           S6 Kinase D027
## 6236       Aurora Kinase D027
## 6237                 PLK D027
## 6238                 Akt D027
## 6239                PI3K D027
## 6240                AMPK D027
## 6241                 Src D027
## 6242    Wnt/beta-catenin D027
## 6243                EGFR D027
## 6244               GSK-3 D027
## 6245               PDGFR D027
## 6246               GSK-3 D027
## 6247                mTOR D027
## 6248                PI3K D027
## 6249    Wnt/beta-catenin D027
## 6250    Wnt/beta-catenin D027
## 6251               c-Met D027
## 6252                 CDK D027
## 6253                 JNK D027
## 6254                 JNK D027
## 6255       TGF-beta/Smad D027
## 6256               VEGFR D027
## 6257               VEGFR D027
## 6258                mTOR D027
## 6259             ATM/ATR D027
## 6260             ATM/ATR D027
## 6261                FLT3 D027
## 6262                 Src D027
## 6263    Wnt/beta-catenin D027
## 6264                EGFR D027
## 6265                EGFR D027
## 6266                 CDK D027
## 6267 Hedgehog/Smoothened D027
## 6268       TGF-beta/Smad D027
## 6269               VEGFR D027
## 6270                 BTK D027
## 6271    Wnt/beta-catenin D027
## 6272               PDGFR D027
## 6273           S6 Kinase D027
## 6274           S6 Kinase D027
## 6275            p38 MAPK D027
## 6276               GSK-3 D027
## 6277       TGF-beta/Smad D027
## 6278                 JAK D027
## 6279                 CDK D027
## 6280                PI3K D027
## 6281                 Akt D027
## 6282     Gamma-secretase D027
## 6283                 MEK D027
## 6284               c-Met D027
## 6285                 CDK D027
## 6286     Gamma-secretase D027
## 6287                 Akt D027
## 6288               c-Met D027
## 6289       Aurora Kinase D027
## 6290       Aurora Kinase D027
## 6291                 Raf D027
## 6292       Aurora Kinase D027
## 6293               VEGFR D027
## 6294             Bcr-Abl D027
## 6295               VEGFR D027
## 6296                 CDK D027
## 6297              IGF-1R D027
## 6298               VEGFR D027
## 6299                 JAK D027
## 6300               c-Met D027
## 6301                 JAK D027
## 6302                EGFR D027
## 6303                 BTK D027
## 6304                mTOR D027
## 6305                EGFR D027
## 6306              IGF-1R D027
## 6307                 CDK D027
## 6308                 JAK D027
## 6309                mTOR D027
## 6310               VEGFR D027
## 6311               VEGFR D027
## 6312                 MEK D027
## 6313                EGFR D027
## 6314             Bcr-Abl D027
## 6315                 MEK D027
## 6316                 MEK D027
## 6317                 MEK D027
## 6318                EGFR D027
## 6319                 FAK D027
## 6320               c-Met D027
## 6321                mTOR D027
## 6322                 FAK D027
## 6323           S6 Kinase D027
## 6324 Hedgehog/Smoothened D027
## 6325                 FAK D027
## 6326                 FAK D027
## 6327            p38 MAPK D027
## 6328               c-Met D027
## 6329       Aurora Kinase D027
## 6330                 CDK D027
## 6331                 CDK D027
## 6332                AMPK D027
## 6333                 Akt D027
## 6334                 Syk D027
## 6335                PI3K D027
## 6336                PI3K D027
## 6337                PI3K D027
## 6338                 MEK D027
## 6339       TGF-beta/Smad D027
## 6340                 Raf D027
## 6341                 Raf D027
## 6342             Bcr-Abl D027
## 6343                 Src D027
## 6344                 Src D027
## 6345                mTOR D027
## 6346              IGF-1R D027
## 6347    Wnt/beta-catenin D027
## 6348                 Syk D027
## 6349                 CDK D027
## 6350                PI3K D027
## 6351                FLT3 D027
## 6352                 Syk D027
## 6353                 Syk D027
## 6354                 CDK D027
## 6355                 Raf D027
## 6356                mTOR D027
## 6357                 MEK D027
## 6358       TGF-beta/Smad D027
## 6359                mTOR D027
## 6360                 PLK D027
## 6361                ROCK D027
## 6362                 BTK D027
## 6363                 PKC D027
## 6364                 CDK D027
## 6365                 PLK D027
## 6366     Gamma-secretase D027
## 6367                 CDK D027
## 6368                 JAK D027
## 6369                 JAK D027
## 6370 Hedgehog/Smoothened D027
## 6371               VEGFR D027
## 6372                PI3K D027
## 6373                 Src D027
## 6374            p38 MAPK D027
## 6375            p38 MAPK D027
## 6376               GSK-3 D027
## 6377            p38 MAPK D027
## 6378               GSK-3 D027
## 6379       TGF-beta/Smad D027
## 6380       TGF-beta/Smad D027
## 6381       TGF-beta/Smad D027
## 6382                 Raf D027
## 6383                 ERK D027
## 6384             ATM/ATR D027
## 6385                 MEK D027
## 6386     Gamma-secretase D027
## 6387               VEGFR D027
## 6388               VEGFR D027
## 6389            p38 MAPK D027
## 6390                 MEK D027
## 6391                 CDK D027
## 6392       Aurora Kinase D027
## 6393                 Raf D027
## 6394                &lt;NA&gt; D027
## 6395                 PKC D027
## 6396                 JNK D027
## 6397               c-Met D027
## 6398                 Src D027
## 6399                 CDK D027
## 6400               VEGFR D027
## 6401                 FAK D027
## 6402                EGFR D027
## 6403                 Raf D027
## 6404            p38 MAPK D027
## 6405                 MEK D027
## 6406       Aurora Kinase D027
## 6407 Hedgehog/Smoothened D027
## 6408                FLT3 D027
## 6409               GSK-3 D027
## 6410               VEGFR D027
## 6411                mTOR D027
## 6412               c-Met D027
## 6413                 CDK D027
## 6414                PI3K D027
## 6415                FLT3 D027
## 6416                 JAK D027
## 6417                PI3K D027
## 6418       TGF-beta/Smad D027
## 6419                ROCK D027
## 6420                 Akt D027
## 6421               GSK-3 D027
## 6422               c-Met D027
## 6423               VEGFR D027
## 6424                 JAK D027
## 6425                 JAK D027
## 6426                mTOR D027
## 6427                 MEK D027
## 6428                 Akt D027
## 6429               VEGFR D027
## 6430               GSK-3 D027
## 6431                EGFR D027
## 6432               PDGFR D027
## 6433                 MEK D027
## 6434                 ERK D027
## 6435                 Akt D027
## 6436                 JNK D027
## 6437                EGFR D027
## 6438               VEGFR D027
## 6439             ATM/ATR D027
## 6440             ATM/ATR D027
## 6441                 Raf D027
## 6442 Hedgehog/Smoothened D027
## 6443                 PLK D027
## 6444                PI3K D027
## 6445                PI3K D027
## 6446                 ERK D027
## 6447       Aurora Kinase D027
## 6448            p38 MAPK D027
## 6449            p38 MAPK D027
## 6450                mTOR D027
## 6451                 Src D027
## 6452                 JAK D027
## 6453    Wnt/beta-catenin D027
## 6454    Wnt/beta-catenin D027
## 6455    Wnt/beta-catenin D027
## 6456                 JAK D027
## 6457                mTOR D027
## 6458                mTOR D027
## 6459                EGFR D027
## 6460                EGFR D027
## 6461                AMPK D027
## 6462                EGFR D027
## 6463    Wnt/beta-catenin D027
## 6464                 JAK D027
## 6465                 ERK D027
## 6466                ROCK D027
## 6467                PI3K D027
## 6468     Gamma-secretase D027
## 6469               VEGFR D027
## 6470               VEGFR D027
## 6471                 Raf D027
## 6472                 JAK D027
## 6473       Aurora Kinase D027
## 6474                mTOR D027
## 6475                PI3K D027
## 6476               GSK-3 D027
## 6477                AMPK D027
## 6478                EGFR D027
## 6479                &lt;NA&gt; D027
## 6480              IGF-1R D027
## 6481                EGFR D027
## 6482                 JAK D027
## 6483       Aurora Kinase D027
## 6484               c-Met D027
## 6485               c-Met D027
## 6486               VEGFR D027
## 6487               GSK-3 D027
## 6488            p38 MAPK D027
## 6489                EGFR D027
## 6490                 Akt D027
## 6491                 CDK D027
## 6492                 Akt D027
## 6493             Bcr-Abl D027
## 6494       Aurora Kinase D027
## 6495     Gamma-secretase D027
## 6496               VEGFR D027
## 6497               PDGFR D027
## 6498                 JAK D027
## 6499               GSK-3 D027
## 6500                 JAK D027
## 6501               GSK-3 D027
## 6502                 Akt D027
## 6503                PI3K D027
## 6504                mTOR D027
## 6505                 MEK D027
## 6506                EGFR D027
## 6507       Aurora Kinase D027
## 6508                 JAK D027
## 6509                 PLK D027
## 6510                 JNK D027
## 6511               GSK-3 D027
## 6512               GSK-3 D027
## 6513            p38 MAPK D027
## 6514                 MEK D027
## 6515                &lt;NA&gt; D027
## 6516                PI3K D027
## 6517                 CDK D027
## 6518              IGF-1R D027
## 6519            p38 MAPK D027
## 6520              IGF-1R D027
## 6521               c-Met D027
## 6522               c-Met D027
## 6523 Hedgehog/Smoothened D027
## 6524                 Src D027
## 6525               VEGFR D027
## 6526               VEGFR D027
## 6527                 CDK D027
## 6528               VEGFR D027
## 6529                PI3K D027
## 6530                mTOR D027
## 6531               VEGFR D027
## 6532                 Raf D027
## 6533                 JAK D027
## 6534               GSK-3 D027
## 6535               GSK-3 D027
## 6536                &lt;NA&gt; D027
## 6537               PDGFR D027
## 6538                EGFR D027
## 6539               c-Met D027
## 6540       Aurora Kinase D027
## 6541                 JAK D027
## 6542       Aurora Kinase D027
## 6543     Gamma-secretase D027
## 6544                 Src D027
## 6545                 JAK D027
## 6546       Aurora Kinase D027
## 6547                 PKC D027
## 6548                AMPK D027
## 6549                mTOR D027
## 6550                ROCK D027
## 6551    Wnt/beta-catenin D027
## 6552                 JAK D027
## 6553                 CDK D027
## 6554               c-Met D027
## 6555                FLT3 D027
## 6556                 Raf D027
## 6557                PI3K D027
## 6558                EGFR D027
## 6559                EGFR D027
## 6560                 PKC D027
## 6561             Bcr-Abl D027
## 6562                 PKC D027
## 6563              IGF-1R D027
## 6564                PI3K D027
## 6565                ROCK D027
## 6566                 PLK D027
## 6567                AMPK D027
## 6568                 Akt D027
## 6569       TGF-beta/Smad D027
## 6570           S6 Kinase D027
## 6571       Aurora Kinase D027
## 6572                 PLK D027
## 6573                 Akt D027
## 6574    Wnt/beta-catenin D027
## 6575               GSK-3 D027
## 6576               PDGFR D027
## 6577               GSK-3 D027
## 6578    Wnt/beta-catenin D027
## 6579    Wnt/beta-catenin D027
## 6580               c-Met D027
## 6581                 CDK D027
## 6582       TGF-beta/Smad D027
## 6583               VEGFR D027
## 6584               VEGFR D027
## 6585                mTOR D027
## 6586             ATM/ATR D027
## 6587             ATM/ATR D027
## 6588                FLT3 D027
## 6589    Wnt/beta-catenin D027
## 6590                EGFR D027
## 6591                EGFR D027
## 6592 Hedgehog/Smoothened D027
## 6593               VEGFR D027
## 6594                 BTK D027
## 6595    Wnt/beta-catenin D027
## 6596               PDGFR D027
## 6597           S6 Kinase D027
## 6598       TGF-beta/Smad D027
## 6599                 JAK D027
## 6600                PI3K D027
## 6601                 Akt D027
## 6602     Gamma-secretase D027
## 6603               c-Met D027
## 6604     Gamma-secretase D027
## 6605                 Akt D027
## 6606       Aurora Kinase D027
## 6607               VEGFR D027
## 6608             Bcr-Abl D027
## 6609               VEGFR D027
## 6610              IGF-1R D027
## 6611               VEGFR D027
## 6612                 JAK D027
## 6613                 JAK D027
## 6614                EGFR D027
## 6615                 BTK D027
## 6616                EGFR D027
## 6617              IGF-1R D027
## 6618                 JAK D027
## 6619                mTOR D027
## 6620               VEGFR D027
## 6621                 MEK D027
## 6622             Bcr-Abl D027
## 6623                 MEK D027
## 6624                 MEK D027
## 6625                 MEK D027
## 6626                EGFR D027
## 6627               c-Met D027
## 6628           S6 Kinase D027
## 6629 Hedgehog/Smoothened D027
## 6630                 FAK D027
## 6631               c-Met D027
## 6632       Aurora Kinase D027
## 6633                 CDK D027
## 6634                 Akt D027
## 6635                PI3K D027
## 6636                PI3K D027
## 6637                PI3K D027
## 6638                 MEK D027
## 6639       TGF-beta/Smad D027
## 6640                 Raf D027
## 6641             Bcr-Abl D027
## 6642                mTOR D027
## 6643    Wnt/beta-catenin D027
## 6644                 Syk D027
## 6645                PI3K D027
## 6646                FLT3 D027
## 6647                 Syk D027
## 6648                 Syk D027
## 6649                 Raf D027
## 6650                mTOR D027
## 6651                 MEK D027
## 6652       TGF-beta/Smad D027
## 6653                mTOR D027
## 6654                 PLK D027
## 6655                ROCK D027
## 6656                 PKC D027
## 6657                 CDK D027
## 6658     Gamma-secretase D027
## 6659                 CDK D027
## 6660                 JAK D027
## 6661                 JAK D027
## 6662 Hedgehog/Smoothened D027
## 6663                PI3K D027
## 6664                 Src D027
## 6665            p38 MAPK D027
## 6666            p38 MAPK D027
## 6667               GSK-3 D027
## 6668            p38 MAPK D027
## 6669               GSK-3 D027
## 6670       TGF-beta/Smad D027
## 6671       TGF-beta/Smad D027
## 6672       TGF-beta/Smad D027
## 6673                 Raf D027
## 6674                 MEK D027
## 6675     Gamma-secretase D027
## 6676                 MEK D027
## 6677                 CDK D027
## 6678       Aurora Kinase D027
## 6679                &lt;NA&gt; D027
## 6680                 PKC D027
## 6681                 JNK D027
## 6682               c-Met D027
## 6683               VEGFR D027
## 6684 Hedgehog/Smoothened D027
## 6685                FLT3 D027
## 6686               VEGFR D027
## 6687                mTOR D027
## 6688                PI3K D027
## 6689                FLT3 D027
## 6690                 JAK D027
## 6691                PI3K D027
## 6692       TGF-beta/Smad D027
## 6693                ROCK D027
## 6694               VEGFR D027
## 6695                 JAK D027
## 6696                 JAK D027
## 6697                 Akt D027
## 6698               VEGFR D027
## 6699               GSK-3 D027
## 6700               PDGFR D027
## 6701                 MEK D027
## 6702                 JNK D027
## 6703               VEGFR D027
## 6704             ATM/ATR D027
## 6705                 Raf D027
## 6706 Hedgehog/Smoothened D027
## 6707                 PLK D027
## 6708                 ERK D027
## 6709       Aurora Kinase D027
## 6710            p38 MAPK D027
## 6711                 Src D027
## 6712                 JAK D027
## 6713    Wnt/beta-catenin D027
## 6714    Wnt/beta-catenin D027
## 6715    Wnt/beta-catenin D027
## 6716                 JAK D027
## 6717                mTOR D027
## 6718                EGFR D027
## 6719                EGFR D027
## 6720                EGFR D027
## 6721    Wnt/beta-catenin D027
## 6722                 JAK D027
## 6723                ROCK D027
## 6724                PI3K D027
## 6725     Gamma-secretase D027
## 6726                 JAK D027
## 6727       Aurora Kinase D027
## 6728                PI3K D027
## 6729               GSK-3 D030
## 6730                PI3K D030
## 6731                 Akt D030
## 6732                AMPK D030
## 6733                PI3K D030
## 6734                AMPK D030
## 6735                EGFR D030
## 6736                &lt;NA&gt; D030
## 6737              IGF-1R D030
## 6738                EGFR D030
## 6739                EGFR D030
## 6740                 JAK D030
## 6741                 Akt D030
## 6742       Aurora Kinase D030
## 6743               c-Met D030
## 6744               c-Met D030
## 6745       Aurora Kinase D030
## 6746                PI3K D030
## 6747               c-Met D030
## 6748               VEGFR D030
## 6749               GSK-3 D030
## 6750                PI3K D030
## 6751                PI3K D030
## 6752            p38 MAPK D030
## 6753                EGFR D030
## 6754                 Akt D030
## 6755                 CDK D030
## 6756                 Akt D030
## 6757             Bcr-Abl D030
## 6758       Aurora Kinase D030
## 6759     Gamma-secretase D030
## 6760                 BTK D030
## 6761               VEGFR D030
## 6762               PDGFR D030
## 6763                 Raf D030
## 6764                 JAK D030
## 6765             ATM/ATR D030
## 6766               GSK-3 D030
## 6767                 JAK D030
## 6768                mTOR D030
## 6769               GSK-3 D030
## 6770               PDGFR D030
## 6771                EGFR D030
## 6772                 Akt D030
## 6773                 CDK D030
## 6774                PI3K D030
## 6775             ATM/ATR D030
## 6776                mTOR D030
## 6777                 MEK D030
## 6778                EGFR D030
## 6779                EGFR D030
## 6780       Aurora Kinase D030
## 6781                 JAK D030
## 6782                PI3K D030
## 6783                 PLK D030
## 6784                 JNK D030
## 6785           S6 Kinase D030
## 6786               GSK-3 D030
## 6787               GSK-3 D030
## 6788            p38 MAPK D030
## 6789                 MEK D030
## 6790                &lt;NA&gt; D030
## 6791                PI3K D030
## 6792                 CDK D030
## 6793              IGF-1R D030
## 6794            p38 MAPK D030
## 6795              IGF-1R D030
## 6796               c-Met D030
## 6797               c-Met D030
## 6798 Hedgehog/Smoothened D030
## 6799                 Src D030
## 6800               VEGFR D030
## 6801               VEGFR D030
## 6802                 CDK D030
## 6803                EGFR D030
## 6804                PI3K D030
## 6805               VEGFR D030
## 6806                &lt;NA&gt; D030
## 6807                PI3K D030
## 6808                PI3K D030
## 6809                mTOR D030
## 6810                 Akt D030
## 6811               VEGFR D030
## 6812                 Raf D030
## 6813                 JAK D030
## 6814                 BTK D030
## 6815             ATM/ATR D030
## 6816                PI3K D030
## 6817               GSK-3 D030
## 6818               GSK-3 D030
## 6819                &lt;NA&gt; D030
## 6820                EGFR D030
## 6821                EGFR D030
## 6822                 BTK D030
## 6823                EGFR D030
## 6824                 MEK D030
## 6825               PDGFR D030
## 6826                EGFR D030
## 6827               PDGFR D030
## 6828               c-Met D030
## 6829       Aurora Kinase D030
## 6830                 JAK D030
## 6831                PI3K D030
## 6832                 Raf D030
## 6833                EGFR D030
## 6834       Aurora Kinase D030
## 6835     Gamma-secretase D030
## 6836                 Src D030
## 6837             Bcr-Abl D030
## 6838                 JAK D030
## 6839                 CDK D030
## 6840                &lt;NA&gt; D030
## 6841       Aurora Kinase D030
## 6842                 PKC D030
## 6843                 ERK D030
## 6844                AMPK D030
## 6845                mTOR D030
## 6846                mTOR D030
## 6847                ROCK D030
## 6848    Wnt/beta-catenin D030
## 6849                 JAK D030
## 6850                 CDK D030
## 6851                &lt;NA&gt; D030
## 6852               c-Met D030
## 6853                 Syk D030
## 6854                FLT3 D030
## 6855                 Akt D030
## 6856                mTOR D030
## 6857                 Raf D030
## 6858                PI3K D030
## 6859                mTOR D030
## 6860                EGFR D030
## 6861                EGFR D030
## 6862                 PKC D030
## 6863             Bcr-Abl D030
## 6864             Bcr-Abl D030
## 6865                 PKC D030
## 6866               c-Met D030
## 6867              IGF-1R D030
## 6868              IGF-1R D030
## 6869                PI3K D030
## 6870                PI3K D030
## 6871                PI3K D030
## 6872                ROCK D030
## 6873                 PLK D030
## 6874                AMPK D030
## 6875                 Akt D030
## 6876                 Raf D030
## 6877       TGF-beta/Smad D030
## 6878             Bcr-Abl D030
## 6879           S6 Kinase D030
## 6880       Aurora Kinase D030
## 6881                 PLK D030
## 6882                 Akt D030
## 6883                PI3K D030
## 6884                AMPK D030
## 6885                 Src D030
## 6886    Wnt/beta-catenin D030
## 6887                EGFR D030
## 6888               GSK-3 D030
## 6889               PDGFR D030
## 6890               GSK-3 D030
## 6891                mTOR D030
## 6892                PI3K D030
## 6893    Wnt/beta-catenin D030
## 6894    Wnt/beta-catenin D030
## 6895               c-Met D030
## 6896                 CDK D030
## 6897                 JNK D030
## 6898                 JNK D030
## 6899       TGF-beta/Smad D030
## 6900               VEGFR D030
## 6901               VEGFR D030
## 6902                mTOR D030
## 6903             ATM/ATR D030
## 6904             ATM/ATR D030
## 6905                FLT3 D030
## 6906                 Src D030
## 6907    Wnt/beta-catenin D030
## 6908                EGFR D030
## 6909                EGFR D030
## 6910                 CDK D030
## 6911 Hedgehog/Smoothened D030
## 6912       TGF-beta/Smad D030
## 6913               VEGFR D030
## 6914                 BTK D030
## 6915    Wnt/beta-catenin D030
## 6916               PDGFR D030
## 6917           S6 Kinase D030
## 6918           S6 Kinase D030
## 6919            p38 MAPK D030
## 6920               GSK-3 D030
## 6921       TGF-beta/Smad D030
## 6922                 JAK D030
## 6923                 CDK D030
## 6924                PI3K D030
## 6925                 Akt D030
## 6926     Gamma-secretase D030
## 6927                 MEK D030
## 6928               c-Met D030
## 6929                 CDK D030
## 6930     Gamma-secretase D030
## 6931                 Akt D030
## 6932               c-Met D030
## 6933       Aurora Kinase D030
## 6934       Aurora Kinase D030
## 6935                 Raf D030
## 6936       Aurora Kinase D030
## 6937               VEGFR D030
## 6938             Bcr-Abl D030
## 6939               VEGFR D030
## 6940                 CDK D030
## 6941              IGF-1R D030
## 6942               VEGFR D030
## 6943                 JAK D030
## 6944               c-Met D030
## 6945                 JAK D030
## 6946                EGFR D030
## 6947                 BTK D030
## 6948                mTOR D030
## 6949                EGFR D030
## 6950              IGF-1R D030
## 6951                 CDK D030
## 6952                 JAK D030
## 6953                mTOR D030
## 6954               VEGFR D030
## 6955               VEGFR D030
## 6956                 MEK D030
## 6957                EGFR D030
## 6958             Bcr-Abl D030
## 6959                 MEK D030
## 6960                 MEK D030
## 6961                 MEK D030
## 6962                EGFR D030
## 6963                 FAK D030
## 6964               c-Met D030
## 6965                mTOR D030
## 6966                 FAK D030
## 6967           S6 Kinase D030
## 6968 Hedgehog/Smoothened D030
## 6969                 FAK D030
## 6970                 FAK D030
## 6971            p38 MAPK D030
## 6972               c-Met D030
## 6973       Aurora Kinase D030
## 6974                 CDK D030
## 6975                 CDK D030
## 6976                AMPK D030
## 6977                 Akt D030
## 6978                 Syk D030
## 6979                PI3K D030
## 6980                PI3K D030
## 6981                PI3K D030
## 6982                 MEK D030
## 6983       TGF-beta/Smad D030
## 6984                 Raf D030
## 6985                 Raf D030
## 6986             Bcr-Abl D030
## 6987                 Src D030
## 6988                 Src D030
## 6989                mTOR D030
## 6990              IGF-1R D030
## 6991    Wnt/beta-catenin D030
## 6992                 Syk D030
## 6993                 CDK D030
## 6994                PI3K D030
## 6995                FLT3 D030
## 6996                 Syk D030
## 6997                 Syk D030
## 6998                 CDK D030
## 6999                 Raf D030
## 7000                mTOR D030
## 7001                 MEK D030
## 7002       TGF-beta/Smad D030
## 7003                mTOR D030
## 7004                 PLK D030
## 7005                ROCK D030
## 7006                 BTK D030
## 7007                 PKC D030
## 7008                 CDK D030
## 7009                 PLK D030
## 7010     Gamma-secretase D030
## 7011                 CDK D030
## 7012                 JAK D030
## 7013                 JAK D030
## 7014 Hedgehog/Smoothened D030
## 7015               VEGFR D030
## 7016                PI3K D030
## 7017                 Src D030
## 7018            p38 MAPK D030
## 7019            p38 MAPK D030
## 7020               GSK-3 D030
## 7021            p38 MAPK D030
## 7022               GSK-3 D030
## 7023       TGF-beta/Smad D030
## 7024       TGF-beta/Smad D030
## 7025       TGF-beta/Smad D030
## 7026                 Raf D030
## 7027                 ERK D030
## 7028             ATM/ATR D030
## 7029                 MEK D030
## 7030     Gamma-secretase D030
## 7031               VEGFR D030
## 7032               VEGFR D030
## 7033            p38 MAPK D030
## 7034                 MEK D030
## 7035                 CDK D030
## 7036       Aurora Kinase D030
## 7037                 Raf D030
## 7038                &lt;NA&gt; D030
## 7039                 PKC D030
## 7040                 JNK D030
## 7041               c-Met D030
## 7042                 Src D030
## 7043                 CDK D030
## 7044               VEGFR D030
## 7045                 FAK D030
## 7046                EGFR D030
## 7047                 Raf D030
## 7048            p38 MAPK D030
## 7049                 MEK D030
## 7050       Aurora Kinase D030
## 7051 Hedgehog/Smoothened D030
## 7052                FLT3 D030
## 7053               GSK-3 D030
## 7054               VEGFR D030
## 7055                mTOR D030
## 7056               c-Met D030
## 7057                 CDK D030
## 7058                PI3K D030
## 7059                FLT3 D030
## 7060                 JAK D030
## 7061                PI3K D030
## 7062       TGF-beta/Smad D030
## 7063                ROCK D030
## 7064                 Akt D030
## 7065               GSK-3 D030
## 7066               c-Met D030
## 7067               VEGFR D030
## 7068                 JAK D030
## 7069                 JAK D030
## 7070                mTOR D030
## 7071                 MEK D030
## 7072                 Akt D030
## 7073               VEGFR D030
## 7074               GSK-3 D030
## 7075                EGFR D030
## 7076               PDGFR D030
## 7077                 MEK D030
## 7078                 ERK D030
## 7079                 Akt D030
## 7080                 JNK D030
## 7081                EGFR D030
## 7082               VEGFR D030
## 7083             ATM/ATR D030
## 7084             ATM/ATR D030
## 7085                 Raf D030
## 7086 Hedgehog/Smoothened D030
## 7087                 PLK D030
## 7088                PI3K D030
## 7089                PI3K D030
## 7090                 ERK D030
## 7091       Aurora Kinase D030
## 7092            p38 MAPK D030
## 7093            p38 MAPK D030
## 7094                mTOR D030
## 7095                 Src D030
## 7096                 JAK D030
## 7097    Wnt/beta-catenin D030
## 7098    Wnt/beta-catenin D030
## 7099    Wnt/beta-catenin D030
## 7100                 JAK D030
## 7101                mTOR D030
## 7102                mTOR D030
## 7103                EGFR D030
## 7104                EGFR D030
## 7105                AMPK D030
## 7106                EGFR D030
## 7107    Wnt/beta-catenin D030
## 7108                 JAK D030
## 7109                 ERK D030
## 7110                ROCK D030
## 7111                PI3K D030
## 7112     Gamma-secretase D030
## 7113               VEGFR D030
## 7114               VEGFR D030
## 7115                 Raf D030
## 7116                 JAK D030
## 7117       Aurora Kinase D030
## 7118                mTOR D030
## 7119                PI3K D030
## 7120               GSK-3 D030
## 7121                PI3K D030
## 7122                 Akt D030
## 7123                AMPK D030
## 7124                PI3K D030
## 7125                AMPK D030
## 7126                EGFR D030
## 7127                &lt;NA&gt; D030
## 7128              IGF-1R D030
## 7129                EGFR D030
## 7130                EGFR D030
## 7131                 JAK D030
## 7132                 Akt D030
## 7133       Aurora Kinase D030
## 7134               c-Met D030
## 7135               c-Met D030
## 7136       Aurora Kinase D030
## 7137                PI3K D030
## 7138               c-Met D030
## 7139               VEGFR D030
## 7140               GSK-3 D030
## 7141                PI3K D030
## 7142                PI3K D030
## 7143            p38 MAPK D030
## 7144                EGFR D030
## 7145                 Akt D030
## 7146                 CDK D030
## 7147                 Akt D030
## 7148             Bcr-Abl D030
## 7149       Aurora Kinase D030
## 7150     Gamma-secretase D030
## 7151                 BTK D030
## 7152               VEGFR D030
## 7153               PDGFR D030
## 7154                 Raf D030
## 7155                 JAK D030
## 7156             ATM/ATR D030
## 7157               GSK-3 D030
## 7158                 JAK D030
## 7159                mTOR D030
## 7160               GSK-3 D030
## 7161               PDGFR D030
## 7162                EGFR D030
## 7163                 Akt D030
## 7164                 CDK D030
## 7165                PI3K D030
## 7166             ATM/ATR D030
## 7167                mTOR D030
## 7168                 MEK D030
## 7169                EGFR D030
## 7170                EGFR D030
## 7171       Aurora Kinase D030
## 7172                 JAK D030
## 7173                PI3K D030
## 7174                 PLK D030
## 7175                 JNK D030
## 7176           S6 Kinase D030
## 7177               GSK-3 D030
## 7178               GSK-3 D030
## 7179            p38 MAPK D030
## 7180                 MEK D030
## 7181                &lt;NA&gt; D030
## 7182                PI3K D030
## 7183                 CDK D030
## 7184              IGF-1R D030
## 7185            p38 MAPK D030
## 7186              IGF-1R D030
## 7187               c-Met D030
## 7188               c-Met D030
## 7189 Hedgehog/Smoothened D030
## 7190                 Src D030
## 7191               VEGFR D030
## 7192               VEGFR D030
## 7193                 CDK D030
## 7194                EGFR D030
## 7195                PI3K D030
## 7196               VEGFR D030
## 7197                &lt;NA&gt; D030
## 7198                PI3K D030
## 7199                PI3K D030
## 7200                mTOR D030
## 7201                 Akt D030
## 7202               VEGFR D030
## 7203                 Raf D030
## 7204                 JAK D030
## 7205                 BTK D030
## 7206             ATM/ATR D030
## 7207                PI3K D030
## 7208               GSK-3 D030
## 7209               GSK-3 D030
## 7210                &lt;NA&gt; D030
## 7211                EGFR D030
## 7212                EGFR D030
## 7213                 BTK D030
## 7214                EGFR D030
## 7215                 MEK D030
## 7216               PDGFR D030
## 7217                EGFR D030
## 7218               PDGFR D030
## 7219               c-Met D030
## 7220       Aurora Kinase D030
## 7221                 JAK D030
## 7222                PI3K D030
## 7223                 Raf D030
## 7224                EGFR D030
## 7225       Aurora Kinase D030
## 7226     Gamma-secretase D030
## 7227                 Src D030
## 7228             Bcr-Abl D030
## 7229                 JAK D030
## 7230                 CDK D030
## 7231                &lt;NA&gt; D030
## 7232       Aurora Kinase D030
## 7233                 PKC D030
## 7234                 ERK D030
## 7235                AMPK D030
## 7236                mTOR D030
## 7237                mTOR D030
## 7238                ROCK D030
## 7239    Wnt/beta-catenin D030
## 7240                 JAK D030
## 7241                 CDK D030
## 7242                &lt;NA&gt; D030
## 7243               c-Met D030
## 7244                 Syk D030
## 7245                FLT3 D030
## 7246                 Akt D030
## 7247                mTOR D030
## 7248                 Raf D030
## 7249                PI3K D030
## 7250                mTOR D030
## 7251                EGFR D030
## 7252                EGFR D030
## 7253                 PKC D030
## 7254             Bcr-Abl D030
## 7255             Bcr-Abl D030
## 7256                 PKC D030
## 7257               c-Met D030
## 7258              IGF-1R D030
## 7259              IGF-1R D030
## 7260                PI3K D030
## 7261                PI3K D030
## 7262                PI3K D030
## 7263                ROCK D030
## 7264                 PLK D030
## 7265                AMPK D030
## 7266                 Akt D030
## 7267                 Raf D030
## 7268       TGF-beta/Smad D030
## 7269             Bcr-Abl D030
## 7270           S6 Kinase D030
## 7271       Aurora Kinase D030
## 7272                 PLK D030
## 7273                 Akt D030
## 7274                PI3K D030
## 7275                AMPK D030
## 7276                 Src D030
## 7277    Wnt/beta-catenin D030
## 7278                EGFR D030
## 7279               GSK-3 D030
## 7280               PDGFR D030
## 7281               GSK-3 D030
## 7282                mTOR D030
## 7283                PI3K D030
## 7284    Wnt/beta-catenin D030
## 7285    Wnt/beta-catenin D030
## 7286               c-Met D030
## 7287                 CDK D030
## 7288                 JNK D030
## 7289                 JNK D030
## 7290       TGF-beta/Smad D030
## 7291               VEGFR D030
## 7292               VEGFR D030
## 7293                mTOR D030
## 7294             ATM/ATR D030
## 7295             ATM/ATR D030
## 7296                FLT3 D030
## 7297                 Src D030
## 7298    Wnt/beta-catenin D030
## 7299                EGFR D030
## 7300                EGFR D030
## 7301                 CDK D030
## 7302 Hedgehog/Smoothened D030
## 7303       TGF-beta/Smad D030
## 7304               VEGFR D030
## 7305                 BTK D030
## 7306    Wnt/beta-catenin D030
## 7307               PDGFR D030
## 7308           S6 Kinase D030
## 7309           S6 Kinase D030
## 7310            p38 MAPK D030
## 7311               GSK-3 D030
## 7312       TGF-beta/Smad D030
## 7313                 JAK D030
## 7314                 CDK D030
## 7315                PI3K D030
## 7316                 Akt D030
## 7317     Gamma-secretase D030
## 7318                 MEK D030
## 7319               c-Met D030
## 7320                 CDK D030
## 7321     Gamma-secretase D030
## 7322                 Akt D030
## 7323               c-Met D030
## 7324       Aurora Kinase D030
## 7325       Aurora Kinase D030
## 7326                 Raf D030
## 7327       Aurora Kinase D030
## 7328               VEGFR D030
## 7329             Bcr-Abl D030
## 7330               VEGFR D030
## 7331                 CDK D030
## 7332              IGF-1R D030
## 7333               VEGFR D030
## 7334                 JAK D030
## 7335               c-Met D030
## 7336                 JAK D030
## 7337                EGFR D030
## 7338                 BTK D030
## 7339                mTOR D030
## 7340                EGFR D030
## 7341              IGF-1R D030
## 7342                 CDK D030
## 7343                 JAK D030
## 7344                mTOR D030
## 7345               VEGFR D030
## 7346               VEGFR D030
## 7347                 MEK D030
## 7348                EGFR D030
## 7349             Bcr-Abl D030
## 7350                 MEK D030
## 7351                 MEK D030
## 7352                 MEK D030
## 7353                EGFR D030
## 7354                 FAK D030
## 7355               c-Met D030
## 7356                mTOR D030
## 7357                 FAK D030
## 7358           S6 Kinase D030
## 7359 Hedgehog/Smoothened D030
## 7360                 FAK D030
## 7361                 FAK D030
## 7362            p38 MAPK D030
## 7363               c-Met D030
## 7364       Aurora Kinase D030
## 7365                 CDK D030
## 7366                 CDK D030
## 7367                AMPK D030
## 7368                 Akt D030
## 7369                 Syk D030
## 7370                PI3K D030
## 7371                PI3K D030
## 7372                PI3K D030
## 7373                 MEK D030
## 7374       TGF-beta/Smad D030
## 7375                 Raf D030
## 7376                 Raf D030
## 7377             Bcr-Abl D030
## 7378                 Src D030
## 7379                 Src D030
## 7380                mTOR D030
## 7381              IGF-1R D030
## 7382    Wnt/beta-catenin D030
## 7383                 Syk D030
## 7384                 CDK D030
## 7385                PI3K D030
## 7386                FLT3 D030
## 7387                 Syk D030
## 7388                 Syk D030
## 7389                 CDK D030
## 7390                 Raf D030
## 7391                mTOR D030
## 7392                 MEK D030
## 7393       TGF-beta/Smad D030
## 7394                mTOR D030
## 7395                 PLK D030
## 7396                ROCK D030
## 7397                 BTK D030
## 7398                 PKC D030
## 7399                 CDK D030
## 7400                 PLK D030
## 7401     Gamma-secretase D030
## 7402                 CDK D030
## 7403                 JAK D030
## 7404                 JAK D030
## 7405 Hedgehog/Smoothened D030
## 7406               VEGFR D030
## 7407                PI3K D030
## 7408                 Src D030
## 7409            p38 MAPK D030
## 7410            p38 MAPK D030
## 7411               GSK-3 D030
## 7412            p38 MAPK D030
## 7413               GSK-3 D030
## 7414       TGF-beta/Smad D030
## 7415       TGF-beta/Smad D030
## 7416       TGF-beta/Smad D030
## 7417                 Raf D030
## 7418                 ERK D030
## 7419             ATM/ATR D030
## 7420                 MEK D030
## 7421     Gamma-secretase D030
## 7422               VEGFR D030
## 7423               VEGFR D030
## 7424            p38 MAPK D030
## 7425                 MEK D030
## 7426                 CDK D030
## 7427       Aurora Kinase D030
## 7428                 Raf D030
## 7429                &lt;NA&gt; D030
## 7430                 PKC D030
## 7431                 JNK D030
## 7432               c-Met D030
## 7433                 Src D030
## 7434                 CDK D030
## 7435               VEGFR D030
## 7436                 FAK D030
## 7437                EGFR D030
## 7438                 Raf D030
## 7439            p38 MAPK D030
## 7440                 MEK D030
## 7441       Aurora Kinase D030
## 7442 Hedgehog/Smoothened D030
## 7443                FLT3 D030
## 7444               GSK-3 D030
## 7445               VEGFR D030
## 7446                mTOR D030
## 7447               c-Met D030
## 7448                 CDK D030
## 7449                PI3K D030
## 7450                FLT3 D030
## 7451                 JAK D030
## 7452                PI3K D030
## 7453       TGF-beta/Smad D030
## 7454                ROCK D030
## 7455                 Akt D030
## 7456               GSK-3 D030
## 7457               c-Met D030
## 7458               VEGFR D030
## 7459                 JAK D030
## 7460                 JAK D030
## 7461                mTOR D030
## 7462                 MEK D030
## 7463                 Akt D030
## 7464               VEGFR D030
## 7465               GSK-3 D030
## 7466                EGFR D030
## 7467               PDGFR D030
## 7468                 MEK D030
## 7469                 ERK D030
## 7470                 Akt D030
## 7471                 JNK D030
## 7472                EGFR D030
## 7473               VEGFR D030
## 7474             ATM/ATR D030
## 7475             ATM/ATR D030
## 7476                 Raf D030
## 7477 Hedgehog/Smoothened D030
## 7478                 PLK D030
## 7479                PI3K D030
## 7480                PI3K D030
## 7481                 ERK D030
## 7482       Aurora Kinase D030
## 7483            p38 MAPK D030
## 7484            p38 MAPK D030
## 7485                mTOR D030
## 7486                 Src D030
## 7487                 JAK D030
## 7488    Wnt/beta-catenin D030
## 7489    Wnt/beta-catenin D030
## 7490    Wnt/beta-catenin D030
## 7491                 JAK D030
## 7492                mTOR D030
## 7493                mTOR D030
## 7494                EGFR D030
## 7495                EGFR D030
## 7496                AMPK D030
## 7497                EGFR D030
## 7498    Wnt/beta-catenin D030
## 7499                 JAK D030
## 7500                 ERK D030
## 7501                ROCK D030
## 7502                PI3K D030
## 7503     Gamma-secretase D030
## 7504               VEGFR D030
## 7505               VEGFR D030
## 7506                 Raf D030
## 7507                 JAK D030
## 7508       Aurora Kinase D030
## 7509                mTOR D030
## 7510                PI3K D030
## 7511               GSK-3 D046
## 7512                PI3K D046
## 7513                 Akt D046
## 7514                AMPK D046
## 7515                PI3K D046
## 7516                AMPK D046
## 7517                EGFR D046
## 7518                &lt;NA&gt; D046
## 7519              IGF-1R D046
## 7520                EGFR D046
## 7521                EGFR D046
## 7522                 JAK D046
## 7523                 Akt D046
## 7524       Aurora Kinase D046
## 7525               c-Met D046
## 7526               c-Met D046
## 7527       Aurora Kinase D046
## 7528                PI3K D046
## 7529               c-Met D046
## 7530               VEGFR D046
## 7531               GSK-3 D046
## 7532                PI3K D046
## 7533                PI3K D046
## 7534            p38 MAPK D046
## 7535                EGFR D046
## 7536                 Akt D046
## 7537                 CDK D046
## 7538                 Akt D046
## 7539             Bcr-Abl D046
## 7540       Aurora Kinase D046
## 7541     Gamma-secretase D046
## 7542                 BTK D046
## 7543               VEGFR D046
## 7544               PDGFR D046
## 7545                 Raf D046
## 7546                 JAK D046
## 7547             ATM/ATR D046
## 7548               GSK-3 D046
## 7549                 JAK D046
## 7550                mTOR D046
## 7551               GSK-3 D046
## 7552               PDGFR D046
## 7553                EGFR D046
## 7554                 Akt D046
## 7555                 CDK D046
## 7556                PI3K D046
## 7557             ATM/ATR D046
## 7558                mTOR D046
## 7559                 MEK D046
## 7560                EGFR D046
## 7561                EGFR D046
## 7562       Aurora Kinase D046
## 7563                 JAK D046
## 7564                PI3K D046
## 7565                 PLK D046
## 7566                 JNK D046
## 7567           S6 Kinase D046
## 7568               GSK-3 D046
## 7569               GSK-3 D046
## 7570            p38 MAPK D046
## 7571                 MEK D046
## 7572                &lt;NA&gt; D046
## 7573                PI3K D046
## 7574                 CDK D046
## 7575              IGF-1R D046
## 7576            p38 MAPK D046
## 7577              IGF-1R D046
## 7578               c-Met D046
## 7579               c-Met D046
## 7580 Hedgehog/Smoothened D046
## 7581                 Src D046
## 7582               VEGFR D046
## 7583               VEGFR D046
## 7584                 CDK D046
## 7585                EGFR D046
## 7586                PI3K D046
## 7587               VEGFR D046
## 7588                &lt;NA&gt; D046
## 7589                PI3K D046
## 7590                PI3K D046
## 7591                mTOR D046
## 7592                 Akt D046
## 7593               VEGFR D046
## 7594                 Raf D046
## 7595                 JAK D046
## 7596                 BTK D046
## 7597             ATM/ATR D046
## 7598                PI3K D046
## 7599               GSK-3 D046
## 7600               GSK-3 D046
## 7601                &lt;NA&gt; D046
## 7602                EGFR D046
## 7603                EGFR D046
## 7604                 BTK D046
## 7605                EGFR D046
## 7606                 MEK D046
## 7607               PDGFR D046
## 7608                EGFR D046
## 7609               PDGFR D046
## 7610               c-Met D046
## 7611       Aurora Kinase D046
## 7612                 JAK D046
## 7613                PI3K D046
## 7614                 Raf D046
## 7615                EGFR D046
## 7616       Aurora Kinase D046
## 7617     Gamma-secretase D046
## 7618                 Src D046
## 7619             Bcr-Abl D046
## 7620                 JAK D046
## 7621                 CDK D046
## 7622                &lt;NA&gt; D046
## 7623       Aurora Kinase D046
## 7624                 PKC D046
## 7625                 ERK D046
## 7626                AMPK D046
## 7627                mTOR D046
## 7628                mTOR D046
## 7629                ROCK D046
## 7630    Wnt/beta-catenin D046
## 7631                 JAK D046
## 7632                 CDK D046
## 7633                &lt;NA&gt; D046
## 7634               c-Met D046
## 7635                 Syk D046
## 7636                FLT3 D046
## 7637                 Akt D046
## 7638                mTOR D046
## 7639                 Raf D046
## 7640                PI3K D046
## 7641                mTOR D046
## 7642                EGFR D046
## 7643                EGFR D046
## 7644                 PKC D046
## 7645             Bcr-Abl D046
## 7646             Bcr-Abl D046
## 7647                 PKC D046
## 7648               c-Met D046
## 7649              IGF-1R D046
## 7650              IGF-1R D046
## 7651                PI3K D046
## 7652                PI3K D046
## 7653                PI3K D046
## 7654                ROCK D046
## 7655                 PLK D046
## 7656                AMPK D046
## 7657                 Akt D046
## 7658                 Raf D046
## 7659       TGF-beta/Smad D046
## 7660             Bcr-Abl D046
## 7661           S6 Kinase D046
## 7662       Aurora Kinase D046
## 7663                 PLK D046
## 7664                 Akt D046
## 7665                PI3K D046
## 7666                AMPK D046
## 7667                 Src D046
## 7668    Wnt/beta-catenin D046
## 7669                EGFR D046
## 7670               GSK-3 D046
## 7671               PDGFR D046
## 7672               GSK-3 D046
## 7673                mTOR D046
## 7674                PI3K D046
## 7675    Wnt/beta-catenin D046
## 7676    Wnt/beta-catenin D046
## 7677               c-Met D046
## 7678                 CDK D046
## 7679                 JNK D046
## 7680                 JNK D046
## 7681       TGF-beta/Smad D046
## 7682               VEGFR D046
## 7683               VEGFR D046
## 7684                mTOR D046
## 7685             ATM/ATR D046
## 7686             ATM/ATR D046
## 7687                FLT3 D046
## 7688                 Src D046
## 7689    Wnt/beta-catenin D046
## 7690                EGFR D046
## 7691                EGFR D046
## 7692                 CDK D046
## 7693 Hedgehog/Smoothened D046
## 7694       TGF-beta/Smad D046
## 7695               VEGFR D046
## 7696                 BTK D046
## 7697    Wnt/beta-catenin D046
## 7698               PDGFR D046
## 7699           S6 Kinase D046
## 7700           S6 Kinase D046
## 7701            p38 MAPK D046
## 7702               GSK-3 D046
## 7703       TGF-beta/Smad D046
## 7704                 JAK D046
## 7705                 CDK D046
## 7706                PI3K D046
## 7707                 Akt D046
## 7708     Gamma-secretase D046
## 7709                 MEK D046
## 7710               c-Met D046
## 7711                 CDK D046
## 7712     Gamma-secretase D046
## 7713                 Akt D046
## 7714               c-Met D046
## 7715       Aurora Kinase D046
## 7716       Aurora Kinase D046
## 7717                 Raf D046
## 7718       Aurora Kinase D046
## 7719               VEGFR D046
## 7720             Bcr-Abl D046
## 7721               VEGFR D046
## 7722                 CDK D046
## 7723              IGF-1R D046
## 7724               VEGFR D046
## 7725                 JAK D046
## 7726               c-Met D046
## 7727                 JAK D046
## 7728                EGFR D046
## 7729                 BTK D046
## 7730                mTOR D046
## 7731                EGFR D046
## 7732              IGF-1R D046
## 7733                 CDK D046
## 7734                 JAK D046
## 7735                mTOR D046
## 7736               VEGFR D046
## 7737               VEGFR D046
## 7738                 MEK D046
## 7739                EGFR D046
## 7740             Bcr-Abl D046
## 7741                 MEK D046
## 7742                 MEK D046
## 7743                 MEK D046
## 7744                EGFR D046
## 7745                 FAK D046
## 7746               c-Met D046
## 7747                mTOR D046
## 7748                 FAK D046
## 7749           S6 Kinase D046
## 7750 Hedgehog/Smoothened D046
## 7751                 FAK D046
## 7752                 FAK D046
## 7753            p38 MAPK D046
## 7754               c-Met D046
## 7755       Aurora Kinase D046
## 7756                 CDK D046
## 7757                 CDK D046
## 7758                AMPK D046
## 7759                 Akt D046
## 7760                 Syk D046
## 7761                PI3K D046
## 7762                PI3K D046
## 7763                PI3K D046
## 7764                 MEK D046
## 7765       TGF-beta/Smad D046
## 7766                 Raf D046
## 7767                 Raf D046
## 7768             Bcr-Abl D046
## 7769                 Src D046
## 7770                 Src D046
## 7771                mTOR D046
## 7772              IGF-1R D046
## 7773    Wnt/beta-catenin D046
## 7774                 Syk D046
## 7775                 CDK D046
## 7776                PI3K D046
## 7777                FLT3 D046
## 7778                 Syk D046
## 7779                 Syk D046
## 7780                 CDK D046
## 7781                 Raf D046
## 7782                mTOR D046
## 7783                 MEK D046
## 7784       TGF-beta/Smad D046
## 7785                mTOR D046
## 7786                 PLK D046
## 7787                ROCK D046
## 7788                 BTK D046
## 7789                 PKC D046
## 7790                 CDK D046
## 7791                 PLK D046
## 7792     Gamma-secretase D046
## 7793                 CDK D046
## 7794                 JAK D046
## 7795                 JAK D046
## 7796 Hedgehog/Smoothened D046
## 7797               VEGFR D046
## 7798                PI3K D046
## 7799                 Src D046
## 7800            p38 MAPK D046
## 7801            p38 MAPK D046
## 7802               GSK-3 D046
## 7803            p38 MAPK D046
## 7804               GSK-3 D046
## 7805       TGF-beta/Smad D046
## 7806       TGF-beta/Smad D046
## 7807       TGF-beta/Smad D046
## 7808                 Raf D046
## 7809                 ERK D046
## 7810             ATM/ATR D046
## 7811                 MEK D046
## 7812     Gamma-secretase D046
## 7813               VEGFR D046
## 7814               VEGFR D046
## 7815            p38 MAPK D046
## 7816                 MEK D046
## 7817                 CDK D046
## 7818       Aurora Kinase D046
## 7819                 Raf D046
## 7820                &lt;NA&gt; D046
## 7821                 PKC D046
## 7822                 JNK D046
## 7823               c-Met D046
## 7824                 Src D046
## 7825                 CDK D046
## 7826               VEGFR D046
## 7827                 FAK D046
## 7828                EGFR D046
## 7829                 Raf D046
## 7830            p38 MAPK D046
## 7831                 MEK D046
## 7832       Aurora Kinase D046
## 7833 Hedgehog/Smoothened D046
## 7834                FLT3 D046
## 7835               GSK-3 D046
## 7836               VEGFR D046
## 7837                mTOR D046
## 7838               c-Met D046
## 7839                 CDK D046
## 7840                PI3K D046
## 7841                FLT3 D046
## 7842                 JAK D046
## 7843                PI3K D046
## 7844       TGF-beta/Smad D046
## 7845                ROCK D046
## 7846                 Akt D046
## 7847               GSK-3 D046
## 7848               c-Met D046
## 7849               VEGFR D046
## 7850                 JAK D046
## 7851                 JAK D046
## 7852                mTOR D046
## 7853                 MEK D046
## 7854                 Akt D046
## 7855               VEGFR D046
## 7856               GSK-3 D046
## 7857                EGFR D046
## 7858               PDGFR D046
## 7859                 MEK D046
## 7860                 ERK D046
## 7861                 Akt D046
## 7862                 JNK D046
## 7863                EGFR D046
## 7864               VEGFR D046
## 7865             ATM/ATR D046
## 7866             ATM/ATR D046
## 7867                 Raf D046
## 7868 Hedgehog/Smoothened D046
## 7869                 PLK D046
## 7870                PI3K D046
## 7871                PI3K D046
## 7872                 ERK D046
## 7873       Aurora Kinase D046
## 7874            p38 MAPK D046
## 7875            p38 MAPK D046
## 7876                mTOR D046
## 7877                 Src D046
## 7878                 JAK D046
## 7879    Wnt/beta-catenin D046
## 7880    Wnt/beta-catenin D046
## 7881    Wnt/beta-catenin D046
## 7882                 JAK D046
## 7883                mTOR D046
## 7884                mTOR D046
## 7885                EGFR D046
## 7886                EGFR D046
## 7887                AMPK D046
## 7888                EGFR D046
## 7889    Wnt/beta-catenin D046
## 7890                 JAK D046
## 7891                 ERK D046
## 7892                ROCK D046
## 7893                PI3K D046
## 7894     Gamma-secretase D046
## 7895               VEGFR D046
## 7896               VEGFR D046
## 7897                 Raf D046
## 7898                 JAK D046
## 7899       Aurora Kinase D046
## 7900                mTOR D046
## 7901                PI3K D046
## 7902               GSK-3 D046
## 7903                PI3K D046
## 7904                 Akt D046
## 7905                AMPK D046
## 7906                PI3K D046
## 7907                AMPK D046
## 7908                EGFR D046
## 7909                &lt;NA&gt; D046
## 7910              IGF-1R D046
## 7911                EGFR D046
## 7912                EGFR D046
## 7913                 JAK D046
## 7914                 Akt D046
## 7915       Aurora Kinase D046
## 7916               c-Met D046
## 7917               c-Met D046
## 7918       Aurora Kinase D046
## 7919                PI3K D046
## 7920               c-Met D046
## 7921               VEGFR D046
## 7922               GSK-3 D046
## 7923                PI3K D046
## 7924                PI3K D046
## 7925            p38 MAPK D046
## 7926                EGFR D046
## 7927                 Akt D046
## 7928                 CDK D046
## 7929                 Akt D046
## 7930             Bcr-Abl D046
## 7931       Aurora Kinase D046
## 7932     Gamma-secretase D046
## 7933                 BTK D046
## 7934               VEGFR D046
## 7935               PDGFR D046
## 7936                 Raf D046
## 7937                 JAK D046
## 7938             ATM/ATR D046
## 7939               GSK-3 D046
## 7940                 JAK D046
## 7941                mTOR D046
## 7942               GSK-3 D046
## 7943               PDGFR D046
## 7944                EGFR D046
## 7945                 Akt D046
## 7946                 CDK D046
## 7947                PI3K D046
## 7948             ATM/ATR D046
## 7949                mTOR D046
## 7950                 MEK D046
## 7951                EGFR D046
## 7952                EGFR D046
## 7953       Aurora Kinase D046
## 7954                 JAK D046
## 7955                PI3K D046
## 7956                 PLK D046
## 7957                 JNK D046
## 7958           S6 Kinase D046
## 7959               GSK-3 D046
## 7960               GSK-3 D046
## 7961            p38 MAPK D046
## 7962                 MEK D046
## 7963                &lt;NA&gt; D046
## 7964                PI3K D046
## 7965                 CDK D046
## 7966              IGF-1R D046
## 7967            p38 MAPK D046
## 7968              IGF-1R D046
## 7969               c-Met D046
## 7970               c-Met D046
## 7971 Hedgehog/Smoothened D046
## 7972                 Src D046
## 7973               VEGFR D046
## 7974               VEGFR D046
## 7975                 CDK D046
## 7976                EGFR D046
## 7977                PI3K D046
## 7978               VEGFR D046
## 7979                &lt;NA&gt; D046
## 7980                PI3K D046
## 7981                PI3K D046
## 7982                mTOR D046
## 7983                 Akt D046
## 7984               VEGFR D046
## 7985                 Raf D046
## 7986                 JAK D046
## 7987                 BTK D046
## 7988             ATM/ATR D046
## 7989                PI3K D046
## 7990               GSK-3 D046
## 7991               GSK-3 D046
## 7992                &lt;NA&gt; D046
## 7993                EGFR D046
## 7994                EGFR D046
## 7995                 BTK D046
## 7996                EGFR D046
## 7997                 MEK D046
## 7998               PDGFR D046
## 7999                EGFR D046
## 8000               PDGFR D046
## 8001               c-Met D046
## 8002       Aurora Kinase D046
## 8003                 JAK D046
## 8004                PI3K D046
## 8005                 Raf D046
## 8006                EGFR D046
## 8007       Aurora Kinase D046
## 8008     Gamma-secretase D046
## 8009                 Src D046
## 8010             Bcr-Abl D046
## 8011                 JAK D046
## 8012                 CDK D046
## 8013                &lt;NA&gt; D046
## 8014       Aurora Kinase D046
## 8015                 PKC D046
## 8016                 ERK D046
## 8017                AMPK D046
## 8018                mTOR D046
## 8019                mTOR D046
## 8020                ROCK D046
## 8021    Wnt/beta-catenin D046
## 8022                 JAK D046
## 8023                 CDK D046
## 8024                &lt;NA&gt; D046
## 8025               c-Met D046
## 8026                 Syk D046
## 8027                FLT3 D046
## 8028                 Akt D046
## 8029                mTOR D046
## 8030                 Raf D046
## 8031                PI3K D046
## 8032                mTOR D046
## 8033                EGFR D046
## 8034                EGFR D046
## 8035                 PKC D046
## 8036             Bcr-Abl D046
## 8037             Bcr-Abl D046
## 8038                 PKC D046
## 8039               c-Met D046
## 8040              IGF-1R D046
## 8041              IGF-1R D046
## 8042                PI3K D046
## 8043                PI3K D046
## 8044                PI3K D046
## 8045                ROCK D046
## 8046                 PLK D046
## 8047                AMPK D046
## 8048                 Akt D046
## 8049                 Raf D046
## 8050       TGF-beta/Smad D046
## 8051             Bcr-Abl D046
## 8052           S6 Kinase D046
## 8053       Aurora Kinase D046
## 8054                 PLK D046
## 8055                 Akt D046
## 8056                PI3K D046
## 8057                AMPK D046
## 8058                 Src D046
## 8059    Wnt/beta-catenin D046
## 8060                EGFR D046
## 8061               GSK-3 D046
## 8062               PDGFR D046
## 8063               GSK-3 D046
## 8064                mTOR D046
## 8065                PI3K D046
## 8066    Wnt/beta-catenin D046
## 8067    Wnt/beta-catenin D046
## 8068               c-Met D046
## 8069                 CDK D046
## 8070                 JNK D046
## 8071                 JNK D046
## 8072       TGF-beta/Smad D046
## 8073               VEGFR D046
## 8074               VEGFR D046
## 8075                mTOR D046
## 8076             ATM/ATR D046
## 8077             ATM/ATR D046
## 8078                FLT3 D046
## 8079                 Src D046
## 8080    Wnt/beta-catenin D046
## 8081                EGFR D046
## 8082                EGFR D046
## 8083                 CDK D046
## 8084 Hedgehog/Smoothened D046
## 8085       TGF-beta/Smad D046
## 8086               VEGFR D046
## 8087                 BTK D046
## 8088    Wnt/beta-catenin D046
## 8089               PDGFR D046
## 8090           S6 Kinase D046
## 8091           S6 Kinase D046
## 8092            p38 MAPK D046
## 8093               GSK-3 D046
## 8094       TGF-beta/Smad D046
## 8095                 JAK D046
## 8096                 CDK D046
## 8097                PI3K D046
## 8098                 Akt D046
## 8099     Gamma-secretase D046
## 8100                 MEK D046
## 8101               c-Met D046
## 8102                 CDK D046
## 8103     Gamma-secretase D046
## 8104                 Akt D046
## 8105               c-Met D046
## 8106       Aurora Kinase D046
## 8107       Aurora Kinase D046
## 8108                 Raf D046
## 8109       Aurora Kinase D046
## 8110               VEGFR D046
## 8111             Bcr-Abl D046
## 8112               VEGFR D046
## 8113                 CDK D046
## 8114              IGF-1R D046
## 8115               VEGFR D046
## 8116                 JAK D046
## 8117               c-Met D046
## 8118                 JAK D046
## 8119                EGFR D046
## 8120                 BTK D046
## 8121                mTOR D046
## 8122                EGFR D046
## 8123              IGF-1R D046
## 8124                 CDK D046
## 8125                 JAK D046
## 8126                mTOR D046
## 8127               VEGFR D046
## 8128               VEGFR D046
## 8129                 MEK D046
## 8130                EGFR D046
## 8131             Bcr-Abl D046
## 8132                 MEK D046
## 8133                 MEK D046
## 8134                 MEK D046
## 8135                EGFR D046
## 8136                 FAK D046
## 8137               c-Met D046
## 8138                mTOR D046
## 8139                 FAK D046
## 8140           S6 Kinase D046
## 8141 Hedgehog/Smoothened D046
## 8142                 FAK D046
## 8143                 FAK D046
## 8144            p38 MAPK D046
## 8145               c-Met D046
## 8146       Aurora Kinase D046
## 8147                 CDK D046
## 8148                 CDK D046
## 8149                AMPK D046
## 8150                 Akt D046
## 8151                 Syk D046
## 8152                PI3K D046
## 8153                PI3K D046
## 8154                PI3K D046
## 8155                 MEK D046
## 8156       TGF-beta/Smad D046
## 8157                 Raf D046
## 8158                 Raf D046
## 8159             Bcr-Abl D046
## 8160                 Src D046
## 8161                 Src D046
## 8162                mTOR D046
## 8163              IGF-1R D046
## 8164    Wnt/beta-catenin D046
## 8165                 Syk D046
## 8166                 CDK D046
## 8167                PI3K D046
## 8168                FLT3 D046
## 8169                 Syk D046
## 8170                 Syk D046
## 8171                 CDK D046
## 8172                 Raf D046
## 8173                mTOR D046
## 8174                 MEK D046
## 8175       TGF-beta/Smad D046
## 8176                mTOR D046
## 8177                 PLK D046
## 8178                ROCK D046
## 8179                 BTK D046
## 8180                 PKC D046
## 8181                 CDK D046
## 8182                 PLK D046
## 8183     Gamma-secretase D046
## 8184                 CDK D046
## 8185                 JAK D046
## 8186                 JAK D046
## 8187 Hedgehog/Smoothened D046
## 8188               VEGFR D046
## 8189                PI3K D046
## 8190                 Src D046
## 8191            p38 MAPK D046
## 8192            p38 MAPK D046
## 8193               GSK-3 D046
## 8194            p38 MAPK D046
## 8195               GSK-3 D046
## 8196       TGF-beta/Smad D046
## 8197       TGF-beta/Smad D046
## 8198       TGF-beta/Smad D046
## 8199                 Raf D046
## 8200                 ERK D046
## 8201             ATM/ATR D046
## 8202                 MEK D046
## 8203     Gamma-secretase D046
## 8204               VEGFR D046
## 8205               VEGFR D046
## 8206            p38 MAPK D046
## 8207                 MEK D046
## 8208                 CDK D046
## 8209       Aurora Kinase D046
## 8210                 Raf D046
## 8211                &lt;NA&gt; D046
## 8212                 PKC D046
## 8213                 JNK D046
## 8214               c-Met D046
## 8215                 Src D046
## 8216                 CDK D046
## 8217               VEGFR D046
## 8218                 FAK D046
## 8219                EGFR D046
## 8220                 Raf D046
## 8221            p38 MAPK D046
## 8222                 MEK D046
## 8223       Aurora Kinase D046
## 8224 Hedgehog/Smoothened D046
## 8225                FLT3 D046
## 8226               GSK-3 D046
## 8227               VEGFR D046
## 8228                mTOR D046
## 8229               c-Met D046
## 8230                 CDK D046
## 8231                PI3K D046
## 8232                FLT3 D046
## 8233                 JAK D046
## 8234                PI3K D046
## 8235       TGF-beta/Smad D046
## 8236                ROCK D046
## 8237                 Akt D046
## 8238               GSK-3 D046
## 8239               c-Met D046
## 8240               VEGFR D046
## 8241                 JAK D046
## 8242                 JAK D046
## 8243                mTOR D046
## 8244                 MEK D046
## 8245                 Akt D046
## 8246               VEGFR D046
## 8247               GSK-3 D046
## 8248                EGFR D046
## 8249               PDGFR D046
## 8250                 MEK D046
## 8251                 ERK D046
## 8252                 Akt D046
## 8253                 JNK D046
## 8254                EGFR D046
## 8255               VEGFR D046
## 8256             ATM/ATR D046
## 8257             ATM/ATR D046
## 8258                 Raf D046
## 8259 Hedgehog/Smoothened D046
## 8260                 PLK D046
## 8261                PI3K D046
## 8262                PI3K D046
## 8263                 ERK D046
## 8264       Aurora Kinase D046
## 8265            p38 MAPK D046
## 8266            p38 MAPK D046
## 8267                mTOR D046
## 8268                 Src D046
## 8269                 JAK D046
## 8270    Wnt/beta-catenin D046
## 8271    Wnt/beta-catenin D046
## 8272    Wnt/beta-catenin D046
## 8273                 JAK D046
## 8274                mTOR D046
## 8275                mTOR D046
## 8276                EGFR D046
## 8277                EGFR D046
## 8278                AMPK D046
## 8279                EGFR D046
## 8280    Wnt/beta-catenin D046
## 8281                 JAK D046
## 8282                 ERK D046
## 8283                ROCK D046
## 8284                PI3K D046
## 8285     Gamma-secretase D046
## 8286               VEGFR D046
## 8287               VEGFR D046
## 8288                 Raf D046
## 8289                 JAK D046
## 8290       Aurora Kinase D046
## 8291                mTOR D046
## 8292                PI3K D046</code></pre>
<div id="factor-shift-moa-by-line" class="section level2">
<h2>factor shift MOA by line</h2>
<pre class="r"><code>z_projected_anno_test_line &lt;- z_projected_anno_test %&gt;% mutate(line = substr(line, 1, 4))

drug_projection_test_result_line &lt;- rbind(
  lm(V1 ~ target + line, data = z_projected_anno_test_line) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor1&quot;),
  lm(V2 ~ target + line, data = z_projected_anno_test_line) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor2&quot;),
  lm(V3 ~ target + line, data = z_projected_anno_test_line) %&gt;% summary() %&gt;% broom::tidy() %&gt;% mutate(factor = &quot;factor3&quot;)) 

drug_projection_test_result_line &lt;- drug_projection_test_result_line %&gt;% 
  filter(term != &quot;(Intercept)&quot;) %&gt;% 
  dplyr::select(term, statistic, factor, p.value)</code></pre>
<pre class="r"><code>hist(drug_projection_test_result_line$p.value)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>moa_factor_shift_line &lt;- drug_projection_test_result_line %&gt;% arrange(p.value) %&gt;% 
  mutate(fdr = p.adjust(p.value, method = &quot;BH&quot;))
  

moa_factor_shift_tbl &lt;- moa_factor_shift_line%&gt;% 
  filter(fdr &lt;= 0.2) %&gt;%
  head(15) %&gt;%
  tableGrob(., theme = ttheme_default(), rows = NULL)

grid.arrange(moa_factor_shift_tbl)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>decomposing the results</p>
<pre class="r"><code>moa_factor_shift_line_tidy &lt;- moa_factor_shift_line %&gt;%
  separate(term, c(&quot;line&quot;, &quot;drug&quot;), remove = FALSE, sep = &quot;:&quot;) %&gt;%
  mutate(type = case_when(is.na(line) ~ &quot;drug&quot;,
                          is.na(drug) ~ &quot;line&quot;, 
                          TRUE ~ &quot;interaction&quot;))</code></pre>
<p>D018T01 is exceptionally strong in factor 2, when treated with MEK inhibitors the line shows a strong response with a shift in factor 1. At a first glance, this is in conflict with the observation that factor 2 high lines are relatively insensitive to MEK inhibtors.</p>
<pre class="r"><code>moa_factor_shift_line %&gt;%
  ggplot(aes(statistic, fdr, color = factor, label = term)) + 
  geom_point() + 
  scale_y_reverse() + 
  geom_hline(yintercept = 0.2) + 
  theme_cowplot() + 
  facet_wrap( ~ factor)+ 
  ggrepel::geom_text_repel(data = moa_factor_shift %&gt;% filter(term == &quot;targetMEK&quot;)) + 
  ggrepel::geom_text_repel(data = moa_factor_shift %&gt;% filter(term == &quot;targetAurora Kinase&quot;))</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>  NULL</code></pre>
<pre><code>## NULL</code></pre>
</div>
<div id="factor-1" class="section level2">
<h2>factor 1</h2>
<pre class="r"><code>moa_factor_shift_line_tidy %&gt;% 
  filter(factor == &quot;factor2&quot;) %&gt;%
  filter(type != &quot;interaction&quot;) %&gt;%
  
  filter(fdr &lt; 0.2)</code></pre>
<pre><code>## # A tibble: 35 x 8
##    term           line          drug  statistic factor   p.value       fdr type 
##    &lt;chr&gt;          &lt;chr&gt;         &lt;chr&gt;     &lt;dbl&gt; &lt;chr&gt;      &lt;dbl&gt;     &lt;dbl&gt; &lt;chr&gt;
##  1 lineD007       lineD007      &lt;NA&gt;     -41.6  facto 0.        0.        line 
##  2 lineD010       lineD010      &lt;NA&gt;     -41.6  facto 0.        0.        line 
##  3 lineD018       lineD018      &lt;NA&gt;      96.8  facto 0.        0.        line 
##  4 lineD020       lineD020      &lt;NA&gt;     -31.7  facto 6.43e-208 6.75e-207 line 
##  5 lineD046       lineD046      &lt;NA&gt;     -30.2  facto 2.11e-189 1.90e-188 line 
##  6 lineD019       lineD019      &lt;NA&gt;      -9.06 facto 1.56e- 19 7.58e- 19 line 
##  7 targetFAK      targetFAK     &lt;NA&gt;       8.85 facto 1.09e- 18 5.07e- 18 line 
##  8 lineD013       lineD013      &lt;NA&gt;      -7.97 facto 1.81e- 15 7.36e- 15 line 
##  9 targetMEK      targetMEK     &lt;NA&gt;       7.45 facto 1.04e- 13 3.84e- 13 line 
## 10 targetp38 MAPK targetp38 MA &lt;NA&gt;      -5.11 facto 3.31e-  7 9.07e-  7 line 
## #  with 25 more rows</code></pre>
<p>factor 1 only using morphology (FDR &lt; 0.1) * line 46, 18, 10 significantly associated with factor1 up * line 22, 30 with decreased factor 1 * mTORi leads to increase in factor 1 * CDK and AURK to a decrease in factor 1</p>
<p>When accounting for line differences, we observed a downward shift in factor1 score for organoids treated with CDK and AURK inhibitors. These findings where in line with the observation that organoids size was reduced visibly in CDK treated organoids. In contrast, mTORi treated organoids showed an increased factor1 score. Given the overrepresentation of IGF signaling mediators within the factor1 loading, we hypothesized that mTOR inhibitor treatment might lead to a previously described disinhibition of IGFR1 signaling. To validate these results we</p>
<p>factor 2 * line 18, 22, 30, 10 factor 2 up * MEKi leads to increase in factor 2, so did AURK, PLK, JNK</p>
<p>The increase in MEKi loading is seen across lines. At the same time MEKi activity has a negative weight within factor2, generally suggesting that factor2 high organoids are relatively MEKi resistant. Given the shift of MEKi treated organoids within factor2 and the relative resistance of organoid lines that are factor2 high in an unperturbed state, we hypothesized that factor2 represents a MEK inhibited state. Organoid lines in this state are generally not perturbed by additional MEK inhibition while the general set of organoid lines respond with an increase in factor2 in phenotype space. <cite Tianzuo>, Based on this model, we effect was concentration dependent we analyzed the factor2 score for all organoid lines in a concentration depend manner. To further investigate this relationship we performed qPCR for the intestinal stem cell marker Lgr5, a key marker of the intestinal stem cell signature which is enriched within the factor2 loadings. Organoids showed an increase in Lgr5 expression when treated with MEK inhibitors, recapituling the increase in factor2 loading</p>
<p>factor 3 * line 22, 20 and 46 with factor 3 up * line 30, and 7 with factor 3 low * JNK, Src to decrease</p>
<pre class="r"><code>moa_factor_shift_line_tidy %&gt;% 
  filter(factor == &quot;factor3&quot;) %&gt;%
  filter(type == &quot;interaction&quot;) %&gt;%
  filter(fdr &lt; 0.1)</code></pre>
<pre><code>## # A tibble: 0 x 8
## #  with 8 variables: term &lt;chr&gt;, line &lt;chr&gt;, drug &lt;chr&gt;, statistic &lt;dbl&gt;,
## #   factor &lt;chr&gt;, p.value &lt;dbl&gt;, fdr &lt;dbl&gt;, type &lt;chr&gt;</code></pre>
<p>factor1 * line18 responds to many drugs with factor 1 <em>decrease</em>, incl IGF, MEK, PDGFR and EGFR. The same is true for AURK, p38</p>
<p>factor 2 * line46 example for strong factor 2 <em>decrease</em> JNK, Src</p>
<p>factor 3 * line 7 with <em>increase</em> to drugs</p>
</div>
</div>
<div id="gene-expression---factor" class="section level1">
<h1>gene expression -&gt; factor</h1>
<div id="training-data" class="section level2">
<h2>training data</h2>
<pre class="r"><code>mofa_expression &lt;- promise_long_filtered_top %&gt;% 
  # renaming columns
  mutate(line = paste0(line, &quot;_&quot;, rep)) %&gt;%
  dplyr::select(sample = line,
                feature = symbol, # setting feature to symbol
                value = expr) %&gt;% 
  mutate(view = &quot;expression&quot;) %&gt;% 
  # averaging feature value
  group_by(feature, sample, view) %&gt;%
  summarise(value = mean(value)) %&gt;%
  # renaming feature jic
  mutate(feature = paste0(feature, &quot;_&quot;, view)) %&gt;%
  dplyr::select(sample, feature, view, value) %&gt;% 
  drop_na() %&gt;% 
  filter(feature != &quot;_expression&quot;)

new_expression &lt;- mofa_expression %&gt;%
  dplyr::select(-view) %&gt;%
  spread(sample, value) %&gt;%
  column_to_rownames(&quot;feature&quot;) %&gt;%
  as.matrix() %&gt;%
  t() %&gt;% 
  scale(center = TRUE, scale = TRUE)
  

W &lt;- get_weights(model, &quot;expression&quot;)[[1]]
Winv &lt;- pracma::pinv(W)

z_projected_expression &lt;-  new_expression %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)</code></pre>
<pre class="r"><code>z_projected_exp_anno &lt;- z_projected_expression %&gt;% 
  mutate(line = substr(id, 1, 7))

z_projected_expression_plot &lt;- z_projected_expression %&gt;% 
  left_join(weights) %&gt;% 
  
  gather(variable, value, -id) %&gt;% 
  mutate(factor = if_else(variable %in% c(&quot;V1&quot;, &quot;factor1&quot;), &quot;factor1&quot;, &quot;none&quot;)) %&gt;%
  mutate(factor = if_else(variable %in% c(&quot;V2&quot;, &quot;factor2&quot;), &quot;factor2&quot;, factor)) %&gt;%
  mutate(factor = if_else(variable %in% c(&quot;V3&quot;, &quot;factor3&quot;), &quot;factor3&quot;, factor)) %&gt;% 
  mutate(source = if_else(grepl(variable, pattern = &quot;factor&quot;), &quot;MOFA&quot;, &quot;pseudoinverse&quot;)) %&gt;% 
  dplyr::select(-variable) 

z_projected_expression_plot %&gt;%
  spread(source, value) %&gt;% 
  ggplot(aes(MOFA, pseudoinverse)) + 
  geom_point() + 
  facet_wrap(~ factor) + 
  theme_cowplot() + 
  geom_smooth(method = &quot;lm&quot;) + 
  labs(title = &quot;gene expression&quot;)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>z_projected_expression_plot %&gt;% 
  spread(factor, value) %&gt;% 
  ggplot(aes(factor1, factor2, color = source)) + 
  geom_point() + 
  geom_path(aes(group = id), color = &quot;black&quot;) + 
  theme_cowplot() + 
  ggrepel::geom_text_repel(aes(label = id), data = z_projected_expression_plot %&gt;% 
  spread(factor, value) %&gt;% filter(source == &quot;MOFA&quot;), color = &quot;black&quot;)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
</div>
<div id="drug-treatment" class="section level2">
<h2>drug treatment</h2>
<div id="gsk-inhibitors" class="section level3">
<h3>GSK inhibitors</h3>
<pre class="r"><code>gsk_expression &lt;- expr_long_gsk %&gt;%
  mutate(sample = paste0(line, &quot;_r&quot;, rep)) %&gt;% 
  mutate(sample = paste0(sample, &quot;_&quot;, treatment)) %&gt;% 
  mutate(feature = paste0(symbol, &quot;_expression&quot;)) %&gt;%
  dplyr::select(value = expr, sample, feature) %&gt;% 
  group_by(feature, sample) %&gt;%
  summarise(value = mean(value)) %&gt;%
  spread(sample, value) %&gt;%
  column_to_rownames(&quot;feature&quot;) %&gt;%
  as.matrix() %&gt;%
  t() %&gt;% 
  scale(center = TRUE, scale = FALSE)

gsk_expression &lt;- gsk_expression[,colnames(gsk_expression) %in% colnames(new_expression)]
joint_expression &lt;- rbind(gsk_expression, new_expression)

W &lt;- get_weights(model, &quot;expression&quot;)[[1]]
Winv &lt;- pracma::pinv(W)

z_projected_expression_gsk &lt;-  gsk_expression %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)
z_projected_expression_joint &lt;-  joint_expression %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)

joint_expression %*% t(Winv) %&gt;% pheatmap::pheatmap(cluster_cols = FALSE)</code></pre>
<pre class="r"><code>gsk_expression %*% t(Winv) %&gt;% pheatmap::pheatmap(cluster_cols = FALSE)</code></pre>
<pre class="r"><code>df &lt;- z_projected_expression_gsk %&gt;%
  as.data.frame() %&gt;%
  separate(id, c(&quot;line&quot;, &quot;replicate&quot;, &quot;treatment&quot;)) 

lm(V3 ~ line + treatment, data = df) %&gt;% summary()

df %&gt;% 
  ggplot(aes(treatment, V3, color = line)) + 
  geom_point(size = 2) + 
  theme_cowplot() + 
  labs(y = &quot;factor 3&quot;) + 
  scale_color_brewer(type = &quot;qual&quot;)</code></pre>
<p>lines with high factor 3 appear to not respond morphologically to GSK inhibitors. Lines that have been treated with GSK inhibitors, move up in factor 3. We can interpret this as the organoids being pushed by the drug in factor space into a direction, which is associated with lower response to GSK inhibitors (possibly because GSK activity is already inhibited in this state). Factor 3 high organoids are more sensitive to AURK inhibitors. Existing literature suggests a crosstalk between AURK and GSK, Akt respectively. A possible mechanism could be that factor 3 high lines show a strong activiation of mTOR and Wnt signaling due to GSK3b inhibition, which could be partially explained by AURK based phosphorylation of GSK. In case GSK is inhibited pharmacologically, the lines do not respond much, because the pathway is already non-active. In case AURK is inhibited, the lines respond strongly - probably because they rely on AURK signaling to maintain viability, possibly via a crosstalk of GSK3b and Akt/mTOR signaling. (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642527/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642527/</a>)</p>
</div>
<div id="mek-inhibitors-1" class="section level3">
<h3>MEK inhibitors</h3>
<pre class="r"><code>mek_expression &lt;- expr_long_mek %&gt;%
  mutate(sample = paste0(line, &quot;_&quot;, treatment)) %&gt;% 
  mutate(sample = paste0(sample, &quot;_&quot;, names)) %&gt;% 
  mutate(feature = paste0(Symbol, &quot;_expression&quot;)) %&gt;%
  dplyr::select(value = expr, sample, feature) %&gt;% 
  group_by(feature, sample) %&gt;%
  summarise(value = mean(value)) %&gt;%
  spread(sample, value) %&gt;%
  column_to_rownames(&quot;feature&quot;) %&gt;%
  as.matrix() %&gt;%
  t()%&gt;% 
  scale(center = TRUE, scale = FALSE)


joint_expression &lt;- left_join(new_expression %&gt;% t() %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;), 
          mek_expression %&gt;% t() %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;)) %&gt;% 
  column_to_rownames(&quot;id&quot;) 

joint_expression &lt;- joint_expression %&gt;% 
  mutate_if(is.numeric,coalesce,0) %&gt;%
  as.matrix() 

mek_expression &lt;- joint_expression[,-c(1:22)] %&gt;% t()
joint_expression &lt;- joint_expression %&gt;% t()



W &lt;- get_weights(model, &quot;expression&quot;)[[1]]
Winv &lt;- pracma::pinv(W)

z_projected_expression_mek &lt;-  mek_expression %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)
z_projected_expression_joint &lt;-  joint_expression %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;id&quot;)

mek_expression %*% t(Winv) %&gt;% pheatmap::pheatmap(cluster_cols = FALSE)</code></pre>
<pre class="r"><code>z_projected_expression_mek %&gt;% 
  ggplot(aes(V2, id)) + 
  geom_point()</code></pre>
<pre class="r"><code>df &lt;- z_projected_expression_mek %&gt;%
  as.data.frame() %&gt;%
  separate(id, c(&quot;line&quot;, &quot;treatment&quot;, &quot;name&quot;)) 

lm(V3 ~ line + treatment, data = df) %&gt;% summary()

df %&gt;% 
  ggplot(aes(treatment, V3, color = line)) + 
  geom_point(size = 2) + 
  theme_cowplot() + 
  labs(y = &quot;factor 3&quot;) + 
  scale_color_brewer(type = &quot;qual&quot;)</code></pre>
<pre class="r"><code>lm(V2 ~ line + treatment, data = df) %&gt;% summary()

df %&gt;% 
  ggplot(aes(treatment, V2, color = line)) + 
  geom_point(size = 2) + 
  theme_cowplot() + 
  labs(y = &quot;factor 2&quot;) + 
  scale_color_brewer(type = &quot;qual&quot;)</code></pre>
<pre class="r"><code>joint_expression %*% t(Winv)  %&gt;% pheatmap::pheatmap(cluster_cols = FALSE)</code></pre>
<pre class="r"><code>joint_expression %&gt;% colSums(na.rm = TRUE) %&gt;% hist()</code></pre>
<div id="factor-weights-for-intestinal-stemness-related-genes" class="section level4">
<h4>factor weights for intestinal stemness related genes</h4>
<pre class="r"><code>loadings_expression %&gt;% 
  filter(grepl(id, &quot;LGR5&quot;))</code></pre>
<p>LGR5 or EPHB1 are not members of the top differentially expressed genes. However, they are a core marker of the intestinal stem cell identity signature. I am now looking specifically at the expression of these target genes and how they are modulated under various drug treatments.</p>
<pre class="r"><code>expr_long_mek %&gt;% 
  filter(Symbol %in% c(&quot;LGR5&quot;, &quot;EPHB2&quot;, &quot;ASCL2&quot;)) %&gt;%
  ggplot(aes(treatment, expr, color = line)) + 
  geom_point() + 
  theme_cowplot() + 
  #ggsignif::geom_signif(comparisons = list(c(&quot;DMSO&quot;, &quot;MEKi&quot;))) +
  facet_wrap(~Symbol)</code></pre>
<pre class="r"><code>df &lt;- expr_long_mek %&gt;% 
  filter(Symbol %in% c(&quot;LGR5&quot;))

lm(expr ~ line + treatment, data = df) %&gt;% summary()</code></pre>
<pre class="r"><code>df &lt;- expr_long_mek %&gt;% 
  filter(Symbol %in% c(&quot;EPHB2&quot;))

lm(expr ~ line + treatment, data = df) %&gt;% summary()</code></pre>
<pre class="r"><code>df &lt;- expr_long_mek %&gt;% 
  filter(Symbol %in% c(&quot;ASCL2&quot;))

lm(expr ~ line + treatment, data = df) %&gt;% summary()</code></pre>
</div>
</div>
</div>
</div>
<div id="factor---gene-expression" class="section level1">
<h1>factor -&gt; gene expression</h1>
<pre class="r"><code>z_projected_matrix &lt;- z_projected %&gt;% column_to_rownames(&quot;id&quot;) %&gt;% as.matrix()

expression_inference &lt;- z_projected_matrix %*% t(get_weights(model, &quot;expression&quot;)[[1]]) %&gt;% as.data.frame() %&gt;% rownames_to_column(&quot;id&quot;) %&gt;% as_tibble() %&gt;% 
  separate(id, c(&quot;line&quot;, &quot;drug&quot;), sep = 7) %&gt;% 
  mutate(drug = substr(drug , 2, nchar(drug))) %&gt;% 
  mutate(drug = ifelse(drug == &quot;&quot;, &quot;DMSO&quot;, drug))</code></pre>
<pre class="r"><code>expression_inference_tidy &lt;- expression_inference %&gt;%  gather(symbol, expr, -drug, -line) %&gt;% mutate(symbol = substr(symbol, 1, nchar(symbol)-nchar(&quot;_expression&quot;))) 

expression_dmso_inference &lt;- promise_long_filtered_top %&gt;% 
  dplyr::select(-line) %&gt;% 
  dplyr::rename(line = id) %&gt;% 
  dplyr::select(line, expr, symbol) %&gt;% 
  left_join(expression_inference_tidy %&gt;% filter(drug == &quot;DMSO&quot;) %&gt;% dplyr::rename(inference = expr))</code></pre>
<pre class="r"><code>expression_dmso_inference %&gt;% 
  drop_na() %&gt;%
  ggplot(aes(expr, inference)) + 
  geom_point(alpha = 0.2) + 
  geom_smooth(aes(group = line))</code></pre>
</div>
<div id="single-organoid-morphology---factor" class="section level1">
<h1>single organoid morphology -&gt; factor</h1>
<pre class="r"><code>new_morphology &lt;- readRDS(here::here(&quot;data/processed/PhenotypeSpectrum/pca_absolute_all_drugs_sampled.Rds&quot;)) %&gt;% 
  dplyr::select(contains(&quot;pc&quot;), uuid) %&gt;% 
  column_to_rownames(&quot;uuid&quot;) %&gt;%
  as.matrix() %&gt;% scale(center = TRUE, scale = FALSE)

z_projected_organoid &lt;-  new_morphology %*% t(Winv) %&gt;% as.data.frame()%&gt;% rownames_to_column(&quot;uuid&quot;)

umap_factor &lt;- umap_df %&gt;% 
  inner_join(z_projected_organoid) %&gt;%
  filter(line != &quot;D020T02&quot;) 

gg_factor_umap &lt;- umap_factor %&gt;% 
  dplyr::select(-size_factor) %&gt;%
  dplyr::rename(factor1 = V1, factor2 = V2, factor3 = V3) %&gt;%
  pivot_longer(cols = contains(&quot;factor&quot;), names_to = &quot;number&quot;, values_to = &quot;value&quot;) %&gt;%
  ggplot(aes(v1, v2, color = log(value))) + 
  ggrastr::geom_point_rast(alpha = 0.1, size = 0.35) + 
  scale_color_viridis_c() +
  cowplot::theme_cowplot() +
  labs(x = &quot;UMAP 1&quot;,
       y = &quot;UMAP 2&quot;,
       color = &quot;factor value&quot;) + 
  facet_wrap(~ number) +
  theme(legend.position = &quot;bottom&quot;) + 
    coord_fixed()

gg_factor_umap + ggsave(here(&quot;factor_overview_organoid_level.pdf&quot;), height = 6 , width = 6)</code></pre>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
